<SEC-DOCUMENT>0001193125-18-117053.txt : 20180413
<SEC-HEADER>0001193125-18-117053.hdr.sgml : 20180413
<ACCEPTANCE-DATETIME>20180413172021
ACCESSION NUMBER:		0001193125-18-117053
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		126
CONFORMED PERIOD OF REPORT:	20171231
FILED AS OF DATE:		20180413
DATE AS OF CHANGE:		20180413

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SELLAS Life Sciences Group, Inc.
		CENTRAL INDEX KEY:			0001390478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33958
		FILM NUMBER:		18755024

	BUSINESS ADDRESS:	
		STREET 1:		315 MADISON AVENUE
		STREET 2:		4TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		(813) 864-4523

	MAIL ADDRESS:	
		STREET 1:		315 MADISON AVENUE
		STREET 2:		4TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Galena Biopharma, Inc.
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXi Pharmaceuticals Corp
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GALENA BIOPHARMA, INC.
		DATE OF NAME CHANGE:	20110922
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>d556278d10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 10-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">10-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9746;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the year ended December&nbsp;31, 2017 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OR </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g556278g0327071551902.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS Life Sciences Group, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Commission File</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">20-8099512</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(State of incorporation)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number: <FONT STYLE="white-space:nowrap">001-33958</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(I.R.S. Employer Identification No.)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>315 Madison Avenue, 4<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor, New York, NY 10017
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(917) <FONT STYLE="white-space:nowrap">438-4353</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Securities registered pursuant to Section&nbsp;12(b) of the Exchange Act: </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:64.15pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title of Each
Class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:137.50pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Name of Exchange on Which
Registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Common Stock, $0.0001 Par Value per Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>The Nasdaq Capital Market</B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Securities
registered pursuant to Section&nbsp;12(b) of the Exchange Act: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>None </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities
Act.&nbsp;&nbsp;&#9744;&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;&#9746;&nbsp;&nbsp;No </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is not required to file
reports pursuant to Section&nbsp;13 or 15(d) of the Exchange Act.&nbsp;&nbsp;&#9744;&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;&#9746;&nbsp;&nbsp;No </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate
by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required
to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&#9746;&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp; &#9744;&nbsp;&nbsp;No </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if disclosure of delinquent filers pursuant to Item&nbsp;405 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> is not contained
herein, and will not be contained, to the best of the registrant&#146;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form <FONT STYLE="white-space:nowrap">10-K</FONT> or any amendment to this
Form <FONT STYLE="white-space:nowrap">10-K.&nbsp;&nbsp;&#9746;&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;&#9744;&nbsp;&nbsp;No</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark
whether the registrant has submitted electronically and posted on it corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-T</FONT>
(&#167;&nbsp;232.405 of this chapter) during the preceding 12 months (or for any such shorter time that the registrant was required to submit and post such files).&nbsp;&nbsp;&#9746;&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp; &#9744;&nbsp;&nbsp;No </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT> fi
ler, a smaller reporting company, or emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company,&#148; and &#147;emerging growth company&#148; in Rule <FONT
STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;&nbsp;&nbsp;(Do not check if a smaller reporting company)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a shell company (as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange
Act):&nbsp;&nbsp;&#9744;&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp; &#9746;&nbsp;&nbsp;No </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the closing price of the registrant&#146;s common stock as
reported on the Nasdaq Capital Market, the aggregate market value of the registrant&#146;s common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> on June&nbsp;30, 2017 (the last business day of the registrant&#146;s most
recently completed second fiscal quarter) was approximately $21,640,272. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of April 6, 2018, the registrant had outstanding 6,572,542 shares of common
stock, $0.0001 par value per share, exclusive of treasury shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DOCUMENTS INCORPORATED BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information required in Part III of this Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> is incorporated from the registrant&#146;s
Proxy Statement for its 2018 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> provided that if such Proxy Statement is not filed within such period, such information will be included in an amendment to this Form <FONT STYLE="white-space:nowrap">10-K</FONT> to be filed within such <FONT
STYLE="white-space:nowrap">120-day</FONT> period. </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of the information contained in this annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> may include forward-looking statements that
reflect our current views with respect to our development programs, business strategy, business plan, financial performance and other future events. These statements include forward-looking statements both with respect to us, specifically, and our
industry, in general. Such forward-looking statements include the words &#147;expect,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;believe,&#148; &#147;project,&#148; &#147;estimate,&#148; &#147;may,&#148; &#147;should,&#148;
&#147;anticipate,&#148; &#147;will&#148; and similar statements of a future or forward-looking nature identify forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs,
expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Forward-looking statements are subject to inherent uncertainties,
risks and changes in circumstances that are difficult to predict and many of which are outside of our control. There are or will be important factors that could cause actual results to differ materially from those indicated in these statements.
These factors include, but are not limited to, those factors set forth in the sections entitled &#147;Risk Factors,&#148; &#147;Legal Proceedings,&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations,&#148; in this annual report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> which you should review carefully. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new
information, future developments or otherwise, except as required by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNUAL REPORT ON FORM <FONT STYLE="white-space:nowrap">10-K</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE YEAR ENDED DECEMBER&nbsp;31, 2017 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.90pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Part&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Item&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page&nbsp;No.</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">I</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx556278_1">Business</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">1A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx556278_2">Risk Factors</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">38</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">1B</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx556278_3">Unresolved Staff Comments</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">84</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx556278_4">Properties</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">84</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx556278_5">Legal Proceedings</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">84</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx556278_6">Mine Safety Disclosures</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">86</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">II</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx556278_7">Market for Registrant&#146;s Common Equity, Related Stockholder Matters and Issuer
 Purchases of Equity Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">87</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx556278_8">Selected Financial Data</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">88</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx556278_9">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">89</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx556278_10">Quantitative and Qualitative Disclosures About Market Risk</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">101</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">II</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx556278_11">Financial Statements and Supplementary Data</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">102</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx556278_12">Changes in and Disagreements with Accountants on Accounting and Financial Disclosures</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">144</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">9A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx556278_13">Controls and Procedures</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">144</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">9B</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx556278_14">Other Information</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">145</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">III</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx556278_15">Directors, Executive Officers and Corporate Governance</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">145</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx556278_16">Executive Compensation</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">145</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx556278_17">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">145</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx556278_18">Certain Relationships and Related Transactions, and Director Independence</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">145</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx556278_19">Principal Accountant Fees and Services</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">145</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">IV</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx556278_20">Exhibits</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">146</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx556278_21">Form <FONT STYLE="white-space:nowrap">10-K</FONT> Summary</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">154</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><A HREF="#tx556278_22">SIGNATURES </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">155</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The names &#147;SELLAS Life Sciences Group, Inc.,&#148; &#147;SELLAS,&#148; the SELLAS logo, and other trademarks or service
marks of SELLAS Life Sciences Group, Inc. appearing in this annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> are the property of SELLAS Life Sciences Group, Inc. Other trademarks, service marks or trade names appearing in this
prospectus are the property of their respective owners. We do not intend the use or display of other companies&#146; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of or by either, of these other
companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the context otherwise indicates, references in these notes to the &#147;Company,&#148; &#147;we,&#148; &#147;us&#148; or
&#147;our&#148; refer to SELLAS Life Sciences Group, Inc. and its wholly owned subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx556278_1"></A>ITEM&nbsp;1. BUSINESS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Merger
of Galena Biopharma, Inc. and SELLAS Life Sciences Group Ltd. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;29, 2017, we completed the business combination with the privately held
Bermuda exempted company, Sellas Life Sciences Group Ltd., or Private SELLAS, in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of August&nbsp;7, 2017 and amended November&nbsp;5, 2017, or the Merger
Agreement, by and among our company, Sellas Intermediate Holdings I, Inc., Sellas Intermediate Holdings II, Inc., Galena Bermuda Merger Sub, Ltd., and Private SELLAS. We refer to this business combination throughout this annual report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> as the Merger. As a result of the Merger, our business is now substantially comprised of the business of Private Sellas, and although we are considered the legal acquiror of Private SELLAS, for accounting
purposes, Private SELLAS is considered to have acquired our company in the Merger. Consequently, the Merger is accounted for as a reverse acquisition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immediately prior to the Merger, we effected a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-30</FONT></FONT> reverse stock split of
our outstanding common stock. Under the terms of the Merger Agreement, we issued shares of our common stock to Private SELLAS&#146; securityholders at an exchange ratio of 43.9972 shares of our common stock in exchange for each common share of
Private SELLAS outstanding immediately prior to the Merger. We also assumed all of the restricted stock units, or RSUs issued and outstanding under the Private SELLAS Stock Incentive Plan #1, and all of the issued and outstanding warrants of Private
SELLAS. Accordingly, such RSUs will now be settled in, and such warrants now are exercisable for, shares of our common stock. Accordingly, immediately after the Merger, there were approximately 5,766,891 shares of our common stock outstanding, with
the former Private SELLAS securityholders owning approximately 67.5% of our fully diluted common stock, and our <FONT STYLE="white-space:nowrap">pre-Merger</FONT> securityholders owning the remaining approximately 32.5%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon completion of the Merger, we changed our name from &#147;Galena Biopharma, Inc.&#148; to &#147;SELLAS Life Sciences Group, Inc.&#148;, our common stock
began trading on The Nasdaq Capital Market under a new ticker symbol &#147;SLS&#148; on January&nbsp;2, 2018 and our financial statements became those of Private SELLAS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As used in this annual report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> the words &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; the
&#147;Company,&#148; and &#147;SELLAS&#148; refer to SELLAS Life Sciences Group, Inc. and its consolidated subsidiaries following completion of the Merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical
company focused on novel cancer immunotherapeutics for a broad range of cancer indications. Our lead product candidate, galinpepimut-S, or GPS, is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that
targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to
address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and we have planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid
leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian cancer. We plan to study GPS in up to four additional indications: as a combination therapy in
small cell lung cancer, colorectal cancer, triple-negative breast cancer; and, as a monotherapy in chronic myelogenous leukemia, or CML. We received Orphan Drug Product Designations from the U.S. Food and Drug Administration, or FDA as well as
Orphan Medicinal Product Designations from the European Medicines Agency, or EMA, for GPS in AML and MPM, as well as Fast Track Designation for AML and MPM from the FDA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our pipeline also includes the legacy development programs of our
<FONT STYLE="white-space:nowrap">pre-Merger</FONT> company, including novel cancer immunotherapy programs for NeuVax&#153; (nelipepimut-S; a vaccine against the E75 peptide derived from the human epidermal growth factor 2 <FONT
STYLE="white-space:nowrap">-or</FONT> HER2- protein), <FONT STYLE="white-space:nowrap">GALE-301</FONT> (a vaccine against the E39 peptide derived from the folate binding protein, or FBP) and <FONT STYLE="white-space:nowrap">GALE-302</FONT> (a
vaccine against the J65 peptide derived from FBP) and <FONT STYLE="white-space:nowrap">GALE-401</FONT> (a controlled release version of the approved drug anagrelide). NeuVax is currently in multiple investigator-sponsored Phase 2 clinical trials in
breast cancer, including a prospective, randomized, single-blinded, controlled Phase 2b independent investigator-sponsored clinical trial of trastuzumab (Herceptin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) +/- NeuVax in HER2 1+/2+
breast cancer patients in the adjuvant setting to prevent recurrences. On April 2, 2018, we announced that a pre-specified interim analysis, conducted by an independent Data Safety Monitoring Board, or DSMB, of the efficacy and safety data for the
study demonstrated a clinically meaningful difference in median disease-free survival, or DFS, in favor of the active arm (NeuVax + Herceptin), a primary endpoint of the study. Based on these results, and the DSMB&#146;s recommendation, we plan to
expeditiously seek regulatory guidance by the FDA for further development of the combination of NeuVax + Herceptin in Triple Negative Breast Cancer, or TNBC, considering the statistically significant benefit of the combination therapy seen in this
population with large unmet medical need. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">GALE-301</FONT> and <FONT STYLE="white-space:nowrap">GALE-302</FONT> have
completed early stage trials in ovarian, endometrial and breast cancers. <FONT STYLE="white-space:nowrap">GALE-401</FONT> is being developed for the treatment of elevated platelets in patients with myeloproliferative neoplasms, or MPNs, and a
completed Phase 2 clinical trial in patients with essential thrombocythemia, or ET for this clinical candidate. Since the closing of the Merger, management has been evaluating <FONT STYLE="white-space:nowrap">GALE-301,</FONT> <FONT
STYLE="white-space:nowrap">GALE-302,</FONT> and <FONT STYLE="white-space:nowrap">GALE-401</FONT> for potential internal development, strategic partnership, or other types of product rationalizations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We seek to use our expertise and
understanding of cancer immunotherapy and general cancer therapeutic product development to develop novel products that have the potential to transform the treatment of cancer patients. The key components of our strategy are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Continue to rapidly advance our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> cancer immunotherapy product candidates and other new products through clinical
development.</I></B> We intend to continue to execute a focused clinical development plan that takes our product candidates through approval by regulatory authorities. This includes developing GPS as both a monotherapy or in combination, in addition
to exploring opportunities for the other product candidates in our pipeline. The entire GPS clinical program currently targets up to eight tumor types, namely AML, MPM, MM, ovarian cancer, small cell lung cancer, colorectal cancer, triple negative
breast cancer, and CML. We may pursue additional development of GPS for other indications, both as a monotherapy or in combination with other therapeutic agents. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>GPS monotherapy</I>: GPS has completed Phase 2 clinical trials and has Phase 3 clinical trials planned (pending funding availability) for
AML and MPM. There is also an ongoing Phase 2 clinical trial of GPS for MM as monotherapy. We also have plans to pursue additional clinical development programs for GPS as a monotherapy, including in chronic myelogenous leukemia, or CML, and AML
treated with hypomethylators. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>GPS combination therapy</I>: GPS has an ongoing Phase 1/2 clinical trial for ovarian cancer, in
combination with nivolumab (Opdivo<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) (the clinical trial is independently sponsored by MSK). We plan to test GPS in combination with other therapeutic agents for various solid and hematologic
cancers. Our leading combination clinical program will be in collaboration with a Merck&nbsp;&amp; Co., Inc., Kenilworth, N.J., USA subsidiary (known as MSD outside the United States and Canada), or Merck subsidiary. The purpose of the trials is to
determine if the administration of GPS in combination with the PD1 blocker pembrolizumab (Keytruda<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) has the potential to demonstrate clinical activity in the presence of macroscopic disease,
where monotherapy with either agent would have a more limited effect. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Utilize rare disease development pathways at the FDA and comparable foreign regulatory agencies to accelerate progression to late-stage development and early approval.</I></B> A component of our strategy is to
focus on rare types of cancers where our cancer immunotherapy product candidates may produce clinical benefit and where we can take advantage of regulatory programs intended to expedite drug development in these types of rare cancers. We received
Orphan Drug Product Designation from the FDA as well as Orphan Medicinal Product Designation from the EMA for GPS in AML and MPM, as well as Fast Track Designation from the FDA for AML, MPM, and NeuVax. We plan to apply for Orphan Drug Designation,
Fast Track Designation, Breakthrough Therapy Designation and Priority Review from the FDA as well as Orphan Medicinal Product Designation, Priority Medicines Designations, and Conditional Authorizations from the EMA for any given indication, if
applicable when pertinent data becomes available, to potentially reduce clinical trial expense and increase speed to commercialization. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Enter into collaboration and license agreements with other biotechnology and pharmaceutical companies to develop our current product candidates and other future product candidates. </I></B>WE seek out
collaborations for additional opportunities and development of programs in our pipeline that require larger clinical trials or extensive commercial infrastructure. Specifically, we plan to advance the development of NeuVax through a partnership or
other strategic collaboration. We are also evaluating licensing and other strategic options for GALE-301, GALE-302 and GALE-401.<B><I> </I></B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Selectively build focused commercial capabilities and establish commercial collaborations to maximize the value of our clinical development pipeline.</I></B> We have not yet defined our sales, marketing or product
distribution strategy for GPS or any future product candidates. Our future commercial strategy may include the use of strategic alliances, distributors, a contract sales force, or the establishment of our own commercial and specialty sales force to
maximize the value of our pipeline. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The chart below summarizes the current status of our clinical development pipeline:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g556278001.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Cancer Immunotherapy Industry </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principle behind cancer immunotherapy
involves stimulating a person&#146;s own immune system to selectively attack cancer cells while keeping normal cells unaffected or delivering certain immune system components in order to inhibit the spread of cancer. Cancer immunotherapy drugs now
constitute a new mode of cancer treatment, alongside more established options such as surgery, chemotherapy, targeted therapy and radiation therapy. A July&nbsp;2016 report by Kelly Scientific Publications estimates that immunotherapies may
eventually be used in as many as 60% of cases of advanced cancer; further, based on a recent Allied Market Research report on the estimated entire market value of oncology drugs in 2020, cancer immunotherapies could represent up to 71% of that total
value. Either in mono or in combination therapies, immunotherapies may produce long-term remissions or even operational &#147;cures&#148; for cancers that have been uniformly fatal until recently. Thus, cancer immunotherapy is an important and
rapidly emerging field, which has led to exciting new clinical research studies and garnered the attention of investors, biotechnology and pharmaceutical companies, regulatory agencies, payors and hospital systems, cancer patients and their families
and the general public at large. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Market </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
global market for cancer drugs (including immunotherapy drugs) is expected to reach $161.3&nbsp;billion by end of 2021, growing at a compound annual growth rate, or CAGR of around 7.4% between 2016 and 2021 (according to a December 2016 report by
Zion Market Research). According to a September 2016 report by MarketsandMarkets, the global cancer immunotherapy market is expected to reach $119.4&nbsp;billion by 2021 from $61.97&nbsp;billion in 2016 at an estimated CAGR of 14.0%. We estimate
that by 2021, 74% of the oncology market worldwide will be supported by usage of cancer immunotherapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The first category of immunotherapies, immune
synapse modulators (which includes checkpoint inhibitors and immune synapse <FONT STYLE="white-space:nowrap">co-stimulators),</FONT> is likely to reach and exceed 90% of the immunotherapy market in the coming years, which leaves approximately 10%
for the other three major categories, which include peptide cancer active immunizers such as our product candidate, GPS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GPS targets malignancies and
tumors characterized by an overexpression of the WT1 protein. The WT1 protein is one of the most widely expressed cancer proteins in multiple malignancies. A 2009 pilot project regarding the prioritization of cancer antigens conducted by the
National Cancer Institute, or NCI, a division of the National Institutes of Health, or NIH, ranked the WT1 protein as a top priority for immunotherapy. WT1 is a protein that resides in the cell&#146;s nucleus and participates in the process of
cancer formation and progression. As such, it is classified as an &#147;oncogene.&#148; WT1 plays a key role in the development of the kidneys in fetal life, but then almost disappears from normal organs and tissues. In a wide variety of cancers (20
or more cancer types), WT1 becomes detectable again in the cells of these cancers. WT1 appears in large amounts (<I>i.e.</I>, becomes &#147;overexpressed&#148;) in numerous hematological malignancies, including AML, MM and chronic myeloid leukemia,
as well as in many solid malignancies such as MPM, gastrointestinal cancers (such as colorectal cancer), glioblastoma multiforme, triple-negative breast cancer, ovarian cancer and small-cell lung cancer. Overall, WT1 is expressed in at least 50% of
tumor pathology specimens in 20 or more cancer types. The following figure shows the ratio of samples testing positive for WT1 to those testing negative for WT1 in a number of different malignancies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WT1 EXPRESSION FREQUENCY ACROSS VARIOUS CANCERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(Positive samples / Total samples) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g556278002.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Data sampling overview from multiple studies in human tumor samples or cancer cell lines </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our other cancer immunotherapy product, NeuVax (nelipepimut-S), utilizes a targeted approach based upon two key areas: preventing secondary recurrence of
human epidermal growth factor receptor, or HER2, positive breast cancer because the number of breast cancer survivors continues to grow; and, primary prevention intended to prevent ductal carcinoma <I>in situ</I>, or DCIS, from becoming invasive
breast cancer. Once a patient&#146;s tumor becomes metastatic, the outcome is often fatal, making the prevention of recurrence a potentially critical component of overall patient care. Our secondary recurrence programs for NeuVax primarily target
patients in the adjuvant, or after-surgery setting who have relatively healthy immune systems but may still have residual disease. Minimal residual disease, or micrometastasis, that are undetectable by current radiographic scanning technologies, can
result in breast cancer recurrence. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While GPS and NeuVax are both anti-cancer vaccines, they have some distinguishing features. GPS is tetravalent
and Neuvax is monovalent. GPS is a direct immunogen emulsified into the clinically safe adjuvant Montanide, and administered subcutaneously after priming the immune system with recombinant human granulocyte macrophage-colony stimulating factor, or
GM-CSF, Sargramostim. NeuVax, on the other hand, uses an immunodominant HER2 peptide combined with GM-CSF as the immune adjuvant, and is administered intradermally. Both GPS and NeuVax, however, work by harnessing the patient&#146;s own immune
system to seek out and attack any residual cancer cells. We believe using peptide immunogens has many potential clinical advantages, including a favorable safety profile, because these therapies may lack the toxicities typical of most cancer
therapies. Peptide immunogens also have the potential to induce immunologic memory and provide long-lasting protection with convenient modes of delivery. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Galinpepimut-S</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GPS is a <FONT STYLE="white-space:nowrap">WT1-targeting</FONT> peptide-based cancer immunotherapeutic being developed as a monotherapy and in combination with
other therapeutic agents to treat different types of cancers that result from uninhibited tumor cell growth. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cancer immunotherapy is an approach to
cancer treatment that harnesses the body&#146;s natural immune system response to fight and/or prevent such tumor growth. An essential feature of the immune system is its ability to recognize foreign, or
<FONT STYLE="white-space:nowrap">non-self,</FONT> threats, including cancerous growths, as distinct from normal, or self, cells. Despite originating from normal cells, tumor cells can be recognized as <FONT STYLE="white-space:nowrap">non-self</FONT>
because of their capacity to elicit the production of tumor antigens. These antigens may be released in the interstitial tissues and, eventually, the bloodstream or remain on the surface of cognate cancer cells. Such tumor-associated antigens, or
TAAs, have been identified in most human cancers. The WT1 protein is one of the most widely expressed TAAs in multiple malignances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The immune system is
a network of tissues, cells, and signaling molecules that work to protect the body by recognizing and attacking foreign cells, including cancer cells. Several different types of cells are important for the development and maintenance of an immune
response against cancer. The most crucial types of cells are antigen-presenting cells, or APCs, and lymphocytes. APCs include various subtypes, such as dendritic cells, monocytes and macrophages. Once a patient is exposed to a TAA (either by the
presence of cancer itself or through active immunization through a vaccine type immunotherapeutic), this antigen gets recognized by the APC and becomes &#147;processed&#148; through digestion into smaller fragments within the APC. Subsequently, the
APC &#147;communicates&#148; with a specific type of lymphocytes called <FONT STYLE="white-space:nowrap">T-cells.</FONT> Inactive <FONT STYLE="white-space:nowrap">T-cells</FONT> search for TAAs by transiently binding to antigens presented by major
histocompatibility complexes, or MHCs, on the APCs. Notably, there is great variability in the expression of different subtypes of MHCs in the human population. The MHC system expresses the <FONT STYLE="white-space:nowrap">so-called</FONT> human
leukocyte antigens, or HLAs, and there are dozens of subclasses that determine the vigor and duration of any given <FONT STYLE="white-space:nowrap">T-cell</FONT> response to a cancer among different patients. Consequently, active immunizers that
work across many HLA types, such as GPS, are predicted to be more efficacious across larger segments of patient populations as compared to agents that act in the context of only one or few HLA types. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">T-cells</FONT> themselves also come in many variants. CD8 cells recognize the processed TAA fragment as foreign and respond.
The CD8 cells also develop properties that can directly kill the <FONT STYLE="white-space:nowrap">TAA-expressing</FONT> cancer cell by becoming &#147;cytotoxic&#148; CD8 cells. The CD8 cells, as well as the APCs, also activate CD4 cells, which are
very important for the development of immunologic memory. Immunologic memory is developed when a host keeps a long-term trace of the TAA associated with the cancer and is a desirable result, as it allows the host to continue attacking the TAA
associated with the cancer. Therefore, activation of CD4 cells helps avoid or mitigate immune &#147;tolerance.&#148; Immune tolerance is an undesirable result, as it dampens the host&#146;s immune response against the cancer. This cascade of events
is collectively called &#147;cellular immunity&#148; and is very important for anti-cancer activity of immunotherapeutic compounds such as GPS. Of note, once <FONT STYLE="white-space:nowrap">T-cells</FONT> are activated, another class of
lymphocytes, called <FONT STYLE="white-space:nowrap">B-cells,</FONT> are also secondarily activated. <FONT STYLE="white-space:nowrap">B-cells</FONT> are responsible for making antibodies against TAAs. These antibodies become expressed on the surface
of the <FONT STYLE="white-space:nowrap">B-cells</FONT> and are eventually secreted as soluble proteins in tissue fluids and blood. Such anti-cancer antibodies can be detected and have variable degree of activity against the cancer itself. This type
of immunity is called &#147;humoral immunity&#148; and complements the actions and effects of the cellular immunity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Key Features </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GPS is a multi-peptide product that we have exclusively licensed from MSK, which has been modified to enhance the degree and duration of the immune response
against the WT1 protein. The modification is based on the fact that two of the four peptides in the peptide mixture comprising GPS are deliberately mutated in a single amino acid residue. These mutated peptides are recognized by the immune system as
non-self entities and are therefore less likely to induce immune tolerance. After administration of these mutated peptides, the patients become immunized against the corresponding native versions of these peptides (which are expressed by the tumor
cells), and thus, are able to cross-react against them, which concept is called the heteroclitic principle. The enhanced immunity and duration are largely independent of a patient&#146;s HLA type. GPS also elicits both CD4 and CD8 immune responses.
As described above, CD8 cells are extremely important, as their activation by GPS would lead to direct cancer cell killing, or cytotoxicity, and eventual establishment of immunologic memory against a
<FONT STYLE="white-space:nowrap">WT1-expressing</FONT> cancer. This occurs by two mechanisms, conversion of some of the activated CD8 cells to CD8 memory cells, and activation of CD4 cells and eventual creation of CD4 terminal effective memory
cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are currently developing GPS for up to eight indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>GPS monotherapy.</I></B> GPS has completed Phase 2 clinical trials and has Phase 3 clinical trials planned (pending funding availability) for AML and
MPM is also in various development phases as a potential treatment for MM and ovarian cancer. There is also an ongoing Phase 2 clinical trial of GPS for MM as monotherapy. We also have plans to pursue additional clinical development programs for GPS
as a monotherapy, including in CML and AML treated with hypomethylators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>GPS combination therapy.</I></B> In October 2017, we announced a clinical
trial collaboration and supply agreement through a Merck&nbsp;subsidiary to conduct a combination clinical trial (using GPS along with the PD1 blocker pembrolizumab (Keytruda)) targeting up to five cancer types, namely colorectal cancer, small cell
lung cancer, triple negative breast cancer, ovarian cancer and AML treated with hypomethylators. We are preparing to start this clinical trial pending funding availability. Separately, a clinical trial in ovarian cancer of GPS in combination with
nivolumab (Opdivo) is being conducted as an independently-sponsored trial by MSK. Finally, we also have GPS delivery technology in preclinical development using licensed technology from Advaxis using a bacterial vector, Lm (which if successful,
could lead to a second-generation product called <FONT STYLE="white-space:nowrap">WT1-Lm).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the key features of GPS:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="65%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Key&nbsp;features&nbsp;of&nbsp;an&nbsp;Optimal&nbsp;Cancer&nbsp;Active</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:143.35pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Immunizer Therapeutic</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:127.40pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>GPS Properties and Clinical Strategy</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Selecting the right target antigen and</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>epitopes within that antigen</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Four peptides and 25 epitopes selected optimally to ensure:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;optimal MHC complex presentation;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;specificity across different
HLA types;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;production of
both CD4 and CD8 activated cells; and</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;the ability to apply the heteroclitic principle, as described above, to overcome
tolerance.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="65%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Key&nbsp;features&nbsp;of&nbsp;an&nbsp;Optimal&nbsp;Cancer&nbsp;Active</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:143.35pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Immunizer Therapeutic</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:127.40pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>GPS Properties and Clinical Strategy</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Optimal <FONT STYLE="white-space:nowrap">T-cell</FONT> engagement leading to</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>cancer cell destruction</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Immune response data from the multiple myeloma clinical study of GPS in 12&nbsp;evaluable patients that was presented at the Society of Hematologic Oncology Fifth Annual Meeting (Dr.&nbsp;Kohne et al.), showed 83.3% frequency of
either CD8+ or CD4+ responses to an <FONT STYLE="white-space:nowrap">all-pool</FONT> mixture of <FONT STYLE="white-space:nowrap">WT1-derived</FONT> antigens after completion of the 12 vaccinations per the study protocol. This evidence of
multi-epitope, broad cross-reactivity along the full-length of the WT1 protein, is suggestive of epitope spreading, as it emerged across epitopes against which the patients were not specifically immunized. These data strongly suggest stimulation of <FONT
STYLE="white-space:nowrap">T-cells</FONT> towards intracellular antigen fragments from <FONT STYLE="white-space:nowrap">GPS-induced</FONT> destruction of tumor cells, which effect is a hallmark of an effective vaccine, e.g., that it is targeting the
right (e.g., chosen by design) epitopes.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overcoming the barriers of an</I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>adverse/immunosuppressive tumor</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>micro-environment, or
TME</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The GPS monotherapy clinical studies are in the setting of complete remission, or CRem, and minimal residual disease, whereby no bulky or measurable tumor deposits exist. This is typically seen after successful frontline therapy in
select cancer types for which such debulking standard therapies exist (<I>e.g.</I>, AML or MPM). In these settings, the TME is substantially absent. We are also pursuing combination therapy with checkpoint inhibitors in tumor settings whereby
measurable disease exists, as contemporaneous checkpoint inhibition would abrogate the immunosuppressive effects of the TME.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overcoming or mitigating immune</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>tolerance</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Heteroclitic peptides are those in which mutations have been deliberately introduced in the amino acid sequence. The use of heteroclitic peptide in an active immunizer, such as GPS, increases immunogenicity without changes in the
antigenicity profile, as well as strengthens MHC binding of the peptide to produce cytotoxic CD8 cells that continue to recognize the corresponding native peptide sequence. This is a key factor differentiating GPS from essentially all previously
developed peptide vaccines, and applies a highly innovative technology platform, peptide heteroclicity, in a clinical late-stage cancer immunotherapeutic candidate product.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Addressing the broadest possible</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>candidate patient population</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">GPS has activity across multiple HLA types that could allow treatment of a vast majority of global patient populations harboring <FONT STYLE="white-space:nowrap">WT1-positive</FONT> malignancies.</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Potential Key Differentiators </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GPS&#146; potential key differentiators as compared to other active immunization or vaccine-type approaches, as well as compared to immunotherapy approaches
more generally, are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">heteroclitic peptides may offer increased immune response and less potential for tolerance; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">multivalent oligopeptide mixture potentially drives differentiated immunotherapeutic efficacy, targeting 25 key epitopes of WT1; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potentially applicable to 20 or more cancer types worldwide and the vast majority of HLA types; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">CRem or minimal residual disease status (after initial tumor debulking with preceding standard therapy) is the preferred setting for GPS monotherapy; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">does not directly compete with current clinical standard of care therapies, but rather complements them in the maintenance setting; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potential for combination approaches with other cancer immunotherapies, due to tolerable adverse event profile; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">anticipated cost-effective manufacturing; allogeneic, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;off-the-shelf,&#148;</FONT></FONT> vialed subcutaneously administered drug that is not
patient-specific; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">positive Phase 2 clinical data on effectiveness (based on overall survival, or OS, in AML and progression-free survival, or PFS, in MM) with good tolerability and an innocuous safety profile. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Mechanism of Action </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GPS has a mechanism of action
that involves direct activation of the patient&#146;s immune system specifically and solely against the WT1 protein. Typically, patients harboring <FONT STYLE="white-space:nowrap">WT1-positive</FONT> malignancies have very few or no <FONT
STYLE="white-space:nowrap">T-lymphocytes</FONT> specifically reactive or responsive to, and therefore activated by, WT1. WT1 is a &#147;self&#148; antigen, against which the immune system is <FONT STYLE="white-space:nowrap">non-reactive,</FONT> or
said to be in a state of immune tolerance. Even if some patients have some innate <FONT STYLE="white-space:nowrap">T-cell</FONT> responses naturally, these responses are weak and not adequate for any anti-cancer effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GPS is a WT1 peptide mixture. It cannot be administered to patients in a water-soluble form, and so it is given under the skin, or subcutaneously. If
administered on its own, GPS would rapidly degrade and would not have the opportunity and the necessary time interval to activate the immune system. Therefore, GPS is mixed with Montanide, creating a dense emulsion. Additionally, prior to the
administration of GPS, patients receive an adjuvant, GM-CSF to <FONT STYLE="white-space:nowrap">non-specifically</FONT> stimulate and activate APCs in the vicinity of the subcutaneous injection of GPS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After subcutaneous injection, the WT1 peptides within GPS disperse locally underneath the injection site and at local lymph nodes, and are ingested by APCs.
Digested peptide fragments are then presented on the surface of APCs to CD8 and CD4 lymphocytes while simultaneously associated on the cell membrane with MHC/HLA molecules. This process activates the CD4 and CD8 cells and sensitizes them to the key
25 epitopes of WT1, thus initiating the process of short- and long-term <FONT STYLE="white-space:nowrap">T-cell-mediated</FONT> immunity against WT1. CD8 cells then circulate around the lymphatic system and blood stream throughout the patient&#146;s
body targeting <FONT STYLE="white-space:nowrap">WT1-positive</FONT> cancer cells. The stimulated CD8 cells transform into cytotoxic <FONT STYLE="white-space:nowrap">T-lymphocytes,</FONT> or CTLs, which are able to attack and destroy specifically <FONT
STYLE="white-space:nowrap">WT1-positive</FONT> cancer cells. Each CTL typically destroys one <FONT STYLE="white-space:nowrap">WT1-positive</FONT> cancer cell, but they have been shown to be able to kill up to 10 to 20
<FONT STYLE="white-space:nowrap">WT1-positive</FONT> cancer cells. Further, CD4 cells are stimulated to produce <FONT STYLE="white-space:nowrap">WT1-specific,</FONT> helper <FONT STYLE="white-space:nowrap">T-cells,</FONT> which are able to in turn
activate CTLs and <FONT STYLE="white-space:nowrap">B-cells.</FONT> The <FONT STYLE="white-space:nowrap">B-cells</FONT> &#147;helped&#148; by the helper <FONT STYLE="white-space:nowrap">T-cells</FONT> produce antibodies to specific WT1 epitopes. The
anti-cancer effect is considered to be a result of a combination of all of the above actions, as well as possible additional, less clear mechanisms involving other immune cell types (<I>e.g.</I>, natural killer cells). The principles behind the
above described mechanism of action of GPS are well established for the class of peptide-based active immunizing therapies of the vaccine type. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following diagram illustrate GPS&#146; mechanism of action: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g556278003.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Targeted Indications </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>GPS Monotherapy for Acute Myeloid Leukemia </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AML is an
aggressive and highly lethal blood cancer characterized by the rapid growth of abnormal white blood cells that build up in the bone marrow and interfere with the production of normal blood cells. Its symptoms include fatigue, shortness of breath,
bruising and bleeding, and increased risk of infection. The cause of AML is unknown, and the disease is typically fatal within weeks or months if untreated. AML most commonly affects adults, and its incidence increases with age. Current treatments
include chemotherapy, and some patients may receive a hematopoietic, or blood-forming, stem cell transplant, or HSCT. The goal of upfront therapy for AML is to achieve a state of CRem. CRem is defined per consensus criteria by the European Leukemia
Net, whereby the hematologic and clinical features of the disease are no longer detected. In principle, an allogeneic HSCT is an immunotherapy used clinically and specifically in AML, which works in four stages: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">achievement of CRem with standard upfront therapy followed by additional very high-dose chemotherapy that completely destroys any remnant of the patient&#146;s blood forming cells, including any residual AML malignant
cells; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">selection of a sufficiently genetically similar donor (usually one of the patient&#146;s close relatives), called a histocompatible donor; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">removal of blood-forming cells from the bloodstream of that donor; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">infusion of these donor cells into the patient for eventual engraftment onto the patient&#146;s bone marrow and eventual creation of a completely <FONT STYLE="white-space:nowrap">re-instituted</FONT> blood-forming
system to sustain life and long-term leukemia-free status for the patient. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Barring the successful completion of an allogeneic HSCT in AML, no therapies have been proven to accord any
meaningful long-term benefit after patients achieve a CRem status. Without allogeneic HSCT, once the disease relapses, second-line therapies can be given, but these have very limited positive clinical impact to date and their benefit is transitory;
this means that eventually essentially all AML patients who do not undergo an allogeneic HSCT succumb to AML or complications associated with it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
overall treatment landscape for AML has remained static for decades, as numerous (at the time, novel) targeted and antiproliferative agents failed to yield meaningful long-term clinical benefits, including increments in survival. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The AML indication was chosen for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> clinical studies of GPS for
the following reasons: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">AML presents a clinical setting in which CRem status can be achieved with standard upfront therapy; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the almost universal expression of WT1 in leukemic blasts, which are AML&#146;s malignant cells, as well as leukemic stem cells, or LSCs, cells that are or become extremely resistant to standard chemotherapy or targeted
agent approaches and which can be realistically eradicated only with immunotherapy methods (including allogeneic HSCT). LSCs have been shown to be susceptible to targeting by cytotoxic <FONT STYLE="white-space:nowrap">T-cells</FONT> (CD8 and CD4
cells) stimulated against leukemia-associated antigens and we predicted this would be the case for GPS; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the fact that WT1 has been associated with the actual development of leukemia; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the positive correlation between the level of expression of WT1 and the prognosis in AML; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the fact that the level of expression of WT1 can be followed over time in patients during and after therapy, including immunotherapy, as a method of monitoring for minimal residual disease, or MRD; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">early evidence from mouse models that vaccination with peptides against select WT1 antigenic epitopes leads to detection of immune response; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">early evidence that human immunocytes sensitized <FONT STYLE="white-space:nowrap">ex-vivo</FONT> to peptides contained in GPS were able to recognize naturally presented WT1 peptides on the surface of several leukemia
cell lines; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">early anecdotal (at the time) clinical data showing antileukemic activity of WT1 monovalent vaccines in the Japanese population (albeit restricted to <FONT STYLE="white-space:nowrap">HLA-A*2401</FONT> type), as well as
a dendritic cell vaccine in the Netherlands (independent of HLA haplotype); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the high degree of unmet medical need in AML and the absence of an effective maintenance therapy over the decades after initial upfront induction until and immediately after achievement of CRem status, particularly in
patients older than 60 years of age; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a predictive assumption of very low to negligible degree of clinical toxicity with a <FONT STYLE="white-space:nowrap">WT1-targeted</FONT> immunotherapy such as GPS, due to the fact that WT1 in normal, <FONT
STYLE="white-space:nowrap">non-cancerous,</FONT> tissues is both expressed at extremely low levels and limited in number of organs and tissues, but also due to the fact that WT1 fragments, or peptide epitopes, in normal cells are presented to host
APCs in a different manner than are WT1 fragments produced in cancer cells; of note, WT1 expression in normal tissues of adults is limited to the podocyte layer of the glomerulus (kidney), Sertoli cells (testis), granulosa cells (ovary), decidual
cells (uterus), mesothelial cells (peritoneum, pleura), mammary duct and lobule (breast), and blood-forming (hematopoietic) progenitor cells (CD34+ cells in the bone marrow); and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the advent of modern immunotherapeutics in cancer and the promise of an innovative, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> immunotherapy for AML, a disease that was
associated with dearth of deep and sustained responses to checkpoint inhibitors. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical Data&#151;AML </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In an initial pilot clinical trial in AML, a total of nine adult patients of all ages with de novo AML were treated with upfront standard chemotherapy and were
able to achieve their first complete remission, or CRem1. Administration of GPS resulted in a median OS that was at least 35 months from the time of GPS administration. In this study, specifically for patients who were 60 yrs and older (n=5), median
OS was at least 33 months from the time of GPS administration or approximately 43&nbsp;months from the time of initial AML diagnosis. The mean time of <FONT STYLE="white-space:nowrap">follow-up</FONT> was 30 months from the time of diagnosis at the
time of this analysis for all patients. Of the eight patients tested for immunologic response, seven, or 87.5%, demonstrated a <FONT STYLE="white-space:nowrap">WT1-specific</FONT> immune response. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In a subsequent Phase 2 clinical trial in AML, a total of 22 adult patients of all ages with de novo AML were treated with upfront standard chemotherapy and
were able to achieve CRem1. Most patients also received one to four cycles of &#147;consolidation&#148; chemotherapy per standard AML treatment guidelines. GPS was then administered within three months from the completion of the consolidation
chemotherapy regimen in up to 12 total doses: Six initial doses (priming immunization) followed by six additional &#147;booster&#148; immunizations over a total period of up to 15 months to qualifying patients (<I>i.e.</I>, patients who were
clinically stable and did not show disease recurrence after the first six injections). This Phase 2 clinical trial met its primary endpoint of an actual OS rate of at least 34%, measured three years into the clinical trial (<I>i.e.</I>, percentage
of patients alive after three years of <FONT STYLE="white-space:nowrap">follow-up).</FONT> An actual OS rate of 47.4% was demonstrated at 3 years <FONT STYLE="white-space:nowrap">post-GPS</FONT> treatment, exceeding historical published data of OS
of 20% to 25% by <FONT STYLE="white-space:nowrap">2.4-</FONT> to <FONT STYLE="white-space:nowrap">1.9-fold</FONT> (or 240% to 190%), respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GPS
administration was also shown to improve OS in comparison to historical data in patients in CRem1. Administration of GPS resulted in a median OS that was poised to exceed 67.6 months from the time of initial AML diagnosis in patients of all ages,
which represents a substantial improvement compared to best standard therapy. Only five of the 22 patients underwent allogeneic HSCT and an ad hoc statistical analysis failed to show a significant effect of the transplant upon OS (either in median
survival times or survival rates at specific landmark time-points). GPS was well tolerated in this patient population, whose median age was 64 years old. Moreover, GPS elicited <FONT STYLE="white-space:nowrap">WT1-specific</FONT> immune responses in
88% of patients, including CD4 and CD8 <FONT STYLE="white-space:nowrap">T-cell</FONT> responses. Further, the heteroclitic principle was confirmed, in that immune responses were seen against the native version of the two mutated WT1 peptides within
the GPS mixture. The results showed a trend in improved clinical outcomes in patients who mounted an immune response with GPS compared to those patients who did not. Importantly, a preplanned subgroup analysis for the cohort of 13 patients within
the clinical trial who were 60 years of age or older demonstrated a median OS of 35.3 months from time of initial diagnosis. This is also a remarkably prolonged value, considering that comparable historical populations have a median OS ranging from
9.5 to 15.8 months from initial diagnosis, which represents a 2.25 to <FONT STYLE="white-space:nowrap">3.75-fold</FONT> improvement in OS as compared to these historical cohorts of broadly comparable patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An additional Phase 2 clinical trial of GPS was performed at the H. Lee Moffitt Cancer Center&nbsp;&amp; Research Institute, or Moffitt. This Phase 2 trial
included ten AML patients who had received first-line therapy for their disease, who then experienced relapse and were subsequently treated with second-line chemotherapy and achieved a second complete remission, or CRem2. This group of patients had
a more advanced disease in comparison to those treated in the other Phase 2 clinical trials discussed above, and typically demonstrated a historical OS of less than ~8 months, even with post-CRem2 allogeneic HSCT. In the Moffitt trial, the efficacy
of GPS (measured as median OS from the time of administration of a maintenance therapy to immediately after achievement of CRem2) was compared with that of &#147;watchful waiting&#148; in a cohort of 15 contemporaneously treated (but not matched by
randomization) broadly comparable patients treated by the same clinical team at Moffitt. GPS administration resulted in a median OS of 16.3 months (495 days) compared to 5.4 months (165&nbsp;days) from the time of achievement of CRem2. This was a
statistically significant difference (P=0.0175). Two of 14 AML patients demonstrated relapse-free survival of more than one year. Both such patients were in CRem2 at time of GPS administration, with duration of their remission exceeding duration of
their CRem1, strongly suggesting a potential benefit based on immune response mechanisms. GPS was well-tolerated in this clinical trial. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Planned Phase 3 Clinical Trial&#151;AML </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are planning a Phase 3 clinical trial for GPS in AML patients 60 years of age or older who have achieved CRem1 following upfront chemotherapy and up to two
cycles of post-remission consolidation chemotherapy, but who will not undergo allogeneic HSCT. This clinical trial has been planned, a principal investigator and the majority of site investigators have been identified and our operational partners
for the execution of the trial are in the process of being identified. After several meetings and correspondence exchanges, the FDA has indicated that the agency has no further comments on the clinical trial design, protocol or statistical analysis
plan. In addition, well-qualified members of an independent data monitoring committee have agreed to join the independent data monitoring committee for this clinical trial upon its establishment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently plan to initiate this clinical trial, pending funding availability, in 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The clinical trial is planned to include up to 180 centers in the United States, Canada, European Union, Eurasian Union, and other countries and an estimated
total sample size of up to 390 patients. Randomization will be 2:1 (GPS:placebo) and <FONT STYLE="white-space:nowrap">on-trial</FONT> treatment duration will be up to approximately 82 weeks (1.58 years). The primary endpoint of the clinical trial is
OS, measured from the time of randomization (not initial diagnosis). No companion diagnostic will be used as AML universally expresses WT1. Randomization will be stratified by region (U.S. compared to
<FONT STYLE="white-space:nowrap">non-U.S.),</FONT> cytogenetic risk at diagnosis (favorable compared to not favorable compared to unknown), and type of AML (de novo compared to secondary). Patients will provide historical cytogenetic analysis
results from initial diagnosis, before the start of their original chemotherapy treatment, to assess National Comprehensive Cancer Network genetic risk category. The clinical trial is currently powered to declare a positive result if GPS provides a <FONT
STYLE="white-space:nowrap">4-month</FONT> OS advantage compared to placebo, namely increasing median OS from ~9 months in the control arm to ~13 months in the active, <FONT STYLE="white-space:nowrap">GPS-treated</FONT> arm with an <FONT
STYLE="white-space:nowrap">1-sided</FONT> &#945; of 2.5%. Three interim analyses (IA1, IA2 and IA3) are planned in addition to a final analysis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
following figure illustrates the AML Phase 3 GPS clinical trial schema described in the above paragraph. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; text-indent:4%">


<IMG SRC="g556278004.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">maximum for final analysis, unless futility or efficacy thresholds are met in Interim Analyses prior to FA </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#094;</TD>
<TD ALIGN="left" VALIGN="top">All agents are administered subcutaneously </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>GPS Monotherapy for Malignant Pleural Mesothelioma </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MPM is an asbestos-related cancer that forms on the protective tissues that cover many of the internal organs. The most common area affected is the lining of
the lungs and abdomen, though it can also form around the lining of the heart. Most cases are traced to <FONT STYLE="white-space:nowrap">job-related</FONT> exposures to asbestos and it can take approximately 40 years between exposure and cancer
formation. Symptoms may include shortness of breath, a swollen abdomen, chest wall pain, cough, feeling tired, and weight loss. MPM is generally resistant to radiation and chemotherapy, and long-term survival is rare, even in cases where aggressive
upfront debulking multimodality therapy (<I>i.e.</I>, extirpative surgery, chemotherapy and in some cases radiotherapy, often described as &#147;trimodality therapy&#148; when used to treat MPM) are used. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assuming absence of distant, systemic metastatic disease, MPM patients can initially present with a very <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> malignancy. The location, geometry, and origin of the tumor in the pleura (the external lining of the lungs and inner lining of the chest cage) present significant challenges for local and
regional disease control. Extensive and complex surgery is initially considered and attempted to be planned. Patients without distant disease are broadly divided in two subgroups: (a)&nbsp;those who are in an inoperable status and (b)&nbsp;those who
are operable. Patients in the former subgroup may be inoperable for two reasons: first, because they may be medically unfit for an extensive &#147;definitive&#148; surgery, most commonly due to <FONT STYLE="white-space:nowrap">co-morbidities</FONT>
(contemporaneously active diseases unrelated to their cancer) or, secondly, for technical reasons (location and/or bulk of tumor); the latter group of patients is defined as harboring &#147;unresectable&#148; disease. In general, approximately 35%
to 40% of patients with <I>a priori</I> unresectable disease can be converted to technically resectable/marginally resectable, particularly if surgical expertise is high, after several cycles of upfront chemotherapy. This preoperative chemotherapy
is termed &#147;neoadjuvant&#148; therapy. After the patient&#146;s tumor becomes technically resectable, they receive extirpative surgery, often followed by more chemotherapy and sometimes radiotherapy. On the other hand, patients who are <I>a
priori</I> operable proceed immediately with definitive surgery, resulting in either R0 or R1 resections, the degree between the two being assessed by surgical pathology review, with R0 corresponding to resection for &#147;curative intent&#148;, and
R1 corresponding to microscopic residual tumor despite complete eradication by visual inspection at the time of surgery. After surgery, this subgroup of patients receives several cycles of chemotherapy and sometimes radiotherapy. This is
postoperative chemotherapy termed &#147;adjuvant&#148; therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In essence, all MPM patients who receive successful upfront trimodality therapy (schema
A: Upfront neoadjuvant chemotherapy, followed by definitive surgery, followed possible further additional chemotherapy and schema B: upfront definitive surgery followed by adjuvant chemotherapy) become free of residual detectable, macroscopic
malignant deposits. Like AML patients who achieve CRem after upfront chemotherapy (in the absence of allogeneic HSCT), virtually all MPM patients will eventually relapse. Recurrent disease is unfortunately minimally responsive to second-line
chemotherapy in MPM and typically these patients succumb to their disease or related complications within a few weeks to months after the emergence of clinically evident recurrent MPM. To date, there is no effective maintenance type of therapy to
delay or prevent MPM relapse after initially successful upfront trimodality therapy. Typical median OS, even when following a fairly aggressive regimen when surgery is feasible, is between 12 and 16 months following diagnosis. Nonetheless, highly
select patients who both undergo R0/R1 extensive surgery and complete a full course (6 cycles) of indicated chemotherapy (specifically those receiving the combination of pemetrexed with cisplatin, either in the neoadjuvant or adjuvant setting) can
survive up to 21.0 to 24.8 months following initial diagnosis. These patients are typically younger, in excellent functional status, without <FONT STYLE="white-space:nowrap">co-morbidities</FONT> and possibly having tumor-related factors related to
better prognosis, such as intrinsically higher sensitivity of MPM cancer cells to chemotherapy-induced destruction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Like AML, MPM represents a
&#147;model&#148; type of solid tumor for testing the effects of GPS in clinical studies for the following reasons: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">MPM presents a clinical setting whereby minimal residual disease status can be achieved with standard upfront therapy; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the universal expression of WT1 in MPM malignant cells; in fact, WT1 expression is an established pathognomonic criterion for the actual diagnosis of MPM and its differentiation of other chest malignancies, for example,
pulmonary adenocarcinoma; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the positive correlation between the level of expression of WT1 and prognosis in MPM; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">preliminary evidence that WT1 expression could be involved in the MPM tumorigenesis and malignant growth promotion; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">early evidence that human APCs sensitized <FONT STYLE="white-space:nowrap">ex-vivo</FONT> to peptides contained in the GPS mixture were able to recognize naturally presented WT1 peptides from MPM cell lysates;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">evidence that CD8 tumor-infiltrating lymphocytes predict favorable prognosis in MPM after resection (with the assumption that these CD8 cells are highly sensitized to tumor-associated antigens, including WT1);
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the high degree of unmet medical need in MPM and the absence of an effective maintenance therapy; indeed, despite extensive research efforts and recent promising, yet preliminary, results with checkpoint inhibitors in
second or third line therapy of MPM patients, few options are available for the treatment of MPM in the maintenance setting after successful debulking with upfront trimodality therapy (with the vast majority being managed with &#147;watchful
waiting&#148; until the disease&#146;s inexorable relapse) and its prognosis remains very poor; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a predictive assumption of very low to negligible degree of clinical toxicity with a <FONT STYLE="white-space:nowrap">WT1-targeted</FONT> immunotherapy such as GPS, due to the fact that WT1 in normal, <FONT
STYLE="white-space:nowrap">non-cancerous,</FONT> tissues is both expressed at extremely low levels and limited in number of organs and tissues, but also due to the fact that WT1 fragments, or peptide epitopes, in normal cells are presented to host
APCs in a different manner than are WT1 fragments produced in cancer cells; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an initial preliminary clinical efficacy &#147;signal&#148; from the Phase 2 clinical trial of GPS at MSK in patients with MPM. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical Data&#151;MPM </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A randomized, double-blind,
placebo-controlled Phase 2 clinical trial in MPM patients enrolled a total of 41&nbsp;patients at MSK and M.D. Anderson Cancer Center. According to the Phase 2 MPM clinical trial data of GPS presented at the 2016 International Mesothelioma Interest
Group and the 2016 Annual Meeting of the American Society of Clinical Oncology, as of May 2016, based on an initial analysis of 40 patients who were eligible at the time with a median <FONT STYLE="white-space:nowrap">follow-up</FONT> of 16.3 months,
a median OS of 24.8 months was recorded for <FONT STYLE="white-space:nowrap">GPS-treated</FONT> MPM patients, compared to a median OS of 16.6 months for patients in the control arm, with a hazard ratio, or HR, of 0.51 in favor of GPS based on an
initial analysis of 40 patients who were eligible at the time. Patients with an R0 tumor resection and subsequent treatment with GPS showed a significant survival benefit compared to those who received a placebo, with a median OS of 39.3 months
compared to 24.8 months (HR: 0.415) in favor of GPS; this was a statistically significant difference (P&lt;0.05). In a subsequent analysis of these endpoints for the entire cohort (n=41) in August 2016, with a median
<FONT STYLE="white-space:nowrap">follow-up</FONT> of 17.2 months, a median OS of 22.8 months was observed for <FONT STYLE="white-space:nowrap">GPS-treated</FONT> MPM patients, compared to a median OS of 18.3 months for patients in the control arm,
with an HR of 0.54 in favor of GPS. Furthermore, in the datasets from both of these analyses, GPS was shown to induce <FONT STYLE="white-space:nowrap">WT1-specific</FONT> CD8 and CD4 <FONT STYLE="white-space:nowrap">T-cell</FONT> activation. GPS
administration in the 19&nbsp;MPM patients in the active arm of the aforementioned study was commonly associated with mild (grade 1 and 2) and self-limited injection site reactions. Clinically significant severe adverse events did not occur. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Planned Phase 3 Clinical Trial&#151;MPM </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have planned a Phase 3 clinical trial in MPM, pending funding availability. The FDA has reviewed the clinical trial design in previous meetings and,
following a formal <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-phase</FONT></FONT> 2 meeting, has indicated that the agency has no further comments on the clinical trial design, protocol or statistical analysis plan. We
are currently evaluating the best strategy to develop GPS in this indication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The planned Phase 3 clinical trial may include up to 120 centers in the
United States, European Union, and other countries and an estimated total sample size ranging from 120 to 500 patients. The sample size is variable due to the Bayesian statistical design of the clinical trial. Randomization will be 1:1 (GPS:placebo)
and <FONT STYLE="white-space:nowrap">on-trial</FONT> treatment duration will be up to 13 to 18&nbsp;months. The primary endpoint of the clinical trial is OS, measured from the time of randomization (not initial diagnosis). No companion diagnostic
will be used as MPM universally expresses WT1. Randomization will be stratified by region (U.S. compared to <FONT STYLE="white-space:nowrap">non-U.S.),</FONT> timing of chemotherapy (neoadjuvant compared to adjuvant setting), and type of
radiotherapy <FONT STYLE="white-space:nowrap">co-administered</FONT> (intensity-modulated radiation therapy compared to other radiotherapy compared to none). The clinical trial will be adequately powered through a Bayesian adaptive approach to
declare a positive result if certain <I>a priori</I> criteria are met, such as GPS providing an eight-month OS advantage compared to placebo, namely increasing median OS from approximately 16&nbsp;months in the control arm to approximately 24 months
in the active, <FONT STYLE="white-space:nowrap">GPS-treated</FONT> arm with a <FONT STYLE="white-space:nowrap">2-sided</FONT> &#945; of 5%; the exact values of the OS in the control and active arms (as well as the difference between the two) may
differ from the above estimates so long as the &#147;two look&#148; group sequential, adaptive statistical design would be able to deliver at least 90% power with an <FONT STYLE="white-space:nowrap">one-sided</FONT> &#945; of 5% at the time of the
definitive &#147;positive signal&#148; analysis. Two interim analyses (IA1, IA2) are planned (the second of the two, if positive for efficacy, would lead to main clinical trial early termination) in addition to a final analysis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following figure illustrates the MPM Phase 3 GPS clinical trial schema. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g556278005.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Final N will be dependent on a priori rules from adaptive design implemented during the trial to ensure achievement of 90% power and <FONT STYLE="white-space:nowrap">1-sided</FONT> &#945; of 5% </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#094;</TD>
<TD ALIGN="left" VALIGN="top">All agents are administered subcutaneously </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>GPS Monotherapy for Multiple Myeloma </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MM is a cancer formed by malignant plasma cells, and its cause is unknown. The overgrowth of plasma cells in the bone marrow crowds out normal blood-forming
cells, causing low blood counts and anemia (a shortage of red blood cells). MM&nbsp;can also cause a shortage of platelets (cells responsible for normal blood clotting) and lead to increased bleeding and bruising, along with problems fighting
infections due to low white cell counts and/or lower levels of infection-fighting antibodies. MM causes a host of organ problems and symptoms, including fatigue, bone pain, fractures, circulatory problems (in small vessels of the brain, eye retina,
heart, bowel, etc.) and kidney failure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Treatment for MM includes chemotherapy, glucocorticoids, drugs that modulate the immune system (immunomodulatory
drugs, or IMiDs), radiation and autologous stem cell transplants, or ASCTs. Recently, several novel targeted agents, such as proteasome inhibitors and immunotherapeutics have been introduced in the treatment paradigms for MM. Most therapies in MM
are applied in combination, sometimes with usage of three to four or even five agents administered concomitantly or sequentially. This has led to a progressive increase in the number of &#147;lines&#148; of therapy that MM patients receive, which
currently can reach up to five to six or even higher. Of note, ASCT can be used more than once, called tandem ASCTs, to debulk the disease and offer prolonged secondary remissions. Finally, allogeneic HSCT is rarely used in MM, but still has its use
in selected high-risk patients who are or become refractory to antimyeloma therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The prognosis in MM is highly variable and depends on numerous risk
factors, some related to the biology of the disease, others to the host (<I>e.g.</I>, age and functional status). Consequently, median survival can vary from up to at least 15 years in <FONT STYLE="white-space:nowrap">non-high-risk</FONT> patients
who achieve CRes, as defined by the International Myeloma Working Group, or IMWG, criteria, to approximately three years (from time of initial treatment) in patients with MM who achieve less than partial response, or PR, after ASCT. There are
patients with MM who fare even more poorly than described above, for example those in the immediately aforementioned group who also have high-risk cytogenetics at baseline who may survive on average less than three years. Similarly, patients who are
ineligible for ASCT and are managed only with chemotherapy and long-term IMiD maintenance (with up to nine cycles of lenalidomide) who also achieve less than CRes and remain <FONT STYLE="white-space:nowrap">MRD-positive</FONT> demonstrate a
three-year OS rate of only about 55%; these landmark three-year OS rates decrease by approximately 40 to 50% in patients who also have high-risk cytogenetics at baseline. Despite significant therapeutic advances in the management of MM, the
prognosis of patients with high risk cytogenetics at the time of diagnosis remains quite poor, even when they successfully complete an ASCT, particularly if such patients continue to have evidence of MRD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MM represents an intriguing opportunity to study both the clinical and immunologic effects of GPS in a hematologic malignancy. Therapeutic targeting of WT1
through immune pathways has largely not been pursued by others to date, and this indication presents an opportunity to target a malignancy that remains &#147;incurable&#148; in a strict sense, even in the face of significant advances that have
accorded significant survival and freedom-from-active-disease benefit in standard risk patients. MM was chosen as a target indication for GPS for the following reasons: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a clinical setting whereby MRD status can be achieved with standard upfront therapy. In this indication, with induction therapy using modern combination regimens followed by melphalan conditioning for myeloablation and
a successful autotransplant, MM patients can achieve either CRes or very good partial response per IMWG criteria. This subgroup of patients would be optimal candidates for GPS therapy, even if they remain MRD(+) by flow cytometry or molecular
markers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the detectable expression of WT1 in MM cells (malignant plasmacytes). In the past, MM was considered not to be a tumor type with strong expression of WT1. This was due to the use of immunohistochemical staining analysis
with <FONT STYLE="white-space:nowrap">anti-WT1</FONT> antibodies that had suboptimal diagnostic sensitivity. It has been recently shown that while WT1 is expressed at lower levels in MM compared to other hematologic and solid tumors, this expression
is almost universally seen and is highly relevant from an immunobiological perspective, as the immune system is able to reliably raise vigorous and sustained <FONT STYLE="white-space:nowrap">WT1-specific</FONT> responses against malignant
plasmacytes in the context of both MM and the rare, very aggressive variant of plasma-cell leukemia; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">preliminary evidence that WT1 expression could be involved in the MM tumorigenesis and promotion; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">early anecdotal (at the time) clinical data showing anti-myeloma activity of WT1 monovalent vaccines in Japanese patients (albeit restricted to <FONT STYLE="white-space:nowrap">HLA-A*2401</FONT> type);
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the high degree of unmet medical need in MM patients with high-risk cytogenetics who also remain MRD(+) after frontline induction therapy and successful autotransplant, even when maintenance therapy is applied with
either bortezomib or IMiDs (thalidomide); this has been shown in multiple studies, and <FONT STYLE="white-space:nowrap">to-date</FONT> few options are available for addition of effective therapies in the maintenance setting to be added to agents
such as lenalidomide (which is now standard of care in this setting); and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a predictive assumption of very low to negligible degree of clinical toxicity with a <FONT STYLE="white-space:nowrap">WT1-targeted</FONT> immunotherapy such as GPS due to the fact that WT1 in normal, <FONT
STYLE="white-space:nowrap">non-cancerous</FONT> tissues is both expressed at extremely low levels and limited in number of organs and tissues, but also due to the fact that WT1 fragments, or peptide epitopes, in normal cells are presented to host
APCs in a different manner than are WT1 fragments produced in cancer cells. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical Data&#151;MM </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have reported comprehensive Phase 2 data for GPS in 19 patients with MM, which indicate promising clinical activity among MM patients with high-risk
cytogenetics at initial diagnosis who also remain at least MRD(+) after successful frontline therapy (induction regimen followed by ASCT). This subgroup of MM patients, when serially assessed per IMWG criteria, typically relapse/progress within 12
to 14 months after ASCT, even when they receive maintenance therapy with IMiDs such as thalidomide or proteasome inhibitors such as bortezomib. Of note, 18&nbsp;of the 19 patients received lenalidomide maintenance starting after the first three GPS
administrations following ASCT; the remaining single patient received bortezomib under the same schedule. All patients had evidence of at least MRD after ASCT, while 15 of the 19 also had high-risk cytogenetics at diagnosis. Combined, these
characteristics typically result in low PFS rates that do not exceed 12 to 14 months following ASCT, even while on maintenance therapy with IMiDs or proteasome inhibitors, which are the current standards of care. As of June&nbsp;2017, median PFS
with GPS was 23.6 months, while median OS had not been reached. Our results compare favorably with an unmatched cohort of broadly comparable MM patients with high-risk cytogenetics published by the Spanish PETHEMA group from the PETHEMA Network
No.&nbsp;2005&#150;001110&#150;41 trial. Our GPS therapy demonstrated a <FONT STYLE="white-space:nowrap">1.87-fold</FONT> increase in median PFS, as well as a <FONT STYLE="white-space:nowrap">1.34-fold</FONT> increase in the PFS rate at 18 months
compared to the aforementioned historical cohort, which included MM patients with high-risk cytogenetics and MRD(+) post-ASCT and on continuous intensive maintenance with thalidomide +/- bortezomib. Our Phase 2 clinical trial started in June 2014
and has enrolled a total of 20 patients of which 19 are currently evaluable. The safety profile was devoid of grade 3/4/5 treatment-related adverse events. All <FONT STYLE="white-space:nowrap">non-progression</FONT> events were confirmed and ongoing
as of the time of the latest presentation (median <FONT STYLE="white-space:nowrap">follow-up</FONT> at 20&nbsp;months for survivors). Immune response data showed that up to 91% of patients had successfully developed
<FONT STYLE="white-space:nowrap">T-cell</FONT> (CD8 or CD4) reactivity to any of the 4 peptides within the GPS mixture, while up to 64% of patients demonstrated immune response positivity (CD4/CD8) against more than 1 WT1 peptide (multivalent
responses). Moreover, multifunctional cross-epitope <FONT STYLE="white-space:nowrap">T-cell</FONT> reactivity was observed in 75% of patients to antigenic epitopes against which hosts were not specifically immunized, in a pattern akin to epitope
spreading. Further,a distinctive link was shown between the evolution of immune responses and changes in clinical response status (achievement of CR/very good partial response clinical status per IMWG criteria) over time following treatment with
GPS, with each patient being used as his or her own control for each longitudinal comparison. This association has not been previously described for a peptide vaccine in MM. In summary, the results offer mechanistic underpinnings for immune
activation against WT1 in patients with aggressive, high-risk MM, and support the potential antimyeloma activity of GPS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>GPS Combination Therapy with <FONT
STYLE="white-space:nowrap">PD-1</FONT> blocker (nivolumab) for Ovarian Cancer </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Epithelial cancer of the ovary, or ovarian cancer, is a relatively
common gynecologic cancer that develops insidiously, and hence is associated with vague or no symptoms that would urge patients to seek medical attention. Not surprisingly, most women with ovarian cancer present with advanced (at least locally or
regionally, and often systemically spread) disease. Ovarian cancer is managed with initial surgical resection followed by platinum-based chemotherapy. During the past decade, incremental advances in chemotherapy, and the introduction of targeted
therapies (such as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">poly-ADP-ribose</FONT></FONT> polymerase inhibitors and several others) and specially formulated compounds (such as liposomal anthracyclines) have resulted in
improved survival and in more effective treatment of relapsed disease. In addition, a better understanding of genetic risk factors, along with aggressive screening, has permitted a tailored approach to preventive strategies, such as bilateral
salpingo-oophorectomy in selected women along in specific patient populations genetically predisposed to this cancer (such as those harboring genetic alterations of the BRCA gene family). Although a complete clinical remission following initial
chemotherapy can be anticipated for many patients, a review of &#147;second-look&#148; laparotomy, when it was </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
often performed as a matter of routine care, indicates that less than 50% of patients are actually free of disease. Furthermore, nearly half of patients with a negative &#147;second-look&#148;
procedure relapse and require additional treatment. Many patients will achieve a second complete clinical response with additional chemotherapy. However, almost all patients will relapse after a short remission interval of nine to 11 months.
Effective strategies, such as introduction of novel immunotherapies, to prolong remission or to prevent relapse are required, as subsequent remissions are of progressively shorter duration until chemotherapy resistance broadly develops, leading to
eventual disease-related demise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ovarian cancer represents an intriguing opportunity to study both the clinical and immunologic effects of GPS in another
solid tumor. Additionally, therapeutic targeting of WT1 through immune pathways has largely not been pursued by others to date for this indication and ovarian cancer remains &#147;incurable&#148; once it advances and becomes disseminated, even in
the face of significant advances in the field. Ovarian cancer was chosen as a target indication for the following reasons: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ovarian cancer presents a clinical setting whereby MRD status can be achieved with standard upfront therapy both immediately after first line therapy, but also after effective debulking of the &#147;first relapse.&#148;
The latter subgroup of patients (after successful second line treatment/first salvage, lacking demonstrable macroscopic residual disease) would be optimal candidates for GPS therapy, as no standard maintenance therapy exists for such patients and
the subsequent relapse patterns and metrics are known and predictable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the high levels of expression of WT1 in ovarian cancer cells. In fact, WT1 expression is so frequent that pathologists routinely use immunohistochemical stains for WT1 (with a standardized convention for describing
expression and determining as &#147;positive&#148; or &#147;negative&#148;) to help distinguish epithelial ovarian cancers from other tumors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">preliminary evidence that WT1 expression may be linked to prognosis in ovarian cancer and that it may play an anti-apoptotic role in ovarian cancer cell lines; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the high degree of unmet medical need in ovarian cancer patients after first (or subsequent) successful &#147;salvage&#148; debulking therapy and the absence of effective therapies for such patients; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a predictive assumption of very low to negligible degree of clinical toxicity with a <FONT STYLE="white-space:nowrap">WT1-targeted</FONT> immunotherapy such as GPS due to the fact that WT1 in normal, <FONT
STYLE="white-space:nowrap">non-cancerous</FONT> tissues is both expressed at extremely low levels and limited in number of organs and tissues, but also due to the fact that WT1 fragments, or peptide epitopes, in normal cells are presented to host
APCs in a different manner than are WT1 fragments produced in cancer cells. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical Data&#151;Ovarian Cancer </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GPS is being studied in combination with nivolumab, a <FONT STYLE="white-space:nowrap">PD-1</FONT> immune checkpoint inhibitor, in an open-label, <FONT
STYLE="white-space:nowrap">non-randomized</FONT> Phase 1/2 clinical trial, which is independently sponsored by MSK. The aim of the study is to evaluate the safety and efficacy of this combination in patients with recurrent ovarian, fallopian tube or
primary peritoneal cancer who are in second or greater clinical remission (after their successful first or subsequent &#147;salvage&#148; therapy). This Phase 1/2 clinical trial was planned to enroll at least ten patients with recurrent ovarian
cancer who are in second or greater clinical remission at MSK. Patients enrolled in the clinical trial received the combination therapy during the clinical trial&#146;s <FONT STYLE="white-space:nowrap">14-week</FONT> treatment period. Individuals
who had not progressed by the end of this period also received a maintenance course of GPS. Initial immune response and clinical evolution data are due in the first half of 2018, as is information on the primary endpoint of this clinical trial,
which is the safety of repeated GPS administrations, for a total of six doses, in combination with seven infusions of nivolumab. This clinical trial addresses the safety of GPS when <FONT STYLE="white-space:nowrap">co-administered</FONT> with a
checkpoint inhibitor, with the goal of possibly detecting an efficacy signal based on PFS and OS (versus historical data of monotherapy with nivolumab in this patient population), as well as documenting the pattern of
<FONT STYLE="white-space:nowrap">WT1-specific</FONT> immune responses <FONT STYLE="white-space:nowrap">post-GPS.</FONT> Pending the successful progress of this clinical trial a larger, <FONT STYLE="white-space:nowrap">follow-on,</FONT> randomized
clinical trial may be planned. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>GPS Combination Therapy with PD1 blocker (pembrolizumab) for Other Cancers </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, given the potential immunobiologic and pharmacodynamic synergy between GPS and a PD1 blocker, as well as the prevalent expression of WT1 in five
select tumor types (colorectal cancer, triple-negative breast cancer, small cell lung cancer, ovarian cancer and AML), we entered into a clinical trial collaboration and supply agreement through a Merck subsidiary for the conduct of a combination
clinical trial of GPS with pembrolizumab (Keytruda). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of this <FONT STYLE="white-space:nowrap">five-arm</FONT> &#147;basket&#148; trial is to
determine if the administration of GPS in combination with pembrolizumab has the potential to demonstrate clinical activity in the presence of macroscopic disease, where monotherapy with either agent would have a more limited effect. The negative
influence of tumor microenvironment factors on the immune response is predicted to be mitigated by PD1 inhibition (by pembrolizumab) thus allowing the patients&#146; own immune cells to invade and destroy cancerous growth deposits specifically
sensitized against WT1 (by concomitantly-administered GPS). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NeuVax&#153; (nelipepimut-S) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NeuVax (nelipepimut-S) is a cancer immunotherapy targeting HER2 expressing cancers. NeuVax is the immunodominant nonapeptide derived from the extracellular
domain of the HER2 protein, a well-established and validated target for therapeutic intervention in breast and gastric carcinomas. The NeuVax vaccine is combined with <FONT STYLE="white-space:nowrap">GM-CSF</FONT> (Sargramostim) for injection in
between the layers of the skin epidermis, ie., intradermal administration. Data has shown that an increased presence of circulating tumor cells, or CTCs, may predict reduced DFS and OS, suggesting a presence of isolated micrometastases, not
detectable clinically, but, over time, can lead to recurrence of cancer, most often in distant sites. After binding to the specific HLA molecules on antigen presenting cells, the nelipepimut-S sequence stimulates specific cytotoxic T lymphocytes, or
CTLs, causing significant clonal expansion. These activated CTLs recognize, neutralize and destroy, through cell lysis, HER2 expressing cancer cells, including occult cancer cells and micrometastatic foci. The nelipepimut immune response can also
generate CTLs to other immunogenic peptides through inter- and intra-antigenic epitope spreading. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>NeuVax for Breast Cancer </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">According to NCI, over 230,000 women in the United States are diagnosed with breast cancer annually. While improved diagnostics and targeted therapies have
decreased breast cancer mortality in the United States, metastatic breast cancer remains incurable. Approximately 75% to 80% of breast cancer patients have tissue test positive for some increased amount of the HER2 receptor, which is associated with
disease progression and decreased survival. Only approximately 20% to 30% of all breast cancer patients-those with HER2 immunohistochemistry, or IHC, 3+ disease, or IHC 2+ and fluorescence in situ hybridization, or FISH, amplified-have a HER2
directed, approved treatment option available after their initial standard of care. This leaves the majority of breast cancer patients with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">low-to-intermediate</FONT></FONT> HER2
expression (IHC 1+, 2+) with tumors that are not HER2-amplified by FISH ineligible for targeted therapy with trastuzumab and without an effective targeted treatment option to prevent cancer recurrence. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently have two investigator-sponsored trials ongoing with NeuVax in combination with trastuzumab
(Herceptin; Genentech/Roche). The combination of trastuzumab and NeuVax has been shown pre-clinically and in a pilot study to be synergistic. Our Phase 2b trial is a multi-center, randomized, single-blinded, placebo-controlled trial in 275 HER2
1+/2+ breast cancer patients with positive nodes and/or TNBC. The study combines NeuVax and trastuzumab (Herceptin) in the adjuvant setting aiming to prevent recurrence or death. Tumors in these women show low levels of expression of HER2, as
measured by IHC, i.e., at a level of either 1+ or 2+ and, hence, these patients are not considered candidates for Herceptin. Patients who are hormone receptor-negative and HER2 1+/2+ by IHC are currently defined as TNBC patients. Eligible patients
are randomized to receive NeuVax + GM-CSF + trastuzumab or trastuzumab + GM-CSF alone. The primary endpoint of the study is DFS. Genentech/Roche is providing the trastuzumab and partial funding for this trial. Data presented in October 2016
demonstrated that this novel combination of trastuzumab and NeuVax with HER2 low-expressing patients is well tolerated and the cardiac effects of trastuzumab are not impacted by the addition of NeuVax. In February 2017, the DSMB reported that there
were no safety concerns with the trial and the trial is not futile. The recommendation from the DSMB was to continue the trial with one revision to the statistical analysis plan regarding the timing of the pre-specified interim analysis. Given the
lengthy duration of enrollment for the trial, the DSMB determined that the pre-specified interim efficacy analysis be moved up from 12 months to 6 months after the last patient is enrolled. Enrollment was completed and the interim efficacy analysis
occurred in late March 2018, as reported by us in a press release dated April 2, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The interim efficacy analysis, conducted by an independent DSMB of
the efficacy and safety data for the study in an overall population of 275 patients as well as the two primary study target patient populations (node-positive and TNBC) after a median follow-up of 19 months, demonstrated a clinically meaningful
difference in median DFS in favor of the active arm (NeuVax + Herceptin), a primary endpoint of the study, with hazard ratios of 0.67 and 0.61 in the intent to treat and modified intent to treat populations (i.e., those who received at least one
dose of vaccine or control) as well as a 34.9% and 39.5% reduction in relative risk of recurrence in the active versus control arms in the intent to treat and modified intent to treat populations, respectively. A clinically meaningful and also
statistically significant difference was found between the two arms in the cohort of patients (n= 98) with TNBC, with a hazard ratio of 0.26 and a p-value of 0.023 in favor of the NeuVax + Herceptin combination. Similarly, a clinically meaningful
and statistically significant difference was found between the two arms in favor of the combination in the cohort of patients not receiving hormonal therapy (n = 110), with a hazard ratio of 0.24 and a p-value of 0.009. This pre-specified interim
analysis also showed an adverse event profile with no notable differences between treatment arms. This analysis confirmed the 2016 data showing that the addition of NeuVax to Herceptin did not result in any additional cardiotoxicity compared to
Herceptin alone. Based on these results, and the DSMB&#146;s recommendation, we plan to expeditiously seek regulatory guidance by the FDA for further development of the combination of NeuVax + Herceptin in TNBC, considering the statistically
significant benefit of the combination therapy seen in this population with large unmet medical need. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our second combination investigator sponsored trial is a Phase 2 in HER2 3+ breast cancer patients who have
completed neoadjuvant therapy with an approved regimen that includes trastuzumab and failed to achieve a pathological complete response, meaning they have microscopic evidence of residual disease and are therefore at an increased risk of disease
recurrence. This multi-center, prospective, randomized, single-blinded Phase 2 clinical trial is enrolled with approximately 100&nbsp;patients with a diagnosis of HER2 3+ breast cancer who are HLA A2+ or HLA A3+ and are determined to be at high-risk
for recurrence. High-risk is defined as having received neoadjuvant therapy with an approved regimen that includes trastuzumab but not obtaining a pathological complete response at surgery, or those who undergo surgery as a first intervention and
are found to be pathologically node-positive. These high-risk patients are known to have higher recurrence rates than other HER2 3+ breast cancer patients. Eligible patients will be randomized to receive NeuVax +
<FONT STYLE="white-space:nowrap">GM-CSF</FONT> + trastuzumab or trastuzumab + <FONT STYLE="white-space:nowrap">GM-CSF</FONT> alone. The primary endpoint of the study is disease-free survival. Funding for this trial was awarded through the
Congressionally Directed Medical Research Program, funded through the Department of Defense, via a breast cancer research program breakthrough award. In February 2017, the DSMB reported that there were no safety concerns with the trial and the trial
is not futile. The <FONT STYLE="white-space:nowrap">pre-specified</FONT> interim safety analysis was also completed on n=50 patients and demonstrated that the agent is well tolerated with no&nbsp;increased cardiotoxicity associated with giving
NeuVax in combination with trastuzumab. The recommendation from the DSMB was to continue the HER2 3+ trial unmodified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Phase 3 PRESENT
(<B>P</B>revention of <B>R</B>ecurrence in <B>E</B>arly- <B>S</B>tage, Node- Positive Breast Cancer with Low to Intermediate HER2 <B>E</B>xpression with <B>N</B>euVax<B> T</B>reatment) study enrolled 758 HER2&nbsp;1+/2+ patients who are
node-positive and HLA A2 or A3 positive. On June&nbsp;27, 2016, the independent data monitoring committee recommended that the Phase 3 PRESENT clinical trial be stopped for futility. The PRESENT trial was stopped, and we initiated an investigation
into the causes of the recommendation. Our analysis of the data showed that there was a separation of the curves, albeit not statistically significant, with the control arm performing better than expected and the NeuVax arm performing consistent
with our protocol assumptions for the control group. Because the study was deemed futile, we closed the PRESENT trial. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>NeuVax for Ductal Carcinoma In
Situ of the Breast </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DCIS is defined by the NCI as a noninvasive condition in which abnormal cells are found in the lining of a breast duct and have not
spread outside the duct to other tissues in the breast. DCIS is the most common type of breast neoplasm with malignant potential. In some cases, DCIS may become invasive cancer and spread to other tissues, and at this time, there is no way to know
which lesions could become invasive. Current treatment options for DCIS include breast-conserving surgery and radiation therapy with or without tamoxifen, breast-conserving surgery without radiation therapy, or total mastectomy with or without
tamoxifen. According to the American Cancer Society, in the United States, there were over 60,000 diagnoses of DCIS in 2015. We are supporting an independent investigator-sponsored, or IST, Phase 2 trial to evaluate women diagnosed with DCIS who are
<FONT STYLE="white-space:nowrap">HLA-A2</FONT> positive, who express HER2 at IHC 1+, 2+, or 3+ levels, and who are pre or post menopausal. Patients will be randomized to one of two arms: NeuVax plus <FONT STYLE="white-space:nowrap">GM-CSF</FONT> or <FONT
STYLE="white-space:nowrap">GM-CSF</FONT> alone. The clinical study name is VADIS: Phase 2 Trial of Nelipepimut-S <B>Va</B>ccine in Women with <B>D</B>C<B>IS</B> of the Breast. The trial is sponsored and operationalized by the NCI, studying
NeuVax&#146;s potential clinical effects in earlier stage disease. The trial has an immunological endpoint evaluating NeuVax peptide-specific cytotoxic T lymphocyte (CTL; CD8+ <FONT STYLE="white-space:nowrap">T-cell)</FONT> response in vaccinated
patients. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>NeuVax for Gastric Cancer </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">According to
the NCI, gastric (stomach) cancer is a disease in which malignant (cancer) cells form in the lining of the stomach. Almost all gastric cancers are adenocarcinomas (cancers that begin in cells that make and release mucus and other fluids). Other
types of gastric cancer are gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, and lymphomas. Infection with bacteria called Helicobacter pylori is thought to be the cause of gastric cancer and age, diet, and stomach disease can
affect the risk of developing gastric cancer. Gastric cancer is often diagnosed at an advanced stage because there are no early signs or symptoms and is the second-most common cancer among males and third-most common among females in Asia and
worldwide with over 63,000 new cases a year in India, where an initial clinical trial of NeuVax is planned. Overexpression of the HER2 receptor occurs in approximately 20% of gastric and gastro-esophageal junction adenocarcinomas, predominantly
those of the intestinal type. Overall, without regard to the stage of cancer, only approximately 28% of patients with stomach cancer live at least five years following diagnosis and new adjuvant treatments are needed to prevent disease recurrence.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently have an agreement with Dr.&nbsp;Reddy&#146;s Laboratories Ltd., or Dr.&nbsp;Reddy&#146;s, to conduct a Phase 2 independent
investigator-sponsored study in gastric cancer in India. To date, Dr.&nbsp;Reddy&#146;s has not initiated the Phase 2 study with NeuVax. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">GALE-301</FONT> and <FONT STYLE="white-space:nowrap">GALE-302</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">GALE-301</FONT> and <FONT STYLE="white-space:nowrap">GALE-302</FONT> are cancer immunotherapies that target FBP
receptor-alpha. FBP is a well-validated therapeutic target that is highly over-express in ovarian, endometrial and breast cancers, and is the source of immunogenic peptides that can stimulate CTLs to recognize and destroy <FONT
STYLE="white-space:nowrap">FBP-expressing</FONT> cancer cells. Current treatments after surgery for these diseases are principally with platinum-based chemotherapeutic agents. These patients suffer a high recurrence rate and most relapse with an
extremely poor prognosis. <FONT STYLE="white-space:nowrap">GALE-301</FONT> and <FONT STYLE="white-space:nowrap">GALE-302</FONT> are immunogenic peptides that consist of a peptide derived from FBP combined with
<FONT STYLE="white-space:nowrap">GM-CSF</FONT> for the prevention of cancer recurrence in the adjuvant setting. <FONT STYLE="white-space:nowrap">GALE-301</FONT> is the E39 peptide, while <FONT STYLE="white-space:nowrap">GALE-302</FONT> is an
attenuated version of this peptide, known as E39&#146;. Two early stage clinical trials have been completed with our FBP peptides in ovarian, endometrial, and breast cancers. In June 2016, the FDA granted two Orphan Drug Product Designations for the
treatment (including prevention of recurrence) of ovarian cancer: One for <FONT STYLE="white-space:nowrap">GALE-301</FONT> (E39) and one for <FONT STYLE="white-space:nowrap">GALE-302</FONT> (E39&#146;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">GALE-301</FONT> and <FONT STYLE="white-space:nowrap">GALE-302</FONT> in Ovarian Cancer </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">According to the NCI&#146;s Surveillance, Epidemiology, and End Results, or SEER Program, new cases of ovarian cancer occur at an annual rate of 11.9&nbsp;per
100,000 women in the United States, with an estimated 22,280 new cases and 14,240 deaths in 2016. Only 46.2% of ovarian cancer patients are expected to survive five years after diagnosis. Approximately 1.3% of women will be diagnosed with ovarian
cancer at some point during their lifetime (2011-2013 data). The prevalence data from 2013 showed an estimated 195,767 women living with ovarian cancer in the United States. Due to the lack of specific symptoms, the majority of ovarian cancer
patients are diagnosed at later stages of the disease, with an estimated 80% of women presenting with advanced-stage (III or IV) disease. These patients have their tumors routinely surgically debulked to minimal residual disease, and then are
treated with platinum- and/or taxane-based chemotherapy. While many patients respond to this treatment regimen and become clinically <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">free-of-disease,</FONT></FONT> the majority of
these patients will relapse. Depending upon their level of residual disease, the risk for recurrence after completion of primary therapy is approximately 70%. Unfortunately, for these women, once the disease recurs, treatment options are limited and
the disease is most likely incurable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">GALE-401</FONT> (anagrelide controlled release) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">GALE-401</FONT> contains the active ingredient anagrelide, an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> product,
for the treatment of patients with MPNs to lower abnormally elevated platelet levels. The currently available immediate release, or IR, version of anagrelide causes adverse events that are believed to be dose and plasma concentration dependent and
may limit the use of the IR version of the drug. Therefore, reducing the maximum concentration, or C max, and increasing the half-life of the drug is hypothesized to reduce the side effects, while preserving the efficacy, potentially allowing a
broader use of the drug. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">GALE-401</FONT> in Essential Thrombocythemia </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ET is a myeloproliferative blood disorder and is characterized by the overproduction of platelets in the bone marrow. Elevated platelets alter the normal
process of blood coagulation and can lead to thromboembolic events. About a third of patients are asymptomatic at the time of diagnosis. However, many patients develop symptoms during the course of the disease that affect the quality of life. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Multiple Phase 1 studies in 98 healthy subjects have shown <FONT STYLE="white-space:nowrap">GALE-401</FONT> reduces the C max of anagrelide and increases the
half-life following oral administration, appears to be well tolerated at the doses administered, and to be capable of reducing platelet levels effectively. The Phase 1 program provided the desired PK/PD (pharmacokinetic/pharmacodynamic) profile to
enable the initiation of the Phase 2 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial. The Phase&nbsp;2, open label, single arm, proof-of concept trial enrolled 18 patients in the United States
for the treatment of thrombocytosis, or elevated platelet counts, in patients with MPNs. Final safety and efficacy data from this Phase 2 trial were presented in December 2015 and demonstrated a prolonged clinical benefit with a potentially improved
safety profile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have analyzed our data and the treatment landscape for MPNs, with a current focus on ET. Subject to completion of the manufacturing of
the new formulation and other internal work, <FONT STYLE="white-space:nowrap">GALE-401</FONT> would be poised to advance into a Phase 3 clinical trial in ET patients who are intolerant or resistant to hydroxyurea. This trial is designed to compare <FONT
STYLE="white-space:nowrap">GALE-401</FONT> (drug arm) versus best available therapy to include a sizable population of patients treated with anagrelide IR. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Strategic Collaborations and License Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we currently have a number of collaborations with corporate partners for the development of our product candidates in various territories worldwide,
the following development collaborations are those that are most significant to us from a financial statement perspective and where significant ongoing collaboration activity exists.<B> </B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exclusive License Agreement&#151;Memorial Sloan Kettering Cancer Center </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2014, we entered into a license agreement with MSK, under which we were granted an exclusive license to develop and commercialize MSK&#146;s WT1
peptide vaccine technology. The MSK original license agreement was first amended in October 2015, further amended in August&nbsp;2016, amended and restated in May 2017 and again amended and restated in October 2017. In connection with the entry of
the original license agreement and its amendments, MSK was issued or assigned an aggregate of 4,846 ordinary shares of Private SELLAS common stock for the year ended December&nbsp;31, 2017. These common stock shares were converted into our common
stock shares upon the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the current amended and restated MSK license agreement, we agreed to pay minimum royalty payments in the
amount of $0.1&nbsp;million each year commencing in 2015 and research funding costs of $0.2&nbsp;million in each year and for three years commencing in January 2016. We also agreed to pay MSK a <FONT STYLE="white-space:nowrap">mid-six</FONT> digit
amount over a one year period in exchange for MSK&#146;s agreement to further amend and restate the MSK license agreement in October 2017, which resulted in the grant of rights to additional intellectual property to us and extension/relaxing of
certain deadlines. In addition, to the extent certain development and commercial milestones are achieved, we also agreed to pay MSK up to $17.4 million in aggregate milestone payments for each licensed product, and for each additional patent
licensed product, up to $2.8&nbsp;million in additional milestone payments. We also agreed to pay MSK a tiered royalty in the <FONT STYLE="white-space:nowrap">mid-single</FONT> digits in the event of commercial sales of any licensed products. We
also agreed to raise $25.0&nbsp;million in gross proceeds no later than December&nbsp;31, 2018. In the event we do not raise such amount by December&nbsp;31, 2018, MSK may terminate the license agreement after complying with the notice and cure
periods of the agreement, or MSK may elect to receive additional common stock shares in an amount equal to 1.5% of our then fully diluted share capital, which would stay the right to terminate for a period of time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless terminated earlier in accordance with its terms, the MSK license agreement as amended and restated, will continue on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product basis, until the later, of:
(a)&nbsp;expiration of the last valid claim embracing such licensed product; (b)&nbsp;expiration of any market exclusivity period granted by law with respect to such licensed product; or (c)&nbsp;ten (10) years from the first commercial sale in such
country. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Merck&nbsp;&amp; Co., Inc. Clinical Trial Collaboration and Supply Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2017, we entered into a clinical trial collaboration and supply agreement through a Merck subsidiary, whereby we agreed with the Merck subsidiary
to collaborate on a research program to evaluate GPS as it is administered in combination with their PD1 blocker pembrolizumab (Keytruda) in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including both hematologic
malignancies and solid tumors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Phase 1/2 clinical trial will utilize a combination of GPS plus pembrolizumab (Keytruda) in patients with WT1+
relapsed or refractory tumors. Specifically, the study is expected to explore the following cancer indications: colorectal (arm enriched in but not exclusive to patients with microsatellite <FONT STYLE="white-space:nowrap">instability-low),</FONT>
ovarian, small cell lung, triple-negative breast, and AML. This study will assess the efficacy and safety of the combination, comparing overall response rates and immune response markers achieved with the combination compared to prespecified rates
based on those seen with pemrolizumab alone in comparable patient populations. The trial is anticipated to begin in the third quarter of 2018 (pending funding availability). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Advaxis, Inc. Research and Development Collaboration Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2017, we entered into a research and development collaboration agreement with Advaxis whereby we agreed to collaborate on a research program to
evaluate, through a PoP trial, a clinical candidate comprised of the combination of Advaxis&#146; proprietary <FONT STYLE="white-space:nowrap">Lm-based</FONT> antigen delivery technology and GPS. Unless terminated earlier in accordance with its
terms, the Advaxis agreement will expire upon the earlier of: (a)&nbsp;completion of the PoP trial or (b)&nbsp;a decision by the parties to cease further development of the clinical candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Advaxis agreement provides for cost-sharing between the parties, with Advaxis being responsible for the costs of performing the research activities and
filing any investigational new drug, or IND, cost-sharing for preparation of the IND, and we being responsible for the costs (exclusive of product costs) of conducting the PoP trial. We also agreed to make certain
<FONT STYLE="white-space:nowrap">non-refundable</FONT> milestone payments to Advaxis having an aggregate amount of up to $108.0&nbsp;million, upon meeting certain clinical, regulatory and commercial milestones. In addition, if net sales exceed
certain targets, we agreed to make <FONT STYLE="white-space:nowrap">non-refundable</FONT> sales milestone payments up to $250.0 million and royalty payments based on specific royalty rates, with a maximum rate capped at a percentage rate in the low
teens if net sales exceed $1.0&nbsp;billion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The University of Texas M. D. Anderson Cancer Center and The Henry M. Jackson Foundation for the
Advancement of Military Medicine, Inc. License Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2006, we acquired rights and assumed obligations under a license agreement
between Apthera and The University Texas M.D. Anderson Cancer Center, or MDACC, and The Henry M. Jackson Foundation, or HJF, which granted us exclusive worldwide rights to an United States patent covering the nelipepimut-S peptide and several United
States and foreign patents and patent applications covering methods of using the peptide as a vaccine. Under the terms of this license, we are required to pay an annual maintenance fee, clinical milestone payments and royalty payments based on sales
of NeuVax, or other therapeutic products developed from the licensed technologies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Biovascular, Inc. Exclusive License Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2013, we acquired worldwide rights to anagrelide controlled release, or CR, formulation, <FONT STYLE="white-space:nowrap">GALE-401,</FONT> through
our acquisition of Mills, LLC, or Mills our wholly owned subsidiary, <FONT STYLE="white-space:nowrap">GALE-401</FONT> contains the active ingredient anagrelide, an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> product that has been in use
since the late 1990s for the treatment of MPNs. Mills entered into an exclusive license agreement with BioVascular, Inc., or BioVascular. The license agreement granted us an exclusive license to develop and commercialize anagrelide CR formulation.
Under the terms of the license agreement and its amendments, Mills agreed to pay BioVascular, a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mid-to-low</FONT></FONT> single digit royalty on net revenue from the sale of licensed
products, as well as, future cash milestone payments based on the achievement of specified regulatory milestones. We are responsible for patent prosecution and maintenance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2017, Mills and BioVascular entered into an amendment to our exclusive license agreement to modify the certain terms of the license agreement,
including but not limited to, (i) eliminating the 3% royalty rate on annual net sales of $50.0 million and the 4% royalty now applies to annual net sales of up to $100.0 million, (ii) making an advance payment of approximately $0.4 million for the
milestone related to the initiation of the Phase 3 clinical trial payable in two tranches with the first payment of $0.2 million payable on or before October 31, 2017 and the second payment of approximately $0.2 million payable 30 days after the
consummation of the Merger but no later than December 31, 2017, (iii) adding a payment for a sublicense by Mills to a third party of 25% of any cash received for upfront fees or milestone payments if the sublicense is executed prior to first patient
enrolled in the Phase 3 clinical trial and 17.5% of any cash received for upfront fees or milestone payments if the sublicense is executed after the first patient is enrolled in the Phase 3 clinical trial, and (iv) if the first patient is not
enrolled in the Phase 3 clinical trial by December 31, 2018, BioVascular shall have the right to terminate the license agreement and the advance payment shall not be repaid to Mills. Under the terms of a September 2017 consent between Comerica Bank,
BioVascular and Mills, Comerica Bank shall receive $0.1 million of the approximately $0.4 million advance payment from Mills. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not own or operate manufacturing facilities for the production of our product candidates nor do we have plans to develop our own manufacturing operations
in the foreseeable future. We currently depend on third-party contract manufacturers for all of our required raw materials, active pharmaceutical ingredients, and finished product candidate for our clinical trials. We do not have any current
contractual arrangements for the manufacture of commercial supplies of any product candidates. We currently employ internal resources and third-party consultants to manage our manufacturing contractors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sales and Marketing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not yet defined our sales,
marketing or product distribution strategy for our product candidates or any future product candidates because they are still in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> or clinical development. Our future commercial strategy may include
the use of strategic partners, distributors, a contract sale force, or the establishment of our own commercial and specialty sales force, as well as similar strategies for regions and territories outside the United States. We plan to further
evaluate these alternatives as we approach approval for the use of our product candidates for one or more indications. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part on our ability to avoid infringing the proprietary rights of third parties, our ability to obtain and maintain
proprietary protection for our technologies where applicable and to prevent others from infringing our proprietary rights. We seek to protect our proprietary technologies by, among other methods, evaluating relevant patents, establishing defensive
positions, monitoring European Union oppositions and pending intellectual property rights, preparing litigation strategies in view of the United States legislative framework and filing United States and international patent applications on
technologies, inventions and improvements that are important to our business. Patents and other intellectual property rights are crucial to our success. It is our policy to protect our intellectual property rights through available means, including
filing and prosecuting patent applications in the United States and other countries, protecting trade secrets, and utilizing regulatory protections such as data exclusivity. We also include restrictions regarding use and disclosure of our
proprietary information in our contracts with third parties, and utilize customary confidentiality agreements with our employees, consultants, clinical investigators and scientific advisors to protect our confidential information and <FONT
STYLE="white-space:nowrap">know-how.</FONT> Together with our licensors, we also rely on trade secrets to protect our combined technology especially where we do not believe patent protection is appropriate or obtainable. It is our policy to operate
without knowingly infringing on, or misappropriating, the proprietary rights of others. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An international patent law treaty, or PCT, provides a unified
procedure for filing patent applications to protect inventions in each of its contracting states. Thus, a single PCT application can be converted into a national stage patent application in any of the more than 145 PCT contracting states, and is
considered a simple, cost-effective means for seeking patent protection in numerous regions or countries. This nationalization (converting into an application in any of the contracting states) typically occurs 18 months after the PCT application
filing date. We also rely on trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> and continuing technological innovation to develop and maintain our proprietary position. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term of individual patents depends upon the legal term of the patents in countries in which they are obtained. In most countries, including the United
States, the patent term is generally 20 years from the earliest date of filing a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application in the applicable country. In the United States, a patent&#146;s term may, in certain cases,
be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the United States Patent and Trademark Office in examining and granting a patent or may be shortened if a patent is terminally disclaimed over a
commonly owned patent or a patent naming a common inventor and having an earlier expiration date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following chart summarizes our intellectual property rights: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Product<BR>Candidate</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Product Candidate<BR>Component</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Jurisdiction</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Indication</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Claims</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Scope</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Latest&nbsp;Estimated</B><br><B>Patent&nbsp;Exclusivity</B><br><B>Period</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GPS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Peptide <FONT STYLE="white-space:nowrap">WT1-A1</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Any</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Composition&nbsp;of Matter</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">1&nbsp;issued</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">03/22/2026*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GPS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Peptide <FONT STYLE="white-space:nowrap">WT1-A1</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Australia, Switzerland, Germany,&nbsp;Spain, France,&nbsp;Great Britain,&nbsp;Italy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Any</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Composition of Matter</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8 issued</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11/30/2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GPS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Peptide <FONT STYLE="white-space:nowrap">WT1-A1</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Canada</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Any</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Composition of Matter&nbsp;and&nbsp;Method of Use</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">1 issued</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11/30/2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GPS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Peptides <FONT STYLE="white-space:nowrap">WT1-427</FONT> long and <FONT STYLE="white-space:nowrap">WT1-331</FONT> long</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">United States</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Any</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Composition of Matter</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">1 issued</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10/26/2031*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GPS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Peptides <FONT STYLE="white-space:nowrap">WT1-427</FONT> long and <FONT STYLE="white-space:nowrap">WT1-331</FONT> long</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">United States</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">WT1-expressing</FONT> cancer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Method of Use</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">1 issued</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10/17/2026</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GPS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">Peptides&nbsp;WT1-427&nbsp;long</FONT> and <FONT STYLE="white-space:nowrap">WT1-331</FONT> long</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">United States</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Any</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Composition of Matter and Method of Use</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">1 pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10/17/2026**</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GPS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">Peptide&nbsp;WT1-427&nbsp;long</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Australia, Switzerland, Germany,&nbsp;Spain, France, Great Britain, Ireland, Italy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Any</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Composition of Matter and Method of Use</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">9 issued</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10/17/2026</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GPS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Peptide <FONT STYLE="white-space:nowrap">WT1-331</FONT> long</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Switzerland, Germany,&nbsp;Spain, France, Great Britain, Ireland, Italy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Any</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Composition of Matter and Method of Use</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8 issued</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10/17/2026</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GPS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Peptide <FONT STYLE="white-space:nowrap">WT1-427</FONT> long</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Canada</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Any</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Composition of Matter and Method of Use</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">1 issued</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10/17/2026</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GPS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Peptides <FONT STYLE="white-space:nowrap">WT1-427</FONT> long and <FONT STYLE="white-space:nowrap">WT1-331</FONT> long</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Canada</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Any</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Composition of Matter and Method of Use</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">1&nbsp;pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10/17/2026**</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GPS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">Non-product</FONT> peptide</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">United States</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Any</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Composition of Matter</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">1 issued</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">12/21/2026</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GPS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">Peptide&nbsp;WT1-122A1&nbsp;long</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">United States</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Any</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Composition of Matter</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">1 issued</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">02/20/2033*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GPS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Peptide <FONT STYLE="white-space:nowrap">WT1-122A1</FONT> long</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">United States</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Any</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Composition of Matter and Method of Use</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">1 pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">04/10/2027**</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GPS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Peptide <FONT STYLE="white-space:nowrap">WT1-122A1</FONT> long</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Austria, Belgium, Switzerland, Germany, Spain, Finland, France, Great Britain, Greece, Ireland, Italy, Netherlands, Poland, Romania, Turkey</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Any</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Composition of Matter and Method of Use</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">15&nbsp;issued</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">04/10/2027</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GPS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Peptide <FONT STYLE="white-space:nowrap">WT1-122A1</FONT> long</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Europe, Canada, Hong Kong</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Any</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Composition of Matter and Method of Use</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3 pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">04/10/2027</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Not&nbsp;applicable</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">Non-product</FONT> peptide</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">United States</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Any</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Composition of Matter and Method of Use</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">1 issued, 1 pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">01/15/2034</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Not applicable</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">Non-product</FONT> peptide</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Australia, Canada, China, Europe, Japan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Any</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Composition of Matter and Method of Use</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5 pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">01/15/2034**</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Product<BR>Candidate</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Product<BR>Candidate<BR>Component</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Jurisdiction</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Indication</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Claims</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Scope</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Latest Estimated</B><br><B>Patent<BR>Exclusivity</B><br><B>Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Not applicable</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Not&nbsp;applicable</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">United States</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Any</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Composition of Matter and Method of Use</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">1 pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">06/30/2038***</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">NeuVax&#153; (nelipepimut-S)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States, Australia, Canada, China, Europe, Hong Kong, Japan, Korea and Mexico</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Recurrence&nbsp;of cancers expressing low to intermediate levels of HER2/neu</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Methods of Use</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">6&nbsp;pending and 10 issued</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">NeuVax&#153; in combination with trastuzumab</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States and Australia</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">HER2/neu expressing cancer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Methods of Use</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2 issued</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">GALE-401</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Vaso-occlusive</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Method of Use</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">1 issued</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">GALE-401</FONT> (Anagrelide Controlled Release)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States, Europe, India, Japan and UK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Platelet Lowering</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Anagrelide Controlled&nbsp;Release Formulations&nbsp;&amp; Methods of Use</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4 pending and 7 issued</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">GALE-301</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States and PCT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Cancers expressing low levels of FBP (IHC 0 or 1+)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Dosage Regimen</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2 pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">GALE-301</FONT> &amp; <FONT STYLE="white-space:nowrap">GALE-302</FONT> Combination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States, Canada, Europe, and Japan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Cancers expressing Folate Binding Protein (FBP)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Compositions&nbsp;&amp; Methods of Use</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">1 pending and 8 issued</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">GALE-301</FONT> &amp; <FONT STYLE="white-space:nowrap">GALE-302</FONT> Combination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Cancers expressing Folate Binding Protein (FBP)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Combination Dosage Regimen</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">1 allowed</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Includes patent term adjustment </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top">Projected expiration date of pending application, if granted </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Projected expiration date of <FONT STYLE="white-space:nowrap">non-provisional</FONT> application to be filed from provisional application </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of the above-referenced pending or issued patents has been licensed by us. To our knowledge, there are no contested proceedings or third-party claims
relating to any of the above pending or issued patents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cancer immunotherapy has become a significant growth area for the biopharmaceutical industry, attracting large pharmaceutical companies as well as small niche
players. Generally, our principal competitors in the cancer immunotherapy market comprise both companies with currently approved products for various indications, such as manufactures of approved bispecific antibodies,
<FONT STYLE="white-space:nowrap">CAR-T</FONT> cells, and checkpoint inhibitors, as well as companies currently engaged in cancer immunotherapy clinical development. The large and <FONT STYLE="white-space:nowrap">medium-size</FONT> players who have
successfully obtained approval for cancer immunotherapy products include Bristol-Myers Squib Company, Merck&nbsp;&amp; Co., Inc., Genentech, Inc. (a subsidiary of Roche Holding AG), AstraZeneca PLC, Celgene Corporation, Johnson&nbsp;&amp;
Johnson/Janssen Pharmaceuticals, Amgen, Novartis, Acerta Pharmaceuticals, Juno Therapeutics, Inc., Kite Pharm, Inc., a wholly-owned subsidiary of Gilead Sicencies, Inc. and Pfizer, Inc./EMD Serono, Inc. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Companies developing novel products with similar indications to those we are pursuing are expected to influence
our ability to penetrate and maintain market share. Principal competitors for our AML indication include both companies with currently approved products in AML, such as Agios Pharmaceuticals, Inc. (the holder of U.S. rights to Idhifa), Novartis AG
(the holder of rights to Rydapt), among others, as well as those with front-line chemotherapy drugs and maintenance therapies such as Jazz Pharmaceuticals plc (the holder of rights to Vyxeos), as well as Pfizer (the holder of rights to Mylotarg),
among others, as well as companies with drugs currently in development in AML. Our principal competitors for the MPM indication include both companies with currently approved products in MPM, such as Eli Lilly and Co. (the holder of rights to
Alimta), among others, as well as those with drugs currently in development in MPM. Our principal competitor for ET patients who are intolerant or resistant to hydroxyurea indication is Incyte Corporation in the United States (the holder of rights
for Jakafi) and Novartis outside the United States (the holder of rights for JAKAVI). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For patients with MPNs, current treatment options include Agrylin
(anagrelide hydrochloride) and its generic equivalents, hydorxyurea and interferon alpha. Agents currently being studied in patients with MPNs include investigational JAK2 inhibitors (e.g., LY2784544 (Eli Lilly), momelotinib (Gilead Sciences),
ruxolitinib (Incyte), fedratinib (Impact Biomedicines/Celgene) and pegylated interferon <FONT STYLE="white-space:nowrap">alfa-2a</FONT> (Pegasys, Genentech/Roche). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For patients with early stage breast cancer, adjuvant therapy is often given to prevent recurrence and increase the chance of long-term disease free survival.
Adjuvant therapy for breast cancer can include chemotherapy, hormonal therapy, radiation therapy, or combinations thereof. In addition, the HER2 targeted drug trastuzumab (Herceptin) &#150; alone or in combination with pertuzumab (Perjeta), both
manufactured and marketed by Roche/Genentech- may be given to patients with tumors with high expression of HER2 (IHC 3+), as well as other novel targets such as MUC1 which may be useful in treating breast cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are a number of cancer vaccines in development for breast cancer, including but not limited to Lapuleucel-T (Dendreon),
<FONT STYLE="white-space:nowrap">AE-37</FONT> (Antigen Express), and Stimuvax (Merck KgA). While these development candidates are aimed at a number of different targets, and <FONT STYLE="white-space:nowrap">AE-37</FONT> has published data in the
HER2 breast cancer patient population, there is no guarantee that any of the these compounds will not in the future be indicated for treatment of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">low-to-intermediate</FONT></FONT>
HER2 breast cancer patients and become directly competitive with NeuVax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A number of chemotherapeutic agents have demonstrated activity in gynecological
carcinomas (ovarian and endometrial), particularly platinum-based regimens. New chemotherapy agents are being evaluated including trabectedin (Yondelis) and belotecan, as well as targeted agents such as bevacizumab (Avastin) and pazopanib
(Votrient). Monoclonal antibodies are also being developed including farletuzumab and catumaxomab. We are not aware of any of these agents being evaluated in the adjuvant setting where <FONT STYLE="white-space:nowrap">GALE-301</FONT> is being
considered for further development. TPIV200 (TapImmune) is in development targeting FBP in ovarian cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of our competitors, either alone or with
their strategic partners, have substantially greater financial, technical and human resources than we do, and experience in obtaining FDA and other regulatory approvals of treatments and commercializing those treatments. Accordingly, our competitors
may be more successful than us in obtaining approval for cancer immunotherapy products and achieving widespread market acceptance. Our competitors&#146; treatments may be more effectively marketed and sold than any products we may commercialize,
thus causing limited market share before we can recover the expenses of developing and commercializing of our cancer immunotherapy product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of our
competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These activities may lead to consolidated efforts that allow for more
rapid development of cancer immunotherapy product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These competitors also compete with us in recruiting and retaining qualified scientific and
management personnel, the ability to work with specific clinical contract organizations due to conflict of interest, and also the conduct of trials in the ability to recruit clinical trial sites and subjects for our clinical trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect any products that we develop and commercialize to compete on the basis of, among other things,
efficacy, safety, price and the availability of reimbursement from government and other third-party payors. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are viewed as safer,
more convenient or less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for our current product candidates or any other
future product candidate, which could result in our competitors establishing a strong market position before we are able to enter the market. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA and other regulatory
authorities at federal, state, and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging,
storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring, and post-approval reporting of biologics such as those we are developing. Along with third-party contractors, we will be required to
navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of its current or future product candidates. The
process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local, and foreign statutes and regulations require the expenditure of substantial time and financial resources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The process required by the FDA before biologic product candidates may be marketed in the United States generally involves the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#146;s current Good Laboratory Practices, or GLP, regulation; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when significant changes are made; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approval by an independent Institutional Review Board, or IRB, or ethics committee at each clinical site before the trial is begun; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">performance of adequate and well-controlled human clinical trials to establish the safety, purity and potency of the proposed biologic product candidate for its intended purpose; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">preparation of and submission to the FDA of a Biologics License Application, or BLA, after completion of all pivotal clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">satisfactory completion of an FDA Advisory Committee review, if applicable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">satisfactory completion of an FDA <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with current
Good Manufacturing Practices, or cGMP, and to assure that the facilities, methods and controls are adequate to preserve the biological product&#146;s continued safety, purity and potency, and of selected clinical investigations to assess compliance
with current Good Clinical Practices, or cGCP; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">FDA review and approval of the BLA to permit commercial marketing of the product for particular indications for use in the United States, which must be updated annually when significant changes are made.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The testing and approval process requires substantial time, effort and financial resources, and, or cGCP, we cannot be certain that any
approvals for our current or future product candidates will be granted on a timely basis, if at all. Prior to beginning the first clinical trial with a product candidate, we must submit an IND to the FDA. An IND is a request for authorization from
the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
investigational plan and the protocol(s) for clinical studies. The IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology, and
pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical
trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the <FONT STYLE="white-space:nowrap">30-day</FONT> time period, raises safety concerns or questions about the proposed clinical trial.
In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization
to begin a clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified
investigators in accordance with cGCP, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other
things, the objectives of the clinical trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during
product development and for any subsequent protocol amendments. Furthermore, an IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial
begins at that site and must monitor the clinical trial until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an
unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical trial sponsor, known as DSMB, which provides
authorization for whether or not a clinical trial may move forward at designated check points based on access to certain data from the clinical trial and may halt the clinical trial if it determines that there is an unacceptable safety risk for
subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical trial results to public registries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Phase 1</B>&#151;The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance,
absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Phase 2</B>&#151;The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to
identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Phase 3</B>&#151;The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for
safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Phase 4</B>&#151;In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These <FONT
STYLE="white-space:nowrap">so-called</FONT> Phase 4 studies may be made a condition to approval of the BLA. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Phase 1, Phase 2 and Phase 3
testing may not be completed successfully within a specified period, if at all, and there can be no assurance that the data collected will support FDA approval or licensure of the product. Concurrent with clinical trials, companies may complete
additional animal studies and develop additional information about the biological characteristics of the product candidate and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The
manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the
safety, purity and potency. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>BLA Submission and Review by the FDA </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development,
nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical and clinical
studies, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#146;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from
company-sponsored clinical studies intended to test the safety and effectiveness of a use of the product, or from a number of alternative sources, including studies initiated by investigators. The submission of a BLA requires payment of a
substantial user fee to FDA, and the sponsor of an approved BLA is also subject to annual product and establishment user fees. These fees are typically increased annually. A waiver of user fees may be obtained under certain limited circumstances.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once a BLA has been submitted, the FDA&#146;s goal is to review the application within ten months after it accepts the application for filing, or, if the
application relates to an unmet medical need in a serious or life-threatening indication, six months after the FDA accepts the application for filing. The review process is often significantly extended by FDA requests for additional information or
clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed, or held meets standards designed to assure the product&#146;s
continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is
manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required
specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with cGCP. If the FDA determines that the application, manufacturing process or manufacturing facilities are not
acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does
not satisfy the regulatory criteria for approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The testing and approval process requires substantial time, effort and financial resources, and each
may take several years to complete. The FDA may not grant approval on a timely basis, or at all, and we may encounter difficulties or unanticipated costs in its efforts to secure necessary governmental approvals, which could delay or preclude us
from marketing its products. After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response
Letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application
is not ready for approval. A Complete Response Letter may request additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information
and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If regulatory approval of a product is granted, such
approval may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a Risk Evaluation and Mitigation Strategy, or REMS, plan to mitigate risks, which could include medication
guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed
labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with <FONT STYLE="white-space:nowrap">pre-</FONT> and post-marketing regulatory standards is not maintained
or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#146;s safety and effectiveness after commercialization and may
limit further marketing of the product based on the results of these post-marketing studies. In addition, new government requirements, including those resulting from new legislation, may be established, or the FDA&#146;s policies may change, which
could delay or prevent regulatory approval of our products under development. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A sponsor may seek approval of its product candidate under programs designed to accelerate FDA&#146;s review and
approval of new drugs and biological products that meet certain criteria. Specifically, new drugs and biological products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition and demonstrate
the potential to address unmet medical needs for the condition. For a product candidate with Fast Track designation, the FDA may consider sections of the BLA for review on a rolling basis before the complete application is submitted if relevant
criteria are met. A Fast Track designated product candidate may also qualify for priority review, under which the FDA sets the target date for FDA action on the BLA at six months after the FDA accepts the application for filing. Priority review is
granted when there is evidence that the proposed product would be a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious condition. If criteria are not met for priority review, the
application is subject to the standard FDA review period of 10 months after FDA accepts the application for filing. Priority review designation does not change the scientific/medical standard for approval or the quality of evidence necessary to
support approval. We have obtained Fast Track designation for GPS in AML, MPM, and NeuVax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Accelerated Approval program, the FDA may approve a
BLA on the basis of either a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on
irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Post-marketing studies or completion of ongoing studies
after marketing approval are generally required to verify the biologic&#146;s clinical benefit in relationship to the surrogate endpoint or ultimate outcome in relationship to the clinical benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, a sponsor may seek FDA designation of its product candidate as a Breakthrough Therapy, if the product candidate is intended, alone or in
combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or
more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. If the FDA designates a breakthrough therapy, it may take actions appropriate to expedite the development and review of the
application. Breakthrough designation also allows the sponsor to file sections of the BLA for review on a rolling basis. we plan to seek designation as a breakthrough therapy for GPS in one or more indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fast Track, Priority Review and Breakthrough Therapy designations do not change the standards for approval but may expedite the development or approval
process. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Orphan Drugs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug
Act, the FDA may grant Orphan Drug Product Designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 individuals in the United States, or a
patient population greater than 200,000 individuals in the United States and when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the
United States for that drug or biologic. Orphan Drug Product Designation must be requested before submitting a BLA. After the FDA grants Orphan Drug Product Designation, the generic identity of the therapeutic agent and its potential orphan use are
disclosed publicly by the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a product that has Orphan Drug Product Designation subsequently receives the first FDA approval for a particular active
ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the same
indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the
availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for
the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of Orphan Drug Product Designation are tax credits for certain research and a waiver of the BLA application user fee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A drug with Orphan Drug Product Designation may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which
it received Orphan Drug Product Designation. In addition, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable
to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. We plan to seek Orphan Drug Product Designation for GPS in specific orphan indications in which there is a medically plausible basis for
the use of GPS for such indications, if applicable. We have obtained Orphan Drug Product Designation for GPS in AML and MPM and for <FONT STYLE="white-space:nowrap">GALE-301</FONT> and one for <FONT STYLE="white-space:nowrap">GALE-302.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Post-Approval Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other
things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as
adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well
as new application fees for supplemental applications with clinical data. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced
inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon our third-party manufacturers and us. Changes to the manufacturing process are strictly regulated, and,
depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party
manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. We cannot
be certain that we or our present or future suppliers will be able to comply with the cGMP regulations and other FDA regulatory requirements. If we or our present or future suppliers are not able to comply with these requirements, the FDA may, among
other things, halt our clinical trials, require us to recall a product from distribution, or withdraw approval of the BLA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely, and expect to
continue to rely, on third parties for the production of clinical quantities of our product candidates and we expect to rely in the future on third parties for the production of commercial quantities. Future FDA and state inspections may identify
compliance issues at the facilities of our contract manufacturers that may disrupt production, distribution, or require substantial resources to correct. In addition, discovery of previously unknown problems with a product or the failure to comply
with applicable requirements may result in restrictions on a product, manufacturer or holder of an approved BLA, including withdrawal or recall of the product from the market or other voluntary, <FONT STYLE="white-space:nowrap">FDA-initiated</FONT>
or judicial action that could delay or prohibit further marketing. The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of
previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add
new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other
things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fines, warning letters or holds on post-approval clinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product seizure or detention, or refusal to permit the import or export of products; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injunctions or the imposition of civil or criminal penalties. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make
only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the
promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties.
Physicians may prescribe legally available products for uses that are not described in the product&#146;s labeling and that differ from those tested by us and approved by the FDA. Such <FONT STYLE="white-space:nowrap">off-label</FONT> uses are
common across medical specialties. Physicians may believe that such <FONT STYLE="white-space:nowrap">off-label</FONT> uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in
their choice of treatments. The FDA does, however, restrict manufacturers&#146; communications on the subject of <FONT STYLE="white-space:nowrap">off-label</FONT> use of their products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Healthcare Laws and Compliance Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our sales, promotion, medical education and other activities following product approval will be subject to regulation by numerous regulatory and law
enforcement authorities in the United States in addition to FDA, including potentially the Federal Trade Commission, the Department of Justice, the Centers for Medicare and Medicaid Services, other divisions of the Department of Health and Human
Services and state and local governments. Our promotional and scientific/educational programs must comply with the federal Anti-Kickback Statute, the Foreign Corrupt Practices Act, the False Claims Act, or FCA, the Veterans Health Care Act,
physician payment transparency laws, privacy laws, security laws, and additional state laws similar to the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The federal Anti-Kickback Statute
prohibits, among other things, the offer, receipt, or payment of remuneration in exchange for or to induce the referral of patients or the use of products or services that would be paid for in whole or part by Medicare, Medicaid or other federal
health care programs. Remuneration has been broadly defined to include anything of value, including cash, improper discounts, and free or reduced price items and services. The government has enforced the Anti-Kickback Statute to reach large
settlements with healthcare companies based on sham research or consulting and other financial arrangements with physicians. Further, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have
committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. Many states have
similar laws that apply to their state health care programs as well as private payors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FCA, imposes liability on persons who, among other things,
present or cause to be presented false or fraudulent claims for payment by a federal health care program. The FCA has been used to prosecute persons submitting claims for payment that are inaccurate or fraudulent, that are for services not provided
as claimed, or for services that are not medically necessary. Actions under the FCA may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. Violations of the FCA can result in significant
monetary penalties and treble damages. The federal government is using the FCA, and the accompanying threat of significant liability, in its investigation and prosecution of pharmaceutical and biotechnology companies throughout the country, for
example, in connection with the promotion of products for unapproved uses and other sales and marketing practices. The government has obtained multi-million and multibillion dollar settlements under the FCA in addition to individual criminal
convictions under applicable criminal statutes. In addition, companies have been forced to implement extensive corrective action plans, and have often become subject to consent decrees or corporate integrity agreements, restricting the manner in
which they conduct their business. The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, also created federal criminal statutes that prohibit, among other things, knowingly and willfully executing a scheme to defraud any
healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of
or payment for healthcare benefits, items or services. Given the significant size of actual and potential settlements, it is expected that the government will continue to devote substantial resources to investigating healthcare providers&#146; and
manufacturers&#146; compliance with applicable fraud and abuse laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, there has been a recent trend of increased federal and state regulation of payments made to
physicians and other healthcare providers. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the Affordable Care Act, among other things, imposed new reporting
requirements on drug manufacturers for payments or other transfers of value made by them to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Failure to submit
required information may result in civil monetary penalties<B>. </B>Certain states also mandate implementation of commercial compliance programs, impose restrictions on drug manufacturer marketing practices and/or require the tracking and reporting
of gifts, compensation and other remuneration to physicians and other healthcare professionals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also be subject to data privacy and security
regulation by both the federal government and the states in which it conducts its business. HIPAA, as amended by the Health Information Technology and Clinical Health Act, or HITECH, and their respective implementing regulations, imposes specified
requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#146;s privacy and security standards directly applicable to &#147;business associates,&#148;
defined as independent contractors or agents of covered entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also increased the civil and
criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal
HIPAA laws and seek attorney&#146;s fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in certain circumstances, many of which differ from each other in
significant ways and may not have the same effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If our operations are found to be in violation of any of such laws or any other governmental
regulations that apply to it, we may be subject to penalties, including, without limitation, civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, exclusion from participation in federal and state
healthcare programs and imprisonment, any of which could adversely affect our ability to operate our business and our financial results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also, the U.S.
Foreign Corrupt Practices Act and similar worldwide anti-bribery laws generally prohibit companies and their intermediaries from making improper payments to foreign officials for the purpose of obtaining or retaining business. We cannot assure you
that our internal control policies and procedures will protect us from reckless or negligent acts committed by our employees, future distributors, partners, collaborators or agents. Violations of these laws, or allegations of such violations, could
result in fines, penalties or prosecution and have a negative impact on our business, results of operations and reputation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Coverage and
Reimbursement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of pharmaceutical products depend significantly on the availability of third-party coverage and reimbursement. Third-party
payors include government health administrative authorities, managed care providers, private health insurers and other organizations. Although we currently believe that third-party payors will provide coverage and reimbursement for our product
candidates, if approved, these third-party payors are increasingly challenging the price and examining the cost-effectiveness of medical products and services. In addition, significant uncertainty exists as to the reimbursement status of newly
approved healthcare products. We may need to conduct expensive clinical studies to demonstrate the comparative cost-effectiveness of its products. GPS for the indications that we develop may not be considered cost-effective. It is time consuming and
expensive for us to seek coverage and reimbursement from third-party payors. Moreover, a payor&#146;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Reimbursement may not be
available or sufficient to allow us to sell our products on a competitive and profitable basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare Reform </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare
system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of
containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
By way of example, in March 2010, the Affordable Care Act was signed into law, intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance
remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. Efforts to replace or repeal the
Affordable Care Act have been repeatedly made, and we cannot know how any legislation that may be passed to repeal or replace the Affordable Care Act will impact our business and potential future business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. These changes include aggregate reductions to
Medicare payments to providers of up to 2% per fiscal year, starting in 2013, which will remain in effect through 2024 unless additional congressional action is taken. In January 2013, the American Taxpayer Relief Act of 2012, which, among other
things, further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new
laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our product candidates, if approved for one or more indications, and, accordingly, our financial
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that the Affordable Care Act, as well as other healthcare reform measures that may be adopted in the future, may result in more
rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar
reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Regulation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to regulations in
the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of its products to the extent we choose to develop or sell any products outside of the United States. The
approval process varies from country to country and the time may be longer or shorter than that required to obtain FDA approval. Additionally, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement
vary greatly from country to country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the European Union, member states require both regulatory clearances by the national competent authority and a
favorable ethics committee opinion prior to the commencement of a clinical trial. Under the European Union regulatory systems, marketing authorization applications may be submitted under either a centralized or decentralized procedure. The
centralized procedure provides for the grant of a single marketing authorization that is valid for all European Union member states. It is compulsory for medicines produced by certain biotechnological processes. Because our products are produced in
that way, we would be subject to the centralized procedure. Under the centralized procedure, pharmaceutical companies submit a single marketing authorization application to the EMA. Once granted by the European Commission, a centralized marketing
authorization is valid in all European Union member states, as well as the European Economic Area countries Iceland, Liechtenstein and Norway. By law, a company can only start to market a medicine once it has received a marketing authorization. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our principal executive offices
are located at 315 Madison Avenue, 4<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor, New York, NY 10017, and our phone number is (917) <FONT STYLE="white-space:nowrap">438-4353.</FONT> Our website address is www.sellaslife.com. We do
not incorporate the information on our website into this annual report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> and you should not consider such information part of this annual report on Form
<FONT STYLE="white-space:nowrap">10-K.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated on April&nbsp;3, 2006 in Delaware as Argonaut Pharmaceuticals, Inc. On
November&nbsp;28, 2006, we changed our name to RXi Pharmaceuticals Corporation and began operations January 2007. On September&nbsp;26, 2011, we changed our name to Galena Biopharma, Inc. In December 2017, we completed the Merger with Private SELLAS
and changed our name to &#147;SELLAS Life Sciences Group, Inc.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;1A. <A NAME="tx556278_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>You should consider carefully the risks and uncertainties described below, together with all of the other information in this annual report on Form <FONT
STYLE="white-space:nowrap">10-K.</FONT> We operate in a dynamic and rapidly changing industry that involves numerous risks and uncertainties. The risks and uncertainties described below are not the only ones we face. Other risks and uncertainties,
including those that we do not currently consider material, may impair our business. If any of the risks discussed below actually occur, our business, financial condition, operating results or cash flows could be materially adversely affected.
This&nbsp;annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking
statements as a result of certain factors, including the risks we face as described below and elsewhere in this annual report on Form <FONT STYLE="white-space:nowrap">10-K.</FONT> </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to Our Financial Position and Capital Needs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing losses for the
foreseeable future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company focused on development of novel cancer immunotherapies for a broad range of
cancer indications. Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that a product candidate will fail to prove effective, gain regulatory
approval or become commercially viable. We do not have any products approved by regulatory authorities and have not generated any revenues from collaboration and licensing agreements or product sales to date, and have incurred significant research,
development and other expenses related to our ongoing operations and expect to continue to incur such expenses. As a result, we have not been profitable and have incurred significant operating losses in every reporting period since our inception.
For the years ended December&nbsp;31, 2017 and 2016, we reported a net loss of $23.8&nbsp;million and $17.7&nbsp;million, respectively, and as of December&nbsp;31, 2017 and 2016, had an accumulated deficit of $54.2&nbsp;million and
$30.4&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not expect to generate revenues for many years, if at all. We expect to continue to incur significant expenses
and operating losses for the foreseeable future. We anticipate these losses to increase as we continue to research, develop and seek regulatory approvals for our product candidates and any additional product candidates we may acquire, and
potentially begin to commercialize product candidates that may achieve regulatory approval. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our
future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues. If any of our product candidates fail in clinical trials or do not gain regulatory approval, or if approved, fail to achieve
market acceptance, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. We anticipate that our expenses will increase in the future as we continue to
invest in research and development of our existing product candidates, investigate and potentially acquire new product candidates and expand our manufacturing and commercialization activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There is substantial doubt about our ability to continue as a going concern. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017, we had a cash balance of approximately $2.3&nbsp;million and restricted cash of $10.4&nbsp;million. In addition, we had
outstanding accounts payable and accrued expenses of $14.9&nbsp;million and an outstanding principal amount of $10.2&nbsp;million as of December&nbsp;31, 2017, which consists of our senior secured debenture with JGB (Cayman) Newton Ltd, or JGB, that
is due November 2018. The outstanding principal amount is maintained in a restricted cash. We expect our existing cash as of December&nbsp;31, 2017, together with&nbsp;the $6.0&nbsp;million of proceeds from the initial&nbsp;closing of our private
placement of Series A 20% convertible preferred stock, or Series A Convertible Preferred, and warrants in March 2018, will enable us to fund our operating expenses and capital expenditure requirements through June 2018. Assuming that all conditions
to the initial closing are met, we expect an additional $4.7 million of cash proceeds from the second closing of the sale of our Series A Convertible Preferred and warrants in the second quarter of 2018. Accordingly, our management concluded that
these matters raise substantial doubt about our ability to continue as a going concern. Our consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Our auditors have included an
explanatory paragraph in their audit report for this uncertainty. If we cannot continue as a viable entity, our securityholders may lose some or all of their investment in us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may fail to realize the anticipated benefit of the Merger. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to achieve our business objectives and raise the necessary capital to fund our operations, including the successful development of our current and
future product candidates, has substantial risk. If we are not able to achieve these objectives, the anticipated benefit of the Merger may not be realized fully, may take longer to realize than expected, or may not be realized at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is possible that the integration and transition process could result in the loss of key employees, the disruption of our ongoing business, an adverse
impact on the value of the our assets, or inconsistencies in standards, controls, procedures or policies that could adversely affect our ability to comply with reporting obligations as a public company, an inability to satisfy our obligations to
third parties or to achieve the anticipated benefit of the Merger, or an inability to raise the necessary capital to fund our operations. Integration efforts between the two companies will also divert management&#146;s attention and resources. Any
delays in the integration process or inability to realize the full extent of the anticipated benefit of the Merger could have an adverse effect on our business and the results of our operations. Such an adverse effect may impact the value of the
shares of the our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Potential difficulties that may be encountered in the integration process include, among other things, the following:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">raising sufficient capital to fund our operations and current clinical programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">using our cash and other assets efficiently to develop our business; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">appropriately managing our liabilities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">loss of key employees; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potential unknown or currently unquantifiable liabilities associated with the Merger and our business operations; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">performance shortfalls at one or both of the companies as a result of the diversion of management&#146;s attention caused by completing the Merger and integrating the companies&#146; operations. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed could force us to
delay, limit, reduce or terminate our product development or commercialization efforts. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to expend substantial resources for the
foreseeable future to continue the clinical development and manufacturing of GPS, our WT1 peptide cancer immunotherapy product candidate exclusively licensed from MSK, the clinical development of our other product candidates including NeuVax, <FONT
STYLE="white-space:nowrap">GALE-301</FONT> and <FONT STYLE="white-space:nowrap">GALE-302,</FONT> and the advancement and expansion of our preclinical research pipeline. These expenditures will include costs associated with research and development,
potentially acquiring new product candidates or technologies, conducting preclinical studies and clinical trials and potentially obtaining regulatory approvals and manufacturing products, as well as marketing and selling products approved for sale,
if any. Under the terms of our amended and restated license agreement with MSK, we are obligated to make royalty payments and payments upon the achievement of certain development and commercial milestones in addition to paying guaranteed annual
minimum royalties, sponsoring research and making other guaranteed payments to MSK. In addition, other unanticipated costs may arise. Further, under the terms of the amended and restated MSK license agreement, we are required to obtain
$25.0&nbsp;million of financing by December&nbsp;31, 2018, and if such financing conditions are not met, MSK has the right to terminate with prior written notice, unless we cure during the notice period. We are agreed to fund the NeuVax programs in
the amount of $3.0 million. Moreover, we have additional payment obligations under our BioVascular license agreement. Because the design and outcome of our planned and anticipated clinical trials is highly uncertain, we cannot reasonably estimate
the actual amounts necessary to successfully complete the development and commercialization of our current or future product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our future capital requirements depend on many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope, progress, results and costs of researching and developing our product candidates, and conducting preclinical studies and clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates if clinical trials are successful; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of commercialization activities for our product candidates, if any of these product candidates is approved for sale, including marketing, sales and distribution costs; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of manufacturing our product candidates for clinical trials in preparation for regulatory approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to establish and maintain strategic licensing or other arrangements and the financial terms of such agreements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs associated with current <FONT STYLE="white-space:nowrap">in-licensed</FONT> product candidates; </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">the costs to <FONT STYLE="white-space:nowrap">in-license</FONT> future product candidates or technologies; </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs in defending and resolving current derivative and securities class action litigation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our operating expenses; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing, receipt and amount of sales of, or royalties on, our future products, if any; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the emergence of competing technologies or other adverse market developments. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect our existing cash as
of December&nbsp;31, 2017, together with the proceeds from the initial closing of our Series A Convertible Preferred in March 2018, will enable the us to fund our planned operations through June 2018. Assuming that all conditions to the initial
closing are met, we expect an additional $4.7 million of cash proceeds from the second closing of the sale of our Series A Convertible Preferred and warrants in the second quarter of 2018. However, our operating plan may change as a result of many
factors currently unknown to us, and we may need additional funds sooner than planned. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our
current or future operating plans. We have only one limited committed external source of funds. Additional funds may not be available when we need them on terms that are acceptable to us, or at all. If adequate funds are not available to us on a
timely basis, we may be required to delay, limit, reduce or terminate preclinical studies, clinical trials or other development activities for one or more of our product candidates or target indications, or delay, limit, reduce or terminate our
establishment of sales and marketing capabilities or other activities that may be necessary to commercialize our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We currently
have no source of revenues. We may never generate revenues or achieve profitability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Currently, we do not generate any revenues from product sales
or otherwise. Even if we are able to successfully achieve regulatory approval for our product candidates, we do not know when we will generate revenues or become profitable, if at all. Our ability to generate revenues from product sales and achieve
profitability will depend on our ability to successfully commercialize products, including our current product candidate, and other product candidates that we may develop, <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire in the future.
Our ability to generate revenues and achieve profitability also depends on a number of additional factors, including our ability to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">successfully complete development activities, including the necessary clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">complete and submit either BLAs, or NDAs to the FDA, and obtain United States regulatory approval for indications for which there is a commercial market; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">complete and submit applications to, and obtain regulatory approval from, foreign regulatory authorities in Europe, Asia and other jurisdictions; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain coverage and adequate reimbursement from third parties, including government and private payors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">set commercially viable prices for our products, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish and maintain supply and manufacturing relationships with reliable third parties and/or build our own manufacturing facility and ensure adequate, legally globally compliant manufacturing of bulk drug substances
and drug products to maintain that supply; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">develop manufacturing and distribution processes for our product candidate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">develop commercial quantities of our product candidates, once approved, at acceptable cost levels; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">achieve market acceptance of our products, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">attract, hire and retain qualified personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">protect our rights in our intellectual property portfolio; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">develop a commercial organization capable of sales, marketing and distribution for any products we intend to sell ourselves, in the markets in which we choose to commercialize on our own; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">find suitable distribution partners to help us market, sell and distribute our approved products in other markets. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our revenues for any product candidate for which regulatory approval is obtained will be dependent, in part, upon the size of the markets in the territories
for which it gains regulatory approval, the accepted price for the product, the ability to get reimbursement at any price, and whether we own the commercial rights for that territory. If the number of our addressable disease patients is not as
significant as our estimates, the indication approved by regulatory authorities is narrower than we expect, or the reasonably accepted population for treatment is narrowed by competition, physician choice or treatment guidelines, we may not generate
significant revenues from sales of such products, even if approved. In addition, we anticipate incurring significant costs associated with commercializing any approved product candidate. As a result, even if we generate revenues, we may not become
profitable and may need to obtain additional funding to continue operations. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and may be
forced to reduce our operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Following the Merger, our business and management is largely that of Private SELLAS, which has a limited operating
history. This may make it difficult for you to evaluate the success of our business to date and to assess our future viability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Private SELLAS was
formed in January 2012. Its operations prior to the Merger were limited to organizing and staffing its company, acquiring product and technology rights and conducting product development activities for its product candidate GPS. As a combined
company, we have not yet demonstrated our ability to start or successfully complete any Phase 3 clinical trials, obtain regulatory approval, manufacture a commercial scale product or arrange for a third party to do so on our behalf, or conduct sales
and marketing activities necessary for successful commercialization for any of our product candidates. In addition, the adoptive cancer immunotherapy technology underlying our peptide cancer immunotherapy product candidate is new and largely
unproven. Any predictions about our future success, performance or viability, particularly in view of the rapidly evolving cancer immunotherapy field, may not be as accurate as they could be if we had a longer operating history as a combined company
or approved products on the market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, our management team is largely composed of Private SELLAS who have limited experience of operating
as an United States public company. We may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will need to transition at some point from a company with a research and development focus to a
company capable of supporting commercial activities. We may not be successful in such a transition. We expect our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year due to a
variety of factors, many of which are beyond our control. Accordingly, any of our interim or annual periods&#146; results are not indicative of future operating performance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our product
candidates on unfavorable terms to us. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may seek additional capital through a variety of means, including through private and public equity
offerings and debt financings. To the extent that we raise additional capital through the sale of equity or convertible debt securities, or through the issuance of shares under management or other types of contracts, or upon exercise or conversion
of outstanding derivative securities, the ownership interest of our stockholders will be diluted, and the terms may include liquidation or other preferences that adversely affect our rights as a stockholder. Debt financing, if available, may involve
additional agreements similar to those that we have in place under our senior secured debenture with JGB, and could include covenants limiting or restricting our ability to take certain actions, such as incurring additional debt, making capital
expenditures, entering into licensing arrangements, or declaring dividends. If we raise additional funds from third parties, we may have to relinquish valuable rights to our technologies or product candidates or grant licenses on terms that are not
favorable to us. If we are unable to raise additional funds through equity or debt financing when needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts for our product candidates, or
grant to others the rights to develop and market product candidates that we would otherwise prefer to develop and market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to continue to
incur significant operating and <FONT STYLE="white-space:nowrap">non-operating</FONT> expenses, which may make it difficult for us to secure sufficient financing and may lead to uncertainty about our ability to continue as a going concern.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Substantial funds were expended to develop our technologies and product candidates, and additional substantial funds will be required for further
preclinical testing and clinical trials of our product candidates, and to manufacture and market any products that are approved for commercial sale. Because the successful development of our products is uncertain, we are unable to precisely estimate
the actual funds we will require to develop and potentially commercialize them. In addition, we may not be able to generate enough revenue, even if we are able to commercialize any of our product candidates, to become profitable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that we are unable to obtain additional financing if needed or if we incur significant expense related to the resolution of the ongoing
government investigation, we may not be able to meet our obligations as they come due, that in turn may raise substantial doubts as to our ability to continue as a going concern. Any such inability to continue as a going concern may result in our
common stock holders losing their entire investment. There is no guaranty that we will be able to secure additional financing if we need such financing. Our financial statements contemplate that we will continue as a going concern and do not contain
any adjustments that might result if we were unable to continue as a going concern. Changes in our operating plans, our existing and anticipated working capital needs, defense costs related to the recent securities and derivative lawsuits, the
acceleration or modification of our development activities, any near-term or future expansion plans, increased expenses, potential acquisitions or other events may affect our ability to continue as a going concern. Future financing may be obtained
through, and future development efforts may be paid for by, the issuance of debt or equity, which may have an adverse effect on our security holders or may otherwise adversely affect our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we raise funds through the issuance of debt or equity, any debt securities or preferred stock issued will have rights, preferences and privileges senior to
those of holders of our common stock in the event of a liquidation. In such event, there is a possibility that once all senior claims are settled, there may be no assets remaining to pay out to the holders of common stock. In addition, if we raise
funds through the issuance of additional equity, whether through private placements or additional public offerings, such an issuance would dilute our security holders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are, and in the future may be, subject to legal or administrative actions that could adversely affect our financial condition and our business.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our predecessor company, Galena was involved in multiple legal proceedings and administrative actions, including stockholder class actions, both
state and federal, some of which are ongoing and to which we are now subject as a result of the Merger.&nbsp;These legal and administrative actions, which we refer to as the Galena Legacy Matters, included allegations relating to federal securities
law violations, claims under the False Claims Act, claims regarding breaches of contract, and other stockholder allegations, including claims of breaches of fiduciary duty by our former directors.&nbsp;In addition, on or about April 9, 2018, JGB
filed a lawsuit in the U.S. District Court for the Southern District of New York. The complaint asserts claims under state law and federal securities law against us, our Chief Executive Officer and our Interim Chief Financial Officer relating to a
debenture agreement between JGB and us. These matters are described in Item 3 &#147;Legal Proceedings&#148; of this annual report on Form 10-K.&nbsp;These legal and administrative proceedings require our management and board of directors to devote a
significant amount of time and resources to defending such claims and addressing such allegations, rather than focusing on executing on our business plans and operations.&nbsp;The settlement of the Galena Legacy Matters has resulted in substantial
payments, some of which have not been covered by our insurance policies. We may continue to incur substantial unreimbursed legal fees and other expenses in connection with the Galena Legacy Matters, the JGB lawsuit or other future legal and
regulatory proceedings that may not qualify for coverage under, or may exceed the limit of, our applicable directors and officers liability insurance policies and could have a material adverse effect on our financial condition, liquidity, and
results of operations. An unfavorable outcome in any of these matters could damage our business and reputation or result in additional claims or proceedings against us.&nbsp;Moreover, in addition to these ongoing and prior matters, we may be exposed
to claims as a result of the Merger, or other legal or administrative actions in the future, which could result in the payment of additional amounts and have a material adverse effect on our financial condition and results of operations. We can make
no assurances as to the time or resources that will need to be devoted to these matters or their outcome, or the impact, if any, that these matters or any resulting legal or administrative proceedings may have on our business or financial condition
but any further action in respect of any such matter by a governmental agency could have a material adverse effect on our results of operation and our business and prospects. Please read Item 3 &#147;Legal Proceedings&#148; of this annual report on
Form 10-K for more information regarding our legal and administrative proceedings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The recently passed comprehensive tax reform bill could
adversely affect our business and financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;22, 2017, President Trump signed into law new legislation that
significantly revises the Internal Revenue Code of 1986, as amended. The newly enacted federal income tax law, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal
rate of 35% to a flat rate of 21%, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
limitation of the tax deduction for interest expense to 30% of adjusted earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80% of current year
taxable income and elimination of net operating loss carrybacks, one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important
exceptions), immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits (including reduction of tax credits under the Orphan Drug Act).
Notwithstanding the reduction in the corporate income tax rate, the overall impact of the new federal tax law is uncertain and our business and financial condition could be adversely affected. In addition, it is uncertain if and to what extent
various states will conform to the newly enacted federal tax law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to use net operating losses to offset future taxable income may be
subject to limitations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017, we had federal and state net operating loss, or NOL, carryforwards of $7.4 million. The
federal and state NOL carryforwards will begin to expire, if not utilized, beginning in 2027. These NOL carryforwards could expire unused and be unavailable to offset future income tax liabilities. Under the newly enacted federal income tax law,
federal NOLs incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such federal NOLs is limited. It is uncertain if and to what extent various states will conform to the newly enacted federal tax law. In
addition, under Section&nbsp;382 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &#147;ownership change,&#148; which is generally defined as a greater than 50% change, by
value, in its equity ownership over a three-year period, the corporation&#146;s ability to use its <FONT STYLE="white-space:nowrap">pre-change</FONT> NOL carryforwards and other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes to
offset its post-change income or taxes may be limited. The Merger constituted an ownership change and as such, our ability to use our NOL carryforwards is materially limited, which may harm our future operating results by effectively increasing our
future tax obligations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to Our Former Commercial Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to U.S. federal and state health care fraud and abuse and false claims laws and regulations, and we recently have been subpoenaed in
connection with marketing and promotional practices related to Abstral <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (fentanyl) sublingual tablets. Prosecutions under such laws have increased in recent years and we may become subject to
such prosecutions or related litigation under these laws. If we have not fully complied with such laws, we could face substantial penalties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
former commercial operations and development programs are subject to various U.S. federal and state fraud and abuse laws, including, without limitation, the federal False Claims Act, federal Anti-Kickback Statute, and the federal Sunshine Act. A
federal investigation led by the U.S. Attorney&#146;s Office for the Southern District of Alabama, or the SDAL, of two of the high-prescribing physicians for Abstral (fentanyl) sublingual tablets resulted in the criminal prosecution of the two
physicians for alleged violations of the federal False Claims Act and other federal statutes. On April&nbsp;28, 2016, a second superseding indictment was filed in the criminal case, which added additional information about the defendant physicians
and provided information regarding the facts and circumstances involving a rebate agreement between us and the defendant physicians&#146; pharmacy as well as their ownership of our common stock. The criminal trial, which began on January&nbsp;4,
2017, concluded with a jury verdict on February&nbsp;23, 2017 finding these physicians guilty on 19 of 20 counts. In May 2017, one physician was sentenced to 20 years in prison, and the other physician was sentenced to 21 years in
prison.<B></B>&nbsp;At the end of the SDAL case, SDAL dismissed count 18 of the indictment charging that the physicians conspired, through the C&amp;R Pharmacy, to receive illegal kickbacks in exchange for prescribing Abstral. To our knowledge, we
were not a target or subject of that investigation. We have also received a subpoena from the U.S. Attorney&#146;s Office for the Southern District of New York in February 2018, seeking documents related to specific physicians. To our knowledge, we
are not a target or subject of that investigation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There have also been federal and state investigations of companies that have products that are in the
same therapeutic class as Abstral, and we have learned that the FDA, and other governmental agencies were investigating our Abstral promotion practices. In December 2015, we announced we had received a subpoena from the U.S. Attorney&#146;s Office
for the District of New Jersey, or the USAO NJ, requesting the production of a broad range of documents pertaining to marketing and promotional practices related to Abstral, a product which we sold to Sentynl Therapeutics Inc. for aggregate gross
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">consideration of $12&nbsp;million in November 2015. In January 2016, we announced that the USAO NJ and the
Department of Justice, or DOJ, were conducting a criminal and civil investigation of us, as well as, possibly one or more then-current and/or former employees. On September&nbsp;8, 2017, DOJ announced a settlement agreement with our company
regarding the USAO NJ and DOJ&#146;s investigation. The settlement involves a <FONT STYLE="white-space:nowrap">non-criminal</FONT> resolution agreement and a civil payment of approximately $7.551&nbsp;million, plus interest accrued since the date of
reaching an agreement in principle payable in equal installments over twelve months, in return for a release of government claims of our company in connection with the investigation. The civil payment was fully paid by us on or about
December&nbsp;29, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may be subject to additional legal or administrative actions as a result of these matters, or the impact of such matters. If
we are found to be in violation of the False Claims Act, Anti-Kickback Statute, Patient Protection and Affordable Care Act, or any other applicable state or any federal fraud and abuse laws, we may be subject to penalties, such as civil and criminal
penalties, damages, fines, or an administrative action of exclusion from government health care reimbursement programs. We can make no assurances as to the time or resources that will need to be devoted to these matters or outcomes, or the impact,
if any, that these matters or any resulting legal or administrative proceedings may have on our business or financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Many of the
regulatory provisions that we are subject to include criminal provisions. If we are unable to comply with these provisions in the operation of our business we may become subject to civil and criminal investigations and proceedings that could have a
material adverse effect on our business, financial condition and prospects. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The federal False Claims Act prohibits persons from knowingly filing,
or causing to be filed, a false claim to, or the knowing use of false statements to obtain payment from, the federal government. Qui tam lawsuit filed under the False Claims Act can be brought by any individual on behalf of the government and such
individuals, commonly known as &#147;relators&#148; or &#147;whistleblowers,&#148; may share in any amounts paid by the entity to the government in fines or settlement. The frequency of filing qui tam actions has increased significantly in recent
years, causing greater numbers of health care companies to have to defend such qui tam actions and pay substantial sums to settle such actions. A qui tam action had been filed against us and others as described in the settlement agreement with DOJ
and USAO NJ. As set forth in that settlement agreement, for a release of all claims against us and our officers and directors and dismissal with prejudice of the qui tam lawsuit, the relator received a portion of the $7.551&nbsp;million payment to
the federal government. As a result of the payment of the settlement amount, the federal government and the relator will dismiss with prejudice their claims against us in the qui tam lawsuit. In a separate settlement agreement, we paid
$0.30&nbsp;million in cash to the relator&#146;s counsel for the statutory mandated attorney&#146;s fees. The federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, offering, receiving, or providing remuneration,
directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing or arranging for a good or service, for which payment may be made under a federal health care program such as the Medicare and Medicaid
programs. Several courts have interpreted the statute&#146;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal health care covered business, the statute has been violated.
The Anti-Kickback Statute is broad, and despite a series of narrow safe harbors, prohibits many arrangements and practices that are lawful in businesses outside of the health care industry. Penalties for violations of the federal Anti-Kickback
Statute include criminal penalties and civil and administrative sanctions such as fines, imprisonment and possible exclusion from Medicare, Medicaid and other federal health care programs. An alleged violation of the Anti- Kickback Statute may be
used as a predicate offense to establish liability pursuant to other federal laws and regulations such as the federal False Claims Act. Many states have also adopted laws similar to the federal Anti-Kickback Statute, some of which apply to the
referral of patients for health care items or services reimbursed by any source, not only Medicare and Medicaid programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The federal Patient Protection
and Affordable Care Act includes provisions expanding the ability of certain relators to bring actions that would have been dismissed under prior law. When an entity is determined to have violated the federal False Claims Act, it may be required to
pay up to three times the actual damages sustained by the government, plus civil penalties for each separate false claim. The Deficit Reduction Act of 2005 encouraged states to enact or modify their state false claims acts to be at least as
effective as the federal False Claims Act by granting states a portion of any federal Medicaid funds recovered through Medicaid-related actions. Most states have enacted state false claims laws, and many of those states included laws including qui
tam provisions. The federal Patient Protection and Affordable Care Act includes provisions known as the Physician Payments Sunshine Act, which requires manufacturers of drugs, biologics, devices and medical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
supplies covered under Medicare and Medicaid to record any transfers of value to physicians and teaching hospitals and to report this data beginning in 2013 to the Centers for Medicare and
Medicaid Services for subsequent public disclosures. Manufacturers must also disclose investment interests held by physicians and their family members. Failure to submit the required information may result in civil monetary penalties of up to
$1&nbsp;million per year for knowing violations and may result in liability under other federal laws or regulations. Similar reporting requirements have also been enacted on the state level in the United States, and an increasing number of countries
worldwide either have adopted or are considering similar laws requiring transparency of interactions with health care professionals. In addition, some states such as Massachusetts and Vermont imposed an outright ban on certain gifts to physicians.
These laws could affect our product promotional activities by limiting the kinds of interactions we could have with hospitals, physicians or other potential purchasers or users of our system. Both the disclosure laws and gift bans also will impose
administrative, cost and compliance burdens on us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face product liability exposure and, if successful claims are brought against us, we may
incur substantial liability if our insurance coverage for those claims is inadequate. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The commercial sale of our products after we are approved as
well as the use of our product candidates in clinical trials exposes us to possible product liability claims. This risk exists even if a product is approved for commercial sale by the FDA and manufactured in facilities licensed and regulated by the
FDA, if our products were sold to third parties, or if our products are provided in clinical trials. Our products are designed to affect important bodily functions and processes. Any side effects, manufacturing defects, misuse or abuse associated
with our products could result in injury to a patient or even death. For example, because the placebo may have performed better than NeuVax in the PRESENT (<B>P</B>revention of<B> R</B>ecurrence in<B> E</B>arly-<B>S</B>tage, Node-Positive Breast
Cancer with Low to Intermediate HER2<B> E</B>xpression with <B>N</B>euVax<B> T</B>reatment) Trial, the use of NeuVax may have worsened the patient&#146;s condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Product liability claims may be brought against us by consumers, health care providers, pharmaceutical companies or others selling or otherwise coming into
contact with our products or generic versions of our products. If we cannot successfully defend ourselves against product liability claims we could incur substantial liabilities. Because we have sold Abstral and Zuplenz (ondansetron) oral soluble
film and provided NeuVax as a study drug in the PRESENT Trial and other clinical trials, regardless of merit or eventual outcome, product liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impairment of our business reputation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">costs of related litigation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">distraction of management&#146;s attention from our primary business; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">substantial monetary awards to patients or other claimants. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have obtained product liability insurance
coverage for commercial product sales with a $10&nbsp;million per occurrence and a $10&nbsp;million annual aggregate coverage limit. Our insurance coverage may not be sufficient to cover all of our product liability related expenses or losses and
may not cover us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and, in the future, we may not be able to maintain insurance coverage at a reasonable cost, in sufficient amounts or upon
adequate terms to protect us against losses due to product liability. If we determine that it is prudent to increase our product liability coverage based on sales of our products, we may be unable to obtain this increased product liability insurance
on commercially reasonable terms or at all. Large judgments have been awarded in class action or individual lawsuit based on drugs that had unanticipated side effects, including side effects that may be less severe than those of our products. A
successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could decrease our cash and have a material adverse effect on our business, results of
operations, financial condition and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business involves the use of hazardous materials and we and our third-party manufacturers and suppliers
must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our third-party manufacturers and
suppliers activities involve the controlled storage, use and disposal of hazardous materials. We and our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these
hazardous materials even after we sell or otherwise dispose of the products. In some cases, these hazardous materials and various wastes resulting from their use will be stored at our contractors or manufacturers&#146; facilities pending use and
disposal. We cannot completely eliminate the risk of contamination, which could cause injury to our employees and others, environmental damage resulting in costly cleanup and liabilities under applicable laws and regulations governing the use,
storage, handling and disposal of these materials and specified waste products. Although we expect that the safety procedures utilized by our third-party contractors and manufacturers for handling and disposing of these materials will generally
comply with the standards prescribed by these laws and regulations, we cannot guarantee that this will be the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any
resulting damages and such liability could exceed our resources. We do not currently carry biological or hazardous waste insurance coverage and our property and casualty and general liability insurance policies specifically exclude coverage for
damages and fines arising from biological or hazardous waste exposure or contamination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will continue to be responsible for certain liabilities
and obligations related to Abstral and Zuplenz, and if unknown liabilities were to arise it could have a material adverse effect on us. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our
respective asset purchase agreements with Sentynl Therapeutics, Inc. and Midatech Pharma PLC, our future obligations under our former agreements with Orexo AB and MonoSol Rx have been assumed by Sentynl and Midatech, respectively, except that we
will continue to be responsible for chargebacks, rebates, patient assistance and certain other product distribution channel liabilities related to Abstral and Zuplenz for a specified period of time post-closing. With respect to Zuplenz, we will
continue to be responsible for any downstream returns from end user customers or returns from wholesalers from inventory existing as of December&nbsp;24, 2015 that was sold by us prior to December&nbsp;24, 2015. As presently believed by us,
responsibilities to Sentynl and Midatech are not material, but if substantial unknown liabilities were to arise, it could have a material adverse effect on our financial condition. In this regard, we have been advised by one of our wholesale
customers that Zuplenz inventory held by that customer under an alleged agreement with us is approaching our expiration date and needs to be swapped with better dated Zuplenz product. We have settled the swap by us paying the customer
$0.50&nbsp;million on October&nbsp;24, 2017. Midatech has advised us that the same Zuplenz inventory is reaching our expiration date and will be returned. Under the terms of the asset purchase agreement, Midatech maintained that the cost of the
return is $1.5&nbsp;million and we need to pay Midatech for the return. Midatech has since withdrawn that claim. We believe the settlement with the customer has resolved any return issues with Midatech without additional cost to us. However, no
assurance can be given that we will not face additional liabilities under these asset purchase agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Development of Our
Product Candidates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are currently a clinical-stage biopharmaceutical company with product candidates in clinical development. If we are unable
to successfully develop and commercialize product candidates or experiences significant delays in doing so, our business may be materially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are currently a clinical-stage biopharmaceutical company with product candidates in clinical development. We have invested substantially all of our efforts
and financial resources in identifying and developing potential product candidates and conducting preclinical studies, clinical trials and manufacturing activities. Our ability to generate revenues, which we do not expect will occur for many years,
if ever, will depend heavily on the successful development and eventual commercialization of our product candidates. The success of our product candidates will depend on several factors, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">completion of preclinical studies and clinical trials with positive results; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">receipt of regulatory approvals from applicable authorities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing or making arrangements with third-party manufacturers or building our own manufacturing facility for commercial manufacturing purposes; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developing manufacturing and distribution processes for our novel WT1 peptide cancer immunotherapy product candidate and other product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manufacturing our product candidates at an acceptable cost; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">launching commercial sales of our product candidates, if approved, whether alone or in collaboration with others; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acceptance of our product candidates, if approved, by patients, the medical community and third-party payors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">effectively competing with other therapies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining and maintaining coverage and adequate reimbursement by third-party payors, including government payors, for our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">protecting our rights in our intellectual property portfolio; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintaining a continued acceptable safety profile of the products following approval; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintaining and growing an organization of scientists and business people who can develop and commercialize our products and technology. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully develop
and commercialize our product candidates, which could materially harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future success is dependent on the regulatory approval of
our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business is substantially dependent on our ability to obtain regulatory approval for, and, if approved, to
successfully commercialize our product candidates in a timely manner. We cannot commercialize product candidates in the United States without first obtaining regulatory approval for the product from the FDA; similarly, we cannot commercialize
product candidates outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of any product candidate for a target indication, we
must demonstrate with substantial evidence gathered in preclinical studies and clinical trials, generally including two well-controlled Phase 3 trials, that the product candidate is safe and effective for use for that target indication and that the
manufacturing facilities, processes and controls are adequate with respect to such product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The time required to obtain approval by the FDA and
comparable foreign regulatory authorities is unpredictable but typically takes many years following the commencement of preclinical studies and clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory
authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#146;s clinical development and may vary among jurisdictions. We have
not obtained regulatory approval for any product candidate and it is possible that our existing product candidate or any future product candidates will ever obtain regulatory approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our current and future product candidates could fail to receive regulatory approval from the FDA or a comparable foreign regulatory authority for many
reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">disagreement with the design or implementation of our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to demonstrate that a product candidate is safe and effective for our proposed indication; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure of clinical trials to meet the level of statistical significance required for approval; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to demonstrate that a product candidate&#146;s clinical and other benefits outweigh our safety risks; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">disagreement with our interpretation of data from preclinical studies or clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the insufficiency of data collected from clinical trials of our product candidates to support the submission and filing of a BLA, NDA or other submission or to obtain regulatory approval; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to obtain approval of our manufacturing processes or facilities of third-party manufacturers with whom we contract for clinical and commercial supplies or our own manufacturing facility; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in the approval policies or regulations that render our preclinical and clinical data insufficient for approval. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA or a comparable foreign regulatory authority may require more information, including additional preclinical or clinical data to support approval or
additional studies, which may delay or prevent approval and our commercialization plans, or we may decide to abandon the development program. If we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer
or more limited indications than it requests (including failing to approve the most commercially promising indications), may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate
with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if a
product candidate were to successfully obtain approval from the FDA and comparable foreign regulatory authorities, any approval might contain significant limitations related to use restrictions for specified age groups, warnings, precautions or
contraindications, or may be subject to burdensome post-approval study or risk management requirements. If we are unable to obtain regulatory approval for one of our product candidates in one or more jurisdictions, or any approval contains
significant limitations, we may not be able to obtain sufficient funding to continue the development of that product or generate revenues attributable to that product candidate. Also, any regulatory approval of our current or future product
candidates, once obtained, may be withdrawn. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our lead product candidate, GPS, represents a new therapeutic approach that presents significant
challenges. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our future success is dependent in part on the successful development of WT1 peptide immunotherapies in general and GPS in particular.
Because this program represents a new approach to cancer immunotherapy for the treatment of cancer and other diseases, developing and commercializing GPS subjects us to a number of challenges, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining regulatory approval from the FDA and other regulatory authorities, which have very limited experience with the development and commercialization of WT1 cancer immunotherapies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ability to obtain, store and use the three components required for administration, GPS, <FONT STYLE="white-space:nowrap">GM-CSF,</FONT> and Montanide; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">training medical personnel regarding the proper preparation of GPS for administration and proper handling thereof once prepared; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">utilizing GPS in combination with other therapies, which may increase the risk of adverse side effects; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">educating medical personnel regarding the potential side effect profile of GPS for each target indication; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developing processes for the safe administration of GPS, including long-term <FONT STYLE="white-space:nowrap">follow-up</FONT> for all patients who receive these product candidate; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sourcing clinical and, if approved, commercial supplies for the materials used to manufacture and process GPS; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developing a manufacturing process and distribution network that can provide a stable supply with a cost of goods that allows for an attractive return on investment; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing sales and marketing capabilities after obtaining any regulatory approval to gain market acceptance, and obtaining adequate coverage, reimbursement and pricing by third-party payors and government
authorities; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developing therapies for types of diseases beyond those initially addressed by GPS. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot be sure that
the manufacturing processes used in connection with GPS will yield a satisfactory product that is safe and effective, scalable or profitable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover,
public perception of safety issues, including adoption of new therapeutics or novel approaches to treatment, may adversely influence the willingness of subjects to participate in clinical trials, or if approved, of physicians to subscribe to the
novel treatment mechanics. Physicians, hospitals and third-party payors often are slow to adopt new products, technologies and treatment practices that require additional upfront costs and training. Physicians may not be willing to undergo training
to adopt this novel therapy, may decide the therapy is too complex to adopt without appropriate training and may choose not to administer the therapy. Based on these and other factors, hospitals and payors may decide that the benefits of this new
therapy do not or will not outweigh our costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates, NeuVax, <FONT STYLE="white-space:nowrap">GALE-301</FONT> and <FONT
STYLE="white-space:nowrap">GALE-302</FONT> may not be a viable product candidates to prevent the recurrence of breast, ovarian cancer or other types of cancers. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2016, an independent data monitoring committee conducted the <FONT STYLE="white-space:nowrap">pre-planned</FONT> interim analysis of the PRESENT Trial
for NeuVax and recommended that we stop the clinical trial because of futility, as the placebo may have performed better than NeuVax in the PRESENT trial. While there may have been factors about the design of the trial that caused the failure, on
factor it may be that NeuVax is not effective as a monotherapy in the treatment of the recurrence of breast cancer. As our product candidates <FONT STYLE="white-space:nowrap">GALE-301</FONT> and <FONT STYLE="white-space:nowrap">GALE-302</FONT> have
a similar mechanism of action to NeuVax, they may no longer be effective product candidates as monotherapies for the prevention of the recurrence of ovarian cancer or other types of cancer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The results of preclinical studies or earlier clinical trials are not necessarily predictive of future results. Our existing product candidates in
clinical trials, and any other product candidates which may advance into clinical trials, may not have favorable results in later clinical trials or receive regulatory approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Success in preclinical studies and early clinical trials does not ensure that later clinical trials will generate adequate data to demonstrate the efficacy and
safety of an investigational drug. A number of companies in the pharmaceutical and biotechnology industries, including those with greater resources and experience than us, have suffered significant setbacks in clinical trials, even after seeing
promising results in earlier preclinical studies or clinical trials. Any of our product candidates which are in, or may advance to, clinical trials may not succeed in clinical trials despite promising
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> data. For example, with respect to GPS, a broadly similar anti-cancer peptide immunotherapeutic against melanoma-specific antigen being developed by GlaxoSmithKline for advanced unresectable
melanoma initially produced positive efficacy data in a Phase 2 clinical study, but subsequently failed to prove more beneficial than placebo in a controlled, blinded and randomized Phase 3, registration-enabling clinical trial in the same
indication in patients after tumor resection. Despite the results reported in earlier preclinical studies or clinical trials for our product candidates, we do not know whether the clinical trials we may conduct will demonstrate adequate efficacy and
safety to result in regulatory approval to market GPS or any of our product candidates for a particular indication, either as a monotherapy or in combination, in any particular jurisdiction. Although we are currently studying GPS as a treatment for
up to eight types of cancers, only two indications (acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM) have completed Phase 2 clinical trials and have Phase 3 clinical trials planned (pending funding availability). Efficacy
data from prospectively designed trials may differ significantly from those obtained from retrospective subgroup analyses. If later-stage clinical trials do not produce favorable results, our ability to achieve regulatory approval for GPS may be
adversely impacted. Even if we believe that we have adequate data to support an application for regulatory approval to market any of our current or future product candidates, the FDA or other regulatory authorities may not agree and may require that
it conducts additional clinical trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may find it difficult to enroll patients in our clinical trials given the limited number of patients who
have the diseases for which our product candidates are being studied. Difficulty in enrolling patients for this or other reasons could delay or prevent clinical trials of our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Identifying and qualifying patients to participate in clinical trials of our current and future product candidates is essential to our success. The timing of
our clinical trials depends in part on the rate at which we can recruit patients to participate in clinical trials of our product candidates, and we may experience delays in our clinical trials if we encounters difficulties in enrollment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The eligibility criteria of our planned clinical trials may further limit the available eligible trial participants as we expect to require that patients have
specific characteristics that we can measure or meet the criteria to assure their conditions are appropriate for inclusion in our clinical trials. For instance, in our planned AML Phase 3 clinical trial, only patients who meet specific inclusion
criteria will enter the study. Primary entry restrictions include being greater than or equal to 60 years of age, having received upfront treatment with chemotherapy agents only, having achieved CRem, as well as demonstrating adequate hematologic
recovery. The estimated prevalence of AML is 12,000 to 20,000 cases in the United States (across all ages) and only a subset of this group satisfies the enrollment criteria for our AML Phase 3 clinical trial. We may not be able to identify, recruit,
and enroll a sufficient number of patients to complete our clinical trials in a timely manner because of the perceived risks and benefits of the product candidate under study, the availability and efficacy of competing therapies and clinical trials,
and the willingness of physicians to participate in our planned clinical trials. If patients are unwilling to participate in our clinical trials for any reason, the timeline for conducting trials and obtaining regulatory approval of our product
candidates may be delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we experience delays in the completion of, or termination of, any clinical trials of our current or future product
candidates, the commercial prospects of our product candidates could be harmed, and our ability to generate product revenue from any of these product candidates could be delayed or prevented. In addition, any delays in completing our clinical trials
would likely increase our overall costs, impair product candidate development and jeopardize our ability to obtain regulatory approval relative to our current plans. Any of these occurrences may harm our business, financial condition, and prospects
significantly. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A number of different factors could prevent us from obtaining regulatory approval or commercializing our product candidates on a
timely basis, or at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical trials of a drug candidate may be suspended at any time for various reasons, including if we or other regulatory
agencies believe the subjects or patients participating in such trials are being exposed to unacceptable health risks. A suspension may come from: us; the FDA or other applicable regulatory authorities; an independent DSMB, governing our clinical
trials; or an institutional review board, which is an independent committee registered with and overseen by the U.S. Department of Health and Human Services, or the HHS, that functions to approve, monitor and review biomedical and behavioral
research involving humans. Among other reasons, adverse side effects of a drug candidate on subjects or patients in a clinical trial could result in the FDA or other regulatory authorities suspending or terminating the trial and refusing to approve
a particular drug candidate for any or all indications of use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical trials of a new drug candidate require the enrollment of a sufficient number of
patients, including patients who are suffering from the disease the drug candidate is intended to treat and who meet other eligibility criteria. Rates of patient enrollment are affected by many factors, and delays in patient enrollment can result in
increased costs and longer development times than we expect at present. Patients who are enrolled at the outset of the trial may eventually choose for personal reasons not to participate in the study. We also compete for eligible patients with other
clinical trials underway, and we may experience delays in patient enrollment due to the dependency of other trials underway in the same patient population. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical trials also require the review and oversight of institutional review boards, which approve and continually review clinical investigations to protect
the rights and welfare of human subjects. An inability or delay in obtaining institutional review board approval could prevent or delay the initiation and completion of clinical trials, and the FDA may decide not to consider any data or information
derived from a clinical investigation not subject to initial and continuing institutional review board review and approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, cancer vaccines are a relatively new form of therapeutic treatment and a very limited number of such
products have received regulatory approval. Therefore, the FDA or other regulatory authority may apply standards for approval of a new cancer vaccine that is different from past experience. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Numerous factors could affect the timing, cost or outcome of our drug development efforts, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties or delays in enrolling patients in our planned clinical trials in conformity with required protocols or projected timelines; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Challenges in locating and enrolling a sufficient number of patients of our clinical trials due to competitors&#146; numerous ongoing trials for the same or similar indications; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conditions imposed on us by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties or delays in arranging for third parties to conduct clinical trials of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">problems in engaging institutional review boards to oversee trials or problems in obtaining or maintaining institutional review board approval of studies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">third-party contractors failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our drug candidates having very different chemical and pharmacological properties in humans than in laboratory testing and interacting with human biological systems in unforeseen, ineffective or harmful ways, and the
possibility that our previous Phase 1 or Phase 2 trials will not be indicative of our drug candidates&#146; performance in larger patient populations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the need to suspend or terminate our clinical trials if the participants are being exposed to unacceptable health risks; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">insufficient or inadequate supply or quality of our drug candidates or other necessary materials necessary to conduct our clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">disruption at our clinical trial sites resulting from local social or political unrest or other geopolitical factors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">effects of our drug candidates not having the desired effects or including undesirable side effects or the drug candidates having other unexpected characteristics; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">negative or inconclusive results from our clinical trials or the clinical trials of others for drug candidates similar to our own or inability to generate statistically significant data confirming the efficacy of the
product being tested; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adverse results obtained by other companies developing similar drugs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">modification of the drug during testing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our capital resources; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reallocation of our financial and other resources to other clinical programs. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is possible that none of the
product candidates that we develop will obtain the appropriate regulatory approvals necessary for us to begin selling them or that any regulatory approval to market a product may be subject to limitations on the indicated uses for which we may
market the product. The time required to obtain FDA and other approvals is unpredictable but often can take years following the commencement of clinical trials, depending upon the complexity of the drug candidate. Any analysis we perform of data
from clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. Any delay or failure in obtaining required approvals could have a material adverse effect on
our ability to generate revenue from the particular drug candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the length of time to develop the product candidates as well as any
regulatory delays in the development and regulatory approval process could cause the patent exclusivity to be unavailable or greatly reduced for each product candidate. The lack of patent exclusivity could have a material adverse effect on our
ability to generate revenue from the particular drug candidate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also subject to numerous foreign regulatory requirements governing the conduct of clinical trials,
manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process includes all of the risks associated with the FDA approval described above as well as risks attributable to the satisfaction of
local regulations in foreign jurisdictions. Approval by the FDA does not assure approval by regulatory authorities outside of the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
may use our financial and human resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates that may be more profitable or for which there is a greater likelihood of success.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because we have limited financial and human resources, we may forego or delay pursuit of opportunities with some programs or potential product
candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or more profitable market opportunities. Our spending on
current and future research and development programs and future product candidates for specific indications may not yield any commercially viable products. We may also enter into additional strategic collaboration agreements to develop and
commercialize some of our programs and potential product candidates in indications with potentially large commercial markets. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, it may
relinquish valuable rights to that product candidate through strategic collaborations, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to
such product candidate, or we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a partnering arrangement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical drug development involves a lengthy and expensive process with an uncertain outcome. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive and can take many years to complete, and our outcome is inherently uncertain. Failure can occur at any time during the clinical
trial process. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical and clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may experience delays in our ongoing or future clinical trials and we do not know whether planned clinical trials will begin or enroll subjects on time,
will need to be redesigned or will be completed on schedule, if at all. There can be no assurance that the FDA will not put clinical trials of any of our product candidates on clinical hold in the future. Clinical trials may be delayed, suspended or
prematurely terminated for a variety of reasons, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay or failure in reaching agreement with the FDA or a comparable foreign regulatory authority on a clinical trial design that we are able to execute; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay or failure in obtaining authorization to commence a trial or inability to comply with conditions imposed by a regulatory authority regarding the scope or design of a trial; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay or failure in reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary
significantly among different CROs and trial sites; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay or failure in obtaining institutional review board, approval or the approval of other reviewing entities, including comparable foreign regulatory authorities, to conduct a clinical trial at each site;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">withdrawal of clinical trial sites from our clinical trials or the ineligibility of a site to participate in our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay or failure in recruiting and enrolling suitable subjects to participate in a trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay or failure in subjects completing a trial or returning for post-treatment <FONT STYLE="white-space:nowrap">follow-up;</FONT></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical sites and investigators deviating from trial protocol, failing to conduct the trial in accordance with regulatory requirements, or dropping out of a trial; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inability to identify and maintain a sufficient number of trial sites, many of which may already be engaged in other clinical trial programs, including some that may be for the same indication; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure of our third-party clinical trial managers, CROs, clinical trial sites, contracted laboratories or other third-party vendors to satisfy their contractual duties, meet expected deadlines or return trustworthy
data; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay or failure in adding new trial sites; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">interim results or data that are ambiguous or negative or are inconsistent with earlier results or data; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">alteration of trial design necessitated by <FONT STYLE="white-space:nowrap">re-evaluation</FONT> of design assumptions based upon observed data; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">feedback from the FDA, the IRB, DSMBs or a comparable foreign regulatory authority, or results from earlier stage or concurrent preclinical studies and clinical trials, that might require modification to the protocol
for a trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a decision by the FDA, the IRB, a comparable foreign regulatory authority, or us, or a recommendation by a DSMB or comparable foreign regulatory authority, to suspend or terminate clinical trials at any time for safety
issues or for any other reason; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unacceptable risk-benefit profile, unforeseen safety issues or adverse side effects; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to demonstrate a benefit from using a product candidate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties in manufacturing or obtaining from third parties sufficient quantities of a product candidate to start or to use in clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lack of adequate funding to continue a trial, including the incurrence of unforeseen costs due to enrollment delays, requirements to conduct additional studies or increased expenses associated with the services of our
CROs and other third parties; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in governmental regulations or administrative actions or lack of adequate funding to continue a clinical trial. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient
population, the severity of the disease under investigation, the proximity of subjects to clinical sites, the patient referral practices of physicians, the eligibility criteria for the trial, the design of the clinical trial, ability to obtain and
maintain patient consents, risk that enrolled subjects will drop out or die before completion, competition for patients from other clinical trials, competing clinical trials and clinicians&#146; and patients&#146; perceptions as to the potential
advantages and risks of the drug being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating. We may not be able to initiate or continue to support clinical trials of
of our product candidates for one or more indications, or any future product candidates if we are unable to locate and enroll a sufficient number of eligible participants in these trials as required by the FDA or other regulatory authorities. Even
if we are able to enroll a sufficient number of patients in our clinical trials, if the pace of enrollment is slower than we expect, the development costs for our product candidates may increase and the completion of our trials may be delayed or our
trials could become too expensive to complete. We rely on CROs, other vendors and clinical trial sites to ensure the proper and timely conduct of our clinical trials, and while we have agreements governing their committed activities, we have limited
influence over their actual performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we experience delays in the completion or termination of any clinical trial of our product candidates, the
approval and commercial prospects of such product candidate will be harmed, and our ability to generate product revenues from such product candidate will be delayed. In addition, any delays in completing our clinical trials will increase our costs,
slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Any delays in completing our clinical trials for our product candidates may also decrease the period of
commercial exclusivity. In addition, many of the factors that could cause a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our current and future product candidates, the methods used to deliver them or their dosage levels may
cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following any regulatory approval.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Undesirable side effects caused by our current or future product candidates, their delivery methods or dosage levels could cause us or regulatory
authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authority. For example, although no high-grade
delayed type hypersensitivity in the skin or systemic anaphylaxis events have been noted after GPS administration in patients treated in our clinical studies to date, it is theoretically possible that such toxicities, or other type of adverse
events, may occur in future clinical studies. As a result of safety or toxicity issues that we may experience in our clinical trials, we may not receive approval to market any product candidates, which could prevent us from ever generating revenues
or achieving profitability. Results of our trials could reveal an unacceptably high severity and incidence of side effects. In such an event, our trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could
order us to cease further development of or deny approval of our product candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled subjects to complete the trial or
result in potential product liability claims. Any of these occurrences may have a material adverse effect on our business, results of operations, financial condition, cash flows and future prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, if any of our product candidates receives regulatory approval, and we or others later identify undesirable side effects caused by such product,
a number of potentially significant negative consequences could result, including that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be forced to suspend marketing of such product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may withdraw their approvals of such product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may require additional warnings on the label that could diminish the usage or otherwise limit the commercial success of such products; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be required to conduct post-marketing studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be required to change the way the product is administered; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we could be sued and held liable for harm caused to subjects or patients; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our reputation may suffer. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us from achieving or maintaining market
acceptance of the particular product candidate, if approved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product development program may not uncover all possible adverse events that
patients who take our product candidates may experience. The number of subjects exposed to product candidates and the average exposure time in the clinical development program may be inadequate to detect rare adverse events, or chance findings, that
may only be detected once the product is administered to more patients and for greater periods of time. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical trials by their nature utilize a
sample of the potential patient population. However, with a limited number of subjects and limited duration of exposure, we cannot be fully assured that rare and severe side effects of our product candidates will be uncovered. Such rare and severe
side effects may only be uncovered with a significantly larger number of patients exposed to our product candidates. If such safety problems occur or are identified after our product candidates reaches the market, the FDA may require that we amend
the labeling of the product or recall the product, or may even withdraw approval for the product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We currently have orphan drug exclusivity for certain product candidates, and may seek Orphan Drug Product
designation for additional product candidates or indications, which might not be received or provide the intended benefit thereof. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regulatory
authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug
intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States. We received Orphan Drug Product designations, from the FDA as well as orphan medicinal
product designations, from the EMA, for GPS in AML and MPM. We also have received Orphan Drug Product designation for <FONT STYLE="white-space:nowrap">GALE-301</FONT> and for <FONT STYLE="white-space:nowrap">GALE-302</FONT> from the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, if a product with an orphan drug designation subsequently receives the first regulatory approval for the indication for which it has such
designation, the product is entitled to a period of marketing exclusivity, which precludes the EMA or the FDA from approving another marketing application for the same drug for that time period. The applicable period is seven years in the United
States and ten years in Europe. The European exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug product designation or if the drug is sufficiently profitable so that market exclusivity is no longer
justified. Orphan drug exclusivity may be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the
rare disease or condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from
competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve a new drug for the same condition if the FDA concludes that the later drug is clinically superior in
that it is shown to be safer, more effective or makes a major contribution to patient care. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We currently have Fast Track designation for certain
product candidates, and may seek Fast Track designation for additional product candidates or indications, which might not be received or provide the intended benefits thereof. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a product candidate is intended for the treatment of a serious condition and nonclinical or clinical data demonstrate the potential to address unmet medical
need for this condition, a product sponsor may apply to the FDA for Fast Track designation, which may or may not be granted by the FDA. The FDA has given us Fast Track designation for GPS in AML and MPM and for NeuVax. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, Fast Track designation does not ensure that we will receive marketing approval or that approval will be granted within any particular timeframe. We
may not experience a faster development or regulatory review or approval process with Fast Track designation compared to conventional FDA procedures. In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no
longer supported by data from our clinical development program. Fast Track designation alone does not guarantee qualification for the FDA&#146;s priority review procedures. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure to obtain regulatory approval in international jurisdictions would prevent our product candidates from being marketed abroad. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to regulations in the United States, to market and sell our product candidates in the European Union, many Asian countries and other jurisdictions,
we must obtain separate regulatory approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ
substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. Clinical trials accepted in one country may not be
accepted by regulatory authorities in other countries. In addition, many countries outside the United States require that a product be approved for reimbursement before it can be approved for sale in that country. A product candidate that has been
approved for sale in a particular country may not receive reimbursement approval in that country. We may not be able to obtain approvals from regulatory authorities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by
regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able
to file for regulatory approvals and may not receive necessary approvals to commercialize our products in any market. If we are unable to obtain approval of any of our current or future product candidates by regulatory authorities in the European
Union, Asia or elsewhere, the commercial prospects of that product candidate may be significantly diminished, our business prospects could decline and this could materially adversely affect our business, results of operations and financial
condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if our current and future product candidates receive regulatory approval, they may still face future development and regulatory
difficulties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if our obtains regulatory approval for a product candidate, it would be subject to ongoing requirements by the FDA and
comparable foreign regulatory authorities governing the manufacture, quality control, further development, labeling, packaging, storage, distribution, adverse event reporting, safety surveillance, import, export, advertising, promotion,
recordkeeping and reporting of safety and other post-marketing information. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance by us and/or our contract
manufacturing organizations, or CMOs, and CROs for any post-approval clinical trials that it conducts. The safety profile of any product will continue to be closely monitored by the FDA and comparable foreign regulatory authorities after approval.
If the FDA or comparable foreign regulatory authorities become aware of new safety information after approval of any of our product candidates, they may require labeling changes or establishment of a risk evaluation and mitigation strategy, impose
significant restrictions on a product&#146;s indicated uses or marketing or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory
authorities for compliance with cGMP, cGCP, and other regulations. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where
the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. If we, our product
candidates or the manufacturing facilities for our product candidates fail to comply with applicable regulatory requirements, a regulatory agency may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issue warning letters or untitled letters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">mandate modifications to promotional materials or require us to provide corrective information to healthcare practitioners; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require us to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions and penalties for noncompliance; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seek an injunction or impose civil or criminal penalties or monetary fines; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspend or withdraw regulatory approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspend any ongoing clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refuse to approve pending applications or supplements to applications filed by us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspend or impose restrictions on operations, including costly new manufacturing requirements; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seize or detain products, refuse to permit the import or export of products, or require us to initiate a product recall. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The occurrence of any event or penalty described above may inhibit our ability to successfully commercialize our products and generate revenues. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Advertising and promotion of any product candidate that obtains approval in the United States will be heavily
scrutinized by the FDA, the DOJ, the Office of Inspector General of HHS, state attorneys general, members of Congress and the public. Additionally, advertising and promotion of any product candidate that obtains approval outside of the United States
will be heavily scrutinized by comparable foreign regulatory authorities. Violations, including actual or alleged promotion of our products for unapproved or <FONT STYLE="white-space:nowrap">off-label</FONT> uses, are subject to enforcement letters,
inquiries and investigations, and civil and criminal sanctions by the FDA. Any actual or alleged failure to comply with labeling and promotion requirements may have a negative impact on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not successfully identify, acquire, develop or commercialize new potential product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Part of our business strategy is to explore and evaluate opportunities to expand our product candidate pipeline by identifying and validating new product
candidates, which we may develop, <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire. In addition, in the event that our existing product candidates do not receive regulatory approval or are not successfully commercialized, then the
success of our business will depend on our ability to expand our product pipeline through <FONT STYLE="white-space:nowrap">in-licensing</FONT> or acquisitions. We may be unable to identify relevant product candidates. If we do identify such product
candidates, we may be unable to reach acceptable terms with any third party from which we desire to <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire them. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not realize the benefits our of strategic alliances that we may form in the future. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may form strategic alliances, create joint ventures or collaborations or enter into licensing arrangements with third parties that we believe will
complement or augment our existing business. These relationships, or those like them, may require us to incur nonrecurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders or
disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic alliances and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a
strategic alliance or other alternative arrangements for any future product candidates and programs because our research and development pipeline may be insufficient, our product candidates and programs may be deemed to be at too early a stage of
development for collaborative effort and third parties may not view our product candidates and programs as having the requisite potential to demonstrate safety and efficacy. If we license products or acquire businesses, we may not be able to realize
the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture. We cannot be certain that, following a strategic transaction or license, we will achieve the revenues or specific net
income that justifies such transaction. Any delays in entering into new strategic alliances agreements related to our product candidates could also delay the development and commercialization of our product candidates and reduce their
competitiveness even if they reach the market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">GALE-401</FONT> must successfully complete a Phase 3 clinical trial
and obtain regulatory approval before we can market the product and our competitors may obtain a successful clinical trial result and regulatory approval before we do. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">GALE-401</FONT> contains the active ingredient, anagrelide, an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> product
for the treatment of patients with MPNs, to lower abnormally elevated platelet levels. The currently available IR, version of anagrelide causes adverse reactions that are believed to be dose and plasma concentration dependent. According to the
Highlights section of the <FONT STYLE="white-space:nowrap">FDA-approved</FONT> prescribing information for AGRYLIN (anagrelide hydrochloride) capsules, for oral use (as revised in July&nbsp;2015), the most common adverse reactions (incidence &gt;
5%) are headache, palpitations, diarrhea, asthenia, edema, nausea, abdominal pain, dizziness, pain, dyspnea, cough, flatulence, vomiting, fever, peripheral edema, rash, chest pain, anorexia, tachycardia, malaise, paresthesia, back pain, pruritus and
dyspepsia. These adverse reactions may limit the use of the IR version of the drug. Therefore, reducing the maximum concentration, is hypothesized to reduce the adverse reactions, while preserving efficacy, potentially allowing broader use of the
drug. We have analyzed data from multiple Phase 1 and 2 <FONT STYLE="white-space:nowrap">GALE-401</FONT> clinical trials and the treatment landscape for MPNs, with a current focus on ET, where we see an unmet medical need in patients who are
intolerant to the current standard of care. The risks include but are not limited to regulatory (agreement with regulatory agency on the development plan), operational (rate of enrollment), and statistical confirmation of the safety and efficacy
endpoints. In addition, pursuant to the terms of the amended Exclusive License Agreement with BioVascular, dated December&nbsp;20, 2013, if the first patient is not enrolled in the Phase 3 clinical trial by December&nbsp;31, 2018, BioVascular shall
have the right to terminate the license agreement. Even if we successfully complete a Phase 3 trial, there are other potential competitors whose clinical trials may be successful and obtain regulatory approval prior to our regulatory approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are dependent on technologies we license, and if we lose the right to license such technologies or we
fail to license new technologies in the future, our ability to develop new products would be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently are dependent on licenses from
third parties for technologies relating to our product candidates. Our current licenses impose, and any future licenses we enter into are likely to impose, various development, funding, royalty, diligence, sublicensing, insurance and other
obligations on us. If our license with respect to any of these technologies is terminated for any reason, the development of the products contemplated by the licenses would be delayed, or suspended altogether, while we seek to license similar
technology or develop new <FONT STYLE="white-space:nowrap">non-infringing</FONT> technology. The costs of obtaining new licenses are high. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks
associated with operating in foreign countries could materially adversely affect our product development. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may conduct future studies in
countries outside of the United States. Consequently, we may be subject to risks related to operating in foreign countries. Risks associated with conducting operations in foreign countries include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">differing regulatory requirements for drug approvals and regulation of approved drugs in foreign countries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">more stringent privacy requirements for data to be supplied to the our operations in the United States, e.g. General Data Protection Regulation, in the European Union; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unexpected changes in tariffs, trade barriers and regulatory requirements; economic weakness, including inflation, or political instability in particular foreign economies and markets; compliance with tax, employment,
immigration and labor laws for employees living or traveling abroad; foreign taxes, including withholding of payroll taxes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">foreign currency fluctuations, which could result in increased operating expenses or reduced revenues, and other obligations incident to doing business or operating in another country; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">workforce uncertainty in countries where labor unrest is more common than in the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">business interruptions resulting from geopolitical actions, including war and terrorism. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to
Our Manufacturing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have limited to no manufacturing, sales, marketing or distribution capability and must rely upon third parties for such.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently have agreements with various third-party manufacturing facilities for production of our product candidates for research and
development and testing purposes. We depend on these manufacturers to meet our deadlines, quality standards and specifications. Our reliance on third parties for the manufacture of our active pharmaceutical ingredient and drug product and, in the
future, any approved products, creates a dependency that could severely disrupt our research and development, our clinical testing, and ultimately our sales and marketing efforts if the source of such supply proves to be unreliable or unavailable.
If the contracted manufacturing source is unreliable or unavailable, we may not be able to manufacture clinical drug supplies of our product candidates, and our preclinical and clinical testing programs may not be able to move forward and our entire
business plan could fail. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Both the active pharmaceutical ingredient and drug product for our product candidates are currently single sourced. We believe
these single sources are currently capable of supplying all anticipated needs of our proposed clinical studies, as well as initial commercial introduction. If we are able to commercialize our products in the future, there is no assurance that our
manufacturers will be able to meet commercialized scale production requirements in a timely manner or in accordance with applicable standards or cGMP. Once the nature and scope of additional indications and their commensurate drug product demands
are established, we will seek secondary suppliers of both the active pharmaceutical ingredient and drug product for our product candidates, but we cannot assure that such secondary suppliers will be found on terms acceptable to us, or at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to a multitude of manufacturing risks, any of which could substantially increase our costs
and limit supply of our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our company and our CMOs will need to conduct significant development work for each product candidate
for each target indication for studies, trials and commercial launch readiness. For example, the processes by which GPS is manufactured were initially developed by MSK for clinical purposes. Concurrent with the license of GPS, we acquired certain
supplies intended for clinical use, from MSK. These MSK clinical supplies may not be adequate for future clinical studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to improve the
existing processes for GPS for more advanced clinical trials or commercialization. Developing commercially viable manufacturing processes is a difficult and uncertain task, and there are risks associated with scaling to the level required for
advanced clinical trials or commercialization, including cost overruns, potential problems with process <FONT STYLE="white-space:nowrap">scale-up,</FONT> process reproducibility, stability issues, consistency and timely availability of reagents or
raw materials. The manufacturing facilities in which our product candidates will be made could be adversely affected by earthquakes and other natural disasters, equipment failures, labor shortages, power failures, and numerous other factors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, the process of manufacturing our product candidates is complex, highly regulated and subject to several risks, including but not limited to:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the manufacturing process is extremely susceptible to product loss due to contamination, equipment failure or improper installation or operation of equipment, or vendor or operator error. Even minor deviations from
normal manufacturing and distribution processes for our product candidates could result in reduced production yields, product defects, and other supply disruptions. Product defects can also occur unexpectedly. If microbial, viral, or other
contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates is made, such manufacturing facilities may need to be closed for an extended period of time to allow us to investigate and
remedy the contamination; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">GPS&#146;s active pharmaceutical ingredient manufacturing is sensitive to heavy metal contamination. As such, extremely low levels of heavy metals are part of the active pharmaceutical ingredient manufacturing process;
GPS&#146;s drug product manufacturing is sensitive to water and oxygen contamination, as such the drug product is lyophilized (to reduce and residual water) and under a nitrogen blanket (to reduce any oxygen). The presence of heavy metals in the
active pharmaceutical ingredient and excess water and oxygen in the drug product can lead to higher than acceptable levels of impurities, which can lead to the active pharmaceutical ingredient or drug product being unacceptable for use.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any adverse developments affecting manufacturing operations for our product candidates may result in shipment delays, inventory shortages,
lot failures, withdrawals or recalls or other interruptions in the supply of our drug substance and drug product, which could delay the development of our product candidates. We may also have to write off inventory, incur other charges and expenses
for supply of drug product that fails to meet specifications, undertake costly remediation efforts, or seek more costly manufacturing alternatives. Inability to meet the demand for our product candidates could damage our reputation and the
reputation of our products among physicians, healthcare payors, patients or the medical community, and cancer treatment centers, which could adversely affect our ability to operate our business and our results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>In the clinical trials using NeuVax and GPS, <FONT STYLE="white-space:nowrap">GM-CSF</FONT> is also administered and our availability is dependent upon
a third-party manufacturer, which may or may not reliably provide <FONT STYLE="white-space:nowrap">GM-CSF,</FONT> thus jeopardizing the completion of the trials. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of our product candidates are administered in combination with <FONT STYLE="white-space:nowrap">GM-CSF,</FONT> available in both liquid and lyopholyzed
forms exclusively from one manufacturer. We will continue to be dependent on that manufacturer for our supply of <FONT STYLE="white-space:nowrap">GM-CSF</FONT> in connection with the ongoing NeuVax and GPS trials and the potential commercial
manufacture of these programs. We have not entered into a supply agreement with the manufacturer for <FONT STYLE="white-space:nowrap">GM-CSF,</FONT> and instead rely on purchase orders to meet our supply needs. Any temporary interruptions or
discontinuation of the availability of <FONT STYLE="white-space:nowrap">GM-CSF,</FONT> or any determination by us to change the <FONT STYLE="white-space:nowrap">GM-CSF</FONT> used with NeuVax or GPS, may have a material adverse effect on our
clinical trials and any commercialization of the assets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If any of our CMOs&#146; clinical manufacturing facilities are damaged or destroyed or production at such
facilities is otherwise interrupted, our business and prospects would be negatively affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If our CMOs&#146; manufacturing facilities or the
equipment in them is damaged or destroyed, we may not be able to quickly or inexpensively replace our manufacturing capacity or replace it at all. In the event of a temporary or protracted loss of this facility or equipment, we might not be able to
transfer manufacturing to another CMO. Even if we could transfer manufacturing to another CMO, the shift would likely be expensive and time-consuming, particularly because the new facility would need to comply with the necessary regulatory
requirements and we would need FDA approval before selling any products manufactured at that facility. Such an event could delay our clinical trials or reduce our product sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Currently, we maintain insurance coverage against damage to our property and to cover business interruption and research and development restoration expenses.
However, our insurance coverage may not reimburse us, or may not be sufficient to reimburse us, for any expenses or losses we may suffer. We may be unable to meet our requirements for our product candidates if there were a catastrophic event or
failure of our current manufacturing facility or processes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Dependence on Third Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third parties to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual
duties or meet expected deadlines, or if we lose any of our CROs or other key third-party vendors, we may not be able to obtain regulatory approval for or commercialize our current or future product candidates on a timely basis, if at all.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have relied upon and plan to continue to rely upon third-party CROs, vendors and contractors to monitor and manage data for our ongoing
preclinical and clinical programs. For example, our collaborating investigators at MSK, along with their clinical and clinical operations teams, manage the conduct of the ongoing clinical trials for GPS as well as perform the analysis, publication
and presentation of data and results related to this program. We also rely on collaborating investigators, along with their clinical and clinical operations teams, at MSK for the collection and transfer of various types of <FONT
STYLE="white-space:nowrap">follow-up</FONT> data regarding studies previously conducted by MSK. We plan to rely on CROs and other third-party vendors for all currently contemplated clinical studies, with services to be rendered by such CROs ranging
from, in the case of assorted Phase 2 trials, specific and need-tailored (<I>e.g.</I>, data management and biostatistics) only to, in the case of in the case of our immune combination (PD1 blockade) Phase 2 trial and all planned Phase 3 trials, <FONT
STYLE="white-space:nowrap">all-encompassing.</FONT> We rely on these parties for the execution of our preclinical studies and clinical trials, and we control only some aspects of their activities. Nevertheless, we are responsible for ensuring that
each of our trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities. We also rely on third parties to assist
in conducting our preclinical studies in accordance with Good Laboratory Practices, and the Animal Welfare Act requirements. Our company and our CROs are required to comply with federal regulations, and GCP, which are international standards meant
to protect the rights and health of patients that are enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area and comparable foreign regulatory authorities for all of our products in clinical development.
Regulatory authorities enforce GCP through periodic inspections of trial sponsors, principal investigators and trial sites. If our company, or any of our partners or CROs, fail to comply with applicable regulations, the clinical data generated in
our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our regulatory applications. We cannot assure you that upon inspection by a
given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with applicable requirements. In addition, our clinical trials must be conducted with product produced under cGMP and other requirements. We
are also required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, clinicaltrials.gov, within a specified timeframe. Failure to comply with these regulations may require us to
repeat preclinical studies and clinical trials, which would delay the regulatory approval process and result in adverse publicity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our CROs, third-party vendors and contractors are not our employees, and except for remedies available to us
under our agreements with such CROs, third-party vendors and contractors, we cannot control whether or not they devote sufficient time and resources, including experienced staff, to our ongoing clinical, nonclinical and preclinical programs. They
may also have relationships with other entities, some of which may be our competitors. If CROs, third-party vendors and contractors do not successfully carry out their contractual duties or obligations or meet expected deadlines or if the quality or
accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to
obtain regulatory approval for or successfully commercialize our current or future product candidates. CRO, vendor or contractor errors could cause our results of operations and the commercial prospects for our current or future product candidates
to be harmed, our costs to increase and our ability to generate revenues to be delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our internal capacity for clinical trial execution and management
is limited and therefore we have relied on third parties. Outsourcing these functions involves risk that third parties may not perform to our standards, may not produce results or data in a timely manner or may fail to perform at all. Other data or
data updates from studies or trials previously conducted by MSK or others may emerge in the future. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the
risk that this information will be misappropriated. We currently have a small number of employees, which limits the internal resources we have available to identify and monitor our third-party providers. To the extent we are unable to identify and
successfully manage the performance of third-party service providers in the future, our business may be adversely affected. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges
or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our CROs, third-party vendors and contractors have the right to terminate their agreements with us in the event of an uncured material breach. In addition,
some of our CROs, third-party vendors and contractors have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such
termination, if we make a general assignment for the benefit of our creditors or if we are liquidated. Identifying, qualifying and managing performance of third-party service providers can be difficult, time consuming and cause delays in our
development programs. In addition, there is a natural transition period when a new CRO, third-party vendor or contractor commences work and the new CRO, third-party vendor or contractor may not provide the same type or level of services as the
original provider. If any of our relationships with our third-party CROs, third-party vendors or contractors terminate, we may not be able to enter into arrangements with alternative CROs, third-party vendors or contractors on a timely basis, on
commercially reasonable terms or at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to establish or maintain the third-party relationships that are necessary to develop or
potentially commercialize some or all of our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to depend on collaborators, partners, licensees, clinical research
organizations and other third parties to support our discovery efforts, to formulate product candidates, to manufacture our product candidates, and to conduct clinical trials for some or all of our product candidates. We cannot guarantee that we
will be able to successfully negotiate agreements for or maintain relationships with collaborators, partners, licensees, clinical investigators, vendors and other third parties on favorable terms, if at all. Our ability to successfully negotiate
such agreements will depend on, among other things, potential partners&#146; evaluation of the superiority of our technology over competing technologies and the quality of the preclinical and clinical data that we have generated, and the perceived
risks specific to developing our product candidates. If we are unable to obtain or maintain these agreements, we may not be able to clinically develop, formulate, manufacture, obtain regulatory approvals for or commercialize our product candidates.
Under certain license agreements that we have already entered into, we have minimum dollar amounts per year that we are obligated to spend on the development of the technology we have licensed from our contract partners and other obligations to
maintain certain licenses. If we fail to meet this requirement under any of our licenses that contain such requirements or any other obligations under these licenses, we may be in breach of our obligations under such agreement, which may result in
the loss of the technology licensed. We cannot necessarily control the amount or timing of resources that our contract partners will devote to our research and development programs, product candidates or potential product candidates, and we cannot
guarantee that these parties will fulfill their obligations to us under these arrangements in a timely fashion. We may not be able to readily terminate any such agreements with contract partners even if such contract partners do not fulfill our
obligations to us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we may receive notices from third parties from time to time alleging that our technology or product
candidates infringe upon the intellectual property rights of those third parties. Any assertion by third parties that our activities or product candidates infringe upon our intellectual property rights may adversely affect our ability to secure
strategic partners or licensees for our technology or product candidates or our ability to secure or maintain manufacturers for our compounds. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If
we fail to meet our obligations under our license agreements, we may lose the ability to develop our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business depends on
our ability to license therapeutic compounds from third parties. If we fail to meet our obligations under our license agreements, we may lose the ability to develop our product candidates, which would adversely affect our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We enter into various contracts in the normal course of our business in which we indemnify the other party to the contract. In the event we have to
perform under these indemnification provisions, it could have a material adverse effect on our business, financial condition and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the normal course of business, we periodically enter into academic, commercial, service, collaboration, licensing, consulting and other agreements that
contain indemnification provisions. With respect to our academic and other research agreements, we typically indemnify the institution and related parties from losses arising from claims relating to the products, processes or services made, used,
sold or performed pursuant to the agreements for which we have secured licenses, and from claims arising from our or our sublicensees&#146; exercise of rights under the agreement. With respect to our collaboration agreements, we indemnify our
collaborators from any third-party product liability claims that could result from the production, use or consumption of the product, as well as for alleged infringements of any patent or other intellectual property right by a third party. With
respect to consultants, we indemnify them from claims arising from the good faith performance of their services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Should our obligation under an
indemnification provision exceed applicable insurance coverage or if we were denied insurance coverage, our business, financial condition and results of operations could be adversely affected. Similarly, if we are relying on a collaborator to
indemnify us and the collaborator is denied insurance coverage or the indemnification obligation exceeds the applicable insurance coverage, and if the collaborator does not have other assets available to indemnify us, our business, financial
condition and results of operations could be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to obtain and enforce patent rights or other intellectual property rights that cover our product candidates and that are of sufficient
breadth to prevent third parties from competing against us. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our success with respect to our product candidates will depend in part on our ability
to obtain and maintain patent protection in the United States and abroad, to preserve our trade secrets, and to prevent third parties from infringing upon our proprietary rights. Our patents and patent applications, however, may not be sufficient to
provide protection for GPS, NeuVax or our other products and product candidates against commercial competition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The four peptide components of GPS are <FONT
STYLE="white-space:nowrap">WT1-A1,</FONT> <FONT STYLE="white-space:nowrap">WT1-427</FONT> long, <FONT STYLE="white-space:nowrap">WT1-331</FONT> long, and <FONT STYLE="white-space:nowrap">WT1-122A1</FONT> long. We have an exclusive license to United
States and foreign patents relating to these peptides from MSK, for all therapeutic and diagnostic uses. Under the license, we have issued patents covering the composition of matter of the <FONT STYLE="white-space:nowrap">WT1-A1</FONT> peptide in
the United States, Australia, Switzerland, Germany, Spain, France, Great Britain, and Italy, and an issued Canadian patent covering the composition of matter and its use for inducing a cytotoxic T cell response in a human that cross-reacts with a
cancer cell that presents a native form of the peptide. The U.S. patent on the <FONT STYLE="white-space:nowrap">WT1-A1</FONT> peptide (U.S. Patent No.&nbsp;7,488,718) will expire on March&nbsp;22, 2026, including patent term adjustment, and the
foreign patents will expire on November&nbsp;30, 2024, absent patent term extension. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have licensed, issued patents covering the composition of matter of the
<FONT STYLE="white-space:nowrap">WT1-427</FONT> long peptide, and methods of use, in the United States, Australia, Switzerland, Germany, Spain, France, Great Britain, Ireland, Italy, and Canada. The United States composition of matter patent on the <FONT
STYLE="white-space:nowrap">WT1-427</FONT> long peptide (U.S. Patent No.&nbsp;8,765,687) will expire on October&nbsp;26, 2031, including patent term adjustment. The United States method of use patent (U.S. Patent No.&nbsp;9,233,149) will expire on
October&nbsp;17, 2026, absent patent term extension, and covers treating a subject with a <FONT STYLE="white-space:nowrap">WT1-expressing</FONT> cancer, reducing an incidence of a <FONT STYLE="white-space:nowrap">WT1-expressing</FONT> cancer, or its
relapse, and inducing the formation and proliferation of a cytotoxic T lymphocyte specific for a <FONT STYLE="white-space:nowrap">WT1-expressing</FONT> cancer. The foreign patents will expire on October&nbsp;17, 2026, absent patent term extension.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have licensed, issued patents covering the composition of matter of the <FONT STYLE="white-space:nowrap">WT1-331</FONT> long peptide, and methods of
use, in the United States, Switzerland, Germany, Spain, France, Great Britain, Ireland, and Italy. The United States composition of matter patent on the <FONT STYLE="white-space:nowrap">WT1-331</FONT> long peptide (U.S. Patent No.&nbsp;8,765,687)
will expire on October&nbsp;26, 2031, including patent term adjustment. The United States method of use patent (U.S. Patent No.&nbsp;9,233,149) will expire on October&nbsp;17, 2026, absent patent term extension, and covers treating a subject with a <FONT
STYLE="white-space:nowrap">WT1-expressing</FONT> cancer, reducing an incidence of a <FONT STYLE="white-space:nowrap">WT1-expressing</FONT> cancer, or its relapse, and inducing the formation and proliferation of a cytotoxic T lymphocyte specific for
a <FONT STYLE="white-space:nowrap">WT1-expressing</FONT> cancer. The&nbsp;foreign patents will expire on October&nbsp;17, 2026, absent patent term extension. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have a licensed, issued United States patent covering the composition of matter of the <FONT STYLE="white-space:nowrap">WT1-1221A1</FONT> long peptide, and
issued patents covering the composition of matter and methods of use, in Austria, Belgium, Switzerland, Germany, Spain, Finland, France, Great Britain, Greece, Ireland, Italy, Netherlands, Poland, Romania, and Turkey. The United States composition
of matter patent on the <FONT STYLE="white-space:nowrap">WT1-1221A1</FONT> long peptide (U.S. Patent No.&nbsp;9,265,816) will expire on February&nbsp;20, 2033, including patent term adjustment. The European patents will expire on April&nbsp;10,
2027, absent patent term extension, and cover the composition of matter and use of the peptide for the preparation of a medicament for treating a <FONT STYLE="white-space:nowrap">WT1-expressing</FONT> cancer or for reducing an incidence of a <FONT
STYLE="white-space:nowrap">WT1-expressing</FONT> cancer or its relapse in a subject. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The active peptide found in NeuVax, the E75 peptide, has been known
and studied for many years. We have one issued U.S. patent, US 6,514,942, covering the composition of matter of the E75 peptide, which expired in <FONT STYLE="white-space:nowrap">mid-2015,</FONT> prior to any potential commercialization of NeuVax.
We do not have and will not be able to obtain any composition of matter patent protection for E75, the active peptide in NeuVax. We also have a license from HJF to issued United States, European, Japanese, Korean, Mexican and Australian method of
use patents, which expire in 2028, that are directed to a method of inducing immunity against breast cancer recurrence by administering a composition comprising the E75 peptide to patients who have both an immunohistochemistry, or IHC, rating of 1+
or 2+ for HER2/neu protein expression, as well as a fluorescence in situ hybridization, or FISH, rating of less than about 2.0 for HER2/neu gene expression. The license further includes an issued United States method of use patent directed to a
method of inducing immunity against recurrence of any HER2/neu expressing tumors by administering the E75 peptide to patients with tumors having a FISH rating of less than about 2.0 for HER2/neu gene expression; an issued United States patent which
includes claims to the use of E75 to reduce the risk of cancer recurrence, including bone only recurrence; and pending applications with similar claims in a number of foreign jurisdiction, all of which expire in 2028. Also included in the license is
a method of use patent, which expires in 2026, that is directed to the use of NeuVax in combination with Herceptin (trastuzumab) to treat any HER2/neu expressing cancer. Thus, our method of use patents may not prevent competitors from seeking to
develop and market NeuVax for use in cancer patients who do not meet these criteria. If any such alternative uses were approved, this could lead to <FONT STYLE="white-space:nowrap">off-label</FONT> use and price erosion for our NeuVax product. We
may seek FDA approval for use of NeuVax to treat cancer patients who fall outside the claimed IHC and FISH ranges and for other cancers as well. Although we are pursuing additional patent protection for NeuVax through pending patent applications, we
may not be able to obtain additional patent protection that would provide us with a significant commercial advantage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Anagrelide hydrochloride, the sole
active pharmaceutical ingredient in <FONT STYLE="white-space:nowrap">GALE-401,</FONT> has been approved for many years and, thus, it is not possible to obtain composition of matter patents that cover anagrelide hydrochloride. As a result,
competitors who obtain the requisite regulatory approval can offer products with the same active pharmaceutical ingredients as <FONT STYLE="white-space:nowrap">GALE-401,</FONT> so long as the competitors do not infringe any formulation patents that
we may have or may obtain or license, if any. The only patent protection that we have or are likely to obtain covering <FONT STYLE="white-space:nowrap">GALE-401</FONT> are patents relating to specific formulations, methods using these formulations,
and methods of manufacturing and packaging. We have an issued United States patent, which expires in 2020, covering methods of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Using anagrelide to reduce platelet count in patients subject to veno-occlusive events. We have granted patents
in the United States, United Kingdom and Japan, which expire in 2029, covering controlled release formulations of anagrelide and methods of use. We also are prosecuting pending patent applications in other territories including, but not limited to,
the United States, Europe, India, and Japan, which may not issue prior to any potential commercialization of <FONT STYLE="white-space:nowrap">GALE-401.</FONT> We may seek FDA approval for use of <FONT STYLE="white-space:nowrap">GALE-401</FONT> to
treat patients with myeloproliferative neoplasms that include several hematological disorders, including essential thrombocythemia. Although we are pursuing additional patent protection for <FONT STYLE="white-space:nowrap">GALE-401</FONT> through
pending patent applications, we may not be able to obtain additional patent protection that would provide us with a significant commercial advantage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
active peptides found in <FONT STYLE="white-space:nowrap">GALE-301</FONT> and <FONT STYLE="white-space:nowrap">GALE-302</FONT> are derived from Folate Binding Protein. One of the active peptides, E39, has been known and studied for many years. The
other active peptide, <FONT STYLE="white-space:nowrap">GALE-302</FONT> (peptide E39&#146;), is a derivative of E39. We have a license from MDACC and HJF to issued and granted patents in the United States, Europe, Canada, and Japan, covering
composition of matter for the E39 derivative peptides, including <FONT STYLE="white-space:nowrap">GALE-302,</FONT> alone and in combination with E39, as well as the use of these compositions for the treatment of cancer. These patents are expected to
expire in 2022, prior to any potential commercialization of <FONT STYLE="white-space:nowrap">GALE-301.</FONT> We also have an allowed United States application with claims to combination dosage regimens of
<FONT STYLE="white-space:nowrap">GALE-301</FONT> and <FONT STYLE="white-space:nowrap">GAL-302</FONT> which will expire in 2036 (excluding PTA). We also have pending United States and International (PCT) applications with claims to methods of
inducing an immune response to tumors with an immunohistochemistry (IHC) rating of 0 or 1+ for folate binding protein expression which, if granted, would expire in 2037. We do not have and will not be able to obtain any composition of matter patent
protection for the E39 peptide in any territory. The license we have from MDACC and HJF grants us the right to develop and market <FONT STYLE="white-space:nowrap">GALE-301</FONT> for any use, including methods of treating cancer. Our patents may not
prevent competitors from seeking to develop and market the E39 peptide alone. If any such alternative uses of compositions containing the E39 peptide were approved, this could lead to off label use and price erosion for <FONT
STYLE="white-space:nowrap">GALE-301.</FONT> We may seek FDA approval for use of <FONT STYLE="white-space:nowrap">GALE-301,</FONT> alone or in combination with <FONT STYLE="white-space:nowrap">GALE-302,</FONT> to treat cancer patients with ovarian
and endometrial cancers and for other cancers, as well. Although we are pursuing additional patent protection for <FONT STYLE="white-space:nowrap">GALE-301</FONT> and the combination of <FONT STYLE="white-space:nowrap">GALE-301</FONT> and <FONT
STYLE="white-space:nowrap">GALE-302</FONT> through pending patent applications, we may not be able to obtain additional patent protection that would provide us with a significant commercial advantage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to obtain, maintain and enforce patents is uncertain and involves complex legal and factual questions. Accordingly, rights under any patents we
have or may obtain or license may not provide us with sufficient protection for our commercial product and product candidates to afford a commercial advantage against competitive products or processes, including those from branded and generic
pharmaceutical companies. In addition, we cannot guarantee that any patents will issue from any pending or future patent applications owned by or licensed to us. Nor can we guarantee that the claims of these patents will be held valid or enforceable
by the courts or will provide us with any significant protection against competitive products or otherwise be commercially valuable to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in
either the patent laws or in the interpretations of patent laws in the United States or abroad may diminish the value of our intellectual property. In addition, on September&nbsp;16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act,
was signed into law. The Leahy-Smith Act includes a number of significant changes to the U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. Accordingly, it is
not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act, in particular the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-to-file</FONT></FONT> provision
and our implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement of or defense of our issued patents, all of which could have a material adverse effect on our business and
financial condition. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
addition, United States Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances in certain situations. From time to time, the United States Supreme Court, other federal courts, the United States
Congress, or interpretation by the United States Patent and Trademark Office or USPTO, may change the standards of patentability and any such changes could have a negative impact on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some cases decided by the United States Supreme Court have involved questions of when claims reciting abstract
ideas, laws of nature, natural phenomena and/or natural products are eligible for a patent, regardless of whether the claimed subject matter is otherwise novel and inventive. These cases include<I></I><I>&nbsp;Association for Molecular Pathology v.
Myriad Genetics, Inc.</I>, 569 U.S. 576 (2013), also known as the Myriad decision;<I>&nbsp;Alice Corp. v. CLS Bank International</I>, 573 U.S. <FONT STYLE="white-space:nowrap">13-298</FONT> (2014), also known as the Alice decision; and<I>&nbsp;Mayo
Collaborative Services v. Prometheus Laboratories, Inc.</I>, also known as the Prometheus decision, 566 U.S. 66 (2012). The full impact of these decisions is not yet known. In view of these and subsequent court decisions, the USPTO has issued
materials to patent examiners providing guidance for determining the patent eligibility of claims reciting laws of nature, natural phenomena, or natural products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our current product candidates include products, or components, derived to various extents from nature; therefore, these decisions and their interpretation by
the courts and the USPTO may impact prosecution, defense, and enforcement of certain types of patent claims in our patent portfolio. In addition to increasing uncertainty with regard to our ability to obtain future patents, this combination of
events has created uncertainty with respect to the value of patents, once obtained. Depending on these and other decisions by United&nbsp;States Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change or
be interpreted in unpredictable ways that would weaken our ability to obtain some patent claims or to enforce patents that may issue to us in the future. In addition, these events may adversely affect our ability to defend patents that may issue in
procedures in the USPTO or in United&nbsp;States courts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While we intend to take actions reasonably necessary to enforce our patent rights, we may not be
able to detect infringement of our own or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, which may be especially difficult for methods of manufacturing or formulation products, and we depend, in part, on our licensors and collaborators
to protect a substantial portion of our proprietary rights. In addition, third parties may challenge our <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and any of our own patents that we may obtain, which could result in the
invalidation or unenforceability of some or all of the relevant patent claims. Litigation or other proceedings to enforce or defend intellectual property rights is very complex, expensive, and may divert our management&#146;s attention from our core
business and may result in unfavorable results that could adversely affect our ability to prevent third parties from competing with us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If another party
has reason to assert a substantial new question of patentability against any of our claims in our own and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, the third party can request that the patent claims be reexamined, which may result
in a loss of scope of some claims or a loss of the entire patent. In addition to potential infringement suits, and interference and reexamination proceedings, we may become a party to patent opposition proceedings where eiher the patentability of
the inventions subject of our patents are challenged, or we are challenging the patents of others. The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful. As the medical device, biotechnology
and pharmaceutical industries expand and more patents are issued, the risk increases that others may assert our commercial product and/or product candidates infringe their patent rights. If a third-party&#146;s patents were found to cover our
commercial product and product candidates, proprietary technologies or our uses, we or our collaborators could be enjoined by a court and required to pay damages and could be unable to continue to commercialize our products or use our proprietary
technologies unless we or it obtained a license to the patent. A license may not be available to us or our collaborators on acceptable terms, if at all. In addition, during litigation, the patent holder could obtain a preliminary injunction or other
equitable relief, which could prohibit us from making, using or selling our commercial product and product candidates pending a trial on the merits, which could be years away. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proprietary trade secrets and unpatented <FONT STYLE="white-space:nowrap">know-how</FONT> are also very important to our business. Although we have taken
steps to protect our trade secrets and unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> by entering into confidentiality agreements with third parties, and proprietary information and invention agreements with certain employees,
consultants and advisors, third parties may still obtain this information or we may be unable to protect our rights. We also have limited control over the protection of trade secrets used by our licensors, collaborators and suppliers. There can be
no assurance that binding agreements will not be breached, that we would have adequate remedies for any breach, or that our trade secrets and unpatented <FONT STYLE="white-space:nowrap">know-how</FONT> will not otherwise become known or be
independently discovered by our competitors. If trade secrets are independently discovered, we would not be able to prevent their use. Enforcing a claim that a third party illegally obtained and is using our trade secrets or unpatented <FONT
STYLE="white-space:nowrap">know-how</FONT> is expensive and time consuming, and the outcome is unpredictable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or
disclosed to us alleged trade secrets of their other clients or former employers. As is common in the biotechnology and pharmaceutical industry, certain of our employees were formerly employed by other biotechnology or pharmaceutical companies,
including our competitors or potential competitors. Moreover, we engage the services of consultants to assist us in the development of our commercial product and product candidates, many of whom were previously employed at or may have previously
been or are currently providing consulting services to, other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees and consultants or we have inadvertently or
otherwise used or disclosed trade secrets or other proprietary information of their former employers or their former or current customers. Litigation may be necessary to defend against these types of claims. Even if we are successful in defending
against any such claims, any such litigation would likely be protracted, expensive, a distraction to our management team, not viewed favorably by investors and other third parties, and may potentially result in an unfavorable outcome. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates may face competition sooner than expected after the expiration of our composition of matter patent protection for such products.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our composition of matter patents for many of our product candidates have expired or will expire prior to any product approval. We intend to seek
data exclusivity or market exclusivity for our GPS as well as our NeuVax, <FONT STYLE="white-space:nowrap">GALE-301</FONT> and <FONT STYLE="white-space:nowrap">GALE-302</FONT> product candidates provided under the Federal Food, Drug and Cosmetic
Act, or FDCA, and similar laws in other countries. We believe that these product candidates will qualify for 12 years of data exclusivity under the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which was enacted as part of the
Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act of 2010 enacted in March 2010. Under the BPCIA, an application for a biosimilar product or BLA cannot be submitted to the FDA until four
years, or if approved by the FDA, until 12 years, after the original brand product identified as the reference product is approved under a BLA. The BPCIA provides an abbreviated pathway for the approval of biosimilar and interchangeable biological
products. The new abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#147;interchangeable&#148; based on our similarity to an
existing brand product. The new law is complex and is only beginning to be interpreted and implemented by the FDA. While it is uncertain when any such processes may be fully adopted by the FDA, any such processes could have a material adverse effect
on the future commercial prospects for our biological product candidates. There is also a risk that the U.S. Congress could amend the BPCIA to shorten this exclusivity period, potentially creating the opportunity for biosimilar competition sooner
than anticipated after the expiration of our patent protection. Moreover, the extent to which a biosimilar, once approved, will be substituted for any reference product in a way that is similar to traditional generic substitution for <FONT
STYLE="white-space:nowrap">non-biological</FONT> products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If our product candidates are not considered biologics that would qualify for exclusivity under the BPCIA, they may be eligible for market exclusivity as
drugs under the FDCA. The FDCA provides a five-year period of <FONT STYLE="white-space:nowrap">non-patent</FONT> marketing exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a
new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for
review an abbreviated new drug application, or ANDA, or a 505(b)(2) NDA, submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval.
However, an application may be submitted after four years if it contains a certification of patent invalidity or <FONT STYLE="white-space:nowrap">non-infringement.</FONT> The FDCA also provides three years of marketing exclusivity for an NDA,
505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by FDA to be essential to the approval of the application, for example,
for new indications, dosages, or strengths of an existing drug. This three-year exclusivity covers only the conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the
original active agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if, as we expect, GPS, NeuVax, <FONT STYLE="white-space:nowrap">GALE-301</FONT> and
<FONT STYLE="white-space:nowrap">GALE-302</FONT> are considered to be reference products eligible for 12 years of exclusivity under the BPCIA or five years of exclusivity under the FDCA, another company could market competing products if the FDA
approves a full BLA or full NDA for such product containing the sponsor&#146;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of the products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some countries outside of the United States, peptide vaccines, such as GPS, NeuVax, <FONT
STYLE="white-space:nowrap">GALE-301</FONT> and <FONT STYLE="white-space:nowrap">GALE-302,</FONT> are regulated as chemical drugs rather than as biologics and may or may not be eligible for <FONT STYLE="white-space:nowrap">non-patent</FONT>
exclusivity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we have received orphan drug designation for both GPS, <FONT STYLE="white-space:nowrap">GALE-301</FONT> and <FONT
STYLE="white-space:nowrap">GALE-302,</FONT> there is no guarantee that these products will be successfully approved by the FDA, that they will be commercially successful in the marketplace, or that another product will not be approved for the same
indication ahead of our product candidate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are sued for infringing the intellectual property rights of third parties, such litigation could
be costly and time-consuming and could prevent or delay our development and commercialization efforts. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our commercial success depends, in part, on
us and our collaborators not infringing the patents and proprietary rights of third parties. There is a substantial amount of litigation and other adversarial proceedings, both within and outside the United States, involving patent and other
intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interference or derivation proceedings, oppositions, and <I>inter partes</I> and post-grant review proceedings before the USPTO
and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> patent offices. Numerous U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> issued patents and pending patent applications owned by third parties exist in the fields in which we are
developing and may develop our current and future product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, and as our product pipeline grows, the risk increases that our product candidates may be
subject to claims of infringement of third parties&#146; patent rights as it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to
interpretation by the courts, and the interpretation is not always uniform or predictable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third parties may assert infringement claims against us based
on existing or future intellectual property rights, alleging that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of
manufacture or methods for treatment related to the use or manufacturing of our product candidates that we failed to identify. For example, applications filed before November&nbsp;29, 2000, and certain applications filed on or after that date that
will not be filed outside the United States, remain confidential until issued as patents. Except for the preceding exceptions, patent applications in the United States and elsewhere are generally published only after a waiting period of
approximately 18 months after the earliest filing date. Therefore, patent applications covering our product candidates, or their use or manufacture, could have been filed by others without our knowledge. In addition, pending patent applications that
have been published, including some of which we are aware, could be later amended in a manner that could cover our product candidates or their use or manufacture. We may analyze patents or patent applications of our competitors that we believe are
relevant to our activities and believe that we are free to operate in relation to any of our product candidates, but our competitors may obtain issued claims, including in patents we consider to be unrelated, which may block our efforts or
potentially result in any of our product candidates or our activities infringing such claims. If we are sued for patent infringement, we would need to demonstrate that our product candidates, products and methods either do not infringe the patent
claims of the relevant patent or that the patent claims are invalid, and we may not be able to do this. Proving that a patent is invalid is difficult. For example, in the United States, proving invalidity in a district court proceeding requires a
showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents, and proving invalidity in an <I>inter partes</I> review proceeding in the USPTO requires a showing of a preponderance of the evidence. Even
if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted, which could have a material adverse effect on us. If any issued third-party patents
were held by a court of competent jurisdiction to cover aspects of our materials, formulations, methods of manufacture or methods for treatment, we could be forced, including by court order, to cease developing, manufacturing or commercializing the
relevant product candidate until such patent expired. Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and to continue developing, manufacturing or marketing the infringing product
candidate. However, we may not be able to obtain any required license on commercially reasonably terms, or at all. Even if we were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the
same intellectual property licensed to us. Ultimately, we could be prevented from commercializing a product candidate, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims,
we are unable to enter into licenses on acceptable terms. This could harm our business significantly. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block
our ability to further develop and commercialize one or more of our product candidates. Defending against claims of patent infringement or misappropriation of trade secrets could be costly and time consuming, regardless of the outcome. Thus, even if
we were to ultimately prevail, or to settle at an early stage, such litigation could burden us with substantial unanticipated costs. In addition, litigation or threatened litigation could result in significant demands on the time and attention of
our management team, distracting them from the pursuit of other company business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#146; fees if we are
found to have willfully infringed a patent, or to redesign our infringing product candidates, which may be impossible or require substantial time and monetary expenditure. we may also elect to enter into license agreements in order to settle patent
infringement claims prior to litigation, and any such license agreement may require us to pay royalties and other fees that could be significant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may
face claims that we misappropriated the confidential information or trade secrets of a third party. If we are found to have misappropriated a third party&#146;s trade secrets, we may be prevented from further using such trade secrets, which could
limit our ability to develop our product candidates. We are not aware of any material threatened or pending claims related to these matters, but in the future litigation may be necessary to defend against such claims. If we fail in defending any
such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to
management. During the course of any patent or other intellectual property litigation, there could be public announcements of the results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or
investors regard these announcements as negative, the perceived value of our product candidates, programs or intellectual property could be diminished. Accordingly, the market price of our shares of common stock may decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of
third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We employ individuals who
were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we have written agreements and makes every effort to ensure that our employees, consultants,
and independent contractors do not use the proprietary information or intellectual property rights of others in their work for us, we may in the future be subject to any claims that our employees, consultants, or independent contractors have
wrongfully used or disclosed confidential information of third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual
property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to protect our intellectual property rights throughout the world. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filing, prosecuting, enforcing and defending patents on our current and future product candidates in all countries throughout the world would be prohibitively
expensive. We or our licensors&#146; intellectual property rights in certain countries outside the United States may be less extensive than those in the United States. In addition, the laws of certain foreign countries do not protect intellectual
property rights to the same extent as laws in the United States. Consequently, we and our licensors may not be able to prevent third parties from practicing our and our licensors&#146; inventions in countries outside the United States, or from
selling or importing infringing products made using our and our licensors&#146; inventions in and into the United States or other jurisdictions. Competitors may use our and our licensors&#146; technologies in jurisdictions where we have not obtained
patent protection or where we do not have exclusive rights under the relevant patent(s) to develop their own products and, further, may export otherwise infringing products to territories where we and our licensors have patent protection but where
enforcement is not as strong as that in the United States. These infringing products may compete with our product candidates in jurisdictions where we or our licensors have no issued patents or where we do not have exclusive rights under the
relevant patent(s), or our patent claims and other intellectual property rights may not be effective or sufficient to prevent them from so competing. Many companies have encountered significant problems in protecting and defending intellectual
property rights </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do
not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us and our licensors to stop the infringement of our and our licensors&#146;
patents or marketing of competing products in violation of our and our licensors&#146; proprietary rights generally. Proceedings to enforce our and our licensors&#146; patent rights in foreign jurisdictions could result in substantial costs and
divert our attention from other aspects of our business, could put our and our licensors&#146; patents at risk of being invalidated or interpreted narrowly, could put our and our licensors&#146; patent applications at risk of not issuing, and could
provoke third parties to assert claims against our or our licensors. We or our licensors may not prevail in any lawsuit that we or our licensors initiate, and even if we or our licensors are successful the damages or other remedies awarded, if any,
may not be commercially meaningful. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have <FONT STYLE="white-space:nowrap">in-licensed</FONT> a significant portion of our intellectual property
from MSK. If we breach our license agreement with MSK, we could lose the ability to continue the development and potential commercialization of GPS. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not currently own any patents or patent applications related to our lead product candidate, GPS. GPS is
<FONT STYLE="white-space:nowrap">licensed-in</FONT> from MSK, and includes an exclusive license to United States and foreign patent applications. Under the MSK license agreement, we are subject to various obligations, including diligence obligations
with respect to funding, development and commercialization activities, payment obligations upon achievement of certain milestones and royalties on product sales, as well as other material obligations. If there is any conflict, dispute, disagreement
or issue of nonperformance between us and MSK regarding our rights or obligations under the license agreements, including any such conflict, dispute or disagreement arising from our failure to satisfy diligence or payment obligations under any such
agreement, we may be liable to pay damages and MSK may have a right to terminate the affected license. The loss of our license agreement with MSK could materially adversely affect our ability to proceed to utilize the affected intellectual property
in our development efforts, our ability to enter into future collaboration, licensing and/or marketing agreements for GPS and our ability to commercialize GPS. The risks described elsewhere pertaining to our patents and other intellectual property
rights also apply to the intellectual property rights that we license, and any failure by us or our licensors to obtain, maintain and enforce these rights could have a material adverse effect on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming and unsuccessful and have a
material adverse effect on the success of our business and on our stock price. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third parties may infringe our patents, the patents of our
licensors, or misappropriate or otherwise violate our or our licensors&#146; intellectual property rights. We and our licensors&#146; patent applications cannot be enforced against third parties practicing the technology claimed in such applications
unless and until a patent issues from such applications, and then only to the extent the issued claims cover the technology. In the future, we or our licensors may elect to initiate legal proceedings to enforce or defend our or our licensors&#146;
intellectual property rights, to protect our or our licensors&#146; trade secrets or to determine the validity or scope of intellectual property rights we own or control. Any claims that we assert against perceived infringers could also provoke
these parties to assert counterclaims against us alleging that we infringe their intellectual property rights or that our intellectual property rights are invalid. In addition, third parties may initiate legal proceedings against us or our licensors
to challenge the validity or scope of intellectual property rights we own or control. The proceedings can be expensive and time-consuming. Many of our or our licensors&#146; adversaries in these proceedings may have the ability to dedicate
substantially greater resources to prosecuting these legal actions than we or our licensors can. Accordingly, despite our or our licensors&#146; efforts, we or our licensors may not be able to prevent third parties from infringing upon or
misappropriating intellectual property rights we own or control, particularly in countries where the laws may not protect our rights as fully as in the United States. Litigation could result in substantial costs and diversion of management
resources, which could harm our business and financial results. In addition, in an infringement proceeding, a court may decide that a patent owned by or licensed to us are invalid or unenforceable, in whole or in part, or may refuse to stop the
other party from using the technology at issue on the grounds that our or our licensors&#146; patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our or our licensors&#146; patents
at risk of being invalidated, held unenforceable or interpreted narrowly. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interference or derivation proceedings provoked by third parties, brought by us or our licensors or
collaborators, or brought by the USPTO or any <FONT STYLE="white-space:nowrap">non-U.S.</FONT> patent authority may be necessary to determine the priority of inventions or matters of inventorship with respect to our or our licensors&#146; patents or
patent applications. We may also become involved in other proceedings, such as reexamination or opposition proceedings, <I>inter partes</I> review, post-grant review or other <FONT STYLE="white-space:nowrap">pre-issuance</FONT> or post-grant
proceedings in the USPTO or our foreign counterparts relating to our intellectual property or the intellectual property of others. An unfavorable outcome in any such proceeding could require us or our licensors to cease using the related technology
and commercializing the affected product candidate, or to attempt to license rights to it from the prevailing party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business could be harmed if the
prevailing party does not offer us or our licensors a license on commercially reasonable terms if any license is offered at all. Even if we or our licensors obtain a license, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby
giving our competitors access to the same technologies licensed to us or our licensors. In addition, if the breadth or strength of protection provided by us or our licensor&#146;s patents and patent applications is threatened, it could dissuade
companies from collaborating with us to license, develop or commercialize current and future product candidates. Even if we successfully defend such litigation or proceeding, we may incur substantial costs and it may distract our management and
other employees. We could be found liable for monetary damages, including treble damages and attorneys&#146; fees, if we are found to have willfully infringed a patent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our
confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or
investors perceive these results to be negative, it could have a substantial adverse effect on the price of shares of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are
unable to protect the confidentiality of our trade secrets and other proprietary information, the value of our technology could be materially adversely affected and our business could be harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to seeking the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary <FONT
STYLE="white-space:nowrap">know-how</FONT> that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce, and other elements of our technology, discovery and development processes that involve
proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> information or technology that is not covered by patents. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to
quickly duplicate or surpass our technological achievements, including by enabling them to develop and commercialize products substantially similar to or competitive with our current or future product candidates, thus eroding our competitive
position in the market. Trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements and invention assignment agreements with our employees, consultants,
and outside scientific advisors, contractors and collaborators. These agreements are designed to protect our proprietary information. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, or
outside scientific advisors might intentionally or inadvertently disclose our trade secrets or confidential, proprietary information to competitors. In addition, competitors may otherwise gain access to our trade secrets or independently develop
substantially equivalent information and techniques. If any of our confidential proprietary information were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from using that
technology or information to compete with us, which could harm our competitive position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Enforcing a claim that a third party illegally obtained and is
using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, the laws of certain foreign countries do not protect proprietary rights such as trade secrets to the same extent or in the same manner as
the laws of the United States. Misappropriation or unauthorized disclosure of our trade secrets to third parties could impair our competitive advantage in the market and could materially adversely affect our business, results of operations and
financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Significant disruptions of information technology systems or breaches of information security could
adversely affect our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely to a large extent upon sophisticated information technology systems to operate our business. In the
ordinary course of business, we collect, store and transmit large amounts of confidential information (including, but not limited to, personal information and intellectual property). We also have outsourced significant elements of our operations to
third parties, including significant elements of our information technology infrastructure and, as a result, we are managing many independent vendor relationships with third parties who may or could have access to our confidential information. The
size and complexity of our information technology and information security systems, and those of our third-party vendors with whom we contract (and the large amounts of confidential information that is present on them), make such systems potentially
vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by our employees or vendors, or from malicious attacks by third parties. Such attacks are of ever-increasing levels of sophistication and are made by
groups and individuals with a wide range of motives (including, but not limited to, industrial espionage and market manipulation) and expertise. While we have invested significantly in the protection of data and information technology, there can be
no assurance that our efforts will prevent service interruptions or security breaches. Any interruption or breach in our systems could adversely affect our business operations and/or result in the loss of critical or sensitive confidential
information or intellectual property, and could result in financial, legal, business and reputational harm to us or allow third parties to gain material, inside information that they use to trade in our securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Commercialization of Our Current and Future Product Candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our commercial success depends upon attaining significant market acceptance of our current and future product candidates, if approved, among physicians,
patients, healthcare payors and cancer treatment centers. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we obtain regulatory approval for any of our current or future product
candidates, the product may not gain market acceptance among physicians, healthcare payors, patients or the medical community, including cancer treatment centers. Market acceptance of any product candidates for which we receive approval depends on a
number of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the efficacy and safety of such product candidates as demonstrated in clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the clinical indications and patient populations for which the product candidate is approved; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acceptance by physicians, major cancer treatment centers and patients of the drug as a safe and effective treatment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the adoption of novel immunotherapies by physicians, hospitals and third-party payors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential and perceived advantages of product candidates over alternative treatments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the safety of product candidates seen in a broader patient group, including our use outside the approved indications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any restrictions on use together with other medications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prevalence and severity of any side effects; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product labeling or product insert requirements of the FDA or other regulatory authorities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of market introduction of our products as well as competitive products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the development of manufacturing and distribution processes for commercial scale manufacturing for our novel WT1 peptide cancer immunotherapy product candidate; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of treatment in relation to alternative treatments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the availability of coverage and adequate reimbursement and pricing by third-party payors and government authorities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">relative convenience and ease of administration; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effectiveness of our sales and marketing efforts and those of our collaborators. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of our current and future product candidates are approved but fail to achieve market acceptance among
physicians, patients, healthcare payors or cancer treatment centers, we will not be able to generate significant revenues, which would compromise our ability to become profitable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we are able to commercialize our current or future product candidates, the products may not receive coverage and adequate reimbursement from
third-party payors in the United States and in other countries in which we seek to commercialize our products, which could harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
ability to commercialize any product successfully will depend, in part, on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private
health insurers and other organizations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Government authorities and third-party payors, such as private health insurers and health maintenance
organizations, determine which medications they will cover and establish reimbursement levels. A primary trend in the healthcare industry is cost containment. Government authorities and third-party payors have attempted to control costs by limiting
coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical
products. Third-party payors may also seek additional clinical evidence, beyond the data required to obtain regulatory approval, demonstrating clinical benefit our and value in specific patient populations before covering our products for those
patients. We cannot be sure that coverage and adequate reimbursement will be available for any product that it commercializes and, if reimbursement is available, what the level of reimbursement will be. Coverage and reimbursement may impact the
demand for, or the price of, any product candidate for which we obtain regulatory approval. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize any product candidate for which we
obtain regulatory approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more
limited than the purposes for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that any drug will be paid for in all cases or at a rate that
covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may only be temporary. Reimbursement rates may vary
according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be
reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the
United States. Third-party payors in the United States often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and profitable reimbursement rates from
both government-funded and private payors for any approved products that it develops could have a material adverse effect on our operating results, ability to raise capital needed to commercialize products and overall financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently enacted and future legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives, may increase the
difficulty and cost for us to obtain regulatory approval of and commercialize our current or future product candidates and affect the prices we may obtain. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The regulations that govern, among other things, regulatory approvals, coverage, pricing and reimbursement for new drug products vary widely from country to
country. In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay regulatory approval of our current or
future product candidates, restrict or regulate post-approval activities and affect our ability to successfully sell any product candidates for which we obtain regulatory approval. Legislative and regulatory proposals have been made to expand
post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be
changed, or what the impact of such changes on the regulatory approvals of our product candidates, if any, may be. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, the European Union and other potentially significant markets for our current and future
product candidates, government authorities and third-party payors are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative products and therapies, which has resulted in lower
average selling prices. Furthermore, the increased emphasis on managed healthcare in the United States and on country and regional pricing and reimbursement controls in the European Union will put additional pressure on product pricing,
reimbursement and usage, which may adversely affect our future product sales and results of operations. These pressures can arise from rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to
Medicare, Medicaid and healthcare reform, pharmaceutical reimbursement policies and pricing in general. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Price controls may be imposed in foreign
markets, which may adversely affect our future profitability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some countries, particularly member states of the European Union, the pricing of
prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of regulatory approval for a product. In addition, there can be considerable
pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations
may continue after reimbursement has been obtained. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between <FONT STYLE="white-space:nowrap">low-priced</FONT> and high-priced member states, can
further reduce prices. In some countries, we or our collaborators may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our product candidates to other available therapies in order to obtain or maintain
reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of our
products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our
relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages,
reputational harm and diminished profits and future earnings. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Healthcare providers, physicians and third-party payors will play a primary role in
the recommendation and prescription of any product candidates for which we obtain regulatory approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and
regulations that may constrain the business or financial arrangements and relationships through which we would market, sell and distribute our products. As a pharmaceutical company, even though we do not and will not control referrals of healthcare
services or bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#146; rights are and will be applicable to our business. Restrictions under
applicable federal and state healthcare laws and regulations that may affect our ability to operate include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal healthcare Anti-Kickback Statute will constrain our marketing practices, educational programs, pricing policies, and relationships with healthcare providers or other entities, by prohibiting, among other
things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for,
or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">federal civil and criminal false claims laws and civil monetary penalty laws impose criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly
presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment or approval that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to
pay money to the federal government; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">HIPAA imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program and also created federal criminal laws that prohibit knowingly and willfully falsifying, concealing or covering
up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or services; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">HIPAA, as amended by HITECH, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal physician sunshine requirements under the Patient Protection Affordable Care Act requires manufacturers of drugs, devices, biologics and medical supplies to report annually to HHS information related to
payments and other transfers of value to physicians, other healthcare providers, and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable group
purchasing organizations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by <FONT
STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers; some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant
compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">state and foreign laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating
compliance efforts. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and
regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other
healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages,
fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any physicians or other healthcare providers or entities with whom we expect to do
business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could
cause significant liability for us and harm our reputation. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of employee fraud or other misconduct, including
intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards we
have established, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or data accurately
or disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not
always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations
or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have
a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Product liability lawsuits against us could cause us to incur substantial liabilities and to limit
commercialization of any products that we may develop. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We face an inherent risk of product liability exposure related to the testing of our
current or future product candidates in human clinical trials and will face an even greater risk if we commercially sell any products that we may develop. Product liability claims may be brought against us by subjects enrolled in our clinical
trials, patients, healthcare providers or others using, administering or selling our products. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we could incur substantial liabilities.
Regardless of merit or eventual outcome, liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">decreased demand for any product candidates or products that we may develop; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">termination of clinical trial sites or entire trial programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injury to our reputation and significant negative media attention; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">withdrawal of clinical trial participants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">significant costs to defend the related litigation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">substantial monetary awards to trial subjects or patients; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">loss of revenue; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">diversion of management and scientific resources from our business operations; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability to commercialize any products that we may develop. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently hold product liability
insurance coverage at a level that we believe is customary for similarly situated companies and adequate to provide us with insurance coverage for foreseeable risks, but which may not be adequate to cover all liabilities that we may incur. Insurance
coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. We intend to expand our insurance coverage for products to include the sale
of commercial products if we obtain regulatory approval for our product candidates in development, but we may be unable to obtain commercially reasonable product liability insurance for any products that receive regulatory approval. Large judgments
have been awarded in class action lawsuits based on drugs that had unanticipated side effects. A successful product liability claim or series of claims brought against us, particularly if judgments exceed our insurance coverage, could decrease our
cash and adversely affect our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to our Business Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We face competition from numerous pharmaceutical and biotechnology enterprises, as well as from academic institutions, government agencies and
private and public research institutions for our current product candidates. Our commercial opportunities will be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer side effects or
are less expensive than any products that we may develop. Competition could result in reduced sales and pricing pressure on our current or future product candidates, if approved, which in turn would reduce our ability to generate meaningful revenues
and have a negative impact on our results of operations. In addition, significant delays in the development of our product candidates could allow our competitors to bring products to market before we and impair any ability to commercialize our
product candidates. The biotechnology industry, including the cancer immunotherapy market, is intensely competitive and involves a high degree of risk. We compete with other companies that have far greater experience and financial, research and
technical resources than us. Potential competitors in the United States and worldwide are numerous and include pharmaceutical and biotechnology companies, educational institutions and research foundations, many of which have substantially greater
capital resources, marketing experience, research and development staffs and facilities than ours. Some of our competitors may develop and commercialize products that compete directly with those incorporating our technology, introduce products to
market earlier than our products or on a more cost effective basis. In addition, our technology may be subject to competition from other technology or methods developed using techniques other than those developed by traditional biotechnology
methods. Our competitors compete with us in recruiting and retaining </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
qualified scientific and management personnel as well as in acquiring technologies complementary to our technology. Our company and our collaborators may face competition with respect to product
efficacy and safety, ease of use and adaptability to various modes of administration, acceptance by physicians, the timing and scope of regulatory approvals, availability of resources, reimbursement coverage, price and patent position, including the
potentially dominant patent positions of others. An inability to successfully complete our product development or commercializing those product candidates could lead having limited prospects for establishing market share or generating revenue from
our technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are several agents in clinical development in similar settings to our planned Phase 3 AML clinical development program for GPS. The
most advanced of these products is oral Vidaza (azacytidine), under development by Celgene Corporation, which is anticipated to report Phase 3 results by the end of 2018. There are a number of other investigational immunotherapies advancing through
Phase 2 and Phase 3 trials for target indications that we believe are also potential target indications for GPS. If these or other therapies are successful in their development, it could negatively impact our ability to enroll our clinical trials
and could negatively impact the commercial potential of GPS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also planning a clinical development program in combination with cancer checkpoint
inhibitors. This is a highly competitive field, with hundreds of such combination trials with various checkpoint inhibitors ongoing. If one or more of these combinations produce positive results in indications which we believe are targets for GPS
(either in combination or in stand-alone administration) this could increase the difficulty for us to conduct our trials and could negatively impact our path to regulatory approval and our ability to successfully commercialize our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of our competitors or potential competitors have significantly greater established presence in the market, financial resources and expertise in research
and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than it does, and as a result may have a competitive advantage over us. Smaller or early-stage companies
may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel,
establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies and technology licenses complementary to our programs or advantageous to our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of these factors, these competitors may obtain regulatory approval of their products before we are able to obtain patent protection or other
intellectual property rights, which will limit our ability to develop or commercialize our current or future product candidates. Our competitors may also develop drugs that are safer, more effective, more widely used and cheaper than ours, and may
also be more successful than us in manufacturing and marketing their products. These appreciable advantages could render our product candidates obsolete or noncompetitive before we can recover the expenses of development and commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our
competitors. Smaller and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining
qualified scientific, management and commercial personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our current or future
product candidates, we may be unable to generate any revenue. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not currently have an organization for the sale, marketing and distribution of
pharmaceutical products and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. In order to market any products that may be approved by the FDA and comparable foreign regulatory authorities,
we must build our sales, marketing, managerial and other <FONT STYLE="white-space:nowrap">non-technical</FONT> capabilities or make arrangements with third parties to perform these services. There are significant risks involved in building and
managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed
sales and marketing team. Any failure or delay in the development of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. If we are unable to establish adequate sales, marketing and distribution
capabilities, whether independently or with third parties, we may not be able to generate product revenues and may not become profitable. We will be competing with many companies that currently have extensive and well-funded sales and marketing
operations. Without an internal commercial organization or the support of a third party to perform sales and marketing functions, we may be unable to compete successfully against these more established companies. If we are not successful in
commercializing our current or future product candidates either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we would incur significant additional losses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need to grow the size of our organization, and we may experience difficulties in managing this growth. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of April 6, 2018, we had eleven full-time employees. We need to grow the size of our organization in order to support our continued development and
potential commercialization of our product candidates. In particular, we will need to add substantial numbers of additional personnel and other resources to support our development and potential commercialization of our product candidates. As our
development and commercialization plans and strategies continue to develop, or as a result of any future acquisitions, our need for additional managerial, operational, manufacturing, sales, marketing, financial and other resources will increase. Our
management, personnel and systems currently in place may not be adequate to support this future growth. Future growth would impose significant added responsibilities on members of management, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">managing our clinical trials effectively; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identifying, recruiting, maintaining, motivating and integrating additional employees; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">managing our internal development efforts effectively while complying with our contractual obligations to licensors, licensees, contractors and other third parties; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">improving our managerial, development, operational, information technology, and finance systems; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expanding our facilities. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As our operations expand, we will also need to manage additional relationships with
various strategic partners, suppliers and other third parties. Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth
effectively. To that end, we must be able to manage our development efforts and preclinical studies and clinical trials effectively and hire, train and integrate additional management, research and development, manufacturing, administrative and
sales and marketing personnel. The failure to accomplish any of these tasks could prevent us from successfully growing our company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to
develop and maintain proper and effective internal control over financial reporting, the accuracy and timeliness of our financial reporting may be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management team is required, pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act, or Section&nbsp;404, to furnish a report by management on, among other
things, the effectiveness of our internal control over financial reporting. In particular, we are required to perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the
effectiveness of its internal control over financial reporting. Prior to the Merger, Private SELLAS, whose financial statements are now our financial statements, was not required to do such an analysis. Testing may reveal deficiencies in our
internal control over financial reporting that are deemed to be material weaknesses. We were informed by our independent registered public accounting firm that we have a material weakness in our internal control over financial reporting due to our
lack of sufficient management and personnel with appropriate expertise in GAAP and SEC rules and regulations with respect to financial reporting. Although, we have since hired three additional finance and accounting personnel to build out our
infrastructure and further develop and document our accounting policies and financial reporting procedures, we cannot assure you that we will be successful in retaining these new hires or that these measures will significantly improve or remediate
the material weakness described above, or any others that it may identify once we conduct a full Section&nbsp;404 evaluation. We also cannot assure you that we have identified all material weaknesses at this time, or that additional material
weaknesses may occur in the future. Accordingly, material weaknesses may still exist. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our independent registered public accounting firm will not be required to attest to the effectiveness of our
internal control over financial reporting for so long as we remain a &#147;smaller reporting company&#148; as defined in applicable SEC regulations. Our management team is required to disclose changes made in our internal controls and procedures on
a quarterly basis. We need to undertake various actions, such as implementing new internal controls and procedures and hiring additional accounting or internal audit staff. Our audit committee must also be advised and regularly updated on
management&#146;s review of internal controls. We are still in early stages of the costly and challenging process of compiling the system and processing documentation necessary to perform our evaluation of its internal control over financial
reporting needed to comply with Section&nbsp;404, and we may not be able to complete its evaluation, testing and any required remediation in a timely fashion. Moreover, if we are not able to comply with the requirements of Section&nbsp;404 in a
timely manner or if it identifies or its independent registered public accounting firm identifies deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, the market price of our common stock could
decline and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities, which would require additional financial and management resources. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The requirements of being a public company may strain our resources, divert management&#146;s attention and affect our ability to attract and retain
qualified board members. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the
Dodd-Frank Act, the listing requirements of Nasdaq and other applicable securities rules and regulations. Compliance with these rules and regulations has increased, and will likely continue to increase, our legal and financial compliance costs, make
some activities more difficult, time-consuming or costly, and place significant strain on our personnel, systems and resources. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating
uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of
specificity, and, as a result, their application in practice may evolve over time. This could result in continuing uncertainty regarding compliance matters, higher administrative expenses and a diversion of management&#146;s time and attention.
Further, if our compliance efforts differ from the activities intended by regulatory or governing bodies due to ambiguities related to practice, regulatory authorities may initiate legal proceedings against us and our business may be harmed. Being a
public company that is subject to these rules and regulations also makes it more expensive for us to obtain and retain director and officer liability insurance, and we may in the future be required to accept reduced coverage or incur substantially
higher costs to obtain or retain adequate coverage. These factors could also make it more difficult for us to attract and retain qualified members of our board of directors and qualified executive officers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become involved in securities class action litigation that could divert management&#146;s attention and harm our business, and insurance coverage
may not be sufficient to cover all costs and damages. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the past, securities class action or stockholder derivative litigation often follows
certain significant business transactions, such as the sale of a business division or announcement of a merger. We may become involved in this type of litigation in the future. Litigation often is expensive and diverts management&#146;s attention
and resources, which could adversely affect the continuing company&#146;s business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future success depends on our ability to retain our
executive officers and to attract, retain and motivate qualified personnel. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are highly dependent upon our personnel, including
Dr.&nbsp;Angelos&nbsp;M. Stergiou (M.D., Sc.D. h.c.), our President and Chief Executive Officer, and member of our board of directors. Our employment agreement with Dr.&nbsp;Stergiou does not prevent him from terminating his employment with us at
any time. The loss of Dr.&nbsp;Stergiou&#146;s services could impede the achievement of our research, development and commercialization objectives. We have not obtained, do not own, nor are we the beneficiary of,
<FONT STYLE="white-space:nowrap">key-person</FONT> life insurance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Governance changes, becoming subject to enhanced regulatory requirements and increased responsibilities
associated with becoming a public company may influence our management personnel and our employees to terminate their employment with us. To enhance our ability to retain our executive management personnel, we have entered into retention agreements
with certain executive officers and may find it beneficial to enter into additional retention agreements with other key personnel in the future, potentially increasing payroll and operating expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our future growth and success depend on our ability to recruit, retain, manage and motivate our employees. The loss of any member of our senior management
team or the inability to hire or retain experienced management personnel could compromise our ability to execute our business plan and harm our operating results. Because of the specialized scientific and managerial nature of our business, we rely
heavily on our ability to attract and retain qualified scientific, technical and managerial personnel. The competition for qualified personnel in the pharmaceutical field is intense and as a result, we may be unable to continue to attract and retain
qualified personnel necessary for the development of our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we and our third-party manufacturers fail to comply with environmental, health and safety laws and
regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and our third-party manufacturers are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory
procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce
hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from
us or our third-party manufacturers&#146; use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and
penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we maintain workers&#146; compensation insurance to cover the costs and expenses we may incur due to injuries to our employees
resulting from the use of hazardous materials with a policy limit that we believe is customary for similarly situated companies and adequate to provide us with insurance coverage for foreseeable risks, this insurance may not provide adequate cover
age against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or
future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions, which could adversely affect our business,
financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business and operations would suffer in the event of computer system failures or
security breaches. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our internal computer systems, and those of MSK, our CROs, our CMOs, and other business vendors on which we rely, are
vulnerable to damage from computer viruses, unauthorized access, natural disasters, fire, terrorism, war and telecommunication and electrical failures. We exercise little or no control over these third parties, which increases our vulnerability to
problems with their systems. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our drug development programs. For example, the loss of clinical trial data from completed, ongoing or
planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data
or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, the further development of our current and future product candidates could be delayed and our business could be otherwise adversely
affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Business disruptions could seriously harm our future revenues and financial condition and increase our costs and expenses. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme
weather conditions, medical epidemics and other natural or manmade disasters or business interruptions, for which We are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and
financial condition and increase our costs and expenses. We rely on third-party manufacturers to produce our product candidates and intends to rely on third-party manufacturers to produce any future product candidates. Our ability to obtain clinical
supplies of product candidates could be disrupted, if the operations of these suppliers are affected by a <FONT STYLE="white-space:nowrap">man-made</FONT> or natural disaster or other business interruption. The ultimate impact on us, our significant
suppliers and our general infrastructure is unknown, but our operations and financial condition could suffer in the event of a major earthquake, fire, hurricane or other natural disaster. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our principal stockholders own a significant percentage of our stock and will be able to exert significant
control over matters subject to stockholder approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our principal stockholders and their affiliates currently beneficially own approximately 46%
of the outstanding shares of our common stock. Therefore, these stockholders have the ability and may continue to have the ability to influence us through this ownership position. These stockholders may be able to determine some or all matters
requiring stockholder approval. For example, these stockholders, acting together, may be able to control elections of directors, amendments of organizational documents, or approval of any merger, sale of assets, or other major corporate transaction.
This may prevent or discourage unsolicited acquisition proposals or offers for shares of our common stock that you may believe are in your best interest as one of our stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to Ownership of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market price and trading volume of shares of our common stock may be volatile. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The market price of shares of our common stock has exhibited substantial volatility recently. Between January&nbsp;1, 2017 and April&nbsp;6, 2018, the trading
price of shares of our common stock as reported on Nasdaq ranged from a low of $3.43 to a high of $72.30. The market price of shares of our common stock could continue to fluctuate significantly for many reasons, including the following factors:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reports of the results of our clinical trials regarding the safety or efficacy of our product candidates and surrogate markers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements of regulatory developments or technological innovations by us or our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements of business or strategic transactions or our success in finalizing such a transaction; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements of legal or regulatory actions against us or any adverse outcome of any such actions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in our relationships with our licensors, licensees and other strategic partners; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">low volume in the number of shares of our common stock traded on Nasdaq; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our quarterly operating results; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements of dilutive financing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements of additional potential reverse stock split; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments in patent or other technology ownership rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additional funds may not be available on terms that are favorable to us and, in the case of equity financings, may result in dilution to our stockholders; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">government regulation of drug pricing; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general changes in the economy, the financial markets or the pharmaceutical or biotechnology industries. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Factors beyond our control may also have an impact on the market price of shares of our common stock. For example, to the extent that other companies within
our industry experience declines in their stock prices, the market price of shares of our common stock may decline as well. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales of substantial amounts of our common stock, or the possibility that such sales could occur,
could adversely affect the market price of our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Future sales in the public market of shares of our common stock, including shares
referred to in the foregoing risk factors or shares issued upon exercise of our outstanding stock options or warrants, or the perception by the market that these sales could occur, could lower the market price of our common stock or make it
difficult for us to raise additional capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017, we had reserved for issuance 10,171 shares of our common stock issuable upon
the exercise of outstanding stock options at a weighted-average exercise price of $1,240.54 per share and 963,000 shares of our common stock issuable upon the exercise of outstanding warrants at a weighted-average exercise price of $94.58 per share.
Upon exercise of these options and warrants, the underlying shares may be resold into the public market. In the case of outstanding options and warrants that have exercise prices that are below the market price of our common stock from time to time,
our stockholders would experience dilution upon the exercise of these options. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have issued and may issue additional preferred stock in the
future, and the terms of the preferred stock may reduce the value of our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are authorized to issue up to 5&nbsp;million shares of
preferred stock in one or more series. Our Board of Directors may determine the terms of future preferred stock offerings without further action by our stockholders. If we issue additional preferred stock, it could affect stockholder rights or
reduce the market value of our outstanding common stock. In particular, specific rights granted to future holders of preferred stock may include voting rights, preferences as to dividends and liquidation, conversion and redemption rights, sinking
fund provisions, and restrictions on our ability to merge with or sell our assets to a third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of Directors has designated 17,500 shares
of our preferred stock as our Series A Convertible Preferred and we have issued or agreed to issue up to an aggregate of 10,700 shares of such Series A Convertible Preferred. The Series A Convertible Preferred is initially convertible into our
common stock based on an initial conversion price of $5.80 per share, which is subject to adjustment in certain circumstances, including anti-dilution price protection through completion of a &#147;Qualified Offering&#148; as defined in the terms of
such Series A Convertible Preferred set out in the Certificate of Designation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have in the past and expect in the future to settle legal claims
through the issuance of freely tradable shares of our common stock, which will result in dilution to holders of our common stock and may adversely affect the market price of our common stock</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have in the past and expect in the future to settle legal claims through the issuance of freely tradable shares of our common stock. As described under the
heading, Our Business&#151;Legal Proceedings, we currently expect to (i)&nbsp;issue $1,250,000 in unrestricted shares of our common stock valued at based on the volume-weighted average closing price for the 20 trading days immediately preceding the
day before the transfer of the settlement stock to the settlement fund to settle the case entitled <I>Patel vs. Galena Biopharma, Inc. et. al</I> and (ii) $200,000 in cash to settle the claim for attorneys&#146; fees in the pending qui tam action in
the U.S. District Court of the District of New Jersey. Payment of these amounts in our common stock will cause significant dilution to our stockholders, and the amount of that dilution will vary depending on the price of our common stock at the time
of the payment (and the 20 trading days prior to such payment in the case of payments made in connection with the <I>Patel </I>litigation). In addition, the issuance of such a significant number of shares of our may cause a decrease in the trading
price of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our senior secured debenture has resulted, and may continue to result, in dilution to the holders of our
common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2016, Galena entered into a securities purchase agreement with JGB, pursuant to which Galena sold to JGB, at a 6.375%
original issue discount, a $25,530,000 senior secured debenture, which was subsequently amended, and warrants to purchase Galena&#146;s common stock. As of December&nbsp;31, 2017, (i)&nbsp;there were 5,766,891 shares of our common stock outstanding
and (ii)&nbsp;647,061 shares of our common stock had been issued by us pursuant to the terms of the senior secured debenture. As of April 6, 2018, we issued an additional 635,894 shares of our common stock to satisfy $3.2&nbsp;million of outstanding
principal and interest redemptions. Assuming all the shares issuable pursuant to the terms of the senior secured debenture subsequent to April 6, 2018 are issued at a stock payment price of $3.23 the lowest stock payment price as of April 6, 2018,
we estimate that the maximum number of shares of common stock that we could issue pursuant to the terms of the senior secured debenture subsequent to April 6, 2018 is approximately 372,443. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may enter or amend our senior secured debenture and with respect to our other liabilities which may result or continue to result, in dilution to the
holders of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-takeover provisions of our Amended and Restated Certificate of Incorporation and our Amended and Restated Bylaws
and provisions of Delaware law could delay or prevent a change of control. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Anti-takeover provisions of our Amended and Restated Certificate of
Incorporation and our Amended and Restated Bylaws may discourage, delay or prevent a merger or other change of control that stockholders may consider favorable or may impede the ability of the holders of our common stock to change our management and
may be constrained by other contractual agreements with third parties. These provisions of our Amended and Restated Certificate of Incorporation and our Amended and Restated Bylaws, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">divide our Board of Directors into three classes, with members of each class to be elected for staggered three-year terms; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limit the right of securityholders to remove directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prohibit stockholders from acting by written consent; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulate how stockholders may present proposals or nominate directors for election at annual meetings of stockholders; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">authorize our Board to issue preferred stock in one or more series, without stockholder approval. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
addition, Section&nbsp;203 of the Delaware General Corporation Law provides that, subject to limited exceptions, persons that acquire, or are affiliated with a person that acquires, more than 15% of the outstanding voting stock of a Delaware
corporation such as We shall not engage in any business combination with that corporation, including by merger, consolidation or acquisitions of additional shares for a three-year period following the date on which that person or our affiliate
crosses the 15% stock ownership threshold. Section&nbsp;203 could operate to delay or prevent a change of control of us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The terms of our
outstanding indebtedness may inhibit potential acquirers. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are prohibited by the terms of our outstanding indebtedness from disposing of any of
our business or property, except with the consent of our lenders or if we were to prepay, which we are not able to do without our lenders consent, the outstanding indebtedness and related fees in accordance with the loan security agreement. Our
outstanding indebtedness may inhibit potential acquirers or other interested parties from seeking to acquire all or a part of our business or assets, and there is no assurance that our lenders would consent to any proposed future transaction that
might be beneficial to our stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our common stock becomes subject to the penny stock rules, it may be more difficult to sell our common
stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally
equity securities with a price of less than $5.00 (other than securities registered on certain national securities exchanges or authorized for quotation on certain automated quotation systems, provided that current price and volume information with
respect to transactions in such securities is provided by the exchange or system). The OTC Bulletin Board does not meet such requirements and if the price of our common stock is less than $5.00 and our common stock is no longer listed on a national
securities exchange such as Nasdaq, our may be deemed a penny stock. The penny stock rules require a broker-dealer, at least two business days prior to a transaction in a penny stock not otherwise exempt from those rules, to deliver to the customer
a standardized risk disclosure document containing specified information and to obtain from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the customer a signed and date acknowledgement of receipt of that document. In addition, the penny stock rules require that prior to effecting any transaction in a penny stock not otherwise
exempt from those rules, a broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive: (i)&nbsp;the purchaser&#146;s written acknowledgment of the receipt of a risk disclosure
statement; (ii)&nbsp;a written agreement to transactions involving penny stocks; and (iii)&nbsp;a signed and dated copy of a written suitability statement. These disclosure requirements may have the effect of reducing the trading activity in the
secondary market for our common stock, and therefore stockholders may have difficulty selling their shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have never declared or paid cash
dividends on our capital stock and we do not anticipate paying cash dividends in the foreseeable future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business requires significant
funding. We currently plan to invest all available funds and future earnings in the development and growth of our business and do not anticipate paying any cash dividends on our common stock in the foreseeable future and are prohibited by the terms
of our outstanding indebtedness from paying dividends on any common stock, except with the prior consent of our lenders. As a result, capital appreciation, if any, of our common stock will be our stockholders&#146; sole source of potential gain for
the foreseeable future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx556278_3"></A>ITEM&nbsp;1B. UNRESOLVED STAFF COMMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx556278_4"></A>ITEM&nbsp;2. PROPERTIES
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We relocated our headquarters to New York, New York following completion of the Merger and occupy 2,033 square feet of office space in New York, New
York under a lease that expires in April 2019. We believe that our facilities are adequate for our current needs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the Merger, Private SELLAS
occupied 1,750 square feet of office space in Hamilton, Bermuda under a lease that expired in November 2017.&nbsp;In December 2017, we terminated the lease for our <FONT STYLE="white-space:nowrap">pre-Merger</FONT> headquarters located at 2000 Crow
Canyon Place, Suite 380, San Ramon, CA 94583. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx556278_5"></A>ITEM&nbsp;3. LEGAL PROCEEDINGS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our predecessor company, Galena was involved in multiple legal proceedings and administrative actions, including stockholder class actions, both state and
federal, some of which are ongoing and to which we are now subject as a result of the Merger. They are as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;16, 2015, we received a subpoena issued by the U.S. Attorney&#146;s Office for the District of
New Jersey, or USAO NJ, requesting the production of a broad range of documents pertaining to our marketing and promotional practices for Abstral, which we had sold to a third party in the fourth quarter of 2015. In September 2017, the Department of
Justice announced that we were to pay more than $7.55&nbsp;million to resolve allegations under the civil False Claims Act that we paid kickbacks to doctors to induce them to prescribe our fentanyl-based drug Abstral. On December 29, 2017, we fully
paid the civil payment to resolve those allegations and the $0.2 million in attorneys&#146; fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;13, 2017, putative shareholder
securities class action complaints were filed in federal court alleging, among other things, that we and certain of our former officers and directors and current employee failed to disclose that our promotional practices for Abstral (fentanyl)
sublingual tablets were allegedly improper and that we may be subject to civil and criminal liability, and that these alleged failures rendered our statements about our business misleading. The actions were consolidated, a lead plaintiff was named
by the court and an amended complaint was filed. We filed a motion to dismiss the amended complaint and the briefing should be completed by April of 2018. Thereafter, the Court will take the matter under advisement. It is not known when the Court
will issue a ruling in this matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;16, 2017, a derivative complaint was filed in the federal court against our current directors and us,
as a nominal defendant. The complaint purports to assert derivative claims for breach of fiduciary duty on our behalf against our directors based on substantially similar facts as alleged in the putative shareholder securities class action
complaints filed in February 2017 mentioned above. This lawsuit is currently stayed pending resolution of the referenced securities class action lawsuit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2017, a putative stockholder class action was filed in Delaware state court seeking relief under Section&nbsp;225 of the DGCL and alleging breaches
of fiduciary duties by our former board of directors and former interim chief executive officer regarding the proposals to amend Galena&#146;s certificate of incorporation to increase the amount of authorized shares of common stock and effectuate a
reverse stock split at the July 2016 and October 2016 stockholder meetings, respectively. On June&nbsp;2, 2017, an amended verified complaint was filed along with a motion to expedite the proceedings. On June&nbsp;5, 2017, Galena filed a verified
petition under Section&nbsp;205 of the DGCL and a motion to expedite the proceedings. On June&nbsp;8, 2017, the Court denied a request by the plaintiff to schedule a preliminary injunction motion and ordered a prompt trial on both the plaintiff and
Galena&#146;s claims. On June&nbsp;20, 2017, the Court consolidated the claims into <I>In re Galena Biopharma, Inc.</I>, C. A. No. <FONT STYLE="white-space:nowrap">2017-0423-JTL.</FONT> On July&nbsp;10, 2017, the Court ordered that the trial of the
claims be held on August&nbsp;28, 30 and 31, 2017. On July&nbsp;24, 2017, we entered into a binding settlement term sheet involving the payment of $50,000 in cash and $1,250,000 in unrestricted shares of our common stock. The Court enforced the
settlement term sheet on November&nbsp;30, 2017, over the objection of the plaintiff. On December&nbsp;8, 2017, the Court set the hearing on the settlement for March&nbsp;15, 2018. On December&nbsp;11, 2017, the Court also granted an order
validating the ratification votes at the special stockholder meeting held on July&nbsp;6, 2017 and the certificate of amendments filed by the Company for the increase in authorized shares in 2011, 2013, 2015, and 2016 as well as for the reverse
stock split in 2016. On February 22, 2018, the plaintiff filed his brief in support of the settlement as well as his request for attorneys&#146; fees and an incentive award. On March 1, 2018, the former directors and former interim chief executive
officer responded to plaintiff&#146;s brief. On February 28, 2018, the former directors and former interim chief executive officer requested the Court continue the date of the hearing to approve the settlement as we were working with the staff of
the SEC to obtain the no-action letter required by the binding settlement term sheet. The Plaintiff objected to such continuance. On March 15, 2018, the Court ruled in favor of us and continued the settlement hearing for 90 days. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;10, 2017, the SEC issued a cease and desist order against we and the former chief executive
officer, or CEO, Mark&nbsp;Ahn, requiring each of them to cease and desist from any future violations of Sections 5(a), 5(b), 5(c), 17(a), and 17(b) of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;10(b), 13(a), and
13(b)(2)(A) of the Exchange Act, and various rules thereunder, which refer to as the SEC Order. Based upon the order, we made a $0.2 million penalty payment as well as a payment of approximately $0.75 million, which was the indemnification payment
of our former CEO for the disgorgement and prejudgment interest payment that he was required to pay by the order. We made such indemnification payment after a special committee of the board of directors determined that we were required under
Delaware law to indemnify our former CEO for the disgorgement and prejudgment interest payment. The former CEO also made a penalty payment of $0.6 million. As a result of the SEC Order, we may not use certain exemptions from registration under the
federal securities laws, including Regulation A and Regulation D. In addition, we are an &#147;ineligible issuer&#148; as the term is defined under Rule 405 promulgated under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July 2017, a complaint was filed in California state court against our former directors and us, as a nominal defendant. The complaint purports to assert
derivative claims for breach of fiduciary duty on our behalf against our former directors based on substantially similar facts as alleged in the derivative complaint filed in early March of 2017 mentioned above. This lawsuit is currently stayed
pending resolution of the referenced securities class action lawsuit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;23, 2018, a complaint captioned was filed in the U.S. District
Court for the District of New Jersey against our former directors, officers and employees and us as a nominal defendant. The complaint purports to assert derivative claims for breach of fiduciary duty on our behalf against our former directors,
officers and employees based on substantially similar facts as alleged in the putative shareholder securities class action complaints and derivative complaints mentioned above, as well as making demand futility allegations against our current board
of directors, who are not named as defendants. It is expected that we and the individual defendants will respond to the complaint through an appropriate pleading or motion and, if necessary, seek an order from the Court staying the proceedings
pending further developments in the securities litigations described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On or about April 9, 2018, JGB filed a lawsuit in the U.S. District Court for
the Southern District of New York captioned <I>JGB (Cayman) Newton, Ltd. v. Sellas Life Sciences Group, Inc., et al.</I>, Case 1:18-cv-3095 (DLC), or the JGB Action. The complaint in the JGB Action asserts claims under state law and federal
securities law against us, our Chief Executive Officer, Angelos M. Stergiou, M.D., ScD H.C, and our Interim Chief Financial Officer, Aleksey N. Krylov (Mr. Krylov together with the Company and Dr.&nbsp;Stergiou, the Defendants). The complaint in the
JGB Action alleges, among other things, that we breached a contractual obligation to deliver certain shares of our common stock to JGB and that, in the course of negotiations related to the senior secured debenture agreement, the Defendants failed
to disclose to JGB certain information regarding positive clinical trial results that was not then public. According to the complaint, JGB seeks to receive 2,483,500 shares of our common stock, damages, and costs and expenses incurred in the JGB
action, among other things. We dispute the claims in the JGB Action and intend to defend against them vigorously. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx556278_6"></A>ITEM&nbsp;4. MINE SAFETY DISCLOSURES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx556278_7"></A>ITEM&nbsp;5. MARKET FOR REGISTRANT&#146;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Market Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Throughout 2017, our common
stock was listed on The Nasdaq Capital Market under the symbol &#147;GALE&#148;. Upon completion of the Merger and upon the next trading day, on January&nbsp;2, 2018, our common stock began trading on The Nasdaq Capital Market under the symbol
&#147;SLS&#148;. The following table shows the high and low <FONT STYLE="white-space:nowrap">per-share</FONT> sale prices of our common stock for the periods indicated after taking effect for the 1-for-20 reverse stock split effected
November&nbsp;11, 2016 and the 1-for-30 reverse stock split effected December&nbsp;29, 2017: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">888.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">354.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1494.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">462.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">72.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April 6,
2018, the closing sale price of a share of our common stock was $6.85 per share and there were 6,572,542 shares of our common stock outstanding. On that date, our shares of common stock were held by approximately 135 stockholders of record. The
number of record holders was determined from the records of our transfer agent and does not include beneficial owners of our common stock whose shares are held in the names of various security brokers, dealers, and registered clearing agencies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never paid any cash dividends and do
not anticipate paying any cash dividends on our common stock in the foreseeable future. We expect to retain future earnings, if any, for use in our development activities and the operation of our business. The payment of any future dividends will be
subject to the discretion of our Board of Directors and will depend, among other things, upon our results of operations, financial condition, cash requirements, prospects and other factors that our Board of Directors may deem relevant. Our
outstanding senior secured debenture with JGB restricts our ability to pay dividends.&nbsp;Series A Convertible Preferred stock issued in our March 2018 private placement limits our ability to pay dividends to the extent we have any unpaid dividends
on such preferred stock.&nbsp;Our ability to pay future dividends may be restricted by the terms of any future securities we may issue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Compensation Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information as of December&nbsp;31, 2017, regarding securities authorized for issuance under our equity
compensation plans: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center">Plan Category</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">(a)<br>Number of<br>Securities&nbsp;to&nbsp;be<br>Issued Upon<br>Exercise of<br>Outstanding<br>Options,<br>Warrants and<br>Rights</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">(b)<br>Weighted-<br>Average<br>Exercise&nbsp;Price<br>of&nbsp;Outstanding<br>Options,<br>Warrants&nbsp;and<br>Rights</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number of<br>Securities<br>Remaining<br>Available for<br>Issuance<br>Under Equity<br>Compensation<br>Plans<br>(Excluding<br>Securities<br>Reflected
in<br>Column (a))</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans approved by our security holders:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amended and Restated&nbsp;2016 Incentive Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,240.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017 Equity Incentive Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">NA</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">574,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee Stock Purchase Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">NA</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">NA</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted stock units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">NA</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans not approved by our security holders:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding warrants (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">320,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">343,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">52.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">632,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The warrants shown were issued in discrete transactions from time to time as compensation for services rendered by consultants, advisers or other third parties, and do not include warrants sold in private placement or
public offering transactions. The material terms of such warrants were determined based upon <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> negotiations with the services providers. The warrant exercise prices approximated the market
price of our common stock at or about the date of grant, and the warrant terms range from three to ten years from the grant date. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent
Sales of Unregistered Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the period covered by this annual report, there were no sales by us of unregistered securities that were not
previously reported by us in a Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or Current Report on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Purchases of Equity Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended
December&nbsp;31, 2017, we did not purchase any of our equity securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx556278_8"></A>ITEM&nbsp;6. SELECTED FINANCIAL DATA </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx556278_9"></A>ITEM&nbsp;7. MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should read the following discussion in conjunction with the consolidated financial statements and the notes to consolidated
financial statements included elsewhere in this annual report on Form <FONT STYLE="white-space:nowrap">10-K.</FONT> This discussion contains forward-looking statements within the meaning of federal securities laws. Such forward-looking statements
are subject to risks and uncertainties that could cause actual results to differ materially from those contained in such forward-looking statements, including those discussed in the section &#147;Risk Factors&#148; in Part I &#151; Item&nbsp;1A of
this annual report on Form <FONT STYLE="white-space:nowrap">10-K.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please see Part I, item 1 &#147;Business&#151;Collaboration and License
Agreements&#148; and Note 6 to our audited consolidated financial statements appearing elsewhere in this annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for more information relating to such arrangements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Merger of Galena Biopharma, Inc.,
or Galena and SELLAS Life Sciences Group Ltd. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;29, 2017, we completed the business combination with Private SELLAS, in accordance with
the terms of the Merger. We refer to this business combination throughout this annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> as the Merger. As a result of the Merger, our business is now substantially comprised of the business
of Private SELLAS, and although we are are considered the legal acquiror of Private SELLAS, for accounting purposes, Private SELLAS is considered have acquired our company in the Merger. Consequently, the Merger is accounted for as a reverse
acquisition and our financial statements are now those of Private SELLAS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immediately prior to the Merger, we effected a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-30</FONT></FONT> reverse stock split of our outstanding common stock. Under the terms of the Merger Agreement, we issued shares of our common stock to Private SELLAS&#146;
securityholders at an exchange ratio of 43.9972 shares of our common stock in exchange for each common share of Private SELLAS outstanding immediately prior to the Merger. We also assumed all of the restricted stock units, or RSUs issued and
outstanding under the Private SELLAS Stock Incentive Plan #1, and all of the issued and outstanding warrants of Private SELLAS. Accordingly, such RSUs will now be settled in, and such warrants now are exercisable for, shares of our common stock.
Accordingly, immediately after the Merger, there were approximately 5,766,891 shares of our common stock outstanding, with the former Private SELLAS securityholders owning approximately 67.5% of our fully diluted common stock, and our <FONT
STYLE="white-space:nowrap">pre-Merger</FONT> securityholders owning the remaining approximately 32.5%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon completion of the Merger, we changed our name
from &#147;Galena Biopharma, Inc.&#148; to &#147;SELLAS Life Sciences Group, Inc&#148; and our common stock began trading on The Nasdaq Capital Market under a new ticker symbol &#147;SLS&#148; on January&nbsp;2, 2018, and our financial statements
became those of Private SELLAS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Private Placement of Series A 20% Convertible Preferred Stock and Warrants </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2018, we entered into a securities purchase agreement with investors pursuant to which we agreed to sell to the investors, in a private placement
pursuant to Rule 4(a)(2) and Regulation S under the Securities Act of 1933, as amended, an aggregate of 10,700 shares of our newly-created <FONT STYLE="white-space:nowrap">non-voting</FONT> Series A Convertible Preferred and warrants to acquire an
aggregate 1,383,631 shares of our common stock at an aggregate purchase price of $10.7&nbsp;million. The Series A Convertible Preferred is initially convertible into 1,844,835 shares of our common stock based on an initial conversion price of $5.80
per share, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The conversion price of the Series A Convertible Preferred and the exercise price of the warrants are both subject to adjustment for certain
transactions affecting our securities (such as stock dividends, stock splits, and the like). Until consummation of a qualified offering (as such term is defined in the applicable documents), the conversion price and exercise price (for a <FONT
STYLE="white-space:nowrap">one-year</FONT> period after consummation of such qualified offering) are also subject to anti-dilution price protection in the event of <FONT STYLE="white-space:nowrap">non-exempt</FONT> equity issuances at a price per
share lower than the then applicable conversion or exercise price, as the case may be. If we have not consummated a qualified offering on or before September&nbsp;9, 2018 (the six month anniversary of the first closing), on each of the six month
anniversary of the first and the second closings, the conversion price is reduced to the lesser of (x)&nbsp;the then applicable conversion price, (y) $3.00 (subject to adjustment for forward and reverse stock splits and the like) and (z)&nbsp;the
lowest volume weighted average price, or VWAP, or for any trading day during the five trading days immediately following each such adjustment date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the first closing of the of the private placement on March&nbsp;9, 2018, we issued an aggregate 5,987 shares
of Series A Convertible Preferred and warrants to acquire 774,186 shares of our common stock for aggregate gross proceeds of $6.0&nbsp;million. The second closing of the remaining 4,713 shares of Series A Convertible Preferred and warrants to
acquire an aggregate of 609,445 shares of our Common Stock, for aggregate gross proceeds of $4.7&nbsp;million, will occur within five business days of receipt of necessary stockholder approval under the applicable rules and regulations of the Nasdaq
Stock Market LLC. We agreed to seek stockholder approval no later than May&nbsp;7, 2018 (within 60 days of the date of the securities purchase agreement), and will file proxy materials with the SEC in connection therewith. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical
company focused on novel cancer immunotherapeutics for a broad range of cancer indications. Our lead product candidate, GPS, is a cancer immunotherapeutic agent licensed from MSK, that targets the WT1, protein, which is present in 20 or more cancer
types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor
indications. Phase 2 clinical trials for GPS have been completed and we have planned Phase 3 clinical trials (pending funding availability) for two indications AML, and or MPM. GPS is also in development as a potential treatment for multiple
myeloma, or MM, and ovarian cancer. We plan to study GPS in up to four additional indications: as a combination therapy in small cell lung cancer, colorectal cancer, triple-negative breast cancer; and, as a monotherapy, in CML. We received Orphan
Drug Product Designations from the FDA as well as Orphan Medicinal Product Designations from the EMA, for GPS in AML and MPM, as well as Fast Track Designation for AML and MPM from the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our pipeline also includes the legacy development programs of our <FONT STYLE="white-space:nowrap">pre-Merger</FONT> company, including novel cancer
immunotherapy programs for NeuVax (nelipepimut-S; a vaccine against the E75 peptide derived from the human epidermal growth factor 2 <FONT STYLE="white-space:nowrap">-or</FONT> HER2- protein), <FONT STYLE="white-space:nowrap">GALE-301</FONT> (a
vaccine against the E39 peptide derived from the FBP) and <FONT STYLE="white-space:nowrap">GALE-302</FONT> (a vaccine against the J65 peptide derived from FBP) and our hematology asset, <FONT STYLE="white-space:nowrap">GALE-401</FONT> (a controlled
release version of the approved drug anagrelide). NeuVax is currently in multiple investigator-sponsored Phase 2 clinical trials in breast cancer. <FONT STYLE="white-space:nowrap">GALE-301</FONT> and <FONT STYLE="white-space:nowrap">GALE-302</FONT>
have completed early stage trials in ovarian, endometrial and breast cancers. <FONT STYLE="white-space:nowrap">GALE-401</FONT> is being developed for the treatment of elevated platelets in patients with MPNs, and we have completed a Phase 2 clinical
trial in patients with ET for this clinical candidate. Since the closing of the Merger, management has been evaluating, <FONT STYLE="white-space:nowrap">GALE-301,</FONT> <FONT STYLE="white-space:nowrap">GALE-302,</FONT> and <FONT
STYLE="white-space:nowrap">GALE-401</FONT> for potential internal development, strategic partnership, or other types of product rationalizations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At
December&nbsp;31, 2017, we had cash and cash equivalents balances of $2.3&nbsp;million. We have incurred operating losses since inception, have not generated any product sales revenue and have not achieved profitable operations. We incurred a net
loss of $23.8 million and $17.7&nbsp;million for the years ended December&nbsp;31, 2017 and 2016, respectively. Our accumulated deficit as of December&nbsp;31, 2017, was $54.2 million, and we expect to continue to incur substantial losses in future
periods. We anticipate that our operating expenses will increase substantially as we continue to advance product candidates. We anticipate that our expenses will increase as we: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B>complete our Phase 2 clinical trials and plan our Phase 3 clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B>continue the research, development and <FONT STYLE="white-space:nowrap">scale-up</FONT> manufacturing capabilities to optimize products and dose forms for which we may obtain regulatory approval;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B>maintain, expand and protect our global intellectual property portfolio; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B>hire additional clinical, manufacturing, and scientific personnel; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B>add, acquire of develop operational, financial and management information systems and personnel, including personnel to support our drug development and potential future commercialization efforts.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to use our existing cash and cash equivalents for working capital and to fund the research and
development of product candidates. We expect that our existing cash as of December&nbsp;31, 2017, together with the proceeds from the first closing of our March 2018 private placement, will enable us to fund our operating expenses and capital
expenditure requirements through June 2018. Assuming that all conditions to the initial closing are met, we expect an additional $4.7 million of cash proceeds from the second closing of the sale of our Series A Convertible Preferred and warrants in
the second quarter of 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Collaboration and License Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we currently have a number of collaborations with corporate partners for the development of our products in various territories worldwide, the
following collaborations and license agreements are those that are most significant to us from a financial statement perspective and where significant ongoing collaboration activity exists. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Memorial Sloan Kettering Cancer Center </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
September 2014, we entered into a license agreement with MSK, under which we were granted an exclusive license to develop and commercialize MSK&#146;s WT1 peptide vaccine technology. The MSK original license agreement was first amended in October
2015, further amended in August 2016, then amended and restated in May 2017 and further amended and restated in October 2017. In connection with the entry of the original license agreement and its amendments, MSK was issued or assigned an aggregate
of 4,846 ordinary shares of Private SELLAS common stock for the year ended December 31, 2017. These common stock shares were converted into our common stock shares upon the Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the current amended and restated MSK license agreement, we agreed to pay minimum royalty payments in the amount of $0.1&nbsp;million each
year commencing in 2015 and research funding costs of $0.2&nbsp;million in each year and for three years commencing in January 2016. We also agreed to pay MSK a <FONT STYLE="white-space:nowrap">mid-six</FONT> digit amount over a one year period in
exchange for MSK&#146;s agreement to further amend and restate the MSK license agreement in October 2017. In addition, to the extent certain development and commercial milestones are achieved, we also agreed to pay MSK up to $17.4&nbsp;million in
aggregate milestone payments for each licensed product, and for each additional patent licensed product, up to $2.8&nbsp;million in additional milestone payments. We also agreed to pay MSK a tiered royalty in the
<FONT STYLE="white-space:nowrap">mid-single</FONT> digits in the event of commercial sales of any licensed products and agreed to raise $25.0&nbsp;million in gross proceeds no later than December&nbsp;31, 2018. In the event we do not raise such
amount by December&nbsp;31, 2018, MSK may terminate the license agreement after complying with the notice and cure periods of the agreement, or MSK may elect to receive additional shares of our capital stock in an amount equal to 1.5% of our then
fully diluted share capital, which would stay the right to terminate for a period of time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless terminated earlier in accordance with its terms, the
MSK license agreement as amended and restated, will continue on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and licensed
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product basis, until the later of: (a)&nbsp;expiration of the last valid claim embracing such licensed product; (b)&nbsp;expiration of any market
exclusivity period granted by law with respect to such licensed product; or (c)&nbsp;ten (10) years from the first commercial sale in such country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For
additional information on our collaboration arrangement with MSK, please read Note 6,<I>&nbsp;Collaborative and License Agreements,</I>&nbsp;to our consolidated financial statements included in this report. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Merck &amp; Co., Inc. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2017, we
entered into a clinical trial collaboration and supply agreement through a Merck subsidiary, whereby we agreed with the Merck subsidiary to collaborate on a research program to evaluate GPS as it is administered in combination with their PD1 blocker
pembrolizumab (Keytruda) in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including both hematologic malignancies and solid tumors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Phase 1/2 clinical trial will utilize a combination of GPS plus pembrolizumab (Keytruda) in patients with WT1+ relapsed or refractory tumors.
Specifically, the study is expected to explore the following cancer indications: colorectal (arm enriched in but not exclusive to patients with microsatellite instability-low), ovarian, small cell lung, triple-negative breast, and AML. This study
will assess the efficacy and safety of the combination, comparing overall response rates and immune response markers achieved with the combination compared to prespecified rates based on those seen with pemrolizumab alone in comparable patient
populations. The trial is anticipated to begin in the third quarter of 2018 (pending funding availability). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Advaxis, Inc. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2017, we entered into a research and development collaboration agreement with Advaxis, Inc. whereby we agreed to collaborate in a research program
to evaluate, through a &#147;proof of principle&#148; trial, or PoP trial, a clinical candidate comprised of the combination of Advaxis&#146; proprietary <FONT STYLE="white-space:nowrap">Lm-based</FONT> antigen delivery technology and GPS, our WT1
peptide. Unless terminated earlier in accordance with its terms, the Advaxis agreement will expire upon the earlier of: (a)&nbsp;completion of the PoP trial, (b)&nbsp;a decision by the parties to cease further development of the clinical candidate
or (c)&nbsp;early termination pursuant to the terms of the Advaxis agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Advaxis agreement provides for cost-sharing between the parties, with Advaxis being responsible for the costs
of performing the research activities and filing any IND, cost-sharing for preparation of the IND, and us being responsible for the costs (exclusive of product costs) of conducting the PoP trial. We also agreed to make certain <FONT
STYLE="white-space:nowrap">non-refundable</FONT> milestone payments to Advaxis having an aggregate amount of up to $108.0&nbsp;million, upon meeting certain clinical, regulatory and commercial milestones. In addition, if net sales exceed certain
targets, we agreed to make <FONT STYLE="white-space:nowrap">non-refundable</FONT> sales milestone payments up to $250.0&nbsp;million and royalty payments based on specific royalty rates, with a maximum rate capped at a percentage rate in the low
double digits if net sales exceed $1.0&nbsp;billion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The University of Texas M. D. Anderson Cancer Center and The Henry M. Jackson Foundation for
the Advancement of Military Medicine, Inc. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In conjunction with the Merger and the acquisition of NeuVax, we acquired rights and assumed
obligations under a license agreement among Apthera and MDACC and HJF which grants exclusive worldwide rights to a United States patent covering the nelipepimut-S peptide and several United States and foreign patents and patent applications covering
methods of using the peptide as a vaccine. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Biovascular, Inc. License Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In conjunction with the Merger, we acquired worldwide rights to anagrelide CR formulation, <FONT STYLE="white-space:nowrap">GALE-401,</FONT> through our
acquisition and Mills became a wholly owned subsidiary, Mills. <FONT STYLE="white-space:nowrap">GALE-401</FONT> contains the active ingredient anagrelide, an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> product that has been in use since the
late 1990s for the treatment of MPNs. Mills holds an exclusive license to develop and commercialize anagrelide CR formulation, pursuant to the license agreement and its amendment with BioVascular. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of our Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and
Development Expense </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expense consists of expenses incurred in connection with the discovery and development of our product
candidates. We expense research and development costs as incurred. These expenses include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expenses incurred under agreements with CROs, as well as investigative sites and consultants that conduct our preclinical studies and clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manufacturing expenses; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">outsourced professional scientific development services; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">employee-related expenses, which include salaries, benefits and stock-based compensation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">payments made under a third-party assignment agreement, under which we acquired intellectual property; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expenses relating to regulatory activities, including filing fees paid to regulatory agencies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">laboratory materials and supplies used to support our research activities; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">allocated expenses, utilities and other facility-related costs. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The successful development of our current and future product candidates is highly uncertain. At this time, we
cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the remainder of the development of, or when, if ever, material net cash inflows may commence from any current or future product
candidates. This uncertainty is due to the numerous risks and uncertainties associated with the duration and cost of clinical trials, which vary significantly over the life of a project as a result of many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of clinical sites included in the trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the length of time required to enroll suitable patients </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of patients that ultimately participate in the trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of doses patients receive; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the duration of patient <FONT STYLE="white-space:nowrap">follow-up;</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the results of our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the expenses associated with manufacturing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the receipt of marketing approvals; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the commercialization of current and future product candidates. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our expenditures are subject to additional
uncertainties, including the terms and timing of regulatory approvals. We may never succeed in achieving regulatory approval for any of our current or future product candidates. We may obtain unexpected results from our clinical trials. We may elect
to discontinue, delay or modify clinical trials of some product candidates or target indications or focus on others. A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant
change in the costs and timing associated with the development of that product candidate. For example, if the FDA, or other regulatory authorities were to require us to conduct clinical trials beyond those that we currently anticipate, or if we
experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development. Cancer immunotherapy product commercialization
may take several years and millions of dollars in development costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development activities are central to our business model. Cancer
immunotherapy product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials.
We expect our research and development expenses to increase significantly over the next several years as it increases personnel costs, including stock-based compensation, conducts clinical trials and prepares regulatory filings for our product
candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expense </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist principally of salaries and related costs for personnel in executive, administrative, finance and legal functions,
including stock-based compensation, travel expenses and recruiting expenses. Other general and administrative expenses include facility related costs, patent filing and prosecution costs and professional fees for business development, legal,
auditing and tax services and insurance costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We anticipate that our general and administrative expenses will increase as a result of increased payroll,
expanded infrastructure and an increase in accounting, consulting, legal and <FONT STYLE="white-space:nowrap">tax-related</FONT> services associated with maintaining compliance with stock exchange listing and SEC requirements, investor relations
costs, and director and officer insurance premiums associated with being a public company. We also anticipate that our general and administrative expenses will increase in support of our clinical trials as we expand and progress our development
programs. Additionally, if and when we believe a regulatory approval of a product candidate appears likely, we anticipate an increase in payroll and expenses as a result of our preparation for commercial operations, particularly as it relates to the
sales and marketing of such cancer immunotherapy product. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Interest Expense, Net </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interest expense, net primarily reflects interest expense incurred on our convertible term notes and other loans held with current and former stockholders,
offset by the interest earned from our cash and cash equivalents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Expense </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other expense consist of foreign currency exchange losses, value added tax, and management fees paid to Equilibria Capital Management, or EQC, Private
SELLAS&#146; strategic advisor and a significant stockholder in 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations for the Years Ended December&nbsp;31, 2017 compared to the
Year Ended December&nbsp;31, 2016 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth our results of operations for the years ended December&nbsp;31, 2017 and 2016 (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,328</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,593</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Severance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,039</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,988</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(704</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(526</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations before income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,501</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,680</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,754</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,681</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses were $6.1&nbsp;million for the year ended December&nbsp;31, 2017 compared to $11.4&nbsp;million for the year ended
December&nbsp;31, 2016. The $5.3&nbsp;million decrease was primarily attributable to a decrease of $2.5 million in fees under licensing and collaboration agreements, a decrease of $1.7&nbsp;million in clinical trial expense, a $1.3&nbsp;million
decrease in manufacturing expenses, a $1.2&nbsp;million decrease in consulting fees, and $0.2&nbsp;million in regulatory expenses. These decreases were partially offset by a $0.7&nbsp;million increase in stock-based compensation and a
$0.9&nbsp;million increase in personnel related expenses. Overall, research and development expenses were reduced in 2017 as we explored various liquidity and capital raising options and focused our efforts on the Merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and
administrative expenses were $15.1&nbsp;million for the year ended December&nbsp;31, 2017 compared to $4.6&nbsp;million for the year ended December&nbsp;31, 2016. The $10.5&nbsp;million increase was primarily driven by $5.7&nbsp;million of
transaction costs incurred related to the Merger and a $2.1&nbsp;million increase in stock-based compensation from the acceleration of restricted stock units, a $1.5&nbsp;million increase in personnel related expenses, $0.6&nbsp;million in
accounting and audit fees, and $0.6&nbsp;million in outside services. The $5.7&nbsp;million of transactions costs consist of $2.9&nbsp;million of banking fees, $1.6&nbsp;million in legal fees, $1.0&nbsp;million incentive fee payable through
approximately $0.1&nbsp;million in cash and the issuance of 119,672 shares of our common stock upon consummation, and $0.2&nbsp;million in accounting and audit fees. The transaction costs incurred related to the Merger are <FONT
STYLE="white-space:nowrap">non-recurring</FONT> expenses for the year 2017. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Severance Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Severance costs incurred during the year ended December&nbsp;31, 2017 include employee-related costs for severance of former Galena employees of
$1.9&nbsp;million. The amount was paid by Galena prior to the consummation of the Merger and subsequently recognized as an expense by the combined company immediately following the closing of the Merger. The termination of former Galena employees
resulted in contingent consideration being paid out in the form of severance based on change of control provisions in their employment agreements. Their employment agreements all required both a change of control and termination of employment, or a
double trigger. Given that there was a change of control as a result of the Merger and Galena terminated all employees prior to the closing, with both provisions of the double trigger were satisfied, the severance is treated as an action triggered
by the accounting acquirer, Private SELLAS. There were no severance costs for the year ended December&nbsp;31, 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Expense, Net
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interest expense, net decreased $0.7&nbsp;million from $1.2&nbsp;million for the year ended December&nbsp;31, 2016 to $0.5&nbsp;million for the
year ended December&nbsp;31, 2017. The decrease was driven by the reduction in our convertible debt during the period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2017 and 2016, we recognized income tax expenses of $0.3 million and $0.0 million, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not generated
any revenue from product sales, and in the years ended December&nbsp;31, 2017 and 2016, we did not generate any revenue from collaboration and licensing agreements. Since inception, we have incurred net losses and have used net cash from our
operations and have funded substantially all of our operations through proceeds of private placements and convertible notes. In December 2017, we completed the Merger and as a result, we acquired $1.8&nbsp;million in cash, and in March 2018, we
closed on the $6.0&nbsp;million from our aggregate $10.7 private placement of our Series A Convertible Preferred and warrants. In addition, in the first quarter of 2018, JGB redeemed $2.6&nbsp;million of outstanding principal, which we satisfied
with 623,749 shares of our common stock and redeemed $0.6&nbsp;million of outstanding principal, which we satisfied in cash, permitting us to transfer $3.2&nbsp;million out of restricted cash and cash equivalents and into unrestricted cash and cash
equivalents to be used to fund our ongoing operations. The outstanding principal balance on the senior secured JGB debenture as of April&nbsp;6, 2018 is $7.0 million and is maintained in restricted cash. We will require additional capital to fund
our operations past June 2018. Alternatively, we will be required to scale back our plans and place certain activities on hold. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While we have agreements for an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;at-the-market&#148;</FONT></FONT> sales issuance facility with future availability of $19.1&nbsp;million, collectively, the ATM facility, its use is subject to certain terms and
condition. We are not currently able to use the ATM facility, and do not expect to be eligible to use it until May&nbsp;1, 2018 at the earliest, when we expect to be able to register certain offerings on Form
<FONT STYLE="white-space:nowrap">S-3.</FONT> However, until the market value of our common stock held by our <FONT STYLE="white-space:nowrap">non-affiliates</FONT> increases to at least $75&nbsp;million, we will be limited in the amounts we may sell
under Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017, we had an accumulated deficit of
$54.2&nbsp;million, a total stockholders&#146; equity of $2.1&nbsp;million, and a cash balance of $2.3&nbsp;million and restricted cash of $10.4&nbsp;million. In addition, we had accounts payable and other accrued expenses of $14.9&nbsp;million and
indebtedness of $11.0 million as of December&nbsp;31, 2017. Our outstanding indebtedness consists of our senior secured debenture with JGB, which is due November 2018. These matters raise substantial doubt about our ability to continue as a going
concern. Our consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this
uncertainty. We anticipate incurring additional losses until such time, if ever, that we can generate significant sales of any current or future product candidates in development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This going concern assumption is based on management&#146;s assessment of the sufficiency of our current and future sources of liquidity considering whether
or not it is probable we will be able to meet our obligations as they become due for at least one year from the date of the issuance of our consolidated financial statements, and if not, whether our liquidation is imminent. Our management believes
that our cash of $2.3&nbsp;million as of December&nbsp;31, 2017, together with the proceeds from the first closing of our Series A Convertible Preferred will be sufficient to fund our planned operations through June 2018. Assuming that all
conditions to the initial closing are met, we expect an additional $4.7 million of cash proceeds from the second closing of the sale of our Series A Convertible Preferred and warrants in the second quarter of 2018. Substantial additional financing
will be needed to fund our operations thereafter and to commercially develop any current or future product candidates. We currently do not have any commitments to obtain additional funds and may be unable to obtain sufficient funding in the future
on acceptable terms, if at all. However, our management is currently evaluating different strategies to obtain the required funding for future operations. These strategies may include, but are not limited to: public and private placements of equity
and/or debt, payments from potential strategic research and development, and licensing and/or marketing arrangements with pharmaceutical companies. Additionally, we continue to engage in active discussions with global and regional pharmaceutical
companies for licensing and/or <FONT STYLE="white-space:nowrap">co-development</FONT> rights to our late- and early-stage pipeline candidates. There can be no assurance that these future funding efforts will be successful. If we cannot obtain the
necessary funding, we will need to delay, scale back or eliminate some or all of our research and development programs; consider other various strategic alternatives, including a merger or sale; or cease operations. However, at this stage our
management does not believe liquidation is imminent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our future operations are highly dependent on a combination of factors, including (i)&nbsp;the
timely and successful completion of additional financing discussed above, (ii)&nbsp;our ability to complete revenue-generating partnerships with pharmaceutical companies, (iii)&nbsp;the success of our research and development, (iv)&nbsp;the
development of competitive therapies by other biotechnology and pharmaceutical companies, and, ultimately, (v)&nbsp;regulatory approval and market acceptance of our proposed future products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our
cash flows for the years ended December&nbsp;31, 2017 and 2016 (amounts in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,989</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,850</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (decrease) increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities of $11.0&nbsp;million during the year ended December&nbsp;31, 2017 was primarily attributable to our net loss of $23.8
million. This amount was offset by various <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $6.7 million, which was comprised of <FONT STYLE="white-space:nowrap">non-cash</FONT> interest, stock-based compensation, losses on extinguishment
of debt and payables, the fair value of shares issued in exchange for research and development services and Merger related charges, among others. The net change in our operating assets and liabilities of $6.0 million is primarily attributable to the
$8.4&nbsp;million increase in our accounts payable as we extend payables until we receive additional financing to be able to meet our obligations when they become due, offset by a $2.4 million decrease in accrued expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities was $11.8&nbsp;million for the year ended December&nbsp;31, 2016, which was primarily attributable to our net loss of
$17.7&nbsp;million. After adjusting for <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $4.5&nbsp;million, the changes in our working capital requirements reflect increases our research and development spend as we prepared for and
advanced our product candidate for its clinical trials and a $1.2&nbsp;million increase in cash paid to our employees and outsourced consultants </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Investing Activities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash provided by
investing activities was $1.8 million for the year ended December 31, 2017 which was acquired,&nbsp;as a result of the Merger.&nbsp;Net cash used in investing activities was $0.1 million for the year ended December 31, 2016, as a result of cash
collateral held with a&nbsp;mid-sized&nbsp;financial institution to support credit card payables. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Financing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities was $5.5&nbsp;million for the year ended December&nbsp;31, 2017 as compared to $16.5&nbsp;million for the year ended
December&nbsp;31, 2016. In 2017, net cash provided by financing activities reflects proceeds from the sale of shares by Private SELLAS prior to the Merger, offset by partial repayment notes that did not convert to Private SELLAS shares in the
financing. In 2016, net cash provided by financing activities reflects proceeds from the sale of convertible notes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Description of Indebtedness
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>JGB Debenture </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2016, our
predecessor company, Galena entered into a securities purchase agreement, with JGB pursuant to which Galena sold to JGB, at a 6.375% original issue discount, a $25.5 million senior secured debenture and warrants to purchase up to 3,333 of the
pre-Merger company&#146;s common stock. The senior secured debenture remains outstanding through the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The senior secured debenture matures on
November 10, 2018 and accrues interest at 9% per year. In addition, on the maturity date of the senior secured debenture (or such earlier date that the principal amount of the senior secured debenture is paid in full by acceleration or otherwise) a
fixed amount, which shall be deemed interest under the senior secured debenture, equal to $0.8 million, will be due and payable to the holder of the senior secured debenture on such date in, at our option, cash and, subject to the same conditions
for the payment of interest in shares of our common stock, or a combination of cash and our common stock. Our option to determine to pay the interest and principal in cash is only available if our cash on hand exceeds the outstanding principal by
$10.0 million. As of December 31, 2017 and the date of the issuance of our consolidated financial statements, we did not exceed the outstanding principal by $10.0 million and therefore interest and principal are payable in shares of our common
stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The outstanding principal and interest of the senior secured debenture that are payable in shares of our common stock at stock payment price of
the lower of (a) 80% of the VWAP for the trading day immediately prior, and (b)&nbsp;80% of the average of the three lowest VWAPs during the 20 consecutive trading day period immediately preceding; provided, however, to the extent that, on any given
trading day, the price per share of our common stock on such trading day on the principal market equals or exceeds 115% of our common stock payment price, then for the such trading day only, each reference to 80% shall be deemed, for such trading
day only, to be 92.5%. The redemptions for outstanding principal are at the option of the holder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017, we had the following contractual commitments: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Payments due by period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Contractual Obligations</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than&nbsp;1<BR>year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">1-3&nbsp;years</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">3-5&nbsp;years</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More&nbsp;than&nbsp;5<BR>years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">298,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">222,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">76,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Operating lease obligations reflect our obligation to make payments in connection with our corporate headquarters in New York, NY. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We did not have during the periods presented, and do not currently have any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements, as defined
in the rules and regulations of the SEC, other than operating leases. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles. The preparation of our consolidated
financial statements and related disclosures requires our management to make estimates and judgments that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated
financial statements, and the reported amounts of revenues and expenses during the reported period. We base such estimates on historical experience, known trends and events and various other factors that are believed to be reasonable under the
circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual
results may differ from these estimates under different assumptions and conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While our significant accounting policies are described in more
detail in the notes to our audited consolidated financial statements appearing elsewhere in this annual report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> we believe that the following accounting policies are those most critical to the
judgments and estimates used in the preparation of our consolidated financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Valuation of Intangible Assets </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In conjunction with our Merger, we have recorded intangible assets related to in-process research and development, or IPR&amp;D. We had total intangible assets
of&nbsp;$17.6 million as of&nbsp;December&nbsp;31, 2017. We had no recorded intangible assets as of December 31, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The identifiable intangible assets
are measured at their respective fair values as of the acquisition date and may be subject to revision within the measurement period, which may be up to one year from the acquisition date. The models used in valuing these intangible assets require
the use of significant estimates and assumptions including but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">estimates of revenues and operating profits related to the products or product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the probability of success for unapproved product candidates considering their stages of development; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the time and resources needed to complete the development and approval of product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the life of the potential commercialized products and associated risks, including the inherent difficulties and uncertainties in developing a product candidate such as obtaining FDA and other regulatory approvals; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">risks related to the viability of and potential alternative treatments in any future target markets. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
believe the fair values used to record intangible assets acquired in connection with a business combination using information known and knowable and are based upon reasonable estimates and assumptions given the facts and circumstances as of the
related valuation dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intangible assets related to IPR&amp;D are considered to be indefinite-lived until the completion or abandonment of the
associated R&amp;D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their
respective estimated useful lives at that point in time. During the period the assets are considered indefinite-lived, they are not amortized but are tested for impairment on an annual basis as well as between annual tests if we become aware of any
events or changes that would indicate that it is more likely than not that the fair value of the IPR&amp;D is below their respective carrying amounts. The fair value of our indefinite-lived intangible assets is dependent on assumptions such as the
expected timing or probability of achieving the specified milestones, changes in projected revenues or changes in discount rates. Significant judgment is employed in determining these assumptions and changes to our assumptions could have a
significant impact on our results of operations in any given period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intangible assets with finite useful lives are reviewed for impairment when facts or
circumstances suggest that the carrying value of these assets may not be recoverable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December 29, 2017, in connection with consummation of the Merger
with Galena, we acquired intangible assets related to IPR&amp;D for NeuVax, GALE-401, and GALE-301 &amp; Gale-302, which had an estimated aggregate fair value of $17.6 Million. See Note&nbsp;5, Goodwill and Intangible Assets of the Notes to
Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Goodwill </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwill is the excess of the cost of an acquired entity over the net amounts assigned to tangible and intangible assets acquired and liabilities assumed.
Goodwill is not amortized but is subject to an annual impairment test. We have a single reporting unit and all goodwill relates to that reporting unit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We perform our annual goodwill impairment test at the reporting unit level on October 1 of each fiscal year or more frequently if changes in circumstances or
the occurrence of events suggest that an impairment exists. Goodwill is evaluated for impairment using the simplified test of goodwill impairment as defined by the FASB Accounting Standards Update No. 2017-04. Under the new guidance, goodwill
impairment will be measured by the amount by which the carrying value of a reporting unit exceeds its fair value, without exceeding the carrying amount of goodwill allocated to that reporting unit. If the fair value of the reporting unit is less
than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the reporting unit&#146;s goodwill is less than the carrying value of the reporting unit&#146;s goodwill. We did not recognize any impairment of
goodwill during the year ended December 31, 2017. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Accrued Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This
process involves reviewing open contracts and purchase orders, communicating with applicable personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the
service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers require advance payments; however, some invoice us in arrears for services performed, on a
<FONT STYLE="white-space:nowrap">pre-determined</FONT> schedule or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances
known to us at that time. We periodically confirm the accuracy of the estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued research and development expenses include fees paid to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">vendors in connection with preclinical development activities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the production of preclinical and clinical trial materials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">CROs in connection with clinical trials; and investigative sites in connection with clinical trials. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We base
our expenses related to preclinical studies and clinical trials on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple research institutions and CROs that conduct and manage preclinical studies
and clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed
the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service
fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual
or prepaid accordingly. Although we do not expect its estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services
performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, we have not made any material adjustments to our prior estimates of accrued research and development expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock-Based Compensation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We account for stock-based
compensation by estimating the fair value of each stock option on the date of grant using the Black-Scholes model. We recognize stock-based compensation expense on a straight line basis over the vesting term. We account for stock-options issued to <FONT
STYLE="white-space:nowrap">non-employees</FONT> by valuing the award using the Black-Scholes model and <FONT STYLE="white-space:nowrap">re-measuring</FONT> such awards to the current fair value until the awards are vested or a performance commitment
has otherwise been reached. Because the fair market value of options granted to <FONT STYLE="white-space:nowrap">non-employees</FONT> is subject to change in the future, the amount of the future compensation expense will include fair value <FONT
STYLE="white-space:nowrap">re-measurements</FONT> until the stock options are fully vested. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Black-Scholes model requires us to make certain
assumptions regarding: (i)&nbsp;the expected volatility in the market price of our shares; (ii)&nbsp;dividend yield; (iii)&nbsp;risk-free interest rates; and (iv)&nbsp;the period of time employees are expected to hold the award prior to exercise
(referred to as the expected holding period). As a result, if we revise our assumptions and estimates, our stock-based compensation expense could change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given our limited history as a publicly traded company following the Merger on December 29, 2017, we did not have sufficient trading data to calculate
volatility based on our own common stock, and the expected volatility was calculated as of each grant date based on a peer group of publicly traded companies. The expected term of the stock options was determined based upon the simplified approach
for employees, allowed under SEC Staff Accounting Bulletin No.&nbsp;110, which assumes that the stock options will be exercised evenly from vesting to expiration. As data associated with future exercises is obtained, the expected term of future
grants will be adjusted accordingly. For <FONT STYLE="white-space:nowrap">non-employee</FONT> awards, we use the remaining contractual term. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We measure compensation for RSUs based on the price of our shares at the grant date and we recognize the expense
on a straight line basis over the vesting period. The expense relating to RSUs that contain both a service and a performance condition is estimated and adjusted on a quarterly basis based upon our assessment of the probability that the performance
condition would be met. As a result, if we revise such assessment, our stock-based compensation expense could change. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2017, the FASB issued ASU <FONT STYLE="white-space:nowrap">2017-11,</FONT> <I>Earnings Per Share (Topic 260); Distinguishing Liabilities from
Equity (Topic</I><I></I><I>&nbsp;480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial
Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. </I>The first part of this update addresses the complexity of accounting for certain financial instruments with down round
features and the second part addresses the complexity of distinguishing liabilities from equity. The guidance is applicable to public business entities for fiscal years beginning after December&nbsp;15, 2018 and interim periods within those years.
We are currently evaluating the potential impact of the adoption of this standard on our consolidated results of operations, financial position and cash flows and related disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2017, the FASB issued Accounting Standard Update No. <FONT STYLE="white-space:nowrap">2017-09,</FONT><I>&nbsp;Compensation&#151;Stock Compensation
(Topic 718): Scope of Modification Accounting</I>. ASU <FONT STYLE="white-space:nowrap">2017-09</FONT> provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting
in Topic 718. Specifically, an entity would not apply modification accounting if the fair value, vesting conditions, and classification of the awards are the same immediately before and after the modification. The guidance is applicable to public
business entities for fiscal years beginning after December&nbsp;15, 2017 and interim periods within those years. Early adoption is permitted, including adoption in any interim period. We do not expect this new guidance to have a material impact on
our consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-18,</FONT> <I>Restricted
cash</I>, amending the presentation of restricted cash within the statement of cash flows. The new guidance requires that restricted cash be included within cash and cash equivalents on the statement of cash flows. The ASU is effective
retrospectively for reporting periods beginning after December&nbsp;15, 2017, with early adoption permitted. We are currently evaluating the impact of our pending adoption of the new standard on the consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2016, the FASB issued Accounting Standards Update <FONT STYLE="white-space:nowrap">2016-09,</FONT><I>&nbsp;Compensation-Stock Compensation</I>. ASU <FONT
STYLE="white-space:nowrap">2016-09</FONT> includes several areas of simplification to stock compensation including simplifications to the accounting for income taxes, classification of excess tax benefits on the Statement of Cash Flows and
forfeitures. ASU <FONT STYLE="white-space:nowrap">2016-09</FONT> is effective for annual reporting periods beginning after December&nbsp;15, 2016. An entity that elects early adoption must adopt all of the amendments in the same period. We adopted
this ASU on January&nbsp;1, 2017. There was no impact to our consolidated financial statements upon adoption. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued Accounting Standards Update No.
<FONT STYLE="white-space:nowrap">2016-02,</FONT><I>&nbsp;Leases</I>, which establishes a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> (&#147;ROU&#148;) model that requires a lessee to record a ROU
asset and a lease liability on the balance sheet for all leases with terms longer than 12&nbsp;months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income
statement. The new standard is effective for fiscal years beginning after December&nbsp;15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating
leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. We are currently evaluating the impact of our pending adoption of the new
standard on the consolidated financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx556278_10"></A>ITEM&nbsp;7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary objective of our investment activities is to preserve capital. We do not utilize hedging contracts or similar instruments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to certain market risks relating primarily to (1)&nbsp;interest rate risk on our cash and cash equivalents and (2)&nbsp;risks relating to the
financial viability of the institutions which hold our capital and through which we have invested our funds. We manage such risks by investing primarily in money market mutual funds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we are exposed to foreign currency exchange rate fluctuations relating to payments we make to certain vendors and suppliers and license partners
using foreign currencies. We do not hedge against foreign currency risks. Consequently, changes in exchange rates could adversely affect our operating results and stock price. Such losses have not been significant to date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx556278_11"></A>ITEM&nbsp;8.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA </B></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC.
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">10-K</FONT> &#151; FISCAL YEAR ENDED DECEMBER&nbsp;31, 2017 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="93%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page&nbsp;No.</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx556278_23">Reports of Independent Registered Public Accounting Firms </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">103</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx556278_24">Consolidated Balance Sheets as of December&nbsp;31, 2017 and
2016</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">105</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx556278_25">Consolidated Statements of Operations for the years ended December&nbsp;
31, 2017 and 2016</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">106</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx556278_26">Consolidated Statements of Stockholders&#146; Equity for the years ended December&nbsp;31,
 2017 and 2016</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">107</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx556278_27">Consolidated Statements of Cash Flows for the years ended December&nbsp;
31, 2017 and 2016</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">108</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx556278_28">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">109</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx556278_23"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Stockholders and the Board of Directors of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SELLAS Life
Sciences Group, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Opinion on the Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying consolidated balance sheet of SELLAS Life Sciences Group, Inc. (the &#147;Company&#148;) as of December 31, 2017, the related
consolidated statements of operations, stockholders&#146; equity (deficit) and cash flows for the year<I> </I>then ended. In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial
position of the Company as of December&nbsp;31, 2017, and the consolidated results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described in Note 1, the total and per share common stock information included in the Company&#146;s 2016 consolidated financial statements has been
retroactively adjusted to give effect to the reverse merger and stock split. The Company also revised its 2016 consolidated financial statements to present net loss per share. We audited the adjustments that were applied to the total and per share
common stock information to give effect to the reverse merger, stock split and the presentation of net loss per share reflected in the 2016 financial statements. In our opinion, such adjustments are appropriate and have been properly applied.
However, we were not engaged to audit, review, or apply any procedures to the 2016 consolidated financial statements of the Company other than with respect to such adjustments and, accordingly, we do not express an opinion or any other form of
assurance on the 2016 consolidated financial statements taken as a whole. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Going Concern Uncertainty </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the
consolidated financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. Management&#146;s plans in regard to these
matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis for Opinion </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These consolidated financial
statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s consolidated financial statements based on our audit. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States) (&#147;PCAOB&#148;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and
Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether the consolidated<I> </I>financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of
its internal control over financial reporting. As part of our audit<I> </I>we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the
Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audit<I> </I>included performing procedures to
assess the risks of material misstatement of the consolidated<I> </I>financial statements, whether due to error or fraud, and performing procedures to respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated
financial statements. We believe that our audit provides a reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Moss Adams LLP </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April 13, 2018 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor since 2017. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx556278_23"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors and Shareholders of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SELLAS Life Sciences
Group Ltd </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited, before the effects of the retrospective changes resulting from the acquisition described in Note 1, and the addition of net
loss per share information to the consolidated financial statements as described in Note 3, the accompanying consolidated balance sheet of SELLAS Life Sciences Group Ltd and subsidiaries as of December&nbsp;31, 2016, and the related consolidated
statements of operations, changes in shareholders&#146; deficit, and cash flows for the year then ended. The 2016 financial statements before the effects of the retrospective changes discussed in Note 1, and the addition of net loss per share
information to the consolidated financial statements as described in Note 3, are not presented herein. These consolidated financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on
these consolidated financial statements based on our audit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audit in accordance with the standards of the Public Company Accounting
Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement
presentation. We believe that our audit provides a reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our opinion, the consolidated financial statements referred to
above, before the effects of the retrospective changes resulting from the acquisition described in Note 1 and the addition of net loss per share information to the consolidated financial statements as described in Note 3, present fairly, in all
material respects, the financial position of SELLAS Life Sciences Group Ltd and subsidiaries as of December&nbsp;31, 2016, and the results of their operations and their cash flows for the year then ended in conformity with U.S. generally accepted
accounting principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were not engaged to audit, review, or apply any procedures to the retrospective changes resulting from the acquisition
described in Note&nbsp;1, nor the net loss per share information added to the consolidated financial statements as described in Note 3 and, accordingly, we do not express an opinion or any other form of assurance about whether such retrospective
changes, net loss per share information are appropriate and have been properly applied. Those retrospective changes were audited by a successor auditor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements as of December 31, 2016 and for the year then ended have been prepared assuming that the Company will
continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has suffered recurring net losses since its inception that raises substantial doubt about its ability to continue as a going concern.
Management&#146;s plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ KPMG Audit Limited </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chartered Professional Accountants </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hamilton, Bermuda </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 22, 2017 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx556278_24"></A>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposits and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>LIABILITIES AND STOCKHOLDERS&#146; EQUITY (DEFICIT)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of convertible debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Litigation settlement payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent purchase price consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible debt, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity (deficit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.0001&nbsp;par value; 5,000,000&nbsp;shares authorized; no shares issued and
outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001&nbsp;par value; 350,000,000&nbsp;shares authorized, 5,766,891 shares issued
and outstanding at December&nbsp;31, 2017; 1,268,489 shares issued and&nbsp;outstanding at December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(54,185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,431</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,997</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx556278_25"></A>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,593</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Severance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses and loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,039</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,988</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,754</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,681</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividend on conversion of 2015 Sely Note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(675</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,681</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted loss per share to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10.44</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18.66</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,340,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">947,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx556278_26"></A>CONSOLIDATED STATEMENT OF STOCKHOLDERS&#146; EQUITY (DEFICIT) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands, except share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Common Stock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Additional<BR><FONT STYLE="white-space:nowrap">Paid-In</FONT><BR>Capital</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Accumulated<BR>Deficit</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Amount</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at January&nbsp;1, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">879,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,750</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,262</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issued as partial consideration of MSK license fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issued pursuant to MSK license agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issued in cancellation of Clarendon license agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issued upon conversion of 2016 convertible term note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">236,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issued in cancellation of long term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,681</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,681</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,268,&nbsp;489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,431</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,997</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issued in connection with amendments to MSK license</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issued upon conversion of 2015 Shareholder Notes and accrued interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">330,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sale of common shares to related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,534,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issued in connection with settlement of related party payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issued upon the acceleration of restricted stock units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issued upon cancellation of Equilibria restricted stock units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issued in connection with acquisition of Galena </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,588,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of assumed options issued in connection with acquisition of Galena </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares and common stock warrants issued upon conversion of 2015 Sely Note and accrued interest to
Equilibria</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">632,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividend associated with conversion of 2015 Sely Note and common stock warrant issuance to
Equilibria</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(675</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(675</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issued to Equilibria for incentive fee payment in connection with the acquisition of Galena
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issued to MSK for anti-dilution provisions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,754</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,754</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,766,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">56,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(54,185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx556278_27"></A>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amounts in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,754</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,681</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustment to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-cash research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of shares issued in exchange for research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of shares issued for incentive fee to Equilibria</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Severance costs paid by Galena </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(477</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,374</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,989</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,850</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from investing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash acquired from acquisition of Galena </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash provided by (used in) investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from financing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net proceeds from issuance of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net proceeds from issuance of convertible debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net proceeds from issuance of long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal payments on convertible debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(473</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash provided by financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net decrease (increase) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at the beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of non-cash investing and financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issued in connection with acquisition of Galena </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of options assumed in connection with acquisition of Galena </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related party payable settled in shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MSK payable settled in shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issued upon conversion of 2015 Shareholder Notes and accrued interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issued upon conversion of 2015 Sely Note and accrued interest to Equilibria</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividend associated with conversion of 2015 Sely Note and common stock warrant issuance to
Equilibria</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx556278_28"></A>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Organization and Description of Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Merger of
Galena Biopharma, Inc. and SELLAS Life Sciences Group Ltd. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As used in this annual report on Form 10-K, the words the &#147;Company,&#148; and
&#147;SELLAS&#148; refer to SELLAS Life Sciences Group, Inc. and its consolidated subsidiaries following completion of the Merger. Said references before the completion of the Merger refer to Private SELLAS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;29, 2017, Galena Biopharma. Inc. (&#147;Galena&#148;) completed the business combination with the privately held Bermuda exempted company,
Sellas Life Sciences Group Ltd. (&#147;Private SELLAS&#148;), in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of August&nbsp;7, 2017 and amended November&nbsp;5, 2017 the (&#147;Merger Agreement&#148;),
by and among the Company, Sellas Intermediate Holdings I, Inc., Sellas Intermediate Holdings II, Inc., Galena Bermuda Merger Sub, Ltd., and Private SELLAS. The Company refers to this business combination throughout this annual report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> as the Merger. As a result of the Merger, the Company&#146;s business is now substantially comprised of the business of Private SELLAS, and although the Company is considered the legal acquiror of Private
SELLAS, for accounting purposes, Private SELLAS is considered to have acquired the Company in the Merger. Consequently, the Merger is accounted for as a reverse acquisition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immediately prior to the Merger, the Galena effected a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-30</FONT></FONT> reverse stock
split of the Company&#146;s outstanding common stock. Under the terms of the Merger Agreement, the Galena issued shares of the its common stock to Private SELLAS&#146; securityholders at an exchange ratio of 43.9972 shares of the its common stock in
exchange for each common share of Private SELLAS outstanding immediately prior to the Merger. The Company also assumed all of the restricted stock units (&#147;RSU&#148;) issued and outstanding under the Private SELLAS Stock Incentive Plan #1, and
all of the issued and outstanding warrants of Private SELLAS. Accordingly, such RSUs will now be settled in, and such warrants now are exercisable for, shares of the Company&#146;s common stock. Accordingly, immediately after the Merger, there were
approximately 5,766,891 shares of the Company&#146;s common stock outstanding, with the former Private SELLAS securityholders owning approximately 67.5% of the Company&#146;s fully diluted common stock, and the Company&#146;s <FONT
STYLE="white-space:nowrap">pre-Merger</FONT> securityholders owning the remaining approximately 32.5%. The number of shares and per share amounts of common stock in the accompanying financial statements and notes to the consolidated financial
statements have been restated to give retroactive effect to the common stock conversion ratio and reverse stock split for all periods presented, including common stock options, restricted stock units, and common stock warrants. The prior year
amounts for outstanding common stock at the $10.00 par value of Private SELLAS&#146; common stock and related additional paid-in capital have been retroactively presented at a $0.0001 par value. These reclassifications had no effect on total equity,
or net loss per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Common stock as included in the consolidated statement of stockholders&#146; equity (deficit) was adjusted to reflect the $0.0001
par value per share and additional paid-in capital was adjusted as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Retroactive<BR>Effect</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016&nbsp;Revised</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at January 1, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issued as partial consideration of MSK license fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issued pursuant to MSK license agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issued in cancellation of Clarendon license agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issued upon conversion of 2016 convertible note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issued in cancellation of long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December 31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon completion of the Merger, the Company changed the Company&#146;s name from &#147;Galena Biopharma, Inc.&#148; to
&#147;SELLAS Life Sciences Group, Inc.&#148;, the Company&#146;s common stock began trading on The Nasdaq Capital Market under a new ticker symbol &#147;SLS&#148; on January&nbsp;2, 2018 and the Company&#146;s financial statements became those of
Private SELLAS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is a
clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The Company&#146;s lead product candidate, galinpepimut-S (&#147;GPS&#148;), is a cancer immunotherapeutic agent licensed
from Memorial Sloan Kettering Cancer Center (&#147;MSK&#148;), that targets the Wilms tumor 1 (&#147;WT1&#148;), protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the
potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and the Company&#146;s
planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia (&#147;AML&#148;), and malignant pleural mesothelioma (&#147;MPM&#148;). GPS is also in development as a potential treatment for multiple
myeloma (&#147;MM&#148;), and ovarian cancer. The Company plans to study GPS in up to four additional indications: as a combination therapy in small cell lung cancer, colorectal cancer, triple-negative breast cancer; and, as a monotherapy in chronic
myelogenous leukemia (&#147;CML&#148;). The Company received Orphan Drug Product Designations from the U.S. Food and Drug Administration (&#147;FDA&#148;) as well as Orphan Medicinal Product Designations from the European Medicines Agency
(&#147;EMA&#148;), for GPS in AML and MPM, as well as Fast Track designation for AML and MPM from the FDA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#150; Continued </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s pipeline also includes the legacy development programs of the <FONT
STYLE="white-space:nowrap">pre-Merger</FONT> company Galena, including novel cancer immunotherapy programs for NeuVax&#153; (nelipepimut-S; a vaccine against the E75 peptide derived from the human epidermal growth factor 2 <FONT
STYLE="white-space:nowrap">-or</FONT> HER2- protein), <FONT STYLE="white-space:nowrap">GALE-301</FONT> (a vaccine against the E39 peptide derived from the folate binding protein (&#147;FBP&#148;)) and <FONT STYLE="white-space:nowrap">GALE-302</FONT>
(a vaccine against the J65 peptide derived from FBP) and <FONT STYLE="white-space:nowrap">GALE-401</FONT> (a controlled release version of the approved drug anagrelide). NeuVax is currently in multiple investigator-sponsored Phase 2 clinical trials
in breast cancer. <FONT STYLE="white-space:nowrap">GALE-301</FONT> and <FONT STYLE="white-space:nowrap">GALE-302</FONT> have completed early stage trials in ovarian, endometrial and breast cancers. <FONT STYLE="white-space:nowrap">GALE-401</FONT> is
being developed for the treatment of elevated platelets in patients with myeloproliferative neoplasms (&#147;MPNs&#148;), and a completed Phase 2 clinical trial in patients with essential thrombocythemia (&#147;ET&#148;) for this clinical candidate.
Since the closing of the Merger, management has been evaluating, <FONT STYLE="white-space:nowrap">GALE-301,</FONT> <FONT STYLE="white-space:nowrap">GALE-302,</FONT> and <FONT STYLE="white-space:nowrap">GALE-401</FONT> for potential internal
development, strategic partnership, or other types of product rationalizations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Liquidity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has not generated any revenues from product sales and has funded operations primarily from the proceeds of private placements of its equity
interests (prior to the Merger) and convertible notes, as well as through the Merger. Substantial additional financing will be required by the Company to continue to fund its research and development activities. No assurance can be given that any
such financing will be available when needed or that the Company&#146;s research and development efforts will be successful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company regularly
explores alternative means of financing its operations and seeks funding through various sources, including public and private securities offerings, collaborative arrangements with third parties and other strategic alliances and business
transactions. On March&nbsp;7, 2018, the Company entered into a definitive securities purchase agreement to issue shares of its convertible preferred stock (&#147;Series A Convertible Preferred&#148;) and warrants to purchase shares of its common
stock in a private placement transaction to a select group of institutional investors. The Series A Convertible Preferred is expected to close in two tranches and result in aggregate gross proceeds to the Company of approximately $10.7&nbsp;million.
The Company closed the first tranche for approximately $6.0&nbsp;million on March&nbsp;9, 2018. The remaining $4.7&nbsp;million will be received at the second closing, which is subject to stockholder approval, and is expected to occur early in the
second quarter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the proceeds from the Series A Convertible Preferred, in the first quarter of 2018, JGB (Cayman) Newton Ltd
(&#147;JGB&#148;) the holder the Company&#146;s senior secured debenture due November 2018 redeemed $2.6&nbsp;million of outstanding principal that was satisfied by the Company with 635,894 shares of the Company&#146;s common stock and redeemed
$0.6&nbsp;million of outstanding principal, which the Company satisfied in cash. As a result of the redemptions, the Company was able to transfer $3.2&nbsp;million out of restricted cash and cash equivalents and into unrestricted cash and cash
equivalents to be used to fund the Company&#146;s ongoing operations. The outstanding principal balance on the senior secured debenture as of April 6, 2018 is $7.0&nbsp;million and is maintained by the Company as restricted cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than as described in Note 15, the Company currently does not have any commitments to obtain additional funds and may be unable to obtain sufficient
funding in the future on acceptable terms, if at all. If the Company cannot obtain the necessary funding, it will need to delay, scale back or eliminate some or all of its research and development programs or enter into collaborations with third
parties to: commercialize potential products or technologies that it might otherwise seek to develop or commercialize independently; consider other various strategic alternatives, including a merger or sale of the Company; or cease operations. If
the Company engages in collaborations, it may receive lower consideration upon commercialization of such products than if it had not entered into such arrangements or if it entered into such arrangements at later stages in the product development
process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has prepared its financial statements assuming that it will continue as a going concern, which contemplates realization of assets
and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses since inception and it expects to generate losses from operations for the foreseeable future primarily due to research and development costs
for its potential product candidates, which raises substantial doubt about the Company&#146;s ability to continue as a going concern. Various internal and external factors will affect whether and when the Company&#146;s product candidates become
approved drugs and how significant their market share will be, some of which are outside of the Company&#146;s control. The length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the
drug approval process will materially affect the Company&#146;s financial condition and future operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset
amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#150; Continued </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017, the Company had a cash balance of approximately $2.3&nbsp;million and
restricted cash at $10.4 million. In addition, the Company had outstanding accounts payable and accrued expenses of $14.9&nbsp;million and indebtedness of $11.0&nbsp;million as of December&nbsp;31, 2017, which consists of the Company&#146;s senior
secured debenture with JGB. The Company expects its existing cash as of December&nbsp;31, 2017, together with&nbsp;the proceeds from the initial&nbsp;closing of its Series A Convertible Preferred in March 2018, will enable the Company to fund its
operating expenses and capital expenditure requirements through June 2018. Assuming that all conditions to the initial closing are met, the Company expects an additional $4.7 million of cash proceeds from the second closing of the sale of the
Company&#146;s Series A Convertible Preferred and warrants in the second quarter of 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.&nbsp;Basis of Presentation and Summary of Significant
Accounting Policies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Basis of Presentation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#147;U.S. GAAP&#148;). Any reference in these notes to applicable guidance is meant to refer to
U.S.&nbsp;GAAP as found in the Accounting Standards Codification (&#147;ASC&#148;) and Accounting Standards Updates (&#147;ASU&#148;) of the Financial Accounting Standards Board (&#147;FASB&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Principles of Consolidation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial
statements include the financial statements of the Company and its wholly owned subsidiaries, SELLAS Bermuda, SELLAS Life Sciences Group UK Ltd (&#147;SELLAS UK&#148;), Apthera, Inc. (&#147;Apthera&#148;) and Mills Pharmaceuticals, LLC
(&#147;Mills&#148;). All significant intercompany accounts and transactions have been eliminated upon consolidation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Use of Estimates </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of these consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment.
Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation, the fair value of the warrants, beneficial conversion features associated with convertible notes, fair value of intangible assets
acquired, carrying value of goodwill, fair value of contingent purchase price consideration, fair value of deferred tax liability assumed and accounting for research and development activities. Management believes its estimates to be reasonable
under the circumstances. Actual results could differ significantly from those estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Fair Value of Financial Instruments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The carrying amounts of the Company&#146;s financial instruments, including cash equivalents, accounts payable, and accrued expenses approximate fair value due
to the short-term nature of those instruments. The carrying amounts of the Company&#146;s outstanding convertible notes approximate fair value due to the debt carrying a variable interest rate that is tied to the current London Interbank Offer Rate
(&#147;LIBOR&#148;) rate. The fair value of the convertible notes is determined using a binomial lattice model that utilizes certain unobservable inputs that fall within Level&nbsp;3 of the fair value hierarchy. The fair value of the warrants is
determine using a Black-Scholes pricing model. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Concentration of Credit Risk </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial
institutions, the balances of which frequently exceed federally insured limits. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#150; Continued </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash and Cash Equivalents </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers any highly liquid investments, such as money market funds, with an original maturity of three months or less to be cash and cash
equivalents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Cash and Cash Equivalents </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Restricted cash consists of the minimum cash covenant as required by the debenture and certificates of deposit on hand with the Company&#146;s financial
institutions as collateral for its corporate credit cards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Intangible Assets </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intangible assets are comprised of identifiable <FONT STYLE="white-space:nowrap">in-process</FONT> research and development (&#147;IPR&amp;D&#148;) assets and
are considered indefinite-lived intangible assets and are assessed for impairment annually on October&nbsp;1 or more frequently if impairment indicators exist. If the associated research and development effort is abandoned, the related assets will
be <FONT STYLE="white-space:nowrap">written-off</FONT> and the Company will record a <FONT STYLE="white-space:nowrap">non-cash</FONT> impairment loss. For those compounds that reach commercialization, the IPR&amp;D assets will be amortized over
their estimated useful lives. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Goodwill </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwill is
the excess of the cost of an acquired entity over the net amounts assigned to tangible and intangible assets acquired and liabilities assumed. Goodwill is not amortized but is subject to an annual impairment test. The Company has a single reporting
unit and all goodwill relates to that reporting unit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company performs its annual goodwill impairment test at the reporting unit level on
October&nbsp;1 of each fiscal year or more frequently if changes in circumstances or the occurrence of events suggest that an impairment exists. Goodwill is evaluated for impairment using the simplified test of goodwill impairment as defined by the
FASB Accounting Standards Update <FONT STYLE="white-space:nowrap">No.&nbsp;2017-04.</FONT> Under the new guidance, goodwill impairment will be measured by the amount by which the carrying value of a reporting unit exceeds its fair value, without
exceeding the carrying amount of goodwill allocated to that reporting unit. If the fair value of the reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the reporting
unit&#146;s goodwill is less than the carrying value of the reporting unit&#146;s goodwill. The Company did not recognize any impairment of goodwill during the year ended December&nbsp;31, 2017. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Severance Costs </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognized and paid
$1.9&nbsp;million of exit costs during 2017 related to severance benefits for former Galena employees terminated immediately prior to the consummation of the Merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Patents and Patent Application Costs </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although the
Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Legal Fees and Insurance Recoveries </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be a
significant time lag between the time that legal fees are incurred and the insurance reimbursement available to offset the related costs. The legal fees are recorded in the period they are incurred, and the insurance recoveries for those costs are
recorded in the period when the insurance reimbursement is deemed probable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock-based Compensation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company follows the provisions of the FASB ASC Topic 718, &#147;<I>Compensation</I><I></I><I>&nbsp;&#151; Stock Compensation&#148;</I> (&#147;ASC
718&#148;), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, and consultants, including stock options and
warrants. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC&nbsp;718 is recognized as an expense over the requisite service period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#150; Continued </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For stock options and warrants granted as consideration for services rendered by <FONT
STYLE="white-space:nowrap">non-employees,</FONT> the Company recognizes compensation expense in accordance with the requirements of FASB ASC Topic <FONT STYLE="white-space:nowrap">505-50</FONT> (&#147;ASC
<FONT STYLE="white-space:nowrap">505-50&#148;),</FONT> &#147;<I>Equity Based Payments to <FONT STYLE="white-space:nowrap">Non-</FONT> Employees</I>.&#148; <FONT STYLE="white-space:nowrap">Non-employee</FONT> option and warrant grants that do not
vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, will
be <FONT STYLE="white-space:nowrap">re-measured</FONT> using the fair value of the Company&#146;s common stock and the <FONT STYLE="white-space:nowrap">non-cash</FONT> compensation recognized during the period will be adjusted accordingly. Since the
fair market value of options and warrants granted to <FONT STYLE="white-space:nowrap">non-employees</FONT> is subject to change in the future, the amount of the future compensation expense will include fair value
<FONT STYLE="white-space:nowrap">re-measurements</FONT> until the stock options are fully vested. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed as incurred. Research and development costs that are paid in advance of performance are capitalized as a prepaid
expense and amortized over the service period as the services are provided. Clinical study costs, a component of research and development expenses, are accrued over the service periods specified in the contracts and adjusted as necessary based on an
ongoing review of the level of effort and costs actually incurred. Payments for a product license prior to regulatory approval of the product and payments for milestones achieved prior to regulatory approval of the product are expensed in the period
incurred as research and development expenses. Milestone payments made in connection with regulatory approvals are capitalized and amortized to cost of revenue over the remaining useful life of the asset. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses primarily consist of the intellectual property and research and development materials acquired, expenses from third parties
who conduct research and development activities on behalf of the Company as well as related wages, benefits and other operating costs. The Company expenses in-process research and development projects acquired as asset acquisitions which have not
reached technological feasibility and which have no alternative future use. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Income Taxes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax
consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and credit carryforwards. Deferred tax assets and liabilities are measured
using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided when it is more likely than not that some portion or all of a
deferred tax asset will not be realized. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on its income tax return it files, if such a position is more likely than not to be sustained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes liabilities or assets for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and
their reported amounts in the financial statements in accordance with FASB <FONT STYLE="white-space:nowrap">ASC&nbsp;740-10,</FONT> &#147;<I>Accounting for Income Taxes&#148; (&#147;ASC <FONT STYLE="white-space:nowrap">740-10&#148;).</FONT></I>
These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled. <I>ASC <FONT STYLE="white-space:nowrap">740-10</FONT></I> requires that a
valuation allowance be established when management determines that it is more likely than not that all or a portion of a deferred asset will not be realized. The Company evaluates the realizability of its net deferred income tax assets and valuation
allowances as necessary, at least on an annual basis. During this evaluation, the Company reviews its forecasts of income in conjunction with other positive and negative evidence surrounding the realizability of its deferred income tax assets to
determine if a valuation allowance is required. Adjustments to the valuation allowance will increase or decrease the Company&#146;s income tax provision or benefit. The recognition and measurement of benefits related to the company&#146;s tax
positions requires significant judgment, as uncertainties often exist with respect to new laws, new interpretations of existing laws, and rulings by taxing authorities. Differences between actual results and the Company&#146;s assumptions or changes
in the Company&#146;s assumptions in future periods are recorded in the period they become known. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#150; Continued </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;22, 2017 the President of the United States signed into law the Tax Cuts and Jobs Act
(&#147;The 2017 Tax Act&#148;).&nbsp;This legislation makes significant changes in the United States tax laws including, but not limited to, reducing the corporate tax rate to 21% starting in 2018. The 2017 Tax Act required the Company to revalue
its deferred tax assets and liabilities to the new rate of 21%.&nbsp;For the years ended December&nbsp;31, 2017 and 2016, the Company recognized income tax expense of $253,000 and $1,000, respectively. Staff Accounting Bulletin No. 118 (&#147;SAB
118&#148;) was issued to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for
certain income tax effects of the Tax Act. In accordance with SAB 118, we determined that the adjustment to deferred taxes was a provisional amount and a reasonable estimate at December 31, 2017. We do not expect any impact on recorded deferred tax
balances as the remeasurement of net deferred tax assets will be offset by a change in valuation allowance. We are analyzing certain aspects of the Tax Act which could potentially affect the remeasurement of the net deferred tax assets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Net Loss Per Share </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic loss per share is computed by
dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities,
such as convertible debt, warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share, the weighted average number of shares
remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they
would be anti-dilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted stock awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amounts in the table reflect the common stock equivalents of the noted instruments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Comprehensive Loss </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has no items of
comprehensive income or loss other than net loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Recently Issued Accounting Pronouncements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2017, the FASB issued ASU <FONT STYLE="white-space:nowrap">2017-11,</FONT> <I>Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity
(Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic
Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. </I>The first part of this update addresses the complexity of accounting for certain financial instruments with down round features and the second part
addresses the complexity of distinguishing liabilities from equity. The guidance is applicable to public business entities for fiscal years beginning after December&nbsp;15, 2018 and interim periods within those years. The Company is currently
evaluating the potential impact of the adoption of this standard on its consolidated results of operations, financial position and cash flows and related disclosures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#150; Continued </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2017, the FASB issued Accounting Standard Update No.
<FONT STYLE="white-space:nowrap">2017-09,</FONT><I>&nbsp;Compensation&#151;Stock Compensation (Topic 718): Scope of Modification Accounting</I>. ASU <FONT STYLE="white-space:nowrap">2017-09</FONT> provides guidance about which changes to the terms
or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. Specifically, an entity would not apply modification accounting if the fair value, vesting conditions, and classification of the awards are
the same immediately before and after the modification. The guidance is applicable to public business entities for fiscal years beginning after December&nbsp;15, 2017 and interim periods within those years. Early adoption is permitted, including
adoption in any interim period. The Company does not expect this new guidance to have a material impact on its consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
November 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-18,</FONT> <I>Restricted cash</I>, amending the presentation of restricted cash within the statement of cash flows. The new guidance requires that restricted cash be
included within cash and cash equivalents on the statement of cash flows. The ASU is effective retrospectively for reporting periods beginning after December&nbsp;15, 2017, with early adoption permitted. The Company is currently evaluating the
impact of its pending adoption of the new standard on the consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2016, the FASB issued Accounting Standards Update <FONT
STYLE="white-space:nowrap">2016-09,</FONT><I>&nbsp;Compensation-Stock Compensation</I>. ASU <FONT STYLE="white-space:nowrap">2016-09</FONT> includes several areas of simplification to stock compensation including simplifications to the accounting
for income taxes, classification of excess tax benefits on the Statement of Cash Flows and forfeitures. ASU <FONT STYLE="white-space:nowrap">2016-09</FONT> is effective for annual reporting periods beginning after December&nbsp;15, 2016. An entity
that elects early adoption must adopt all of the amendments in the same period. The Company adopted this ASU on January&nbsp;1, 2017. There was no impact to the Company&#146;s consolidated financial statements upon adoption. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued Accounting Standards Update No. <FONT STYLE="white-space:nowrap">2016-02,</FONT><I>&nbsp;Leases</I>, which establishes a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> (&#147;ROU&#148;) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months.
Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December&nbsp;15, 2018, including
interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the
financial statements, with certain practical expedients available. The Company is currently evaluating the impact of its pending adoption of the new standard on the consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Business Combination </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;29, 2017, the
Company completed the Merger with Private SELLAS as discussed in Note 1. The Merger was accounted for as reverse merger under the acquisition method of accounting whereby Private SELLAS was considered to have acquired the Company for financial
reporting purposes because, immediately upon completion of the Merger, Private SELLAS stockholders held a majority of the voting interest of the combined company. Immediately after the Merger, stockholders of Private SELLAS and the Company&#146;s
common stock, warrants and options owned approximately 67.5% and 32.5% of the fully diluted common stock of the Company, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#150; Continued </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purchase consideration in a reverse acquisition is determined with reference to the value of equity that
the accounting acquirer, in this case, Private SELLAS, would have had to issue to the owners of the accounting acquiree, the Company, to give the <FONT STYLE="white-space:nowrap">pre-acquisition</FONT> equity holders of the Company the same
percentage interest in Private SELLAS that such <FONT STYLE="white-space:nowrap">pre-acquisition</FONT> equity holders held in the Company immediately following the Merger. The purchase price was calculated as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of the Company&#146;s <FONT STYLE="white-space:nowrap">pre-Merger</FONT> shares
outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated fair value of the Company&#146;s <FONT STYLE="white-space:nowrap">per-Merger</FONT>
stock options outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total purchase price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Merger transaction has been accounted for using the acquisition method of accounting, which requires that assets acquired
and liabilities assumed be recognized at their fair values as of the acquisition date. See Note 5 for the valuation technique utilized to value the IPR&amp;D. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the allocation of the purchase price to the assets acquired and liabilities assumed as of the acquisition date (in thousands):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets acquired:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets acquired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities assumed:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Litigation settlement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent purchase price consideration of Apthera, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities assumed</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net assets acquired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Qualitative factors supporting the recognition of goodwill due to the Merger include the Company&#146;s anticipated enhanced
ability to secure additional capital and gain access to capital market opportunities as a public company. The goodwill is not deductible for income tax purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#150; Continued </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following summary pro forma consolidated financial information reflects the Merger as if it had occurred
on January&nbsp;1, 2016 for purposes of the statements of operations. This summary pro forma information is not necessarily representative of what the Company&#146;s results of operations would have been had the Merger in fact occurred on
January&nbsp;1, 2016, and is not intended to project the Company&#146;s results of operations for any future period. In addition, transaction costs associated with the Merger of $5.7&nbsp;million are included in general and administrative expense in
the statement of operations for the year ended December 31, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pro forma consolidated financial information for 2017 and 2016 (unaudited): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenues (in thousands)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss (in thousands)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-recurring</FONT> pro forma transaction costs directly attributable to the Merger were
$5.7&nbsp;million for the year ended December&nbsp;31, 2017 and have been deducted from the net loss presented above. The costs deducted from the year ended December&nbsp;31, 2017 period included a success fee and other transaction costs&nbsp;of
$4.8 million and issued 119,672 shares of common stock with a fair value of $0.9&nbsp;million as a fee to Equilibria Capital Management Limited (&#147;Equilibria&#148;). Additionally, the Company incurred approximately $1.9&nbsp;million in severance
costs as a result of resignations of executive officers immediately prior to the Merger. These costs are excluded from the pro forma financial information for the year ended December&nbsp;31, 2017. The Company excluded a $5.2&nbsp;million impairment
charge incurred by the Company as well as combined transaction costs from Galena and the Company in the amount of $8.7&nbsp;million from the pro forma financial information for the year ended December&nbsp;31, 2017. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Goodwill and Intangible Assets </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company completes
its annual impairment test on October&nbsp;1 each year, or more frequently if triggering events indicate a possible impairment. The Company continually evaluates financial performance, economic conditions and other relevant developments in assessing
if an interim period impairment test is necessary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in the carrying amount of goodwill for the period ended December&nbsp;31, 2017 consisted of
the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of January 1, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill as a result of the Merger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intangible assets consist of IPR&amp;D acquired as part of the Merger. IPR&amp;D assets represent research and development
assets that have not yet reached commercialization. At December&nbsp;31, 2017, the significant components of the Company&#146;s IPR&amp;D assets consist of the NeuVax program for the prevention of recurrence in breast cancer, the <FONT
STYLE="white-space:nowrap">GALE-401</FONT> program for treatment of essential thrombocythemia, and the <FONT STYLE="white-space:nowrap">GALE-301</FONT> &amp; <FONT STYLE="white-space:nowrap">GALE-302</FONT> programs for prevention of cancer
recurrent in ovarian and endometrial cancer patients in the adjuvant setting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#150; Continued </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s allocation of purchase price to acquired IPR&amp;D was $17.6&nbsp;million. The estimated
fair value of the <FONT STYLE="white-space:nowrap">GALE-401</FONT> and NeuVax IPR&amp;D assets were determined using a &#147;income approach,&#148; which is a valuation technique that provides an estimate of the fair value of an asset based on
market participant expectations of the cash flows an asset would generate over its remaining useful life. The fair values of the <FONT STYLE="white-space:nowrap">GALE-401</FONT> and NeuVax programs were $9.1&nbsp;million and $5.7&nbsp;million,
respectively. Some of the more significant assumptions inherent in the development of those asset valuations include the estimated net cash flows for each year for the asset or product (including net revenues, cost of sales, research and development
costs, selling and marketing costs and working capital/asset contributory asset charges), the appropriate discount rate to select in stream, the assessment of the asset&#146;s life cycle, the potential regulatory and commercial success risks,
competitive trends impacting the asset cash flow stream as well as other factors. The fair value of the <FONT STYLE="white-space:nowrap">GALE-301</FONT> &amp; <FONT STYLE="white-space:nowrap">GALE-302</FONT> programs was $2.8&nbsp;million as
determined using the replacement cost approach given the Phase 1/2a development status of the programs and the lack of projected financial information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IPR&amp;D assets are required to be classified as indefinite-lived assets until the successful commercialization of the asset or the abandonment of the
associated R&amp;D effort. These assets are assessed for impairment annually on October&nbsp;1 or more frequently if impairment indicators exist. Accordingly, during the development period after the date of acquisition, these assets will not be
amortized until commercialization is reached. For those programs that reach commercialization, the Company will determine the useful life of the asset, reclassify the asset out of IPR&amp;D and begin amortization. If the associated R&amp;D effort is
abandoned, the related IPR&amp;D assets will likely be <FONT STYLE="white-space:nowrap">written-off,</FONT> and the Company will record a <FONT STYLE="white-space:nowrap">non-cash</FONT> impairment loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Collaboration and License Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of its
business, the Company enters into licensing agreements with third parties that often require milestone and royalty payments based on the progress of the licensed asset through development and commercial stages. Milestone payments may be required,
for example, upon approval of the product for marketing by a regulatory agency, and the Company may be required to make royalty payments based upon a percentage of net sales of the product. The expenditures required under these arrangements in any
period may be material and are likely to fluctuate from period to period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These arrangements sometimes permit the Company to unilaterally terminate
development of the product and thereby avoid future contingent payments; however, the Company is unlikely to cease development if the compound successfully achieves clinical testing objectives. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Memorial Sloan Kettering Cancer Center </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
September&nbsp;4, 2014, (the &#147;MSK Effective Date&#148;) the Company entered into a license agreement (the &#147;Original MSK License Agreement&#148;) with MSK under which the Company was granted an exclusive license to develop and commercialize
MSK&#146;s WT1 peptide vaccine technology. Under the terms of the Original MSK License Agreement, the Company is required to obtain certain levels of financing. If such financing is not met, MSK will have the right to terminate the Original MSK
License Agreement with prior written notice, unless the Company manages to overcome the shortfall during the term of the notice period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the
consideration for the rights, privileges and licenses granted under the Original MSK License Agreement, the Company agreed to issue 13,199 shares to MSK representing 1.5% of the Company&#146;s fully diluted share capital as of the MSK Effective
Date, which obligation was satisfied by assignment of 6,599&nbsp;shares from each of the Company&#146;s Chief Executive Officer, <FONT STYLE="white-space:nowrap">co-founder</FONT> and Vice Chairman of the Board, Dr.&nbsp;Angelos&nbsp;M. Stergiou
(M.D., Sc.D. h.c), and the Company&#146;s other <FONT STYLE="white-space:nowrap">co-founder,</FONT> Dr.&nbsp;Miltiadis Sougioultzoglou (M.D.), to MSK for which they received no consideration. Additionally, the Company was obligated to pay upfront
license fees in an amount equal to $1.3&nbsp;million. The Company recognized this amount as research and development expense during the year ended December&nbsp;31, 2014, as it had no alternative future use. The Company would further be obligated to
pay minimum royalty payments in the amount of $0.1&nbsp;million each year commencing in 2015 and research funding costs of $0.2&nbsp;million in each year and for three years commencing in January 2015. In addition, to the extent certain development
and commercial milestones are achieved, the Company will be required to pay MSK up to $17.4&nbsp;million in milestone payments for each licensed product, in addition to royalties in the event of commercial sales of any licensed products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#150; Continued </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Original MSK License Agreement, unless terminated earlier in accordance with the terms of the Original
MSK License Agreement, will continue on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and licensed
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product basis, until the later of: (a)&nbsp;expiration of the last valid claim embracing such licensed product; (b)&nbsp;expiration of any market
exclusivity period granted by law with respect to such licensed product; or (c)&nbsp;ten (10)&nbsp;years from the first commercial sale in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;30, 2015, the Company and MSK entered into the License Amendment, Waiver and Share Issuance Agreement (the &#147;First MSK Amendment&#148;).
The First MSK Amendment extended the date required for the Company to obtain financing from August&nbsp;1, 2015 to December&nbsp;31, 2016, modified the amount of required financing and waived past
<FONT STYLE="white-space:nowrap">non-compliance</FONT> with certain related provisions of the Original MSK License Agreement. In exchange for the First MSK Amendment, the Company agreed to issue an aggregate of 10,867 shares to MSK, which
represented 1% of the fully diluted share capital of the Company at such date. The First MSK Amendment added certain anti-dilution protection clauses and entitled MSK to issuance of additional shares to the extent the Company was not able to obtain
the required financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;10, 2016, the Company and MSK entered into the Second License Amendment, Waiver and Agreement
(the&nbsp;&#147;Second MSK Amendment&#148;). The Second MSK Amendment extended further the date required for the Company to obtain financing from December&nbsp;31, 2016 to June&nbsp;30, 2017, amended the anti-dilution provisions of the First MSK
Amendment and waived past <FONT STYLE="white-space:nowrap">non-compliance</FONT> with certain related provisions of the First MSK Amendment. Under the Second MSK Amendment, outstanding obligations of the Company to MSK in an amount of
$0.9&nbsp;million were converted into 13,815 shares effective November&nbsp;1, 2016 upon the Company&#146;s <FONT STYLE="white-space:nowrap">re-domiciliation</FONT> to Bermuda. In consideration for this amendment and pursuant to the anti-dilution
provisions in the Original MSK License Agreement as amended by the First MSK Amendment and the Second MSK Amendment, the Company issued MSK 30,314 additional shares and incurred accordingly $2.0&nbsp;million of research and development expense,
which reflected the fair value of the Company&#146;s shares at such date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2017, the Company incurred
$1.0&nbsp;million of expenses relating to $0.7&nbsp;million of milestone payments, $0.1&nbsp;million of guaranteed minimum royal payments and $0.2&nbsp;million of research funding costs. For the year ended December&nbsp;31, 2016 the Company incurred
$0.6&nbsp;million of expenses relating to $0.3&nbsp;million of milestone payments, $0.1&nbsp;million of guaranteed minimum royal payments and $0.2&nbsp;million of research funding costs. Such expenses have been included in research and development
costs. Further, under the Second MSK Amendment, the Company is obligated to pay MSK $0.7&nbsp;million in milestone payments in two equal installments, within 60 days following the initiation of its Phase 3 AML and mesothelioma clinical studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;25, 2017, the Company and MSK entered into an Amended and Restated Exclusive License Agreement (the &#147;MSK A&amp;R License Agreement&#148;).
Under the MSK A&amp;R License Agreement, the Company expanded its license under the original MSK License Agreement, as amended, to include a license to commercially develop certain additional WT1 peptides through a program of exploiting certain
patents and other rights covering such peptides. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The MSK A&amp;R License Agreement, amongst others, added certain milestone payments for each additional
patent licensed product as defined in the MSK A&amp;R License Agreement, and amended the milestone payments due upon commencement of the Phase 3 AML and mesothelioma clinical trials from $0.3&nbsp;million to $0.4&nbsp;million. In consideration for
the MSK A&amp;R License Agreement, the Company issued 8,799 shares to MSK. Pursuant to a side letter to the MSK A&amp;R License Agreement, dated May&nbsp;25, 2017 (the &#147;MSK Side Letter&#148;), MSK converted the next milestone payment of
$0.2&nbsp;million, which was due June&nbsp;30, 2017, into shares. Further, in consideration for the MSK Side Letter, Dr.&nbsp;Angelos&nbsp;M. Stergiou (M.D., Sc.D. h.c.), the Company&#146;s Chief Executive Officer, assigned 15,399 of his shares to
MSK, for which Dr.&nbsp;Stergiou received no cash consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;11, 2017, the Company and MSK entered into a second Amended and Restated
Exclusive License Agreement (the &#147;Second MSK A&amp;R License Agreement&#148;). Under the Second MSK A&amp;R License Agreement, the Company and MSK extended the dates for the Company to have obtained necessary financing, and certain milestone
dates, in exchange for increased milestone payments, clarification regarding MSK&#146;s anti-dilution rights, and termination of the MSK Side Letter dated May&nbsp;25, 2017. In connection with the MSK A&amp;R License Agreement, the Company issued
74,795 shares to MSK. Prior to the Merger, the Company issued an additional 7,700 shares to MSK in connection with their anti-dilution rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#150; Continued </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Merck&nbsp;&amp; Co., Inc. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;21, 2017, the Company entered into a clinical trial collaboration and supply agreement through a Merck&nbsp;&amp; Co., Inc. subsidiary, Merck
Sharp&nbsp;&amp; Dohme B.V. (&#147;Merck subsidiary&#148;), whereby the Company agreed with the Merck subsidiary to collaborate in a research program to evaluate GPS as it is administered in combination with Merck&#146;s PD1 blocker pembrolizumab
(Keytruda<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including both hematologic malignancies and solid tumors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of the clinical trials is to determine if the administration of GPS in combination with pembrolizumab has the potential to demonstrate clinical
activity in the presence of macroscopic disease, where monotherapy with either agent would have a more limited effect. The rationale for the study is based upon the presumed immunobiologic and pharmacodynamic synergy between the two agents, whereby
the negative influence of tumor microenvironment factors on the immune response is mitigated by PD1 inhibition (by pembrolizumab) thus allowing the patients&#146; own immune cells to invade and destroy cancerous growth deposits specifically
sensitized against WT1 by GPS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Phase 1/2 clinical trial will utilize a combination of GPS plus pembrolizumab (Keytruda) in patients with WT1+
relapsed or refractory tumors. Specifically, the study is expected to explore the following cancer indications: colorectal (arm enriched in but not exclusive to patients with microsatellite <FONT STYLE="white-space:nowrap">instability-low),</FONT>
ovarian, small cell lung, triple-negative breast, and AML. This study will assess the efficacy and safety of the combination, comparing overall response rates and immune response markers achieved with the combination compared to prespecified rates
based on those seen with pemrolizumab alone in comparable patient populations. The trial is anticipated to begin in the third quarter of 2018 (pending funding availability). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Advaxis, Inc. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;24, 2017, the Company and
Advaxis, Inc. (&#147;Advaxis&#148;) entered into a research and development collaboration agreement, whereby both parties will collaborate in a research program to evaluate, through a &#147;proof of principle&#148; trial or trials (&#147;PoP
Clinical Trial&#148;), a clinical candidate comprised of the combination of Advaxis&#146; proprietary<I>&nbsp;Lm-</I>based antigen delivery technology and the Company&#146;s patented WT1 targeted heteroclitic peptide antigen mixture (GPS). The term
of the Advaxis agreement will expire upon the earlier of: (a)&nbsp;completion of the PoP Clinical Trial, (b)&nbsp;a decision by the parties to cease further development of the clinical candidate and (c)&nbsp;early termination of the Advaxis
agreement pursuant to the terms thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Advaxis agreement provides for cost-sharing between the parties, with Advaxis being responsible for the
costs of performing the research activities and filing any investigational new drug application (&#147;IND&#148;), cost-sharing for preparation of the IND, and the Company being responsible for the costs (exclusive of product costs) of conducting
the PoP trial. The Company also agreed to make certain <FONT STYLE="white-space:nowrap">non-refundable</FONT> milestone payments to Advaxis having an aggregate amount of up to $108.0&nbsp;million, upon meeting certain clinical, regulatory and
commercial milestones. In addition, if net sales exceed certain targets, the Company agreed to make <FONT STYLE="white-space:nowrap">non-refundable</FONT> sales milestone payments up to $250.0&nbsp;million and royalty payments based on specific
royalty rates, with a maximum rate capped at a percentage rate in the low double digits if net sales exceed $1.0&nbsp;billion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#150; Continued </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Trojantec Ltd. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;14, 2014, the Company entered into a license agreement with Trojantec Ltd., (&#147;Trojantec&#148;), a company incorporated in Cyprus, under
which the Company was granted an exclusive license to develop and commercialize Trojantec&#146;s TR1 Antenapedia/p21 protein treatment. In consideration for entering into the Trojantec License Agreement and for the rights, privileges and licenses
granted, the Company incurred $0.3&nbsp;million of license fees during the year ended December&nbsp;31, 2014. Under the license agreement, the Company would be obligated to pay Trojantec royalties on net sales, if any, and milestone payments related
to the achievement of certain clinical and regulatory goals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;14, 2015, the Company and Trojantec entered into the First Amended and Restated
Exclusive License Agreement. The amendment reinstated the obligations of the Company under the original license agreement and further obligated the Company to pay project management fees of up to $0.4&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;15, 2016, the Company entered into an agreement with Trojantec to terminate the license agreement. In consideration for the termination
agreement, the Company incurred and paid in cash $0.1&nbsp;million of termination fees. Such fees were included in research and development expenses for the year ended December&nbsp;31, 2016. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clarendon Trading e Investimentos LDA </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
January&nbsp;18, 2016, the Company entered into a license arrangement with Clarendon Trading e Investimentos LDA (&#147;Clarendon&#148;), a company incorporated in Portugal. Under the license agreement, the Company was granted an exclusive license
to <FONT STYLE="white-space:nowrap">know-how</FONT> to use for development and to manufacture products involving therapeutic use of Clarendon&#146;s intellectual property. In consideration for this assignment, the Company incurred expenses of EUR
0.5&nbsp;million. Under the license agreement, in the event that the Company was successful in obtaining regulatory approval for any commercial exploitation of the therapeutic uses of Zolpidem, the Company would be obligated to pay Clarendon a
yearly success fee and guaranteed minimum royalty payments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective September&nbsp;30, 2016, the Company entered into termination agreement with
Clarendon to terminate the license agreement. In consideration for the termination agreement and in complete satisfaction of the Company&#146;s outstanding liabilities, the Company agreed to pay Clarendon $0.3&nbsp;million in cash and issue
Clarendon 7,700 shares. In extinguishment of the Company&#146;s outstanding liabilities to Clarendon, the Company incurred an additional $0.2&nbsp;million of expense to reflect the fair value of the shares issued to Clarendon. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#150; Continued </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s predecessor company, Galena entered into the following licensing and/or supply agreements,
which the Company acquired through the Merger: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The University of Texas M. D. Anderson Cancer Center and The Henry M. Jackson Foundation for the
Advancement of Military Medicine, Inc. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;11, 2006, the Company acquired rights and assumed obligations under a license agreement among
Apthera and The University of Texas M. D. Anderson Cancer Center (&#147;MDACC&#148;) and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (&#147;HJF&#148;) which grants exclusive worldwide rights to a United States
patent covering the nelipepimut-S peptide and several United States and foreign patents and patent applications covering methods of using the peptide as a vaccine. Under the terms of this license, the Company is required to pay an annual maintenance
fee of&nbsp;$0.2&nbsp;million, clinical milestone payments and royalty payments based on sales of NeuVax or other therapeutic products developed from the licensed technologies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Biovascular, Inc. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;20, 2013, Mills and
BioVascular, Inc. (&#147;BioVascular&#148;) entered into an exclusive license agreement. In 2014, through the Company&#146;s acquisition of Mills, the Company&#146;s wholly owned subsidiary, the Company acquired worldwide rights to to develop and
commercialize anagrelide controlled release formulation, <FONT STYLE="white-space:nowrap">GALE-401.</FONT> <FONT STYLE="white-space:nowrap">GALE-401</FONT> contains the active ingredient anagrelide, an
<FONT STYLE="white-space:nowrap">FDA-approved</FONT> product that has been in use since the late 1990s for the treatment of myleoproliferative neoplasms. Under the terms of the license agreement, Mills has agreed to pay BioVascular a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mid-to-low</FONT></FONT> single digit royalty on net revenue from the sale of licensed products, pay future cash milestone payments based on the achievement of specified regulatory
milestones and is responsible for patent prosecution and maintenance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;5, 2017, Mills and BioVascular entered into an amendment to
license agreement to modify the certain terms of the license agreement, including but not limited to, (i)&nbsp;eliminating the 3% royalty rate on annual net sales of $50.0&nbsp;million and the 4% royalty now applies to annual net sales of up to
$100.0&nbsp;million, (ii)&nbsp;making an advance payment of approximately $0.4&nbsp;million for the milestone related to the initiation of the Phase 3 clinical trial payable in two tranches with the first payment of $0.2&nbsp;million payable on or
before October&nbsp;31, 2017 and the second payment of approximately $0.2&nbsp;million payable 30 days after the consummation of the Merger but no later than December&nbsp;31, 2017, (iii) adding a payment for a sublicense by Mills to a third party
of 25% of any cash received for upfront fees or milestone payments if the sublicense is executed prior to first patient enrolled in the Phase 3 clinical trial and 17.5% of any cash received for upfront fees or milestone payments if the sublicense is
executed after the first patient is enrolled in the Phase 3 clinical trial, and (iv)&nbsp;if the first patient is not enrolled in the Phase 3 clinical trial by December&nbsp;31, 2018, BioVascular shall have the right to terminate the license
agreement and the advance payment shall not be repaid to Mills. Under the terms of a September&nbsp;5, 2017 consent between Comerica Bank, BioVascular and Mills, Comerica Bank shall receive $0.1&nbsp;million of the approximately $0.4&nbsp;million
advance payment from Mills. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#150; Continued </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Teva Pharmaceuticals </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In conjunction with the Merger, acquisition of NeuVax, and effective December&nbsp;3, 2012, the Company entered into a license and supply agreement with ABIC
Marketing Limited (&#147;ABIC&#148;), a subsidiary of Teva Pharmaceuticals. Under the agreement, the Company granted ABIC exclusive rights to seek marketing approval in Israel for NeuVax for the treatment of breast cancer following its approval by
the FDA or the EMA, and to market, sell and distribute NeuVax in Israel assuming such approval is obtained. ABIC&#146;s rights also include a right of first refusal in Israel for all future indications for which NeuVax may be approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the license and supply agreement, ABIC will assume responsibility for regulatory registration of NeuVax in Israel, provide financial support for local
development, and commercialize the product in the region in exchange for making royalty payments to us based on future sales of NeuVax. ABIC also agrees in the license and supply agreement to purchase all supplies of NeuVax from the Company at a
price determined according to a specified formula. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dr.&nbsp;Reddy&#146;s Laboratories Ltd. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In conjunction with the Merger, acquisition of NeuVax, and effective January&nbsp;14, 2014, the Company entered into a strategic development and
commercialization partnership with Dr.&nbsp;Reddy&#146;s Laboratories Ltd. (&#147;Dr.&nbsp;Reddy&#146;s&#148;), under which the Company licensed commercial rights in India to Dr.&nbsp;Reddy&#146;s for NeuVax in breast and gastric cancers. The
Company has an agreement with Dr.&nbsp;Reddy&#146;s to conduct a Phase 2 investigational study in gastric cancer in India. To date, Dr.&nbsp;Reddy&#146;s has not initiated the Phase 2 study with NeuVax. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Kwang Dong Pharmaceutical Co., Ltd. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In conjunction with
the Merger, acquisition of NeuVax, and effective April&nbsp;30, 2009, the Company entered into a license agreement with Kwang Dong Pharmaceutical Co, Ltd. (&#147;Kwang Dong&#148;). Under the agreement, the Company granted Kwang Dong exclusive rights
to seek marketing approval in The Republic of Korea, or South Korea for NeuVax for the treatment of breast cancer following its approval by the FDA or the EMA, and to market, sell and distribute NeuVax in South Korea assuming such approval is
obtained. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Fair Value Measurements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following
tables present information about the Company&#146;s assets and liabilities measured at fair value on a recurring basis in the consolidated balance sheets (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">December&nbsp;31,<BR>2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Quoted&nbsp;Prices&nbsp;In<br>Active Markets<br>(Level 1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Significant&nbsp;Other<br>Observable<br>Inputs (Level 2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Unobservable<br>Inputs<br>(Level 3)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets measured and recorded at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants potentially settleable in cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities measured and recorded at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#150; Continued </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company did not transfer any financial instruments into or out of Level&nbsp;3 classification during the
year ended December&nbsp;31, 2017. The contingent consideration was assumed by the Company in connection with the Merger and recorded at fair value as of the consummation of the Merger, which approximates fair value as of December&nbsp;31, 2017. The
fair value of the contingent consideration is measured at the end of each reporting period using Level 3 inputs in a probability-weighted, discounted cash-outflow model. The contingent consideration relates to Galena&#146;s acquisition of Apthera,
Inc. in 2011 and the future contingent payments of up to $32 million based on the achievement of certain development and commercial milestones relating to the Company&#146;s NeuVaxTM product candidate. The contingent consideration is payable at the
election of the Company in either cash or shares of common stock, provided that the Company may not issue any shares in satisfaction of any contingent consideration unless it has first obtained approval of its stockholders in accordance with Rule
5635(a) of the Nasdaq Marketplace Rules. The significant unobservable assumptions include the probability of achieving each milestone, the date we expect to reach the milestone, and a determination of present value factors used to discount future
expected cash outflows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2016, the estimated fair value of the 2015 Notes was $7.3&nbsp;million, which compared to a carrying value
of $7.4&nbsp;million. See also Note 9. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See Note 12 for discussion of the Level&nbsp;3 liabilities relating to warrants accounted for as liabilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Accrued Expenses and Other Current Liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities consist of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Value added tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rebates and returns</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation and related benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clinical trial costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Debt </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Debt and
convertible debt consist of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of Senior Secured Debenture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-current portion of Senior Secured Debenture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2015 Shareholder Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2015 Sely Note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total convertible debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#150; Continued </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Senior Secured Debenture </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;10, 2016, the Company&#146;s predecessor company, Galena entered into a securities purchase agreement, with JGB pursuant to which Galena sold to
JGB, at a 6.375% original issue discount, a $25.5&nbsp;million senior secured debenture (the&nbsp;&#147;Senior Secured Debenture&#148;) and warrants to purchase up to 3,333 shares of Galena&#146;s common stock, $0.0001 par value per share. Net
proceeds to Galena from sale of the Senior Secured Debenture and warrants, after payment of commissions and legal fees, was approximately $23.4 million. The Senior Secured Debenture contained no conversion features to shares of common stock. The
Senior Secured Debenture remains outstanding for the Company through the consummation of the Merger with Galena on December&nbsp;29, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Senior
Secured Debenture matures on November&nbsp;10, 2018, and accrues interest at&nbsp;9%&nbsp;per year, payable monthly. In addition, on the maturity date of the Senior Secured Debenture (or such earlier date that the principal amount of the Senior
Secured Debenture is paid in full by acceleration or otherwise) a fixed amount, which shall be deemed interest under the Senior Secured Debenture, equal to&nbsp;$0.8&nbsp;million will be due and payable to JQB of the Senior Secured Debenture on such
date in, at the option of the Company, cash and, subject to the same conditions for the payment of interest in shares of the Company&#146;s common stock, or a combination of cash and the Company&#146;s common stock </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s obligations under the Senior Secured Debenture are secured under the security purchase agreement by a senior lien on all of the
Company&#146;s assets, including all of the Company&#146;s interests in its consolidated subsidiaries. Under the subsidiary guarantee agreement, each subsidiary guarantees the performance of the Company of the securities purchase agreement, Senior
Secured Debenture and related agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Senior Secured Debenture was amended in August 2016, May 2017, July 2017 and August 2017. After giving
effect to the amendments, the Senior Secured Debenture contains the following modified and/or additional terms, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">JGB can from time to time during the term of the Senior Secured Debenture require the Company to prepay in cash all or a portion of the outstanding principal plus accrued and unpaid interest (the &#147;Outstanding
Amount&#148;) on written notice to the Company, provided, that such prepayment amount shall not exceed the lesser of $18.5&nbsp;million and the outstanding principal amount. If JGB elects such prepayment of the Senior Secured Debenture, then the
number of shares subject to the warrants issued to the holder will be reduced in proportion to the percentage of principal and accrued interest required to be prepaid by the Company. The Company does not have the right to prepay. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">JGB has the right, which commenced on November&nbsp;10, 2016, to require the Company to redeem the outstanding principal amount, up to the outstanding principal amount of the Senior Secured Debenture by written notice
to the Company and may deliver an unlimited number of redemption notices during any calendar month. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The Company has the option to pay outstanding principal redemptions and monthly interest in shares of common stock, cash, or a combination of shares of common stock and cash. Among the various conditions that must be
satisfied (or waived) in order for the Company to be able to elect to satisfy the redemption amounts in shares of common stock: (a)&nbsp;the VWAP of&nbsp;$10.50 per share on any trading day that a redemption notice is delivered (b)&nbsp;no event of
default has occurred and is continuing and (c)&nbsp;the Company&#146;s cash on hand exceeds the outstanding principal amount by at least $10.0&nbsp;million. In the event that any of these conditions are not met, the Company does not have the option
to pay outstanding principal redemptions and monthly interest in cash. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The stock payment price to satisfy outstanding principal redemptions and monthly interest is the lower of (a)&nbsp;80%&nbsp;of the VWAP for the trading day immediately prior to the date of the applicable redemption
notice (the&nbsp;&#147;Prior Day VWAP&#148;) and (b)&nbsp;80%&nbsp;of the average of the three lowest VWAPs during the&nbsp;20&nbsp;consecutive trading day period immediately preceding the date of the applicable redemption notice (the &#147;Twenty
Day VWAP&#148;); provided, however, to the extent that, on any given trading day, the price per share of common stock on such trading day equals or exceeds&nbsp;115%&nbsp;of the Prior Day VWAP or Twenty Day VWAP, then for the such trading day, and
such trading day only, each reference to 80% shall be deemed, for such trading day only, to be 92.5% </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#150; Continued </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The Company was required to maintain a minimum of the lesser of $18.5&nbsp;million or the outstanding principal amount of unencumbered cash in a restricted account. As of December&nbsp;31, 2017, the Company maintained
$10.2&nbsp;million of cash and cash equivalents in a restricted account equal to the outstanding principal amount. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31,
2017, the outstanding principal balance of the Senior Secured Debenture was $10.2&nbsp;million. In addition to the outstanding principal balance, on the earlier of the maturity date or the date that the principal amount is paid in full, the Senior
Secured Debenture has a $0.8 million additional interest amount that is included in the current portion of long-term debt as of December 31, 2017. Subsequent to December 31, 2017, the holder of the Senior Secured Debenture redeemed an additional
$2.6&nbsp;million of outstanding principal, which the Company satisfied with a combination of 623,749 shares of the Company&#146;s common stock and redeemed $0.6&nbsp;million of outstanding principal, which the Company satisfied with
$0.6&nbsp;million in cash. As of result of the redemptions, the Company was able to transfer $3.2 million out of restricted cash and cash equivalents and into unrestricted cash and cash equivalents to be used to fund the Company&#146;s ongoing
operations. The principal redemptions of $2.6 million subsequent to December 31, 2017 that were satisfied with shares of the Company&#146;s common stock are classified as long-term debt, as of December 31, 2017, as the amounts were not satisfied
with working capital. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2015 Convertible Term Notes, as of December 31, 2017 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;2, 2015, the Company issued an aggregate of $1.5&nbsp;million in principal amount of convertible term notes to certain stockholders of the
Company (the &#147;2015 Shareholder Notes&#148;) and on May&nbsp;7, 2015, the Company issued a convertible term note in the principal amount of $5.0&nbsp;million to EQC Biotech Sely I Fund (&#147;EQC Sely I Fund&#148;), a related party of the
Company (the&nbsp;&#147;2015 Sely Note&#148; and, together with the 2015 Shareholder Notes, the &#147;2015 Notes&#148;). The holders of the 2015 Shareholder Notes include two of the significant stockholders and founding investors of the Company,
Drs. Angelos M. Stergiou (M.D., ScD h.c.), the Company&#146;s CEO and Miltiadis Sougioultzoglou (M.D.). The 2015 Notes were issued at par and bear an interest rate of 8%. The 2015 Shareholder Notes matured on April&nbsp;2, 2017 and the 2015 Sely
Note originally matured on May&nbsp;7, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2017, the Company and EQC Sely I Fund further amended the 2015 Sely Note to agree the number of
shares issuable upon consummation of the Merger. Accordingly, contingent upon and effective immediately prior to completion of the Merger, the Company will issue to EQC Sely I Fund 632,328 of its common shares
<FONT STYLE="white-space:nowrap">and&nbsp;5-year&nbsp;warrants</FONT> to purchase 316,163 of its common shares at a post-Merger price equal to 105% of the volume weighted average price of Galena common stock for the 30&nbsp;calendar days following
the closing date of the Merger (described above in Note 1), in full satisfaction of the 2015 Sely Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;13, 2017, the Board of Directors
approved a $7.3&nbsp;million capital increase (the &#147;Bridge Financing&#148;), pursuant to which an aggregate of 1,865,261 shares were issued at a price per share equal to approximately $3.91. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the Bridge Financing, an aggregate of $1.3&nbsp;million (330,551 shares) was subscribed by certain stockholders who are also the holders of the
2015 Shareholder Notes. The cash proceeds were used to partially offset the principal ($1.2 million) and cumulative accrued interest ($0.1 million) due on the 2015 Shareholder Notes. Following the Bridge Financing, the Company extinguished in cash
its remaining obligations on the 2015 Shareholder Notes, which included $0.3&nbsp;million of principal and $0.2&nbsp;million of cumulative accrued interest as of June&nbsp;21, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;29, 2017, the Company issued 632,326 shares of common stock and warrants to purchase 316,163 of its common stock in full satisfaction of the
2015 Sely Note. The 2015 Sely Note conversion was considered to be an induced conversion and extinguishment and the Company realized a loss of $0.7&nbsp;million during the year ended December&nbsp;31, 2017. The Company considered the extinguishment
to be a capital transaction and it was therefore recorded in the Company&#146;s consolidated statements of stockholders&#146; equity (deficit). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#150; Continued </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2016 Convertible Term Note </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;30, 2016, the Company issued a $15.0&nbsp;million convertible term note to EQC Sely I Fund (the &#147;2016 Note&#148;). The 2016 Note was issued
at par and had an interest rate of 8%. The 2016 Note was issued with similar terms to the 2015 Notes (excluding the warrant coverage) whereby the 2016 Note is mandatorily convertible into equity upon the earlier to occur: a) the closing of a
qualified IPO, b) a change in the Company&#146;s domicile from Switzerland to Bermuda or c) the <FONT STYLE="white-space:nowrap">six-month</FONT> anniversary of the note. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;1, 2016, the Company redomiciled its operations from Switzerland to Bermuda and therefore, the 2016 Note, together with accrued interest, was
converted into 236,705 shares of its common stock based upon a <FONT STYLE="white-space:nowrap">pre-agreed</FONT> valuation, which represented fair value at the commitment date. Interest accrued on the 2016 Note up to the date of conversion was
$0.4&nbsp;million. No gain or loss was recognized upon the conversion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Long-term Debt </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;2, 2015, the Company entered into a loan agreement with a third party whereby the third party granted a $2.5 million loan to the Company (the
&#147;2015 Loan Agreement&#148;). On December&nbsp;24, 2015, the counterparty to the 2015 Loan Agreement reassigned all of its rights, interests and benefits under such agreement to Starcove Ltd., a company incorporated in Cyprus and a shareholder
of the Company (&#147;Starcove&#148;). There were no further changes made to the 2015 Loan Agreement as a result of the reassignment. The term of the loan granted under the 2015 Loan Agreement was 24 months with an interest rate of 8%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;6, 2016, the Company entered into a second loan agreement with Starcove (the &#147;Framework Loan Agreement&#148;), whereby Starcove extended a
line of credit to the Company of $1.5 million with an interest rate of 6%. The term of the Framework Loan Agreement was three years. All principal and accrued interest would be payable in a single payment on April&nbsp;6, 2019 unless earlier paid
but no sooner than six months from the date of the Framework Loan Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, the Company had made three withdrawals under
the credit line: (1)&nbsp;$0.6 million on April&nbsp;12, 2016, (2)&nbsp;$0.6&nbsp;million on May&nbsp;12, 2016 and (3)&nbsp;$0.3 million on June&nbsp;2, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;1, 2016, an aggregate amount of $4.4 million, which represented the principal and accrued interest under the 2015 Loan Agreement and the
Framework Loan Agreement (together, the &#147;Starcove Loans&#148;), was extinguished upon the issuance of 67,140 shares of the Company&#146;s common stock with an estimated fair value equal to the carrying value of the debt. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;25, 2013, the Company entered into a loan agreement with a shareholder, whereby the shareholder granted a EUR 1.8&nbsp;million loan to the
Company (the &#147;2013 Loan Agreement&#148;). The term of the loan was open-ended and had an interest rate of 5%. On January&nbsp;1, 2014, the principal amount of the 2013 Loan Agreement, together with accrued interest, was re-assigned on a 50:50
basis to the Company&#146;s co-founders, Drs.&nbsp;Angelos M. Stergiou (M.D., Sc.D. h.c.) and Miltiadis Sougioultzoglou (M.D.). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;31,
2015, the Company entered into an agreement with each of Drs. Stergiou and Sougioultzoglou, whereby the Company&#146;s aggregate obligation of EUR 1.8&nbsp;million, together with accrued interest equal to EUR 0.1&nbsp;million as of such date, as
well as an additional EUR 0.1&nbsp;million of payables due to them from the Company, were offset by an aggregate amount of EUR 0.7&nbsp;million representing receivables due to the Company from Drs. Stergiou and Sougioultzoglou pursuant to various
other agreements that were entered into in 2012 and 2013. As a result, as of December&nbsp;31, 2015, the amount of the Company&#146;s outstanding loans to Drs. Stergiou and Sougioultzoglou were EUR 0.7&nbsp;million and EUR 0.6&nbsp;million,
respectively (each, a &#147;Founder Loan&#148; and together, the &#147;Founder Loans&#148;). The interest rate on the Founder Loans was 2.5% and the term of the Founder Loans was three years. The original and modified loans were not considered
substantially different as the difference between the present value of the remaining cash flows under the original and the modified terms was less than 10%. As such, extinguishment accounting did not apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;1, 2016, an aggregate amount of EUR 0.7&nbsp;million and EUR 0.6&nbsp;million, which represented the principal and accrued interest under
each respective Founder Loan, were converted into 11,571 and 10,383 shares, respectively. The number of shares issued was based on the fair value of the Company&#146;s shares at the conversion date and therefore no gain or loss was recognized upon
the cancellation of the loans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Legal Proceedings </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, the Company is
subject to various pending or threatened legal actions and proceedings, including those that arise in the ordinary course of its business, which may include employment matters, breach of contract disputes and stockholder litigation. Such actions and
proceedings are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time. The Company records a liability in its consolidated financial statements for costs related
to claims, including future legal costs, settlements and judgments, when the Company has assessed that a loss is probable and an amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, the Company records the
most probable estimate of the loss or the minimum amount when no amount within the range is a better estimate than any other amount. The Company discloses a contingent liability even if the liability is not probable or the amount is not estimable,
or both, if there is a reasonable possibility that a material loss may have been incurred. In the opinion of management, as of the date hereof, the amount of liability, if any, with respect to these matters, individually or in the aggregate, will
not materially affect the Company&#146;s consolidated results of operations, financial position or cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s predecessor company,
Galena was involved in multiple legal proceedings and administrative actions, including stockholder class actions, both state and federal, some of which are ongoing and to which the Company is now subject as a result of the Merger. They are as
follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Settled Matters </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;16, 2015, Galena
received a subpoena issued by the U.S. Attorney&#146;s Office for the District of New Jersey (&#147;USAO NJ&#148;), requesting the production of a broad range of documents pertaining to Galena&#146;s marketing and promotional practices for Abstral.
Through its communications with the USAO NJ and the U.S. Department of Justice (&#147;DOJ&#148;), Galena came to understand that the investigation being undertaken by the USAO NJ and DOJ was a criminal investigation in addition to a civil
investigation that could ultimately involve Galena as well as one or more former employees. Pursuant to Galena&#146;s charter, Galena was reimbursing certain former employees&#146; attorney&#146;s fees with respect to the investigation but stopped
on May&nbsp;1, 2017. Galena cooperated with the civil, and is continuing to cooperate with the criminal, investigations, and on September&nbsp;8, 2017, DOJ announced a settlement agreement with Galena regarding the USAO NJ&#146;s and DOJ&#146;s
investigation. The settlement agreement involves a <FONT STYLE="white-space:nowrap">non-criminal</FONT> resolution and a civil payment in equal installments over twelve months of approximately $7.6&nbsp;million, plus interest accrued since the date
of reaching an agreement in principle, in return for a release of government claims in connection with the investigation. The $7.6&nbsp;million civil payment is payable over four equal quarterly installments, with the first payment being made in the
third quarter of 2017. As set forth in that settlement agreement, for a release of all claims against Galena and its officers and directors and dismissal with prejudice of the qui tam lawsuit described below, the relator received a portion of the
civil payment to the federal government. On December&nbsp;29, 2017, Galena made the remaining three payments to the federal government, which has advised us that all sums due and payable under the settlement agreement have been paid. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#150; Continued </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, there is a qui tam action pending in the U.S. District Court of the District of New Jersey
related to the investigation by USAO NJ and DOJ. On September&nbsp;18, 2017, Galena executed a settlement agreement with the attorneys for the relator in the qui tam action to settle the statutorily mandated attorney fees award by payment of $0.1
million in cash and $0.2 million in Galena common stock subject to court approval, which amounts were accrued during the second quarter 2017. Galena also obtained the consent of Private SELLAS under the terms of the Merger Agreement. However on
November&nbsp;7, 2017, attorneys for the qui tam relator agreed to have Galena pay the $0.2 million in cash. Galena also obtained the consent of Private SELLAS under the terms of the Merger Agreement. Galena paid the $0.3 million in cash for the
statutorily mandated attorney fees award in the fourth quarter of 2017. As a result of receiving the portion of the civil settlement payment noted above and the settlement payment of the statutorily mandated attorney fees award, the relator will
dismiss with prejudice the claims against Galena in the qui tam lawsuit. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Open Matters </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;13, 2016, Galena filed a complaint in the Circuit Court for the County of Multnomah for the State of Oregon against Aon Risk Insurance Services
West, Inc. (Aon) where Galena is seeking attorney&#146;s fees, costs and expenses incurred by Galena related to its coverage dispute with a certain insurer and for amounts Galena was required to contribute to the settlements of In re Galena
Biopharma, Inc. Derivative Litigation and In re Galena Biopharma, Inc. Securities Litigation as a direct result of certain insurer&#146;s failure to pay its full policy limits of liability and other relief. Galena and Aon are currently engaged in
written discovery. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;13, 2017, a putative stockholder securities class action complaint was filed in the U.S. District Court for the
District of New Jersey captioned, Miller v. Galena Biopharma, Inc., et al. On February&nbsp;15, 2017, a putative stockholder securities class action complaint was filed in the U.S. District Court for the District of New Jersey entitled, Kattuah v.
Galena Biopharma, Inc., et al. The actions assert that the defendants failed to disclose that Galena&#146;s promotional practices for Abstral<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (fentanyl sublingual tablets were allegedly
improper and that Galena may be subject to civil and criminal liability, and that these alleged failures rendered Galena&#146;s statements about its business misleading. Two groups of stockholders and one individual stockholder filed three motions
to be appointed lead plaintiff on April&nbsp;14, 2017 and April&nbsp;17, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequently, one of the stockholders groups withdrew its motion for lead
plaintiff status and the individual stockholder notified the Court that he does not object to the appointment of the remaining stockholder group, GALE investor group, as lead plaintiff. On July&nbsp;17, 2017, the Court approved the GALE investor
group as named lead plaintiff and its counsel as lead and liaison counsel. The Court also consolidated both actions. An amended complaint was filed on October&nbsp;6, 2017. On December&nbsp;15, 2017, Galena and the former officers and employees
filed a motion to dismiss the amended complaint. The plaintiffs have responded to a former officer&#146;s motion to dismiss on February&nbsp;13, 2018 and will respond to Galena&#146;s and the other former officers&#146; and employees&#146; motion to
dismiss on March&nbsp;2, 2018. Galena and the former officers and employees are expected to file a reply in April of 2018. Thereafter, Galena will take the matter under advisement. It is not known when the Court will issue a ruling in this matter.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;16, 2017, a complaint captioned Keller v. Ashton et al., CA No.
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2:17-cv-01777</FONT></FONT> was filed in the U.S. District Court for the District of New Jersey against Galena&#146;s former directors and the Company, as a nominal defendant. The
complaint purports to assert derivative claims for breach of fiduciary duty on Galena&#146;s behalf against its former directors based on substantially similar facts as alleged in the putative stockholder securities class action complaints mentioned
above. Galena&#146;s response to the complaint was due on June&nbsp;1, 2017; however, the Court on May&nbsp;21, 2017, entered a stay of the proceedings pending resolution of motions to dismiss in the securities litigations described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Galena also received a stockholder demand dated April&nbsp;14, 2017, pursuant to 8 Del. C. Sec. 220, from a stockholder (Albert Zhang) demanding access to
Galena&#146;s books and records relating to its sales of Abstral and the U.S. Attorney&#146;s investigation into Galena&#146;s sale of Abstral in order for Mr.&nbsp;Zhang to determine, among other things, whether to file a derivative lawsuit against
Galena&#146;s former management and directors. Galena has responded to the demand and Mr.&nbsp;Zhang has indicated that he will file a derivative complaint soon. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#150; Continued </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;27, 2017, a putative stockholder class action was filed in the Court of Chancery of the State
of Delaware captioned Patel vs. Galena Biopharma, Inc. et. al, CA No. <FONT STYLE="white-space:nowrap">2017-0325-JTL</FONT> seeking relief under Section&nbsp;225 of the Delaware General Corporation Law (DGCL) and alleging breaches of fiduciary
duties by Galena&#146;s former board of directors and former interim chief executive officer regarding proposals to amend Galena&#146;s certificate of incorporation to increase the amount of authorized shares of common stock and effectuate a reverse
stock split at the July 2016 and October 2016 stockholder meetings, respectively. On June&nbsp;2, 2017, an amended verified complaint was filed along with a motion to expedite the proceedings. On June&nbsp;5, 2017, Galena filed a verified petition
under Section&nbsp;205 of the DGCL and a motion to expedite the proceedings. On June&nbsp;8, 2017, the Court denied a request by the plaintiff to schedule a preliminary injunction motion and ordered a prompt trial on both the plaintiff and
Galena&#146;s claims. On June&nbsp;20, 2017, the Court consolidated the claims into In re Galena Biopharma, Inc., C. A. No. <FONT STYLE="white-space:nowrap">2017-0423-JTL.</FONT> On July&nbsp;10, 2017, the Court ordered that the trial of the claims
be held on August&nbsp;28, 30 and 31, 2017. On July&nbsp;24, 2017, Galena entered into a binding settlement term sheet, which the Court enforced on November&nbsp;30, 2017, over the objection of the plaintiff. On December&nbsp;8, 2017, the Court set
the hearing on the settlement for March&nbsp;15, 2018. On December&nbsp;11, 2017, the Court also granted an order validating the ratification votes at the special stockholder meeting held on July&nbsp;6, 2017 and the certificate of amendments filed
by Galena for the increase in authorized shares in 2011, 2013, 2015, and 2016 as well as for the reverse stock split in 2016. On February&nbsp;22, 2018, the plaintiff filed his brief in support of the settlement as well as his request for
attorneys&#146; fees and an incentive award. On March&nbsp;1, 2018, the former directors and former interim chief executive officer responded to plaintiff&#146;s brief. On February&nbsp;28, 2018, the former directors and former interim chief
executive officer requested the Court continue the date of the hearing to approve the settlement as the Company was working with the staff of the SEC to obtain the <FONT STYLE="white-space:nowrap">no-action</FONT> letter required by the binding
settlement term sheet. The Plaintiff objected to such continuance. On March&nbsp;15, 2018, the Court ruled in favor of the Company and continued the settlement hearing for 90 days. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the settlement, the class will receive a settlement payment of $1.3&nbsp;million, in addition to attorney fees in an amount to be approved
by the Court. The settlement payment of $1.3&nbsp;million consists of $50,000 in cash to be paid by the Company or its insurers and $1,250,000 in unrestricted shares of the Company&#146;s common stock (&#147;Settlement Stock&#148;), which valuation
will be based on the volume-weighted average closing price for the 20 trading days immediately preceding the day before the transfer of the Settlement Stock to the settlement fund pursuant to the terms and conditions of the settlement. The Company
anticipates that the Settlement Stock will be issued, pursuant to the terms of the Stipulation of Settlement, in a transaction that is exempt from the registration requirements of the Securities Act of 1933, as amended (the &#147;Securities
Act&#148;), pursuant to Section&nbsp;3(a)(10) of the Securities Act. Any amounts awarded by the Court for attorneys&#146; fees will be paid in part by the settlement fund and in part by the Company&#146;s insurance carriers. Upon the effectiveness
of the proposed settlement, the individual defendants will be released from the claims that were asserted or could have been asserted in the class action by class members participating in the settlement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;6, 2017, a complaint captioned Jacob v. Schwartz et al., Case No. C17-01222, was filed in the Superior Court of California, County of Contra
Costa against Galena&#146;s former directors and the Company, as a nominal defendant. The complaint purports to assert derivative claims for breach of fiduciary duty on Galena&#146;s behalf against its former directors based on substantially similar
facts as alleged in the derivative complaint mentioned above. Galena&#146;s response to the complaint was due on July&nbsp;7, 2017; however, the Court on September&nbsp;5, 2017, entered a stay of the proceedings pending resolution of motions to
dismiss in the securities litigations described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;7, 2017, a written demand was made on Galena by a stockholder requesting that
additional financial projections and valuation analyses be made in Galena&#146;s Form <FONT STYLE="white-space:nowrap">S-4</FONT> relating to the Merger, which was declared effective on November&nbsp;6, 2017. The demand stated, among other thing,
that, if such disclosures are not made within a reasonable period of time, the stockholder intends to file a securities class action lawsuit in federal court. Galena has resolved the matters raised in the demand letter through a nominal monetary
payment and additional disclosures in the Form <FONT STYLE="white-space:nowrap">S-4.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#150; Continued </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;23, 2018, a complaint captioned Johnson v Schwartz et al., CA No. <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2:18-cv-00903</FONT></FONT> was filed in the U.S. District Court for the District of New Jersey against Galena&#146;s former directors, officers and employees and the Company as a nominal
defendant. The complaint purports to assert derivative claims for breach of fiduciary duty on Galena&#146;s behalf against its former directors, officers and employees based on substantially similar facts as alleged in the putative stockholder
securities class action complaints and derivative complaints mentioned above, as well as making demand futility allegations against the current board of directors, who are not named as defendants. It is expected that the Company and the individual
defendants will respond to the complaint through an appropriate pleading or motion and, if necessary, seek an order from the Court staying the proceedings pending further developments in the securities litigations described above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On or about April 9, 2018, JGB filed a lawsuit in the U.S. District Court for the Southern District of New York captioned <I>JGB (Cayman) Newton, Ltd. v.
Sellas Life Sciences Group, Inc., et al.</I>, Case 1:18-cv-3095 (DLC), or the JGB Action. The complaint in the JGB Action asserts claims under state law and federal securities law against us, our Chief Executive Officer, Angelos M. Stergiou, M.D.,
ScD H.C, and our Interim Chief Financial Officer, Aleksey N. Krylov (Mr. Krylov together with the Company and Dr.&nbsp;Stergiou, the Defendants). The complaint in the JGB Action alleges, among other things, that we breached a contractual obligation
to deliver certain shares of our common stock to JGB and that, in the course of negotiations related to the senior secured debenture agreement, the Defendants failed to disclose to JGB certain information regarding positive clinical trial results
that was not then public. According to the complaint, JGB seeks to receive 2,483,500 shares of our common stock, damages, and costs and expenses incurred in the JGB action, among other things. We dispute the claims in the JGB Action and intend to
defend against them vigorously. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Contingent Consideration related to Development, Regulatory and Commercial Milestone Payments and Business
Combinations </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company acquires assets still in development and enters into research and development arrangements with third parties that often
require milestone and royalty payments based on the progress of the asset through development stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency. In certain agreements, the
Company is required to make royalty payments based upon a percentage of the sales. Because of the contingent nature of these payments, they are not included in the table of contractual obligations shown below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These arrangements may be material individually, and in the unlikely event that milestones for multiple products covered by these arrangements were reached in
the same period, the aggregate charge to expense could be material to the results of operations. In addition, these arrangements often give the Company the discretion to unilaterally terminate development of the product, which would allow the
Company to avoid making the contingent payments; however, the Company is unlikely to cease development if the compound successfully achieves clinical testing objectives. For additional information on the Company&#146;s commitments under
collaboration and license agreements read Note 6 to these consolidated financial statements. For additional information on the Company&#146;s commitments of contingent consideration read Note 7 to these consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Commitments </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company rents office space under a <FONT
STYLE="white-space:nowrap">non-cancelable</FONT> operating lease. Rental expense amounted to $0.2&nbsp;million for the years ended December&nbsp;31, 2017 and 2016. The Company&#146;s contractual obligations that may require future cash payments as
of December&nbsp;31, 2017 under the <FONT STYLE="white-space:nowrap">non-cancelable</FONT> operating lease are as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Operating<br>Leases</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#150; Continued </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Stockholders&#146; Equity (Deficit) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;13, 2017, the Board of Directors approved the Bridge Financing, pursuant to which an aggregate of 1,865,262 shares were issued at a price per
share equal to approximately $3.91. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the same valuation terms as the Bridge Financing, the Company issued 38,321 shares to MSK in cancellation of a
$0.2&nbsp;million milestone payment due June&nbsp;30, 2017, as contemplated by the MSK Side Letter. In addition, the Company issued 30,094 shares in cancellation of a $0.1&nbsp;million Equilibria management fee that was payable for March to June
2017, and 28,246 shares in cancellation of net compensation of $0.1&nbsp;million due to Dr.&nbsp;Angelos Stergiou (M.D., Sc.D. h.c.), the Company&#146;s Chief Executive Officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shares of common stock as of December&nbsp;31, 2017 for future issuance are reserved for as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="91%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted stock units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options reserved for future issuance under the Company&#146;s 2017 Equity Incentive Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares reserved for future issuance under the Employee Stock Purchase Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total reserved for future issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#150; Continued </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a summary of warrant activity for the years ended December&nbsp;31, 2017 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:61.50pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Warrant Issuance</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Outstanding,<BR>January&nbsp;1,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Granted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Assumed</B><br><B>through<BR>Merger</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Expired</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Outstanding,<BR>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Expiration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017 Equilibria</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">December&nbsp;2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Galena February 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">February 2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Galena other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Various&nbsp;to&nbsp;2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Warrants assumed in connection with the acquisition of Galena consist of warrants that may be settled in cash, which are
liability-classified warrants, and equity-classified warrants. Subsequent to December&nbsp;31, 2017, 501,000 the Company&#146;s February 2017 warrants to purchase shares of common stock were cancelled under various warrant exchange agreements as
disclosed in Note&nbsp;16. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Warrants classified as liabilities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Liability-classified warrants consist of warrants to purchase common stock issued in connection with previous equity financings for the February 2017 financing
and various other equity financings (the Company) that were assumed by the Company at the consummation of the Merger. These warrants may settle in cash and were determined not to be indexed to the Company&#146;s common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The estimated fair value of outstanding warrants accounted for as liabilities is determined at each balance sheet date. Any decrease or increase in the
estimated fair value of the warrant liability since the most recent balance sheet date is recorded in the consolidated statement of operations as other income (expense). The fair value of the warrants as of December&nbsp;31, 2017 is estimated using
a Black-Scholes pricing model with the following inputs: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:61.50pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Warrant Issuance</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Outstanding&nbsp;(in<BR>thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Strike&nbsp;price&nbsp;(per<BR>share)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Expected&nbsp;term<BR>(years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Volatility%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Risk-free&nbsp;rate</FONT><BR>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Galena February 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79.29</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.09</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Galena other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">888.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72.46</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#150; Continued </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The expected volatility assumptions are based on the Company&#146;s implied volatility in combination with
the implied volatilities of similar publicly traded entities. The expected term assumptions are based on the remaining contractual terms of the warrants. The risk-free rate is based on the <FONT STYLE="white-space:nowrap">zero-coupon</FONT> rates in
effect at the time of valuation. The dividend yield used in the pricing model is zero, because the Company has no present intention to pay cash dividends. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The changes in fair value of the warrant liability for the year ended December&nbsp;31, 2017 were as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:61.50pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Warrant Issuance</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Warrant<BR>liability,<BR>January&nbsp;1,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;value&nbsp;of<BR>warrants<BR>granted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;value&nbsp;of<BR>warrants<BR>acquired</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change&nbsp;in&nbsp;fair<BR>value of<BR>warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Warrant<BR>liability,<BR>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Galena February 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Galena other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<BR></TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Warrants classified as equity </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company issued 316,163 warrants to purchase shares of the Company&#146;s common stock at an exercise price of $7.42, maturing five years from issuance, to
EQC Private Markets SAC Fund Ltd&#151;EQC Biotech Sely I Fund on December&nbsp;29, 2017. These warrants are recorded in equity at fair value upon issuance, and not as liabilities, and are not subject to adjustment to fair value in subsequent
reporting periods. The fair value of the warrants granted was&nbsp;$5.60&nbsp;per share using the Black-Scholes pricing model with the fair value assumptions for the grant including a volatility of&nbsp;90.10%, expected term of&nbsp;five&nbsp;years,
risk free rate of&nbsp;2.20%, and a dividend rate of&nbsp;0.00. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Stock-Based Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Share and per share amounts below have been retroactively adjusted to reflect the exchange ratio and reverse stock split as described in Note 1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2017 Equity Incentive Plan </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;29, 2017.
the 2017 Equity Incentive Plan was approved, and currently allows for the issuance of up to a maximum of approximately 575,000 shares of common stock in connection with the grant of stock-based awards, including stock options, restricted stock,
restricted stock units, stock appreciation rights and other types of awards as deemed appropriate, not including shares subject to awards assumed in connection with certain transactions, including the Merger. As of December&nbsp;31, 2017, an
aggregate of approximately 575,000 shares of common stock were reserved for issuance under the Company&#146;s 2017 Equity Incentive Plan. Upon the consummation of the Merger, the Company assumed approximately 10,171 shares subject to outstanding
common stock options granted under the Company&#146;s 2016 Incentive Plan that will remain exercisable for one year for former Company employees and directors. There are approximately 575,000 shares available for future grants based on adjustments
in the 2017 Equity Incentive Plan. There were no common stock options granted under the 2017 Equity Incentive Plan for the years ended December&nbsp;31, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amount of shares reserved for issuance under the 2017 Equity Incentive Plan will automatically increase on January 1<SUP
STYLE="font-size:85%; vertical-align:top">st</SUP>&nbsp;of each year, for a period of not more than ten years, commencing on January 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>&nbsp;of the year following the year in which the Effective
Date occurs and ending on (and including) January&nbsp;1, 2027, in an amount equal to 4% of the total number of shares of common stock outstanding on December 31<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>&nbsp;of the preceding calendar
year. Notwithstanding the foregoing, the board of directors may act prior to January 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>&nbsp;of a given year to provide that there will be no January
1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>&nbsp;increase in the share reserve for such year or that the increase in the share reserve for such year will be a lesser number of shares of common stock than would otherwise occur pursuant
to the preceding sentence. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#150; Continued </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;1, 2016, the Board of Directors approved the Company&#146;s 2016 Incentive Plan under which
189,627 shares were reserved for issuance. The 2017 Equity Incentive Plan replaced the 2016 Incentive Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the 2016 Incentive Plan,
the Company&#146;s employees, directors and consultants are eligible to <FONT STYLE="white-space:nowrap">receive&nbsp;non-qualified&nbsp;and</FONT> incentive stock options and RSUs. The stock options generally vest over <FONT
STYLE="white-space:nowrap">a&nbsp;3-year&nbsp;period</FONT> and expire 10 years from the date of the grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the components
of stock-based compensation expense in the consolidated statements of operations for the years ended December&nbsp;31, 2017 and 2016, respectively (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">729</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Options to Purchase Shares of Common Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no stock options granted during the year ended December&nbsp;31, 2017. The weighted-average grant date fair value of options granted during the year
ended December&nbsp;31, 2016 was $38.03. The Company uses the Black-Scholes option-pricing model and the following assumptions were used to determine the fair value of all its stock options granted in 2016: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">1.82-2.32%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">85-94%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected lives (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">5.13-10.00</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017, there was no unrecognized compensation cost related to outstanding stock options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes stock option activity of the Company: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>Number of</B><br><B>Shares</B><br><B>(In&nbsp;Thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Exercise</B><br><B>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic Value<BR>(In&nbsp;Thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of January 1, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">52.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December 31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">52.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed in connection with the Merger with Galena</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,240.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Canceled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,240.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercisable at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,240.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#150; Continued </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic values of outstanding and exercisable stock options at December&nbsp;31, 2017 were
calculated based on the closing price of the Company&#146;s common stock as reported on the Nasdaq Capital Market on December&nbsp;31, 2017 of $7.86 per share. The aggregate intrinsic value equals the positive difference between the closing fair
market value of the Company&#146;s common stock and the exercise price of the underlying stock options. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Units with Time-Based
Conditions </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;7, 2017, the Board of Directors accelerated the vesting of all outstanding restricted stock units (&#147; RSUs&#148;) with
time-based conditions and all $1.2&nbsp;million of unrecognized stock-based compensation was recognized upon acceleration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table outlines
RSU activity with only a time-based condition: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>Number of</B><br><B>Shares</B><br><B>(In&nbsp;Thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Grant&nbsp;Date&nbsp;Fair<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at January 1, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">52.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December 31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">52.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">52.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Canceled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>RSUs with Time-Based and Performance-Based Conditions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the RSUs with time-based conditions, the Company granted RSUs subject to both time-based and performance-based vesting conditions to certain of
its employees <FONT STYLE="white-space:nowrap">and&nbsp;non-employees&nbsp;pursuant</FONT> to the 2016 Incentive Plan. These RSUs vest based on both (i)&nbsp;continued service either over a three-year measurement period or at the end of the required
service period and (ii)&nbsp;the achievement of a liquidity event. The vesting dates for these RSUs are January&nbsp;1, 2018, January&nbsp;1, 2019, January&nbsp;1, 2020 or February&nbsp;27, 2018. The liquidity event, as defined in the relevant RSU
grant agreements, will be satisfied upon the earlier of either: a) change of control or b) a qualified initial public offering. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>Number of</B><br><B>Shares</B><br><B>(In&nbsp;Thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Grant&nbsp;Date&nbsp;Fair<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at January 1, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">52.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December 31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">52.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">NA</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Canceled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">52.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">52.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes compensation expense related to these RSUs when the liquidity event is deemed probable. As such, no
compensation expense was recorded during the years ended December&nbsp;31, 2017 and 2016, as the liquidity event is outside the Company&#146;s control and not deemed probable until it occurs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#150; Continued </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2017 Employee Stock Purchase Plan</I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company also has an employee stock purchase plan (&#147;ESPP&#148;) which allows employees to contribute up to&nbsp;15%&nbsp;of their cash earnings,
subject to certain maximums, to be used to purchase shares of the Company&#146;s common stock on each semi-annual purchase date. On each offering date, each eligible employee, pursuant to an offering made under the ESPP, will be granted a right to
purchase up to that number of shares of Common Stock purchasable either with a percentage or with a maximum dollar amount, as designated by the Board, but in either case not exceeding fifteen percent (15%) of such employee&#146;s earnings (as
defined by the Board in each offering) during the period that begins on the offering date (or such later date as the Board determines for a particular offering) and ends on the date stated in the offering, which date will be no later than the end of
the Offering. As of December&nbsp;31, 2017, the board of directors has not established the various parameters under the ESPP and no shares have been delivered under the ESPP. There are approximately 57,000 shares of common stock reserved for
issuance under the ESPP , plus the number of shares of common stock that are automatically added on January 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>&nbsp;of each year for a period of up to ten years, commencing on the first January 1<SUP
STYLE="font-size:85%; vertical-align:top">st</SUP>&nbsp;following the effective date and ending on (and including) January&nbsp;1, 2027, in an amount equal to the lesser of (i) 1% of the total number of shares of common stock outstanding on December
31<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>&nbsp;of the preceding calendar year, and (ii)&nbsp;102,279 shares of Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.
Income Taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The loss before income taxes is as follows (in thousands): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">As of December 31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2016</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non - U.S.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,766</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,788</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,501</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,680</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of federal and state income tax expense are as follows (in thousands): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">As&nbsp;of&nbsp;December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2016</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of net deferred tax assets are as follows (in thousands): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">As of December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2016</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax credit carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Licensing deduction deferral</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,658</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,508</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#150; Continued </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of net deferred tax liabilities are as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">As&nbsp;of&nbsp;December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2016</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">In-process</FONT> research and development not subject to future
amortization for tax purposes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross deferred tax liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The provision for income taxes differs from the provision computed by applying the federal statutory rate to net loss before
income taxes as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">As&nbsp;of&nbsp;December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2016</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. federal statutory income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State and local taxes, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign rate differential</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Permanent differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax rate change and true-up</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.4</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At December 31, 2017, the Company had domestic federal and state net operating loss carryforwards of approximately $3.7 million
and $3.7 million, respectively, available to reduce future taxable income, which expire at various dates beginning in 2027. The Company also had federal research and development tax credit carryforwards of approximately $0.4 million, respectively,
available to reduce future tax liabilities and which expire at various dates beginning in 2027. The income tax expense for the year ended December 31, 2016 relates to both the indefinite lived deferred tax liabilities and the December 22, 2017
enactment of the Tax Cuts and Jobs Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the provisions of the Internal Revenue Code, the net operating losses (&#147;NOL&#148;) and tax credit
carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the
ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Sections&nbsp;382 and 383 of the Internal Revenue Code of 1986, respectively, as well as similar state tax provisions. This could limit the
amount of tax attributes that the Company can utilize annually to offset future taxable income or tax liabilities. The amount of the annual limitation, if any, will be determined based on the value of the Company immediately prior to the ownership
change. Subsequent ownership changes may further affect the limitation in future years. The Company has completed several financings since its inception, which may have resulted in a change in control as defined by Sections 382 and 383 of the
Internal Revenue Code or could result in a change in control in the future. Utilization of the net operating loss and tax credits carryforwards may be limited by &#147;ownership change&#148; rules, as defined in Section 382 of the Internal Revenue
Code of 1986, as amended, and similar state provisions. This annual limitation may result in the expiration of the net operating losses and credits before utilization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In assessing the need for a valuation allowance the Company may utilize indefinite-lived deferred tax liabilities from an indefinite-lived intangible asset as
a future source of income.&nbsp;The Company&#146;s IPR&amp;D, as recorded in acquisition accounting, can be utilized as a source of income arising from the future reversal of temporary difference that can be offset against post 2017 indefinite-lived
NOLs.&nbsp;Therefore, the Company is permitted to offset the indefinite-lived DTL up to the 80 percent limitation for NOL&#146;s generated subsequent to January 1, 2018.&nbsp;As such, an indefinite-lived NOL was recorded in acquisition accounting as
a reduction to the valuation allowance related to deferred tax assets in the amount of $1.8 million. The valuation allowance increased by $1.2 million and $1.8 million for the years ended December 31, 2017 and 2016, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company files income tax returns in the United States and various state jurisdictions. The Company is subject to tax examinations for the 2012 tax year
and beyond. The Company does not recognize tax benefits that are not more-likely-than-not to be supported based upon the technical merits of the tax position taken. In assessing its unrecognized tax benefits, the Company has analyzed its tax return
filing positions in all of the federal, state and foreign filing jurisdictions where it is required to file income tax returns, as well as all open years in those jurisdictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#150; Continued </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table indicates the changes to the Company&#146;s unrecognized tax benefits (in thousands):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">As&nbsp;of&nbsp;December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2016</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning of the Year - unrecognized tax benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<BR>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;<BR>&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increases/ (Decrease) - prior year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increases - current year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">End of the Year - unrecognized tax benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unrecognized tax benefits, if recognized and in absence of full valuation allowance, would impact the income tax provision
by $28,000 and $44,000 as of December 31, 2017 and 2016, respectively. As of December 31, 2017, the Company does not believe that it is reasonably possible that its unrecognized tax benefits would significantly change in the following 12 months.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In assessing the realizability of deferred tax assets, management considers whether it is more-likely-than-not that some portion or all of the deferred
tax assets will not be realized in the near term. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December 22, 2017, the Tax Cuts and Jobs Act (the &#147;2017 Tax Act&#148;) was enacted. The 2017 Tax Act includes a number of changes to existing United
States tax laws that impact the company, most notably a reduction of the United States corporate income tax rate from 34% to 21% for tax years beginning after December 31, 2017. The 2017 Tax Act also provides for a one-time transition tax on certain
foreign earnings and the acceleration of depreciation for certain assets placed into service after September 27, 2017 as well as prospective changes beginning in 2018, including repeal of the domestic manufacturing deduction, acceleration of tax
revenue recognition, capitalization of research and development expenditures, additional limitations on executive compensation and limitations on the deductibility of interest. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Related Party Transactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Management and
Strategic Collaboration Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective in June&nbsp;2016, the Company and Equilibria, a company incorporated in Bermuda and a significant
stockholder of the Company, entered into the management and strategic collaboration agreement. Under the Equilibria collaboration agreement, Equilibria, amongst other services, is engaged to provide certain strategic, management and capital raising
advice to the Company. The Equilibria collaboration agreement is effective for three years and will be renewable thereafter only upon the mutual written agreement of both parties. The Equilibria collaboration agreement will automatically terminate
upon the closing of an IPO or a strategic sale. During the term of the Equilibria collaboration agreement, the Company, in exchange for the services received, paid Equilibria a quarterly fee of $0.1&nbsp;million (the &#147;Equilibria Management
Fee&#148;). The Equilibria Management Fee can be paid in cash or, at the mutual agreement of the parties, in shares of the Company at a valuation equal to the Company&#146;s most recent financing round. In addition to the Equilibria Management Fee,
the Company has agreed to pay Equilibria any expenses reasonably incurred in performing the services agreed. For the years ended December&nbsp;31, 2017 and 2016, the Company had incurred and paid in cash $0.3&nbsp;million and $0.2&nbsp;million,
respectively, of Equilibria Management Fees. These amounts are included in general and administrative expense in the consolidated statements of operations. As of December&nbsp;31, 2017, the Company had an outstanding payable of $0.1&nbsp;million
payable to Equilibria. As of December&nbsp;31, 2016, there was no outstanding fee payable to Equilibria. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the provision of the management and
strategic collaboration services, the Company also agreed to pay Equilibria an incentive fee equal to 2% of the post-money market value of the Company on the date of its IPO. Such fee will be payable in shares with a
<FONT STYLE="white-space:nowrap">per-share</FONT> price equal to the price set for the sale of the Company&#146;s shares to other investors in its IPO. The Company and Equilibria, may jointly agree to settle the incentive fee earlier, if deemed
appropriate for achieving a successful IPO, through either a cash payment, issuance of shares, or a combination of the two. In the event that the Company is sold as part of a strategic sale, the incentive fee will be equal to 2% of the gross value
paid by the purchaser in cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2017, the Company and Equilibria entered into an amendment of the Equilibria collaboration agreement. Under
the amendment, in the event that the Company entered into a reverse merger transaction in lieu of an initial public offering, the incentive fee to Equilibria was 2% of the post-merger fully diluted market value of the Company immediately after the
closing of the reverse merger transaction, payable in a combination of cash and shares of common stock of the Company. The cash payment was based on the per share price equaling the intrinsic value of the Company&#146;s shares in the Merger. The
share-based component of the incentive fee was based on the post-closing fully diluted number of shares outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#150; Continued </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2017, the Company and Equilibria further amended the Equilibria collaboration agreement to fix the
compensation payable to Equilibria in connection with the completion of the Merger, described above in Note 1. Accordingly, upon consummation of the Merger on December&nbsp;29, 2017, the Company incurred $0.1&nbsp;million to Equilibria and issued
119,672 shares of common stock to Equilibria at a fair value of $0.9&nbsp;million. These amounts are included in general and administrative expense in the consolidated statements of operations. Also, upon consummation of the Merger and pursuant to
the amended Equilibria collaboration agreement, such agreement was terminated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Debt </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has entered into several related party debt transactions with stockholders, which are described in Note 9. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>MSK License Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See Note 6 for information
regarding the MSK License Agreement entered into by the Company. MSK owned 3.7% and 5.4% of the Company&#146;s outstanding share capital as of December&nbsp;31, 2017 and 2016, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Related Party Transactions </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s
Chief Executive Officer, Dr.&nbsp;Angelos&nbsp;M. Stergiou (M.D., Sc.D. h.c.) is a significant stockholder of the Company owning 7.8% and 24.0% of the Company&#146;s outstanding share capital as of December&nbsp;31, 2017 and 2016, respectively.
Further transactions involving the Company and Dr.&nbsp;Stergiou are described in Note 6 and Note 9. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;28, 2016, the Company granted 3,651
stock options to a prior member of the Company&#146;s Board of Directors. Such prior director is additionally a full-time employee of MSK. The option was terminated on August&nbsp;6, 2017 in consideration of an approximately $30,000 cash payment.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;28, 2016, the Company granted 9,107 RSUs to a member of the Company&#146;s Scientific Advisory Board pursuant to a consulting agreement
for scientific advisory services to be performed on behalf of the Company (see Note 13). Additionally, such member and consultant is a full-time employee of MSK (see Note 6). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Subsequent Events </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Warrant Exchange Agreements
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;6, 2018, the Company and CVI Investments, Inc. (&#147;CVI&#148;) entered into a warrant exchange agreement (the &#147;CVI
Agreement&#148;). The Company had previously issued to CVI a warrant to purchase 99,333 shares (on a post-reverse split basis) (the &#147;CVI Warrant&#148;) of its common stock, par value $0.0001 per share (the &#147;Common Stock&#148;) pursuant to
the registered offering described in the Company&#146;s prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b)(5) under the Securities Act of 1933 on February&nbsp;9, 2017 (the &#147;2017 Offering&#148; and the warrants
issued in such offering, the &#147;2017 Warrants&#148;). Pursuant to the CVI Agreement, in exchange for CVI&#146;s agreement to surrender the CVI Warrant for cancellation, the Company agreed to issue to CVI a number of shares of Common Stock equal
to the quotient resulting from dividing $232,440 by the closing sale price of the Common Stock on the first completed trading day following the first public announcement by the Company of the material terms and conditions of a Company financing
transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The CVI Agreement contained a &#147;Most Favored Nations&#148; (&#147;MFN&#148;) clause, allowing CVI to opt to substitute terms of warrant
exchange agreements entered with other warrant holders from the 2017 Offering if CVI deemed those terms more favorable. Pursuant to this MFN provision, effective as of March 1, CVI Agreement was deemed modified as follows: Pursuant to the CVI
Agreement, in exchange for the surrender and cancellation of the CVI Warrants, the Company issued to CVI a convertible promissory note in the aggregate principal amount of $232,440.00 (the &#147;CVI Note&#148;). The CVI Note accrues interest on the
outstanding principal amount at a rate of 5.0% per annum and the entire principal and accrued interest is due and payable on August 13, 2018. The interest rate increases to 18% per annum during a period in which there is an &#147;event of
default&#148; under the CVI Note. The holder has the right, from time to time after April 30, 2018, to convert the outstanding principal and accrued interest into shares of Common Stock at a conversion price equal to $7.00 per share (subject to
adjustments for stock splits, combinations and the like) (the &#147;Conversion Price&#148;), provided that CVI may not affect any such conversions to the extent it would beneficially own in excess of 4.99% of the Company&#146;s outstanding Common
Stock. At any time after an event of default has occurred (whether or not the Company has cured such default), CVI may elect to convert the outstanding principal and accrued interest into shares of Common Stock at an alternate conversion price equal
to the lower of (i) the Conversion Price then in effect at the time of such conversion, or (ii) 70% of the lowest VWAP of the Common Stock on a trading day during the 10-trading period prior to such conversion. For purposes of the CVI Note, an
&#147;event of default&#148; is deemed to have occurred upon (A) the suspension of trading of the Common Stock on the Nasdaq Capital Market for a period of five consecutive trading days, (B) the Company&#146;s failure to timely deliver shares of
Common Stock upon a conversion </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#150; Continued </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
within five trading days of the applicable conversion date or upon the Company&#146;s notice that it does not intend to comply a request by Empery to convert, (C) the Company&#146;s or any of its
subsidiaries&#146; failure to timely pay any amount due under the CVI Note or the CVI Agreement, (D) the Company&#146;s bankruptcy, insolvency, liquidation, or similar proceeding, or (E) a breach by the Company of any representation, warranty or
covenant contained in the CVI Note or the CVI Agreement that remains uncured for a period of three consecutive trading days. On April 2, 2018, the Company and CVI mutually agreed to waive the April 30, 2018 start date for the conversion right of the
CVI Note, and CVI converted the entire outstanding balance of principal and interest on the CVI Note into 33,356 shares of Company&#146;s Common Stock. As a result, the CVI Note is fully paid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;7, 2018, the Company entered into a warrant exchange agreement (the &#147;Anson Agreement&#148;) with Anson Investments Master Fund LP
(&#147;Anson&#148;). The Company previously issued to Anson a warrant to purchase 30,000 shares (on a post-reverse split basis) of Common Stock (the &#147;Anson Warrant&#148;) in the 2017 Offering. Pursuant to the Anson Agreement, on
February&nbsp;8, 2018, the Company issued to Anson Investments 12,536 shares of Common Stock in exchange for the surrender and cancellation of the Anson Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;9, 2018, the Company entered into a warrant exchange agreement (the &#147;Sabby Agreement&#148;) with Sabby Healthcare Master Fund Ltd. and
Sabby Volatility Warrant Master Fund Ltd (collectively, &#147;Sabby&#148;). The Company had previously issued to Sabby warrants to purchase an aggregate of 83,333 shares (on a post-reverse split basis) of Common Stock (the &#147;Sabby
Warrants&#148;) pursuant to the 2017 Offering. Pursuant to the Sabby Agreement, in exchange for the surrender and cancellation of the Sabby Warrants, the Company will issue to Sabby a number of shares of Common Stock determined by dividing $195,000
by the closing sale price of the Common Stock on the date of the closing date of the exchange. Such closing is expected to occur on or before February&nbsp;13, 2018, and the Sabby Agreement will terminate if such closing does not occur by such date.
The Sabby Agreement also provides that during the <FONT STYLE="white-space:nowrap">30-trading</FONT> day period following the closing of the exchange, Sabby will not sell in open market transactions more than 2% of the daily trading volume of Common
Stock on any one trading day. Further, the Sabby Agreement provides that if the Company enters into an agreement with a holder of the 2017 Warrants that provides for the exchange of such warrants on terms more favorable than those contained in the
Sabby Agreement, as determined in the reasonable discretion of Sabby, then the Company will provide written notice to Sabby and the Sabby Agreement will be deemed to have been modified in an economically and legally equivalent manner such that Sabby
would receive such more favorable terms, unless Sabby elects not to accept such terms. For purposes of determining whether terms are more favorable than the terms contained in the Sabby Agreement, an exchange ratio that is based upon 100% of the
then market price of the Common Stock, even if less than the price applicable to the exchange of the Sabby Warrants, is not more favorable than the terms of the Sabby Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on February&nbsp;9, 2018, the Company entered into a warrant exchange agreement (the &#147;Hudson Bay Agreement&#148;) with Hudson Bay Master Fund Ltd
(&#147;Hudson Bay&#148;). The Company had previously issued to Hudson Bay a warrant to purchase an aggregate of 146,666 shares (on a post-reverse split basis) of Common Stock (the &#147;Hudson Bay Warrant&#148;) pursuant to the 2017 Offering.
Pursuant to the Hudson Bay Agreement, in exchange for the surrender and cancellation of the Hudson Bay Warrant, the Company issued to Hudson Bay a convertible promissory note in the principal amount of $343,200 (the &#147;Hudson Bay Note&#148;). The
Hudson Bay Agreement also provides that provides that if the Company enters into an agreement with a holder of the 2017 Warrants that provides for the exchange of such warrants on terms more favorable than those contained in the Hudson Bay
Agreement, including without limitation, with respect to ratio of any cash paid, or principal amount of notes or value of Common Stock paid in exchange for such warrants, then the Company is to provide notice to Hudson Bay within one trading day of
such agreement and the terms of the Hudson Bay Agreement will be deemed to have been modified in an economically and legally equivalent manner such that Hudson Bay would receive the benefit of such more favorable terms, unless Hudson Bay elects not
to accept such terms by a notice delivered to the Company within 10 trading days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Hudson Bay Note accrues interest on the outstanding principal
amount at a rate of 5% per annum and the entire principal and accrued interest is due and payable on August&nbsp;9, 2018. The interest rate increases to 18% per annum during a period in which there is an &#147;event of default&#148; under the Hudson
Bay Note. The holder has the right, from time to time after April&nbsp;30, 2018, to convert the outstanding principal and accrued interest into shares of Common Stock at a conversion price equal to $7.00 per share (subject to adjustments for stock
splits, combinations and the like) (the &#147;Conversion Price&#148;), provided that Hudson Bay may not affect any such conversions to the extent it would beneficially own in excess of 9.99% of the Company&#146;s outstanding Common Stock. At and any
time after an event of default has occurred (whether or not the Company has cured such default), Hudson Bay may elect to convert the outstanding principal and accrued interest into shares of Common Stock at an alternate conversion price equal to the
lower of (i)&nbsp;the Conversion Price then in effect at the time of such conversion, or (ii) 70% of the lowest volume-weighted average price of the Common Stock on a trading day during the <FONT STYLE="white-space:nowrap">10-trading</FONT> period
prior to such conversion. For purposes of the Hudson Bay Note, an &#147;event of default&#148; is deemed to have occurred upon (A)&nbsp;the suspension of trading of the Common Stock on the Nasdaq Capital Market for a period of five consecutive
trading days, (B)&nbsp;the Company&#146;s failure to timely deliver shares of Common Stock upon a conversion within five trading days of the applicable conversion date or upon the Company&#146;s notice that it does not intend to comply a request by
Hudson Bay to convert, (C)&nbsp;the Company&#146;s or any of its subsidiaries&#146; failure to timely pay any amount due under the Hudson Bay Note or the Hudson Bay Agreement, (D)&nbsp;the Company&#146;s bankruptcy, insolvency, liquidation, or
similar proceeding, or (E)&nbsp;a breach by the Company of any representation, warranty or covenant contained in the Hudson Bay Note or the Hudson Bay Agreement that remains uncured for a period of three consecutive trading days. On April 3, 2018,
the Company and Hudson Bay mutually agreed to waive the April 30, 2018 start date for the conversion right of the Hudson Bay Note, and Hudson Bay converted the entire outstanding balance of principal and interest on the Hudson Bay Note into 49,390
shares of Company&#146;s Common Stock. As a result, the Hudson Bay Note is fully paid. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#150; Continued </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February 13, 2018, the Company and Alto Opportunity Master Fund, SPC &#150; Segregated Master Portfolio B
(&#147;Alto&#148;) entered into a warrant exchange agreement (the &#147;Alto Agreement&#148;). The Company had previously issued to Alto a warrant to purchase 106,667 shares (on a post-reverse split basis) (the &#147;Alto Warrant&#148;) of its
Common Stock pursuant to the 2017 Offering. Pursuant to the Alto Agreement, in exchange for Alto&#146;s agreement to surrender the Alto Warrant for cancellation, the Company agreed to issue to Alto a number of shares of Common Stock equal to the
quotient resulting from dividing $249,600 by the closing sale price of the Common Stock on the closing date of the exchange. Pursuant to the Alto Agreement, on February 15, 2018, the Company issued to Alto 45,464 shares of Common Stock in exchange
for the surrender and cancellation of the Alto Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Alto Agreement contained a MFN clause, allowing Alto to opt to substitute terms of Warrant
Exchange Agreements entered with other warrant holders from the 2017 Offering if Alto deemed those terms more favorable. Pursuant to this MFN clause, effective as of February 13, 2018, shares previously issued to Alto under the Alto Agreement were
returned/cancelled and the Alto Agreement was deemed modified as follows: Pursuant to the Alto Agreement, in exchange for the surrender and cancellation of the Alto Warrants, the Company issued to Alto a convertible promissory note in the aggregate
principal amount of $249,600.00 (the &#147;Alto Note&#148;). The Alto Note accrues interest on the outstanding principal amount at a rate of 5.0% per annum and the entire principal and accrued interest is due and payable on August 13, 2018. The
interest rate increases to 18% per annum during a period in which there is an &#147;event of default&#148; under the Alto Note. The holder has the right, from time to time after April 30, 2018, to convert the outstanding principal and accrued
interest into shares of Common Stock at the Conversion Price provided that Alto may not affect any such conversions to the extent it would beneficially own in excess of 9.99% of the Company&#146;s outstanding Common Stock. At any time after an event
of default has occurred (whether or not the Company has cured such default), Alto may elect to convert the outstanding principal and accrued interest into shares of Common Stock at an alternate conversion price equal to the lower of (i) the
Conversion Price then in effect at the time of such conversion, or (ii) 70% of the lowest volume-weighted average price of the Common Stock on a trading day during the 10-trading period prior to such conversion. For purposes of the Alto Note, an
&#147;event of default&#148; is deemed to have occurred upon (A) the suspension of trading of the Common Stock on the Nasdaq Capital Market for a period of five consecutive trading days, (B) the Company&#146;s failure to timely deliver shares of
Common Stock upon a conversion within five trading days of the applicable conversion date or upon the Company&#146;s notice that it does not intend to comply a request by Empery to convert, (C) the Company&#146;s or any of its subsidiaries&#146;
failure to timely pay any amount due under the Alto Note or the Alto Agreement, (D) the Company&#146;s bankruptcy, insolvency, liquidation, or similar proceeding, or (E) a breach by the Company of any representation, warranty or covenant contained
in the Alto Note or the Alto Agreement that remains uncured for a period of three consecutive trading days. On April 2, 2018, the Company and Alto mutually agreed to waive the April 30, 2018 start date for the conversion right of the Alto Note, and
Alto converted the entire outstanding balance of principal and interest on the Alto Note into 35,998 shares of Company&#146;s Common Stock. As a result, the Alto Note is fully paid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February 14, 2018, the Company entered into a warrant exchange agreement (the &#147;Lincoln Park Agreement&#148;) with Lincoln Park Capital Fund LLC
(&#147;Lincoln Park&#148;). The Company previously issued to Lincoln Park a warrant to purchase 8,333 shares (on a post-reverse split basis) of Common Stock (the &#147;Lincoln Park Warrant&#148;) in the 2017 Offering. Pursuant to the Lincoln Park
Agreement, on February 19, 2018, the Company issued to Lincoln Park Capital 3,421 shares of Common Stock in exchange for the surrender and cancellation of the Lincoln Park Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;22, 2018, the Company entered into a warrant exchange agreement (the &#147;Empery Agreement&#148;) with Empery Asset Master Ltd., Empery Tax
Efficient, LP and Empery Tax Efficient II, LP (collectively, &#147;Empery&#148;). The Company had previously issued to Empery warrants to purchase an aggregate of 26,668 shares (on a post-reverse split basis) (the &#147;Empery Warrants&#148;) of its
common stock, par value $0.0001 per share (the &#147;Common Stock&#148;) pursuant to the registered offering described in the Company&#146;s prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b)(5) under the Securities
Act of 1933 on February&nbsp;9, 2017 (the &#147;2017 Offering&#148; and the warrants issued in such offering, the &#147;2017 Warrants&#148;). Pursuant to the Empery Agreement, in exchange for the surrender and cancellation of the Empery Warrants,
the Company issued to Empery convertible promissory notes in the aggregate principal amount of $64,403.12 (the &#147;Empery Notes&#148;). The Empery Agreement also provides that if the Company enters into an agreement with a holder of the 2017
Warrants that provides for the exchange of such warrants on terms more favorable than those contained in the Empery Agreement, including without limitation, with respect to ratio of any cash paid, or principal amount of notes or value of Common
Stock paid in exchange for such warrants, then the Company is to provide notice to Empery within one trading day of such agreement and the terms of the Empery Agreement will be deemed to have been modified in an economically and legally equivalent
manner such that Empery would receive the benefit of such more favorable terms, unless Empery elects not to accept such terms by a notice delivered to the Company within 10 trading days. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Empery Notes accrue interest on the outstanding principal amount at a rate of 4.75% per annum and the entire principal and accrued interest is due and
payable on August&nbsp;22, 2018. The interest rate increases to 18% per annum during a period in which there is an &#147;event of default&#148; under the Empery Notes. The holder has the right, from time to time after April&nbsp;30, 2018, to convert
the outstanding principal and accrued interest into shares of Common Stock at the Conversion Price, provided that Empery may not affect any such conversions to the extent it would beneficially own in excess of 9.99% of the Company&#146;s outstanding
Common Stock. At any time after an event of default has occurred (whether or not the Company has cured such default), Empery may elect to convert the outstanding principal and accrued interest into shares of Common Stock at an alternate conversion
price equal to the lower of (i)&nbsp;the Conversion Price then in effect at the time of such conversion, or (ii) 70% of the lowest volume-weighted average price of the Common Stock on a trading day during the
<FONT STYLE="white-space:nowrap">10-trading</FONT> period prior to such conversion. For purposes of the Empery Notes, an &#147;event of default&#148; is deemed to have occurred upon (A)&nbsp;the suspension of trading of the Common Stock on the
Nasdaq Capital Market for a period of five consecutive trading days, (B)&nbsp;the Company&#146;s failure to timely deliver shares of Common Stock upon a conversion within five trading days of the applicable conversion date or upon the Company&#146;s
notice that it does not intend to comply a request by Empery to convert, (C)&nbsp;the Company&#146;s or any of its subsidiaries&#146; failure to timely pay any amount due under the Empery Notes or the Empery Agreement, (D)&nbsp;the Company&#146;s
bankruptcy, insolvency, liquidation, or similar proceeding, or (E)&nbsp;a breach by the Company of any representation, warranty or covenant contained in the Empery Notes or the Empery Agreement that remains uncured for a period of three consecutive
trading days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s entry into each of the warrant exchange agreements were the result of separate private negotiations between the Company
and each of the named companies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Series A Convertible Preferred </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;7, 2018, the Company entered into a Securities Purchase Agreement with investors, pursuant to which the Company agreed to sell to the Investors,
in a private placement pursuant to Rule 4(a)(2) and Regulation S under the Securities Act of 1933, as amended, an aggregate of 10,700 shares of the Company&#146;s newly-created <FONT STYLE="white-space:nowrap">non-voting</FONT> Series A Convertible
Preferred, and warrants to acquire an aggregate 1,383,631 shares of the Company&#146;s common stock, par value $0.0001 per share at an aggregate purchase price of $10,700,000. The Series A Convertible Preferred is initially convertible into
1,844,835 shares of common stock based on an initial conversion price of $5.80 per share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#150; Continued </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the first closing of the Series A Convertible Preferred on March&nbsp;9, 2018, the Company issued an
aggregate 5,987 shares of Series A Convertible Preferred and 774,186 Warrants for aggregate gross proceeds of $5,987,000. The second closing of the remaining 4,713 shares of the Series A Convertible Preferred and 609,445 shares of common stock, for
aggregate gross proceeds of $4,713,000 will occur within five business days of receipt of necessary stockholder approval under the applicable rules and regulations of the Nasdaq Stock Market LLC. Under the Series A Convertible Preferred, the Company
is obligated to seek stockholder approval no later than May&nbsp;7, 2018 (within 60 days of the date of the Series A Convertible Preferred), and will file proxy materials with the U.S. Securities and Exchange Commission in connection therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s directors, executive officers and beneficial owners of more than 10% of the Company&#146;s common stock, who collectively hold more than
50% of the Company&#146;s outstanding voting power, entered into voting agreements dated March&nbsp;9, 2018, pursuant to which they agreed to vote in favor of any resolution presented to the stockholders of the Company to approve the issuance, in
the aggregate, of greater than 19.99% of the common stock outstanding prior to the entry into the Series A Convertible Preferred, for less than the greater of the book or market value of the common stock as required by the listing rules of The
Nasdaq Stock Market. In addition, such persons also entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements pursuant to which they agreed to refrain from certain transactions in the Company&#146;s equity securities until the earlier
of (i)&nbsp;September&nbsp;9, 2018 (the six month anniversary of the first closing) and (ii)&nbsp;the initial closing date of a Qualified Offering (as such term is defined in the purchase agreement). Under the Series A Convertible Preferred, the
Company also agreed to refrain from issuing, or entering into any agreement to issue, or announcing the issuance or proposed issuance of any shares of common stock or common stock equivalents (subject to certain exclusions) prior to obtaining such
stockholder approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Qualified Offering is defined in the purchase agreement and the Certificate of Designation (as defined below) as a public offering
raising aggregate gross proceeds of no less than $20.0&nbsp;million. In the event of a Qualified Offering, under the Series A Convertible Preferred, investors have the right to acquire the securities sold in such Qualified Offering by converting
their shares of Series A Convertible Preferred into the same securities on a $1.00 for $1.00 basis based on the stated value of their shares of Series A Convertible Preferred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Series A Convertible Preferred</U>: On March&nbsp;8, 2018, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series
A 20% Convertible Preferred Stock (the &#147;Certificate of Designation&#148;) with the Secretary of State of the State of Delaware, which designated up to 17,500 shares of Series A Convertible Preferred. The shares of Series A Convertible Preferred
have a stated value equal to $1,000 and bear cumulative dividends, payable in cash or shares of common stock at the Company&#146; option, at a rate of 20% per annum, payable semiannually in arrears on June&nbsp;30 and December&nbsp;31, beginning on
the first such date after issuance, and upon conversion if accrued and unpaid at such time. Such dividends cease to accrue upon the consummation of a Qualified Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shares of Series A Convertible Preferred are convertible into common stock at the option the holder from time to time. Prior to receipt of stockholder
approval, such conversion is limited to an Investor&#146;s <I>pro rata</I> share of the aggregate 19.99% limit under applicable Nasdaq rules and regulations. Following receipt of stockholder approval, conversion is subject to a beneficial ownership
limitation of 4.99% (or 9.99% at the option of the Investor). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The initial conversion price is $5.80 per share of common stock, subject to standard
adjustments for certain transactions affecting the Company&#146;s securities (such as stock dividends, stock splits, and the like). Until consummation of a Qualified Offering, such conversion price is also subject to anti-dilution price protection
in the event of <FONT STYLE="white-space:nowrap">non-exempt</FONT> equity issuances at a price per share lower than the then applicable conversion price. If the Company has not consummated a Qualified Offering (as defined in the Certificate of
Designation) on or before September&nbsp;9, 2018 (the six month anniversary of the first closing), on each of the six month anniversary of the first and the second closings, the Conversion Price shall be reduced to the lesser of (x)&nbsp;the then
applicable Conversion Price, as adjusted, (y) $3.00 (subject to adjustment for forward and reverse stock splits and the like) and (z)&nbsp;the lowest VWAP for any trading day during the five trading days immediately following each such adjustment
date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#150; Continued </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Series A Convertible Preferred generally have no voting rights. However, for so long as any shares of
Series A Convertible Preferred are outstanding, the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Convertible Preferred is required to: (a)&nbsp;alter or change adversely the powers, preferences or
rights given to the Series A Convertible Preferred or alter or amend the Certificate of Designation, (b)&nbsp;authorize or create any class of stock ranking as to dividends, redemption or distribution of assets upon a Liquidation (as defined in the
Certificate of Designation) senior to, or otherwise <I>pari passu</I> with, the Series A Convertible Preferred (c)&nbsp;amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders
of Series A Convertible Preferred, (d)&nbsp;increase the number of authorized shares of Series A Convertible Preferred, or (e)&nbsp;enter into any agreement with respect to any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon any liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company, whether voluntary or involuntary that is not a
Fundamental Transaction (as defined in the Certificate of Designation), the holders of Series A Convertible Preferred are entitled to receive out of the assets the Company the same amount they would have received on an as converted basis,
disregarding any conversion limitations. Such amounts are paid on a<I>&nbsp;pari</I><I></I><I>&nbsp;passu </I>basis with all holders of Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Warrants</U>: Under the Purchase Agreement, the Company agreed to issue Warrants to acquire an aggregate of 1,383,631 shares of Common Stock, or
approximately 75% of the shares of Common Stock into which the Series A Convertible Preferred are initially exercisable. The Warrants have an initial exercise price of $6.59 per share, subject to adjustment in certain circumstances, may not be
exercised until the date that is six months after issuance, and have a term of five years from the initial exercise date. Prior to receipt of stockholder approval, exercise of the Warrants is limited to an Investor&#146;s pro rata share of the
aggregate 19.99% limit under applicable Nasdaq rules and regulations. Exercise is also subject to a beneficial ownership limitation of 4.99% (or 9.99% at the option of the Investor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Placement Agent</U>: Cantor Fitzgerald&nbsp;&amp; Co. (&#147;Cantor&#148;) acted as placement agent pursuant to an engagement letter dated January&nbsp;16,
2018 (the &#147;Engagement Letter&#148;). Under the engagement letter, the Company agreed to pay Cantor a fee equal to 7% of the gross proceeds received by the Company from United States based Investors. The Company also agreed to reimburse Cantor
for its actual, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> accountable expenses (including legal fees and expenses) incurred in connection with the Private Placement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Neuvax Phase 2b Clinical Trial</I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April 2, 2018 and in
connection with the Company&#146;s single-blinded, controlled Phase 2b independent investigator-sponsored clinical trial of Herceptin: Genentech/Roche) +/- NeuVax in HER2 1+/2+ breast cancer patients, we announced the interim efficacy analysis,
conducted by an independent Data Safety Monitoring Board of the efficacy and safety data for the study in an overall population of 275 patients as well as the two primary study target patient populations (node-positive and triple negative breast
cancer (&#147;TNBC&#148;)) after a median follow-up of 19 months, demonstrated a clinically meaningful difference in median disease-free survival in favor of the active arm (NeuVax + Herceptin), a primary endpoint of the study, with hazard ratios of
0.67 and 0.61 in the intent to treat and modified intent to treat populations (i.e., those who received at least one dose of vaccine or control) as well as a 34.9% and 39.5% reduction in relative risk of recurrence in the active versus control arms
in the intent to treat and modified intent to treat populations, respectively. A clinically meaningful and also statistically significant difference was found between the two arms in the cohort of patients (n= 98) with TNBC, with a hazard ratio of
0.26 and a p-value of 0.023 in favor of the NeuVax + Herceptin combination. Similarly, a clinically meaningful and statistically significant difference was found between the two arms in favor of the combination in the cohort of patients not
receiving hormonal therapy (n = 110), with a hazard ratio of 0.24 and a p-value of 0.009. This pre-specified interim analysis also showed an adverse event profile with no notable differences between treatment arms. This analysis confirmed the 2016
data showing that the addition of NeuVax to Herceptin did not result in any additional cardiotoxicity compared to Herceptin alone. Based on these results, and the independent Data Safety Monitoring Board&#146;s recommendation, the Company plans to
expeditiously seek regulatory guidance by the FDA for further development of the combination of NeuVax + Herceptin in TNBC, considering the statistically significant benefit of the combination therapy seen in this population with large unmet medical
need. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>JGB Action </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On or about April 9, 2018, JGB
filed a lawsuit in the U.S. District Court for the Southern District of New York captioned <I>JGB (Cayman) Newton, Ltd. v. Sellas Life Sciences Group, Inc., et al.</I>, Case 1:18-cv-3095 (DLC), or the JGB Action. The complaint in the JGB Action
asserts claims under state law and federal securities law against the Company, the Company&#146;s Chief Executive Officer, Dr. Stergiou and Angelos M. Stergiou, M.D., ScD H.C, and the Company&#146;s Interim Chief Financial Officer, Aleksey N. Krylov
(Mr.&nbsp;Krylov together with the Company and Dr.&nbsp;Stergiou, the &#147;Defendants&#148;). The complaint in the JGB Action alleges, among other things, that we breached a contractual obligation to deliver certain shares of the Company&#146;s
common stock to JGB and that, in the course of negotiations related to the senior secured debenture agreement, the Defendants failed to disclose to JGB certain information regarding positive clinical trial results that was not then public. According
to the complaint, JGB seeks to receive 2,483,500 shares of the Company&#146;s common stock, damages, and costs and expenses incurred in the JGB action, among other things. The Company disputes the claims in the JGB Action and intends to defend
against them vigorously. The Company has retained the law firm Skadden, Arps, Slate, Meagher &amp; Flom LLP, as its defense counsel for the JGB Action. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx556278_12"></A>ITEM&nbsp;9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Not applicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx556278_13">
</A>ITEM&nbsp;9A. CONTROLS AND PROCEDURES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Evaluation of Disclosure Controls and Procedures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the evaluation of our disclosure controls and procedures (as defined in the <FONT STYLE="white-space:nowrap">Rules&nbsp;13a-15(e)</FONT> and <FONT
STYLE="white-space:nowrap">15d-15(e)</FONT> under the Securities Exchange Act of 1934, or the Exchange Act) required by Exchange Act <FONT STYLE="white-space:nowrap">Rules&nbsp;13a-15(b)</FONT> or <FONT STYLE="white-space:nowrap">15d-15(b),</FONT>
our principal executive officer and our interim principal financial officer have concluded that as of the end of the period covered by this report, our disclosure controls and procedures were not effective as a result of the material weakness in our
internal control over financial reporting discussed below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Management&#146;s Report on Internal Control over Financial Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. We maintain a system of internal control
that is designed to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding that we do not qualify for the relief afforded by Instruction 1 to Item 308 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> to newly
public companies, management has not assessed nor attested to our internal control over financial reporting as is set forth in Item 308 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> promulgated under the Securities Exchange Act 1934, as
amended, and Section&nbsp;404 of the Sarbanes-Oxley Act as of December&nbsp;31, 2017, the end of our last fiscal year. We will do so initially as of December&nbsp;31, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were unable to conduct the required assessment primarily due to the Merger occurring on December&nbsp;29, 2017 and the resulting substantial change in
operational focus, management and the internal control environment. Following the Merger, Private SELLAS historical operations, and not that of our Company, represent virtually the entirety of the combined business. In addition, following the Merger
our accounting and financial systems, as well as personnel, were replaced by those of Private SELLAS. Due to the extensive changes to our internal control environment, it was impractical for us to develop, implement, and assess our system of
internal control, and conduct management&#146;s assessment of internal control over financial reporting as of December&nbsp;31, 2017. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material
Weakness and Remediation Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such
that there is a reasonable possibility that a misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were informed by our independent registered public accounting firm that we had a material weakness in our internal control over financial reporting due to
our lack of sufficient management and personnel with appropriate expertise in GAAP and SEC rules and regulations with respect to financial reporting during the year ending December 31, 2017. At that time, we had only one designated finance and
accounting employee and relied primarily on consultants to provide many accounting, book-keeping and administrative services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December 30, 2017, we
hired three additional finance and accounting personnel to build out our financial reporting team and further develop and document accounting policies and procedures. During the first quarter of 2018, we engaged a consulting firm to assist us in
evaluating the design of our internal controls, including disclosure controls and procedures. Our goal is to remediate this material weakness as soon as practical as part of our plan to implement and mature our system of internal control. We will
complete our annual assessment of internal control over financial reporting as of period ending December 31, 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx556278_14"></A>ITEM&nbsp;9B. OTHER INFORMATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART III </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx556278_15"></A>ITEM&nbsp;10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information required by this item is incorporated herein by reference to the information to be contained in the Proxy Statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx556278_16"></A>ITEM&nbsp;11. EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information required by this item is incorporated herein by reference to the information to be contained in the Proxy Statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx556278_17"></A>ITEM&nbsp;12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information required by this item is incorporated herein by reference to the information to be contained in the Proxy Statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx556278_18"></A>ITEM&nbsp;13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information required by this item is incorporated herein by reference to the information to be contained in the Proxy Statement.<B> </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx556278_19"></A>ITEM&nbsp;14. PRINCIPAL ACCOUNTANT FEES AND SERVICES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information required by this item is incorporated herein by reference to the information to be contained in the Proxy Statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx556278_20"></A>ITEM&nbsp;15. EXHIBITS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:91.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Incorporated by
Reference</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.45pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:41.70pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Registrant&#146;s<BR>Form</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date Filed with</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:52.40pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>the SEC</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.45pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;2.1&#094;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517336114/d452403d424b3.htm#toc452403_102">Agreement and Plan of Merger, dated as of August<U></U>&nbsp;
7, 2017, by and among the Registrant, Galena Bermuda Merger Sub, Ltd., Sellas Intermediate Holdings I, Inc., Sellas Intermediate Holdings II, Inc. and SELLAS Life Sciences Group Ltd, as amended (included as Annex<U></U>&nbsp;
A to the proxy statement/prospectus/consent solicitation statement) </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">424B</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">November&nbsp;8,&nbsp;2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">Annex&nbsp;A</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d556278dex31.htm">Composite Amended and Restated Certificate of Incorporation of the Registrant (formerly, Galena Biopharma, Inc.), amended as of December&nbsp;27, 2017 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518079472/d536405dex31.htm">Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">March&nbsp;12, 2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex33.htm">Amended and Restated <FONT STYLE="white-space:nowrap">By-Laws</FONT> of the Registrant </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">January&nbsp;5, 2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">3.3</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d556278dex41.htm">Form of Common Stock Certificate </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000142/gale-20160822xex103.htm">The Registrant&#146;s 2016 Incentive Plan effective as of July<U></U>&nbsp;14, 2016 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">August&nbsp;22, 2016</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.3</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d556278dex102.htm">Form Incentive Stock Option granted under the Registrant&#146;s 2016 Incentive Plan </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d556278dex103.htm">Form Nonstatutory Stock Option granted under the Registrant&#146;s 2016 Incentive Plan </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1061.htm">SELLAS Life Sciences Group, Ltd Stock Incentive Plan #1 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-4/A</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">October&nbsp;30, 2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.61</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1063.htm">SELLAS Life Sciences Group Ltd Notice of Grant of Restricted Stock Units </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-4/A</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">October&nbsp;30, 2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.63</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex1010.htm">2017 Equity Incentive Plan of the Registrant </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">January&nbsp;5, 2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.10</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex1011.htm">2017 Employee Stock Purchase Plan of the Registrant </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">January&nbsp;5, 2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.11</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518088034/d538010dex102.htm">Form of Stock Option Grant Notice and Option Agreement under the 2017 Equity Incentive Plan. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">March&nbsp;19, 2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.2</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d556278dex109.htm">Form of Restricted Stock Unit Grant under the 2017 Equity Incentive Plan.</A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1053.htm">Employment Agreement by and between SELLAS Life Sciences Group AG and Angelos Stergiou, effective September<U></U>&nbsp;1, 2016 </A></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-4/A</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">October&nbsp;30, 2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.53</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1054.htm">Employment Agreement by and between SELLAS Life Sciences Group AG and Gregory Torre, effective September<U></U>&nbsp;1, 2016 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-4/A</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">October&nbsp;30, 2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.54</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1055.htm">Employment Agreement by and between SELLAS Life Sciences Group AG and Nicholas Sarlis, effective September<U></U>&nbsp;19, 2016 </A></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-4/A</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">October&nbsp;30, 2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1057.htm">Retention Agreement Letter by and between SELLAS Life Sciences Group Ltd and Gregory Torre, dated July<U></U>&nbsp;31, 2017 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-4/A</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">October&nbsp;30, 2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.57</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:91.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Incorporated by
Reference</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.45pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:41.70pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Registrant&#146;s<BR>Form</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date Filed with</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:52.40pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>the SEC</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.45pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1058.htm">Retention Agreement Letter by and between SELLAS Life Sciences Group Ltd and Nicholas Sarlis, dated August<U></U>&nbsp;2, 2017 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-4/A</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">October&nbsp;30, 2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.58</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1056.htm">Employment Agreement by and between SELLAS Life Sciences Group Ltd and Aleksey Krylov, dated October<U></U>&nbsp;24, 2017 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-4/A</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">October&nbsp;30, 2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.56</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.16*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518088034/d538010dex101.htm">Letter Employment Agreement by and between SELLAS Life Sciences Group, Inc. and Barbara Wood, dated March<U></U>&nbsp;14, 2018 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">March&nbsp;19, 2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.17*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000088/gale-20151231xex1038.htm">Amendment, dated December<U></U>&nbsp;31, 2015, to Employment Offer Letter effective June<U></U>&nbsp;
25, 2015, between Galena Biopharma, Inc. and Thomas J. Knapp </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">10-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">March&nbsp;10, 2016</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.38</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.18*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000150/gale-20161006ex101.htm">Second Amendment to Offer Letter between Galena Biopharma, Inc. and Thomas J. Knapp </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">October&nbsp;6, 2016</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.19*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000009/a201702078k102.htm">Third Amendment to Offer Letter between Galena Biopharma, Inc. and Thomas J. Knapp, dated as of January<U></U>&nbsp;31, 2017 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">February&nbsp;7,&nbsp;2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.2</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.20*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000036/gale-20170331xex106.htm">Retention Agreement between Thomas J. Knapp and Galena Biopharma, Inc. dated February<U></U>&nbsp;23, 2017 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">10-Q</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">May&nbsp;10, 2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.6</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.21*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000036/gale-2017x3031xex101.htm">Separation Agreement and General Release between Mark W. Schwartz and Galena Biopharma, Inc. executed on January<U></U>&nbsp;
31, 2017 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">10-Q</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">May&nbsp;10, 2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.22*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000159/gale-20161103xex992.htm">Employment Agreement between Galena Biopharma, Inc. and Stephen Ghiglieri dated November<U></U>&nbsp;1, 2016 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">November&nbsp;3,&nbsp;2016</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">99.2</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.22*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000013/gale-20170221ex101.htm">First Amendment to Employment Agreement between Galena Biopharma, Inc. and Stephen Ghiglieri, dated as of February<U></U>&nbsp;
21, 2017 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">February&nbsp;21,&nbsp;2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.23*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000036/gale-20170331xex103.htm">Retention Agreement between Stephen Ghiglieri and Galena Biopharma, Inc. dated February<U></U>&nbsp;23, 2017 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">10-Q</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">May&nbsp;10, 2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.3</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.24*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000142/gale-20160822xex102.htm">Second Amendment to Employment Agreement, dated as of August<U></U>&nbsp;
22, 2016, between Galena Biopharma, Inc. and Bijan Nejadnik </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">August&nbsp;22, 2016</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.2</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.25*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000036/gale-20170331xex104.htm">Retention Agreement between Bijan Nejadnik and Galena Biopharma, Inc. dated February<U></U>&nbsp;23, 2017 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">10-Q</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">May&nbsp;10, 2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.4</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.26*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000142/gale-20160822xex101.htm">Severance Agreement, dated as of August<U></U>&nbsp;22, 2016, between Galena Biopharma, Inc. and John T. Burns </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">August&nbsp;22,&nbsp;2016</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.27*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000036/gale-20170331xex105.htm">Retention Agreement between John Burns and Galena Biopharma, Inc. dated February<U></U>&nbsp;23, 2017 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">10-Q</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">May&nbsp;10, 2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.5</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:91.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Incorporated by
Reference</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.45pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:41.70pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Registrant&#146;s<BR>Form</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date Filed with</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:52.40pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>the SEC</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.45pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.28+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w1.htm">Patent and Technology License Agreement, dated September<U></U>&nbsp;
11, 2006, by and among the Board of Regents of the University of Texas System, the University of Texas M.D. Anderson Cancer Center, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and Apthera, Inc. (formerly Advanced Peptide
 Therapeutics, Inc.) </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">10-Q</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">August&nbsp;15, 2011</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.29</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w2.htm">Amendment No.<U></U>&nbsp;1 to Patent and Technology License Agreement, dated December<U></U>&nbsp;
21, 2007, by and among the Board of Regents of the University of Texas System, the University of Texas M.D. Anderson Cancer Center, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and Apthera, Inc. (formerly Advanced Peptide
 Therapeutics, Inc.) </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">10-Q</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">August&nbsp;15, 2011</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.2</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.30</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w3.htm">Amendment No.<U></U>&nbsp;2 to Patent and Technology License Agreement, dated September<U></U>&nbsp;
3, 2008, by and among the Board of Regents of the University of Texas System, the University of Texas M.D. Anderson Cancer Center, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and Apthera, Inc. (formerly Advanced Peptide
 Therapeutics, Inc.) </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">10-Q</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">August&nbsp;15,&nbsp;2011</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.3</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.31</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w4.htm">Amendment No.<U></U>&nbsp;3 to Patent and Technology License Agreement, dated July<U></U>&nbsp;
8, 2009, by and among the Board of Regents of the University of Texas System, the University of Texas M.D. Anderson Cancer Center, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and Apthera, Inc. (formerly Advanced Peptide
 Therapeutics, Inc.) </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">10-Q</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">August&nbsp;15, 2011</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.4</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.32+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w5.htm">Amendment No.<U></U>&nbsp;4 to Patent and Technology License Agreement, dated February<U></U>&nbsp;
11, 2010, by and among the Board of Regents of the University of Texas System, the University of Texas M.D. Anderson Cancer Center, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and Apthera, Inc. (formerly Advanced Peptide
 Therapeutics, Inc.) </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">10-Q</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">August&nbsp;15, 2011</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.5</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.33+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w6.htm">Amendment No.<U></U>&nbsp;5 to Patent and Technology License Agreement, dated January<U></U>&nbsp;
10, 2011, by and among the Board of Regents of the University of Texas System, the University of Texas M.D. Anderson Cancer Center, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and Apthera, Inc. (formerly Advanced Peptide
 Therapeutics, Inc.) </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">10-Q</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">August&nbsp;15, 2011</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.6</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.34</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w10.htm">Scientific Advisory Agreement between the Registrant (formerly Galena Biopharma, Inc.) and George E. Peoples, Ph.D., dated April<U></U>&nbsp;13,
 2011 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">10-Q</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">August&nbsp;15, 2011</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.10</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.35+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311077641/b86941exv10w12.htm">Exclusive License Agreement, dated as of July<U></U>&nbsp;
11, 2011, by and among The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., the Registrant (formerly Galena Biopharma, Inc.) and its wholly owned subsidiary, Apthera, Inc. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">10-Q</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">August&nbsp;15, 2011</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.12</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.36+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311085837/b88330exv10w1.htm">Exclusive License Agreement, dated as of September<U></U>&nbsp;
16, 2011, by and among The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Board of Regents of the University of Texas System, The University of Texas M. D. Anderson Cancer Center and the Registrant (formerly Galena Biopharma,
 Inc.) </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">September&nbsp;21,&nbsp;2011</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:91.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Incorporated by
Reference</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.45pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:41.70pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Registrant&#146;s<BR>Form</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date Filed with</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:52.40pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>the SEC</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.45pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.37</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000095012311035465/b86058exv10w1.htm">Form of Contingent Value Rights Agreement among the Registrant (formerly RXi Pharmaceuticals Corporation), Computershare Trust Company, N.A.,
 Computershare Inc., and Robert E Kennedy, dated April<U></U>&nbsp;13, 2011 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">April&nbsp;14, 2011</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.38</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312512137599/d275067dex102.htm">First Amendment to Contingent Value Rights Agreement among the Registrant (formerly RXi Pharmaceuticals Corporation), Computershare Trust Company,
 N.A., Computershare Inc., and Robert E Kennedy, dated February<U></U>&nbsp;15, 2012 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">10-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">March&nbsp;28, 2012</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.2</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.39+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312512137599/d275067dex1045.htm">License Agreement, effective as of April<U></U>&nbsp;30, 2009, between Kwangdong Pharmaceutical Co., Ltd. and Apthera, Inc. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">10-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">March&nbsp;28,&nbsp;2012</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.45</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.40</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312512137599/d275067dex1046.htm">Amendment No.<U></U>&nbsp;1 to License Agreement, dated as of January<U></U>&nbsp;
13, 2012, by and among Apthera, Inc., Kwangdong Pharmaceutical Co., Ltd., and the Registrant </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">10-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">March&nbsp;28, 2012</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.46</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.38+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312513103307/d459781dex1043.htm">License and Supply Agreement, effective December<U></U>&nbsp;
3, 2012, by and between the Registrant and ABIC Marketing Limited, a subsidiary of Teva Pharmaceuticals </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">10-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">March&nbsp;12, 2013</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.43</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.39</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312513235700/d542241dex13.htm">At Market Issuance Sales Agreement dated May<U></U>&nbsp;24, 2013 between the Registrant and Maxim Group LLC </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">Form <FONT STYLE="white-space:nowrap">S-3</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">May&nbsp;24, 2013</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">1.3</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.40</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312513235700/d542241dex12.htm">At Market Issuance Sales agreements dated May<U></U>&nbsp;24, 2013 between the Registrant and FBR<U></U>&nbsp;
&amp; Co, formerly known as MLV<U></U>&nbsp;&amp; Co. LLC </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">May&nbsp;24, 2013</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">1.2</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.41+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047814000016/gale-20131231xex1036.htm">License and Development Agreement, dated January<U></U>&nbsp;13, 2014, between the Registrant and Dr.<U></U>&nbsp;
Reddy&#146;s Laboratories, Ltd. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">10-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">March&nbsp;17, 2014</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.36</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.42+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047814000016/gale-20131231xex1037.htm">Exclusive License Agreement, dated as of December<U></U>&nbsp;20, 2013, between Mills Pharmaceuticals, LLC and BioVascular, Inc.
</A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">10-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">March&nbsp;17, 2014</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.37</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.43</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000061/gale-20170911x8kex101.htm">Amendment of the Exclusive License Agreement by and between Mills Pharmaceuticals, LLC and BioVascular, Inc. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">September&nbsp;11, 2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.44</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000164/gale20160930ex102.htm">Amendment dated August<U></U>&nbsp;8, 2016 to the Purchase Agreement, dated as of November<U></U>&nbsp;
18, 2014, by and between Galena Biopharma, Inc. and Lincoln Park Capital Fund, LLC </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">10-Q</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">November&nbsp;9,&nbsp;2016</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.2</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.45</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000009/a201702078k101.htm">Second Amendment to the Purchase Agreement, dated as of February<U></U>&nbsp;
6, 2017, by and between Galena Biopharma, Inc. and Lincoln Park Capital Fund, LLC </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">February&nbsp;7, 2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.46</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1064.htm">License Agreement by and between SELLAS Life Sciences, Inc. and Madison Avenue Suites LLC, dated March<U></U>&nbsp;20, 2017 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">Form&nbsp;S-4/A</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">October&nbsp;30, 2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.64</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.47+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517323493/d452403dex1065.htm">Amended and Restated Exclusive License Agreement by and between SELLAS Life Sciences Group Ltd and Memorial Sloan Kettering Cancer Center, effective
 October<U></U>&nbsp;11, 2017 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">Form <FONT STYLE="white-space:nowrap">S-4/A</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">October&nbsp;30, 2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.65</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:91.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Incorporated by
Reference</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.45pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:41.70pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Registrant&#146;s<BR>Form</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date Filed with</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:52.40pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>the SEC</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.45pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.48</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex101.htm">Securities Purchase Agreement dated May<U></U>&nbsp;10, 2016 between the Registrant and Purchasers </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">10-Q</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">May&nbsp;10, 2016</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.49</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex-103.htm">Registration Rights Agreement dated May<U></U>&nbsp;10, 2016 between the Registrant and Purchasers </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">10-Q</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">May&nbsp;10, 2016</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.3</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.50</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex42.htm">Series A Common Stock Purchase Warrant assigned to JGB (Cayman) Newton Ltd. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">10-Q</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">May&nbsp;10, 2016</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4.2</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.51</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex43.htm">Series B Common Stock Purchase Warrant assigned to JGB (Cayman) Newton Ltd. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">10-Q</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">May&nbsp;10, 2016</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4.3</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.52</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex-102.htm">Subsidiary Guarantee dated May<U></U>&nbsp;10, 2016 between the Registrant and JGB Collateral LLC </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">10-Q</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">May&nbsp;10, 2016</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.2</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.53</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000110/gale20160331ex-104.htm">Security Agreement dated May<U></U>&nbsp;10, 2016 between the Registrant and JGB Collateral LLC </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">10-Q</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">May&nbsp;10, 2016</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.4</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.54</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000146/gale-20160823xex101.htm">Amendment Agreement between the Registrant and JGB (Cayman) Newton Ltd. dated August<U></U>&nbsp;22, 2016 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">August&nbsp;23, 2016</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.55</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047816000146/gale-20160823xex41.htm">Amended and Restated 9% Original Issue Discount Senior Secured Debenture Due November<U></U>&nbsp;
10, 2018, issued to JGB (Cayman) Newton Ltd. as of August<U></U>&nbsp;22, 2016 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">August&nbsp;23, 2016</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.56</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000009/a201702078k103.htm">Waiver dated December<U></U>&nbsp;14, 2016 to the Securities Purchase Agreement, dated as of May<U></U>&nbsp;
10, 2016 by and between the Registrant and JGB Newton, Ltd </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">February&nbsp;7, 2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.3</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.57</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000027/gale-20170403ex101.htm">Waiver dated April<U></U>&nbsp;1, 2017 to the Securities Purchase Agreement, dated as of May<U></U>&nbsp;
10, 2016 by and between the Registrant and JGB Newton, Ltd. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">April&nbsp;3, 2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.58</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000031/gale-20170501xex101.htm">Amendment Agreement dated May<U></U>&nbsp;1, 2017 between the Registrant and JGB (Cayman) Newton Ltd. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">May&nbsp;2, 2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.59</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000045/gale-20170710xex41.htm">Amendment Agreement, dated as of July<U></U>&nbsp;
10, 2017, by and between JGB Cayman (Newton) Ltd. and the Registrant with respect to the 9% Original Issue Discount Senior Secured Convertible Debenture in the Original Issue Amount of $25,350,000 Issued and Sold to JGB Cayman (Newton) Ltd. by the Registrant
 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">July&nbsp;11, 2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.60</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517250556/d434413dex103.htm">Consent, dated as of August<U></U>&nbsp;7, 2017, made by JGB (Cayman) Newton Ltd., in favor of the Registrant </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">August&nbsp;8,&nbsp;2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.3</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:91.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Incorporated by
Reference</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.45pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:41.70pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Registrant&#146;s<BR>Form</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date Filed with</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:52.40pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>the SEC</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.45pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.63</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312513211191/d515003dex107.htm">Form of warrants granted on May<U></U>&nbsp;8, 2013 under the Loan and Security Agreement </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">10-Q</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">May&nbsp;9, 2013</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.7</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.64</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047813000024/exhibit41-warrantagreement.htm">Form of Warrant Agreement by and among the Registrant, Computershare Inc. and Computershare Trust Company, N.A. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">September&nbsp;18, 2013</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.65</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047815000037/gale-20150630xex41.htm">Warrant Agreement, dated as of March<U></U>&nbsp;
18, 2015, by and among the Registrant, Computershare, Inc. and Computershare Trust Company, N.A. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">10-Q</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">August&nbsp;6, 2015</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.66</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312516423538/d106844dex41.htm">Form of Warrant Agreement by and among the Registrant, Computershare Inc. and Computershare Trust Company, N.A. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">January&nbsp;7, 2016</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.67</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312516643945/d174442dex41.htm">Form of Warrant, issued by the Registrant to the Investors on July<U></U>&nbsp;13, 2016 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">July&nbsp;8, 2016</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.68</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000139047817000011/a201702088k41.htm">Form of Warrant Agreement, including the Form of Warrant, issued by the Registrant to the Investors on February<U></U>&nbsp;13, 2017
</A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">February&nbsp;10, 2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.69</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517250556/d434413dex102.htm">Form of Support Agreement, by and between the Registrant and certain directors, officers and shareholders of SELLAS Life Sciences Group Ltd
</A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">August&nbsp;8, 2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.2</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.70</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312517250556/d434413dex101.htm">Form of Support Agreement, by and between SELLAS Life Sciences Group Ltd and certain directors, officers and stockholders of the Registrant
</A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">August&nbsp;8, 2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.71</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex105.htm">Warrant issued to EQC Private Markets SAC Fund Ltd &#150; EQC Biotech Sely I Fund </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">January&nbsp;5, 2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.5</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.72</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex108.htm">Form of Indemnity Agreement between the Registrant and each of its directors and executive officers </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">January&nbsp;5, 2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.8</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.73</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d556278dex1073.htm">Warrant Exchange Agreement by and between the Registrant and CVI Investments, Inc., dated February&nbsp;6, 2018 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.74</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d556278dex1074.htm">Promissory Note by and between the Registrant and CVI Investments, Inc., dated February&nbsp;6, 2018 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.75</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d556278dex1075.htm">Warrant Exchange Agreement by and between the Registrant and Anson Investments Master Fund LP, dated February&nbsp;7, 2018 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.76</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d556278dex1076.htm">Warrant Exchange Agreement by and between the Registrant, Sabby&nbsp;Healthcare Master Fund Ltd and Sabby Volatility Warrant Master Fund Ltd, dated February&nbsp;8, 2018 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:91.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Incorporated by
Reference</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.45pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:41.70pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Registrant&#146;s<BR>Form</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date Filed with</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:52.40pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>the SEC</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.45pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.77</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d556278dex1077.htm">Warrant Exchange Agreement by and between the Registrant and Hudson Bay Master Fund Agreement, dated February&nbsp;9, 2018 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.78</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d556278dex1078.htm">Promissory Note by and between the Registrant and Hudson Bay Master Fund Agreement, dated February&nbsp;9, 2018 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.79</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d556278dex1079.htm">Warrant Exchange Agreement by and between the Registrant and Alto Opportunity Master Fund, SPC&#151;Segregated Master Portfolio B, dated February&nbsp;13, 2018 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.80</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d556278dex1080.htm">Promissory Note by and between the Registrant and Alto Opportunity Master Fund, SPC&#151;Segregated Master Portfolio B, dated February&nbsp;13, 2018 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.81</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d556278dex1081.htm">Warrant Exchange Agreement by and between the Registrant and Lincoln Park Capital LLC, dated February&nbsp;14, 2018</A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.82</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d556278dex1082.htm">Warrant Exchange Agreement by and between the Registrant and Empery Asset Master, Ltd., dated February&nbsp;21, 2018 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.83</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d556278dex1083.htm">Warrant Exchange Agreement by and between the Registrant and Empery Tax Efficient, LP, dated February&nbsp;21, 2018 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.84</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d556278dex1084.htm">Warrant Exchange Agreement by and between the Registrant and Empery Tax Efficient II, LP, dated February&nbsp;21, 2018 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.85</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d556278dex1085.htm">Promissory Note by and between the Registrant and Empery Asset Master, Ltd., dated February&nbsp;21, 2018</A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.86</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d556278dex1086.htm">Promissory Note by and between the Registrant and Empery Tax Efficient, LP, dated February&nbsp;21, 2018</A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.87</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d556278dex1087.htm">Promissory Note by and between the Registrant and Empery Tax Efficient II, LP, dated February&nbsp;21, 2018 </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.88</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518079472/d536405dex101.htm">Securities Purchase Agreement dated March<U></U>&nbsp;7, 2018 by and between the Registrant and certain investors </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">March&nbsp;12, 2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.89</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518079472/d536405dex102.htm">Form of Voting Agreement by and between the Registrant and its named executives, Board of Directors and certain stockholders </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">March&nbsp;12, 2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.2</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.90</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518079472/d536405dex103.htm">Form of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement by and between the Registrant and its named executives, Board of Directors
 and certain stockholders </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">March&nbsp;12, 2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.3</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.91</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518079472/d536405dex41.htm">Form of Warrant issued pursuant to that certain Securities Purchase Agreement dated March<U></U>&nbsp;
7, 2018 by and between the Registrant and the certain investors </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">March&nbsp;12, 2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:91.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Incorporated by
Reference</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.45pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:41.70pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Registrant&#146;s<BR>Form</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date Filed with</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:52.40pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>the SEC</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.45pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>14.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex141.htm">Code of Business Conduct and Ethics </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">January&nbsp;5, 2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>16.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1390478/000119312518116930/d569643dex161.htm">Letter from KPMG Audit Limited dated April 12, 2018, regarding change in certifying accountant. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8-K/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">April 13, 2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d556278dex211.htm">Subsidiaries of the Registrant </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d556278dex231.htm">Consent of Moss Adams LLP, Independent Registered Public Accounting Firm to the Registrant </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d556278dex232.htm">Consent of KPMG Audited Limited, Independent Registered Public Accounting Firm to SELLAS Life Sciences Group Ltd </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#tx556278_22">Powers of Attorney (included on signature page hereto) </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>31.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d556278dex311.htm">Certification of Principal Executive Officer pursuant to <FONT STYLE="white-space:nowrap">Rule13a-14(a)</FONT> and Rule <FONT STYLE="white-space:nowrap">15d-14(a)</FONT> of the Securities and Exchange Act, as
 amended. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>31.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d556278dex312.htm">Certification of Principal Financial Officer pursuant to <FONT STYLE="white-space:nowrap">Rule13a-14(a)</FONT> and Rule <FONT STYLE="white-space:nowrap">15d-14(a)</FONT> of the Securities and Exchange Act, as
 amended. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>32.1**</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d556278dex321.htm">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.INS***</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">XBRL Instance Document</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.SCH***</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Schema</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.CAL***</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Calculation Linkbase Document</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.DEF***</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Definition Linkbase Document</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.LAB***</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Label Linkbase Document</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.PRE***</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Presentation Linkbase Document</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Indicates management contract or compensatory plans or arrangements. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top">The certifications attached as Exhibit 32.1 accompany this Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the
Sarbanes-Oxley Act of 2002, and shall not be deemed &#147;filed&#148; by the Company for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#094;</TD>
<TD ALIGN="left" VALIGN="top">The schedules and exhibits to this exhibit have been omitted pursuant to Item&nbsp;601(b)(2) of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K.</FONT> A copy of any omitted schedule and/or exhibit will be
furnished to the SEC upon request. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">+</TD>
<TD ALIGN="left" VALIGN="top">Confidential treatment has been granted with respect to certain portions of this exhibit. Omitted portions have been filed separately with the SEC. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">In accordance with Rule 406T of Regulation <FONT STYLE="white-space:nowrap">S-T,</FONT> the Interactive Data Files in Exhibit 101 are deemed not filed or part of a registration statement or prospectus for purposes of
Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section&nbsp;18 of the Exchange Act of 1934, as amended, and otherwise are not subject to liability under these sections. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx556278_21"></A>ITEM&nbsp;16. FORM <FONT STYLE="white-space:nowrap">10-K</FONT> SUMMARY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Not Applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx556278_22"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized, on April 13,&nbsp;2018. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: April&nbsp;13, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">SELLAS LIFE SCIENCES GROUP, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><I>/s/ Angelos M. Stergiou</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Angelos M. Stergiou, MD, ScD h.c.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes
and appoints David Moser and YiYi Lam, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign
any and all amendments (including post-effective amendments) to this annual report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said
attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do
in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of
the registrant and in the capacities and on the dates indicated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:41.70pt; display:inline; font-size:10pt; font-family:Times New Roman; " ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.05pt; display:inline; font-size:10pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:10pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Angelos M. Stergiou </I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Angelos M. Stergiou, MD, ScD h.c.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">President, Chief Executive Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Principal Executive Officer) and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right">April&nbsp;13, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Aleksey Krylov</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Aleksey Krylov, CFA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Interim Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Principal Financial and Accounting Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right">April&nbsp;13, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Jane Wasman</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Jane Wasman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Chairman of the Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right">April&nbsp;13, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Fabio Lopez</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Fabio Lopez</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right">April&nbsp;13, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Robert Van Nostrand</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Robert Van Nostrand</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right">April&nbsp;13, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ David Scheinberg</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">David Scheinberg, M.D., PhD.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right">April&nbsp;13, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ John Varian</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">John Varian</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right">April&nbsp;13, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Stephen F. Ghiglieri</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Stephen F. Ghiglieri</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right">April&nbsp;13, 2018</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>d556278dex31.htm
<DESCRIPTION>EX-3.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Delaware </U></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The First
State </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED ARE TRUE AND CORRECT COPIES
OF ALL DOCUMENTS FILED FROM AND INCLUDING THE RESTATED CERTIFICATE OR A MERGER WITH A RESTATED CERTIFICATE ATTACHED OF &#147;SELLAS LIFE SCIENCES GROUP, INC.&#148; AS RECEIVED AND FILED IN THIS OFFICE. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>THE FOLLOWING DOCUMENTS HAVE BEEN CERTIFIED: </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>RESTATED CERTIFICATE, FILED THE SIXTH DAY OF FEBRUARY, A.D. 2008, AT 4:40 O&#146;CLOCK P.M. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>CERTIFICATE OF AMENDMENT, FILED THE TWENTY-SIXTH DAY OF JULY, A.D. 2011, AT 4:08 O&#146;CLOCK P.M. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>CERTIFICATE OF OWNERSHIP, CHANGING ITS NAME FROM &#147;RXI PHARMACEUTICALS CORPORATION&#148; TO &#147;GALENA BIOPHARMA, INC.&#148;, FILED
THE TWENTY-SIXTH DAY OF SEPTEMBER, A.D. 2011, AT 10:28 O&#146;CLOCK A.M. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>CERTIFICATE OF AMENDMENT, FILED THE TWENTY-EIGHTH DAY OF
JUNE, A.D. 2013, AT 4:56 O&#146;CLOCK P.M. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3" ALIGN="center">


<IMG SRC="g556278dsp1a.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g556278dsp1b.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4136433 8100X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Authentication: 202360615</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SR# 20182068968</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Date: 03-20-18</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">You may verify this certificate online at corp.delaware.gov/authver.shtml</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Delaware </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The First State </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>CERTIFICATE
OF CHANGE OF REGISTERED AGENT, FILED THE TWENTY-SECOND DAY OF JULY, A.D. 2013, AT 9:13 O&#146;CLOCK A.M. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>CERTIFICATE OF AMENDMENT,
FILED THE NINETEENTH DAY OF JUNE, A.D. 2015, AT 2:23 O&#146;CLOCK P.M. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>CERTIFICATE OF AMENDMENT, FILED THE SEVENTEENTH DAY OF
OCTOBER, A.D. 2016, AT 10 O&#146;CLOCK A.M. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>CERTIFICATE OF AMENDMENT, FILED THE SECOND DAY OF NOVEMBER, A.D. 2016, AT 10
O&#146;CLOCK A.M. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>CERTIFICATE OF VALIDATION, FILED THE SIXTH DAY OF JULY, A.D. 2017, AT 1:43 O&#146;CLOCK P.M. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>CERTIFICATE OF VALIDATION, FILED THE SIXTH DAY OF JULY, A.D. 2017, AT 1:44 O&#146;CLOCK P.M. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>CERTIFICATE OF VALIDATION, FILED THE SIXTH DAY OF JULY, A.D. 2017, AT 1:45 O&#146;CLOCK P.M. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>CERTIFICATE OF VALIDATION, FILED THE SIXTH DAY OF JULY, A.D. 2017, AT 1:46 O&#146;CLOCK P.M. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>CERTIFICATE OF VALIDATION, FILED THE SIXTH DAY OF JULY, A.D. 2017, AT 1:47 O&#146;CLOCK P.M. </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3" ALIGN="center">


<IMG SRC="g556278dsp1a.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g556278dsp1b.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4136433 8100X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Authentication: 202360615</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SR# 20182068968</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Date: 03-20-18</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">You may verify this certificate online at corp.delaware.gov/authver.shtml</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Delaware </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The First State </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>CERTIFICATE
OF AMENDMENT, FILED THE TWENTY-NINTH DAY OF DECEMBER, A.D. 2017, AT 9:30 O&#146;CLOCK A.M. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>AND I DO HEREBY FURTHER CERTIFY THAT
THE EFFECTIVE DATE OF THE AFORESAID CERTIFICATE OF AMENDMENT IS THE TWENTY-NINTH DAY OF DECEMBER, A.D. 2017 AT 4:15 O&#146;CLOCK P.M. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>CERTIFICATE OF AMENDMENT, CHANGING ITS NAME FROM &#147;GALENA BIOPHARMA, INC.&#148; TO &#147;SELLAS LIFE SCIENCES GROUP, INC.&#148;, FILED
THE TWENTY-NINTH DAY OF DECEMBER, A.D. 2017, AT 11 O&#146;CLOCK A.M. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>AND I DO HEREBY FURTHER CERTIFY THAT THE EFFECTIVE DATE OF
THE AFORESAID CERTIFICATE OF AMENDMENT IS THE TWENTY-NINTH DAY OF DECEMBER, A.D. 2017 AT 4:45 O&#146;CLOCK P.M. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>CERTIFICATE OF
DESIGNATION, FILED THE EIGHTH DAY OF MARCH, A.D. 2018, AT 4:26 O&#146;CLOCK P.M. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3" ALIGN="center">


<IMG SRC="g556278dsp1a.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g556278dsp1b.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4136433 8100X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Authentication: 202360615</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SR# 20182068968</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Date: 03-20-18</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">You may verify this certificate online at corp.delaware.gov/authver.shtml</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>State of Delaware</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Secretary of State</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><I>Division of Corporations</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><I>Delivered 04:49 PM 02/06/2008</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><I>FILED 04:40 PM 02/06/2008</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><I>SRV 080127383 - 4136433 FILE</I></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RXI PHARMACEUTICALS
CORPORATION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>a Delaware Corporation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RXi Pharmaceuticals Corporation, a corporation organized and existing under the laws of the State of Delaware (the &#147;Corporation&#148;), does hereby
submit this Amended and Restated Certificate of Incorporation, duly adopted pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware, for the purpose of amending and restating the Certificate of Incorporation of the
Corporation, as originally filed with the Secretary of State of the State of Delaware on April&nbsp;3, 2006 and as subsequently amended on November&nbsp;28, 2006,&nbsp;January&nbsp;8, 2007 and June&nbsp;19, 2007. The text of the Certificate of
Incorporation is hereby restated and amended to read in its entirety as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The name of this corporation is RXi Pharmaceuticals Corporation. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nature of
the business and the purposes to be conducted and promoted by the Corporation shall be to conduct any lawful business, to promote any lawful purpose, and to engage in any lawful act or activity for which corporations may be organized under the
General Corporation Law of the State of Delaware (the &#147;DGCL&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A. Classes of Stock. </B>This corporation is authorized to issue 55,000,000 shares. 50,000,000 shares shall be Common Stock with a par
value of $0.0001 per share (&#147;Common Stock&#148;) and 5,000,000 shares shall be Preferred Stock with a par value of $0.0001 per share (&#147;Preferred Stock&#148;).<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B. Rights, Preferences, Privileges and Restrictions of Preferred Stock. </B>Preferred Stock may be issued from time to time in one or more
series, each of such series to have such terms as stated or expressed herein and in the resolution or resolutions providing for the issue of such series adopted by the Board of Directors of the Corporation (the &#147;Board of Directors&#148;) as
hereinafter provided. Any shares of Preferred Stock that may be redeemed, purchased or acquired by the Corporation may be reissued except as otherwise provided by law or this Certificate of Incorporation. Different series of Preferred Stock shall
not be construed to constitute different classes of shares for the purposes of voting by classes unless expressly provided in the resolution or resolutions providing for the issue of such series adopted by the Board of Directors as hereinafter
provided.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Authority is hereby expressly granted to the Board of Directors from time to time to issue the Preferred Stock in one or
more series, and in connection with the creation of any such series, by resolution or resolutions providing for the issue of the shares thereof, to determine and fix such voting powers, full or limited, or no voting powers, and such designations,
preferences and relative participating, optional or other special rights, and qualifications, limitations or restrictions thereof, </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including without limitation thereof, dividend rights, conversion rights, redemption privileges and liquidation preferences, as shall be stated and expressed in such resolutions, all to the full
extent now or hereafter permitted by the DGCL. Without limiting the generality of the foregoing, the resolutions providing for issuance of any series of Preferred Stock may provide that such series shall be superior or rank equally or be junior to
the Preferred Stock of any other series to the extent permitted by law and this Certificate of Incorporation. Except as otherwise provided in this Certificate of Incorporation, no vote of the holders of the Preferred Stock or Common Stock shall be a
prerequisite to the designation or issuance of any shares of any series of the Preferred Stock authorized by and complying with the conditions of this Certificate of Incorporation, the right to have such vote being expressly waived by all present
and future holders of the capital stock of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C. Common Stock. </B>The voting, dividend and liquidation rights of the
holders of the Common Stock are subject to and qualified by the rights of the holders of the Preferred Stock of any series as may be designated by the Board of Directors upon issuance of any such Preferred Stock. The holders of the Common Stock
shall have no preemptive rights to subscribe for any shares of any class of stock of the Corporation whether now or hereafter authorized.<B> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"><U>Dividend Rights</U>. Dividends may be declared and paid on the Common Stock from funds lawfully available therefor as and when determined by the Board of Directors and subject to any preferential dividend rights of
any then outstanding Preferred Stock. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"><U>Liquidation Rights</U>. Upon the dissolution or liquidation of the Corporation, whether voluntary or involuntary, holders of Common Stock will be entitled to receive all assets of the Corporation available for
distribution to its stockholders, subject to any preferential rights of any then outstanding Preferred Stock. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"><U>Redemption</U>. The Common Stock is not redeemable. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"><U>Voting Rights</U>. Each share of Common Stock shall be entitled to one vote. There shall be no cumulative voting. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"><U>Number</U>. The number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the
stock of the Corporation entitled to vote, irrespective of the provisions of Section&nbsp;242(b)(2) of the DGCL. </TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE
IV </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The corporation is to have perpetual existence. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except to the
extent that the DGCL prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty, no director of the Corporation shall be personally liable to the Corporation or its stockholders for monetary damages for any
breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability. No amendment to or repeal of this provision shall apply to or have any effect on the liability or alleged liability of any director of the
Corporation or with respect to any acts or omissions of such director occurring prior to such amendment or repeal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The corporation shall, to the fullest extent permitted by the provisions of Section&nbsp;145 of the General Corporation Law of the State of
Delaware, as the same may be amended and supplemented, indemnify any and all persons whom it shall have power to indemnify under said Section from and against any and all of the expenses, liabilities, or other matters referred to in or covered by
said section, and the indemnification provided for herein shall not be deemed exclusive of any other rights to which those indemnified may be entitled under any Bylaw, agreement, vote of stockholders or disinterested directors or otherwise, both as
to action in his official capacity and as to action in another capacity while holding such office, and shall continue as to a person who has ceased to be a director, officer, employee, or agent and shall inure to the benefit of the heirs, executors,
and administrators of such person. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A. Indemnification. </B>The Corporation shall, to the maximum extent permitted under the DGCL and except as set forth below, indemnify and
upon request advance expenses to each person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the
fact that he is or was, or has agreed to become, a director or officer of the Corporation, or is or was serving, or has agreed to serve, at the request of the Corporation, as a director, officer, employee or trustee of, or in a similar capacity
with, another corporation, partnership, joint venture, trust or other enterprise, including any employee benefit plan (all such persons being referred to hereafter as an &#147;Indemnitee&#148;), or by reason of any action alleged to have been taken
or omitted in such capacity, against all expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him or on his behalf in connection with such action, suit or proceeding and any
appeal therefrom, if he acted in good faith and in a manner he reasonably believed to be in, or not opposed to, the best interests of the Corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his
conduct was unlawful. Notwithstanding anything to the contrary in this Article, the Corporation shall not indemnify an Indemnitee seeking indemnification in connection with any action, suit, proceeding, claim or counterclaim, or part thereof,
initiated by the Indemnitee unless the initiation thereof was approved by the Board of Directors.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B. Determination of
Entitlement to Indemnification. </B>Any indemnification under Paragraph A of this Article (unless ordered by a court) shall be made by the Corporation only as authorized in the specific case upon a determination that indemnification is proper in the
circumstances because such person has either met the applicable standard of conduct set forth in this Article and that the amount requested has been actually and reasonably incurred. Such determination shall be made:<B> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">by a majority vote of the directors who are not parties to such action, suit or proceeding, even though less than a quorum; or </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">by a committee of such directors designated by a majority vote of such directors, even though less than a quorum; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">if there are no such directors, or if such directors so direct, by independent legal counsel in a written opinion; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">by the holders of the Common Stock. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C. Advance of Expenses. </B>Notwithstanding any other
provisions of this Certificate of Incorporation, the <FONT STYLE="white-space:nowrap">By-Laws</FONT> of the Corporation, or any agreement, vote of stockholders or disinterested directors, or arrangement to the contrary, the Corporation may advance
payment of expenses incurred by an Indemnitee in advance of the final disposition of any matter only to the extent such advance is not prohibited by applicable law, and then only upon receipt of an undertaking by or on behalf of the Indemnitee to
repay all amounts so advanced in the event that it shall ultimately be determined that the Indemnitee is not entitled to be indemnified by the Corporation as authorized in this Article. Such undertaking may be accepted without reference to the
financial ability of the Indemnitee to make such repayment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>D. Subsequent Amendment. </B>No amendment, termination or repeal of this
Article or of the relevant provisions of the DGCL or any other applicable laws shall affect or diminish in any way the rights of any Indemnitee to indemnification under the provisions hereof with respect to any action, suit, proceeding or
investigation arising out of or relating to any actions, transactions or facts occurring prior to the final adoption of such amendment, termination or repeal. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>E. Other Rights. </B>This corporation may, to the extent authorized from time to time by its Board of Directors, grant indemnification
rights to other employees or agents of the Corporation or other persons serving the Corporation and such rights may be equivalent to, or greater or less than, those set forth in this Article. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>F. Merger or Consolidation. </B>If the Corporation is merged into or consolidated with another corporation and the Corporation is not the
surviving corporation, the surviving corporation shall assume the obligations of the Corporation under this Article with respect to any action, suit, proceeding or investigation arising out of or relating to any actions, transactions or facts
occurring prior to the date of such merger or consolidation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>G. Savings Clause. </B>If this Article or any portion hereof shall be
invalidated on any ground by any court of competent jurisdiction, then the Corporation shall nevertheless indemnify each Indemnitee as to any expenses, including attorneys&#146; fees, judgments, fines and amounts paid in settlement in connection
with any action, suit, proceeding or investigation, whether civil, criminal or administrative, including an action by or in the right of the Corporation, to the fullest extent permitted by any applicable portion of this Article that shall not have
been invalidated and to the fullest extent permitted by applicable law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>H. Scope of Article. </B>Indemnification and advancement of
expenses, as authorized by the preceding provisions of this Article, shall not be deemed exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under any agreement, vote of stockholders or
disinterested directors or otherwise, both as to action in an official capacity and as to action in another capacity while holding such office. The indemnification and advancement of expenses provided by or granted pursuant to this Article shall,
unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be an authorized representative and shall inure to the benefit of the heirs, executors and administrators of such a person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I. Insurance. </B>The Corporation may purchase and maintain insurance on behalf of any person
who is or was a director, officer, trustee, employee or agent of the Corporation, or is or was serving at the request of the Corporation as a director, officer, trustee, employee or agent of another corporation, partnership, joint venture, trust or
other enterprise against any liability asserted against the person and incurred by the person in any such capacity, or arising out of his or her status as such, whether or not the Corporation would have the power or the obligation to indemnify such
person against such liability under the provisions of this Article. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VIII </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporation reserves the right to amend, alter, change or repeal any provision contained in this Certificate of Incorporation, in the
manner now or hereafter prescribed by statute and this Certificate of Incorporation, and all rights conferred upon stockholders herein are granted subject to this reservation. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IX </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Article
is inserted for the management of the business and for the conduct of the affairs of the Corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A. Number of Directors. </B>The
Board of Directors shall consist of one or more members, each of whom shall be a natural person. The exact number of directors within the limitations specified in the preceding sentence shall be fixed from time to time by, or in the manner provided
in, the <FONT STYLE="white-space:nowrap">By-Laws</FONT> of the Corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B. Classes of Directors. </B>The Board of Directors shall
<B></B>b<B></B>e<B> </B>and is divided into three classes: Class&nbsp;I, Class&nbsp;II and Class&nbsp;III. No one class shall have more than one director more than any other class. If a fraction is contained in the quotient arrived at by dividing
the designated number of directors by three, then, if such fraction is <FONT STYLE="white-space:nowrap">one-third,</FONT> the extra director shall be a member of Class&nbsp;III, and if such fraction is
<FONT STYLE="white-space:nowrap">two-thirds,</FONT> one of the extra directors shall be a member of Class&nbsp;III and one of the extra directors shall be a member of Class&nbsp;II, unless otherwise provided from time to time by resolution adopted
by the Board of Directors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C. Election of Directors. </B>Elections of directors need not be by written ballot except as and to the
extent provided in the <FONT STYLE="white-space:nowrap">By-Laws</FONT> of the Corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>D. Terms of Office. </B>Except as provided
in Paragraph G of this Article, each director shall serve for a term ending on the date of the third annual meeting following the annual meeting at which such director was elected; <U>provided</U>, <U>however</U>, that each initial director in
Class&nbsp;I shall serve for a term ending on the date of the annual meeting in 2008; each initial director in Class&nbsp;II shall serve for a term ending on the date of the annual meeting in 2009; and each initial director in Class&nbsp;III shall
serve for a term ending on the date of the annual meeting in 2010; and <U>provided</U>, <U>further</U>, that the term of each director shall be subject to the election and qualification of his successor and to his earlier death, resignation or
removal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 5 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>E. Allocation of Directors Among Classes in the Event of Increases or Decreases in the Number
of Directors. </B>In the event of any increase or decrease in the authorized number of directors, (i) each director then serving as such shall nevertheless continue as a director of the class of which he is a member and (ii)&nbsp;the newly created
or eliminated directorships resulting from such increase or decrease shall be apportioned by the Board of Directors among the three classes of directors so as to ensure that no one class has more than one director more than any other class. To the
extent possible, consistent with the foregoing rule, any newly created directorships shall be added to those classes whose terms of office are to expire at the latest dates following such allocation, and any newly eliminated directorships shall be
subtracted from those classes whose terms of offices are to expire at the earliest dates following such allocation, unless otherwise provided from time to time by resolution adopted by the Board of Directors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>F. </B><B>Removal</B>. The directors of the Corporation may be removed only for cause by the affirmative vote of the holders of at least
seventy five percent (75%) of the outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, cast at a meeting of the stockholders called for that purpose. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>G. Vacancies. </B>Any vacancy in the Board of Directors, however occurring, and any newly created directorship resulting from an enlargement
of the Board, shall be filled only by vote of a majority of the directors then in office, although less than a quorum, or by a sole remaining director. A director elected to fill a vacancy shall be elected for the unexpired term of his predecessor
in office, and a director chosen to fill a position resulting from an increase in the number of directors shall hold office until the next election of the class for which such director shall have been chosen, subject to the election and
qualification of his successor and to his earlier death, resignation or removal. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>H. Stockholder Nominations and Introduction of
Business, Etc. </B>Advance notice of stockholder nominations for election of directors and other business to be brought by stockholders before either an annual or special meeting of stockholders shall be given in the manner provided by the <FONT
STYLE="white-space:nowrap">By-Laws</FONT> of the Corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I. Amendment to Article. </B>Notwithstanding any other provisions of law,
this Certificate of Incorporation or the <FONT STYLE="white-space:nowrap">By-Laws,</FONT> each as amended, and notwithstanding the fact that a lesser percentage may be specified by law, this Certificate of Incorporation or the <FONT
STYLE="white-space:nowrap">By-Laws</FONT> of the Corporation, the affirmative vote of at least seventy five percent (75%) of the outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, voting
together as a single class, shall be required to amend or repeal, or to adopt any provisions inconsistent with the purpose or intent of this Article IX. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE X </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as
otherwise provided in the <FONT STYLE="white-space:nowrap">By-Laws,</FONT> the stockholders of the Corporation and the Board of Directors may hold their meetings and have an office or offices outside of the State of Delaware and, subject to the
provisions of the laws of said State, may keep the books of the corporation outside of said State at such places as may, from time to time, be designated by the Board of Directors or by the <FONT STYLE="white-space:nowrap">By-Laws</FONT> of the
Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 6 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XI </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time during which a class of capital stock of the Corporation is registered under Section&nbsp;12 of the Securities Exchange Act of
1934 or any similar successor statute, stockholders of the Corporation may not take any action by written consent in lieu of a meeting. Notwithstanding any other provisions of law, this Certificate of Incorporation or the <FONT
STYLE="white-space:nowrap">By-Laws,</FONT> each as amended, and notwithstanding the fact that a lesser percentage may be specified by law, this Certificate of Incorporation or the <FONT STYLE="white-space:nowrap">By-Laws</FONT> of the Corporation,
the affirmative vote of at least seventy five percent (75%) of the outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required to amend or
repeal or to adopt any provisions inconsistent with the purpose or intent of this Article XI. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XII </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Special meetings of stockholders may be called at any time only by the Chairman of the Board of Directors, the Chief Executive Officer (or if
there is no Chief Executive Officer, the President) or the Board of Directors. Any business transacted at any special meeting of stockholders shall be limited to matters relating to the purpose or purposes stated in the notice of meeting.
Notwithstanding any other provisions of law, this Certificate of Incorporation or the <FONT STYLE="white-space:nowrap">By-Laws,</FONT> each as amended, and notwithstanding the fact that a lesser percentage may be specified by law, this Certificate
of Incorporation or the <FONT STYLE="white-space:nowrap">By-Laws</FONT> of the Corporation, the affirmative vote of at least seventy five percent (75%) of the outstanding shares of capital stock of the Corporation entitled to vote generally in the
election of directors, voting together as a single class, shall be required to amend or repeal or to adopt any provisions inconsistent with the purpose or intent of this Article XII. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XIII </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
registered office of the corporation in the State of Delaware is Corporation Trust Center, 1209 Orange Street, City of Wilmington, County of New Castle. The name of its registered agent at such office is The Corporation Trust Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 7 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Corporation has caused this Certificate of Incorporation to be signed by
its President and Chief Executive Officer on this 5th day of February, 2008. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">RXI PHARMACEUTICALS CORPORATION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Tod Woolf</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Tod Woolf</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 8 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>State of Delaware</I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Secretary of State</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Division of Corporations</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>Delivered 04:08 PM 07/26/2011</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>FILED 04:08 PM 07/26/2011</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>SRV 110859225 - 4136433 FILE</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AMENDMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESTATED CERTIFICATE
OF INCORPORATION OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RXi PHARMACEUTICALS CORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">RXi Pharmaceuticals Corporation, a Delaware corporation (the &#147;Company&#148;), hereby certifies that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1. The following resolution has been unanimously adopted by the Company&#146;s Board of Directors and has been approved by the holders of a
majority of the Company&#146;s outstanding common stock in accordance with the Delaware General Corporation Law for the purpose of amending the Company&#146;s Restated Certificate of Incorporation: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">RESOLVED, that the Restated Certificate of Incorporation of the Company be amended by deleting in its entirety Article III, Section A, and by
replacing it with the following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;A. Classes of Stock. </B>This Corporation is authorized to issue 130,000,000
shares, of which 125,000,000 shares shall be Common Stock with a par value of $0.0001 per share (&#147;<U>Common Stock</U>&#148;) and 5,000,000 shares will be Preferred Stock with a part value of $0.0001 per share (&#147;<U>Preferred
Stock</U>&#148;).&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2. The above amendment was duly adopted by the Company in accordance with the provisions of Section&nbsp;242 of
the Delaware General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, RXi Pharmaceuticals Corporation has caused this Certificate of Amendment to be
signed by a duly authorized officer this 18<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day of July 2011. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">RXi Pharmaceuticals Corporation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Ahn</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark Ahn</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>State of Delaware</I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Secretary of State</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Division of Corporations</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><I>Delivered 10:28 AM 09/26/2011</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><I>FILED 10:28 AM 09/26/2011</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><I>SRV 111039489 - 4136433 FILE</I></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATE OF OWNERSHIP AND MERGER </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MERGING </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">GALENA BIOPHARMA, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(a Delaware corporation) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">WITH AND INTO </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">RXI PHARMACEUTICALS
CORPORATION </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(a Delaware corporation) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Pursuant to Section&nbsp;253 of the Delaware General Corporation Law) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">RXi Pharmaceuticals Corporation, a Delaware corporation (the &#147;<U>Company</U>&#148;), does hereby certify to the following facts relating
to the merger (the &#147;<U>Merger</U>&#148;) of Galena Biopharma, Inc., a Delaware corporation (the &#147;<U>Subsidiary</U>&#148;), with and into the Company, with the Company remaining as the surviving corporation under the name of &#147;Galena
Biopharma, Inc.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1. The Subsidiary is a corporation incorporated on September&nbsp;8, 2011 under the Delaware General Corporation Law
(the &#147;<U>DGCL</U>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2. The Company is a corporation incorporated on April&nbsp;3, 2006 under the DGCL. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3. The Company is the owner of all of the outstanding shares of the capital stock of the Subsidiary. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4. The Board of Directors of the Company, by resolutions duly adopted at a meeting of the Board of Directors of the Company held on
August&nbsp;23, 2011, determined to merge into itself the Subsidiary, and to effect a change of the Company&#146;s name to &#147;Galena Biopharma, Inc.&#148; in connection with such merger, pursuant to Section&nbsp;253 of the DGCL. Such resolutions
are as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">WHEREAS, in view of the Company&#146;s proposed transfer and contribution to a wholly-owed subsidiary of the Company of
certain RNAi assets and related obligations of RXi Pharmaceuticals Corporation (the &#147;<U>Company</U>&#148;) (the &#147;<U><FONT STYLE="white-space:nowrap">Spin-Off</FONT></U>&#148;), the Company has proposed to change its corporate name so as
not to include the name &#147;RXi&#148; or &#147;RNAi&#148;; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">WHEREAS, after thorough consideration, the Board of Directors believes
it is advisable and in the best interests of the Company and its stockholders to change the name of the Company to Galena Biopharma, Inc. from RXi Pharmaceuticals Corporation (the &#147;<U>Name Change</U>&#148;), and to effect such Name Change
pursuant to the provisions of Section&nbsp;253 of the Delaware General Corporation Law (the &#147;<U>DGCL</U>&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">WHEREAS, in
order to effect the Name Change, the Company desires to form a new corporation named Galena Biopharma, Inc., a Delaware corporation (the &#147;<U>Subsidiary</U>&#148;), and to acquire shares of common stock, par value $0.0001 per share, of the
Subsidiary (collectively, the &#147;<U>Incorporation</U>&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">WHEREAS, following the effectiveness of the Incorporation, the
Company will own all of the outstanding shares of the capital stock of the Subsidiary; and </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">WHEREAS, in order to consummate the Name Change, the Board of Directors of the Company believes
it is advisable and in the best interests of the Company and its stockholders that, following the effectiveness of the Incorporation, the Subsidiary be merged with and into the Company (the &#147;<U>Merger</U>&#148;) pursuant to Section&nbsp;253 of
the DGCL, so that the Company will be the surviving corporation following the Merger and that the Name Change be effected as part of the Merger as permitted under the DGCL; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, BE IT RESOLVED, that the Incorporation is hereby authorized and approved in all respects; and it is </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">RESOLVED FURTHER, that the officers of the Company be and each hereby is authorized, empowered and directed, by and on behalf of the Company
and in its name, to prepare or cause to be prepared, and to execute and file with the Delaware Secretary of State a Certificate of Incorporation to form the Subsidiary, and to take all such other actions as they or any one of them shall deem
necessary or appropriate to consummate the Incorporation; and it is </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">RESOLVED FURTHER, that the Merger and the Name Change are hereby
authorized and approved; and it is </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">RESOLVED FURTHER, that following the Incorporation, the officers of the Company be and each hereby is
authorized, empowered and directed, by and on behalf of the Company and in its name, to effect the Name Change by merging the Subsidiary with and into the Company pursuant to Section&nbsp;253 of the DGCL, so that the Company will be the surviving
corporation and possess all of the Subsidiary&#146;s property, rights, privileges and powers, and assume all of the Subsidiary&#146;s liabilities and obligations; and it is </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">RESOLVED FURTHER, that by virtue of the Merger and without any action on the part of the holder thereof, each then outstanding share of common
stock, par value $0.0001 per share, of the Company (the &#147;<U>Common Stock</U>&#148;) shall remain unchanged and continue to remain outstanding as one share of Common Stock, held by the person who was the holder of such share of Common Stock
immediately prior to the Merger; and it is </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">RESOLVED FURTHER, that by virtue of the Merger and without any action on the part of the
holder thereof, each then outstanding share of common stock, par value $0.0001 per share, of the Subsidiary shall be cancelled and no consideration shall be issued in respect thereof; and it is </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">RESOLVED FURTHER, that the directors and officers of the Company immediately prior to the Merger shall continue to remain the directors and
officers of the Company until the earlier of their death, resignation or removal or until their respective successors are duly elected and qualified, as the case may be; and it is </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">RESOLVED FURTHER, that, pursuant to Section&nbsp;253(b) of the DGCL, upon the effective date of the Merger, the corporate name of the Company
shall be changed to Galena Biopharma, Inc.; and it is </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">RESOLVED FURTHER, that the Certificate of Incorporation of the Company as in effect
immediately prior to the effective time of the Merger shall be the certificate of incorporation of the surviving corporation, except that Article I thereof shall be amended in its entirety to read as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;ARTICLE I </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">The name of this corporation is Galena Biopharma, Inc.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">RESOLVED FURTHER, that the Bylaws of the Company as in effect immediately prior to the effective time of the Merger shall be amended and
restated to reflect the Name Change; and it is </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">RESOLVED FURTHER, that the officers of the Company be and each hereby is authorized,
empowered and directed, in the name and on behalf of the Company, to prepare or cause to be prepared, and to execute and file with the Delaware Secretary of State a Certificate of Ownership and Merger that sets forth therein a copy of these
resolutions and the date that such resolutions were adopted by the Board of Directors; and it is </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">RESOLVED FURTHER, that the officers of
the Company be, and each of them hereby is, authorized, empowered and directed, in the name and on behalf of the Company, to (i)&nbsp;notify the Company&#146;s transfer agent and registrar for the Company&#146;s common stock of the Name Change,
(ii)&nbsp;obtain a new CUSIP number, (iii) prepare and file with the SEC a current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> to disclose the transactions contemplated by the foregoing resolutions, and (iv)&nbsp;execute such
documents, disburse such funds, engage such persons, and take all such other actions that such officer may deem necessary or advisable in connection with the Name Change and the Merger and to carry out the intent and purpose of the foregoing
resolutions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5. The Company shall be the surviving corporation <B></B>of<B> </B>the Merger. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6. The Certificate of Incorporation of the Company as in effect immediately prior to the effective time of the Merger shall be the certificate
of incorporation of the surviving corporation, except that Article I thereof shall be amended in its entirety to read as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;ARTICLE I </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">The name of this corporation is Galena Biopharma, Inc.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7. The Merger shall be effective as of September 26, 2011. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, RXi Pharmaceuticals Corporation has caused this Certificate of Ownership and Merger to be signed by its duly authorized
officer, this 26 day of September 2011. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">RXI PHARMACEUTICALS CORPORATION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark J. Ahn</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark J. Ahn, Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>State of Delaware</I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Secretary of State</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Division of Corporations</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>Delivered 04:59 PM 06/28/2013</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>FILED 04:56 PM 06/28/2013</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>SRV 130832067 - 4136433 FILE</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AMENDMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GALENA BIOPHARMA, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Galena Biopharma, Inc., a Delaware corporation (the &#147;<U>Corporation</U>&#148;), hereby certifies that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1. The following resolution has been unanimously adopted by the Corporation&#146;s Board of Directors and has been approved by the holders of a
majority of the Corporation&#146;s outstanding common stock in accordance with the Delaware General Corporation Law for the purpose of amending the Corporation&#146;s Amended and Restated Certificate of Incorporation: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">RESOLVED, that ARTICLE III, Section A of the Amended and Restated Certificate of Incorporation of the Corporation shall be amended to read in
its entirety as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;A. Classes of Stock. </B>This Corporation is authorized to issue 205,000,000 shares, of
which 200,000,000 shares shall be Common Stock with a par value of $0.0001 per share (&#147;<U>Common Stock</U>&#148;) and 5,000,000 shares shall be Preferred Stock with a par value of $0.0001 per share (&#147;<U>Preferred Stock</U>&#148;).&#148;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2. The above amendment was duly adopted by the Corporation in accordance with the provisions of Section&nbsp;242 of the Delaware General
Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, Galena Biopharma, Inc. has caused this Certificate of Amendment to be signed by a duly authorized
officer this 28<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day of June 2013. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Galena Biopharma, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark J. Ahn</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark J. Ahn, Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>State of Delaware</I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Secretary of State</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Division of Corporations</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>Delivered 11:17 AM 07/22/2013</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>FILED 09:13 AM 07/22/2013</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>SRV 130900861 - 4136433 FILE</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATE OF CHANGE OF LOCATION OF REGISTERED OFFICE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AND OF REGISTERED AGENT </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OF </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GALENA BIOPHARMA, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is hereby
certified that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1. The name of the corporation (hereinafter called the &#147;corporation&#148;) is: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GALENA BIOPHARMA, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2. The registered office of the corporation within the State of Delaware is hereby changed to 2711 Centerville Road, Suite 400, City of
Wilmington 19808, County of New Castle. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3. The registered agent of the corporation within the State of Delaware is hereby changed to
Corporation Service Company, the business office of which is identical with the registered office of the corporation as hereby changed. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4. The corporation has authorized the changes hereinbefore set forth by resolution of its Board of Directors. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Signed:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Galena Biopharma,
Inc.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark W. Schwartz</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Mark W. Schwartz, Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Executive Vice President&nbsp;&amp; COO</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>State of Delaware</I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Secretary of State</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Division of Corporations</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>Delivered 02:36 PM 06/19/2015</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>FILED 02:23 PM 06/19/2015</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>SRV 150947213 - 4136433 FILE</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AMENDMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GALENA BIOPHARMA, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Galena Biopharma, Inc., a Delaware corporation (the &#147;Corporation&#148;), hereby certifies that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The following resolution has been unanimously adopted by the Corporation&#146;s Board of Directors and has been approved by the holders of a
majority of the Corporation&#146;s outstanding common stock in accordance with the Delaware General Corporation Law for the purpose of amending the Corporation&#146;s Amended and Restated Certificate of Incorporation: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">RESOLVED, that ARTICLE III, Section A of the Amended and Restated Certificate of Incorporation of the Corporation shall be amended to read in
its entirety as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;A. Classes of Stock. </B>This Corporation is authorized to issue 280,000,000 shares, of
which 275,000,000 shares shall be Common Stock with a par value of $0.0001 per share (&#147;Common Stock&#148;) and 5,000,000 shares shall be Preferred Stock with a par value of $0.0001 per share (&#147;Preferred Stock&#148;).&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. The above amendment was duly adopted by the Corporation in accordance with the provisions of Section&nbsp;242 of the Delaware General
Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, Galena Biopharma, Inc. has caused this Certificate of Amendment to be signed by a duly authorized
officer this 19<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day of June 2015. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Galena Biopharma, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark W. Schwartz</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark W. Schwartz, Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">State of Delaware</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Secretary of State</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Division of
Corporations</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Delivered 10:00 AM 10/17/2016</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FILED 10:00 AM 10/17/2016</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">SR 20166250740 - File Number 4136433</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STATE OF DELAWARE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AMENDMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF CERTIFICATE OF INCORPORATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Galena
Biopharma, Inc., organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FIRST</B>:
That at a meeting of the Board of Directors of Galena Biopharma, Inc. resolutions were duly adopted setting forth a proposed amendment of the Certificate of Incorporation of said corporation, declaring said amendment to be advisable and calling a
meeting of the stockholders of said corporation for consideration thereof. The resolution setting forth the proposed amendment is as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RESOLVED, </B>that the Certificate of Incorporation of this corporation be amended by changing the Article thereof numbered &#147;Section (A)&nbsp;of
Article III&#148; so that, as amended, said Article shall be and read as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A. Classes of Stock. </B>This Corporation is authorized to issue
355,000,000 shares, of which 350,000,000 shares shall be Common Stock with a par value of $0.0001 per share (&#147;Common Stock&#148;) and 5,000,000 shares shall be Preferred Stock with a par value of $0.0001 per share (&#147;Preferred Stock&#148;).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECOND</B>: That thereafter, pursuant to resolution of its Board of Directors, at the annual meeting of the stockholders of said corporation duly
called and held upon notice in accordance with Section&nbsp;222 of the General Corporation Law of the State of Delaware at which meeting the necessary number of shares as required by statute were voted in favor of the amendment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIRD: </B>That said amendment was duly adopted in accordance with the provisions of Section&nbsp;242 of the General Corporation Law of the State of
Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, said corporation has caused this certificate to be signed this
14<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day of September 2016. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Thomas J. Knapp</P></TD></TR></TABLE></DIV>
<DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Authorized Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Corporate Secretary</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Thomas J. Knapp</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">State of Delaware</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Secretary of State</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Division of Corporations</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Delivered 10:00 AM 11/02/2016</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">FILED 10:00 AM 11/02/2016</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">SR 20166468004 - File Number 4136433</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STATE OF DELAWARE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AMENDMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF CERTIFICATE OF INCORPORATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Galena
Biopharma, Inc., organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FIRST</B>:
That at a meeting of the Board of Directors of Galena Biopharma, Inc., resolutions were duly adopted setting forth an amendment of the Certificate of Incorporation of said corporation, declaring said amendment to be effective based on the vote of
stockholders at a special meeting of the stockholders of said corporation. The resolution setting forth the amendment is as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RESOLVED,
</B>that the Certificate of Incorporation of this corporation be amended by changing the Article thereof numbered &#147;Section (A)&nbsp;of Article III&#148; so that, as amended and restated, said Article shall be and read as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;A. Classes of Stock. This Corporation is authorized to issue 355,000,000 shares, of which 350,000,000 shall be Common Stock with a par value of $0.0001
per share (the &#147;Common Stock&#148;) and 5,000,000 shares shall be Preferred Stock with a par value of $0.0001 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Reverse Stock Split</U>.
Effective at 12:01 a.m., Eastern Standard Time on November&nbsp;11, 2016 (the &#147;Effective Time&#148;), each 20 shares of common stock issued and outstanding or held by the Corporation in treasury immediately prior to the Effective Time (the
&#147;Old Common Stock&#148;) shall automatically without further action on the part of the Corporation or any holder of Old Common Stock, be reclassified, combined and changed into one fully paid and nonassessable share of new common stock (the
&#147;New Common Stock&#148;). There shall be no fractional shares issued with respect to the New Common Stock. In lieu thereof, the aggregate of all fractional shares otherwise issuable to the holders of record of Old Common Stock shall be issued
to Computershare (the &#147;Transfer Agent&#148;), as agent, for the accounts of all holders of record of Old Common Stock otherwise entitled to have a fraction of a share issued to them. The sale of all fractional interests will be effected by the
Transfer Agent as soon as practicable after the Effective Time on the basis of prevailing market prices of the New Common Stock at the time of sale. After such sale and upon the surrender of the stockholders&#146; stock certificates, the Transfer
Agent will pay to such holders of record their pro rata share of the net proceeds derived from the sale of the fractional interests. From and after the Effective Time, certificates representing the Old Common Stock shall represent the number of
whole shares of New Common Stock into which such Old Common Stock shall have been reclassified, combined and changed pursuant to this Certificate of Amendment, subject to the elimination of fractional share interests as described above.&#148; </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECOND</B>: That pursuant to resolution of its Board of Directors, at the special meeting of the stockholders
of said corporation duly called and held upon notice in accordance with Section&nbsp;222 of the General Corporation Law of the State of Delaware at which meeting the necessary number of shares as required by statute were voted in favor of the
amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIRD</B>: That said amendment was duly adopted in accordance with the provisions of Section&nbsp;242 of the General Corporation Law of the
State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, said corporation has caused this certificate to be signed this 1<SUP
STYLE="font-size:85%; vertical-align:top">st</SUP> day of November 2016. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Thomas J. Knapp</P></TD></TR></TABLE></DIV>
<DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Authorized Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Corporate Secretary</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Thomas J. Knapp</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">State of Delaware</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Secretary of State</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Division of
Corporations</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Delivered 01:43 PM 07/06/2017</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FILED 01:43 PM 07/06/2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">SR 20175230494 - File Number 4136433</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF VALIDATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GALENA BIOPHARMA,
INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Pursuant to Section&nbsp;204 of the </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>General Corporation Law of the State of Delaware </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Galena Biopharma, Inc., a corporation organized and existing under the laws of the State of Delaware (the &#147;Corporation&#148;), certifies
as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The defective corporate acts that are the subject of this Certificate of Validation are the filing and effectiveness of the
Certificate of Amendment of the Certificate of Incorporation of the Corporation (the &#147;Certificate of Amendment&#148;) on July&nbsp;26, 2011 and the increase in the authorized number of shares of common stock, par value $0.0001 per share, of the
Corporation effected thereby. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. The nature of the failure of authorization in respect of the filing and effectiveness of the Certificate
of Amendment and such increase was that the vote of the Corporation&#146;s stockholders in favor of the proposal to adopt the amendment set forth in the Certificate of Amendment may not have been tabulated in conformity with the disclosure set forth
in the proxy statement for the meeting of stockholders at which it was approved. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. The defective corporate acts that are the subject of
this Certificate of Validation were duly ratified in accordance with Section&nbsp;204 of General Corporation Law of the State of Delaware (the &#147;DGCL&#148;) pursuant to resolutions of the Board of Directors of the Corporation adopted on
May&nbsp;30, 2017 and resolutions of the stockholders of the Corporation adopted on July 6, 2017. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. The Certificate of Amendment was
previously filed under Section&nbsp;103 of the DGCL in respect of the defective corporate acts that are the subject of this Certificate of Validation on July&nbsp;26, 2011. A copy of the Certificate of Amendment is attached as <U>Exhibit A</U> to
this Certificate of Validation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page Follows</I>] </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Corporation has caused this Certificate of Validation to be executed by
its duly authorized officer as of this 6th day of July, 2017. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>GALENA BIOPHARMA, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Thomas J. Knapp</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Thomas J. Knapp</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Corporate Secretary</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">State of Delaware</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Secretary of State</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Division of Corporations</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Delivered 04:08 PM 07/26/2011</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">FILED 04:08 PM 07/26/2011</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">SRV 110859225 &#150; 4136433 FILE</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AMENDMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESTATED CERTIFICATE
OF INCORPORATION OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RXi PHARMACEUTICALS CORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">RXi Pharmaceuticals Corporation, a Delaware corporation (the &#147;Company&#148;), hereby certifies that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The following resolution has been unanimously adopted by the Company&#146;s Board of Directors and has been approved by the holders of a
majority of the Company&#146;s outstanding common stock in accordance with the Delaware General Corporation Law for the purpose of amending the Company&#146;s Restated Certificate of Incorporation: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">RESOLVED, that the Restated Certificate of Incorporation of the Company be amended by deleting in its entirety Article III, Section A, and by
replacing it with the following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>A. Classes of Stock</B>. This Corporation is authorized to issue 130,000,000
shares, of which 125,000,000 shares shall be Common Stock with a par value of $0.0001 per share (&#147;<U>Common Stock</U>&#148;) and 5,000,000 shares will be Preferred Stock with a part value of $0.0001 per share (&#147;<U>Preferred
Stock</U>&#148;).&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. The above amendment was duly adopted by the Company in accordance with the provisions of Section&nbsp;242 of
the Delaware General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, RXi Pharmaceuticals Corporation has caused this Certificate of Amendment to be
signed by a duly authorized officer this 18<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day of July 2011. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">RXi Pharmaceuticals Corporation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Ahn</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark Ahn</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">State of Delaware</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Secretary of State</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Division of
Corporations</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Delivered 01:44 PM 07/06/2017</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FILED 01:44 PM 07/06/2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">SR 20175230569 - File Number 4136433</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF VALIDATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GALENA BIOPHARMA,
INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Pursuant to Section&nbsp;204 of the </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>General Corporation Law of the State of Delaware </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Galena Biopharma, Inc., a corporation organized and existing under the laws of the State of Delaware (the &#147;Corporation&#148;), certifies
as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The defective corporate acts that are the subject of this Certificate of Validation are the filing and effectiveness of the
Certificate of Amendment of the Certificate of Incorporation of the Corporation (the &#147;Certificate of Amendment&#148;) on June&nbsp;28, 2013 and the increase in the authorized number of shares of common stock, par value $0.0001 per share, of the
Corporation effected thereby. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. The nature of the failure of authorization in respect of the filing and effectiveness of the Certificate
of Amendment and such increase was that the vote of the Corporation&#146;s stockholders in favor of the proposal to adopt the amendment set forth in the Certificate of Amendment may not have been tabulated in conformity with the disclosure set forth
in the proxy statement for the meeting of stockholders at which it was approved. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. The defective corporate acts that are the subject of
this Certificate of Validation were duly ratified in accordance with Section&nbsp;204 of General Corporation Law of the State of Delaware (the &#147;DGCL&#148;) pursuant to resolutions of the Board of Directors of the Corporation adopted on
May&nbsp;30, 2017 and resolutions of the stockholders of the Corporation adopted on July 6, 2017. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. The Certificate of Amendment was
previously filed under Section&nbsp;103 of the DGCL in respect of the defective corporate acts that are the subject of this Certificate of Validation on June&nbsp;28, 2013. A copy of the Certificate of Amendment is attached as <U>Exhibit A</U> to
this Certificate of Validation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page Follows</I>] </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Corporation has caused this Certificate of Validation to be executed by
its duly authorized officer as of this 6th day of July, 2017. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>GALENA&nbsp;BIOPHARMA,&nbsp;INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Thomas J. Knapp</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Thomas J. Knapp</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Corporate Secretary</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>State of Delaware</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>Secretary of State</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>Division of Corporations</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>Delivered 04:59 PM 06/28/2013</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>FILED 04:56 PM 06/28/2013</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>SRV 130832067 &#150; 4136433 FILE</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AMENDMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GALENA BIOPHARMA, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Galena Biopharma, Inc., a Delaware corporation (the &#147;<U>Corporation</U>&#148;), hereby certifies that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The following resolution has been unanimously adopted by the Corporation&#146;s Board of Directors and has been approved by the holders of a
majority of the Corporation&#146;s outstanding common stock in accordance with the Delaware General Corporation Law for the purpose of amending the Corporation&#146;s Amended and Restated Certificate of Incorporation: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">RESOLVED, that ARTICLE III. Section A of the Amended and Restated Certificate of Incorporation of the Corporation shall be amended to read in
its entirety as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;A. Classes of Stock. </B>This Corporation is authorized to issue 205,000,000 shares, of
which 200,000,000 shares shall be Common Stock with a par value of $0.0001 per share (<U>&#147;Common Stock</U>&#148;) and 5,000,000 shares shall be Preferred Stock with a par value of $0.0001 per share (&#147;<U>Preferred Stock</U>&#148;).&#148;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. The above amendment was duly adopted by the Corporation in accordance with the provisions of Section&nbsp;242 of the Delaware General
Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, Galena Biopharma, Inc. has caused this Certificate of Amendment to be signed by a duly authorized
officer this 28<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day of June 2013. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Galena&nbsp;Biopharma, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark J. Ahn</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark J. Ahn, Ph. D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>State of Delaware</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>Secretary of State</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>Division of Corporations</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>Delivered 01:45 PM 07/06/2017</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>FILED 01:45 PM 07/06/2017</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>SR 20175230621 &#150; File Number 4136433</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF VALIDATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GALENA BIOPHARMA,
INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Pursuant to Section&nbsp;204 of the </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>General Corporation Law of the State of Delaware </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Galena Biopharma, Inc., a corporation organized and existing under the laws of the State of Delaware (the &#147;Corporation&#148;), certifies
as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The defective corporate acts that are the subject of this Certificate of Validation are the filing and effectiveness of the
Certificate of Amendment of the Certificate of Incorporation of the Corporation (the &#147;Certificate of Amendment&#148;) on June&nbsp;19, 2015 and the increase in the authorized number of shares of common stock, par value $0.0001 per share, of the
Corporation effected thereby. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. The nature of the failure of authorization in respect of the filing and effectiveness of the Certificate
of Amendment and such increase was that the vote of the Corporation&#146;s stockholders in favor of the proposal to adopt the amendment set forth in the Certificate of Amendment may not have been tabulated in conformity with the disclosure set forth
in the proxy statement for the meeting of stockholders at which it was approved. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. The defective corporate acts that are the subject of
this Certificate of Validation were duly ratified in accordance with Section&nbsp;204 of General Corporation Law of the State of Delaware (the &#147;DGCL&#148;) pursuant to resolutions of the Board of Directors of the Corporation adopted on
May&nbsp;30, 2017 and resolutions of the stockholders of the Corporation adopted on July&nbsp;6, 2017. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. The Certificate of Amendment was
previously filed under Section&nbsp;103 of the DGCL in respect of the defective corporate acts that were the subject of this Certificate of Validation on June&nbsp;19, 2015. A copy of the Certificate of Amendment is attached as <U>Exhibit&nbsp;A</U>
to this Certificate of Validation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page Follows</I>] </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Corporation has caused this Certificate of Validation to be executed by
its duly authorized officer as of this 6th day of July, 2017. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>GALENA&nbsp;BIOPHARMA,&nbsp;INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Thomas J. Knapp</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Thomas J. Knapp</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Corporate Secretary</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>State of Delaware</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Secretary of State</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>Division of Corporations</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>Delivered 02:36 PM 06/19/2015</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>FILED 02:23 PM 06/19/2015</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>SRV 150947213 &#150; 4136433 FILE</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AMENDMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GALENA BIOPHARMA, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Galena Biopharma, Inc., a Delaware corporation (the &#147;Corporation&#148;), hereby certifies that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The following resolution has been unanimously adopted by the Corporation&#146;s Board of Directors and has been approved by the holders of a
majority of the Corporation&#146;s outstanding common stock in accordance with the Delaware General Corporation Law for the purpose of amending the Corporation&#146;s Amended and Restated Certificate of Incorporation: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">RESOLVED, that ARTICLE III, Section A of the Amended and Restated Certificate of Incorporation of the Corporation shall be amended to read in
its entirety as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;A. Classes of Stock.</B> This Corporation is authorized to issue 280,000,000 shares, of
which 275,000,000 shares shall be Common Stock with a par value of $0.0001 per share (&#147;Common Stock&#148;) and 5,000,000 shares shall be Preferred Stock with a par value of $0.0001 per share (&#147;Preferred Stock&#148;).&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. The above amendment was duly adopted by the Corporation in accordance with the provisions of Section&nbsp;242 of the Delaware General
Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, Galena Biopharma, Inc. has caused this Certificate of Amendment to be signed by a duly authorized
officer this 19<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day of June 2015. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Galena&nbsp;Biopharma,&nbsp;Inc.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark W. Schwartz</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark W. Schwartz, Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">State of Delaware</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Secretary of State</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Division of
Corporations</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Delivered 01:46 PM 07/06/2017</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FILED 01:46 PM 07/06/2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">SR 20175230694 - File Number 4136433</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF VALIDATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GALENA BIOPHARMA,
INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Pursuant to Section&nbsp;204 of the </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>General Corporation Law of the State of Delaware</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Galena Biopharma, Inc., a corporation organized and existing under the laws of the State of Delaware (the &#147;Corporation&#148;), certifies
as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The defective corporate acts that are the subject of this Certificate of Validation are the filing and effectiveness of the
Certificate of Amendment of the Certificate of Incorporation of the Corporation (the &#147;Certificate of Amendment&#148;) on October&nbsp;17, 2016 and the increase in the authorized number of shares <B></B>of <B></B>common stock, par value $0.0001
per share, of the Corporation effected thereby. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. The nature of the failure of authorization in respect of the filing and effectiveness
of the Certificate of Amendment and such increase was that the vote of the Corporation&#146;s stockholders in favor of the proposal to adopt the amendment set forth in the Certificate of Amendment may not have been tabulated in conformity with the
disclosure set forth in the proxy statement for the meeting of stockholders at which it was approved. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. The defective corporate acts that
are the subject of this Certificate of Validation were duly ratified in accordance with Section&nbsp;204 <B></B>of<B> </B>General Corporation Law of the State of Delaware (the &#147;DGCL&#148;) pursuant to resolutions of the Board of Directors of
the Corporation adopted on May&nbsp;30, 2017 and resolutions of the stockholders of the Corporation adopted on July 6, 2017. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. The
Certificate of Amendment was previously filed under Section&nbsp;103 of the DGCL in respect of the defective corporate acts that are the subject of this Certificate of Validation on October&nbsp;17, 2016. A copy of the Certificate of Amendment is
attached as <U>Exhibit A</U> to this Certificate of Validation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page Follows</I>] </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Corporation has caused this Certificate of Validation to be executed by
its duly authorized officer as of this 6th day of July, 2017. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>GALENA BIOPHARMA, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Thomas J. Knapp</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Thomas J. Knapp</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Corporate Secretary</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">State of Delaware</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Secretary of State</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Division of Corporations</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Delivered 10:00 AM 10/17/2016</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">FILED 10:00 AM 10/17/2016</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">SR 20166250740 - File Number 4136433</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STATE OF DELAWARE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AMENDMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Galena Biopharma, Inc., organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby
certify: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>FIRST</B>: That at a meeting of the Board of Directors of Galena Biopharma, Inc. resolutions were duly adopted setting forth
a proposed amendment of the Certificate of Incorporation of said corporation, declaring said amendment to be advisable and calling a meeting of the stockholders of said corporation for consideration thereof. The resolution setting forth the proposed
amendment is as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>RESOLVED</B>, that the Certificate of Incorporation of this corporation be amended by changing the Article
thereof numbered &#147;Section (A)&nbsp;of Article III&#148; so that, as amended, said Article shall be and read as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>A.
Classes of Stock</B>. This Corporation is authorized to issue 355,000,000 shares, of which 350,000,000 shares shall be Common Stock with a par value of $0.0001 per share (&#147;Common Stock&#148;) and 5,000,000 shares shall be Preferred Stock with a
par value of $0.0001 per share (&#147;Preferred Stock&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECOND</B>: That thereafter, pursuant to resolution of its Board of
Directors, at the annual meeting of the stockholders of said corporation duly called and held upon notice in accordance with Section&nbsp;222 of the General Corporation Law of the State of Delaware at which meeting the necessary number of shares as
required by statute were voted in favor of the amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>THIRD</B>: That said amendment was duly adopted in accordance with the
provisions of Section&nbsp;242 of the General Corporation Law of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, said corporation has
caused this certificate to be signed this 14<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day of September 2016. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Thomas J. Knapp</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Authorized Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Corporate Secretary</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Thomas J. Knapp</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">State of Delaware</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Secretary of State</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Division of
Corporations</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Delivered 01:47 PM 07/06/2017</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FILED 01:47 PM 07/06/2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">SR 20175230716 - File Number 4136433</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF VALIDATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GALENA BIOPHARMA,
INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Pursuant to Section&nbsp;204 of the </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>General Corporation Law of the State of Delaware </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Galena Biopharma, Inc., a corporation organized and existing under the laws of the State of Delaware (the &#147;Corporation&#148;), certifies
as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The defective corporate acts that are the subject of this Certificate of Validation are the filing and effectiveness of the
Certificate of Amendment of the Certificate of Incorporation of the Corporation (the &#147;Certificate of Amendment&#148;) on November&nbsp;2, 2016 and the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-20</FONT></FONT>
reverse stock split of the common stock, par value $0.0001 per share, of the Corporation effected thereby. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. The nature of the failure of
authorization in respect of the filing and effectiveness of the Certificate of Amendment and such reverse stock split was that the vote of the Corporation&#146;s stockholders in favor of the proposal to adopt the amendment set forth in the
Certificate of Amendment may not have been tabulated in conformity with the disclosure set forth in the proxy statement for the meeting of stockholders at which it was approved, and that the amendment set forth in the Certificate of Amendment
differed from the form of amendment set forth in the proxy statement for the meeting of stockholders at which it was approved and may not have been approved in accordance with Section&nbsp;242 of the General Corporation Law of the State of Delaware
(the &#147;DGCL&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. The defective corporate acts that are the subject of this Certificate of Validation were duly ratified in
accordance with Section&nbsp;204 of the DGCL pursuant to resolutions of the Board of Directors of the Corporation adopted on May&nbsp;30, 2017 and resolutions of the stockholders of the Corporation adopted on July&nbsp;6, 2017. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. The Certificate of Amendment was previously filed under Section&nbsp;103 of the DGCL in respect of the defective corporate acts that are the
subject of this Certificate of Validation on November 2, 2016. A copy of the Certificate of Amendment is attached as <U>Exhibit A</U> to this Certificate of Validation. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page Follows</I>] </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Corporation has caused this Certificate of Validation to be executed by
its duly authorized officer as of this 6th day of July, 2017. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>GALENA BIOPHARMA, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Thomas J. Knapp</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Thomas J. Knapp</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Corporate Secretary</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">State of Delaware</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Secretary of State</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Division of Corporations</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Delivered 10:00 AM 11/02/2016</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">FILED 10:00 AM 11/02/2016</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">SR 20166468004 - File Number 4136433</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STATE OF DELAWARE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AMENDMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Galena Biopharma, Inc., organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby
certify: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>FIRST:</B> That at a meeting of the Board of Directors of Galena Biopharma, Inc., resolutions were duly adopted setting forth
an amendment of the Certificate of Incorporation of said corporation, declaring said amendment to be effective based on the vote of stockholders at a special meeting of the stockholders of said corporation. The resolution setting forth the amendment
is as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>RESOLVED,</B> that the Certificate of Incorporation of this corporation be amended by changing the Article thereof
numbered &#147;Section (A)&nbsp;of Article III&#148; so that, as amended and restated, said Article shall be and read as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;A.
Classes of Stock. This Corporation is authorized to issue 355,000,000 shares, of which 350,000,000 shall be Common Stock with a par value of $0.0001 per share (the &#147;Common Stock&#148;) and 5,000,000 shares shall be Preferred Stock with a par
value of $0.0001 per share. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Reverse Stock Split</U>. Effective at 12:01 a.m., Eastern Standard Time on November 11, 2016 (the
&#147;Effective Time&#148;), each 20 shares of common stock issued and outstanding or held by the Corporation in treasury immediately prior to the Effective Time (the &#147;Old Common Stock&#148;) shall automatically without further action on the
part of the Corporation or any holder of Old Common Stock, be reclassified, combined and changed into one fully paid and nonassessable share of new common stock (the &#147;New Common Stock&#148;). There shall be no fractional shares issued with
respect to the New Common Stock. In lieu thereof, the aggregate of all fractional shares otherwise issuable to the holders of record of Old Common Stock shall be issued to Computershare (the &#147;Transfer Agent&#148;), as agent, for the accounts of
all holders of record of Old Common Stock otherwise entitled to have a fraction of a share issued to them. The sale of all fractional interests will be effected by the Transfer Agent as soon as practicable after the Effective Time on the basis of
prevailing market prices of the New Common Stock at the time of sale. After such sale and upon the surrender of the stockholders&#146; stock certificates, the Transfer Agent will pay to such holders of record their pro rata share of the net proceeds
derived from the sale of the fractional interests. From and after the Effective Time, certificates representing the Old Common Stock shall represent the number of whole shares of New Common Stock into which such Old Common Stock shall have been
reclassified, combined and changed pursuant to this Certificate of Amendment, subject to the elimination of fractional share interests as described above.&#148; </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>SECOND:</B> That pursuant to resolution of its Board of Directors, at the special meeting of
the stockholders of said corporation duly called and held upon notice in accordance with Section&nbsp;222 of the General Corporation Law of the State of Delaware at which meeting the necessary number of shares as required by statute were voted in
favor of the amendment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>THIRD:</B> That said amendment was duly adopted in accordance with the provisions of Section&nbsp;242 of the
General Corporation Law of the State of Delaware. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, said corporation has caused this certificate to be signed
this 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> day of November 2016. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Thomas J. Knapp</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Authorized Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Corporate Secretary</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Thomas J. Knapp</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">State of Delaware</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Secretary of State</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Division of Corporations</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Delivered 09:30 AM 12/29/2017</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">FILED 09:30 AM 12/29/2017</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">SR 20177841406 - File Number 4136433</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AMENDMENT OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GALENA BIOPHARMA,
INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Pursuant to Sections 242 of the </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>General Corporation Law of the State of Delaware) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Galena Biopharma, Inc., organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the &#147;Corporation&#148;), does
hereby certify: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FIRST: </B>That Section (A)&nbsp;of Article III of the Amended and Restated Certificate of Incorporation of the Corporation, as
heretofore amended, be, and hereby is, amended in its entirety to read as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>A. Classes of Stock. </B>This Corporation is
authorized to issue 355,000,000 shares, of which 350,000,000 shall be Common Stock with a par value of $0.0001 per share (&#147;Common Stock&#148;) and 5,000,000 shares shall be Preferred Stock with a par value of $0.0001 per share
(&#147;<B>Preferred Stock</B>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Reverse Stock Split</U>. Upon the effectiveness of the filing of this Certificate of Amendment
(the &#147;Effective Time&#148;), each 10 to 30 shares of common stock issued and outstanding or held by the Corporation in treasury immediately prior to the Effective Time (the &#147;Old Common Stock&#148;) shall automatically be reclassified into
one fully paid and nonassessable share of new common stock (the &#147;New Common Stock&#148;), with the exact ratio within such range to be determined by the board of directors of the Corporation prior to the Effective Time and set forth in a public
announcement made by the Corporation (the &#147;Reverse Stock Split&#148;). No fractional shares of New Common Stock shall be issued in connection with the Reverse Stock Split. In lieu of any fractional shares of New Common Stock that would be
issued in connection with the Reverse Stock Split, the aggregate of all such fractional shares otherwise issuable to the holders of record of Old Common Stock shall be issued to Computershare Trust Company, N.A. (the &#147;Transfer Agent&#148;), as
agent, for the accounts of all holders of record of Old Common Stock otherwise entitled to have a fraction of a share issued to them. The sale of all such fractional shares will be effected by the Transfer Agent as soon as practicable after the
Effective Time on the basis of prevailing market prices of the New Common Stock at the time of sale. After such sale and upon the surrender of the stockholders&#146; stock certificates, the Transfer Agent will pay to such holders of record the
portion of the net proceeds derived from the sale of the fractional interests to which they are entitled. From and after the Effective Time, certificates </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
representing shares of the Old Common Stock shall represent the number of whole shares of New Common Stock into which such shares of Old Common Stock shall have been reclassified pursuant to this
Certificate of Amendment, subject to the elimination of fractional share interests as described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECOND:</B> That pursuant to resolution of its
Board of Directors, at the special meeting of the stockholders of said corporation duly called and held upon notice in accordance with Section&nbsp;222 of the General Corporation Law of the State of Delaware at which meeting the necessary number of
shares as required by statute were voted in favor of the amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIRD:</B> That said amendment was duly adopted in accordance with the provisions
of Section 242 of the General Corporation Law of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FOURTH:</B> That said amendment shall become effective at 4:15 p.m. (Eastern
Time) on December&nbsp;29, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, said corporation has caused this certificate to be signed this 29 day of December 2017. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Thomas J. Knapp</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Authorized Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Interim General Counsel &amp; Corporate Secretary</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Thomas J. Knapp</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Certificate of Amendment of </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Amended and Restated Certificate of Incorporation (Reverse Stock Split)] </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">State of Delaware</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Secretary of State</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Division of Corporations</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Delivered 11:00 AM 12/29/2017</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">FILED 11:00 AM 12/29/2017</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">SR 20177844707 - File Number 4136433</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AMENDMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GALENA BIOPHARMA, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Pursuant to Sections 242 of the </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>General Corporation Law of the State of Delaware) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Galena Biopharma, Inc., organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the &#147;Corporation&#148;), does
hereby certify: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FIRST: </B>That Article I of the Amended and Restated Certificate of Incorporation of the Corporation, as heretofore amended, be, and
hereby is, amended in its entirety to read as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE I </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The name of this corporation is &#147;SELLAS Life Sciences Group, Inc.&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECOND: </B>That said amendment was duly adopted in accordance with the provisions of Section&nbsp;242 of the General Corporation Law of the State of
Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIRD: </B>That said amendment shall become effective at 4:45 p.m. (Eastern Time) on December&nbsp;29, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF, </B>said corporation has caused this certificate to be signed this 29th day of December 2017. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Thomas J. Knapp</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Authorized Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Interim General Counsel&nbsp;&amp; Corporate Secretary</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Thomas J. Knapp</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">State of Delaware</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Secretary of State</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Division of
Corporations</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Delivered 04:26 PM 03/08/2018</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FILED 04:26 PM 03/08/2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">SR 20181800105 - File Number 4136433</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF DESIGNATION OF PREFERENCES, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RIGHTS AND LIMITATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SERIES A 20%
CONVERTIBLE PREFERRED STOCK </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PURSUANT TO SECTION 151 OF THE </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">GENERAL CORPORATION LAW OF THE STATE OF DELAWARE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SELLAS Life Sciences Group, Inc., a Delaware corporation (the &#147;<U>Corporation</U>&#148;), does hereby certify that, pursuant to
Section&nbsp;151 of the General Corporation Law of the State of Delaware, the following resolution was duly adopted by the board of directors of the Corporation (the &#147;<U>Board of Directors</U>&#148;): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the certificate of incorporation of the Corporation provides for a class of its authorized stock known as preferred stock, consisting
of 5,000,000 shares, $0.0001 par value per share, issuable from time to time in one or more series; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Board of Directors is
authorized to fix the dividend rights, dividend rate, voting rights, conversion rights, rights and terms of redemption and liquidation preferences of any wholly unissued series of preferred stock and the number of shares constituting any series and
the designation thereof, of any of them; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, it is the desire of the Board of Directors, pursuant to its authority as aforesaid,
to fix the rights, preferences, restrictions and other matters relating to a series of the preferred stock, which shall consist of, except as otherwise set forth in the Purchase Agreement, up to 17,500 shares of the preferred stock which the
Corporation has the authority to issue, as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, BE IT RESOLVED, that the Board of Directors does hereby provide for
the issuance of a series of preferred stock for cash or exchange of other securities, rights or property and does hereby fix and determine the rights, preferences, restrictions and other matters relating to such series of preferred stock as follows:
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERMS OF PREFERRED STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;1</U>. <U>Definitions</U>. For the purposes hereof, the following terms shall have the following
meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Affiliate</U>&#148; means any Person that, directly or indirectly through one or more intermediaries,
controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 of the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Alternate Consideration</U>&#148; shall have the meaning set forth in Section&nbsp;7(e). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Base Conversion Price</U>&#148; shall have the meaning set forth in Section&nbsp;7(b). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Beneficial Ownership Limitation</U>&#148; shall have the meaning set forth in Section 6(d). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Business Day</U>&#148; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the
United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">Buy-In</FONT></U>&#148; shall have the meaning set forth in Section&nbsp;6(c)(iv).
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Change of Control Transaction</U>&#148; means the occurrence after the Original Issue Date of any of (a)&nbsp;an
acquisition by an individual or legal entity or &#147;group&#148; (as described in Rule <FONT STYLE="white-space:nowrap">13d-5(b)(l)</FONT> promulgated under the Exchange Act) of effective control (whether through legal or beneficial ownership of
capital stock of the Corporation, by contract or otherwise) of in excess of 33% of the voting securities of the Corporation (other than by means of conversion or exercise of Preferred Stock and the Securities issued together with the Preferred
Stock), (b) the Corporation merges into or consolidates with any other Person, or any Person merges into or consolidates with the Corporation and, after giving effect to such transaction, the stockholders of the Corporation immediately prior to such
transaction own less than 66% of the aggregate voting power of the Corporation or the successor entity of such transaction, (c)&nbsp;the Corporation sells or transfers all or substantially all of its assets to another Person and the stockholders of
the Corporation immediately prior to such transaction own less than 66% of the aggregate voting power of the acquiring entity immediately after the transaction, (d)&nbsp;a replacement at one time or within a one year period of more than <FONT
STYLE="white-space:nowrap">one-half</FONT> of the members of the Board of Directors which is not approved by a majority of those individuals who are members of the Board of Directors on the Original Issue Date (or by those individuals who are
serving as members of the Board of Directors on any date whose nomination to the Board of Directors was approved by a majority of the members of the Board of Directors who are members on the Original Issue Date), or (e)&nbsp;the execution by the
Corporation of an agreement to which the Corporation is a party or by which it is bound, providing for any of the events set forth in clauses (a)&nbsp;through (d) above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closings</U>&#148; means the First Closing and the Second Closing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closing Date</U>&#148; means either the First Closing Date or the Second Closing Date, as the case may be. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Commission</U>&#148; means the United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Common Stock</U>&#148; means the Corporation&#146;s common stock, par value $0.0001 per share, and any other class of
securities into which such securities may hereafter be reclassified or changed. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Common Stock
Equivalents</U>&#148; means any securities of the Corporation or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or
other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Conversion Amount</U>&#148; means the sum of the Stated Value at issue. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Conversion Date</U>&#148; shall have the meaning set forth in Section&nbsp;6(a). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Conversion Price</U>&#148; shall have the meaning set forth in Section&nbsp;6(b). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Conversion Shares</U>&#148; means, collectively, the shares of Common Stock issuable upon conversion of the shares of
Preferred Stock in accordance with the terms hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Dilutive Issuance</U>&#148; shall have the meaning set forth
in Section&nbsp;7(b). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Dilutive Issuance Notice</U>&#148; shall have the meaning set forth in Section&nbsp;7(b).
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Dividend Conversion Rate</U>&#148; means the lesser of (a)&nbsp;the Conversion Price or (b) 90% of the lesser of
(i)&nbsp;the average of the VWAPs for the 20 consecutive Trading Days ending on the Trading Day that is immediately prior to the applicable Dividend Payment Date or (ii)&nbsp;the average of the VWAPs for the 20 consecutive Trading Days ending on the
Trading Day that is immediately prior to the date the applicable Dividend Conversion Shares are issued and delivered if such delivery is after the Dividend Payment Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Dividend Conversion Shares</U>&#148; shall have the meaning set forth in Section&nbsp;3(a). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Dividend Notice Period</U>&#148; shall have the meaning set forth in Section&nbsp;3(a). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Dividend Payment Date</U>&#148; shall have the meaning set forth in Section&nbsp;3(a). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Dividend Share Amount</U>&#148; shall have the meaning set forth in Section&nbsp;3(a). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Equity Conditions</U>&#148; means, during the period in question,
(a)&nbsp;the Corporation shall have duly honored all conversions scheduled to occur or occurring by virtue of one or more Notices of Conversion of the applicable Holder on or prior to the dates so requested or required, if any, (b)&nbsp;the
Corporation shall have paid all liquidated damages and other amounts owing to the applicable Holder in respect of the Preferred Stock, (c)&nbsp;all of the Conversion Shares issuable pursuant to the Transaction Documents (and shares issuable in lieu
of cash payments of dividends) may be resold pursuant to Rule 144 without volume or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> restrictions or current public information requirements as determined
by the counsel to the Corporation as set forth in a written opinion letter to such effect, addressed and acceptable to the Transfer Agent and the affected Holders, (d)&nbsp;the Common Stock is trading on a Trading Market and all of the shares
issuable pursuant to the Transaction Documents are listed or quoted for trading on such Trading Market (and the Corporation believes, in good faith, that trading of the Common Stock on a Trading Market will continue uninterrupted for the foreseeable
future), (e) there is a sufficient number of authorized, but unissued and otherwise unreserved, shares of Common Stock for the issuance of all of the shares then issuable pursuant to the Transaction Documents, (f)&nbsp;the issuance of the shares in
question to the applicable Holder would not violate the limitations set forth in Section&nbsp;6(d) and Section&nbsp;6(e) herein, (g)&nbsp;there has been no public announcement of a pending or proposed Fundamental Transaction or Change of Control
Transaction that has not been consummated, (h)&nbsp;the applicable Holder is not in possession of any information provided by the Corporation, any of its Subsidiaries, or any of their officers, directors, employees, agents or Affiliates, that
constitutes, or may constitute, material <FONT STYLE="white-space:nowrap">non-public</FONT> information, and (i)&nbsp;for each Trading Day in a period of 20 consecutive Trading Days prior to the applicable date in question, the daily trading volume
for the Common Stock on the principal Trading Market exceeds $50,000 of shares per Trading Day (subject to adjustment for forward and reverse stock splits and the like). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange Act</U>&#148; means the Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exempt Issuance</U>&#148; means the issuance of (a)&nbsp;shares of Common Stock, options
or other awards to employees, independent contractors, consultants, officers or directors of the Corporation pursuant to any stock or option plan duly adopted by a majority of the <FONT STYLE="white-space:nowrap">non-employee</FONT> members of the
Board of Directors or a majority of the members of a committee of <FONT STYLE="white-space:nowrap">non-employee</FONT> directors established for such purpose for services rendered to the Corporation (provided, however, any such issuances to
independent contractors and consultants shall not exceed, in the aggregate, $250,000 in any three month period), (b) securities issued and issuable pursuant to the Purchase Agreement and securities issued and issuable upon the exercise or exchange
of or conversion of any securities issued pursuant to the Purchase Agreement and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of the Purchase Agreement, provided
that such securities have not been amended since the date of the Purchase Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of any such securities (other than in connection with
stock splits or combinations) or to extend the term of such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
securities, (c)&nbsp;securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Corporation, provided that such securities
are issued as &#147;restricted securities&#148; (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith during the prohibition period in Section&nbsp;4.12(a)
of the Purchase Agreement, and provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with
the business of the Corporation and shall provide to the Corporation additional benefits in addition to the investment of funds, but shall not include a transaction in which the Corporation is issuing securities primarily for the purpose of raising
capital or to an entity whose primary business is investing in securities, and (d)&nbsp;issuances to independent contractors and consultants of the Corporation, provided that such securities are issued as &#147;restricted securities&#148; (as
defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>First Closing</U>&#148; means the closing of the purchase and sale of the Securities pursuant to Section&nbsp;2.1(a)
of the Purchase Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>First Closing Date</U>&#148; means the Trading Day on which all of the Transaction
Documents have been executed and delivered by the applicable parties thereto, and all conditions precedent to (i)&nbsp;each Holder&#146;s obligations to pay the Subscription Amount and (ii)&nbsp;the Corporation&#146;s obligations to deliver the
Securities issuable at the First Closing, in each case, have been satisfied or waived. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Fundamental
Transaction</U>&#148; shall have the meaning set forth in Section&nbsp;7(e). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>GAAP</U>&#148; means United States
generally accepted accounting principles. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Holder</U>&#148; shall have the meaning given such term in
Section&nbsp;2. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Issuable Maximum</U>&#148; shall have the meaning set forth in Section&nbsp;6(e). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Issue Date</U>&#148; means the Original Issue Date or the Subsequent Issue Date, as the case may be. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Junior Securities</U>&#148; means the Common Stock and all other Common Stock Equivalents of the Corporation other
than those securities which are explicitly senior or <U>pari</U> <U>passu</U> to the Preferred Stock in dividend rights or liquidation preference. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Liens</U>&#148; means a lien, charge, security interest, encumbrance, right of first refusal, preemptive right or
other restriction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Liquidation</U>&#148; shall have the meaning set forth in Section&nbsp;5. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>New York Courts</U>&#148; shall have the meaning set forth in Section&nbsp;8(d). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Notice of Conversion</U>&#148; shall have the meaning set forth in
Section&nbsp;6(a). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Original Issue Date</U>&#148; means the date of the first issuance of any shares of the
Preferred Stock, regardless of the number of transfers of any particular shares of Preferred Stock, and regardless of the number of certificates which may be issued to evidence such Preferred Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Person</U>&#148; means an individual or corporation, partnership, trust, incorporated or unincorporated association,
joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Preferred Stock</U>&#148; shall have the meaning set forth in Section&nbsp;2. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Purchase Agreement</U>&#148; means the Securities Purchase Agreement, dated as of the Original Issue Date, among the
Corporation and the original Holders, as amended, modified or supplemented from time to time in accordance with its terms. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Qualified Offering</U>&#148; means a public offering, as defined in Nasdaq <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">IM-5635-3,</FONT></FONT> that raises gross proceeds equal to at least the aggregate gross proceeds from the sale of Preferred Stock at the First Closing and the Second Closing (exclusive of any proceeds from the exercise
of the Warrants), but in no event less than $20,000,000. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Rule 144</U>&#148; means Rule 144 promulgated by the
Commission pursuant to the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Second Closing</U>&#148; means the second closing of the purchase and sale of the Securities pursuant to
Section&nbsp;2.1(b) of the Purchase Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Second Closing Date</U>&#148; means the Trading Day on which all
of the Transaction Documents have been executed and delivered by the applicable parties thereto, and all conditions precedent to (i)&nbsp;each Holder&#146;s obligations to pay the Subscription Amount and (ii)&nbsp;the Corporation&#146;s obligations
to deliver the Securities issuable at the Second Closing, in each case, have been satisfied or waived. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Securities</U>&#148; means the Preferred Stock, the Warrants, the Warrant Shares and the Underlying Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Securities Act</U>&#148; means the Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Share Delivery Date</U>&#148; shall have the meaning set forth in Section&nbsp;6(c). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Stated Value</U>&#148; shall have the meaning set forth in
Section&nbsp;2, as the same may be increased pursuant to Section&nbsp;3. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Shareholder Approval</U>&#148; means
such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market (or any successor entity) from the shareholders of the Corporation with respect to the transactions contemplated by the Transaction Documents,
including any reset, adjustment or anti-dilution provision in the Transaction Documents and the issuance of all of the Underlying Shares in excess of 19.99% of the issued and outstanding Common Stock on the First Closing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Subscription Amount</U>&#148; shall mean, as to each Holder, the aggregate amount to be paid for the Preferred Stock
purchased pursuant to the Purchase Agreement as specified below such Holder&#146;s name on the signature page of the Purchase Agreement and next to the heading &#147;Subscription Amount,&#148; in United States dollars and in immediately available
funds. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Subsequent Issue Date</U>&#148; means the date of the issuance of any shares of the Preferred Stock on the
Second Closing Date, regardless of the number of transfers of any particular shares of Preferred Stock, and regardless of the number of certificates which may be issued to evidence such Preferred Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Subsidiary</U>&#148; means any subsidiary of the Corporation as set forth on <U>Schedule 3.1(a)</U> of the Purchase
Agreement and shall, where applicable, also include any direct or indirect subsidiary of the Corporation formed or acquired after the date of the Purchase Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Successor Entity</U>&#148; shall have the meaning set forth in Section&nbsp;7(e). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trading Day</U>&#148; means a day on which the principal Trading Market is open for business. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trading Market</U>&#148; means any of the following markets or exchanges on which the Common Stock is listed or quoted
for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York Stock Exchange (or any successors to any of the foregoing). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transaction Documents</U>&#148; means this Certificate of Designation, the Purchase Agreement, the Warrants, the
Voting Agreement, all exhibits and schedules thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated pursuant to the Purchase Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transfer Agent</U>&#148; means Computershare Trust Company, N.A., the current transfer agent of the Corporation with a
mailing address of 250 Royall St., Canton, MA 02021 and a facsimile number of +1 303 262 0609, and any successor transfer agent of the Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Underlying Shares</U>&#148; means the shares of Common Stock issued and
issuable upon conversion of the Preferred Stock, upon exercise of the Warrants and issued and issuable in lieu of the cash payment of dividends on the Preferred Stock in accordance with the terms of this Certificate of Designation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Variable Rate Transaction</U>&#148; shall have the meaning ascribed to such term in Section&nbsp;4.12(b) of the
Purchase Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Voting Agreement</U>&#148; means the written agreement, in the form of <U>Exhibit B</U>
attached to the Purchase Agreement, of all of the officers, directors and stockholders holding more than 10% of the issued and outstanding shares of Common Stock on the date of the Purchase Agreement to vote all Common Stock over which such Persons
have voting control as of the record date for the meeting of stockholders of the Corporation, amounting to, in the aggregate, at least 50% of the issued and outstanding Common Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>VWAP</U>&#148; means, for any date, the price determined by the first of the following clauses that applies:
(a)&nbsp;if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or
quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date
(or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in the &#147;Pink Sheets&#148; published by
OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common
Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Corporation, the fees and expenses of which shall be paid by the
Corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Warrants</U>&#148; means, collectively, the Common Stock purchase warrants delivered to the Holder
at each Closing in accordance with Section&nbsp;2.2(a) of the Purchase Agreement, which Warrants shall be exercisable on the six month anniversary of the date of issuance and have a term of exercise equal to five (5)&nbsp;years from such date, in
the form of <U>Exhibit C</U> attached to the Purchase Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Warrant Shares</U>&#148; means the shares of
Common Stock issuable upon exercise of the Warrants. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;2</U>. <U>Designation, Amount and Par
Value</U>. The series of preferred stock shall be designated as its Series A 20% Convertible Preferred Stock (the &#147;<U>Preferred</U> <U>Stock</U>&#148;) and the number of shares so designated shall be up to 17,500 (which shall not be subject to
increase without the written consent of Holders of a majority in interest of the Preferred Stock (each, a &#147;<U>Holder</U>&#148; and collectively, the &#147;<U>Holders</U>&#148;)). Each share of Preferred Stock shall have a par value of $0.0001
per share and a stated value equal to $1,000, subject to increase set forth in Section&nbsp;3 below (the &#147;<U>Stated Value</U>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;3</U>. <U>Dividends</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <U>Dividends in Cash or in Kind</U>. Holders shall be entitled to receive, and the Corporation shall pay, cumulative
dividends at the rate per share (as a percentage of the Stated Value per share) of 20% per annum, payable semiannually on June&nbsp;30 and December&nbsp;31, beginning on the first such date after the applicable Issue Date and on each Conversion Date
(with respect only to Preferred Stock being converted) (each such date, a &#147;<U>Dividend Payment Date</U>&#148;) (if any Dividend Payment Date is not a Trading Day, the applicable payment shall be due on the next succeeding Trading Day) in cash,
or at the Corporation&#146;s option, in duly authorized, validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock as set forth in this Section&nbsp;3(a), or a combination thereof (the dollar amount
to be paid in shares of Common Stock, the &#147;<U>Dividend Share Amount</U>&#148;). Upon the consummation of a Qualified Offering, and the receipt by the Corporation of the proceeds therefrom, dividends payable pursuant to this Section&nbsp;3(a)
shall cease to accrue; provided, however, any such dividends that have accrued prior to such Qualified Offering shall be paid on the tenth Trading Day immediately preceding the consummation of a Qualified Offering. The form of dividend payments to
each Holder shall be determined in the following order of priority: (i)&nbsp;if funds are legally available for the payment of dividends and the Equity Conditions have not been met during the 20 consecutive Trading Days immediately prior to the
applicable Dividend Payment Date (the &#147;<U>Dividend Notice Period</U>&#148;), in cash only, (ii)&nbsp;if funds are legally available for the payment of dividends and the Equity Conditions have been met during the Dividend Notice Period, at the
sole election of the Corporation, in cash or shares of Common Stock which shall be valued at the Dividend Conversion Rate, (iii)&nbsp;if funds are not legally available for the payment of dividends and the Equity Conditions have been met during the
Dividend Notice Period, in shares of Common Stock which shall be valued at the Dividend Conversion Rate, and (iv)&nbsp;if funds are not legally available for the payment of dividends and the Equity Conditions have not been met during the Dividend
Notice Period, then, at the election of such Holder, such dividends shall accrue to the next Dividend Payment Date or shall be accreted to, and increase, the outstanding Stated Value. In addition, as a condition to paying dividends in shares of
Common Stock, as to such Dividend Payment Date, prior to such Dividend Notice Period (but not more than five (5)&nbsp;Trading Days prior to the commencement of such Dividend Notice Period), the Corporation shall have delivered to each Holder&#146;s
account with The Depository Trust Company a number of shares of Common Stock to be applied against such Dividend Share Amount equal to the quotient of (x)&nbsp;the applicable Dividend Share Amount divided by (y)&nbsp;the Dividend Conversion Rate,
assuming for such purposes that the Dividend Payment Date is the Trading Day immediately prior to the commencement of the Dividend Notice Period (the &#147;<U>Dividend Conversion Shares</U>&#148;). The Holders shall have the same rights and remedies
with respect to the delivery of any such shares as if such shares were being issued pursuant to Section&nbsp;6. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <U>Corporation&#146;s Ability to Pay Dividends in Cash or Kind</U>. On each
Closing Date, the Corporation shall have notified the Holders whether or not it may legally pay cash dividends as of the applicable Closing Date. The Corporation shall promptly notify the Holders at any time the Corporation shall become able or
unable, as the case may be, to legally pay cash dividends. If at any time the Corporation has the right to pay dividends in cash or shares of Common Stock, the Corporation must provide the Holders with at least 20 Trading Days&#146; notice of its
election to pay a regularly scheduled dividend in shares of Common Stock (the Corporation may indicate in such notice that the election contained in such notice shall continue for later periods until revised by a subsequent notice). The aggregate
number of shares of Common Stock otherwise issuable to a Holder on a Dividend Payment Date shall be reduced by the number of shares of Common Stock previously issued to such Holder in connection with such Dividend Payment Date. If any Dividend
Conversion Shares are issued to a Holder in connection with a Dividend Payment Date and are not applied against a Dividend Share Amount, then such Holder shall promptly return such excess shares to the Corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <U>Dividend Calculations</U>. Dividends on the Preferred Stock shall be calculated on the basis of a <FONT
STYLE="white-space:nowrap">360-day</FONT> year, consisting of twelve 30 <FONT STYLE="white-space:nowrap">calendar-day</FONT> periods, and shall accrue daily commencing on the applicable Issue Date, and shall be deemed to accrue from such date
whether or not earned or declared and whether or not there are profits, surplus or other funds of the Corporation legally available for the payment of dividends. Payment of dividends in shares of Common Stock shall otherwise occur pursuant to
Section&nbsp;6(c)(i) herein and, solely for purposes of the payment of dividends in shares, the Dividend Payment Date shall be deemed the Conversion Date. Dividends shall cease to accrue with respect to any Preferred Stock converted, provided that,
the Corporation actually delivers the Conversion Shares within the time period required by Section&nbsp;6(c)(i) herein. Except as otherwise provided herein, if at any time the Corporation pays dividends partially in cash and partially in shares,
then such payment shall be distributed ratably among the Holders based upon the number of shares of Preferred Stock held by each Holder on such Dividend Payment Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <U>Late Fees</U>. Any dividends, whether paid in cash or shares of Common Stock, that are not paid within three Trading Days
following a Dividend Payment Date shall continue to accrue and shall entail a late fee, which must be paid in cash, at the rate of 18% per annum or the lesser rate permitted by applicable law which shall accrue daily from the Dividend Payment Date
through and including the date of actual payment in full. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <U>Other Securities</U>. So long as any Preferred Stock shall
remain outstanding, neither the Corporation nor any Subsidiary thereof shall redeem, purchase or otherwise acquire directly or indirectly any Junior Securities. So long as any Preferred Stock shall remain outstanding, neither the Corporation nor any
Subsidiary thereof shall directly or indirectly pay or declare any dividend or make any distribution upon (other than a dividend or distribution described in Section&nbsp;6 or dividends due and paid in the ordinary course on preferred stock of the
Corporation at such times when the Corporation is in compliance with its payment and other obligations hereunder), nor shall any distribution </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
be made in respect of, any Junior Securities as long as any dividends due on the Preferred Stock remain unpaid, nor shall any monies be set aside for or applied to the purchase or redemption
(through a sinking fund or otherwise) of any Junior Securities or shares <U>pari</U> <U>passu</U> with the Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;4</U>. <U>Voting Rights</U>. Except as otherwise provided herein or as otherwise required by law, the Preferred
Stock shall have no voting rights. However, as long as any shares of Preferred Stock are outstanding, the Corporation shall not, without the affirmative vote of the Holders of a majority of the then outstanding shares of the Preferred Stock,
(a)&nbsp;alter or change adversely the powers, preferences or rights given to the Preferred Stock or alter or amend this Certificate of Designation, (b)&nbsp;authorize or create any class of stock ranking as to dividends, redemption or distribution
of assets upon a Liquidation (as defined in Section&nbsp;5) senior to, or otherwise <U>pari passu</U> with, the Preferred Stock, (c)&nbsp;amend its certificate of incorporation or other charter documents in any manner that adversely affects any
rights of the Holders, (d)&nbsp;increase the number of authorized shares of Preferred Stock, or (e)&nbsp;enter into any agreement with respect to any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;5</U>. <U>Liquidation</U>. Upon any liquidation, dissolution or
<FONT STYLE="white-space:nowrap">winding-up</FONT> of the Corporation, whether voluntary or involuntary (a &#147;<U>Liquidation</U>&#148;), the Holders shall be entitled to receive out of the assets, whether capital or surplus, of the Corporation an
amount equal to the Stated Value, plus any accrued and unpaid dividends thereon and any other fees or liquidated damages then due and owing thereon under this Certificate of Designation, for each share of Preferred Stock before any distribution or
payment shall be made to the holders of any Junior Securities, and if the assets of the Corporation shall be insufficient to pay in full such amounts, then the entire assets to be distributed to the Holders shall be ratably distributed among the
Holders in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full. The Corporation shall mail written notice of any such Liquidation, not less than 45 days prior to the payment
date stated therein, to each Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;6</U>. <U>Conversion</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <U>Conversions at Option of Holder</U>. Each share of Preferred Stock shall be convertible, at any time and from time to
time from and after the applicable Issue Date at the option of the Holder thereof, into that number of shares of Common Stock (subject to the limitations set forth in Section&nbsp;6(d) and Section&nbsp;6(e)) determined by dividing the Stated Value
of such share of Preferred Stock by the Conversion Price. Holders shall effect conversions by providing the Corporation with the form of conversion notice attached hereto as <U>Annex A</U> (a &#147;<U>Notice of Conversion</U>&#148;). Each Notice of
Conversion shall specify the number of shares of Preferred Stock to be converted, the number of shares of Preferred Stock owned prior to the conversion at issue, the number of shares of Preferred Stock owned subsequent to the conversion at issue and
the date on which such conversion is to be effected, which date may not be prior to the date the applicable Holder delivers by facsimile such Notice of Conversion to the Corporation (such date, the &#147;<U>Conversion</U> <U>Date</U>&#148;). If no
Conversion Date is specified in a Notice of Conversion, the Conversion Date shall be the date that such Notice of Conversion to the Corporation is deemed delivered hereunder. No <FONT STYLE="white-space:nowrap">ink-original</FONT> Notice of
Conversion shall be required, nor shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">any medallion guarantee (or other type of guarantee or notarization) of any Notice of Conversion
form be required. The calculations and entries set forth in the Notice of Conversion shall control in the absence of manifest or mathematical error. To effect conversions of shares of Preferred Stock, a Holder shall not be required to surrender the
certificate(s) representing the shares of Preferred Stock to the Corporation unless all of the shares of Preferred Stock represented thereby are so converted, in which case such Holder shall deliver the certificate representing such shares of
Preferred Stock promptly following the Conversion Date at issue. Shares of Preferred Stock converted into Common Stock or redeemed in accordance with the terms hereof shall be canceled and shall not be reissued. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <U>Conversion Price</U>. The conversion price for the Preferred Stock shall equal $5.80, subject to adjustment herein (the
&#147;<U>Conversion Price</U>&#148;). In addition, in the event that a Qualified Offering has not been consummated on or before the six month anniversary of the First Closing Date, on both (i)&nbsp;the six month anniversary of the First Closing Date
and (ii)&nbsp;six month anniversary of the Second Closing Date (each such date, a &#147;<U>Trigger Date</U>&#148;), the Conversion Price shall be reduced, and only reduced, to the lesser of (x)&nbsp;the then Conversion Price, as adjusted, (y) $3.00
(subject to adjustment for forward and reverse stock splits and the like) and (z)&nbsp;the lowest VWAP for any Trading Day during the five Trading Days immediately following each such Trigger Date (the &#147;<U>Reset</U> <U>Conversion
Price</U>&#148;, which shall thereafter be the new Conversion Price, subject to further adjustment hereunder, and such five (5)&nbsp;Trading Day period shall be referred to herein as a &#147;<U>Measurement Period</U>&#148;). The Corporation shall
notify each Holder of the adjustment to the Conversion Price as of such date (each a &#147;<U>Trigger Date Adjustment Notice</U>&#148;). For purposes of clarification, whether or not the Corporation provides a Trigger Date Adjustment Notice pursuant
to this Section&nbsp;6(b), each Holder shall receive a number of Conversion Shares and retain a number of shares of Preferred Stock based upon the Conversion Price as adjusted pursuant to this Section, regardless of whether a Holder accurately
refers to such price or number of shares of Preferred Stock converted in any Notice of Conversion. Any adjustment to the Conversion Price pursuant to this Section shall be effective retroactively to the first Trading Day during each Measurement
Period. Accordingly, with respect to Notices of Conversion effected during a Measurement Period, in the event the Conversion Price is reduced pursuant to this Section, within the two (2)&nbsp;Trading Days immediately following the end of such
Measurement Period, the Corporation shall issue the applicable Holder additional Conversion Shares based on a Conversion Price equal to the Reset Conversion Price with respect to such Notices of Conversion. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <U>Mechanics of Conversion</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">i. <U>Delivery of Conversion Shares Upon Conversion</U>. Not later than the earlier of (i)&nbsp;two (2) Trading Days and
(ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period (as defined below) after each Conversion Date (the &#147;<U>Share Delivery Date</U>&#148;), the Corporation shall deliver, or cause to be delivered, to the converting
Holder (A)&nbsp;the number of Conversion Shares being acquired upon the conversion of the Preferred Stock (including, if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
the Corporation has given continuous notice pursuant to Section&nbsp;3(b) for payment of dividends in shares of Common Stock at least 20 Trading Days prior to the date on which the Notice of
Conversion is delivered to the Corporation, shares of Common Stock representing the payment of accrued dividends otherwise determined pursuant to Section&nbsp;3(a) but assuming that the Dividend Notice Period is the 20 Trading Days period
immediately prior to the date on which the Notice of Conversion is delivered to the Corporation and excluding for such issuance the condition that the Corporation deliver the Dividend Share Amount as to such dividend payment prior to the
commencement of the Dividend Notice Period) which, on or after the six month anniversary of the applicable Issue Date, shall be free of restrictive legends and trading restrictions (other than those which may then be required by the Purchase
Agreement), and (B)&nbsp;a bank check in the amount of accrued and unpaid dividends (if the Corporation has elected or is required to pay accrued dividends in cash). On or after the six month anniversary of the applicable Issue Date, the Corporation
shall deliver the Conversion Shares required to be delivered by the Corporation under this Section&nbsp;6 electronically through the Depository Trust Company or another established clearing corporation performing similar functions. As used herein,
&#147;<U>Standard Settlement Period</U>&#148; means the standard settlement period, expressed in a number of Trading Days, on the Corporation&#146;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the
Notice of Conversion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">ii. <U>Failure to Deliver Conversion Shares</U>. If, in the case of any Notice of Conversion, such
Conversion Shares are not delivered to or as directed by the applicable Holder by the Share Delivery Date, the Holder shall be entitled to elect by written notice to the Corporation at any time on or before its receipt of such Conversion Shares, to
rescind such Conversion, in which event the Corporation shall promptly return to the Holder any original Preferred Stock certificate delivered to the Corporation and the Holder shall promptly return to the Corporation the Conversion Shares issued to
such Holder pursuant to the rescinded Notice of Conversion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">iii. <U>Obligation Absolute; Partial Liquidated Damages</U>.
The Corporation&#146;s obligation to issue and deliver the Conversion Shares upon conversion of Preferred Stock in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by a Holder to enforce the
same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach
by such Holder or any other Person of any obligation to the Corporation or any violation or alleged violation of law by such Holder or any other person, and irrespective of any other circumstance which might otherwise limit such obligation of the
Corporation to such Holder in connection with the issuance of such Conversion Shares; <U>provided</U>, <U>however</U>, that such delivery shall not operate as a waiver by the Corporation of any such action that the Corporation may have against such
Holder. In the event a Holder shall elect to convert any or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
all of the Stated Value of its Preferred Stock, the Corporation may not refuse conversion based on any claim that such Holder or any one associated or affiliated with such Holder has been engaged
in any violation of law, agreement or for any other reason, unless an injunction from a court, on notice to Holder, restraining and/or enjoining conversion of all or part of the Preferred Stock of such Holder shall have been sought and obtained, and
the Corporation posts a surety bond for the benefit of such Holder in the amount of 150% of the Stated Value of Preferred Stock which is subject to the injunction, which bond shall remain in effect until the completion of arbitration/litigation of
the underlying dispute and the proceeds of which shall be payable to such Holder to the extent it obtains judgment. In the absence of such injunction, the Corporation shall issue Conversion Shares and, if applicable, cash, upon a properly noticed
conversion. If the Corporation fails to deliver to a Holder such Conversion Shares pursuant to Section&nbsp;6(c)(i) by the Share Delivery Date applicable to such conversion, the Corporation shall pay to such Holder, in cash, as liquidated damages
and not as a penalty, for each $5,000 of Stated Value of Preferred Stock being converted, $50 per Trading Day (increasing to $100 per Trading Day on the third Trading Day and increasing to $200 per Trading Day on the sixth Trading Day after such
damages begin to accrue) for each Trading Day after the Share Delivery Date until such Conversion Shares are delivered or Holder rescinds such conversion. Nothing herein shall limit a Holder&#146;s right to pursue actual damages for the
Corporation&#146;s failure to deliver Conversion Shares within the period specified herein and such Holder shall have the right to pursue all remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific
performance and/or injunctive relief. The exercise of any such rights shall not prohibit a Holder from seeking to enforce damages pursuant to any other Section hereof or under applicable law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">iv. <U>Compensation for <FONT STYLE="white-space:nowrap">Buy-In</FONT> on Failure to Timely Deliver Conversion Shares Upon
Conversion</U>. In addition to any other rights available to the Holder, if the Corporation fails for any reason to deliver to a Holder the applicable Conversion Shares by the Share Delivery Date pursuant to Section&nbsp;6(c)(i), and if after such
Share Delivery Date such Holder is required by its brokerage firm to purchase (in an open market transaction or otherwise), or the Holder&#146;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by such
Holder of the Conversion Shares which such Holder was entitled to receive upon the conversion relating to such Share Delivery Date (a &#147;<U><FONT STYLE="white-space:nowrap">Buy-In</FONT></U>&#148;), then the Corporation shall (A)&nbsp;pay in cash
to such Holder (in addition to any other remedies available to or elected by such Holder) the amount, if any, by which (x)&nbsp;such Holder&#146;s total purchase price (including any brokerage commissions) for the Common Stock so purchased exceeds
(y)&nbsp;the product of (1)&nbsp;the aggregate number of shares of Common Stock that such Holder was entitled to receive from the conversion at issue multiplied by (2)&nbsp;the actual sale price at which the sell order giving rise to such purchase
obligation was executed (including any brokerage commissions) and (B)&nbsp;at the option of such Holder, either reissue (if surrendered) the shares of Preferred Stock equal to the number of shares of Preferred Stock
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
submitted for conversion (in which case, such conversion shall be deemed rescinded) or deliver to such Holder the number of shares of Common Stock that would have been issued if the Corporation
had timely complied with its delivery requirements under Section&nbsp;6(c)(i). For example, if a Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover a <FONT STYLE="white-space:nowrap">Buy-In</FONT> with respect
to an attempted conversion of shares of Preferred Stock with respect to which the actual sale price of the Conversion Shares (including any brokerage commissions) giving rise to such purchase obligation was a total of $10,000 under clause
(A)&nbsp;of the immediately preceding sentence, the Corporation shall be required to pay such Holder $1,000. The Holder shall provide the Corporation written notice indicating the amounts payable to such Holder in respect of the <FONT
STYLE="white-space:nowrap">Buy-In</FONT> and, upon request of the Corporation, evidence of the amount of such loss. Nothing herein shall limit a Holder&#146;s right to pursue any other remedies available to it hereunder, at law or in equity
including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Corporation&#146;s failure to timely deliver the Conversion Shares upon conversion of the shares of Preferred Stock as required pursuant to
the terms hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">v. <U>Reservation of Shares Issuable Upon Conversion</U>. The Corporation covenants that it will at all
times reserve and keep available out of its authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Preferred Stock and payment of dividends on the Preferred Stock, each as herein provided, free from
preemptive rights or any other actual contingent purchase rights of Persons other than the Holder (and the other holders of the Preferred Stock), not less than such aggregate number of shares of the Common Stock as shall (subject to the terms and
conditions set forth in the Purchase Agreement) be then accrued but unpaid and issuable (taking into account the adjustments and restrictions of Section&nbsp;7) upon the conversion of the then outstanding shares of Preferred Stock and payment of
dividends then accrued but unpaid hereunder. The Corporation covenants that all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid and nonassessable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">vi. <U>Fractional Shares</U>. No fractional shares or scrip representing fractional shares shall be issued upon the conversion
of the Preferred Stock. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such conversion, the Corporation shall at its election, either pay a cash adjustment in respect of such final fraction in an amount
equal to such fraction multiplied by the Conversion Price or round up to the next whole share. Notwithstanding anything to the contrary contained herein, but consistent with the provisions of this subsection with respect to fractional Conversion
Shares, nothing shall prevent any Holder from converting fractional shares of Preferred Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">vii. <U>Transfer Taxes and Expenses</U>. The issuance of Conversion Shares on
conversion of this Preferred Stock shall be made without charge to any Holder for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such Conversion Shares, provided that the Corporation shall not be
required to pay any tax that may be payable in respect of any transfer involved in the issuance and delivery of any such Conversion Shares upon conversion in a name other than that of the Holders of such shares of Preferred Stock and the Corporation
shall not be required to issue or deliver such Conversion Shares unless or until the Person or Persons requesting the issuance thereof shall have paid to the Corporation the amount of such tax or shall have established to the satisfaction of the
Corporation that such tax has been paid. The Corporation shall pay all Transfer Agent fees required for <FONT STYLE="white-space:nowrap">same-day</FONT> processing of any Notice of Conversion and all fees to the Depository Trust Company (or another
established clearing corporation performing similar functions) required for <FONT STYLE="white-space:nowrap">same-day</FONT> electronic delivery of the Conversion Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <U>Beneficial Ownership Limitation</U>. The Corporation shall not effect any conversion of the Preferred Stock, and a Holder
shall not have the right to convert any portion of the Preferred Stock, to the extent that, after giving effect to the conversion set forth on the applicable Notice of Conversion, such Holder (together with such Holder&#146;s Affiliates, and any
Persons acting as a group together with such Holder or any of such Holder&#146;s Affiliates (such Persons, &#147;<U>Attribution Parties</U>&#148;)) would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For
purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by such Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon conversion of the Preferred Stock
with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which are issuable upon (i)&nbsp;conversion of the remaining, unconverted Stated Value of Preferred Stock beneficially owned by such
Holder or any of its Affiliates or Attribution Parties and (ii)&nbsp;exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation subject to a limitation on conversion or exercise analogous to the
limitation contained herein (including, without limitation, the Preferred Stock or the Warrants) beneficially owned by such Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this
Section&nbsp;6(d), beneficial ownership shall be calculated in accordance with Section&nbsp;13(d) of the Exchange Act and the rules and regulations promulgated thereunder. To the extent that the limitation contained in this Section&nbsp;6(d)
applies, the determination of whether the Preferred Stock is convertible (in relation to other securities owned by such Holder together with any Affiliates and Attribution Parties) and of how many shares of Preferred Stock are convertible shall be
in the sole discretion of such Holder, and the submission of a Notice of Conversion shall be deemed to be such Holder&#146;s determination of whether the shares of Preferred Stock may be converted (in relation to other securities owned by such
Holder together with any Affiliates and Attribution Parties) and how many shares of the Preferred Stock are convertible, in each case subject to the Beneficial Ownership Limitation. To ensure compliance with this restriction, each Holder will be
deemed to represent to the Corporation each time it delivers a Notice of Conversion that such Notice of Conversion has not violated the restrictions set forth in this paragraph and the Corporation shall have no obligation to verify or confirm the
accuracy of such determination. In addition, a determination as to any group status as contemplated above </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
shall be determined in accordance with Section&nbsp;13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section&nbsp;6(d), in determining the
number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as stated in the most recent of the following: (i)&nbsp;the Corporation&#146;s most recent periodic or annual report filed with the
Commission, as the case may be, (ii)&nbsp;a more recent public announcement by the Corporation or (iii)&nbsp;a more recent written notice by the Corporation or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon
the written or oral request of a Holder, the Corporation shall within one Trading Day confirm orally and in writing to such Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock
shall be determined after giving effect to the conversion or exercise of securities of the Corporation, including the Preferred Stock, by such Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding
shares of Common Stock was reported. The &#147;<U>Beneficial Ownership Limitation</U>&#148; shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable
upon conversion of Preferred Stock held by the applicable Holder. A Holder, upon notice to the Corporation, may increase or decrease the Beneficial Ownership Limitation provisions of this Section&nbsp;6(d) applicable to its Preferred Stock provided
that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon conversion of this Preferred Stock held by the
Holder and the provisions of this Section&nbsp;6(d) shall continue to apply. Any such increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> day after such notice is
delivered to the Corporation and shall only apply to such Holder and no other Holder. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section&nbsp;6(d) to
correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation contained herein or to make changes or supplements necessary or desirable to properly give effect to such
limitation. The limitations contained in this paragraph shall apply to a successor holder of Preferred Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">e)
<U>Issuance Limitations</U>. Notwithstanding anything herein to the contrary, if the Corporation has not obtained Shareholder Approval, then the Corporation may not issue, upon conversion of the Preferred Stock, a number of shares of Common Stock
which, when aggregated with any shares of Common Stock issued (i)&nbsp;in connection with any conversion of Preferred Stock issued pursuant to the Purchase Agreement, (ii)&nbsp;in connection with the exercise of any Warrants issued pursuant to the
Purchase Agreement and (iii)&nbsp;in connection with the exercise of any warrants issued to any registered broker-dealer as a fee in connection with the issuance of the Securities pursuant to the Purchase Agreement, would exceed 1,196,680 shares of
Common Stock (subject to adjustment for forward and reverse stock splits, recapitalizations and the like) (such number of shares, the &#147;<U>Issuable Maximum</U>&#148;). Each Holder shall be entitled to a portion of the Issuable Maximum equal to
the quotient obtained by dividing (x)&nbsp;the Stated Value of such Holder&#146;s Preferred Stock issued or issuable pursuant to the Purchase Agreement by (y) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the aggregate Stated Value of all Preferred Stock issued or issuable to all Holders pursuant to the Purchase Agreement, In addition, each Holder may allocate its
<FONT STYLE="white-space:nowrap">pro-rata</FONT> portion of the Issuable Maximum among Preferred Stock and Warrants held by it in its sole discretion. Such portion shall be adjusted upward ratably in the event a Holder no longer holds any Preferred
Stock or Warrants and the amount of shares issued to such Holder pursuant to such Holder&#146;s Preferred Stock and Warrants was less than such Holder&#146;s <FONT STYLE="white-space:nowrap">pro-rata</FONT> share of the Issuable Maximum. For
avoidance of doubt, unless and until any required Shareholder Approval is obtained and effective, warrants issued to any registered broker-dealer as a fee in connection with the Securities issued pursuant to the Purchase Agreement as described in
clause (iii)&nbsp;above shall provide that such warrants shall not be allocated any portion of the Issuable Maximum and shall be unexercisable unless and until such Shareholder Approval is obtained and effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;7</U>. <U>Certain Adjustments</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <U>Stock Dividends and Stock Splits</U>. If the Corporation, at any time while this Preferred Stock is outstanding:
(i)&nbsp;pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock on shares of Common Stock or any other Common Stock Equivalents (which, for avoidance of doubt, shall not include any shares of
Common Stock issued by the Corporation upon conversion of, or payment of a dividend on, this Preferred Stock), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii)&nbsp;combines (including by way of a reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv)&nbsp;issues, in the event of a reclassification of shares of the Common Stock, any shares of capital stock of the Corporation, then the Conversion Price shall
be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding any treasury shares of the Corporation) outstanding immediately before such event, and of which the denominator shall be the number of shares
of Common Stock outstanding immediately after such event. Any adjustment made pursuant to this Section&nbsp;7(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or
distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or <FONT STYLE="white-space:nowrap">re-classification.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <U>Subsequent Equity Sales</U>. From the Original Issue Date until a Qualified Offering has been consummated, and any
adjustment pursuant to this Section&nbsp;7(b) has been made as a result of the Qualified Offering, if the Corporation or any Subsidiary, as applicable sells or grants any option to purchase or sells or grants any right to reprice, or otherwise
disposes of or issues (or announces any sale, grant or any option to purchase or other disposition), any Common Stock or Common Stock Equivalents entitling any Person to acquire shares of Common Stock at an effective price per share that is lower
than the then Conversion Price (such lower price, the &#147;<U>Base Conversion Price</U>&#148; and such issuances, collectively, a &#147;<U>Dilutive Issuance</U>&#148;) (if the holder of the Common Stock or Common Stock Equivalents so issued shall
at any time, whether by operation of purchase price adjustments, reset provisions, floating conversion, exercise or exchange prices or otherwise, or due to warrants, options or rights per share which are issued in connection
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
with such issuance, be entitled to receive shares of Common Stock at an effective price per share that is lower than the Conversion Price, such issuance shall be deemed to have occurred for less
than the Conversion Price on such date of the Dilutive Issuance), then the Conversion Price shall be reduced to equal the Base Conversion Price. Such adjustment shall be made whenever such Common Stock or Common Stock Equivalents are issued.
Notwithstanding the foregoing, no adjustment will be made under this Section&nbsp;7(b) in respect of an Exempt Issuance. If the Corporation enters into a Variable Rate Transaction, despite the prohibition set forth in the Purchase Agreement, the
Corporation shall be deemed to have issued Common Stock or Common Stock Equivalents at the lowest possible conversion price at which such securities may be converted or exercised. The Corporation shall notify the Holders in writing, no later than
the Trading Day following the issuance of any Common Stock or Common Stock Equivalents subject to this Section&nbsp;7(b), indicating therein the applicable issuance price, or applicable reset price, exchange price, conversion price and other pricing
terms (such notice, the &#147;<U>Dilutive Issuance Notice</U>&#148;). For purposes of clarification, whether or not the Corporation provides a Dilutive Issuance Notice pursuant to this Section&nbsp;7(b), upon the occurrence of any Dilutive Issuance,
the Holders are entitled to receive a number of Conversion Shares based upon the Base Conversion Price on or after the date of such Dilutive Issuance, regardless of whether a Holder accurately refers to the Base Conversion Price in the Notice of
Conversion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section&nbsp;7(a) above, if
at any time the Corporation grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the &#147;<U>Purchase
Rights</U>&#148;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock
acquirable upon complete conversion of such Holder&#146;s Preferred Stock (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is
taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided,
however, that, to the extent that the Holder&#146;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right
to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto
would not result in the Holder exceeding the Beneficial Ownership Limitation). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <U>Pro Rata Distributions</U>. During
such time as this Preferred Stock is outstanding, if the Corporation declares or makes any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise
(including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#147;<U>Distribution</U>&#148;), at any time after the issuance of this Preferred Stock, then,
in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete conversion of
this Preferred Stock (without regard to any limitations on conversion hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is
taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>, to the extent that the Holder&#146;s right to participate in any such
Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result
of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <U>Fundamental Transaction</U>. If, at any time while this Preferred Stock is outstanding, (i)&nbsp;the
Corporation, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Corporation with or into another Person, (ii)&nbsp;the Corporation, directly or indirectly, effects any sale, lease, license,
assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii)&nbsp;any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the
Corporation or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the
outstanding Common Stock, (iv)&nbsp;the Corporation, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which
the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v)&nbsp;the Corporation, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other
business combination (including, without limitation, a reorganization, recapitalization, <FONT STYLE="white-space:nowrap">spin-off</FONT> or scheme of arrangement) with another Person whereby such other Person acquires more than 50% of the
outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement
or other business combination) (each a &#147;<U>Fundamental Transaction</U>&#148;), then, upon any subsequent conversion of this Preferred Stock, the Holder shall have the right to receive, for each Conversion Share that would have been issuable
upon such conversion immediately prior to the occurrence of such Fundamental Transaction (without regard to any limitation in Section&nbsp;6(d) and Section&nbsp;6(e) on the conversion of this Preferred Stock), the number of shares of Common Stock of
the successor or acquiring corporation or of the Corporation, if it is the surviving corporation, and any additional consideration (the &#147;<U>Alternate Consideration</U>&#148;) receivable as a result of such Fundamental Transaction by a holder of
the number of shares of Common Stock for which this Preferred Stock is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
convertible immediately prior to such Fundamental Transaction (without regard to any limitation in Section&nbsp;6(d) and Section&nbsp;6(e) on the conversion of this Preferred Stock). For purposes
of any such conversion, the determination of the Conversion Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such
Fundamental Transaction, and the Corporation shall apportion the Conversion Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common
Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any conversion of this Preferred Stock
following such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any successor to the Corporation or surviving entity in such Fundamental Transaction shall file a new Certificate of Designation with the same
terms and conditions and issue to the Holders new preferred stock consistent with the foregoing provisions and evidencing the Holders&#146; right to convert such preferred stock into Alternate Consideration. The Corporation shall cause any successor
entity in a Fundamental Transaction in which the Corporation is not the survivor (the &#147;<U>Successor Entity</U>&#148;) to assume in writing all of the obligations of the Corporation under this Certificate of Designation and the other Transaction
Documents (as defined in the Purchase Agreement) in accordance with the provisions of this Section&nbsp;7(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable
delay) prior to such Fundamental Transaction and shall, at the option of the holder of this Preferred Stock, deliver to the Holder in exchange for this Preferred Stock a security of the Successor Entity evidenced by a written instrument
substantially similar in form and substance to this Preferred Stock which is convertible for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and
receivable upon conversion of this Preferred Stock (without regard to any limitations on the conversion of this Preferred Stock) prior to such Fundamental Transaction, and with a conversion price which applies the conversion price hereunder to such
shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such conversion
price being for the purpose of protecting the economic value of this Preferred Stock immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the
occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Certificate of Designation and the other
Transaction Documents referring to the &#147;Corporation&#148; shall refer instead to the Successor Entity), and may exercise every right and power of the Corporation and shall assume all of the obligations of the Corporation under this Certificate
of Designation and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Corporation herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) <U>Calculations</U>. All calculations under this Section&nbsp;7 shall be made
to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section&nbsp;7, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of
Common Stock (excluding any treasury shares of the Corporation) issued and outstanding. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">g) <U>Notice to the Holders</U>.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">i. <U>Adjustment to Conversion Price</U>. Whenever the Conversion Price is adjusted pursuant to any provision of this
Section&nbsp;7, the Corporation shall promptly deliver to each Holder by facsimile or email a notice setting forth the Conversion Price after such adjustment and setting forth a brief statement of the facts requiring such adjustment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">ii. <U>Notice to Allow Conversion by Holder</U>. If (A)&nbsp;the Corporation shall declare a dividend (or any other
distribution in whatever form) on the Common Stock, (B)&nbsp;the Corporation shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C)&nbsp;the Corporation shall authorize the granting to all holders of the
Common Stock of rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D)&nbsp;the approval of any stockholders of the Corporation shall be required in connection with any reclassification of the
Common Stock, any consolidation or merger to which the Corporation is a party, any sale or transfer of all or substantially all of the assets of the Corporation, or any compulsory share exchange whereby the Common Stock is converted into other
securities, cash or property or (E)&nbsp;the Corporation shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Corporation, then, in each case, the Corporation shall cause to be filed at each
office or agency maintained for the purpose of conversion of this Preferred Stock, and shall cause to be delivered by facsimile or email to each Holder at its last facsimile number or email address as it shall appear upon the stock books of the
Corporation, at least twenty (20)&nbsp;calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x)&nbsp;the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y)&nbsp;the
date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange
their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange, provided that the failure to deliver such notice or any defect therein or in the
delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided hereunder constitutes, or contains, material, <FONT STYLE="white-space:nowrap">non-public</FONT>
information regarding the Corporation or any of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
Subsidiaries, the Corporation shall simultaneously file such notice with the Commission pursuant to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> The Holder shall remain
entitled to convert the Conversion Amount of this Preferred Stock (or any part hereof) during the <FONT STYLE="white-space:nowrap">20-day</FONT> period commencing on the date of such notice through the effective date of the event triggering such
notice except as may otherwise be expressly set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;8</U>. <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <U>Notices</U>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including,
without limitation, any Notice of Conversion, shall be in writing and delivered personally, by <FONT STYLE="white-space:nowrap">e-mail</FONT> attachment, or sent by a nationally recognized overnight courier service, addressed to the Corporation, at
the address set forth above Attention: Angelos Stergiou, M.D., Sc.D., h.c.., <FONT STYLE="white-space:nowrap">e-mail</FONT> address astergiou@sellaslife.com, with a copy to David Moser, <FONT STYLE="white-space:nowrap">e-mail</FONT> address
dmoser@sellaslife.com, or such other <FONT STYLE="white-space:nowrap">e-mail</FONT> address or address as the Corporation may specify for such purposes by notice to the Holders delivered in accordance with this Section&nbsp;8. Any and all notices or
other communications or deliveries to be provided by the Corporation hereunder shall be in writing and delivered personally, by facsimile or <FONT STYLE="white-space:nowrap">e-mail</FONT> attachment, or sent by a nationally recognized overnight
courier service addressed to each Holder at the facsimile number, <FONT STYLE="white-space:nowrap">e-mail</FONT> address or address of such Holder appearing on the books of the Corporation, or if no such facsimile number, <FONT
STYLE="white-space:nowrap">e-mail</FONT> address or address appears on the books of the Corporation, at the principal place of business of such Holder, as set forth in the Purchase Agreement, Any notice or other communication or deliveries hereunder
shall be deemed given and effective on the earliest of (i)&nbsp;the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number or <FONT STYLE="white-space:nowrap">e-mail</FONT> attachment at the <FONT
STYLE="white-space:nowrap">e-mail</FONT> address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii)&nbsp;the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile
at the facsimile number or <FONT STYLE="white-space:nowrap">e-mail</FONT> attachment at the <FONT STYLE="white-space:nowrap">e-mail</FONT> address set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York City
time) on any Trading Day, (iii)&nbsp;the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv)&nbsp;upon actual receipt by the party to whom such notice is required to be given.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <U>Absolute Obligation</U>. Except as expressly provided herein, no provision of this Certificate of Designation shall
alter or impair the obligation of the Corporation, which is absolute and unconditional, to pay liquidated damages, accrued dividends and accrued interest, as applicable, on the shares of Preferred Stock at the time, place, and rate, and in the coin
or currency, herein prescribed. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <U>Lost or Mutilated Preferred Stock Certificate</U>. If a Holder&#146;s Preferred
Stock certificate shall be mutilated, lost, stolen or destroyed, the Corporation shall execute and deliver, in exchange and substitution for and upon cancellation of a mutilated certificate, or in lieu of or in substitution for a lost, stolen or
destroyed certificate, a new certificate for the shares of Preferred Stock so mutilated, lost, stolen or destroyed, but only upon receipt of evidence of such loss, theft or destruction of such certificate, and of the ownership hereof reasonably
satisfactory to the Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <U>Governing Law</U>. All questions concerning the construction, validity,
enforcement and interpretation of this Certificate of Designation shall be governed by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard to the principles of conflict of laws thereof. All legal
proceedings concerning the interpretation, enforcement and defense of the transactions contemplated by any of the Transaction Documents (whether brought against a party hereto or its respective Affiliates, directors, officers, shareholders,
employees or agents) shall be commenced in the state and federal courts sitting in the City of New York, Borough of Manhattan (the &#147;<U>New York Courts</U>&#148;). The Corporation and each Holder hereby irrevocably submits to the exclusive
jurisdiction of the New York Courts for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction
Documents), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of such New York Courts, or such New York Courts are improper or inconvenient
venue for such proceeding. The Corporation and each Holder hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail
or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Certificate of Designation and agrees that such service shall constitute good and sufficient service of process and notice thereof.
Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by applicable law. The Corporation and each Holder hereby irrevocably waives, to the fullest extent permitted by applicable law,
any and all right to trial by jury in any legal proceeding arising out of or relating to this Certificate of Designation or the transactions contemplated hereby. If the Corporation or any Holder shall commence an action or proceeding to enforce any
provisions of this Certificate of Designation, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its attorneys&#146; fees and other costs and expenses incurred in the investigation, preparation and
prosecution of such action or proceeding. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <U>Waiver</U>. Any waiver by the Corporation or a Holder of a breach of any
provision of this Certificate of Designation shall not operate as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Certificate of Designation or a waiver by any other Holders. The
failure of the Corporation or a Holder to insist upon strict adherence to any term of this Certificate of Designation on one or more occasions shall not be considered a waiver or deprive that party (or any other Holder) of the right thereafter to
insist upon strict adherence to that term or any other term of this Certificate of Designation on any other occasion. Any waiver by the Corporation or a Holder must be in writing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) <U>Severability</U>. If any provision of this Certificate of Designation is
invalid, illegal or unenforceable, the balance of this Certificate of Designation shall remain in effect, and if any provision is inapplicable to any Person or circumstance, it shall nevertheless remain applicable to all other Persons and
circumstances. If it shall be found that any interest or other amount deemed interest due hereunder violates the applicable law governing usury, the applicable rate of interest due hereunder shall automatically be lowered to equal the maximum rate
of interest permitted under applicable law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">g) <U>Next Business Day</U>. Whenever any payment or other obligation
hereunder shall be due on a day other than a Business Day, such payment shall be made on the next succeeding Business Day. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">h) <U>Headings</U>. The headings contained herein are for convenience only, do not constitute a part of this Certificate of
Designation and shall not be deemed to limit or affect any of the provisions hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">i) <U>Status of Converted or Redeemed
Preferred Stock</U>. Shares of Preferred Stock may only be issued pursuant to the Purchase Agreement. If any shares of Preferred Stock shall be converted, redeemed or reacquired by the Corporation, such shares shall resume the status of authorized
but unissued shares of preferred stock and shall no longer be designated as Series A 20% Convertible Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">********************* </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RESOLVED, FURTHER, that the Chairman, the president or any vice-president, and the secretary or any assistant
secretary, of the Corporation be and they hereby are authorized and directed to prepare and file this Certificate of Designation of Preferences, Rights and Limitations in accordance with the foregoing resolution and the provisions of Delaware law.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have executed this Certificate this 8th day of March 2018. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Angelos M. Stergiou</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: Angelos M. Stergiou, MD, ScD h.c.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:
President&nbsp;&amp; Chief Executive Officer</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEX A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NOTICE OF CONVERSION </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(TO BE
EXECUTED BY THE REGISTERED HOLDER IN ORDER TO CONVERT SHARES </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OF PREFERRED STOCK) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned hereby elects to convert the number of shares of Series A 20% Convertible Preferred Stock indicated below into shares of common stock, par
value $0.0001 per share (the &#147;<U>Common Stock</U>&#148;), of SELLAS Life Sciences Group, Inc., a Delaware corporation (the &#147;<U>Corporation</U>&#148;), according to the conditions hereof, as of the date written below. If shares of Common
Stock are to be issued in the name of a Person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as may be required by the Corporation in
accordance with the Purchase Agreement. No fee will be charged to the Holders for any conversion, except for any such transfer taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Conversion
calculations: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="95%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Date to Effect Conversion:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Number of shares of Preferred Stock owned prior to Conversion:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Number of shares of Preferred Stock to be Converted:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Stated Value of shares of Preferred Stock to be Converted:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Number of shares of Common Stock to be Issued:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Applicable Conversion Price:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Number of shares of Preferred Stock subsequent to Conversion:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Address for Delivery:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>or</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">DWAC Instructions:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Broker no: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Account no: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">[HOLDER]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>d556278dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g556278dsp073.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK PAR VALUE $0.0001 COMMON STOCK Certificate Number ZQ00000000 Shares * *
000000 ****************** * * * 000000 ***************** **** 000000 **************** ***** 000000 *************** ****** 000000 SELLAS LIFE SCIENCES GROUP, INC. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE THIS CERTIFIES THAT CUSIP 81642T
10 0 SEE REVERSE FOR CERTAIN DEFINITIONS is the owner of THIS CERTIFICATE IS TRANSFERABLE IN CITIES DESIGNATED BY THE TRANSFER AGENT, AVAILABLE ONLINE AT www.computershare.com FULLY-PAID AND NON-ASSESSABLE SHARES OF THE COMMON STOCK OF SELLAS LIFE
SCIENCES GROUP, INC. (hereinafter called the &#147;Company&#148;), transferable on the books of the Company in person or by duly authorized attorney, upon surrender of this Certificate properly endorsed. This Certificate and the shares represented
hereby, are issued and shall be held subject to all of the provisions of the Amended and Restated Certificate of Incorporation, as amended, and the Amended and Restated By-Laws, as amended, of the Company (copies of which are on file with the
Company and with the Transfer Agent), to all of which each holder, by acceptance hereof, assents. This Certificate is not valid unless countersigned and registered by the Transfer Agent and Registrar. Witness the facsimile seal of the Company and
the facsimile signatures of its duly authorized officers. President&nbsp;&amp; Chief Executive Officer Corporate Secretary DATED DD-MMM-YYYY COUNTERSIGNED AND REGISTERED: COMPUTERSHARE TRUST COMPANY, N.A. TRANSFER AGENT AND REGISTRAR, By AUTHORIZED
SIGNATURE CUSIP XXXXXX XX X Holder ID XXXXXXXXXX Insurance Value 00.1,000,000 Number of Shares 123456 DTC 12345678901234512345678 Certificate Numbers Num/No Denom. Total. 1234567890/1234567890 111 1234567890/1234567890 222 1234567890/1234567890 333
1234567890/1234567890 444 1234567890/1234567890 555 1234567890/1234567890 666 Total Transaction 7 </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g556278dsp074.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">SELLAS LIFE SCIENCES GROUP, INC. THE COMPANY WILL FURNISH WITHOUT CHARGE TO EACH SHAREHOLDER WHO SO REQUESTS, A SUMMARY OF THE POWERS,
DESIGNATIONS, PREFERENCES AND RELATIVE, PARTICIPATING, OPTIONAL OR OTHER SPECIAL RIGHTS OF EACH CLASS OF STOCK OF THE COMPANY AND THE QUALIFICATIONS, LIMITATIONS OR RESTRICTIONS OF SUCH PREFERENCES AND RIGHTS, AND THE VARIATIONS IN RIGHTS,
PREFERENCES AND LIMITATIONS DETERMINED FOR EACH SERIES, WHICH ARE FIXED BY THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THE COMPANY, AS AMENDED, AND THE RESOLUTIONS OF THE BOARD OF DIRECTORS OF THE COMPANY, AND THE AUTHORITY OF THE BOARD
OF DIRECTORS TO DETERMINE VARIATIONS FOR FUTURE SERIES. SUCH REQUEST MAY BE MADE TO THE OFFICE OF THE SECRETARY OF THE COMPANY OR TO THE TRANSFER AGENT. THE BOARD OF DIRECTORS MAY REQUIRE THE OWNER OF A LOST OR DESTROYED STOCK CERTIFICATE, OR HIS
LEGAL REPRESENTATIVES, TO GIVE THE COMPANY A BOND TO INDEMNIFY IT AND ITS TRANSFER AGENTS AND REGISTRARS AGAINST ANY CLAIM THAT MAY BE MADE AGAINST THEM ON ACCOUNT OF THE ALLEGED LOSS OR DESTRUCTION OF ANY SUCH CERTIFICATE. The following
abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable laws or regulations: TEN COM&#151;as tenants in common UNIF GIFT MIN ACT-.Custodian
(Cust) (Minor) TEN ENT&#151;as tenants by the entireties under Uniform Gifts to Minors Act (State) JT TEN&#151;as joint tenants with right of survivorship UNIF TRF MIN ACT. Custodian (until age) and not as tenants in common (Cust) (Minor) under
Uniform Transfers to Minors Act (State) Additional abbreviations may also be used though not in the above list. PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER OF ASSIGNEE For value received, hereby sell, assign and transfer unto (PLEASE
PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING POSTAL ZIP CODE, OF ASSIGNEE) Shares of the common stock represented by the within Certificate, and do hereby irrevocably constitute and appoint Attorney to transfer the said stock on the books of the
within-named Corporation with full power of substitution in the premises. Dated: 20 Signature: Signature: Notice: The signature to this assignment must correspond with the name as written upon the face of the certificate, in every particular,
without alteration or enlargement, or any change whatever. Signature(s) Guaranteed: Medallion Guarantee Stamp THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (Banks, Stockbrokers, Savings and Loan Associations and Credit
Unions) WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15. The IRS requires that we report the cost basis of certain shares acquired after January&nbsp;1, 2011. If your shares were covered by the
legislation and you have sold or transferred the shares and requested a specific cost basis calculation method, we have processed as requested. If you did not specify a cost basis calculation method, we have defaulted to the first in, first out
(FIFO) method. Please visit our website or consult your tax advisor if you need additional information about cost basis. If you do not keep in contact with us or do not have any activity in your account for the time periods specified by state law,
your property could become subject to state unclaimed property laws and transferred to the appropriate state. </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>4
<FILENAME>d556278dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Incentive Stock Option </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Granted
Under Galena Biopharma 2016 Incentive Plan </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;Grant of Option. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This certificate evidences an incentive stock option (this &#147;Stock Option&#148;) granted by Galena Biopharma, Inc.,<I> </I>a Delaware
corporation (the &#147;Company&#148;), [MMDD, YYYY] (the&nbsp;&#147;Date of Grant&#148;) to
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, an employee of the
Company (the&nbsp;&#147;Participant&#148;) pursuant to the Company&#146;s 2016 Incentive Plan (as from time to time in effect, the &#147;Plan&#148;). Under this Stock Option, the Participant may purchase, in whole or in part, on the terms herein
provided, a total of <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> shares of common stock of the Company (the &#147;Shares&#148;) at
$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> per Share, which is not less than the fair market value of the Shares on the Date of Grant. The latest date on which this Stock Option, or any
part thereof, may be exercised is [MMDD, YYYY] (the &#147;Final Exercise Date&#148;). The Stock Option evidenced by this certificate is intended to be an incentive stock option as defined in section 422 of the Internal Revenue Code of 1986, as
amended from time to time (the&nbsp;&#147;Code&#148;). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">This Stock Option shall vest and become exercisable in equal <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> installments over
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> years beginning<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;months after the Grant Date. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, upon termination of the Participant&#146;s Employment, any portion of this Stock Option that is not then exercisable will
immediately expire and the remainder of this Stock Option will remain exercisable for three months (unless termination of the Participant&#146;s Employment resulted from reasons that in the determination of the Administrator cast such discredit on
the Participant as to justify immediate forfeiture of this Stock Option, in which case this entire Option shall immediately expire and no portion thereof shall remain exercisable); <I>provided</I>, that<SUP STYLE="font-size:85%; vertical-align:top">
</SUP>any portion of this Stock Option held by the Participant immediately prior to the Participant&#146;s death, to the extent then exercisable, will remain exercisable for one year following the Participant&#146;s death; <I>and further
provided</I>, that in no event shall any portion of this Stock Option be exercisable after the Final Exercise Date.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;Exercise of Stock Option. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each election to exercise this Stock Option shall be in writing, signed by the Participant or the Participant&#146;s executor, administrator,
or legally appointed representative (in the event of the Participant&#146;s incapacity) or the person or persons to whom this Stock Option is transferred by will or the applicable laws of descent and distribution (collectively, the &#147;Option
Holder&#148;), and received by the Company at its principal office, accompanied by this certificate and payment in full as provided in the Plan. Subject to the further terms and conditions provided in the Plan, the purchase price may be paid as
follows: (i)&nbsp;by delivery of cash or check acceptable to the Administrator; (ii)&nbsp;upon and following an initial public offering of the Company and to the extent permitted by applicable law (as determined by
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Administrator), through a broker-assisted exercise program acceptable to the Administrator; or (iii)&nbsp;through any combination of the foregoing. In the event that this Stock Option is
exercised by an Option Holder other than the Participant, the Company will be under no obligation to deliver Shares hereunder unless and until it is satisfied as to the authority of the Option Holder to exercise this Stock Option. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;Notice of Disposition. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The person exercising this Stock Option shall notify the Company when making any disposition of the Shares acquired upon exercise of this Stock
Option, whether by sale, gift or otherwise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;Restrictions on Transfer of Shares. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If at the time this Stock Option is exercised the Company or any of its stockholders is a party to any agreement restricting the transfer of
any outstanding shares of the Company&#146;s common stock, the Administrator may provide that this Stock Option may be exercised only if the Shares so acquired are made subject to the transfer restrictions set forth in that agreement (or if more
than one such agreement is then in effect, the agreement or agreements specified by the Administrator). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If requested by the Corporation
and the managing underwriter of an offering by the Corporation of Common Stock pursuant to a registration statement under the Securities Act of 1933, as amended, each stockholder who acquires shares by exercise of this Option shall agree, by
executing and delivering such form of agreement as the Company and such underwriter shall reasonably request, not to sell publicly or otherwise transfer or dispose of any shares held by such stockholder or other securities of the Corporation held by
such stockholder for a specified period of time (not to exceed 180 days) immediately following the effective date of such registration statement; <I>provided</I>, that such agreement shall apply only to the initial public offering of the
Corporation&#146;s securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.&nbsp;&nbsp;&nbsp;&nbsp;Withholding Agreement to Provide Security. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If at the time this Stock Option is exercised the Company determines that under applicable law and regulations it could be liable for the
withholding of any federal or state tax upon exercise or with respect to a disposition of any Shares acquired upon exercise of this Stock Option, this Stock Option may not be exercised unless the person exercising this Stock Option remits to the
Company any amounts determined by the Company to be required to be withheld upon exercise (or makes other arrangements satisfactory to the Company for the payment of such taxes) and gives such security as the Company deems adequate to meet its
potential liability for the withholding of tax upon a disposition of the Shares and agrees to augment such security from time to time in any amount reasonably determined by the Company to be necessary to preserve the adequacy of such security. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.&nbsp;&nbsp;&nbsp;&nbsp;Nontransferability of Stock Option. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Stock Option is not transferable by the Participant otherwise than by will or the laws of descent and distribution and is exercisable
during the Participant&#146;s lifetime only by the Participant (or in the event of the Participant&#146;s incapacity, the person or persons legally appointed to act on the Participant&#146;s behalf). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.&nbsp;&nbsp;&nbsp;&nbsp;Provisions of the Plan. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Stock Option is subject to the provisions of the Plan, which are incorporated herein by reference. A copy of the Plan as in effect on the
date of the grant of this Stock Option has been furnished to the Participant. By exercising all or any part of this Stock Option, the Participant agrees to be bound by the terms of the Plan and this certificate. All initially capitalized terms used
herein will have the meaning specified in the Plan, unless another meaning is specified herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this instrument to be executed by its duly authorized
officer. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Galena Biopharma, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Name:</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Title:</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Acknowledged</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>5
<FILENAME>d556278dex103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Nonstatutory Stock Option </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Granted Under Galena Biopharma, Inc. 2016 Incentive Plan </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;Grant of Option; Vesting. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This certificate evidences a nonstatutory stock option (this &#147;Stock Option&#148;) granted by Galena Biopharma, Inc., a Delaware
corporation (the &#147;Company&#148;), [MMDD, YYYY] (the &#147;Date of Grant&#148;) to
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, (the &#147;Participant&#148;) pursuant to the
Company&#146;s 2016 Incentive Plan (as from time to time in effect, the &#147;Plan&#148;). Under this Stock Option, the Participant may purchase, in whole or in part, on the terms herein provided, a total of
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> shares of common stock of the Company (the &#147;Shares&#148;) at
$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> per share, which is not less than the fair market value of the Shares on the Date of Grant. The latest date on which this Stock Option, or any
part thereof, may be exercised is [MMDD, YYYY] (the &#147;Final Exercise Date&#148;). The Stock Option evidenced by this certificate is intended to be, and is hereby designated, a nonstatutory option, that is, an option that does <I>not</I> qualify
as an incentive stock option as defined in section 422 of the Internal Revenue Code of 1986, as amended from time to time (the &#147;Code&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Stock Option shall vest and become exercisable in equal amounts of [XXX] options per month for
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> months, such that the grant will be fully exercisable on [MMDD, YYYY]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding any other provision of this Stock Option, upon termination of the Participant&#146;s contractual relationship, any portion of
this Stock Option that is not then exercisable will promptly expire and the remainder of this Stock Option will remain exercisable for three months unless the Participant&#146;s service as a consultant is terminated for cause, this entire Stock
Option shall immediately expire and no portion thereof shall remain exercisable. In addition, in no event shall any portion of this Stock Option be exercisable after the Final Exercise Date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;Exercise of Stock Option. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each election to exercise this Stock Option shall be in writing, signed by the Participant or the Participant&#146;s executor, administrator,
or legally appointed representative (in the event of the Participant&#146;s incapacity) or the person or persons to whom this Stock Option is transferred by will or the applicable laws of descent and distribution (collectively, the &#147;Option
Holder&#148;), and received by the Company at its principal office, accompanied by this certificate and payment in full as provided in the Plan. Subject to the further terms and conditions provided in the Plan, the purchase price may be paid as
follows: (i)&nbsp;by delivery of cash or check acceptable to the Administrator; (ii)&nbsp;upon and following the registration of the common stock of the Company under the Securities and Exchange Act of 1934 and to the extent permitted be applicable
law (as determined by the Administrator), through a broker-assisted exercise program acceptable to the Administrator; or (iii)&nbsp;through the delivery of shares of common stock of the Company that have been outstanding for at least six months and
that have a fair market value equal to the exercise price; or (iv)&nbsp;through any combination of the foregoing. In the event that this Stock Option is exercised by an Option Holder other than the Participant, the Company will be under no
obligation to deliver Shares hereunder unless and until it is satisfied as to the authority of the Option Holder to exercise this Stock Option. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;Restrictions on Transfer of Shares. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If at the time this Stock Option is exercised the Company or any of its shareholders is a party to any agreement restricting the transfer of
any outstanding shares of the Company&#146;s common stock, the Administrator may provide that this Stock Option may be exercised only if the Shares so acquired are made subject to the transfer restrictions set forth in that agreement (or if more
than one such agreement is then in effect, the agreement or agreements specified by the Administrator). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;Withholding
Agreement to Provide Security. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If at the time this Stock Option is exercised the Company determines that under applicable law and
regulations it could be liable for the withholding of any federal or state tax upon exercise or with respect to a disposition of any Shares acquired upon exercise of this Stock Option, this Stock Option may not be exercised unless the person
exercising this Stock Option remits to the Company any amounts determined by the Company to be required to be withheld upon exercise (or makes other arrangements satisfactory to the Company for the payment of such taxes) and gives such security as
the Company deems adequate to meet its potential liability for the withholding of tax upon a disposition of the Shares and agrees to augment such security from time to time in any amount reasonably determined by the Company to be necessary to
preserve the adequacy of such security. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.&nbsp;&nbsp;&nbsp;&nbsp;Nontransferability of Stock Option. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Stock Option is not transferable by the Participant otherwise than by will or the laws of descent and distribution, and is exercisable
during the Participant&#146;s lifetime only by the Participant (or in the event of the Participant&#146;s incapacity, the person or persons legally appointed to act on the Participant&#146;s behalf). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.&nbsp;&nbsp;&nbsp;&nbsp;Provisions of the Plan. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Stock Option is subject to the provisions of the Plan, which are incorporated herein by reference. A copy of the Plan an prospectus as in
effect on the date of the grant of this Stock Option has been furnished to the Participant. By exercising all or any part of this Stock Option, the Participant agrees to be bound by the terms of the Plan and this certificate. All initially
capitalized terms used herein will have the meaning specified in the Plan, unless another meaning is specified herein. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this instrument to be executed by its duly authorized
officer. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Galena Biopharma, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Name:</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Title:</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Acknowledged</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>6
<FILENAME>d556278dex109.htm
<DESCRIPTION>EX-10.9
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.9</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>E<SMALL>XHIBIT</SMALL> 10.9 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS L<SMALL>IFE</SMALL> S<SMALL>CIENCES</SMALL> G<SMALL>ROUP</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R<SMALL>ESTRICTED</SMALL> S<SMALL>TOCK</SMALL> U<SMALL>NIT</SMALL> G<SMALL>RANT</SMALL> N<SMALL>OTICE</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(2017 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL>) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SELLAS Life Sciences Group, Inc. (the &#147;<B><I>Company</I></B>&#148;), pursuant to its 2017 Equity Incentive Plan (the &#147;<B><I>Plan</I></B>&#148;),
hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company&#146;s Common Stock (&#147;<B><I>Restricted Stock Units</I></B>&#148;) set forth below (the &#147;<B><I>Award</I></B>&#148;). The Award is subject to
all of the terms and conditions as set forth in this notice of grant (this &#147;<B><I>Restricted Stock Unit Grant Notice</I></B>&#148;), and in the Plan and the Restricted Stock Unit Award Agreement (the &#147;<B><I>Award Agreement</I></B>&#148;),
both of which are attached hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined herein shall have the meanings set forth in the Plan or the Award Agreement. In the event of any conflict between the terms in this
Restricted Stock Unit Grant Notice or the Award Agreement and the Plan, the terms of the Plan shall control. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="7%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Participant:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date of Grant:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting Commencement Date:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of Restricted Stock Units:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="22%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Vesting Schedule: </B> </P></TD>
<TD>[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,<I> </I>subject to Participant&#146;s Continuous Service through each such vesting date.] </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="22%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Issuance Schedule: </B> </P></TD>
<TD>Subject to any Capitalization Adjustment, one share of Common Stock (or its cash equivalent, at the discretion of the Company) will be issued for each Restricted Stock Unit that vests at the time set forth in Section&nbsp;6 of the Award
Agreement. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Terms/Acknowledgements:</B> Participant acknowledges receipt of, and understands and agrees to, this Restricted
Stock Unit Grant Notice, the Award Agreement and the Plan. Participant acknowledges and agrees that this Restricted Stock Unit Grant Notice and the Award Agreement may not be modified, amended, or revised except as provided in the Plan. Participant
further acknowledges that as of the Date of Grant, this Restricted Stock Unit Grant Notice, the Award Agreement and the Plan set forth the entire understanding between Participant and the Company regarding the acquisition of the Common Stock
pursuant to the Award specified above and supersede all prior oral and written agreements on the terms of this Award, with the exception, if applicable, of (i)&nbsp;equity awards previously granted and delivered to Participant, (ii)&nbsp;any
compensation recovery policy that is adopted by the Company or is otherwise required by applicable law and (iii)&nbsp;any written employment or severance arrangement or other written agreement entered into between the Company and Participant
specifying the terms that should govern this Award upon the terms and conditions set forth therein. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By accepting this Award, Participant acknowledges having received and read the Restricted Stock Unit Grant
Notice, the Award Agreement and the Plan and agrees to all of the terms and conditions set forth in these documents. Participant consents to receive Plan and related documents by electronic delivery and to participate in the Plan through an <FONT
STYLE="white-space:nowrap">on-line</FONT> or electronic system established and maintained by the Company or another third party designated by the Company. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SELLAS L<SMALL>IFE</SMALL> S<SMALL>CIENCES</SMALL> G<SMALL>ROUP</SMALL>, I<SMALL>NC</SMALL>.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>P<SMALL>ARTICIPANT</SMALL></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>TTACHMENTS</SMALL></B><SMALL></SMALL>: Award Agreement and 2017 Equity Incentive Plan </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>TTACHMENT</SMALL> I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS L<SMALL>IFE</SMALL> S<SMALL>CIENCES</SMALL> G<SMALL>ROUP</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2017 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R<SMALL>ESTRICTED</SMALL> S<SMALL>TOCK</SMALL> U<SMALL>NIT</SMALL> A<SMALL>WARD</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Restricted Stock Unit Grant Notice (the &#147;<B><I>Grant Notice</I></B>&#148;) and this Restricted Stock Unit Award Agreement
(the &#147;<B><I>Agreement</I></B>&#148;), SELLAS Life Sciences Group, Inc. (the &#147;<B><I>Company</I></B>&#148;) has awarded you (&#147;<B><I>Participant</I></B>&#148;) a Restricted Stock Unit Award (the &#147;<B><I>Award</I></B>&#148;) pursuant
to the Company&#146;s 2017 Equity Incentive Plan (the &#147;<B><I>Plan</I></B>&#148;) for the number of Restricted Stock Units/shares indicated in the Grant Notice. Capitalized terms not explicitly defined in this Agreement or the Grant Notice shall
have the same meanings given to them in the Plan. The terms of your Award, in addition to those set forth in the Grant Notice, are as follows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>G<SMALL>RANT</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> A<SMALL>WARD</SMALL>. </B>This Award represents
the right to be issued on a future date one (1)&nbsp;share of Common Stock for each Restricted Stock Unit that vests on the applicable vesting date(s) (subject to any adjustment under Section&nbsp;3 below) as indicated in the Grant Notice. As of the
Date of Grant, the Company will credit to a bookkeeping account maintained by the Company for your benefit (the &#147;<B><I>Account</I></B>&#148;) the number of Restricted Stock Units/shares of Common Stock subject to the Award. Notwithstanding the
foregoing, the Company reserves the right to issue you the cash equivalent of Common Stock, in part or in full satisfaction of the delivery of Common Stock in connection with the vesting of the Restricted Stock Units, and, to the extent applicable,
references in this Agreement and the Grant Notice to Common Stock issuable in connection with your Restricted Stock Units will include the potential issuance of its cash equivalent pursuant to such right. This Award was granted in consideration of
your services to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>V<SMALL>ESTING</SMALL>. </B>Subject to the limitations contained
herein, your Award will vest, if at all, in accordance with the vesting schedule provided in the Grant Notice. Vesting will cease upon the termination of your Continuous Service and the Restricted Stock Units credited to the Account that were not
vested on the date of such termination will be forfeited at no cost to the Company and you will have no further right, title or interest in or to such Award or the shares of Common Stock to be issued in respect of such portion of the Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>N<SMALL>UMBER</SMALL> <SMALL>OF</SMALL> S<SMALL>HARES</SMALL>. </B>The number of Restricted Stock Units
subject to your Award may be adjusted from time to time for Capitalization Adjustments, as provided in the Plan. Any additional Restricted Stock Units, shares, cash or other property that becomes subject to the Award pursuant to this Section&nbsp;3,
if any, shall be subject, in a manner determined by the Board, to the same forfeiture restrictions, restrictions on transferability, and time and manner of delivery as applicable to the other Restricted Stock Units and shares covered by your Award.
Notwithstanding the provisions of this Section&nbsp;3, no fractional shares or rights for fractional shares of Common Stock shall be created pursuant to this Section&nbsp;3. Any fraction of a share will be rounded down to the nearest whole share.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>S<SMALL>ECURITIES</SMALL> L<SMALL>AW</SMALL> C<SMALL>OMPLIANCE</SMALL></B><SMALL></SMALL>. You may
not be issued any Common Stock under your Award unless the shares of Common Stock underlying the Restricted Stock Units are either (i)&nbsp;then registered under the Securities Act, or (ii)&nbsp;the Company has determined that such issuance would be
exempt from the registration requirements of the Securities Act. Your Award must also comply with other applicable laws and regulations governing the Award, and you shall not receive such Common Stock if the Company determines that such receipt
would not be in material compliance with such laws and regulations. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>T<SMALL>RANSFER</SMALL>
R<SMALL>ESTRICTIONS</SMALL></B><SMALL></SMALL>. Prior to the time that shares of Common Stock have been delivered to you, you may not transfer, pledge, sell or otherwise dispose of this Award or the shares issuable in respect of your Award, except
as expressly provided in this Section&nbsp;5. For example, you may not use shares that may be issued in respect of your Restricted Stock Units as security for a loan. The restrictions on transfer set forth herein will lapse upon delivery to you of
shares in respect of your vested Restricted Stock Units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) Death</B>. Your Award is transferable by will and by the laws of descent
and distribution. At your death, vesting of your Award will cease and your executor or administrator of your estate shall be entitled to receive, on behalf of your estate, any Common Stock or other consideration that vested but was not issued before
your death. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) Domestic Relations Orders.</B> Upon receiving written permission from the Board or its duly authorized designee, and
provided that you and the designated transferee enter into transfer and other agreements required by the Company, you may transfer your right to receive the distribution of Common Stock or other consideration hereunder, pursuant to a domestic
relations order, marital settlement agreement or other divorce or separation instrument as permitted by applicable law that contains the information required by the Company to effectuate the transfer. You are encouraged to discuss the proposed terms
of any division of this Award with the Company General Counsel prior to finalizing the domestic relations order or marital settlement agreement to verify that you may make such transfer, and if so, to help ensure the required information is
contained within the domestic relations order or marital settlement agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.&nbsp;&nbsp;&nbsp;&nbsp;D<SMALL>ATE</SMALL>
<SMALL>OF</SMALL> I<SMALL>SSUANCE</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>The issuance of shares in respect of the Restricted Stock Units is intended to
comply with Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)(4)</FONT> and will be construed and administered in such a manner. Subject to the satisfaction of the Withholding Obligation set forth in Section&nbsp;11 of
this Agreement, in the event one or more Restricted Stock Units vests, the Company shall issue to you one (1)&nbsp;share of Common Stock for each Restricted Stock Unit that vests on the applicable vesting date(s) (subject to any adjustment under
Section&nbsp;3 above, and subject to any different provisions in the Grant Notice). Each issuance date determined by this paragraph is referred to as an &#147;<B><I>Original Issuance Date</I></B>&#148;. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>If the Original Issuance Date falls on a date that is not a business day, delivery shall instead occur on the next following
business day. In addition, if: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>the Original Issuance Date does not occur (1)&nbsp;during an &#147;open window period&#148;
applicable to you, as determined by the Company in accordance with the Company&#146;s then-effective policy on trading in Company securities, or (2)&nbsp;on a date when you are otherwise permitted to sell shares of Common Stock on an established
stock exchange or stock market (including but not limited to under a previously established written trading plan that meets the requirements of Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act and was entered into in
compliance with the Company&#146;s policies (a &#147;<B><I><FONT STYLE="white-space:nowrap">10b5-1</FONT> Arrangement</I></B>&#148;)), <I>and</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>either (1)&nbsp;a Withholding Obligation does not apply, or (2)&nbsp;the Company decides, prior to the Original Issuance Date,
(A)&nbsp;not to satisfy the Withholding Obligation by withholding shares of Common Stock from the shares otherwise due, on the Original Issuance Date, to you under this Award, and (B)&nbsp;not to permit you to enter into a &#147;same day sale&#148;
commitment with a broker-dealer pursuant to Section&nbsp;11 of this Agreement (including but not limited to a commitment under a <FONT STYLE="white-space:nowrap">10b5-1</FONT> Arrangement) and (C)&nbsp;not to permit you to pay your Withholding
Obligation in cash, </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>then</U> the shares that would otherwise be issued to you on the Original Issuance Date will
not be delivered on such Original Issuance Date and will instead be delivered on the first business day when you are not prohibited from selling shares of the Company&#146;s Common Stock in the open public market, but in no event later than
December&nbsp;31 of the calendar year in which the Original Issuance Date occurs (that is, the last day of your taxable year in which the Original Issuance Date occurs), or, <U>if and only if</U> permitted in a manner that complies with Treasury
Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)(4),</FONT> no later than the date that is the 15th day of the third calendar month of the applicable year following the year in which the shares of Common Stock under this Award
are no longer subject to a &#147;substantial risk of forfeiture&#148; within the meaning of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(d).</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>The form of delivery (<I>e.g.</I>, a stock certificate or electronic entry evidencing such shares) shall be determined by the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>D<SMALL>IVIDENDS</SMALL>.</B> You shall receive no benefit or adjustment to your Award with
respect to any cash dividend, stock dividend or other distribution that does not result from a Capitalization Adjustment; provided, however, that this sentence will not apply with respect to any shares of Common Stock that are delivered to you in
connection with your Award after such shares have been delivered to you. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>R<SMALL>ESTRICTIVE</SMALL>
L<SMALL>EGENDS</SMALL>.</B> The shares of Common Stock issued in respect of your Award shall be endorsed with appropriate legends as determined by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>E<SMALL>XECUTION</SMALL> <SMALL>OF</SMALL> D<SMALL>OCUMENTS</SMALL>.</B> You hereby acknowledge and agree
that the manner selected by the Company by which you indicate your consent to your Grant Notice is also deemed to be your execution of your Grant Notice and of this Agreement. You further agree that such manner of indicating consent may be relied
upon as your signature for establishing your execution of any documents to be executed in the future in connection with your Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>A<SMALL>WARD</SMALL> <SMALL>NOT</SMALL> <SMALL>A</SMALL> S<SMALL>ERVICE</SMALL>
C<SMALL>ONTRACT</SMALL></B><SMALL></SMALL>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>Nothing in this Agreement (including, but not limited to, the vesting of your Award
or the issuance of the shares in respect of your Award), the Plan or any covenant of good faith and fair dealing that may be found implicit in this Agreement or the Plan shall: (i)&nbsp;confer upon you any right to continue in the employ or service
of, or affiliation with, the Company or an Affiliate; (ii)&nbsp;constitute any promise or commitment by the Company or an Affiliate regarding the fact or nature of future positions, future work assignments, future compensation or any other term or
condition of employment or affiliation; (iii)&nbsp;confer any right or benefit under this Agreement or the Plan unless such right or benefit has specifically accrued under the terms of this Agreement or Plan; or (iv)&nbsp;deprive the Company of the
right to terminate you at will and without regard to any future vesting opportunity that you may have. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>By accepting this Award,
you acknowledge and agree that the right to continue vesting in the Award pursuant to the vesting schedule provided in the Grant Notice may not be earned unless (in addition to any other conditions described in the Grant Notice and this Agreement)
you continue as an employee, director or consultant at the will of the Company and affiliate, as applicable (not through the act of being hired, being granted this Award or any other award or benefit) and that the Company has the right to
reorganize, sell, <FONT STYLE="white-space:nowrap">spin-out</FONT> or otherwise restructure one or more of its businesses or Affiliates at any time or from time to time, as it deems appropriate (a &#147;<B><I>reorganization</I></B>&#148;). You
acknowledge and agree that such a reorganization could result in the termination of your Continuous Service, or the termination of Affiliate status of your employer and the loss of benefits available to you under this Agreement, including but not
limited to, the termination of the right to continue vesting in the Award. You further acknowledge and agree that this Agreement, the Plan, the transactions contemplated </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
hereunder and the vesting schedule set forth herein or any covenant of good faith and fair dealing that may be found implicit in any of them do not constitute an express or implied promise of
continued engagement as an employee or consultant for the term of this Agreement, for any period, or at all, and shall not interfere in any way with the Company&#146;s right to terminate your Continuous Service at any time, with or without your
cause or notice, or to conduct a reorganization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.&nbsp;&nbsp;&nbsp;&nbsp;W<SMALL>ITHHOLDING</SMALL> O<SMALL>BLIGATION</SMALL>.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) On each vesting date, and on or before the time you receive a distribution of the shares of Common Stock in respect of your
Restricted Stock Units, and at any other time as reasonably requested by the Company in accordance with applicable tax laws, you hereby authorize any required withholding from the Common Stock issuable to you and/or otherwise agree to make adequate
provision, including in cash, for any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or any Affiliate that arise in connection with your Award (the &#147;<B><I>Withholding
Obligation</I></B>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) By accepting this Award, you acknowledge and agree that the Company or any Affiliate may, in its sole
discretion, satisfy all or any portion of the Withholding Obligation relating to your Restricted Stock Units by any of the following means or by a combination of such means: (i)&nbsp;causing you to pay any portion of the Withholding Obligation in
cash; (ii)&nbsp;withholding from any compensation otherwise payable to you by the Company; (iii)&nbsp;withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to you in connection with the Award with a Fair
Market Value (measured as of the date shares of Common Stock are issued pursuant to Section&nbsp;6) equal to the amount of such Withholding Obligation; provided, however, that the number of such shares of Common Stock so withheld will not exceed the
amount necessary to satisfy the Withholding Obligation using the maximum statutory withholding rates for federal, state, local and foreign tax purposes, including payroll taxes, that are applicable to supplemental taxable income; and
<I>provided</I>, further, that to the extent necessary to qualify for an exemption from application of Section&nbsp;16(b) of the Exchange Act, if applicable, such share withholding procedure will be subject to the express prior approval of the Board
or the Company&#146;s Compensation Committee; and/or (iv)&nbsp;permitting or requiring you to enter into a &#147;same day sale&#148; commitment, if applicable, with a broker-dealer that is a member of the Financial Industry Regulatory Authority (a
&#147;<B><I>FINRA Dealer</I></B>&#148;), pursuant to this authorization and without further consent, whereby you irrevocably elect to sell a portion of the shares to be delivered in connection with your Restricted Stock Units to satisfy the
Withholding Obligation and whereby the FINRA Dealer irrevocably commits to forward the proceeds necessary to satisfy the Withholding Obligation directly to the Company and/or its Affiliates. Unless the Withholding Obligation is satisfied, the
Company shall have no obligation to deliver to you any Common Stock or any other consideration pursuant to this Award. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) In the event
the Withholding Obligation arises prior to the delivery to you of Common Stock or it is determined after the delivery of Common Stock to you that the amount of the Withholding Obligation was greater than the amount withheld by the Company, you agree
to indemnify and hold the Company harmless from any failure by the Company to withhold the proper amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>T<SMALL>AX</SMALL> C<SMALL>ONSEQUENCES</SMALL>.</B> The Company has no duty or obligation to minimize the
tax consequences to you of this Award and shall not be liable to you for any adverse tax consequences to you arising in connection with this Award. You are hereby advised to consult with your own personal tax, financial and/or legal advisors
regarding the tax consequences of this Award and by signing the Grant Notice, you have agreed that you have done so or knowingly and voluntarily declined to do so. You understand that you (and not the Company) shall be responsible for your own tax
liability that may arise as a result of this investment or the transactions contemplated by this Agreement. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>U<SMALL>NSECURED</SMALL> O<SMALL>BLIGATION</SMALL>. </B>Your
Award is unfunded, and as a holder of a vested Award, you shall be considered an unsecured creditor of the Company with respect to the Company&#146;s obligation, if any, to issue shares or other property pursuant to this Agreement. You shall not
have voting or any other rights as a stockholder of the Company with respect to the shares to be issued pursuant to this Agreement until such shares are issued to you pursuant to Section&nbsp;6 of this Agreement. Upon such issuance, you will obtain
full voting and other rights as a stockholder of the Company. Nothing contained in this Agreement, and no action taken pursuant to its provisions, shall create or be construed to create a trust of any kind or a fiduciary relationship between you and
the Company or any other person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>N<SMALL>OTICES</SMALL></B><SMALL></SMALL>. Any notice or request
required or permitted hereunder shall be given in writing (including electronically) and will be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five (5)&nbsp;days after deposit in the United
States mail, postage prepaid, addressed to you at the last address you provided to the Company. The Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this Award by electronic means or to
request your consent to participate in the Plan by electronic means. By accepting this Award, you consent to receive such documents by electronic delivery and to participate in the Plan through an <FONT STYLE="white-space:nowrap">on-line</FONT> or
electronic system established and maintained by the Company or another third party designated by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>H<SMALL>EADINGS</SMALL></B><SMALL></SMALL>. The headings of the Sections in this Agreement are inserted
for convenience only and shall not be deemed to constitute a part of this Agreement or to affect the meaning of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>M<SMALL>ISCELLANEOUS</SMALL></B><SMALL></SMALL>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>The rights and obligations of the Company under your Award shall be transferable by the Company to any one or more persons or
entities, and all covenants and agreements hereunder shall inure to the benefit of, and be enforceable by, the Company&#146;s successors and assigns. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the
Company to carry out the purposes or intent of your Award. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>You acknowledge and agree that you have reviewed your Award in its
entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your Award and fully understand all provisions of your Award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>This Agreement shall be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies
or national securities exchanges as may be required. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e) </B>All obligations of the Company under the Plan and this Agreement shall be
binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and/or assets of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>G<SMALL>OVERNING</SMALL> P<SMALL>LAN</SMALL> D<SMALL>OCUMENT</SMALL></B><SMALL></SMALL>. Your Award is
subject to all the provisions of the Plan, the provisions of which are hereby made a part of your Award, and is further subject to all interpretations, amendments, rules and regulations which may from time to time be promulgated and adopted pursuant
to the Plan. Your Award (and any compensation paid or shares issued under your Award) is subject to recoupment in accordance with The Dodd&#150;Frank Wall Street Reform and Consumer Protection Act and any implementing regulations thereunder, any
clawback policy adopted by the Company and any </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
compensation recovery policy otherwise required by applicable law. No recovery of compensation under such a clawback policy will be an event giving rise to a right to voluntarily terminate
employment upon a resignation for &#147;good reason,&#148; or for a &#147;constructive termination&#148; or any similar term under any plan of or agreement with the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>18.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>E<SMALL>FFECT</SMALL> <SMALL>ON</SMALL> O<SMALL>THER</SMALL> E<SMALL>MPLOYEE</SMALL>
B<SMALL>ENEFIT</SMALL> P<SMALL>LANS</SMALL>.</B> The value of the Award subject to this Agreement shall not be included as compensation, earnings, salaries, or other similar terms used when calculating benefits under any employee benefit plan (other
than the Plan) sponsored by the Company or any Affiliate except as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any or all of the employee benefit plans of the Company or any
Affiliate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>19.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>S<SMALL>EVERABILITY</SMALL></B><SMALL></SMALL>. If all or any part of this Agreement or
the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity shall not invalidate any portion of this Agreement or the Plan not declared to be unlawful or invalid. Any Section of this
Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful
and valid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>20.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>O<SMALL>THER</SMALL> D<SMALL>OCUMENTS</SMALL></B><SMALL></SMALL>. You hereby acknowledge
receipt or the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act. In addition, you acknowledge receipt of the Company&#146;s policy permitting certain individuals to sell shares
only during certain &#147;window&#148; periods and the Company&#146;s insider trading policy, in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>A<SMALL>MENDMENT</SMALL>.</B> This Agreement may not be modified, amended or terminated except by an
instrument in writing, signed by you and by a duly authorized representative of the Company. Notwithstanding the foregoing, this Agreement may be amended solely by the Board by a writing which specifically states that it is amending this Agreement,
so long as a copy of such amendment is delivered to you, and provided that, except as otherwise expressly provided in the Plan, no such amendment materially adversely affecting your rights hereunder may be made without your written consent. Without
limiting the foregoing, the Board reserves the right to change, by written notice to you, the provisions of this Agreement in any way it may deem necessary or advisable to carry out the purpose of the Award as a result of any change in applicable
laws or regulations or any future law, regulation, ruling, or judicial decision, provided that any such change shall be applicable only to rights relating to that portion of the Award which is then subject to restrictions as provided herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>22.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>C<SMALL>OMPLIANCE</SMALL> <SMALL>WITH</SMALL>
S<SMALL>ECTION</SMALL></B><SMALL><B></B><B></B></SMALL><B>&nbsp;409A <SMALL>OF</SMALL> <SMALL>THE</SMALL> C<SMALL>ODE</SMALL></B><SMALL><I></I></SMALL><I>.</I> This Award is intended to be exempt from the application of Section&nbsp;409A of the
Code, including but not limited to by reason of complying with the &#147;short-term deferral&#148; rule set forth in Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)(4)</FONT> and any ambiguities herein shall be
interpreted accordingly. Notwithstanding the foregoing, if it is determined that the Award fails to satisfy the requirements of the short-term deferral rule and is otherwise not exempt from, and determined to be deferred compensation subject to
Section&nbsp;409A of the Code, this Award shall comply with Section&nbsp;409A to the extent necessary to avoid adverse personal tax consequences and any ambiguities herein shall be interpreted accordingly. If it is determined that the Award is
deferred compensation subject to Section&nbsp;409A and you are a &#147;Specified Employee&#148; (within the meaning set forth in Section&nbsp;409A(a)(2)(B)(i) of the Code) as of the date of your &#147;Separation from Service&#148; (as defined in
Section&nbsp;409A), then the issuance of any shares that would otherwise be made upon the date of your Separation from Service or within the first six (6)&nbsp;months thereafter will not be made on the originally scheduled date(s) and will instead
be issued in a lump sum on the date that is six (6)&nbsp;months and one day after the date of the Separation from Service, with the balance of the shares issued thereafter </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in accordance with the original vesting and issuance schedule set forth above, but if and only if such delay in the issuance of the shares is necessary to avoid the imposition of adverse taxation
on you in respect of the shares under Section&nbsp;409A of the Code. Each installment of shares that vests is intended to constitute a &#147;separate payment&#148; for purposes of Treasury Regulation
<FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2).</FONT><B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * * </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Restricted Stock Unit Award Agreement shall be deemed to be signed by the Company and the Participant upon the signing by the Participant
of the Restricted Stock Unit Grant Notice to which it is attached. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>TTACHMENT</SMALL> II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2017 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL> </B></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.73
<SEQUENCE>7
<FILENAME>d556278dex1073.htm
<DESCRIPTION>EX-10.73
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.73</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.73 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT EXCHANGE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Warrant Exchange Agreement (this &#147;<U>Agreement</U>&#148;) is made as of February 6, 2018 (the&nbsp;&#148;<U>Effective
Date</U>&#148;), by and between SELLAS Life Sciences Group, Inc., a Delaware corporation (the &#147;Company&#148;), and CVI INVESTMENTS, INC. (the &#147;<U>Holder</U>&#148;). This Agreement hereby supersedes and replaces that certain Warrant
Exchange Agreement entered into by the Company and Holder effective as of the Effective Date (the &#147;<U>Original Agreement</U>&#148;), and the Original Agreement shall have no further force or effect from and after the execution of this
Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Holder currently holds 99,333 warrants (the &#147;<U>Warrants</U>&#148;) to purchase shares of the Company&#146;s common stock,
par value $0.0001 per share (&#147;<U>Common Stock</U>&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, subject to the terms and conditions set forth herein, the
Company and the Holder desire to cancel and retire the Warrants in exchange (the &#147;<U>Exchange</U>&#148;) for a convertible promissory note (the &#147;<U>Exchange Note</U>&#148;), in the amount of $232,440.00 on such other terms as set forth in
the form of Exchange Note attached as Exhibit A, in reliance on the exemption from registration provided by Section&nbsp;3(a)(9) of the Securities Act of 1933, as amended (the &#147;<U>Securities Act</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt of which is
hereby acknowledged, the Company and the Holder hereby agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 1. EXCHANGE AND TERMINATION. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a)
In consideration of and in express reliance upon the representations, warranties, covenants, terms and conditions of this Agreement, the Holder agrees to deliver and surrender to the Company for cancellation the Warrants and the Original Agreement
in exchange for the Exchange Note, and the Company agrees to execute and deliver the Exchange Note to the Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) The closing under
this Agreement (the &#147;<U>Closing</U>&#148;) shall take place upon the satisfaction of each of the conditions set forth in Sections 4 and 5 hereof (the &#147;<U>Closing Date</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) If the Closing has not occurred by the third trading day after the date hereof, this Agreement shall terminate. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 2. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby represents and warrants as of the date hereof to, and covenants with, the Holder as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <B>Organization and Standing. </B>The Company has been duly incorporated and is validly existing as a corporation in good standing under the
laws of Delaware, has full corporate power and authority to own or lease its properties and conduct its business as presently conducted, and is duly qualified as a foreign corporation and in good standing in each jurisdiction in which the character
of the property owned or leased or the nature of the business transacted by it makes qualification necessary, except where the failure to be so qualified would not have a Material Adverse Effect (as defined below). As used in this Agreement,
&#147;<U>Material Adverse Effect</U>&#148; means any material adverse effect on the business, properties, assets, liabilities, operations, results of operations, condition (financial or otherwise) or prospects of the Company and its subsidiaries
(the &#147;<U>Subsidiaries</U>&#148;), if any, individually or taken as a whole, or on the transactions contemplated hereby or on the Exchange Documents (as defined below) or by the agreements and instruments to be entered into (or entered into) in
connection herewith or therewith, or on the authority or ability of the Company to perform its obligations under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b)
<B>Authorization; Corporate Power. </B>This Agreement has been duly authorized, validly executed and delivered on behalf of the Company and is a valid and binding obligation of the Company enforceable against the Company in accordance with its terms
(except as limited by (i) applicable bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or affecting the enforcement of creditors&#146; rights generally, and (ii)&nbsp;equitable principles generally, including any
specific performance), and the Company has the requisite corporate power and authority to execute and deliver this Agreement and the other agreements and documents contemplated hereby and to perform its obligations hereunder and thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <B>Valid Issuance and Delivery of New Securities. </B>The issuance of the Exchange Note is duly authorized and, upon issuance in accordance
with the terms of this Agreement, the shares of Common Stock issuable upon conversion or otherwise pursuant to the terms of the Exchange Note (collectively, the &#147;<U>Conversion Shares</U>&#148;, and together with the Exchange Note, the
&#147;<U>New Securities</U>&#148;) shall be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and free from all preemptive or similar rights, mortgages, defects, claims, liens, pledges, charges, taxes, rights of
first refusal, encumbrances, security interests and other encumbrances (collectively &#147;<U>Liens</U>&#148;) with respect to the issuance thereof. As of the date hereof, the Company has reserved from its duly authorized capital stock not less than
150% of the maximum number of Conversion Shares issuable upon conversion of the Exchange Notes (assuming for purposes hereof that (x)&nbsp;the Exchange Notes are convertible at the Alternate Conversion Price (as defined in the Notes) assuming a date
of conversion as of the date hereof, (y)&nbsp;interest on the Notes shall accrue through the Maturity Date (as defined in the Exchange Note) and will be converted in shares of Common Stock (as defined below) at a conversion price equal to the
Alternate Conversion Price assuming a date of conversion as of the date hereof and (z)&nbsp;any such conversion shall not take into account any limitations on the conversion of the Exchange Notes set forth in the Exchange Notes). Upon issuance or
conversion in accordance with the Exchange Notes the Conversion Shares when issued, will be validly issued, fully paid and nonassessable and free from all preemptive or similar rights or Liens with respect to the issue thereof, with the holders
being entitled to all rights accorded to a holder of Common Stock. The offer and issuance by the Company of the New Securities is exempt from registration under the Securities Act. Each of the New Securities will be freely tradable and shall not be
required to bear, and shall not bear, any Securities Act or other restrictive legend. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <B>Consents. </B>No consent, waiver, approval or authorization of or designation, declaration
or filing with any Person (as defined below) on the part of the Company is required in connection with the valid execution and delivery of this Agreement or the offer, sale or issuance of the New Securities or the consummation of any other
transaction contemplated by this Agreement. For purposes of this Agreement, (i) &#147;Person&#148; means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other
entity and any Governmental Entity or any department or agency thereof; and (ii) &#147;<U>Governmental Entity</U>&#148; means any nation, state, county, city, town, village, district, or other political jurisdiction of any nature, federal, state,
local, municipal, foreign, or other government, governmental or quasi-governmental authority of any nature (including any governmental agency, branch, department, official, or entity and any court or other tribunal), multi-national organization or
body; or body exercising, or entitled to exercise, any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power of any nature or instrumentality of any of the foregoing, including any entity or enterprise
owned or controlled by a government or a public international organization or any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <B>No Default or Violation.
</B>The execution and delivery of the Agreement and the consummation of the transactions contemplated by this Agreement by the Company will not (i)&nbsp;result in a breach of or a default under any of the terms or provisions of (A)&nbsp;the
Company&#146;s certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws,</FONT> or (B)&nbsp;any material provision of any indenture, mortgage, deed of trust or other material agreement or instrument to which the Company is a party or
by which it or any of its material properties or assets is bound or (ii)&nbsp;result in a violation of any provision of any law, statute, rule, regulation, or any existing applicable decree, judgment or order by any court, Federal or state
regulatory body, administrative agency, or other governmental body having jurisdiction over the Company, or any of its material properties or assets except in the case of clauses (i)(B) or (ii)&nbsp;for any such breaches, defaults or violations
which would not have a Material Adverse Effect. The Company has not violated any law or any governmental regulation or requirement which violation has had or would reasonably be expected to have a Material Adverse Effect, and the Company has not
received written notice of any such violation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) <B>Offering. </B>Neither the Company, nor any of its affiliates, nor any Person acting
on its or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D) in connection with the offer or sale of the New Securities. The Company shall be responsible for the payment of any
placement agent&#146;s fees, financial advisory fees, or brokers&#146; commissions (other than for persons engaged by the Holder or its investment advisor) relating to or arising out of the transactions contemplated hereby. The Company shall pay,
and hold the Holder harmless against, any liability, loss or expense (including, without limitation, attorney&#146;s fees and out-of-pocket expenses) arising in connection with any such claim. Neither the Company nor any of its Subsidiaries has
engaged any placement agent or other agent in connection with the Exchange and the issuance of the New Securities. The offer, exchange and issuance, as applicable, of the New Securities as contemplated by this Agreement are exempt from the
registration requirements of the Securities Act and the qualification or registration requirements of state securities laws or other applicable blue sky laws. Neither the Company nor any authorized agent acting on its behalf will take any action
hereafter that would cause the loss of such exemptions. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">g) <B>Absence of Litigation. </B>Except as set forth in the reports, schedules, forms, statements
and other documents required to be filed by the Company with the Securities and Exchange Commission (the &#147;<U>SEC</U>&#148;) pursuant to the reporting requirements of the Securities Exchange Act of 1934, as amended (the &#147;<U>Exchange
Act</U>&#148;), there is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the Company, threatened against or affecting
the Company, the Common Stock, any securities of the Company or any of the Company&#146;s officers or directors in their capacities as such. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">h) <B>No Group. </B>The Company acknowledges that, to the Company&#146;s knowledge, the Holder is acting independently in connection with this
Agreement and the transactions contemplated hereby, and is not acting as part of a &#147;group&#148; as such term is defined under Section&nbsp;13(d) of the Securities Act and the rules and regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">i) <B>Validity; Enforcement. </B>This Agreement and each other Exchange Document to which the Company is a party have been duly and validly
authorized, executed and delivered on behalf of the Company and shall constitute the legal, valid and binding obligations of the Company enforceable against the Company in accordance with their respective terms, except as such enforceability may be
limited by general principles of equity or to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable creditors&#146; rights and remedies.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">j) [Intentionally Omitted.] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">k) <B>Disclosure of Agreement. </B>On or before 8:30 a.m., New York City time, on March 9, 2018 (the &#147;<U>Cleansing Deadline</U>&#148;),
the Company shall have publicly, whether through one or more press releases or Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC, all material terms of the transactions contemplated hereby and any other material,
nonpublic information provided to the Holder from the Company or any of its Subsidiaries or any of their respective officers, directors, employees, affiliates or agents, including by attaching the form of this Agreement as an exhibit to a Current
Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC prior to the Cleansing Deadline. From and after the Cleansing Deadline, the Holder shall not be in possession of any material, nonpublic information received from the
Company or any of its Subsidiaries or any of their respective officers, directors, employees, affiliates or agents, that has not been publicly disclosed. The Company shall not, and shall cause its officers, directors, employees, affiliates and
agents, not to, provide the Holder with any material, nonpublic information regarding the Company from and after the Cleansing Deadline without the express written consent of the Holder. To the extent that the Company delivers any material, <FONT
STYLE="white-space:nowrap">non-public</FONT> information to the Holder after the Cleansing Deadline without the Holder&#146;s express prior written consent, the Company hereby covenants and agrees that the Holder shall not have any duty of
confidentiality to the Company, any of its Subsidiaries or any of their respective officers, directors, employees, affiliates or agents with respect to, or a duty to the Company, any of its Subsidiaries or any of their respective officers,
directors, employees, affiliates or agents not to trade on the basis of, such material, <FONT STYLE="white-space:nowrap">non-public</FONT> information. The Company shall not disclose the name of the Holder in any filing, announcement, release or
otherwise, unless such disclosure is required by law or regulation. In addition, effective upon the Cleansing Deadline, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written
or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, affiliates, employees or agents, on the one hand, and the Holder or any of its affiliates, on the other hand, shall terminate and be of no further
force or effect. The Company understands and confirms that the Holder will rely on the foregoing representations in effecting transactions in securities of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>l)</B> <B>Blue Sky. </B>The Company shall make all filings and reports relating to each
Exchange required under applicable securities or &#147;Blue Sky&#148; laws of the states of the United States following the date hereof, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">m) <B>No Integration. </B>None of the Company, its Subsidiaries, any of their affiliates, or any Person acting on their behalf shall, directly
or indirectly, make any offers or sales of any security (as defined in the Securities Act) or solicit any offers to buy any security or take any other actions, under circumstances that would require registration of any of the New Securities under
the Securities Act or cause this offering of the New Securities to be integrated with such offering or any prior offerings by the Company for purposes of Regulation D under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">n) <B>Listing. </B>The Company shall promptly secure the listing or designation for quotation (as applicable) of all of the Conversion Shares
upon the Nasdaq Capital Market (subject to official notice of issuance) and shall maintain such listing of all the Conversion Shares from time to time issuable under the terms of the Exchange Documents. The Company shall maintain the Common
Stock&#146;s authorization for quotation on the Nasdaq Capital Market. Neither the Company nor any of its Subsidiaries shall take any action which would be reasonably expected to result in the delisting or suspension of the Common Stock from the
Nasdaq Capital Market. The Company shall pay all fees and expenses in connection with satisfying its obligations under this Section&nbsp;2(n). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">o) <B>Holding Period. </B>For the purposes of Rule 144 and in reliance upon the advice of counsel, the Company acknowledges that (i)&nbsp;the
holding period of the Exchange Note (and upon conversion of the Exchange Note, the Conversion Shares) may be tacked onto the holding period of the Warrants, (ii)&nbsp;the Company is not aware of any event reasonably likely to occur that would
reasonably be expected to result in the New Securities becoming ineligible to be resold by the Holder pursuant to Rule 144 and (iii)&nbsp;in connection with any resale of any New Securities pursuant to Rule 144, the Holder shall solely be required
to provide reasonable assurances that such New Securities are eligible for resale, assignment or transfer under Rule 144, which shall not include an opinion of Holder&#146;s counsel. The Company shall be responsible for any transfer agent fees or
Depository Trust Company fees or legal fees of the Company&#146; s counsel with respect to the removal of legends, if any, or issuance of New Securities in accordance herewith. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 3. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE HOLDER. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) The Holder represents and warrants to and covenants with the Company that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <B>Valid Existence; Good Standing. </B>To the extent the Holder is a corporation, limited liability company or other type of entity, the
Holder is validly existing and in good standing under the laws of the jurisdiction of its organization. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <B>Authority; Authorization. </B>The Holder has full right, power, authority and capacity to
enter into this Agreement and the other agreements and documents contemplated hereby and to perform its obligations hereunder and thereunder and has taken all necessary action to authorize the execution, delivery and performance of this Agreement.
Upon the execution and delivery of this Agreement by the Holder, this Agreement shall constitute a valid and binding obligation of the Holder, enforceable in accordance with its terms (except (i)&nbsp;as limited by applicable bankruptcy, insolvency,
reorganization, moratorium or similar laws relating to or affecting the enforcement of creditors&#146; rights generally, and (ii)&nbsp;as limited by equitable principles generally, including any specific performance). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <B>Title. </B>The Holder owns and holds the entire right, title and interest in and to, and is the record and beneficial owner of, the
Warrants and the Holder owns the Warrants free and clear of all Liens. The Holder has the full power and authority to vote, transfer and dispose of the Warrants free and clear of any right or Liens. There is no restriction affecting the ability of
the Holder to transfer the legal and beneficial title and ownership of the Warrants to the Company and, at the Closing, the Company will acquire legal and valid title to the Warrants, free and clear of all Liens. Other than the transactions
contemplated by this Agreement, there is no outstanding vote, plan, pending proposal, or other right of any person to acquire all or any of the Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <B>Purchase of Warrants in the Registered Offering. </B>The Holder purchased the Warrants in the Company&#146;s offering of Common Stock
and warrants made pursuant to the Company&#146;s prospectus filed with the Securities and Exchange Commission (the &#147;SEC&#148;) pursuant to Rule 424(b)(5) on February 9, 2017 (the <B>&#147;Registered Offering&#148;).</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <B>Securities Act Exemption. </B>Neither the Holder nor anyone acting on behalf of the Holder has received any commission or remuneration
directly or indirectly in connection with or in order to solicit or facilitate the Exchange. The Holder understands that the Exchange contemplated hereby is intended to be exempt from registration by virtue of Section&nbsp;3(a)(9) of the Securities
Act. The Holder understands that the Company is relying upon the truth and accuracy of the representations, warranties, agreements, acknowledgments and understandings of the Holder set forth herein for purposes of qualifying for the exemption under
Section&nbsp;3(a)(9) of the Securities Act as well as qualifying for exemptions under applicable state securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) <B><FONT
STYLE="white-space:nowrap">Non-Affiliate.</FONT> </B>The Holder is not an Affiliate (as defined below) of the Company and has not been an Affiliate during the three months prior to the date hereof. &#147;Affiliate&#148; means, with respect to any
Person, any other Person that directly or indirectly controls, is controlled by, or is under common control with, such Person, it being understood for purposes of this definition that &#147;control&#148; of a Person means the power directly or
indirectly either to vote 10% or more of the stock having ordinary voting power for the election of directors of such Person or direct or cause the direction of the management and policies of such Person whether by contract or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) <B>Information. </B>The Holder has, in connection with its decision to acquire the Exchange Note, relied with respect to the Company and
its affairs solely upon the Company&#146;s filings with the SEC and the representations and warranties of the Company contained herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) <B>Advisors. </B>The Holder understands that nothing in this Agreement or any other materials
presented to the Holder in connection with the exchange of the Warrants and execution and acquisition of the Exchange Note constitutes legal, tax or investment advice. The Holder has consulted such legal, tax and investment advisors as it, in its
sole discretion, has deemed necessary or appropriate in connection with its acquisition of the Exchange Note. With respect to such matters, the Holder relies solely on such advisors and not on any statements or representations of the Company or any
of its agents, written or oral. The Holder understands that it (and not the Company) shall be responsible for its own tax liability that may arise as a result of this investment or the transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 4. CONDITIONS TO COMPANY&#146;S OBLIGATIONS AT THE CLOSING. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s obligation to complete the issuance of the Exchange Note and deliver the Exchange Note to the Holder at the Closing shall be
subject to the following conditions to the extent not waived by the Company: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <B>Execution and Delivery. </B>The Holder shall have
executed and delivered this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <B>Covenants. </B>The Holder shall have performed, satisfied and complied in all material
respects with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Holder at or prior to the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <B>Surrender of Warrants. </B>The Company shall have received in physical form or through book-entry transfer from the Holder all
certificates or book-entry notation representing the Warrants as well as the Original Agreement, to be exchanged for the Exchange Note. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <B>Representations and Warranties. </B>The representations and warranties of the Holder shall be true and correct in all material respects
as of the date when made and as of the Closing Date as though made at that time, except for representations and warranties that are expressly made as of a particular date, which shall be true and correct in all material respects as of such date.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 5. CONDITIONS TO THE HOLDER&#146;S OBLIGATIONS AT THE CLOSING. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Holder&#146;s obligation to deliver the Warrants and accept delivery of the Exchange Note shall be subject to the following conditions to
the extent not waived by the Holder: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <B>Execution and Delivery. </B>The Company shall have executed and delivered this Agreement and
the Exchange Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <B>Covenants. </B>The Company shall have performed, satisfied and complied in all material respects with all
covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <B>Delivery of Exchange Note. </B>The Company shall have delivered the Exchange Note in accordance with the instructions provided pursuant
to Section&nbsp;1.b) hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <B>Representations and Warranties. </B>Each of the representations and warranties of the Company shall
be true and correct in all material respects as of the date when made and as of the Closing Date as though made at that time, except for representations and warranties that are expressly made as of a particular date, which shall be true and correct
in all material respects as of such date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 6. NOTICES. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All notices, requests, consents and other communications hereunder shall be in writing, shall be sent by confirmed electronic mail, or mailed
by first-class registered or certified airmail, or nationally recognized overnight express courier, postage prepaid, and shall be deemed given when so sent in the case of electronic mail transmission, or when so received in the case of mail or
courier, and addressed as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) If to the Company, to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">SELLAS Life Sciences Group, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">315 Madison, 4<SUP STYLE="font-size:85%; vertical-align:top">th </SUP>Flr. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York, New York 10017 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Angelos Stergiou, M.D., ScD h.c. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-Mail:</FONT> astergiou@sellaslife.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">or to such other person at such other place as the Company shall designate to the Holder in writing; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) if to the Holder, at the address as set forth at the end of this Agreement, or at such other address as may have been furnished by the
Holder to the Company in writing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 7. MISCELLANEOUS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <B>Headings. </B>The headings of the various sections of this Agreement have been inserted for convenience of reference only and shall not
be deemed to be part of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <B>Severability. </B>In case any provision contained in this Agreement should be invalid,
illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>c) Intentionally Omitted</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <B>Governing Law. </B>This Agreement shall be governed by and construed under the laws of the State of New York without regard to the
choice of law principles thereof. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the State of New York located in The City of New York, Borough of Manhattan for the adjudication of any
dispute hereunder or in connection herewith or with any transaction contemplated hereby or thereby, and hereby irrevocably waives any objection that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit,
action or proceeding is improper. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY
TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <B>Counterparts. </B>This Agreement may be executed in two or more counterparts, each of which
shall constitute an original, but all of which, when taken together, shall constitute but one instrument, and shall become effective when one or more counterparts have been signed by each party hereto and delivered to the other parties. In the event
that any signature is delivered by facsimile transmission or by an <FONT STYLE="white-space:nowrap">e-mail</FONT> which contains an electronic file of an executed signature page, such signature page shall create a valid and binding obligation of the
party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or electronic file signature page (as the case may be) were an original thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) <B>Successors and Assigns. </B>Except as otherwise expressly provided herein, the provisions hereof shall inure to the benefit of, and be
binding upon, the successors, permitted assigns, heirs, executors and administrators of the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">g) <B>Entire Agreement;
Amendments. </B>This Agreement and other documents delivered pursuant hereto constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and thereof. This Agreement may be amended, modified,
superseded, cancelled, renewed or extended, and the terms and conditions hereof may be waived, only by a written instrument signed by all parties, or, in the case of a waiver, by the party waiving compliance. Except as expressly stated herein, no
delay on the part of any party in exercising any right, power or privilege hereunder shall operate as a waiver thereof, nor shall any waiver on the part of any party of any right, power or privilege hereunder preclude any other or future exercise of
any other right, power or privilege hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">h) <B>Survival. </B>The representations, warranties, covenants and agreements made in this
Agreement shall survive the closing of the transactions contemplated hereby and the exchange and delivery of the Warrants and the Exchange Note. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">i) <B>Further Assurances. </B>Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall
execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions
contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">j) <B>No Third Party Beneficiaries. </B>This Agreement is intended for the benefit of the parties hereto and their
respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[signature pages follow] </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF, </B>the parties hereto have caused this Agreement to be executed by their
duly authorized representatives as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SELLAS LIFE SCIENCES GROUP, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Angelos Stergiou</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Angelos Stergiou, M.D., ScD h.c.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">COMPANY SIGNATURE PAGE TO </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">WARRANT EXCHANGE AGREEMENT </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">CONFIDENTIAL DRAFT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HOLDER: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CVI INVESTMENTS, INC. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Martin Kobinger</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Martin Kobinger</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Investment Manager</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Address:</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DWAC Instructions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Account Number at DTC Participant (if applicable): </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.74
<SEQUENCE>8
<FILENAME>d556278dex1074.htm
<DESCRIPTION>EX-10.74
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.74</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.74 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONVERTIBLE PROMISSORY NOTE </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>$232,440.00</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">February&nbsp;6, 2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>New York, NY</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For value received <B>SELLAS Life Sciences Group, Inc., </B>a Delaware corporation (the
<I>&#147;</I><B><I>Company</I></B><I>&#148;)</I><B><I>, </I></B>promises to pay to <B>CVI INVESTMENTS, INC. </B>or its assigns <I>(&#147;</I><B><I>Holder</I></B><I>&#148;)</I><B><I> </I></B>the principal sum of <B>$232,440.00 </B>(the
&#147;<B><I>Principal</I></B><I>&#148;</I><B><I>) </I></B>together with accrued and unpaid interest thereon (the <I>&#147;</I><B><I>Interest</I></B><I>&#148;)</I><B><I>, </I></B>each due and payable on the date and in the manner set forth below.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This convertible promissory note (the <I>&#147;</I><B><I>Note</I></B><I>&#148;)</I><B><I> </I></B>was issued in reliance on the exemption
provided in Rule 3(a)(9) of the Securities Act of 1933, as amended, pursuant to the terms of that certain Exchange Agreement, dated as of February&nbsp;6 2018 (the <I>&#147;</I><B><I>Exchange Agreement</I></B><I>&#148;)</I><B><I>, </I></B>by and
between the Company and the Holder in exchange for that certain Warrant (as defined in the Exchange Agreement) originally issued on February 13, 2017 and shall be subject to the following terms (capitalized terms not defined herein shall have the
meaning as set forth in the Exchange Agreement): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B>Repayment. </B>All payments of Interest and Principal shall be in lawful
money of the United States of America. All payments shall be applied first to accrued Interest, and thereafter to Principal. The outstanding Principal amount of the Note shall be due and payable on August 6, 2018 (the <I>&#147;</I><B><I>Maturity
Date</I></B><I>&#148;).</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B> Interest. The Company promises to pay simple Interest on the outstanding Principal amount hereof
from the date hereof until payment in full, which Interest shall be payable at the rate of 5% per annum (the <I>&#147;</I><B><I>Interest Rate</I></B><I>&#148;) </I>or the maximum rate permissible by law, whichever is less. Interest shall be due and
payable by way of inclusion of the Interest in the Conversion Amount on any Conversion Date in accordance with Section&nbsp;3 below or in cash on the Maturity Date and shall be calculated on the basis of a 365-day year for the actual number of days
elapsed. From and after the occurrence and during the continuance of any Event of Default (as defined below), the Interest Rate shall automatically be increased to eighteen percent (18.0%) per annum (the <I>&#147;</I><B><I>Default
Rate</I></B><I>&#148;). </I>In the event that such Event of Default is subsequently cured (and no other Event of Default then exists (including, without limitation, for the Company&#146;s failure to pay such Interest at the Default Rate on the
Maturity Date)), the adjustment referred to in the preceding sentence shall cease to be effective as of the calendar day immediately following the date of such cure; provided that the Interest as calculated and unpaid at such increased rate during
the continuance of such Event of Default shall continue to apply to the extent relating to the days after the occurrence of such Event of Default through and including the date of such cure of such Event of Default. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3. Conversion.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the election of the Holder made at any time after April 30, 2018, this Note shall be convertible into validly issued, fully paid and <FONT
STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock (as defined below), on the terms and conditions set forth in this Section&nbsp;3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Conversion Right. </B>Subject to the provisions of Section&nbsp;3(d), at any time or times on or after April&nbsp;30, 2018, the
Holder shall be entitled to convert any portion of the outstanding and unpaid Conversion Amount (as defined below) into validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock in accordance with
Section&nbsp;3(c), at the Conversion Rate (as defined below). The Company shall not issue any fraction of a share of Common Stock upon any conversion. If the issuance would result in the issuance of a fraction of a share of Common Stock, the Company
shall round such fraction of a share of Common Stock up to the nearest whole share. The Company shall pay any and all transfer, stamp, issuance and similar taxes, costs and expenses (including, without limitation, fees and expenses of the
Company&#146;s transfer agent (the <B><I>&#147;Transfer Agent&#148;)) </I></B>that may be payable with respect to the issuance and delivery of Common Stock upon conversion of any Conversion Amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Conversion Rate.</B> The number of shares of Common Stock issuable upon conversion of any Conversion Amount pursuant to
Section&nbsp;3(a) shall be determined by dividing (x)&nbsp;such Conversion Amount by (y)&nbsp;the Conversion Price (the <I>&#147;</I><B><I>Conversion Rate</I></B><I>&#148;)</I><B><I>.</I></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <I></I><B><I></I></B>&#147;<B><I>Conversion Amount</I></B><I>&#148;</I><B><I> </I></B>means the sum of(x) portion of the Principal to be
converted, redeemed or otherwise with respect to which this determination is being made and (y)&nbsp;all accrued and unpaid Interest with respect to such portion of the Principal amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) <I></I><B><I></I></B>&#147;<B><I>Conversion Price</I></B><I>&#148;</I><B><I> </I></B>means, as of any Conversion Date or other date of
determination, $7.00, subject to adjustment as provided herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) Mechanics of Conversion.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <B>Optional Conversion. </B>To convert any Conversion Amount into shares of Common Stock on any date (a <I>&#147;</I><B><I>Conversion
Date</I></B><I>&#148;)</I><B><I>, </I></B>the Holder shall deliver (whether via facsimile, electronic mail or otherwise), for receipt on or prior to 11:59 p.m., New York time, on such date, a copy of an executed notice of conversion (the
<I>&#147;</I><B><I>Conversion Notice</I></B><I>&#148;)</I><B><I> </I></B>to the Company. If required by Section&nbsp;3(c)(iii), within two (2)&nbsp;Trading Days following a conversion of this Note as aforesaid, the Holder shall surrender this Note
to a nationally recognized overnight delivery service for delivery to the Company (or an indemnification undertaking with respect to this Note in the case of its loss, theft or destruction). On or before the first (1st) Trading Day following the
date of receipt of a Conversion Notice, the Company shall transmit by facsimile or electronic mail an acknowledgment of confirmation and representation as to whether such shares of Common Stock may then be resold pursuant to Rule 144 or an effective
and available registration statement, of receipt of such Conversion Notice to the Holder and the Transfer Agent which confirmation shall constitute an instruction to the Transfer Agent to process such Conversion Notice in accordance with the terms
herein. On or before the second (2nd) Trading Day following the date on which the Company has received a Conversion Notice (or such earlier date as required pursuant to the Exchange Act or other applicable law, rule or regulation for the settlement
of a trade initiated on the applicable Conversion Date of such shares of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Common Stock issuable pursuant to such Conversion Notice) (the <I>&#147;</I><B><I>Share Delivery Deadline</I></B><I>&#148;),</I><B><I> </I></B>the Company shall (1)&nbsp;provided that the
Transfer Agent is participating in the DTC Fast Automated Securities Transfer Program, credit such aggregate number of shares of Common Stock to which the Holder shall be entitled pursuant to such conversion to the Holder&#146;s or its
designee&#146;s balance account with DTC through its Deposit/Withdrawal at Custodian system or (2)&nbsp;if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program, upon the request of the Holder, issue and
deliver (via reputable overnight courier) to the address as specified in the Conversion Notice, a certificate, registered in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder shall be entitled
pursuant to such conversion. If this Note is physically surrendered for conversion pursuant to Section&nbsp;3(c)(iii) and the outstanding Principal of this Note is greater than the Principal portion of the Conversion Amount being converted, then the
Company shall as soon as practicable and in no event later than two (2)&nbsp;Business Days after receipt of this Note and at its own expense, issue and deliver to the Holder (or its designee) a new Note representing the outstanding Principal not
converted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) <B>Company&#146;s Failure to Timely Convert. </B>If the Company shall fail, for any reason or for no reason, on or prior
to the applicable Share Delivery Deadline, if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program, to issue and deliver to the Holder (or its designee) a certificate for the number of shares of Common Stock
to which the Holder is entitled and register such shares of Common Stock on the Company&#146;s share register or, if the Transfer Agent is participating in the DTC Fast Automated Securities Transfer Program, to credit the balance account of the
Holder or the Holder&#146;s designee with DTC for such number of shares of Common Stock to which the Holder is entitled upon the Holder&#146;s conversion of this Note (as the case may be) (a <I>&#147;</I><B><I>Conversion
Failure</I></B><I>&#148;),</I><B><I> </I></B>and if on or after such Share Delivery Deadline the Holder purchases (in an open market transaction or otherwise) shares of Common Stock corresponding to all or any portion of the number of shares of
Common Stock issuable upon such conversion that the Holder is entitled to receive from the Company and has not received from the Company in connection with such Conversion Failure (a
<I>&#147;</I><B><I><FONT STYLE="white-space:nowrap">Buy-In</FONT></I></B><I>&#148;),</I><B><I> </I></B>then, in addition to all other remedies available to the Holder, the Company shall, within two (2)&nbsp;Business Days after receipt of the
Holder&#146;s request and in the Holder&#146;s discretion, either: (I)&nbsp;pay cash to the Holder in an amount equal to the Holder&#146;s total purchase price (including brokerage commissions and other <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, if any) for the shares of Common Stock so purchased (including, without limitation, by any other Person in respect, or on behalf, of the Holder) (the &#147;<B>Buy-In
Price</B>&#148;),<B> </B>at which point the Company&#146;s obligation to so issue and deliver such certificate (and to issue such shares of Common Stock) or credit the balance account of such Holder or such Holder&#146;s designee, as applicable,
with DTC for the number of shares of Common Stock to which the Holder is entitled upon the Holder&#146;s conversion hereunder (as the case may be) (and to issue such shares of Common Stock) shall terminate, or (II)&nbsp;promptly honor its obligation
to so issue and deliver to the Holder a certificate or certificates representing such shares of Common Stock or credit the balance account of such Holder or such Holder&#146;s designee, as applicable, with DTC for the number of shares of Common
Stock to which the Holder is entitled upon the Holder&#146;s conversion hereunder (as the case may be) and pay cash to the Holder in an amount equal to the excess (if any) of the <FONT STYLE="white-space:nowrap">Buy-In</FONT> Price over the product
of (x)&nbsp;such number of shares of Common Stock multiplied by (y)&nbsp;the lowest Closing Sale Price of the Common Stock on any Trading Day during the period commencing on the date of the applicable Conversion Notice and ending on the date of such
issuance and payment under this clause (II) (the <I>&#147;</I><B><I>Buy-</I></B><B><I>InPayment Amount</I></B><I>&#148; ).</I><B><I> </I></B>Nothing shall limit </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the Holder&#146;s right to pursue any other remedies available to it hereunder, at law or in equity, including,
without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#146;s failure to timely deliver certificates representing shares of Common Stock (or to electronically deliver such shares of Common Stock)
upon the conversion of this Note as required pursuant to the terms hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(iii) <B>Registration; Book-Entry. </B>The Holder and the
Company shall maintain records showing the Principal and Interest converted and/or Paid (as the case may be) and the dates of such conversions, and/or payments (as the case may be) or shall use such other method, reasonably satisfactory to the
Holder and the Company, so as not to require physical surrender of this Note upon conversion. Notwithstanding anything to the contrary set forth in this Section&nbsp;3, following conversion of any portion of this Note in accordance with the terms
hereof, the Holder shall not be required to physically surrender this Note to the Company unless (A)&nbsp;the full Conversion Amount represented by this Note is being converted (in which event this Note shall be delivered to the Company following
conversion thereof as contemplated by Section&nbsp;3(c)(i)) or (B)&nbsp;the Holder has provided the Company with prior written notice (which notice may be included in a Conversion Notice) requesting reissuance of this Note upon physical surrender of
this Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Limitations on Conversions. </B>The Company shall not effect the conversion of any portion of this Note, and the
Holder shall not have the right to convert any portion of this Note pursuant to the terms and conditions of this Note and any such conversion shall be null and void and treated as if never made, to the extent that after giving effect to such
conversion, the Holder together with the other Attribution Parties collectively would beneficially own in excess of 4.99% (the <I>&#147;</I><B><I>Maximum Percentage</I></B><I>&#148;)</I><B><I> </I></B>of the shares of Common Stock outstanding
immediately after giving effect to such conversion. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by the Holder and the other Attribution Parties shall include the number of shares of
Common Stock held by the Holder and all other Attribution Parties plus the number of shares of Common Stock issuable upon conversion of this Note with respect to which the determination of such sentence is being made, but shall exclude shares of
Common Stock which would be issuable upon (A)&nbsp;conversion of the remaining, nonconverted portion of this Note beneficially owned by the Holder or any of the other Attribution Parties and (B)&nbsp;exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any convertible notes or convertible preferred stock or warrants, including, without limitation, the Warrants) beneficially owned by the Holder or any other
Attribution Party subject to a limitation on conversion or exercise analogous to the limitation contained in this Section&nbsp;3(d). For purposes of this Section&nbsp;3(d), beneficial ownership shall be calculated in accordance with
Section&nbsp;13(d) of the Exchange Act. For purposes of determining the number of outstanding shares of Common Stock the Holder may acquire upon the conversion of this Note without exceeding the Maximum Percentage, the Holder may rely on the number
of outstanding shares of Common Stock as reflected in (x)&nbsp;the Company&#146;s most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Report
on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or other public filing with the SEC, as the case may be, (y)&nbsp;a more recent public announcement by the Company or (z)&nbsp;any other written notice by the Company or the Transfer Agent, if any,
setting forth the number of shares of Common Stock outstanding (the <I>&#147;</I><B><I>Reported Outstanding Share Number</I></B><I>&#148;).</I><B><I> </I></B>If the Company receives a Conversion Notice from the Holder at a time when the actual
number of outstanding shares of Common Stock is less than the Reported Outstanding Share </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Number, the Company shall notify the Holder in writing of the number of shares of Common Stock then outstanding and, to the extent that such Conversion Notice would otherwise cause the
Holder&#146;s beneficial ownership, as determined pursuant to this Section&nbsp;3(d), to exceed the Maximum Percentage, the Holder must notify the Company of a reduced number of shares of Common Stock to be purchased pursuant to such Conversion
Notice. For any reason at any time, upon the written or oral request of the Holder, the Company shall within one (1)&nbsp;Business Day confirm orally and in writing or by electronic mail to the Holder the number of shares of Common Stock then
outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Note, by the Holder and any other Attribution Party since
the date as of which the Reported Outstanding Share Number was reported. In the event that the issuance of shares of Common Stock to the Holder upon conversion of this Note results in the Holder and the other Attribution Parties being deemed to
beneficially own, in the aggregate, more than the Maximum Percentage of the number of outstanding shares of Common Stock (as determined under Section&nbsp;13(d) of the Exchange Act), the number of shares so issued by which the Holder&#146;s and the
other Attribution Parties&#146; aggregate beneficial ownership exceeds the Maximum Percentage (the &#147;<B>Excess Shares</B>&#148;)<B> </B>shall be deemed null and void and shall be cancelled ab initio, and the Holder shall not have the power to
vote or to transfer the Excess Shares. Upon delivery of a written notice to the Company, the Holder may from time to time increase (with such increase not effective until the sixty-first (6!51) day after delivery of such notice) or decrease the
Maximum Percentage to any other percentage not in excess of 4.99% as specified in such notice; provided that (i)&nbsp;any such increase in the Maximum Percentage will not be effective until the sixty-first (61s1) day after such notice is delivered
to the Company and (ii)&nbsp;any such increase or decrease will apply only to the Holder and the other Attribution Parties and not to any other holder of Notes that is not an Attribution Party of the Holder. For purposes of clarity, the shares of
Common Stock issuable pursuant to the terms of this Note in excess of the Maximum Percentage shall not be deemed to be beneficially owned by the Holder for any purpose including for purposes of Section&nbsp;13(d) or Rule <FONT
STYLE="white-space:nowrap">16a-l(a)(l)</FONT> of the Exchange Act. No prior inability to convert this Note pursuant to this paragraph shall have any effect on the applicability of the provisions of this paragraph with respect to any subsequent
determination of convertibility. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section&nbsp;3(d) to the extent necessary to correct this paragraph (or any
portion of this paragraph) which may be defective or inconsistent with the intended beneficial ownership limitation contained in this Section&nbsp;3(d) or to make changes or supplements necessary or desirable to properly give effect to such
limitation. The limitation contained in this paragraph may not be waived and shall apply to a successor holder of this Note. Further, notwithstanding anything in this Note to the contrary, under no circumstances shall the Company be obligated to
issue or the Holder entitled to receive, an aggregate number of shares of Common Stock that would exceed 19.9% of the total number of shares of Common Stock issued and outstanding as of the date of this Note (the <I>&#147;</I><B><I>Maximum
Issuance</I></B><I>&#148;);</I><B><I> </I></B>provided, that to the extent the aggregate number of shares of Common Stock would exceed the Maximum Issuance, the Company shall issue and deliver to Holder a number of shares of Common Stock up to the
Maximum Issuance and the unconverted Principal of this Note shall remain outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e) Right of Alternate Conversion.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <U>General.</U> At any time at any time after the occurrence of an Event of Default (regardless of whether such Event of Default has been
cured), the Holder may, at the Holder&#146;s option, convert (each, an <I>&#147;</I><B><I>Alternate Conversion</I></B><I>&#148;,</I><B><I> </I></B>and the date of such Alternate Conversion, each, an <I>&#147;</I><B><I>Alternate Conversion
Date</I></B><I>&#148;)</I><B><I> </I></B>all , or any part of, the Conversion Amount (such portion of the Conversion Amount subject to such Alternate Conversion, the <I>&#147;</I><B><I>Alternate Conversion Amount</I></B><I>&#148;)</I><B><I>
</I></B>into shares of Common Stock at the Alternate Conversion Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) <U>Mechanics of Alternate Conversion.</U> On any Alternate
Conversion Date, the Holder may voluntarily convert any Alternate Conversion Amount pursuant to Section&nbsp;3(c) (with &#147;Alternate Conversion Price&#148; replacing &#147;Conversion Price&#148; for all purposes hereunder with respect to such
Alternate Conversion) by designating in the Conversion Notice delivered pursuant to this Section&nbsp;3(e) of this Note that the Holder is electing to use the Alternate Conversion Price for such conversion. Notwithstanding anything to the contrary
in this Section&nbsp;3(e), but subject to Section&nbsp;3(d), until the Company delivers shares of Common Stock representing the applicable Alternate Conversion Amount to the Holder, such Alternate Conversion Amount may be converted by the Holder
into shares of Common Stock pursuant to Section&nbsp;3(c) without regard to this Section&nbsp;3(e). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) <B>Voluntary Adjustment by
Company. </B>The Company may at any time during the term of this Note, with the prior written consent of the Holder, reduce the then current Conversion Price of each of the Notes to any amount and for any period of time deemed appropriate by the
board of directors of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B>Maturity. </B>Unless this Note has been previously converted or prepaid in accordance
with the terms of Section&nbsp;3(a) above, the entire outstanding Conversion Amount shall become fully due and payable in cash on the Maturity Date; provided, that if the Conversion Amount is not paid in full in cash on the Maturity Date, subject to
Section&nbsp;3(d) above, the Holder shall retain the right to convert all, or any part, at such Holder&#146;s sole discretion, of the Conversion Amount into shares of Common Stock in accordance with Section&nbsp;3 above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B>Expenses. </B>In the event of any default hereunder, the Company shall pay all reasonable attorneys&#146; fees and court costs
incurred by Holder in enforcing and collecting this Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B>Prepayment. </B>The Company may prepay this Note and accrued but
unpaid Interest prior to the Maturity Date at any time without the consent of the Holder; provided, that the Company may not prepay any Conversion Amount submitted for conversion pursuant to Section&nbsp;3 above from and after the applicable
Conversion Date unless such corresponding Conversion Notice is withdrawn by the Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7. Default.</B> If there shall be any Event of
Default hereunder, at the option and upon the declaration of the Holder and upon written notice to the Company (which election and notice shall not be required in the case of an Event of Default under Section&nbsp;7(v), 7(vi) or 7(vii)), this Note
shall accelerate and all Principal and unpaid accrued Interest shall become immediately due and payable. The occurrence of any one or more of the following shall constitute an <B><I>&#147;Event of Default&#146;:</I></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> the suspension (or threatened suspension) from trading or the failure (or threatened failure) of the Common Stock to be trading or
listed (as applicable) on the Nasdaq Capital Market for a period of five (5) consecutive Trading Days; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> the Company&#146;s (A)&nbsp;failure to cure a Conversion Failure by delivery of the
required number of shares of Common Stock within five (5)&nbsp;Trading Days after the applicable Conversion Date or exercise date (as the case may be) or (B)&nbsp;notice, written or oral, to any holder of the Notes, including, without limitation, by
way of public announcement or through any of its agents, at any time, of its intention not to comply, as required, with a request for conversion of any Notes into shares of Common Stock that is requested in accordance with the provisions of the
Notes, other than pursuant to Section&nbsp;3(d); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> the Company&#146;s or any Subsidiary&#146;s failure to pay to the Holder
any amount of Principal, Interest or other amounts when and as due under this Note (including, without limitation, the Company&#146;s failure to pay any redemption payments or amounts hereunder) or any other Exchange Document or any other agreement,
document, certificate or other instrument delivered in connection with the transactions contemplated hereby and thereby, except, in the case of a failure to pay Interest when and as due, in which case only if such failure remains uncured for a
period of at least two (2)&nbsp;Trading Days; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> [INTENTIONALLY OMITTED]; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings for the relief of debtors shall be
instituted by or against the Company or any Subsidiary and, if instituted against the Company or any Subsidiary by a third party, shall not be dismissed within thirty (30)&nbsp;days of their initiation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> the commencement by the Company or any Subsidiary of a voluntary case or proceeding under any applicable federal, state or
foreign bankruptcy, insolvency, reorganization or other similar law or of any other case or proceeding to be adjudicated a bankrupt or insolvent, or the consent by it to the entry of a decree, order, judgment or other similar document in respect of
the Company or any Subsidiary in an involuntary case or proceeding under any applicable federal, state or foreign bankruptcy, insolvency, reorganization or other similar law or to the commencement of any bankruptcy or insolvency case or proceeding
against it, or the filing by it of a petition or answer or consent seeking reorganization or relief under any applicable federal, state or foreign law, or the consent by it to the filing of such petition or to the appointment of or taking possession
by a custodian, receiver, liquidator, assignee, trustee, sequestrator or other similar official of the Company or any Subsidiary or of any substantial part of its property, or the making by it of an assignment for the benefit of creditors, or the
execution of a composition of debts, or the occurrence of any other similar federal, state or foreign proceeding, or the admission by it in writing of its inability to pay its debts generally as they become due, the taking of corporate action by the
Company or any Subsidiary in furtherance of any such action or the taking of any action by any Person to commence a Uniform Commercial Code foreclosure sale or any other similar action under federal, state or foreign law; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vii)</B> the entry by a court of (i)&nbsp;a decree, order, judgment or other similar
document in respect of the Company or any Subsidiary of a voluntary or involuntary case or proceeding under any applicable federal, state or foreign bankruptcy, insolvency, reorganization or other similar law or (ii)&nbsp;a decree, order, judgment
or other similar document adjudging the Company or any Subsidiary as bankrupt or insolvent, or approving as properly filed a petition seeking liquidation, reorganization, arrangement, adjustment or composition of or in respect of the Company or any
Subsidiary under any applicable federal, state or foreign law or (iii)&nbsp;a decree, order, judgment or other similar document appointing a custodian, receiver, liquidator, assignee, trustee, sequestrator or other similar official of the Company or
any Subsidiary or of any substantial part of its property, or ordering the winding up or liquidation of its affairs, and the continuance of any such decree, order, judgment or other similar document or any such other decree, order, judgment or other
similar document unstayed and in effect for a period of thirty (30)&nbsp;consecutive days; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(viii)</B> other than as specifically
set forth in another clause of this Section&nbsp;7, the Company or any Subsidiary breaches any representation, warranty, covenant or other term or condition of any Exchange Document, except, in the case of a breach of a covenant or other term or
condition that is curable, only if such breach remains uncured for a period of three (3)&nbsp;consecutive Trading Days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.</B>
<B>Adjustment of Conversion Price upon Subdivision or Combination of Common Stock. </B>If the Company at any time on or after the date hereof subdivides (by any stock split, stock dividend, stock combination, recapitalization or other similar
transaction) one or more classes of its outstanding shares of Common Stock into a greater number of shares, the Conversion Price in effect immediately prior to such subdivision will be proportionately reduced. If the Company at any time on or after
the date hereof combines (by any stock split, stock dividend, stock combination, recapitalization or other similar transaction) one or more classes of its outstanding shares of Common Stock into a smaller number of shares, the Conversion Price in
effect immediately prior to such combination will be proportionately increased. Any adjustment pursuant to this Section&nbsp;8 shall become effective immediately after the effective date of such subdivision or combination. If any event requiring an
adjustment under this Section&nbsp;8 occurs during the period that a Conversion Price is calculated hereunder, then the calculation of such Conversion Price shall be adjusted appropriately to reflect such event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.</B> <B>Rights upon Fundamental Transaction. </B>The Company shall not enter into or be party to a Fundamental Transaction unless
(i)&nbsp;the Successor Entity assumes in writing all of the obligations of the Company under this Note and the other Exchange Documents in accordance with the provisions of this Section&nbsp;9 pursuant to written agreements in form and substance
satisfactory to the Holder and approved by the Holder prior to such Fundamental Transaction, including agreements to deliver to each holder of Notes in exchange for such Notes a security of the Successor Entity evidenced by a written instrument
substantially similar in form and substance to the Notes, including, without limitation, having a principal amount and interest rate equal to the principal amounts then outstanding and the interest rates of the Notes held by such holder, having
similar conversion rights as the Notes and having similar ranking and security to the Notes, and satisfactory to the Holder and (ii)&nbsp;the Successor Entity (including its Parent Entity) is a publicly traded corporation whose common stock is
quoted on or listed for trading on an Eligible Market. Upon the occurrence of any Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Note and the other Exchange Documents referring to the &#147;Company&#148; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this
Note and the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other Exchange Documents with the same effect as if such Successor Entity had been named as the Company herein. Upon consummation of a Fundamental Transaction, the Successor Entity shall deliver
to the Holder confirmation that there shall be issued upon conversion or redemption of this Note at any time after the consummation of such Fundamental Transaction, in lieu of the shares of Common Stock (or other securities, cash, assets or other
property (except such items still issuable under Sections 10(a) and 11, which shall continue to be receivable thereafter) issuable upon the conversion or redemption of the Notes prior to such Fundamental Transaction, such shares of the publicly
traded common stock (or their equivalent) of the Successor Entity (including its Parent Entity) which the Holder would have been entitled to receive upon the happening of such Fundamental Transaction had this Note been converted immediately prior to
such Fundamental Transaction (without regard to any limitations on the conversion of this Note), as adjusted in accordance with the provisions of this Note. Notwithstanding the foregoing, the Holder may elect, at its sole option, by delivery of
written notice to the Company to waive this Section&nbsp;9 to permit the Fundamental Transaction without the assumption of this Note. The provisions of this Section&nbsp;9 shall apply similarly and equally to successive Fundamental Transactions and
shall be applied without regard to any limitations on the conversion of this Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10. Rights Upon Issuance of Purchase Rights and
Other Corporate Events. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Purchase Rights. </B>If at any time the Company grants, issues or sells any Options,
Convertible Securities or rights to purchase stock, warrants, securities or other property pro rata to all or substantially all of the record holders of any class of Common Stock (the <I>&#147;</I><B><I>Purchase Rights</I></B><I>&#148;),</I><B><I>
</I></B>then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon
complete conversion of this Note (without taking into account any limitations or restrictions on the convertibility of this Note and assuming for such purpose that the Note was converted at the Alternate Conversion Price as of the applicable record
date) immediately prior to the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the
grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that to the extent that the Holder&#146;s right to participate in any such Purchase Right would result in the Holder and the other Attribution Parties exceeding the
Maximum Percentage, then the Holder shall not be entitled to participate in such Purchase Right to the extent of the Maximum Percentage (and shall not be entitled to beneficial ownership of such shares of Common Stock as a result of such Purchase
Right (and beneficial ownership) to the extent of any such excess) and such Purchase Right to such extent shall be held in abeyance (and, if such Purchase Right has an expiration date, maturity date or other similar provision, such term shall be
extended by such number of days held in abeyance, if applicable) for the benefit of the Holder until such time or times, if ever, as its right thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage,
at which time or times the Holder shall be granted such right (and any Purchase Right granted, issued or sold on such initial Purchase Right or on any subsequent Purchase Right held similarly in abeyance (and, if such Purchase Right has an
expiration date, maturity date or other similar provision, such term shall be extended by such number of days held in abeyance, if applicable)) to the same extent as if there had been no such limitation). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B><B>Other Corporate Events. </B>In addition to and not in substitution for any other
rights hereunder, prior to the consummation of any Fundamental Transaction pursuant to which holders of shares of Common Stock are entitled to receive securities or other assets with respect to or in exchange for shares of Common Stock (a
<I>&#147;</I><B><I>Corporate</I></B><B><I> </I></B><B><I>Even</I></B><B><I>t</I></B><I>&#148;</I><I>),</I><B><I> </I></B>the Company shall make appropriate provision to ensure that the Holder will thereafter have the right to receive upon a
conversion of this Note, at the Holder&#146;s option (i) in addition to the shares of Common Stock receivable upon such conversion, such securities or other assets to which the Holder would have been entitled with respect to such shares of Common
Stock had such shares of Common Stock been held by the Holder upon the consummation of such Corporate Event (without taking into account any limitations or restrictions on the convertibility of this Note) or (ii) in lieu of the shares of Common
Stock otherwise receivable upon such conversion, such securities or other assets received by the holders of shares of Common Stock in connection with the consummation of such Corporate Event in such amounts as the Holder would have been entitled to
receive had this Note initially been issued with conversion rights for the form of such consideration (as opposed to shares of Common Stock) at a conversion rate for such consideration commensurate with the Conversion Rate. Provision made pursuant
to the preceding sentence shall be in a form and substance satisfactory to the Holder. The provisions of this Section lO(b) shall apply similarly and equally to successive Corporate Events and shall be applied without regard to any limitations on
the conversion or redemption of this Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.</B> <B>Remedies, Characterizations, Other Obligations, Breaches and Injunctive Relief.
</B>The remedies provided in this Note shall be cumulative and in addition to all other remedies available under this Note and any of the other Exchange Documents at law or in equity (including a decree of specific performance and/or other
injunctive relief), and nothing herein shall limit the Holder&#146;s right to pursue actual and consequential damages for any failure by the Company to comply with the terms of this Note. The Company covenants to the Holder that there shall be no
characterization concerning this instrument other than as expressly provided herein. Amounts set forth or provided for herein with respect to payments, conversion and the like (and the computation thereof) shall be the amounts to be received by the
Holder and shall not, except as expressly provided herein, be subject to any other obligation of the Company (or the performance thereof). The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the
Holder and that the remedy at law for any such breach may be inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach, the Holder shall be entitled, in addition to all other available remedies, to specific
performance and/or temporary, preliminary and permanent injunctive or other equitable relief from any court of competent jurisdiction in any such case without the necessity of proving actual damages and without posting a bond or other security. The
Company shall provide all information and documentation to the Holder that is requested by the Holder to enable the Holder to confirm the Company&#146;s compliance with the terms and conditions of this Note. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.</B> <B>Severability. </B>If any provision of this Note is prohibited by law or otherwise determined to be invalid or unenforceable by a
court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of
such provision shall not affect the validity of the remaining provisions of this Note so long as this Note as so modified continues to express, without material change, the original intentions of the parties as to the subject matter hereof and the
prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be
conferred upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited,
invalid or unenforceable provision(s). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.</B> <B>Maximum Payments. </B>Nothing contained herein shall be deemed to establish or
require the payment of a rate of interest or other charges in excess of the maximum permitted by applicable law. In the event that the rate of interest required to be paid or other charges hereunder exceed the maximum permitted by such law, any
payments in excess of such maximum shall be credited against amounts owed by the Company to the Holder and thus refunded to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.</B> <B>Waiver. </B>The Company hereby waives demand, notice, presentment, protest and notice of dishonor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.</B> <B>Governing Law. </B>This Note shall be construed and enforced in accordance with, and all questions concerning the construction,
validity, interpretation and performance of this Note shall be governed by, the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other
jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York. The Company hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The City of New York,
Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding,
any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein shall be
deemed or operate to preclude the Holder from bringing suit or taking other legal action against the Company in any other jurisdiction to collect on the Company&#146;s obligations to the Holder, to realize on any collateral or any other security for
such obligations, or to enforce a judgment or other court ruling in favor of the Holder. THE COMPANY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN
CONNECTION WITH OR ARISING OUT OF THIS NOTE OR ANY TRANSACTION CONTEMPLATED HEREBY. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.</B> <B>Failure Or Indulgence Not Waiver.
</B>No failure or delay on the part of the Holder in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further
exercise thereof or of any other right, power or privilege. No waiver shall be effective unless it is in writing and signed by an authorized representative of the waiving party. Notwithstanding the foregoing, nothing contained in this
Section&nbsp;16 shall permit any waiver of any provision of Section&nbsp;3(d). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.</B> <B>Amending the Terms of this Note. </B>The prior written consent of the Holder shall
be required for any change, waiver or amendment to this Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>18. Notices; Currency; Payments. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Notices. </B>Whenever notice is required to be given under this Note, unless otherwise provided herein, such notice shall be
given in accordance with the terms of the Exchange Agreement. The Company shall provide the Holder with prompt written notice of all actions taken pursuant to this Note, including in reasonable detail a description of such action and the reason
therefore. Without limiting the generality of the foregoing, the Company will give written notice to the Holder (i)&nbsp;immediately upon any adjustment of the Conversion Price, setting forth in reasonable detail, and certifying, the calculation of
such adjustment and (ii)&nbsp;at least fifteen (15)&nbsp;days prior to the date on which the Company closes its books or takes a record (A)&nbsp;with respect to any dividend or distribution upon the Common Stock, and (B)&nbsp;for determining rights
to vote with respect to any Fundamental Transaction, dissolution or liquidation, provided in each case that such information shall be made known to the public prior to or in conjunction with such notice being provided to the Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Currency. </B>All dollar amounts referred to in this Note are in United States Dollars <I>(&#147;</I><B><I>U.S.
Dollars</I></B><I>&#148;),</I><B><I> </I></B>and all amounts owing under this Note shall be paid in U.S. Dollars. All amounts denominated in other currencies (if any) shall be converted into the U.S.&nbsp;Dollar equivalent amount in accordance with
the Exchange Rate on the date of calculation. <I>&#147;</I><B><I>Exchange Rate</I></B><I>&#148;</I><B><I> </I></B>means, in relation to any amount of currency to be converted into U.S. Dollars pursuant to this Note, the U.S.&nbsp;Dollar exchange
rate as published in the Wall Street Journal on the relevant date of calculation (it being understood and agreed that where an amount is calculated with reference to, or over, a period of time, the date of calculation shall be the final date of such
period of time). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Payments. </B>Whenever any payment of cash is to be made by the Company to any Person pursuant to this
Note, unless otherwise expressly set forth herein, such payment shall be made in lawful money of the United States of America by a certified check drawn on the account of the Company and sent via overnight courier service to such Person at such
address as previously provided to the Company in writing, provided that the Holder may elect to receive a payment of cash via wire transfer of immediately available funds by providing the Company with prior written notice setting out such request
and the Holder&#146;s wire transfer instructions. Whenever any amount expressed to be due by the terms of this Note is due on any day which is not a Business Day, the same shall instead be due on the next succeeding day which is a Business Day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>19.</B> <B>Waiver of Notice. </B>To the extent permitted by law, the Company hereby irrevocably waives demand, notice, presentment, protest
and all other demands and notices in connection with the delivery, acceptance, performance, default or enforcement of this Note and the Exchange Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>20.</B> <B>Assignment. </B>This Note may be transferred only upon its surrender to the Company for registration of transfer, duly endorsed,
or accompanied by a duly executed written instrument of transfer in form satisfactory to the Company. Thereupon, this Note shall be reissued to, and registered in the name of, the transferee, or a new Note for like Principal amount and Interest
shall be issued to, and registered in the name of, the transferee. Interest and Principal shall be paid solely to the registered holder of this Note. Such payment shall constitute full discharge of the Company&#146;s obligation to pay such Interest
and Principal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.</B> <U>CERTAIN DEFINITIONS.</U> For purposes of this Note, the following terms shall have
the following meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><I>&#147;Adjustment Right&#148; </I></B>means any right granted with respect to any securities
issued in connection with, or with respect to, any issuance or sale (or deemed issuance or sale) of shares of Common Stock that could result in a decrease in the net consideration received by the Company in connection with, or with respect to, such
securities (including, without limitation, any cash settlement rights, cash adjustment or other similar rights). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>
<B><I>&#147;Alternate Conversion Price&#148; </I></B>means, with respect to any Alternate Conversion that price which shall be the lowest of (i)&nbsp;the applicable Conversion Price as in effect on the applicable Conversion Date of the applicable
Alternate Conversion, (ii) 70% of the lowest VWAP of the Common Stock as of the Trading Day during the ten (10)&nbsp;consecutive Trading Day period ending and including the applicable Alternate Conversion Date (such period, the
<I>&#147;</I><B><I>Alternate Conversion Measuring Period</I></B><I>&#148;</I><B><I>). </I></B>All such determinations to be appropriately adjusted for any stock dividend, stock split, stock combination, reclassification or similar transaction that
proportionately decreases or increases the Common Stock during such Alternate Conversion Measuring Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>
<B><I>&#147;Attribution Parties&#148; </I></B>means, collectively, the following Persons and entities: (i)&nbsp;any investment vehicle, including, any funds, feeder funds or managed accounts, currently, or from time to time after the date hereof,
directly or indirectly managed or advised by the Holder&#146;s investment manager or any of its Affiliates or principals, (ii)&nbsp;any direct or indirect Affiliates of the Holder or any of the foregoing, (iii)&nbsp;any Person acting or who could be
deemed to be acting as a Group together with the Holder or any of the foregoing and (iv)&nbsp;any other Persons whose beneficial ownership of the Company&#146;s Common Stock would or could be aggregated with the Holder&#146;s and the other
Attribution Parties for purposes of Section&nbsp;13(d) of the Exchange Act. For clarity, the purpose of the foregoing is to subject collectively the Holder and all other Attribution Parties to the Maximum Percentage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B><I>&#147;Bloomberg&#148; </I></B>means Bloomberg, L.P. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B><I>&#147;Business Day&#148; </I></B>means any day other than Saturday, Sunday or other day on which commercial banks in The City
of New York are authorized or required by law to remain closed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(t) </B><B><I>&#147;Closing Bid Price&#148; </I></B>and
<B><I>&#147;Closing Sale Price&#148; </I></B>means, for any security as of any date, the last closing bid price and last closing trade price, respectively, for such security on the Principal Market, as reported by Bloomberg, or, if the Principal
Market begins to operate on an extended hours basis and does not designate the closing bid price or the closing trade price (as the case may be) then the last bid price or last trade price, respectively, of such security prior to 4:00:00 p.m., New
York time, as reported by Bloomberg, or, if the Principal Market is not the principal securities exchange or trading market for such security, the last closing bid price or last trade price, respectively, of such security on the principal securities
exchange or trading market where such security is listed or traded as reported by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Bloomberg, or if the foregoing do not apply, the last closing bid price or last trade price, respectively, of such security in the over-the-counter market on the electronic bulletin board for
such security as reported by Bloomberg, or, if no closing bid price or last trade price, respectively, is reported for such security by Bloomberg, the average of the bid prices, or the ask prices, respectively, of any market makers for such security
as reported in the &#147;pink sheets&#148; by OTC Markets Group Inc. (formerly Pink Sheets LLC). If the Closing Bid Price or the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing
Bid Price or the Closing Sale Price (as the case may be) of such security on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value
of such security, then such dispute shall be resolved in accordance with the procedures in Section&nbsp;22. All such determinations shall be appropriately adjusted for any stock splits, stock dividends, stock combinations, recapitalizations or other
similar transactions during such period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B><I>&#147;Common Stock&#148; </I></B>means (i)&nbsp;the Company&#146;s shares of
common stock, $0.0001 par value per share, and (ii)&nbsp;any capital stock into which such common stock shall have been changed or any share capital resulting from a reclassification of such common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B><I>&#147;Convertible Securities&#148; </I></B>means any stock or other security (other than Options) that is at any time and
under any circumstances, directly or indirectly, convertible into, exercisable or exchangeable for, or which otherwise entitles the holder thereof to acquire, any shares of Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B><I>&#147;Eligible Market&#148; </I></B>means The New York Stock Exchange, the NYSE American, the Nasdaq Global Select Market,
the Nasdaq Global Market or the Principal Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> <B><I>&#147;Fundamental Transaction&#148; </I></B>means (A) that the Company
shall, directly or indirectly, including through subsidiaries, Affiliates or otherwise, in one or more related transactions, (i) consolidate or merge with or into (whether or not the Company is the surviving corporation) another Subject Entity, or
(ii) sell, assign, transfer, convey or otherwise dispose of all or substantially all of the properties or assets of the Company or any of its &#147;significant subsidiaries&#148; (as defined in Rule 1-02 of Regulation S-X) to one or more Subject
Entities, or (iii) make, or allow one or more Subject Entities to make, or allow the Company to be subject to or have its Common Stock be subject to or party to one or more Subject Entities making, a purchase, tender or exchange offer that is
accepted by the holders of at least either (x) 50% of the outstanding shares of Common Stock, (y) 50% of the outstanding shares of Common Stock calculated as if any shares of Common Stock held by all Subject Entities making or party to, or
Affiliated with any Subject Entities making or party to, such purchase, tender or exchange offer were not outstanding; or (z) such number of shares of Common Stock such that all Subject Entities making or party to, or Affiliated with any Subject
Entity making or party to, such purchase, tender or exchange offer, become collectively the beneficial owners (as defined in Rule 13d-3 under the Exchange Act) of at least 50% of the outstanding shares of Common Stock, or (iv) consummate a stock or
share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with one or more Subject Entities whereby all such Subject Entities, individually or in the
aggregate, acquire, either (x) at least 50% of the outstanding shares of Common Stock, (y) at least 50% of the outstanding shares of Common Stock calculated as if any shares of Common Stock held by all the Subject Entities making or party to, or
Affiliated with any Subject Entity making or party to, such stock purchase agreement or other business </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
combination were not outstanding; or (z)&nbsp;such number of shares of Common Stock such that the Subject Entities become collectively the beneficial owners (as defined in Rule 13d-3 under the
Exchange Act) of at least 50% of the outstanding shares of Common Stock, or (v)&nbsp;reorganize, recapitalize or reclassify its Common Stock, (B)&nbsp;that the Company shall, directly or indirectly, including through subsidiaries, Affiliates or
otherwise, in one or more related transactions, allow any Subject Entity individually or the Subject Entities in the aggregate to be or become the &#147; beneficial owner&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under
the Exchange Act), directly or indirectly, whether through acquisition, purchase, assignment, conveyance, tender, tender offer, exchange, reduction in outstanding shares of Common Stock, merger, consolidation, business combination, reorganization,
recapitalization, <FONT STYLE="white-space:nowrap">spin-off,</FONT> scheme of arrangement, reorganization, recapitalization or reclassification or otherwise in any manner whatsoever, of either (x)&nbsp;at least 50% of the aggregate ordinary voting
power represented by issued and outstanding Common Stock, (y)&nbsp;at least 50% of the aggregate ordinary voting power represented by issued and outstanding Common Stock not held by all such Subject Entities as of the date of this Note calculated as
if any shares of Common Stock held by all such Subject Entities were not outstanding, or (z)&nbsp;a percentage of the aggregate ordinary voting power represented by issued and outstanding shares of Common Stock or other equity securities of the
Company sufficient to allow such Subject Entities to effect a statutory short form merger or other transaction requiring other shareholders of the Company to surrender their shares of Common Stock without approval of the shareholders of the Company
or (C)&nbsp;directly or indirectly, including through subsidiaries, Affiliates or otherwise, in one or more related transactions, the issuance of or the entering into any other instrument or transaction structured in a manner to circumvent, or that
circumvents, the intent of this definition in which case this definition shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this definition to the extent necessary to correct this definition or any
portion of this definition which may be defective or inconsistent with the intended treatment of such instrument or transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> <B><I>&#147;Group&#148; </I></B>means a &#147;group&#148; as that term is used in Section&nbsp;13(d) of the Exchange Act and as
defined in Rule <FONT STYLE="white-space:nowrap">13d-5</FONT> thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(I)</B> <B><I>&#147;Options&#148; </I></B>means any rights,
warrants or options to subscribe for or purchase shares of Common Stock or Convertible Securities issued to Persons other than the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> <B><I>&#147;Parent Entity&#148; </I></B>of a Person means an entity that, directly or indirectly, controls the applicable Person
and whose common stock or equivalent equity security is quoted or listed on an Eligible Market, or, if there is more than one such Person or Parent Entity, the Person or Parent Entity with the largest public market capitalization as of the date of
consummation of the Fundamental Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> <B><I>&#147;Principal Market&#148; </I></B>means the Nasdaq Capital Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> <B><I>&#147;Subject Entity&#148; </I></B>means any Person, Persons or Group or any Affiliate or associate of any such Person,
Persons or Group. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(p)</B> <B><I>&#147;Successor Entity&#148; </I></B>means the Person (or, if so elected by the Holder, the Parent
Entity) formed by, resulting from or surviving any Fundamental Transaction or the Person (or, if so elected by the Holder, the Parent Entity) with which such Fundamental Transaction shall have been entered into. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(q)</B> <B><I>&#147;Trading Day&#148; </I></B>means, as applicable, (x)&nbsp;with respect to
all price or trading volume determinations relating to the Common Stock, any day on which the Common Stock is traded on the Principal Market, or, if the Principal Market is not the principal trading market for the Common Stock, then on the principal
securities exchange or securities market on which the Common Stock is then traded, provided that &#147;Trading Day&#148; shall not include any day on which the Common Stock is scheduled to trade on such exchange or market for less than 4.5 hours or
any day that the Common Stock is suspended from trading during the final hour of trading on such exchange or market (or if such exchange or market does not designate in advance the closing time of trading on such exchange or market, then during the
hour ending at 4:00:00 p.m., New York time) unless such day is otherwise designated as a Trading Day in writing by the Holder or (y)&nbsp;with respect to all determinations other than price determinations relating to the Common Stock, any day on
which The New York Stock Exchange (or any successor thereto) is open for trading of securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(r)</B> <B><I>&#147;VWA.P&#146;
</I></B>means, for any security as of any date, the dollar volume-weighted average price for such security on the Principal Market (or, if the Principal Market is not the principal trading market for such security, then on the principal securities
exchange or securities market on which such security is then traded) during the period beginning at 9:30:01 a.m., New York time, and ending at 4:00:00 p.m., New York time, as reported by Bloomberg through its &#147;HP&#148; function (set to weighted
average) or, if the foregoing does not apply, the dollar volume-weighted average price of such security in the <FONT STYLE="white-space:nowrap">over-the-counter</FONT> market on the electronic bulletin board for such security during the period
beginning at 9:30:01 a.m., New York time, and ending at 4:00:00 p.m., New York time, as reported by Bloomberg, or, if no dollar volume-weighted average price is reported for such security by Bloomberg for such hours, the average of the highest
closing bid price and the lowest closing ask price of any of the market makers for such security as reported in the &#147;pink sheets&#148; by OTC Markets Group Inc. (formerly Pink Sheets LLC). If the VWAP cannot be calculated for such security on
such date on any of the foregoing bases, the VWAP of such security on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such
security, then such dispute shall be resolved in accordance with the procedures in Section&nbsp;22. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination, recapitalization or other similar
transaction during such period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>22.</B> <B>Disclosure. </B>Upon receipt or delivery by the Company of any notice in accordance with
the terms of this Note, unless the Company has in good faith determined that the matters relating to such notice do not constitute material, non-public information relating to the Company or any of its Subsidiaries, the Company shall within the
later of (a)&nbsp;the Cleansing Deadline and (b)&nbsp;one (1) Business Day after any such receipt or delivery, publicly disclose such material, <FONT STYLE="white-space:nowrap">non-public</FONT> information on a Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> or otherwise. In the event that the Company believes that a notice contains material, <FONT STYLE="white-space:nowrap">non-public</FONT> information relating to the Company or any of its Subsidiaries, the
Company so shall indicate to the Holder contemporaneously with delivery of such notice, and in the absence of any such indication, the Holder shall be allowed to presume that all matters relating to such notice do not constitute material, <FONT
STYLE="white-space:nowrap">non-public</FONT> information relating to the Company or any of its Subsidiaries. If the Company or any of its Subsidiaries provides material <FONT STYLE="white-space:nowrap">non-public</FONT> information to the Holder
after the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Cleansing Deadline that is not simultaneously filed in a Current Report on Form 8-K and the Holder has not agreed to receive such material non-public information, the Company hereby covenants and
agrees that the Holder shall not have any duty of confidentiality to the Company, any of its Subsidiaries or any of their respective officers, directors, employees, affiliates or agents with respect to, or a duty to any of the foregoing not to trade
on the basis of, such material non-public information. Nothing contained in this Section&nbsp;22 shall limit any obligations of the Company, or any rights of the Holder, under the Exchange Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[signature page follows] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[SIGNATURE PAGE TO CONVERTIBLE PROMISSORY NOTE OF SELLAS LIFE SCIENCES GROUP, INC.] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>SELLAS LIFE SCIENCES GROUP, INC.</B> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Angelos Stergiou</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Angelos Stergiou, M.D., ScD h.c.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.75
<SEQUENCE>9
<FILENAME>d556278dex1075.htm
<DESCRIPTION>EX-10.75
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.75</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.75 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>CONFIDENTIAL DRAFT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT EXCHANGE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Warrant Exchange Agreement (this &#147;<U>Agreement</U>&#148;) is made as of February&nbsp;7, 2018 (&#147;Effective Date&#148;), by and
between SELLAS Life Sciences Group, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), and ANSON INVESTMENTS MASTER FUND LP (collectively, the &#147;<U>Holder</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the
Holder currently holds 30,000 warrants (the &#147;<U>Warrants</U>&#148;) to purchase shares of the Company&#146;s common stock, par value $0.0001 per share (&#147;<U>Common Stock</U>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, subject to the terms and conditions set forth herein, the Company and the Holder desire to cancel and retire the Warrants in exchange
(the &#147;<U>Exchange</U>&#148;) for shares of Common Stock (the &#147;<U>Exchange Shares</U>&#148;), the number of which is the quotient of $70,200.00 divided by the closing price of the Exchange Shares on the NASDAQ Capital Market on the Closing
Date of the Exchange Shares in reliance on the exemption from registration provided by Section&nbsp;3(a)(9) of the Securities Act of 1933, as amended (the &#147;<U>Securities Act</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt of which is
hereby acknowledged, the Company and the Holder hereby agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 1. EXCHANGE AND TERMINATION. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a)
In consideration of and in express reliance upon the representations, warranties, covenants, terms and conditions of this Agreement, the Holder agrees to deliver and surrender to the Company for cancellation the Warrants in exchange for the Exchange
Shares, and the Company agrees to issue and deliver the Exchange Shares to the Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) The closing under this Agreement (the
&#147;<U>Closing</U>&#148;) shall take place upon the satisfaction of each of the conditions set forth in Sections 4 and 5 hereof (the &#147;<U>Closing Date</U>&#148;). By February&nbsp;8, 2018, (i) the Company shall cause the transfer agent for the
Common Stock to issue and deliver the Exchange Shares duly registered and freely tradable through the facilities of DTC by DWAC to the custodian and account provided to the Company in writing by the Holder and (ii)&nbsp;the Holder shall deliver and
surrender or cause to be delivered and surrendered to the Company for cancellation the Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) If the Closing has not occurred by
February&nbsp;6, 2018, this Agreement shall terminate. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 2. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby represents and warrants as of the date hereof to, and covenants with, the Holder as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <B>Organization and Standing.</B> The Company has been duly incorporated and is validly existing as a corporation in good standing under the
laws of Delaware, has full corporate power and authority to own or lease its properties and conduct its business as presently conducted, and is duly qualified as a foreign corporation and in good standing in each jurisdiction in which the character
of the property owned or leased or the nature of the business transacted by it makes qualification necessary, except where the failure to be so qualified would not have a material adverse effect on the business, properties, financial condition or
results or operations of the Company (a &#147;<U>Material Adverse Effect</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <B>Authorization; Corporate Power.</B> This
Agreement has been duly authorized, validly executed and delivered on behalf of the Company and is a valid and binding obligation of the Company enforceable against the Company in accordance with its terms (except as limited by (i)&nbsp;applicable
bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or affecting the enforcement of creditors&#146; rights generally, and (ii)&nbsp;equitable principles generally, including any specific performance), and the Company has
the requisite corporate power and authority to execute and deliver this Agreement and the other agreements and documents contemplated hereby and to perform its obligations hereunder and thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <B>Issuance and Delivery of the Exchange Shares.</B> The Exchange Shares have been duly authorized and, will be validly issued, fully paid
and nonassessable. Assuming the Warrants were purchased by Holder in the Company&#146;s offering of Common Stock and warrants made pursuant to the Company&#146;s prospectus filed with the Securities and Exchange Commission (the
&#147;<U>SEC</U>&#148;) pursuant to Rule 424(b)(5) on February&nbsp;9, 2017 (the &#147;<U>Registered Offering</U>&#148;) and the Holder is not an &#147;<U>Affiliate</U>&#148; (as such term is defined in Rule 405 promulgated under the Securities Act
of 1933, as amended (the &#147;<U>Securities Act</U>&#148;)) of the Company, the Exchange Shares will be issued to the Holder without legend and will be freely tradable by the Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <B>Governmental Consents. </B>No consent, approval or authorization of or designation, declaration or filing with any governmental
authority on the part of the Company is required in connection with the valid execution and delivery of this Agreement or the offer, sale or issuance of the Exchange Shares or the consummation of any other transaction contemplated by this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <B>No Default or Violation</B>. The execution and delivery of the Agreement and the consummation of the transactions contemplated by
this Agreement by the Company will not (i)&nbsp;result in a breach of or a default under any of the terms or provisions of (A)&nbsp;the Company&#146;s certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws,</FONT> or (B)&nbsp;any
material provision of any indenture, mortgage, deed of trust or other material agreement or instrument to which the Company is a party or by which it or any of its material properties or assets is bound or (ii)&nbsp;result in a violation of any
provision of any law, statute, rule, regulation, or any existing applicable decree, judgment or order by any court, Federal or state regulatory body, administrative agency, or other governmental body having jurisdiction over the Company, or any of
its material properties or assets except in the case of clauses (i)(B) or (ii)&nbsp;for any such breaches, defaults or violations which would not have a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) <B>Disclosure of Agreement.</B> The Company shall, on or before 8:30 a.m., New York City time,
on February&nbsp;13, 2018 file with the SEC a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> disclosing all material terms of the transaction contemplated hereby (such Current Report on Form
<FONT STYLE="white-space:nowrap">8-K,</FONT> the <FONT STYLE="white-space:nowrap">&#147;8-K</FONT> Filing&#148;). From and after the filing of the <FONT STYLE="white-space:nowrap">8-K</FONT> Filing, the Holder shall not be in possession of any
material, nonpublic information received from the Company or any of its subsidiaries or any of their respective officers, directors, employees, affiliates or agents, that is not disclosed in the <FONT STYLE="white-space:nowrap">8-K</FONT> Filing.
The Company shall not, and shall cause its officers, directors, employees, affiliates and agents, not to, provide the Holder with any material, nonpublic information regarding the Company from and after the filing of the <FONT
STYLE="white-space:nowrap">8-K</FONT> Filing without the express written consent of the Holder. To the extent that the Company delivers any material, <FONT STYLE="white-space:nowrap">non-public</FONT> information to the Holder without the
Holder&#146;s express prior written consent, the Company hereby covenants and agrees that the Holder shall not have any duty of confidentiality to the Company, any of its subsidiaries or any of their respective officers, directors, employees,
affiliates or agents with respect to, or a duty to the Company, any of its subsidiaries or any of their respective officers, directors, employees, affiliates or agents not to trade on the basis of, such material,
<FONT STYLE="white-space:nowrap">non-public</FONT> information. The Company shall not disclose the name of the Holder in any filing, announcement, release or otherwise, unless such disclosure is required by law or regulation. In addition, effective
upon the filing of the <FONT STYLE="white-space:nowrap">8-K</FONT> Filing, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its
subsidiaries or any of their respective officers, directors, affiliates, employees or agents, on the one hand, and the Holder or any of its affiliates, on the other hand, shall terminate and be of no further force or effect. The Company understands
and confirms that the Holder will rely on the foregoing representations in effecting transactions in securities of the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 3.
REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE HOLDER. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) The Holder represents and warrants to and covenants with the Company that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <B>Valid Existence; Good Standing</B>. To the extent the Holder is a corporation, limited liability company or other type of entity, the
Holder is validly existing and in good standing under the laws of the jurisdiction of its organization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <B>Authority;
Authorization</B>. The Holder has full right, power, authority and capacity to enter into this Agreement and the other agreements and documents contemplated hereby and to perform its obligations hereunder and thereunder and has taken all necessary
action to authorize the execution, delivery and performance of this Agreement. Upon the execution and delivery of this Agreement by the Holder, this Agreement shall constitute a valid and binding obligation of the Holder, enforceable in accordance
with its terms (except (i)&nbsp;as limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or affecting the enforcement of creditors&#146; rights generally, and (ii)&nbsp;as limited by equitable
principles generally, including any specific performance). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <B>Title</B>. The Holder owns and holds the entire right, title and interest in and to, and
is the record and beneficial owner of, the Warrants and the Holder owns the Warrants free and clear of all Encumbrances (as defined below). The Holder has the full power and authority to vote, transfer and dispose of the Warrants free and clear of
any right or Encumbrances. There is no restriction affecting the ability of the Holder to transfer the legal and beneficial title and ownership of the Warrants to the Company and, at the Closing, the Company will acquire legal and valid title to the
Warrants, free and clear of all Encumbrances. Other than the transactions contemplated by this Agreement, there is no outstanding vote, plan, pending proposal, or other right of any person to acquire all or any of the Warrants.
&#147;Encumbrances&#148; shall mean any security or other property interest or right, claim, lien, pledge, option, charge, security interest, contingent or conditional sale, or other title claim or retention agreement, interest or other right or
claim of third parties, whether perfected or not perfected, voluntarily incurred or arising by operation of law, and including any agreement (other than this Agreement) to grant or submit to any of the foregoing in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <B>Purchase of Warrants in the Registered Offering. </B>The Holder purchased the Warrants in the Registered Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <B>Securities Act Exemption</B>. Neither the Holder nor anyone acting on behalf of the Holder has received any commission or remuneration
directly or indirectly in connection with or in order to solicit or facilitate the Exchange. The Holder understands that the Exchange contemplated hereby is intended to be exempt from registration by virtue of Section&nbsp;3(a)(9) of the Securities
Act. The Holder understands that the Company is relying upon the truth and accuracy of the representations, warranties, agreements, acknowledgments and understandings of the Holder set forth herein for purposes of qualifying for the exemption under
Section&nbsp;3(a)(9) of the Securities Act as well as qualifying for exemptions under applicable state securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) <B><FONT
STYLE="white-space:nowrap">Non-Affiliate</FONT></B>. The Holder is not an Affiliate of the Company and has not been an Affiliate during the three months prior to the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) <B>Information</B>. The Holder has, in connection with its decision to acquire the Exchange Shares, relied with respect to the Company and
its affairs solely upon the Company&#146;s filings with the SEC and the representations and warranties of the Company contained herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) <B>Advisors</B>. The Holder understands that nothing in this Agreement or any other materials presented to the Holder in connection with
the exchange of the Warrants and issuance and acquisition of the Exchange Shares constitutes legal, tax or investment advice. The Holder has consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed necessary or
appropriate in connection with its acquisition of the Exchange Shares. With respect to such matters, the Holder relies solely on such advisors and not on any statements or representations of the Company or any of its agents, written or oral. The
Holder understands that it (and not the Company) shall be responsible for its own tax liability that may arise as a result of this investment or the transactions contemplated by this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) <B>Limitation on Resales</B>. For thirty (30)&nbsp;trading days following the Closing Date,
the Holder shall not sell more than 2.0% of trading volume of Common Stock as reported by Bloomberg, LP for the applicable date of determination through open market sales through the NASDAQ Capital Market on any trading day in which the NASDAQ
Capital Market is open for trading. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 4. CONDITIONS TO COMPANY&#146;S OBLIGATIONS AT THE CLOSING. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s obligation to complete the issuance of the Exchange Shares and deliver the Exchange Shares to the Holder at the Closing
shall be subject to the following conditions to the extent not waived by the Company: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <B>Execution and Delivery</B>. The Holder shall
have executed and delivered this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <B>Covenants</B>. The Holder shall have performed, satisfied and complied in all material
respects with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Holder at or prior to the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <B>Surrender of Warrants.</B> The Company shall have received in physical form or through book-entry transfer from the Holder all
certificates or book-entry notation representing the Warrants to be exchanged for the Exchange Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <B>Representations and
Warranties. </B>The representations and warranties of the Holder shall be true and correct in all material respects as of the date when made and as of the Closing Date as though made at that time, except for representations and warranties that are
expressly made as of a particular date, which shall be true and correct in all material respects as of such date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 5. CONDITIONS TO THE
HOLDER&#146;S OBLIGATIONS AT THE CLOSING. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Holder&#146;s obligation to deliver the Warrants and accept delivery of the Exchange
Shares shall be subject to the following conditions to the extent not waived by the Holder: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)<B>&nbsp;Execution and Delivery</B>. The
Company shall have executed and delivered this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)<B>&nbsp;Covenants</B>. The Company shall have performed, satisfied and
complied in all material respects with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <B>Delivery of Exchange Shares.</B> The Company shall have delivered the Exchange Shares in accordance with the instructions provided
pursuant to Section&nbsp;1.b) hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e)<B>&nbsp;Representations and Warranties.</B> Each of the representations and warranties of the
Company shall be true and correct in all material respects as of the date when made and as of the Closing Date as though made at that time, except for representations and warranties that are expressly made as of a particular date, which shall be
true and correct in all material respects as of such date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 6. NOTICES. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All notices, requests, consents and other communications hereunder shall be in writing, shall be sent by confirmed electronic mail, or mailed
by first-class registered or certified airmail, or nationally recognized overnight express courier, postage prepaid, and shall be deemed given when so sent in the case of electronic mail transmission, or when so received in the case of mail or
courier, and addressed as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) if to the Company, to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">SELLAS Life Sciences Group, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">315 Madison, 4<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Flr. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York, New York 10017 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Angelos Stergiou, M.D., ScD h.c. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-Mail:</FONT> astergiou@sellaslife.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">or to such other person at such other place as the Company shall designate to the Holder in writing; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) if to the Holder, at the address as set forth at the end of this Agreement, or at such other address as may have been furnished by the
Holder to the Company in writing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 7. MISCELLANEOUS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <B>Headings.</B> The headings of the various sections of this Agreement have been inserted for convenience of reference only and shall not
be deemed to be part of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <B>Severability.</B> In case any provision contained in this Agreement should be invalid,
illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <B>Governing Law.</B> This Agreement shall be governed by and construed under the laws of the State of New York without regard to the
choice of law principles thereof. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the State of New York located in The City of New York, Borough of Manhattan for the adjudication of any
dispute hereunder or in connection herewith or with any transaction contemplated hereby or thereby, and hereby irrevocably waives any objection that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit,
action or proceeding is improper. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY
TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <B>Counterparts.</B> This Agreement may be executed in two or more counterparts, each of which
shall constitute an original, but all of which, when taken together, shall constitute but one instrument, and shall become effective when one or more counterparts have been signed by each party hereto and delivered to the other parties. In the event
that any signature is delivered by facsimile transmission or by an <FONT STYLE="white-space:nowrap">e-mail</FONT> which contains an electronic file of an executed signature page, such signature page shall create a valid and binding obligation of the
party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or electronic file signature page (as the case may be) were an original thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <B>Successors and Assigns.</B> Except as otherwise expressly provided herein, the provisions hereof shall inure to the benefit of, and be
binding upon, the successors, permitted assigns, heirs, executors and administrators of the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) <B>Entire Agreement;
Amendments.</B> This Agreement and other documents delivered pursuant hereto constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and thereof. This Agreement may be amended, modified,
superseded, cancelled, renewed or extended, and the terms and conditions hereof may be waived, only by a written instrument signed by all parties, or, in the case of a waiver, by the party waiving compliance. Except as expressly stated herein, no
delay on the part of any party in exercising any right, power or privilege hereunder shall operate as a waiver thereof, nor shall any waiver on the part of any party of any right, power or privilege hereunder preclude any other or future exercise of
any other right, power or privilege hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">g) <B>Survival. </B>The representations, warranties, covenants and agreements made in this
Agreement shall survive the closing of the transactions contemplated hereby and the exchange and delivery of the Warrants and the Exchange Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[signature pages follow] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have caused this Agreement to be executed by their
duly authorized representatives as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SELLAS LIFE SCIENCES GROUP, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By: </TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Angelos Stergiou</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Angelos Stergiou, M.D., ScD h.c.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">COMPANY SIGNATURE PAGE TO </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">WARRANT EXCHANGE AGREEMENT </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>HOLDER: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ANSON INVESTMENTS MASTER FUND LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Amin Nathoo</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Amin Nathoo</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Advising Rep, Anson Advisors Inc.</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Address:</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="82%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E-Mail:&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">DWAC INSTRUCTIONS</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Broker Name and DTC Number:</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Account Number at DTC Participant</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">(if
applicable):&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">HOLDER SIGNATURE PAGE TO </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">WARRANT EXCHANGE AGREEMENT </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.76
<SEQUENCE>10
<FILENAME>d556278dex1076.htm
<DESCRIPTION>EX-10.76
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.76</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.76 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Confidential Draft </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT EXCHANGE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Warrant Exchange Agreement (this &#147;<U>Agreement</U>&#148;) is made as of February&nbsp;8, 2018 (&#147;Effective Date&#148;), by and
between SELLAS Life Sciences Group, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), and SABBY HEALTHCARE MASTER FUND LTD and SABBY VOLATILITY WARRANT MASTER FUND LTD (collectively, the &#147;<U>Holder</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the
Holder currently holds 83,333 warrants (the &#147;<U>Warrants</U>&#148;) to purchase shares of the Company&#146;s common stock, par value $0.0001 per share (&#147;<U>Common Stock</U>&#148;) as shown on the attached <U>Appendix A</U>; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, subject to the terms and conditions set forth herein, the Company and the Holder desire to cancel and retire the Warrants in exchange
(the &#147;<U>Exchange</U>&#148;) for a number of shares of Common Stock (the &#147;<U>Exchange Shares</U>&#148;) determined by the quotient of $195,000.00 divided by the closing price of the Common Stock on the NASDAQ Capital Market on the Closing
Date (such price, the &#147;<U>Closing Price</U>&#148;, and such price on the Closing Date, the &#147;<U>First Closing Price</U>&#148;)), in reliance on the exemption from registration provided by Section&nbsp;3(a)(9) of the Securities Act of 1933,
as amended (the &#147;<U>Securities Act</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the mutual covenants contained in this Agreement, and for other
good and valuable consideration, the receipt of which is hereby acknowledged, the Company and the Holder hereby agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 1. EXCHANGE AND
TERMINATION. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) In consideration of and in express reliance upon the representations, warranties, covenants, terms and conditions of
this Agreement, the Holder agrees to deliver and surrender to the Company for cancellation the Warrants in exchange for the Exchange Shares, and the Company agrees to issue and deliver the Exchange Shares to the Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) The closing under this Agreement (the &#147;<U>Closing</U>&#148;) shall take place upon the satisfaction of each of the conditions set
forth in Sections 4 and 5 hereof, and in any event within 2 Trading Days of the date hereof (the &#147;<U>Closing Date</U>&#148;). At the Closing, (i)&nbsp;the Company shall cause the transfer agent for the Common Stock to issue and deliver the
Exchange Shares duly registered and freely tradable through the facilities of DTC by DWAC to the custodian and account provided to the Company in writing by the Holder and (ii)&nbsp;the Holder shall instruct the transfer agent of the Company to
surrender the Warrants to the Company for cancellation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) If the Closing has not occurred by February&nbsp;8, 2018, this Agreement shall
terminate; <I>provided, however</I>, that no such termination will affect the right of any party to sue for any breach by any other party (or parties) of their respective obligations hereunder. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 2. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby represents and warrants as of the date hereof to, and covenants with, the Holder as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <B>Organization and Standing.</B> The Company has been duly incorporated and is validly existing as a corporation in good standing under the
laws of Delaware, has full corporate power and authority to own or lease its properties and conduct its business as presently conducted, and is duly qualified as a foreign corporation and in good standing in each jurisdiction in which the character
of the property owned or leased or the nature of the business transacted by it makes qualification necessary, except where the failure to be so qualified would not have a material adverse effect on the business, properties, financial condition or
results or operations of the Company (a &#147;<U>Material Adverse Effect</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <B>Authorization; Corporate Power.</B> This
Agreement has been duly authorized, validly executed and delivered on behalf of the Company and is a valid and binding obligation of the Company enforceable against the Company in accordance with its terms (except as limited by (i)&nbsp;applicable
bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or affecting the enforcement of creditors&#146; rights generally, and (ii)&nbsp;equitable principles generally, including any specific performance), and the Company has
the requisite corporate power and authority to execute and deliver this Agreement and the other agreements and documents contemplated hereby and to perform its obligations hereunder and thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <B>Issuance and Delivery of the Exchange Shares.</B> The Exchange Shares have been duly authorized and, will be validly issued, fully paid
and nonassessable. Assuming the Warrants were purchased by Holder in the Company&#146;s offering of Common Stock and warrants made pursuant to the Company&#146;s prospectus filed with the Securities and Exchange Commission (the
&#147;<U>SEC</U>&#148;) pursuant to Rule 424(b)(5) on February&nbsp;9, 2017 (the &#147;<U>Registered Offering</U>&#148;) and the Holder is not an &#147;<U>Affiliate</U>&#148; (as such term is defined in Rule 405 promulgated under the Securities Act
of 1933, as amended (the &#147;<U>Securities Act</U>&#148;)) of the Company, the Exchange Shares will be issued to the Holder without legend and will be freely tradable by the Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <B>Governmental Consents. </B>No consent, approval or authorization of or designation, declaration or filing with any governmental
authority on the part of the Company is required in connection with the valid execution and delivery of this Agreement or the offer, sale or issuance of the Exchange Shares or the consummation of any other transaction contemplated by this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <B>No Default or Violation</B>. The execution and delivery of the Agreement and the consummation of the transactions contemplated by
this Agreement by the Company will not (i)&nbsp;result in a breach of or a default under any of the terms or provisions of (A)&nbsp;the Company&#146;s certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws,</FONT> or (B)&nbsp;any
material provision of any indenture, mortgage, deed of trust or other material agreement or instrument to which the Company is a party or by which it or any of its material properties or assets is bound or (ii)&nbsp;result in a violation of any
provision of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any law, statute, rule, regulation, or any existing applicable decree, judgment or order by any court, Federal or state regulatory body, administrative agency, or other governmental body having
jurisdiction over the Company, or any of its material properties or assets except in the case of clauses (i)(B) or (ii)&nbsp;for any such breaches, defaults or violations which would not have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) <B>Disclosure of Agreement.</B> The Company shall, on or before 8:30 a.m., New York City time, on February&nbsp;14, 2018 file with the SEC
a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> disclosing all material terms of the transactions contemplated hereby (such Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> the &#147;<U><FONT
STYLE="white-space:nowrap">8-K</FONT> Filing</U>&#148;). From and after the earlier of (i)&nbsp;the time that a public announcement of certain material <FONT STYLE="white-space:nowrap">non-public</FONT> information in possession of the Holder is
made public (&#147;<U>Other MNPI</U>&#148;) and (ii)&nbsp;February&nbsp;21, 2018 (&#147;<U>Cleansing Time</U>&#148;), the Holder shall not be in possession of any material, nonpublic information received from the Company or any of its subsidiaries
or any of their respective officers, directors, employees, affiliates or agents. After the date hereof, other than the contents of the Form <FONT STYLE="white-space:nowrap">8-K</FONT> and the Other MNPI, the Company shall not, and shall cause its
officers, directors, employees, affiliates and agents, not to, provide the Holder with any material, nonpublic information regarding the Company without the express written consent of the Holder. To the extent that the Company delivers any such
material, <FONT STYLE="white-space:nowrap">non-public</FONT> information to the Holder without the Holder&#146;s express prior written consent, the Company hereby covenants and agrees that the Holder shall not have any duty of confidentiality to the
Company, any of its subsidiaries or any of their respective officers, directors, employees, affiliates or agents with respect to, or a duty to the Company, any of its subsidiaries or any of their respective officers, directors, employees, affiliates
or agents not to trade on the basis of, such material, <FONT STYLE="white-space:nowrap">non-public</FONT> information. The Company shall not disclose the name of the Holder in any filing, announcement, release or otherwise, unless such disclosure is
required by law or regulation. In addition, effective following the Cleansing Time, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of
its subsidiaries or any of their respective officers, directors, affiliates, employees or agents, on the one hand, and the Holder or any of its affiliates, on the other hand, shall terminate and be of no further force or effect. The Company
understands and confirms that the Holder will rely on the foregoing representations in effecting transactions in securities of the Company. Notwithstanding anything herein to the contrary, in the event that the Closing Price on the date of the
Cleansing Time is less than the First Closing Price, the Company shall issue additional shares of Common Stock to the Holder equal to the difference between what the Holder would have received if the Exchange Shares had been calculated using such
Closing Price and the number of Exchange Shares issued on the Closing Date. Such shares shall be issued within 2 trading days of the date of the Cleansing Time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 3. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE HOLDER. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) The Holder represents and warrants to and covenants with the Company that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <B>Valid Existence; Good Standing</B>. To the extent the Holder is a corporation, limited liability company or other type of entity, the
Holder is validly existing and in good standing under the laws of the jurisdiction of its organization. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <B>Authority; Authorization</B>. The Holder has full right, power, authority and capacity to
enter into this Agreement and the other agreements and documents contemplated hereby and to perform its obligations hereunder and thereunder and has taken all necessary action to authorize the execution, delivery and performance of this Agreement.
Upon the execution and delivery of this Agreement by the Holder, this Agreement shall constitute a valid and binding obligation of the Holder, enforceable in accordance with its terms (except (i)&nbsp;as limited by applicable bankruptcy, insolvency,
reorganization, moratorium or similar laws relating to or affecting the enforcement of creditors&#146; rights generally, and (ii)&nbsp;as limited by equitable principles generally, including any specific performance). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <B>Title</B>. The Holder owns and holds the entire right, title and interest in and to, and is the record and beneficial owner of, the
Warrants and the Holder owns the Warrants free and clear of all Encumbrances (as defined below). The Holder has the full power and authority to vote, transfer and dispose of the Warrants free and clear of any right or Encumbrances. There is no
restriction affecting the ability of the Holder to transfer the legal and beneficial title and ownership of the Warrants to the Company and, at the Closing, the Company will acquire legal and valid title to the Warrants, free and clear of all
Encumbrances. Other than the transactions contemplated by this Agreement, there is no outstanding vote, plan, pending proposal, or other right of any person to acquire all or any of the Warrants. &#147;Encumbrances&#148; shall mean any security or
other property interest or right, claim, lien, pledge, option, charge, security interest, contingent or conditional sale, or other title claim or retention agreement, interest or other right or claim of third parties, whether perfected or not
perfected, voluntarily incurred or arising by operation of law, and including any agreement (other than this Agreement) to grant or submit to any of the foregoing in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <B>Purchase of Warrants in the Registered Offering. </B>The Holder purchased the Warrants in the Registered Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <B>Securities Act Exemption</B>. Neither the Holder nor anyone acting on behalf of the Holder has received any commission or remuneration
directly or indirectly in connection with or in order to solicit or facilitate the Exchange. The Holder understands that the Exchange contemplated hereby is intended to be exempt from registration by virtue of Section&nbsp;3(a)(9) of the Securities
Act. The Holder understands that the Company is relying upon the truth and accuracy of the representations, warranties, agreements, acknowledgments and understandings of the Holder set forth herein for purposes of qualifying for the exemption under
Section&nbsp;3(a)(9) of the Securities Act as well as qualifying for exemptions under applicable state securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) <B><FONT
STYLE="white-space:nowrap">Non-Affiliate</FONT></B>. The Holder is not an Affiliate of the Company and has not been an Affiliate during the three months prior to the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) <B>Information</B>. The Holder has, in connection with its decision to acquire the Exchange Shares, relied with respect to the Company and
its affairs solely upon the Company&#146;s filings with the SEC and the representations and warranties of the Company contained herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) <B>Advisors</B>. The Holder understands that nothing in this Agreement or any other materials
presented to the Holder in connection with the exchange of the Warrants and issuance and acquisition of the Exchange Shares constitutes legal, tax or investment advice. The Holder has consulted such legal, tax and investment advisors as it, in its
sole discretion, has deemed necessary or appropriate in connection with its acquisition of the Exchange Shares. With respect to such matters, the Holder relies solely on such advisors and not on any statements or representations of the Company or
any of its agents, written or oral. The Holder understands that it (and not the Company) shall be responsible for its own tax liability that may arise as a result of this investment or the transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) <B>Limitation on Resales</B>. During the thirty (30)&nbsp;trading days following the Closing Date, on any trading day on which the NASDAQ
Capital Market is open for trading, the Holder shall not sell, through open market sales on the NASDAQ Capital Market, a number of Exchange Shares in excess of 2.0% of the trading volume of Common Stock as reported by Bloomberg, LP for the
applicable trading day. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 4. CONDITIONS TO COMPANY&#146;S OBLIGATIONS AT THE CLOSING. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s obligation to complete the issuance of the Exchange Shares and deliver the Exchange Shares to the Holder at the Closing
shall be subject to the following conditions to the extent not waived by the Company: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">a) <B>Execution and Delivery</B>. The Holder shall
have executed and delivered this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">b) <B>Covenants</B>. The Holder shall have performed, satisfied and complied in all material
respects with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Holder at or prior to the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">c) <B>Surrender of Warrants.</B> The Company shall have received in physical form or through book-entry transfer from the Holder all
certificates or book-entry notation representing the Warrants to be exchanged for the Exchange Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">d) <B>Representations and
Warranties. </B>The representations and warranties of the Holder shall be true and correct in all material respects as of the date when made and as of the Closing Date as though made at that time, except for representations and warranties that are
expressly made as of a particular date, which shall be true and correct in all material respects as of such date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 5. CONDITIONS TO THE
HOLDER&#146;S OBLIGATIONS AT THE CLOSING. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Holder&#146;s obligation to deliver the Warrants and accept delivery of the Exchange
Shares shall be subject to the following conditions to the extent not waived by the Holder: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)<B>&nbsp;Execution and Delivery</B>. The
Company shall have executed and delivered this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)<B>&nbsp;Covenants</B>. The Company shall have performed, satisfied and
complied in all material respects with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to the Closing Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <B>Delivery of Exchange Shares.</B> The Company shall have delivered the Exchange Shares in
accordance with the instructions provided pursuant to Section&nbsp;1.b) hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d)<B>&nbsp;Representations and Warranties.</B> Each of
the representations and warranties of the Company shall be true and correct in all material respects as of the date when made and as of the Closing Date as though made at that time, except for representations and warranties that are expressly made
as of a particular date, which shall be true and correct in all material respects as of such date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 6. NOTICES. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All notices, requests, consents and other communications hereunder shall be in writing, shall be sent by confirmed electronic mail, or mailed
by first-class registered or certified airmail, or nationally recognized overnight express courier, postage prepaid, and shall be deemed given when so sent in the case of electronic mail transmission, or when so received in the case of mail or
courier, and addressed as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) if to the Company, to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">SELLAS Life Sciences Group, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">315 Madison, 4<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Flr. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York, New York 10017 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Angelos Stergiou, M.D., ScD h.c. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-Mail:</FONT> astergiou@sellaslife.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">or to such other person at such other place as the Company shall designate to the Holder in writing; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) if to the Holder, at the address as set forth at the end of this Agreement, or at such other address as may have been furnished by the
Holder to the Company in writing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 7. MISCELLANEOUS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <B>Headings.</B> The headings of the various sections of this Agreement have been inserted for convenience of reference only and shall not
be deemed to be part of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <B>Severability.</B> In case any provision contained in this Agreement should be invalid,
illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>Most Favored Nations</B>.&nbsp;The Company covenants and agrees that it has not entered into a warrant exchange agreement with any
other holder of Warrants of the Registered Offering (&#147;<U>Other Holder</U>&#148;) for any material amendments, modifications or exchanges to the terms of such Warrants (or settlement or exchange of such Warrants for other material consideration)
(each a &#147;<U>More Favorable Agreement</U>&#148;), that is more favorable to such Other Holder than those of the Holder pursuant to this Agreement (it being understood that the pricing formula used to determine the number of shares of Common
Stock issuable in any More Favorable Agreement may be based </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
on 100% of the then market price (using substantially the same formula hereunder), even if the price goes down (but not including any other consideration that may be granted or other type of
security, if used)). If the Company enters into a More Favorable Agreement with terms that are materially different from this Agreement (&#147;material&#148; shall be in the reasonable determination of the Holder), then (i)&nbsp;the Company shall
provide written notice thereof to the Holder promptly following the occurrence thereof and (ii)&nbsp;the terms and conditions of this Agreement that shall be, without any further action by the Holder or the Company, automatically and retroactively
to the date hereof, amended and modified in an economically and legally equivalent manner such that the Holder shall receive the benefit of such more favorable material terms and/or conditions (as the case may be) set forth in such More Favorable
Agreement, provided that upon written notice to the Company within five business days of such Company&#146;s written notice, the Holder may elect not to accept the benefit of any such amended or modified material term or condition, in which event
the material term or condition contained in this Agreement shall continue to apply to the Holder as it was in effect immediately prior to such amendment or modification as if such amendment or modification never occurred with respect to the
Holder.&nbsp;The provisions of this paragraph shall apply similarly and equally to each More Favorable Agreement shall be effective whether or not the Holder holds Exchange Shares at such time. The Company shall not enter into any More Favorable
Agreement that would obligate the Company (after taking into consideration this clause b)) to issue to the Holder and the Other Holders, in the aggregate, a number of shares of Common Stock that would exceed 19.9% of the total number of shares of
Common Stock issued and outstanding as of the date hereof. The Company will notify the Holder any time it enters into any agreement with any Other Holder relating to the Warrants and, at the request of the Holder, provide the Holder with such
agreement for its review. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <B>Governing Law.</B> This Agreement shall be governed by and construed under the laws of the State of New
York without regard to the choice of law principles thereof. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the State of New York located in The City of New York, Borough of Manhattan
for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or thereby, and hereby irrevocably waives any objection that such suit, action or proceeding is brought in an inconvenient forum or
that the venue of such suit, action or proceeding is improper. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND
AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <B>Counterparts.</B> This Agreement may be executed in two or more counterparts, each of which shall constitute an original, but all of
which, when taken together, shall constitute but one instrument, and shall become effective when one or more counterparts have been signed by each party hereto and delivered to the other parties. In the event that any signature is delivered by
facsimile transmission or by an <FONT STYLE="white-space:nowrap">e-mail</FONT> which contains an electronic file of an executed signature page, such signature page shall create a valid and binding obligation of the party executing (or on whose
behalf such signature is executed) with the same force and effect as if such facsimile or electronic file signature page (as the case may be) were an original thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <B>Successors and Assigns.</B> Except as otherwise expressly provided herein, the provisions
hereof shall inure to the benefit of, and be binding upon, the successors, permitted assigns, heirs, executors and administrators of the parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) <B>Entire Agreement; Amendments.</B> This Agreement and other documents delivered pursuant hereto constitute the full and entire
understanding and agreement between the parties with regard to the subjects hereof and thereof. This Agreement may be amended, modified, superseded, cancelled, renewed or extended, and the terms and conditions hereof may be waived, only by a written
instrument signed by all parties, or, in the case of a waiver, by the party waiving compliance. Except as expressly stated herein, no delay on the part of any party in exercising any right, power or privilege hereunder shall operate as a waiver
thereof, nor shall any waiver on the part of any party of any right, power or privilege hereunder preclude any other or future exercise of any other right, power or privilege hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">g) <B>Survival. </B>The representations, warranties, covenants and agreements made in this Agreement shall survive the closing of the
transactions contemplated hereby and the exchange and delivery of the Warrants and the Exchange Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[signature pages follow] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have caused this Agreement to be executed by their
duly authorized representatives as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SELLAS LIFE SCIENCES GROUP, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Angelos Stergiou</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Angelos Stergiou, M.D., ScD h.c.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">COMPANY SIGNATURE PAGE TO </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">WARRANT EXCHANGE AGREEMENT </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>HOLDER: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">SABBY VOLATILITY WARRANT MASTER FUND LTD</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">SABBY HEALTHCARE MASTER FUND LTD</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Robert Grundstein</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Robert Grundstein</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">/s/ Robert Grundstein</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">/s/ Robert Grundstein</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Title:</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:10pt">COO of Purchaser&#146;s Investment Manager</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">COO of Purchaser&#146;s Investment Manager</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Address:</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E-Mail:</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E-Mail:</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="36%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">DWAC INSTRUCTIONS</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">DWAC INSTRUCTIONS</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Broker Name and DTC Number:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Broker Name and DTC Number:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Account Number at DTC Participant</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Account Number at DTC Participant</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(if&nbsp;applicable):</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(if&nbsp;applicable):</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">HOLDER SIGNATURE PAGE TO </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">WARRANT EXCHANGE AGREEMENT </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">APPENDIX A </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Warrants subject to Exchange </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Common Stock
Purchase Warrants of the Company to purchase up to 83,333 shares of common stock with an exercise price of $36.30 and an expiration date of February&nbsp;13, 2022. </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.77
<SEQUENCE>11
<FILENAME>d556278dex1077.htm
<DESCRIPTION>EX-10.77
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.77</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.77 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS
LIFE SCIENCES GROUP, INC. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT EXCHANGE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Warrant Exchange Agreement (this &#147;<U>Agreement</U>&#148;) is made as of February&nbsp;9, 2018 (&#147;<U>Effective Date</U>&#148;),
by and between SELLAS Life Sciences Group, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), and HUDSON BAY MASTER FUND LTD ( collectively, the &#147;<U>Holder</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the
Holder currently holds 146,666 warrants (the &#147;<U>Warrants</U>&#148;) to purchase shares of the Company&#146;s common stock, par value $0.0001 per share (&#147;<U>Common Stock</U>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, subject to the terms and conditions set forth herein, the Company and the Holder desire to cancel and retire the Warrants in exchange
(the &#147;<U>Exchange</U>&#148;) for a convertible promissory note (the &#147;<U>Exchange Note</U>&#148;), in the amount of $343,200.00 on such other terms as set forth in the form of Exchange Note attached as Exhibit A, in reliance on the
exemption from registration provided by Section&nbsp;3(a)(9) of the Securities Act of 1933, as amended (the &#147;<U>Securities Act</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt of which is
hereby acknowledged, the Company and the Holder hereby agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 1. EXCHANGE AND TERMINATION. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a)
In consideration of and in express reliance upon the representations, warranties, covenants, terms and conditions of this Agreement, the Holder agrees to deliver and surrender to the Company for cancellation the Warrants in exchange for the Exchange
Note, and the Company agrees to execute and deliver the Exchange Note to the Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) The closing under this Agreement (the
&#147;<U>Closing</U>&#148;) shall take place upon the satisfaction of each of the conditions set forth in Sections 4 and 5 hereof (the &#147;<U>Closing Date</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) If the Closing has not occurred by the second trading day after the date hereof, this Agreement shall terminate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 2. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby represents and warrants as of the date hereof to, and covenants with, the Holder as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <B>Organization and Standing.</B> The Company has been duly incorporated and is validly existing as a corporation in good standing under the
laws of Delaware, has full corporate power and authority to own or lease its properties and conduct its business as presently conducted, </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and is duly qualified as a foreign corporation and in good standing in each jurisdiction in which the character of the property owned or leased or the nature of the business transacted by it
makes qualification necessary, except where the failure to be so qualified would not have a Material Adverse Effect (as defined below). As used in this Agreement, &#147;<U>Material Adverse Effect</U>&#148; means any material adverse effect on the
business, properties, assets, liabilities, operations, results of operations, condition (financial or otherwise) or prospects of the Company and its subsidiaries (the &#147;<U>Subsidiaries</U>&#148;), if any, individually or taken as a whole, or on
the transactions contemplated hereby or on the Exchange Documents (as defined below) or by the agreements and instruments to be entered into (or entered into) in connection herewith or therewith, or on the authority or ability of the Company to
perform its obligations under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <B>Authorization; Corporate Power.</B> This Agreement has been duly authorized, validly
executed and delivered on behalf of the Company and is a valid and binding obligation of the Company enforceable against the Company in accordance with its terms (except as limited by (i)&nbsp;applicable bankruptcy, insolvency, reorganization,
moratorium or similar laws relating to or affecting the enforcement of creditors&#146; rights generally, and (ii)&nbsp;equitable principles generally, including any specific performance), and the Company has the requisite corporate power and
authority to execute and deliver this Agreement and the other agreements and documents contemplated hereby and to perform its obligations hereunder and thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <B>Valid Issuance and Delivery of New Securities.</B> The issuance of the Exchange Note is duly authorized and, upon issuance in accordance
with the terms of this Agreement, the shares of Common Stock issuable upon conversion or otherwise pursuant to the terms of the Exchange Note (collectively, the &#147;<U>Conversion Shares</U>&#148;, and together with the Exchange Note, the
&#147;<U>New Securities</U>&#148;) shall be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and free from all preemptive or similar rights, mortgages, defects, claims, liens, pledges, charges, taxes, rights of
first refusal, encumbrances, security interests and other encumbrances (collectively &#147;<U>Liens</U>&#148;) with respect to the issuance thereof. As of the date hereof, the Company has reserved from its duly authorized capital stock not less than
150% of the maximum number of Conversion Shares issuable upon conversion of the Exchange Notes (assuming for purposes hereof that (x)&nbsp;the Exchange Notes are convertible at the Alternate Conversion Price (as defined in the Notes) assuming a date
of conversion as of the date hereof, (y)&nbsp;interest on the Notes shall accrue through the Maturity Date (as defined in the Exchange Note) and will be converted in shares of Common Stock (as defined below) at a conversion price equal to the
Alternate Conversion Price assuming a date of conversion as of the date hereof and (z)&nbsp;any such conversion shall not take into account any limitations on the conversion of the Exchange Notes set forth in the Exchange Notes). Upon issuance or
conversion in accordance with the Exchange Notes the Conversion Shares when issued, will be validly issued, fully paid and nonassessable and free from all preemptive or similar rights or Liens with respect to the issue thereof, with the holders
being entitled to all rights accorded to a holder of Common Stock. The offer and issuance by the Company of the New Securities is exempt from registration under the Securities Act. Each of the New Securities will be freely tradable and shall not be
required to bear, and shall not bear, any Securities Act or other restrictive legend. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <B>Consents. </B>No consent, waiver, approval or
authorization of or designation, declaration or filing with any Person (as defined below) on the part of the Company is required in connection with the valid execution and delivery of this Agreement or the offer, sale or issuance of the New
Securities or the consummation of any other transaction contemplated by this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement. For purposes of this Agreement, (i) &#147;Person&#148; means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated
organization, any other entity and any Governmental Entity or any department or agency thereof; and (ii) &#147;<U>Governmental Entity</U>&#148; means any nation, state, county, city, town, village, district, or other political jurisdiction of any
nature, federal, state, local, municipal, foreign, or other government, governmental or quasi-governmental authority of any nature (including any governmental agency, branch, department, official, or entity and any court or other tribunal),
multi-national organization or body; or body exercising, or entitled to exercise, any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power of any nature or instrumentality of any of the foregoing,
including any entity or enterprise owned or controlled by a government or a public international organization or any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">e)
<B>No Default or Violation</B>. The execution and delivery of the Agreement and the consummation of the transactions contemplated by this Agreement by the Company will not (i)&nbsp;result in a breach of or a default under any of the terms or
provisions of (A)&nbsp;the Company&#146;s certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws,</FONT> or (B)&nbsp;any material provision of any indenture, mortgage, deed of trust or other material agreement or instrument to
which the Company is a party or by which it or any of its material properties or assets is bound or (ii)&nbsp;result in a violation of any provision of any law, statute, rule, regulation, or any existing applicable decree, judgment or order by any
court, Federal or state regulatory body, administrative agency, or other governmental body having jurisdiction over the Company, or any of its material properties or assets except in the case of clauses (i)(B) or (ii)&nbsp;for any such breaches,
defaults or violations which would not have a Material Adverse Effect. The Company has not violated any law or any governmental regulation or requirement which violation has had or would reasonably be expected to have a Material Adverse Effect, and
the Company has not received written notice of any such violation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) <B>Offering</B>. Neither the Company, nor any of its affiliates,
nor any Person acting on its or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D) in connection with the offer or sale of the New Securities. The Company shall be responsible
for the payment of any placement agent&#146;s fees, financial advisory fees, or brokers&#146; commissions (other than for persons engaged by the Holder or its investment advisor) relating to or arising out of the transactions contemplated hereby.
The Company shall pay, and hold the Holder harmless against, any liability, loss or expense (including, without limitation, attorney&#146;s fees and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT>
expenses) arising in connection with any such claim. Neither the Company nor any of its Subsidiaries has engaged any placement agent or other agent in connection with the Exchange and the issuance of the New Securities. The offer, exchange and
issuance, as applicable, of the New Securities as contemplated by this Agreement are exempt from the registration requirements of the Securities Act and the qualification or registration requirements of state securities laws or other applicable blue
sky laws. Neither the Company nor any authorized agent acting on its behalf will take any action hereafter that would cause the loss of such exemptions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">g) <B>Absence of Litigation</B>. Except as set forth in the reports, schedules, forms, statements and other documents required to be filed by
the Company with the Securities and Exchange Commission (the &#147;<U>SEC</U>&#148;) pursuant to the reporting requirements of the Securities Exchange Act of 1934, as amended (the &#147;<U>Exchange Act</U>&#148;), there is no action, suit,
proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the Company, threatened against or affecting the Company, the Common Stock, any
securities of the Company or any of the Company&#146;s officers or directors in their capacities as such. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">h) <B>No Group</B>. The Company acknowledges that, to the Company&#146;s knowledge, the Holder is
acting independently in connection with this Agreement and the transactions contemplated hereby, and is not acting as part of a &#147;group&#148; as such term is defined under Section&nbsp;13(d) of the Securities Act and the rules and regulations
promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">i) <B>Validity; Enforcement</B>. This Agreement and each other Exchange Document to which the Company is a party
have been duly and validly authorized, executed and delivered on behalf of the Company and shall constitute the legal, valid and binding obligations of the Company enforceable against the Company in accordance with their respective terms, except as
such enforceability may be limited by general principles of equity or to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable
creditors&#146; rights and remedies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">j) [Intentionally Omitted.] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">k) <B>Disclosure of Agreement.</B> On or before 8:30 a.m., New York City time, on March&nbsp;5, 2018 (the &#147;<U>Cleansing
Deadline</U>&#148;), the Company shall have publicly, whether through one or more press releases or Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC, all material terms of the transactions contemplated hereby
and any other material, nonpublic information provided to the Holder from the Company or any of its Subsidiaries or any of their respective officers, directors, employees, affiliates or agents, including by attaching the form of this Agreement as an
exhibit to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC prior to the Cleansing Deadline. From and after the Cleansing Deadline, the Holder shall not be in possession of any material, nonpublic information
received from the Company or any of its Subsidiaries or any of their respective officers, directors, employees, affiliates or agents, that has not been publicly disclosed. The Company shall not, and shall cause its officers, directors, employees,
affiliates and agents, not to, provide the Holder with any material, nonpublic information regarding the Company from and after the Cleansing Deadline without the express written consent of the Holder. To the extent that the Company delivers any
material, <FONT STYLE="white-space:nowrap">non-public</FONT> information to the Holder after the Cleansing Deadline without the Holder&#146;s express prior written consent, the Company hereby covenants and agrees that the Holder shall not have any
duty of confidentiality to the Company, any of its Subsidiaries or any of their respective officers, directors, employees, affiliates or agents with respect to, or a duty to the Company, any of its Subsidiaries or any of their respective officers,
directors, employees, affiliates or agents not to trade on the basis of, such material, <FONT STYLE="white-space:nowrap">non-public</FONT> information. The Company shall not disclose the name of the Holder in any filing, announcement, release or
otherwise, unless such disclosure is required by law or regulation. In addition, effective upon the Cleansing Deadline, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written
or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, affiliates, employees or agents, on the one hand, and the Holder or any of its affiliates, on the other hand, shall terminate and be of no further
force or effect. The Company understands and confirms that the Holder will rely on the foregoing representations in effecting transactions in securities of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">l) <B>Blue Sky</B>. The Company shall make all filings and reports relating to each Exchange
required under applicable securities or &#147;Blue Sky&#148; laws of the states of the United States following the date hereof, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">m) <B>No Integration</B>. None of the Company, its Subsidiaries, any of their affiliates, or any Person acting on their behalf shall, directly
or indirectly, make any offers or sales of any security (as defined in the Securities Act) or solicit any offers to buy any security or take any other actions, under circumstances that would require registration of any of the New Securities under
the Securities Act or cause this offering of the New Securities to be integrated with such offering or any prior offerings by the Company for purposes of Regulation D under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">n) <B>Listing</B>. The Company shall promptly secure the listing or designation for quotation (as applicable) of all of the Conversion Shares
upon the Nasdaq Capital Market (subject to official notice of issuance) and shall maintain such listing of all the Conversion Shares from time to time issuable under the terms of the Exchange Documents. The Company shall maintain the Common
Stock&#146;s authorization for quotation on the Nasdaq Capital Market. Neither the Company nor any of its Subsidiaries shall take any action which would be reasonably expected to result in the delisting or suspension of the Common Stock from the
Nasdaq Capital Market. The Company shall pay all fees and expenses in connection with satisfying its obligations under this Section&nbsp;2(n). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">o) <B>Holding Period</B>. For the purposes of Rule&nbsp;144 and in reliance upon the advice of counsel, the Company acknowledges that
(i)&nbsp;the holding period of the Exchange Note (and upon conversion of the Exchange Note, the Conversion Shares) may be tacked onto the holding period of the Warrants, (ii)&nbsp;the Company is not aware of any event reasonably likely to occur that
would reasonably be expected to result in the New Securities becoming ineligible to be resold by the Holder pursuant to Rule 144 and (iii)&nbsp;in connection with any resale of any New Securities pursuant to Rule 144, the Holder shall solely be
required to provide reasonable assurances that such New Securities are eligible for resale, assignment or transfer under Rule 144, which shall not include an opinion of Holder&#146;s counsel. The Company shall be responsible for any transfer agent
fees or Depository Trust Company fees or legal fees of the Company&#146;s counsel with respect to the removal of legends, if any, or issuance of New Securities in accordance herewith. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 3. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE HOLDER. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) The Holder represents and warrants to and covenants with the Company that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <B>Valid Existence; Good Standing</B>. To the extent the Holder is a corporation, limited liability company or other type of entity, the
Holder is validly existing and in good standing under the laws of the jurisdiction of its organization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <B>Authority;
Authorization</B>. The Holder has full right, power, authority and capacity to enter into this Agreement and the other agreements and documents contemplated hereby and to perform its obligations hereunder and thereunder and has taken all necessary
action to authorize the execution, delivery and performance of this Agreement. Upon the execution and delivery of this Agreement by the Holder, this Agreement shall constitute a valid and binding obligation of the Holder, enforceable in accordance
with its terms (except (i)&nbsp;as limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or affecting the enforcement of creditors&#146; rights generally, and (ii)&nbsp;as limited by equitable
principles generally, including any specific performance). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <B>Title</B>. The Holder owns and holds the entire right, title and interest in and to, and
is the record and beneficial owner of, the Warrants and the Holder owns the Warrants free and clear of all Liens. The Holder has the full power and authority to vote, transfer and dispose of the Warrants free and clear of any right or Liens. There
is no restriction affecting the ability of the Holder to transfer the legal and beneficial title and ownership of the Warrants to the Company and, at the Closing, the Company will acquire legal and valid title to the Warrants, free and clear of all
Liens. Other than the transactions contemplated by this Agreement, there is no outstanding vote, plan, pending proposal, or other right of any person to acquire all or any of the Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <B>Purchase of Warrants in the Registered Offering. </B>The Holder purchased the Warrants in the Company&#146;s offering of Common Stock
and warrants made pursuant to the Company&#146;s prospectus filed with the Securities and Exchange Commission (the &#147;SEC&#148;) pursuant to Rule 424(b)(5) on February&nbsp;9, 2017 (the &#147;<B>Registered Offering</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <B>Securities Act Exemption</B>. Neither the Holder nor anyone acting on behalf of the Holder has received any commission or remuneration
directly or indirectly in connection with or in order to solicit or facilitate the Exchange. The Holder understands that the Exchange contemplated hereby is intended to be exempt from registration by virtue of Section&nbsp;3(a)(9) of the Securities
Act. The Holder understands that the Company is relying upon the truth and accuracy of the representations, warranties, agreements, acknowledgments and understandings of the Holder set forth herein for purposes of qualifying for the exemption under
Section&nbsp;3(a)(9) of the Securities Act as well as qualifying for exemptions under applicable state securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) <B><FONT
STYLE="white-space:nowrap">Non-Affiliate</FONT></B>. The Holder is not an Affiliate (as defined below) of the Company and has not been an Affiliate during the three months prior to the date hereof. &#147;Affiliate&#148; means, with respect to any
Person, any other Person that directly or indirectly controls, is controlled by, or is under common control with, such Person, it being understood for purposes of this definition that &#147;control&#148; of a Person means the power directly or
indirectly either to vote 10% or more of the stock having ordinary voting power for the election of directors of such Person or direct or cause the direction of the management and policies of such Person whether by contract or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) <B>Information</B>. The Holder has, in connection with its decision to acquire the Exchange Note, relied with respect to the Company and
its affairs solely upon the Company&#146;s filings with the SEC and the representations and warranties of the Company contained herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) <B>Advisors</B>. The Holder understands that nothing in this Agreement or any other materials presented to the Holder in connection with
the exchange of the Warrants and execution and acquisition of the Exchange Note constitutes legal, tax or investment advice. The Holder has consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed necessary or
appropriate in connection with its acquisition of the Exchange Note. With respect to such matters, the Holder relies solely on such advisors and not on any statements or representations of the Company or any of its agents, written or oral. The
Holder understands that it (and not the Company) shall be responsible for its own tax liability that may arise as a result of this investment or the transactions contemplated by this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 4. CONDITIONS TO COMPANY&#146;S OBLIGATIONS AT THE CLOSING. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s obligation to complete the issuance of the Exchange Note and deliver the Exchange Note to the Holder at the Closing shall be
subject to the following conditions to the extent not waived by the Company: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <B>Execution and Delivery</B>. The Holder shall have
executed and delivered this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <B>Covenants</B>. The Holder shall have performed, satisfied and complied in all material
respects with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Holder at or prior to the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <B>Surrender of Warrants.</B> The Company shall have received in physical form or through book-entry transfer from the Holder all
certificates or book-entry notation representing the Warrants to be exchanged for the Exchange Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <B>Representations and
Warranties. </B>The representations and warranties of the Holder shall be true and correct in all material respects as of the date when made and as of the Closing Date as though made at that time, except for representations and warranties that are
expressly made as of a particular date, which shall be true and correct in all material respects as of such date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 5. CONDITIONS TO THE
HOLDER&#146;S OBLIGATIONS AT THE CLOSING. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Holder&#146;s obligation to deliver the Warrants and accept delivery of the Exchange
Note shall be subject to the following conditions to the extent not waived by the Holder: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)<B>&nbsp;Execution and Delivery</B>. The
Company shall have executed and delivered this Agreement and the Exchange Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)<B>&nbsp;Covenants</B>. The Company shall have
performed, satisfied and complied in all material respects with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <B>Delivery of Exchange Note.</B> The Company shall have delivered the Exchange Note in accordance with the instructions provided pursuant
to Section&nbsp;1.b) hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d)<B>&nbsp;Representations and Warranties.</B> Each of the representations and warranties of the Company
shall be true and correct in all material respects as of the date when made and as of the Closing Date as though made at that time, except for representations and warranties that are expressly made as of a particular date, which shall be true and
correct in all material respects as of such date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 6. NOTICES. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All notices, requests, consents and other communications hereunder shall be in writing, shall be sent by confirmed electronic mail, or mailed
by first-class registered or certified airmail, or nationally recognized overnight express courier, postage prepaid, and shall be deemed given when so sent in the case of electronic mail transmission, or when so received in the case of mail or
courier, and addressed as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) if to the Company, to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">SELLAS Life Sciences Group, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">315 Madison, 4<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Flr. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York, New York 10017 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Angelos Stergiou, M.D., ScD h.c. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-Mail:</FONT> astergiou@sellaslife.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">or to such other person at such other place as the Company shall designate to the Holder in writing; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) if to the Holder, at the address as set forth at the end of this Agreement, or at such other address as may have been furnished by the
Holder to the Company in writing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 7. MISCELLANEOUS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <B>Headings.</B> The headings of the various sections of this Agreement have been inserted for convenience of reference only and shall not
be deemed to be part of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <B>Severability.</B> In case any provision contained in this Agreement should be invalid,
illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <B>Most Favored Nations</B>. The Company hereby represents and warrants as of the date hereof and covenants and agrees that no agreement
entered into (or to be entered into) with any Person with respect to the Exchange or other transaction involving the warrants issued in the Registered Offering, including, without limitation with respect to any consent, release, amendment,
settlement, or waiver relating to any Exchange or such other transaction involving the warrants issued in the Registered Offering (each a &#147;<U>Settlement Document</U>&#148;), is or will be more favorable to such Person (other than any
reimbursement of legal fees) than those of the Holder and this Agreement, including without limitation the ratio of warrants to the cash paid, principal amount of notes, value of any shares of Common Stock (valued as the VWAP of the Common Stock on
the Trading Day immediately preceding the public announcement of such issuance), or value of any Options, Convertible Securities or Adjustment Rights (valued on the Trading Day immediately preceding the public announcement of such issuance, as the
greater of (a)&nbsp;the VWAP of the Common Stock multiplied by the number of underlying shares and (b)&nbsp;the Black Scholes Consideration Value) conveyed in such Settlement Document. If, and whenever on or after the date hereof, the Company enters
into a Settlement Document, then (i)&nbsp;the Company shall provide notice thereof to the Holder within one (1)&nbsp;Trading Day following the occurrence thereof and (ii)&nbsp;the terms and conditions of this Agreement shall be, without any further
action by the Holder or the Company, automatically amended and modified in an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
economically and legally equivalent manner such that the Holder shall receive the benefit of the more favorable terms and/or conditions (as the case may be) set forth in such Settlement Document,
provided that upon written notice to the Company within ten (10)&nbsp;Trading Days of receipt of notice of such Settlement Document the Holder may notify the Company in writing of Holder&#146;s election not to accept the benefit of any such amended
or modified term or condition, in which event the term or condition contained in this Agreement shall apply to the Holder as it was in effect immediately prior to such amendment or modification as if such amendment or modification never occurred
with respect to the Holder. The provisions of this Section&nbsp;7(c) shall apply similarly and equally to each Settlement Document. For purposes hereof, &#147;Black Scholes Consideration Value&#148; means the value of the applicable Option,
Convertible Security or Adjustment Right (as the case may be) as of the date of issuance thereof calculated using the Black Scholes Option Pricing Model obtained from the &#147;OV&#148; function on Bloomberg utilizing (i)&nbsp;an underlying price
per share equal to the Closing Sale Price of the Common Stock on the Trading Day immediately preceding the public announcement of the execution of definitive documents with respect to the issuance of such Option or Convertible Security (as the case
may be), (ii) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining term of such Option, Convertible Security or Adjustment Right (as the case may be) as of the date of issuance of such Option,
Convertible Security or Adjustment Right (as the case may be), (iii) a zero cost of borrow and (iv)&nbsp;an expected volatility equal to the greater of 100% and the 30 day volatility obtained from the &#147;HVT&#148; function on Bloomberg
(determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the date of issuance of such Option, Convertible Security or Adjustment Right (as the case may be). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <B>Governing Law.</B> This Agreement shall be governed by and construed under the laws of the State of New York without regard to the
choice of law principles thereof. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the State of New York located in The City of New York, Borough of Manhattan for the adjudication of any
dispute hereunder or in connection herewith or with any transaction contemplated hereby or thereby, and hereby irrevocably waives any objection that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit,
action or proceeding is improper. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY
TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <B>Counterparts.</B> This Agreement may be executed in two or more counterparts, each of which shall constitute an original, but all of
which, when taken together, shall constitute but one instrument, and shall become effective when one or more counterparts have been signed by each party hereto and delivered to the other parties. In the event that any signature is delivered by
facsimile transmission or by an <FONT STYLE="white-space:nowrap">e-mail</FONT> which contains an electronic file of an executed signature page, such signature page shall create a valid and binding obligation of the party executing (or on whose
behalf such signature is executed) with the same force and effect as if such facsimile or electronic file signature page (as the case may be) were an original thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) <B>Successors and Assigns.</B> Except as otherwise expressly provided herein, the provisions
hereof shall inure to the benefit of, and be binding upon, the successors, permitted assigns, heirs, executors and administrators of the parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">g) <B>Entire Agreement; Amendments.</B> This Agreement and other documents delivered pursuant hereto constitute the full and entire
understanding and agreement between the parties with regard to the subjects hereof and thereof. This Agreement may be amended, modified, superseded, cancelled, renewed or extended, and the terms and conditions hereof may be waived, only by a written
instrument signed by all parties, or, in the case of a waiver, by the party waiving compliance. Except as expressly stated herein, no delay on the part of any party in exercising any right, power or privilege hereunder shall operate as a waiver
thereof, nor shall any waiver on the part of any party of any right, power or privilege hereunder preclude any other or future exercise of any other right, power or privilege hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">h) <B>Survival. </B>The representations, warranties, covenants and agreements made in this Agreement shall survive the closing of the
transactions contemplated hereby and the exchange and delivery of the Warrants and the Exchange Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">i) <B>Further Assurances</B>. Each
party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request in order to
carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">j) <B>No
Third Party Beneficiaries</B>. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[signature pages follow] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have caused this Agreement to be executed by their
duly authorized representatives as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SELLAS LIFE SCIENCES GROUP, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Angelos Stergiou</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Angelos Stergiou, M.D., ScD h.c.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">COMPANY SIGNATURE PAGE TO </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">WARRANT EXCHANGE AGREEMENT </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>HOLDER: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HUDSON BAY MASTER FUND LTD</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ George Antonopoulos</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">George Antonopoulos</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Authorized Signatory</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">c/o Hudson Bay Capital Management LP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">777 Third Ave, 30th Fl</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">New York, NY 10017</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E-Mail:</FONT> <U>investments @hudsonbaycapital.com</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">DWAC INSTRUCTIONS</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Broker Name and DTC Number:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Account Number at DTC Participant</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">(if&nbsp;applicable):&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.78
<SEQUENCE>12
<FILENAME>d556278dex1078.htm
<DESCRIPTION>EX-10.78
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.78</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.78 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONVERTIBLE PROMISSORY NOTE </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>$343,200.00</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">February 9, 2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>New York, NY</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For value received <B>SELLAS Life Sciences Group, Inc.</B>, a Delaware corporation (the
&#147;<B><I>Company</I></B>&#148;), promises to pay to <B>HUDSON BAY MASTER FUND LTD</B> or its assigns (&#147;<B><I>Holder</I></B>&#148;) the principal sum of $<B>343,200.00</B> (the &#147;<B><I>Principal</I></B>&#148;) together with accrued and
unpaid interest thereon (the &#147;<B><I>Interest</I></B>&#148;), each due and payable on the date and in the manner set forth below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This convertible promissory note (the &#147;<B><I>Note</I></B>&#148;) was issued in reliance on the exemption provided in Rule 3(a)(9) of the
Securities Act of 1933, as amended, pursuant to the terms of that certain Exchange Agreement, dated February&nbsp;9, 2018 (the &#147;<B><I>Exchange Agreement</I></B>&#148;), by and between the Company and the Holder in exchange for that certain
Warrant (as defined in the Exchange Agreement) originally issued on February&nbsp;13, 2017 and shall be subject to the following terms (capitalized terms not defined herein shall have the meaning as set forth in the Exchange Agreement):<B> </B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B>Repayment. </B>All payments of Interest and Principal shall be in lawful money of the United States of America. All payments shall
be applied first to accrued Interest, and thereafter to Principal. The outstanding Principal amount of the Note shall be due and payable on August&nbsp;9, 2018 (the &#147;<B><I>Maturity Date</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B>Interest.</B> The Company promises to pay simple<B> </B>Interest on the outstanding Principal amount hereof from the date hereof
until payment in full, which Interest shall be payable at the rate of 5% per annum (the &#147;<B><I>Interest Rate</I></B>&#148;) or the maximum rate permissible by law, whichever is less. Interest shall be due and payable by way of inclusion of the
Interest in the Conversion Amount on any Conversion Date in accordance with Section&nbsp;3 below or in cash on the Maturity Date and shall be calculated on the basis of a <FONT STYLE="white-space:nowrap">365-day</FONT> year for the actual number of
days elapsed. From and after the occurrence and during the continuance of any Event of Default (as defined below), the Interest Rate shall automatically be increased to eighteen percent (18.0%) per annum (the &#147;<B><I>Default Rate</I></B>&#148;).
In the event that such Event of Default is subsequently cured (and no other Event of Default then exists (including, without limitation, for the Company&#146;s failure to pay such Interest at the Default Rate on the Maturity Date)), the adjustment
referred to in the preceding sentence shall cease to be effective as of the calendar day immediately following the date of such cure; provided that the Interest as calculated and unpaid at such increased rate during the continuance of such Event of
Default shall continue to apply to the extent relating to the days after the occurrence of such Event of Default through and including the date of such cure of such Event of Default. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3. Conversion. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the election of the
Holder made at any time after April&nbsp;30, 2018, this Note shall be convertible into validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock (as defined below), on the terms and conditions set
forth in this Section&nbsp;3. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 2. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Conversion Right</B>. Subject to the provisions of Section&nbsp;3(d), at any time
or times on or after April&nbsp;30, 2018, the Holder shall be entitled to convert any portion of the outstanding and unpaid Conversion Amount (as defined below) into validly issued, fully paid and
<FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock in accordance with Section&nbsp;3(c), at the Conversion Rate (as defined below). The Company shall not issue any fraction of a share of Common Stock upon any conversion.
If the issuance would result in the issuance of a fraction of a share of Common Stock, the Company shall round such fraction of a share of Common Stock up to the nearest whole share. The Company shall pay any and all transfer, stamp, issuance and
similar taxes, costs and expenses (including, without limitation, fees and expenses of the Company&#146;s transfer agent (the &#147;<B><I>Transfer Agent</I></B>&#148;)) that may be payable with respect to the issuance and delivery of Common Stock
upon conversion of any Conversion Amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Conversion Rate</B>. The number of shares of Common Stock issuable upon
conversion of any Conversion Amount pursuant to Section&nbsp;3(a) shall be determined by dividing (x)&nbsp;such Conversion Amount by (y)&nbsp;the Conversion Price (the &#147;<B><I>Conversion Rate</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> &#147;<B><I>Conversion Amount</I></B>&#148; means the sum of (x)&nbsp;portion of the Principal to be converted, redeemed or
otherwise with respect to which this determination is being made and (y)&nbsp;all accrued and unpaid Interest with respect to such portion of the Principal amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> &#147;<B><I>Conversion Price</I></B>&#148; means, as of any Conversion Date or other date of determination, $7.00, subject to
adjustment as provided herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Mechanics of Conversion</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Optional Conversion</B>. To convert any Conversion Amount into shares of Common Stock on any date (a &#147;<B><I>Conversion
Date</I></B>&#148;), the Holder shall deliver (whether via facsimile, electronic mail or otherwise), for receipt on or prior to 11:59 p.m., New York time, on such date, a copy of an executed notice of conversion (the &#147;<B><I>Conversion
Notice</I></B>&#148;) to the Company. If required by Section&nbsp;3(c)(iii), within two (2)&nbsp;Trading Days following a conversion of this Note as aforesaid, the Holder shall surrender this Note to a nationally recognized overnight delivery
service for delivery to the Company (or an indemnification undertaking with respect to this Note in the case of its loss, theft or destruction). On or before the first (1st) Trading Day following the date of receipt of a Conversion Notice, the
Company shall transmit by facsimile or electronic mail an acknowledgment of confirmation and representation as to whether such shares of Common Stock may then be resold pursuant to Rule 144 or an effective and available registration statement, of
receipt of such Conversion Notice to the Holder and the Transfer Agent which confirmation shall constitute an instruction to the Transfer Agent to process such Conversion Notice in accordance with the terms herein. On or before the second (2nd)
Trading Day following the date on which the Company has received a Conversion Notice (or such earlier date as required pursuant to the Exchange Act or other applicable law, rule or regulation for the settlement of a trade initiated on the applicable
Conversion Date of such shares of Common Stock issuable pursuant to such Conversion Notice) (the &#147;<B><I>Share Delivery Deadline</I></B><I>&#148;</I><I>),</I> the Company shall (1)&nbsp;provided that the Transfer Agent is participating in the
DTC Fast Automated Securities Transfer Program, credit such aggregate number of shares of Common Stock to which the Holder shall be entitled pursuant to such conversion to the Holder&#146;s or its designee&#146;s balance account with DTC through its
Deposit/Withdrawal at Custodian system or (2)&nbsp;if the Transfer Agent is not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 3. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
participating in the DTC Fast Automated Securities Transfer Program, upon the request of the Holder, issue and deliver (via reputable overnight courier) to the address as specified in the
Conversion Notice, a certificate, registered in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder shall be entitled pursuant to such conversion. If this Note is physically surrendered for conversion
pursuant to Section&nbsp;3(c)(iii) and the outstanding Principal of this Note is greater than the Principal portion of the Conversion Amount being converted, then the Company shall as soon as practicable and in no event later than two
(2)&nbsp;Business Days after receipt of this Note and at its own expense, issue and deliver to the Holder (or its designee) a new Note representing the outstanding Principal not converted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Company</B><B>&#146;</B><B>s Failure to Timely Convert</B>. If the Company shall fail, for any reason or for no reason, on or
prior to the applicable Share Delivery Deadline, if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program, to issue and deliver to the Holder (or its designee) a certificate for the number of shares of Common
Stock to which the Holder is entitled and register such shares of Common Stock on the Company&#146;s share register or, if the Transfer Agent is participating in the DTC Fast Automated Securities Transfer Program, to credit the balance account of
the Holder or the Holder&#146;s designee with DTC for such number of shares of Common Stock to which the Holder is entitled upon the Holder&#146;s conversion of this Note (as the case may be) (a &#147;<B><I>Conversion Failure</I></B>&#148;), and if
on or after such Share Delivery Deadline the Holder purchases (in an open market transaction or otherwise) shares of Common Stock corresponding to all or any portion of the number of shares of Common Stock issuable upon such conversion that the
Holder is entitled to receive from the Company and has not received from the Company in connection with such Conversion Failure (a &#147;<B><I><FONT STYLE="white-space:nowrap">Buy-In</FONT></I></B>&#148;), then, in addition to all other remedies
available to the Holder, the Company shall, within two (2)&nbsp;Business Days after receipt of the Holder&#146;s request and in the Holder&#146;s discretion, either: (I)&nbsp;pay cash to the Holder in an amount equal to the Holder&#146;s total
purchase price (including brokerage commissions and other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, if any) for the shares of Common Stock so purchased (including, without limitation, by
any other Person in respect, or on behalf, of the Holder) (the &#147;<B><FONT STYLE="white-space:nowrap">Buy-In</FONT> Price</B>&#148;), at which point the Company&#146;s obligation to so issue and deliver such certificate (and to issue such shares
of Common Stock) or credit the balance account of such Holder or such Holder&#146;s designee, as applicable, with DTC for the number of shares of Common Stock to which the Holder is entitled upon the Holder&#146;s conversion hereunder (as the case
may be) (and to issue such shares of Common Stock) shall terminate, or (II)&nbsp;promptly honor its obligation to so issue and deliver to the Holder a certificate or certificates representing such shares of Common Stock or credit the balance account
of such Holder or such Holder&#146;s designee, as applicable, with DTC for the number of shares of Common Stock to which the Holder is entitled upon the Holder&#146;s conversion hereunder (as the case may be) and pay cash to the Holder in an amount
equal to the excess (if any) of the <FONT STYLE="white-space:nowrap">Buy-In</FONT> Price over the product of (x)&nbsp;such number of shares of Common Stock multiplied by (y)&nbsp;the lowest Closing Sale Price of the Common Stock on any Trading Day
during the period commencing on the date of the applicable Conversion Notice and ending on the date of such issuance and payment under this clause (II) (the &#147;<B><I><FONT STYLE="white-space:nowrap">Buy-In</FONT> Payment Amount</I></B>&#148;).
Nothing shall limit the Holder&#146;s right to pursue any other remedies available to it hereunder, at law or in equity, including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#146;s
failure to timely deliver certificates representing shares of Common Stock (or to electronically deliver such shares of Common Stock) upon the conversion of this Note as required pursuant to the terms hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 4. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> <B>Registration; Book-Entry</B>. The Holder and the Company shall maintain records
showing the Principal and Interest converted and/or paid (as the case may be) and the dates of such conversions, and/or payments (as the case may be) or shall use such other method, reasonably satisfactory to the Holder and the Company, so as not to
require physical surrender of this Note upon conversion. Notwithstanding anything to the contrary set forth in this Section&nbsp;3, following conversion of any portion of this Note in accordance with the terms hereof, the Holder shall not be
required to physically surrender this Note to the Company unless (A)&nbsp;the full Conversion Amount represented by this Note is being converted (in which event this Note shall be delivered to the Company following conversion thereof as contemplated
by Section&nbsp;3(c)(i)) or (B)&nbsp;the Holder has provided the Company with prior written notice (which notice may be included in a Conversion Notice) requesting reissuance of this Note upon physical surrender of this Note. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Limitations on Conversions</B>. The Company shall not effect the conversion of any portion of this Note, and the Holder shall
not have the right to convert any portion of this Note pursuant to the terms and conditions of this Note and any such conversion shall be null and void and treated as if never made, to the extent that after giving effect to such conversion, the
Holder together with the other Attribution Parties collectively would beneficially own in excess of 9.99% (the &#147;<B><I>Maximum Percentage</I></B>&#148;) of the shares of Common Stock outstanding immediately after giving effect to such
conversion. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by the Holder and the other Attribution Parties shall include the number of shares of Common Stock held by the Holder and all other
Attribution Parties plus the number of shares of Common Stock issuable upon conversion of this Note with respect to which the determination of such sentence is being made, but shall exclude shares of Common Stock which would be issuable upon
(A)&nbsp;conversion of the remaining, nonconverted portion of this Note beneficially owned by the Holder or any of the other Attribution Parties and (B)&nbsp;exercise or conversion of the unexercised or nonconverted portion of any other securities
of the Company (including, without limitation, any convertible notes or convertible preferred stock or warrants, including, without limitation, the Warrants) beneficially owned by the Holder or any other Attribution Party subject to a limitation on
conversion or exercise analogous to the limitation contained in this Section&nbsp;3(d). For purposes of this Section&nbsp;3(d), beneficial ownership shall be calculated in accordance with Section&nbsp;13(d) of the Exchange Act. For purposes of
determining the number of outstanding shares of Common Stock the Holder may acquire upon the conversion of this Note without exceeding the Maximum Percentage, the Holder may rely on the number of outstanding shares of Common Stock as reflected in
(x)&nbsp;the Company&#146;s most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or
other public filing with the SEC, as the case may be, (y)&nbsp;a more recent public announcement by the Company or (z)&nbsp;any other written notice by the Company or the Transfer Agent, if any, setting forth the number of shares of Common Stock
outstanding (the &#147;<B><I>Reported Outstanding Share Number</I></B>&#148;). If the Company receives a Conversion Notice from the Holder at a time when the actual number of outstanding shares of Common Stock is less than the Reported Outstanding
Share Number, the Company shall notify the Holder in writing of the number of shares of Common Stock then outstanding and, to the extent that such Conversion Notice would otherwise cause the Holder&#146;s beneficial ownership, as determined pursuant
to this Section&nbsp;3(d), to exceed the Maximum Percentage, the Holder must notify the Company of a reduced number of shares of Common Stock to be purchased pursuant to such Conversion Notice. For any reason at any time, upon the written or oral
request of the Holder, the Company shall within one (1)&nbsp;Business Day </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 5. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
confirm orally and in writing or by electronic mail to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be
determined after giving effect to the conversion or exercise of securities of the Company, including this Note, by the Holder and any other Attribution Party since the date as of which the Reported Outstanding Share Number was reported. In the event
that the issuance of shares of Common Stock to the Holder upon conversion of this Note results in the Holder and the other Attribution Parties being deemed to beneficially own, in the aggregate, more than the Maximum Percentage of the number of
outstanding shares of Common Stock (as determined under Section&nbsp;13(d) of the Exchange Act), the number of shares so issued by which the Holder&#146;s and the other Attribution Parties&#146; aggregate beneficial ownership exceeds the Maximum
Percentage (the &#147;<B>Excess Shares</B>&#148;) shall be deemed null and void and shall be cancelled ab initio, and the Holder shall not have the power to vote or to transfer the Excess Shares. Upon delivery of a written notice to the Company, the
Holder may from time to time increase (with such increase not effective until the sixty-first (61<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>) day after delivery of such notice) or decrease the Maximum Percentage to any other percentage
not in excess of 9.99% as specified in such notice; provided that (i)&nbsp;any such increase in the Maximum Percentage will not be effective until the sixty-first (61<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>) day after such notice is
delivered to the Company and (ii)&nbsp;any such increase or decrease will apply only to the Holder and the other Attribution Parties and not to any other holder of Notes that is not an Attribution Party of the Holder. For purposes of clarity, the
shares of Common Stock issuable pursuant to the terms of this Note in excess of the Maximum Percentage shall not be deemed to be beneficially owned by the Holder for any purpose including for purposes of Section&nbsp;13(d) or Rule <FONT
STYLE="white-space:nowrap">16a-1(a)(1)</FONT> of the Exchange Act. No prior inability to convert this Note pursuant to this paragraph shall have any effect on the applicability of the provisions of this paragraph with respect to any subsequent
determination of convertibility. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section&nbsp;3(d) to the extent necessary to correct this paragraph (or any
portion of this paragraph) which may be defective or inconsistent with the intended beneficial ownership limitation contained in this Section&nbsp;3(d) or to make changes or supplements necessary or desirable to properly give effect to such
limitation. The limitation contained in this paragraph may not be waived and shall apply to a successor holder of this Note. Further, notwithstanding anything in this Note to the contrary, under no circumstances shall the Company be obligated to
issue or the Holder entitled to receive, an aggregate number of shares of Common Stock that would exceed 19.9% of the total number of shares of Common Stock issued and outstanding as of the date of this Note (the &#147;<B><I>Maximum
Issuance</I></B>&#148;); provided, that to the extent the aggregate number of shares of Common Stock would exceed the Maximum Issuance, the Company shall issue and deliver to Holder a number of shares of Common Stock up to the Maximum Issuance and
the unconverted Principal of this Note shall remain outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e) Right of Alternate Conversion. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <U>General</U>. At any time at any time after the occurrence of an Event of Default (regardless of whether such Event of Default
has been cured), the Holder may, at the Holder&#146;s option, convert (each, an &#147;<B><I>Alternate Conversion</I></B>&#148;, and the date of such Alternate Conversion, each, an &#147;<B><I>Alternate Conversion Date</I></B>&#148;) all, or any part
of, the Conversion Amount (such portion of the Conversion Amount subject to such Alternate Conversion, the &#147;<B><I>Alternate Conversion Amount</I></B>&#148;) into shares of Common Stock at the Alternate Conversion Price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 6. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <U>Mechanics of Alternate Conversion</U>. On any Alternate Conversion Date, the
Holder may voluntarily convert any Alternate Conversion Amount pursuant to Section&nbsp;3(c) (with &#147;Alternate Conversion Price&#148; replacing &#147;Conversion Price&#148; for all purposes hereunder with respect to such Alternate Conversion) by
designating in the Conversion Notice delivered pursuant to this Section&nbsp;3(e) of this Note that the Holder is electing to use the Alternate Conversion Price for such conversion. Notwithstanding anything to the contrary in this Section&nbsp;3(e),
but subject to Section&nbsp;3(d), until the Company delivers shares of Common Stock representing the applicable Alternate Conversion Amount to the Holder, such Alternate Conversion Amount may be converted by the Holder into shares of Common Stock
pursuant to Section&nbsp;3(c) without regard to this Section&nbsp;3(e). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B>Voluntary Adjustment by Company</B>. The Company
may at any time during the term of this Note, with the prior written consent of the Holder, reduce the then current Conversion Price of each of the Notes to any amount and for any period of time deemed appropriate by the board of directors of the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B>Maturity.</B> Unless this Note has been previously converted or prepaid in accordance with the terms of
Section&nbsp;3(a) above, the entire outstanding Conversion Amount shall become fully due and payable in cash on the Maturity Date; provided, that if the Conversion Amount is not paid in full in cash on the Maturity Date, subject to Section&nbsp;3(d)
above, the Holder shall retain the right to convert all, or any part, at such Holder&#146;s sole discretion, of the Conversion Amount into shares of Common Stock in accordance with Section&nbsp;3 above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B>Expenses. </B>In the event of any default hereunder, the Company shall pay all reasonable attorneys&#146; fees and court costs
incurred by Holder in enforcing and collecting this Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B>Prepayment.</B> The Company may prepay this Note and accrued but
unpaid Interest prior to the Maturity Date at any time without the consent of the Holder; provided, that the Company may not prepay any Conversion Amount submitted for conversion pursuant to Section&nbsp;3 above from and after the applicable
Conversion Date unless such corresponding Conversion Notice is withdrawn by the Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B>Default. </B>If there shall be any
Event of Default hereunder, at the option and upon the declaration of the Holder and upon written notice to the Company (which election and notice shall not be required in the case of an Event of Default under Section&nbsp;7(v), 7(vi) or 7(vii)),
this Note shall accelerate and all Principal and unpaid accrued Interest shall become immediately due and payable. The occurrence of any one or more of the following shall constitute an &#147;<B><I>Event of Default</I></B>&#148;: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> the suspension (or threatened suspension) from trading or the failure (or threatened failure) of the Common Stock to be trading or
listed (as applicable) on the Nasdaq Capital Market for a period of five (5)&nbsp;consecutive Trading Days; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> the
Company&#146;s (A)&nbsp;failure to cure a Conversion Failure by delivery of the required number of shares of Common Stock within five (5)&nbsp;Trading Days after the applicable Conversion Date or exercise date (as the case may be) or
(B)&nbsp;notice, written or oral, to any holder of the Notes, including, without limitation, by way of public announcement or through any of its agents, at any time, of its intention not to comply, as required, with a request for conversion of any
Notes into shares of Common Stock that is requested in accordance with the provisions of the Notes, other than pursuant to Section&nbsp;3(d); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 7. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> the Company&#146;s or any Subsidiary&#146;s failure to pay to the Holder any amount
of Principal, Interest or other amounts when and as due under this Note (including, without limitation, the Company&#146;s failure to pay any redemption payments or amounts hereunder) or any other Exchange Document or any other agreement, document,
certificate or other instrument delivered in connection with the transactions contemplated hereby and thereby, except, in the case of a failure to pay Interest when and as due, in which case only if such failure remains uncured for a period of at
least two (2)&nbsp;Trading Days; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> [INTENTIONALLY OMITTED]; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings for the relief of debtors shall be
instituted by or against the Company or any Subsidiary and, if instituted against the Company or any Subsidiary by a third party, shall not be dismissed within thirty (30)&nbsp;days of their initiation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> the commencement by the Company or any Subsidiary of a voluntary case or proceeding under any applicable federal, state or
foreign bankruptcy, insolvency, reorganization or other similar law or of any other case or proceeding to be adjudicated a bankrupt or insolvent, or the consent by it to the entry of a decree, order, judgment or other similar document in respect of
the Company or any Subsidiary in an involuntary case or proceeding under any applicable federal, state or foreign bankruptcy, insolvency, reorganization or other similar law or to the commencement of any bankruptcy or insolvency case or proceeding
against it, or the filing by it of a petition or answer or consent seeking reorganization or relief under any applicable federal, state or foreign law, or the consent by it to the filing of such petition or to the appointment of or taking possession
by a custodian, receiver, liquidator, assignee, trustee, sequestrator or other similar official of the Company or any Subsidiary or of any substantial part of its property, or the making by it of an assignment for the benefit of creditors, or the
execution of a composition of debts, or the occurrence of any other similar federal, state or foreign proceeding, or the admission by it in writing of its inability to pay its debts generally as they become due, the taking of corporate action by the
Company or any Subsidiary in furtherance of any such action or the taking of any action by any Person to commence a Uniform Commercial Code foreclosure sale or any other similar action under federal, state or foreign law; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vii)</B> the entry by a court of (i)&nbsp;a decree, order, judgment or other similar document in respect of the Company or any Subsidiary
of a voluntary or involuntary case or proceeding under any applicable federal, state or foreign bankruptcy, insolvency, reorganization or other similar law or (ii)&nbsp;a decree, order, judgment or other similar document adjudging the Company or any
Subsidiary as bankrupt or insolvent, or approving as properly filed a petition seeking liquidation, reorganization, arrangement, adjustment or composition of or in respect of the Company or any Subsidiary under any applicable federal, state or
foreign law or (iii)&nbsp;a decree, order, judgment or other similar document appointing a custodian, receiver, liquidator, assignee, trustee, sequestrator or other similar official of the Company or any Subsidiary or of any substantial part of its
property, or ordering the winding up or liquidation of its affairs, and the continuance of any such decree, order, judgment or other similar document or any such other decree, order, judgment or other similar document unstayed and in effect for a
period of thirty (30)&nbsp;consecutive days; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 8. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(viii)</B> other than as specifically set forth in another clause of this Section&nbsp;7, the
Company or any Subsidiary breaches any representation, warranty, covenant or other term or condition of any Exchange Document, except, in the case of a breach of a covenant or other term or condition that is curable, only if such breach remains
uncured for a period of three (3)&nbsp;consecutive Trading Days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.</B> <B>Adjustment of Conversion Price upon Subdivision or
Combination of Common Stock</B>. If the Company at any time on or after the date hereof subdivides (by any stock split, stock dividend, stock combination, recapitalization or other similar transaction) one or more classes of its outstanding shares
of Common Stock into a greater number of shares, the Conversion Price in effect immediately prior to such subdivision will be proportionately reduced. If the Company at any time on or after the date hereof combines (by any stock split, stock
dividend, stock combination, recapitalization or other similar transaction) one or more classes of its outstanding shares of Common Stock into a smaller number of shares, the Conversion Price in effect immediately prior to such combination will be
proportionately increased. Any adjustment pursuant to this Section&nbsp;8 shall become effective immediately after the effective date of such subdivision or combination. If any event requiring an adjustment under this Section&nbsp;8 occurs during
the period that a Conversion Price is calculated hereunder, then the calculation of such Conversion Price shall be adjusted appropriately to reflect such event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.</B> <B>Rights upon Fundamental Transaction</B>. The Company shall not enter into or be party to a Fundamental Transaction unless
(i)&nbsp;the Successor Entity assumes in writing all of the obligations of the Company under this Note and the other Exchange Documents in accordance with the provisions of this Section&nbsp;9 pursuant to written agreements in form and substance
satisfactory to the Holder and approved by the Holder prior to such Fundamental Transaction, including agreements to deliver to each holder of Notes in exchange for such Notes a security of the Successor Entity evidenced by a written instrument
substantially similar in form and substance to the Notes, including, without limitation, having a principal amount and interest rate equal to the principal amounts then outstanding and the interest rates of the Notes held by such holder, having
similar conversion rights as the Notes and having similar ranking and security to the Notes, and satisfactory to the Holder and (ii)&nbsp;the Successor Entity (including its Parent Entity) is a publicly traded corporation whose common stock is
quoted on or listed for trading on an Eligible Market. Upon the occurrence of any Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Note and the other Exchange Documents referring to the &#147;Company&#148; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this
Note and the other Exchange Documents with the same effect as if such Successor Entity had been named as the Company herein. Upon consummation of a Fundamental Transaction, the Successor Entity shall deliver to the Holder confirmation that there
shall be issued upon conversion or redemption of this Note at any time after the consummation of such Fundamental Transaction, in lieu of the shares of Common Stock (or other securities, cash, assets or other property (except such items still
issuable under Sections 10(a) and 11, which shall continue to be receivable thereafter) issuable upon the conversion or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 9. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
redemption of the Notes prior to such Fundamental Transaction, such shares of the publicly traded common stock (or their equivalent) of the Successor Entity (including its Parent Entity) which
the Holder would have been entitled to receive upon the happening of such Fundamental Transaction had this Note been converted immediately prior to such Fundamental Transaction (without regard to any limitations on the conversion of this Note), as
adjusted in accordance with the provisions of this Note. Notwithstanding the foregoing, the Holder may elect, at its sole option, by delivery of written notice to the Company to waive this Section&nbsp;9 to permit the Fundamental Transaction without
the assumption of this Note. The provisions of this Section&nbsp;9 shall apply similarly and equally to successive Fundamental Transactions and shall be applied without regard to any limitations on the conversion of this Note. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10. Rights Upon Issuance of Purchase Rights and Other Corporate Events. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Purchase Rights</B>. If at any time the Company grants, issues or sells any Options, Convertible Securities or rights to
purchase stock, warrants, securities or other property pro rata to all or substantially all of the record holders of any class of Common Stock (the &#147;<B><I>Purchase Rights</I></B>&#148;), then the Holder will be entitled to acquire, upon the
terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete conversion of this Note (without taking into account
any limitations or restrictions on the convertibility of this Note and assuming for such purpose that the Note was converted at the Alternate Conversion Price as of the applicable record date) immediately prior to the date on which a record is taken
for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>,
<U>however</U>, that to the extent that the Holder&#146;s right to participate in any such Purchase Right would result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to
participate in such Purchase Right to the extent of the Maximum Percentage (and shall not be entitled to beneficial ownership of such shares of Common Stock as a result of such Purchase Right (and beneficial ownership) to the extent of any such
excess) and such Purchase Right to such extent shall be held in abeyance (and, if such Purchase Right has an expiration date, maturity date or other similar provision, such term shall be extended by such number of days held in abeyance, if
applicable) for the benefit of the Holder until such time or times, if ever, as its right thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, at which time or times the Holder shall be granted
such right (and any Purchase Right granted, issued or sold on such initial Purchase Right or on any subsequent Purchase Right held similarly in abeyance (and, if such Purchase Right has an expiration date, maturity date or other similar provision,
such term shall be extended by such number of days held in abeyance, if applicable)) to the same extent as if there had been no such limitation). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Other Corporate Events</B>. In addition to and not in substitution for any other rights hereunder, prior to the consummation of
any Fundamental Transaction pursuant to which holders of shares of Common Stock are entitled to receive securities or other assets with respect to or in exchange for shares of Common Stock (a &#147;<B><I>Corporate Event</I></B>&#148;), the Company
shall make appropriate provision to ensure that the Holder will thereafter have the right to receive upon a conversion of this Note, at the Holder&#146;s option (i)&nbsp;in addition to the shares of Common Stock receivable upon such conversion, such
securities or other assets to which the Holder would have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 10. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
been entitled with respect to such shares of Common Stock had such shares of Common Stock been held by the Holder upon the consummation of such Corporate Event (without taking into account any
limitations or restrictions on the convertibility of this Note) or (ii)&nbsp;in lieu of the shares of Common Stock otherwise receivable upon such conversion, such securities or other assets received by the holders of shares of Common Stock in
connection with the consummation of such Corporate Event in such amounts as the Holder would have been entitled to receive had this Note initially been issued with conversion rights for the form of such consideration (as opposed to shares of Common
Stock) at a conversion rate for such consideration commensurate with the Conversion Rate. Provision made pursuant to the preceding sentence shall be in a form and substance satisfactory to the Holder. The provisions of this Section&nbsp;10(b) shall
apply similarly and equally to successive Corporate Events and shall be applied without regard to any limitations on the conversion or redemption of this Note. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.</B> <B>Remedies, Characterizations, Other Obligations, Breaches and Injunctive Relief</B>. The remedies provided in this Note shall be
cumulative and in addition to all other remedies available under this Note and any of the other Exchange Documents at law or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the
Holder&#146;s right to pursue actual and consequential damages for any failure by the Company to comply with the terms of this Note. The Company covenants to the Holder that there shall be no characterization concerning this instrument other than as
expressly provided herein. Amounts set forth or provided for herein with respect to payments, conversion and the like (and the computation thereof) shall be the amounts to be received by the Holder and shall not, except as expressly provided herein,
be subject to any other obligation of the Company (or the performance thereof). The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder and that the remedy at law for any such breach may be
inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach, the Holder shall be entitled, in addition to all other available remedies, to specific performance and/or temporary, preliminary and permanent
injunctive or other equitable relief from any court of competent jurisdiction in any such case without the necessity of proving actual damages and without posting a bond or other security. The Company shall provide all information and documentation
to the Holder that is requested by the Holder to enable the Holder to confirm the Company&#146;s compliance with the terms and conditions of this Note. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.</B> <B>Severability</B>. If any provision of this Note is prohibited by law or otherwise determined to be invalid or unenforceable by a
court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of
such provision shall not affect the validity of the remaining provisions of this Note so long as this Note as so modified continues to express, without material change, the original intentions of the parties as to the subject matter hereof and the
prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be
conferred upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited,
invalid or unenforceable provision(s). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 11. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.</B> <B>Maximum Payments</B>. Nothing contained herein shall be deemed to establish or
require the payment of a rate of interest or other charges in excess of the maximum permitted by applicable law. In the event that the rate of interest required to be paid or other charges hereunder exceed the maximum permitted by such law, any
payments in excess of such maximum shall be credited against amounts owed by the Company to the Holder and thus refunded to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.</B> <B>Waiver. </B>The Company hereby waives demand, notice, presentment, protest and notice of dishonor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.</B> <B>Governing Law. </B>This Note shall be construed and enforced in accordance with, and all questions concerning the construction,
validity, interpretation and performance of this Note shall be governed by, the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other
jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York. The Company hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The City of New York,
Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding,
any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein shall be
deemed or operate to preclude the Holder from bringing suit or taking other legal action against the Company in any other jurisdiction to collect on the Company&#146;s obligations to the Holder, to realize on any collateral or any other security for
such obligations, or to enforce a judgment or other court ruling in favor of the Holder. THE COMPANY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN
CONNECTION WITH OR ARISING OUT OF THIS NOTE OR ANY TRANSACTION CONTEMPLATED HEREBY. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.</B> <B>Failure Or Indulgence Not Waiver</B>.
No failure or delay on the part of the Holder in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further
exercise thereof or of any other right, power or privilege. No waiver shall be effective unless it is in writing and signed by an authorized representative of the waiving party. Notwithstanding the foregoing, nothing contained in this
Section&nbsp;16 shall permit any waiver of any provision of Section&nbsp;3(d). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.</B> <B>Amending the Terms of this Note</B>. The
prior written consent of the Holder shall be required for any change, waiver or amendment to this Note. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 12. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>18.</B> <B>Notices; Currency; Payments</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Notices</B>. Whenever notice is required to be given under this Note, unless otherwise provided herein, such notice shall be
given in accordance with the terms of the Exchange Agreement. The Company shall provide the Holder with prompt written notice of all actions taken pursuant to this Note, including in reasonable detail a description of such action and the reason
therefore. Without limiting the generality of the foregoing, the Company will give written notice to the Holder (i)&nbsp;immediately upon any adjustment of the Conversion Price, setting forth in reasonable detail, and certifying, the calculation of
such adjustment and (ii)&nbsp;at least fifteen (15)&nbsp;days prior to the date on which the Company closes its books or takes a record (A)&nbsp;with respect to any dividend or distribution upon the Common Stock, and (B)&nbsp;for determining rights
to vote with respect to any Fundamental Transaction, dissolution or liquidation, provided in each case that such information shall be made known to the public prior to or in conjunction with such notice being provided to the Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Currency</B>. All dollar amounts referred to in this Note are in United States Dollars (&#147;<B><I>U.S. Dollars</I></B>&#148;),
and all amounts owing under this Note shall be paid in U.S. Dollars. All amounts denominated in other currencies (if any) shall be converted into the U.S.&nbsp;Dollar equivalent amount in accordance with the Exchange Rate on the date of calculation.
&#147;<B><I>Exchange Rate</I></B>&#148;<B> </B>means, in relation to any amount of currency to be converted into U.S. Dollars pursuant to this Note, the U.S.&nbsp;Dollar exchange rate as published in the Wall Street Journal on the relevant date of
calculation (it being understood and agreed that where an amount is calculated with reference to, or over, a period of time, the date of calculation shall be the final date of such period of time). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Payments</B>. Whenever any payment of cash is to be made by the Company to any Person pursuant to this Note, unless otherwise
expressly set forth herein, such payment shall be made in lawful money of the United States of America by a certified check drawn on the account of the Company and sent via overnight courier service to such Person at such address as previously
provided to the Company in writing, provided that the Holder may elect to receive a payment of cash via wire transfer of immediately available funds by providing the Company with prior written notice setting out such request and the Holder&#146;s
wire transfer instructions. Whenever any amount expressed to be due by the terms of this Note is due on any day which is not a Business Day, the same shall instead be due on the next succeeding day which is a Business Day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>19.</B> <B>Waiver of Notice</B>. To the extent permitted by law, the Company hereby irrevocably waives demand, notice, presentment, protest
and all other demands and notices in connection with the delivery, acceptance, performance, default or enforcement of this Note and the Exchange Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>20.</B> <B>Assignment.</B> This Note may be transferred only upon its surrender to the Company for registration of transfer, duly endorsed,
or accompanied by a duly executed written instrument of transfer in form satisfactory to the Company. Thereupon, this Note shall be reissued to, and registered in the name of, the transferee, or a new Note for like Principal amount and Interest
shall be issued to, and registered in the name of, the transferee. Interest and Principal shall be paid solely to the registered holder of this Note. Such payment shall constitute full discharge of the Company&#146;s obligation to pay such Interest
and Principal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 13. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.</B> <U>CERTAIN DEFINITIONS</U>. For purposes of this Note, the following terms shall have
the following meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <I>&#147;</I><B><I>Adjustment Right&#148;</I></B><B> </B>means any right granted with respect to any
securities issued in connection with, or with respect to, any issuance or sale (or deemed issuance or sale) of shares of Common Stock that could result in a decrease in the net consideration received by the Company in connection with, or with
respect to, such securities (including, without limitation, any cash settlement rights, cash adjustment or other similar rights). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> &#147;<B><I>Alternate Conversion Price</I></B>&#148; means, with respect to any Alternate Conversion that price which shall be the
lowest of (i)&nbsp;the applicable Conversion Price as in effect on the applicable Conversion Date of the applicable Alternate Conversion, (ii) 70% of the lowest VWAP of the Common Stock as of the Trading Day during the ten (10)&nbsp;consecutive
Trading Day period ending and including the applicable Alternate Conversion Date (such period, the &#147;<B><I>Alternate Conversion Measuring Period</I></B>&#148;). All such determinations to be appropriately adjusted for any stock dividend, stock
split, stock combination, reclassification or similar transaction that proportionately decreases or increases the Common Stock during such Alternate Conversion Measuring Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> &#147;<B><I>Attribution Parties</I></B>&#148; means, collectively, the following Persons and entities: (i)&nbsp;any investment
vehicle, including, any funds, feeder funds or managed accounts, currently, or from time to time after the date hereof, directly or indirectly managed or advised by the Holder&#146;s investment manager or any of its Affiliates or principals,
(ii)&nbsp;any direct or indirect Affiliates of the Holder or any of the foregoing, (iii)&nbsp;any Person acting or who could be deemed to be acting as a Group together with the Holder or any of the foregoing and (iv)&nbsp;any other Persons whose
beneficial ownership of the Company&#146;s Common Stock would or could be aggregated with the Holder&#146;s and the other Attribution Parties for purposes of Section&nbsp;13(d) of the Exchange Act. For clarity, the purpose of the foregoing is to
subject collectively the Holder and all other Attribution Parties to the Maximum Percentage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>
&#147;<B><I>Bloomberg</I></B>&#148; means Bloomberg, L.P. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> &#147;<B><I>Business Day</I></B>&#148; means any day other than
Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> &#147;<B><I>Closing Bid Price</I></B>&#148; and &#147;<B><I>Closing Sale Price</I></B>&#148; means, for any security as of any
date, the last closing bid price and last closing trade price, respectively, for such security on the Principal Market, as reported by Bloomberg, or, if the Principal Market begins to operate on an extended hours basis and does not designate the
closing bid price or the closing trade price (as the case may be) then the last bid price or last trade price, respectively, of such security prior to 4:00:00 p.m., New York time, as reported by Bloomberg, or, if the Principal Market is not the
principal securities exchange or trading market for such security, the last closing bid price or last trade price, respectively, of such security on the principal securities exchange or trading market where such security is listed or traded as
reported by Bloomberg, or if the foregoing do not apply, the last closing bid price or last trade price, respectively, of such security in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on
the electronic bulletin board for such security as reported by Bloomberg, or, if no closing bid price or last trade price, respectively, is reported for such security by Bloomberg, the average of the bid prices, or the ask prices, respectively, of
any market makers for such security as reported in the &#147;pink sheets&#148; by OTC Markets Group Inc. (formerly Pink Sheets LLC). If the Closing Bid Price or the Closing Sale Price cannot be calculated for a security on a particular date on any
of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 14. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the foregoing bases, the Closing Bid Price or the Closing Sale Price (as the case may be) of such security on such date shall be the fair market value as mutually determined by the Company and
the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then such dispute shall be resolved in accordance with the procedures in Section&nbsp;22. All such determinations shall be appropriately
adjusted for any stock splits, stock dividends, stock combinations, recapitalizations or other similar transactions during such period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> &#147;<B><I>Common Stock</I></B>&#148; means (i)&nbsp;the Company&#146;s shares of common stock, $0.0001 par value per share, and
(ii)&nbsp;any capital stock into which such common stock shall have been changed or any share capital resulting from a reclassification of such common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> &#147;<B><I>Convertible Securities</I></B>&#148; means any stock or other security (other than Options) that is at any time and
under any circumstances, directly or indirectly, convertible into, exercisable or exchangeable for, or which otherwise entitles the holder thereof to acquire, any shares of Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> &#147;<B><I>Eligible Market</I></B>&#148; means The New York Stock Exchange, the NYSE American, the Nasdaq Global Select Market,
the Nasdaq Global Market or the Principal Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> &#147;<B><I>Fundamental Transaction</I></B>&#148; means (A)&nbsp;that the
Company shall, directly or indirectly, including through subsidiaries, Affiliates or otherwise, in one or more related transactions, (i)&nbsp;consolidate or merge with or into (whether or not the Company is the surviving corporation) another Subject
Entity, or (ii)&nbsp;sell, assign, transfer, convey or otherwise dispose of all or substantially all of the properties or assets of the Company or any of its &#147;significant subsidiaries&#148; (as defined in Rule
<FONT STYLE="white-space:nowrap">1-02</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X)</FONT> to one or more Subject Entities, or (iii)&nbsp;make, or allow one or more Subject Entities to make, or allow the Company to be subject to or have
its Common Stock be subject to or party to one or more Subject Entities making, a purchase, tender or exchange offer that is accepted by the holders of at least either (x) 50% of the outstanding shares of Common Stock, (y) 50% of the outstanding
shares of Common Stock calculated as if any shares of Common Stock held by all Subject Entities making or party to, or Affiliated with any Subject Entities making or party to, such purchase, tender or exchange offer were not outstanding; or
(z)&nbsp;such number of shares of Common Stock such that all Subject Entities making or party to, or Affiliated with any Subject Entity making or party to, such purchase, tender or exchange offer, become collectively the beneficial owners (as
defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) of at least 50% of the outstanding shares of Common Stock, or (iv)&nbsp;consummate a stock or share purchase agreement or other business combination (including,
without limitation, a reorganization, recapitalization, <FONT STYLE="white-space:nowrap">spin-off</FONT> or scheme of arrangement) with one or more Subject Entities whereby all such Subject Entities, individually or in the aggregate, acquire, either
(x)&nbsp;at least 50% of the outstanding shares of Common Stock, (y)&nbsp;at least 50% of the outstanding shares of Common Stock calculated as if any shares of Common Stock held by all the Subject Entities making or party to, or Affiliated with any
Subject Entity making or party to, such stock purchase agreement or other business combination were not outstanding; or (z)&nbsp;such number of shares of Common Stock such that the Subject Entities become collectively the beneficial owners (as
defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) of at least 50% of the outstanding shares of Common Stock, or (v)&nbsp;reorganize, recapitalize or reclassify its Common Stock, (B)&nbsp;that the Company shall,
directly or indirectly, including through subsidiaries, Affiliates or otherwise, in one or more related transactions, allow any Subject Entity individually or the Subject Entities in the aggregate to be or become the &#147;beneficial owner&#148; (as
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 15. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act), directly or indirectly, whether through acquisition, purchase, assignment, conveyance, tender, tender offer,
exchange, reduction in outstanding shares of Common Stock, merger, consolidation, business combination, reorganization, recapitalization, <FONT STYLE="white-space:nowrap">spin-off,</FONT> scheme of arrangement, reorganization, recapitalization or
reclassification or otherwise in any manner whatsoever, of either (x)&nbsp;at least 50% of the aggregate ordinary voting power represented by issued and outstanding Common Stock, (y)&nbsp;at least 50% of the aggregate ordinary voting power
represented by issued and outstanding Common Stock not held by all such Subject Entities as of the date of this Note calculated as if any shares of Common Stock held by all such Subject Entities were not outstanding, or (z)&nbsp;a percentage of the
aggregate ordinary voting power represented by issued and outstanding shares of Common Stock or other equity securities of the Company sufficient to allow such Subject Entities to effect a statutory short form merger or other transaction requiring
other shareholders of the Company to surrender their shares of Common Stock without approval of the shareholders of the Company or (C)&nbsp;directly or indirectly, including through subsidiaries, Affiliates or otherwise, in one or more related
transactions, the issuance of or the entering into any other instrument or transaction structured in a manner to circumvent, or that circumvents, the intent of this definition in which case this definition shall be construed and implemented in a
manner otherwise than in strict conformity with the terms of this definition to the extent necessary to correct this definition or any portion of this definition which may be defective or inconsistent with the intended treatment of such instrument
or transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> &#147;<B><I>Group</I></B>&#148; means a &#147;group&#148; as that term is used in Section&nbsp;13(d) of the
Exchange Act and as defined in Rule <FONT STYLE="white-space:nowrap">13d-5</FONT> thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(l)</B>
&#147;<B><I>Options</I></B>&#148; means any rights, warrants or options to subscribe for or purchase shares of Common Stock or Convertible Securities issued to Persons other than the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> &#147;<B><I>Parent Entity</I></B>&#148; of a Person means an entity that, directly or indirectly, controls the applicable Person
and whose common stock or equivalent equity security is quoted or listed on an Eligible Market, or, if there is more than one such Person or Parent Entity, the Person or Parent Entity with the largest public market capitalization as of the date of
consummation of the Fundamental Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> &#147;<B><I>Principal Market</I></B>&#148; means the Nasdaq Capital Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> <B>&#147;</B><B><I>Subject Entity</I></B>&#148; means any Person, Persons or Group or any Affiliate or associate of any such
Person, Persons or Group. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(p)</B> &#147;<B><I>Successor Entity</I></B>&#148; means the Person (or, if so elected by the Holder, the
Parent Entity) formed by, resulting from or surviving any Fundamental Transaction or the Person (or, if so elected by the Holder, the Parent Entity) with which such Fundamental Transaction shall have been entered into. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(q)</B> &#147;<B><I>Trading Day</I></B>&#148; means, as applicable, (x)&nbsp;with respect to all price or trading volume determinations
relating to the Common Stock, any day on which the Common Stock is traded on the Principal Market, or, if the Principal Market is not the principal trading market for the Common Stock, then on the principal securities exchange or securities market
on which the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 16. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Common Stock is then traded, provided that &#147;Trading Day&#148; shall not include any day on which the Common Stock is scheduled to trade on such exchange or market for less than 4.5 hours or
any day that the Common Stock is suspended from trading during the final hour of trading on such exchange or market (or if such exchange or market does not designate in advance the closing time of trading on such exchange or market, then during the
hour ending at 4:00:00 p.m., New York time) unless such day is otherwise designated as a Trading Day in writing by the Holder or (y)&nbsp;with respect to all determinations other than price determinations relating to the Common Stock, any day on
which The New York Stock Exchange (or any successor thereto) is open for trading of securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(r)</B> &#147;<B><I>VWAP</I></B>&#148;
means, for any security as of any date, the dollar volume-weighted average price for such security on the Principal Market (or, if the Principal Market is not the principal trading market for such security, then on the principal securities exchange
or securities market on which such security is then traded) during the period beginning at 9:30:01 a.m., New York time, and ending at 4:00:00 p.m., New York time, as reported by Bloomberg through its &#147;HP&#148; function (set to weighted average)
or, if the foregoing does not apply, the dollar volume-weighted average price of such security in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the electronic bulletin board for such
security during the period beginning at 9:30:01 a.m., New York time, and ending at 4:00:00 p.m., New York time, as reported by Bloomberg, or, if no dollar volume-weighted average price is reported for such security by Bloomberg for such hours, the
average of the highest closing bid price and the lowest closing ask price of any of the market makers for such security as reported in the &#147;pink sheets&#148; by OTC Markets Group Inc. (formerly Pink Sheets LLC). If the VWAP cannot be calculated
for such security on such date on any of the foregoing bases, the VWAP of such security on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair
market value of such security, then such dispute shall be resolved in accordance with the procedures in Section&nbsp;22. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination, recapitalization
or other similar transaction during such period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>22.</B> <B>Disclosure</B>. Upon receipt or delivery by the Company of any notice in
accordance with the terms of this Note, unless the Company has in good faith determined that the matters relating to such notice do not constitute material, <FONT STYLE="white-space:nowrap">non-public</FONT> information relating to the Company or
any of its Subsidiaries, the Company shall within the later of (a)&nbsp;the Cleansing Deadline and (b)&nbsp;one (1) Business Day after any such receipt or delivery, publicly disclose such material, <FONT STYLE="white-space:nowrap">non-public</FONT>
information on a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or otherwise. In the event that the Company believes that a notice contains material, <FONT STYLE="white-space:nowrap">non-public</FONT> information relating to the
Company or any of its Subsidiaries, the Company so shall indicate to the Holder contemporaneously with delivery of such notice, and in the absence of any such indication, the Holder shall be allowed to presume that all matters relating to such
notice do not constitute material, <FONT STYLE="white-space:nowrap">non-public</FONT> information relating to the Company or any of its Subsidiaries. If the Company or any of its Subsidiaries provides material
<FONT STYLE="white-space:nowrap">non-public</FONT> information to the Holder after the Cleansing Deadline that is not simultaneously filed in a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and the Holder has not agreed to
receive such material <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company hereby covenants and agrees that the Holder shall not have any duty of confidentiality to the Company, any of its Subsidiaries or any of their
respective officers, directors, employees, affiliates or agents with respect to, or a duty to any of the foregoing not to trade on the basis of, such material <FONT STYLE="white-space:nowrap">non-public</FONT> information. Nothing contained in this
Section&nbsp;22 shall limit any obligations of the Company, or any rights of the Holder, under the Exchange Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[signature page
follows] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 17. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[S<SMALL>IGNATURE</SMALL> <SMALL>PAGE</SMALL> <SMALL>TO</SMALL> C<SMALL>ONVERTIBLE</SMALL>
P<SMALL>ROMISSORY</SMALL> N<SMALL>OTE</SMALL> <SMALL>OF</SMALL> SELLAS L<SMALL>IFE</SMALL> S<SMALL>CIENCES</SMALL> G<SMALL>ROUP</SMALL>, I<SMALL>NC</SMALL>.] </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SELLAS LIFE SCIENCES GROUP, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Angelos Stergiou</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Angelos Stergiou, M.D., ScD h.c.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Holder:&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Principal Amount of Note:&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date of
Note:&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.79
<SEQUENCE>13
<FILENAME>d556278dex1079.htm
<DESCRIPTION>EX-10.79
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.79</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.79 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS
LIFE SCIENCES GROUP, INC. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT EXCHANGE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Warrant Exchange Agreement (this &#147;Agreement&#148;) is made as of February&nbsp;13, 2018 (the &#147;Effective Date&#148;), by and between SELLAS Life
Sciences Group, Inc., a Delaware corporation (the &#147;Company&#148;), and Alto Opportunity Master Fund, SPC&#151;Segregated Master Portfolio B (the &#147;Holder&#148;). This Agreement hereby supersedes and replaces that certain Warrant Exchange
Agreement entered into by the Company and Holder effective as of the Effective Date (the &#147;Original Agreement&#148;), and the Original Agreement shall have no further force or effect from and after the execution of this Agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the
Holder currently holds 106,667 warrants (the &#147;<U>Warrants</U>&#148;) to purchase shares of the Company&#146;s common stock, par value $0.0001 per share (&#147;<U>Common Stock</U>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, subject to the terms and conditions set forth herein, the Company and the Holder desire to cancel and retire the Warrants in exchange
(the &#147;<U>Exchange</U>&#148;) for a convertible promissory note (the &#147;<U>Exchange Note</U>&#148;), in the amount of $249,600.00 on such other terms as set forth in the form of Exchange Note attached as Exhibit A, in reliance on the
exemption from registration provided by Section&nbsp;3(a)(9) of the Securities Act of 1933, as amended (the &#147;<U>Securities Act</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt of which is
hereby acknowledged, the Company and the Holder hereby agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 1. EXCHANGE AND TERMINATION. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a)
In consideration of and in express reliance upon the representations, warranties, covenants, terms and conditions of this Agreement, the Holder agrees to deliver and surrender to the Company for cancellation the Warrants and the Original Agreement,
and to return via DWAC withdrawal all Company Common Stock previously issued to Holder in connection with the Original Agreement, in exchange for the Exchange Note, and the Company agrees to execute and deliver the Exchange Note to the Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) The closing under this Agreement (the &#147;<U>Closing</U>&#148;) shall take place upon the satisfaction of each of the conditions set
forth in Sections 4 and 5 hereof (the &#147;<U>Closing Date</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) If the Closing has not occurred by the third trading day after
the date hereof, this Agreement shall terminate. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 2. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby represents and warrants as of the date hereof to, and covenants with, the Holder as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <B>Organization and Standing.</B> The Company has been duly incorporated and is validly existing as a corporation in good standing under the
laws of Delaware, has full corporate power and authority to own or lease its properties and conduct its business as presently conducted, and is duly qualified as a foreign corporation and in good standing in each jurisdiction in which the character
of the property owned or leased or the nature of the business transacted by it makes qualification necessary, except where the failure to be so qualified would not have a Material Adverse Effect (as defined below). As used in this Agreement,
&#147;<U>Material Adverse Effect</U>&#148; means any material adverse effect on the business, properties, assets, liabilities, operations, results of operations, condition (financial or otherwise) or prospects of the Company and its subsidiaries
(the &#147;<U>Subsidiaries</U>&#148;), if any, individually or taken as a whole, or on the transactions contemplated hereby or on the Exchange Documents (as defined below) or by the agreements and instruments to be entered into (or entered into) in
connection herewith or therewith, or on the authority or ability of the Company to perform its obligations under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b)
<B>Authorization; Corporate Power.</B> This Agreement has been duly authorized, validly executed and delivered on behalf of the Company and is a valid and binding obligation of the Company enforceable against the Company in accordance with its terms
(except as limited by (i)&nbsp;applicable bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or affecting the enforcement of creditors&#146; rights generally, and (ii)&nbsp;equitable principles generally, including any
specific performance), and the Company has the requisite corporate power and authority to execute and deliver this Agreement and the other agreements and documents contemplated hereby and to perform its obligations hereunder and thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <B>Valid Issuance and Delivery of New Securities.</B> The issuance of the Exchange Note is duly authorized and, upon issuance in accordance
with the terms of this Agreement, the shares of Common Stock issuable upon conversion or otherwise pursuant to the terms of the Exchange Note (collectively, the &#147;<U>Conversion Shares</U>&#148;, and together with the Exchange Note, the
&#147;<U>New Securities</U>&#148;) shall be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and free from all preemptive or similar rights, mortgages, defects, claims, liens, pledges, charges, taxes, rights of
first refusal, encumbrances, security interests and other encumbrances (collectively &#147;<U>Liens</U>&#148;) with respect to the issuance thereof. As of the date hereof, the Company has reserved from its duly authorized capital stock not less than
150% of the maximum number of Conversion Shares issuable upon conversion of the Exchange Notes (assuming for purposes hereof that (x)&nbsp;the Exchange Notes are convertible at the Alternate Conversion Price (as defined in the Notes) assuming a date
of conversion as of the date hereof, (y)&nbsp;interest on the Notes shall accrue through the Maturity Date (as defined in the Exchange Note) and will be converted in shares of Common Stock (as defined below) at a conversion price equal to the
Alternate Conversion Price assuming a date of conversion as of the date hereof and (z)&nbsp;any such conversion shall not take into account any limitations on the conversion of the Exchange Notes set forth in the Exchange Notes). Upon issuance or
conversion in accordance with the Exchange Notes the Conversion Shares when issued, will be validly issued, fully paid and nonassessable and free from all preemptive or similar rights or Liens with respect to the issue thereof, with the holders
being entitled to all rights accorded to a holder of Common Stock. The offer and issuance by the Company of the New Securities is exempt from registration under the Securities Act. Each of the New Securities will be freely tradable and shall not be
required to bear, and shall not bear, any Securities Act or other restrictive legend. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <B>Consents. </B>No consent, waiver, approval or authorization of or designation, declaration
or filing with any Person (as defined below) on the part of the Company is required in connection with the valid execution and delivery of this Agreement or the offer, sale or issuance of the New Securities or the consummation of any other
transaction contemplated by this Agreement. For purposes of this Agreement, (i) &#147;Person&#148; means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other
entity and any Governmental Entity or any department or agency thereof; and (ii) &#147;<U>Governmental Entity</U>&#148; means any nation, state, county, city, town, village, district, or other political jurisdiction of any nature, federal, state,
local, municipal, foreign, or other government, governmental or quasi-governmental authority of any nature (including any governmental agency, branch, department, official, or entity and any court or other tribunal), multi-national organization or
body; or body exercising, or entitled to exercise, any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power of any nature or instrumentality of any of the foregoing, including any entity or enterprise
owned or controlled by a government or a public international organization or any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <B>No Default or Violation</B>.
The execution and delivery of the Agreement and the consummation of the transactions contemplated by this Agreement by the Company will not (i)&nbsp;result in a breach of or a default under any of the terms or provisions of (A)&nbsp;the
Company&#146;s certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws,</FONT> or (B)&nbsp;any material provision of any indenture, mortgage, deed of trust or other material agreement or instrument to which the Company is a party or
by which it or any of its material properties or assets is bound or (ii)&nbsp;result in a violation of any provision of any law, statute, rule, regulation, or any existing applicable decree, judgment or order by any court, Federal or state
regulatory body, administrative agency, or other governmental body having jurisdiction over the Company, or any of its material properties or assets except in the case of clauses (i)(B) or (ii)&nbsp;for any such breaches, defaults or violations
which would not have a Material Adverse Effect. The Company has not violated any law or any governmental regulation or requirement which violation has had or would reasonably be expected to have a Material Adverse Effect, and the Company has not
received written notice of any such violation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) <B>Offering</B>. Neither the Company, nor any of its affiliates, nor any Person acting
on its or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D) in connection with the offer or sale of the New Securities. The Company shall be responsible for the payment of any
placement agent&#146;s fees, financial advisory fees, or brokers&#146; commissions (other than for persons engaged by the Holder or its investment advisor) relating to or arising out of the transactions contemplated hereby. The Company shall pay,
and hold the Holder harmless against, any liability, loss or expense (including, without limitation, attorney&#146;s fees and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses) arising in
connection with any such claim. Neither the Company nor any of its Subsidiaries has engaged any placement agent or other agent in connection with the Exchange and the issuance of the New Securities. The offer, exchange and issuance, as applicable,
of the New Securities as contemplated by this Agreement are exempt from the registration requirements of the Securities Act and the qualification or registration requirements of state securities laws or other applicable blue sky laws. Neither the
Company nor any authorized agent acting on its behalf will take any action hereafter that would cause the loss of such exemptions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">g) <B>Absence of Litigation</B>. Except as set forth in the reports, schedules, forms, statements
and other documents required to be filed by the Company with the Securities and Exchange Commission (the &#147;<U>SEC</U>&#148;) pursuant to the reporting requirements of the Securities Exchange Act of 1934, as amended (the &#147;<U>Exchange
Act</U>&#148;), there is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the Company, threatened against or affecting
the Company, the Common Stock, any securities of the Company or any of the Company&#146;s officers or directors in their capacities as such. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">h) <B>No Group</B>. The Company acknowledges that, to the Company&#146;s knowledge, the Holder is acting independently in connection with this
Agreement and the transactions contemplated hereby, and is not acting as part of a &#147;group&#148; as such term is defined under Section&nbsp;13(d) of the Securities Act and the rules and regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">i) <B>Validity; Enforcement</B>. This Agreement and each other Exchange Document to which the Company is a party have been duly and validly
authorized, executed and delivered on behalf of the Company and shall constitute the legal, valid and binding obligations of the Company enforceable against the Company in accordance with their respective terms, except as such enforceability may be
limited by general principles of equity or to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable creditors&#146; rights and remedies.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">j) [Intentionally Omitted.] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">k) <B>Disclosure of Agreement.</B> On or before 8:30 a.m., New York City time, on March&nbsp;5, 2018 (the &#147;<U>Cleansing
Deadline</U>&#148;), the Company shall have publicly, whether through one or more press releases or Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC, all material terms of the transactions contemplated hereby
and any other material, nonpublic information provided to the Holder from the Company or any of its Subsidiaries or any of their respective officers, directors, employees, affiliates or agents, including by attaching the form of this Agreement as an
exhibit to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC prior to the Cleansing Deadline. From and after the Cleansing Deadline, the Holder shall not be in possession of any material, nonpublic information
received from the Company or any of its Subsidiaries or any of their respective officers, directors, employees, affiliates or agents, that has not been publicly disclosed. The Company shall not, and shall cause its officers, directors, employees,
affiliates and agents, not to, provide the Holder with any material, nonpublic information regarding the Company from and after the Cleansing Deadline without the express written consent of the Holder. To the extent that the Company delivers any
material, <FONT STYLE="white-space:nowrap">non-public</FONT> information to the Holder after the Cleansing Deadline without the Holder&#146;s express prior written consent, the Company hereby covenants and agrees that the Holder shall not have any
duty of confidentiality to the Company, any of its Subsidiaries or any of their respective officers, directors, employees, affiliates or agents with respect to, or a duty to the Company, any of its Subsidiaries or any of their respective officers,
directors, employees, affiliates or agents not to trade on the basis of, such material, <FONT STYLE="white-space:nowrap">non-public</FONT> information. The Company shall not disclose the name of the Holder in any filing, announcement,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
release or otherwise, unless such disclosure is required by law or regulation. In addition, effective upon the Cleansing Deadline, the Company acknowledges and agrees that any and all
confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, affiliates, employees or agents, on the one hand, and the Holder or any
of its affiliates, on the other hand, shall terminate and be of no further force or effect. The Company understands and confirms that the Holder will rely on the foregoing representations in effecting transactions in securities of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">l) <B>Blue Sky</B>. The Company shall make all filings and reports relating to each Exchange required under applicable securities or
&#147;Blue Sky&#148; laws of the states of the United States following the date hereof, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">m) <B>No Integration</B>. None of the
Company, its Subsidiaries, any of their affiliates, or any Person acting on their behalf shall, directly or indirectly, make any offers or sales of any security (as defined in the Securities Act) or solicit any offers to buy any security or take any
other actions, under circumstances that would require registration of any of the New Securities under the Securities Act or cause this offering of the New Securities to be integrated with such offering or any prior offerings by the Company for
purposes of Regulation D under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">n) <B>Listing</B>. The Company shall promptly secure the listing or designation for
quotation (as applicable) of all of the Conversion Shares upon the Nasdaq Capital Market (subject to official notice of issuance) and shall maintain such listing of all the Conversion Shares from time to time issuable under the terms of the Exchange
Documents. The Company shall maintain the Common Stock&#146;s authorization for quotation on the Nasdaq Capital Market. Neither the Company nor any of its Subsidiaries shall take any action which would be reasonably expected to result in the
delisting or suspension of the Common Stock from the Nasdaq Capital Market. The Company shall pay all fees and expenses in connection with satisfying its obligations under this Section&nbsp;2(n). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">o) <B>Holding Period</B>. For the purposes of Rule&nbsp;144 and in reliance upon the advice of counsel, the Company acknowledges that
(i)&nbsp;the holding period of the Exchange Note (and upon conversion of the Exchange Note, the Conversion Shares) may be tacked onto the holding period of the Warrants, (ii)&nbsp;the Company is not aware of any event reasonably likely to occur that
would reasonably be expected to result in the New Securities becoming ineligible to be resold by the Holder pursuant to Rule 144 and (iii)&nbsp;in connection with any resale of any New Securities pursuant to Rule 144, the Holder shall solely be
required to provide reasonable assurances that such New Securities are eligible for resale, assignment or transfer under Rule 144, which shall not include an opinion of Holder&#146;s counsel. The Company shall be responsible for any transfer agent
fees or Depository Trust Company fees or legal fees of the Company&#146;s counsel with respect to the removal of legends, if any, or issuance of New Securities in accordance herewith. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 3. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE HOLDER. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) The Holder represents and warrants to and covenants with the Company that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <B>Valid Existence; Good Standing</B>. To the extent the Holder is a corporation, limited liability company or other type of entity, the
Holder is validly existing and in good standing under the laws of the jurisdiction of its organization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <B>Authority;
Authorization</B>. The Holder has full right, power, authority and capacity to enter into this Agreement and the other agreements and documents contemplated hereby and to perform its obligations hereunder and thereunder and has taken all necessary
action to authorize the execution, delivery and performance of this Agreement. Upon the execution and delivery of this Agreement by the Holder, this Agreement shall constitute a valid and binding obligation of the Holder, enforceable in accordance
with its terms (except (i)&nbsp;as limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or affecting the enforcement of creditors&#146; rights generally, and (ii)&nbsp;as limited by equitable
principles generally, including any specific performance). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <B>Title</B>. The Holder owns and holds the entire right, title and
interest in and to, and is the record and beneficial owner of, the Warrants and the Holder owns the Warrants free and clear of all Liens. The Holder has the full power and authority to vote, transfer and dispose of the Warrants free and clear of any
right or Liens. There is no restriction affecting the ability of the Holder to transfer the legal and beneficial title and ownership of the Warrants to the Company and, at the Closing, the Company will acquire legal and valid title to the Warrants,
free and clear of all Liens. Other than the transactions contemplated by this Agreement, there is no outstanding vote, plan, pending proposal, or other right of any person to acquire all or any of the Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <B>Purchase of Warrants in the Registered Offering. </B>The Holder purchased the Warrants in the Company&#146;s offering of Common Stock
and warrants made pursuant to the Company&#146;s prospectus filed with the Securities and Exchange Commission (the &#147;SEC&#148;) pursuant to Rule 424(b)(5) on February&nbsp;9, 2017 (the &#147;<B>Registered Offering</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <B>Securities Act Exemption</B>. Neither the Holder nor anyone acting on behalf of the Holder has received any commission or remuneration
directly or indirectly in connection with or in order to solicit or facilitate the Exchange. The Holder understands that the Exchange contemplated hereby is intended to be exempt from registration by virtue of Section&nbsp;3(a)(9) of the Securities
Act. The Holder understands that the Company is relying upon the truth and accuracy of the representations, warranties, agreements, acknowledgments and understandings of the Holder set forth herein for purposes of qualifying for the exemption under
Section&nbsp;3(a)(9) of the Securities Act as well as qualifying for exemptions under applicable state securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) <B><FONT
STYLE="white-space:nowrap">Non-Affiliate</FONT></B>. The Holder is not an Affiliate (as defined below) of the Company and has not been an Affiliate during the three months prior to the date hereof. &#147;Affiliate&#148; means, with respect to any
Person, any other Person that directly or indirectly controls, is controlled by, or is under common control with, such Person, it being understood for purposes of this definition that &#147;control&#148; of a Person means the power directly or
indirectly either to vote 10% or more of the stock having ordinary voting power for the election of directors of such Person or direct or cause the direction of the management and policies of such Person whether by contract or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) <B>Information</B>. The Holder has, in connection with its decision to acquire the Exchange
Note, relied with respect to the Company and its affairs solely upon the Company&#146;s filings with the SEC and the representations and warranties of the Company contained herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) <B>Advisors</B>. The Holder understands that nothing in this Agreement or any other materials presented to the Holder in connection with
the exchange of the Warrants and execution and acquisition of the Exchange Note constitutes legal, tax or investment advice. The Holder has consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed necessary or
appropriate in connection with its acquisition of the Exchange Note. With respect to such matters, the Holder relies solely on such advisors and not on any statements or representations of the Company or any of its agents, written or oral. The
Holder understands that it (and not the Company) shall be responsible for its own tax liability that may arise as a result of this investment or the transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 4. CONDITIONS TO COMPANY&#146;S OBLIGATIONS AT THE CLOSING. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s obligation to complete the issuance of the Exchange Note and deliver the Exchange Note to the Holder at the Closing shall be
subject to the following conditions to the extent not waived by the Company: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <B>Execution and Delivery</B>. The Holder shall have
executed and delivered this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <B>Covenants</B>. The Holder shall have performed, satisfied and complied in all material
respects with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Holder at or prior to the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <B>Surrender of Warrants.</B> The Company shall have received in physical form or through book-entry transfer from the Holder all
certificates or book-entry notation representing the Warrants as well as the Original Agreement marked for cancellation/rescission; In addition, Holder shall return (via DWAC withdrawal) all Company Common Stock previously issued to Holder in
connection with the Original Agreement, to be exchanged for the Exchange Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <B>Representations and Warranties. </B>The
representations and warranties of the Holder shall be true and correct in all material respects as of the date when made and as of the Closing Date as though made at that time, except for representations and warranties that are expressly made as of
a particular date, which shall be true and correct in all material respects as of such date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 5. CONDITIONS TO THE HOLDER&#146;S OBLIGATIONS AT
THE CLOSING. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Holder&#146;s obligation to deliver the Warrants and accept delivery of the Exchange Note shall be subject to the
following conditions to the extent not waived by the Holder: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)<B>&nbsp;Execution and Delivery</B>. The Company shall have executed and
delivered this Agreement and the Exchange Note. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)<B>&nbsp;Covenants</B>. The Company shall have performed, satisfied and complied in all
material respects with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <B>Delivery of Exchange Note.</B> The Company shall have delivered the Exchange Note in accordance with the instructions provided pursuant
to Section&nbsp;1.b) hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d)<B>&nbsp;Representations and Warranties.</B> Each of the representations and warranties of the Company
shall be true and correct in all material respects as of the date when made and as of the Closing Date as though made at that time, except for representations and warranties that are expressly made as of a particular date, which shall be true and
correct in all material respects as of such date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 6. NOTICES. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All notices, requests, consents and other communications hereunder shall be in writing, shall be sent by confirmed electronic mail, or mailed
by first-class registered or certified airmail, or nationally recognized overnight express courier, postage prepaid, and shall be deemed given when so sent in the case of electronic mail transmission, or when so received in the case of mail or
courier, and addressed as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) if to the Company, to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">SELLAS Life Sciences Group, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">315 Madison, 4<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Flr. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York, New York 10017 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Angelos Stergiou, M.D., ScD h.c. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-Mail:</FONT> astergiou@sellaslife.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">or to such other person at such other place as the Company shall designate to the Holder in writing; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) if to the Holder, at the address as set forth at the end of this Agreement, or at such other address as may have been furnished by the
Holder to the Company in writing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 7. MISCELLANEOUS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <B>Headings.</B> The headings of the various sections of this Agreement have been inserted for convenience of reference only and shall not
be deemed to be part of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <B>Severability.</B> In case any provision contained in this Agreement should be invalid,
illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <B>Most Favored Nations. </B>The Company hereby represents and warrants as of the date hereof and covenants and agrees that no agreement
entered into (or to be entered into) with any Person with respect to the Exchange or other transaction involving the warrants issued in the Registered Offering, including, without limitation with respect to any consent, release,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amendment, settlement, or waiver relating to any Exchange or such other transaction involving the warrants issued in the Registered Offering, including without limitation, any amendment,
settlement or waiver relating to any securities issued in connection with an exchange of warrants issued in the Registered Offering (including the Exchange Note or other derivative security) (each a &#147;Settlement Document&#148;), is or will be
more favorable to such Person (other than any reimbursement of legal fees) than those of the Holder and this Agreement, including without limitation the ratio of warrants to the cash paid, principal amount of notes, value of any shares of Common
Stock (valued as the VWAP of the Common Stock on the Trading Day immediately preceding the public announcement of such issuance), or value of any Options, Convertible Securities or Adjustment Rights (as such terms are defined in the Exchange Note)
(valued on the Trading Day immediately preceding the public announcement of such issuance, as the greater of (a)&nbsp;the VWAP of the Common Stock multiplied by the number of underlying shares and (b)&nbsp;the Black Scholes Consideration Value)
conveyed in such Settlement Document. If, and whenever on or after the date hereof, the Company enters into a Settlement Document, then (i)&nbsp;the Company shall provide notice thereof to the Holder within one (1)&nbsp;Trading Day following the
occurrence thereof and (ii)&nbsp;the terms and conditions of this Agreement shall be, without any further action by the Holder or the Company, automatically amended and modified in an economically and legally equivalent manner such that the Holder
shall receive the benefit of the more favorable terms and/or conditions (as the case may be) set forth in such Settlement Document, provided that upon written notice to the Company within ten (10)&nbsp;Trading Days of receipt of notice of such
Settlement Document the Holder may notify the Company in writing of Holder&#146;s election not to accept the benefit of any such amended or modified term or condition, in which event the term or condition contained in this Agreement shall apply to
the Holder as it was in effect immediately prior to such amendment or modification as if such amendment or modification never occurred with respect to the Holder. The provisions of this Section&nbsp;7(c) shall apply similarly and equally to each
Settlement Document. For purposes hereof, &#147;Black Scholes Consideration Value&#148; means the value of the applicable Option, Convertible Security or Adjustment Right (as the case may be) as of the date of issuance thereof calculated using the
Black Scholes Option Pricing Model obtained from the &#147;OV&#148; function on Bloomberg utilizing (i)&nbsp;an underlying price per share equal to the Closing Sale Price of the Common Stock on the Trading Day immediately preceding the public
announcement of the execution of definitive documents with respect to the issuance of such Option or Convertible Security (as the case may be), (ii) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the
remaining term of such Option, Convertible Security or Adjustment Right (as the case may be) as of the date of issuance of such Option, Convertible Security or Adjustment Right (as the case may be), (iii) a zero cost of borrow and (iv)&nbsp;an
expected volatility equal to the greater of 100% and the 30 day volatility obtained from the &#147;HVT&#148; function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the date of issuance
of such Option, Convertible Security or Adjustment Right (as the case may be). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <B>Governing Law.</B> This Agreement shall be governed
by and construed under the laws of the State of New York without regard to the choice of law principles thereof. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the State of New York
located in The City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or thereby, and hereby irrevocably waives any objection that such suit, action
or proceeding is brought in an inconvenient forum or that the venue of such suit, action or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proceeding is improper. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT
MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <B>Counterparts.</B> This Agreement may be executed in two or more counterparts, each of which shall constitute an original, but all of
which, when taken together, shall constitute but one instrument, and shall become effective when one or more counterparts have been signed by each party hereto and delivered to the other parties. In the event that any signature is delivered by
facsimile transmission or by an <FONT STYLE="white-space:nowrap">e-mail</FONT> which contains an electronic file of an executed signature page, such signature page shall create a valid and binding obligation of the party executing (or on whose
behalf such signature is executed) with the same force and effect as if such facsimile or electronic file signature page (as the case may be) were an original thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) <B>Successors and Assigns.</B> Except as otherwise expressly provided herein, the provisions hereof shall inure to the benefit of, and be
binding upon, the successors, permitted assigns, heirs, executors and administrators of the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">g) <B>Entire Agreement;
Amendments.</B> This Agreement and other documents delivered pursuant hereto constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and thereof. This Agreement may be amended, modified,
superseded, cancelled, renewed or extended, and the terms and conditions hereof may be waived, only by a written instrument signed by all parties, or, in the case of a waiver, by the party waiving compliance. Except as expressly stated herein, no
delay on the part of any party in exercising any right, power or privilege hereunder shall operate as a waiver thereof, nor shall any waiver on the part of any party of any right, power or privilege hereunder preclude any other or future exercise of
any other right, power or privilege hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">h) <B>Survival. </B>The representations, warranties, covenants and agreements made in this
Agreement shall survive the closing of the transactions contemplated hereby and the exchange and delivery of the Warrants and the Exchange Note. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">i) <B>Further Assurances</B>. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall
execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions
contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">j) <B>No Third Party Beneficiaries</B>. This Agreement is intended for the benefit of the parties hereto and their
respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[signature pages follow] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have caused this Agreement to be executed by their
duly authorized representatives as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SELLAS LIFE SCIENCES GROUP, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Angelos Stergiou</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Angelos Stergiou, M.D., ScD h.c.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">COMPANY SIGNATURE PAGE TO </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">WARRANT EXCHANGE AGREEMENT </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>HOLDER: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ALTO OPPORTUNITY MASTER FUND, SPC &#150; SEGREGATED MASTER PORTFOLIO B</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>By:</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Waqas Khatri</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Name:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Waqas Khatri</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Title:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Director</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Address:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>c/o<B></B><B> Ayrton Capital LLC 222 Broadway, 19th Floor, New York, NY 10038</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><FONT STYLE="white-space:nowrap">E-Mail:</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>wk@ayrtonllc.com</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" NOWRAP><B>DWAC INSTRUCTIONS Broker Name and DTC Number:</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" NOWRAP><B>Account Number at DTC Participant (if applicable):</B></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.80
<SEQUENCE>14
<FILENAME>d556278dex1080.htm
<DESCRIPTION>EX-10.80
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.80</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.80 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>CONFIDENTIAL DRAFT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONVERTIBLE PROMISSORY NOTE </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">$<B>249,600.00</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">February 13, 2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>New York</B>, <B>NY</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For value received <B>SELLAS Life Sciences Group, Inc.</B>, a Delaware corporation (the
&#147;<B><I>Company</I></B>&#148;), promises to pay to <B>Alto Opportunity Master Fund, SPC&#151;Segregated Master</B><B> </B><B></B><B></B><B></B><B>Portfolio B</B> or its assigns (&#147;<B><I>Holder</I></B>&#148;) the principal sum of
$<B>249,600.00</B> (the &#147;<B><I>Principal</I></B>&#148;) together with accrued and unpaid interest thereon (the &#147;<B><I>Interest</I></B>&#148;), each due and payable on the date and in the manner set forth below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This convertible promissory note (the &#147;<B><I>Note</I></B>&#148;) was issued in reliance on the exemption provided in Rule 3(a)(9) of the
Securities Act of 1933, as amended, pursuant to the terms of that certain Exchange Agreement, dated February&nbsp;13 2018 (the &#147;<B><I>Exchange Agreement</I></B>&#148;), by and between the Company and the Holder in exchange for that certain
Warrant (as defined in the Exchange Agreement) originally issued on February&nbsp;13, 2017 and shall be subject to the following terms (capitalized terms not defined herein shall have the meaning as set forth in the Exchange Agreement):<B> </B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B>Repayment. </B>All payments of Interest and Principal shall be in lawful money of the United States of America. All payments shall
be applied first to accrued Interest, and thereafter to Principal. The outstanding Principal amount of the Note shall be due and payable on August&nbsp;13, 2018 (the &#147;<B><I>Maturity Date</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B>Interest.</B> The Company promises to pay simple<B> </B>Interest on the outstanding Principal amount hereof from the date hereof
until payment in full, which Interest shall be payable at the rate of 5% per annum (the &#147;<B><I>Interest Rate</I></B>&#148;) or the maximum rate permissible by law, whichever is less. Interest shall be due and payable by way of inclusion of the
Interest in the Conversion Amount on any Conversion Date in accordance with Section&nbsp;3 below or in cash on the Maturity Date and shall be calculated on the basis of a <FONT STYLE="white-space:nowrap">365-day</FONT> year for the actual number of
days elapsed. From and after the occurrence and during the continuance of any Event of Default (as defined below), the Interest Rate shall automatically be increased to eighteen percent (18.0%) per annum (the &#147;<B><I>Default Rate</I></B>&#148;).
In the event that such Event of Default is subsequently cured (and no other Event of Default then exists (including, without limitation, for the Company&#146;s failure to pay such Interest at the Default Rate on the Maturity Date)), the adjustment
referred to in the preceding sentence shall cease to be effective as of the calendar day immediately following the date of such cure; provided that the Interest as calculated and unpaid at such increased rate during the continuance of such Event of
Default shall continue to apply to the extent relating to the days after the occurrence of such Event of Default through and including the date of such cure of such Event of Default. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3. Conversion. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the election of the
Holder made at any time after April&nbsp;30, 2018, this Note shall be convertible into validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock (as defined below), on the terms and conditions set
forth in this Section&nbsp;3. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 2. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Conversion Right</B>. Subject to the provisions of Section&nbsp;3(d), at any time
or times on or after April&nbsp;30, 2018, the Holder shall be entitled to convert any portion of the outstanding and unpaid Conversion Amount (as defined below) into validly issued, fully paid and
<FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock in accordance with Section&nbsp;3(c), at the Conversion Rate (as defined below). The Company shall not issue any fraction of a share of Common Stock upon any conversion.
If the issuance would result in the issuance of a fraction of a share of Common Stock, the Company shall round such fraction of a share of Common Stock up to the nearest whole share. The Company shall pay any and all transfer, stamp, issuance and
similar taxes, costs and expenses (including, without limitation, fees and expenses of the Company&#146;s transfer agent (the &#147;<B><I>Transfer Agent</I></B>&#148;)) that may be payable with respect to the issuance and delivery of Common Stock
upon conversion of any Conversion Amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Conversion Rate</B>. The number of shares of Common Stock issuable upon
conversion of any Conversion Amount pursuant to Section&nbsp;3(a) shall be determined by dividing (x)&nbsp;such Conversion Amount by (y)&nbsp;the Conversion Price (the &#147;<B><I>Conversion Rate</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(</B><B>i</B><B>)</B> &#147;<B><I>Conversion Amount</I></B>&#148; means the sum of (x)&nbsp;portion of the Principal to be converted,
redeemed or otherwise with respect to which this determination is being made and (y)&nbsp;all accrued and unpaid Interest with respect to such portion of the Principal amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> &#147;<B><I>Conversion Price</I></B>&#148; means, as of any Conversion Date or other date of determination, $7.00, subject to
adjustment as provided herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Mechanics of Conversion</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(</B><B>i</B><B>)</B> <B>Optional Conversion</B>. To convert any Conversion Amount into shares of Common Stock on any date (a
&#147;<B><I>Conversion Date</I></B>&#148;), the Holder shall deliver (whether via facsimile, electronic mail or otherwise), for receipt on or prior to 11:59 p.m., New York time, on such date, a copy of an executed notice of conversion (the
&#147;<B><I>Conversion Notice</I></B>&#148;) to the Company. If required by Section&nbsp;3(c)(iii), within two (2)&nbsp;Trading Days following a conversion of this Note as aforesaid, the Holder shall surrender this Note to a nationally recognized
overnight delivery service for delivery to the Company (or an indemnification undertaking with respect to this Note in the case of its loss, theft or destruction). On or before the first (1st) Trading Day following the date of receipt of a
Conversion Notice, the Company shall transmit by facsimile or electronic mail an acknowledgment of confirmation and representation as to whether such shares of Common Stock may then be resold pursuant to Rule 144 or an effective and available
registration statement, of receipt of such Conversion Notice to the Holder and the Transfer Agent which confirmation shall constitute an instruction to the Transfer Agent to process such Conversion Notice in accordance with the terms herein. On or
before the second (2nd) Trading Day following the date on which the Company has received a Conversion Notice (or such earlier date as required pursuant to the Exchange Act or other applicable law, rule or regulation for the settlement of a trade
initiated on the applicable Conversion Date of such shares of Common Stock issuable pursuant to such Conversion Notice) (the &#147;<B><I>Share Delivery Deadline</I></B><I>&#148;</I><I>),</I> the Company shall (1)&nbsp;provided that the Transfer
Agent is participating in the DTC Fast Automated Securities Transfer Program, credit such aggregate number of shares of Common Stock to which the Holder shall be entitled pursuant to such conversion to the Holder&#146;s or its designee&#146;s
balance account with DTC through its Deposit/Withdrawal at Custodian system or (2)&nbsp;if the Transfer Agent is not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 3. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
participating in the DTC Fast Automated Securities Transfer Program, upon the request of the Holder, issue and deliver (via reputable overnight courier) to the address as specified in the
Conversion Notice, a certificate, registered in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder shall be entitled pursuant to such conversion. If this Note is physically surrendered for conversion
pursuant to Section&nbsp;3(c)(iii) and the outstanding Principal of this Note is greater than the Principal portion of the Conversion Amount being converted, then the Company shall as soon as practicable and in no event later than two
(2)&nbsp;Business Days after receipt of this Note and at its own expense, issue and deliver to the Holder (or its designee) a new Note representing the outstanding Principal not converted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Company</B><B>&#146;</B><B>s Failure to Timely Convert</B>. If the Company shall fail, for any reason or for no reason, on or
prior to the applicable Share Delivery Deadline, if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program, to issue and deliver to the Holder (or its designee) a certificate for the number of shares of Common
Stock to which the Holder is entitled and register such shares of Common Stock on the Company&#146;s share register or, if the Transfer Agent is participating in the DTC Fast Automated Securities Transfer Program, to credit the balance account of
the Holder or the Holder&#146;s designee with DTC for such number of shares of Common Stock to which the Holder is entitled upon the Holder&#146;s conversion of this Note (as the case may be) (a &#147;<B><I>Conversion Failure</I></B>&#148;), and if
on or after such Share Delivery Deadline the Holder purchases (in an open market transaction or otherwise) shares of Common Stock corresponding to all or any portion of the number of shares of Common Stock issuable upon such conversion that the
Holder is entitled to receive from the Company and has not received from the Company in connection with such Conversion Failure (a &#147;<B><I><FONT STYLE="white-space:nowrap">Buy-In</FONT></I></B>&#148;), then, in addition to all other remedies
available to the Holder, the Company shall, within two (2)&nbsp;Business Days after receipt of the Holder&#146;s request and in the Holder&#146;s discretion, either: (I)&nbsp;pay cash to the Holder in an amount equal to the Holder&#146;s total
purchase price (including brokerage commissions and other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, if any) for the shares of Common Stock so purchased (including, without limitation, by
any other Person in respect, or on behalf, of the Holder) (the &#147;<B><FONT STYLE="white-space:nowrap">Buy-In</FONT> Price</B>&#148;), at which point the Company&#146;s obligation to so issue and deliver such certificate (and to issue such shares
of Common Stock) or credit the balance account of such Holder or such Holder&#146;s designee, as applicable, with DTC for the number of shares of Common Stock to which the Holder is entitled upon the Holder&#146;s conversion hereunder (as the case
may be) (and to issue such shares of Common Stock) shall terminate, or (II)&nbsp;promptly honor its obligation to so issue and deliver to the Holder a certificate or certificates representing such shares of Common Stock or credit the balance account
of such Holder or such Holder&#146;s designee, as applicable, with DTC for the number of shares of Common Stock to which the Holder is entitled upon the Holder&#146;s conversion hereunder (as the case may be) and pay cash to the Holder in an amount
equal to the excess (if any) of the <FONT STYLE="white-space:nowrap">Buy-In</FONT> Price over the product of (x)&nbsp;such number of shares of Common Stock multiplied by (y)&nbsp;the lowest Closing Sale Price of the Common Stock on any Trading Day
during the period commencing on the date of the applicable Conversion Notice and ending on the date of such issuance and payment under this clause (II) (the &#147;<B><I><FONT STYLE="white-space:nowrap">Buy-In</FONT> Payment Amount</I></B>&#148;).
Nothing shall limit the Holder&#146;s right to pursue any other remedies available to it hereunder, at law or in equity, including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#146;s
failure to timely deliver certificates representing shares of Common Stock (or to electronically deliver such shares of Common Stock) upon the conversion of this Note as required pursuant to the terms hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 4. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> <B>Registration; Book-Entry</B>. The Holder and the Company shall maintain records
showing the Principal and Interest converted and/or paid (as the case may be) and the dates of such conversions, and/or payments (as the case may be) or shall use such other method, reasonably satisfactory to the Holder and the Company, so as not to
require physical surrender of this Note upon conversion. Notwithstanding anything to the contrary set forth in this Section&nbsp;3, following conversion of any portion of this Note in accordance with the terms hereof, the Holder shall not be
required to physically surrender this Note to the Company unless (A)&nbsp;the full Conversion Amount represented by this Note is being converted (in which event this Note shall be delivered to the Company following conversion thereof as contemplated
by Section&nbsp;3(c)(i)) or (B)&nbsp;the Holder has provided the Company with prior written notice (which notice may be included in a Conversion Notice) requesting reissuance of this Note upon physical surrender of this Note. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Limitations on Conversions</B>. The Company shall not effect the conversion of any portion of this Note, and the Holder shall
not have the right to convert any portion of this Note pursuant to the terms and conditions of this Note and any such conversion shall be null and void and treated as if never made, to the extent that after giving effect to such conversion, the
Holder together with the other Attribution Parties collectively would beneficially own in excess of 9.99% (the &#147;<B><I>Maximum Percentage</I></B>&#148;) of the shares of Common Stock outstanding immediately after giving effect to such
conversion. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by the Holder and the other Attribution Parties shall include the number of shares of Common Stock held by the Holder and all other
Attribution Parties plus the number of shares of Common Stock issuable upon conversion of this Note with respect to which the determination of such sentence is being made, but shall exclude shares of Common Stock which would be issuable upon
(A)&nbsp;conversion of the remaining, nonconverted portion of this Note beneficially owned by the Holder or any of the other Attribution Parties and (B)&nbsp;exercise or conversion of the unexercised or nonconverted portion of any other securities
of the Company (including, without limitation, any convertible notes or convertible preferred stock or warrants, including, without limitation, the Warrants) beneficially owned by the Holder or any other Attribution Party subject to a limitation on
conversion or exercise analogous to the limitation contained in this Section&nbsp;3(d). For purposes of this Section&nbsp;3(d), beneficial ownership shall be calculated in accordance with Section&nbsp;13(d) of the Exchange Act. For purposes of
determining the number of outstanding shares of Common Stock the Holder may acquire upon the conversion of this Note without exceeding the Maximum Percentage, the Holder may rely on the number of outstanding shares of Common Stock as reflected in
(x)&nbsp;the Company&#146;s most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or
other public filing with the SEC, as the case may be, (y)&nbsp;a more recent public announcement by the Company or (z)&nbsp;any other written notice by the Company or the Transfer Agent, if any, setting forth the number of shares of Common Stock
outstanding (the &#147;<B><I>Reported Outstanding Share Number</I></B>&#148;). If the Company receives a Conversion Notice from the Holder at a time when the actual number of outstanding shares of Common Stock is less than the Reported Outstanding
Share Number, the Company shall notify the Holder in writing of the number of shares of Common Stock then outstanding and, to the extent that such Conversion Notice would otherwise cause the Holder&#146;s beneficial ownership, as determined pursuant
to this Section&nbsp;3(d), to exceed the Maximum Percentage, the Holder must notify the Company of a reduced number of shares of Common Stock to be purchased pursuant to such Conversion Notice. For any reason at any time, upon the written or oral
request of the Holder, the Company shall within one (1)&nbsp;Business Day </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 5. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
confirm orally and in writing or by electronic mail to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be
determined after giving effect to the conversion or exercise of securities of the Company, including this Note, by the Holder and any other Attribution Party since the date as of which the Reported Outstanding Share Number was reported. In the event
that the issuance of shares of Common Stock to the Holder upon conversion of this Note results in the Holder and the other Attribution Parties being deemed to beneficially own, in the aggregate, more than the Maximum Percentage of the number of
outstanding shares of Common Stock (as determined under Section&nbsp;13(d) of the Exchange Act), the number of shares so issued by which the Holder&#146;s and the other Attribution Parties&#146; aggregate beneficial ownership exceeds the Maximum
Percentage (the &#147;<B>Excess Shares</B>&#148;) shall be deemed null and void and shall be cancelled ab initio, and the Holder shall not have the power to vote or to transfer the Excess Shares. Upon delivery of a written notice to the Company, the
Holder may from time to time increase (with such increase not effective until the sixty-first (61<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>) day after delivery of such notice) or decrease the Maximum Percentage to any other percentage
not in excess of 9.99% as specified in such notice; provided that (i)&nbsp;any such increase in the Maximum Percentage will not be effective until the sixty-first (61<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>) day after such notice is
delivered to the Company and (ii)&nbsp;any such increase or decrease will apply only to the Holder and the other Attribution Parties and not to any other holder of Notes that is not an Attribution Party of the Holder. For purposes of clarity, the
shares of Common Stock issuable pursuant to the terms of this Note in excess of the Maximum Percentage shall not be deemed to be beneficially owned by the Holder for any purpose including for purposes of Section&nbsp;13(d) or Rule <FONT
STYLE="white-space:nowrap">16a-1(a)(1)</FONT> of the Exchange Act. No prior inability to convert this Note pursuant to this paragraph shall have any effect on the applicability of the provisions of this paragraph with respect to any subsequent
determination of convertibility. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section&nbsp;3(d) to the extent necessary to correct this paragraph (or any
portion of this paragraph) which may be defective or inconsistent with the intended beneficial ownership limitation contained in this Section&nbsp;3(d) or to make changes or supplements necessary or desirable to properly give effect to such
limitation. The limitation contained in this paragraph may not be waived and shall apply to a successor holder of this Note. Further, notwithstanding anything in this Note to the contrary, under no circumstances shall the Company be obligated to
issue or the Holder entitled to receive, an aggregate number of shares of Common Stock that would exceed 19.9% of the total number of shares of Common Stock issued and outstanding as of the date of this Note (the &#147;<B><I>Maximum
Issuance</I></B>&#148;); provided, that to the extent the aggregate number of shares of Common Stock would exceed the Maximum Issuance, the Company shall issue and deliver to Holder a number of shares of Common Stock up to the Maximum Issuance and
the unconverted Principal of this Note shall remain outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Right of Alternate Conversion</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <U>General</U>. At any time at any time after the occurrence of an Event of Default (regardless of whether such Event of Default
has been cured), the Holder may, at the Holder&#146;s option, convert (each, an &#147;<B><I>Alternate Conversion</I></B>&#148;, and the date of such Alternate Conversion, each, an &#147;<B><I>Alternate Conversion Date</I></B>&#148;) all, or any part
of, the Conversion Amount (such portion of the Conversion Amount subject to such Alternate Conversion, the &#147;<B><I>Alternate Conversion Amount</I></B>&#148;) into shares of Common Stock at the Alternate Conversion Price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 6. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <U>Mechanics of Alternate Conversion</U>. On any Alternate Conversion Date, the
Holder may voluntarily convert any Alternate Conversion Amount pursuant to Section&nbsp;3(c) (with &#147;Alternate Conversion Price&#148; replacing &#147;Conversion Price&#148; for all purposes hereunder with respect to such Alternate Conversion) by
designating in the Conversion Notice delivered pursuant to this Section&nbsp;3(e) of this Note that the Holder is electing to use the Alternate Conversion Price for such conversion. Notwithstanding anything to the contrary in this Section&nbsp;3(e),
but subject to Section&nbsp;3(d), until the Company delivers shares of Common Stock representing the applicable Alternate Conversion Amount to the Holder, such Alternate Conversion Amount may be converted by the Holder into shares of Common Stock
pursuant to Section&nbsp;3(c) without regard to this Section&nbsp;3(e). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B>Voluntary Adjustment by Company</B>. The Company
may at any time during the term of this Note, with the prior written consent of the Holder, reduce the then current Conversion Price of each of the Notes to any amount and for any period of time deemed appropriate by the board of directors of the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B>Maturity.</B> Unless this Note has been previously converted or prepaid in accordance with the terms of
Section&nbsp;3(a) above, the entire outstanding Conversion Amount shall become fully due and payable in cash on the Maturity Date; provided, that if the Conversion Amount is not paid in full in cash on the Maturity Date, subject to Section&nbsp;3(d)
above, the Holder shall retain the right to convert all, or any part, at such Holder&#146;s sole discretion, of the Conversion Amount into shares of Common Stock in accordance with Section&nbsp;3 above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B>Expenses. </B>In the event of any default hereunder, the Company shall pay all reasonable attorneys&#146; fees and court costs
incurred by Holder in enforcing and collecting this Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B>Prepayment.</B> The Company may prepay this Note and accrued but
unpaid Interest prior to the Maturity Date at any time without the consent of the Holder; provided, that the Company may not prepay any Conversion Amount submitted for conversion pursuant to Section&nbsp;3 above from and after the applicable
Conversion Date unless such corresponding Conversion Notice is withdrawn by the Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B>Default. </B>If there shall be any
Event of Default hereunder, at the option and upon the declaration of the Holder and upon written notice to the Company (which election and notice shall not be required in the case of an Event of Default under Section&nbsp;7(v), 7(vi) or 7(vii)),
this Note shall accelerate and all Principal and unpaid accrued Interest shall become immediately due and payable. The occurrence of any one or more of the following shall constitute an &#147;<B><I>Event of Default</I></B>&#148;: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> the suspension (or threatened suspension) from trading or the failure (or threatened failure) of the Common Stock to be trading or
listed (as applicable) on the Nasdaq Capital Market for a period of five (5)&nbsp;consecutive Trading Days; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> the
Company&#146;s (A)&nbsp;failure to cure a Conversion Failure by delivery of the required number of shares of Common Stock within five (5)&nbsp;Trading Days after the applicable Conversion Date or exercise date (as the case may be) or
(B)&nbsp;notice, written or oral, to any holder of the Notes, including, without limitation, by way of public announcement or through any of its agents, at any time, of its intention not to comply, as required, with a request for conversion of any
Notes into shares of Common Stock that is requested in accordance with the provisions of the Notes, other than pursuant to Section&nbsp;3(d); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 7. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> the Company&#146;s or any Subsidiary&#146;s failure to pay to the Holder any amount
of Principal, Interest or other amounts when and as due under this Note (including, without limitation, the Company&#146;s failure to pay any redemption payments or amounts hereunder) or any other Exchange Document or any other agreement, document,
certificate or other instrument delivered in connection with the transactions contemplated hereby and thereby, except, in the case of a failure to pay Interest when and as due, in which case only if such failure remains uncured for a period of at
least two (2)&nbsp;Trading Days; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> [INTENTIONALLY OMITTED]; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings for the relief of debtors shall be
instituted by or against the Company or any Subsidiary and, if instituted against the Company or any Subsidiary by a third party, shall not be dismissed within thirty (30)&nbsp;days of their initiation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> the commencement by the Company or any Subsidiary of a voluntary case or proceeding under any applicable federal, state or
foreign bankruptcy, insolvency, reorganization or other similar law or of any other case or proceeding to be adjudicated a bankrupt or insolvent, or the consent by it to the entry of a decree, order, judgment or other similar document in respect of
the Company or any Subsidiary in an involuntary case or proceeding under any applicable federal, state or foreign bankruptcy, insolvency, reorganization or other similar law or to the commencement of any bankruptcy or insolvency case or proceeding
against it, or the filing by it of a petition or answer or consent seeking reorganization or relief under any applicable federal, state or foreign law, or the consent by it to the filing of such petition or to the appointment of or taking possession
by a custodian, receiver, liquidator, assignee, trustee, sequestrator or other similar official of the Company or any Subsidiary or of any substantial part of its property, or the making by it of an assignment for the benefit of creditors, or the
execution of a composition of debts, or the occurrence of any other similar federal, state or foreign proceeding, or the admission by it in writing of its inability to pay its debts generally as they become due, the taking of corporate action by the
Company or any Subsidiary in furtherance of any such action or the taking of any action by any Person to commence a Uniform Commercial Code foreclosure sale or any other similar action under federal, state or foreign law; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vii)</B> the entry by a court of (i)&nbsp;a decree, order, judgment or other similar document in respect of the Company or any Subsidiary
of a voluntary or involuntary case or proceeding under any applicable federal, state or foreign bankruptcy, insolvency, reorganization or other similar law or (ii)&nbsp;a decree, order, judgment or other similar document adjudging the Company or any
Subsidiary as bankrupt or insolvent, or approving as properly filed a petition seeking liquidation, reorganization, arrangement, adjustment or composition of or in respect of the Company or any Subsidiary under any applicable federal, state or
foreign law or (iii)&nbsp;a decree, order, judgment or other similar document appointing a custodian, receiver, liquidator, assignee, trustee, sequestrator or other similar official of the Company or any Subsidiary or of any substantial part of its
property, or ordering the winding up or liquidation of its affairs, and the continuance of any such decree, order, judgment or other similar document or any such other decree, order, judgment or other similar document unstayed and in effect for a
period of thirty (30)&nbsp;consecutive days; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 8. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(viii)</B> other than as specifically set forth in another clause of this Section&nbsp;7, the
Company or any Subsidiary breaches any representation, warranty, covenant or other term or condition of any Exchange Document, except, in the case of a breach of a covenant or other term or condition that is curable, only if such breach remains
uncured for a period of three (3)&nbsp;consecutive Trading Days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.</B> <B>Adjustment of Conversion Price upon Subdivision or
Combination of Common Stock</B>. If the Company at any time on or after the date hereof subdivides (by any stock split, stock dividend, stock combination, recapitalization or other similar transaction) one or more classes of its outstanding shares
of Common Stock into a greater number of shares, the Conversion Price in effect immediately prior to such subdivision will be proportionately reduced. If the Company at any time on or after the date hereof combines (by any stock split, stock
dividend, stock combination, recapitalization or other similar transaction) one or more classes of its outstanding shares of Common Stock into a smaller number of shares, the Conversion Price in effect immediately prior to such combination will be
proportionately increased. Any adjustment pursuant to this Section&nbsp;8 shall become effective immediately after the effective date of such subdivision or combination. If any event requiring an adjustment under this Section&nbsp;8 occurs during
the period that a Conversion Price is calculated hereunder, then the calculation of such Conversion Price shall be adjusted appropriately to reflect such event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.</B> <B>Rights upon Fundamental Transaction</B>. The Company shall not enter into or be party to a Fundamental Transaction unless
(i)&nbsp;the Successor Entity assumes in writing all of the obligations of the Company under this Note and the other Exchange Documents in accordance with the provisions of this Section&nbsp;9 pursuant to written agreements in form and substance
satisfactory to the Holder and approved by the Holder prior to such Fundamental Transaction, including agreements to deliver to each holder of Notes in exchange for such Notes a security of the Successor Entity evidenced by a written instrument
substantially similar in form and substance to the Notes, including, without limitation, having a principal amount and interest rate equal to the principal amounts then outstanding and the interest rates of the Notes held by such holder, having
similar conversion rights as the Notes and having similar ranking and security to the Notes, and satisfactory to the Holder and (ii)&nbsp;the Successor Entity (including its Parent Entity) is a publicly traded corporation whose common stock is
quoted on or listed for trading on an Eligible Market. Upon the occurrence of any Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Note and the other Exchange Documents referring to the &#147;Company&#148; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this
Note and the other Exchange Documents with the same effect as if such Successor Entity had been named as the Company herein. Upon consummation of a Fundamental Transaction, the Successor Entity shall deliver to the Holder confirmation that there
shall be issued upon conversion or redemption of this Note at any time after the consummation of such Fundamental Transaction, in lieu of the shares of Common Stock (or other securities, cash, assets or other property (except such items still
issuable under Sections 10(a) and 11, which shall continue to be receivable thereafter) issuable upon the conversion or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 9. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
redemption of the Notes prior to such Fundamental Transaction, such shares of the publicly traded common stock (or their equivalent) of the Successor Entity (including its Parent Entity) which
the Holder would have been entitled to receive upon the happening of such Fundamental Transaction had this Note been converted immediately prior to such Fundamental Transaction (without regard to any limitations on the conversion of this Note), as
adjusted in accordance with the provisions of this Note. Notwithstanding the foregoing, the Holder may elect, at its sole option, by delivery of written notice to the Company to waive this Section&nbsp;9 to permit the Fundamental Transaction without
the assumption of this Note. The provisions of this Section&nbsp;9 shall apply similarly and equally to successive Fundamental Transactions and shall be applied without regard to any limitations on the conversion of this Note. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10. Rights Upon Issuance of Purchase Rights and Other Corporate Events. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Purchase Rights</B>. If at any time the Company grants, issues or sells any Options, Convertible Securities or rights to
purchase stock, warrants, securities or other property pro rata to all or substantially all of the record holders of any class of Common Stock (the &#147;<B><I>Purchase Rights</I></B>&#148;), then the Holder will be entitled to acquire, upon the
terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete conversion of this Note (without taking into account
any limitations or restrictions on the convertibility of this Note and assuming for such purpose that the Note was converted at the Alternate Conversion Price as of the applicable record date) immediately prior to the date on which a record is taken
for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>,
<U>however</U>, that to the extent that the Holder&#146;s right to participate in any such Purchase Right would result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to
participate in such Purchase Right to the extent of the Maximum Percentage (and shall not be entitled to beneficial ownership of such shares of Common Stock as a result of such Purchase Right (and beneficial ownership) to the extent of any such
excess) and such Purchase Right to such extent shall be held in abeyance (and, if such Purchase Right has an expiration date, maturity date or other similar provision, such term shall be extended by such number of days held in abeyance, if
applicable) for the benefit of the Holder until such time or times, if ever, as its right thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, at which time or times the Holder shall be granted
such right (and any Purchase Right granted, issued or sold on such initial Purchase Right or on any subsequent Purchase Right held similarly in abeyance (and, if such Purchase Right has an expiration date, maturity date or other similar provision,
such term shall be extended by such number of days held in abeyance, if applicable)) to the same extent as if there had been no such limitation). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Other Corporate Events</B>. In addition to and not in substitution for any other rights hereunder, prior to the consummation of
any Fundamental Transaction pursuant to which holders of shares of Common Stock are entitled to receive securities or other assets with respect to or in exchange for shares of Common Stock (a &#147;<B><I>Corporate Event</I></B>&#148;), the Company
shall make appropriate provision to ensure that the Holder will thereafter have the right to receive upon a conversion of this Note, at the Holder&#146;s option (i)&nbsp;in addition to the shares of Common Stock receivable upon such conversion, such
securities or other assets to which the Holder would have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 10. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
been entitled with respect to such shares of Common Stock had such shares of Common Stock been held by the Holder upon the consummation of such Corporate Event (without taking into account any
limitations or restrictions on the convertibility of this Note) or (ii)&nbsp;in lieu of the shares of Common Stock otherwise receivable upon such conversion, such securities or other assets received by the holders of shares of Common Stock in
connection with the consummation of such Corporate Event in such amounts as the Holder would have been entitled to receive had this Note initially been issued with conversion rights for the form of such consideration (as opposed to shares of Common
Stock) at a conversion rate for such consideration commensurate with the Conversion Rate. Provision made pursuant to the preceding sentence shall be in a form and substance satisfactory to the Holder. The provisions of this Section&nbsp;10(b) shall
apply similarly and equally to successive Corporate Events and shall be applied without regard to any limitations on the conversion or redemption of this Note. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.</B> <B>Remedies, Characterizations, Other Obligations, Breaches and Injunctive Relief</B>. The remedies provided in this Note shall be
cumulative and in addition to all other remedies available under this Note and any of the other Exchange Documents at law or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the
Holder&#146;s right to pursue actual and consequential damages for any failure by the Company to comply with the terms of this Note. The Company covenants to the Holder that there shall be no characterization concerning this instrument other than as
expressly provided herein. Amounts set forth or provided for herein with respect to payments, conversion and the like (and the computation thereof) shall be the amounts to be received by the Holder and shall not, except as expressly provided herein,
be subject to any other obligation of the Company (or the performance thereof). The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder and that the remedy at law for any such breach may be
inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach, the Holder shall be entitled, in addition to all other available remedies, to specific performance and/or temporary, preliminary and permanent
injunctive or other equitable relief from any court of competent jurisdiction in any such case without the necessity of proving actual damages and without posting a bond or other security. The Company shall provide all information and documentation
to the Holder that is requested by the Holder to enable the Holder to confirm the Company&#146;s compliance with the terms and conditions of this Note. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.</B> <B>Severability</B>. If any provision of this Note is prohibited by law or otherwise determined to be invalid or unenforceable by a
court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of
such provision shall not affect the validity of the remaining provisions of this Note so long as this Note as so modified continues to express, without material change, the original intentions of the parties as to the subject matter hereof and the
prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be
conferred upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited,
invalid or unenforceable provision(s). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 11. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.</B> <B>Maximum Payments</B>. Nothing contained herein shall be deemed to establish or
require the payment of a rate of interest or other charges in excess of the maximum permitted by applicable law. In the event that the rate of interest required to be paid or other charges hereunder exceed the maximum permitted by such law, any
payments in excess of such maximum shall be credited against amounts owed by the Company to the Holder and thus refunded to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.</B> <B>Waiver. </B>The Company hereby waives demand, notice, presentment, protest and notice of dishonor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.</B> <B>Governing Law. </B>This Note shall be construed and enforced in accordance with, and all questions concerning the construction,
validity, interpretation and performance of this Note shall be governed by, the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other
jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York. The Company hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The City of New York,
Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding,
any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein shall be
deemed or operate to preclude the Holder from bringing suit or taking other legal action against the Company in any other jurisdiction to collect on the Company&#146;s obligations to the Holder, to realize on any collateral or any other security for
such obligations, or to enforce a judgment or other court ruling in favor of the Holder. THE COMPANY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN
CONNECTION WITH OR ARISING OUT OF THIS NOTE OR ANY TRANSACTION CONTEMPLATED HEREBY. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.</B> <B>Failure </B><B>Or</B><B> Indulgence Not
Waiver</B>. No failure or delay on the part of the Holder in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or
further exercise thereof or of any other right, power or privilege. No waiver shall be effective unless it is in writing and signed by an authorized representative of the waiving party. Notwithstanding the foregoing, nothing contained in this
Section&nbsp;16 shall permit any waiver of any provision of Section&nbsp;3(d). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.</B> <B>Amending the Terms of this Note</B>. The
prior written consent of the Holder shall be required for any change, waiver or amendment to this Note. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 12. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>18.</B> <B>Notices; Currency; Payments</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Notices</B>. Whenever notice is required to be given under this Note, unless otherwise provided herein, such notice shall be
given in accordance with the terms of the Exchange Agreement. The Company shall provide the Holder with prompt written notice of all actions taken pursuant to this Note, including in reasonable detail a description of such action and the reason
therefore. Without limiting the generality of the foregoing, the Company will give written notice to the Holder (i)&nbsp;immediately upon any adjustment of the Conversion Price, setting forth in reasonable detail, and certifying, the calculation of
such adjustment and (ii)&nbsp;at least fifteen (15)&nbsp;days prior to the date on which the Company closes its books or takes a record (A)&nbsp;with respect to any dividend or distribution upon the Common Stock, and (B)&nbsp;for determining rights
to vote with respect to any Fundamental Transaction, dissolution or liquidation, provided in each case that such information shall be made known to the public prior to or in conjunction with such notice being provided to the Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Currency</B>. All dollar amounts referred to in this Note are in United States Dollars (&#147;<B><I>U.S. Dollars</I></B>&#148;),
and all amounts owing under this Note shall be paid in U.S. Dollars. All amounts denominated in other currencies (if any) shall be converted into the U.S.&nbsp;Dollar equivalent amount in accordance with the Exchange Rate on the date of calculation.
&#147;<B><I>Exchange Rate</I></B>&#148;<B> </B>means, in relation to any amount of currency to be converted into U.S. Dollars pursuant to this Note, the U.S.&nbsp;Dollar exchange rate as published in the Wall Street Journal on the relevant date of
calculation (it being understood and agreed that where an amount is calculated with reference to, or over, a period of time, the date of calculation shall be the final date of such period of time). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Payments</B>. Whenever any payment of cash is to be made by the Company to any Person pursuant to this Note, unless otherwise
expressly set forth herein, such payment shall be made in lawful money of the United States of America by a certified check drawn on the account of the Company and sent via overnight courier service to such Person at such address as previously
provided to the Company in writing, provided that the Holder may elect to receive a payment of cash via wire transfer of immediately available funds by providing the Company with prior written notice setting out such request and the Holder&#146;s
wire transfer instructions. Whenever any amount expressed to be due by the terms of this Note is due on any day which is not a Business Day, the same shall instead be due on the next succeeding day which is a Business Day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>19.</B> <B>Waiver of Notice</B>. To the extent permitted by law, the Company hereby irrevocably waives demand, notice, presentment, protest
and all other demands and notices in connection with the delivery, acceptance, performance, default or enforcement of this Note and the Exchange Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>20.</B> <B>Assignment.</B> This Note may be transferred only upon its surrender to the Company for registration of transfer, duly endorsed,
or accompanied by a duly executed written instrument of transfer in form satisfactory to the Company. Thereupon, this Note shall be reissued to, and registered in the name of, the transferee, or a new Note for like Principal amount and Interest
shall be issued to, and registered in the name of, the transferee. Interest and Principal shall be paid solely to the registered holder of this Note. Such payment shall constitute full discharge of the Company&#146;s obligation to pay such Interest
and Principal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 13. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.</B> <U>CERTAIN DEFINITIONS</U>. For purposes of this Note, the following terms shall have
the following meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <I>&#147;</I><B><I>Adjustment Right&#148;</I></B><B> </B>means any right granted with respect to any
securities issued in connection with, or with respect to, any issuance or sale (or deemed issuance or sale) of shares of Common Stock that could result in a decrease in the net consideration received by the Company in connection with, or with
respect to, such securities (including, without limitation, any cash settlement rights, cash adjustment or other similar rights). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> &#147;<B><I>Alternate Conversion Price</I></B>&#148; means, with respect to any Alternate Conversion that price which shall be the
lowest of (i)&nbsp;the applicable Conversion Price as in effect on the applicable Conversion Date of the applicable Alternate Conversion, (ii) 70% of the lowest VWAP of the Common Stock as of the Trading Day during the ten (10)&nbsp;consecutive
Trading Day period ending and including the applicable Alternate Conversion Date (such period, the &#147;<B><I>Alternate Conversion Measuring Period</I></B>&#148;). All such determinations to be appropriately adjusted for any stock dividend, stock
split, stock combination, reclassification or similar transaction that proportionately decreases or increases the Common Stock during such Alternate Conversion Measuring Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> &#147;<B><I>Attribution Parties</I></B>&#148; means, collectively, the following Persons and entities: (i)&nbsp;any investment
vehicle, including, any funds, feeder funds or managed accounts, currently, or from time to time after the date hereof, directly or indirectly managed or advised by the Holder&#146;s investment manager or any of its Affiliates or principals,
(ii)&nbsp;any direct or indirect Affiliates of the Holder or any of the foregoing, (iii)&nbsp;any Person acting or who could be deemed to be acting as a Group together with the Holder or any of the foregoing and (iv)&nbsp;any other Persons whose
beneficial ownership of the Company&#146;s Common Stock would or could be aggregated with the Holder&#146;s and the other Attribution Parties for purposes of Section&nbsp;13(d) of the Exchange Act. For clarity, the purpose of the foregoing is to
subject collectively the Holder and all other Attribution Parties to the Maximum Percentage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>
&#147;<B><I>Bloomberg</I></B>&#148; means Bloomberg, L.P. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> &#147;<B><I>Business Day</I></B>&#148; means any day other than
Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> &#147;<B><I>Closing Bid Price</I></B>&#148; and &#147;<B><I>Closing Sale Price</I></B>&#148; means, for any security as of any
date, the last closing bid price and last closing trade price, respectively, for such security on the Principal Market, as reported by Bloomberg, or, if the Principal Market begins to operate on an extended hours basis and does not designate the
closing bid price or the closing trade price (as the case may be) then the last bid price or last trade price, respectively, of such security prior to 4:00:00 p.m., New York time, as reported by Bloomberg, or, if the Principal Market is not the
principal securities exchange or trading market for such security, the last closing bid price or last trade price, respectively, of such security on the principal securities exchange or trading market where such security is listed or traded as
reported by Bloomberg, or if the foregoing do not apply, the last closing bid price or last trade price, respectively, of such security in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on
the electronic bulletin board for such security as reported by Bloomberg, or, if no closing bid price or last trade price, respectively, is reported for such security by Bloomberg, the average of the bid prices, or the ask prices, respectively, of
any market makers for such security as reported in the &#147;pink sheets&#148; by OTC Markets Group Inc. (formerly Pink Sheets LLC). If the Closing Bid Price or the Closing Sale Price cannot be calculated for a security on a particular date on any
of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 14. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the foregoing bases, the Closing Bid Price or the Closing Sale Price (as the case may be) of such security on such date shall be the fair market value as mutually determined by the Company and
the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then such dispute shall be resolved in accordance with the procedures in Section&nbsp;22. All such determinations shall be appropriately
adjusted for any stock splits, stock dividends, stock combinations, recapitalizations or other similar transactions during such period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> &#147;<B><I>Common Stock</I></B>&#148; means (i)&nbsp;the Company&#146;s shares of common stock, $0.0001 par value per share, and
(ii)&nbsp;any capital stock into which such common stock shall have been changed or any share capital resulting from a reclassification of such common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> &#147;<B><I>Convertible Securities</I></B>&#148; means any stock or other security (other than Options) that is at any time and
under any circumstances, directly or indirectly, convertible into, exercisable or exchangeable for, or which otherwise entitles the holder thereof to acquire, any shares of Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(</B><B>i</B><B>)</B> &#147;<B><I>Eligible Market</I></B>&#148; means The New York Stock Exchange, the NYSE American, the Nasdaq Global
Select Market, the Nasdaq Global Market or the Principal Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> &#147;<B><I>Fundamental Transaction</I></B>&#148; means
(A)&nbsp;that the Company shall, directly or indirectly, including through subsidiaries, Affiliates or otherwise, in one or more related transactions, (i)&nbsp;consolidate or merge with or into (whether or not the Company is the surviving
corporation) another Subject Entity, or (ii)&nbsp;sell, assign, transfer, convey or otherwise dispose of all or substantially all of the properties or assets of the Company or any of its &#147;significant subsidiaries&#148; (as defined in Rule <FONT
STYLE="white-space:nowrap">1-02</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X)</FONT> to one or more Subject Entities, or (iii)&nbsp;make, or allow one or more Subject Entities to make, or allow the Company to be subject to or have its
Common Stock be subject to or party to one or more Subject Entities making, a purchase, tender or exchange offer that is accepted by the holders of at least either (x) 50% of the outstanding shares of Common Stock, (y) 50% of the outstanding shares
of Common Stock calculated as if any shares of Common Stock held by all Subject Entities making or party to, or Affiliated with any Subject Entities making or party to, such purchase, tender or exchange offer were not outstanding; or (z)&nbsp;such
number of shares of Common Stock such that all Subject Entities making or party to, or Affiliated with any Subject Entity making or party to, such purchase, tender or exchange offer, become collectively the beneficial owners (as defined in Rule <FONT
STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) of at least 50% of the outstanding shares of Common Stock, or (iv)&nbsp;consummate a stock or share purchase agreement or other business combination (including, without limitation, a
reorganization, recapitalization, <FONT STYLE="white-space:nowrap">spin-off</FONT> or scheme of arrangement) with one or more Subject Entities whereby all such Subject Entities, individually or in the aggregate, acquire, either (x)&nbsp;at least 50%
of the outstanding shares of Common Stock, (y)&nbsp;at least 50% of the outstanding shares of Common Stock calculated as if any shares of Common Stock held by all the Subject Entities making or party to, or Affiliated with any Subject Entity making
or party to, such stock purchase agreement or other business combination were not outstanding; or (z)&nbsp;such number of shares of Common Stock such that the Subject Entities become collectively the beneficial owners (as defined in Rule <FONT
STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) of at least 50% of the outstanding shares of Common Stock, or (v)&nbsp;reorganize, recapitalize or reclassify its Common Stock, (B)&nbsp;that the Company shall, directly or indirectly,
including through subsidiaries, Affiliates or otherwise, in one or more related transactions, allow any Subject Entity individually or the Subject Entities in the aggregate to be or become the &#147;beneficial owner&#148; (as
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 15. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act), directly or indirectly, whether through acquisition, purchase, assignment, conveyance, tender, tender offer,
exchange, reduction in outstanding shares of Common Stock, merger, consolidation, business combination, reorganization, recapitalization, <FONT STYLE="white-space:nowrap">spin-off,</FONT> scheme of arrangement, reorganization, recapitalization or
reclassification or otherwise in any manner whatsoever, of either (x)&nbsp;at least 50% of the aggregate ordinary voting power represented by issued and outstanding Common Stock, (y)&nbsp;at least 50% of the aggregate ordinary voting power
represented by issued and outstanding Common Stock not held by all such Subject Entities as of the date of this Note calculated as if any shares of Common Stock held by all such Subject Entities were not outstanding, or (z)&nbsp;a percentage of the
aggregate ordinary voting power represented by issued and outstanding shares of Common Stock or other equity securities of the Company sufficient to allow such Subject Entities to effect a statutory short form merger or other transaction requiring
other shareholders of the Company to surrender their shares of Common Stock without approval of the shareholders of the Company or (C)&nbsp;directly or indirectly, including through subsidiaries, Affiliates or otherwise, in one or more related
transactions, the issuance of or the entering into any other instrument or transaction structured in a manner to circumvent, or that circumvents, the intent of this definition in which case this definition shall be construed and implemented in a
manner otherwise than in strict conformity with the terms of this definition to the extent necessary to correct this definition or any portion of this definition which may be defective or inconsistent with the intended treatment of such instrument
or transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> &#147;<B><I>Group</I></B>&#148; means a &#147;group&#148; as that term is used in Section&nbsp;13(d) of the
Exchange Act and as defined in Rule <FONT STYLE="white-space:nowrap">13d-5</FONT> thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(l)</B>
&#147;<B><I>Options</I></B>&#148; means any rights, warrants or options to subscribe for or purchase shares of Common Stock or Convertible Securities issued to Persons other than the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> &#147;<B><I>Parent Entity</I></B>&#148; of a Person means an entity that, directly or indirectly, controls the applicable Person
and whose common stock or equivalent equity security is quoted or listed on an Eligible Market, or, if there is more than one such Person or Parent Entity, the Person or Parent Entity with the largest public market capitalization as of the date of
consummation of the Fundamental Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> &#147;<B><I>Principal Market</I></B>&#148; means the Nasdaq Capital Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> <B>&#147;</B><B><I>Subject Entity</I></B>&#148; means any Person, Persons or Group or any Affiliate or associate of any such
Person, Persons or Group. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(p)</B> &#147;<B><I>Successor Entity</I></B>&#148; means the Person (or, if so elected by the Holder, the
Parent Entity) formed by, resulting from or surviving any Fundamental Transaction or the Person (or, if so elected by the Holder, the Parent Entity) with which such Fundamental Transaction shall have been entered into. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(q)</B> &#147;<B><I>Trading Day</I></B>&#148; means, as applicable, (x)&nbsp;with respect to all price or trading volume determinations
relating to the Common Stock, any day on which the Common Stock is traded on the Principal Market, or, if the Principal Market is not the principal trading market for the Common Stock, then on the principal securities exchange or securities market
on which the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 16. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Common Stock is then traded, provided that &#147;Trading Day&#148; shall not include any day on which the Common Stock is scheduled to trade on such exchange or market for less than 4.5 hours or
any day that the Common Stock is suspended from trading during the final hour of trading on such exchange or market (or if such exchange or market does not designate in advance the closing time of trading on such exchange or market, then during the
hour ending at 4:00:00 p.m., New York time) unless such day is otherwise designated as a Trading Day in writing by the Holder or (y)&nbsp;with respect to all determinations other than price determinations relating to the Common Stock, any day on
which The New York Stock Exchange (or any successor thereto) is open for trading of securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(r)</B> &#147;<B><I>VWAP</I></B>&#148;
means, for any security as of any date, the dollar volume-weighted average price for such security on the Principal Market (or, if the Principal Market is not the principal trading market for such security, then on the principal securities exchange
or securities market on which such security is then traded) during the period beginning at 9:30:01 a.m., New York time, and ending at 4:00:00 p.m., New York time, as reported by Bloomberg through its &#147;HP&#148; function (set to weighted average)
or, if the foregoing does not apply, the dollar volume-weighted average price of such security in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the electronic bulletin board for such
security during the period beginning at 9:30:01 a.m., New York time, and ending at 4:00:00 p.m., New York time, as reported by Bloomberg, or, if no dollar volume-weighted average price is reported for such security by Bloomberg for such hours, the
average of the highest closing bid price and the lowest closing ask price of any of the market makers for such security as reported in the &#147;pink sheets&#148; by OTC Markets Group Inc. (formerly Pink Sheets LLC). If the VWAP cannot be calculated
for such security on such date on any of the foregoing bases, the VWAP of such security on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair
market value of such security, then such dispute shall be resolved in accordance with the procedures in Section&nbsp;22. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination, recapitalization
or other similar transaction during such period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>22.</B> <B>Disclosure</B>. Upon receipt or delivery by the Company of any notice in
accordance with the terms of this Note, unless the Company has in good faith determined that the matters relating to such notice do not constitute material, <FONT STYLE="white-space:nowrap">non-public</FONT> information relating to the Company or
any of its Subsidiaries, the Company shall within the later of (a)&nbsp;the Cleansing Deadline and (b)&nbsp;one (1) Business Day after any such receipt or delivery, publicly disclose such material, <FONT STYLE="white-space:nowrap">non-public</FONT>
information on a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or otherwise. In the event that the Company believes that a notice contains material, <FONT STYLE="white-space:nowrap">non-public</FONT> information relating to the
Company or any of its Subsidiaries, the Company so shall indicate to the Holder contemporaneously with delivery of such notice, and in the absence of any such indication, the Holder shall be allowed to presume that all matters relating to such
notice do not constitute material, <FONT STYLE="white-space:nowrap">non-public</FONT> information relating to the Company or any of its Subsidiaries. If the Company or any of its Subsidiaries provides material
<FONT STYLE="white-space:nowrap">non-public</FONT> information to the Holder after the Cleansing Deadline that is not simultaneously filed in a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and the Holder has not agreed to
receive such material <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company hereby covenants and agrees that the Holder shall not have any duty of confidentiality to the Company, any of its Subsidiaries or any of their
respective officers, directors, employees, affiliates or agents with respect to, or a duty to any of the foregoing not to trade on the basis of, such material non-public information. Nothing contained in this Section&nbsp;22 shall limit any
obligations of the Company, or any rights of the Holder, under the Exchange Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[signature page follows] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 17. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[S<SMALL>IGNATURE</SMALL> <SMALL>PAGE</SMALL> <SMALL>TO</SMALL> C<SMALL>ONVERTIBLE</SMALL>
P<SMALL>ROMISSORY</SMALL> N<SMALL>OTE</SMALL> <SMALL>OF</SMALL> SELLAS L<SMALL>IFE</SMALL> S<SMALL>CIENCES</SMALL> G<SMALL>ROUP</SMALL>, I<SMALL>NC</SMALL>.] </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SELLAS LIFE SCIENCES GROUP, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Angelos Stergiou</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Angelos Stergiou, M.D., ScD h.c.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Holder:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Principal Amount of Note:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date of Note:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.81
<SEQUENCE>15
<FILENAME>d556278dex1081.htm
<DESCRIPTION>EX-10.81
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.81</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.81 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>CONFIDENTIAL DRAFT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT EXCHANGE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Warrant Exchange Agreement (this &#147;<U>Agreement</U>&#148;) is made as of February&nbsp;14, 2018 (&#147;Effective Date&#148;), by and
between SELLAS Life Sciences Group, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), and LINCOLN PARK CAPITAL FUND LLC. (collectively, the &#147;<U>Holder</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the
Holder currently holds 8,333 warrants (the &#147;<U>Warrants</U>&#148;) to purchase shares of the Company&#146;s common stock, par value $0.0001 per share (&#147;<U>Common Stock</U>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, subject to the terms and conditions set forth herein, the Company and the Holder desire to cancel and retire the Warrants in exchange
(the &#147;<U>Exchange</U>&#148;) for shares of Common Stock (the &#147;<U>Exchange Shares</U>&#148;), the number of which is the quotient of $19,500.00 divided by the closing price of the Exchange Shares on the NASDAQ Capital Market on the trading
day preceding the Closing Date of the Exchange Shares in reliance on the exemption from registration provided by Section&nbsp;3(a)(9) of the Securities Act of 1933, as amended (the &#147;<U>Securities Act</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt of which is
hereby acknowledged, the Company and the Holder hereby agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 1. EXCHANGE AND TERMINATION. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a)
In consideration of and in express reliance upon the representations, warranties, covenants, terms and conditions of this Agreement, the Holder agrees to deliver and surrender to the Company for cancellation the Warrants in exchange for the Exchange
Shares, and the Company agrees to issue and deliver the Exchange Shares to the Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) The closing under this Agreement (the
&#147;<U>Closing</U>&#148;) shall take place upon the satisfaction of each of the conditions set forth in Sections 4 and 5 hereof (the &#147;<U>Closing Date</U>&#148;). By February&nbsp;16, 2018, (i) the Company shall cause the transfer agent for
the Common Stock to issue and deliver the Exchange Shares duly registered and freely tradable through the facilities of DTC by DWAC to the custodian and account provided to the Company in writing by the Holder and (ii)&nbsp;the Holder shall deliver
and surrender or cause to be delivered and surrendered to the Company for cancellation the Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) If the Closing has not occurred
by February&nbsp;16, 2018, this Agreement shall terminate. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 2. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby represents and warrants as of the date hereof to, and covenants with, the Holder as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <B>Organization and Standing.</B> The Company has been duly incorporated and is validly existing as a corporation in good standing under the
laws of Delaware, has full corporate power and authority to own or lease its properties and conduct its business as presently conducted, and is duly qualified as a foreign corporation and in good standing in each jurisdiction in which the character
of the property owned or leased or the nature of the business transacted by it makes qualification necessary, except where the failure to be so qualified would not have a material adverse effect on the business, properties, financial condition or
results or operations of the Company (a &#147;<U>Material Adverse Effect</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <B>Authorization; Corporate Power.</B> This
Agreement has been duly authorized, validly executed and delivered on behalf of the Company and is a valid and binding obligation of the Company enforceable against the Company in accordance with its terms (except as limited by (i)&nbsp;applicable
bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or affecting the enforcement of creditors&#146; rights generally, and (ii)&nbsp;equitable principles generally, including any specific performance), and the Company has
the requisite corporate power and authority to execute and deliver this Agreement and the other agreements and documents contemplated hereby and to perform its obligations hereunder and thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <B>Issuance and Delivery of the Exchange Shares.</B> The Exchange Shares have been duly authorized and, will be validly issued, fully paid
and nonassessable. Assuming the Warrants were purchased by Holder in the Company&#146;s offering of Common Stock and warrants made pursuant to the Company&#146;s prospectus filed with the Securities and Exchange Commission (the
&#147;<U>SEC</U>&#148;) pursuant to Rule 424(b)(5) on February&nbsp;9, 2017 (the &#147;<U>Registered Offering</U>&#148;) and the Holder is not an &#147;<U>Affiliate</U>&#148; (as such term is defined in Rule 405 promulgated under the Securities Act
of 1933, as amended (the &#147;<U>Securities Act</U>&#148;)) of the Company, the Exchange Shares will be issued to the Holder without legend and will be freely tradable by the Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <B>Governmental Consents. </B>No consent, approval or authorization of or designation, declaration or filing with any governmental
authority on the part of the Company is required in connection with the valid execution and delivery of this Agreement or the offer, sale or issuance of the Exchange Shares or the consummation of any other transaction contemplated by this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <B>No Default or Violation</B>. The execution and delivery of the Agreement and the consummation of the transactions contemplated by
this Agreement by the Company will not (i)&nbsp;result in a breach of or a default under any of the terms or provisions of (A)&nbsp;the Company&#146;s certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws,</FONT> or (B)&nbsp;any
material provision of any indenture, mortgage, deed of trust or other material agreement or instrument to which the Company is a party or by which it or any of its material properties or assets is bound or (ii)&nbsp;result in a violation of any
provision of any law, statute, rule, regulation, or any existing applicable decree, judgment or order by any court, Federal or state regulatory body, administrative agency, or other governmental body having jurisdiction over the Company, or any of
its material properties or assets except in the case of clauses (i)(B) or (ii)&nbsp;for any such breaches, defaults or violations which would not have a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) <B>Disclosure of Agreement.</B> The Company shall, on or before 8:30 a.m., New York City time,
on February&nbsp;20, 2018 issue a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> disclosing all material terms of the transactions contemplated hereby (such Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> the <FONT
STYLE="white-space:nowrap">&#147;8-K</FONT> Filing&#148;). From and after the filing of the <FONT STYLE="white-space:nowrap">8-K</FONT> Filing, the Holder shall not be in possession of any material, nonpublic information received from the Company or
any of its subsidiaries or any of their respective officers, directors, employees, affiliates or agents, that is not disclosed in the <FONT STYLE="white-space:nowrap">8-K</FONT> Filing. The Company shall not, and shall cause its officers, directors,
employees, affiliates and agents, not to, provide the Holder with any material, nonpublic information regarding the Company from and after the filing of the <FONT STYLE="white-space:nowrap">8-K</FONT> Filing without the express written consent of
the Holder. To the extent that the Company delivers any material, <FONT STYLE="white-space:nowrap">non-public</FONT> information to the Holder without the Holder&#146;s express prior written consent, the Company hereby covenants and agrees that the
Holder shall not have any duty of confidentiality to the Company, any of its subsidiaries or any of their respective officers, directors, employees, affiliates or agents with respect to, or a duty to the Company, any of its subsidiaries or any of
their respective officers, directors, employees, affiliates or agents not to trade on the basis of, such material, <FONT STYLE="white-space:nowrap">non-public</FONT> information. The Company shall not disclose the name of the Holder in any filing,
announcement, release or otherwise, unless such disclosure is required by law or regulation. In addition, effective upon the filing of the <FONT STYLE="white-space:nowrap">8-K</FONT> Filing, the Company acknowledges and agrees that any and all
confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its subsidiaries or any of their respective officers, directors, affiliates, employees or agents, on the one hand, and the Holder or any
of its affiliates, on the other hand, shall terminate and be of no further force or effect. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 3. REPRESENTATIONS, WARRANTIES AND COVENANTS OF
THE HOLDER. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) The Holder represents and warrants to and covenants with the Company that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <B>Valid Existence; Good Standing</B>. To the extent the Holder is a corporation, limited liability company or other type of entity, the
Holder is validly existing and in good standing under the laws of the jurisdiction of its organization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <B>Authority;
Authorization</B>. The Holder has full right, power, authority and capacity to enter into this Agreement and the other agreements and documents contemplated hereby and to perform its obligations hereunder and thereunder and has taken all necessary
action to authorize the execution, delivery and performance of this Agreement. Upon the execution and delivery of this Agreement by the Holder, this Agreement shall constitute a valid and binding obligation of the Holder, enforceable in accordance
with its terms (except (i)&nbsp;as limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or affecting the enforcement of creditors&#146; rights generally, and (ii)&nbsp;as limited by equitable
principles generally, including any specific performance). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <B>Title</B>. The Holder owns and holds the entire right, title and interest in and to, and
is the record and beneficial owner of, the Warrants and the Holder owns the Warrants free and clear of all Encumbrances (as defined below). The Holder has the full power and authority to vote, transfer and dispose of the Warrants free and clear of
any right or Encumbrances. There is no restriction affecting the ability of the Holder to transfer the legal and beneficial title and ownership of the Warrants to the Company and, at the Closing, the Company will acquire legal and valid title to the
Warrants, free and clear of all Encumbrances. Other than the transactions contemplated by this Agreement, there is no outstanding vote, plan, pending proposal, or other right of any person to acquire all or any of the Warrants.
&#147;Encumbrances&#148; shall mean any security or other property interest or right, claim, lien, pledge, option, charge, security interest, contingent or conditional sale, or other title claim or retention agreement, interest or other right or
claim of third parties, whether perfected or not perfected, voluntarily incurred or arising by operation of law, and including any agreement (other than this Agreement) to grant or submit to any of the foregoing in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <B>Purchase of Warrants in the Registered Offering. </B>The Holder purchased the Warrants in the Registered Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <B>Securities Act Exemption</B>. Neither the Holder nor anyone acting on behalf of the Holder has received any commission or remuneration
directly or indirectly in connection with or in order to solicit or facilitate the Exchange. The Holder understands that the Exchange contemplated hereby is intended to be exempt from registration by virtue of Section&nbsp;3(a)(9) of the Securities
Act. The Holder understands that the Company is relying upon the truth and accuracy of the representations, warranties, agreements, acknowledgments and understandings of the Holder set forth herein for purposes of qualifying for the exemption under
Section&nbsp;3(a)(9) of the Securities Act as well as qualifying for exemptions under applicable state securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) <B><FONT
STYLE="white-space:nowrap">Non-Affiliate</FONT></B>. The Holder is not an Affiliate of the Company and has not been an Affiliate during the three months prior to the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) <B>Information</B>. The Holder has, in connection with its decision to acquire the Exchange Shares, relied with respect to the Company and
its affairs solely upon the Company&#146;s filings with the SEC and the representations and warranties of the Company contained herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) <B>Advisors</B>. The Holder understands that nothing in this Agreement or any other materials presented to the Holder in connection with
the exchange of the Warrants and issuance and acquisition of the Exchange Shares constitutes legal, tax or investment advice. The Holder has consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed necessary or
appropriate in connection with its acquisition of the Exchange Shares. With respect to such matters, the Holder relies solely on such advisors and not on any statements or representations of the Company or any of its agents, written or oral. The
Holder understands that it (and not the Company) shall be responsible for its own tax liability that may arise as a result of this investment or the transactions contemplated by this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) <B>Limitation on Resales</B>. For thirty (30)&nbsp;trading days following the Closing Date,
the Holder shall not sell more than 2.0% of trading volume of Common Stock as reported by Bloomberg, LP for the applicable date of determination through open market sales through the NASDAQ Capital Market on any trading day in which the NASDAQ
Capital Market is open for trading. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 4. CONDITIONS TO COMPANY&#146;S OBLIGATIONS AT THE CLOSING. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s obligation to complete the issuance of the Exchange Shares and deliver the Exchange Shares to the Holder at the Closing
shall be subject to the following conditions to the extent not waived by the Company: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <B>Execution and Delivery</B>. The Holder shall
have executed and delivered this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <B>Covenants</B>. The Holder shall have performed, satisfied and complied in all material
respects with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Holder at or prior to the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <B>Surrender of Warrants.</B> The Company shall have received in physical form or through book-entry transfer from the Holder all
certificates or book-entry notation representing the Warrants to be exchanged for the Exchange Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <B>Representations and
Warranties. </B>The representations and warranties of the Holder shall be true and correct in all material respects as of the date when made and as of the Closing Date as though made at that time, except for representations and warranties that are
expressly made as of a particular date, which shall be true and correct in all material respects as of such date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 5. CONDITIONS TO THE
HOLDER&#146;S OBLIGATIONS AT THE CLOSING. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Holder&#146;s obligation to deliver the Warrants and accept delivery of the Exchange
Shares shall be subject to the following conditions to the extent not waived by the Holder: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)<B>&nbsp;Execution and Delivery</B>. The
Company shall have executed and delivered this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)<B>&nbsp;Covenants</B>. The Company shall have performed, satisfied and
complied in all material respects with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <B>Delivery of Exchange Shares.</B> The Company shall have delivered the Exchange Shares in accordance with the instructions provided
pursuant to Section&nbsp;1.b) hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e)<B>&nbsp;Representations and Warranties.</B> Each of the representations and warranties of the
Company shall be true and correct in all material respects as of the date when made and as of the Closing Date as though made at that time, except for representations and warranties that are expressly made as of a particular date, which shall be
true and correct in all material respects as of such date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 6. NOTICES. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All notices, requests, consents and other communications hereunder shall be in writing, shall be sent by confirmed electronic mail, or mailed
by first-class registered or certified airmail, or nationally recognized overnight express courier, postage prepaid, and shall be deemed given when so sent in the case of electronic mail transmission, or when so received in the case of mail or
courier, and addressed as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) if to the Company, to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">SELLAS Life Sciences Group, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">315 Madison, 4<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Flr. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York, New York 10017 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Angelos Stergiou, M.D., ScD h.c. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-Mail:</FONT> astergiou@sellaslife.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">or to such other person at such other place as the Company shall designate to the Holder in writing; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) if to the Holder, at the address as set forth at the end of this Agreement, or at such other address as may have been furnished by the
Holder to the Company in writing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 7. MISCELLANEOUS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <B>Headings.</B> The headings of the various sections of this Agreement have been inserted for convenience of reference only and shall not
be deemed to be part of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <B>Severability.</B> In case any provision contained in this Agreement should be invalid,
illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <B>Governing Law.</B> This Agreement shall be governed by and construed under the laws of the State of New York without regard to the
choice of law principles thereof. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the State of New York located in The City of New York, Borough of Manhattan for the adjudication of any
dispute hereunder or in connection herewith or with any transaction contemplated hereby or thereby, and hereby irrevocably waives any objection that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit,
action or proceeding is improper. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY
TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <B>Counterparts.</B> This Agreement may be executed in two or more counterparts, each of which
shall constitute an original, but all of which, when taken together, shall constitute but one instrument, and shall become effective when one or more counterparts have been signed by each party hereto and delivered to the other parties. In the event
that any signature is delivered by facsimile transmission or by an <FONT STYLE="white-space:nowrap">e-mail</FONT> which contains an electronic file of an executed signature page, such signature page shall create a valid and binding obligation of the
party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or electronic file signature page (as the case may be) were an original thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <B>Successors and Assigns.</B> Except as otherwise expressly provided herein, the provisions hereof shall inure to the benefit of, and be
binding upon, the successors, permitted assigns, heirs, executors and administrators of the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) <B>Entire Agreement;
Amendments.</B> This Agreement and other documents delivered pursuant hereto constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and thereof. This Agreement may be amended, modified,
superseded, cancelled, renewed or extended, and the terms and conditions hereof may be waived, only by a written instrument signed by all parties, or, in the case of a waiver, by the party waiving compliance. Except as expressly stated herein, no
delay on the part of any party in exercising any right, power or privilege hereunder shall operate as a waiver thereof, nor shall any waiver on the part of any party of any right, power or privilege hereunder preclude any other or future exercise of
any other right, power or privilege hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">g) <B>Survival. </B>The representations, warranties, covenants and agreements made in this
Agreement shall survive the closing of the transactions contemplated hereby and the exchange and delivery of the Warrants and the Exchange Shares. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[signature pages follow] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have caused this Agreement to be executed by their
duly authorized representatives as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SELLAS LIFE SCIENCES GROUP, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Angelos Stergiou</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Angelos Stergiou, M.D., ScD h.c.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">COMPANY SIGNATURE PAGE TO </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">WARRANT EXCHANGE AGREEMENT </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>HOLDER: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LINCOLN PARK CAPITAL LLC.</B></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Name:</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Title:</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Address:</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt"><FONT STYLE="white-space:nowrap">E-Mail:</FONT></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">DWAC INSTRUCTIONS</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Broker&nbsp;Name&nbsp;and&nbsp;DTC&nbsp;Number:<U></U></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Account Number at DTC Participant</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="69%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(if&nbsp;applicable):<U></U>&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">HOLDER SIGNATURE PAGE TO </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">WARRANT EXCHANGE AGREEMENT </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.82
<SEQUENCE>16
<FILENAME>d556278dex1082.htm
<DESCRIPTION>EX-10.82
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.82</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.82 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS
LIFE SCIENCES GROUP, INC. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT EXCHANGE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Warrant Exchange Agreement (this &#147;<U>Agreement</U>&#148;) is made as of February&nbsp;21, 2018 (&#147;<U>Effective Date</U>&#148;),
by and between SELLAS Life Sciences Group, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), and EMPERY ASSET MASTER, LTD. ( collectively, the &#147;<U>Holder</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the
Holder currently holds 346,287 warrants (the &#147;<U>Warrants</U>&#148;) to purchase 11,543 shares of the Company&#146;s common stock, par value $0.0001 per share (&#147;<U>Common Stock</U>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, subject to the terms and conditions set forth herein, the Company and the Holder desire to cancel and retire the Warrants in exchange
(the &#147;<U>Exchange</U>&#148;) for a convertible promissory note (the &#147;<U>Exchange Note</U>&#148;), in the amount of $27,010.62 on such other terms as set forth in the form of Exchange Note attached as Exhibit A, in reliance on the exemption
from registration provided by Section&nbsp;3(a)(9) of the Securities Act of 1933, as amended (the &#147;<U>Securities Act</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt of which is hereby acknowledged, the Company and the Holder hereby agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 1. EXCHANGE AND
TERMINATION. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) In consideration of and in express reliance upon the representations, warranties, covenants, terms and conditions of
this Agreement, the Holder agrees to deliver and surrender to the Company for cancellation the Warrants in exchange for the Exchange Note, and the Company agrees to execute and deliver the Exchange Note to the Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) The closing under this Agreement (the &#147;<U>Closing</U>&#148;) shall take place upon the satisfaction of each of the conditions set
forth in Sections 4 and 5 hereof (the &#147;<U>Closing Date</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) If the Closing has not occurred by the second trading day
after the date hereof, this Agreement shall terminate. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 2. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby represents and warrants as of the date hereof to, and covenants with, the Holder as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <B>Organization and Standing.</B> The Company has been duly incorporated and is validly existing as a corporation in good standing under the
laws of Delaware, has full corporate power and authority to own or lease its properties and conduct its business as presently conducted, and is duly qualified as a foreign corporation and in good standing in each jurisdiction in which the character
of the property owned or leased or the nature of the business transacted by it makes qualification necessary, except where the failure to be so qualified would not have a Material Adverse Effect (as defined below). As used in this Agreement,
&#147;<U>Material Adverse Effect</U>&#148; means any material adverse effect on the business, properties, assets, liabilities, operations, results of operations, condition (financial or otherwise) or prospects of the Company and its subsidiaries
(the &#147;<U>Subsidiaries</U>&#148;), if any, individually or taken as a whole, or on the transactions contemplated hereby or on the Exchange Documents (as defined below) or by the agreements and instruments to be entered into (or entered into) in
connection herewith or therewith, or on the authority or ability of the Company to perform its obligations under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b)
<B>Authorization; Corporate Power.</B> This Agreement has been duly authorized, validly executed and delivered on behalf of the Company and is a valid and binding obligation of the Company enforceable against the Company in accordance with its terms
(except as limited by (i)&nbsp;applicable bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or affecting the enforcement of creditors&#146; rights generally, and (ii)&nbsp;equitable principles generally, including any
specific performance), and the Company has the requisite corporate power and authority to execute and deliver this Agreement and the other agreements and documents contemplated hereby and to perform its obligations hereunder and thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <B>Valid Issuance and Delivery of New Securities.</B> The issuance of the Exchange Note is duly authorized and, upon issuance in accordance
with the terms of this Agreement, the shares of Common Stock issuable upon conversion or otherwise pursuant to the terms of the Exchange Note (collectively, the &#147;<U>Conversion Shares</U>&#148;, and together with the Exchange Note, the
&#147;<U>New Securities</U>&#148;) shall be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and free from all preemptive or similar rights, mortgages, defects, claims, liens, pledges, charges, taxes, rights of
first refusal, encumbrances, security interests and other encumbrances (collectively &#147;<U>Liens</U>&#148;) with respect to the issuance thereof. As of the date hereof, the Company has reserved from its duly authorized capital stock not less than
150% of the maximum number of Conversion Shares issuable upon conversion of the Exchange Note (assuming for purposes hereof that (x)&nbsp;the Exchange Note is convertible at the Alternate Conversion Price (as defined in the Exchange Note) assuming a
date of conversion as of the date hereof, (y)&nbsp;interest on the Exchange Note shall accrue through the Maturity Date (as defined in the Exchange Note) and will be converted in shares of Common Stock (as defined below) at a conversion price equal
to the Alternate Conversion Price assuming a date of conversion as of the date hereof and (z)&nbsp;any such conversion shall not take into account any limitations on the conversion of the Exchange Note set forth in the Exchange Note). Upon issuance
or conversion in accordance with the Exchange Note the Conversion Shares when issued, will be validly issued, fully paid and nonassessable and free from all preemptive or similar rights or Liens with respect to the issue thereof, with the holders
being entitled to all rights accorded to a holder of Common Stock. The offer and issuance by the Company of the New Securities is exempt from registration under the Securities Act. Each of the New Securities will be freely tradable and shall not be
required to bear, and shall not bear, any Securities Act or other restrictive legend. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <B>Consents. </B>No consent, waiver, approval or authorization of or designation, declaration
or filing with any Person (as defined below) on the part of the Company is required in connection with the valid execution and delivery of this Agreement or the offer, sale or issuance of the New Securities or the consummation of any other
transaction contemplated by this Agreement. For purposes of this Agreement, (i) &#147;Person&#148; means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other
entity and any Governmental Entity or any department or agency thereof; and (ii) &#147;<U>Governmental Entity</U>&#148; means any nation, state, county, city, town, village, district, or other political jurisdiction of any nature, federal, state,
local, municipal, foreign, or other government, governmental or quasi-governmental authority of any nature (including any governmental agency, branch, department, official, or entity and any court or other tribunal), multi-national organization or
body; or body exercising, or entitled to exercise, any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power of any nature or instrumentality of any of the foregoing, including any entity or enterprise
owned or controlled by a government or a public international organization or any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <B>No Default or Violation</B>.
The execution and delivery of the Agreement and the consummation of the transactions contemplated by this Agreement by the Company will not (i)&nbsp;result in a breach of or a default under any of the terms or provisions of (A)&nbsp;the
Company&#146;s certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws,</FONT> or (B)&nbsp;any material provision of any indenture, mortgage, deed of trust or other material agreement or instrument to which the Company is a party or
by which it or any of its material properties or assets is bound or (ii)&nbsp;result in a violation of any provision of any law, statute, rule, regulation, or any existing applicable decree, judgment or order by any court, Federal or state
regulatory body, administrative agency, or other governmental body having jurisdiction over the Company, or any of its material properties or assets except in the case of clauses (i)(B) or (ii)&nbsp;for any such breaches, defaults or violations
which would not have a Material Adverse Effect. The Company has not violated any law or any governmental regulation or requirement which violation has had or would reasonably be expected to have a Material Adverse Effect, and the Company has not
received written notice of any such violation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) <B>Offering</B>. Neither the Company, nor any of its affiliates, nor any Person acting
on its or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D) in connection with the offer or sale of the New Securities. The Company shall be responsible for the payment of any
placement agent&#146;s fees, financial advisory fees, or brokers&#146; commissions (other than for persons engaged by the Holder or its investment advisor) relating to or arising out of the transactions contemplated hereby. The Company shall pay,
and hold the Holder harmless against, any liability, loss or expense (including, without limitation, attorney&#146;s fees and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses) arising in
connection with any such claim. Neither the Company nor any of its Subsidiaries has engaged any placement agent or other agent in connection with the Exchange and the issuance of the New Securities. The offer, exchange and issuance, as applicable,
of the New Securities as contemplated by this Agreement are exempt from the registration requirements of the Securities Act and the qualification or registration requirements of state securities laws or other applicable blue sky laws. Neither the
Company nor any authorized agent acting on its behalf will take any action hereafter that would cause the loss of such exemptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">g)
<B>Absence of Litigation</B>. Except as set forth in the reports, schedules, forms, statements and other documents required to be filed by the Company with the Securities and Exchange Commission (the &#147;<U>SEC</U>&#148;) pursuant to the reporting
requirements of the Securities Exchange Act of 1934, as amended (the &#147;<U>Exchange Act</U>&#148;), there is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory
organization or body pending or, to the knowledge of the Company, threatened against or affecting the Company, the Common Stock, any securities of the Company or any of the Company&#146;s officers or directors in their capacities as such. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">h) <B>No Group</B>. The Company acknowledges that, to the Company&#146;s knowledge, the Holder is
acting independently in connection with this Agreement and the transactions contemplated hereby, and is not acting as part of a &#147;group&#148; as such term is defined under Section&nbsp;13(d) of the Securities Act and the rules and regulations
promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">i) <B>Validity; Enforcement</B>. This Agreement and each other Exchange Document to which the Company is a party
have been duly and validly authorized, executed and delivered on behalf of the Company and shall constitute the legal, valid and binding obligations of the Company enforceable against the Company in accordance with their respective terms, except as
such enforceability may be limited by general principles of equity or to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable
creditors&#146; rights and remedies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">j) [Intentionally Omitted.] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">k) <B>Disclosure of Agreement.</B> On or before 8:30 a.m., New York City time, on March&nbsp;15, 2018 (the &#147;<U>Cleansing
Deadline</U>&#148;), the Company shall have publicly, whether through one or more press releases or Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC, all material terms of the transactions contemplated hereby
and any other material, nonpublic information provided to the Holder from the Company or any of its Subsidiaries or any of their respective officers, directors, employees, affiliates or agents, including by attaching the form of this Agreement as an
exhibit to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC prior to the Cleansing Deadline. From and after the Cleansing Deadline, the Holder shall not be in possession of any material, nonpublic information
received from the Company or any of its Subsidiaries or any of their respective officers, directors, employees, affiliates or agents, that has not been publicly disclosed. The Company shall not, and shall cause its officers, directors, employees,
affiliates and agents, not to, provide the Holder with any material, nonpublic information regarding the Company from and after the Cleansing Deadline without the express written consent of the Holder. To the extent that the Company delivers any
material, <FONT STYLE="white-space:nowrap">non-public</FONT> information to the Holder after the Cleansing Deadline without the Holder&#146;s express prior written consent, the Company hereby covenants and agrees that the Holder shall not have any
duty of confidentiality to the Company, any of its Subsidiaries or any of their respective officers, directors, employees, affiliates or agents with respect to, or a duty to the Company, any of its Subsidiaries or any of their respective officers,
directors, employees, affiliates or agents not to trade on the basis of, such material, <FONT STYLE="white-space:nowrap">non-public</FONT> information. The Company shall not disclose the name of the Holder in any filing, announcement, release or
otherwise, unless such disclosure is required by law or regulation. In addition, effective upon the Cleansing Deadline, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written
or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, affiliates, employees or agents, on the one hand, and the Holder or any of its affiliates, on the other hand, shall terminate and be of no further
force or effect. The Company understands and confirms that the Holder will rely on the foregoing representations in effecting transactions in securities of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">l) <B>Blue Sky</B>. The Company shall make all filings and reports relating to each Exchange
required under applicable securities or &#147;Blue Sky&#148; laws of the states of the United States following the date hereof, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">m) <B>No Integration</B>. None of the Company, its Subsidiaries, any of their affiliates, or any Person acting on their behalf shall, directly
or indirectly, make any offers or sales of any security (as defined in the Securities Act) or solicit any offers to buy any security or take any other actions, under circumstances that would require registration of any of the New Securities under
the Securities Act or cause this offering of the New Securities to be integrated with such offering or any prior offerings by the Company for purposes of Regulation D under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">n) <B>Listing</B>. The Company shall promptly secure the listing or designation for quotation (as applicable) of all of the Conversion Shares
upon the Nasdaq Capital Market (subject to official notice of issuance) and shall maintain such listing of all the Conversion Shares from time to time issuable under the terms of the Exchange Documents. The Company shall maintain the Common
Stock&#146;s authorization for quotation on the Nasdaq Capital Market. Neither the Company nor any of its Subsidiaries shall take any action which would be reasonably expected to result in the delisting or suspension of the Common Stock from the
Nasdaq Capital Market. The Company shall pay all fees and expenses in connection with satisfying its obligations under this Section&nbsp;2(n). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">o) <B>Holding Period</B>. The Company acknowledges that the Exchange Note will take on the registered characteristics of the Warrants. The
Company further acknowledges that Exchange Note, and upon conversion thereof, the Conversion Shares, will not bear any restrictive legends and will be freely tradable. The Company shall be responsible for any transfer agent fees or Depository Trust
Company fees or legal fees of the Company&#146;s counsel with respect to the issuance of New Securities in accordance herewith. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 3.
REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE HOLDER. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) The Holder represents and warrants to and covenants with the Company that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <B>Valid Existence; Good Standing</B>. To the extent the Holder is a corporation, limited liability company or other type of entity, the
Holder is validly existing and in good standing under the laws of the jurisdiction of its organization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <B>Authority;
Authorization</B>. The Holder has full right, power, authority and capacity to enter into this Agreement and the other agreements and documents contemplated hereby and to perform its obligations hereunder and thereunder and has taken all necessary
action to authorize the execution, delivery and performance of this Agreement. Upon the execution and delivery of this Agreement by the Holder, this Agreement shall constitute a valid and binding obligation of the Holder, enforceable in accordance
with its terms (except (i)&nbsp;as limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or affecting the enforcement of creditors&#146; rights generally, and (ii)&nbsp;as limited by equitable
principles generally, including any specific performance). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <B>Title</B>. The Holder owns and holds the entire right, title and interest in and to, and
is the record and beneficial owner of, the Warrants and the Holder owns the Warrants free and clear of all Liens. The Holder has the full power and authority to vote, transfer and dispose of the Warrants free and clear of any right or Liens. There
is no restriction affecting the ability of the Holder to transfer the legal and beneficial title and ownership of the Warrants to the Company and, at the Closing, the Company will acquire legal and valid title to the Warrants, free and clear of all
Liens. Other than the transactions contemplated by this Agreement, there is no outstanding vote, plan, pending proposal, or other right of any person to acquire all or any of the Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <B>Purchase of Warrants in the Registered Offering. </B>The Holder purchased the Warrants in the Company&#146;s offering of Common Stock
and warrants made pursuant to the Company&#146;s prospectus filed with the Securities and Exchange Commission (the &#147;SEC&#148;) pursuant to Rule 424(b)(5) on February&nbsp;9, 2017 (the &#147;<B>Registered Offering</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <B>Securities Act Exemption</B>. Neither the Holder nor anyone acting on behalf of the Holder has received any commission or remuneration
directly or indirectly in connection with or in order to solicit or facilitate the Exchange. The Holder understands that the Exchange contemplated hereby is intended to be exempt from registration by virtue of Section&nbsp;3(a)(9) of the Securities
Act. The Holder understands that the Company is relying upon the truth and accuracy of the representations, warranties, agreements, acknowledgments and understandings of the Holder set forth herein for purposes of qualifying for the exemption under
Section&nbsp;3(a)(9) of the Securities Act as well as qualifying for exemptions under applicable state securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) <B><FONT
STYLE="white-space:nowrap">Non-Affiliate</FONT></B>. The Holder is not an Affiliate (as defined below) of the Company and has not been an Affiliate during the three months prior to the date hereof. &#147;Affiliate&#148; means, with respect to any
Person, any other Person that directly or indirectly controls, is controlled by, or is under common control with, such Person, it being understood for purposes of this definition that &#147;control&#148; of a Person means the power directly or
indirectly either to vote 10% or more of the stock having ordinary voting power for the election of directors of such Person or direct or cause the direction of the management and policies of such Person whether by contract or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) <B>Information</B>. The Holder has, in connection with its decision to acquire the Exchange Note, relied with respect to the Company and
its affairs solely upon the Company&#146;s filings with the SEC and the representations and warranties of the Company contained herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) <B>Advisors</B>. The Holder understands that nothing in this Agreement or any other materials presented to the Holder in connection with
the exchange of the Warrants and execution and acquisition of the Exchange Note constitutes legal, tax or investment advice. The Holder has consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed necessary or
appropriate in connection with its acquisition of the Exchange Note. With respect to such matters, the Holder relies solely on such advisors and not on any statements or representations of the Company or any of its agents, written or oral. The
Holder understands that it (and not the Company) shall be responsible for its own tax liability that may arise as a result of this investment or the transactions contemplated by this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 4. CONDITIONS TO COMPANY&#146;S OBLIGATIONS AT THE CLOSING. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s obligation to complete the issuance of the Exchange Note and deliver the Exchange Note to the Holder at the Closing shall be
subject to the following conditions to the extent not waived by the Company: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <B>Execution and Delivery</B>. The Holder shall have
executed and delivered this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <B>Covenants</B>. The Holder shall have performed, satisfied and complied in all material
respects with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Holder at or prior to the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <B>Surrender of Warrants.</B> The Company shall have received in physical form or through book-entry transfer from the Holder all
certificates or book-entry notation representing the Warrants to be exchanged for the Exchange Note; provided, that the foregoing shall be deemed to have been satisfied by instructions from the Company to its transfer agent to cancel the Warrants
upon confirmation of delivery of the Exchange Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <B>Representations and Warranties. </B>The representations and warranties of the
Holder shall be true and correct in all material respects as of the date when made and as of the Closing Date as though made at that time, except for representations and warranties that are expressly made as of a particular date, which shall be true
and correct in all material respects as of such date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 5. CONDITIONS TO THE HOLDER&#146;S OBLIGATIONS AT THE CLOSING. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Holder&#146;s obligation to deliver the Warrants and accept delivery of the Exchange Note shall be subject to the following conditions to
the extent not waived by the Holder: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)<B>&nbsp;Execution and Delivery</B>. The Company shall have executed and delivered this Agreement
and the Exchange Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)<B>&nbsp;Covenants</B>. The Company shall have performed, satisfied and complied in all material respects with
all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>Delivery of Exchange Note.</B> The Company shall have delivered the Exchange Note in accordance with the instructions provided pursuant
to Section&nbsp;1.b) hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)<B>&nbsp;Representations and Warranties.</B> Each of the representations and warranties of the Company
shall be true and correct in all material respects as of the date when made and as of the Closing Date as though made at that time, except for representations and warranties that are expressly made as of a particular date, which shall be true and
correct in all material respects as of such date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 6. NOTICES. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All notices, requests, consents and other communications hereunder shall be in writing, shall be sent by electronic mail, or mailed by
first-class registered or certified airmail, or nationally recognized overnight express courier, postage prepaid, and shall be deemed given when so sent in the case of electronic mail transmission so long as the sending party does not receive an
automatically generated message from the recipient&#146;s <FONT STYLE="white-space:nowrap">e-mail</FONT> server that such <FONT STYLE="white-space:nowrap">e-mail</FONT> could not be delivered to the receiving party, or when so received in the case
of mail or courier, and addressed as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) if to the Company, to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">SELLAS Life Sciences Group, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">315 Madison, 4<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Flr. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York, New York 0 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Angelos Stergiou, M.D., ScD h.c. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-Mail:</FONT> astergiou@sellaslife.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">or to such other person at such other place as the Company shall designate to the Holder in writing; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) if to the Holder, at the address as set forth at the end of this Agreement, or at such other address as may have been furnished by the
Holder to the Company in writing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 7. MISCELLANEOUS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <B>Headings.</B> The headings of the various sections of this Agreement have been inserted for convenience of reference only and shall not
be deemed to be part of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <B>Severability.</B> In case any provision contained in this Agreement should be invalid,
illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <B>Most Favored Nations</B>. The Company hereby represents and warrants as of the date hereof and covenants and agrees that no agreement
entered into (or to be entered into) with any Person with respect to the Exchange or other transaction involving the warrants issued in the Registered Offering, including, without limitation with respect to any consent, release, amendment,
settlement, or waiver relating to any Exchange or such other transaction involving the warrants issued in the Registered Offering, including without limitation, any amendment, settlement or waiver relating to any securities issued in connection with
an exchange of warrants issued in the Registered Offering (including the Exchange Note or other derivative security) (each a &#147;<U>Settlement Document</U>&#148;), is or will be more favorable to such Person (other than any reimbursement of legal
fees) than those of the Holder and this Agreement, including without limitation the ratio of warrants to the cash paid, principal amount of notes, value of any shares of Common Stock (valued as the VWAP of the Common Stock on the Trading Day
immediately preceding the public announcement of such issuance), or value of any Options, Convertible Securities or Adjustment Rights (as such terms are defined in the Exchange Note) (valued on the Trading Day immediately preceding the public
announcement of such issuance, as the greater of (a)&nbsp;the VWAP of the Common Stock multiplied by the number of underlying shares and (b)&nbsp;the Black Scholes Consideration Value) conveyed in such Settlement Document. If, and whenever on or
after the date hereof, the Company enters into a Settlement Document, then (i)&nbsp;the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company shall provide notice thereof to the Holder within one (1)&nbsp;Trading Day following the occurrence thereof and (ii)&nbsp;the terms and conditions of this Agreement shall be, without any
further action by the Holder or the Company, automatically amended and modified in an economically and legally equivalent manner such that the Holder shall receive the benefit of the more favorable terms and/or conditions (as the case may be) set
forth in such Settlement Document, provided that upon written notice to the Company within ten (10)&nbsp;Trading Days of receipt of notice of such Settlement Document the Holder may notify the Company in writing of Holder&#146;s election not to
accept the benefit of any such amended or modified term or condition, in which event the term or condition contained in this Agreement shall apply to the Holder as it was in effect immediately prior to such amendment or modification as if such
amendment or modification never occurred with respect to the Holder. The provisions of this Section&nbsp;7(c) shall apply similarly and equally to each Settlement Document. For purposes hereof, &#147;Black Scholes Consideration Value&#148; means the
value of the applicable Option, Convertible Security or Adjustment Right (as the case may be) as of the date of issuance thereof calculated using the Black Scholes Option Pricing Model obtained from the &#147;OV&#148; function on Bloomberg utilizing
(i)&nbsp;an underlying price per share equal to the Closing Sale Price of the Common Stock on the Trading Day immediately preceding the public announcement of the execution of definitive documents with respect to the issuance of such Option or
Convertible Security (as the case may be), (ii) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining term of such Option, Convertible Security or Adjustment Right (as the case may be) as of the date
of issuance of such Option, Convertible Security or Adjustment Right (as the case may be), (iii) a zero cost of borrow and (iv)&nbsp;an expected volatility equal to the greater of 100% and the 30 day volatility obtained from the &#147;HVT&#148;
function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the date of issuance of such Option, Convertible Security or Adjustment Right (as the case may be). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <B>Governing Law.</B> This Agreement shall be governed by and construed under the laws of the State of New York without regard to the
choice of law principles thereof. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the State of New York located in The City of New York, Borough of Manhattan for the adjudication of any
dispute hereunder or in connection herewith or with any transaction contemplated hereby or thereby, and hereby irrevocably waives any objection that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit,
action or proceeding is improper. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY
TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <B>Counterparts.</B> This Agreement may be executed in two or more counterparts, each of which shall constitute an original, but all of
which, when taken together, shall constitute but one instrument, and shall become effective when one or more counterparts have been signed by each party hereto and delivered to the other parties. In the event that any signature is delivered by
facsimile transmission or by an <FONT STYLE="white-space:nowrap">e-mail</FONT> which contains an electronic file of an executed signature page, such signature page shall create a valid and binding obligation of the party executing (or on whose
behalf such signature is executed) with the same force and effect as if such facsimile or electronic file signature page (as the case may be) were an original thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) <B>Successors and Assigns.</B> Except as otherwise expressly provided herein, the provisions
hereof shall inure to the benefit of, and be binding upon, the successors, permitted assigns, heirs, executors and administrators of the parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">g) <B>Entire Agreement; Amendments.</B> This Agreement and other documents delivered pursuant hereto constitute the full and entire
understanding and agreement between the parties with regard to the subjects hereof and thereof. This Agreement may be amended, modified, superseded, cancelled, renewed or extended, and the terms and conditions hereof may be waived, only by a written
instrument signed by all parties, or, in the case of a waiver, by the party waiving compliance. Except as expressly stated herein, no delay on the part of any party in exercising any right, power or privilege hereunder shall operate as a waiver
thereof, nor shall any waiver on the part of any party of any right, power or privilege hereunder preclude any other or future exercise of any other right, power or privilege hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">h) <B>Survival. </B>The representations, warranties, covenants and agreements made in this Agreement shall survive the closing of the
transactions contemplated hereby and the exchange and delivery of the Warrants and the Exchange Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">i) <B>Further Assurances</B>. Each
party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request in order to
carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">j) <B>No
Third Party Beneficiaries</B>. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[signature pages follow] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have caused this Agreement to be executed by their
duly authorized representatives as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SELLAS LIFE SCIENCES GROUP, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Angelos Stergiou</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Angelos Stergiou, M.D., ScD h.c.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">COMPANY SIGNATURE PAGE TO </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">WARRANT EXCHANGE AGREEMENT </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>HOLDER: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EMPERY ASSET MASTER, LTD.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>By: Empery Asset Management, LP, its authorized agent</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Brett Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Brett Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">General Counsel</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Empery Asset Management, LP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1
Rockefeller Plaza, Suite 1205</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">New York, NY 10020</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E-Mail:</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">notices@emperyam.com</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.83
<SEQUENCE>17
<FILENAME>d556278dex1083.htm
<DESCRIPTION>EX-10.83
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.83</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.83 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT EXCHANGE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Warrant Exchange Agreement (this &#147;<U>Agreement</U>&#148;) is made as of February&nbsp;21, 2018 (&#147;<U>Effective Date</U>&#148;),
by and between SELLAS Life Sciences Group, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), and EMPERY TAX EFFICIENT, LP ( collectively, the &#147;<U>Holder</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the
Holder currently holds 174,902 warrants (the &#147;<U>Warrants</U>&#148;) to purchase 5,831 shares of the Company&#146;s common stock, par value $0.0001 per share (&#147;<U>Common Stock</U>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, subject to the terms and conditions set forth herein, the Company and the Holder desire to cancel and retire the Warrants in exchange
(the &#147;<U>Exchange</U>&#148;) for a convertible promissory note (the &#147;<U>Exchange Note</U>&#148;), in the amount of $13,644.54 on such other terms as set forth in the form of Exchange Note attached as Exhibit A, in reliance on the exemption
from registration provided by Section&nbsp;3(a)(9) of the Securities Act of 1933, as amended (the &#147;<U>Securities Act</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt of which is hereby acknowledged, the Company and the Holder hereby agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 1. EXCHANGE AND
TERMINATION. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) In consideration of and in express reliance upon the representations, warranties, covenants, terms and conditions of
this Agreement, the Holder agrees to deliver and surrender to the Company for cancellation the Warrants in exchange for the Exchange Note, and the Company agrees to execute and deliver the Exchange Note to the Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) The closing under this Agreement (the &#147;<U>Closing</U>&#148;) shall take place upon the satisfaction of each of the conditions set
forth in Sections 4 and 5 hereof (the &#147;<U>Closing Date</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) If the Closing has not occurred by the second trading day
after the date hereof, this Agreement shall terminate. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 2. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby represents and warrants as of the date hereof to, and covenants with, the Holder as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <B>Organization and Standing.</B> The Company has been duly incorporated and is validly existing as a corporation in good standing under the
laws of Delaware, has full corporate power and authority to own or lease its properties and conduct its business as presently conducted, and is duly qualified as a foreign corporation and in good standing in each jurisdiction in which the character
of the property owned or leased or the nature of the business transacted by it makes qualification necessary, except where the failure to be so qualified would not have a Material Adverse Effect (as defined below). As used in this Agreement,
&#147;<U>Material Adverse Effect</U>&#148; means any material adverse effect on the business, properties, assets, liabilities, operations, results of operations, condition (financial or otherwise) or prospects of the Company and its subsidiaries
(the &#147;<U>Subsidiaries</U>&#148;), if any, individually or taken as a whole, or on the transactions contemplated hereby or on the Exchange Documents (as defined below) or by the agreements and instruments to be entered into (or entered into) in
connection herewith or therewith, or on the authority or ability of the Company to perform its obligations under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b)
<B>Authorization; Corporate Power.</B> This Agreement has been duly authorized, validly executed and delivered on behalf of the Company and is a valid and binding obligation of the Company enforceable against the Company in accordance with its terms
(except as limited by (i)&nbsp;applicable bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or affecting the enforcement of creditors&#146; rights generally, and (ii)&nbsp;equitable principles generally, including any
specific performance), and the Company has the requisite corporate power and authority to execute and deliver this Agreement and the other agreements and documents contemplated hereby and to perform its obligations hereunder and thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <B>Valid Issuance and Delivery of New Securities.</B> The issuance of the Exchange Note is duly authorized and, upon issuance in accordance
with the terms of this Agreement, the shares of Common Stock issuable upon conversion or otherwise pursuant to the terms of the Exchange Note (collectively, the &#147;<U>Conversion Shares</U>&#148;, and together with the Exchange Note, the
&#147;<U>New Securities</U>&#148;) shall be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and free from all preemptive or similar rights, mortgages, defects, claims, liens, pledges, charges, taxes, rights of
first refusal, encumbrances, security interests and other encumbrances (collectively &#147;<U>Liens</U>&#148;) with respect to the issuance thereof. As of the date hereof, the Company has reserved from its duly authorized capital stock not less than
150% of the maximum number of Conversion Shares issuable upon conversion of the Exchange Note (assuming for purposes hereof that (x)&nbsp;the Exchange Note is convertible at the Alternate Conversion Price (as defined in the Exchange Note) assuming a
date of conversion as of the date hereof, (y)&nbsp;interest on the Exchange Note shall accrue through the Maturity Date (as defined in the Exchange Note) and will be converted in shares of Common Stock (as defined below) at a conversion price equal
to the Alternate Conversion Price assuming a date of conversion as of the date hereof and (z)&nbsp;any such conversion shall not take into account any limitations on the conversion of the Exchange Note set forth in the Exchange Note). Upon issuance
or conversion in accordance with the Exchange Note the Conversion Shares when issued, will be validly issued, fully paid and nonassessable and free from all preemptive or similar rights or Liens with respect to the issue thereof, with the holders
being entitled to all rights accorded to a holder of Common Stock. The offer and issuance by the Company of the New Securities is exempt from registration under the Securities Act. Each of the New Securities will be freely tradable and shall not be
required to bear, and shall not bear, any Securities Act or other restrictive legend. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <B>Consents. </B>No consent, waiver, approval or authorization of or designation, declaration
or filing with any Person (as defined below) on the part of the Company is required in connection with the valid execution and delivery of this Agreement or the offer, sale or issuance of the New Securities or the consummation of any other
transaction contemplated by this Agreement. For purposes of this Agreement, (i) &#147;Person&#148; means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other
entity and any Governmental Entity or any department or agency thereof; and (ii) &#147;<U>Governmental Entity</U>&#148; means any nation, state, county, city, town, village, district, or other political jurisdiction of any nature, federal, state,
local, municipal, foreign, or other government, governmental or quasi-governmental authority of any nature (including any governmental agency, branch, department, official, or entity and any court or other tribunal), multi-national organization or
body; or body exercising, or entitled to exercise, any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power of any nature or instrumentality of any of the foregoing, including any entity or enterprise
owned or controlled by a government or a public international organization or any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <B>No Default or Violation</B>.
The execution and delivery of the Agreement and the consummation of the transactions contemplated by this Agreement by the Company will not (i)&nbsp;result in a breach of or a default under any of the terms or provisions of (A)&nbsp;the
Company&#146;s certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws,</FONT> or (B)&nbsp;any material provision of any indenture, mortgage, deed of trust or other material agreement or instrument to which the Company is a party or
by which it or any of its material properties or assets is bound or (ii)&nbsp;result in a violation of any provision of any law, statute, rule, regulation, or any existing applicable decree, judgment or order by any court, Federal or state
regulatory body, administrative agency, or other governmental body having jurisdiction over the Company, or any of its material properties or assets except in the case of clauses (i)(B) or (ii)&nbsp;for any such breaches, defaults or violations
which would not have a Material Adverse Effect. The Company has not violated any law or any governmental regulation or requirement which violation has had or would reasonably be expected to have a Material Adverse Effect, and the Company has not
received written notice of any such violation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) <B>Offering</B>. Neither the Company, nor any of its affiliates, nor any Person acting
on its or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D) in connection with the offer or sale of the New Securities. The Company shall be responsible for the payment of any
placement agent&#146;s fees, financial advisory fees, or brokers&#146; commissions (other than for persons engaged by the Holder or its investment advisor) relating to or arising out of the transactions contemplated hereby. The Company shall pay,
and hold the Holder harmless against, any liability, loss or expense (including, without limitation, attorney&#146;s fees and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses) arising in
connection with any such claim. Neither the Company nor any of its Subsidiaries has engaged any placement agent or other agent in connection with the Exchange and the issuance of the New Securities. The offer, exchange and issuance, as applicable,
of the New Securities as contemplated by this Agreement are exempt from the registration requirements of the Securities Act and the qualification or registration requirements of state securities laws or other applicable blue sky laws. Neither the
Company nor any authorized agent acting on its behalf will take any action hereafter that would cause the loss of such exemptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">g)
<B>Absence of Litigation</B>. Except as set forth in the reports, schedules, forms, statements and other documents required to be filed by the Company with the Securities and Exchange Commission (the &#147;<U>SEC</U>&#148;) pursuant to the reporting
requirements of the Securities Exchange Act of 1934, as amended (the &#147;<U>Exchange Act</U>&#148;), there is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory
organization or body pending or, to the knowledge of the Company, threatened against or affecting the Company, the Common Stock, any securities of the Company or any of the Company&#146;s officers or directors in their capacities as such. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">h) <B>No Group</B>. The Company acknowledges that, to the Company&#146;s knowledge, the Holder is
acting independently in connection with this Agreement and the transactions contemplated hereby, and is not acting as part of a &#147;group&#148; as such term is defined under Section&nbsp;13(d) of the Securities Act and the rules and regulations
promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">i) <B>Validity; Enforcement</B>. This Agreement and each other Exchange Document to which the Company is a party
have been duly and validly authorized, executed and delivered on behalf of the Company and shall constitute the legal, valid and binding obligations of the Company enforceable against the Company in accordance with their respective terms, except as
such enforceability may be limited by general principles of equity or to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable
creditors&#146; rights and remedies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">j) [Intentionally Omitted.] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">k) <B>Disclosure of Agreement.</B> On or before 8:30 a.m., New York City time, on March&nbsp;15, 2018 (the &#147;<U>Cleansing
Deadline</U>&#148;), the Company shall have publicly, whether through one or more press releases or Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC, all material terms of the transactions contemplated hereby
and any other material, nonpublic information provided to the Holder from the Company or any of its Subsidiaries or any of their respective officers, directors, employees, affiliates or agents, including by attaching the form of this Agreement as an
exhibit to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC prior to the Cleansing Deadline. From and after the Cleansing Deadline, the Holder shall not be in possession of any material, nonpublic information
received from the Company or any of its Subsidiaries or any of their respective officers, directors, employees, affiliates or agents, that has not been publicly disclosed. The Company shall not, and shall cause its officers, directors, employees,
affiliates and agents, not to, provide the Holder with any material, nonpublic information regarding the Company from and after the Cleansing Deadline without the express written consent of the Holder. To the extent that the Company delivers any
material, <FONT STYLE="white-space:nowrap">non-public</FONT> information to the Holder after the Cleansing Deadline without the Holder&#146;s express prior written consent, the Company hereby covenants and agrees that the Holder shall not have any
duty of confidentiality to the Company, any of its Subsidiaries or any of their respective officers, directors, employees, affiliates or agents with respect to, or a duty to the Company, any of its Subsidiaries or any of their respective officers,
directors, employees, affiliates or agents not to trade on the basis of, such material, <FONT STYLE="white-space:nowrap">non-public</FONT> information. The Company shall not disclose the name of the Holder in any filing, announcement, release or
otherwise, unless such disclosure is required by law or regulation. In addition, effective upon the Cleansing Deadline, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written
or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, affiliates, employees or agents, on the one hand, and the Holder or any of its affiliates, on the other hand, shall terminate and be of no further
force or effect. The Company understands and confirms that the Holder will rely on the foregoing representations in effecting transactions in securities of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">l) <B>Blue Sky</B>. The Company shall make all filings and reports relating to each Exchange
required under applicable securities or &#147;Blue Sky&#148; laws of the states of the United States following the date hereof, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">m) <B>No Integration</B>. None of the Company, its Subsidiaries, any of their affiliates, or any Person acting on their behalf shall, directly
or indirectly, make any offers or sales of any security (as defined in the Securities Act) or solicit any offers to buy any security or take any other actions, under circumstances that would require registration of any of the New Securities under
the Securities Act or cause this offering of the New Securities to be integrated with such offering or any prior offerings by the Company for purposes of Regulation D under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">n) <B>Listing</B>. The Company shall promptly secure the listing or designation for quotation (as applicable) of all of the Conversion Shares
upon the Nasdaq Capital Market (subject to official notice of issuance) and shall maintain such listing of all the Conversion Shares from time to time issuable under the terms of the Exchange Documents. The Company shall maintain the Common
Stock&#146;s authorization for quotation on the Nasdaq Capital Market. Neither the Company nor any of its Subsidiaries shall take any action which would be reasonably expected to result in the delisting or suspension of the Common Stock from the
Nasdaq Capital Market. The Company shall pay all fees and expenses in connection with satisfying its obligations under this Section&nbsp;2(n). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">o) <B>Holding Period</B>. The Company acknowledges that the Exchange Note will take on the registered characteristics of the Warrants. The
Company further acknowledges that Exchange Note, and upon conversion thereof, the Conversion Shares, will not bear any restrictive legends and will be freely tradable. The Company shall be responsible for any transfer agent fees or Depository Trust
Company fees or legal fees of the Company&#146;s counsel with respect to the issuance of New Securities in accordance herewith. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 3.
REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE HOLDER. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) The Holder represents and warrants to and covenants with the Company that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <B>Valid Existence; Good Standing</B>. To the extent the Holder is a corporation, limited liability company or other type of entity, the
Holder is validly existing and in good standing under the laws of the jurisdiction of its organization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <B>Authority;
Authorization</B>. The Holder has full right, power, authority and capacity to enter into this Agreement and the other agreements and documents contemplated hereby and to perform its obligations hereunder and thereunder and has taken all necessary
action to authorize the execution, delivery and performance of this Agreement. Upon the execution and delivery of this Agreement by the Holder, this Agreement shall constitute a valid and binding obligation of the Holder, enforceable in accordance
with its terms (except (i)&nbsp;as limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or affecting the enforcement of creditors&#146; rights generally, and (ii)&nbsp;as limited by equitable
principles generally, including any specific performance). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <B>Title</B>. The Holder owns and holds the entire right, title and interest in and to, and
is the record and beneficial owner of, the Warrants and the Holder owns the Warrants free and clear of all Liens. The Holder has the full power and authority to vote, transfer and dispose of the Warrants free and clear of any right or Liens. There
is no restriction affecting the ability of the Holder to transfer the legal and beneficial title and ownership of the Warrants to the Company and, at the Closing, the Company will acquire legal and valid title to the Warrants, free and clear of all
Liens. Other than the transactions contemplated by this Agreement, there is no outstanding vote, plan, pending proposal, or other right of any person to acquire all or any of the Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <B>Purchase of Warrants in the Registered Offering. </B>The Holder purchased the Warrants in the Company&#146;s offering of Common Stock
and warrants made pursuant to the Company&#146;s prospectus filed with the Securities and Exchange Commission (the &#147;SEC&#148;) pursuant to Rule 424(b)(5) on February&nbsp;9, 2017 (the &#147;<B>Registered Offering</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <B>Securities Act Exemption</B>. Neither the Holder nor anyone acting on behalf of the Holder has received any commission or remuneration
directly or indirectly in connection with or in order to solicit or facilitate the Exchange. The Holder understands that the Exchange contemplated hereby is intended to be exempt from registration by virtue of Section&nbsp;3(a)(9) of the Securities
Act. The Holder understands that the Company is relying upon the truth and accuracy of the representations, warranties, agreements, acknowledgments and understandings of the Holder set forth herein for purposes of qualifying for the exemption under
Section&nbsp;3(a)(9) of the Securities Act as well as qualifying for exemptions under applicable state securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) <B><FONT
STYLE="white-space:nowrap">Non-Affiliate</FONT></B>. The Holder is not an Affiliate (as defined below) of the Company and has not been an Affiliate during the three months prior to the date hereof. &#147;Affiliate&#148; means, with respect to any
Person, any other Person that directly or indirectly controls, is controlled by, or is under common control with, such Person, it being understood for purposes of this definition that &#147;control&#148; of a Person means the power directly or
indirectly either to vote 10% or more of the stock having ordinary voting power for the election of directors of such Person or direct or cause the direction of the management and policies of such Person whether by contract or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) <B>Information</B>. The Holder has, in connection with its decision to acquire the Exchange Note, relied with respect to the Company and
its affairs solely upon the Company&#146;s filings with the SEC and the representations and warranties of the Company contained herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) <B>Advisors</B>. The Holder understands that nothing in this Agreement or any other materials presented to the Holder in connection with
the exchange of the Warrants and execution and acquisition of the Exchange Note constitutes legal, tax or investment advice. The Holder has consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed necessary or
appropriate in connection with its acquisition of the Exchange Note. With respect to such matters, the Holder relies solely on such advisors and not on any statements or representations of the Company or any of its agents, written or oral. The
Holder understands that it (and not the Company) shall be responsible for its own tax liability that may arise as a result of this investment or the transactions contemplated by this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 4. CONDITIONS TO COMPANY&#146;S OBLIGATIONS AT THE CLOSING. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s obligation to complete the issuance of the Exchange Note and deliver the Exchange Note to the Holder at the Closing shall be
subject to the following conditions to the extent not waived by the Company: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <B>Execution and Delivery</B>. The Holder shall have
executed and delivered this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <B>Covenants</B>. The Holder shall have performed, satisfied and complied in all material
respects with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Holder at or prior to the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <B>Surrender of Warrants.</B> The Company shall have received in physical form or through book-entry transfer from the Holder all
certificates or book-entry notation representing the Warrants to be exchanged for the Exchange Note; provided, that the foregoing shall be deemed to have been satisfied by instructions from the Company to its transfer agent to cancel the Warrants
upon confirmation of delivery of the Exchange Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <B>Representations and Warranties. </B>The representations and warranties of the
Holder shall be true and correct in all material respects as of the date when made and as of the Closing Date as though made at that time, except for representations and warranties that are expressly made as of a particular date, which shall be true
and correct in all material respects as of such date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 5. CONDITIONS TO THE HOLDER&#146;S OBLIGATIONS AT THE CLOSING. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Holder&#146;s obligation to deliver the Warrants and accept delivery of the Exchange Note shall be subject to the following conditions to
the extent not waived by the Holder: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)<B>&nbsp;Execution and Delivery</B>. The Company shall have executed and delivered this Agreement
and the Exchange Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)<B>&nbsp;Covenants</B>. The Company shall have performed, satisfied and complied in all material respects with
all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <B>Delivery of Exchange Note.</B> The Company shall have delivered the Exchange Note in accordance with the instructions provided pursuant
to Section&nbsp;1.b) hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d)<B>&nbsp;Representations and Warranties.</B> Each of the representations and warranties of the Company
shall be true and correct in all material respects as of the date when made and as of the Closing Date as though made at that time, except for representations and warranties that are expressly made as of a particular date, which shall be true and
correct in all material respects as of such date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 6. NOTICES. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All notices, requests, consents and other communications hereunder shall be in writing, shall be sent by electronic mail, or mailed by
first-class registered or certified airmail, or nationally recognized overnight express courier, postage prepaid, and shall be deemed given when so sent in the case of electronic mail transmission so long as the sending party does not receive an
automatically generated message from the recipient&#146;s <FONT STYLE="white-space:nowrap">e-mail</FONT> server that such <FONT STYLE="white-space:nowrap">e-mail</FONT> could not be delivered to the receiving party, or when so received in the case
of mail or courier, and addressed as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) if to the Company, to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">SELLAS Life Sciences Group, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">315 Madison, 4<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Flr. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York, New York 0 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Angelos Stergiou, M.D., ScD h.c. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-Mail:</FONT> astergiou@sellaslife.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">or to such other person at such other place as the Company shall designate to the Holder in writing; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) if to the Holder, at the address as set forth at the end of this Agreement, or at such other address as may have been furnished by the
Holder to the Company in writing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 7. MISCELLANEOUS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <B>Headings.</B> The headings of the various sections of this Agreement have been inserted for convenience of reference only and shall not
be deemed to be part of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <B>Severability.</B> In case any provision contained in this Agreement should be invalid,
illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <B>Most Favored Nations</B>. The Company hereby represents and warrants as of the date hereof and covenants and agrees that no agreement
entered into (or to be entered into) with any Person with respect to the Exchange or other transaction involving the warrants issued in the Registered Offering, including, without limitation with respect to any consent, release, amendment,
settlement, or waiver relating to any Exchange or such other transaction involving the warrants issued in the Registered Offering, including without limitation, any amendment, settlement or waiver relating to any securities issued in connection with
an exchange of warrants issued in the Registered Offering (including the Exchange Note or other derivative security) (each a &#147;<U>Settlement Document</U>&#148;), is or will be more favorable to such Person (other than any reimbursement of legal
fees) than those of the Holder and this Agreement, including without limitation the ratio of warrants to the cash paid, principal amount of notes, value of any shares of Common Stock (valued as the VWAP of the Common Stock on the Trading Day
immediately preceding the public announcement of such issuance), or value of any Options, Convertible Securities or Adjustment Rights (as such terms are defined in the Exchange Note) (valued on the Trading Day immediately preceding the public
announcement of such issuance, as the greater of (a)&nbsp;the VWAP of the Common Stock multiplied by the number of underlying shares and (b)&nbsp;the Black Scholes Consideration Value) conveyed in such Settlement Document. If, and whenever on or
after the date hereof, the Company enters into a Settlement Document, then (i)&nbsp;the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company shall provide notice thereof to the Holder within one (1)&nbsp;Trading Day following the occurrence thereof and (ii)&nbsp;the terms and conditions of this Agreement shall be, without any
further action by the Holder or the Company, automatically amended and modified in an economically and legally equivalent manner such that the Holder shall receive the benefit of the more favorable terms and/or conditions (as the case may be) set
forth in such Settlement Document, provided that upon written notice to the Company within ten (10)&nbsp;Trading Days of receipt of notice of such Settlement Document the Holder may notify the Company in writing of Holder&#146;s election not to
accept the benefit of any such amended or modified term or condition, in which event the term or condition contained in this Agreement shall apply to the Holder as it was in effect immediately prior to such amendment or modification as if such
amendment or modification never occurred with respect to the Holder. The provisions of this Section&nbsp;7(c) shall apply similarly and equally to each Settlement Document. For purposes hereof, &#147;Black Scholes Consideration Value&#148; means the
value of the applicable Option, Convertible Security or Adjustment Right (as the case may be) as of the date of issuance thereof calculated using the Black Scholes Option Pricing Model obtained from the &#147;OV&#148; function on Bloomberg utilizing
(i)&nbsp;an underlying price per share equal to the Closing Sale Price of the Common Stock on the Trading Day immediately preceding the public announcement of the execution of definitive documents with respect to the issuance of such Option or
Convertible Security (as the case may be), (ii) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining term of such Option, Convertible Security or Adjustment Right (as the case may be) as of the date
of issuance of such Option, Convertible Security or Adjustment Right (as the case may be), (iii) a zero cost of borrow and (iv)&nbsp;an expected volatility equal to the greater of 100% and the 30 day volatility obtained from the &#147;HVT&#148;
function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the date of issuance of such Option, Convertible Security or Adjustment Right (as the case may be). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <B>Governing Law.</B> This Agreement shall be governed by and construed under the laws of the State of New York without regard to the
choice of law principles thereof. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the State of New York located in The City of New York, Borough of Manhattan for the adjudication of any
dispute hereunder or in connection herewith or with any transaction contemplated hereby or thereby, and hereby irrevocably waives any objection that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit,
action or proceeding is improper. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY
TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <B>Counterparts.</B> This Agreement may be executed in two or more counterparts, each of which shall constitute an original, but all of
which, when taken together, shall constitute but one instrument, and shall become effective when one or more counterparts have been signed by each party hereto and delivered to the other parties. In the event that any signature is delivered by
facsimile transmission or by an <FONT STYLE="white-space:nowrap">e-mail</FONT> which contains an electronic file of an executed signature page, such signature page shall create a valid and binding obligation of the party executing (or on whose
behalf such signature is executed) with the same force and effect as if such facsimile or electronic file signature page (as the case may be) were an original thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) <B>Successors and Assigns.</B> Except as otherwise expressly provided herein, the provisions
hereof shall inure to the benefit of, and be binding upon, the successors, permitted assigns, heirs, executors and administrators of the parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">g) <B>Entire Agreement; Amendments.</B> This Agreement and other documents delivered pursuant hereto constitute the full and entire
understanding and agreement between the parties with regard to the subjects hereof and thereof. This Agreement may be amended, modified, superseded, cancelled, renewed or extended, and the terms and conditions hereof may be waived, only by a written
instrument signed by all parties, or, in the case of a waiver, by the party waiving compliance. Except as expressly stated herein, no delay on the part of any party in exercising any right, power or privilege hereunder shall operate as a waiver
thereof, nor shall any waiver on the part of any party of any right, power or privilege hereunder preclude any other or future exercise of any other right, power or privilege hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">h) <B>Survival. </B>The representations, warranties, covenants and agreements made in this Agreement shall survive the closing of the
transactions contemplated hereby and the exchange and delivery of the Warrants and the Exchange Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">i) <B>Further Assurances</B>. Each
party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request in order to
carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">j) <B>No
Third Party Beneficiaries</B>. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[signature pages follow] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have caused this Agreement to be executed by their
duly authorized representatives as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SELLAS LIFE SCIENCES GROUP, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Angelos Stergiou</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Angelos Stergiou, M.D., ScD h.c.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: &nbsp;&nbsp;Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">COMPANY SIGNATURE PAGE TO </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">WARRANT EXCHANGE AGREEMENT </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>HOLDER: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>EMPERY TAX EFFICIENT, LP</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>By: Empery Asset Management, LP, its authorized agent</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Brett Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Brett Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">General Counsel</TD></TR></TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">c/o Empery Asset Management, LP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1 Rockefeller Plaza, Suite 1205</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">New York, NY 10020</TD></TR></TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="white-space:nowrap">E-Mail:</FONT> notices@emperyam.com</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.84
<SEQUENCE>18
<FILENAME>d556278dex1084.htm
<DESCRIPTION>EX-10.84
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.84</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.84 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLAS LIFE SCIENCES GROUP, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT EXCHANGE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Warrant Exchange Agreement (this &#147;<U>Agreement</U>&#148;) is made as of February&nbsp;21, 2018 (&#147;<U>Effective Date</U>&#148;),
by and between SELLAS Life Sciences Group, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), and EMPERY TAX EFFICIENT II, LP ( collectively, the &#147;<U>Holder</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the
Holder currently holds 278,811 warrants (the &#147;<U>Warrants</U>&#148;) to purchase 9,294 shares of the Company&#146;s common stock, par value $0.0001 per share (&#147;<U>Common Stock</U>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, subject to the terms and conditions set forth herein, the Company and the Holder desire to cancel and retire the Warrants in exchange
(the &#147;<U>Exchange</U>&#148;) for a convertible promissory note (the &#147;<U>Exchange Note</U>&#148;), in the amount of $21,747.96 on such other terms as set forth in the form of Exchange Note attached as Exhibit A, in reliance on the exemption
from registration provided by Section&nbsp;3(a)(9) of the Securities Act of 1933, as amended (the &#147;<U>Securities Act</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt of which is hereby acknowledged, the Company and the Holder hereby agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 1. EXCHANGE AND
TERMINATION. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) In consideration of and in express reliance upon the representations, warranties, covenants, terms and conditions of
this Agreement, the Holder agrees to deliver and surrender to the Company for cancellation the Warrants in exchange for the Exchange Note, and the Company agrees to execute and deliver the Exchange Note to the Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) The closing under this Agreement (the &#147;<U>Closing</U>&#148;) shall take place upon the satisfaction of each of the conditions set
forth in Sections 4 and 5 hereof (the &#147;<U>Closing Date</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) If the Closing has not occurred by the second trading day
after the date hereof, this Agreement shall terminate. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 2. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby represents and warrants as of the date hereof to, and covenants with, the Holder as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <B>Organization and Standing.</B> The Company has been duly incorporated and is validly existing as a corporation in good standing under the
laws of Delaware, has full corporate power and authority to own or lease its properties and conduct its business as presently conducted, and is duly qualified as a foreign corporation and in good standing in each jurisdiction in which the character
of the property owned or leased or the nature of the business transacted by it makes qualification necessary, except where the failure to be so qualified would not have a Material Adverse Effect (as defined below). As used in this Agreement,
&#147;<U>Material Adverse Effect</U>&#148; means any material adverse effect on the business, properties, assets, liabilities, operations, results of operations, condition (financial or otherwise) or prospects of the Company and its subsidiaries
(the &#147;<U>Subsidiaries</U>&#148;), if any, individually or taken as a whole, or on the transactions contemplated hereby or on the Exchange Documents (as defined below) or by the agreements and instruments to be entered into (or entered into) in
connection herewith or therewith, or on the authority or ability of the Company to perform its obligations under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b)
<B>Authorization; Corporate Power.</B> This Agreement has been duly authorized, validly executed and delivered on behalf of the Company and is a valid and binding obligation of the Company enforceable against the Company in accordance with its terms
(except as limited by (i)&nbsp;applicable bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or affecting the enforcement of creditors&#146; rights generally, and (ii)&nbsp;equitable principles generally, including any
specific performance), and the Company has the requisite corporate power and authority to execute and deliver this Agreement and the other agreements and documents contemplated hereby and to perform its obligations hereunder and thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <B>Valid Issuance and Delivery of New Securities.</B> The issuance of the Exchange Note is duly authorized and, upon issuance in accordance
with the terms of this Agreement, the shares of Common Stock issuable upon conversion or otherwise pursuant to the terms of the Exchange Note (collectively, the &#147;<U>Conversion Shares</U>&#148;, and together with the Exchange Note, the
&#147;<U>New Securities</U>&#148;) shall be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and free from all preemptive or similar rights, mortgages, defects, claims, liens, pledges, charges, taxes, rights of
first refusal, encumbrances, security interests and other encumbrances (collectively &#147;<U>Liens</U>&#148;) with respect to the issuance thereof. As of the date hereof, the Company has reserved from its duly authorized capital stock not less than
150% of the maximum number of Conversion Shares issuable upon conversion of the Exchange Note (assuming for purposes hereof that (x)&nbsp;the Exchange Note is convertible at the Alternate Conversion Price (as defined in the Exchange Note) assuming a
date of conversion as of the date hereof, (y)&nbsp;interest on the Exchange Note shall accrue through the Maturity Date (as defined in the Exchange Note) and will be converted in shares of Common Stock (as defined below) at a conversion price equal
to the Alternate Conversion Price assuming a date of conversion as of the date hereof and (z)&nbsp;any such conversion shall not take into account any limitations on the conversion of the Exchange Note set forth in the Exchange Note). Upon issuance
or conversion in accordance with the Exchange Note the Conversion Shares when issued, will be validly issued, fully paid and nonassessable and free from all preemptive or similar rights or Liens with respect to the issue thereof, with the holders
being entitled to all rights accorded to a holder of Common Stock. The offer and issuance by the Company of the New Securities is exempt from registration under the Securities Act. Each of the New Securities will be freely tradable and shall not be
required to bear, and shall not bear, any Securities Act or other restrictive legend. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <B>Consents. </B>No consent, waiver, approval or authorization of or designation, declaration
or filing with any Person (as defined below) on the part of the Company is required in connection with the valid execution and delivery of this Agreement or the offer, sale or issuance of the New Securities or the consummation of any other
transaction contemplated by this Agreement. For purposes of this Agreement, (i) &#147;Person&#148; means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other
entity and any Governmental Entity or any department or agency thereof; and (ii) &#147;<U>Governmental Entity</U>&#148; means any nation, state, county, city, town, village, district, or other political jurisdiction of any nature, federal, state,
local, municipal, foreign, or other government, governmental or quasi-governmental authority of any nature (including any governmental agency, branch, department, official, or entity and any court or other tribunal), multi-national organization or
body; or body exercising, or entitled to exercise, any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power of any nature or instrumentality of any of the foregoing, including any entity or enterprise
owned or controlled by a government or a public international organization or any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <B>No Default or Violation</B>.
The execution and delivery of the Agreement and the consummation of the transactions contemplated by this Agreement by the Company will not (i)&nbsp;result in a breach of or a default under any of the terms or provisions of (A)&nbsp;the
Company&#146;s certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws,</FONT> or (B)&nbsp;any material provision of any indenture, mortgage, deed of trust or other material agreement or instrument to which the Company is a party or
by which it or any of its material properties or assets is bound or (ii)&nbsp;result in a violation of any provision of any law, statute, rule, regulation, or any existing applicable decree, judgment or order by any court, Federal or state
regulatory body, administrative agency, or other governmental body having jurisdiction over the Company, or any of its material properties or assets except in the case of clauses (i)(B) or (ii)&nbsp;for any such breaches, defaults or violations
which would not have a Material Adverse Effect. The Company has not violated any law or any governmental regulation or requirement which violation has had or would reasonably be expected to have a Material Adverse Effect, and the Company has not
received written notice of any such violation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) <B>Offering</B>. Neither the Company, nor any of its affiliates, nor any Person acting
on its or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D) in connection with the offer or sale of the New Securities. The Company shall be responsible for the payment of any
placement agent&#146;s fees, financial advisory fees, or brokers&#146; commissions (other than for persons engaged by the Holder or its investment advisor) relating to or arising out of the transactions contemplated hereby. The Company shall pay,
and hold the Holder harmless against, any liability, loss or expense (including, without limitation, attorney&#146;s fees and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses) arising in
connection with any such claim. Neither the Company nor any of its Subsidiaries has engaged any placement agent or other agent in connection with the Exchange and the issuance of the New Securities. The offer, exchange and issuance, as applicable,
of the New Securities as contemplated by this Agreement are exempt from the registration requirements of the Securities Act and the qualification or registration requirements of state securities laws or other applicable blue sky laws. Neither the
Company nor any authorized agent acting on its behalf will take any action hereafter that would cause the loss of such exemptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">g)
<B>Absence of Litigation</B>. Except as set forth in the reports, schedules, forms, statements and other documents required to be filed by the Company with the Securities and Exchange Commission (the &#147;<U>SEC</U>&#148;) pursuant to the reporting
requirements of the Securities Exchange Act of 1934, as amended (the &#147;<U>Exchange Act</U>&#148;), there is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory
organization or body pending or, to the knowledge of the Company, threatened against or affecting the Company, the Common Stock, any securities of the Company or any of the Company&#146;s officers or directors in their capacities as such. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">h) <B>No Group</B>. The Company acknowledges that, to the Company&#146;s knowledge, the Holder is
acting independently in connection with this Agreement and the transactions contemplated hereby, and is not acting as part of a &#147;group&#148; as such term is defined under Section&nbsp;13(d) of the Securities Act and the rules and regulations
promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">i) <B>Validity; Enforcement</B>. This Agreement and each other Exchange Document to which the Company is a party
have been duly and validly authorized, executed and delivered on behalf of the Company and shall constitute the legal, valid and binding obligations of the Company enforceable against the Company in accordance with their respective terms, except as
such enforceability may be limited by general principles of equity or to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable
creditors&#146; rights and remedies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">j) [Intentionally Omitted.] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">k) <B>Disclosure of Agreement.</B> On or before 8:30 a.m., New York City time, on March&nbsp;15, 2018 (the &#147;<U>Cleansing
Deadline</U>&#148;), the Company shall have publicly, whether through one or more press releases or Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC, all material terms of the transactions contemplated hereby
and any other material, nonpublic information provided to the Holder from the Company or any of its Subsidiaries or any of their respective officers, directors, employees, affiliates or agents, including by attaching the form of this Agreement as an
exhibit to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC prior to the Cleansing Deadline. From and after the Cleansing Deadline, the Holder shall not be in possession of any material, nonpublic information
received from the Company or any of its Subsidiaries or any of their respective officers, directors, employees, affiliates or agents, that has not been publicly disclosed. The Company shall not, and shall cause its officers, directors, employees,
affiliates and agents, not to, provide the Holder with any material, nonpublic information regarding the Company from and after the Cleansing Deadline without the express written consent of the Holder. To the extent that the Company delivers any
material, <FONT STYLE="white-space:nowrap">non-public</FONT> information to the Holder after the Cleansing Deadline without the Holder&#146;s express prior written consent, the Company hereby covenants and agrees that the Holder shall not have any
duty of confidentiality to the Company, any of its Subsidiaries or any of their respective officers, directors, employees, affiliates or agents with respect to, or a duty to the Company, any of its Subsidiaries or any of their respective officers,
directors, employees, affiliates or agents not to trade on the basis of, such material, <FONT STYLE="white-space:nowrap">non-public</FONT> information. The Company shall not disclose the name of the Holder in any filing, announcement, release or
otherwise, unless such disclosure is required by law or regulation. In addition, effective upon the Cleansing Deadline, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written
or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, affiliates, employees or agents, on the one hand, and the Holder or any of its affiliates, on the other hand, shall terminate and be of no further
force or effect. The Company understands and confirms that the Holder will rely on the foregoing representations in effecting transactions in securities of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">l) <B>Blue Sky</B>. The Company shall make all filings and reports relating to each Exchange
required under applicable securities or &#147;Blue Sky&#148; laws of the states of the United States following the date hereof, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">m) <B>No Integration</B>. None of the Company, its Subsidiaries, any of their affiliates, or any Person acting on their behalf shall, directly
or indirectly, make any offers or sales of any security (as defined in the Securities Act) or solicit any offers to buy any security or take any other actions, under circumstances that would require registration of any of the New Securities under
the Securities Act or cause this offering of the New Securities to be integrated with such offering or any prior offerings by the Company for purposes of Regulation D under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">n) <B>Listing</B>. The Company shall promptly secure the listing or designation for quotation (as applicable) of all of the Conversion Shares
upon the Nasdaq Capital Market (subject to official notice of issuance) and shall maintain such listing of all the Conversion Shares from time to time issuable under the terms of the Exchange Documents. The Company shall maintain the Common
Stock&#146;s authorization for quotation on the Nasdaq Capital Market. Neither the Company nor any of its Subsidiaries shall take any action which would be reasonably expected to result in the delisting or suspension of the Common Stock from the
Nasdaq Capital Market. The Company shall pay all fees and expenses in connection with satisfying its obligations under this Section&nbsp;2(n). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">o) <B>Holding Period</B>. The Company acknowledges that the Exchange Note will take on the registered characteristics of the Warrants. The
Company further acknowledges that Exchange Note, and upon conversion thereof, the Conversion Shares, will not bear any restrictive legends and will be freely tradable. The Company shall be responsible for any transfer agent fees or Depository Trust
Company fees or legal fees of the Company&#146;s counsel with respect to the issuance of New Securities in accordance herewith. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 3.
REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE HOLDER. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) The Holder represents and warrants to and covenants with the Company that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <B>Valid Existence; Good Standing</B>. To the extent the Holder is a corporation, limited liability company or other type of entity, the
Holder is validly existing and in good standing under the laws of the jurisdiction of its organization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <B>Authority;
Authorization</B>. The Holder has full right, power, authority and capacity to enter into this Agreement and the other agreements and documents contemplated hereby and to perform its obligations hereunder and thereunder and has taken all necessary
action to authorize the execution, delivery and performance of this Agreement. Upon the execution and delivery of this Agreement by the Holder, this Agreement shall constitute a valid and binding obligation of the Holder, enforceable in accordance
with its terms (except (i)&nbsp;as limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or affecting the enforcement of creditors&#146; rights generally, and (ii)&nbsp;as limited by equitable
principles generally, including any specific performance). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <B>Title</B>. The Holder owns and holds the entire right, title and interest in and to, and
is the record and beneficial owner of, the Warrants and the Holder owns the Warrants free and clear of all Liens. The Holder has the full power and authority to vote, transfer and dispose of the Warrants free and clear of any right or Liens. There
is no restriction affecting the ability of the Holder to transfer the legal and beneficial title and ownership of the Warrants to the Company and, at the Closing, the Company will acquire legal and valid title to the Warrants, free and clear of all
Liens. Other than the transactions contemplated by this Agreement, there is no outstanding vote, plan, pending proposal, or other right of any person to acquire all or any of the Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <B>Purchase of Warrants in the Registered Offering. </B>The Holder purchased the Warrants in the Company&#146;s offering of Common Stock
and warrants made pursuant to the Company&#146;s prospectus filed with the Securities and Exchange Commission (the &#147;SEC&#148;) pursuant to Rule 424(b)(5) on February&nbsp;9, 2017 (the &#147;<B>Registered Offering</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <B>Securities Act Exemption</B>. Neither the Holder nor anyone acting on behalf of the Holder has received any commission or remuneration
directly or indirectly in connection with or in order to solicit or facilitate the Exchange. The Holder understands that the Exchange contemplated hereby is intended to be exempt from registration by virtue of Section&nbsp;3(a)(9) of the Securities
Act. The Holder understands that the Company is relying upon the truth and accuracy of the representations, warranties, agreements, acknowledgments and understandings of the Holder set forth herein for purposes of qualifying for the exemption under
Section&nbsp;3(a)(9) of the Securities Act as well as qualifying for exemptions under applicable state securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) <B><FONT
STYLE="white-space:nowrap">Non-Affiliate</FONT></B>. The Holder is not an Affiliate (as defined below) of the Company and has not been an Affiliate during the three months prior to the date hereof. &#147;Affiliate&#148; means, with respect to any
Person, any other Person that directly or indirectly controls, is controlled by, or is under common control with, such Person, it being understood for purposes of this definition that &#147;control&#148; of a Person means the power directly or
indirectly either to vote 10% or more of the stock having ordinary voting power for the election of directors of such Person or direct or cause the direction of the management and policies of such Person whether by contract or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) <B>Information</B>. The Holder has, in connection with its decision to acquire the Exchange Note, relied with respect to the Company and
its affairs solely upon the Company&#146;s filings with the SEC and the representations and warranties of the Company contained herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) <B>Advisors</B>. The Holder understands that nothing in this Agreement or any other materials presented to the Holder in connection with
the exchange of the Warrants and execution and acquisition of the Exchange Note constitutes legal, tax or investment advice. The Holder has consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed necessary or
appropriate in connection with its acquisition of the Exchange Note. With respect to such matters, the Holder relies solely on such advisors and not on any statements or representations of the Company or any of its agents, written or oral. The
Holder understands that it (and not the Company) shall be responsible for its own tax liability that may arise as a result of this investment or the transactions contemplated by this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 4. CONDITIONS TO COMPANY&#146;S OBLIGATIONS AT THE CLOSING. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s obligation to complete the issuance of the Exchange Note and deliver the Exchange Note to the Holder at the Closing shall be
subject to the following conditions to the extent not waived by the Company: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <B>Execution and Delivery</B>. The Holder shall have
executed and delivered this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <B>Covenants</B>. The Holder shall have performed, satisfied and complied in all material
respects with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Holder at or prior to the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <B>Surrender of Warrants.</B> The Company shall have received in physical form or through book-entry transfer from the Holder all
certificates or book-entry notation representing the Warrants to be exchanged for the Exchange Note; provided, that the foregoing shall be deemed to have been satisfied by instructions from the Company to its transfer agent to cancel the Warrants
upon confirmation of delivery of the Exchange Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <B>Representations and Warranties. </B>The representations and warranties of the
Holder shall be true and correct in all material respects as of the date when made and as of the Closing Date as though made at that time, except for representations and warranties that are expressly made as of a particular date, which shall be true
and correct in all material respects as of such date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 5. CONDITIONS TO THE HOLDER&#146;S OBLIGATIONS AT THE CLOSING. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Holder&#146;s obligation to deliver the Warrants and accept delivery of the Exchange Note shall be subject to the following conditions to
the extent not waived by the Holder: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)<B>&nbsp;Execution and Delivery</B>. The Company shall have executed and delivered this Agreement
and the Exchange Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)<B>&nbsp;Covenants</B>. The Company shall have performed, satisfied and complied in all material respects with
all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <B>Delivery of Exchange Note.</B> The Company shall have delivered the Exchange Note in accordance with the instructions provided pursuant
to Section&nbsp;1.b) hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d)<B>&nbsp;Representations and Warranties.</B> Each of the representations and warranties of the Company
shall be true and correct in all material respects as of the date when made and as of the Closing Date as though made at that time, except for representations and warranties that are expressly made as of a particular date, which shall be true and
correct in all material respects as of such date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 6. NOTICES. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All notices, requests, consents and other communications hereunder shall be in writing, shall be sent by electronic mail, or mailed by
first-class registered or certified airmail, or nationally recognized overnight express courier, postage prepaid, and shall be deemed given when so sent in the case of electronic mail transmission so long as the sending party does not receive an
automatically generated message from the recipient&#146;s <FONT STYLE="white-space:nowrap">e-mail</FONT> server that such <FONT STYLE="white-space:nowrap">e-mail</FONT> could not be delivered to the receiving party, or when so received in the case
of mail or courier, and addressed as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) if to the Company, to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">SELLAS Life Sciences Group, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">315 Madison, 4<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Flr. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York, New York 0 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Angelos Stergiou, M.D., ScD h.c. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-Mail:</FONT> astergiou@sellaslife.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">or to such other person at such other place as the Company shall designate to the Holder in writing; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) if to the Holder, at the address as set forth at the end of this Agreement, or at such other address as may have been furnished by the
Holder to the Company in writing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 7. MISCELLANEOUS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <B>Headings.</B> The headings of the various sections of this Agreement have been inserted for convenience of reference only and shall not
be deemed to be part of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <B>Severability.</B> In case any provision contained in this Agreement should be invalid,
illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <B>Most Favored Nations</B>. The Company hereby represents and warrants as of the date hereof and covenants and agrees that no agreement
entered into (or to be entered into) with any Person with respect to the Exchange or other transaction involving the warrants issued in the Registered Offering, including, without limitation with respect to any consent, release, amendment,
settlement, or waiver relating to any Exchange or such other transaction involving the warrants issued in the Registered Offering, including without limitation, any amendment, settlement or waiver relating to any securities issued in connection with
an exchange of warrants issued in the Registered Offering (including the Exchange Note or other derivative security) (each a &#147;<U>Settlement Document</U>&#148;), is or will be more favorable to such Person (other than any reimbursement of legal
fees) than those of the Holder and this Agreement, including without limitation the ratio of warrants to the cash paid, principal amount of notes, value of any shares of Common Stock (valued as the VWAP of the Common Stock on the Trading Day
immediately preceding the public announcement of such issuance), or value of any Options, Convertible Securities or Adjustment Rights (as such terms are defined in the Exchange Note) (valued on the Trading Day immediately preceding the public
announcement of such issuance, as the greater of (a)&nbsp;the VWAP of the Common Stock multiplied by the number of underlying shares and (b)&nbsp;the Black Scholes Consideration Value) conveyed in such Settlement Document. If, and whenever on or
after the date hereof, the Company enters into a Settlement Document, then (i)&nbsp;the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company shall provide notice thereof to the Holder within one (1)&nbsp;Trading Day following the occurrence thereof and (ii)&nbsp;the terms and conditions of this Agreement shall be, without any
further action by the Holder or the Company, automatically amended and modified in an economically and legally equivalent manner such that the Holder shall receive the benefit of the more favorable terms and/or conditions (as the case may be) set
forth in such Settlement Document, provided that upon written notice to the Company within ten (10)&nbsp;Trading Days of receipt of notice of such Settlement Document the Holder may notify the Company in writing of Holder&#146;s election not to
accept the benefit of any such amended or modified term or condition, in which event the term or condition contained in this Agreement shall apply to the Holder as it was in effect immediately prior to such amendment or modification as if such
amendment or modification never occurred with respect to the Holder. The provisions of this Section&nbsp;7(c) shall apply similarly and equally to each Settlement Document. For purposes hereof, &#147;Black Scholes Consideration Value&#148; means the
value of the applicable Option, Convertible Security or Adjustment Right (as the case may be) as of the date of issuance thereof calculated using the Black Scholes Option Pricing Model obtained from the &#147;OV&#148; function on Bloomberg utilizing
(i)&nbsp;an underlying price per share equal to the Closing Sale Price of the Common Stock on the Trading Day immediately preceding the public announcement of the execution of definitive documents with respect to the issuance of such Option or
Convertible Security (as the case may be), (ii) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining term of such Option, Convertible Security or Adjustment Right (as the case may be) as of the date
of issuance of such Option, Convertible Security or Adjustment Right (as the case may be), (iii) a zero cost of borrow and (iv)&nbsp;an expected volatility equal to the greater of 100% and the 30 day volatility obtained from the &#147;HVT&#148;
function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the date of issuance of such Option, Convertible Security or Adjustment Right (as the case may be). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <B>Governing Law.</B> This Agreement shall be governed by and construed under the laws of the State of New York without regard to the
choice of law principles thereof. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the State of New York located in The City of New York, Borough of Manhattan for the adjudication of any
dispute hereunder or in connection herewith or with any transaction contemplated hereby or thereby, and hereby irrevocably waives any objection that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit,
action or proceeding is improper. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY
TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <B>Counterparts.</B> This Agreement may be executed in two or more counterparts, each of which shall constitute an original, but all of
which, when taken together, shall constitute but one instrument, and shall become effective when one or more counterparts have been signed by each party hereto and delivered to the other parties. In the event that any signature is delivered by
facsimile transmission or by an <FONT STYLE="white-space:nowrap">e-mail</FONT> which contains an electronic file of an executed signature page, such signature page shall create a valid and binding obligation of the party executing (or on whose
behalf such signature is executed) with the same force and effect as if such facsimile or electronic file signature page (as the case may be) were an original thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) <B>Successors and Assigns.</B> Except as otherwise expressly provided herein, the provisions
hereof shall inure to the benefit of, and be binding upon, the successors, permitted assigns, heirs, executors and administrators of the parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">g) <B>Entire Agreement; Amendments.</B> This Agreement and other documents delivered pursuant hereto constitute the full and entire
understanding and agreement between the parties with regard to the subjects hereof and thereof. This Agreement may be amended, modified, superseded, cancelled, renewed or extended, and the terms and conditions hereof may be waived, only by a written
instrument signed by all parties, or, in the case of a waiver, by the party waiving compliance. Except as expressly stated herein, no delay on the part of any party in exercising any right, power or privilege hereunder shall operate as a waiver
thereof, nor shall any waiver on the part of any party of any right, power or privilege hereunder preclude any other or future exercise of any other right, power or privilege hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">h) <B>Survival. </B>The representations, warranties, covenants and agreements made in this Agreement shall survive the closing of the
transactions contemplated hereby and the exchange and delivery of the Warrants and the Exchange Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">i) <B>Further Assurances</B>. Each
party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request in order to
carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">j) <B>No
Third Party Beneficiaries</B>. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[signature pages follow] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have caused this Agreement to be executed by their
duly authorized representatives as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SELLAS LIFE SCIENCES GROUP, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Angelos Stergiou</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-size:10pt">Name: Angelos Stergiou, M.D., ScD h.c.</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-size:10pt">Title: &nbsp;&nbsp;Chief Executive Officer</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">COMPANY SIGNATURE PAGE TO </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">WARRANT EXCHANGE AGREEMENT </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>HOLDER: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>EMPERY TAX EFFICIENT II, LP</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>By: Empery Asset Management, LP, its authorized agent</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Brett Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Brett Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">General Counsel</TD></TR></TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">c/o Empery Asset Management, LP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1 Rockefeller Plaza, Suite 1205</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">New York, NY 10020</TD></TR></TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="white-space:nowrap">E-Mail:</FONT> notices@emperyam.com</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.85
<SEQUENCE>19
<FILENAME>d556278dex1085.htm
<DESCRIPTION>EX-10.85
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.85</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.85 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONVERTIBLE PROMISSORY NOTE </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>$27,010.62</B> </P></TD>
<TD ALIGN="right">February 21, 2018 </TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>New York</B>, <B>NY</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For value received <B>SELLAS Life Sciences Group, Inc.</B>, a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), promises to pay to
<B>EMPERY ASSET MASTER, LTD.</B> or its assigns (&#147;<B><I>Holder</I></B>&#148;) the principal sum of <B>$27,010.62</B> (the &#147;<B><I>Principal</I></B>&#148;) together with accrued and unpaid interest thereon (the
&#147;<B><I>Interest</I></B>&#148;), each due and payable on the date and in the manner set forth below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This convertible promissory note
(the &#147;<B><I>Note</I></B>&#148;) was issued in reliance on the exemption provided in Rule 3(a)(9) of the Securities Act of 1933, as amended, pursuant to the terms of that certain Exchange Agreement, dated February&nbsp;21, 2018 (the
&#147;<B><I>Exchange Agreement</I></B>&#148;), by and between the Company and the Holder in exchange for that certain Warrant (as defined in the Exchange Agreement) originally issued on February&nbsp;13, 2017 and shall be subject to the following
terms (capitalized terms not defined herein shall have the meaning as set forth in the Exchange Agreement):<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B>
<B>Repayment. </B>All payments of Interest and Principal shall be in lawful money of the United States of America. All payments shall be applied first to accrued Interest, and thereafter to Principal. The outstanding Principal amount of the Note
shall be due and payable on August&nbsp;9, 2018 (the &#147;<B><I>Maturity Date</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B>Interest.</B> The Company
promises to pay simple<B> </B>Interest on the outstanding Principal amount hereof from the date hereof until payment in full, which Interest shall be payable at the rate of 4.75% per annum (the &#147;<B><I>Interest Rate</I></B>&#148;) or the maximum
rate permissible by law, whichever is less. Interest shall be due and payable by way of inclusion of the Interest in the Conversion Amount on any Conversion Date in accordance with Section&nbsp;3 below or in cash on the Maturity Date and shall be
calculated on the basis of a <FONT STYLE="white-space:nowrap">365-day</FONT> year for the actual number of days elapsed. From and after the occurrence and during the continuance of any Event of Default (as defined below), the Interest Rate shall
automatically be increased to eighteen percent (18.0%) per annum (the &#147;<B><I>Default Rate</I></B>&#148;). In the event that such Event of Default is subsequently cured (and no other Event of Default then exists (including, without limitation,
for the Company&#146;s failure to pay such Interest at the Default Rate on the Maturity Date)), the adjustment referred to in the preceding sentence shall cease to be effective as of the calendar day immediately following the date of such cure;
provided that the Interest as calculated and unpaid at such increased rate during the continuance of such Event of Default shall continue to apply to the extent relating to the days after the occurrence of such Event of Default through and including
the date of such cure of such Event of Default. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3. Conversion. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the election of the Holder made at any time after April&nbsp;30, 2018, this Note shall be convertible into validly issued, fully paid and <FONT
STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock (as defined below), on the terms and conditions set forth in this Section&nbsp;3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Conversion Right</B>. Subject to the provisions of Section&nbsp;3(d), at any time or times on or after April&nbsp;30, 2018, the
Holder shall be entitled to convert any portion of the outstanding and unpaid Conversion Amount (as defined below) into validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock in accordance with
Section&nbsp;3(c), at the Conversion Rate (as defined below). The Company shall not issue any fraction of a share of Common Stock upon any conversion. If the issuance would result in the issuance of a fraction of a share of Common Stock, the Company
shall round such fraction of a share of Common Stock up to the nearest whole share. The Company shall pay any and all transfer, stamp, issuance and similar taxes, costs and expenses (including, without limitation, fees and expenses of the
Company&#146;s transfer agent (the &#147;<B><I>Transfer Agent</I></B>&#148;)) that may be payable with respect to the issuance and delivery of Common Stock upon conversion of any Conversion Amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Conversion Rate</B>. The number of shares of Common Stock issuable upon conversion of any Conversion Amount pursuant to
Section&nbsp;3(a) shall be determined by dividing (x)&nbsp;such Conversion Amount by (y)&nbsp;the Conversion Price (the &#147;<B><I>Conversion Rate</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> &#147;<B><I>Conversion Amount</I></B>&#148; means the sum of (x)&nbsp;portion of the Principal to be converted, redeemed or
otherwise with respect to which this determination is being made and (y)&nbsp;all accrued and unpaid Interest with respect to such portion of the Principal amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> &#147;<B><I>Conversion Price</I></B>&#148; means, as of any Conversion Date or other date of determination, $7.00, subject to
adjustment as provided herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Mechanics of Conversion</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Optional Conversion</B>. To convert any Conversion Amount into shares of Common Stock on any date (a &#147;<B><I>Conversion
Date</I></B>&#148;), the Holder shall deliver (whether via facsimile, electronic mail or otherwise), for receipt on or prior to 11:59 p.m., New York time, on such date, a copy of an executed notice of conversion (the &#147;<B><I>Conversion
Notice</I></B>&#148;) to the Company. If required by Section&nbsp;3(c)(iii), within two (2)&nbsp;Trading Days following a conversion of this Note as aforesaid, the Holder shall surrender this Note to a nationally recognized overnight delivery
service for delivery to the Company (or an indemnification undertaking with respect to this Note in the case of its loss, theft or destruction). On or before the first (1st) Trading Day following the date of receipt of a Conversion Notice, the
Company shall transmit by facsimile or electronic mail an acknowledgment of confirmation and representation as to whether such shares of Common Stock may then be resold pursuant to Rule 144 or an effective and available registration statement, of
receipt of such Conversion Notice to the Holder and the Transfer Agent which confirmation shall constitute an instruction to the Transfer Agent to process such Conversion Notice in accordance with the terms herein. On or before the second (2nd)
Trading Day following the date on which the Company has received a Conversion Notice (or such earlier date as required pursuant to the Exchange Act or other applicable law, rule or regulation for the settlement of a trade initiated on the applicable
Conversion Date of such shares of Common Stock issuable pursuant to such Conversion Notice) (the &#147;<B><I>Share Delivery Deadline</I></B><I>&#148;</I><I>),</I> the Company shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(1) provided that the Transfer Agent is participating in the DTC Fast Automated Securities Transfer Program, credit such aggregate number of shares of Common Stock to which the Holder shall be
entitled pursuant to such conversion to the Holder&#146;s or its designee&#146;s balance account with DTC through its Deposit/Withdrawal at Custodian system or (2)&nbsp;if the Transfer Agent is not participating in the DTC Fast Automated Securities
Transfer Program, upon the request of the Holder, issue and deliver (via reputable overnight courier) to the address as specified in the Conversion Notice, a certificate, registered in the name of the Holder or its designee, for the number of shares
of Common Stock to which the Holder shall be entitled pursuant to such conversion. If this Note is physically surrendered for conversion pursuant to Section&nbsp;3(c)(iii) and the outstanding Principal of this Note is greater than the Principal
portion of the Conversion Amount being converted, then the Company shall as soon as practicable and in no event later than two (2)&nbsp;Business Days after receipt of this Note and at its own expense, issue and deliver to the Holder (or its
designee) a new Note representing the outstanding Principal not converted. While this Note remains outstanding, the Company shall use a transfer agent that participates in the DTC Fast Automated Securities Transfer Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Company</B><B>&#146;</B><B>s Failure to Timely Convert</B>. If the Company shall fail, for any reason or for no reason, on or
prior to the applicable Share Delivery Deadline, if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program, to issue and deliver to the Holder (or its designee) a certificate for the number of shares of Common
Stock to which the Holder is entitled and register such shares of Common Stock on the Company&#146;s share register or, if the Transfer Agent is participating in the DTC Fast Automated Securities Transfer Program, to credit the balance account of
the Holder or the Holder&#146;s designee with DTC for such number of shares of Common Stock to which the Holder is entitled upon the Holder&#146;s conversion of this Note (as the case may be) (a &#147;<B><I>Conversion Failure</I></B>&#148;), and if
on or after such Share Delivery Deadline the Holder purchases (in an open market transaction or otherwise) shares of Common Stock corresponding to all or any portion of the number of shares of Common Stock issuable upon such conversion that the
Holder is entitled to receive from the Company and has not received from the Company in connection with such Conversion Failure (a &#147;<B><I><FONT STYLE="white-space:nowrap">Buy-In</FONT></I></B>&#148;), then, in addition to all other remedies
available to the Holder, the Company shall, within two (2)&nbsp;Business Days after receipt of the Holder&#146;s request and in the Holder&#146;s discretion, either: (I)&nbsp;pay cash to the Holder in an amount equal to the Holder&#146;s total
purchase price (including brokerage commissions and other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, if any) for the shares of Common Stock so purchased (including, without limitation, by
any other Person in respect, or on behalf, of the Holder) (the &#147;<B><FONT STYLE="white-space:nowrap">Buy-In</FONT> Price</B>&#148;), at which point the Company&#146;s obligation to so issue and deliver such certificate (and to issue such shares
of Common Stock) or credit the balance account of such Holder or such Holder&#146;s designee, as applicable, with DTC for the number of shares of Common Stock to which the Holder is entitled upon the Holder&#146;s conversion hereunder (as the case
may be) (and to issue such shares of Common Stock) shall terminate, or (II)&nbsp;promptly honor its obligation to so issue and deliver to the Holder a certificate or certificates representing such shares of Common Stock or credit the balance account
of such Holder or such Holder&#146;s designee, as applicable, with DTC for the number of shares of Common Stock to which the Holder is entitled upon the Holder&#146;s conversion hereunder (as the case may be) and pay cash to the Holder in an amount
equal to the excess (if any) of the <FONT STYLE="white-space:nowrap">Buy-In</FONT> Price over the product of (x)&nbsp;such number of shares of Common Stock multiplied by (y)&nbsp;the lowest Closing Sale Price of the Common Stock on any Trading Day
during the period commencing on the date of the applicable Conversion Notice and ending on the date of such issuance and payment under this clause (II) (the &#147;<B><I><FONT STYLE="white-space:nowrap">Buy-In</FONT> Payment Amount</I></B>&#148;).
Nothing shall limit </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Holder&#146;s right to pursue any other remedies available to it hereunder, at law or in equity, including, without limitation, a decree of specific performance and/or injunctive relief with
respect to the Company&#146;s failure to timely deliver certificates representing shares of Common Stock (or to electronically deliver such shares of Common Stock) upon the conversion of this Note as required pursuant to the terms hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> <B>Registration; Book-Entry</B>. The Holder and the Company shall maintain records showing the Principal and Interest converted
and/or paid (as the case may be) and the dates of such conversions, and/or payments (as the case may be) or shall use such other method, reasonably satisfactory to the Holder and the Company, so as not to require physical surrender of this Note upon
conversion. Notwithstanding anything to the contrary set forth in this Section&nbsp;3, following conversion of any portion of this Note in accordance with the terms hereof, the Holder shall not be required to physically surrender this Note to the
Company unless (A)&nbsp;the full Conversion Amount represented by this Note is being converted (in which event this Note shall be delivered to the Company following conversion thereof as contemplated by Section&nbsp;3(c)(i)) or (B)&nbsp;the Holder
has provided the Company with prior written notice (which notice may be included in a Conversion Notice) requesting reissuance of this Note upon physical surrender of this Note. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Limitations on Conversions</B>. The Company shall not effect the conversion of any portion of this Note, and the Holder shall
not have the right to convert any portion of this Note pursuant to the terms and conditions of this Note and any such conversion shall be null and void and treated as if never made, to the extent that after giving effect to such conversion, the
Holder together with the other Attribution Parties collectively would beneficially own in excess of 9.99% (the &#147;<B><I>Maximum Percentage</I></B>&#148;) of the shares of Common Stock outstanding immediately after giving effect to such
conversion. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by the Holder and the other Attribution Parties shall include the number of shares of Common Stock held by the Holder and all other
Attribution Parties plus the number of shares of Common Stock issuable upon conversion of this Note with respect to which the determination of such sentence is being made, but shall exclude shares of Common Stock which would be issuable upon
(A)&nbsp;conversion of the remaining, nonconverted portion of this Note beneficially owned by the Holder or any of the other Attribution Parties and (B)&nbsp;exercise or conversion of the unexercised or nonconverted portion of any other securities
of the Company (including, without limitation, any convertible notes or convertible preferred stock or warrants, including, without limitation, the Warrants) beneficially owned by the Holder or any other Attribution Party subject to a limitation on
conversion or exercise analogous to the limitation contained in this Section&nbsp;3(d). For purposes of this Section&nbsp;3(d), beneficial ownership shall be calculated in accordance with Section&nbsp;13(d) of the Exchange Act. For purposes of
determining the number of outstanding shares of Common Stock the Holder may acquire upon the conversion of this Note without exceeding the Maximum Percentage, the Holder may rely on the number of outstanding shares of Common Stock as reflected in
(x)&nbsp;the Company&#146;s most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or
other public filing with the SEC, as the case may be, (y)&nbsp;a more recent public announcement by the Company or (z)&nbsp;any other written notice by the Company or the Transfer Agent, if any, setting forth the number of shares of Common Stock
outstanding (the &#147;<B><I>Reported Outstanding Share Number</I></B>&#148;). If the Company receives a Conversion Notice from the Holder at a time when the actual number of outstanding shares of Common Stock is less than the Reported Outstanding
Share </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Number, the Company shall notify the Holder in writing of the number of shares of Common Stock then outstanding and, to the extent that such Conversion Notice would otherwise cause the
Holder&#146;s beneficial ownership, as determined pursuant to this Section&nbsp;3(d), to exceed the Maximum Percentage, the Holder must notify the Company of a reduced number of shares of Common Stock to be purchased pursuant to such Conversion
Notice. For any reason at any time, upon the written or oral request of the Holder, the Company shall within one (1)&nbsp;Business Day confirm orally and in writing or by electronic mail to the Holder the number of shares of Common Stock then
outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Note, by the Holder and any other Attribution Party since
the date as of which the Reported Outstanding Share Number was reported. In the event that the issuance of shares of Common Stock to the Holder upon conversion of this Note results in the Holder and the other Attribution Parties being deemed to
beneficially own, in the aggregate, more than the Maximum Percentage of the number of outstanding shares of Common Stock (as determined under Section&nbsp;13(d) of the Exchange Act), the number of shares so issued by which the Holder&#146;s and the
other Attribution Parties&#146; aggregate beneficial ownership exceeds the Maximum Percentage (the &#147;<B>Excess Shares</B>&#148;) shall be deemed null and void and shall be cancelled ab initio, and the Holder shall not have the power to vote or
to transfer the Excess Shares. Upon delivery of a written notice to the Company, the Holder may from time to time increase (with such increase not effective until the sixty-first (61<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>) day after
delivery of such notice) or decrease the Maximum Percentage to any other percentage not in excess of 9.99% as specified in such notice; provided that (i)&nbsp;any such increase in the Maximum Percentage will not be effective until the sixty-first
(61<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>) day after such notice is delivered to the Company and (ii)&nbsp;any such increase or decrease will apply only to the Holder and the other Attribution Parties and not to any other holder of
Notes that is not an Attribution Party of the Holder. For purposes of clarity, the shares of Common Stock issuable pursuant to the terms of this Note in excess of the Maximum Percentage shall not be deemed to be beneficially owned by the Holder for
any purpose including for purposes of Section&nbsp;13(d) or Rule <FONT STYLE="white-space:nowrap">16a-1(a)(1)</FONT> of the Exchange Act. No prior inability to convert this Note pursuant to this paragraph shall have any effect on the applicability
of the provisions of this paragraph with respect to any subsequent determination of convertibility. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this
Section&nbsp;3(d) to the extent necessary to correct this paragraph (or any portion of this paragraph) which may be defective or inconsistent with the intended beneficial ownership limitation contained in this Section&nbsp;3(d) or to make changes or
supplements necessary or desirable to properly give effect to such limitation. The limitation contained in this paragraph may not be waived and shall apply to a successor holder of this Note. Further, notwithstanding anything in this Note to the
contrary, under no circumstances shall the Company be obligated to issue or the Holder entitled to receive, an aggregate number of shares of Common Stock that would exceed 19.9% of the total number of shares of Common Stock issued and outstanding as
of the date of this Note (the &#147;<B><I>Maximum Issuance</I></B>&#148;); provided, that to the extent the aggregate number of shares of Common Stock would exceed the Maximum Issuance, the Company shall issue and deliver to Holder a number of
shares of Common Stock up to the Maximum Issuance and the unconverted Principal of this Note shall remain outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Right of Alternate Conversion</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <U>General</U>. At any time at any time after the occurrence of an Event of Default (regardless of whether such Event of Default
has been cured), the Holder may, at the Holder&#146;s option, convert (each, an &#147;<B><I>Alternate Conversion</I></B>&#148;, and the date of such Alternate Conversion, each, an &#147;<B><I>Alternate Conversion Date</I></B>&#148;) all, or any part
of, the Conversion Amount (such portion of the Conversion Amount subject to such Alternate Conversion, the &#147;<B><I>Alternate Conversion Amount</I></B>&#148;) into shares of Common Stock at the Alternate Conversion Price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <U>Mechanics of Alternate Conversion</U>. On any Alternate Conversion Date, the Holder may voluntarily convert any Alternate
Conversion Amount pursuant to Section&nbsp;3(c) (with &#147;Alternate Conversion Price&#148; replacing &#147;Conversion Price&#148; for all purposes hereunder with respect to such Alternate Conversion) by designating in the Conversion Notice
delivered pursuant to this Section&nbsp;3(e) of this Note that the Holder is electing to use the Alternate Conversion Price for such conversion. Notwithstanding anything to the contrary in this Section&nbsp;3(e), but subject to Section&nbsp;3(d),
until the Company delivers shares of Common Stock representing the applicable Alternate Conversion Amount to the Holder, such Alternate Conversion Amount may be converted by the Holder into shares of Common Stock pursuant to Section&nbsp;3(c)
without regard to this Section&nbsp;3(e). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B>Voluntary Adjustment by Company</B>. The Company may at any time during the term
of this Note, with the prior written consent of the Holder, reduce the then current Conversion Price of this Note to any amount and for any period of time deemed appropriate by the board of directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B>Maturity.</B> Unless this Note has been previously converted or prepaid in accordance with the terms of Section&nbsp;3(a) above,
the entire outstanding Conversion Amount shall become fully due and payable in cash on the Maturity Date; provided, that if the Conversion Amount is not paid in full in cash on the Maturity Date, subject to Section&nbsp;3(d) above, the Holder shall
retain the right to convert all, or any part, at such Holder&#146;s sole discretion, of the Conversion Amount into shares of Common Stock in accordance with Section&nbsp;3 above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B>Expenses. </B>In the event of any default hereunder, the Company shall pay all reasonable attorneys&#146; fees and court costs
incurred by Holder in enforcing and collecting this Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B>Prepayment.</B> The Company may prepay this Note and accrued but
unpaid Interest prior to the Maturity Date at any time without the consent of the Holder; provided, that the Company may not prepay any Conversion Amount submitted for conversion pursuant to Section&nbsp;3 above from and after the applicable
Conversion Date unless such corresponding Conversion Notice is withdrawn by the Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B>Default. </B>If there shall be any
Event of Default hereunder, at the option and upon the declaration of the Holder and upon written notice to the Company (which election and notice shall not be required in the case of an Event of Default under Section&nbsp;7(v), 7(vi) or 7(vii)),
this Note shall accelerate and all Principal and unpaid accrued Interest shall become immediately due and payable. The occurrence of any one or more of the following shall constitute an &#147;<B><I>Event of Default</I></B>&#148;: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> the suspension (or threatened suspension) from trading or the failure (or threatened failure) of the Common Stock to be trading or
listed (as applicable) on the Nasdaq Capital Market for a period of five (5)&nbsp;consecutive Trading Days; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> the Company&#146;s (A)&nbsp;failure to cure a Conversion Failure by delivery of the
required number of shares of Common Stock within five (5)&nbsp;Trading Days after the applicable Conversion Date or exercise date (as the case may be) or (B)&nbsp;notice, written or oral, to any holder of the Notes, including, without limitation, by
way of public announcement or through any of its agents, at any time, of its intention not to comply, as required, with a request for conversion of any Notes into shares of Common Stock that is requested in accordance with the provisions of the
Notes, other than pursuant to Section&nbsp;3(d); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> the Company&#146;s or any Subsidiary&#146;s failure to pay to the Holder
any amount of Principal, Interest or other amounts when and as due under this Note (including, without limitation, the Company&#146;s failure to pay any redemption payments or amounts hereunder) or any other Exchange Document or any other agreement,
document, certificate or other instrument delivered in connection with the transactions contemplated hereby and thereby, except, in the case of a failure to pay Interest when and as due, in which case only if such failure remains uncured for a
period of at least two (2)&nbsp;Trading Days; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> [INTENTIONALLY OMITTED]; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings for the relief of debtors shall be
instituted by or against the Company or any Subsidiary and, if instituted against the Company or any Subsidiary by a third party, shall not be dismissed within thirty (30)&nbsp;days of their initiation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> the commencement by the Company or any Subsidiary of a voluntary case or proceeding under any applicable federal, state or
foreign bankruptcy, insolvency, reorganization or other similar law or of any other case or proceeding to be adjudicated a bankrupt or insolvent, or the consent by it to the entry of a decree, order, judgment or other similar document in respect of
the Company or any Subsidiary in an involuntary case or proceeding under any applicable federal, state or foreign bankruptcy, insolvency, reorganization or other similar law or to the commencement of any bankruptcy or insolvency case or proceeding
against it, or the filing by it of a petition or answer or consent seeking reorganization or relief under any applicable federal, state or foreign law, or the consent by it to the filing of such petition or to the appointment of or taking possession
by a custodian, receiver, liquidator, assignee, trustee, sequestrator or other similar official of the Company or any Subsidiary or of any substantial part of its property, or the making by it of an assignment for the benefit of creditors, or the
execution of a composition of debts, or the occurrence of any other similar federal, state or foreign proceeding, or the admission by it in writing of its inability to pay its debts generally as they become due, the taking of corporate action by the
Company or any Subsidiary in furtherance of any such action or the taking of any action by any Person to commence a Uniform Commercial Code foreclosure sale or any other similar action under federal, state or foreign law; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vii)</B> the entry by a court of (i)&nbsp;a decree, order, judgment or other similar
document in respect of the Company or any Subsidiary of a voluntary or involuntary case or proceeding under any applicable federal, state or foreign bankruptcy, insolvency, reorganization or other similar law or (ii)&nbsp;a decree, order, judgment
or other similar document adjudging the Company or any Subsidiary as bankrupt or insolvent, or approving as properly filed a petition seeking liquidation, reorganization, arrangement, adjustment or composition of or in respect of the Company or any
Subsidiary under any applicable federal, state or foreign law or (iii)&nbsp;a decree, order, judgment or other similar document appointing a custodian, receiver, liquidator, assignee, trustee, sequestrator or other similar official of the Company or
any Subsidiary or of any substantial part of its property, or ordering the winding up or liquidation of its affairs, and the continuance of any such decree, order, judgment or other similar document or any such other decree, order, judgment or other
similar document unstayed and in effect for a period of thirty (30)&nbsp;consecutive days; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(viii)</B> other than as specifically
set forth in another clause of this Section&nbsp;7, the Company or any Subsidiary breaches any representation, warranty, covenant or other term or condition of any Exchange Document, except, in the case of a breach of a covenant or other term or
condition that is curable, only if such breach remains uncured for a period of three (3)&nbsp;consecutive Trading Days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.</B>
<B>Adjustment of Conversion Price upon Subdivision or Combination of Common Stock</B>. If the Company at any time on or after the date hereof subdivides (by any stock split, stock dividend, stock combination, recapitalization or other similar
transaction) one or more classes of its outstanding shares of Common Stock into a greater number of shares, the Conversion Price in effect immediately prior to such subdivision will be proportionately reduced. If the Company at any time on or after
the date hereof combines (by any stock split, stock dividend, stock combination, recapitalization or other similar transaction) one or more classes of its outstanding shares of Common Stock into a smaller number of shares, the Conversion Price in
effect immediately prior to such combination will be proportionately increased. Any adjustment pursuant to this Section&nbsp;8 shall become effective immediately after the effective date of such subdivision or combination. If any event requiring an
adjustment under this Section&nbsp;8 occurs during the period that a Conversion Price is calculated hereunder, then the calculation of such Conversion Price shall be adjusted appropriately to reflect such event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.</B> <B>Rights upon Fundamental Transaction</B>. The Company shall not enter into or be party to a Fundamental Transaction unless
(i)&nbsp;the Successor Entity assumes in writing all of the obligations of the Company under this Note and the other Exchange Documents in accordance with the provisions of this Section&nbsp;9 pursuant to written agreements in form and substance
satisfactory to the Holder and approved by the Holder prior to such Fundamental Transaction, including agreements to deliver to each holder of Notes in exchange for such Notes a security of the Successor Entity evidenced by a written instrument
substantially similar in form and substance to the Notes, including, without limitation, having a principal amount and interest rate equal to the principal amounts then outstanding and the interest rates of the Notes held by such holder, having
similar conversion rights as the Notes and having similar ranking and security to the Notes, and satisfactory to the Holder and (ii)&nbsp;the Successor Entity (including its Parent Entity) is a publicly traded corporation whose common stock is
quoted on or listed for trading on an Eligible Market. Upon the occurrence of any Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Note and the other Exchange Documents referring to the &#147;Company&#148; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
all of the obligations of the Company under this Note and the other Exchange Documents with the same effect as if such Successor Entity had been named as the Company herein. Upon consummation of
a Fundamental Transaction, the Successor Entity shall deliver to the Holder confirmation that there shall be issued upon conversion or redemption of this Note at any time after the consummation of such Fundamental Transaction, in lieu of the shares
of Common Stock (or other securities, cash, assets or other property (except such items still issuable under Sections 10(a) and 11, which shall continue to be receivable thereafter) issuable upon the conversion or redemption of the Notes prior to
such Fundamental Transaction, such shares of the publicly traded common stock (or their equivalent) of the Successor Entity (including its Parent Entity) which the Holder would have been entitled to receive upon the happening of such Fundamental
Transaction had this Note been converted immediately prior to such Fundamental Transaction (without regard to any limitations on the conversion of this Note), as adjusted in accordance with the provisions of this Note. Notwithstanding the foregoing,
the Holder may elect, at its sole option, by delivery of written notice to the Company to waive this Section&nbsp;9 to permit the Fundamental Transaction without the assumption of this Note. The provisions of this Section&nbsp;9 shall apply
similarly and equally to successive Fundamental Transactions and shall be applied without regard to any limitations on the conversion of this Note. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10. Rights Upon Issuance of Purchase Rights and Other Corporate Events. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Purchase Rights</B>. If at any time the Company grants, issues or sells any Options, Convertible Securities or rights to
purchase stock, warrants, securities or other property pro rata to all or substantially all of the record holders of any class of Common Stock (the &#147;<B><I>Purchase Rights</I></B>&#148;), then the Holder will be entitled to acquire, upon the
terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete conversion of this Note (without taking into account
any limitations or restrictions on the convertibility of this Note and assuming for such purpose that the Note was converted at the Alternate Conversion Price as of the applicable record date) immediately prior to the date on which a record is taken
for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>,
<U>however</U>, that to the extent that the Holder&#146;s right to participate in any such Purchase Right would result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to
participate in such Purchase Right to the extent of the Maximum Percentage (and shall not be entitled to beneficial ownership of such shares of Common Stock as a result of such Purchase Right (and beneficial ownership) to the extent of any such
excess) and such Purchase Right to such extent shall be held in abeyance (and, if such Purchase Right has an expiration date, maturity date or other similar provision, such term shall be extended by such number of days held in abeyance, if
applicable) for the benefit of the Holder until such time or times, if ever, as its right thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, at which time or times the Holder shall be granted
such right (and any Purchase Right granted, issued or sold on such initial Purchase Right or on any subsequent Purchase Right held similarly in abeyance (and, if such Purchase Right has an expiration date, maturity date or other similar provision,
such term shall be extended by such number of days held in abeyance, if applicable)) to the same extent as if there had been no such limitation). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Other Corporate Events</B>. In addition to and not in substitution for any other
rights hereunder, prior to the consummation of any Fundamental Transaction pursuant to which holders of shares of Common Stock are entitled to receive securities or other assets with respect to or in exchange for shares of Common Stock (a
&#147;<B><I>Corporate Event</I></B>&#148;), the Company shall make appropriate provision to ensure that the Holder will thereafter have the right to receive upon a conversion of this Note, at the Holder&#146;s option (i)&nbsp;in addition to the
shares of Common Stock receivable upon such conversion, such securities or other assets to which the Holder would have been entitled with respect to such shares of Common Stock had such shares of Common Stock been held by the Holder upon the
consummation of such Corporate Event (without taking into account any limitations or restrictions on the convertibility of this Note) or (ii)&nbsp;in lieu of the shares of Common Stock otherwise receivable upon such conversion, such securities or
other assets received by the holders of shares of Common Stock in connection with the consummation of such Corporate Event in such amounts as the Holder would have been entitled to receive had this Note initially been issued with conversion rights
for the form of such consideration (as opposed to shares of Common Stock) at a conversion rate for such consideration commensurate with the Conversion Rate. Provision made pursuant to the preceding sentence shall be in a form and substance
satisfactory to the Holder. The provisions of this Section&nbsp;10(b) shall apply similarly and equally to successive Corporate Events and shall be applied without regard to any limitations on the conversion or redemption of this Note. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.</B> <B>Remedies, Characterizations, Other Obligations, Breaches and Injunctive Relief</B>. The remedies provided in this Note shall be
cumulative and in addition to all other remedies available under this Note and any of the other Exchange Documents at law or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the
Holder&#146;s right to pursue actual and consequential damages for any failure by the Company to comply with the terms of this Note. The Company covenants to the Holder that there shall be no characterization concerning this instrument other than as
expressly provided herein. Amounts set forth or provided for herein with respect to payments, conversion and the like (and the computation thereof) shall be the amounts to be received by the Holder and shall not, except as expressly provided herein,
be subject to any other obligation of the Company (or the performance thereof). The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder and that the remedy at law for any such breach may be
inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach, the Holder shall be entitled, in addition to all other available remedies, to specific performance and/or temporary, preliminary and permanent
injunctive or other equitable relief from any court of competent jurisdiction in any such case without the necessity of proving actual damages and without posting a bond or other security. The Company shall provide all information and documentation
to the Holder that is requested by the Holder to enable the Holder to confirm the Company&#146;s compliance with the terms and conditions of this Note. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.</B> <B>Severability</B>. If any provision of this Note is prohibited by law or otherwise determined to be invalid or unenforceable by a
court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of
such provision shall not affect the validity of the remaining provisions of this Note so long as this Note as so modified continues to express, without material change, the original intentions of the parties as to the subject matter hereof and the
prohibited nature, invalidity or unenforceability of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise
be conferred upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited,
invalid or unenforceable provision(s). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.</B> <B>Maximum Payments</B>. Nothing contained herein shall be deemed to establish or
require the payment of a rate of interest or other charges in excess of the maximum permitted by applicable law. In the event that the rate of interest required to be paid or other charges hereunder exceed the maximum permitted by such law, any
payments in excess of such maximum shall be credited against amounts owed by the Company to the Holder and thus refunded to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.</B> <B>Waiver. </B>The Company hereby waives demand, notice, presentment, protest and notice of dishonor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.</B> <B>Governing Law. </B>This Note shall be construed and enforced in accordance with, and all questions concerning the construction,
validity, interpretation and performance of this Note shall be governed by, the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other
jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York. The Company hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The City of New York,
Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding,
any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein shall be
deemed or operate to preclude the Holder from bringing suit or taking other legal action against the Company in any other jurisdiction to collect on the Company&#146;s obligations to the Holder, to realize on any collateral or any other security for
such obligations, or to enforce a judgment or other court ruling in favor of the Holder. THE COMPANY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN
CONNECTION WITH OR ARISING OUT OF THIS NOTE OR ANY TRANSACTION CONTEMPLATED HEREBY. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.</B> <B>Failure Or Indulgence Not Waiver</B>.
No failure or delay on the part of the Holder in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further
exercise thereof or of any other right, power or privilege. No waiver shall be effective unless it is in writing and signed by an authorized representative of the waiving party. Notwithstanding the foregoing, nothing contained in this
Section&nbsp;16 shall permit any waiver of any provision of Section&nbsp;3(d). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.</B> <B>Amending the Terms of this Note</B>. The prior written consent of the Holder shall
be required for any change, waiver or amendment to this Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>18.</B> <B>Notices; Currency; Payments</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Notices</B>. Whenever notice is required to be given under this Note, unless otherwise provided herein, such notice shall be
given in accordance with the terms of the Exchange Agreement. The Company shall provide the Holder with prompt written notice of all actions taken pursuant to this Note, including in reasonable detail a description of such action and the reason
therefore. Without limiting the generality of the foregoing, the Company will give written notice to the Holder (i)&nbsp;immediately upon any adjustment of the Conversion Price, setting forth in reasonable detail, and certifying, the calculation of
such adjustment and (ii)&nbsp;at least fifteen (15)&nbsp;days prior to the date on which the Company closes its books or takes a record (A)&nbsp;with respect to any dividend or distribution upon the Common Stock, and (B)&nbsp;for determining rights
to vote with respect to any Fundamental Transaction, dissolution or liquidation, provided in each case that such information shall be made known to the public prior to or in conjunction with such notice being provided to the Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Currency</B>. All dollar amounts referred to in this Note are in United States Dollars (&#147;<B><I>U.S. Dollars</I></B>&#148;),
and all amounts owing under this Note shall be paid in U.S. Dollars. All amounts denominated in other currencies (if any) shall be converted into the U.S.&nbsp;Dollar equivalent amount in accordance with the Exchange Rate on the date of calculation.
&#147;<B><I>Exchange Rate</I></B>&#148;<B> </B>means, in relation to any amount of currency to be converted into U.S. Dollars pursuant to this Note, the U.S.&nbsp;Dollar exchange rate as published in the Wall Street Journal on the relevant date of
calculation (it being understood and agreed that where an amount is calculated with reference to, or over, a period of time, the date of calculation shall be the final date of such period of time). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Payments</B>. Whenever any payment of cash is to be made by the Company to any Person pursuant to this Note, unless otherwise
expressly set forth herein, such payment shall be made in lawful money of the United States of America by a certified check drawn on the account of the Company and sent via overnight courier service to such Person at such address as previously
provided to the Company in writing, provided that the Holder may elect to receive a payment of cash via wire transfer of immediately available funds by providing the Company with prior written notice setting out such request and the Holder&#146;s
wire transfer instructions. Whenever any amount expressed to be due by the terms of this Note is due on any day which is not a Business Day, the same shall instead be due on the next succeeding day which is a Business Day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>19.</B> <B>Waiver of Notice</B>. To the extent permitted by law, the Company hereby irrevocably waives demand, notice, presentment, protest
and all other demands and notices in connection with the delivery, acceptance, performance, default or enforcement of this Note and the Exchange Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>20.</B> <B>Assignment.</B> This Note may be transferred only upon its surrender to the Company for registration of transfer, duly endorsed,
or accompanied by a duly executed written instrument of transfer in form satisfactory to the Company. Thereupon, this Note shall be reissued to, and registered in the name of, the transferee, or a new Note for like Principal amount and Interest
shall be issued to, and registered in the name of, the transferee. Interest and Principal shall be paid solely to the registered holder of this Note. Such payment shall constitute full discharge of the Company&#146;s obligation to pay such Interest
and Principal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.</B> <U>CERTAIN DEFINITIONS</U>. For purposes of this Note, the following terms shall have
the following meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <I>&#147;</I><B><I>Adjustment Right&#148;</I></B><B> </B>means any right granted with respect to any
securities issued in connection with, or with respect to, any issuance or sale (or deemed issuance or sale) of shares of Common Stock that could result in a decrease in the net consideration received by the Company in connection with, or with
respect to, such securities (including, without limitation, any cash settlement rights, cash adjustment or other similar rights). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> &#147;<B><I>Alternate Conversion Price</I></B>&#148; means, with respect to any Alternate Conversion that price which shall be the
lowest of (i)&nbsp;the applicable Conversion Price as in effect on the applicable Conversion Date of the applicable Alternate Conversion, (ii) 70% of the lowest VWAP of the Common Stock as of the Trading Day during the ten (10)&nbsp;consecutive
Trading Day period ending and including the applicable Alternate Conversion Date (such period, the &#147;<B><I>Alternate Conversion Measuring Period</I></B>&#148;). All such determinations to be appropriately adjusted for any stock dividend, stock
split, stock combination, reclassification or similar transaction that proportionately decreases or increases the Common Stock during such Alternate Conversion Measuring Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> &#147;<B><I>Attribution Parties</I></B>&#148; means, collectively, the following Persons and entities: (i)&nbsp;any investment
vehicle, including, any funds, feeder funds or managed accounts, currently, or from time to time after the date hereof, directly or indirectly managed or advised by the Holder&#146;s investment manager or any of its Affiliates or principals,
(ii)&nbsp;any direct or indirect Affiliates of the Holder or any of the foregoing, (iii)&nbsp;any Person acting or who could be deemed to be acting as a Group together with the Holder or any of the foregoing and (iv)&nbsp;any other Persons whose
beneficial ownership of the Company&#146;s Common Stock would or could be aggregated with the Holder&#146;s and the other Attribution Parties for purposes of Section&nbsp;13(d) of the Exchange Act. For clarity, the purpose of the foregoing is to
subject collectively the Holder and all other Attribution Parties to the Maximum Percentage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>
&#147;<B><I>Bloomberg</I></B>&#148; means Bloomberg, L.P. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> &#147;<B><I>Business Day</I></B>&#148; means any day other than
Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> &#147;<B><I>Closing Bid Price</I></B>&#148; and &#147;<B><I>Closing Sale Price</I></B>&#148; means, for any security as of any
date, the last closing bid price and last closing trade price, respectively, for such security on the Principal Market, as reported by Bloomberg, or, if the Principal Market begins to operate on an extended hours basis and does not designate the
closing bid price or the closing trade price (as the case may be) then the last bid price or last trade price, respectively, of such security prior to 4:00:00 p.m., New York time, as reported by Bloomberg, or, if the Principal Market is not the
principal securities exchange or trading market for such security, the last closing bid price or last trade price, respectively, of such security on the principal securities exchange or trading market
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
where such security is listed or traded as reported by Bloomberg, or if the foregoing do not apply, the last closing bid price or last trade price, respectively, of such security in the <FONT
STYLE="white-space:nowrap">over-the-counter</FONT> market on the electronic bulletin board for such security as reported by Bloomberg, or, if no closing bid price or last trade price, respectively, is reported for such security by Bloomberg, the
average of the bid prices, or the ask prices, respectively, of any market makers for such security as reported in the &#147;pink sheets&#148; by OTC Markets Group Inc. (formerly Pink Sheets LLC). If the Closing Bid Price or the Closing Sale Price
cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Bid Price or the Closing Sale Price (as the case may be) of such security on such date shall be the fair market value as mutually determined by the
Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then such dispute shall be resolved in accordance with the procedures in Section&nbsp;22. All such determinations shall be
appropriately adjusted for any stock splits, stock dividends, stock combinations, recapitalizations or other similar transactions during such period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> &#147;<B><I>Common Stock</I></B>&#148; means (i)&nbsp;the Company&#146;s shares of common stock, $0.0001 par value per share, and
(ii)&nbsp;any capital stock into which such common stock shall have been changed or any share capital resulting from a reclassification of such common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> &#147;<B><I>Convertible Securities</I></B>&#148; means any stock or other security (other than Options) that is at any time and
under any circumstances, directly or indirectly, convertible into, exercisable or exchangeable for, or which otherwise entitles the holder thereof to acquire, any shares of Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> &#147;<B><I>Eligible Market</I></B>&#148; means The New York Stock Exchange, the NYSE American, the Nasdaq Global Select Market,
the Nasdaq Global Market or the Principal Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> &#147;<B><I>Fundamental Transaction</I></B>&#148; means (A)&nbsp;that the
Company shall, directly or indirectly, including through subsidiaries, Affiliates or otherwise, in one or more related transactions, (i)&nbsp;consolidate or merge with or into (whether or not the Company is the surviving corporation) another Subject
Entity, or (ii)&nbsp;sell, assign, transfer, convey or otherwise dispose of all or substantially all of the properties or assets of the Company or any of its &#147;significant subsidiaries&#148; (as defined in Rule
<FONT STYLE="white-space:nowrap">1-02</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X)</FONT> to one or more Subject Entities, or (iii)&nbsp;make, or allow one or more Subject Entities to make, or allow the Company to be subject to or have
its Common Stock be subject to or party to one or more Subject Entities making, a purchase, tender or exchange offer that is accepted by the holders of at least either (x) 50% of the outstanding shares of Common Stock, (y) 50% of the outstanding
shares of Common Stock calculated as if any shares of Common Stock held by all Subject Entities making or party to, or Affiliated with any Subject Entities making or party to, such purchase, tender or exchange offer were not outstanding; or
(z)&nbsp;such number of shares of Common Stock such that all Subject Entities making or party to, or Affiliated with any Subject Entity making or party to, such purchase, tender or exchange offer, become collectively the beneficial owners (as
defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) of at least 50% of the outstanding shares of Common Stock, or (iv)&nbsp;consummate a stock or share purchase agreement or other business combination (including,
without limitation, a reorganization, recapitalization, <FONT STYLE="white-space:nowrap">spin-off</FONT> or scheme of arrangement) with one or more Subject Entities whereby all such Subject Entities, individually or in the aggregate, acquire, either
(x)&nbsp;at least 50% of the outstanding shares of Common Stock, (y)&nbsp;at least 50% of the outstanding shares of Common Stock calculated as if any shares of Common Stock held by all the Subject Entities making or party to, or Affiliated with any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Subject Entity making or party to, such stock purchase agreement or other business combination were not outstanding; or (z)&nbsp;such number of shares of Common Stock such that the Subject
Entities become collectively the beneficial owners (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) of at least 50% of the outstanding shares of Common Stock, or (v)&nbsp;reorganize, recapitalize or
reclassify its Common Stock, (B)&nbsp;that the Company shall, directly or indirectly, including through subsidiaries, Affiliates or otherwise, in one or more related transactions, allow any Subject Entity individually or the Subject Entities in the
aggregate to be or become the &#147;beneficial owner&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act), directly or indirectly, whether through acquisition, purchase, assignment, conveyance, tender,
tender offer, exchange, reduction in outstanding shares of Common Stock, merger, consolidation, business combination, reorganization, recapitalization, <FONT STYLE="white-space:nowrap">spin-off,</FONT> scheme of arrangement, reorganization,
recapitalization or reclassification or otherwise in any manner whatsoever, of either (x)&nbsp;at least 50% of the aggregate ordinary voting power represented by issued and outstanding Common Stock, (y)&nbsp;at least 50% of the aggregate ordinary
voting power represented by issued and outstanding Common Stock not held by all such Subject Entities as of the date of this Note calculated as if any shares of Common Stock held by all such Subject Entities were not outstanding, or (z)&nbsp;a
percentage of the aggregate ordinary voting power represented by issued and outstanding shares of Common Stock or other equity securities of the Company sufficient to allow such Subject Entities to effect a statutory short form merger or other
transaction requiring other shareholders of the Company to surrender their shares of Common Stock without approval of the shareholders of the Company or (C)&nbsp;directly or indirectly, including through subsidiaries, Affiliates or otherwise, in one
or more related transactions, the issuance of or the entering into any other instrument or transaction structured in a manner to circumvent, or that circumvents, the intent of this definition in which case this definition shall be construed and
implemented in a manner otherwise than in strict conformity with the terms of this definition to the extent necessary to correct this definition or any portion of this definition which may be defective or inconsistent with the intended treatment of
such instrument or transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> &#147;<B><I>Group</I></B>&#148; means a &#147;group&#148; as that term is used in
Section&nbsp;13(d) of the Exchange Act and as defined in Rule <FONT STYLE="white-space:nowrap">13d-5</FONT> thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(l)</B>
<B><I>&#147;Notes&#148;</I></B> means this Note and one or more additional convertible notes issued pursuant to one or more agreements relating to the issuance of notes in exchange for warrants issued pursuant to the Registered Offering (as defined
in the Exchange Agreement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> &#147;<B><I>Options</I></B>&#148; means any rights, warrants or options to subscribe for or
purchase shares of Common Stock or Convertible Securities issued to Persons other than the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> &#147;<B><I>Parent
Entity</I></B>&#148; of a Person means an entity that, directly or indirectly, controls the applicable Person and whose common stock or equivalent equity security is quoted or listed on an Eligible Market, or, if there is more than one such Person
or Parent Entity, the Person or Parent Entity with the largest public market capitalization as of the date of consummation of the Fundamental Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> &#147;<B><I>Principal Market</I></B>&#148; means the Nasdaq Capital Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(p)</B> <B>&#147;</B><B><I>Subject Entity</I></B>&#148; means any Person, Persons or Group or any Affiliate or associate of any such
Person, Persons or Group. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(q)</B> &#147;<B><I>Successor Entity</I></B>&#148; means the Person (or, if so elected by the
Holder, the Parent Entity) formed by, resulting from or surviving any Fundamental Transaction or the Person (or, if so elected by the Holder, the Parent Entity) with which such Fundamental Transaction shall have been entered into. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(r)</B> &#147;<B><I>Trading Day</I></B>&#148; means, as applicable, (x)&nbsp;with respect to all price or trading volume determinations
relating to the Common Stock, any day on which the Common Stock is traded on the Principal Market, or, if the Principal Market is not the principal trading market for the Common Stock, then on the principal securities exchange or securities market
on which the Common Stock is then traded, provided that &#147;Trading Day&#148; shall not include any day on which the Common Stock is scheduled to trade on such exchange or market for less than 4.5 hours or any day that the Common Stock is
suspended from trading during the final hour of trading on such exchange or market (or if such exchange or market does not designate in advance the closing time of trading on such exchange or market, then during the hour ending at 4:00:00 p.m., New
York time) unless such day is otherwise designated as a Trading Day in writing by the Holder or (y)&nbsp;with respect to all determinations other than price determinations relating to the Common Stock, any day on which The New York Stock Exchange
(or any successor thereto) is open for trading of securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(s)</B> &#147;<B><I>VWAP</I></B>&#148; means, for any security as of any
date, the dollar volume-weighted average price for such security on the Principal Market (or, if the Principal Market is not the principal trading market for such security, then on the principal securities exchange or securities market on which such
security is then traded) during the period beginning at 9:30:01 a.m., New York time, and ending at 4:00:00 p.m., New York time, as reported by Bloomberg through its &#147;HP&#148; function (set to weighted average) or, if the foregoing does not
apply, the dollar volume-weighted average price of such security in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the electronic bulletin board for such security during the period
beginning at 9:30:01 a.m., New York time, and ending at 4:00:00 p.m., New York time, as reported by Bloomberg, or, if no dollar volume-weighted average price is reported for such security by Bloomberg for such hours, the average of the highest
closing bid price and the lowest closing ask price of any of the market makers for such security as reported in the &#147;pink sheets&#148; by OTC Markets Group Inc. (formerly Pink Sheets LLC). If the VWAP cannot be calculated for such security on
such date on any of the foregoing bases, the VWAP of such security on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such
security, then such dispute shall be resolved in accordance with the procedures in Section&nbsp;22. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination, recapitalization or other similar
transaction during such period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>22.</B> <B>Disclosure</B>. Upon receipt or delivery by the Company of any notice in accordance with
the terms of this Note, unless the Company has in good faith determined that the matters relating to such notice do not constitute material, <FONT STYLE="white-space:nowrap">non-public</FONT> information relating to the Company or any of its
Subsidiaries, the Company shall within the later of (a)&nbsp;the Cleansing Deadline and (b)&nbsp;one (1) Business Day after any such receipt or delivery, publicly disclose such material, <FONT STYLE="white-space:nowrap">non-public</FONT> information
on a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or otherwise. In the event that the Company believes that a notice contains material, <FONT STYLE="white-space:nowrap">non-public</FONT> information relating to the Company or
any of its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Subsidiaries, the Company so shall indicate to the Holder contemporaneously with delivery of such notice, and in the absence of any such indication, the Holder shall be allowed to presume that
all matters relating to such notice do not constitute material, <FONT STYLE="white-space:nowrap">non-public</FONT> information relating to the Company or any of its Subsidiaries. If the Company or any of its Subsidiaries provides material <FONT
STYLE="white-space:nowrap">non-public</FONT> information to the Holder after the Cleansing Deadline that is not simultaneously filed in a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and the Holder has not agreed to receive
such material <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company hereby covenants and agrees that the Holder shall not have any duty of confidentiality to the Company, any of its Subsidiaries or any of their respective
officers, directors, employees, affiliates or agents with respect to, or a duty to any of the foregoing not to trade on the basis of, such material <FONT STYLE="white-space:nowrap">non-public</FONT> information. Nothing contained in this
Section&nbsp;22 shall limit any obligations of the Company, or any rights of the Holder, under the Exchange Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[signature page
follows] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[S<SMALL>IGNATURE</SMALL> <SMALL>PAGE</SMALL> <SMALL>TO</SMALL> C<SMALL>ONVERTIBLE</SMALL>
P<SMALL>ROMISSORY</SMALL> N<SMALL>OTE</SMALL> <SMALL>OF</SMALL> SELLAS L<SMALL>IFE</SMALL> S<SMALL>CIENCES</SMALL> G<SMALL>ROUP</SMALL>, I<SMALL>NC</SMALL>.] </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SELLAS LIFE SCIENCES GROUP, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Angelos Stergiou</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Angelos Stergiou, M.D., ScD h.c.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holder:
<U></U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Principal Amount of
Note:<U></U> <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date of Note:
<U></U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.86
<SEQUENCE>20
<FILENAME>d556278dex1086.htm
<DESCRIPTION>EX-10.86
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.86</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.86 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONVERTIBLE PROMISSORY NOTE </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>$13,644.54</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">February 21, 2018</TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>New York, NY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For value received <B>SELLAS Life Sciences Group, Inc.</B>, a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), promises to pay to
<B>EMPERY TAX EFFICIENT, LP</B> or its assigns (&#147;<B><I>Holder</I></B>&#148;) the principal sum of <B>$13,644.54</B> (the &#147;<B><I>Principal</I></B>&#148;) together with accrued and unpaid interest thereon (the
&#147;<B><I>Interest</I></B>&#148;), each due and payable on the date and in the manner set forth below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This convertible promissory note
(the &#147;<B><I>Note</I></B>&#148;) was issued in reliance on the exemption provided in Rule 3(a)(9) of the Securities Act of 1933, as amended, pursuant to the terms of that certain Exchange Agreement, dated February&nbsp;21, 2018 (the
&#147;<B><I>Exchange Agreement</I></B>&#148;), by and between the Company and the Holder in exchange for that certain Warrant (as defined in the Exchange Agreement) originally issued on February&nbsp;13, 2017 and shall be subject to the following
terms (capitalized terms not defined herein shall have the meaning as set forth in the Exchange Agreement):<B> </B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B>
<B>Repayment. </B>All payments of Interest and Principal shall be in lawful money of the United States of America. All payments shall be applied first to accrued Interest, and thereafter to Principal. The outstanding Principal amount of the Note
shall be due and payable on August&nbsp;9, 2018 (the &#147;<B><I>Maturity Date</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B>Interest.</B> The Company
promises to pay simple<B> </B>Interest on the outstanding Principal amount hereof from the date hereof until payment in full, which Interest shall be payable at the rate of 4.75% per annum (the &#147;<B><I>Interest Rate</I></B>&#148;) or the maximum
rate permissible by law, whichever is less. Interest shall be due and payable by way of inclusion of the Interest in the Conversion Amount on any Conversion Date in accordance with Section&nbsp;3 below or in cash on the Maturity Date and shall be
calculated on the basis of a <FONT STYLE="white-space:nowrap">365-day</FONT> year for the actual number of days elapsed. From and after the occurrence and during the continuance of any Event of Default (as defined below), the Interest Rate shall
automatically be increased to eighteen percent (18.0%) per annum (the &#147;<B><I>Default Rate</I></B>&#148;). In the event that such Event of Default is subsequently cured (and no other Event of Default then exists (including, without limitation,
for the Company&#146;s failure to pay such Interest at the Default Rate on the Maturity Date)), the adjustment referred to in the preceding sentence shall cease to be effective as of the calendar day immediately following the date of such cure;
provided that the Interest as calculated and unpaid at such increased rate during the continuance of such Event of Default shall continue to apply to the extent relating to the days after the occurrence of such Event of Default through and including
the date of such cure of such Event of Default. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3. Conversion. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the election of the Holder made at any time after April&nbsp;30, 2018, this Note shall be convertible into validly issued, fully paid and <FONT
STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock (as defined below), on the terms and conditions set forth in this Section&nbsp;3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Conversion Right</B>. Subject to the provisions of Section&nbsp;3(d), at any time or times on or after April&nbsp;30, 2018, the
Holder shall be entitled to convert any portion of the outstanding and unpaid Conversion Amount (as defined below) into validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock in accordance with
Section&nbsp;3(c), at the Conversion Rate (as defined below). The Company shall not issue any fraction of a share of Common Stock upon any conversion. If the issuance would result in the issuance of a fraction of a share of Common Stock, the Company
shall round such fraction of a share of Common Stock up to the nearest whole share. The Company shall pay any and all transfer, stamp, issuance and similar taxes, costs and expenses (including, without limitation, fees and expenses of the
Company&#146;s transfer agent (the &#147;<B><I>Transfer Agent</I></B>&#148;)) that may be payable with respect to the issuance and delivery of Common Stock upon conversion of any Conversion Amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Conversion Rate</B>. The number of shares of Common Stock issuable upon conversion of any Conversion Amount pursuant to
Section&nbsp;3(a) shall be determined by dividing (x)&nbsp;such Conversion Amount by (y)&nbsp;the Conversion Price (the &#147;<B><I>Conversion Rate</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> &#147;<B><I>Conversion Amount</I></B>&#148; means the sum of (x)&nbsp;portion of the Principal to be converted, redeemed or
otherwise with respect to which this determination is being made and (y)&nbsp;all accrued and unpaid Interest with respect to such portion of the Principal amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> &#147;<B><I>Conversion Price</I></B>&#148; means, as of any Conversion Date or other date of determination, $7.00, subject to
adjustment as provided herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Mechanics of Conversion</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Optional Conversion</B>. To convert any Conversion Amount into shares of Common Stock on any date (a &#147;<B><I>Conversion
Date</I></B>&#148;), the Holder shall deliver (whether via facsimile, electronic mail or otherwise), for receipt on or prior to 11:59 p.m., New York time, on such date, a copy of an executed notice of conversion (the &#147;<B><I>Conversion
Notice</I></B>&#148;) to the Company. If required by Section&nbsp;3(c)(iii), within two (2)&nbsp;Trading Days following a conversion of this Note as aforesaid, the Holder shall surrender this Note to a nationally recognized overnight delivery
service for delivery to the Company (or an indemnification undertaking with respect to this Note in the case of its loss, theft or destruction). On or before the first (1st) Trading Day following the date of receipt of a Conversion Notice, the
Company shall transmit by facsimile or electronic mail an acknowledgment of confirmation and representation as to whether such shares of Common Stock may then be resold pursuant to Rule 144 or an effective and available registration statement, of
receipt of such Conversion Notice to the Holder and the Transfer Agent which confirmation shall constitute an instruction to the Transfer Agent to process such Conversion Notice in accordance with the terms herein. On or before the second (2nd)
Trading Day following the date on which the Company has received a Conversion Notice (or such earlier date as required pursuant to the Exchange Act or other applicable law, rule or regulation for the settlement of a trade initiated on the applicable
Conversion Date of such shares of Common Stock issuable pursuant to such Conversion Notice) (the &#147;<B><I>Share Delivery Deadline</I></B><I>&#148;</I><I>),</I> the Company shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(1) provided that the Transfer Agent is participating in the DTC Fast Automated Securities Transfer Program, credit such aggregate number of shares of Common Stock to which the Holder shall be
entitled pursuant to such conversion to the Holder&#146;s or its designee&#146;s balance account with DTC through its Deposit/Withdrawal at Custodian system or (2)&nbsp;if the Transfer Agent is not participating in the DTC Fast Automated Securities
Transfer Program, upon the request of the Holder, issue and deliver (via reputable overnight courier) to the address as specified in the Conversion Notice, a certificate, registered in the name of the Holder or its designee, for the number of shares
of Common Stock to which the Holder shall be entitled pursuant to such conversion. If this Note is physically surrendered for conversion pursuant to Section&nbsp;3(c)(iii) and the outstanding Principal of this Note is greater than the Principal
portion of the Conversion Amount being converted, then the Company shall as soon as practicable and in no event later than two (2)&nbsp;Business Days after receipt of this Note and at its own expense, issue and deliver to the Holder (or its
designee) a new Note representing the outstanding Principal not converted. While this Note remains outstanding, the Company shall use a transfer agent that participates in the DTC Fast Automated Securities Transfer Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Company</B><B>&#146;</B><B>s Failure to Timely Convert</B>. If the Company shall fail, for any reason or for no reason, on or
prior to the applicable Share Delivery Deadline, if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program, to issue and deliver to the Holder (or its designee) a certificate for the number of shares of Common
Stock to which the Holder is entitled and register such shares of Common Stock on the Company&#146;s share register or, if the Transfer Agent is participating in the DTC Fast Automated Securities Transfer Program, to credit the balance account of
the Holder or the Holder&#146;s designee with DTC for such number of shares of Common Stock to which the Holder is entitled upon the Holder&#146;s conversion of this Note (as the case may be) (a &#147;<B><I>Conversion Failure</I></B>&#148;), and if
on or after such Share Delivery Deadline the Holder purchases (in an open market transaction or otherwise) shares of Common Stock corresponding to all or any portion of the number of shares of Common Stock issuable upon such conversion that the
Holder is entitled to receive from the Company and has not received from the Company in connection with such Conversion Failure (a &#147;<B><I><FONT STYLE="white-space:nowrap">Buy-In</FONT></I></B>&#148;), then, in addition to all other remedies
available to the Holder, the Company shall, within two (2)&nbsp;Business Days after receipt of the Holder&#146;s request and in the Holder&#146;s discretion, either: (I)&nbsp;pay cash to the Holder in an amount equal to the Holder&#146;s total
purchase price (including brokerage commissions and other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, if any) for the shares of Common Stock so purchased (including, without limitation, by
any other Person in respect, or on behalf, of the Holder) (the &#147;<B><FONT STYLE="white-space:nowrap">Buy-In</FONT> Price</B>&#148;), at which point the Company&#146;s obligation to so issue and deliver such certificate (and to issue such shares
of Common Stock) or credit the balance account of such Holder or such Holder&#146;s designee, as applicable, with DTC for the number of shares of Common Stock to which the Holder is entitled upon the Holder&#146;s conversion hereunder (as the case
may be) (and to issue such shares of Common Stock) shall terminate, or (II)&nbsp;promptly honor its obligation to so issue and deliver to the Holder a certificate or certificates representing such shares of Common Stock or credit the balance account
of such Holder or such Holder&#146;s designee, as applicable, with DTC for the number of shares of Common Stock to which the Holder is entitled upon the Holder&#146;s conversion hereunder (as the case may be) and pay cash to the Holder in an amount
equal to the excess (if any) of the <FONT STYLE="white-space:nowrap">Buy-In</FONT> Price over the product of (x)&nbsp;such number of shares of Common Stock multiplied by (y)&nbsp;the lowest Closing Sale Price of the Common Stock on any Trading Day
during the period commencing on the date of the applicable Conversion Notice and ending on the date of such issuance and payment under this clause (II) (the &#147;<B><I><FONT STYLE="white-space:nowrap">Buy-In</FONT> Payment Amount</I></B>&#148;).
Nothing shall limit </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Holder&#146;s right to pursue any other remedies available to it hereunder, at law or in equity, including, without limitation, a decree of specific performance and/or injunctive relief with
respect to the Company&#146;s failure to timely deliver certificates representing shares of Common Stock (or to electronically deliver such shares of Common Stock) upon the conversion of this Note as required pursuant to the terms hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> <B>Registration; Book-Entry</B>. The Holder and the Company shall maintain records showing the Principal and Interest converted
and/or paid (as the case may be) and the dates of such conversions, and/or payments (as the case may be) or shall use such other method, reasonably satisfactory to the Holder and the Company, so as not to require physical surrender of this Note upon
conversion. Notwithstanding anything to the contrary set forth in this Section&nbsp;3, following conversion of any portion of this Note in accordance with the terms hereof, the Holder shall not be required to physically surrender this Note to the
Company unless (A)&nbsp;the full Conversion Amount represented by this Note is being converted (in which event this Note shall be delivered to the Company following conversion thereof as contemplated by Section&nbsp;3(c)(i)) or (B)&nbsp;the Holder
has provided the Company with prior written notice (which notice may be included in a Conversion Notice) requesting reissuance of this Note upon physical surrender of this Note. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Limitations on Conversions</B>. The Company shall not effect the conversion of any portion of this Note, and the Holder shall
not have the right to convert any portion of this Note pursuant to the terms and conditions of this Note and any such conversion shall be null and void and treated as if never made, to the extent that after giving effect to such conversion, the
Holder together with the other Attribution Parties collectively would beneficially own in excess of 9.99% (the &#147;<B><I>Maximum Percentage</I></B>&#148;) of the shares of Common Stock outstanding immediately after giving effect to such
conversion. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by the Holder and the other Attribution Parties shall include the number of shares of Common Stock held by the Holder and all other
Attribution Parties plus the number of shares of Common Stock issuable upon conversion of this Note with respect to which the determination of such sentence is being made, but shall exclude shares of Common Stock which would be issuable upon
(A)&nbsp;conversion of the remaining, nonconverted portion of this Note beneficially owned by the Holder or any of the other Attribution Parties and (B)&nbsp;exercise or conversion of the unexercised or nonconverted portion of any other securities
of the Company (including, without limitation, any convertible notes or convertible preferred stock or warrants, including, without limitation, the Warrants) beneficially owned by the Holder or any other Attribution Party subject to a limitation on
conversion or exercise analogous to the limitation contained in this Section&nbsp;3(d). For purposes of this Section&nbsp;3(d), beneficial ownership shall be calculated in accordance with Section&nbsp;13(d) of the Exchange Act. For purposes of
determining the number of outstanding shares of Common Stock the Holder may acquire upon the conversion of this Note without exceeding the Maximum Percentage, the Holder may rely on the number of outstanding shares of Common Stock as reflected in
(x)&nbsp;the Company&#146;s most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or
other public filing with the SEC, as the case may be, (y)&nbsp;a more recent public announcement by the Company or (z)&nbsp;any other written notice by the Company or the Transfer Agent, if any, setting forth the number of shares of Common Stock
outstanding (the &#147;<B><I>Reported Outstanding Share Number</I></B>&#148;). If the Company receives a Conversion Notice from the Holder at a time when the actual number of outstanding shares of Common Stock is less than the Reported Outstanding
Share </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Number, the Company shall notify the Holder in writing of the number of shares of Common Stock then outstanding and, to the extent that such Conversion Notice would otherwise cause the
Holder&#146;s beneficial ownership, as determined pursuant to this Section&nbsp;3(d), to exceed the Maximum Percentage, the Holder must notify the Company of a reduced number of shares of Common Stock to be purchased pursuant to such Conversion
Notice. For any reason at any time, upon the written or oral request of the Holder, the Company shall within one (1)&nbsp;Business Day confirm orally and in writing or by electronic mail to the Holder the number of shares of Common Stock then
outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Note, by the Holder and any other Attribution Party since
the date as of which the Reported Outstanding Share Number was reported. In the event that the issuance of shares of Common Stock to the Holder upon conversion of this Note results in the Holder and the other Attribution Parties being deemed to
beneficially own, in the aggregate, more than the Maximum Percentage of the number of outstanding shares of Common Stock (as determined under Section&nbsp;13(d) of the Exchange Act), the number of shares so issued by which the Holder&#146;s and the
other Attribution Parties&#146; aggregate beneficial ownership exceeds the Maximum Percentage (the &#147;<B>Excess Shares</B>&#148;) shall be deemed null and void and shall be cancelled ab initio, and the Holder shall not have the power to vote or
to transfer the Excess Shares. Upon delivery of a written notice to the Company, the Holder may from time to time increase (with such increase not effective until the sixty-first (61<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>) day after
delivery of such notice) or decrease the Maximum Percentage to any other percentage not in excess of 9.99% as specified in such notice; provided that (i)&nbsp;any such increase in the Maximum Percentage will not be effective until the sixty-first
(61<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>) day after such notice is delivered to the Company and (ii)&nbsp;any such increase or decrease will apply only to the Holder and the other Attribution Parties and not to any other holder of
Notes that is not an Attribution Party of the Holder. For purposes of clarity, the shares of Common Stock issuable pursuant to the terms of this Note in excess of the Maximum Percentage shall not be deemed to be beneficially owned by the Holder for
any purpose including for purposes of Section&nbsp;13(d) or Rule <FONT STYLE="white-space:nowrap">16a-1(a)(1)</FONT> of the Exchange Act. No prior inability to convert this Note pursuant to this paragraph shall have any effect on the applicability
of the provisions of this paragraph with respect to any subsequent determination of convertibility. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this
Section&nbsp;3(d) to the extent necessary to correct this paragraph (or any portion of this paragraph) which may be defective or inconsistent with the intended beneficial ownership limitation contained in this Section&nbsp;3(d) or to make changes or
supplements necessary or desirable to properly give effect to such limitation. The limitation contained in this paragraph may not be waived and shall apply to a successor holder of this Note. Further, notwithstanding anything in this Note to the
contrary, under no circumstances shall the Company be obligated to issue or the Holder entitled to receive, an aggregate number of shares of Common Stock that would exceed 19.9% of the total number of shares of Common Stock issued and outstanding as
of the date of this Note (the &#147;<B><I>Maximum Issuance</I></B>&#148;); provided, that to the extent the aggregate number of shares of Common Stock would exceed the Maximum Issuance, the Company shall issue and deliver to Holder a number of
shares of Common Stock up to the Maximum Issuance and the unconverted Principal of this Note shall remain outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Right of Alternate Conversion</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <U>General</U>. At any time at any time after the occurrence of an Event of Default (regardless of whether such Event of Default
has been cured), the Holder may, at the Holder&#146;s option, convert (each, an &#147;<B><I>Alternate Conversion</I></B>&#148;, and the date of such Alternate Conversion, each, an &#147;<B><I>Alternate Conversion Date</I></B>&#148;) all, or any part
of, the Conversion Amount (such portion of the Conversion Amount subject to such Alternate Conversion, the &#147;<B><I>Alternate Conversion Amount</I></B>&#148;) into shares of Common Stock at the Alternate Conversion Price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <U>Mechanics of Alternate Conversion</U>. On any Alternate Conversion Date, the Holder may voluntarily convert any Alternate
Conversion Amount pursuant to Section&nbsp;3(c) (with &#147;Alternate Conversion Price&#148; replacing &#147;Conversion Price&#148; for all purposes hereunder with respect to such Alternate Conversion) by designating in the Conversion Notice
delivered pursuant to this Section&nbsp;3(e) of this Note that the Holder is electing to use the Alternate Conversion Price for such conversion. Notwithstanding anything to the contrary in this Section&nbsp;3(e), but subject to Section&nbsp;3(d),
until the Company delivers shares of Common Stock representing the applicable Alternate Conversion Amount to the Holder, such Alternate Conversion Amount may be converted by the Holder into shares of Common Stock pursuant to Section&nbsp;3(c)
without regard to this Section&nbsp;3(e). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B>Voluntary Adjustment by Company</B>. The Company may at any time during the term
of this Note, with the prior written consent of the Holder, reduce the then current Conversion Price of this Note to any amount and for any period of time deemed appropriate by the board of directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B>Maturity.</B> Unless this Note has been previously converted or prepaid in accordance with the terms of Section&nbsp;3(a) above,
the entire outstanding Conversion Amount shall become fully due and payable in cash on the Maturity Date; provided, that if the Conversion Amount is not paid in full in cash on the Maturity Date, subject to Section&nbsp;3(d) above, the Holder shall
retain the right to convert all, or any part, at such Holder&#146;s sole discretion, of the Conversion Amount into shares of Common Stock in accordance with Section&nbsp;3 above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B>Expenses. </B>In the event of any default hereunder, the Company shall pay all reasonable attorneys&#146; fees and court costs
incurred by Holder in enforcing and collecting this Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B>Prepayment.</B> The Company may prepay this Note and accrued but
unpaid Interest prior to the Maturity Date at any time without the consent of the Holder; provided, that the Company may not prepay any Conversion Amount submitted for conversion pursuant to Section&nbsp;3 above from and after the applicable
Conversion Date unless such corresponding Conversion Notice is withdrawn by the Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B>Default. </B>If there shall be any
Event of Default hereunder, at the option and upon the declaration of the Holder and upon written notice to the Company (which election and notice shall not be required in the case of an Event of Default under Section&nbsp;7(v), 7(vi) or 7(vii)),
this Note shall accelerate and all Principal and unpaid accrued Interest shall become immediately due and payable. The occurrence of any one or more of the following shall constitute an &#147;<B><I>Event of Default</I></B>&#148;: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> the suspension (or threatened suspension) from trading or the failure (or threatened failure) of the Common Stock to be trading or
listed (as applicable) on the Nasdaq Capital Market for a period of five (5)&nbsp;consecutive Trading Days; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> the Company&#146;s (A)&nbsp;failure to cure a Conversion Failure by delivery of the
required number of shares of Common Stock within five (5)&nbsp;Trading Days after the applicable Conversion Date or exercise date (as the case may be) or (B)&nbsp;notice, written or oral, to any holder of the Notes, including, without limitation, by
way of public announcement or through any of its agents, at any time, of its intention not to comply, as required, with a request for conversion of any Notes into shares of Common Stock that is requested in accordance with the provisions of the
Notes, other than pursuant to Section&nbsp;3(d); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> the Company&#146;s or any Subsidiary&#146;s failure to pay to the Holder
any amount of Principal, Interest or other amounts when and as due under this Note (including, without limitation, the Company&#146;s failure to pay any redemption payments or amounts hereunder) or any other Exchange Document or any other agreement,
document, certificate or other instrument delivered in connection with the transactions contemplated hereby and thereby, except, in the case of a failure to pay Interest when and as due, in which case only if such failure remains uncured for a
period of at least two (2)&nbsp;Trading Days; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> [INTENTIONALLY OMITTED]; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings for the relief of debtors shall be
instituted by or against the Company or any Subsidiary and, if instituted against the Company or any Subsidiary by a third party, shall not be dismissed within thirty (30)&nbsp;days of their initiation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> the commencement by the Company or any Subsidiary of a voluntary case or proceeding under any applicable federal, state or
foreign bankruptcy, insolvency, reorganization or other similar law or of any other case or proceeding to be adjudicated a bankrupt or insolvent, or the consent by it to the entry of a decree, order, judgment or other similar document in respect of
the Company or any Subsidiary in an involuntary case or proceeding under any applicable federal, state or foreign bankruptcy, insolvency, reorganization or other similar law or to the commencement of any bankruptcy or insolvency case or proceeding
against it, or the filing by it of a petition or answer or consent seeking reorganization or relief under any applicable federal, state or foreign law, or the consent by it to the filing of such petition or to the appointment of or taking possession
by a custodian, receiver, liquidator, assignee, trustee, sequestrator or other similar official of the Company or any Subsidiary or of any substantial part of its property, or the making by it of an assignment for the benefit of creditors, or the
execution of a composition of debts, or the occurrence of any other similar federal, state or foreign proceeding, or the admission by it in writing of its inability to pay its debts generally as they become due, the taking of corporate action by the
Company or any Subsidiary in furtherance of any such action or the taking of any action by any Person to commence a Uniform Commercial Code foreclosure sale or any other similar action under federal, state or foreign law; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vii)</B> the entry by a court of (i)&nbsp;a decree, order, judgment or other similar
document in respect of the Company or any Subsidiary of a voluntary or involuntary case or proceeding under any applicable federal, state or foreign bankruptcy, insolvency, reorganization or other similar law or (ii)&nbsp;a decree, order, judgment
or other similar document adjudging the Company or any Subsidiary as bankrupt or insolvent, or approving as properly filed a petition seeking liquidation, reorganization, arrangement, adjustment or composition of or in respect of the Company or any
Subsidiary under any applicable federal, state or foreign law or (iii)&nbsp;a decree, order, judgment or other similar document appointing a custodian, receiver, liquidator, assignee, trustee, sequestrator or other similar official of the Company or
any Subsidiary or of any substantial part of its property, or ordering the winding up or liquidation of its affairs, and the continuance of any such decree, order, judgment or other similar document or any such other decree, order, judgment or other
similar document unstayed and in effect for a period of thirty (30)&nbsp;consecutive days; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(viii)</B> other than as specifically
set forth in another clause of this Section&nbsp;7, the Company or any Subsidiary breaches any representation, warranty, covenant or other term or condition of any Exchange Document, except, in the case of a breach of a covenant or other term or
condition that is curable, only if such breach remains uncured for a period of three (3)&nbsp;consecutive Trading Days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.</B>
<B>Adjustment of Conversion Price upon Subdivision or Combination of Common Stock</B>. If the Company at any time on or after the date hereof subdivides (by any stock split, stock dividend, stock combination, recapitalization or other similar
transaction) one or more classes of its outstanding shares of Common Stock into a greater number of shares, the Conversion Price in effect immediately prior to such subdivision will be proportionately reduced. If the Company at any time on or after
the date hereof combines (by any stock split, stock dividend, stock combination, recapitalization or other similar transaction) one or more classes of its outstanding shares of Common Stock into a smaller number of shares, the Conversion Price in
effect immediately prior to such combination will be proportionately increased. Any adjustment pursuant to this Section&nbsp;8 shall become effective immediately after the effective date of such subdivision or combination. If any event requiring an
adjustment under this Section&nbsp;8 occurs during the period that a Conversion Price is calculated hereunder, then the calculation of such Conversion Price shall be adjusted appropriately to reflect such event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.</B> <B>Rights upon Fundamental Transaction</B>. The Company shall not enter into or be party to a Fundamental Transaction unless
(i)&nbsp;the Successor Entity assumes in writing all of the obligations of the Company under this Note and the other Exchange Documents in accordance with the provisions of this Section&nbsp;9 pursuant to written agreements in form and substance
satisfactory to the Holder and approved by the Holder prior to such Fundamental Transaction, including agreements to deliver to each holder of Notes in exchange for such Notes a security of the Successor Entity evidenced by a written instrument
substantially similar in form and substance to the Notes, including, without limitation, having a principal amount and interest rate equal to the principal amounts then outstanding and the interest rates of the Notes held by such holder, having
similar conversion rights as the Notes and having similar ranking and security to the Notes, and satisfactory to the Holder and (ii)&nbsp;the Successor Entity (including its Parent Entity) is a publicly traded corporation whose common stock is
quoted on or listed for trading on an Eligible Market. Upon the occurrence of any Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Note and the other Exchange Documents referring to the &#147;Company&#148; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
all of the obligations of the Company under this Note and the other Exchange Documents with the same effect as if such Successor Entity had been named as the Company herein. Upon consummation of
a Fundamental Transaction, the Successor Entity shall deliver to the Holder confirmation that there shall be issued upon conversion or redemption of this Note at any time after the consummation of such Fundamental Transaction, in lieu of the shares
of Common Stock (or other securities, cash, assets or other property (except such items still issuable under Sections 10(a) and 11, which shall continue to be receivable thereafter) issuable upon the conversion or redemption of the Notes prior to
such Fundamental Transaction, such shares of the publicly traded common stock (or their equivalent) of the Successor Entity (including its Parent Entity) which the Holder would have been entitled to receive upon the happening of such Fundamental
Transaction had this Note been converted immediately prior to such Fundamental Transaction (without regard to any limitations on the conversion of this Note), as adjusted in accordance with the provisions of this Note. Notwithstanding the foregoing,
the Holder may elect, at its sole option, by delivery of written notice to the Company to waive this Section&nbsp;9 to permit the Fundamental Transaction without the assumption of this Note. The provisions of this Section&nbsp;9 shall apply
similarly and equally to successive Fundamental Transactions and shall be applied without regard to any limitations on the conversion of this Note. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10. Rights Upon Issuance of Purchase Rights and Other Corporate Events. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Purchase Rights</B>. If at any time the Company grants, issues or sells any Options, Convertible Securities or rights to
purchase stock, warrants, securities or other property pro rata to all or substantially all of the record holders of any class of Common Stock (the &#147;<B><I>Purchase Rights</I></B>&#148;), then the Holder will be entitled to acquire, upon the
terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete conversion of this Note (without taking into account
any limitations or restrictions on the convertibility of this Note and assuming for such purpose that the Note was converted at the Alternate Conversion Price as of the applicable record date) immediately prior to the date on which a record is taken
for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>,
<U>however</U>, that to the extent that the Holder&#146;s right to participate in any such Purchase Right would result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to
participate in such Purchase Right to the extent of the Maximum Percentage (and shall not be entitled to beneficial ownership of such shares of Common Stock as a result of such Purchase Right (and beneficial ownership) to the extent of any such
excess) and such Purchase Right to such extent shall be held in abeyance (and, if such Purchase Right has an expiration date, maturity date or other similar provision, such term shall be extended by such number of days held in abeyance, if
applicable) for the benefit of the Holder until such time or times, if ever, as its right thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, at which time or times the Holder shall be granted
such right (and any Purchase Right granted, issued or sold on such initial Purchase Right or on any subsequent Purchase Right held similarly in abeyance (and, if such Purchase Right has an expiration date, maturity date or other similar provision,
such term shall be extended by such number of days held in abeyance, if applicable)) to the same extent as if there had been no such limitation). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Other Corporate Events</B>. In addition to and not in substitution for any other
rights hereunder, prior to the consummation of any Fundamental Transaction pursuant to which holders of shares of Common Stock are entitled to receive securities or other assets with respect to or in exchange for shares of Common Stock (a
&#147;<B><I>Corporate Event</I></B>&#148;), the Company shall make appropriate provision to ensure that the Holder will thereafter have the right to receive upon a conversion of this Note, at the Holder&#146;s option (i)&nbsp;in addition to the
shares of Common Stock receivable upon such conversion, such securities or other assets to which the Holder would have been entitled with respect to such shares of Common Stock had such shares of Common Stock been held by the Holder upon the
consummation of such Corporate Event (without taking into account any limitations or restrictions on the convertibility of this Note) or (ii)&nbsp;in lieu of the shares of Common Stock otherwise receivable upon such conversion, such securities or
other assets received by the holders of shares of Common Stock in connection with the consummation of such Corporate Event in such amounts as the Holder would have been entitled to receive had this Note initially been issued with conversion rights
for the form of such consideration (as opposed to shares of Common Stock) at a conversion rate for such consideration commensurate with the Conversion Rate. Provision made pursuant to the preceding sentence shall be in a form and substance
satisfactory to the Holder. The provisions of this Section&nbsp;10(b) shall apply similarly and equally to successive Corporate Events and shall be applied without regard to any limitations on the conversion or redemption of this Note. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.</B> <B>Remedies, Characterizations, Other Obligations, Breaches and Injunctive Relief</B>. The remedies provided in this Note shall be
cumulative and in addition to all other remedies available under this Note and any of the other Exchange Documents at law or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the
Holder&#146;s right to pursue actual and consequential damages for any failure by the Company to comply with the terms of this Note. The Company covenants to the Holder that there shall be no characterization concerning this instrument other than as
expressly provided herein. Amounts set forth or provided for herein with respect to payments, conversion and the like (and the computation thereof) shall be the amounts to be received by the Holder and shall not, except as expressly provided herein,
be subject to any other obligation of the Company (or the performance thereof). The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder and that the remedy at law for any such breach may be
inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach, the Holder shall be entitled, in addition to all other available remedies, to specific performance and/or temporary, preliminary and permanent
injunctive or other equitable relief from any court of competent jurisdiction in any such case without the necessity of proving actual damages and without posting a bond or other security. The Company shall provide all information and documentation
to the Holder that is requested by the Holder to enable the Holder to confirm the Company&#146;s compliance with the terms and conditions of this Note. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.</B> <B>Severability</B>. If any provision of this Note is prohibited by law or otherwise determined to be invalid or unenforceable by a
court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of
such provision shall not affect the validity of the remaining provisions of this Note so long as this Note as so modified continues to express, without material change, the original intentions of the parties as to the subject matter hereof and the
prohibited nature, invalidity or unenforceability of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise
be conferred upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited,
invalid or unenforceable provision(s). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.</B> <B>Maximum Payments</B>. Nothing contained herein shall be deemed to establish or
require the payment of a rate of interest or other charges in excess of the maximum permitted by applicable law. In the event that the rate of interest required to be paid or other charges hereunder exceed the maximum permitted by such law, any
payments in excess of such maximum shall be credited against amounts owed by the Company to the Holder and thus refunded to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.</B> <B>Waiver. </B>The Company hereby waives demand, notice, presentment, protest and notice of dishonor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.</B> <B>Governing Law. </B>This Note shall be construed and enforced in accordance with, and all questions concerning the construction,
validity, interpretation and performance of this Note shall be governed by, the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other
jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York. The Company hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The City of New York,
Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding,
any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein shall be
deemed or operate to preclude the Holder from bringing suit or taking other legal action against the Company in any other jurisdiction to collect on the Company&#146;s obligations to the Holder, to realize on any collateral or any other security for
such obligations, or to enforce a judgment or other court ruling in favor of the Holder. THE COMPANY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN
CONNECTION WITH OR ARISING OUT OF THIS NOTE OR ANY TRANSACTION CONTEMPLATED HEREBY. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.</B> <B>Failure Or Indulgence Not Waiver</B>.
No failure or delay on the part of the Holder in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further
exercise thereof or of any other right, power or privilege. No waiver shall be effective unless it is in writing and signed by an authorized representative of the waiving party. Notwithstanding the foregoing, nothing contained in this
Section&nbsp;16 shall permit any waiver of any provision of Section&nbsp;3(d). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.</B> <B>Amending the Terms of this Note</B>. The prior written consent of the Holder shall
be required for any change, waiver or amendment to this Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>18.</B> <B>Notices; Currency; Payments</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Notices</B>. Whenever notice is required to be given under this Note, unless otherwise provided herein, such notice shall be
given in accordance with the terms of the Exchange Agreement. The Company shall provide the Holder with prompt written notice of all actions taken pursuant to this Note, including in reasonable detail a description of such action and the reason
therefore. Without limiting the generality of the foregoing, the Company will give written notice to the Holder (i)&nbsp;immediately upon any adjustment of the Conversion Price, setting forth in reasonable detail, and certifying, the calculation of
such adjustment and (ii)&nbsp;at least fifteen (15)&nbsp;days prior to the date on which the Company closes its books or takes a record (A)&nbsp;with respect to any dividend or distribution upon the Common Stock, and (B)&nbsp;for determining rights
to vote with respect to any Fundamental Transaction, dissolution or liquidation, provided in each case that such information shall be made known to the public prior to or in conjunction with such notice being provided to the Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Currency</B>. All dollar amounts referred to in this Note are in United States Dollars (&#147;<B><I>U.S. Dollars</I></B>&#148;),
and all amounts owing under this Note shall be paid in U.S. Dollars. All amounts denominated in other currencies (if any) shall be converted into the U.S.&nbsp;Dollar equivalent amount in accordance with the Exchange Rate on the date of calculation.
&#147;<B><I>Exchange Rate</I></B>&#148;<B> </B>means, in relation to any amount of currency to be converted into U.S. Dollars pursuant to this Note, the U.S.&nbsp;Dollar exchange rate as published in the Wall Street Journal on the relevant date of
calculation (it being understood and agreed that where an amount is calculated with reference to, or over, a period of time, the date of calculation shall be the final date of such period of time). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Payments</B>. Whenever any payment of cash is to be made by the Company to any Person pursuant to this Note, unless otherwise
expressly set forth herein, such payment shall be made in lawful money of the United States of America by a certified check drawn on the account of the Company and sent via overnight courier service to such Person at such address as previously
provided to the Company in writing, provided that the Holder may elect to receive a payment of cash via wire transfer of immediately available funds by providing the Company with prior written notice setting out such request and the Holder&#146;s
wire transfer instructions. Whenever any amount expressed to be due by the terms of this Note is due on any day which is not a Business Day, the same shall instead be due on the next succeeding day which is a Business Day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>19.</B> <B>Waiver of Notice</B>. To the extent permitted by law, the Company hereby irrevocably waives demand, notice, presentment, protest
and all other demands and notices in connection with the delivery, acceptance, performance, default or enforcement of this Note and the Exchange Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>20.</B> <B>Assignment.</B> This Note may be transferred only upon its surrender to the Company for registration of transfer, duly endorsed,
or accompanied by a duly executed written instrument of transfer in form satisfactory to the Company. Thereupon, this Note shall be reissued to, and registered in the name of, the transferee, or a new Note for like Principal amount and Interest
shall be issued to, and registered in the name of, the transferee. Interest and Principal shall be paid solely to the registered holder of this Note. Such payment shall constitute full discharge of the Company&#146;s obligation to pay such Interest
and Principal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.</B> <U>CERTAIN DEFINITIONS</U>. For purposes of this Note, the following terms shall have
the following meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <I>&#147;</I><B><I>Adjustment Right&#148;</I></B><B> </B>means any right granted with respect to any
securities issued in connection with, or with respect to, any issuance or sale (or deemed issuance or sale) of shares of Common Stock that could result in a decrease in the net consideration received by the Company in connection with, or with
respect to, such securities (including, without limitation, any cash settlement rights, cash adjustment or other similar rights). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> &#147;<B><I>Alternate Conversion Price</I></B>&#148; means, with respect to any Alternate Conversion that price which shall be the
lowest of (i)&nbsp;the applicable Conversion Price as in effect on the applicable Conversion Date of the applicable Alternate Conversion, (ii) 70% of the lowest VWAP of the Common Stock as of the Trading Day during the ten (10)&nbsp;consecutive
Trading Day period ending and including the applicable Alternate Conversion Date (such period, the &#147;<B><I>Alternate Conversion Measuring Period</I></B>&#148;). All such determinations to be appropriately adjusted for any stock dividend, stock
split, stock combination, reclassification or similar transaction that proportionately decreases or increases the Common Stock during such Alternate Conversion Measuring Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> &#147;<B><I>Attribution Parties</I></B>&#148; means, collectively, the following Persons and entities: (i)&nbsp;any investment
vehicle, including, any funds, feeder funds or managed accounts, currently, or from time to time after the date hereof, directly or indirectly managed or advised by the Holder&#146;s investment manager or any of its Affiliates or principals,
(ii)&nbsp;any direct or indirect Affiliates of the Holder or any of the foregoing, (iii)&nbsp;any Person acting or who could be deemed to be acting as a Group together with the Holder or any of the foregoing and (iv)&nbsp;any other Persons whose
beneficial ownership of the Company&#146;s Common Stock would or could be aggregated with the Holder&#146;s and the other Attribution Parties for purposes of Section&nbsp;13(d) of the Exchange Act. For clarity, the purpose of the foregoing is to
subject collectively the Holder and all other Attribution Parties to the Maximum Percentage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>
&#147;<B><I>Bloomberg</I></B>&#148; means Bloomberg, L.P. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> &#147;<B><I>Business Day</I></B>&#148; means any day other than
Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> &#147;<B><I>Closing Bid Price</I></B>&#148; and &#147;<B><I>Closing Sale Price</I></B>&#148; means, for any security as of any
date, the last closing bid price and last closing trade price, respectively, for such security on the Principal Market, as reported by Bloomberg, or, if the Principal Market begins to operate on an extended hours basis and does not designate the
closing bid price or the closing trade price (as the case may be) then the last bid price or last trade price, respectively, of such security prior to 4:00:00 p.m., New York time, as reported by Bloomberg, or, if the Principal Market is not the
principal securities exchange or trading market for such security, the last closing bid price or last trade price, respectively, of such security on the principal securities exchange or trading market
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
where such security is listed or traded as reported by Bloomberg, or if the foregoing do not apply, the last closing bid price or last trade price, respectively, of such security in the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the electronic bulletin board for such security as reported by Bloomberg, or, if no closing bid price or last trade price, respectively, is reported
for such security by Bloomberg, the average of the bid prices, or the ask prices, respectively, of any market makers for such security as reported in the &#147;pink sheets&#148; by OTC Markets Group Inc. (formerly Pink Sheets LLC). If the Closing
Bid Price or the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Bid Price or the Closing Sale Price (as the case may be) of such security on such date shall be the fair market
value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then such dispute shall be resolved in accordance with the procedures in Section&nbsp;22. All
such determinations shall be appropriately adjusted for any stock splits, stock dividends, stock combinations, recapitalizations or other similar transactions during such period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> &#147;<B><I>Common Stock</I></B>&#148; means (i)&nbsp;the Company&#146;s shares of common stock, $0.0001 par value per share, and
(ii)&nbsp;any capital stock into which such common stock shall have been changed or any share capital resulting from a reclassification of such common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> &#147;<B><I>Convertible Securities</I></B>&#148; means any stock or other security (other than Options) that is at any time and
under any circumstances, directly or indirectly, convertible into, exercisable or exchangeable for, or which otherwise entitles the holder thereof to acquire, any shares of Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> &#147;<B><I>Eligible Market</I></B>&#148; means The New York Stock Exchange, the NYSE American, the Nasdaq Global Select Market,
the Nasdaq Global Market or the Principal Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(j) </B>&#147;<B><I>Fundamental Transaction</I></B>&#148; means (A) that the Company
shall, directly or indirectly, including through subsidiaries, Affiliates or otherwise, in one or more related transactions, (i) consolidate or merge with or into (whether or not the Company is the surviving corporation) another Subject Entity, or
(ii) sell, assign, transfer, convey or otherwise dispose of all or substantially all of the properties or assets of the Company or any of its &#147;significant subsidiaries&#148; (as defined in Rule 1-02 of Regulation S-X) to one or more Subject
Entities, or (iii) make, or allow one or more Subject Entities to make, or allow the Company to be subject to or have its Common Stock be subject to or party to one or more Subject Entities making, a purchase, tender or exchange offer that is
accepted by the holders of at least either (x) 50% of the outstanding shares of Common Stock, (y) 50% of the outstanding shares of Common Stock calculated as if any shares of Common Stock held by all Subject Entities making or party to, or
Affiliated with any Subject Entities making or party to, such purchase, tender or exchange offer were not outstanding; or (z) such number of shares of Common Stock such that all Subject Entities making or party to, or Affiliated with any Subject
Entity making or party to, such purchase, tender or exchange offer, become collectively the beneficial owners (as defined in Rule 13d-3 under the Exchange Act) of at least 50% of the outstanding shares of Common Stock, or (iv) consummate a stock or
share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with one or more Subject Entities whereby all such Subject Entities, individually or in the
aggregate, acquire, either (x) at least 50% of the outstanding shares of Common Stock, (y) at least 50% of the outstanding shares of Common Stock calculated as if any shares of Common Stock held by all the Subject Entities making or party to, or
Affiliated with any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Subject Entity making or party to, such stock purchase agreement or other business combination were not outstanding; or (z) such number of shares of Common Stock such that the Subject Entities
become collectively the beneficial owners (as defined in Rule 13d-3 under the Exchange Act) of at least 50% of the outstanding shares of Common Stock, or (v) reorganize, recapitalize or reclassify its Common Stock, (B) that the Company shall,
directly or indirectly, including through subsidiaries, Affiliates or otherwise, in one or more related transactions, allow any Subject Entity individually or the Subject Entities in the aggregate to be or become the &#147;beneficial owner&#148; (as
defined in Rule 13d-3 under the Exchange Act), directly or indirectly, whether through acquisition, purchase, assignment, conveyance, tender, tender offer, exchange, reduction in outstanding shares of Common Stock, merger, consolidation, business
combination, reorganization, recapitalization, spin-off, scheme of arrangement, reorganization, recapitalization or reclassification or otherwise in any manner whatsoever, of either (x) at least 50% of the aggregate ordinary voting power represented
by issued and outstanding Common Stock, (y) at least 50% of the aggregate ordinary voting power represented by issued and outstanding Common Stock not held by all such Subject Entities as of the date of this Note calculated as if any shares of
Common Stock held by all such Subject Entities were not outstanding, or (z) a percentage of the aggregate ordinary voting power represented by issued and outstanding shares of Common Stock or other equity securities of the Company sufficient to
allow such Subject Entities to effect a statutory short form merger or other transaction requiring other shareholders of the Company to surrender their shares of Common Stock without approval of the shareholders of the Company or (C) directly or
indirectly, including through subsidiaries, Affiliates or otherwise, in one or more related transactions, the issuance of or the entering into any other instrument or transaction structured in a manner to circumvent, or that circumvents, the intent
of this definition in which case this definition shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this definition to the extent necessary to correct this definition or any portion of this
definition which may be defective or inconsistent with the intended treatment of such instrument or transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(k)</B>
&#147;<B><I>Group</I></B>&#148; means a &#147;group&#148; as that term is used in Section&nbsp;13(d) of the Exchange Act and as defined in Rule <FONT STYLE="white-space:nowrap">13d-5</FONT> thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> <B><I>&#147;Notes&#148;</I></B> means this Note and one or more additional convertible notes issued pursuant to one or more
agreements relating to the issuance of notes in exchange for warrants issued pursuant to the Registered Offering (as defined in the Exchange Agreement). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> &#147;<B><I>Options</I></B>&#148; means any rights, warrants or options to subscribe for or purchase shares of Common Stock or
Convertible Securities issued to Persons other than the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> &#147;<B><I>Parent Entity</I></B>&#148; of a Person means an
entity that, directly or indirectly, controls the applicable Person and whose common stock or equivalent equity security is quoted or listed on an Eligible Market, or, if there is more than one such Person or Parent Entity, the Person or Parent
Entity with the largest public market capitalization as of the date of consummation of the Fundamental Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(o)</B>
&#147;<B><I>Principal Market</I></B>&#148; means the Nasdaq Capital Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(p)</B> <B>&#147;</B><B><I>Subject Entity</I></B>&#148;
means any Person, Persons or Group or any Affiliate or associate of any such Person, Persons or Group. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(q)</B> &#147;<B><I>Successor Entity</I></B>&#148; means the Person (or, if so elected by the
Holder, the Parent Entity) formed by, resulting from or surviving any Fundamental Transaction or the Person (or, if so elected by the Holder, the Parent Entity) with which such Fundamental Transaction shall have been entered into. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(r)</B> &#147;<B><I>Trading Day</I></B>&#148; means, as applicable, (x)&nbsp;with respect to all price or trading volume determinations
relating to the Common Stock, any day on which the Common Stock is traded on the Principal Market, or, if the Principal Market is not the principal trading market for the Common Stock, then on the principal securities exchange or securities market
on which the Common Stock is then traded, provided that &#147;Trading Day&#148; shall not include any day on which the Common Stock is scheduled to trade on such exchange or market for less than 4.5 hours or any day that the Common Stock is
suspended from trading during the final hour of trading on such exchange or market (or if such exchange or market does not designate in advance the closing time of trading on such exchange or market, then during the hour ending at 4:00:00 p.m., New
York time) unless such day is otherwise designated as a Trading Day in writing by the Holder or (y)&nbsp;with respect to all determinations other than price determinations relating to the Common Stock, any day on which The New York Stock Exchange
(or any successor thereto) is open for trading of securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(s)</B> &#147;<B><I>VWAP</I></B>&#148; means, for any security as of any
date, the dollar volume-weighted average price for such security on the Principal Market (or, if the Principal Market is not the principal trading market for such security, then on the principal securities exchange or securities market on which such
security is then traded) during the period beginning at 9:30:01 a.m., New York time, and ending at 4:00:00 p.m., New York time, as reported by Bloomberg through its &#147;HP&#148; function (set to weighted average) or, if the foregoing does not
apply, the dollar volume-weighted average price of such security in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the electronic bulletin board for such security during the period
beginning at 9:30:01 a.m., New York time, and ending at 4:00:00 p.m., New York time, as reported by Bloomberg, or, if no dollar volume-weighted average price is reported for such security by Bloomberg for such hours, the average of the highest
closing bid price and the lowest closing ask price of any of the market makers for such security as reported in the &#147;pink sheets&#148; by OTC Markets Group Inc. (formerly Pink Sheets LLC). If the VWAP cannot be calculated for such security on
such date on any of the foregoing bases, the VWAP of such security on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such
security, then such dispute shall be resolved in accordance with the procedures in Section&nbsp;22. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination, recapitalization or other similar
transaction during such period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>22.</B> <B>Disclosure</B>. Upon receipt or delivery by the Company of any notice in accordance with
the terms of this Note, unless the Company has in good faith determined that the matters relating to such notice do not constitute material, <FONT STYLE="white-space:nowrap">non-public</FONT> information relating to the Company or any of its
Subsidiaries, the Company shall within the later of (a)&nbsp;the Cleansing Deadline and (b)&nbsp;one (1) Business Day after any such receipt or delivery, publicly disclose such material, <FONT STYLE="white-space:nowrap">non-public</FONT> information
on a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or otherwise. In the event that the Company believes that a notice contains material, <FONT STYLE="white-space:nowrap">non-public</FONT> information relating to the Company or
any of its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Subsidiaries, the Company so shall indicate to the Holder contemporaneously with delivery of such notice, and in the absence of any such indication, the Holder shall be allowed to presume that
all matters relating to such notice do not constitute material, <FONT STYLE="white-space:nowrap">non-public</FONT> information relating to the Company or any of its Subsidiaries. If the Company or any of its Subsidiaries provides material <FONT
STYLE="white-space:nowrap">non-public</FONT> information to the Holder after the Cleansing Deadline that is not simultaneously filed in a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and the Holder has not agreed to receive
such material <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company hereby covenants and agrees that the Holder shall not have any duty of confidentiality to the Company, any of its Subsidiaries or any of their respective
officers, directors, employees, affiliates or agents with respect to, or a duty to any of the foregoing not to trade on the basis of, such material <FONT STYLE="white-space:nowrap">non-public</FONT> information. Nothing contained in this
Section&nbsp;22 shall limit any obligations of the Company, or any rights of the Holder, under the Exchange Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[signature page
follows] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[S<SMALL>IGNATURE</SMALL> <SMALL>PAGE</SMALL> <SMALL>TO</SMALL> C<SMALL>ONVERTIBLE</SMALL>
P<SMALL>ROMISSORY</SMALL> N<SMALL>OTE</SMALL> <SMALL>OF</SMALL> SELLAS L<SMALL>IFE</SMALL> S<SMALL>CIENCES</SMALL> G<SMALL>ROUP</SMALL>, I<SMALL>NC</SMALL>.] </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SELLAS LIFE SCIENCES GROUP, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Angelos Stergiou, M.D., ScD h.c.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holder:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Principal Amount of Note:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date of Note:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp; </U> </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.87
<SEQUENCE>21
<FILENAME>d556278dex1087.htm
<DESCRIPTION>EX-10.87
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.87</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.87 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONVERTIBLE PROMISSORY NOTE </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>$21,747.96</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">February 21, 2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>New York, NY</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For value received <B>SELLAS Life Sciences Group, Inc.</B>, a Delaware corporation (the
&#147;<B><I>Company</I></B>&#148;), promises to pay to <B>EMPERY TAX EFFICIENT II, LP</B> or its assigns (&#147;<B><I>Holder</I></B>&#148;) the principal sum of <B>$21,747.96</B> (the &#147;<B><I>Principal</I></B>&#148;) together with accrued and
unpaid interest thereon (the &#147;<B><I>Interest</I></B>&#148;), each due and payable on the date and in the manner set forth below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This convertible promissory note (the &#147;<B><I>Note</I></B>&#148;) was issued in reliance on the exemption provided in Rule 3(a)(9) of the
Securities Act of 1933, as amended, pursuant to the terms of that certain Exchange Agreement, dated February&nbsp;21, 2018 (the &#147;<B><I>Exchange Agreement</I></B>&#148;), by and between the Company and the Holder in exchange for that certain
Warrant (as defined in the Exchange Agreement) originally issued on February&nbsp;13, 2017 and shall be subject to the following terms (capitalized terms not defined herein shall have the meaning as set forth in the Exchange Agreement):<B> </B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B>Repayment. </B>All payments of Interest and Principal shall be in lawful money of the United States of America. All payments shall
be applied first to accrued Interest, and thereafter to Principal. The outstanding Principal amount of the Note shall be due and payable on August&nbsp;9, 2018 (the &#147;<B><I>Maturity Date</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B>Interest.</B> The Company promises to pay simple<B> </B>Interest on the outstanding Principal amount hereof from the date hereof
until payment in full, which Interest shall be payable at the rate of 4.75% per annum (the &#147;<B><I>Interest Rate</I></B>&#148;) or the maximum rate permissible by law, whichever is less. Interest shall be due and payable by way of inclusion of
the Interest in the Conversion Amount on any Conversion Date in accordance with Section&nbsp;3 below or in cash on the Maturity Date and shall be calculated on the basis of a <FONT STYLE="white-space:nowrap">365-day</FONT> year for the actual number
of days elapsed. From and after the occurrence and during the continuance of any Event of Default (as defined below), the Interest Rate shall automatically be increased to eighteen percent (18.0%) per annum (the &#147;<B><I>Default
Rate</I></B>&#148;). In the event that such Event of Default is subsequently cured (and no other Event of Default then exists (including, without limitation, for the Company&#146;s failure to pay such Interest at the Default Rate on the Maturity
Date)), the adjustment referred to in the preceding sentence shall cease to be effective as of the calendar day immediately following the date of such cure; provided that the Interest as calculated and unpaid at such increased rate during the
continuance of such Event of Default shall continue to apply to the extent relating to the days after the occurrence of such Event of Default through and including the date of such cure of such Event of Default. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3. Conversion. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the election of the Holder made at any time after April&nbsp;30, 2018, this Note shall be convertible into validly issued, fully paid and <FONT
STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock (as defined below), on the terms and conditions set forth in this Section&nbsp;3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Conversion Right</B>. Subject to the provisions of Section&nbsp;3(d), at any time or times on or after April&nbsp;30, 2018, the
Holder shall be entitled to convert any portion of the outstanding and unpaid Conversion Amount (as defined below) into validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock in accordance with
Section&nbsp;3(c), at the Conversion Rate (as defined below). The Company shall not issue any fraction of a share of Common Stock upon any conversion. If the issuance would result in the issuance of a fraction of a share of Common Stock, the Company
shall round such fraction of a share of Common Stock up to the nearest whole share. The Company shall pay any and all transfer, stamp, issuance and similar taxes, costs and expenses (including, without limitation, fees and expenses of the
Company&#146;s transfer agent (the &#147;<B><I>Transfer Agent</I></B>&#148;)) that may be payable with respect to the issuance and delivery of Common Stock upon conversion of any Conversion Amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Conversion Rate</B>. The number of shares of Common Stock issuable upon conversion of any Conversion Amount pursuant to
Section&nbsp;3(a) shall be determined by dividing (x)&nbsp;such Conversion Amount by (y)&nbsp;the Conversion Price (the &#147;<B><I>Conversion Rate</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> &#147;<B><I>Conversion Amount</I></B>&#148; means the sum of (x)&nbsp;portion of the Principal to be converted, redeemed or
otherwise with respect to which this determination is being made and (y)&nbsp;all accrued and unpaid Interest with respect to such portion of the Principal amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> &#147;<B><I>Conversion Price</I></B>&#148; means, as of any Conversion Date or other date of determination, $7.00, subject to
adjustment as provided herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Mechanics of Conversion</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Optional Conversion</B>. To convert any Conversion Amount into shares of Common Stock on any date (a &#147;<B><I>Conversion
Date</I></B>&#148;), the Holder shall deliver (whether via facsimile, electronic mail or otherwise), for receipt on or prior to 11:59 p.m., New York time, on such date, a copy of an executed notice of conversion (the &#147;<B><I>Conversion
Notice</I></B>&#148;) to the Company. If required by Section&nbsp;3(c)(iii), within two (2)&nbsp;Trading Days following a conversion of this Note as aforesaid, the Holder shall surrender this Note to a nationally recognized overnight delivery
service for delivery to the Company (or an indemnification undertaking with respect to this Note in the case of its loss, theft or destruction). On or before the first (1st) Trading Day following the date of receipt of a Conversion Notice, the
Company shall transmit by facsimile or electronic mail an acknowledgment of confirmation and representation as to whether such shares of Common Stock may then be resold pursuant to Rule 144 or an effective and available registration statement, of
receipt of such Conversion Notice to the Holder and the Transfer Agent which confirmation shall constitute an instruction to the Transfer Agent to process such Conversion Notice in accordance with the terms herein. On or before the second (2nd)
Trading Day following the date on which the Company has received a Conversion Notice (or such earlier date as required pursuant to the Exchange Act or other applicable law, rule or regulation for the settlement of a trade initiated on the applicable
Conversion Date of such shares of Common Stock issuable pursuant to such Conversion Notice) (the &#147;<B><I>Share Delivery Deadline</I></B><I>&#148;</I><I>),</I> the Company shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(1) provided that the Transfer Agent is participating in the DTC Fast Automated Securities Transfer Program, credit such aggregate number of shares of Common Stock to which the Holder shall be
entitled pursuant to such conversion to the Holder&#146;s or its designee&#146;s balance account with DTC through its Deposit/Withdrawal at Custodian system or (2)&nbsp;if the Transfer Agent is not participating in the DTC Fast Automated Securities
Transfer Program, upon the request of the Holder, issue and deliver (via reputable overnight courier) to the address as specified in the Conversion Notice, a certificate, registered in the name of the Holder or its designee, for the number of shares
of Common Stock to which the Holder shall be entitled pursuant to such conversion. If this Note is physically surrendered for conversion pursuant to Section&nbsp;3(c)(iii) and the outstanding Principal of this Note is greater than the Principal
portion of the Conversion Amount being converted, then the Company shall as soon as practicable and in no event later than two (2)&nbsp;Business Days after receipt of this Note and at its own expense, issue and deliver to the Holder (or its
designee) a new Note representing the outstanding Principal not converted. While this Note remains outstanding, the Company shall use a transfer agent that participates in the DTC Fast Automated Securities Transfer Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B><B> Company</B><B>&#146;</B><B>s Failure to Timely Convert</B>. If the Company shall fail, for any reason or for no reason, on or
prior to the applicable Share Delivery Deadline, if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program, to issue and deliver to the Holder (or its designee) a certificate for the number of shares of Common
Stock to which the Holder is entitled and register such shares of Common Stock on the Company&#146;s share register or, if the Transfer Agent is participating in the DTC Fast Automated Securities Transfer Program, to credit the balance account of
the Holder or the Holder&#146;s designee with DTC for such number of shares of Common Stock to which the Holder is entitled upon the Holder&#146;s conversion of this Note (as the case may be) (a &#147;<B><I>Conversion Failure</I></B>&#148;), and if
on or after such Share Delivery Deadline the Holder purchases (in an open market transaction or otherwise) shares of Common Stock corresponding to all or any portion of the number of shares of Common Stock issuable upon such conversion that the
Holder is entitled to receive from the Company and has not received from the Company in connection with such Conversion Failure (a &#147;<B><I><FONT STYLE="white-space:nowrap">Buy-In</FONT></I></B>&#148;), then, in addition to all other remedies
available to the Holder, the Company shall, within two (2)&nbsp;Business Days after receipt of the Holder&#146;s request and in the Holder&#146;s discretion, either: (I)&nbsp;pay cash to the Holder in an amount equal to the Holder&#146;s total
purchase price (including brokerage commissions and other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, if any) for the shares of Common Stock so purchased (including, without limitation, by
any other Person in respect, or on behalf, of the Holder) (the &#147;<B><FONT STYLE="white-space:nowrap">Buy-In</FONT> Price</B>&#148;), at which point the Company&#146;s obligation to so issue and deliver such certificate (and to issue such shares
of Common Stock) or credit the balance account of such Holder or such Holder&#146;s designee, as applicable, with DTC for the number of shares of Common Stock to which the Holder is entitled upon the Holder&#146;s conversion hereunder (as the case
may be) (and to issue such shares of Common Stock) shall terminate, or (II)&nbsp;promptly honor its obligation to so issue and deliver to the Holder a certificate or certificates representing such shares of Common Stock or credit the balance account
of such Holder or such Holder&#146;s designee, as applicable, with DTC for the number of shares of Common Stock to which the Holder is entitled upon the Holder&#146;s conversion hereunder (as the case may be) and pay cash to the Holder in an amount
equal to the excess (if any) of the <FONT STYLE="white-space:nowrap">Buy-In</FONT> Price over the product of (x)&nbsp;such number of shares of Common Stock multiplied by (y)&nbsp;the lowest Closing Sale Price of the Common Stock on any Trading Day
during the period commencing on the date of the applicable Conversion Notice and ending on the date of such issuance and payment under this clause (II) (the &#147;<B><I><FONT STYLE="white-space:nowrap">Buy-In</FONT> Payment Amount</I></B>&#148;).
Nothing shall limit </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Holder&#146;s right to pursue any other remedies available to it hereunder, at law or in equity, including, without limitation, a decree of specific performance and/or injunctive relief with
respect to the Company&#146;s failure to timely deliver certificates representing shares of Common Stock (or to electronically deliver such shares of Common Stock) upon the conversion of this Note as required pursuant to the terms hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> <B>Registration; Book-Entry</B>. The Holder and the Company shall maintain records showing the Principal and Interest converted
and/or paid (as the case may be) and the dates of such conversions, and/or payments (as the case may be) or shall use such other method, reasonably satisfactory to the Holder and the Company, so as not to require physical surrender of this Note upon
conversion. Notwithstanding anything to the contrary set forth in this Section&nbsp;3, following conversion of any portion of this Note in accordance with the terms hereof, the Holder shall not be required to physically surrender this Note to the
Company unless (A)&nbsp;the full Conversion Amount represented by this Note is being converted (in which event this Note shall be delivered to the Company following conversion thereof as contemplated by Section&nbsp;3(c)(i)) or (B)&nbsp;the Holder
has provided the Company with prior written notice (which notice may be included in a Conversion Notice) requesting reissuance of this Note upon physical surrender of this Note. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Limitations on Conversions</B>. The Company shall not effect the conversion of any portion of this Note, and the Holder shall
not have the right to convert any portion of this Note pursuant to the terms and conditions of this Note and any such conversion shall be null and void and treated as if never made, to the extent that after giving effect to such conversion, the
Holder together with the other Attribution Parties collectively would beneficially own in excess of 9.99% (the &#147;<B><I>Maximum Percentage</I></B>&#148;) of the shares of Common Stock outstanding immediately after giving effect to such
conversion. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by the Holder and the other Attribution Parties shall include the number of shares of Common Stock held by the Holder and all other
Attribution Parties plus the number of shares of Common Stock issuable upon conversion of this Note with respect to which the determination of such sentence is being made, but shall exclude shares of Common Stock which would be issuable upon
(A)&nbsp;conversion of the remaining, nonconverted portion of this Note beneficially owned by the Holder or any of the other Attribution Parties and (B)&nbsp;exercise or conversion of the unexercised or nonconverted portion of any other securities
of the Company (including, without limitation, any convertible notes or convertible preferred stock or warrants, including, without limitation, the Warrants) beneficially owned by the Holder or any other Attribution Party subject to a limitation on
conversion or exercise analogous to the limitation contained in this Section&nbsp;3(d). For purposes of this Section&nbsp;3(d), beneficial ownership shall be calculated in accordance with Section&nbsp;13(d) of the Exchange Act. For purposes of
determining the number of outstanding shares of Common Stock the Holder may acquire upon the conversion of this Note without exceeding the Maximum Percentage, the Holder may rely on the number of outstanding shares of Common Stock as reflected in
(x)&nbsp;the Company&#146;s most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or
other public filing with the SEC, as the case may be, (y)&nbsp;a more recent public announcement by the Company or (z)&nbsp;any other written notice by the Company or the Transfer Agent, if any, setting forth the number of shares of Common Stock
outstanding (the &#147;<B><I>Reported Outstanding Share Number</I></B>&#148;). If the Company receives a Conversion Notice from the Holder at a time when the actual number of outstanding shares of Common Stock is less than the Reported Outstanding
Share </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Number, the Company shall notify the Holder in writing of the number of shares of Common Stock then outstanding and, to the extent that such Conversion Notice would otherwise cause the
Holder&#146;s beneficial ownership, as determined pursuant to this Section&nbsp;3(d), to exceed the Maximum Percentage, the Holder must notify the Company of a reduced number of shares of Common Stock to be purchased pursuant to such Conversion
Notice. For any reason at any time, upon the written or oral request of the Holder, the Company shall within one (1)&nbsp;Business Day confirm orally and in writing or by electronic mail to the Holder the number of shares of Common Stock then
outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Note, by the Holder and any other Attribution Party since
the date as of which the Reported Outstanding Share Number was reported. In the event that the issuance of shares of Common Stock to the Holder upon conversion of this Note results in the Holder and the other Attribution Parties being deemed to
beneficially own, in the aggregate, more than the Maximum Percentage of the number of outstanding shares of Common Stock (as determined under Section&nbsp;13(d) of the Exchange Act), the number of shares so issued by which the Holder&#146;s and the
other Attribution Parties&#146; aggregate beneficial ownership exceeds the Maximum Percentage (the &#147;<B>Excess Shares</B>&#148;) shall be deemed null and void and shall be cancelled ab initio, and the Holder shall not have the power to vote or
to transfer the Excess Shares. Upon delivery of a written notice to the Company, the Holder may from time to time increase (with such increase not effective until the sixty-first (61<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>) day after
delivery of such notice) or decrease the Maximum Percentage to any other percentage not in excess of 9.99% as specified in such notice; provided that (i)&nbsp;any such increase in the Maximum Percentage will not be effective until the sixty-first
(61<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>) day after such notice is delivered to the Company and (ii)&nbsp;any such increase or decrease will apply only to the Holder and the other Attribution Parties and not to any other holder of
Notes that is not an Attribution Party of the Holder. For purposes of clarity, the shares of Common Stock issuable pursuant to the terms of this Note in excess of the Maximum Percentage shall not be deemed to be beneficially owned by the Holder for
any purpose including for purposes of Section&nbsp;13(d) or Rule <FONT STYLE="white-space:nowrap">16a-1(a)(1)</FONT> of the Exchange Act. No prior inability to convert this Note pursuant to this paragraph shall have any effect on the applicability
of the provisions of this paragraph with respect to any subsequent determination of convertibility. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this
Section&nbsp;3(d) to the extent necessary to correct this paragraph (or any portion of this paragraph) which may be defective or inconsistent with the intended beneficial ownership limitation contained in this Section&nbsp;3(d) or to make changes or
supplements necessary or desirable to properly give effect to such limitation. The limitation contained in this paragraph may not be waived and shall apply to a successor holder of this Note. Further, notwithstanding anything in this Note to the
contrary, under no circumstances shall the Company be obligated to issue or the Holder entitled to receive, an aggregate number of shares of Common Stock that would exceed 19.9% of the total number of shares of Common Stock issued and outstanding as
of the date of this Note (the &#147;<B><I>Maximum Issuance</I></B>&#148;); provided, that to the extent the aggregate number of shares of Common Stock would exceed the Maximum Issuance, the Company shall issue and deliver to Holder a number of
shares of Common Stock up to the Maximum Issuance and the unconverted Principal of this Note shall remain outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Right of Alternate Conversion</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <U>General</U>. At any time at any time after the occurrence of an Event of Default (regardless of whether such Event of Default
has been cured), the Holder may, at the Holder&#146;s option, convert (each, an &#147;<B><I>Alternate Conversion</I></B>&#148;, and the date of such Alternate Conversion, each, an &#147;<B><I>Alternate Conversion Date</I></B>&#148;) all, or any part
of, the Conversion Amount (such portion of the Conversion Amount subject to such Alternate Conversion, the &#147;<B><I>Alternate Conversion Amount</I></B>&#148;) into shares of Common Stock at the Alternate Conversion Price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <U>Mechanics of Alternate Conversion</U>. On any Alternate Conversion Date, the Holder may voluntarily convert any Alternate
Conversion Amount pursuant to Section&nbsp;3(c) (with &#147;Alternate Conversion Price&#148; replacing &#147;Conversion Price&#148; for all purposes hereunder with respect to such Alternate Conversion) by designating in the Conversion Notice
delivered pursuant to this Section&nbsp;3(e) of this Note that the Holder is electing to use the Alternate Conversion Price for such conversion. Notwithstanding anything to the contrary in this Section&nbsp;3(e), but subject to Section&nbsp;3(d),
until the Company delivers shares of Common Stock representing the applicable Alternate Conversion Amount to the Holder, such Alternate Conversion Amount may be converted by the Holder into shares of Common Stock pursuant to Section&nbsp;3(c)
without regard to this Section&nbsp;3(e). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B>Voluntary Adjustment by Company</B>. The Company may at any time during the term
of this Note, with the prior written consent of the Holder, reduce the then current Conversion Price of this Note to any amount and for any period of time deemed appropriate by the board of directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B>Maturity.</B> Unless this Note has been previously converted or prepaid in accordance with the terms of Section&nbsp;3(a) above,
the entire outstanding Conversion Amount shall become fully due and payable in cash on the Maturity Date; provided, that if the Conversion Amount is not paid in full in cash on the Maturity Date, subject to Section&nbsp;3(d) above, the Holder shall
retain the right to convert all, or any part, at such Holder&#146;s sole discretion, of the Conversion Amount into shares of Common Stock in accordance with Section&nbsp;3 above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B>Expenses. </B>In the event of any default hereunder, the Company shall pay all reasonable attorneys&#146; fees and court costs
incurred by Holder in enforcing and collecting this Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B>Prepayment.</B> The Company may prepay this Note and accrued but
unpaid Interest prior to the Maturity Date at any time without the consent of the Holder; provided, that the Company may not prepay any Conversion Amount submitted for conversion pursuant to Section&nbsp;3 above from and after the applicable
Conversion Date unless such corresponding Conversion Notice is withdrawn by the Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B>Default. </B>If there shall be any
Event of Default hereunder, at the option and upon the declaration of the Holder and upon written notice to the Company (which election and notice shall not be required in the case of an Event of Default under Section&nbsp;7(v), 7(vi) or 7(vii)),
this Note shall accelerate and all Principal and unpaid accrued Interest shall become immediately due and payable. The occurrence of any one or more of the following shall constitute an &#147;<B><I>Event of Default</I></B>&#148;: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> the suspension (or threatened suspension) from trading or the failure (or threatened failure) of the Common Stock to be trading or
listed (as applicable) on the Nasdaq Capital Market for a period of five (5)&nbsp;consecutive Trading Days; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> the Company&#146;s (A)&nbsp;failure to cure a Conversion Failure by delivery of the
required number of shares of Common Stock within five (5)&nbsp;Trading Days after the applicable Conversion Date or exercise date (as the case may be) or (B)&nbsp;notice, written or oral, to any holder of the Notes, including, without limitation, by
way of public announcement or through any of its agents, at any time, of its intention not to comply, as required, with a request for conversion of any Notes into shares of Common Stock that is requested in accordance with the provisions of the
Notes, other than pursuant to Section&nbsp;3(d); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> the Company&#146;s or any Subsidiary&#146;s failure to pay to the Holder
any amount of Principal, Interest or other amounts when and as due under this Note (including, without limitation, the Company&#146;s failure to pay any redemption payments or amounts hereunder) or any other Exchange Document or any other agreement,
document, certificate or other instrument delivered in connection with the transactions contemplated hereby and thereby, except, in the case of a failure to pay Interest when and as due, in which case only if such failure remains uncured for a
period of at least two (2)&nbsp;Trading Days; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> [INTENTIONALLY OMITTED]; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings for the relief of debtors shall be
instituted by or against the Company or any Subsidiary and, if instituted against the Company or any Subsidiary by a third party, shall not be dismissed within thirty (30)&nbsp;days of their initiation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> the commencement by the Company or any Subsidiary of a voluntary case or proceeding under any applicable federal, state or
foreign bankruptcy, insolvency, reorganization or other similar law or of any other case or proceeding to be adjudicated a bankrupt or insolvent, or the consent by it to the entry of a decree, order, judgment or other similar document in respect of
the Company or any Subsidiary in an involuntary case or proceeding under any applicable federal, state or foreign bankruptcy, insolvency, reorganization or other similar law or to the commencement of any bankruptcy or insolvency case or proceeding
against it, or the filing by it of a petition or answer or consent seeking reorganization or relief under any applicable federal, state or foreign law, or the consent by it to the filing of such petition or to the appointment of or taking possession
by a custodian, receiver, liquidator, assignee, trustee, sequestrator or other similar official of the Company or any Subsidiary or of any substantial part of its property, or the making by it of an assignment for the benefit of creditors, or the
execution of a composition of debts, or the occurrence of any other similar federal, state or foreign proceeding, or the admission by it in writing of its inability to pay its debts generally as they become due, the taking of corporate action by the
Company or any Subsidiary in furtherance of any such action or the taking of any action by any Person to commence a Uniform Commercial Code foreclosure sale or any other similar action under federal, state or foreign law; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vii)</B> the entry by a court of (i)&nbsp;a decree, order, judgment or other similar
document in respect of the Company or any Subsidiary of a voluntary or involuntary case or proceeding under any applicable federal, state or foreign bankruptcy, insolvency, reorganization or other similar law or (ii)&nbsp;a decree, order, judgment
or other similar document adjudging the Company or any Subsidiary as bankrupt or insolvent, or approving as properly filed a petition seeking liquidation, reorganization, arrangement, adjustment or composition of or in respect of the Company or any
Subsidiary under any applicable federal, state or foreign law or (iii)&nbsp;a decree, order, judgment or other similar document appointing a custodian, receiver, liquidator, assignee, trustee, sequestrator or other similar official of the Company or
any Subsidiary or of any substantial part of its property, or ordering the winding up or liquidation of its affairs, and the continuance of any such decree, order, judgment or other similar document or any such other decree, order, judgment or other
similar document unstayed and in effect for a period of thirty (30)&nbsp;consecutive days; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(viii)</B> other than as specifically
set forth in another clause of this Section&nbsp;7, the Company or any Subsidiary breaches any representation, warranty, covenant or other term or condition of any Exchange Document, except, in the case of a breach of a covenant or other term or
condition that is curable, only if such breach remains uncured for a period of three (3)&nbsp;consecutive Trading Days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.</B>
<B>Adjustment of Conversion Price upon Subdivision or Combination of Common Stock</B>. If the Company at any time on or after the date hereof subdivides (by any stock split, stock dividend, stock combination, recapitalization or other similar
transaction) one or more classes of its outstanding shares of Common Stock into a greater number of shares, the Conversion Price in effect immediately prior to such subdivision will be proportionately reduced. If the Company at any time on or after
the date hereof combines (by any stock split, stock dividend, stock combination, recapitalization or other similar transaction) one or more classes of its outstanding shares of Common Stock into a smaller number of shares, the Conversion Price in
effect immediately prior to such combination will be proportionately increased. Any adjustment pursuant to this Section&nbsp;8 shall become effective immediately after the effective date of such subdivision or combination. If any event requiring an
adjustment under this Section&nbsp;8 occurs during the period that a Conversion Price is calculated hereunder, then the calculation of such Conversion Price shall be adjusted appropriately to reflect such event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.</B> <B>Rights upon Fundamental Transaction</B>. The Company shall not enter into or be party to a Fundamental Transaction unless
(i)&nbsp;the Successor Entity assumes in writing all of the obligations of the Company under this Note and the other Exchange Documents in accordance with the provisions of this Section&nbsp;9 pursuant to written agreements in form and substance
satisfactory to the Holder and approved by the Holder prior to such Fundamental Transaction, including agreements to deliver to each holder of Notes in exchange for such Notes a security of the Successor Entity evidenced by a written instrument
substantially similar in form and substance to the Notes, including, without limitation, having a principal amount and interest rate equal to the principal amounts then outstanding and the interest rates of the Notes held by such holder, having
similar conversion rights as the Notes and having similar ranking and security to the Notes, and satisfactory to the Holder and (ii)&nbsp;the Successor Entity (including its Parent Entity) is a publicly traded corporation whose common stock is
quoted on or listed for trading on an Eligible Market. Upon the occurrence of any Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Note and the other Exchange Documents referring to the &#147;Company&#148; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
all of the obligations of the Company under this Note and the other Exchange Documents with the same effect as if such Successor Entity had been named as the Company herein. Upon consummation of
a Fundamental Transaction, the Successor Entity shall deliver to the Holder confirmation that there shall be issued upon conversion or redemption of this Note at any time after the consummation of such Fundamental Transaction, in lieu of the shares
of Common Stock (or other securities, cash, assets or other property (except such items still issuable under Sections 10(a) and 11, which shall continue to be receivable thereafter) issuable upon the conversion or redemption of the Notes prior to
such Fundamental Transaction, such shares of the publicly traded common stock (or their equivalent) of the Successor Entity (including its Parent Entity) which the Holder would have been entitled to receive upon the happening of such Fundamental
Transaction had this Note been converted immediately prior to such Fundamental Transaction (without regard to any limitations on the conversion of this Note), as adjusted in accordance with the provisions of this Note. Notwithstanding the foregoing,
the Holder may elect, at its sole option, by delivery of written notice to the Company to waive this Section&nbsp;9 to permit the Fundamental Transaction without the assumption of this Note. The provisions of this Section&nbsp;9 shall apply
similarly and equally to successive Fundamental Transactions and shall be applied without regard to any limitations on the conversion of this Note. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10. Rights Upon Issuance of Purchase Rights and Other Corporate Events.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Purchase Rights</B>. If at any time the Company grants, issues or sells any Options, Convertible Securities or rights to
purchase stock, warrants, securities or other property pro rata to all or substantially all of the record holders of any class of Common Stock (the &#147;<B><I>Purchase Rights</I></B>&#148;), then the Holder will be entitled to acquire, upon the
terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete conversion of this Note (without taking into account
any limitations or restrictions on the convertibility of this Note and assuming for such purpose that the Note was converted at the Alternate Conversion Price as of the applicable record date) immediately prior to the date on which a record is taken
for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>,
<U>however</U>, that to the extent that the Holder&#146;s right to participate in any such Purchase Right would result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to
participate in such Purchase Right to the extent of the Maximum Percentage (and shall not be entitled to beneficial ownership of such shares of Common Stock as a result of such Purchase Right (and beneficial ownership) to the extent of any such
excess) and such Purchase Right to such extent shall be held in abeyance (and, if such Purchase Right has an expiration date, maturity date or other similar provision, such term shall be extended by such number of days held in abeyance, if
applicable) for the benefit of the Holder until such time or times, if ever, as its right thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, at which time or times the Holder shall be granted
such right (and any Purchase Right granted, issued or sold on such initial Purchase Right or on any subsequent Purchase Right held similarly in abeyance (and, if such Purchase Right has an expiration date, maturity date or other similar provision,
such term shall be extended by such number of days held in abeyance, if applicable)) to the same extent as if there had been no such limitation). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Other Corporate Events</B>. In addition to and not in substitution for any other
rights hereunder, prior to the consummation of any Fundamental Transaction pursuant to which holders of shares of Common Stock are entitled to receive securities or other assets with respect to or in exchange for shares of Common Stock (a
&#147;<B><I>Corporate Event</I></B>&#148;), the Company shall make appropriate provision to ensure that the Holder will thereafter have the right to receive upon a conversion of this Note, at the Holder&#146;s option (i)&nbsp;in addition to the
shares of Common Stock receivable upon such conversion, such securities or other assets to which the Holder would have been entitled with respect to such shares of Common Stock had such shares of Common Stock been held by the Holder upon the
consummation of such Corporate Event (without taking into account any limitations or restrictions on the convertibility of this Note) or (ii)&nbsp;in lieu of the shares of Common Stock otherwise receivable upon such conversion, such securities or
other assets received by the holders of shares of Common Stock in connection with the consummation of such Corporate Event in such amounts as the Holder would have been entitled to receive had this Note initially been issued with conversion rights
for the form of such consideration (as opposed to shares of Common Stock) at a conversion rate for such consideration commensurate with the Conversion Rate. Provision made pursuant to the preceding sentence shall be in a form and substance
satisfactory to the Holder. The provisions of this Section&nbsp;10(b) shall apply similarly and equally to successive Corporate Events and shall be applied without regard to any limitations on the conversion or redemption of this Note. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.</B> <B>Remedies, Characterizations, Other Obligations, Breaches and Injunctive Relief</B>. The remedies provided in this Note shall be
cumulative and in addition to all other remedies available under this Note and any of the other Exchange Documents at law or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the
Holder&#146;s right to pursue actual and consequential damages for any failure by the Company to comply with the terms of this Note. The Company covenants to the Holder that there shall be no characterization concerning this instrument other than as
expressly provided herein. Amounts set forth or provided for herein with respect to payments, conversion and the like (and the computation thereof) shall be the amounts to be received by the Holder and shall not, except as expressly provided herein,
be subject to any other obligation of the Company (or the performance thereof). The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder and that the remedy at law for any such breach may be
inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach, the Holder shall be entitled, in addition to all other available remedies, to specific performance and/or temporary, preliminary and permanent
injunctive or other equitable relief from any court of competent jurisdiction in any such case without the necessity of proving actual damages and without posting a bond or other security. The Company shall provide all information and documentation
to the Holder that is requested by the Holder to enable the Holder to confirm the Company&#146;s compliance with the terms and conditions of this Note. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.</B> <B>Severability</B>. If any provision of this Note is prohibited by law or otherwise determined to be invalid or unenforceable by a
court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of
such provision shall not affect the validity of the remaining provisions of this Note so long as this Note as so modified continues to express, without material change, the original intentions of the parties as to the subject matter hereof and the
prohibited nature, invalidity or unenforceability of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise
be conferred upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited,
invalid or unenforceable provision(s). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.</B> <B>Maximum Payments</B>. Nothing contained herein shall be deemed to establish or
require the payment of a rate of interest or other charges in excess of the maximum permitted by applicable law. In the event that the rate of interest required to be paid or other charges hereunder exceed the maximum permitted by such law, any
payments in excess of such maximum shall be credited against amounts owed by the Company to the Holder and thus refunded to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.</B> <B>Waiver. </B>The Company hereby waives demand, notice, presentment, protest and notice of dishonor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.</B> <B>Governing Law. </B>This Note shall be construed and enforced in accordance with, and all questions concerning the construction,
validity, interpretation and performance of this Note shall be governed by, the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other
jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York. The Company hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The City of New York,
Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding,
any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein shall be
deemed or operate to preclude the Holder from bringing suit or taking other legal action against the Company in any other jurisdiction to collect on the Company&#146;s obligations to the Holder, to realize on any collateral or any other security for
such obligations, or to enforce a judgment or other court ruling in favor of the Holder. THE COMPANY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN
CONNECTION WITH OR ARISING OUT OF THIS NOTE OR ANY TRANSACTION CONTEMPLATED HEREBY. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.</B> <B>Failure Or Indulgence Not Waiver</B>.
No failure or delay on the part of the Holder in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further
exercise thereof or of any other right, power or privilege. No waiver shall be effective unless it is in writing and signed by an authorized representative of the waiving party. Notwithstanding the foregoing, nothing contained in this
Section&nbsp;16 shall permit any waiver of any provision of Section&nbsp;3(d). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.</B> <B>Amending the Terms of this Note</B>. The prior written consent of the Holder shall
be required for any change, waiver or amendment to this Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>18.</B> <B>Notices; Currency; Payments</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Notices</B>. Whenever notice is required to be given under this Note, unless otherwise provided herein, such notice shall be
given in accordance with the terms of the Exchange Agreement. The Company shall provide the Holder with prompt written notice of all actions taken pursuant to this Note, including in reasonable detail a description of such action and the reason
therefore. Without limiting the generality of the foregoing, the Company will give written notice to the Holder (i)&nbsp;immediately upon any adjustment of the Conversion Price, setting forth in reasonable detail, and certifying, the calculation of
such adjustment and (ii)&nbsp;at least fifteen (15)&nbsp;days prior to the date on which the Company closes its books or takes a record (A)&nbsp;with respect to any dividend or distribution upon the Common Stock, and (B)&nbsp;for determining rights
to vote with respect to any Fundamental Transaction, dissolution or liquidation, provided in each case that such information shall be made known to the public prior to or in conjunction with such notice being provided to the Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Currency</B>. All dollar amounts referred to in this Note are in United States Dollars (&#147;<B><I>U.S. Dollars</I></B>&#148;),
and all amounts owing under this Note shall be paid in U.S. Dollars. All amounts denominated in other currencies (if any) shall be converted into the U.S.&nbsp;Dollar equivalent amount in accordance with the Exchange Rate on the date of calculation.
&#147;<B><I>Exchange Rate</I></B>&#148;<B> </B>means, in relation to any amount of currency to be converted into U.S. Dollars pursuant to this Note, the U.S.&nbsp;Dollar exchange rate as published in the Wall Street Journal on the relevant date of
calculation (it being understood and agreed that where an amount is calculated with reference to, or over, a period of time, the date of calculation shall be the final date of such period of time). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Payments</B>. Whenever any payment of cash is to be made by the Company to any Person pursuant to this Note, unless otherwise
expressly set forth herein, such payment shall be made in lawful money of the United States of America by a certified check drawn on the account of the Company and sent via overnight courier service to such Person at such address as previously
provided to the Company in writing, provided that the Holder may elect to receive a payment of cash via wire transfer of immediately available funds by providing the Company with prior written notice setting out such request and the Holder&#146;s
wire transfer instructions. Whenever any amount expressed to be due by the terms of this Note is due on any day which is not a Business Day, the same shall instead be due on the next succeeding day which is a Business Day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>19.</B> <B>Waiver of Notice</B>. To the extent permitted by law, the Company hereby irrevocably waives demand, notice, presentment, protest
and all other demands and notices in connection with the delivery, acceptance, performance, default or enforcement of this Note and the Exchange Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>20.</B> <B>Assignment.</B> This Note may be transferred only upon its surrender to the Company for registration of transfer, duly endorsed,
or accompanied by a duly executed written instrument of transfer in form satisfactory to the Company. Thereupon, this Note shall be reissued to, and registered in the name of, the transferee, or a new Note for like Principal amount and Interest
shall be issued to, and registered in the name of, the transferee. Interest and Principal shall be paid solely to the registered holder of this Note. Such payment shall constitute full discharge of the Company&#146;s obligation to pay such Interest
and Principal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.</B> <U>CERTAIN DEFINITIONS</U>. For purposes of this Note, the following terms shall have
the following meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <I>&#147;</I><B><I>Adjustment Right&#148;</I></B><B> </B>means any right granted with respect to any
securities issued in connection with, or with respect to, any issuance or sale (or deemed issuance or sale) of shares of Common Stock that could result in a decrease in the net consideration received by the Company in connection with, or with
respect to, such securities (including, without limitation, any cash settlement rights, cash adjustment or other similar rights). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> &#147;<B><I>Alternate Conversion Price</I></B>&#148; means, with respect to any Alternate Conversion that price which shall be the
lowest of (i)&nbsp;the applicable Conversion Price as in effect on the applicable Conversion Date of the applicable Alternate Conversion, (ii) 70% of the lowest VWAP of the Common Stock as of the Trading Day during the ten (10)&nbsp;consecutive
Trading Day period ending and including the applicable Alternate Conversion Date (such period, the &#147;<B><I>Alternate Conversion Measuring Period</I></B>&#148;). All such determinations to be appropriately adjusted for any stock dividend, stock
split, stock combination, reclassification or similar transaction that proportionately decreases or increases the Common Stock during such Alternate Conversion Measuring Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> &#147;<B><I>Attribution Parties</I></B>&#148; means, collectively, the following Persons and entities: (i)&nbsp;any investment
vehicle, including, any funds, feeder funds or managed accounts, currently, or from time to time after the date hereof, directly or indirectly managed or advised by the Holder&#146;s investment manager or any of its Affiliates or principals,
(ii)&nbsp;any direct or indirect Affiliates of the Holder or any of the foregoing, (iii)&nbsp;any Person acting or who could be deemed to be acting as a Group together with the Holder or any of the foregoing and (iv)&nbsp;any other Persons whose
beneficial ownership of the Company&#146;s Common Stock would or could be aggregated with the Holder&#146;s and the other Attribution Parties for purposes of Section&nbsp;13(d) of the Exchange Act. For clarity, the purpose of the foregoing is to
subject collectively the Holder and all other Attribution Parties to the Maximum Percentage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>
&#147;<B><I>Bloomberg</I></B>&#148; means Bloomberg, L.P. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> &#147;<B><I>Business Day</I></B>&#148; means any day other than
Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> &#147;<B><I>Closing Bid Price</I></B>&#148; and &#147;<B><I>Closing Sale Price</I></B>&#148; means, for any security as of any
date, the last closing bid price and last closing trade price, respectively, for such security on the Principal Market, as reported by Bloomberg, or, if the Principal Market begins to operate on an extended hours basis and does not designate the
closing bid price or the closing trade price (as the case may be) then the last bid price or last trade price, respectively, of such security prior to 4:00:00 p.m., New York time, as reported by Bloomberg, or, if the Principal Market is not the
principal securities exchange or trading market for such security, the last closing bid price or last trade price, respectively, of such security on the principal securities exchange or trading market
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
where such security is listed or traded as reported by Bloomberg, or if the foregoing do not apply, the last closing bid price or last trade price, respectively, of such security in the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the electronic bulletin board for such security as reported by Bloomberg, or, if no closing bid price or last trade price, respectively, is reported
for such security by Bloomberg, the average of the bid prices, or the ask prices, respectively, of any market makers for such security as reported in the &#147;pink sheets&#148; by OTC Markets Group Inc. (formerly Pink Sheets LLC). If the Closing
Bid Price or the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Bid Price or the Closing Sale Price (as the case may be) of such security on such date shall be the fair market
value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then such dispute shall be resolved in accordance with the procedures in Section&nbsp;22. All
such determinations shall be appropriately adjusted for any stock splits, stock dividends, stock combinations, recapitalizations or other similar transactions during such period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> &#147;<B><I>Common Stock</I></B>&#148; means (i)&nbsp;the Company&#146;s shares of common stock, $0.0001 par value per share, and
(ii)&nbsp;any capital stock into which such common stock shall have been changed or any share capital resulting from a reclassification of such common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> &#147;<B><I>Convertible Securities</I></B>&#148; means any stock or other security (other than Options) that is at any time and
under any circumstances, directly or indirectly, convertible into, exercisable or exchangeable for, or which otherwise entitles the holder thereof to acquire, any shares of Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> &#147;<B><I>Eligible Market</I></B>&#148; means The New York Stock Exchange, the NYSE American, the Nasdaq Global Select Market,
the Nasdaq Global Market or the Principal Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> &#147;<B><I>Fundamental Transaction</I></B>&#148; means (A)&nbsp;that the
Company shall, directly or indirectly, including through subsidiaries, Affiliates or otherwise, in one or more related transactions, (i)&nbsp;consolidate or merge with or into (whether or not the Company is the surviving corporation) another Subject
Entity, or (ii)&nbsp;sell, assign, transfer, convey or otherwise dispose of all or substantially all of the properties or assets of the Company or any of its &#147;significant subsidiaries&#148; (as defined in Rule
<FONT STYLE="white-space:nowrap">1-02</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X)</FONT> to one or more Subject Entities, or (iii)&nbsp;make, or allow one or more Subject Entities to make, or allow the Company to be subject to or have
its Common Stock be subject to or party to one or more Subject Entities making, a purchase, tender or exchange offer that is accepted by the holders of at least either (x) 50% of the outstanding shares of Common Stock, (y) 50% of the outstanding
shares of Common Stock calculated as if any shares of Common Stock held by all Subject Entities making or party to, or Affiliated with any Subject Entities making or party to, such purchase, tender or exchange offer were not outstanding; or
(z)&nbsp;such number of shares of Common Stock such that all Subject Entities making or party to, or Affiliated with any Subject Entity making or party to, such purchase, tender or exchange offer, become collectively the beneficial owners (as
defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) of at least 50% of the outstanding shares of Common Stock, or (iv)&nbsp;consummate a stock or share purchase agreement or other business combination (including,
without limitation, a reorganization, recapitalization, <FONT STYLE="white-space:nowrap">spin-off</FONT> or scheme of arrangement) with one or more Subject Entities whereby all such Subject Entities, individually or in the aggregate, acquire, either
(x)&nbsp;at least 50% of the outstanding shares of Common Stock, (y)&nbsp;at least 50% of the outstanding shares of Common Stock calculated as if any shares of Common Stock held by all the Subject Entities making or party to, or Affiliated with any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Subject Entity making or party to, such stock purchase agreement or other business combination were not outstanding; or (z)&nbsp;such number of shares of Common Stock such that the Subject
Entities become collectively the beneficial owners (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) of at least 50% of the outstanding shares of Common Stock, or (v)&nbsp;reorganize, recapitalize or
reclassify its Common Stock, (B)&nbsp;that the Company shall, directly or indirectly, including through subsidiaries, Affiliates or otherwise, in one or more related transactions, allow any Subject Entity individually or the Subject Entities in the
aggregate to be or become the &#147;beneficial owner&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act), directly or indirectly, whether through acquisition, purchase, assignment, conveyance, tender,
tender offer, exchange, reduction in outstanding shares of Common Stock, merger, consolidation, business combination, reorganization, recapitalization, <FONT STYLE="white-space:nowrap">spin-off,</FONT> scheme of arrangement, reorganization,
recapitalization or reclassification or otherwise in any manner whatsoever, of either (x)&nbsp;at least 50% of the aggregate ordinary voting power represented by issued and outstanding Common Stock, (y)&nbsp;at least 50% of the aggregate ordinary
voting power represented by issued and outstanding Common Stock not held by all such Subject Entities as of the date of this Note calculated as if any shares of Common Stock held by all such Subject Entities were not outstanding, or (z)&nbsp;a
percentage of the aggregate ordinary voting power represented by issued and outstanding shares of Common Stock or other equity securities of the Company sufficient to allow such Subject Entities to effect a statutory short form merger or other
transaction requiring other shareholders of the Company to surrender their shares of Common Stock without approval of the shareholders of the Company or (C)&nbsp;directly or indirectly, including through subsidiaries, Affiliates or otherwise, in one
or more related transactions, the issuance of or the entering into any other instrument or transaction structured in a manner to circumvent, or that circumvents, the intent of this definition in which case this definition shall be construed and
implemented in a manner otherwise than in strict conformity with the terms of this definition to the extent necessary to correct this definition or any portion of this definition which may be defective or inconsistent with the intended treatment of
such instrument or transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> &#147;<B><I>Group</I></B>&#148; means a &#147;group&#148; as that term is used in
Section&nbsp;13(d) of the Exchange Act and as defined in Rule <FONT STYLE="white-space:nowrap">13d-5</FONT> thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(l)</B>
<B><I>&#147;Notes&#148;</I></B> means this Note and one or more additional convertible notes issued pursuant to one or more agreements relating to the issuance of notes in exchange for warrants issued pursuant to the Registered Offering (as defined
in the Exchange Agreement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> &#147;<B><I>Options</I></B>&#148; means any rights, warrants or options to subscribe for or
purchase shares of Common Stock or Convertible Securities issued to Persons other than the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> &#147;<B><I>Parent
Entity</I></B>&#148; of a Person means an entity that, directly or indirectly, controls the applicable Person and whose common stock or equivalent equity security is quoted or listed on an Eligible Market, or, if there is more than one such Person
or Parent Entity, the Person or Parent Entity with the largest public market capitalization as of the date of consummation of the Fundamental Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> &#147;<B><I>Principal Market</I></B>&#148; means the Nasdaq Capital Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(p)</B> <B>&#147;</B><B><I>Subject Entity</I></B>&#148; means any Person, Persons or Group or any Affiliate or associate of any such
Person, Persons or Group. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(q)</B> &#147;<B><I>Successor Entity</I></B>&#148; means the Person (or, if so elected by the
Holder, the Parent Entity) formed by, resulting from or surviving any Fundamental Transaction or the Person (or, if so elected by the Holder, the Parent Entity) with which such Fundamental Transaction shall have been entered into. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(r)</B> &#147;<B><I>Trading Day</I></B>&#148; means, as applicable, (x)&nbsp;with respect to all price or trading volume determinations
relating to the Common Stock, any day on which the Common Stock is traded on the Principal Market, or, if the Principal Market is not the principal trading market for the Common Stock, then on the principal securities exchange or securities market
on which the Common Stock is then traded, provided that &#147;Trading Day&#148; shall not include any day on which the Common Stock is scheduled to trade on such exchange or market for less than 4.5 hours or any day that the Common Stock is
suspended from trading during the final hour of trading on such exchange or market (or if such exchange or market does not designate in advance the closing time of trading on such exchange or market, then during the hour ending at 4:00:00 p.m., New
York time) unless such day is otherwise designated as a Trading Day in writing by the Holder or (y)&nbsp;with respect to all determinations other than price determinations relating to the Common Stock, any day on which The New York Stock Exchange
(or any successor thereto) is open for trading of securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(s)</B> &#147;<B><I>VWAP</I></B>&#148; means, for any security as of any
date, the dollar volume-weighted average price for such security on the Principal Market (or, if the Principal Market is not the principal trading market for such security, then on the principal securities exchange or securities market on which such
security is then traded) during the period beginning at 9:30:01 a.m., New York time, and ending at 4:00:00 p.m., New York time, as reported by Bloomberg through its &#147;HP&#148; function (set to weighted average) or, if the foregoing does not
apply, the dollar volume-weighted average price of such security in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the electronic bulletin board for such security during the period
beginning at 9:30:01 a.m., New York time, and ending at 4:00:00 p.m., New York time, as reported by Bloomberg, or, if no dollar volume-weighted average price is reported for such security by Bloomberg for such hours, the average of the highest
closing bid price and the lowest closing ask price of any of the market makers for such security as reported in the &#147;pink sheets&#148; by OTC Markets Group Inc. (formerly Pink Sheets LLC). If the VWAP cannot be calculated for such security on
such date on any of the foregoing bases, the VWAP of such security on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such
security, then such dispute shall be resolved in accordance with the procedures in Section&nbsp;22. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination, recapitalization or other similar
transaction during such period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>22.</B> <B>Disclosure</B>. Upon receipt or delivery by the Company of any notice in accordance with
the terms of this Note, unless the Company has in good faith determined that the matters relating to such notice do not constitute material, <FONT STYLE="white-space:nowrap">non-public</FONT> information relating to the Company or any of its
Subsidiaries, the Company shall within the later of (a)&nbsp;the Cleansing Deadline and (b)&nbsp;one (1) Business Day after any such receipt or delivery, publicly disclose such material, <FONT STYLE="white-space:nowrap">non-public</FONT> information
on a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or otherwise. In the event that the Company believes that a notice contains material, <FONT STYLE="white-space:nowrap">non-public</FONT> information relating to the Company or
any of its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Subsidiaries, the Company so shall indicate to the Holder contemporaneously with delivery of such notice, and in the absence of any such indication, the Holder shall be allowed to presume that
all matters relating to such notice do not constitute material, <FONT STYLE="white-space:nowrap">non-public</FONT> information relating to the Company or any of its Subsidiaries. If the Company or any of its Subsidiaries provides material <FONT
STYLE="white-space:nowrap">non-public</FONT> information to the Holder after the Cleansing Deadline that is not simultaneously filed in a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and the Holder has not agreed to receive
such material <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company hereby covenants and agrees that the Holder shall not have any duty of confidentiality to the Company, any of its Subsidiaries or any of their respective
officers, directors, employees, affiliates or agents with respect to, or a duty to any of the foregoing not to trade on the basis of, such material <FONT STYLE="white-space:nowrap">non-public</FONT> information. Nothing contained in this
Section&nbsp;22 shall limit any obligations of the Company, or any rights of the Holder, under the Exchange Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[signature page
follows] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Note: Page 17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[S<SMALL>IGNATURE</SMALL> <SMALL>PAGE</SMALL> <SMALL>TO</SMALL> C<SMALL>ONVERTIBLE</SMALL>
P<SMALL>ROMISSORY</SMALL> N<SMALL>OTE</SMALL> <SMALL>OF</SMALL> SELLAS L<SMALL>IFE</SMALL> S<SMALL>CIENCES</SMALL> G<SMALL>ROUP</SMALL>, I<SMALL>NC</SMALL>.] </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>SELLAS LIFE SCIENCES GROUP, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Angelos Stergiou</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Angelos Stergiou, M.D., ScD h.c.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holder:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U></U><U>&nbsp;&nbsp;</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Principal Amount of Note:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date of Note:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U> </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>22
<FILENAME>d556278dex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-21.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 21 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SELLAS Life Sciences Group, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following
is a list of subsidiaries of the Company as of December&nbsp;31, 2017, omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SUBSIDIARY</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:194.30pt; display:inline; font-size:10pt; font-family:Times New Roman; "><B>(Name under which subsidiary does business)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>STATE OF OTHER JURISDICTION OF</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>INCORPORATION OR ORGANIZATION</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SELLAS Life Sciences Group LTD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Bermuda</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mills Pharmaceuticals, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Apthera, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Delaware</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>23
<FILENAME>d556278dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the incorporation by reference in the Registration Statements on Form S-1 (No. 333-213908), and Form S-8
<FONT STYLE="white-space:nowrap">(333-174819,</FONT> 333-182578, 333-210833, and 333-213248) of SELLAS Life Sciences Group, Inc. (the &#147;Company&#148;) of our report dated April&nbsp;13, 2018, relating to the consolidated financial statements of
the Company (which report expresses an unqualified opinion and includes an explanatory paragraph regarding the Company&#146;s going concern uncertainty), appearing in the Company&#146;s Annual Report on Form 10-K for the year ended December&nbsp;31,
2017, filed with the Securities and Exchange Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Moss Adams LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April 13, 2018 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>24
<FILENAME>d556278dex232.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SELLAS Life Sciences Group, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the incorporation by reference in the registration statements on Form S-1 (No. 333-213908) and on Form S-8 (333-174819, 333-182578, 333-210833,
and 333-213248) of SELLAS Life Sciences Group, Inc. of our report dated September 22, 2017, with respect to the consolidated balance sheet of SELLAS Life Sciences Group, Ltd. as of December&nbsp;31, 2016, and the related consolidated statements of
operations, changes in shareholders&#146; deficit, and cash flows for the year then ended, and the related notes, before the effects of the retrospective changes resulting from the merger described in Note 1, and the addition of net loss per share
information to the consolidated financial statements as described in Note 3 (collectively, the &#147;consolidated financial statements&#148;), not included herein, which report appears in the December&nbsp;31, 2017 annual report on Form 10-K of
SELLAS Life Sciences Group, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our report dated September 22, 2017 contains an explanatory paragraph that states that the Company has suffered
recurring net losses since its inception, which raises substantial doubt about its ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ KMPG Audit Limited </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chartered Professional Accountants
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hamilton, Bermuda </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April 12, 2018 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>25
<FILENAME>d556278dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit&nbsp;31.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION OF CHIEF EXECUTIVE OFFICER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Angelos M. Stergiou, MD, certify that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. I have reviewed
this Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of SELLAS Life Sciences Group, Inc.; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. Based on my knowledge, this report does
not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by
this report; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. The
registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act <FONT STYLE="white-space:nowrap">Rules&nbsp;13a-15(e)</FONT> and <FONT
STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the registrant
and have: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to
provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c) Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">d) Disclosed in
this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has
materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. The
registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors
(or persons performing the equivalent functions): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a) All significant deficiencies and material weaknesses in the design or operation of internal control
over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over
financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: April&nbsp;13, 2018 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>/s/ Angelos M. Stergiou</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Angelos M. Stergiou, MD, ScD h.c.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer</P></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>26
<FILENAME>d556278dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit&nbsp;31.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION OF INTERIM CHIEF FINANCIAL OFFICER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Aleksey Krylov, certify that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. I have reviewed this Annual
Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of SELLAS Life Sciences Group, Inc.; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. Based on my knowledge, this report does not contain
any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. The
registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act <FONT STYLE="white-space:nowrap">Rules&nbsp;13a-15(e)</FONT> and <FONT
STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the registrant
and have: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to
provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c) Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">d) Disclosed in
this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has
materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. The
registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors
(or persons performing the equivalent functions): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a) All significant deficiencies and material weaknesses in the design or operation of internal control
over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over
financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: April&nbsp;13, 2018 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>/s/ Aleksey Krylov</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aleksey Krylov, CFA</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interim Chief Financial Officer</P></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>27
<FILENAME>d556278dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit&nbsp;32.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>18 U.S.C. SECTION 1350 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS ADOPTED PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the accompanying Annual Report of SELLAS Life Sciences Group, Inc., (the &#147;Company&#148;) on <FONT
STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December&nbsp;31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), the undersigned officers of the Company certify, pursuant to
18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. The Report fully complies with the
requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. The information contained in the Report fairly presents, in
all material respects, the Company&#146;s financial condition and result of operations. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>/s/ Angelos M. Stergiou</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Angelos M. Stergiou, MD, ScD h.c.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dated: April&nbsp;13, 2018</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>/s/ Aleksey Krylov</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aleksey Krylov, CFA</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interim Chief Financial Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dated: April&nbsp;13, 2018</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>A signed original of this written statement required by <FONT STYLE="white-space:nowrap">Rule&nbsp;13a-14(b)</FONT>
of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section&nbsp;1350 has been provided to the Registrant and will be retained by the Registrant and furnished to the Securities and Exchange Commission or its staff upon request.
</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This certification accompanies the Form <FONT STYLE="white-space:nowrap">10-K</FONT> to which it relates, is not deemed filed with the Securities
and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, (whether made before or after the date of the
Report), irrespective of any general incorporation language contained in such filing. </I></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>28
<FILENAME>sls-20171231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="yes" ?>
<!-- DFS Xcelerate Instance Document - http://www.dfsco.com/financial-services/ -->
<!-- Version:  6.23.6 -->
<!-- Round: 7 -->
<!-- Creation date: 2018-04-13T14:49:15Z -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:sls="http://imetrix.edgar-online.com/20171231" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <xbrll:schemaRef xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="sls-20171231.xsd" xlink:type="simple" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink"/>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE735624--1710-K0010_STD_0_20131125_0_2435412x2653900_2435465x2895689" decimals="INF" id="id_10184323_605916AC-C5ED-4608-88F5-0ECE677D1051_10009_12" unitRef="pure">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:LongTermDebt contextRef="eol_PE735624--1710-K0010_STD_0_20131125_0_2435412x2653900_2435465x2895689" decimals="-5" id="id_10184323_605916AC-C5ED-4608-88F5-0ECE677D1051_10009_11" unitRef="iso4217_EUR">1800000</us-gaap:LongTermDebt>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE735624--1710-K0010_STD_0_20160510_0_2435465x2668673_2442761x2448459" decimals="INF" id="id_10184323_7C57095F-6BE6-461C-985F-421C56134E37_2001_2" unitRef="shares">3333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE735624--1710-K0010_STD_0_20160510_0_2435465x2668673_2442761x2448459" decimals="INF" id="id_10184323_7C57095F-6BE6-461C-985F-421C56134E37_2001_0" unitRef="pure">0.06375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE735624--1710-K0010_STD_0_20160510_0_2435465x2668673_2442761x2448459" decimals="-5" id="id_10184323_7C57095F-6BE6-461C-985F-421C56134E37_2001_1" unitRef="iso4217_USD">25500000</us-gaap:DebtInstrumentFaceAmount>
  <sls:AdditionalSharesIssuedInConnectionWithLicensingAgreement contextRef="eol_PE735624--1710-K0010_STD_0_20160810_0_2435412x2684763_2450320x3049265" decimals="INF" id="id_10184323_ABC96FF7-852E-4C01-BAB6-07DFCC073646_2002_4" unitRef="shares">30314</sls:AdditionalSharesIssuedInConnectionWithLicensingAgreement>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="eol_PE735624--1710-K0010_STD_0_20161101_0_2445234x2694343" decimals="INF" id="id_10184323_9ECB7ABE-2922-4EDD-8686-2D062156261F_1001_0" unitRef="shares">189627</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <sls:CashPaymentOnContractTermination contextRef="eol_PE735624--1710-K0010_STD_0_20161128_0_2446922x3049599" decimals="0" id="id_10184323_E50A7EA9-3E22-4DEA-94B7-9F1B0DC7EC0A_2001_2" unitRef="iso4217_USD">30000</sls:CashPaymentOnContractTermination>
  <sls:SharesIssuedUnderLicenseAgreement contextRef="eol_PE735624--1710-K0010_STD_0_20170525_0_2435412x2684763" decimals="0" id="id_10184323_2FD32AA0-A930-44AC-AC5B-368ED818A07E_2001_2" unitRef="shares">8799</sls:SharesIssuedUnderLicenseAgreement>
  <sls:SharesIssuedUnderLicenseAgreement contextRef="eol_PE735624--1710-K0010_STD_0_20170525_0_2435412x2684763_2447148x3049698" decimals="0" id="id_10184323_2FD32AA0-A930-44AC-AC5B-368ED818A07E_3001_4" unitRef="shares">15399</sls:SharesIssuedUnderLicenseAgreement>
  <sls:AdditionalSharesIssuedInConnectionWithLicensingAgreement contextRef="eol_PE735624--1710-K0010_STD_0_20170525_0_2435412x2684763_2450320x3049580" decimals="INF" id="id_10184323_60CE9ABA-FD62-46D5-9804-52F35C1524C9_1002_1" unitRef="shares">7700</sls:AdditionalSharesIssuedInConnectionWithLicensingAgreement>
  <sls:MilestonePaymentsReceivable contextRef="eol_PE735624--1710-K0010_STD_0_20171031_0_2442761x2733354_2450320x2719233" decimals="-5" id="id_10184323_EB70FBE9-B630-4F16-AAD3-DAE66E48DD68_1002_4" unitRef="iso4217_USD">200000</sls:MilestonePaymentsReceivable>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE735624--1710-K0010_STD_0_20180206_0_2449888x2449609_2450320x3050643" decimals="INF" id="id_10184323_7C3F664A-6FA4-4C13-9D84-AB4E108D9869_2001_1" unitRef="iso4217_USD_per_shares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:SharesIssued contextRef="eol_PE735624--1710-K0010_STD_0_20180206_0_2449888x2449609_2450320x3050643" decimals="INF" id="id_10184323_7C3F664A-6FA4-4C13-9D84-AB4E108D9869_2001_0" unitRef="shares">99333</us-gaap:SharesIssued>
  <sls:DebtInstrumentConvertiblePercentageOfPrincipalAndAccruedInterest contextRef="eol_PE735624--1710-K0010_STD_0_20180206_0_2449888x2449609_2450320x3050643" decimals="3" id="id_10184323_0923ACBC-60D6-406C-9A7B-BAF10275441E_2001_1" unitRef="pure">0.050</sls:DebtInstrumentConvertiblePercentageOfPrincipalAndAccruedInterest>
  <sls:MinimumOwnershipPercentageOfOutstandingSharesOfCommonStockForConversionToTakeEffect contextRef="eol_PE735624--1710-K0010_STD_0_20180206_0_2449888x2449609_2450320x3050643" decimals="4" id="id_10184323_0923ACBC-60D6-406C-9A7B-BAF10275441E_2001_4" unitRef="pure">0.0499</sls:MinimumOwnershipPercentageOfOutstandingSharesOfCommonStockForConversionToTakeEffect>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE735624--1710-K0010_STD_0_20180207_0_2449888x2449609_2450320x3050644" decimals="INF" id="id_10184323_6860ECBD-9644-4F3D-A4F7-F67AF3C97DD8_2001_0" unitRef="shares">30000</us-gaap:CommonStockSharesIssued>
  <sls:DebtInstrumentConvertiblePercentageOfPrincipalAndAccruedInterest contextRef="eol_PE735624--1710-K0010_STD_0_20180209_0_2449888x2449609_2450320x3050035" decimals="2" id="id_10184323_8C21463C-B1CF-46A6-A842-AB82CFE473AD_2001_0" unitRef="pure">0.05</sls:DebtInstrumentConvertiblePercentageOfPrincipalAndAccruedInterest>
  <sls:MinimumOwnershipPercentageOfOutstandingSharesOfCommonStockForConversionToTakeEffect contextRef="eol_PE735624--1710-K0010_STD_0_20180209_0_2449888x2449609_2450320x3050035" decimals="4" id="id_10184323_8C21463C-B1CF-46A6-A842-AB82CFE473AD_2001_3" unitRef="pure">0.0999</sls:MinimumOwnershipPercentageOfOutstandingSharesOfCommonStockForConversionToTakeEffect>
  <sls:DebtInstrumentConvertiblePercentageOfPrincipalAndAccruedInterest contextRef="eol_PE735624--1710-K0010_STD_0_20180213_0_2449888x2449609_2450320x3051911" decimals="3" id="id_10184323_C64DAB48-0CCD-49B2-AEB5-BBFF5AA5F572_2001_1" unitRef="pure">0.050</sls:DebtInstrumentConvertiblePercentageOfPrincipalAndAccruedInterest>
  <sls:MinimumOwnershipPercentageOfOutstandingSharesOfCommonStockForConversionToTakeEffect contextRef="eol_PE735624--1710-K0010_STD_0_20180213_0_2449888x2449609_2450320x3051911" decimals="4" id="id_10184323_C64DAB48-0CCD-49B2-AEB5-BBFF5AA5F572_2001_3" unitRef="pure">0.0999</sls:MinimumOwnershipPercentageOfOutstandingSharesOfCommonStockForConversionToTakeEffect>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE735624--1710-K0010_STD_0_20180222_0_2449888x2449609_2450320x3050038" decimals="INF" id="id_10184323_E3D57259-5823-4EC1-A03F-8CA5760B830C_2001_1" unitRef="iso4217_USD_per_shares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:SharesIssued contextRef="eol_PE735624--1710-K0010_STD_0_20180222_0_2449888x2449609_2450320x3050038" decimals="INF" id="id_10184323_E3D57259-5823-4EC1-A03F-8CA5760B830C_2001_0" unitRef="shares">26668</us-gaap:SharesIssued>
  <sls:DebtInstrumentConvertiblePercentageOfPrincipalAndAccruedInterest contextRef="eol_PE735624--1710-K0010_STD_0_20180822_0_2449888x2449609_2450320x3050038" decimals="4" id="id_10184323_9B7A1C4C-D7B3-4386-9B85-CC005E05F0E8_2001_0" unitRef="pure">0.0475</sls:DebtInstrumentConvertiblePercentageOfPrincipalAndAccruedInterest>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE735624--1710-K0010_STD_0_20150302_0_2435412x2660097_2435465x3053908" decimals="INF" id="id_10184323_605916AC-C5ED-4608-88F5-0ECE677D1051_11001_2" unitRef="pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:LongTermDebt contextRef="eol_PE735624--1710-K0010_STD_0_20150302_0_2435412x2660097_2435465x3053908" decimals="-5" id="id_10184323_605916AC-C5ED-4608-88F5-0ECE677D1051_11001_0" unitRef="iso4217_USD">2500000</us-gaap:LongTermDebt>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE735624--1710-K0010_STD_0_20150402_0_2435465x3049445" decimals="-5" id="id_10184323_73988A1A-61DF-48A4-8418-E24491ABE072_3001_0" unitRef="iso4217_USD">1500000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:LongTermLineOfCredit contextRef="eol_PE735624--1710-K0010_STD_0_20160406_0_2435412x3053914_2435465x3053912_2442761x2442444" decimals="-5" id="id_10184323_605916AC-C5ED-4608-88F5-0ECE677D1051_12002_3" unitRef="iso4217_USD">1500000</us-gaap:LongTermLineOfCredit>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="eol_PE735624--1710-K0010_STD_0_20180307_0_2448913x2672262_2449888x2449609_2450320x2737197" decimals="INF" id="id_10184323_B621CDDD-ED2C-4D8B-BD64-236C561D1500_2001_2" unitRef="iso4217_USD_per_shares">6.59</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE735624--1710-K0010_STD_0_20180307_0_2448913x2672262_2449888x2449609_2450320x2737197" decimals="INF" id="id_10184323_B621CDDD-ED2C-4D8B-BD64-236C561D1500_2001_0" unitRef="shares">1383631</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <sls:ConvertiblePreferredStockIssuedShares contextRef="eol_PE735624--1710-K0010_STD_0_20180307_0_2448913x2672262_2449888x2449609_2450320x2737197" decimals="INF" id="id_10184323_8CAA6ACD-505E-4CCF-8B90-187A04FCBEF7_2001_0" unitRef="shares">10700</sls:ConvertiblePreferredStockIssuedShares>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE735624--1710-K0010_STD_0_20180307_0_2449888x2449609_2450320x2737197" decimals="INF" id="id_10184323_8CAA6ACD-505E-4CCF-8B90-187A04FCBEF7_3001_1" unitRef="shares">1383631</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE735624--1710-K0010_STD_0_20180307_0_2449888x2449609_2450320x2737197" decimals="INF" id="id_10184323_8CAA6ACD-505E-4CCF-8B90-187A04FCBEF7_3001_2" unitRef="iso4217_USD_per_shares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="eol_PE735624--1710-K0010_STD_0_20180307_0_2449888x2449609_2450320x2737197" decimals="INF" id="id_10184323_8CAA6ACD-505E-4CCF-8B90-187A04FCBEF7_3001_4" unitRef="shares">1844835</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <sls:ConversionPriceOfPreferredStock contextRef="eol_PE735624--1710-K0010_STD_0_20180307_0_2449888x2449609_2450320x2737197" decimals="2" id="id_10184323_8CAA6ACD-505E-4CCF-8B90-187A04FCBEF7_3001_5" unitRef="iso4217_USD_per_shares">5.80</sls:ConversionPriceOfPreferredStock>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="eol_PE735624--1710-K0010_STD_0_20180308_0_2447194x2442860_2448913x2672262_2449888x2449609" decimals="INF" id="id_10184323_B24A3240-0935-416B-B841-FFF55EBD4E15_2001_1" unitRef="shares">17500</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE735624--1710-K0010_STD_0_20180308_0_2448913x2672262_2449888x2449609" decimals="2" id="id_10184323_B24A3240-0935-416B-B841-FFF55EBD4E15_3001_3" unitRef="pure">0.20</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="eol_PE735624--1710-K0010_STD_0_20180308_0_2448913x2672262_2449888x2449609" decimals="4" id="id_10184323_C609B174-0DFA-4782-9E5F-1C6D1850B6C1_2001_0" unitRef="pure">0.0999</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE735624--1710-K0010_STD_0_20180308_0_2448913x2672262_2449888x2449609" decimals="INF" id="id_10184323_B24A3240-0935-416B-B841-FFF55EBD4E15_3001_2" unitRef="iso4217_USD_per_shares">1000</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired contextRef="eol_PE735624--1710-K0010_STD_0_20180309_0_2447194x2443301_2449888x2449609_2450320x3050049" decimals="2" id="id_10184323_59666AC9-612A-4157-9704-A809A64DEE7B_2001_1" unitRef="pure">0.50</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
  <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="eol_PE735624--1710-K0010_STD_0_20180309_0_2447194x2443301_2449888x2449609_2450320x3050049" decimals="2" id="id_10184323_59666AC9-612A-4157-9704-A809A64DEE7B_2001_0" unitRef="pure">0.10</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
  <sls:MinimumProceedRequiredUnderQualifiedOffering contextRef="eol_PE735624--1710-K0010_STD_0_20180309_0_2448913x2672262_2449620x2731166_2449888x2449609_2450320x2737197" decimals="-5" id="id_10184323_8AC584F9-D761-4F0C-BE3C-B72942791F84_2001_0" unitRef="iso4217_USD">20000000</sls:MinimumProceedRequiredUnderQualifiedOffering>
  <sls:ConvertiblePreferredStockIssuedShares contextRef="eol_PE735624--1710-K0010_STD_0_20180309_0_2448913x2672262_2449620x3050114_2449888x2449609_2450320x2737197" decimals="INF" id="id_10184323_5A383C6B-7512-437A-B4E3-A3E8E1E63BA0_2002_0" unitRef="shares">5987</sls:ConvertiblePreferredStockIssuedShares>
  <sls:ConvertiblePreferredStockIssuedShares contextRef="eol_PE735624--1710-K0010_STD_0_20180309_0_2448913x2672262_2449620x3050115_2449888x2449609_2450320x2737197" decimals="INF" id="id_10184323_5A383C6B-7512-437A-B4E3-A3E8E1E63BA0_2003_0" unitRef="shares">4713</sls:ConvertiblePreferredStockIssuedShares>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE735624--1710-K0010_STD_0_20180406_0" decimals="INF" id="id_10184323_C91A2C78-0B97-47A5-BD75-FD7EC3655142_2_8" unitRef="shares">6572542</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:DebtInstrumentCarryingAmount contextRef="eol_PE735624--1710-K0010_STD_0_20180406_0_2435465x2728214_2449888x2449609" decimals="-5" id="id_10184323_547744F2-B474-40B5-8C1C-43342EA2E4DB_1002_4" unitRef="iso4217_USD">7000000</us-gaap:DebtInstrumentCarryingAmount>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE735624--1710-K0010_STD_0_20160630_0_2435465x3049453" decimals="-5" id="id_10184323_2EB30C43-4544-40D7-B257-5BD00BD9BD61_2001_0" unitRef="iso4217_USD">15000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:CommonStockSharesSubscriptions contextRef="eol_PE735624--1710-K0010_STD_0_20170613_0_2432521x3049445_2435465x2685828" decimals="-5" id="id_10184323_2727C554-B3C9-448F-9151-38276CA98CE4_2002_0" unitRef="iso4217_USD">1300000</us-gaap:CommonStockSharesSubscriptions>
  <us-gaap:CommonStockSharesSubscribedButUnissued contextRef="eol_PE735624--1710-K0010_STD_0_20170613_0_2432521x3049445_2435465x2685828" decimals="INF" id="id_10184323_2727C554-B3C9-448F-9151-38276CA98CE4_2002_1" unitRef="shares">330551</us-gaap:CommonStockSharesSubscribedButUnissued>
  <us-gaap:BridgeLoan contextRef="eol_PE735624--1710-K0010_STD_0_20170613_0_2435465x2685828" decimals="-5" id="id_10184323_7E0FA6FC-DA72-4FC9-8F1A-4873171726F0_1001_0" unitRef="iso4217_USD">7300000</us-gaap:BridgeLoan>
  <us-gaap:SharesIssuedPricePerShare contextRef="eol_PE735624--1710-K0010_STD_0_20170613_0_2435465x2685828" decimals="INF" id="id_10184323_7E0FA6FC-DA72-4FC9-8F1A-4873171726F0_1001_2" unitRef="iso4217_USD_per_shares">3.91</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssued contextRef="eol_PE735624--1710-K0010_STD_0_20170613_0_2435465x2685828" decimals="INF" id="id_10184323_7E0FA6FC-DA72-4FC9-8F1A-4873171726F0_1001_1" unitRef="shares">1865261</us-gaap:SharesIssued>
  <dei:EntityPublicFloat contextRef="eol_PE735624--1710-K0010_STD_0_20170630_0" decimals="0" id="id_10184323_C91A2C78-0B97-47A5-BD75-FD7EC3655142_3_9" unitRef="iso4217_USD">21640272</dei:EntityPublicFloat>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE735624--1710-K0010_STD_0_20180630_0_2448913x2672262_2449305x2447800_2449888x2449609" decimals="2" id="id_10184323_B24A3240-0935-416B-B841-FFF55EBD4E15_3002_4" unitRef="pure">0.20</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <sls:AnnualMaintenanceFee contextRef="eol_PE735624--1710-K0010_STD_0_20060911_0_2450320x2659749" decimals="-5" id="id_10184323_D438D7A8-7B19-4951-B493-178ED7B2F689_1001_0" unitRef="iso4217_USD">200000</sls:AnnualMaintenanceFee>
  <sls:SharesIssuedUnderLicenseAgreement contextRef="eol_PE735624--1710-K0010_STD_0_20140904_0_2435412x2684763_2447148x2442380" decimals="INF" id="id_10184323_5F9BC149-0B54-4ECF-8EF0-02C65FCB12FC_3001_0" unitRef="shares">13199</sls:SharesIssuedUnderLicenseAgreement>
  <sls:SharesIssuedUnderLicenseAgreement contextRef="eol_PE735624--1710-K0010_STD_0_20140904_0_2435412x2684763_2447148x2442380_2449718x2715035" decimals="INF" id="id_10184323_5F9BC149-0B54-4ECF-8EF0-02C65FCB12FC_4001_4" unitRef="shares">6599</sls:SharesIssuedUnderLicenseAgreement>
  <sls:SharesIssuedUnderLicenseAgreement contextRef="eol_PE735624--1710-K0010_STD_0_20140904_0_2435412x2684763_2447148x2442380_2449718x2723027" decimals="INF" id="id_10184323_5F9BC149-0B54-4ECF-8EF0-02C65FCB12FC_5001_3" unitRef="shares">6599</sls:SharesIssuedUnderLicenseAgreement>
  <sls:SharesIssuedUnderLicenseAgreement contextRef="eol_PE735624--1710-K0010_STD_0_20140904_0_2435412x2684763_2447148x2442380_2449718x3049267" decimals="INF" id="id_10184323_5F9BC149-0B54-4ECF-8EF0-02C65FCB12FC_6001_2" unitRef="shares">6599</sls:SharesIssuedUnderLicenseAgreement>
  <sls:SharesIssuedUnderLicenseAgreement contextRef="eol_PE735624--1710-K0010_STD_0_20151030_0_2435412x2684763_2450320x3049264" decimals="INF" id="id_10184323_7CC330AF-0F17-4C8A-A46A-21EB8ECE9C38_2001_2" unitRef="shares">10867</sls:SharesIssuedUnderLicenseAgreement>
  <sls:SharesIssuableForConsiderationForLicenseTerminationAgreement contextRef="eol_PE735624--1710-K0010_STD_0_20160930_0_2450320x3049289" decimals="INF" id="id_10184323_985350E3-948F-4241-987D-FE157762C3AA_2001_2" unitRef="shares">7700</sls:SharesIssuableForConsiderationForLicenseTerminationAgreement>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE735624--1710-K0010_STD_0_20170831_0_2435465x3049445_2446928x3049446" decimals="INF" id="id_10184323_B94B5804-D9E4-477D-B874-50C21EDE265C_2001_2" unitRef="shares">316163</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <sls:MilestonePaymentsReceivable contextRef="eol_PE735624--1710-K0010_STD_0_20170905_0_2450320x2719233" decimals="-5" id="id_10184323_EB70FBE9-B630-4F16-AAD3-DAE66E48DD68_2001_4" unitRef="iso4217_USD">400000</sls:MilestonePaymentsReceivable>
  <sls:SharesIssuedUnderLicenseAgreement contextRef="eol_PE735624--1710-K0010_STD_0_20171011_0_2435412x2684763_2450320x3049580" decimals="0" id="id_10184323_60CE9ABA-FD62-46D5-9804-52F35C1524C9_1001_0" unitRef="shares">74795</sls:SharesIssuedUnderLicenseAgreement>
  <sls:BusinessCombinationContingentConsiderationPayableUponAchievementOfMilestones contextRef="eol_PE735624--1710-K0010_STD_0_20111231_0_2447194x2442860" decimals="-6" id="id_10184323_1D6B063F-84C4-4E05-921C-0D6D9D8B6537_1001_0" unitRef="iso4217_USD">32000000</sls:BusinessCombinationContingentConsiderationPayableUponAchievementOfMilestones>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE735624--1710-K0010_STD_0_20151231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_4001_28" unitRef="iso4217_USD">1397000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="eol_PE735624--1710-K0010_STD_0_20151231_0" decimals="-3" id="id_10184323_18A7C5E6-643A-43B9-96BE-7B5CEADC0C13_1001_2" unitRef="iso4217_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:StockholdersEquity contextRef="eol_PE735624--1710-K0010_STD_0_20151231_0" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_1005_800001" unitRef="iso4217_USD">-12262000</us-gaap:StockholdersEquity>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE735624--1710-K0010_STD_0_20151231_0_2435465x3053943" decimals="INF" id="id_10184323_605916AC-C5ED-4608-88F5-0ECE677D1051_13010_21" unitRef="pure">0.025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:LongTermDebt contextRef="eol_PE735624--1710-K0010_STD_0_20151231_0_2435465x3053943_2446928x3053940" decimals="-5" id="id_10184323_605916AC-C5ED-4608-88F5-0ECE677D1051_14010_19" unitRef="iso4217_EUR">700000</us-gaap:LongTermDebt>
  <us-gaap:LongTermDebt contextRef="eol_PE735624--1710-K0010_STD_0_20151231_0_2435465x3053943_2446928x3053941" decimals="-5" id="id_10184323_605916AC-C5ED-4608-88F5-0ECE677D1051_15010_20" unitRef="iso4217_EUR">600000</us-gaap:LongTermDebt>
  <us-gaap:LongTermDebt contextRef="eol_PE735624--1710-K0010_STD_0_20151231_0_2446928x3053940" decimals="-5" id="id_10184323_605916AC-C5ED-4608-88F5-0ECE677D1051_16010_14" unitRef="iso4217_EUR">1800000</us-gaap:LongTermDebt>
  <us-gaap:LongTermDebt contextRef="eol_PE735624--1710-K0010_STD_0_20151231_0_2446928x3053941" decimals="-5" id="id_10184323_605916AC-C5ED-4608-88F5-0ECE677D1051_17010_15" unitRef="iso4217_EUR">1800000</us-gaap:LongTermDebt>
  <us-gaap:LongTermLoansPayable contextRef="eol_PE735624--1710-K0010_STD_0_20151231_0_2446928x3053942" decimals="-5" id="id_10184323_605916AC-C5ED-4608-88F5-0ECE677D1051_18010_17" unitRef="iso4217_EUR">100000</us-gaap:LongTermLoansPayable>
  <us-gaap:LoansReceivableNet contextRef="eol_PE735624--1710-K0010_STD_0_20151231_0_2446928x3053942" decimals="-5" id="id_10184323_605916AC-C5ED-4608-88F5-0ECE677D1051_18010_18" unitRef="iso4217_EUR">700000</us-gaap:LoansReceivableNet>
  <us-gaap:StockholdersEquity contextRef="eol_PE735624--1710-K0010_STD_0_20151231_0_2448914x2432358" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_1003_600001" unitRef="iso4217_USD">488000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE735624--1710-K0010_STD_0_20151231_0_2448914x2432358_2449305x2447520" decimals="-3" id="id_10184323_316093F4-0A93-43A3-8E21-CC3759FEB2D1_1002_1" unitRef="iso4217_USD">200000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE735624--1710-K0010_STD_0_20151231_0_2448914x2432358_2449305x2448174" decimals="-3" id="id_10184323_316093F4-0A93-43A3-8E21-CC3759FEB2D1_1001_1" unitRef="iso4217_USD">288000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE735624--1710-K0010_STD_0_20151231_0_2448914x2434572" decimals="INF" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_1001_400002" unitRef="shares">879994</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE735624--1710-K0010_STD_0_20151231_0_2448914x2447681" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_1004_700001" unitRef="iso4217_USD">-12750000</us-gaap:StockholdersEquity>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_2_15" unitRef="iso4217_USD">4049000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_2_5" unitRef="iso4217_USD">6379000</us-gaap:AssetsCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="-3" id="id_10184323_7A3A21F0-5BB2-496B-8ED5-DE36EEDBD4E3_1002_0" unitRef="iso4217_USD">1077000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_2_36" unitRef="iso4217_USD">25434000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:Assets contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_2_9" unitRef="iso4217_USD">6420000</us-gaap:Assets>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_2_2" unitRef="iso4217_USD">5962000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_2_24" unitRef="iso4217_USD" xsi:nil="true"/>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="INF" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_2_33" unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="INF" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_2_35" unitRef="shares">1268489</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="-3" id="id_10184323_1DED8646-51CA-4296-813D-28D45E65FF74_1004_1" unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ConvertibleDebtCurrent contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_2_13" unitRef="iso4217_USD">1709000</us-gaap:ConvertibleDebtCurrent>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="INF" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_2_32" unitRef="iso4217_USD_per_shares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="INF" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_2_34" unitRef="shares">1268489</us-gaap:CommonStockSharesIssued>
  <us-gaap:ConvertibleDebt contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="-3" id="id_10184323_FE021226-8779-4F3F-9E81-97BECB281DE3_1002_5" unitRef="iso4217_USD">7368000</us-gaap:ConvertibleDebt>
  <us-gaap:ConvertibleDebtNoncurrent contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_2_22" unitRef="iso4217_USD">5659000</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:DeferredTaxAssetsGross contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="-3" id="id_10184323_89791292-640C-4FAB-B99E-F8172E2F4893_2_6" unitRef="iso4217_USD">3549000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsNet contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="-3" id="id_10184323_89791292-640C-4FAB-B99E-F8172E2F4893_2_8" unitRef="iso4217_USD">41000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsOtherTaxCarryforwards contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="-3" id="id_10184323_89791292-640C-4FAB-B99E-F8172E2F4893_2_5" unitRef="iso4217_USD">81000</us-gaap:DeferredTaxAssetsOtherTaxCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="-3" id="id_10184323_89791292-640C-4FAB-B99E-F8172E2F4893_2_1" unitRef="iso4217_USD">3145000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="-3" id="id_10184323_89791292-640C-4FAB-B99E-F8172E2F4893_2_2" unitRef="iso4217_USD">295000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="-3" id="id_10184323_89791292-640C-4FAB-B99E-F8172E2F4893_2_7" unitRef="iso4217_USD">3508000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="-3" id="id_10184323_89791292-640C-4FAB-B99E-F8172E2F4893_2_3" unitRef="iso4217_USD">28000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DepositsAssetsNoncurrent contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_2_8" unitRef="iso4217_USD">41000</us-gaap:DepositsAssetsNoncurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="-3" id="id_10184323_7A3A21F0-5BB2-496B-8ED5-DE36EEDBD4E3_1002_3" unitRef="iso4217_USD">249000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:Liabilities contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_2_23" unitRef="iso4217_USD">11417000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_2_39" unitRef="iso4217_USD">6420000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_2_17" unitRef="iso4217_USD">5758000</us-gaap:LiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="-3" id="id_10184323_7A3A21F0-5BB2-496B-8ED5-DE36EEDBD4E3_1002_5" unitRef="iso4217_USD">227000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="INF" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_2_27" unitRef="iso4217_USD_per_shares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="INF" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_2_28" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockValue contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_2_26" unitRef="iso4217_USD" xsi:nil="true"/>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_2_4" unitRef="iso4217_USD">332000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="INF" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_2_29" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="INF" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_2_30" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_2_3" unitRef="iso4217_USD">85000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_2_37" unitRef="iso4217_USD">-30431000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="-3" id="id_10184323_18A7C5E6-643A-43B9-96BE-7B5CEADC0C13_3001_4" unitRef="iso4217_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="-3" id="id_10184323_F20F2A7E-6CA6-4B06-A237-1C397810BBCA_3001_4" unitRef="shares">55000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="2" id="id_10184323_A30F3FDC-E7BB-4D8B-8348-6E7E5CF4A544_3001_4" unitRef="iso4217_USD_per_shares">52.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:StockholdersEquity contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_2_38" unitRef="iso4217_USD">-4997000</us-gaap:StockholdersEquity>
  <sls:ContractResearchPayable contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="-3" id="id_10184323_7A3A21F0-5BB2-496B-8ED5-DE36EEDBD4E3_1002_4" unitRef="iso4217_USD">2496000</sls:ContractResearchPayable>
  <sls:ImpactOnTaxProvisionFromUnrecognizedTaxBenefits contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0" decimals="0" id="id_10184323_41FCF947-D145-4446-9704-AC454811373C_1002_0" unitRef="iso4217_USD">44000</sls:ImpactOnTaxProvisionFromUnrecognizedTaxBenefits>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0_2433414x3049142" decimals="2" id="id_10184323_964D25B1-77A6-4A1B-9793-F1EFEA20AD93_3001_4" unitRef="iso4217_USD_per_shares">52.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0_2433414x3049142" decimals="-3" id="id_10184323_D93819D1-11DB-4503-A4A0-55D8D07DE92D_3001_4" unitRef="shares">46000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0_2433414x3049145" decimals="2" id="id_10184323_E1E0D8FA-4A9F-405E-8BE5-5925DE89D6F4_3001_4" unitRef="iso4217_USD_per_shares">52.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0_2433414x3049145" decimals="-3" id="id_10184323_C82FDB47-92A3-46C4-A21E-3367B6C36CF4_3001_4" unitRef="shares">21000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0_2434520x2884867" decimals="-3" id="id_10184323_1DED8646-51CA-4296-813D-28D45E65FF74_1002_1" unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0_2434520x2884905" decimals="-3" id="id_10184323_1DED8646-51CA-4296-813D-28D45E65FF74_1003_1" unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0_2434520x3050116" decimals="-3" id="id_10184323_1DED8646-51CA-4296-813D-28D45E65FF74_1001_1" unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ConvertibleDebt contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0_2442761x2679970" decimals="-5" id="id_10184323_328D9573-A76A-4119-BD4A-23EE8578F9E7_1001_1" unitRef="iso4217_USD">7400000</us-gaap:ConvertibleDebt>
  <us-gaap:DebtInstrumentFairValue contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0_2442761x2679970" decimals="-5" id="id_10184323_328D9573-A76A-4119-BD4A-23EE8578F9E7_1001_0" unitRef="iso4217_USD">7300000</us-gaap:DebtInstrumentFairValue>
  <us-gaap:ConvertibleDebt contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0_2442761x3049779" decimals="-3" id="id_10184323_FE021226-8779-4F3F-9E81-97BECB281DE3_3002_3" unitRef="iso4217_USD">1709000</us-gaap:ConvertibleDebt>
  <us-gaap:ConvertibleDebt contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0_2442761x3049991" decimals="-3" id="id_10184323_FE021226-8779-4F3F-9E81-97BECB281DE3_4002_4" unitRef="iso4217_USD">5659000</us-gaap:ConvertibleDebt>
  <us-gaap:ManagementFeePayable contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0_2446922x3049598" decimals="-5" id="id_10184323_0944809B-2ACB-4431-8932-A05505810103_2003_3" unitRef="iso4217_USD">0</us-gaap:ManagementFeePayable>
  <us-gaap:StockholdersEquity contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0_2448914x2432358" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_3003_600016" unitRef="iso4217_USD">25434000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0_2448914x2432358_2449305x2447520" decimals="-3" id="id_10184323_316093F4-0A93-43A3-8E21-CC3759FEB2D1_3002_8" unitRef="iso4217_USD">288000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0_2448914x2432358_2449305x2448174" decimals="-3" id="id_10184323_316093F4-0A93-43A3-8E21-CC3759FEB2D1_3001_8" unitRef="iso4217_USD">25146000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0_2448914x2434572" decimals="INF" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_3001_400017" unitRef="shares">1268489</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE735624--1710-K0010_STD_0_20161231_0_2448914x2447681" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_3004_700016" unitRef="iso4217_USD">-30431000</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE735624--1710-K0010_STD_0_20171229_0" decimals="INF" id="id_10184323_D5995E5A-4042-43AF-A402-DA196989731F_1_3" unitRef="shares">5766891</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE735624--1710-K0010_STD_0_20171229_0" decimals="INF" id="id_10184323_D5995E5A-4042-43AF-A402-DA196989731F_1_7" unitRef="iso4217_USD_per_shares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="eol_PE735624--1710-K0010_STD_0_20171229_0" decimals="3" id="id_10184323_DEDE4CB5-C2B7-43EC-84DD-8AB2C7F7E202_2001_1" unitRef="pure">0.325</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
  <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="eol_PE735624--1710-K0010_STD_0_20171229_0" decimals="3" id="id_10184323_DEDE4CB5-C2B7-43EC-84DD-8AB2C7F7E202_2001_0" unitRef="pure">0.675</us-gaap:MinorityInterestOwnershipPercentageByParent>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="eol_PE735624--1710-K0010_STD_0_20171229_0_2433694x2884874" decimals="-3" id="id_10184323_2025F87D-CB31-4A06-AFD5-AA1FE34C0D4A_1_1" unitRef="iso4217_USD">1812000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="eol_PE735624--1710-K0010_STD_0_20171229_0_2433694x2884874" decimals="-3" id="id_10184323_2025F87D-CB31-4A06-AFD5-AA1FE34C0D4A_1_14" unitRef="iso4217_USD">22256000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets contextRef="eol_PE735624--1710-K0010_STD_0_20171229_0_2433694x2884874" decimals="-3" id="id_10184323_2025F87D-CB31-4A06-AFD5-AA1FE34C0D4A_1_3" unitRef="iso4217_USD">3103000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent contextRef="eol_PE735624--1710-K0010_STD_0_20171229_0_2433694x2884874" decimals="-3" id="id_10184323_2025F87D-CB31-4A06-AFD5-AA1FE34C0D4A_1_13" unitRef="iso4217_USD">1673000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="eol_PE735624--1710-K0010_STD_0_20171229_0_2433694x2884874" decimals="-3" id="id_10184323_2025F87D-CB31-4A06-AFD5-AA1FE34C0D4A_1_6" unitRef="iso4217_USD">34775000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability contextRef="eol_PE735624--1710-K0010_STD_0_20171229_0_2433694x2884874" decimals="-3" id="id_10184323_2025F87D-CB31-4A06-AFD5-AA1FE34C0D4A_1_11" unitRef="iso4217_USD">1294000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt contextRef="eol_PE735624--1710-K0010_STD_0_20171229_0_2433694x2884874" decimals="-3" id="id_10184323_2025F87D-CB31-4A06-AFD5-AA1FE34C0D4A_1_10" unitRef="iso4217_USD">10988000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="eol_PE735624--1710-K0010_STD_0_20171229_0_2433694x2884874" decimals="-5" id="id_10184323_53D2D076-9A56-45C4-9678-A7059D55856D_1001_0" unitRef="iso4217_USD">17600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="eol_PE735624--1710-K0010_STD_0_20171229_0_2433694x2884874" decimals="-3" id="id_10184323_2025F87D-CB31-4A06-AFD5-AA1FE34C0D4A_1_15" unitRef="iso4217_USD">12519000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
  <us-gaap:Goodwill contextRef="eol_PE735624--1710-K0010_STD_0_20171229_0_2433694x2884874" decimals="-3" id="id_10184323_2025F87D-CB31-4A06-AFD5-AA1FE34C0D4A_1_5" unitRef="iso4217_USD">1914000</us-gaap:Goodwill>
  <sls:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses contextRef="eol_PE735624--1710-K0010_STD_0_20171229_0_2433694x2884874" decimals="-3" id="id_10184323_2025F87D-CB31-4A06-AFD5-AA1FE34C0D4A_1_8" unitRef="iso4217_USD">5692000</sls:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses>
  <sls:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash contextRef="eol_PE735624--1710-K0010_STD_0_20171229_0_2433694x2884874" decimals="-3" id="id_10184323_2025F87D-CB31-4A06-AFD5-AA1FE34C0D4A_1_2" unitRef="iso4217_USD">10346000</sls:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash>
  <sls:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement contextRef="eol_PE735624--1710-K0010_STD_0_20171229_0_2433694x2884874" decimals="-3" id="id_10184323_2025F87D-CB31-4A06-AFD5-AA1FE34C0D4A_1_9" unitRef="iso4217_USD">1300000</sls:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement>
  <sls:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability contextRef="eol_PE735624--1710-K0010_STD_0_20171229_0_2433694x2884874" decimals="-3" id="id_10184323_2025F87D-CB31-4A06-AFD5-AA1FE34C0D4A_1_12" unitRef="iso4217_USD">1309000</sls:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="eol_PE735624--1710-K0010_STD_0_20171229_0_2433694x2884874_2447148x3049740" decimals="-5" id="id_10184323_53D2D076-9A56-45C4-9678-A7059D55856D_2001_1" unitRef="iso4217_USD">9100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="eol_PE735624--1710-K0010_STD_0_20171229_0_2433694x2884874_2447148x3050157" decimals="-5" id="id_10184323_53D2D076-9A56-45C4-9678-A7059D55856D_3001_3" unitRef="iso4217_USD">2800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="eol_PE735624--1710-K0010_STD_0_20171229_0_2433694x2884874_2447148x3050369" decimals="-5" id="id_10184323_53D2D076-9A56-45C4-9678-A7059D55856D_4001_2" unitRef="iso4217_USD">5700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="eol_PE735624--1710-K0010_STD_0_20171229_0_2434520x3050116" decimals="INF" id="id_10184323_BAE9134F-EE87-42C2-9C94-8E7554FBFBEF_1001_1" unitRef="iso4217_USD_per_shares">7.42</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE735624--1710-K0010_STD_0_20171229_0_2434520x3050116" decimals="INF" id="id_10184323_BAE9134F-EE87-42C2-9C94-8E7554FBFBEF_1001_0" unitRef="shares">316163</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <sls:FairValueofWarrantsGrantedperShare contextRef="eol_PE735624--1710-K0010_STD_0_20171229_0_2434520x3050116" decimals="2" id="id_10184323_BAE9134F-EE87-42C2-9C94-8E7554FBFBEF_1001_3" unitRef="iso4217_USD_per_shares">5.60</sls:FairValueofWarrantsGrantedperShare>
  <sls:AccruedCompensationIncentive contextRef="eol_PE735624--1710-K0010_STD_0_20171229_0_2446922x3049598" decimals="-5" id="id_10184323_6C3DD794-76CF-450E-BA3D-7B48417B6F85_2001_0" unitRef="iso4217_USD">100000</sls:AccruedCompensationIncentive>
  <sls:PercentageOfFullyDilutedShareCapitalOwned contextRef="eol_PE735624--1710-K0010_STD_0_20171229_0_2448914x3049254" decimals="3" id="id_10184323_D5995E5A-4042-43AF-A402-DA196989731F_3001_5" unitRef="pure">0.325</sls:PercentageOfFullyDilutedShareCapitalOwned>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE735624--1710-K0010_STD_0_20171229_0_2448914x3049260" decimals="INF" id="id_10184323_D5995E5A-4042-43AF-A402-DA196989731F_1001_6" unitRef="iso4217_USD_per_shares">10.00</us-gaap:CommonStockParOrStatedValuePerShare>
  <sls:PercentageOfFullyDilutedShareCapitalOwned contextRef="eol_PE735624--1710-K0010_STD_0_20171229_0_2448914x3049260" decimals="3" id="id_10184323_D5995E5A-4042-43AF-A402-DA196989731F_1001_4" unitRef="pure">0.675</sls:PercentageOfFullyDilutedShareCapitalOwned>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-5" id="id_10184323_0EB4735D-5C6A-4D6F-9C9A-33FF5206CA8F_1001_2" unitRef="iso4217_USD">14900000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_1_15" unitRef="iso4217_USD">3201000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_1_5" unitRef="iso4217_USD">13087000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_153041E6-307E-4CC4-9A83-C9B28DC93AA7_1_3" unitRef="iso4217_USD">11907000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AccruedExchangeFeeRebateCurrent contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_7A3A21F0-5BB2-496B-8ED5-DE36EEDBD4E3_1001_2" unitRef="iso4217_USD">223000</us-gaap:AccruedExchangeFeeRebateCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_7A3A21F0-5BB2-496B-8ED5-DE36EEDBD4E3_1001_0" unitRef="iso4217_USD">1744000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_1_36" unitRef="iso4217_USD">56254000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_1_14" unitRef="iso4217_USD">11691000</us-gaap:AccountsPayableCurrent>
  <us-gaap:Assets contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_1_9" unitRef="iso4217_USD">33526000</us-gaap:Assets>
  <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_153041E6-307E-4CC4-9A83-C9B28DC93AA7_1_6" unitRef="iso4217_USD">1294000</us-gaap:BusinessCombinationContingentConsiderationLiability>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_1_2" unitRef="iso4217_USD">2319000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_1_24" unitRef="iso4217_USD" xsi:nil="true"/>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="INF" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_1_33" unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="INF" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_1_35" unitRef="shares">5766891</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_153041E6-307E-4CC4-9A83-C9B28DC93AA7_1_1" unitRef="iso4217_USD">1662000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_1DED8646-51CA-4296-813D-28D45E65FF74_3004_5" unitRef="shares">963000</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_6D05E079-E1CA-4C2D-8202-C9541A2A0FB2_1001_6" unitRef="shares">1619000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="INF" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_1_32" unitRef="iso4217_USD_per_shares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="INF" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_1_34" unitRef="shares">5766891</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockValue contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_1_31" unitRef="iso4217_USD">1000</us-gaap:CommonStockValue>
  <us-gaap:DeferredIncomeTaxLiabilities contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_54BD3E5B-7015-4D60-8E59-F37ED4845AAE_1_1" unitRef="iso4217_USD">3438000</us-gaap:DeferredIncomeTaxLiabilities>
  <us-gaap:DeferredTaxAssetsGross contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_89791292-640C-4FAB-B99E-F8172E2F4893_1_6" unitRef="iso4217_USD">6423000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsNet contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_89791292-640C-4FAB-B99E-F8172E2F4893_1_8" unitRef="iso4217_USD">1765000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsOtherTaxCarryforwards contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_89791292-640C-4FAB-B99E-F8172E2F4893_1_5" unitRef="iso4217_USD">395000</us-gaap:DeferredTaxAssetsOtherTaxCarryforwards>
  <us-gaap:DebtInstrumentCarryingAmount contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-5" id="id_10184323_06E78774-183E-4369-8A52-B2A87A240BE7_3002_0" unitRef="iso4217_USD">10200000</us-gaap:DebtInstrumentCarryingAmount>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_89791292-640C-4FAB-B99E-F8172E2F4893_1_1" unitRef="iso4217_USD">1028000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_89791292-640C-4FAB-B99E-F8172E2F4893_1_2" unitRef="iso4217_USD">345000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_1_18" unitRef="iso4217_USD">1673000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-5" id="id_10184323_32907868-21F8-4A59-B617-E9DD62A46EB3_1001_1" unitRef="iso4217_USD">3700000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_89791292-640C-4FAB-B99E-F8172E2F4893_1_7" unitRef="iso4217_USD">4658000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-5" id="id_10184323_32907868-21F8-4A59-B617-E9DD62A46EB3_1001_0" unitRef="iso4217_USD">3700000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_89791292-640C-4FAB-B99E-F8172E2F4893_1_3" unitRef="iso4217_USD">2550000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_54BD3E5B-7015-4D60-8E59-F37ED4845AAE_1_0" unitRef="iso4217_USD">3438000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
  <us-gaap:DepositsAssetsNoncurrent contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_1_8" unitRef="iso4217_USD">925000</us-gaap:DepositsAssetsNoncurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_7A3A21F0-5BB2-496B-8ED5-DE36EEDBD4E3_1001_3" unitRef="iso4217_USD">566000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:Goodwill contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_1_7" unitRef="iso4217_USD">1914000</us-gaap:Goodwill>
  <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_1_6" unitRef="iso4217_USD">17600000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
  <us-gaap:InterestReceivable contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-5" id="id_10184323_06E78774-183E-4369-8A52-B2A87A240BE7_3002_5" unitRef="iso4217_USD">800000</us-gaap:InterestReceivable>
  <us-gaap:Liabilities contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_1_23" unitRef="iso4217_USD">31456000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_1_39" unitRef="iso4217_USD">33526000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_1_17" unitRef="iso4217_USD">24569000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_153041E6-307E-4CC4-9A83-C9B28DC93AA7_1_7" unitRef="iso4217_USD">2603000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:LongTermDebt contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_0EB4735D-5C6A-4D6F-9C9A-33FF5206CA8F_1001_3" unitRef="iso4217_USD">10988000</us-gaap:LongTermDebt>
  <us-gaap:LongTermDebtCurrent contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_1_12" unitRef="iso4217_USD">8377000</us-gaap:LongTermDebtCurrent>
  <us-gaap:LitigationReserveCurrent contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_1_16" unitRef="iso4217_USD">1300000</us-gaap:LitigationReserveCurrent>
  <us-gaap:LongTermDebtNoncurrent contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_1_21" unitRef="iso4217_USD">2611000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_7A3A21F0-5BB2-496B-8ED5-DE36EEDBD4E3_1001_5" unitRef="iso4217_USD">191000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_932B8955-FC23-49E1-8DA1-F7D0AC1BBD5E_1001_2" unitRef="iso4217_USD">299000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_932B8955-FC23-49E1-8DA1-F7D0AC1BBD5E_1001_1" unitRef="iso4217_USD">76000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_932B8955-FC23-49E1-8DA1-F7D0AC1BBD5E_1001_0" unitRef="iso4217_USD">223000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="INF" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_1_27" unitRef="iso4217_USD_per_shares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="INF" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_1_28" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockValue contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_1_26" unitRef="iso4217_USD" xsi:nil="true"/>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_1_4" unitRef="iso4217_USD">337000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="INF" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_1_29" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="INF" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_1_30" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_1_3" unitRef="iso4217_USD">10431000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_1_37" unitRef="iso4217_USD">-54185000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:SaleOfStockPricePerShare contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="2" id="id_10184323_D1F63F81-9E2D-4475-B8D6-D83E18FCCDFC_1001_0" unitRef="iso4217_USD_per_shares">7.86</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_18A7C5E6-643A-43B9-96BE-7B5CEADC0C13_5001_7" unitRef="iso4217_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_F20F2A7E-6CA6-4B06-A237-1C397810BBCA_5001_8" unitRef="shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="2" id="id_10184323_A30F3FDC-E7BB-4D8B-8348-6E7E5CF4A544_5001_8" unitRef="iso4217_USD_per_shares">1240.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_F20F2A7E-6CA6-4B06-A237-1C397810BBCA_5001_7" unitRef="shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="2" id="id_10184323_A30F3FDC-E7BB-4D8B-8348-6E7E5CF4A544_5001_7" unitRef="iso4217_USD_per_shares">1240.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:StockholdersEquity contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_1_38" unitRef="iso4217_USD">2070000</us-gaap:StockholdersEquity>
  <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_33F2FDB9-F32B-459B-9FE9-F2CA43E2E922_1001_3" unitRef="iso4217_USD">72000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:TaxesPayableCurrent contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_7A3A21F0-5BB2-496B-8ED5-DE36EEDBD4E3_1001_1" unitRef="iso4217_USD">426000</us-gaap:TaxesPayableCurrent>
  <sls:ContingentPurchasePriceConsiderationNetOfCurrentPortion contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_1_20" unitRef="iso4217_USD">1294000</sls:ContingentPurchasePriceConsiderationNetOfCurrentPortion>
  <sls:FairValueOfWarrantsPotentiallySettleableInCash contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_153041E6-307E-4CC4-9A83-C9B28DC93AA7_1_5" unitRef="iso4217_USD">1309000</sls:FairValueOfWarrantsPotentiallySettleableInCash>
  <sls:WarrantLiability contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_E6CD4718-DBAF-442B-A66C-B2686BCCB826_1_19" unitRef="iso4217_USD">1309000</sls:WarrantLiability>
  <sls:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledIntrinsicValue contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_18A7C5E6-643A-43B9-96BE-7B5CEADC0C13_5001_6" unitRef="iso4217_USD">0</sls:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledIntrinsicValue>
  <sls:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAggregateIntrinsicValue contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_18A7C5E6-643A-43B9-96BE-7B5CEADC0C13_5001_8" unitRef="iso4217_USD">0</sls:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAggregateIntrinsicValue>
  <sls:DeferredTaxAssetsLicensingDeductionDeferral contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_89791292-640C-4FAB-B99E-F8172E2F4893_1_4" unitRef="iso4217_USD">2105000</sls:DeferredTaxAssetsLicensingDeductionDeferral>
  <sls:RestrictedCashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_153041E6-307E-4CC4-9A83-C9B28DC93AA7_1_2" unitRef="iso4217_USD">10245000</sls:RestrictedCashAndCashEquivalentsFairValueDisclosure>
  <sls:DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-5" id="id_10184323_FF1169F2-4481-44E9-82B6-4E32DB0850BA_1001_1" unitRef="iso4217_USD">1800000</sls:DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife>
  <sls:FairValueOfWarrantsLiabilities contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_4B76D830-5163-4ACC-B094-4F802F4CE47B_3003_5" unitRef="iso4217_USD">1309000</sls:FairValueOfWarrantsLiabilities>
  <sls:NumberOfStockOptionsGranted contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="INF" id="id_10184323_A4ABC7FA-8304-4E13-94A0-97527A012220_1001_0" unitRef="Option">0</sls:NumberOfStockOptionsGranted>
  <sls:ContractResearchPayable contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-3" id="id_10184323_7A3A21F0-5BB2-496B-8ED5-DE36EEDBD4E3_1001_4" unitRef="iso4217_USD">51000</sls:ContractResearchPayable>
  <sls:DebtInstrumentCovenantPrepayLesserAccruedAndUnpaidInterest contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="-5" id="id_10184323_4AE9789E-26BF-45DC-9023-B98209369792_1001_0" unitRef="iso4217_USD">18500000</sls:DebtInstrumentCovenantPrepayLesserAccruedAndUnpaidInterest>
  <sls:ImpactOnTaxProvisionFromUnrecognizedTaxBenefits contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0" decimals="0" id="id_10184323_41FCF947-D145-4446-9704-AC454811373C_1001_0" unitRef="iso4217_USD">28000</sls:ImpactOnTaxProvisionFromUnrecognizedTaxBenefits>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2433414x2438181" decimals="-3" id="id_10184323_6D05E079-E1CA-4C2D-8202-C9541A2A0FB2_3001_4" unitRef="shares">575000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2433414x2447365" decimals="-3" id="id_10184323_6D05E079-E1CA-4C2D-8202-C9541A2A0FB2_4001_3" unitRef="shares">13000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2433414x2666068" decimals="INF" id="id_10184323_F0588A4C-1948-49EE-820D-9A0244D94BB5_2001_1" unitRef="shares">57000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2433414x3049145" decimals="2" id="id_10184323_E1E0D8FA-4A9F-405E-8BE5-5925DE89D6F4_6001_7" unitRef="iso4217_USD_per_shares">52.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2433414x3049145" decimals="-3" id="id_10184323_C82FDB47-92A3-46C4-A21E-3367B6C36CF4_6001_7" unitRef="shares">13000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2434520x2884867" decimals="-3" id="id_10184323_1DED8646-51CA-4296-813D-28D45E65FF74_3002_5" unitRef="shares">567000</us-gaap:ClassOfWarrantOrRightOutstanding>
  <sls:FairValueOfWarrantsLiabilities contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2434520x2884867" decimals="-3" id="id_10184323_4B76D830-5163-4ACC-B094-4F802F4CE47B_3001_5" unitRef="iso4217_USD">1305000</sls:FairValueOfWarrantsLiabilities>
  <sls:WarrantStrikePrice contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2434520x2884867" decimals="2" id="id_10184323_7D1D15E3-211A-4DE0-83DD-923D2AC9F85F_2001_2" unitRef="iso4217_USD_per_shares">33.00</sls:WarrantStrikePrice>
  <sls:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2434520x2884867" decimals="4" id="id_10184323_7D1D15E3-211A-4DE0-83DD-923D2AC9F85F_2001_5" unitRef="pure">0.0209</sls:WarrantsFairValueAssumptionsRiskFreeInterestRate>
  <sls:WarrantsFairValueAssumptionsExpectedVolatility contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2434520x2884867" decimals="4" id="id_10184323_7D1D15E3-211A-4DE0-83DD-923D2AC9F85F_2001_4" unitRef="pure">0.7929</sls:WarrantsFairValueAssumptionsExpectedVolatility>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2434520x2884905" decimals="-3" id="id_10184323_1DED8646-51CA-4296-813D-28D45E65FF74_3003_5" unitRef="shares">80000</us-gaap:ClassOfWarrantOrRightOutstanding>
  <sls:FairValueOfWarrantsLiabilities contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2434520x2884905" decimals="-3" id="id_10184323_4B76D830-5163-4ACC-B094-4F802F4CE47B_3002_5" unitRef="iso4217_USD">4000</sls:FairValueOfWarrantsLiabilities>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2434520x3050116" decimals="-3" id="id_10184323_1DED8646-51CA-4296-813D-28D45E65FF74_3001_5" unitRef="shares">316000</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2434520x3054786" decimals="-3" id="id_10184323_7D1D15E3-211A-4DE0-83DD-923D2AC9F85F_2002_1" unitRef="shares">76000</us-gaap:ClassOfWarrantOrRightOutstanding>
  <sls:WarrantStrikePrice contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2434520x3054786" decimals="2" id="id_10184323_7D1D15E3-211A-4DE0-83DD-923D2AC9F85F_2002_2" unitRef="iso4217_USD_per_shares">888.22</sls:WarrantStrikePrice>
  <sls:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2434520x3054786" decimals="4" id="id_10184323_7D1D15E3-211A-4DE0-83DD-923D2AC9F85F_2002_5" unitRef="pure">0.0200</sls:WarrantsFairValueAssumptionsRiskFreeInterestRate>
  <sls:WarrantsFairValueAssumptionsExpectedVolatility contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2434520x3054786" decimals="4" id="id_10184323_7D1D15E3-211A-4DE0-83DD-923D2AC9F85F_2002_4" unitRef="pure">0.7246</sls:WarrantsFairValueAssumptionsExpectedVolatility>
  <sls:DebtInstrumentCovenantLiquidityCovenant contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2435465x2668673_2442761x2448459" decimals="-5" id="id_10184323_81F99559-0CED-4A20-9A28-CF5501C7DD37_1001_0" unitRef="iso4217_USD">18500000</sls:DebtInstrumentCovenantLiquidityCovenant>
  <sls:DebtInstrumentCovenantLiquidityCovenant contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2435465x2743860_2442761x2448459" decimals="-5" id="id_10184323_81F99559-0CED-4A20-9A28-CF5501C7DD37_2001_1" unitRef="iso4217_USD">10200000</sls:DebtInstrumentCovenantLiquidityCovenant>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2438028x2437665_2438324x2438356" decimals="-3" id="id_10184323_153041E6-307E-4CC4-9A83-C9B28DC93AA7_2_3" unitRef="iso4217_USD">11907000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2438028x2437665_2438324x2438356" decimals="-3" id="id_10184323_153041E6-307E-4CC4-9A83-C9B28DC93AA7_2_1" unitRef="iso4217_USD">1662000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <sls:RestrictedCashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2438028x2437665_2438324x2438356" decimals="-3" id="id_10184323_153041E6-307E-4CC4-9A83-C9B28DC93AA7_2_2" unitRef="iso4217_USD">10245000</sls:RestrictedCashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2438028x2438072_2438324x2438356" decimals="-3" id="id_10184323_153041E6-307E-4CC4-9A83-C9B28DC93AA7_4_6" unitRef="iso4217_USD">1294000</us-gaap:BusinessCombinationContingentConsiderationLiability>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2438028x2438072_2438324x2438356" decimals="-3" id="id_10184323_153041E6-307E-4CC4-9A83-C9B28DC93AA7_4_7" unitRef="iso4217_USD">2603000</us-gaap:LiabilitiesFairValueDisclosure>
  <sls:FairValueOfWarrantsPotentiallySettleableInCash contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2438028x2438072_2438324x2438356" decimals="-3" id="id_10184323_153041E6-307E-4CC4-9A83-C9B28DC93AA7_4_5" unitRef="iso4217_USD">1309000</sls:FairValueOfWarrantsPotentiallySettleableInCash>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2439166x2449596" decimals="-3" id="id_10184323_6D05E079-E1CA-4C2D-8202-C9541A2A0FB2_5001_2" unitRef="shares">10000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2439166x2450820" decimals="-3" id="id_10184323_6D05E079-E1CA-4C2D-8202-C9541A2A0FB2_6001_1" unitRef="shares">963000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2440733x2437443" decimals="-5" id="id_10184323_32907868-21F8-4A59-B617-E9DD62A46EB3_2001_3" unitRef="iso4217_USD">400000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2442761x2448459" decimals="2" id="id_10184323_707591D2-3D9C-49D9-9F8B-74368CF7D8DF_1001_0" unitRef="pure">0.09</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <sls:DebtInstrumentCashInExcessOfDebenture contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2442761x2448459_2447194x2443301_2448914x2434572" decimals="-5" id="id_10184323_8CF5BA34-FCF6-4604-9160-A4FC926041DB_2001_1" unitRef="iso4217_USD">10000000</sls:DebtInstrumentCashInExcessOfDebenture>
  <sls:MilestonePaymentsReceivable contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2442761x2687738_2450320x2719233" decimals="-5" id="id_10184323_EB70FBE9-B630-4F16-AAD3-DAE66E48DD68_1003_4" unitRef="iso4217_USD">200000</sls:MilestonePaymentsReceivable>
  <us-gaap:LongTermDebtCurrent contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2442761x2884929" decimals="-3" id="id_10184323_FE021226-8779-4F3F-9E81-97BECB281DE3_2001_0" unitRef="iso4217_USD">8377000</us-gaap:LongTermDebtCurrent>
  <us-gaap:LongTermDebtNoncurrent contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2442761x2884929" decimals="-3" id="id_10184323_FE021226-8779-4F3F-9E81-97BECB281DE3_2001_1" unitRef="iso4217_USD">2611000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2445234x2909678" decimals="INF" id="id_10184323_FFAC4CFC-19C8-4B2E-9186-C7FE5A6F4884_2001_0" unitRef="shares">575000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <sls:CancellationOfMilestonePayment contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2446922x2684763" decimals="INF" id="id_10184323_01D9D5C4-C799-4CF0-A8BB-86DCB738BD4C_4001_1" unitRef="iso4217_USD">200000</sls:CancellationOfMilestonePayment>
  <us-gaap:ManagementFeePayable contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2446922x3049598" decimals="-5" id="id_10184323_0944809B-2ACB-4431-8932-A05505810103_2002_3" unitRef="iso4217_USD">100000</us-gaap:ManagementFeePayable>
  <sls:CancellationOfManagementFee contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2446922x3049598" decimals="INF" id="id_10184323_01D9D5C4-C799-4CF0-A8BB-86DCB738BD4C_5001_3" unitRef="iso4217_USD">100000</sls:CancellationOfManagementFee>
  <us-gaap:StockholdersEquity contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2448914x2432358" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_5003_600041" unitRef="iso4217_USD">56254000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2448914x2434572" decimals="INF" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_5001_400042" unitRef="shares">5766891</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2448914x2434572" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_5001_500041" unitRef="iso4217_USD">1000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2448914x2447681" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_5004_700041" unitRef="iso4217_USD">-54185000</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2449620x2438180" decimals="-3" id="id_10184323_6D05E079-E1CA-4C2D-8202-C9541A2A0FB2_7001_5" unitRef="shares">58000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <sls:CancellationOfManagementFee contextRef="eol_PE735624--1710-K0010_STD_0_20171231_0_2449718x2434781" decimals="INF" id="id_10184323_01D9D5C4-C799-4CF0-A8BB-86DCB738BD4C_6001_5" unitRef="iso4217_USD">100000</sls:CancellationOfManagementFee>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE735624--1710-K0010_STD_0_20180101_0_2449888x2449609" decimals="INF" id="id_10184323_B1FE480D-9549-4EED-9D3F-DD8D163AD62A_1001_0" unitRef="shares">501000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE735624--1710-K0010_STD_0_20181231_0_2448913x2672262_2449305x2447800_2449888x2449609" decimals="2" id="id_10184323_B24A3240-0935-416B-B841-FFF55EBD4E15_3003_4" unitRef="pure">0.20</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <sls:LicenseAgreementDate contextRef="eol_PE735624--1710-K0010_STD_1_20141114_0_2435412x3049272_2450320x3049275" id="id_10184323_81492B21-7CEE-4EA7-A0FF-74ED94EA21CF_1001_1">2014-11-14</sls:LicenseAgreementDate>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="eol_PE735624--1710-K0010_STD_1_20150507_0_2435465x3049445_2446928x3049446" decimals="-5" id="id_10184323_73988A1A-61DF-48A4-8418-E24491ABE072_2003_4" unitRef="iso4217_USD">5000000</us-gaap:ProceedsFromConvertibleDebt>
  <sls:ProceedsfromIssuanceofLongtermDebtandWarrantsNet contextRef="eol_PE735624--1710-K0010_STD_1_20160510_0_2435465x2668673_2442761x2448459" decimals="-5" id="id_10184323_7C57095F-6BE6-461C-985F-421C56134E37_1001_3" unitRef="iso4217_USD">23400000</sls:ProceedsfromIssuanceofLongtermDebtandWarrantsNet>
  <us-gaap:ProceedsFromLinesOfCredit contextRef="eol_PE735624--1710-K0010_STD_1_20160512_0_2442761x2442444" decimals="-5" id="id_10184323_605916AC-C5ED-4608-88F5-0ECE677D1051_8005_8" unitRef="iso4217_USD">600000</us-gaap:ProceedsFromLinesOfCredit>
  <sls:LicenseAgreementDateSecondAmended contextRef="eol_PE735624--1710-K0010_STD_1_20160809_0_2435412x2684763_2450320x3049265" id="id_10184323_ABC96FF7-852E-4C01-BAB6-07DFCC073646_1001_1">2016-12-31</sls:LicenseAgreementDateSecondAmended>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE735624--1710-K0010_STD_1_20160810_0_2435412x2684763_2450320x3049265" decimals="-5" id="id_10184323_ABC96FF7-852E-4C01-BAB6-07DFCC073646_1002_5" unitRef="iso4217_USD">2000000</us-gaap:ResearchAndDevelopmentExpense>
  <sls:LicenseAgreementDateSecondAmended contextRef="eol_PE735624--1710-K0010_STD_1_20160810_0_2435412x2684763_2450320x3049265" id="id_10184323_ABC96FF7-852E-4C01-BAB6-07DFCC073646_1002_1">2017-06-30</sls:LicenseAgreementDateSecondAmended>
  <sls:LicenseAgreementAmendmentDate contextRef="eol_PE735624--1710-K0010_STD_1_20160810_0_2435412x2684763_2450320x3049265" id="id_10184323_ABC96FF7-852E-4C01-BAB6-07DFCC073646_1002_0">2016-08-10</sls:LicenseAgreementAmendmentDate>
  <sls:LicenseAgreementOutstandingAmountPayable contextRef="eol_PE735624--1710-K0010_STD_1_20160810_0_2435412x2684763_2450320x3049265" decimals="-5" id="id_10184323_ABC96FF7-852E-4C01-BAB6-07DFCC073646_1002_2" unitRef="iso4217_USD">900000</sls:LicenseAgreementOutstandingAmountPayable>
  <sls:StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement contextRef="eol_PE735624--1710-K0010_STD_1_20160810_0_2435412x2684763_2450320x3049265" decimals="INF" id="id_10184323_ABC96FF7-852E-4C01-BAB6-07DFCC073646_1002_3" unitRef="shares">13815</sls:StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="eol_PE735624--1710-K0010_STD_1_20161101_0_2435465x3049453" decimals="INF" id="id_10184323_9C0BDF91-2D2C-41FA-8341-1A0687CCE02D_1001_0" unitRef="shares">236705</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="eol_PE735624--1710-K0010_STD_1_20161101_0_2435465x3049453" decimals="-5" id="id_10184323_9C0BDF91-2D2C-41FA-8341-1A0687CCE02D_1001_1" unitRef="iso4217_USD">400000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
  <sls:DebtConversionConvertedInstrumentGainLossRecognized contextRef="eol_PE735624--1710-K0010_STD_1_20161101_0_2435465x3049453" decimals="-6" id="id_10184323_9C0BDF91-2D2C-41FA-8341-1A0687CCE02D_1001_2" unitRef="iso4217_USD">0</sls:DebtConversionConvertedInstrumentGainLossRecognized>
  <us-gaap:ExtinguishmentOfDebtAmount contextRef="eol_PE735624--1710-K0010_STD_1_20161101_0_2435465x3053920" decimals="-5" id="id_10184323_605916AC-C5ED-4608-88F5-0ECE677D1051_4007_9" unitRef="iso4217_USD">4400000</us-gaap:ExtinguishmentOfDebtAmount>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE735624--1710-K0010_STD_1_20161101_0_2435465x3053920" decimals="0" id="id_10184323_605916AC-C5ED-4608-88F5-0ECE677D1051_4007_10" unitRef="iso4217_USD">67140</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <sls:DebtConversionConvertedInstrumentGainLossRecognized contextRef="eol_PE735624--1710-K0010_STD_1_20161101_0_2435465x3053943" decimals="0" id="id_10184323_605916AC-C5ED-4608-88F5-0ECE677D1051_5008_28" unitRef="iso4217_EUR">0</sls:DebtConversionConvertedInstrumentGainLossRecognized>
  <us-gaap:DebtInstrumentPeriodicPayment contextRef="eol_PE735624--1710-K0010_STD_1_20161101_0_2435465x3053943_2446928x3053940" decimals="-5" id="id_10184323_605916AC-C5ED-4608-88F5-0ECE677D1051_6008_24" unitRef="iso4217_EUR">700000</us-gaap:DebtInstrumentPeriodicPayment>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="eol_PE735624--1710-K0010_STD_1_20161101_0_2435465x3053943_2446928x3053940" decimals="INF" id="id_10184323_605916AC-C5ED-4608-88F5-0ECE677D1051_6008_26" unitRef="shares">11571</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:DebtInstrumentPeriodicPayment contextRef="eol_PE735624--1710-K0010_STD_1_20161101_0_2435465x3053943_2446928x3053941" decimals="-5" id="id_10184323_605916AC-C5ED-4608-88F5-0ECE677D1051_7008_25" unitRef="iso4217_EUR">600000</us-gaap:DebtInstrumentPeriodicPayment>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="eol_PE735624--1710-K0010_STD_1_20161101_0_2435465x3053943_2446928x3053941" decimals="INF" id="id_10184323_605916AC-C5ED-4608-88F5-0ECE677D1051_7008_27" unitRef="shares">10383</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="eol_PE735624--1710-K0010_STD_1_20161101_0_2445234x2694343" id="id_10184323_C6B68006-3E32-4587-AC0F-69DB861AAE04_1001_1">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE735624--1710-K0010_STD_1_20161101_0_2445234x2694343" id="id_10184323_C6B68006-3E32-4587-AC0F-69DB861AAE04_1001_0">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <sls:NonrefundableMilestonePayments contextRef="eol_PE735624--1710-K0010_STD_1_20170224_0_2447194x2442860_2450320x3050216" decimals="INF" id="id_10184323_9DB0E031-462D-42D0-B40C-972F095DAE64_1001_0" unitRef="iso4217_USD">108000000</sls:NonrefundableMilestonePayments>
  <sls:NonrefundableSalesMilestonePayments contextRef="eol_PE735624--1710-K0010_STD_1_20170224_0_2447194x2442860_2450320x3050216" decimals="INF" id="id_10184323_9DB0E031-462D-42D0-B40C-972F095DAE64_1001_1" unitRef="iso4217_USD">250000000</sls:NonrefundableSalesMilestonePayments>
  <sls:MilestoneFeePaymentsUponCommencementOfClinicalTrials contextRef="eol_PE735624--1710-K0010_STD_1_20170525_0_2435412x2684763" decimals="-5" id="id_10184323_2FD32AA0-A930-44AC-AC5B-368ED818A07E_1_0" unitRef="iso4217_USD">300000</sls:MilestoneFeePaymentsUponCommencementOfClinicalTrials>
  <sls:MilestonePayments contextRef="eol_PE735624--1710-K0010_STD_1_20170525_0_2435412x2684763_2447148x3049698" decimals="-5" id="id_10184323_2FD32AA0-A930-44AC-AC5B-368ED818A07E_1001_3" unitRef="iso4217_USD">200000</sls:MilestonePayments>
  <sls:MilestoneFeePaymentsUponCommencementOfClinicalTrials contextRef="eol_PE735624--1710-K0010_STD_1_20170525_0_2435412x2684763_2447148x3049698" decimals="-5" id="id_10184323_2FD32AA0-A930-44AC-AC5B-368ED818A07E_1001_1" unitRef="iso4217_USD">400000</sls:MilestoneFeePaymentsUponCommencementOfClinicalTrials>
  <us-gaap:PaymentsForLegalSettlements contextRef="eol_PE735624--1710-K0010_STD_1_20171107_0_2442667x3048903" decimals="-5" id="id_10184323_EBE3AF3E-3D0E-4502-A0D9-5B760EBCC562_1002_0" unitRef="iso4217_USD">300000</us-gaap:PaymentsForLegalSettlements>
  <us-gaap:DebtInstrumentInterestRateIncreaseDecrease contextRef="eol_PE735624--1710-K0010_STD_1_20180206_0_2449888x2449609_2450320x3050643" decimals="2" id="id_10184323_0923ACBC-60D6-406C-9A7B-BAF10275441E_1001_2" unitRef="pure">0.18</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
  <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="eol_PE735624--1710-K0010_STD_1_20180206_0_2449888x2449609_2450320x3050643" decimals="2" id="id_10184323_0923ACBC-60D6-406C-9A7B-BAF10275441E_1001_5" unitRef="pure">0.70</us-gaap:DebtInstrumentRedemptionPricePercentage>
  <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="eol_PE735624--1710-K0010_STD_1_20180206_0_2449888x2449609_2450320x3050643" decimals="2" id="id_10184323_0923ACBC-60D6-406C-9A7B-BAF10275441E_1001_0" unitRef="iso4217_USD">232440.00</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
  <sls:ConvertibleNotesConversionPricePerShareOfCommonStock contextRef="eol_PE735624--1710-K0010_STD_1_20180206_0_2449888x2449609_2450320x3050643" decimals="2" id="id_10184323_0923ACBC-60D6-406C-9A7B-BAF10275441E_1001_3" unitRef="iso4217_USD_per_shares">7.00</sls:ConvertibleNotesConversionPricePerShareOfCommonStock>
  <sls:DenominatorBaseForIssuanceOfCommonStockValue contextRef="eol_PE735624--1710-K0010_STD_1_20180206_0_2449888x2449609_2450320x3050643" decimals="0" id="id_10184323_7C3F664A-6FA4-4C13-9D84-AB4E108D9869_1001_2" unitRef="iso4217_USD">232440</sls:DenominatorBaseForIssuanceOfCommonStockValue>
  <sls:StockIssuedDuringPeriodSharesShareWarrantsExercised contextRef="eol_PE735624--1710-K0010_STD_1_20180207_0_2449888x2449609_2450320x3050644" decimals="0" id="id_10184323_6860ECBD-9644-4F3D-A4F7-F67AF3C97DD8_1001_1" unitRef="shares">12536</sls:StockIssuedDuringPeriodSharesShareWarrantsExercised>
  <us-gaap:DebtInstrumentInterestRateIncreaseDecrease contextRef="eol_PE735624--1710-K0010_STD_1_20180209_0_2449888x2449609_2450320x3050035" decimals="2" id="id_10184323_8C21463C-B1CF-46A6-A842-AB82CFE473AD_1001_1" unitRef="pure">0.18</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
  <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="eol_PE735624--1710-K0010_STD_1_20180209_0_2449888x2449609_2450320x3050035" decimals="2" id="id_10184323_8C21463C-B1CF-46A6-A842-AB82CFE473AD_1001_4" unitRef="pure">0.70</us-gaap:DebtInstrumentRedemptionPricePercentage>
  <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="eol_PE735624--1710-K0010_STD_1_20180209_0_2449888x2449609_2450320x3050035" decimals="0" id="id_10184323_3D892AFC-0BEB-432B-83DF-28BCA7041BB1_1001_1" unitRef="iso4217_USD">343200</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
  <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits contextRef="eol_PE735624--1710-K0010_STD_1_20180209_0_2449888x2449609_2450320x3050035" decimals="INF" id="id_10184323_3D892AFC-0BEB-432B-83DF-28BCA7041BB1_1001_0" unitRef="shares">146666</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
  <sls:ConvertibleNotesConversionPricePerShareOfCommonStock contextRef="eol_PE735624--1710-K0010_STD_1_20180209_0_2449888x2449609_2450320x3050035" decimals="2" id="id_10184323_8C21463C-B1CF-46A6-A842-AB82CFE473AD_1001_2" unitRef="iso4217_USD_per_shares">7.00</sls:ConvertibleNotesConversionPricePerShareOfCommonStock>
  <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits contextRef="eol_PE735624--1710-K0010_STD_1_20180209_0_2449888x2449609_2450320x3050036" decimals="INF" id="id_10184323_5D3E4677-88B1-46AA-B987-513A3924DEDD_1001_0" unitRef="shares">83333</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
  <sls:AggregateSalesPriceOfCommonStock contextRef="eol_PE735624--1710-K0010_STD_1_20180209_0_2449888x2449609_2450320x3050036" decimals="0" id="id_10184323_5D3E4677-88B1-46AA-B987-513A3924DEDD_1001_1" unitRef="iso4217_USD">195000</sls:AggregateSalesPriceOfCommonStock>
  <sls:PercentageOfMarketAveragePriceOfShares contextRef="eol_PE735624--1710-K0010_STD_1_20180209_0_2449888x2449609_2450320x3050036" decimals="2" id="id_10184323_5D3E4677-88B1-46AA-B987-513A3924DEDD_1001_3" unitRef="pure">1.00</sls:PercentageOfMarketAveragePriceOfShares>
  <sls:MinimumPercentageOfTradingPriceOfCommonStock contextRef="eol_PE735624--1710-K0010_STD_1_20180213_0_2449888x2449609_2450320x3050036" decimals="2" id="id_10184323_5D3E4677-88B1-46AA-B987-513A3924DEDD_1002_2" unitRef="pure">0.02</sls:MinimumPercentageOfTradingPriceOfCommonStock>
  <us-gaap:DebtInstrumentInterestRateIncreaseDecrease contextRef="eol_PE735624--1710-K0010_STD_1_20180213_0_2449888x2449609_2450320x3051911" decimals="2" id="id_10184323_C64DAB48-0CCD-49B2-AEB5-BBFF5AA5F572_1001_2" unitRef="pure">0.18</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
  <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="eol_PE735624--1710-K0010_STD_1_20180213_0_2449888x2449609_2450320x3051911" decimals="2" id="id_10184323_C64DAB48-0CCD-49B2-AEB5-BBFF5AA5F572_1001_4" unitRef="pure">0.70</us-gaap:DebtInstrumentRedemptionPricePercentage>
  <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="eol_PE735624--1710-K0010_STD_1_20180213_0_2449888x2449609_2450320x3051911" decimals="2" id="id_10184323_C64DAB48-0CCD-49B2-AEB5-BBFF5AA5F572_1001_0" unitRef="iso4217_USD">249600.00</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
  <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits contextRef="eol_PE735624--1710-K0010_STD_1_20180213_0_2449888x2449609_2450320x3051911" decimals="INF" id="id_10184323_7DBB3706-F885-4B97-97F5-030C9A8C1A15_1001_0" unitRef="shares">106667</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
  <sls:AggregateSalesPriceOfCommonStock contextRef="eol_PE735624--1710-K0010_STD_1_20180213_0_2449888x2449609_2450320x3051911" decimals="0" id="id_10184323_7DBB3706-F885-4B97-97F5-030C9A8C1A15_1001_1" unitRef="iso4217_USD">249600</sls:AggregateSalesPriceOfCommonStock>
  <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits contextRef="eol_PE735624--1710-K0010_STD_1_20180214_0_2449888x2449609_2450320x3051912" decimals="INF" id="id_10184323_38FCF326-D003-43C9-98B3-0322198478AA_1001_0" unitRef="shares">8333</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
  <sls:StockIssuedDuringPeriodSharesShareWarrantsExercised contextRef="eol_PE735624--1710-K0010_STD_1_20180215_0_2449888x2449609_2450320x3051911" decimals="0" id="id_10184323_7DBB3706-F885-4B97-97F5-030C9A8C1A15_1002_2" unitRef="shares">45464</sls:StockIssuedDuringPeriodSharesShareWarrantsExercised>
  <sls:StockIssuedDuringPeriodSharesShareWarrantsExercised contextRef="eol_PE735624--1710-K0010_STD_1_20180219_0_2449888x2449609_2450320x3051912" decimals="0" id="id_10184323_38FCF326-D003-43C9-98B3-0322198478AA_1002_1" unitRef="shares">3421</sls:StockIssuedDuringPeriodSharesShareWarrantsExercised>
  <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="eol_PE735624--1710-K0010_STD_1_20180222_0_2449888x2449609_2450320x3050038" decimals="2" id="id_10184323_E3D57259-5823-4EC1-A03F-8CA5760B830C_1001_2" unitRef="iso4217_USD">64403.12</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
  <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="eol_PE735624--1710-K0010_STD_1_20180430_0_2449888x2449609_2450320x3050038" decimals="2" id="id_10184323_9B7A1C4C-D7B3-4386-9B85-CC005E05F0E8_1002_2" unitRef="pure">0.70</us-gaap:DebtInstrumentRedemptionPricePercentage>
  <us-gaap:DebtInstrumentInterestRateIncreaseDecrease contextRef="eol_PE735624--1710-K0010_STD_1_20180822_0_2449888x2449609_2450320x3050038" decimals="2" id="id_10184323_9B7A1C4C-D7B3-4386-9B85-CC005E05F0E8_1001_1" unitRef="pure">0.18</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
  <us-gaap:DebtInstrumentTerm contextRef="eol_PE735624--1710-K0010_STD_1_20150302_0_2435412x2660097_2435465x3053908" id="id_10184323_605916AC-C5ED-4608-88F5-0ECE677D1051_2001_1">P24M</us-gaap:DebtInstrumentTerm>
  <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="eol_PE735624--1710-K0010_STD_1_20150402_0_2435465x3049445" decimals="2" id="id_10184323_73988A1A-61DF-48A4-8418-E24491ABE072_1001_2" unitRef="pure">0.08</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
  <sls:NumberOfSignificantShareholders contextRef="eol_PE735624--1710-K0010_STD_1_20150402_0_2435465x3049445" decimals="INF" id="id_10184323_73988A1A-61DF-48A4-8418-E24491ABE072_1001_1" unitRef="Holder">2000000</sls:NumberOfSignificantShareholders>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE735624--1710-K0010_STD_1_20160406_0_2435412x3053914_2435465x3053912_2442761x2442444" id="id_10184323_605916AC-C5ED-4608-88F5-0ECE677D1051_3002_7">2019-04-06</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentTerm contextRef="eol_PE735624--1710-K0010_STD_1_20160406_0_2435412x3053914_2435465x3053912_2442761x2442444" id="id_10184323_605916AC-C5ED-4608-88F5-0ECE677D1051_3002_5">P3Y</us-gaap:DebtInstrumentTerm>
  <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod contextRef="eol_PE735624--1710-K0010_STD_1_20160406_0_2435412x3053914_2435465x3053912_2442761x2442444" decimals="2" id="id_10184323_605916AC-C5ED-4608-88F5-0ECE677D1051_3002_4" unitRef="pure">0.06</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
  <us-gaap:ProceedsFromLinesOfCredit contextRef="eol_PE735624--1710-K0010_STD_1_20160412_0_2442761x2442444" decimals="-5" id="id_10184323_605916AC-C5ED-4608-88F5-0ECE677D1051_8004_8" unitRef="iso4217_USD">600000</us-gaap:ProceedsFromLinesOfCredit>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="eol_PE735624--1710-K0010_STD_1_20180307_0_2448913x2672262_2449620x2678536_2449888x2449609" decimals="-5" id="id_10184323_12F0B7E2-D102-4053-B194-EC0E11281945_1001_2" unitRef="iso4217_USD">4700000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="eol_PE735624--1710-K0010_STD_1_20180307_0_2448913x2672262_2449620x2743081_2449888x2449609" decimals="-5" id="id_10184323_12F0B7E2-D102-4053-B194-EC0E11281945_2001_1" unitRef="iso4217_USD">6000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="eol_PE735624--1710-K0010_STD_1_20180307_0_2448913x2672262_2449888x2449609" decimals="-5" id="id_10184323_12F0B7E2-D102-4053-B194-EC0E11281945_3001_0" unitRef="iso4217_USD">10700000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="eol_PE735624--1710-K0010_STD_1_20180307_0_2448913x2672262_2449888x2449609_2450320x2737197" decimals="2" id="id_10184323_B621CDDD-ED2C-4D8B-BD64-236C561D1500_1001_1" unitRef="pure">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
  <sls:WarrantExcercisableTerm contextRef="eol_PE735624--1710-K0010_STD_1_20180307_0_2448913x2672262_2449888x2449609_2450320x2737197" id="id_10184323_B621CDDD-ED2C-4D8B-BD64-236C561D1500_1001_3">P5Y</sls:WarrantExcercisableTerm>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="eol_PE735624--1710-K0010_STD_1_20180307_0_2449888x2449609_2450320x2737197" decimals="INF" id="id_10184323_8CAA6ACD-505E-4CCF-8B90-187A04FCBEF7_1001_3" unitRef="iso4217_USD">10700000</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
  <us-gaap:PreferredUnitsDescription contextRef="eol_PE735624--1710-K0010_STD_1_20180308_0_2448913x2672262_2449888x2449609" id="id_10184323_B24A3240-0935-416B-B841-FFF55EBD4E15_1001_0">Series A Convertible Preferred: On March 8, 2018, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series A 20% Convertible Preferred Stock (the &#x201C;Certificate of Designation&#x201D;) with the Secretary of State of the State of Delaware, which designated up to 17,500 shares of Series A Convertible Preferred.</us-gaap:PreferredUnitsDescription>
  <sls:TradingDays contextRef="eol_PE735624--1710-K0010_STD_1_20180308_0_2448913x2672262_2449888x2449609" id="id_10184323_241B8E92-0C0B-4E77-A65F-95E16DB856C4_1001_1">P5D</sls:TradingDays>
  <sls:ConvertiblePreferredStockBeneficialOwnershipLimitationPercentage contextRef="eol_PE735624--1710-K0010_STD_1_20180308_0_2448913x2672262_2449888x2449609" decimals="4" id="id_10184323_C609B174-0DFA-4782-9E5F-1C6D1850B6C1_1001_1" unitRef="pure">0.0499</sls:ConvertiblePreferredStockBeneficialOwnershipLimitationPercentage>
  <sls:StockConversionLimitPercentage contextRef="eol_PE735624--1710-K0010_STD_1_20180308_0_2448913x2672262_2449888x2449609" decimals="4" id="id_10184323_C609B174-0DFA-4782-9E5F-1C6D1850B6C1_1001_2" unitRef="pure">0.1999</sls:StockConversionLimitPercentage>
  <sls:AdjustmentToCommonStockInConnectionWithReverseForwardStockSplit contextRef="eol_PE735624--1710-K0010_STD_1_20180308_0_2448913x2672262_2449888x2449609" decimals="2" id="id_10184323_241B8E92-0C0B-4E77-A65F-95E16DB856C4_1001_0" unitRef="iso4217_USD">3.00</sls:AdjustmentToCommonStockInConnectionWithReverseForwardStockSplit>
  <sls:CommonStockPercentageIssuedPriorToPurchaseAgreement contextRef="eol_PE735624--1710-K0010_STD_1_20180309_0_2447194x2443301_2449888x2449609_2450320x3050049" decimals="4" id="id_10184323_59666AC9-612A-4157-9704-A809A64DEE7B_1001_2" unitRef="pure">0.1999</sls:CommonStockPercentageIssuedPriorToPurchaseAgreement>
  <us-gaap:PreferredStockConversionBasis contextRef="eol_PE735624--1710-K0010_STD_1_20180309_0_2448913x2672262_2449620x2731166_2449888x2449609_2450320x2737197" id="id_10184323_8AC584F9-D761-4F0C-BE3C-B72942791F84_1001_1">On a $1.00 for $1.00 basis</us-gaap:PreferredStockConversionBasis>
  <sls:QualifiedOfferingDescription contextRef="eol_PE735624--1710-K0010_STD_1_20180309_0_2448913x2672262_2449620x2731166_2449888x2449609_2450320x2737197" id="id_10184323_8AC584F9-D761-4F0C-BE3C-B72942791F84_1001_2">Qualified Offering is defined in the purchase agreement and the Certificate of Designation (as defined below) as a public offering raising aggregate gross proceeds of no less than $20.0 million.</sls:QualifiedOfferingDescription>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="eol_PE735624--1710-K0010_STD_1_20180309_0_2448913x2672262_2449620x3050114_2449888x2449609_2450320x2737197" decimals="INF" id="id_10184323_5A383C6B-7512-437A-B4E3-A3E8E1E63BA0_1002_1" unitRef="iso4217_USD">5987000</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
  <sls:WarrantsIssuedShares contextRef="eol_PE735624--1710-K0010_STD_1_20180309_0_2448913x2672262_2449620x3050114_2449888x2449609_2450320x2737197" decimals="0" id="id_10184323_5A383C6B-7512-437A-B4E3-A3E8E1E63BA0_1002_2" unitRef="shares">774186</sls:WarrantsIssuedShares>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="eol_PE735624--1710-K0010_STD_1_20180309_0_2448913x2672262_2449620x3050115_2449888x2449609_2450320x2737197" decimals="INF" id="id_10184323_5A383C6B-7512-437A-B4E3-A3E8E1E63BA0_1003_1" unitRef="iso4217_USD">4713000</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
  <sls:WarrantsIssuedShares contextRef="eol_PE735624--1710-K0010_STD_1_20180309_0_2448913x2672262_2449620x3050115_2449888x2449609_2450320x2737197" decimals="0" id="id_10184323_5A383C6B-7512-437A-B4E3-A3E8E1E63BA0_1003_2" unitRef="shares">609445</sls:WarrantsIssuedShares>
  <sls:DateByWhichStockHolderApprovalRequired contextRef="eol_PE735624--1710-K0010_STD_1_20180309_0_2448913x2672262_2449888x2449609_2450320x2737197" id="id_10184323_5A383C6B-7512-437A-B4E3-A3E8E1E63BA0_1001_3">2018-05-07</sls:DateByWhichStockHolderApprovalRequired>
  <sls:StockholderApprovalPeriod contextRef="eol_PE735624--1710-K0010_STD_1_20180309_0_2448913x2672262_2449888x2449609_2450320x2737197" id="id_10184323_5A383C6B-7512-437A-B4E3-A3E8E1E63BA0_1001_4">P60D</sls:StockholderApprovalPeriod>
  <sls:PercentageOfReductionInRiskRecurrence contextRef="eol_PE735624--1710-K0010_STD_1_20180402_0_2447194x2442860_2449888x2449609" decimals="INF" id="id_10184323_3D71BD20-F208-490F-B316-4544CA31E644_1002_0" unitRef="pure">0.395</sls:PercentageOfReductionInRiskRecurrence>
  <sls:PercentageOfReductionInRiskRecurrence contextRef="eol_PE735624--1710-K0010_STD_1_20180402_0_2447194x2443301_2449888x2449609" decimals="INF" id="id_10184323_3D71BD20-F208-490F-B316-4544CA31E644_1001_0" unitRef="pure">0.349</sls:PercentageOfReductionInRiskRecurrence>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="eol_PE735624--1710-K0010_STD_1_20180402_0_2449888x2449609_2450320x3050643" decimals="INF" id="id_10184323_0923ACBC-60D6-406C-9A7B-BAF10275441E_1002_6" unitRef="shares">33356</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="eol_PE735624--1710-K0010_STD_1_20180402_0_2449888x2449609_2450320x3051911" decimals="INF" id="id_10184323_C64DAB48-0CCD-49B2-AEB5-BBFF5AA5F572_1002_5" unitRef="shares">35998</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="eol_PE735624--1710-K0010_STD_1_20180403_0_2449888x2449609_2450320x3050035" decimals="INF" id="id_10184323_D086FDEA-4F31-4508-87A8-5945DAA012D8_1001_0" unitRef="shares">49390</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <sls:LitigationSettlementIssuanceofCommonStockShares contextRef="eol_PE735624--1710-K0010_STD_1_20180409_0_2442667x3054137_2449888x2449609" decimals="0" id="id_10184323_C1C33FD4-0911-4CFD-99FA-BC9210817999_1001_0" unitRef="shares">2483500</sls:LitigationSettlementIssuanceofCommonStockShares>
  <sls:ProjectManagementFeesPayable contextRef="eol_PE735624--1710-K0010_STD_1_20150714_0_2435412x3049272_2447194x2442860_2450320x3049279" decimals="-5" id="id_10184323_C0E3BA2A-BB33-4C8E-BD26-84BCA3FBF1FD_1001_1" unitRef="iso4217_USD">400000</sls:ProjectManagementFeesPayable>
  <sls:LicenseAgreementDate contextRef="eol_PE735624--1710-K0010_STD_1_20150714_0_2435412x3049272_2450320x3049279" id="id_10184323_C0E3BA2A-BB33-4C8E-BD26-84BCA3FBF1FD_3001_0">2015-07-14</sls:LicenseAgreementDate>
  <us-gaap:ProceedsFromLinesOfCredit contextRef="eol_PE735624--1710-K0010_STD_1_20160602_0_2442761x2442444" decimals="-5" id="id_10184323_605916AC-C5ED-4608-88F5-0ECE677D1051_8006_8" unitRef="iso4217_USD">300000</us-gaap:ProceedsFromLinesOfCredit>
  <sls:LicenseAgreementTerminationDate contextRef="eol_PE735624--1710-K0010_STD_1_20160615_0_2435412x3049272_2450320x3049275" id="id_10184323_C0E3BA2A-BB33-4C8E-BD26-84BCA3FBF1FD_2002_2">2016-06-15</sls:LicenseAgreementTerminationDate>
  <us-gaap:PaymentForManagementFee contextRef="eol_PE735624--1710-K0010_STD_1_20160630_0_2446922x3049598" decimals="-5" id="id_10184323_0944809B-2ACB-4431-8932-A05505810103_1001_1" unitRef="iso4217_USD">100000</us-gaap:PaymentForManagementFee>
  <sls:Incentivefeepercentageequaltogrossvaluepaidbypurchaserincash contextRef="eol_PE735624--1710-K0010_STD_1_20160630_0_2446922x3049598" decimals="2" id="id_10184323_5E537872-3119-4423-9BE9-3849814AD724_1001_1" unitRef="pure">0.02</sls:Incentivefeepercentageequaltogrossvaluepaidbypurchaserincash>
  <sls:IncentiveFeePercentageEqualToPostMoneyMarketValue contextRef="eol_PE735624--1710-K0010_STD_1_20160630_0_2446922x3049598" decimals="2" id="id_10184323_5E537872-3119-4423-9BE9-3849814AD724_1001_0" unitRef="pure">0.02</sls:IncentiveFeePercentageEqualToPostMoneyMarketValue>
  <sls:EffectivePeriodOfAgreement contextRef="eol_PE735624--1710-K0010_STD_1_20160630_0_2446922x3049598" id="id_10184323_0944809B-2ACB-4431-8932-A05505810103_1001_0">P3Y</sls:EffectivePeriodOfAgreement>
  <us-gaap:InterestPaid contextRef="eol_PE735624--1710-K0010_STD_1_20170613_0_2432521x3049445_2435465x2685828" decimals="-5" id="id_10184323_2727C554-B3C9-448F-9151-38276CA98CE4_1002_3" unitRef="iso4217_USD">100000</us-gaap:InterestPaid>
  <us-gaap:RepaymentsOfNotesPayable contextRef="eol_PE735624--1710-K0010_STD_1_20170613_0_2432521x3049445_2435465x2685828" decimals="-5" id="id_10184323_2727C554-B3C9-448F-9151-38276CA98CE4_1002_2" unitRef="iso4217_USD">1200000</us-gaap:RepaymentsOfNotesPayable>
  <us-gaap:InterestPaid contextRef="eol_PE735624--1710-K0010_STD_1_20170621_0_2432521x3049445_2435465x2685828" decimals="-5" id="id_10184323_2727C554-B3C9-448F-9151-38276CA98CE4_1001_3" unitRef="iso4217_USD">200000</us-gaap:InterestPaid>
  <us-gaap:RepaymentsOfNotesPayable contextRef="eol_PE735624--1710-K0010_STD_1_20170621_0_2432521x3049445_2435465x2685828" decimals="-5" id="id_10184323_2727C554-B3C9-448F-9151-38276CA98CE4_1001_2" unitRef="iso4217_USD">300000</us-gaap:RepaymentsOfNotesPayable>
  <sls:UpfrontLicenseFees contextRef="eol_PE735624--1710-K0010_STD_1_20140904_0_2435412x2684763" decimals="-5" id="id_10184323_5F9BC149-0B54-4ECF-8EF0-02C65FCB12FC_1_5" unitRef="iso4217_USD">1300000</sls:UpfrontLicenseFees>
  <sls:LicenseAgreementEffectiveDate contextRef="eol_PE735624--1710-K0010_STD_1_20140904_0_2435412x2684763" id="id_10184323_442F9C33-935A-445A-8EED-D95CF4445D26_1_0">2014-09-04</sls:LicenseAgreementEffectiveDate>
  <sls:LicenseAgreementExpirationTerm contextRef="eol_PE735624--1710-K0010_STD_1_20140904_0_2435412x2684763" id="id_10184323_5F9BC149-0B54-4ECF-8EF0-02C65FCB12FC_1_9">P10Y</sls:LicenseAgreementExpirationTerm>
  <sls:PercentageOfFullyDilutedShareCapital contextRef="eol_PE735624--1710-K0010_STD_1_20140904_0_2435412x2684763_2447148x2442380" decimals="3" id="id_10184323_5F9BC149-0B54-4ECF-8EF0-02C65FCB12FC_1001_1" unitRef="pure">0.015</sls:PercentageOfFullyDilutedShareCapital>
  <sls:MilestonePayments contextRef="eol_PE735624--1710-K0010_STD_1_20140904_0_2435412x2684763_2447194x2442860" decimals="INF" id="id_10184323_5F9BC149-0B54-4ECF-8EF0-02C65FCB12FC_2001_8" unitRef="iso4217_USD">17400000</sls:MilestonePayments>
  <sls:LicenseAgreementAmendmentExtendedDateForFinancing contextRef="eol_PE735624--1710-K0010_STD_1_20151029_0_2435412x2684763_2450320x3049264" id="id_10184323_7CC330AF-0F17-4C8A-A46A-21EB8ECE9C38_1002_1">2015-08-01</sls:LicenseAgreementAmendmentExtendedDateForFinancing>
  <sls:LicenseAgreementAmendmentDate contextRef="eol_PE735624--1710-K0010_STD_1_20151030_0_2435412x2684763_2450320x3049264" id="id_10184323_7CC330AF-0F17-4C8A-A46A-21EB8ECE9C38_1001_0">2015-10-30</sls:LicenseAgreementAmendmentDate>
  <sls:LicenseAgreementAmendmentExtendedDateForFinancing contextRef="eol_PE735624--1710-K0010_STD_1_20151030_0_2435412x2684763_2450320x3049264" id="id_10184323_7CC330AF-0F17-4C8A-A46A-21EB8ECE9C38_1001_1">2016-12-31</sls:LicenseAgreementAmendmentExtendedDateForFinancing>
  <sls:PercentageOfFullyDilutedShareCapital contextRef="eol_PE735624--1710-K0010_STD_1_20151030_0_2435412x2684763_2450320x3049264" decimals="2" id="id_10184323_7CC330AF-0F17-4C8A-A46A-21EB8ECE9C38_1001_3" unitRef="pure">0.01</sls:PercentageOfFullyDilutedShareCapital>
  <sls:LicenseAgreementTerminationDate contextRef="eol_PE735624--1710-K0010_STD_1_20160930_0_2450320x3049289" id="id_10184323_985350E3-948F-4241-987D-FE157762C3AA_1001_0">2016-09-30</sls:LicenseAgreementTerminationDate>
  <sls:LiabilitiesUnderTerminationAgreementPayableInCash contextRef="eol_PE735624--1710-K0010_STD_1_20160930_0_2450320x3049289" decimals="-5" id="id_10184323_985350E3-948F-4241-987D-FE157762C3AA_1001_1" unitRef="iso4217_USD">300000</sls:LiabilitiesUnderTerminationAgreementPayableInCash>
  <sls:AdditionalExpenseIncurredToReflectFairValueOfSharesIssued contextRef="eol_PE735624--1710-K0010_STD_1_20160930_0_2450320x3049289" decimals="-5" id="id_10184323_985350E3-948F-4241-987D-FE157762C3AA_1001_3" unitRef="iso4217_USD">200000</sls:AdditionalExpenseIncurredToReflectFairValueOfSharesIssued>
  <sls:RoyaltyOnNetSalesValue contextRef="eol_PE735624--1710-K0010_STD_1_20170905_0_2450320x2719233" decimals="INF" id="id_10184323_EB70FBE9-B630-4F16-AAD3-DAE66E48DD68_1001_3" unitRef="iso4217_USD">100000000</sls:RoyaltyOnNetSalesValue>
  <sls:ProceedsFromMilestoneBasedPayments contextRef="eol_PE735624--1710-K0010_STD_1_20170905_0_2450320x2719233" decimals="-5" id="id_10184323_EB70FBE9-B630-4F16-AAD3-DAE66E48DD68_1001_8" unitRef="iso4217_USD">100000</sls:ProceedsFromMilestoneBasedPayments>
  <sls:NumberOfTranches contextRef="eol_PE735624--1710-K0010_STD_1_20170905_0_2450320x2719233" decimals="INF" id="id_10184323_EB70FBE9-B630-4F16-AAD3-DAE66E48DD68_1001_5" unitRef="Tranche">2</sls:NumberOfTranches>
  <sls:PreviousRoyaltyObligationPercentage contextRef="eol_PE735624--1710-K0010_STD_1_20170905_0_2450320x2719233" decimals="2" id="id_10184323_EB70FBE9-B630-4F16-AAD3-DAE66E48DD68_1001_0" unitRef="pure">0.03</sls:PreviousRoyaltyObligationPercentage>
  <sls:RoyaltyRatePercentage contextRef="eol_PE735624--1710-K0010_STD_1_20170905_0_2450320x2719233" decimals="2" id="id_10184323_EB70FBE9-B630-4F16-AAD3-DAE66E48DD68_1001_1" unitRef="pure">0.04</sls:RoyaltyRatePercentage>
  <sls:PreviousRoyaltyOnNetSalesValue contextRef="eol_PE735624--1710-K0010_STD_1_20170905_0_2450320x2719233" decimals="INF" id="id_10184323_EB70FBE9-B630-4F16-AAD3-DAE66E48DD68_1001_2" unitRef="iso4217_USD">50000000</sls:PreviousRoyaltyOnNetSalesValue>
  <sls:SublicenseFeePayablePercentageIfExecutedPriorToFirstPatientEnrolledInPhaseThreeClinicalTrial contextRef="eol_PE735624--1710-K0010_STD_1_20170905_0_2450320x2719233" decimals="2" id="id_10184323_EB70FBE9-B630-4F16-AAD3-DAE66E48DD68_1001_6" unitRef="pure">0.25</sls:SublicenseFeePayablePercentageIfExecutedPriorToFirstPatientEnrolledInPhaseThreeClinicalTrial>
  <sls:SublicenseFeePayablePercentageIfExecutedAfterFirstPatientEnrolledInPhaseThreeClinicalTrial contextRef="eol_PE735624--1710-K0010_STD_1_20170905_0_2450320x2719233" decimals="3" id="id_10184323_EB70FBE9-B630-4F16-AAD3-DAE66E48DD68_1001_7" unitRef="pure">0.175</sls:SublicenseFeePayablePercentageIfExecutedAfterFirstPatientEnrolledInPhaseThreeClinicalTrial>
  <us-gaap:LicenseCosts contextRef="eol_PE735624--1710-K0010_STD_1_20160118_0_2435412x3049284_2450320x3049289" decimals="-5" id="id_10184323_9053F4BC-D138-4C2D-968C-9D5D13965062_1001_0" unitRef="iso4217_EUR">500000</us-gaap:LicenseCosts>
  <sls:LicenseAgreementDate contextRef="eol_PE735624--1710-K0010_STD_1_20160118_0_2435412x3049284_2450320x3049289" id="id_10184323_9053F4BC-D138-4C2D-968C-9D5D13965062_1001_1">2016-01-18</sls:LicenseAgreementDate>
  <us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1 contextRef="eol_PE735624--1710-K0010_STD_1_20171229_0_2433694x2884874" id="id_10184323_DEDE4CB5-C2B7-43EC-84DD-8AB2C7F7E202_1001_2">2017-12-29</us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE735624--1710-K0010_STD_1_20171229_0_2434520x3050116" decimals="4" id="id_10184323_BAE9134F-EE87-42C2-9C94-8E7554FBFBEF_1_7" unitRef="pure">0.0000</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE735624--1710-K0010_STD_1_20171229_0_2434520x3050116" id="id_10184323_BAE9134F-EE87-42C2-9C94-8E7554FBFBEF_1_5">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE735624--1710-K0010_STD_1_20171229_0_2434520x3050116" decimals="4" id="id_10184323_BAE9134F-EE87-42C2-9C94-8E7554FBFBEF_1_4" unitRef="pure">0.9010</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE735624--1710-K0010_STD_1_20171229_0_2434520x3050116" decimals="4" id="id_10184323_BAE9134F-EE87-42C2-9C94-8E7554FBFBEF_1_6" unitRef="pure">0.0220</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <sls:ClassOfWarrantOrRightTerm contextRef="eol_PE735624--1710-K0010_STD_1_20171229_0_2434520x3050116" id="id_10184323_BAE9134F-EE87-42C2-9C94-8E7554FBFBEF_1_2">P5Y</sls:ClassOfWarrantOrRightTerm>
  <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1 contextRef="eol_PE735624--1710-K0010_STD_1_20171229_0_2435465x3049445" decimals="INF" id="id_10184323_6E24AB61-4C80-4B3E-B627-7E6A479B0DF2_1001_1" unitRef="shares">316163</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="eol_PE735624--1710-K0010_STD_1_20171229_0_2435465x3049445" decimals="INF" id="id_10184323_6E24AB61-4C80-4B3E-B627-7E6A479B0DF2_1001_0" unitRef="shares">632326</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE735624--1710-K0010_STD_1_20171229_0_2446922x3049598" decimals="-5" id="id_10184323_6C3DD794-76CF-450E-BA3D-7B48417B6F85_1001_2" unitRef="iso4217_USD">900000</us-gaap:GeneralAndAdministrativeExpense>
  <sls:StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares contextRef="eol_PE735624--1710-K0010_STD_1_20171229_0_2446922x3049598" decimals="0" id="id_10184323_6C3DD794-76CF-450E-BA3D-7B48417B6F85_1001_1" unitRef="shares">119672</sls:StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares>
  <sls:GrossProceedsPercentage contextRef="eol_PE735624--1710-K0010_STD_1_20180116_0_2449888x2449609_2450320x3050065" decimals="2" id="id_10184323_FDD3A9CF-1223-4046-85DE-FB6F70880919_1001_0" unitRef="pure">0.07</sls:GrossProceedsPercentage>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE735624--1710-K0010_STD_27_20161128_0_2433414x2679417_2446922x3049599" decimals="INF" id="id_10184323_CA08F067-FB5B-42FE-B5D9-4A7803EE725E_1001_0" unitRef="shares">9107</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE735624--1710-K0010_STD_27_20161128_0_2446922x3049599" decimals="INF" id="id_10184323_E50A7EA9-3E22-4DEA-94B7-9F1B0DC7EC0A_1001_0" unitRef="shares">3651</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <sls:ContractualAgreementTerminationDate contextRef="eol_PE735624--1710-K0010_STD_27_20161128_0_2446922x3049599" id="id_10184323_E50A7EA9-3E22-4DEA-94B7-9F1B0DC7EC0A_1001_1">2017-08-06</sls:ContractualAgreementTerminationDate>
  <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="eol_PE735624--1710-K0010_STD_28_20160630_0_2435465x3049453" decimals="2" id="id_10184323_2EB30C43-4544-40D7-B257-5BD00BD9BD61_1001_1" unitRef="pure">0.08</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
  <us-gaap:DecreaseInRestrictedCash contextRef="eol_PE735624--1710-K0010_STD_31_20180131_0_2435465x2728214_2449888x2449609" decimals="-5" id="id_10184323_06E78774-183E-4369-8A52-B2A87A240BE7_1001_4" unitRef="iso4217_USD">3200000</us-gaap:DecreaseInRestrictedCash>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="eol_PE735624--1710-K0010_STD_31_20180131_0_2449888x2449609" decimals="INF" id="id_10184323_06E78774-183E-4369-8A52-B2A87A240BE7_2001_2" unitRef="shares">623749</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:RepaymentsOfSecuredDebt contextRef="eol_PE735624--1710-K0010_STD_31_20180131_0_2449888x2449609" decimals="-5" id="id_10184323_06E78774-183E-4369-8A52-B2A87A240BE7_2001_3" unitRef="iso4217_USD">600000</us-gaap:RepaymentsOfSecuredDebt>
  <sls:DebtInstrumentRedemptionPrincipalAmountRedeemed contextRef="eol_PE735624--1710-K0010_STD_31_20180131_0_2449888x2449609" decimals="-5" id="id_10184323_06E78774-183E-4369-8A52-B2A87A240BE7_2001_1" unitRef="iso4217_USD">2600000</sls:DebtInstrumentRedemptionPrincipalAmountRedeemed>
  <sls:StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithAcquisition contextRef="eol_PE735624--1710-K0010_STD_31_20170831_0_2435465x3049445_2446928x3049446" decimals="0" id="id_10184323_B94B5804-D9E4-477D-B874-50C21EDE265C_1001_0" unitRef="shares">632328</sls:StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithAcquisition>
  <sls:WarrantExercisePriceAsPercentOfDebtConversion contextRef="eol_PE735624--1710-K0010_STD_31_20170831_0_2435465x3049445_2446928x3049446" decimals="2" id="id_10184323_B94B5804-D9E4-477D-B874-50C21EDE265C_1001_3" unitRef="pure">1.05</sls:WarrantExercisePriceAsPercentOfDebtConversion>
  <sls:DebtInstrumentConvertibleTermOfNotes contextRef="eol_PE735624--1710-K0010_STD_31_20170831_0_2435465x3049445_2446928x3049446" id="id_10184323_B94B5804-D9E4-477D-B874-50C21EDE265C_1001_4">P30D</sls:DebtInstrumentConvertibleTermOfNotes>
  <sls:IssuanceOfWarrantsTerm contextRef="eol_PE735624--1710-K0010_STD_31_20170831_0_2435465x3049445_2446928x3049446" id="id_10184323_B94B5804-D9E4-477D-B874-50C21EDE265C_1001_1">P5Y</sls:IssuanceOfWarrantsTerm>
  <us-gaap:LicenseCosts contextRef="eol_PE735624--1710-K0010_STD_365_20141231_0_2435412x3049272_2450320x3049275" decimals="-5" id="id_10184323_81492B21-7CEE-4EA7-A0FF-74ED94EA21CF_1002_0" unitRef="iso4217_USD">300000</us-gaap:LicenseCosts>
  <sls:MinimumAnnualRoyaltyPayment contextRef="eol_PE735624--1710-K0010_STD_365_20151231_0_2435412x2684763" decimals="INF" id="id_10184323_5F9BC149-0B54-4ECF-8EF0-02C65FCB12FC_2_6" unitRef="iso4217_USD">100000</sls:MinimumAnnualRoyaltyPayment>
  <sls:ResearchFundingCosts contextRef="eol_PE735624--1710-K0010_STD_365_20151231_0_2435412x2684763" decimals="-5" id="id_10184323_5F9BC149-0B54-4ECF-8EF0-02C65FCB12FC_2_7" unitRef="iso4217_USD">200000</sls:ResearchFundingCosts>
  <us-gaap:DebtInstrumentTerm contextRef="eol_PE735624--1710-K0010_STD_365_20151231_0_2435465x3053943" id="id_10184323_605916AC-C5ED-4608-88F5-0ECE677D1051_5010_22">P3Y</us-gaap:DebtInstrumentTerm>
  <sls:ModifiedTermsOnLoanPercentageMaximum contextRef="eol_PE735624--1710-K0010_STD_365_20151231_0_2435465x3053943" decimals="2" id="id_10184323_605916AC-C5ED-4608-88F5-0ECE677D1051_5010_23" unitRef="pure">0.10</sls:ModifiedTermsOnLoanPercentageMaximum>
  <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="eol_PE735624--1710-K0010_STD_365_20151231_0_2446928x3053942" decimals="-5" id="id_10184323_605916AC-C5ED-4608-88F5-0ECE677D1051_9010_16" unitRef="iso4217_EUR">100000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
  <dei:AmendmentFlag contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_F0B6D6C0-B9E1-472A-9203-93F8C51981B8_1_1">false</dei:AmendmentFlag>
  <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_05AED7B4-B0AD-48C8-89C1-BBCCE0BFA177_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;8. Accrued Expenses and Other Current Liabilities&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Accrued expenses and other current liabilities consist of the
 following (in thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="82%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"&gt;
 &lt;b&gt;Year&amp;#xA0;Ended&amp;#xA0;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Professional fees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,744&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,077&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Value added tax&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;426&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Rebates and returns&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;223&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Compensation and related benefits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;566&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;249&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Clinical trial costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,496&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;191&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;227&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accrued expenses and other current liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,201&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,049&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_229FFD7D-7F91-4834-828C-8E345BAB60A3_1_2" unitRef="iso4217_USD">3169000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="0" id="id_10184323_89149E78-1DB1-40DA-95B5-345B45F730E2_1_3" unitRef="shares">986</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_7005_800039" unitRef="iso4217_USD">3169000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_38CF6218-B6A1-4D37-B903-AD80F2D9E61B_1_1" unitRef="iso4217_USD">24089000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
  <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_38CF6218-B6A1-4D37-B903-AD80F2D9E61B_1_0" unitRef="iso4217_USD">0</us-gaap:BusinessAcquisitionsProFormaRevenue>
  <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_78026569-3185-40AC-AC91-30FAE85254A7_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;b&gt;1. Organization and Description of Business&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;b&gt;Merger of Galena Biopharma, Inc. and SELLAS Life Sciences Group
 Ltd.&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 As used in this annual report on Form 10-K, the words the
 &amp;#x201C;Company,&amp;#x201D; and &amp;#x201C;SELLAS&amp;#x201D; refer to SELLAS
 Life Sciences Group, Inc. and its consolidated subsidiaries
 following completion of the Merger. Said references before the
 completion of the Merger refer to Private SELLAS.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On December&amp;#xA0;29, 2017, Galena Biopharma. Inc.
 (&amp;#x201C;Galena&amp;#x201D;) completed the business combination with the
 privately held Bermuda exempted company, Sellas Life Sciences Group
 Ltd. (&amp;#x201C;Private SELLAS&amp;#x201D;), in accordance with the terms
 of the Agreement and Plan of Merger and Reorganization, dated as of
 August&amp;#xA0;7, 2017 and amended November&amp;#xA0;5, 2017 the
 (&amp;#x201C;Merger Agreement&amp;#x201D;), by and among the Company, Sellas
 Intermediate Holdings I, Inc., Sellas Intermediate Holdings II,
 Inc., Galena Bermuda Merger Sub, Ltd., and Private SELLAS. The
 Company refers to this business combination throughout this annual
 report on Form&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;10-K&lt;/font&gt;&amp;#xA0;as the Merger.
 As a result of the Merger, the Company&amp;#x2019;s business is now
 substantially comprised of the business of Private SELLAS, and
 although the Company is considered the legal acquiror of Private
 SELLAS, for accounting purposes, Private SELLAS is considered to
 have acquired the Company in the Merger. Consequently, the Merger
 is accounted for as a reverse acquisition.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 Immediately prior to the Merger, the Galena effected
 a&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;1-for-30&lt;/font&gt;&lt;/font&gt;&amp;#xA0;reverse
 stock split of the Company&amp;#x2019;s outstanding common stock. Under
 the terms of the Merger Agreement, the Galena issued shares of the
 its common stock to Private SELLAS&amp;#x2019; securityholders at an
 exchange ratio of 43.9972 shares of the its common stock in
 exchange for each common share of Private SELLAS outstanding
 immediately prior to the Merger. The Company also assumed all of
 the restricted stock units (&amp;#x201C;RSU&amp;#x201D;) issued and
 outstanding under the Private SELLAS Stock Incentive Plan #1, and
 all of the issued and outstanding warrants of Private SELLAS.
 Accordingly, such RSUs will now be settled in, and such warrants
 now are exercisable for, shares of the Company&amp;#x2019;s common
 stock. Accordingly, immediately after the Merger, there were
 approximately 5,766,891 shares of the Company&amp;#x2019;s common stock
 outstanding, with the former Private SELLAS securityholders owning
 approximately 67.5% of the Company&amp;#x2019;s fully diluted common
 stock, and the Company&amp;#x2019;s&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;pre-Merger&lt;/font&gt;&amp;#xA0;securityholders
 owning the remaining approximately 32.5%. The number of shares and
 per share amounts of common stock in the accompanying financial
 statements and notes to the consolidated financial statements have
 been restated to give retroactive effect to the common stock
 conversion ratio and reverse stock split for all periods presented,
 including common stock options, restricted stock units, and common
 stock warrants. The prior year amounts for outstanding common stock
 at the $10.00 par value of Private SELLAS&amp;#x2019; common stock and
 related additional paid-in capital have been retroactively
 presented at a $0.0001 par value. These reclassifications had no
 effect on total equity, or net loss per share.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 Common stock as included in the consolidated statement of
 stockholders&amp;#x2019; equity (deficit) was adjusted to reflect the
 $0.0001 par value per share and additional paid-in capital was
 adjusted as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Retroactive&lt;br /&gt;
 Effect&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&amp;#xA0;Revised&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Balance at January 1, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;288&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;200&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;488&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Shares issued as partial consideration of MSK license fees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;897&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;900&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Shares issued pursuant to MSK license agreement&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,967&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,976&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Shares issued in cancellation of Clarendon license agreement&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;502&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Shares issued upon conversion of 2016 convertible note&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,357&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;54&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,411&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Shares issued in cancellation of long-term debt&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,783&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,803&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Stock-based compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;354&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;354&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Balance at December 31, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25,146&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;288&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25,434&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 Upon completion of the Merger, the Company changed the
 Company&amp;#x2019;s name from &amp;#x201C;Galena Biopharma, Inc.&amp;#x201D; to
 &amp;#x201C;SELLAS Life Sciences Group, Inc.&amp;#x201D;, the Company&amp;#x2019;s
 common stock began trading on The Nasdaq Capital Market under a new
 ticker symbol &amp;#x201C;SLS&amp;#x201D; on January&amp;#xA0;2, 2018 and the
 Company&amp;#x2019;s financial statements became those of Private
 SELLAS.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;b&gt;Overview&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The Company is a clinical-stage biopharmaceutical company focused
 on novel cancer immunotherapeutics for a broad range of cancer
 indications. The Company&amp;#x2019;s lead product candidate,
 galinpepimut-S (&amp;#x201C;GPS&amp;#x201D;), is a cancer immunotherapeutic
 agent licensed from Memorial Sloan Kettering Cancer Center
 (&amp;#x201C;MSK&amp;#x201D;), that targets the Wilms tumor 1
 (&amp;#x201C;WT1&amp;#x201D;), protein, which is present in 20 or more cancer
 types. Based on its mechanism of action as a directly immunizing
 agent, GPS has the potential as a monotherapy or in combination
 with other immunotherapeutic agents to address a broad spectrum of
 hematologic, or blood, cancers and solid tumor indications. Phase 2
 clinical trials for GPS have been completed and the Company&amp;#x2019;s
 planned Phase 3 clinical trials (pending funding availability) for
 two indications, acute myeloid leukemia (&amp;#x201C;AML&amp;#x201D;), and
 malignant pleural mesothelioma (&amp;#x201C;MPM&amp;#x201D;). GPS is also in
 development as a potential treatment for multiple myeloma
 (&amp;#x201C;MM&amp;#x201D;), and ovarian cancer. The Company plans to study
 GPS in up to four additional indications: as a combination therapy
 in small cell lung cancer, colorectal cancer, triple-negative
 breast cancer; and, as a monotherapy in chronic myelogenous
 leukemia (&amp;#x201C;CML&amp;#x201D;). The Company received Orphan Drug
 Product Designations from the U.S. Food and Drug Administration
 (&amp;#x201C;FDA&amp;#x201D;) as well as Orphan Medicinal Product
 Designations from the European Medicines Agency
 (&amp;#x201C;EMA&amp;#x201D;), for GPS in AML and MPM, as well as Fast Track
 designation for AML and MPM from the FDA.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The Company&amp;#x2019;s pipeline also includes the legacy development
 programs of the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;pre-Merger&lt;/font&gt;&amp;#xA0;company
 Galena, including novel cancer immunotherapy programs for
 NeuVax&amp;#x2122; (nelipepimut-S; a vaccine against the E75 peptide
 derived from the human epidermal growth factor
 2&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;-or&lt;/font&gt;&amp;#xA0;HER2-
 protein),&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;GALE-301&lt;/font&gt;&amp;#xA0;(a vaccine
 against the E39 peptide derived from the folate binding protein
 (&amp;#x201C;FBP&amp;#x201D;)) and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;GALE-302&lt;/font&gt;&amp;#xA0;(a vaccine
 against the J65 peptide derived from FBP)
 and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;GALE-401&lt;/font&gt;&amp;#xA0;(a
 controlled release version of the approved drug anagrelide). NeuVax
 is currently in multiple investigator-sponsored Phase 2 clinical
 trials in breast cancer.&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;GALE-301&lt;/font&gt;&amp;#xA0;and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;GALE-302&lt;/font&gt;&amp;#xA0;have
 completed early stage trials in ovarian, endometrial and breast
 cancers.&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;GALE-401&lt;/font&gt;&amp;#xA0;is being
 developed for the treatment of elevated platelets in patients with
 myeloproliferative neoplasms (&amp;#x201C;MPNs&amp;#x201D;), and a completed
 Phase 2 clinical trial in patients with essential thrombocythemia
 (&amp;#x201C;ET&amp;#x201D;) for this clinical candidate. Since the closing
 of the Merger, management has been
 evaluating,&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;GALE-301,&lt;/font&gt;&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;GALE-302,&lt;/font&gt;&amp;#xA0;and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;GALE-401&lt;/font&gt;&amp;#xA0;for
 potential internal development, strategic partnership, or other
 types of product rationalizations.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_DE59C969-9726-4D86-B6F8-2B3A2613115A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The accompanying consolidated financial statements have been
 prepared in conformity with accounting principles generally
 accepted in the United States (&amp;#x201C;U.S. GAAP&amp;#x201D;). Any
 reference in these notes to applicable guidance is meant to refer
 to U.S.&amp;#xA0;GAAP as found in the Accounting Standards Codification
 (&amp;#x201C;ASC&amp;#x201D;) and Accounting Standards Updates
 (&amp;#x201C;ASU&amp;#x201D;) of the Financial Accounting Standards Board
 (&amp;#x201C;FASB&amp;#x201D;).&lt;/p&gt;
 &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_85217D97-1DEF-4E12-89AD-77CDBE9A836F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 Pro forma consolidated financial information for 2017 and 2016
 (unaudited):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="80%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Year&amp;#xA0;ended&amp;#xA0;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net revenues (in thousands)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net loss (in thousands)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24,089&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28,389&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Basic and diluted net loss per share&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.15&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.61&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;br class="Apple-interchange-newline" /&gt;

 &lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
  <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_02BA9B88-9563-4EF2-AA2B-2AE073CCF50A_1_2" unitRef="iso4217_USD">12519000</us-gaap:BusinessCombinationConsiderationTransferred1>
  <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_D9A3A44D-1763-4143-B46E-2090E60B25F3_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;b&gt;4. Business Combination&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On December&amp;#xA0;29, 2017, the Company completed the Merger with
 Private SELLAS as discussed in Note 1. The Merger was accounted for
 as reverse merger under the acquisition method of accounting
 whereby Private SELLAS was considered to have acquired the Company
 for financial reporting purposes because, immediately upon
 completion of the Merger, Private SELLAS stockholders held a
 majority of the voting interest of the combined company.
 Immediately after the Merger, stockholders of Private SELLAS and
 the Company&amp;#x2019;s common stock, warrants and options owned
 approximately 67.5% and 32.5% of the fully diluted common stock of
 the Company, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The purchase consideration in a reverse acquisition is determined
 with reference to the value of equity that the accounting acquirer,
 in this case, Private SELLAS, would have had to issue to the owners
 of the accounting acquiree, the Company, to give
 the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;pre-acquisition&lt;/font&gt;&amp;#xA0;equity
 holders of the Company the same percentage interest in Private
 SELLAS that such&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;pre-acquisition&lt;/font&gt;&amp;#xA0;equity
 holders held in the Company immediately following the Merger. The
 purchase price was calculated as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="88%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Fair value of the Company&amp;#x2019;s&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;pre-Merger&lt;/font&gt;&amp;#xA0;shares
 outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,487&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Estimated fair value of the
 Company&amp;#x2019;s&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;per-Merger&lt;/font&gt;&amp;#xA0;stock
 options outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;32&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total purchase price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,519&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The Merger transaction has been accounted for using the acquisition
 method of accounting, which requires that assets acquired and
 liabilities assumed be recognized at their fair values as of the
 acquisition date. See Note 5 for the valuation technique utilized
 to value the IPR&amp;amp;D.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The following table summarizes the allocation of the purchase price
 to the assets acquired and liabilities assumed as of the
 acquisition date (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="88%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Assets acquired:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,812&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Restricted cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,346&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Prepaid expenses and other assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,103&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Intangible assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,600&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Goodwill&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,914&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total assets acquired&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34,775&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Liabilities assumed:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accounts payable and accrued expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,692&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Litigation settlement&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,300&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Long-term debt&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,988&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Contingent purchase price consideration of Apthera, Inc.&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,294&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Warrant liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,309&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred tax liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,673&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total liabilities assumed&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22,256&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net assets acquired&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,519&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 Qualitative factors supporting the recognition of goodwill due to
 the Merger include the Company&amp;#x2019;s anticipated enhanced ability
 to secure additional capital and gain access to capital market
 opportunities as a public company. The goodwill is not deductible
 for income tax purposes.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The following summary pro forma consolidated financial information
 reflects the Merger as if it had occurred on January&amp;#xA0;1, 2016
 for purposes of the statements of operations. This summary pro
 forma information is not necessarily representative of what the
 Company&amp;#x2019;s results of operations would have been had the
 Merger in fact occurred on January&amp;#xA0;1, 2016, and is not
 intended to project the Company&amp;#x2019;s results of operations for
 any future period. In addition, transaction costs associated with
 the Merger of $5.7&amp;#xA0;million are included in general and
 administrative expense in the statement of operations for the year
 ended December 31, 2017.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 Pro forma consolidated financial information for 2017 and 2016
 (unaudited):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="80%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Year&amp;#xA0;ended&amp;#xA0;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net revenues (in thousands)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net loss (in thousands)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24,089&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28,389&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Basic and diluted net loss per share&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.15&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.61&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;font style="WHITE-SPACE: nowrap"&gt;Non-recurring&lt;/font&gt;&amp;#xA0;pro
 forma transaction costs directly attributable to the Merger were
 $5.7&amp;#xA0;million for the year ended December&amp;#xA0;31, 2017 and
 have been deducted from the net loss presented above. The costs
 deducted from the year ended December&amp;#xA0;31, 2017 period included
 a success fee and other transaction costs&amp;#xA0;of $4.8 million and
 issued 119,672 shares of common stock with a fair value of
 $0.9&amp;#xA0;million as a fee to Equilibria Capital Management Limited
 (&amp;#x201C;Equilibria&amp;#x201D;). Additionally, the Company incurred
 approximately $1.9&amp;#xA0;million in severance costs as a result of
 resignations of executive officers immediately prior to the Merger.
 These costs are excluded from the pro forma financial information
 for the year ended December&amp;#xA0;31, 2017. The Company excluded a
 $5.2&amp;#xA0;million impairment charge incurred by the Company as well
 as combined transaction costs from Galena and the Company in the
 amount of $8.7&amp;#xA0;million from the pro forma financial
 information for the year ended December&amp;#xA0;31, 2017.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
  <us-gaap:ConcentrationRiskCreditRisk contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_0CAD2DB1-EED7-4B54-B945-6C7E9248B3DA_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Financial instruments that potentially expose the Company to
 concentrations of credit risk consist principally of cash on
 deposit with multiple financial institutions, the balances of which
 frequently exceed federally insured limits.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:ConsolidationPolicyTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_F4D37EEF-E981-4637-8A13-C873FF2F8F97_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Principles of Consolidation&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The consolidated financial statements include the financial
 statements of the Company and its wholly owned subsidiaries, SELLAS
 Bermuda, SELLAS Life Sciences Group UK Ltd (&amp;#x201C;SELLAS
 UK&amp;#x201D;), Apthera, Inc. (&amp;#x201C;Apthera&amp;#x201D;) and Mills
 Pharmaceuticals, LLC (&amp;#x201C;Mills&amp;#x201D;). All significant
 intercompany accounts and transactions have been eliminated upon
 consolidation.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_2D2B3170-8FA0-4068-9EC0-D0C77443A2FC_1_0">&lt;div&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company considers any highly liquid investments, such as money
 market funds, with an original maturity of three months or less to
 be cash and cash equivalents.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_45BA6791-1E6D-43A3-8C0E-09EA23385E61_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Restricted Cash and Cash Equivalents&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Restricted cash consists of the minimum cash covenant as required
 by the debenture and certificates of deposit on hand with the
 Company&amp;#x2019;s financial institutions as collateral for its
 corporate credit cards.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_BD3511A0-B0DB-4A78-9BE5-3C20FA431DA0_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;b&gt;6. Collaboration and License Agreements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 As part of its business, the Company enters into licensing
 agreements with third parties that often require milestone and
 royalty payments based on the progress of the licensed asset
 through development and commercial stages. Milestone payments may
 be required, for example, upon approval of the product for
 marketing by a regulatory agency, and the Company may be required
 to make royalty payments based upon a percentage of net sales of
 the product. The expenditures required under these arrangements in
 any period may be material and are likely to fluctuate from period
 to period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 These arrangements sometimes permit the Company to unilaterally
 terminate development of the product and thereby avoid future
 contingent payments; however, the Company is unlikely to cease
 development if the compound successfully achieves clinical testing
 objectives.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;Memorial Sloan Kettering Cancer Center&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On September&amp;#xA0;4, 2014, (the &amp;#x201C;MSK Effective Date&amp;#x201D;)
 the Company entered into a license agreement (the &amp;#x201C;Original
 MSK License Agreement&amp;#x201D;) with MSK under which the Company was
 granted an exclusive license to develop and commercialize
 MSK&amp;#x2019;s WT1 peptide vaccine technology. Under the terms of the
 Original MSK License Agreement, the Company is required to obtain
 certain levels of financing. If such financing is not met, MSK will
 have the right to terminate the Original MSK License Agreement with
 prior written notice, unless the Company manages to overcome the
 shortfall during the term of the notice period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 As part of the consideration for the rights, privileges and
 licenses granted under the Original MSK License Agreement, the
 Company agreed to issue 13,199 shares to MSK representing 1.5% of
 the Company&amp;#x2019;s fully diluted share capital as of the MSK
 Effective Date, which obligation was satisfied by assignment of
 6,599&amp;#xA0;shares from each of the Company&amp;#x2019;s Chief Executive
 Officer,&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;co-founder&lt;/font&gt;&amp;#xA0;and Vice
 Chairman of the Board, Dr.&amp;#xA0;Angelos&amp;#xA0;M. Stergiou (M.D.,
 Sc.D. h.c), and the Company&amp;#x2019;s
 other&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;co-founder,&lt;/font&gt;&amp;#xA0;Dr.&amp;#xA0;Miltiadis
 Sougioultzoglou (M.D.), to MSK for which they received no
 consideration. Additionally, the Company was obligated to pay
 upfront license fees in an amount equal to $1.3&amp;#xA0;million. The
 Company recognized this amount as research and development expense
 during the year ended December&amp;#xA0;31, 2014, as it had no
 alternative future use. The Company would further be obligated to
 pay minimum royalty payments in the amount of $0.1&amp;#xA0;million
 each year commencing in 2015 and research funding costs of
 $0.2&amp;#xA0;million in each year and for three years commencing in
 January 2015. In addition, to the extent certain development and
 commercial milestones are achieved, the Company will be required to
 pay MSK up to $17.4&amp;#xA0;million in milestone payments for each
 licensed product, in addition to royalties in the event of
 commercial sales of any licensed products.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The Original MSK License Agreement, unless terminated earlier in
 accordance with the terms of the Original MSK License Agreement,
 will continue on a&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;country-by-country&lt;/font&gt;&lt;/font&gt;&amp;#xA0;and
 licensed&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;product-by-licensed&lt;/font&gt;&lt;/font&gt;&amp;#xA0;product
 basis, until the later of: (a)&amp;#xA0;expiration of the last valid
 claim embracing such licensed product; (b)&amp;#xA0;expiration of any
 market exclusivity period granted by law with respect to such
 licensed product; or (c)&amp;#xA0;ten (10)&amp;#xA0;years from the first
 commercial sale in such country.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On October&amp;#xA0;30, 2015, the Company and MSK entered into the
 License Amendment, Waiver and Share Issuance Agreement (the
 &amp;#x201C;First MSK Amendment&amp;#x201D;). The First MSK Amendment
 extended the date required for the Company to obtain financing from
 August&amp;#xA0;1, 2015 to December&amp;#xA0;31, 2016, modified the amount
 of required financing and waived
 past&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-compliance&lt;/font&gt;&amp;#xA0;with
 certain related provisions of the Original MSK License Agreement.
 In exchange for the First MSK Amendment, the Company agreed to
 issue an aggregate of 10,867 shares to MSK, which represented 1% of
 the fully diluted share capital of the Company at such date. The
 First MSK Amendment added certain anti-dilution protection clauses
 and entitled MSK to issuance of additional shares to the extent the
 Company was not able to obtain the required financing.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On August&amp;#xA0;10, 2016, the Company and MSK entered into the
 Second License Amendment, Waiver and Agreement
 (the&amp;#xA0;&amp;#x201C;Second MSK Amendment&amp;#x201D;). The Second MSK
 Amendment extended further the date required for the Company to
 obtain financing from December&amp;#xA0;31, 2016 to June&amp;#xA0;30, 2017,
 amended the anti-dilution provisions of the First MSK Amendment and
 waived past&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-compliance&lt;/font&gt;&amp;#xA0;with
 certain related provisions of the First MSK Amendment. Under the
 Second MSK Amendment, outstanding obligations of the Company to MSK
 in an amount of $0.9&amp;#xA0;million were converted into 13,815 shares
 effective November&amp;#xA0;1, 2016 upon the
 Company&amp;#x2019;s&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;re-domiciliation&lt;/font&gt;&amp;#xA0;to
 Bermuda. In consideration for this amendment and pursuant to the
 anti-dilution provisions in the Original MSK License Agreement as
 amended by the First MSK Amendment and the Second MSK Amendment,
 the Company issued MSK 30,314 additional shares and incurred
 accordingly $2.0&amp;#xA0;million of research and development expense,
 which reflected the fair value of the Company&amp;#x2019;s shares at
 such date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 For the year ended December&amp;#xA0;31, 2017, the Company incurred
 $1.0&amp;#xA0;million of expenses relating to $0.7&amp;#xA0;million of
 milestone payments, $0.1&amp;#xA0;million of guaranteed minimum royal
 payments and $0.2&amp;#xA0;million of research funding costs. For the
 year ended December&amp;#xA0;31, 2016 the Company incurred
 $0.6&amp;#xA0;million of expenses relating to $0.3&amp;#xA0;million of
 milestone payments, $0.1&amp;#xA0;million of guaranteed minimum royal
 payments and $0.2&amp;#xA0;million of research funding costs. Such
 expenses have been included in research and development costs.
 Further, under the Second MSK Amendment, the Company is obligated
 to pay MSK $0.7&amp;#xA0;million in milestone payments in two equal
 installments, within 60 days following the initiation of its Phase
 3 AML and mesothelioma clinical studies.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On May&amp;#xA0;25, 2017, the Company and MSK entered into an Amended
 and Restated Exclusive License Agreement (the &amp;#x201C;MSK A&amp;amp;R
 License Agreement&amp;#x201D;). Under the MSK A&amp;amp;R License Agreement,
 the Company expanded its license under the original MSK License
 Agreement, as amended, to include a license to commercially develop
 certain additional WT1 peptides through a program of exploiting
 certain patents and other rights covering such peptides.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The MSK A&amp;amp;R License Agreement, amongst others, added certain
 milestone payments for each additional patent licensed product as
 defined in the MSK A&amp;amp;R License Agreement, and amended the
 milestone payments due upon commencement of the Phase 3 AML and
 mesothelioma clinical trials from $0.3&amp;#xA0;million to
 $0.4&amp;#xA0;million. In consideration for the MSK A&amp;amp;R License
 Agreement, the Company issued 8,799 shares to MSK. Pursuant to a
 side letter to the MSK A&amp;amp;R License Agreement, dated
 May&amp;#xA0;25, 2017 (the &amp;#x201C;MSK Side Letter&amp;#x201D;), MSK
 converted the next milestone payment of $0.2&amp;#xA0;million, which
 was due June&amp;#xA0;30, 2017, into shares. Further, in consideration
 for the MSK Side Letter, Dr.&amp;#xA0;Angelos&amp;#xA0;M. Stergiou (M.D.,
 Sc.D. h.c.), the Company&amp;#x2019;s Chief Executive Officer, assigned
 15,399 of his shares to MSK, for which Dr.&amp;#xA0;Stergiou received
 no cash consideration.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On October&amp;#xA0;11, 2017, the Company and MSK entered into a second
 Amended and Restated Exclusive License Agreement (the &amp;#x201C;Second
 MSK A&amp;amp;R License Agreement&amp;#x201D;). Under the Second MSK A&amp;amp;R
 License Agreement, the Company and MSK extended the dates for the
 Company to have obtained necessary financing, and certain milestone
 dates, in exchange for increased milestone payments, clarification
 regarding MSK&amp;#x2019;s anti-dilution rights, and termination of the
 MSK Side Letter dated May&amp;#xA0;25, 2017. In connection with the MSK
 A&amp;amp;R License Agreement, the Company issued 74,795 shares to MSK.
 Prior to the Merger, the Company issued an additional 7,700 shares
 to MSK in connection with their anti-dilution rights.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;Merck&amp;#xA0;&amp;amp; Co., Inc.&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On September&amp;#xA0;21, 2017, the Company entered into a clinical
 trial collaboration and supply agreement through a Merck&amp;#xA0;&amp;amp;
 Co., Inc. subsidiary, Merck Sharp&amp;#xA0;&amp;amp; Dohme B.V.
 (&amp;#x201C;Merck subsidiary&amp;#x201D;), whereby the Company agreed with
 the Merck subsidiary to collaborate in a research program to
 evaluate GPS as it is administered in combination with
 Merck&amp;#x2019;s PD1 blocker pembrolizumab (Keytruda&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;) in a Phase 1/2
 clinical trial enrolling patients in up to five cancer indications,
 including both hematologic malignancies and solid tumors.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The purpose of the clinical trials is to determine if the
 administration of GPS in combination with pembrolizumab has the
 potential to demonstrate clinical activity in the presence of
 macroscopic disease, where monotherapy with either agent would have
 a more limited effect. The rationale for the study is based upon
 the presumed immunobiologic and pharmacodynamic synergy between the
 two agents, whereby the negative influence of tumor
 microenvironment factors on the immune response is mitigated by PD1
 inhibition (by pembrolizumab) thus allowing the patients&amp;#x2019; own
 immune cells to invade and destroy cancerous growth deposits
 specifically sensitized against WT1 by GPS.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The Phase 1/2 clinical trial will utilize a combination of GPS plus
 pembrolizumab (Keytruda) in patients with WT1+ relapsed or
 refractory tumors. Specifically, the study is expected to explore
 the following cancer indications: colorectal (arm enriched in but
 not exclusive to patients with
 microsatellite&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;instability-low),&lt;/font&gt;&amp;#xA0;ovarian,
 small cell lung, triple-negative breast, and AML. This study will
 assess the efficacy and safety of the combination, comparing
 overall response rates and immune response markers achieved with
 the combination compared to prespecified rates based on those seen
 with pemrolizumab alone in comparable patient populations. The
 trial is anticipated to begin in the third quarter of 2018 (pending
 funding availability).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;Advaxis, Inc.&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On February&amp;#xA0;24, 2017, the Company and Advaxis, Inc.
 (&amp;#x201C;Advaxis&amp;#x201D;) entered into a research and development
 collaboration agreement, whereby both parties will collaborate in a
 research program to evaluate, through a &amp;#x201C;proof of
 principle&amp;#x201D; trial or trials (&amp;#x201C;PoP Clinical
 Trial&amp;#x201D;), a clinical candidate comprised of the combination of
 Advaxis&amp;#x2019; proprietary&lt;i&gt;&amp;#xA0;Lm-&lt;/i&gt;based antigen delivery
 technology and the Company&amp;#x2019;s patented WT1 targeted
 heteroclitic peptide antigen mixture (GPS). The term of the Advaxis
 agreement will expire upon the earlier of: (a)&amp;#xA0;completion of
 the PoP Clinical Trial, (b)&amp;#xA0;a decision by the parties to cease
 further development of the clinical candidate and (c)&amp;#xA0;early
 termination of the Advaxis agreement pursuant to the terms
 thereof.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The Advaxis agreement provides for cost-sharing between the
 parties, with Advaxis being responsible for the costs of performing
 the research activities and filing any investigational new drug
 application (&amp;#x201C;IND&amp;#x201D;), cost-sharing for preparation of
 the IND, and the Company being responsible for the costs (exclusive
 of product costs) of conducting the PoP trial. The Company also
 agreed to make certain&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-refundable&lt;/font&gt;&amp;#xA0;milestone
 payments to Advaxis having an aggregate amount of up to
 $108.0&amp;#xA0;million, upon meeting certain clinical, regulatory and
 commercial milestones. In addition, if net sales exceed certain
 targets, the Company agreed to make&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-refundable&lt;/font&gt;&amp;#xA0;sales
 milestone payments up to $250.0&amp;#xA0;million and royalty payments
 based on specific royalty rates, with a maximum rate capped at a
 percentage rate in the low double digits if net sales exceed
 $1.0&amp;#xA0;billion.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;Trojantec Ltd.&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On November&amp;#xA0;14, 2014, the Company entered into a license
 agreement with Trojantec Ltd., (&amp;#x201C;Trojantec&amp;#x201D;), a company
 incorporated in Cyprus, under which the Company was granted an
 exclusive license to develop and commercialize Trojantec&amp;#x2019;s
 TR1 Antenapedia/p21 protein treatment. In consideration for
 entering into the Trojantec License Agreement and for the rights,
 privileges and licenses granted, the Company incurred
 $0.3&amp;#xA0;million of license fees during the year ended
 December&amp;#xA0;31, 2014. Under the license agreement, the Company
 would be obligated to pay Trojantec royalties on net sales, if any,
 and milestone payments related to the achievement of certain
 clinical and regulatory goals.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On July&amp;#xA0;14, 2015, the Company and Trojantec entered into the
 First Amended and Restated Exclusive License Agreement. The
 amendment reinstated the obligations of the Company under the
 original license agreement and further obligated the Company to pay
 project management fees of up to $0.4&amp;#xA0;million.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On June&amp;#xA0;15, 2016, the Company entered into an agreement with
 Trojantec to terminate the license agreement. In consideration for
 the termination agreement, the Company incurred and paid in cash
 $0.1&amp;#xA0;million of termination fees. Such fees were included in
 research and development expenses for the year ended
 December&amp;#xA0;31, 2016.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;Clarendon Trading e Investimentos LDA&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On January&amp;#xA0;18, 2016, the Company entered into a license
 arrangement with Clarendon Trading e Investimentos LDA
 (&amp;#x201C;Clarendon&amp;#x201D;), a company incorporated in Portugal.
 Under the license agreement, the Company was granted an exclusive
 license to&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;know-how&lt;/font&gt;&amp;#xA0;to use for
 development and to manufacture products involving therapeutic use
 of Clarendon&amp;#x2019;s intellectual property. In consideration for
 this assignment, the Company incurred expenses of EUR
 0.5&amp;#xA0;million. Under the license agreement, in the event that
 the Company was successful in obtaining regulatory approval for any
 commercial exploitation of the therapeutic uses of Zolpidem, the
 Company would be obligated to pay Clarendon a yearly success fee
 and guaranteed minimum royalty payments.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 Effective September&amp;#xA0;30, 2016, the Company entered into
 termination agreement with Clarendon to terminate the license
 agreement. In consideration for the termination agreement and in
 complete satisfaction of the Company&amp;#x2019;s outstanding
 liabilities, the Company agreed to pay Clarendon $0.3&amp;#xA0;million
 in cash and issue Clarendon 7,700 shares. In extinguishment of the
 Company&amp;#x2019;s outstanding liabilities to Clarendon, the Company
 incurred an additional $0.2&amp;#xA0;million of expense to reflect the
 fair value of the shares issued to Clarendon.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The Company&amp;#x2019;s predecessor company, Galena entered into the
 following licensing and/or supply agreements, which the Company
 acquired through the Merger:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;The University of Texas M. D. Anderson Cancer Center and The
 Henry M. Jackson Foundation for the Advancement of Military
 Medicine, Inc.&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On September&amp;#xA0;11, 2006, the Company acquired rights and assumed
 obligations under a license agreement among Apthera and The
 University of Texas M. D. Anderson Cancer Center
 (&amp;#x201C;MDACC&amp;#x201D;) and The Henry M. Jackson Foundation for the
 Advancement of Military Medicine, Inc. (&amp;#x201C;HJF&amp;#x201D;) which
 grants exclusive worldwide rights to a United States patent
 covering the nelipepimut-S peptide and several United States and
 foreign patents and patent applications covering methods of using
 the peptide as a vaccine. Under the terms of this license, the
 Company is required to pay an annual maintenance fee
 of&amp;#xA0;$0.2&amp;#xA0;million, clinical milestone payments and royalty
 payments based on sales of NeuVax or other therapeutic products
 developed from the licensed technologies.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;Biovascular, Inc.&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On December&amp;#xA0;20, 2013, Mills and BioVascular, Inc.
 (&amp;#x201C;BioVascular&amp;#x201D;) entered into an exclusive license
 agreement. In 2014, through the Company&amp;#x2019;s acquisition of
 Mills, the Company&amp;#x2019;s wholly owned subsidiary, the Company
 acquired worldwide rights to to develop and commercialize
 anagrelide controlled release
 formulation,&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;GALE-401.&lt;/font&gt;&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;GALE-401&lt;/font&gt;&amp;#xA0;contains
 the active ingredient anagrelide, an&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;FDA-approved&lt;/font&gt;&amp;#xA0;product
 that has been in use since the late 1990s for the treatment of
 myleoproliferative neoplasms. Under the terms of the license
 agreement, Mills has agreed to pay BioVascular
 a&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;mid-to-low&lt;/font&gt;&lt;/font&gt;&amp;#xA0;single
 digit royalty on net revenue from the sale of licensed products,
 pay future cash milestone payments based on the achievement of
 specified regulatory milestones and is responsible for patent
 prosecution and maintenance.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On September&amp;#xA0;5, 2017, Mills and BioVascular entered into an
 amendment to license agreement to modify the certain terms of the
 license agreement, including but not limited to,
 (i)&amp;#xA0;eliminating the 3% royalty rate on annual net sales of
 $50.0&amp;#xA0;million and the 4% royalty now applies to annual net
 sales of up to $100.0&amp;#xA0;million, (ii)&amp;#xA0;making an advance
 payment of approximately $0.4&amp;#xA0;million for the milestone
 related to the initiation of the Phase 3 clinical trial payable in
 two tranches with the first payment of $0.2&amp;#xA0;million payable on
 or before October&amp;#xA0;31, 2017 and the second payment of
 approximately $0.2&amp;#xA0;million payable 30 days after the
 consummation of the Merger but no later than December&amp;#xA0;31,
 2017, (iii) adding a payment for a sublicense by Mills to a third
 party of 25% of any cash received for upfront fees or milestone
 payments if the sublicense is executed prior to first patient
 enrolled in the Phase 3 clinical trial and 17.5% of any cash
 received for upfront fees or milestone payments if the sublicense
 is executed after the first patient is enrolled in the Phase 3
 clinical trial, and (iv)&amp;#xA0;if the first patient is not enrolled
 in the Phase 3 clinical trial by December&amp;#xA0;31, 2018,
 BioVascular shall have the right to terminate the license agreement
 and the advance payment shall not be repaid to Mills. Under the
 terms of a September&amp;#xA0;5, 2017 consent between Comerica Bank,
 BioVascular and Mills, Comerica Bank shall receive
 $0.1&amp;#xA0;million of the approximately $0.4&amp;#xA0;million advance
 payment from Mills.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;Teva Pharmaceuticals&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 In conjunction with the Merger, acquisition of NeuVax, and
 effective December&amp;#xA0;3, 2012, the Company entered into a license
 and supply agreement with ABIC Marketing Limited
 (&amp;#x201C;ABIC&amp;#x201D;), a subsidiary of Teva Pharmaceuticals. Under
 the agreement, the Company granted ABIC exclusive rights to seek
 marketing approval in Israel for NeuVax for the treatment of breast
 cancer following its approval by the FDA or the EMA, and to market,
 sell and distribute NeuVax in Israel assuming such approval is
 obtained. ABIC&amp;#x2019;s rights also include a right of first refusal
 in Israel for all future indications for which NeuVax may be
 approved.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 Under the license and supply agreement, ABIC will assume
 responsibility for regulatory registration of NeuVax in Israel,
 provide financial support for local development, and commercialize
 the product in the region in exchange for making royalty payments
 to us based on future sales of NeuVax. ABIC also agrees in the
 license and supply agreement to purchase all supplies of NeuVax
 from the Company at a price determined according to a specified
 formula.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;Dr.&amp;#xA0;Reddy&amp;#x2019;s Laboratories Ltd.&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 In conjunction with the Merger, acquisition of NeuVax, and
 effective January&amp;#xA0;14, 2014, the Company entered into a
 strategic development and commercialization partnership with
 Dr.&amp;#xA0;Reddy&amp;#x2019;s Laboratories Ltd.
 (&amp;#x201C;Dr.&amp;#xA0;Reddy&amp;#x2019;s&amp;#x201D;), under which the Company
 licensed commercial rights in India to Dr.&amp;#xA0;Reddy&amp;#x2019;s for
 NeuVax in breast and gastric cancers. The Company has an agreement
 with Dr.&amp;#xA0;Reddy&amp;#x2019;s to conduct a Phase 2 investigational
 study in gastric cancer in India. To date, Dr.&amp;#xA0;Reddy&amp;#x2019;s
 has not initiated the Phase 2 study with NeuVax.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;Kwang Dong Pharmaceutical Co., Ltd.&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 In conjunction with the Merger, acquisition of NeuVax, and
 effective April&amp;#xA0;30, 2009, the Company entered into a license
 agreement with Kwang Dong Pharmaceutical Co, Ltd. (&amp;#x201C;Kwang
 Dong&amp;#x201D;). Under the agreement, the Company granted Kwang Dong
 exclusive rights to seek marketing approval in The Republic of
 Korea, or South Korea for NeuVax for the treatment of breast cancer
 following its approval by the FDA or the EMA, and to market, sell
 and distribute NeuVax in South Korea assuming such approval is
 obtained.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_156506F5-ABE0-4918-BDD9-B5BBCDF413A3_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;10. Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;i&gt;Legal Proceedings&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 From time to time, the Company is subject to various pending or
 threatened legal actions and proceedings, including those that
 arise in the ordinary course of its business, which may include
 employment matters, breach of contract disputes and stockholder
 litigation. Such actions and proceedings are subject to many
 uncertainties and to outcomes that are not predictable with
 assurance and that may not be known for extended periods of time.
 The Company records a liability in its consolidated financial
 statements for costs related to claims, including future legal
 costs, settlements and judgments, when the Company has assessed
 that a loss is probable and an amount can be reasonably estimated.
 If the reasonable estimate of a probable loss is a range, the
 Company records the most probable estimate of the loss or the
 minimum amount when no amount within the range is a better estimate
 than any other amount. The Company discloses a contingent liability
 even if the liability is not probable or the amount is not
 estimable, or both, if there is a reasonable possibility that a
 material loss may have been incurred. In the opinion of management,
 as of the date hereof, the amount of liability, if any, with
 respect to these matters, individually or in the aggregate, will
 not materially affect the Company&amp;#x2019;s consolidated results of
 operations, financial position or cash flows.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company&amp;#x2019;s predecessor company, Galena was involved in
 multiple legal proceedings and administrative actions, including
 stockholder class actions, both state and federal, some of which
 are ongoing and to which the Company is now subject as a result of
 the Merger. They are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 Settled Matters&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 On December&amp;#xA0;16, 2015, Galena received a subpoena issued by the
 U.S. Attorney&amp;#x2019;s Office for the District of New Jersey
 (&amp;#x201C;USAO NJ&amp;#x201D;), requesting the production of a broad range
 of documents pertaining to Galena&amp;#x2019;s marketing and promotional
 practices for Abstral. Through its communications with the USAO NJ
 and the U.S. Department of Justice (&amp;#x201C;DOJ&amp;#x201D;), Galena came
 to understand that the investigation being undertaken by the USAO
 NJ and DOJ was a criminal investigation in addition to a civil
 investigation that could ultimately involve Galena as well as one
 or more former employees. Pursuant to Galena&amp;#x2019;s charter,
 Galena was reimbursing certain former employees&amp;#x2019;
 attorney&amp;#x2019;s fees with respect to the investigation but stopped
 on May&amp;#xA0;1, 2017. Galena cooperated with the civil, and is
 continuing to cooperate with the criminal, investigations, and on
 September&amp;#xA0;8, 2017, DOJ announced a settlement agreement with
 Galena regarding the USAO NJ&amp;#x2019;s and DOJ&amp;#x2019;s investigation.
 The settlement agreement involves a &lt;font style="WHITE-SPACE: nowrap"&gt;non-criminal&lt;/font&gt; resolution and a civil
 payment in equal installments over twelve months of approximately
 $7.6&amp;#xA0;million, plus interest accrued since the date of reaching
 an agreement in principle, in return for a release of government
 claims in connection with the investigation. The $7.6&amp;#xA0;million
 civil payment is payable over four equal quarterly installments,
 with the first payment being made in the third quarter of 2017. As
 set forth in that settlement agreement, for a release of all claims
 against Galena and its officers and directors and dismissal with
 prejudice of the qui tam lawsuit described below, the relator
 received a portion of the civil payment to the federal government.
 On December&amp;#xA0;29, 2017, Galena made the remaining three payments
 to the federal government, which has advised us that all sums due
 and payable under the settlement agreement have been paid.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 In addition, there is a qui tam action pending in the U.S. District
 Court of the District of New Jersey related to the investigation by
 USAO NJ and DOJ. On September&amp;#xA0;18, 2017, Galena executed a
 settlement agreement with the attorneys for the relator in the qui
 tam action to settle the statutorily mandated attorney fees award
 by payment of $0.1 million in cash and $0.2 million in Galena
 common stock subject to court approval, which amounts were accrued
 during the second quarter 2017. Galena also obtained the consent of
 Private SELLAS under the terms of the Merger Agreement. However on
 November&amp;#xA0;7, 2017, attorneys for the qui tam relator agreed to
 have Galena pay the $0.2 million in cash. Galena also obtained the
 consent of Private SELLAS under the terms of the Merger Agreement.
 Galena paid the $0.3 million in cash for the statutorily mandated
 attorney fees award in the fourth quarter of 2017. As a result of
 receiving the portion of the civil settlement payment noted above
 and the settlement payment of the statutorily mandated attorney
 fees award, the relator will dismiss with prejudice the claims
 against Galena in the qui tam lawsuit.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 Open Matters&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 On October&amp;#xA0;13, 2016, Galena filed a complaint in the Circuit
 Court for the County of Multnomah for the State of Oregon against
 Aon Risk Insurance Services West, Inc. (Aon) where Galena is
 seeking attorney&amp;#x2019;s fees, costs and expenses incurred by
 Galena related to its coverage dispute with a certain insurer and
 for amounts Galena was required to contribute to the settlements of
 In re Galena Biopharma, Inc. Derivative Litigation and In re Galena
 Biopharma, Inc. Securities Litigation as a direct result of certain
 insurer&amp;#x2019;s failure to pay its full policy limits of liability
 and other relief. Galena and Aon are currently engaged in written
 discovery.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 On February&amp;#xA0;13, 2017, a putative stockholder securities class
 action complaint was filed in the U.S. District Court for the
 District of New Jersey captioned, Miller v. Galena Biopharma, Inc.,
 et al. On February&amp;#xA0;15, 2017, a putative stockholder securities
 class action complaint was filed in the U.S. District Court for the
 District of New Jersey entitled, Kattuah v. Galena Biopharma, Inc.,
 et al. The actions assert that the defendants failed to disclose
 that Galena&amp;#x2019;s promotional practices for Abstral&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt; (fentanyl
 sublingual tablets were allegedly improper and that Galena may be
 subject to civil and criminal liability, and that these alleged
 failures rendered Galena&amp;#x2019;s statements about its business
 misleading. Two groups of stockholders and one individual
 stockholder filed three motions to be appointed lead plaintiff on
 April&amp;#xA0;14, 2017 and April&amp;#xA0;17, 2017.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Subsequently, one of the stockholders groups withdrew its motion
 for lead plaintiff status and the individual stockholder notified
 the Court that he does not object to the appointment of the
 remaining stockholder group, GALE investor group, as lead
 plaintiff. On July&amp;#xA0;17, 2017, the Court approved the GALE
 investor group as named lead plaintiff and its counsel as lead and
 liaison counsel. The Court also consolidated both actions. An
 amended complaint was filed on October&amp;#xA0;6, 2017. On
 December&amp;#xA0;15, 2017, Galena and the former officers and
 employees filed a motion to dismiss the amended complaint. The
 plaintiffs have responded to a former officer&amp;#x2019;s motion to
 dismiss on February&amp;#xA0;13, 2018 and will respond to
 Galena&amp;#x2019;s and the other former officers&amp;#x2019; and
 employees&amp;#x2019; motion to dismiss on March&amp;#xA0;2, 2018. Galena
 and the former officers and employees are expected to file a reply
 in April of 2018. Thereafter, Galena will take the matter under
 advisement. It is not known when the Court will issue a ruling in
 this matter.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 On March&amp;#xA0;16, 2017, a complaint captioned Keller v. Ashton et
 al., CA No. &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;2:17-cv-01777&lt;/font&gt;&lt;/font&gt; was filed in the
 U.S. District Court for the District of New Jersey against
 Galena&amp;#x2019;s former directors and the Company, as a nominal
 defendant. The complaint purports to assert derivative claims for
 breach of fiduciary duty on Galena&amp;#x2019;s behalf against its
 former directors based on substantially similar facts as alleged in
 the putative stockholder securities class action complaints
 mentioned above. Galena&amp;#x2019;s response to the complaint was due
 on June&amp;#xA0;1, 2017; however, the Court on May&amp;#xA0;21, 2017,
 entered a stay of the proceedings pending resolution of motions to
 dismiss in the securities litigations described above.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Galena also received a stockholder demand dated April&amp;#xA0;14,
 2017, pursuant to 8 Del. C. Sec. 220, from a stockholder (Albert
 Zhang) demanding access to Galena&amp;#x2019;s books and records
 relating to its sales of Abstral and the U.S. Attorney&amp;#x2019;s
 investigation into Galena&amp;#x2019;s sale of Abstral in order for
 Mr.&amp;#xA0;Zhang to determine, among other things, whether to file a
 derivative lawsuit against Galena&amp;#x2019;s former management and
 directors. Galena has responded to the demand and Mr.&amp;#xA0;Zhang
 has indicated that he will file a derivative complaint soon.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 On April&amp;#xA0;27, 2017, a putative stockholder class action was
 filed in the Court of Chancery of the State of Delaware captioned
 Patel vs. Galena Biopharma, Inc. et. al, CA No. &lt;font style="WHITE-SPACE: nowrap"&gt;2017-0325-JTL&lt;/font&gt; seeking relief under
 Section&amp;#xA0;225 of the Delaware General Corporation Law (DGCL) and
 alleging breaches of fiduciary duties by Galena&amp;#x2019;s former
 board of directors and former interim chief executive officer
 regarding proposals to amend Galena&amp;#x2019;s certificate of
 incorporation to increase the amount of authorized shares of common
 stock and effectuate a reverse stock split at the July 2016 and
 October 2016 stockholder meetings, respectively. On June&amp;#xA0;2,
 2017, an amended verified complaint was filed along with a motion
 to expedite the proceedings. On June&amp;#xA0;5, 2017, Galena filed a
 verified petition under Section&amp;#xA0;205 of the DGCL and a motion
 to expedite the proceedings. On June&amp;#xA0;8, 2017, the Court denied
 a request by the plaintiff to schedule a preliminary injunction
 motion and ordered a prompt trial on both the plaintiff and
 Galena&amp;#x2019;s claims. On June&amp;#xA0;20, 2017, the Court
 consolidated the claims into In re Galena Biopharma, Inc., C. A.
 No. &lt;font style="WHITE-SPACE: nowrap"&gt;2017-0423-JTL.&lt;/font&gt; On
 July&amp;#xA0;10, 2017, the Court ordered that the trial of the claims
 be held on August&amp;#xA0;28, 30 and 31, 2017. On July&amp;#xA0;24, 2017,
 Galena entered into a binding settlement term sheet, which the
 Court enforced on November&amp;#xA0;30, 2017, over the objection of the
 plaintiff. On December&amp;#xA0;8, 2017, the Court set the hearing on
 the settlement for March&amp;#xA0;15, 2018. On December&amp;#xA0;11, 2017,
 the Court also granted an order validating the ratification votes
 at the special stockholder meeting held on July&amp;#xA0;6, 2017 and
 the certificate of amendments filed by Galena for the increase in
 authorized shares in 2011, 2013, 2015, and 2016 as well as for the
 reverse stock split in 2016. On February&amp;#xA0;22, 2018, the
 plaintiff filed his brief in support of the settlement as well as
 his request for attorneys&amp;#x2019; fees and an incentive award. On
 March&amp;#xA0;1, 2018, the former directors and former interim chief
 executive officer responded to plaintiff&amp;#x2019;s brief. On
 February&amp;#xA0;28, 2018, the former directors and former interim
 chief executive officer requested the Court continue the date of
 the hearing to approve the settlement as the Company was working
 with the staff of the SEC to obtain the &lt;font style="WHITE-SPACE: nowrap"&gt;no-action&lt;/font&gt; letter required by the
 binding settlement term sheet. The Plaintiff objected to such
 continuance. On March&amp;#xA0;15, 2018, the Court ruled in favor of
 the Company and continued the settlement hearing for 90 days.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Under the terms of the settlement, the class will receive a
 settlement payment of $1.3&amp;#xA0;million, in addition to attorney
 fees in an amount to be approved by the Court. The settlement
 payment of $1.3&amp;#xA0;million consists of $50,000 in cash to be paid
 by the Company or its insurers and $1,250,000 in unrestricted
 shares of the Company&amp;#x2019;s common stock (&amp;#x201C;Settlement
 Stock&amp;#x201D;), which valuation will be based on the volume-weighted
 average closing price for the 20 trading days immediately preceding
 the day before the transfer of the Settlement Stock to the
 settlement fund pursuant to the terms and conditions of the
 settlement. The Company anticipates that the Settlement Stock will
 be issued, pursuant to the terms of the Stipulation of Settlement,
 in a transaction that is exempt from the registration requirements
 of the Securities Act of 1933, as amended (the &amp;#x201C;Securities
 Act&amp;#x201D;), pursuant to Section&amp;#xA0;3(a)(10) of the Securities
 Act. Any amounts awarded by the Court for attorneys&amp;#x2019; fees
 will be paid in part by the settlement fund and in part by the
 Company&amp;#x2019;s insurance carriers. Upon the effectiveness of the
 proposed settlement, the individual defendants will be released
 from the claims that were asserted or could have been asserted in
 the class action by class members participating in the
 settlement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 On July&amp;#xA0;6, 2017, a complaint captioned Jacob v. Schwartz et
 al., Case No. C17-01222, was filed in the Superior Court of
 California, County of Contra Costa against Galena&amp;#x2019;s former
 directors and the Company, as a nominal defendant. The complaint
 purports to assert derivative claims for breach of fiduciary duty
 on Galena&amp;#x2019;s behalf against its former directors based on
 substantially similar facts as alleged in the derivative complaint
 mentioned above. Galena&amp;#x2019;s response to the complaint was due
 on July&amp;#xA0;7, 2017; however, the Court on September&amp;#xA0;5, 2017,
 entered a stay of the proceedings pending resolution of motions to
 dismiss in the securities litigations described above.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 On November&amp;#xA0;7, 2017, a written demand was made on Galena by a
 stockholder requesting that additional financial projections and
 valuation analyses be made in Galena&amp;#x2019;s Form &lt;font style="WHITE-SPACE: nowrap"&gt;S-4&lt;/font&gt; relating to the Merger, which was
 declared effective on November&amp;#xA0;6, 2017. The demand stated,
 among other thing, that, if such disclosures are not made within a
 reasonable period of time, the stockholder intends to file a
 securities class action lawsuit in federal court. Galena has
 resolved the matters raised in the demand letter through a nominal
 monetary payment and additional disclosures in the Form
 &lt;font style="WHITE-SPACE: nowrap"&gt;S-4.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 On January&amp;#xA0;23, 2018, a complaint captioned Johnson v Schwartz
 et al., CA No. &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;2:18-cv-00903&lt;/font&gt;&lt;/font&gt; was filed in the
 U.S. District Court for the District of New Jersey against
 Galena&amp;#x2019;s former directors, officers and employees and the
 Company as a nominal defendant. The complaint purports to assert
 derivative claims for breach of fiduciary duty on Galena&amp;#x2019;s
 behalf against its former directors, officers and employees based
 on substantially similar facts as alleged in the putative
 stockholder securities class action complaints and derivative
 complaints mentioned above, as well as making demand futility
 allegations against the current board of directors, who are not
 named as defendants. It is expected that the Company and the
 individual defendants will respond to the complaint through an
 appropriate pleading or motion and, if necessary, seek an order
 from the Court staying the proceedings pending further developments
 in the securities litigations described above.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 On or about April 9, 2018, JGB filed a lawsuit in the U.S. District
 Court for the Southern District of New York captioned &lt;i&gt;JGB
 (Cayman) Newton, Ltd. v. Sellas Life Sciences Group, Inc., et
 al.&lt;/i&gt;, Case 1:18-cv-3095 (DLC), or the JGB Action. The complaint
 in the JGB Action asserts claims under state law and federal
 securities law against us, our Chief Executive Officer, Angelos M.
 Stergiou, M.D., ScD H.C, and our Interim Chief Financial Officer,
 Aleksey N. Krylov (Mr. Krylov together with the Company and
 Dr.&amp;#xA0;Stergiou, the Defendants). The complaint in the JGB Action
 alleges, among other things, that we breached a contractual
 obligation to deliver certain shares of our common stock to JGB and
 that, in the course of negotiations related to the senior secured
 debenture agreement, the Defendants failed to disclose to JGB
 certain information regarding positive clinical trial results that
 was not then public. According to the complaint, JGB seeks to
 receive 2,483,500 shares of our common stock, damages, and costs
 and expenses incurred in the JGB action, among other things. We
 dispute the claims in the JGB Action and intend to defend against
 them vigorously.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Contingent Consideration related to Development, Regulatory and
 Commercial Milestone Payments and Business Combinations&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company acquires assets still in development and enters into
 research and development arrangements with third parties that often
 require milestone and royalty payments based on the progress of the
 asset through development stages. Milestone payments may be
 required, for example, upon approval of the product for marketing
 by a regulatory agency. In certain agreements, the Company is
 required to make royalty payments based upon a percentage of the
 sales. Because of the contingent nature of these payments, they are
 not included in the table of contractual obligations shown
 below.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 These arrangements may be material individually, and in the
 unlikely event that milestones for multiple products covered by
 these arrangements were reached in the same period, the aggregate
 charge to expense could be material to the results of operations.
 In addition, these arrangements often give the Company the
 discretion to unilaterally terminate development of the product,
 which would allow the Company to avoid making the contingent
 payments; however, the Company is unlikely to cease development if
 the compound successfully achieves clinical testing objectives. For
 additional information on the Company&amp;#x2019;s commitments under
 collaboration and license agreements read Note 6 to these
 consolidated financial statements. For additional information on
 the Company&amp;#x2019;s commitments of contingent consideration read
 Note 7 to these consolidated financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Commitments&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company rents office space under a &lt;font style="WHITE-SPACE: nowrap"&gt;non-cancelable&lt;/font&gt; operating lease. Rental
 expense amounted to $0.2&amp;#xA0;million for the years ended
 December&amp;#xA0;31, 2017 and 2016. The Company&amp;#x2019;s contractual
 obligations that may require future cash payments as of
 December&amp;#xA0;31, 2017 under the &lt;font style="WHITE-SPACE: nowrap"&gt;non-cancelable&lt;/font&gt; operating lease are as
 follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="88%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Operating&lt;br /&gt;
 Leases&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;223&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2019&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;76&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;299&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:CashAcquiredFromAcquisition contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_1_18" unitRef="iso4217_USD">1812000</us-gaap:CashAcquiredFromAcquisition>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_1_27" unitRef="iso4217_USD">-3643000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_C3AA077F-30F1-4145-890C-36624097ECC1_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Severance Costs&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company recognized and paid $1.9&amp;#xA0;million of exit costs
 during 2017 related to severance benefits for former Galena
 employees terminated immediately prior to the consummation of the
 Merger.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
  <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_E3D64427-1A16-404F-9FF3-EE7F3DD5B1A6_1_1" unitRef="iso4217_USD">76000</us-gaap:CurrentFederalTaxExpenseBenefit>
  <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_E3D64427-1A16-404F-9FF3-EE7F3DD5B1A6_1_3" unitRef="iso4217_USD">0</us-gaap:CurrentForeignTaxExpenseBenefit>
  <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_E3D64427-1A16-404F-9FF3-EE7F3DD5B1A6_1_4" unitRef="iso4217_USD">214000</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_E3D64427-1A16-404F-9FF3-EE7F3DD5B1A6_1_2" unitRef="iso4217_USD">138000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_E3D64427-1A16-404F-9FF3-EE7F3DD5B1A6_1_8" unitRef="iso4217_USD">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
  <us-gaap:ContractualObligationFiscalYearMaturityScheduleTableTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_BF3ADB37-F69F-4EB1-A79B-98078C70B40C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company&amp;#x2019;s contractual obligations that may require future
 cash payments as of December&amp;#xA0;31, 2017 under the &lt;font style="WHITE-SPACE: nowrap"&gt;non-cancelable&lt;/font&gt; operating lease are as
 follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="88%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Operating&lt;br /&gt;
 Leases&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;223&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2019&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;76&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;299&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_C91A2C78-0B97-47A5-BD75-FD7EC3655142_1_3">--12-31</dei:CurrentFiscalYearEndDate>
  <us-gaap:DebtDisclosureTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_6394B1CD-AEE0-475D-AF7A-AD3B11C24D55_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;b&gt;9. Debt&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 Debt and convertible debt consist of the following (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="81%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Year&amp;#xA0;Ended&amp;#xA0;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Debt&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Current portion of Senior Secured Debenture&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,377&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Non-current portion of Senior Secured Debenture&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,611&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total debt&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,988&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Convertible debt&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2015 Shareholder Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,709&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2015 Sely Note&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,659&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total convertible debt&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,368&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;Senior Secured Debenture&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On May&amp;#xA0;10, 2016, the Company&amp;#x2019;s predecessor company,
 Galena entered into a securities purchase agreement, with JGB
 pursuant to which Galena sold to JGB, at a 6.375% original issue
 discount, a $25.5&amp;#xA0;million senior secured debenture
 (the&amp;#xA0;&amp;#x201C;Senior Secured Debenture&amp;#x201D;) and warrants to
 purchase up to 3,333 shares of Galena&amp;#x2019;s common stock, $0.0001
 par value per share. Net proceeds to Galena from sale of the Senior
 Secured Debenture and warrants, after payment of commissions and
 legal fees, was approximately $23.4 million. The Senior Secured
 Debenture contained no conversion features to shares of common
 stock. The Senior Secured Debenture remains outstanding for the
 Company through the consummation of the Merger with Galena on
 December&amp;#xA0;29, 2017.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The Senior Secured Debenture matures on November&amp;#xA0;10, 2018, and
 accrues interest at&amp;#xA0;9%&amp;#xA0;per year, payable monthly. In
 addition, on the maturity date of the Senior Secured Debenture (or
 such earlier date that the principal amount of the Senior Secured
 Debenture is paid in full by acceleration or otherwise) a fixed
 amount, which shall be deemed interest under the Senior Secured
 Debenture, equal to&amp;#xA0;$0.8&amp;#xA0;million will be due and payable
 to JQB of the Senior Secured Debenture on such date in, at the
 option of the Company, cash and, subject to the same conditions for
 the payment of interest in shares of the Company&amp;#x2019;s common
 stock, or a combination of cash and the Company&amp;#x2019;s common
 stock&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The Company&amp;#x2019;s obligations under the Senior Secured Debenture
 are secured under the security purchase agreement by a senior lien
 on all of the Company&amp;#x2019;s assets, including all of the
 Company&amp;#x2019;s interests in its consolidated subsidiaries. Under
 the subsidiary guarantee agreement, each subsidiary guarantees the
 performance of the Company of the securities purchase agreement,
 Senior Secured Debenture and related agreements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The Senior Secured Debenture was amended in August 2016, May 2017,
 July 2017 and August 2017. After giving effect to the amendments,
 the Senior Secured Debenture contains the following modified and/or
 additional terms, among others:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;JGB can from time to time during the
 term of the Senior Secured Debenture require the Company to prepay
 in cash all or a portion of the outstanding principal plus accrued
 and unpaid interest (the &amp;#x201C;Outstanding Amount&amp;#x201D;) on
 written notice to the Company, provided, that such prepayment
 amount shall not exceed the lesser of $18.5&amp;#xA0;million and the
 outstanding principal amount. If JGB elects such prepayment of the
 Senior Secured Debenture, then the number of shares subject to the
 warrants issued to the holder will be reduced in proportion to the
 percentage of principal and accrued interest required to be prepaid
 by the Company. The Company does not have the right to prepay.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;JGB has the right, which commenced on
 November&amp;#xA0;10, 2016, to require the Company to redeem the
 outstanding principal amount, up to the outstanding principal
 amount of the Senior Secured Debenture by written notice to the
 Company and may deliver an unlimited number of redemption notices
 during any calendar month.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;The Company has the option to pay
 outstanding principal redemptions and monthly interest in shares of
 common stock, cash, or a combination of shares of common stock and
 cash. Among the various conditions that must be satisfied (or
 waived) in order for the Company to be able to elect to satisfy the
 redemption amounts in shares of common stock: (a)&amp;#xA0;the VWAP
 of&amp;#xA0;$10.50 per share on any trading day that a redemption
 notice is delivered (b)&amp;#xA0;no event of default has occurred and
 is continuing and (c)&amp;#xA0;the Company&amp;#x2019;s cash on hand exceeds
 the outstanding principal amount by at least $10.0&amp;#xA0;million. In
 the event that any of these conditions are not met, the Company
 does not have the option to pay outstanding principal redemptions
 and monthly interest in cash.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;The stock payment price to satisfy
 outstanding principal redemptions and monthly interest is the lower
 of (a)&amp;#xA0;80%&amp;#xA0;of the VWAP for the trading day immediately
 prior to the date of the applicable redemption notice
 (the&amp;#xA0;&amp;#x201C;Prior Day VWAP&amp;#x201D;) and (b)&amp;#xA0;80%&amp;#xA0;of
 the average of the three lowest VWAPs during
 the&amp;#xA0;20&amp;#xA0;consecutive trading day period immediately
 preceding the date of the applicable redemption notice (the
 &amp;#x201C;Twenty Day VWAP&amp;#x201D;); provided, however, to the extent
 that, on any given trading day, the price per share of common stock
 on such trading day equals or exceeds&amp;#xA0;115%&amp;#xA0;of the Prior
 Day VWAP or Twenty Day VWAP, then for the such trading day, and
 such trading day only, each reference to 80% shall be deemed, for
 such trading day only, to be 92.5%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;The Company was required to maintain
 a minimum of the lesser of $18.5&amp;#xA0;million or the outstanding
 principal amount of unencumbered cash in a restricted account. As
 of December&amp;#xA0;31, 2017, the Company maintained
 $10.2&amp;#xA0;million of cash and cash equivalents in a restricted
 account equal to the outstanding principal amount.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 As of December&amp;#xA0;31, 2017, the outstanding principal balance of
 the Senior Secured Debenture was $10.2&amp;#xA0;million. In addition to
 the outstanding principal balance, on the earlier of the maturity
 date or the date that the principal amount is paid in full, the
 Senior Secured Debenture has a $0.8 million additional interest
 amount that is included in the current portion of long-term debt as
 of December 31, 2017. Subsequent to December 31, 2017, the holder
 of the Senior Secured Debenture redeemed an additional
 $2.6&amp;#xA0;million of outstanding principal, which the Company
 satisfied with a combination of 623,749 shares of the
 Company&amp;#x2019;s common stock and redeemed $0.6&amp;#xA0;million of
 outstanding principal, which the Company satisfied with
 $0.6&amp;#xA0;million in cash. As of result of the redemptions, the
 Company was able to transfer $3.2 million out of restricted cash
 and cash equivalents and into unrestricted cash and cash
 equivalents to be used to fund the Company&amp;#x2019;s ongoing
 operations. The principal redemptions of $2.6 million subsequent to
 December 31, 2017 that were satisfied with shares of the
 Company&amp;#x2019;s common stock are classified as long-term debt, as
 of December 31, 2017, as the amounts were not satisfied with
 working capital.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;2015 Convertible Term Notes, as of December 31, 2017&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On April&amp;#xA0;2, 2015, the Company issued an aggregate of
 $1.5&amp;#xA0;million in principal amount of convertible term notes to
 certain stockholders of the Company (the &amp;#x201C;2015 Shareholder
 Notes&amp;#x201D;) and on May&amp;#xA0;7, 2015, the Company issued a
 convertible term note in the principal amount of $5.0&amp;#xA0;million
 to EQC Biotech Sely I Fund (&amp;#x201C;EQC Sely I Fund&amp;#x201D;), a
 related party of the Company (the&amp;#xA0;&amp;#x201C;2015 Sely Note&amp;#x201D;
 and, together with the 2015 Shareholder Notes, the &amp;#x201C;2015
 Notes&amp;#x201D;). The holders of the 2015 Shareholder Notes include
 two of the significant stockholders and founding investors of the
 Company, Drs. Angelos M. Stergiou (M.D., ScD h.c.), the
 Company&amp;#x2019;s CEO and Miltiadis Sougioultzoglou (M.D.). The 2015
 Notes were issued at par and bear an interest rate of 8%. The 2015
 Shareholder Notes matured on April&amp;#xA0;2, 2017 and the 2015 Sely
 Note originally matured on May&amp;#xA0;7, 2017.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 In August 2017, the Company and EQC Sely I Fund further amended the
 2015 Sely Note to agree the number of shares issuable upon
 consummation of the Merger. Accordingly, contingent upon and
 effective immediately prior to completion of the Merger, the
 Company will issue to EQC Sely I Fund 632,328 of its common
 shares&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;and&amp;#xA0;5-year&amp;#xA0;warrants&lt;/font&gt;&amp;#xA0;to
 purchase 316,163 of its common shares at a post-Merger price equal
 to 105% of the volume weighted average price of Galena common stock
 for the 30&amp;#xA0;calendar days following the closing date of the
 Merger (described above in Note 1), in full satisfaction of the
 2015 Sely Note.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On June&amp;#xA0;13, 2017, the Board of Directors approved a
 $7.3&amp;#xA0;million capital increase (the &amp;#x201C;Bridge
 Financing&amp;#x201D;), pursuant to which an aggregate of 1,865,261
 shares were issued at a price per share equal to approximately
 $3.91.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 As part of the Bridge Financing, an aggregate of $1.3&amp;#xA0;million
 (330,551 shares) was subscribed by certain stockholders who are
 also the holders of the 2015 Shareholder Notes. The cash proceeds
 were used to partially offset the principal ($1.2 million) and
 cumulative accrued interest ($0.1 million) due on the 2015
 Shareholder Notes. Following the Bridge Financing, the Company
 extinguished in cash its remaining obligations on the 2015
 Shareholder Notes, which included $0.3&amp;#xA0;million of principal
 and $0.2&amp;#xA0;million of cumulative accrued interest as of
 June&amp;#xA0;21, 2017.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On December&amp;#xA0;29, 2017, the Company issued 632,326 shares of
 common stock and warrants to purchase 316,163 of its common stock
 in full satisfaction of the 2015 Sely Note. The 2015 Sely Note
 conversion was considered to be an induced conversion and
 extinguishment and the Company realized a loss of $0.7&amp;#xA0;million
 during the year ended December&amp;#xA0;31, 2017. The Company
 considered the extinguishment to be a capital transaction and it
 was therefore recorded in the Company&amp;#x2019;s consolidated
 statements of stockholders&amp;#x2019; equity (deficit).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;2016 Convertible Term Note&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On June&amp;#xA0;30, 2016, the Company issued a $15.0&amp;#xA0;million
 convertible term note to EQC Sely I Fund (the &amp;#x201C;2016
 Note&amp;#x201D;). The 2016 Note was issued at par and had an interest
 rate of 8%. The 2016 Note was issued with similar terms to the 2015
 Notes (excluding the warrant coverage) whereby the 2016 Note is
 mandatorily convertible into equity upon the earlier to occur: a)
 the closing of a qualified IPO, b) a change in the Company&amp;#x2019;s
 domicile from Switzerland to Bermuda or c)
 the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt;&amp;#xA0;anniversary
 of the note.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On November&amp;#xA0;1, 2016, the Company redomiciled its operations
 from Switzerland to Bermuda and therefore, the 2016 Note, together
 with accrued interest, was converted into 236,705 shares of its
 common stock based upon a&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;pre-agreed&lt;/font&gt;&amp;#xA0;valuation,
 which represented fair value at the commitment date. Interest
 accrued on the 2016 Note up to the date of conversion was
 $0.4&amp;#xA0;million. No gain or loss was recognized upon the
 conversion.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;Long-term Debt&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On March&amp;#xA0;2, 2015, the Company entered into a loan agreement
 with a third party whereby the third party granted a $2.5 million
 loan to the Company (the &amp;#x201C;2015 Loan Agreement&amp;#x201D;). On
 December&amp;#xA0;24, 2015, the counterparty to the 2015 Loan Agreement
 reassigned all of its rights, interests and benefits under such
 agreement to Starcove Ltd., a company incorporated in Cyprus and a
 shareholder of the Company (&amp;#x201C;Starcove&amp;#x201D;). There were no
 further changes made to the 2015 Loan Agreement as a result of the
 reassignment. The term of the loan granted under the 2015 Loan
 Agreement was 24 months with an interest rate of 8%.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On April&amp;#xA0;6, 2016, the Company entered into a second loan
 agreement with Starcove (the &amp;#x201C;Framework Loan
 Agreement&amp;#x201D;), whereby Starcove extended a line of credit to
 the Company of $1.5 million with an interest rate of 6%. The term
 of the Framework Loan Agreement was three years. All principal and
 accrued interest would be payable in a single payment on
 April&amp;#xA0;6, 2019 unless earlier paid but no sooner than six
 months from the date of the Framework Loan Agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 As of December&amp;#xA0;31, 2016, the Company had made three
 withdrawals under the credit line: (1)&amp;#xA0;$0.6 million on
 April&amp;#xA0;12, 2016, (2)&amp;#xA0;$0.6&amp;#xA0;million on May&amp;#xA0;12,
 2016 and (3)&amp;#xA0;$0.3 million on June&amp;#xA0;2, 2016.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On November&amp;#xA0;1, 2016, an aggregate amount of $4.4 million,
 which represented the principal and accrued interest under the 2015
 Loan Agreement and the Framework Loan Agreement (together, the
 &amp;#x201C;Starcove Loans&amp;#x201D;), was extinguished upon the issuance
 of 67,140 shares of the Company&amp;#x2019;s common stock with an
 estimated fair value equal to the carrying value of the debt.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On November&amp;#xA0;25, 2013, the Company entered into a loan
 agreement with a shareholder, whereby the shareholder granted a EUR
 1.8&amp;#xA0;million loan to the Company (the &amp;#x201C;2013 Loan
 Agreement&amp;#x201D;). The term of the loan was open-ended and had an
 interest rate of 5%. On January&amp;#xA0;1, 2014, the principal amount
 of the 2013 Loan Agreement, together with accrued interest, was
 re-assigned on a 50:50 basis to the Company&amp;#x2019;s co-founders,
 Drs.&amp;#xA0;Angelos M. Stergiou (M.D., Sc.D. h.c.) and Miltiadis
 Sougioultzoglou (M.D.).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On December&amp;#xA0;31, 2015, the Company entered into an agreement
 with each of Drs. Stergiou and Sougioultzoglou, whereby the
 Company&amp;#x2019;s aggregate obligation of EUR 1.8&amp;#xA0;million,
 together with accrued interest equal to EUR 0.1&amp;#xA0;million as of
 such date, as well as an additional EUR 0.1&amp;#xA0;million of
 payables due to them from the Company, were offset by an aggregate
 amount of EUR 0.7&amp;#xA0;million representing receivables due to the
 Company from Drs. Stergiou and Sougioultzoglou pursuant to various
 other agreements that were entered into in 2012 and 2013. As a
 result, as of December&amp;#xA0;31, 2015, the amount of the
 Company&amp;#x2019;s outstanding loans to Drs. Stergiou and
 Sougioultzoglou were EUR 0.7&amp;#xA0;million and EUR 0.6&amp;#xA0;million,
 respectively (each, a &amp;#x201C;Founder Loan&amp;#x201D; and together, the
 &amp;#x201C;Founder Loans&amp;#x201D;). The interest rate on the Founder
 Loans was 2.5% and the term of the Founder Loans was three years.
 The original and modified loans were not considered substantially
 different as the difference between the present value of the
 remaining cash flows under the original and the modified terms was
 less than 10%. As such, extinguishment accounting did not
 apply.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On November&amp;#xA0;1, 2016, an aggregate amount of EUR
 0.7&amp;#xA0;million and EUR 0.6&amp;#xA0;million, which represented the
 principal and accrued interest under each respective Founder Loan,
 were converted into 11,571 and 10,383 shares, respectively. The
 number of shares issued was based on the fair value of the
 Company&amp;#x2019;s shares at the conversion date and therefore no gain
 or loss was recognized upon the cancellation of the loans.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_E3D64427-1A16-404F-9FF3-EE7F3DD5B1A6_1_6" unitRef="iso4217_USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_E3D64427-1A16-404F-9FF3-EE7F3DD5B1A6_1_9" unitRef="iso4217_USD">39000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_E3D64427-1A16-404F-9FF3-EE7F3DD5B1A6_1_7" unitRef="iso4217_USD">39000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="2" id="id_10184323_4057F5D7-0584-4138-8CED-8368A48EFB93_1_11" unitRef="iso4217_USD_per_shares">-10.44</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="3" id="id_10184323_7AD9BED1-97A1-4F8A-8327-635515D3BD72_1_8" unitRef="pure">0.011</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_B31AC5A3-51A3-4171-85D7-31FB24B7FC2B_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;b&gt;13. Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 Share and per share amounts below have been retroactively adjusted
 to reflect the exchange ratio and reverse stock split as described
 in Note 1.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;2017 Equity Incentive Plan&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On December&amp;#xA0;29, 2017. the 2017 Equity Incentive Plan was
 approved, and currently allows for the issuance of up to a maximum
 of approximately 575,000 shares of common stock in connection with
 the grant of stock-based awards, including stock options,
 restricted stock, restricted stock units, stock appreciation rights
 and other types of awards as deemed appropriate, not including
 shares subject to awards assumed in connection with certain
 transactions, including the Merger. As of December&amp;#xA0;31, 2017,
 an aggregate of approximately 575,000 shares of common stock were
 reserved for issuance under the Company&amp;#x2019;s 2017 Equity
 Incentive Plan. Upon the consummation of the Merger, the Company
 assumed approximately 10,171 shares subject to outstanding common
 stock options granted under the Company&amp;#x2019;s 2016 Incentive Plan
 that will remain exercisable for one year for former Company
 employees and directors. There are approximately 575,000 shares
 available for future grants based on adjustments in the 2017 Equity
 Incentive Plan. There were no common stock options granted under
 the 2017 Equity Incentive Plan for the years ended
 December&amp;#xA0;31, 2017.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The amount of shares reserved for issuance under the 2017 Equity
 Incentive Plan will automatically increase on January 1&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;st&lt;/sup&gt;&amp;#xA0;of each year,
 for a period of not more than ten years, commencing on January
 1&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;st&lt;/sup&gt;&amp;#xA0;of
 the year following the year in which the Effective Date occurs and
 ending on (and including) January&amp;#xA0;1, 2027, in an amount equal
 to 4% of the total number of shares of common stock outstanding on
 December 31&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;st&lt;/sup&gt;&amp;#xA0;of the
 preceding calendar year. Notwithstanding the foregoing, the board
 of directors may act prior to January 1&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;st&lt;/sup&gt;&amp;#xA0;of a given
 year to provide that there will be no January 1&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;st&lt;/sup&gt;&amp;#xA0;increase in
 the share reserve for such year or that the increase in the share
 reserve for such year will be a lesser number of shares of common
 stock than would otherwise occur pursuant to the preceding
 sentence.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On November&amp;#xA0;1, 2016, the Board of Directors approved the
 Company&amp;#x2019;s 2016 Incentive Plan under which 189,627 shares were
 reserved for issuance. The 2017 Equity Incentive Plan replaced the
 2016 Incentive Plan.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 In accordance with the 2016 Incentive Plan, the Company&amp;#x2019;s
 employees, directors and consultants are eligible
 to&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;receive&amp;#xA0;non-qualified&amp;#xA0;and&lt;/font&gt;&amp;#xA0;incentive
 stock options and RSUs. The stock options generally vest
 over&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;a&amp;#xA0;3-year&amp;#xA0;period&lt;/font&gt;&amp;#xA0;and
 expire 10 years from the date of the grant.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The following table summarizes the components of stock-based
 compensation expense in the consolidated statements of operations
 for the years ended December&amp;#xA0;31, 2017 and 2016, respectively
 (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="84%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;729&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;23&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,440&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;331&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total stock-based compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,169&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;354&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;Options to Purchase Shares of Common Stock&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 There were no stock options granted during the year ended
 December&amp;#xA0;31, 2017. The weighted-average grant date fair value
 of options granted during the year ended December&amp;#xA0;31, 2016 was
 $38.03. The Company uses the Black-Scholes option-pricing model and
 the following assumptions were used to determine the fair value of
 all its stock options granted in 2016:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="84%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;1.82-2.32%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;85-94%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected lives (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;5.13-10.00&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0%&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 As of December&amp;#xA0;31, 2017, there was no unrecognized
 compensation cost related to outstanding stock options.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The following table summarizes stock option activity of the
 Company:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Number of&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Shares&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(In&amp;#xA0;Thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Exercise&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Aggregate&lt;br /&gt;
 Intrinsic Value&lt;br /&gt;
 (In&amp;#xA0;Thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Balance as of January 1, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;55&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52.94&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at December 31, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;55&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52.94&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Assumed in connection with the Merger with Galena&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,240.55&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Canceled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(55&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52.94&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at December&amp;#xA0;31, 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,240.55&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Options exercisable at December&amp;#xA0;31, 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,240.55&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The aggregate intrinsic values of outstanding and exercisable stock
 options at December&amp;#xA0;31, 2017 were calculated based on the
 closing price of the Company&amp;#x2019;s common stock as reported on
 the Nasdaq Capital Market on December&amp;#xA0;31, 2017 of $7.86 per
 share. The aggregate intrinsic value equals the positive difference
 between the closing fair market value of the Company&amp;#x2019;s common
 stock and the exercise price of the underlying stock options.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;Restricted Stock Units with Time-Based Conditions&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On August&amp;#xA0;7, 2017, the Board of Directors accelerated the
 vesting of all outstanding restricted stock units (&amp;#x201C;
 RSUs&amp;#x201D;) with time-based conditions and all $1.2&amp;#xA0;million
 of unrecognized stock-based compensation was recognized upon
 acceleration.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The following table outlines RSU activity with only a time-based
 condition:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Number of&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Shares&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(In&amp;#xA0;Thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Grant&amp;#xA0;Date&amp;#xA0;Fair&lt;br /&gt;
 Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at January 1, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;46&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52.94&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at December 31, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;46&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52.94&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;58&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.91&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Vested&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(46&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52.94&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Canceled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(58&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.91&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at December&amp;#xA0;31, 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;RSUs with Time-Based and Performance-Based Conditions&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 In addition to the RSUs with time-based conditions, the Company
 granted RSUs subject to both time-based and performance-based
 vesting conditions to certain of its
 employees&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;and&amp;#xA0;non-employees&amp;#xA0;pursuant&lt;/font&gt;&amp;#xA0;to
 the 2016 Incentive Plan. These RSUs vest based on both
 (i)&amp;#xA0;continued service either over a three-year measurement
 period or at the end of the required service period and
 (ii)&amp;#xA0;the achievement of a liquidity event. The vesting dates
 for these RSUs are January&amp;#xA0;1, 2018, January&amp;#xA0;1, 2019,
 January&amp;#xA0;1, 2020 or February&amp;#xA0;27, 2018. The liquidity
 event, as defined in the relevant RSU grant agreements, will be
 satisfied upon the earlier of either: a) change of control or b) a
 qualified initial public offering.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Number of&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Shares&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(In&amp;#xA0;Thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Grant&amp;#xA0;Date&amp;#xA0;Fair&lt;br /&gt;
 Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at January 1, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52.94&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at December 31, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52.94&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Vested&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;NA&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Canceled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52.94&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at December&amp;#xA0;31, 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52.94&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The Company recognizes compensation expense related to these RSUs
 when the liquidity event is deemed probable. As such, no
 compensation expense was recorded during the years ended
 December&amp;#xA0;31, 2017 and 2016, as the liquidity event is outside
 the Company&amp;#x2019;s control and not deemed probable until it
 occurs.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;2017 Employee Stock Purchase Plan&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The Company also has an employee stock purchase plan
 (&amp;#x201C;ESPP&amp;#x201D;) which allows employees to contribute up
 to&amp;#xA0;15%&amp;#xA0;of their cash earnings, subject to certain
 maximums, to be used to purchase shares of the Company&amp;#x2019;s
 common stock on each semi-annual purchase date. On each offering
 date, each eligible employee, pursuant to an offering made under
 the ESPP, will be granted a right to purchase up to that number of
 shares of Common Stock purchasable either with a percentage or with
 a maximum dollar amount, as designated by the Board, but in either
 case not exceeding fifteen percent (15%) of such employee&amp;#x2019;s
 earnings (as defined by the Board in each offering) during the
 period that begins on the offering date (or such later date as the
 Board determines for a particular offering) and ends on the date
 stated in the offering, which date will be no later than the end of
 the Offering. As of December&amp;#xA0;31, 2017, the board of directors
 has not established the various parameters under the ESPP and no
 shares have been delivered under the ESPP. There are approximately
 57,000 shares of common stock reserved for issuance under the ESPP
 , plus the number of shares of common stock that are automatically
 added on January 1&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;st&lt;/sup&gt;&amp;#xA0;of each year
 for a period of up to ten years, commencing on the first January
 1&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;st&lt;/sup&gt;&amp;#xA0;following the
 effective date and ending on (and including) January&amp;#xA0;1, 2027,
 in an amount equal to the lesser of (i) 1% of the total number of
 shares of common stock outstanding on December 31&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;st&lt;/sup&gt;&amp;#xA0;of the
 preceding calendar year, and (ii)&amp;#xA0;102,279 shares of Common
 Stock.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_F0B6D6C0-B9E1-472A-9203-93F8C51981B8_1_4">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_F0B6D6C0-B9E1-472A-9203-93F8C51981B8_1_3">2017</dei:DocumentFiscalYearFocus>
  <dei:DocumentType contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_F0B6D6C0-B9E1-472A-9203-93F8C51981B8_1_0">10-K</dei:DocumentType>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_B3DB0183-767C-444B-A4D4-34530217457E_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Net Loss Per Share&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Basic loss per share is computed by dividing net loss applicable to
 common stockholders by the weighted average number of shares of
 common stock outstanding during each period. Diluted loss per share
 includes the effect, if any, from the potential exercise or
 conversion of securities, such as convertible debt, warrants, stock
 options and unvested restricted stock that would result in the
 issuance of incremental shares of common stock. In computing the
 basic and diluted net loss per share, the weighted average number
 of shares remains the same for both calculations due to the fact
 that when a net loss exists, dilutive shares are not included in
 the calculation as the impact is anti-dilutive.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The following potentially dilutive securities outstanding have been
 excluded from the computation of diluted weighted average shares
 outstanding, as they would be anti-dilutive:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="78%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"&gt;
 &lt;b&gt;Year&amp;#xA0;ended&amp;#xA0;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Common stock warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;963&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Stock options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;55&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Unvested restricted stock awards&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;67&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;986&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;122&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Amounts in the table reflect the common stock equivalents of the
 noted instruments.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="INF" id="id_10184323_7AD9BED1-97A1-4F8A-8327-635515D3BD72_1_0" unitRef="pure">0.340</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="3" id="id_10184323_7AD9BED1-97A1-4F8A-8327-635515D3BD72_1_6" unitRef="pure">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <dei:DocumentPeriodEndDate contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_F0B6D6C0-B9E1-472A-9203-93F8C51981B8_1_2">2017-12-31</dei:DocumentPeriodEndDate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="3" id="id_10184323_7AD9BED1-97A1-4F8A-8327-635515D3BD72_1_1" unitRef="pure">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <dei:EntityRegistrantName contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_C91A2C78-0B97-47A5-BD75-FD7EC3655142_1_1">SELLAS LIFE SCIENCES GROUP, INC.</dei:EntityRegistrantName>
  <dei:EntityVoluntaryFilers contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_C91A2C78-0B97-47A5-BD75-FD7EC3655142_1_6">No</dei:EntityVoluntaryFilers>
  <dei:EntityCentralIndexKey contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_C91A2C78-0B97-47A5-BD75-FD7EC3655142_1_2">0001390478</dei:EntityCentralIndexKey>
  <dei:EntityWellKnownSeasonedIssuer contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_C91A2C78-0B97-47A5-BD75-FD7EC3655142_1_4">No</dei:EntityWellKnownSeasonedIssuer>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_0AA6A487-967F-4041-9A43-CC0A7BC9FFFC_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The carrying amounts of the Company&amp;#x2019;s financial instruments,
 including cash equivalents, accounts payable, and accrued expenses
 approximate fair value due to the short-term nature of those
 instruments. The carrying amounts of the Company&amp;#x2019;s
 outstanding convertible notes approximate fair value due to the
 debt carrying a variable interest rate that is tied to the current
 London Interbank Offer Rate (&amp;#x201C;LIBOR&amp;#x201D;) rate. The fair
 value of the convertible notes is determined using a binomial
 lattice model that utilizes certain unobservable inputs that fall
 within Level&amp;#xA0;3 of the fair value hierarchy. The fair value of
 the warrants is determine using a Black-Scholes pricing model.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="3" id="id_10184323_7AD9BED1-97A1-4F8A-8327-635515D3BD72_1_4" unitRef="pure">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="3" id="id_10184323_7AD9BED1-97A1-4F8A-8327-635515D3BD72_1_2" unitRef="pure">0.344</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="3" id="id_10184323_7AD9BED1-97A1-4F8A-8327-635515D3BD72_1_5" unitRef="pure">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="3" id="id_10184323_7AD9BED1-97A1-4F8A-8327-635515D3BD72_1_7" unitRef="pure">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
  <dei:EntityCurrentReportingStatus contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_C91A2C78-0B97-47A5-BD75-FD7EC3655142_1_5">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_C91A2C78-0B97-47A5-BD75-FD7EC3655142_1_7">Smaller Reporting Company</dei:EntityFilerCategory>
  <us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_0271CF0F-4A1A-4F0C-85C3-AADE7F5F3EE6_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;b&gt;7. Fair Value Measurements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The following tables present information about the Company&amp;#x2019;s
 assets and liabilities measured at fair value on a recurring basis
 in the consolidated balance sheets (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="55%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WIDTH: 39.5pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt; DISPLAY: inline"&gt;
 &lt;b&gt;Description&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;December&amp;#xA0;31,&lt;br /&gt;
 2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Quoted&amp;#xA0;Prices&amp;#xA0;In&lt;br /&gt;
 Active Markets&lt;br /&gt;
 (Level 1)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Significant&amp;#xA0;Other&lt;br /&gt;
 Observable&lt;br /&gt;
 Inputs (Level 2)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Unobservable&lt;br /&gt;
 Inputs&lt;br /&gt;
 (Level 3)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,662&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,662&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Restricted cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,245&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,245&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total assets measured and recorded at fair value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,907&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,907&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Liabilities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Warrants potentially settleable in cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,309&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,309&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Contingent consideration&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,294&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,294&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total liabilities measured and recorded at fair value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,603&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,603&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The Company did not transfer any financial instruments into or out
 of Level&amp;#xA0;3 classification during the year ended
 December&amp;#xA0;31, 2017. The contingent consideration was assumed by
 the Company in connection with the Merger and recorded at fair
 value as of the consummation of the Merger, which approximates fair
 value as of December&amp;#xA0;31, 2017. The fair value of the
 contingent consideration is measured at the end of each reporting
 period using Level 3 inputs in a probability-weighted, discounted
 cash-outflow model. The contingent consideration relates to
 Galena&amp;#x2019;s acquisition of Apthera, Inc. in 2011 and the future
 contingent payments of up to $32 million based on the achievement
 of certain development and commercial milestones relating to the
 Company&amp;#x2019;s NeuVaxTM product candidate. The contingent
 consideration is payable at the election of the Company in either
 cash or shares of common stock, provided that the Company may not
 issue any shares in satisfaction of any contingent consideration
 unless it has first obtained approval of its stockholders in
 accordance with Rule 5635(a) of the Nasdaq Marketplace Rules. The
 significant unobservable assumptions include the probability of
 achieving each milestone, the date we expect to reach the
 milestone, and a determination of present value factors used to
 discount future expected cash outflows.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 At December&amp;#xA0;31, 2016, the estimated fair value of the 2015
 Notes was $7.3&amp;#xA0;million, which compared to a carrying value of
 $7.4&amp;#xA0;million. See also Note 9.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 See Note 12 for discussion of the Level&amp;#xA0;3 liabilities relating
 to warrants accounted for as liabilities.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
  <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_7B988DAC-005E-431B-BBDF-8F23C838D7AB_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;5. Goodwill and Intangible Assets&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company completes its annual impairment test on October&amp;#xA0;1
 each year, or more frequently if triggering events indicate a
 possible impairment. The Company continually evaluates financial
 performance, economic conditions and other relevant developments in
 assessing if an interim period impairment test is necessary.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Changes in the carrying amount of goodwill for the period ended
 December&amp;#xA0;31, 2017 consisted of the following (in
 thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="68%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="89%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Balance as of January 1, 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Goodwill as a result of the Merger&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,914&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Balance as of December&amp;#xA0;31, 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,914&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Intangible assets consist of IPR&amp;amp;D acquired as part of the
 Merger. IPR&amp;amp;D assets represent research and development assets
 that have not yet reached commercialization. At December&amp;#xA0;31,
 2017, the significant components of the Company&amp;#x2019;s IPR&amp;amp;D
 assets consist of the NeuVax program for the prevention of
 recurrence in breast cancer, the &lt;font style="white-space:nowrap"&gt;GALE-401&lt;/font&gt; program for treatment of
 essential thrombocythemia, and the &lt;font style="white-space:nowrap"&gt;GALE-301&lt;/font&gt; &amp;amp; &lt;font style="white-space:nowrap"&gt;GALE-302&lt;/font&gt; programs for prevention of
 cancer recurrent in ovarian and endometrial cancer patients in the
 adjuvant setting.&lt;/p&gt;
 &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company&amp;#x2019;s allocation of purchase price to acquired
 IPR&amp;amp;D was $17.6&amp;#xA0;million. The estimated fair value of the
 &lt;font style="white-space:nowrap"&gt;GALE-401&lt;/font&gt; and NeuVax
 IPR&amp;amp;D assets were determined using a &amp;#x201C;income
 approach,&amp;#x201D; which is a valuation technique that provides an
 estimate of the fair value of an asset based on market participant
 expectations of the cash flows an asset would generate over its
 remaining useful life. The fair values of the &lt;font style="white-space:nowrap"&gt;GALE-401&lt;/font&gt; and NeuVax programs were
 $9.1&amp;#xA0;million and $5.7&amp;#xA0;million, respectively. Some of the
 more significant assumptions inherent in the development of those
 asset valuations include the estimated net cash flows for each year
 for the asset or product (including net revenues, cost of sales,
 research and development costs, selling and marketing costs and
 working capital/asset contributory asset charges), the appropriate
 discount rate to select in stream, the assessment of the
 asset&amp;#x2019;s life cycle, the potential regulatory and commercial
 success risks, competitive trends impacting the asset cash flow
 stream as well as other factors. The fair value of the &lt;font style="white-space:nowrap"&gt;GALE-301&lt;/font&gt; &amp;amp; &lt;font style="white-space:nowrap"&gt;GALE-302&lt;/font&gt; programs was $2.8&amp;#xA0;million
 as determined using the replacement cost approach given the Phase
 1/2a development status of the programs and the lack of projected
 financial information.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 IPR&amp;amp;D assets are required to be classified as indefinite-lived
 assets until the successful commercialization of the asset or the
 abandonment of the associated R&amp;amp;D effort. These assets are
 assessed for impairment annually on October&amp;#xA0;1 or more
 frequently if impairment indicators exist. Accordingly, during the
 development period after the date of acquisition, these assets will
 not be amortized until commercialization is reached. For those
 programs that reach commercialization, the Company will determine
 the useful life of the asset, reclassify the asset out of IPR&amp;amp;D
 and begin amortization. If the associated R&amp;amp;D effort is
 abandoned, the related IPR&amp;amp;D assets will likely be &lt;font style="white-space:nowrap"&gt;written-off,&lt;/font&gt; and the Company will
 record a &lt;font style="white-space:nowrap"&gt;non-cash&lt;/font&gt;
 impairment loss.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
  <us-gaap:GoodwillAcquiredDuringPeriod contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_C15D4C36-AB8F-47AA-A0B8-C32B9D383FAE_1_1" unitRef="iso4217_USD">1914000</us-gaap:GoodwillAcquiredDuringPeriod>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_D7BD0BE0-D0A7-43F4-81C4-877F346A4120_1_0" unitRef="iso4217_USD">265000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_D7BD0BE0-D0A7-43F4-81C4-877F346A4120_1_2" unitRef="iso4217_USD">-23501000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_D7BD0BE0-D0A7-43F4-81C4-877F346A4120_1_1" unitRef="iso4217_USD">-23766000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_04AFF518-0F3C-47F0-B10A-7952A4C14536_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;b&gt;14. Income Taxes&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The loss before income taxes is as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="78%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;As of December 31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 U.S.&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;265&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;108&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Non - U.S.&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(23,766&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(17,788&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(23,501&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(17,680&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The components of federal and state income tax expense are as
 follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="86%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;As&amp;#xA0;of&amp;#xA0;December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Current&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Federal&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;76&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 State&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;138&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;42&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Foreign&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total current&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;214&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;42&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Federal&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 State&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;39&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(41&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Foreign&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total deferred&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;39&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(41&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total income tax expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;253&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The components of net deferred tax assets are as follows (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="80%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;As of December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net operating loss carryforwards&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,028&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,145&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Tax credit carryforwards&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;345&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;295&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Stock based compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,550&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Licensing deduction deferral&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,105&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;395&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;81&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Gross deferred tax assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,423&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,549&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4,658&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,508&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net deferred tax asset&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,765&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;41&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The components of net deferred tax liabilities are as follows (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="84%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;As&amp;#xA0;of&amp;#xA0;December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;font style="WHITE-SPACE: nowrap"&gt;In-process&lt;/font&gt;&amp;#xA0;research
 and development not subject to future amortization for tax
 purposes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,438&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Gross deferred tax liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,438&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The provision for income taxes differs from the provision computed
 by applying the federal statutory rate to net loss before income
 taxes as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="84%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;As&amp;#xA0;of&amp;#xA0;December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 U.S. federal statutory income tax rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(34.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(34.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 State and local taxes, net of federal benefit&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Foreign rate differential&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Permanent differences&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Tax rate change and true-up&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Tax credits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Effective income tax rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 At December 31, 2017, the Company had domestic federal and state
 net operating loss carryforwards of approximately $3.7 million and
 $3.7 million, respectively, available to reduce future taxable
 income, which expire at various dates beginning in 2027. The
 Company also had federal research and development tax credit
 carryforwards of approximately $0.4 million, respectively,
 available to reduce future tax liabilities and which expire at
 various dates beginning in 2027. The income tax expense for the
 year ended December 31, 2016 relates to both the indefinite lived
 deferred tax liabilities and the December 22, 2017 enactment of the
 Tax Cuts and Jobs Act.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 Under the provisions of the Internal Revenue Code, the net
 operating losses (&amp;#x201C;NOL&amp;#x201D;) and tax credit carryforwards
 are subject to review and possible adjustment by the Internal
 Revenue Service and state tax authorities. NOL and tax credit
 carryforwards may become subject to an annual limitation in the
 event of certain cumulative changes in the ownership interest of
 significant shareholders over a three-year period in excess of 50%,
 as defined under Sections&amp;#xA0;382 and 383 of the Internal Revenue
 Code of 1986, respectively, as well as similar state tax
 provisions. This could limit the amount of tax attributes that the
 Company can utilize annually to offset future taxable income or tax
 liabilities. The amount of the annual limitation, if any, will be
 determined based on the value of the Company immediately prior to
 the ownership change. Subsequent ownership changes may further
 affect the limitation in future years. The Company has completed
 several financings since its inception, which may have resulted in
 a change in control as defined by Sections 382 and 383 of the
 Internal Revenue Code or could result in a change in control in the
 future. Utilization of the net operating loss and tax credits
 carryforwards may be limited by &amp;#x201C;ownership change&amp;#x201D;
 rules, as defined in Section 382 of the Internal Revenue Code of
 1986, as amended, and similar state provisions. This annual
 limitation may result in the expiration of the net operating losses
 and credits before utilization.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 In assessing the need for a valuation allowance the Company may
 utilize indefinite-lived deferred tax liabilities from an
 indefinite-lived intangible asset as a future source of
 income.&amp;#xA0;The Company&amp;#x2019;s IPR&amp;amp;D, as recorded in
 acquisition accounting, can be utilized as a source of income
 arising from the future reversal of temporary difference that can
 be offset against post 2017 indefinite-lived NOLs.&amp;#xA0;Therefore,
 the Company is permitted to offset the indefinite-lived DTL up to
 the 80 percent limitation for NOL&amp;#x2019;s generated subsequent to
 January 1, 2018.&amp;#xA0;As such, an indefinite-lived NOL was recorded
 in acquisition accounting as a reduction to the valuation allowance
 related to deferred tax assets in the amount of $1.8 million. The
 valuation allowance increased by $1.2 million and $1.8 million for
 the years ended December 31, 2017 and 2016, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The Company files income tax returns in the United States and
 various state jurisdictions. The Company is subject to tax
 examinations for the 2012 tax year and beyond. The Company does not
 recognize tax benefits that are not more-likely-than-not to be
 supported based upon the technical merits of the tax position
 taken. In assessing its unrecognized tax benefits, the Company has
 analyzed its tax return filing positions in all of the federal,
 state and foreign filing jurisdictions where it is required to file
 income tax returns, as well as all open years in those
 jurisdictions.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The following table indicates the changes to the Company&amp;#x2019;s
 unrecognized tax benefits (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="85%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;As&amp;#xA0;of&amp;#xA0;December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Beginning of the Year - unrecognized tax benefits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;br /&gt;
 &amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&amp;#x2014;&lt;br /&gt;
 &amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;br /&gt;
 &amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Increases/ (Decrease) - prior year tax positions&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;44&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Increases - current year tax positions&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 End of the Year - unrecognized tax benefits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;72&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The unrecognized tax benefits, if recognized and in absence of full
 valuation allowance, would impact the income tax provision by
 $28,000 and $44,000 as of December 31, 2017 and 2016, respectively.
 As of December 31, 2017, the Company does not believe that it is
 reasonably possible that its unrecognized tax benefits would
 significantly change in the following 12 months.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 In assessing the realizability of deferred tax assets, management
 considers whether it is more-likely-than-not that some portion or
 all of the deferred tax assets will not be realized in the near
 term. The ultimate realization of deferred tax assets is dependent
 upon the generation of future taxable income during the periods in
 which those temporary differences become deductible.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On December 22, 2017, the Tax Cuts and Jobs Act (the &amp;#x201C;2017
 Tax Act&amp;#x201D;) was enacted. The 2017 Tax Act includes a number of
 changes to existing United States tax laws that impact the company,
 most notably a reduction of the United States corporate income tax
 rate from 34% to 21% for tax years beginning after December 31,
 2017. The 2017 Tax Act also provides for a one-time transition tax
 on certain foreign earnings and the acceleration of depreciation
 for certain assets placed into service after September 27, 2017 as
 well as prospective changes beginning in 2018, including repeal of
 the domestic manufacturing deduction, acceleration of tax revenue
 recognition, capitalization of research and development
 expenditures, additional limitations on executive compensation and
 limitations on the deductibility of interest.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_6AA5D776-475F-4795-A978-38ED2D9632A1_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;Income Taxes&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The Company uses the asset and liability method of accounting for
 income taxes. Deferred tax assets and liabilities are recognized
 for the estimated future tax consequences attributable to
 differences between the financial statement carrying amounts of
 existing assets and liabilities and their respective tax bases and
 operating loss and credit carryforwards. Deferred tax assets and
 liabilities are measured using enacted tax rates expected to apply
 to taxable income in the years in which those temporary differences
 are expected to be recovered or settled. A valuation allowance is
 provided when it is more likely than not that some portion or all
 of a deferred tax asset will not be realized. The Company
 recognizes the benefit of an uncertain tax position that it has
 taken or expects to take on its income tax return it files, if such
 a position is more likely than not to be sustained.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The Company recognizes liabilities or assets for the deferred tax
 consequences of temporary differences between the tax basis of
 assets or liabilities and their reported amounts in the financial
 statements in accordance with FASB&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASC&amp;#xA0;740-10,&lt;/font&gt;&amp;#xA0;&amp;#x201C;&lt;i&gt;Accounting
 for Income Taxes&amp;#x201D; (&amp;#x201C;ASC&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;740-10&amp;#x201D;).&lt;/font&gt;&lt;/i&gt;These temporary
 differences will result in taxable or deductible amounts in future
 years when the reported amounts of the assets or liabilities are
 recovered or
 settled.&amp;#xA0;&lt;i&gt;ASC&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;740-10&lt;/font&gt;&lt;/i&gt;&amp;#xA0;requires
 that a valuation allowance be established when management
 determines that it is more likely than not that all or a portion of
 a deferred asset will not be realized. The Company evaluates the
 realizability of its net deferred income tax assets and valuation
 allowances as necessary, at least on an annual basis. During this
 evaluation, the Company reviews its forecasts of income in
 conjunction with other positive and negative evidence surrounding
 the realizability of its deferred income tax assets to determine if
 a valuation allowance is required. Adjustments to the valuation
 allowance will increase or decrease the Company&amp;#x2019;s income tax
 provision or benefit. The recognition and measurement of benefits
 related to the company&amp;#x2019;s tax positions requires significant
 judgment, as uncertainties often exist with respect to new laws,
 new interpretations of existing laws, and rulings by taxing
 authorities. Differences between actual results and the
 Company&amp;#x2019;s assumptions or changes in the Company&amp;#x2019;s
 assumptions in future periods are recorded in the period they
 become known.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On December&amp;#xA0;22, 2017 the President of the United States signed
 into law the Tax Cuts and Jobs Act (&amp;#x201C;The 2017 Tax
 Act&amp;#x201D;).&amp;#xA0;This legislation makes significant changes in the
 United States tax laws including, but not limited to, reducing the
 corporate tax rate to 21% starting in 2018. The 2017 Tax Act
 required the Company to revalue its deferred tax assets and
 liabilities to the new rate of 21%.&amp;#xA0;For the years ended
 December&amp;#xA0;31, 2017 and 2016, the Company recognized income tax
 expense of $253,000 and $1,000, respectively. Staff Accounting
 Bulletin No. 118 (&amp;#x201C;SAB 118&amp;#x201D;) was issued to address the
 application of U.S. GAAP in situations when a registrant does not
 have the necessary information available, prepared, or analyzed
 (including computations) in reasonable detail to complete the
 accounting for certain income tax effects of the Tax Act. In
 accordance with SAB 118, we determined that the adjustment to
 deferred taxes was a provisional amount and a reasonable estimate
 at December 31, 2017. We do not expect any impact on recorded
 deferred tax balances as the remeasurement of net deferred tax
 assets will be offset by a change in valuation allowance. We are
 analyzing certain aspects of the Tax Act which could potentially
 affect the remeasurement of the net deferred tax assets.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_1_15" unitRef="iso4217_USD">-2374000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_4057F5D7-0584-4138-8CED-8368A48EFB93_1_7" unitRef="iso4217_USD">253000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_1_14" unitRef="iso4217_USD">8366000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_1_13" unitRef="iso4217_USD">-73000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:InterestIncomeExpenseNet contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_4057F5D7-0584-4138-8CED-8368A48EFB93_1_5" unitRef="iso4217_USD">-462000</us-gaap:InterestIncomeExpenseNet>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_1_9" unitRef="iso4217_USD">941000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <us-gaap:LeaseAndRentalExpense contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-5" id="id_10184323_7B554A29-1BC5-4FC7-BF72-947781049FD1_1_0" unitRef="iso4217_USD">200000</us-gaap:LeaseAndRentalExpense>
  <us-gaap:LegalCostsPolicyTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_6FBD1592-2E9C-42BF-B8EF-73A4D7171315_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Legal Fees and Insurance Recoveries&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 There can be a significant time lag between the time that legal
 fees are incurred and the insurance reimbursement available to
 offset the related costs. The legal fees are recorded in the period
 they are incurred, and the insurance recoveries for those costs are
 recorded in the period when the insurance reimbursement is deemed
 probable.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:LegalCostsPolicyTextBlock>
  <us-gaap:LiquidationBasisOfAccountingTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_FDCA209E-F4D8-4370-BB61-110ABAD12721_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;b&gt;2. Liquidity&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The Company has not generated any revenues from product sales and
 has funded operations primarily from the proceeds of private
 placements of its equity interests (prior to the Merger) and
 convertible notes, as well as through the Merger. Substantial
 additional financing will be required by the Company to continue to
 fund its research and development activities. No assurance can be
 given that any such financing will be available when needed or that
 the Company&amp;#x2019;s research and development efforts will be
 successful.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The Company regularly explores alternative means of financing its
 operations and seeks funding through various sources, including
 public and private securities offerings, collaborative arrangements
 with third parties and other strategic alliances and business
 transactions. On March&amp;#xA0;7, 2018, the Company entered into a
 definitive securities purchase agreement to issue shares of its
 convertible preferred stock (&amp;#x201C;Series A Convertible
 Preferred&amp;#x201D;) and warrants to purchase shares of its common
 stock in a private placement transaction to a select group of
 institutional investors. The Series A Convertible Preferred is
 expected to close in two tranches and result in aggregate gross
 proceeds to the Company of approximately $10.7&amp;#xA0;million. The
 Company closed the first tranche for approximately
 $6.0&amp;#xA0;million on March&amp;#xA0;9, 2018. The remaining
 $4.7&amp;#xA0;million will be received at the second closing, which is
 subject to stockholder approval, and is expected to occur early in
 the second quarter.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 In addition to the proceeds from the Series A Convertible
 Preferred, in the first quarter of 2018, JGB (Cayman) Newton Ltd
 (&amp;#x201C;JGB&amp;#x201D;) the holder the Company&amp;#x2019;s senior secured
 debenture due November 2018 redeemed $2.6&amp;#xA0;million of
 outstanding principal that was satisfied by the Company with
 635,894 shares of the Company&amp;#x2019;s common stock and redeemed
 $0.6&amp;#xA0;million of outstanding principal, which the Company
 satisfied in cash. As a result of the redemptions, the Company was
 able to transfer $3.2&amp;#xA0;million out of restricted cash and cash
 equivalents and into unrestricted cash and cash equivalents to be
 used to fund the Company&amp;#x2019;s ongoing operations. The
 outstanding principal balance on the senior secured debenture as of
 April 6, 2018 is $7.0&amp;#xA0;million and is maintained by the Company
 as restricted cash.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 Other than as described in Note 15, the Company currently does not
 have any commitments to obtain additional funds and may be unable
 to obtain sufficient funding in the future on acceptable terms, if
 at all. If the Company cannot obtain the necessary funding, it will
 need to delay, scale back or eliminate some or all of its research
 and development programs or enter into collaborations with third
 parties to: commercialize potential products or technologies that
 it might otherwise seek to develop or commercialize independently;
 consider other various strategic alternatives, including a merger
 or sale of the Company; or cease operations. If the Company engages
 in collaborations, it may receive lower consideration upon
 commercialization of such products than if it had not entered into
 such arrangements or if it entered into such arrangements at later
 stages in the product development process.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The Company has prepared its financial statements assuming that it
 will continue as a going concern, which contemplates realization of
 assets and the satisfaction of liabilities in the normal course of
 business. The Company has incurred net losses since inception and
 it expects to generate losses from operations for the foreseeable
 future primarily due to research and development costs for its
 potential product candidates, which raises substantial doubt about
 the Company&amp;#x2019;s ability to continue as a going concern. Various
 internal and external factors will affect whether and when the
 Company&amp;#x2019;s product candidates become approved drugs and how
 significant their market share will be, some of which are outside
 of the Company&amp;#x2019;s control. The length of time and cost of
 developing and commercializing these product candidates and/or
 failure of them at any stage of the drug approval process will
 materially affect the Company&amp;#x2019;s financial condition and
 future operations. The consolidated financial statements do not
 include any adjustments relating to the recoverability and
 classification of recorded asset amounts or the amounts and
 classification of liabilities that might result from the outcome of
 this uncertainty.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 As of December&amp;#xA0;31, 2017, the Company had a cash balance of
 approximately $2.3&amp;#xA0;million and restricted cash at $10.4
 million. In addition, the Company had outstanding accounts payable
 and accrued expenses of $14.9&amp;#xA0;million and indebtedness of
 $11.0&amp;#xA0;million as of December&amp;#xA0;31, 2017, which consists of
 the Company&amp;#x2019;s senior secured debenture with JGB. The Company
 expects its existing cash as of December&amp;#xA0;31, 2017, together
 with&amp;#xA0;the proceeds from the initial&amp;#xA0;closing of its Series
 A Convertible Preferred in March 2018, will enable the Company to
 fund its operating expenses and capital expenditure requirements
 through June 2018. Assuming that all conditions to the initial
 closing are met, the Company expects an additional $4.7 million of
 cash proceeds from the second closing of the sale of the
 Company&amp;#x2019;s Series A Convertible Preferred and warrants in the
 second quarter of 2018.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:LiquidationBasisOfAccountingTextBlock>
  <us-gaap:LitigationSettlementAmountAwardedFromOtherParty contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-5" id="id_10184323_CA378F64-E90B-484F-98B6-B1B16B6C72B7_1_0" unitRef="iso4217_USD">1300000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_4057F5D7-0584-4138-8CED-8368A48EFB93_1_10" unitRef="iso4217_USD">-24429000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_1_20" unitRef="iso4217_USD">1812000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_1_26" unitRef="iso4217_USD">5534000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_1_16" unitRef="iso4217_USD">-10989000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_7005_800040" unitRef="iso4217_USD">-23754000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_4057F5D7-0584-4138-8CED-8368A48EFB93_1_4" unitRef="iso4217_USD">-23039000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_3F80FFA1-3029-418A-900B-A8977D21043A_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Recently Issued Accounting Pronouncements&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 In July 2017, the FASB issued ASU &lt;font style="white-space:nowrap"&gt;2017-11,&lt;/font&gt; &lt;i&gt;Earnings Per Share (Topic
 260); Distinguishing Liabilities from Equity (Topic 480);
 Derivatives and Hedging (Topic 815): (Part I) Accounting for
 Certain Financial Instruments with Down Round Features, (Part II)
 Replacement of the Indefinite Deferral for Mandatorily Redeemable
 Financial Instruments of Certain Nonpublic Entities and Certain
 Mandatorily Redeemable Noncontrolling Interests with a Scope
 Exception.&lt;/i&gt; The first part of this update addresses the
 complexity of accounting for certain financial instruments with
 down round features and the second part addresses the complexity of
 distinguishing liabilities from equity. The guidance is applicable
 to public business entities for fiscal years beginning after
 December&amp;#xA0;15, 2018 and interim periods within those years. The
 Company is currently evaluating the potential impact of the
 adoption of this standard on its consolidated results of
 operations, financial position and cash flows and related
 disclosures.&lt;/p&gt;
 &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 In May 2017, the FASB issued Accounting Standard Update No.
 &lt;font style="white-space:nowrap"&gt;2017-09,&lt;/font&gt;&lt;i&gt;&amp;#xA0;Compensation&amp;#x2014;Stock
 Compensation (Topic 718): Scope of Modification Accounting&lt;/i&gt;. ASU
 &lt;font style="white-space:nowrap"&gt;2017-09&lt;/font&gt; provides guidance
 about which changes to the terms or conditions of a share-based
 payment award require an entity to apply modification accounting in
 Topic 718. Specifically, an entity would not apply modification
 accounting if the fair value, vesting conditions, and
 classification of the awards are the same immediately before and
 after the modification. The guidance is applicable to public
 business entities for fiscal years beginning after
 December&amp;#xA0;15, 2017 and interim periods within those years.
 Early adoption is permitted, including adoption in any interim
 period. The Company does not expect this new guidance to have a
 material impact on its consolidated financial statements.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 In November 2016, the FASB issued ASU &lt;font style="white-space:nowrap"&gt;No.&amp;#xA0;2016-18,&lt;/font&gt; &lt;i&gt;Restricted
 cash&lt;/i&gt;, amending the presentation of restricted cash within the
 statement of cash flows. The new guidance requires that restricted
 cash be included within cash and cash equivalents on the statement
 of cash flows. The ASU is effective retrospectively for reporting
 periods beginning after December&amp;#xA0;15, 2017, with early adoption
 permitted. The Company is currently evaluating the impact of its
 pending adoption of the new standard on the consolidated financial
 statements.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 In March 2016, the FASB issued Accounting Standards Update
 &lt;font style="white-space:nowrap"&gt;2016-09,&lt;/font&gt;&lt;i&gt;&amp;#xA0;Compensation-Stock
 Compensation&lt;/i&gt;. ASU &lt;font style="white-space:nowrap"&gt;2016-09&lt;/font&gt; includes several areas of
 simplification to stock compensation including simplifications to
 the accounting for income taxes, classification of excess tax
 benefits on the Statement of Cash Flows and forfeitures. ASU
 &lt;font style="white-space:nowrap"&gt;2016-09&lt;/font&gt; is effective for
 annual reporting periods beginning after December&amp;#xA0;15, 2016. An
 entity that elects early adoption must adopt all of the amendments
 in the same period. The Company adopted this ASU on January&amp;#xA0;1,
 2017. There was no impact to the Company&amp;#x2019;s consolidated
 financial statements upon adoption.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 In February 2016, the FASB issued Accounting Standards Update No.
 &lt;font style="white-space:nowrap"&gt;2016-02,&lt;/font&gt;&lt;i&gt;&amp;#xA0;Leases&lt;/i&gt;, which
 establishes a &lt;font style="white-space:nowrap"&gt;&lt;font style="white-space:nowrap"&gt;right-of-use&lt;/font&gt;&lt;/font&gt; (&amp;#x201C;ROU&amp;#x201D;)
 model that requires a lessee to record a ROU asset and a lease
 liability on the balance sheet for all leases with terms longer
 than 12 months. Leases will be classified as either finance or
 operating, with classification affecting the pattern of expense
 recognition in the income statement. The new standard is effective
 for fiscal years beginning after December&amp;#xA0;15, 2018, including
 interim periods within those fiscal years. A modified retrospective
 transition approach is required for lessees for capital and
 operating leases existing at, or entered into after, the beginning
 of the earliest comparative period presented in the financial
 statements, with certain practical expedients available. The
 Company is currently evaluating the impact of its pending adoption
 of the new standard on the consolidated financial statements.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_7B969E8A-FD4A-4790-8805-CA2B6CB79076_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;b&gt;3.&amp;#xA0;Basis of Presentation and Summary of Significant
 Accounting Policies&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The accompanying consolidated financial statements have been
 prepared in conformity with accounting principles generally
 accepted in the United States (&amp;#x201C;U.S. GAAP&amp;#x201D;). Any
 reference in these notes to applicable guidance is meant to refer
 to U.S.&amp;#xA0;GAAP as found in the Accounting Standards Codification
 (&amp;#x201C;ASC&amp;#x201D;) and Accounting Standards Updates
 (&amp;#x201C;ASU&amp;#x201D;) of the Financial Accounting Standards Board
 (&amp;#x201C;FASB&amp;#x201D;).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;Principles of Consolidation&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The consolidated financial statements include the financial
 statements of the Company and its wholly owned subsidiaries, SELLAS
 Bermuda, SELLAS Life Sciences Group UK Ltd (&amp;#x201C;SELLAS
 UK&amp;#x201D;), Apthera, Inc. (&amp;#x201C;Apthera&amp;#x201D;) and Mills
 Pharmaceuticals, LLC (&amp;#x201C;Mills&amp;#x201D;). All significant
 intercompany accounts and transactions have been eliminated upon
 consolidation.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The preparation of these consolidated financial statements in
 accordance with U.S. GAAP requires management to make estimates and
 assumptions that affect the reported amounts of assets and
 liabilities and disclosure of contingent assets and liabilities at
 the date of the financial statements and the reported amounts of
 expenses during the reporting period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On an ongoing basis, the Company evaluates its estimates using
 historical experience and other factors, including the current
 economic environment. Significant items subject to such estimates
 are assumptions used for purposes of determining stock-based
 compensation, the fair value of the warrants, beneficial conversion
 features associated with convertible notes, fair value of
 intangible assets acquired, carrying value of goodwill, fair value
 of contingent purchase price consideration, fair value of deferred
 tax liability assumed and accounting for research and development
 activities. Management believes its estimates to be reasonable
 under the circumstances. Actual results could differ significantly
 from those estimates.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The carrying amounts of the Company&amp;#x2019;s financial instruments,
 including cash equivalents, accounts payable, and accrued expenses
 approximate fair value due to the short-term nature of those
 instruments. The carrying amounts of the Company&amp;#x2019;s
 outstanding convertible notes approximate fair value due to the
 debt carrying a variable interest rate that is tied to the current
 London Interbank Offer Rate (&amp;#x201C;LIBOR&amp;#x201D;) rate. The fair
 value of the convertible notes is determined using a binomial
 lattice model that utilizes certain unobservable inputs that fall
 within Level&amp;#xA0;3 of the fair value hierarchy. The fair value of
 the warrants is determine using a Black-Scholes pricing model.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 Financial instruments that potentially expose the Company to
 concentrations of credit risk consist principally of cash on
 deposit with multiple financial institutions, the balances of which
 frequently exceed federally insured limits.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The Company considers any highly liquid investments, such as money
 market funds, with an original maturity of three months or less to
 be cash and cash equivalents.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;Restricted Cash and Cash Equivalents&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 Restricted cash consists of the minimum cash covenant as required
 by the debenture and certificates of deposit on hand with the
 Company&amp;#x2019;s financial institutions as collateral for its
 corporate credit cards.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;Intangible Assets&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 Intangible assets are comprised of
 identifiable&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;in-process&lt;/font&gt;&amp;#xA0;research
 and development (&amp;#x201C;IPR&amp;amp;D&amp;#x201D;) assets and are considered
 indefinite-lived intangible assets and are assessed for impairment
 annually on October&amp;#xA0;1 or more frequently if impairment
 indicators exist. If the associated research and development effort
 is abandoned, the related assets will
 be&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;written-off&lt;/font&gt;&amp;#xA0;and the
 Company will record a&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-cash&lt;/font&gt;&amp;#xA0;impairment
 loss. For those compounds that reach commercialization, the
 IPR&amp;amp;D assets will be amortized over their estimated useful
 lives.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;Goodwill&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 Goodwill is the excess of the cost of an acquired entity over the
 net amounts assigned to tangible and intangible assets acquired and
 liabilities assumed. Goodwill is not amortized but is subject to an
 annual impairment test. The Company has a single reporting unit and
 all goodwill relates to that reporting unit.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The Company performs its annual goodwill impairment test at the
 reporting unit level on October&amp;#xA0;1 of each fiscal year or more
 frequently if changes in circumstances or the occurrence of events
 suggest that an impairment exists. Goodwill is evaluated for
 impairment using the simplified test of goodwill impairment as
 defined by the FASB Accounting Standards
 Update&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2017-04.&lt;/font&gt;&amp;#xA0;Under
 the new guidance, goodwill impairment will be measured by the
 amount by which the carrying value of a reporting unit exceeds its
 fair value, without exceeding the carrying amount of goodwill
 allocated to that reporting unit. If the fair value of the
 reporting unit is less than its carrying value, an impairment loss
 is recorded to the extent that the implied fair value of the
 reporting unit&amp;#x2019;s goodwill is less than the carrying value of
 the reporting unit&amp;#x2019;s goodwill. The Company did not recognize
 any impairment of goodwill during the year ended December&amp;#xA0;31,
 2017.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;Severance Costs&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The Company recognized and paid $1.9&amp;#xA0;million of exit costs
 during 2017 related to severance benefits for former Galena
 employees terminated immediately prior to the consummation of the
 Merger.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;Patents and Patent Application Costs&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 Although the Company believes that its patents and underlying
 technology have continuing value, the amount of future benefits to
 be derived from the patents is uncertain. Patent costs are,
 therefore, expensed as incurred.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;Legal Fees and Insurance Recoveries&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 There can be a significant time lag between the time that legal
 fees are incurred and the insurance reimbursement available to
 offset the related costs. The legal fees are recorded in the period
 they are incurred, and the insurance recoveries for those costs are
 recorded in the period when the insurance reimbursement is deemed
 probable.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;Stock-based Compensation&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The Company follows the provisions of the FASB ASC Topic 718,
 &amp;#x201C;&lt;i&gt;Compensation&lt;/i&gt;&lt;i&gt;&amp;#xA0;&amp;#x2014; Stock
 Compensation&amp;#x201D;&lt;/i&gt;&amp;#xA0;(&amp;#x201C;ASC 718&amp;#x201D;),
 which requires the measurement and recognition of compensation
 expense for all stock-based payment awards made to
 employees,&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-employee&lt;/font&gt;&amp;#xA0;directors,
 and consultants, including stock options and warrants. Stock
 compensation expense based on the grant date fair value estimated
 in accordance with the provisions of ASC&amp;#xA0;718 is recognized as
 an expense over the requisite service period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 For stock options and warrants granted as consideration for
 services rendered by&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-employees,&lt;/font&gt;&amp;#xA0;the
 Company recognizes compensation expense in accordance with the
 requirements of FASB ASC Topic&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;505-50&lt;/font&gt;&amp;#xA0;(&amp;#x201C;ASC&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;505-50&amp;#x201D;),&lt;/font&gt;&amp;#xA0;&amp;#x201C;&lt;i&gt;Equity
 Based Payments to&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;Non-&lt;/font&gt;&amp;#xA0;Employees&lt;/i&gt;.&amp;#x201D;&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;Non-employee&lt;/font&gt;option
 and warrant grants that do not vest immediately upon grant are
 recorded as an expense over the vesting period. At the end of each
 financial reporting period prior to vesting, the value of these
 options and warrants, as calculated using the Black-Scholes
 option-pricing model, will be&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;re-measured&lt;/font&gt;&amp;#xA0;using
 the fair value of the Company&amp;#x2019;s common stock and
 the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-cash&lt;/font&gt;&amp;#xA0;compensation
 recognized during the period will be adjusted accordingly. Since
 the fair market value of options and warrants granted
 to&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-employees&lt;/font&gt;&amp;#xA0;is
 subject to change in the future, the amount of the future
 compensation expense will include fair
 value&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;re-measurements&lt;/font&gt;&amp;#xA0;until
 the stock options are fully vested.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;Research and Development Expenses&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 Research and development costs are expensed as incurred. Research
 and development costs that are paid in advance of performance are
 capitalized as a prepaid expense and amortized over the service
 period as the services are provided. Clinical study costs, a
 component of research and development expenses, are accrued over
 the service periods specified in the contracts and adjusted as
 necessary based on an ongoing review of the level of effort and
 costs actually incurred. Payments for a product license prior to
 regulatory approval of the product and payments for milestones
 achieved prior to regulatory approval of the product are expensed
 in the period incurred as research and development expenses.
 Milestone payments made in connection with regulatory approvals are
 capitalized and amortized to cost of revenue over the remaining
 useful life of the asset.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 Research and development expenses primarily consist of the
 intellectual property and research and development materials
 acquired, expenses from third parties who conduct research and
 development activities on behalf of the Company as well as related
 wages, benefits and other operating costs. The Company expenses
 in-process research and development projects acquired as asset
 acquisitions which have not reached technological feasibility and
 which have no alternative future use.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;Income Taxes&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The Company uses the asset and liability method of accounting for
 income taxes. Deferred tax assets and liabilities are recognized
 for the estimated future tax consequences attributable to
 differences between the financial statement carrying amounts of
 existing assets and liabilities and their respective tax bases and
 operating loss and credit carryforwards. Deferred tax assets and
 liabilities are measured using enacted tax rates expected to apply
 to taxable income in the years in which those temporary differences
 are expected to be recovered or settled. A valuation allowance is
 provided when it is more likely than not that some portion or all
 of a deferred tax asset will not be realized. The Company
 recognizes the benefit of an uncertain tax position that it has
 taken or expects to take on its income tax return it files, if such
 a position is more likely than not to be sustained.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The Company recognizes liabilities or assets for the deferred tax
 consequences of temporary differences between the tax basis of
 assets or liabilities and their reported amounts in the financial
 statements in accordance with FASB&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASC&amp;#xA0;740-10,&lt;/font&gt;&amp;#xA0;&amp;#x201C;&lt;i&gt;Accounting
 for Income Taxes&amp;#x201D; (&amp;#x201C;ASC&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;740-10&amp;#x201D;).&lt;/font&gt;&lt;/i&gt;These temporary
 differences will result in taxable or deductible amounts in future
 years when the reported amounts of the assets or liabilities are
 recovered or
 settled.&amp;#xA0;&lt;i&gt;ASC&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;740-10&lt;/font&gt;&lt;/i&gt;&amp;#xA0;requires
 that a valuation allowance be established when management
 determines that it is more likely than not that all or a portion of
 a deferred asset will not be realized. The Company evaluates the
 realizability of its net deferred income tax assets and valuation
 allowances as necessary, at least on an annual basis. During this
 evaluation, the Company reviews its forecasts of income in
 conjunction with other positive and negative evidence surrounding
 the realizability of its deferred income tax assets to determine if
 a valuation allowance is required. Adjustments to the valuation
 allowance will increase or decrease the Company&amp;#x2019;s income tax
 provision or benefit. The recognition and measurement of benefits
 related to the company&amp;#x2019;s tax positions requires significant
 judgment, as uncertainties often exist with respect to new laws,
 new interpretations of existing laws, and rulings by taxing
 authorities. Differences between actual results and the
 Company&amp;#x2019;s assumptions or changes in the Company&amp;#x2019;s
 assumptions in future periods are recorded in the period they
 become known.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On December&amp;#xA0;22, 2017 the President of the United States signed
 into law the Tax Cuts and Jobs Act (&amp;#x201C;The 2017 Tax
 Act&amp;#x201D;).&amp;#xA0;This legislation makes significant changes in the
 United States tax laws including, but not limited to, reducing the
 corporate tax rate to 21% starting in 2018. The 2017 Tax Act
 required the Company to revalue its deferred tax assets and
 liabilities to the new rate of 21%.&amp;#xA0;For the years ended
 December&amp;#xA0;31, 2017 and 2016, the Company recognized income tax
 expense of $253,000 and $1,000, respectively. Staff Accounting
 Bulletin No. 118 (&amp;#x201C;SAB 118&amp;#x201D;) was issued to address the
 application of U.S. GAAP in situations when a registrant does not
 have the necessary information available, prepared, or analyzed
 (including computations) in reasonable detail to complete the
 accounting for certain income tax effects of the Tax Act. In
 accordance with SAB 118, we determined that the adjustment to
 deferred taxes was a provisional amount and a reasonable estimate
 at December 31, 2017. We do not expect any impact on recorded
 deferred tax balances as the remeasurement of net deferred tax
 assets will be offset by a change in valuation allowance. We are
 analyzing certain aspects of the Tax Act which could potentially
 affect the remeasurement of the net deferred tax assets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;Net Loss Per Share&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 Basic loss per share is computed by dividing net loss applicable to
 common stockholders by the weighted average number of shares of
 common stock outstanding during each period. Diluted loss per share
 includes the effect, if any, from the potential exercise or
 conversion of securities, such as convertible debt, warrants, stock
 options and unvested restricted stock that would result in the
 issuance of incremental shares of common stock. In computing the
 basic and diluted net loss per share, the weighted average number
 of shares remains the same for both calculations due to the fact
 that when a net loss exists, dilutive shares are not included in
 the calculation as the impact is anti-dilutive.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The following potentially dilutive securities outstanding have been
 excluded from the computation of diluted weighted average shares
 outstanding, as they would be anti-dilutive:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="78%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Year&amp;#xA0;ended&amp;#xA0;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Common stock warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;963&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Stock options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;55&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unvested restricted stock awards&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;67&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;986&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;122&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 Amounts in the table reflect the common stock equivalents of the
 noted instruments.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;Comprehensive Loss&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The Company has no items of comprehensive income or loss other than
 net loss.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;Recently Issued Accounting Pronouncements&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 In July 2017, the FASB issued ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2017-11,&lt;/font&gt;&amp;#xA0;&lt;i&gt;Earnings
 Per Share (Topic 260); Distinguishing Liabilities from Equity
 (Topic 480); Derivatives and Hedging (Topic 815): (Part I)
 Accounting for Certain Financial Instruments with Down Round
 Features, (Part II) Replacement of the Indefinite Deferral for
 Mandatorily Redeemable Financial Instruments of Certain Nonpublic
 Entities and Certain Mandatorily Redeemable Noncontrolling
 Interests with a Scope Exception.&amp;#xA0;&lt;/i&gt;The first
 part of this update addresses the complexity of accounting for
 certain financial instruments with down round features and the
 second part addresses the complexity of distinguishing liabilities
 from equity. The guidance is applicable to public business entities
 for fiscal years beginning after December&amp;#xA0;15, 2018 and interim
 periods within those years. The Company is currently evaluating the
 potential impact of the adoption of this standard on its
 consolidated results of operations, financial position and cash
 flows and related disclosures.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 In May 2017, the FASB issued Accounting Standard Update
 No.&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2017-09,&lt;/font&gt;&lt;i&gt;&amp;#xA0;Compensation&amp;#x2014;Stock
 Compensation (Topic 718): Scope of Modification Accounting&lt;/i&gt;.
 ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2017-09&lt;/font&gt;&amp;#xA0;provides
 guidance about which changes to the terms or conditions of a
 share-based payment award require an entity to apply modification
 accounting in Topic 718. Specifically, an entity would not apply
 modification accounting if the fair value, vesting conditions, and
 classification of the awards are the same immediately before and
 after the modification. The guidance is applicable to public
 business entities for fiscal years beginning after
 December&amp;#xA0;15, 2017 and interim periods within those years.
 Early adoption is permitted, including adoption in any interim
 period. The Company does not expect this new guidance to have a
 material impact on its consolidated financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 In November 2016, the FASB issued
 ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;2016-18,&lt;/font&gt;&amp;#xA0;&lt;i&gt;Restricted
 cash&lt;/i&gt;, amending the presentation of restricted cash within the
 statement of cash flows. The new guidance requires that restricted
 cash be included within cash and cash equivalents on the statement
 of cash flows. The ASU is effective retrospectively for reporting
 periods beginning after December&amp;#xA0;15, 2017, with early adoption
 permitted. The Company is currently evaluating the impact of its
 pending adoption of the new standard on the consolidated financial
 statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 In March 2016, the FASB issued Accounting Standards
 Update&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-09,&lt;/font&gt;&lt;i&gt;&amp;#xA0;Compensation-Stock
 Compensation&lt;/i&gt;. ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-09&lt;/font&gt;&amp;#xA0;includes
 several areas of simplification to stock compensation including
 simplifications to the accounting for income taxes, classification
 of excess tax benefits on the Statement of Cash Flows and
 forfeitures. ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-09&lt;/font&gt;&amp;#xA0;is effective
 for annual reporting periods beginning after December&amp;#xA0;15,
 2016. An entity that elects early adoption must adopt all of the
 amendments in the same period. The Company adopted this ASU on
 January&amp;#xA0;1, 2017. There was no impact to the Company&amp;#x2019;s
 consolidated financial statements upon adoption.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 In February 2016, the FASB issued Accounting Standards Update
 No.&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-02,&lt;/font&gt;&lt;i&gt;&amp;#xA0;Leases&lt;/i&gt;, which
 establishes a&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;right-of-use&lt;/font&gt;&lt;/font&gt;&amp;#xA0;(&amp;#x201C;ROU&amp;#x201D;)
 model that requires a lessee to record a ROU asset and a lease
 liability on the balance sheet for all leases with terms longer
 than 12 months. Leases will be classified as either finance or
 operating, with classification affecting the pattern of expense
 recognition in the income statement. The new standard is effective
 for fiscal years beginning after December&amp;#xA0;15, 2018, including
 interim periods within those fiscal years. A modified retrospective
 transition approach is required for lessees for capital and
 operating leases existing at, or entered into after, the beginning
 of the earliest comparative period presented in the financial
 statements, with certain practical expedients available. The
 Company is currently evaluating the impact of its pending adoption
 of the new standard on the consolidated financial statements.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:OptionIndexedToIssuersEquityDescriptionTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_589A03AD-C2F6-477E-B055-A411A0541176_1_0">&lt;div&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;12. Warrants&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The following is a summary of warrant activity for the years ended
 December&amp;#xA0;31, 2017 (in thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="49%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:61.50pt; display:inline; font-size:8pt; font-family:Times New Roman;"&gt;
 &lt;b&gt;Warrant Issuance&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Outstanding,&lt;br /&gt;
 January&amp;#xA0;1,&lt;br /&gt;
 2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Granted&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Assumed&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;through&lt;br /&gt;
 Merger&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Expired&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Outstanding,&lt;br /&gt;
 December&amp;#xA0;31,&lt;br /&gt;
 2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Expiration&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 2017 Equilibria&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;316&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;316&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;December&amp;#xA0;2022&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Galena February 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;567&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;567&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;February 2022&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Galena other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;80&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;80&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;Various&amp;#xA0;to&amp;#xA0;2022&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;316&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;647&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;963&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Warrants assumed in connection with the acquisition of Galena
 consist of warrants that may be settled in cash, which are
 liability-classified warrants, and equity-classified warrants.
 Subsequent to December&amp;#xA0;31, 2017, 501,000 the Company&amp;#x2019;s
 February 2017 warrants to purchase shares of common stock were
 cancelled under various warrant exchange agreements as disclosed in
 Note&amp;#xA0;16.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Warrants classified as liabilities&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Liability-classified warrants consist of warrants to purchase
 common stock issued in connection with previous equity financings
 for the February 2017 financing and various other equity financings
 (the Company) that were assumed by the Company at the consummation
 of the Merger. These warrants may settle in cash and were
 determined not to be indexed to the Company&amp;#x2019;s common
 stock.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The estimated fair value of outstanding warrants accounted for as
 liabilities is determined at each balance sheet date. Any decrease
 or increase in the estimated fair value of the warrant liability
 since the most recent balance sheet date is recorded in the
 consolidated statement of operations as other income (expense). The
 fair value of the warrants as of December&amp;#xA0;31, 2017 is
 estimated using a Black-Scholes pricing model with the following
 inputs:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="50%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:61.50pt; display:inline; font-size:8pt; font-family:Times New Roman;"&gt;
 &lt;b&gt;Warrant Issuance&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Outstanding&amp;#xA0;(in&lt;br /&gt;
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;
 &lt;b&gt;Strike&amp;#xA0;price&amp;#xA0;(per&lt;br /&gt;
 share)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Expected&amp;#xA0;term&lt;br /&gt;
 (years)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Volatility%&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;&lt;font style="white-space:nowrap"&gt;Risk-free&amp;#xA0;rate&lt;/font&gt;&lt;br /&gt;
 %&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Galena February 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;567&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;33.00&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.12&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;79.29&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.09&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Galena other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;76&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;888.22&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.74&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;72.46&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.00&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The expected volatility assumptions are based on the
 Company&amp;#x2019;s implied volatility in combination with the implied
 volatilities of similar publicly traded entities. The expected term
 assumptions are based on the remaining contractual terms of the
 warrants. The risk-free rate is based on the &lt;font style="white-space:nowrap"&gt;zero-coupon&lt;/font&gt; rates in effect at the time
 of valuation. The dividend yield used in the pricing model is zero,
 because the Company has no present intention to pay cash
 dividends.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The changes in fair value of the warrant liability for the year
 ended December&amp;#xA0;31, 2017 were as follows (in thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="56%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:61.50pt; display:inline; font-size:8pt; font-family:Times New Roman;"&gt;
 &lt;b&gt;Warrant Issuance&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Warrant&lt;br /&gt;
 liability,&lt;br /&gt;
 January&amp;#xA0;1,&lt;br /&gt;
 2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;
 &lt;b&gt;Fair&amp;#xA0;value&amp;#xA0;of&lt;br /&gt;
 warrants&lt;br /&gt;
 granted&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;
 &lt;b&gt;Fair&amp;#xA0;value&amp;#xA0;of&lt;br /&gt;
 warrants&lt;br /&gt;
 acquired&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;
 &lt;b&gt;Change&amp;#xA0;in&amp;#xA0;fair&lt;br /&gt;
 value of&lt;br /&gt;
 warrants&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Warrant&lt;br /&gt;
 liability,&lt;br /&gt;
 December&amp;#xA0;31,&lt;br /&gt;
 2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Galena February 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,305&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,305&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Galena other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;br /&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;br /&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;br /&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,309&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,309&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Warrants classified as equity&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company issued 316,163 warrants to purchase shares of the
 Company&amp;#x2019;s common stock at an exercise price of $7.42,
 maturing five years from issuance, to EQC Private Markets SAC Fund
 Ltd&amp;#x2014;EQC Biotech Sely I Fund on December&amp;#xA0;29, 2017. These
 warrants are recorded in equity at fair value upon issuance, and
 not as liabilities, and are not subject to adjustment to fair value
 in subsequent reporting periods. The fair value of the warrants
 granted was&amp;#xA0;$5.60&amp;#xA0;per share using the Black-Scholes
 pricing model with the fair value assumptions for the grant
 including a volatility of&amp;#xA0;90.10%, expected term
 of&amp;#xA0;five&amp;#xA0;years, risk free rate of&amp;#xA0;2.20%, and a
 dividend rate of&amp;#xA0;0.00.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:OptionIndexedToIssuersEquityDescriptionTextBlock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_1_22" unitRef="iso4217_USD">6007000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProductionRelatedImpairmentsOrCharges contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-5" id="id_10184323_4828D19F-FB8A-4A68-A803-4CA2B717ED01_1_5" unitRef="iso4217_USD">5200000</us-gaap:ProductionRelatedImpairmentsOrCharges>
  <us-gaap:RepaymentsOfConvertibleDebt contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_1_25" unitRef="iso4217_USD">473000</us-gaap:RepaymentsOfConvertibleDebt>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_E374560D-CF31-4AFE-8AE4-7655A053740A_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;15. Related Party Transactions&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Management and Strategic Collaboration Agreement&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Effective in June&amp;#xA0;2016, the Company and Equilibria, a company
 incorporated in Bermuda and a significant stockholder of the
 Company, entered into the management and strategic collaboration
 agreement. Under the Equilibria collaboration agreement,
 Equilibria, amongst other services, is engaged to provide certain
 strategic, management and capital raising advice to the Company.
 The Equilibria collaboration agreement is effective for three years
 and will be renewable thereafter only upon the mutual written
 agreement of both parties. The Equilibria collaboration agreement
 will automatically terminate upon the closing of an IPO or a
 strategic sale. During the term of the Equilibria collaboration
 agreement, the Company, in exchange for the services received, paid
 Equilibria a quarterly fee of $0.1&amp;#xA0;million (the
 &amp;#x201C;Equilibria Management Fee&amp;#x201D;). The Equilibria Management
 Fee can be paid in cash or, at the mutual agreement of the parties,
 in shares of the Company at a valuation equal to the
 Company&amp;#x2019;s most recent financing round. In addition to the
 Equilibria Management Fee, the Company has agreed to pay Equilibria
 any expenses reasonably incurred in performing the services agreed.
 For the years ended December&amp;#xA0;31, 2017 and 2016, the Company
 had incurred and paid in cash $0.3&amp;#xA0;million and
 $0.2&amp;#xA0;million, respectively, of Equilibria Management Fees.
 These amounts are included in general and administrative expense in
 the consolidated statements of operations. As of December&amp;#xA0;31,
 2017, the Company had an outstanding payable of $0.1&amp;#xA0;million
 payable to Equilibria. As of December&amp;#xA0;31, 2016, there was no
 outstanding fee payable to Equilibria.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 For the provision of the management and strategic collaboration
 services, the Company also agreed to pay Equilibria an incentive
 fee equal to 2% of the post-money market value of the Company on
 the date of its IPO. Such fee will be payable in shares with a
 &lt;font style="white-space:nowrap"&gt;per-share&lt;/font&gt; price equal to
 the price set for the sale of the Company&amp;#x2019;s shares to other
 investors in its IPO. The Company and Equilibria, may jointly agree
 to settle the incentive fee earlier, if deemed appropriate for
 achieving a successful IPO, through either a cash payment, issuance
 of shares, or a combination of the two. In the event that the
 Company is sold as part of a strategic sale, the incentive fee will
 be equal to 2% of the gross value paid by the purchaser in
 cash.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 In February 2017, the Company and Equilibria entered into an
 amendment of the Equilibria collaboration agreement. Under the
 amendment, in the event that the Company entered into a reverse
 merger transaction in lieu of an initial public offering, the
 incentive fee to Equilibria was 2% of the post-merger fully diluted
 market value of the Company immediately after the closing of the
 reverse merger transaction, payable in a combination of cash and
 shares of common stock of the Company. The cash payment was based
 on the per share price equaling the intrinsic value of the
 Company&amp;#x2019;s shares in the Merger. The share-based component of
 the incentive fee was based on the post-closing fully diluted
 number of shares outstanding.&lt;/p&gt;
 &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 In August 2017, the Company and Equilibria further amended the
 Equilibria collaboration agreement to fix the compensation payable
 to Equilibria in connection with the completion of the Merger,
 described above in Note 1. Accordingly, upon consummation of the
 Merger on December&amp;#xA0;29, 2017, the Company incurred
 $0.1&amp;#xA0;million to Equilibria and issued 119,672 shares of common
 stock to Equilibria at a fair value of $0.9&amp;#xA0;million. These
 amounts are included in general and administrative expense in the
 consolidated statements of operations. Also, upon consummation of
 the Merger and pursuant to the amended Equilibria collaboration
 agreement, such agreement was terminated.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Debt&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company has entered into several related party debt
 transactions with stockholders, which are described in Note 9.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;MSK License Agreement&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 See Note 6 for information regarding the MSK License Agreement
 entered into by the Company. MSK owned 3.7% and 5.4% of the
 Company&amp;#x2019;s outstanding share capital as of December&amp;#xA0;31,
 2017 and 2016, respectively.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Other Related Party Transactions&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company&amp;#x2019;s Chief Executive Officer,
 Dr.&amp;#xA0;Angelos&amp;#xA0;M. Stergiou (M.D., Sc.D. h.c.) is a
 significant stockholder of the Company owning 7.8% and 24.0% of the
 Company&amp;#x2019;s outstanding share capital as of December&amp;#xA0;31,
 2017 and 2016, respectively. Further transactions involving the
 Company and Dr.&amp;#xA0;Stergiou are described in Note 6 and Note
 9.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 On November&amp;#xA0;28, 2016, the Company granted 3,651 stock options
 to a prior member of the Company&amp;#x2019;s Board of Directors. Such
 prior director is additionally a full-time employee of MSK. The
 option was terminated on August&amp;#xA0;6, 2017 in consideration of an
 approximately $30,000 cash payment.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 On November&amp;#xA0;28, 2016, the Company granted 9,107 RSUs to a
 member of the Company&amp;#x2019;s Scientific Advisory Board pursuant to
 a consulting agreement for scientific advisory services to be
 performed on behalf of the Company (see Note 13). Additionally,
 such member and consultant is a full-time employee of MSK (see Note
 6).&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_4057F5D7-0584-4138-8CED-8368A48EFB93_1_1" unitRef="iso4217_USD">6067000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_796637D2-A3E7-46E4-9499-FB4737B04E3C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Research and Development Expenses&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Research and development costs are expensed as incurred. Research
 and development costs that are paid in advance of performance are
 capitalized as a prepaid expense and amortized over the service
 period as the services are provided. Clinical study costs, a
 component of research and development expenses, are accrued over
 the service periods specified in the contracts and adjusted as
 necessary based on an ongoing review of the level of effort and
 costs actually incurred. Payments for a product license prior to
 regulatory approval of the product and payments for milestones
 achieved prior to regulatory approval of the product are expensed
 in the period incurred as research and development expenses.
 Milestone payments made in connection with regulatory approvals are
 capitalized and amortized to cost of revenue over the remaining
 useful life of the asset.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Research and development expenses primarily consist of the
 intellectual property and research and development materials
 acquired, expenses from third parties who conduct research and
 development activities on behalf of the Company as well as related
 wages, benefits and other operating costs. The Company expenses
 in-process research and development projects acquired as asset
 acquisitions which have not reached technological feasibility and
 which have no alternative future use.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:ResearchAndDevelopmentInProcess contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_1_8" unitRef="iso4217_USD">449000</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_A1433079-EBFD-418D-831A-325DE147145C_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The following potentially dilutive securities outstanding have been
 excluded from the computation of diluted weighted average shares
 outstanding, as they would be anti-dilutive:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="78%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"&gt;
 &lt;b&gt;Year&amp;#xA0;ended&amp;#xA0;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Common stock warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;963&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Stock options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;55&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Unvested restricted stock awards&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;67&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;986&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;122&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_2D715EE9-B6CF-4ABA-9847-870DDD7E0B5E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The components of federal and state income tax expense are as
 follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="86%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;As&amp;#xA0;of&amp;#xA0;December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Current&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Federal&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;76&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 State&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;138&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;42&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Foreign&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total current&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;214&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;42&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Federal&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 State&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;39&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(41&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Foreign&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total deferred&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;39&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(41&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total income tax expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;253&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
  <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_EA5A63C2-4FCD-43E7-8C5A-ECC027EE11B9_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 The purchase price was calculated as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="88%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Fair value of the Company&amp;#x2019;s &lt;font style="WHITE-SPACE: nowrap"&gt;pre-Merger&lt;/font&gt; shares outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,487&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Estimated fair value of the Company&amp;#x2019;s &lt;font style="WHITE-SPACE: nowrap"&gt;per-Merger&lt;/font&gt; stock options
 outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;32&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total purchase price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,519&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
  <us-gaap:ScheduleOfDebtTableTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_6974D483-E39F-44D0-AF9A-F5500C77BCC6_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Debt and convertible debt consist of the following (in
 thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="81%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"&gt;
 &lt;b&gt;Year&amp;#xA0;Ended&amp;#xA0;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Debt&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Current portion of Senior Secured Debenture&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,377&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Non-current portion of Senior Secured Debenture&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,611&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total debt&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,988&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Convertible debt&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 2015 Shareholder Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,709&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 2015 Sely Note&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,659&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total convertible debt&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,368&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_71CAE71B-0F0B-438D-B505-D72E98751118_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The following table summarizes the components of stock-based
 compensation expense in the consolidated statements of operations
 for the years ended December&amp;#xA0;31, 2017 and 2016, respectively
 (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="84%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;729&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;23&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,440&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;331&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total stock-based compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,169&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;354&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_D301E321-7540-4A9B-9C28-2B34E0D71871_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 Common stock as included in the consolidated statement of
 stockholders&amp;#x2019; equity (deficit) was adjusted to reflect the
 $0.0001 par value per share and additional paid-in capital was
 adjusted as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Retroactive&lt;br /&gt;
 Effect&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&amp;#xA0;Revised&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Balance at January 1, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;288&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;200&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;488&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Shares issued as partial consideration of MSK license fees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;897&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;900&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Shares issued pursuant to MSK license agreement&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,967&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,976&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Shares issued in cancellation of Clarendon license agreement&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;502&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Shares issued upon conversion of 2016 convertible note&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,357&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;54&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,411&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Shares issued in cancellation of long-term debt&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,783&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,803&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Stock-based compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;354&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;354&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Balance at December 31, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25,146&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;288&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25,434&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;br class="Apple-interchange-newline" /&gt;

 &lt;/div&gt;</us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock>
  <us-gaap:ScheduleOfGoodwillTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_8EE3262E-0554-4E6A-B619-12CB8852D7EE_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Changes in the carrying amount of goodwill for the period ended
 December&amp;#xA0;31, 2017 consisted of the following (in
 thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="68%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="89%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Balance as of January 1, 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Goodwill as a result of the Merger&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,914&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Balance as of December&amp;#xA0;31, 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,914&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
  <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_C694E60B-4E83-440D-90BA-E3924923E46C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The loss before income taxes is as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="78%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;As of December 31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 U.S.&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;265&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;108&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Non - U.S.&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(23,766&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(17,788&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(23,501&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(17,680&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_B2B135B9-4E05-49C0-B01A-37069FC44890_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Accrued expenses and other current liabilities consist of the
 following (in thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="82%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"&gt;
 &lt;b&gt;Year&amp;#xA0;Ended&amp;#xA0;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Professional fees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,744&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,077&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Value added tax&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;426&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Rebates and returns&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;223&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Compensation and related benefits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;566&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;249&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Clinical trial costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,496&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;191&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;227&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accrued expenses and other current liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,201&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,049&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_8224A6F6-B217-456F-99D1-0394958AEEA4_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The following table outlines RSU activity with only a time-based
 condition:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Number of&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Shares&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(In&amp;#xA0;Thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Grant&amp;#xA0;Date&amp;#xA0;Fair&lt;br /&gt;
 Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at January 1, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;46&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52.94&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at December 31, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;46&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52.94&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;58&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.91&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Vested&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(46&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52.94&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Canceled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(58&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.91&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at December&amp;#xA0;31, 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;br class="Apple-interchange-newline" /&gt;

 &lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
  <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_5D0E278C-4E6C-4647-A9B1-4F52B20EF6CE_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The following table indicates the changes to the Company&amp;#x2019;s
 unrecognized tax benefits (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="85%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;As&amp;#xA0;of&amp;#xA0;December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Beginning of the Year - unrecognized tax benefits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;br /&gt;
 &amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&amp;#x2014;&lt;br /&gt;
 &amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;br /&gt;
 &amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Increases/ (Decrease) - prior year tax positions&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;44&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Increases - current year tax positions&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 End of the Year - unrecognized tax benefits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;72&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;div&gt;&amp;#xA0;&lt;/div&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_C81EE56E-6BCD-451F-A823-0E64744A77B0_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The provision for income taxes differs from the provision computed
 by applying the federal statutory rate to net loss before income
 taxes as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="84%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;As&amp;#xA0;of&amp;#xA0;December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 U.S. federal statutory income tax rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(34.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(34.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 State and local taxes, net of federal benefit&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Foreign rate differential&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Permanent differences&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Tax rate change and true-up&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Tax credits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Effective income tax rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_28C4ED32-0C77-4BF9-B83B-E644B2E50868_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The liquidity event, as defined in the relevant RSU grant
 agreements, will be satisfied upon the earlier of either: a) change
 of control or b) a qualified initial public offering.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Number of&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Shares&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(In&amp;#xA0;Thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Grant&amp;#xA0;Date&amp;#xA0;Fair&lt;br /&gt;
 Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at January 1, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52.94&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at December 31, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52.94&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Vested&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;NA&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Canceled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52.94&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at December&amp;#xA0;31, 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52.94&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock>
  <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_19CD2A56-35BF-457A-853F-034532A936CC_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The following table summarizes the allocation of the purchase price
 to the assets acquired and liabilities assumed as of the
 acquisition date (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="88%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Assets acquired:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,812&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Restricted cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,346&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Prepaid expenses and other assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,103&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Intangible assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,600&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Goodwill&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,914&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total assets acquired&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34,775&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Liabilities assumed:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accounts payable and accrued expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,692&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Litigation settlement&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,300&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Long-term debt&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,988&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Contingent purchase price consideration of Apthera, Inc.&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,294&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Warrant liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,309&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred tax liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,673&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total liabilities assumed&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22,256&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net assets acquired&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,519&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_27D26922-41D4-40D5-AC0A-E0F0E195A343_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The following table summarizes stock option activity of the
 Company:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Number of&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Shares&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(In&amp;#xA0;Thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Exercise&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Aggregate&lt;br /&gt;
 Intrinsic Value&lt;br /&gt;
 (In&amp;#xA0;Thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Balance as of January 1, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;55&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52.94&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at December 31, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;55&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52.94&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Assumed in connection with the Merger with Galena&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,240.55&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Canceled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(55&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52.94&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at December&amp;#xA0;31, 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,240.55&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Options exercisable at December&amp;#xA0;31, 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,240.55&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_9081CC5F-EC7F-41BD-B2B8-5EFB29C3183E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company uses the Black-Scholes option-pricing model and the
 following assumptions were used to determine the fair value of all
 its stock options granted in 2016:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="84%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;1.82-2.32%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;85-94%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected lives (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;5.13-10.00&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0%&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_09DE029F-5DB7-4DBA-9B6E-7FA0FFBD7331_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The following tables present information about the Company&amp;#x2019;s
 assets and liabilities measured at fair value on a recurring basis
 in the consolidated balance sheets (in thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="55%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; display:inline; font-size:8pt; font-family:Times New Roman;"&gt;
 &lt;b&gt;Description&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;December&amp;#xA0;31,&lt;br /&gt;
 2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;
 Quoted&amp;#xA0;Prices&amp;#xA0;In&lt;br /&gt;
 Active Markets&lt;br /&gt;
 (Level 1)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;Significant&amp;#xA0;Other&lt;br /&gt;
 Observable&lt;br /&gt;
 Inputs (Level 2)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;Unobservable&lt;br /&gt;
 Inputs&lt;br /&gt;
 (Level 3)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,662&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,662&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Restricted cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,245&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,245&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total assets measured and recorded at fair value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,907&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,907&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Liabilities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Warrants potentially settleable in cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,309&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,309&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Contingent consideration&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,294&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,294&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total liabilities measured and recorded at fair value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,603&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,603&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_1_6" unitRef="iso4217_USD">3169000</us-gaap:ShareBasedCompensation>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_4057F5D7-0584-4138-8CED-8368A48EFB93_1_2" unitRef="iso4217_USD">15089000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_F20F2A7E-6CA6-4B06-A237-1C397810BBCA_7001_6" unitRef="shares">55000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="2" id="id_10184323_A30F3FDC-E7BB-4D8B-8348-6E7E5CF4A544_7001_6" unitRef="iso4217_USD_per_shares">52.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="2" id="id_10184323_A30F3FDC-E7BB-4D8B-8348-6E7E5CF4A544_7001_5" unitRef="iso4217_USD_per_shares">1240.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_1394A519-C6D5-4FBB-A917-EE2C24141DE0_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Stock-based Compensation&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company follows the provisions of the FASB ASC Topic 718,
 &amp;#x201C;&lt;i&gt;Compensation&lt;/i&gt;&lt;i&gt;&amp;#xA0;&amp;#x2014; Stock
 Compensation&amp;#x201D;&lt;/i&gt; (&amp;#x201C;ASC 718&amp;#x201D;), which requires the
 measurement and recognition of compensation expense for all
 stock-based payment awards made to employees, &lt;font style="white-space:nowrap"&gt;non-employee&lt;/font&gt; directors, and
 consultants, including stock options and warrants. Stock
 compensation expense based on the grant date fair value estimated
 in accordance with the provisions of ASC&amp;#xA0;718 is recognized as
 an expense over the requisite service period.&lt;/p&gt;
 &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 For stock options and warrants granted as consideration for
 services rendered by &lt;font style="white-space:nowrap"&gt;non-employees,&lt;/font&gt; the Company recognizes
 compensation expense in accordance with the requirements of FASB
 ASC Topic &lt;font style="white-space:nowrap"&gt;505-50&lt;/font&gt;
 (&amp;#x201C;ASC &lt;font style="white-space:nowrap"&gt;505-50&amp;#x201D;),&lt;/font&gt;
 &amp;#x201C;&lt;i&gt;Equity Based Payments to &lt;font style="white-space:nowrap"&gt;Non-&lt;/font&gt; Employees&lt;/i&gt;.&amp;#x201D; &lt;font style="white-space:nowrap"&gt;Non-employee&lt;/font&gt; option and warrant grants
 that do not vest immediately upon grant are recorded as an expense
 over the vesting period. At the end of each financial reporting
 period prior to vesting, the value of these options and warrants,
 as calculated using the Black-Scholes option-pricing model, will be
 &lt;font style="white-space:nowrap"&gt;re-measured&lt;/font&gt; using the fair
 value of the Company&amp;#x2019;s common stock and the &lt;font style="white-space:nowrap"&gt;non-cash&lt;/font&gt; compensation recognized during
 the period will be adjusted accordingly. Since the fair market
 value of options and warrants granted to &lt;font style="white-space:nowrap"&gt;non-employees&lt;/font&gt; is subject to change in
 the future, the amount of the future compensation expense will
 include fair value &lt;font style="white-space:nowrap"&gt;re-measurements&lt;/font&gt; until the stock options
 are fully vested.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_7005_800029" unitRef="iso4217_USD">12487000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:SeveranceCosts1 contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_1_11" unitRef="iso4217_USD">1883000</us-gaap:SeveranceCosts1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_F20F2A7E-6CA6-4B06-A237-1C397810BBCA_7001_5" unitRef="shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_01B56568-F5B7-4731-B8E1-4A1A20CFE4AF_1_0">&lt;div&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;11. Stockholders&amp;#x2019; Equity (Deficit)&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 On June&amp;#xA0;13, 2017, the Board of Directors approved the Bridge
 Financing, pursuant to which an aggregate of 1,865,262 shares were
 issued at a price per share equal to approximately $3.91.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Under the same valuation terms as the Bridge Financing, the Company
 issued 38,321 shares to MSK in cancellation of a $0.2&amp;#xA0;million
 milestone payment due June&amp;#xA0;30, 2017, as contemplated by the
 MSK Side Letter. In addition, the Company issued 30,094 shares in
 cancellation of a $0.1&amp;#xA0;million Equilibria management fee that
 was payable for March to June 2017, and 28,246 shares in
 cancellation of net compensation of $0.1&amp;#xA0;million due to
 Dr.&amp;#xA0;Angelos Stergiou (M.D., Sc.D. h.c.), the Company&amp;#x2019;s
 Chief Executive Officer.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Shares of common stock as of December&amp;#xA0;31, 2017 for future
 issuance are reserved for as follows (in thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="68%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="91%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Warrants outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;963&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Stock options outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Restricted stock units&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Options reserved for future issuance under the Company&amp;#x2019;s 2017
 Equity Incentive Plan&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;575&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Shares reserved for future issuance under the Employee Stock
 Purchase Plan&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;58&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total reserved for future issuance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,619&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="2" id="id_10184323_D5995E5A-4042-43AF-A402-DA196989731F_2_0" unitRef="pure">0.03</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_7005_800021" unitRef="iso4217_USD">1294000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockholdersEquityReverseStockSplit contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_D5995E5A-4042-43AF-A402-DA196989731F_2_1">Immediately prior to the Merger, the Galena effected a 1-for-30 reverse stock split of the Company&#xe2;&#x20AC;&#x2122;s outstanding common stock.</us-gaap:StockholdersEquityReverseStockSplit>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_7005_800023" unitRef="iso4217_USD">6007000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_33F2FDB9-F32B-459B-9FE9-F2CA43E2E922_1_2" unitRef="iso4217_USD">28000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:SubsequentEventsTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_2FF84378-F4EF-477E-997F-F5818D357FCE_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;b&gt;16. Subsequent Events&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;Warrant Exchange Agreements&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On February&amp;#xA0;6, 2018, the Company and CVI Investments, Inc.
 (&amp;#x201C;CVI&amp;#x201D;) entered into a warrant exchange agreement (the
 &amp;#x201C;CVI Agreement&amp;#x201D;). The Company had previously issued to
 CVI a warrant to purchase 99,333 shares (on a post-reverse split
 basis) (the &amp;#x201C;CVI Warrant&amp;#x201D;) of its common stock, par
 value $0.0001 per share (the &amp;#x201C;Common Stock&amp;#x201D;) pursuant
 to the registered offering described in the Company&amp;#x2019;s
 prospectus filed with the Securities and Exchange Commission
 pursuant to Rule 424(b)(5) under the Securities Act of 1933 on
 February&amp;#xA0;9, 2017 (the &amp;#x201C;2017 Offering&amp;#x201D; and the
 warrants issued in such offering, the &amp;#x201C;2017 Warrants&amp;#x201D;).
 Pursuant to the CVI Agreement, in exchange for CVI&amp;#x2019;s
 agreement to surrender the CVI Warrant for cancellation, the
 Company agreed to issue to CVI a number of shares of Common Stock
 equal to the quotient resulting from dividing $232,440 by the
 closing sale price of the Common Stock on the first completed
 trading day following the first public announcement by the Company
 of the material terms and conditions of a Company financing
 transaction.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The CVI Agreement contained a &amp;#x201C;Most Favored Nations&amp;#x201D;
 (&amp;#x201C;MFN&amp;#x201D;) clause, allowing CVI to opt to substitute terms
 of warrant exchange agreements entered with other warrant holders
 from the 2017 Offering if CVI deemed those terms more favorable.
 Pursuant to this MFN provision, effective as of March 1, CVI
 Agreement was deemed modified as follows: Pursuant to the CVI
 Agreement, in exchange for the surrender and cancellation of the
 CVI Warrants, the Company issued to CVI a convertible promissory
 note in the aggregate principal amount of $232,440.00 (the
 &amp;#x201C;CVI Note&amp;#x201D;). The CVI Note accrues interest on the
 outstanding principal amount at a rate of 5.0% per annum and the
 entire principal and accrued interest is due and payable on August
 13, 2018. The interest rate increases to 18% per annum during a
 period in which there is an &amp;#x201C;event of default&amp;#x201D; under
 the CVI Note. The holder has the right, from time to time after
 April 30, 2018, to convert the outstanding principal and accrued
 interest into shares of Common Stock at a conversion price equal to
 $7.00 per share (subject to adjustments for stock splits,
 combinations and the like) (the &amp;#x201C;Conversion Price&amp;#x201D;),
 provided that CVI may not affect any such conversions to the extent
 it would beneficially own in excess of 4.99% of the Company&amp;#x2019;s
 outstanding Common Stock. At any time after an event of default has
 occurred (whether or not the Company has cured such default), CVI
 may elect to convert the outstanding principal and accrued interest
 into shares of Common Stock at an alternate conversion price equal
 to the lower of (i) the Conversion Price then in effect at the time
 of such conversion, or (ii) 70% of the lowest VWAP of the Common
 Stock on a trading day during the 10-trading period prior to such
 conversion. For purposes of the CVI Note, an &amp;#x201C;event of
 default&amp;#x201D; is deemed to have occurred upon (A) the suspension
 of trading of the Common Stock on the Nasdaq Capital Market for a
 period of five consecutive trading days, (B) the Company&amp;#x2019;s
 failure to timely deliver shares of Common Stock upon a conversion
 within five trading days of the applicable conversion date or upon
 the Company&amp;#x2019;s notice that it does not intend to comply a
 request by Empery to convert, (C) the Company&amp;#x2019;s or any of its
 subsidiaries&amp;#x2019; failure to timely pay any amount due under the
 CVI Note or the CVI Agreement, (D) the Company&amp;#x2019;s bankruptcy,
 insolvency, liquidation, or similar proceeding, or (E) a breach by
 the Company of any representation, warranty or covenant contained
 in the CVI Note or the CVI Agreement that remains uncured for a
 period of three consecutive trading days. On April 2, 2018, the
 Company and CVI mutually agreed to waive the April 30, 2018 start
 date for the conversion right of the CVI Note, and CVI converted
 the entire outstanding balance of principal and interest on the CVI
 Note into 33,356 shares of Company&amp;#x2019;s Common Stock. As a
 result, the CVI Note is fully paid.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On February&amp;#xA0;7, 2018, the Company entered into a warrant
 exchange agreement (the &amp;#x201C;Anson Agreement&amp;#x201D;) with Anson
 Investments Master Fund LP (&amp;#x201C;Anson&amp;#x201D;). The Company
 previously issued to Anson a warrant to purchase 30,000 shares (on
 a post-reverse split basis) of Common Stock (the &amp;#x201C;Anson
 Warrant&amp;#x201D;) in the 2017 Offering. Pursuant to the Anson
 Agreement, on February&amp;#xA0;8, 2018, the Company issued to Anson
 Investments 12,536 shares of Common Stock in exchange for the
 surrender and cancellation of the Anson Warrant.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On February&amp;#xA0;9, 2018, the Company entered into a warrant
 exchange agreement (the &amp;#x201C;Sabby Agreement&amp;#x201D;) with Sabby
 Healthcare Master Fund Ltd. and Sabby Volatility Warrant Master
 Fund Ltd (collectively, &amp;#x201C;Sabby&amp;#x201D;). The Company had
 previously issued to Sabby warrants to purchase an aggregate of
 83,333 shares (on a post-reverse split basis) of Common Stock (the
 &amp;#x201C;Sabby Warrants&amp;#x201D;) pursuant to the 2017 Offering.
 Pursuant to the Sabby Agreement, in exchange for the surrender and
 cancellation of the Sabby Warrants, the Company will issue to Sabby
 a number of shares of Common Stock determined by dividing $195,000
 by the closing sale price of the Common Stock on the date of the
 closing date of the exchange. Such closing is expected to occur on
 or before February&amp;#xA0;13, 2018, and the Sabby Agreement will
 terminate if such closing does not occur by such date. The Sabby
 Agreement also provides that during
 the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;30-trading&lt;/font&gt;&amp;#xA0;day
 period following the closing of the exchange, Sabby will not sell
 in open market transactions more than 2% of the daily trading
 volume of Common Stock on any one trading day. Further, the Sabby
 Agreement provides that if the Company enters into an agreement
 with a holder of the 2017 Warrants that provides for the exchange
 of such warrants on terms more favorable than those contained in
 the Sabby Agreement, as determined in the reasonable discretion of
 Sabby, then the Company will provide written notice to Sabby and
 the Sabby Agreement will be deemed to have been modified in an
 economically and legally equivalent manner such that Sabby would
 receive such more favorable terms, unless Sabby elects not to
 accept such terms. For purposes of determining whether terms are
 more favorable than the terms contained in the Sabby Agreement, an
 exchange ratio that is based upon 100% of the then market price of
 the Common Stock, even if less than the price applicable to the
 exchange of the Sabby Warrants, is not more favorable than the
 terms of the Sabby Agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 Also on February&amp;#xA0;9, 2018, the Company entered into a warrant
 exchange agreement (the &amp;#x201C;Hudson Bay Agreement&amp;#x201D;) with
 Hudson Bay Master Fund Ltd (&amp;#x201C;Hudson Bay&amp;#x201D;). The Company
 had previously issued to Hudson Bay a warrant to purchase an
 aggregate of 146,666 shares (on a post-reverse split basis) of
 Common Stock (the &amp;#x201C;Hudson Bay Warrant&amp;#x201D;) pursuant to the
 2017 Offering. Pursuant to the Hudson Bay Agreement, in exchange
 for the surrender and cancellation of the Hudson Bay Warrant, the
 Company issued to Hudson Bay a convertible promissory note in the
 principal amount of $343,200 (the &amp;#x201C;Hudson Bay Note&amp;#x201D;).
 The Hudson Bay Agreement also provides that provides that if the
 Company enters into an agreement with a holder of the 2017 Warrants
 that provides for the exchange of such warrants on terms more
 favorable than those contained in the Hudson Bay Agreement,
 including without limitation, with respect to ratio of any cash
 paid, or principal amount of notes or value of Common Stock paid in
 exchange for such warrants, then the Company is to provide notice
 to Hudson Bay within one trading day of such agreement and the
 terms of the Hudson Bay Agreement will be deemed to have been
 modified in an economically and legally equivalent manner such that
 Hudson Bay would receive the benefit of such more favorable terms,
 unless Hudson Bay elects not to accept such terms by a notice
 delivered to the Company within 10 trading days.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The Hudson Bay Note accrues interest on the outstanding principal
 amount at a rate of 5% per annum and the entire principal and
 accrued interest is due and payable on August&amp;#xA0;9, 2018. The
 interest rate increases to 18% per annum during a period in which
 there is an &amp;#x201C;event of default&amp;#x201D; under the Hudson Bay
 Note. The holder has the right, from time to time after
 April&amp;#xA0;30, 2018, to convert the outstanding principal and
 accrued interest into shares of Common Stock at a conversion price
 equal to $7.00 per share (subject to adjustments for stock splits,
 combinations and the like) (the &amp;#x201C;Conversion Price&amp;#x201D;),
 provided that Hudson Bay may not affect any such conversions to the
 extent it would beneficially own in excess of 9.99% of the
 Company&amp;#x2019;s outstanding Common Stock. At and any time after an
 event of default has occurred (whether or not the Company has cured
 such default), Hudson Bay may elect to convert the outstanding
 principal and accrued interest into shares of Common Stock at an
 alternate conversion price equal to the lower of (i)&amp;#xA0;the
 Conversion Price then in effect at the time of such conversion, or
 (ii) 70% of the lowest volume-weighted average price of the Common
 Stock on a trading day during the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;10-trading&lt;/font&gt;&amp;#xA0;period
 prior to such conversion. For purposes of the Hudson Bay Note, an
 &amp;#x201C;event of default&amp;#x201D; is deemed to have occurred upon
 (A)&amp;#xA0;the suspension of trading of the Common Stock on the
 Nasdaq Capital Market for a period of five consecutive trading
 days, (B)&amp;#xA0;the Company&amp;#x2019;s failure to timely deliver shares
 of Common Stock upon a conversion within five trading days of the
 applicable conversion date or upon the Company&amp;#x2019;s notice that
 it does not intend to comply a request by Hudson Bay to convert,
 (C)&amp;#xA0;the Company&amp;#x2019;s or any of its subsidiaries&amp;#x2019;
 failure to timely pay any amount due under the Hudson Bay Note or
 the Hudson Bay Agreement, (D)&amp;#xA0;the Company&amp;#x2019;s bankruptcy,
 insolvency, liquidation, or similar proceeding, or (E)&amp;#xA0;a
 breach by the Company of any representation, warranty or covenant
 contained in the Hudson Bay Note or the Hudson Bay Agreement that
 remains uncured for a period of three consecutive trading days. On
 April 3, 2018, the Company and Hudson Bay mutually agreed to waive
 the April 30, 2018 start date for the conversion right of the
 Hudson Bay Note, and Hudson Bay converted the entire outstanding
 balance of principal and interest on the Hudson Bay Note into
 49,390 shares of Company&amp;#x2019;s Common Stock. As a result, the
 Hudson Bay Note is fully paid.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On February 13, 2018, the Company and Alto Opportunity Master Fund,
 SPC &amp;#x2013; Segregated Master Portfolio B (&amp;#x201C;Alto&amp;#x201D;)
 entered into a warrant exchange agreement (the &amp;#x201C;Alto
 Agreement&amp;#x201D;). The Company had previously issued to Alto a
 warrant to purchase 106,667 shares (on a post-reverse split basis)
 (the &amp;#x201C;Alto Warrant&amp;#x201D;) of its Common Stock pursuant to
 the 2017 Offering. Pursuant to the Alto Agreement, in exchange for
 Alto&amp;#x2019;s agreement to surrender the Alto Warrant for
 cancellation, the Company agreed to issue to Alto a number of
 shares of Common Stock equal to the quotient resulting from
 dividing $249,600 by the closing sale price of the Common Stock on
 the closing date of the exchange. Pursuant to the Alto Agreement,
 on February 15, 2018, the Company issued to Alto 45,464 shares of
 Common Stock in exchange for the surrender and cancellation of the
 Alto Warrant.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The Alto Agreement contained a MFN clause, allowing Alto to opt to
 substitute terms of Warrant Exchange Agreements entered with other
 warrant holders from the 2017 Offering if Alto deemed those terms
 more favorable. Pursuant to this MFN clause, effective as of
 February 13, 2018, shares previously issued to Alto under the Alto
 Agreement were returned/cancelled and the Alto Agreement was deemed
 modified as follows: Pursuant to the Alto Agreement, in exchange
 for the surrender and cancellation of the Alto Warrants, the
 Company issued to Alto a convertible promissory note in the
 aggregate principal amount of $249,600.00 (the &amp;#x201C;Alto
 Note&amp;#x201D;). The Alto Note accrues interest on the outstanding
 principal amount at a rate of 5.0% per annum and the entire
 principal and accrued interest is due and payable on August 13,
 2018. The interest rate increases to 18% per annum during a period
 in which there is an &amp;#x201C;event of default&amp;#x201D; under the Alto
 Note. The holder has the right, from time to time after April 30,
 2018, to convert the outstanding principal and accrued interest
 into shares of Common Stock at the Conversion Price provided that
 Alto may not affect any such conversions to the extent it would
 beneficially own in excess of 9.99% of the Company&amp;#x2019;s
 outstanding Common Stock. At any time after an event of default has
 occurred (whether or not the Company has cured such default), Alto
 may elect to convert the outstanding principal and accrued interest
 into shares of Common Stock at an alternate conversion price equal
 to the lower of (i) the Conversion Price then in effect at the time
 of such conversion, or (ii) 70% of the lowest volume-weighted
 average price of the Common Stock on a trading day during the
 10-trading period prior to such conversion. For purposes of the
 Alto Note, an &amp;#x201C;event of default&amp;#x201D; is deemed to have
 occurred upon (A) the suspension of trading of the Common Stock on
 the Nasdaq Capital Market for a period of five consecutive trading
 days, (B) the Company&amp;#x2019;s failure to timely deliver shares of
 Common Stock upon a conversion within five trading days of the
 applicable conversion date or upon the Company&amp;#x2019;s notice that
 it does not intend to comply a request by Empery to convert, (C)
 the Company&amp;#x2019;s or any of its subsidiaries&amp;#x2019; failure to
 timely pay any amount due under the Alto Note or the Alto
 Agreement, (D) the Company&amp;#x2019;s bankruptcy, insolvency,
 liquidation, or similar proceeding, or (E) a breach by the Company
 of any representation, warranty or covenant contained in the Alto
 Note or the Alto Agreement that remains uncured for a period of
 three consecutive trading days. On April 2, 2018, the Company and
 Alto mutually agreed to waive the April 30, 2018 start date for the
 conversion right of the Alto Note, and Alto converted the entire
 outstanding balance of principal and interest on the Alto Note into
 35,998 shares of Company&amp;#x2019;s Common Stock. As a result, the
 Alto Note is fully paid.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On February 14, 2018, the Company entered into a warrant exchange
 agreement (the &amp;#x201C;Lincoln Park Agreement&amp;#x201D;) with Lincoln
 Park Capital Fund LLC (&amp;#x201C;Lincoln Park&amp;#x201D;). The Company
 previously issued to Lincoln Park a warrant to purchase 8,333
 shares (on a post-reverse split basis) of Common Stock (the
 &amp;#x201C;Lincoln Park Warrant&amp;#x201D;) in the 2017 Offering. Pursuant
 to the Lincoln Park Agreement, on February 19, 2018, the Company
 issued to Lincoln Park Capital 3,421 shares of Common Stock in
 exchange for the surrender and cancellation of the Lincoln Park
 Warrant.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On February&amp;#xA0;22, 2018, the Company entered into a warrant
 exchange agreement (the &amp;#x201C;Empery Agreement&amp;#x201D;) with Empery
 Asset Master Ltd., Empery Tax Efficient, LP and Empery Tax
 Efficient II, LP (collectively, &amp;#x201C;Empery&amp;#x201D;). The Company
 had previously issued to Empery warrants to purchase an aggregate
 of 26,668 shares (on a post-reverse split basis) (the &amp;#x201C;Empery
 Warrants&amp;#x201D;) of its common stock, par value $0.0001 per share
 (the &amp;#x201C;Common Stock&amp;#x201D;) pursuant to the registered
 offering described in the Company&amp;#x2019;s prospectus filed with the
 Securities and Exchange Commission pursuant to Rule 424(b)(5) under
 the Securities Act of 1933 on February&amp;#xA0;9, 2017 (the
 &amp;#x201C;2017 Offering&amp;#x201D; and the warrants issued in such
 offering, the &amp;#x201C;2017 Warrants&amp;#x201D;). Pursuant to the Empery
 Agreement, in exchange for the surrender and cancellation of the
 Empery Warrants, the Company issued to Empery convertible
 promissory notes in the aggregate principal amount of $64,403.12
 (the &amp;#x201C;Empery Notes&amp;#x201D;). The Empery Agreement also
 provides that if the Company enters into an agreement with a holder
 of the 2017 Warrants that provides for the exchange of such
 warrants on terms more favorable than those contained in the Empery
 Agreement, including without limitation, with respect to ratio of
 any cash paid, or principal amount of notes or value of Common
 Stock paid in exchange for such warrants, then the Company is to
 provide notice to Empery within one trading day of such agreement
 and the terms of the Empery Agreement will be deemed to have been
 modified in an economically and legally equivalent manner such that
 Empery would receive the benefit of such more favorable terms,
 unless Empery elects not to accept such terms by a notice delivered
 to the Company within 10 trading days.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The Empery Notes accrue interest on the outstanding principal
 amount at a rate of 4.75% per annum and the entire principal and
 accrued interest is due and payable on August&amp;#xA0;22, 2018. The
 interest rate increases to 18% per annum during a period in which
 there is an &amp;#x201C;event of default&amp;#x201D; under the Empery Notes.
 The holder has the right, from time to time after April&amp;#xA0;30,
 2018, to convert the outstanding principal and accrued interest
 into shares of Common Stock at the Conversion Price, provided that
 Empery may not affect any such conversions to the extent it would
 beneficially own in excess of 9.99% of the Company&amp;#x2019;s
 outstanding Common Stock. At any time after an event of default has
 occurred (whether or not the Company has cured such default),
 Empery may elect to convert the outstanding principal and accrued
 interest into shares of Common Stock at an alternate conversion
 price equal to the lower of (i)&amp;#xA0;the Conversion Price then in
 effect at the time of such conversion, or (ii) 70% of the lowest
 volume-weighted average price of the Common Stock on a trading day
 during the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;10-trading&lt;/font&gt;&amp;#xA0;period
 prior to such conversion. For purposes of the Empery Notes, an
 &amp;#x201C;event of default&amp;#x201D; is deemed to have occurred upon
 (A)&amp;#xA0;the suspension of trading of the Common Stock on the
 Nasdaq Capital Market for a period of five consecutive trading
 days, (B)&amp;#xA0;the Company&amp;#x2019;s failure to timely deliver shares
 of Common Stock upon a conversion within five trading days of the
 applicable conversion date or upon the Company&amp;#x2019;s notice that
 it does not intend to comply a request by Empery to convert,
 (C)&amp;#xA0;the Company&amp;#x2019;s or any of its subsidiaries&amp;#x2019;
 failure to timely pay any amount due under the Empery Notes or the
 Empery Agreement, (D)&amp;#xA0;the Company&amp;#x2019;s bankruptcy,
 insolvency, liquidation, or similar proceeding, or (E)&amp;#xA0;a
 breach by the Company of any representation, warranty or covenant
 contained in the Empery Notes or the Empery Agreement that remains
 uncured for a period of three consecutive trading days.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The Company&amp;#x2019;s entry into each of the warrant exchange
 agreements were the result of separate private negotiations between
 the Company and each of the named companies.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;Series A Convertible Preferred&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On March&amp;#xA0;7, 2018, the Company entered into a Securities
 Purchase Agreement with investors, pursuant to which the Company
 agreed to sell to the Investors, in a private placement pursuant to
 Rule 4(a)(2) and Regulation S under the Securities Act of 1933, as
 amended, an aggregate of 10,700 shares of the Company&amp;#x2019;s
 newly-created&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-voting&lt;/font&gt;&amp;#xA0;Series A
 Convertible Preferred, and warrants to acquire an aggregate
 1,383,631 shares of the Company&amp;#x2019;s common stock, par value
 $0.0001 per share at an aggregate purchase price of $10,700,000.
 The Series A Convertible Preferred is initially convertible into
 1,844,835 shares of common stock based on an initial conversion
 price of $5.80 per share.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 At the first closing of the Series A Convertible Preferred on
 March&amp;#xA0;9, 2018, the Company issued an aggregate 5,987 shares of
 Series A Convertible Preferred and 774,186 Warrants for aggregate
 gross proceeds of $5,987,000. The second closing of the remaining
 4,713 shares of the Series A Convertible Preferred and 609,445
 shares of common stock, for aggregate gross proceeds of $4,713,000
 will occur within five business days of receipt of necessary
 stockholder approval under the applicable rules and regulations of
 the Nasdaq Stock Market LLC. Under the Series A Convertible
 Preferred, the Company is obligated to seek stockholder approval no
 later than May&amp;#xA0;7, 2018 (within 60 days of the date of the
 Series A Convertible Preferred), and will file proxy materials with
 the U.S. Securities and Exchange Commission in connection
 therewith.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The Company&amp;#x2019;s directors, executive officers and beneficial
 owners of more than 10% of the Company&amp;#x2019;s common stock, who
 collectively hold more than 50% of the Company&amp;#x2019;s outstanding
 voting power, entered into voting agreements dated March&amp;#xA0;9,
 2018, pursuant to which they agreed to vote in favor of any
 resolution presented to the stockholders of the Company to approve
 the issuance, in the aggregate, of greater than 19.99% of the
 common stock outstanding prior to the entry into the Series A
 Convertible Preferred, for less than the greater of the book or
 market value of the common stock as required by the listing rules
 of The Nasdaq Stock Market. In addition, such persons also entered
 into&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;lock-up&lt;/font&gt;&amp;#xA0;agreements
 pursuant to which they agreed to refrain from certain transactions
 in the Company&amp;#x2019;s equity securities until the earlier of
 (i)&amp;#xA0;September&amp;#xA0;9, 2018 (the six month anniversary of the
 first closing) and (ii)&amp;#xA0;the initial closing date of a
 Qualified Offering (as such term is defined in the purchase
 agreement). Under the Series A Convertible Preferred, the Company
 also agreed to refrain from issuing, or entering into any agreement
 to issue, or announcing the issuance or proposed issuance of any
 shares of common stock or common stock equivalents (subject to
 certain exclusions) prior to obtaining such stockholder
 approval.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 Qualified Offering is defined in the purchase agreement and the
 Certificate of Designation (as defined below) as a public offering
 raising aggregate gross proceeds of no less than
 $20.0&amp;#xA0;million. In the event of a Qualified Offering, under the
 Series A Convertible Preferred, investors have the right to acquire
 the securities sold in such Qualified Offering by converting their
 shares of Series A Convertible Preferred into the same securities
 on a $1.00 for $1.00 basis based on the stated value of their
 shares of Series A Convertible Preferred.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;u&gt;Series A Convertible Preferred&lt;/u&gt;: On March&amp;#xA0;8, 2018, the
 Company filed a Certificate of Designation of Preferences, Rights
 and Limitations of Series A 20% Convertible Preferred Stock (the
 &amp;#x201C;Certificate of Designation&amp;#x201D;) with the Secretary of
 State of the State of Delaware, which designated up to 17,500
 shares of Series A Convertible Preferred. The shares of Series A
 Convertible Preferred have a stated value equal to $1,000 and bear
 cumulative dividends, payable in cash or shares of common stock at
 the Company&amp;#x2019; option, at a rate of 20% per annum, payable
 semiannually in arrears on June&amp;#xA0;30 and December&amp;#xA0;31,
 beginning on the first such date after issuance, and upon
 conversion if accrued and unpaid at such time. Such dividends cease
 to accrue upon the consummation of a Qualified Offering.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 Shares of Series A Convertible Preferred are convertible into
 common stock at the option the holder from time to time. Prior to
 receipt of stockholder approval, such conversion is limited to an
 Investor&amp;#x2019;s&amp;#xA0;&lt;i&gt;pro
 rata&lt;/i&gt;&amp;#xA0;share of the aggregate 19.99% limit
 under applicable Nasdaq rules and regulations. Following receipt of
 stockholder approval, conversion is subject to a beneficial
 ownership limitation of 4.99% (or 9.99% at the option of the
 Investor).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The initial conversion price is $5.80 per share of common stock,
 subject to standard adjustments for certain transactions affecting
 the Company&amp;#x2019;s securities (such as stock dividends, stock
 splits, and the like). Until consummation of a Qualified Offering,
 such conversion price is also subject to anti-dilution price
 protection in the event of&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-exempt&lt;/font&gt;&amp;#xA0;equity
 issuances at a price per share lower than the then applicable
 conversion price. If the Company has not consummated a Qualified
 Offering (as defined in the Certificate of Designation) on or
 before September&amp;#xA0;9, 2018 (the six month anniversary of the
 first closing), on each of the six month anniversary of the first
 and the second closings, the Conversion Price shall be reduced to
 the lesser of (x)&amp;#xA0;the then applicable Conversion Price, as
 adjusted, (y) $3.00 (subject to adjustment for forward and reverse
 stock splits and the like) and (z)&amp;#xA0;the lowest VWAP for any
 trading day during the five trading days immediately following each
 such adjustment date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The Series A Convertible Preferred generally have no voting rights.
 However, for so long as any shares of Series A Convertible
 Preferred are outstanding, the affirmative vote of the holders of a
 majority of the then outstanding shares of the Series A Convertible
 Preferred is required to: (a)&amp;#xA0;alter or change adversely the
 powers, preferences or rights given to the Series A Convertible
 Preferred or alter or amend the Certificate of Designation,
 (b)&amp;#xA0;authorize or create any class of stock ranking as to
 dividends, redemption or distribution of assets upon a Liquidation
 (as defined in the Certificate of Designation) senior to, or
 otherwise&amp;#xA0;&lt;i&gt;pari
 passu&lt;/i&gt;&amp;#xA0;with, the Series A Convertible
 Preferred (c)&amp;#xA0;amend its certificate of incorporation or other
 charter documents in any manner that adversely affects any rights
 of the holders of Series A Convertible Preferred, (d)&amp;#xA0;increase
 the number of authorized shares of Series A Convertible Preferred,
 or (e)&amp;#xA0;enter into any agreement with respect to any of the
 foregoing.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 Upon any liquidation, dissolution or&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;winding-up&lt;/font&gt;&amp;#xA0;of the
 Company, whether voluntary or involuntary that is not a Fundamental
 Transaction (as defined in the Certificate of Designation), the
 holders of Series A Convertible Preferred are entitled to receive
 out of the assets the Company the same amount they would have
 received on an as converted basis, disregarding any conversion
 limitations. Such amounts are paid on
 a&lt;i&gt;&amp;#xA0;pari&lt;/i&gt;&lt;i&gt;&amp;#xA0;passu&amp;#xA0;&lt;/i&gt;basis with
 all holders of Common Stock.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;u&gt;Warrants&lt;/u&gt;: Under the Purchase Agreement, the Company agreed
 to issue Warrants to acquire an aggregate of 1,383,631 shares of
 Common Stock, or approximately 75% of the shares of Common Stock
 into which the Series A Convertible Preferred are initially
 exercisable. The Warrants have an initial exercise price of $6.59
 per share, subject to adjustment in certain circumstances, may not
 be exercised until the date that is six months after issuance, and
 have a term of five years from the initial exercise date. Prior to
 receipt of stockholder approval, exercise of the Warrants is
 limited to an Investor&amp;#x2019;s pro rata share of the aggregate
 19.99% limit under applicable Nasdaq rules and regulations.
 Exercise is also subject to a beneficial ownership limitation of
 4.99% (or 9.99% at the option of the Investor.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;u&gt;Placement Agent&lt;/u&gt;: Cantor Fitzgerald&amp;#xA0;&amp;amp; Co.
 (&amp;#x201C;Cantor&amp;#x201D;) acted as placement agent pursuant to an
 engagement letter dated January&amp;#xA0;16, 2018 (the
 &amp;#x201C;Engagement Letter&amp;#x201D;). Under the engagement letter, the
 Company agreed to pay Cantor a fee equal to 7% of the gross
 proceeds received by the Company from United States based
 Investors. The Company also agreed to reimburse Cantor for its
 actual,&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;out-of-pocket&lt;/font&gt;&lt;/font&gt;&amp;#xA0;accountable
 expenses (including legal fees and expenses) incurred in connection
 with the Private Placement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;Neuvax Phase 2b Clinical Trial&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On April 2, 2018 and in connection with the Company&amp;#x2019;s
 single-blinded, controlled Phase 2b independent
 investigator-sponsored clinical trial of Herceptin:
 Genentech/Roche) +/- NeuVax in HER2 1+/2+ breast cancer patients,
 we announced the interim efficacy analysis, conducted by an
 independent Data Safety Monitoring Board of the efficacy and safety
 data for the study in an overall population of 275 patients as well
 as the two primary study target patient populations (node-positive
 and triple negative breast cancer (&amp;#x201C;TNBC&amp;#x201D;)) after a
 median follow-up of 19 months, demonstrated a clinically meaningful
 difference in median disease-free survival in favor of the active
 arm (NeuVax + Herceptin), a primary endpoint of the study, with
 hazard ratios of 0.67 and 0.61 in the intent to treat and modified
 intent to treat populations (i.e., those who received at least one
 dose of vaccine or control) as well as a 34.9% and 39.5% reduction
 in relative risk of recurrence in the active versus control arms in
 the intent to treat and modified intent to treat populations,
 respectively. A clinically meaningful and also statistically
 significant difference was found between the two arms in the cohort
 of patients (n= 98) with TNBC, with a hazard ratio of 0.26 and a
 p-value of 0.023 in favor of the NeuVax + Herceptin combination.
 Similarly, a clinically meaningful and statistically significant
 difference was found between the two arms in favor of the
 combination in the cohort of patients not receiving hormonal
 therapy (n = 110), with a hazard ratio of 0.24 and a p-value of
 0.009. This pre-specified interim analysis also showed an adverse
 event profile with no notable differences between treatment arms.
 This analysis confirmed the 2016 data showing that the addition of
 NeuVax to Herceptin did not result in any additional cardiotoxicity
 compared to Herceptin alone. Based on these results, and the
 independent Data Safety Monitoring Board&amp;#x2019;s recommendation,
 the Company plans to expeditiously seek regulatory guidance by the
 FDA for further development of the combination of NeuVax +
 Herceptin in TNBC, considering the statistically significant
 benefit of the combination therapy seen in this population with
 large unmet medical need.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;i&gt;JGB Action&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On or about April 9, 2018, JGB filed a lawsuit in the U.S. District
 Court for the Southern District of New York
 captioned&amp;#xA0;&lt;i&gt;JGB (Cayman) Newton, Ltd. v. Sellas
 Life Sciences Group, Inc., et al.&lt;/i&gt;, Case 1:18-cv-3095 (DLC), or
 the JGB Action. The complaint in the JGB Action asserts claims
 under state law and federal securities law against the Company, the
 Company&amp;#x2019;s Chief Executive Officer, Dr. Stergiou and Angelos
 M. Stergiou, M.D., ScD H.C, and the Company&amp;#x2019;s Interim Chief
 Financial Officer, Aleksey N. Krylov (Mr.&amp;#xA0;Krylov together with
 the Company and Dr.&amp;#xA0;Stergiou, the &amp;#x201C;Defendants&amp;#x201D;).
 The complaint in the JGB Action alleges, among other things, that
 we breached a contractual obligation to deliver certain shares of
 the Company&amp;#x2019;s common stock to JGB and that, in the course of
 negotiations related to the senior secured debenture agreement, the
 Defendants failed to disclose to JGB certain information regarding
 positive clinical trial results that was not then public. According
 to the complaint, JGB seeks to receive 2,483,500 shares of the
 Company&amp;#x2019;s common stock, damages, and costs and expenses
 incurred in the JGB action, among other things. The Company
 disputes the claims in the JGB Action and intends to defend against
 them vigorously. The Company has retained the law firm Skadden,
 Arps, Slate, Meagher &amp;amp; Flom LLP, as its defense counsel for the
 JGB Action.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <dei:TradingSymbol contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_C91A2C78-0B97-47A5-BD75-FD7EC3655142_1_0">SLS</dei:TradingSymbol>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_33F2FDB9-F32B-459B-9FE9-F2CA43E2E922_1_1" unitRef="iso4217_USD">44000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="0" id="id_10184323_4057F5D7-0584-4138-8CED-8368A48EFB93_1_12" unitRef="shares">2340368</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-5" id="id_10184323_FF1169F2-4481-44E9-82B6-4E32DB0850BA_1_2" unitRef="iso4217_USD">1200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:UseOfEstimates contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_1432FEC5-9D70-4A3A-9CBA-9D12E69C1762_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The preparation of these consolidated financial statements in
 accordance with U.S. GAAP requires management to make estimates and
 assumptions that affect the reported amounts of assets and
 liabilities and disclosure of contingent assets and liabilities at
 the date of the financial statements and the reported amounts of
 expenses during the reporting period.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 On an ongoing basis, the Company evaluates its estimates using
 historical experience and other factors, including the current
 economic environment. Significant items subject to such estimates
 are assumptions used for purposes of determining stock-based
 compensation, the fair value of the warrants, beneficial conversion
 features associated with convertible notes, fair value of
 intangible assets acquired, carrying value of goodwill, fair value
 of contingent purchase price consideration, fair value of deferred
 tax liability assumed and accounting for research and development
 activities. Management believes its estimates to be reasonable
 under the circumstances. Actual results could differ significantly
 from those estimates.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:UseOfEstimates>
  <sls:LitigationSettlementAmountCash contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="0" id="id_10184323_CA378F64-E90B-484F-98B6-B1B16B6C72B7_1_1" unitRef="iso4217_USD">50000</sls:LitigationSettlementAmountCash>
  <sls:NonCashResearchAndDevelopmentExpense contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_1_4" unitRef="iso4217_USD">258000</sls:NonCashResearchAndDevelopmentExpense>
  <sls:ChangeInFairValueOfWarrantLiabilities contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_4B76D830-5163-4ACC-B094-4F802F4CE47B_4003_4" unitRef="iso4217_USD">0</sls:ChangeInFairValueOfWarrantLiabilities>
  <sls:FairValueOfWarrantsExercised contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_4B76D830-5163-4ACC-B094-4F802F4CE47B_4003_3" unitRef="iso4217_USD">1309000</sls:FairValueOfWarrantsExercised>
  <sls:ClassOfWarrantOrRightGranted contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_1DED8646-51CA-4296-813D-28D45E65FF74_4004_2" unitRef="shares">316000</sls:ClassOfWarrantOrRightGranted>
  <sls:ClassOfWarrantOrRightExpired contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_1DED8646-51CA-4296-813D-28D45E65FF74_4004_4" unitRef="shares">0</sls:ClassOfWarrantOrRightExpired>
  <sls:ClassOfWarrantOrRightAssumedInAcquisition contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_1DED8646-51CA-4296-813D-28D45E65FF74_4004_3" unitRef="shares">647000</sls:ClassOfWarrantOrRightAssumedInAcquisition>
  <sls:OperatingLossCarryforwardsExpirationYearRangeStart contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_32907868-21F8-4A59-B617-E9DD62A46EB3_1_2">2027</sls:OperatingLossCarryforwardsExpirationYearRangeStart>
  <sls:OperatingLossCarryforwardsExpirationYearRangeEnd contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_32907868-21F8-4A59-B617-E9DD62A46EB3_1_5">2027</sls:OperatingLossCarryforwardsExpirationYearRangeEnd>
  <sls:ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_5207D1E9-C9E4-424A-8763-C281F6D367C2_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 The components of net deferred tax liabilities are as follows (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="84%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;As&amp;#xA0;of&amp;#xA0;December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;font style="WHITE-SPACE: nowrap"&gt;In-process&lt;/font&gt; research and
 development not subject to future amortization for tax purposes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,438&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Gross deferred tax liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,438&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</sls:ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock>
  <sls:GoodwillPolicyTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_FFDC3D62-31B7-41C3-A325-4EB5D9853FB7_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Goodwill&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Goodwill is the excess of the cost of an acquired entity over the
 net amounts assigned to tangible and intangible assets acquired and
 liabilities assumed. Goodwill is not amortized but is subject to an
 annual impairment test. The Company has a single reporting unit and
 all goodwill relates to that reporting unit.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company performs its annual goodwill impairment test at the
 reporting unit level on October&amp;#xA0;1 of each fiscal year or more
 frequently if changes in circumstances or the occurrence of events
 suggest that an impairment exists. Goodwill is evaluated for
 impairment using the simplified test of goodwill impairment as
 defined by the FASB Accounting Standards Update &lt;font style="white-space:nowrap"&gt;No.&amp;#xA0;2017-04.&lt;/font&gt; Under the new
 guidance, goodwill impairment will be measured by the amount by
 which the carrying value of a reporting unit exceeds its fair
 value, without exceeding the carrying amount of goodwill allocated
 to that reporting unit. If the fair value of the reporting unit is
 less than its carrying value, an impairment loss is recorded to the
 extent that the implied fair value of the reporting unit&amp;#x2019;s
 goodwill is less than the carrying value of the reporting
 unit&amp;#x2019;s goodwill. The Company did not recognize any impairment
 of goodwill during the year ended December&amp;#xA0;31, 2017.&lt;/p&gt;
 &lt;/div&gt;</sls:GoodwillPolicyTextBlock>
  <sls:CommonStockAreReservedForFutureIssuanceTableTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_512D825F-6F40-4A1D-9050-2EB846F65CAC_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Shares of common stock as of December&amp;#xA0;31, 2017 for future
 issuance are reserved for as follows (in thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="68%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="91%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Warrants outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;963&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Stock options outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Restricted stock units&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Options reserved for future issuance under the Company&amp;#x2019;s 2017
 Equity Incentive Plan&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;575&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Shares reserved for future issuance under the Employee Stock
 Purchase Plan&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;58&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total reserved for future issuance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,619&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</sls:CommonStockAreReservedForFutureIssuanceTableTextBlock>
  <sls:ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_69C5DFFA-C9BF-49E0-94B0-C3C0A97DADB3_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The components of net deferred tax assets are as follows (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="80%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;As of December&amp;#xA0;31,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net operating loss carryforwards&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,028&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,145&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Tax credit carryforwards&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;345&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;295&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Stock based compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,550&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Licensing deduction deferral&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,105&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;395&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;81&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Gross deferred tax assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,423&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,549&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4,658&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,508&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net deferred tax asset&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,765&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;41&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</sls:ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock>
  <sls:BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="2" id="id_10184323_38CF6218-B6A1-4D37-B903-AD80F2D9E61B_1_2" unitRef="iso4217_USD_per_shares">5.15</sls:BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted>
  <sls:EffectiveIncomeTaxRateReconciliationPermanentDifferences contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="3" id="id_10184323_7AD9BED1-97A1-4F8A-8327-635515D3BD72_1_3" unitRef="pure">0.011</sls:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
  <sls:ChangesInFairValueOfWarrantLiabilityTableTableTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_A35E8427-B6AD-496E-A70C-415841A8BB18_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The changes in fair value of the warrant liability for the year
 ended December&amp;#xA0;31, 2017 were as follows (in thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="56%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:61.50pt; display:inline; font-size:8pt; font-family:Times New Roman;"&gt;
 &lt;b&gt;Warrant Issuance&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Warrant&lt;br /&gt;
 liability,&lt;br /&gt;
 January&amp;#xA0;1,&lt;br /&gt;
 2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;
 &lt;b&gt;Fair&amp;#xA0;value&amp;#xA0;of&lt;br /&gt;
 warrants&lt;br /&gt;
 granted&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;
 &lt;b&gt;Fair&amp;#xA0;value&amp;#xA0;of&lt;br /&gt;
 warrants&lt;br /&gt;
 acquired&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;
 &lt;b&gt;Change&amp;#xA0;in&amp;#xA0;fair&lt;br /&gt;
 value of&lt;br /&gt;
 warrants&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Warrant&lt;br /&gt;
 liability,&lt;br /&gt;
 December&amp;#xA0;31,&lt;br /&gt;
 2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Galena February 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,305&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,305&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Galena other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;br /&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;br /&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;br /&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,309&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,309&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</sls:ChangesInFairValueOfWarrantLiabilityTableTableTextBlock>
  <sls:FairValueofWarrantsGranted contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_4B76D830-5163-4ACC-B094-4F802F4CE47B_4003_2" unitRef="iso4217_USD">0</sls:FairValueofWarrantsGranted>
  <sls:IssuanceofCommonStockforLitigationSettlement contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="0" id="id_10184323_CA378F64-E90B-484F-98B6-B1B16B6C72B7_1_2" unitRef="iso4217_USD">1250000</sls:IssuanceofCommonStockforLitigationSettlement>
  <sls:PatentsAndPatentApplicationCostsPolicyPolicyTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_46357B81-D968-4FB9-A4BB-3DDEED600FBD_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Patents and Patent Application Costs&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Although the Company believes that its patents and underlying
 technology have continuing value, the amount of future benefits to
 be derived from the patents is uncertain. Patent costs are,
 therefore, expensed as incurred.&lt;/p&gt;
 &lt;/div&gt;</sls:PatentsAndPatentApplicationCostsPolicyPolicyTextBlock>
  <sls:ScheduleOfWarrantValuationAssumptionsTableTableTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_D3D077DA-1CE1-470F-8BA2-AEBD3D4C5E15_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The fair value of the warrants as of December&amp;#xA0;31, 2017 is
 estimated using a Black-Scholes pricing model with the following
 inputs:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="50%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:61.50pt; display:inline; font-size:8pt; font-family:Times New Roman;"&gt;
 &lt;b&gt;Warrant Issuance&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Outstanding&amp;#xA0;(in&lt;br /&gt;
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;
 &lt;b&gt;Strike&amp;#xA0;price&amp;#xA0;(per&lt;br /&gt;
 share)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Expected&amp;#xA0;term&lt;br /&gt;
 (years)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Volatility%&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;&lt;font style="white-space:nowrap"&gt;Risk-free&amp;#xA0;rate&lt;/font&gt;&lt;br /&gt;
 %&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Galena February 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;567&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;33.00&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.12&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;79.29&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.09&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Galena other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;76&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;888.22&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.74&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;72.46&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.00&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</sls:ScheduleOfWarrantValuationAssumptionsTableTableTextBlock>
  <sls:ScheduleOfWarrantActivityTableTableTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_D897629E-83FB-44A2-8117-16E040039EB4_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The following is a summary of warrant activity for the years ended
 December&amp;#xA0;31, 2017 (in thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="49%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:61.50pt; display:inline; font-size:8pt; font-family:Times New Roman;"&gt;
 &lt;b&gt;Warrant Issuance&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Outstanding,&lt;br /&gt;
 January&amp;#xA0;1,&lt;br /&gt;
 2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Granted&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Assumed&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;through&lt;br /&gt;
 Merger&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Expired&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Outstanding,&lt;br /&gt;
 December&amp;#xA0;31,&lt;br /&gt;
 2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Expiration&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 2017 Equilibria&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;316&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;316&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;December&amp;#xA0;2022&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Galena February 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;567&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;567&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;February 2022&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Galena other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;80&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;80&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;Various&amp;#xA0;to&amp;#xA0;2022&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;316&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;647&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;963&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</sls:ScheduleOfWarrantActivityTableTableTextBlock>
  <sls:StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_7005_800019" unitRef="iso4217_USD">388000</sls:StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue>
  <sls:StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_7005_800025" unitRef="iso4217_USD">378000</sls:StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable>
  <sls:StockIssuedForAntiDilutionProvisions contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_7005_800037" unitRef="iso4217_USD">61000</sls:StockIssuedForAntiDilutionProvisions>
  <sls:StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_7005_800035" unitRef="iso4217_USD">941000</sls:StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod>
  <sls:SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_7005_800032" unitRef="iso4217_USD">6739000</sls:SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod>
  <sls:IntangibleAssetsIndefinitelivedPolicyPolicyTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_A033AD85-DFFE-4AA1-898A-8D9A62161B3B_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Intangible Assets&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Intangible assets are comprised of identifiable &lt;font style="white-space:nowrap"&gt;in-process&lt;/font&gt; research and development
 (&amp;#x201C;IPR&amp;amp;D&amp;#x201D;) assets and are considered
 indefinite-lived intangible assets and are assessed for impairment
 annually on October&amp;#xA0;1 or more frequently if impairment
 indicators exist. If the associated research and development effort
 is abandoned, the related assets will be &lt;font style="white-space:nowrap"&gt;written-off&lt;/font&gt; and the Company will record
 a &lt;font style="white-space:nowrap"&gt;non-cash&lt;/font&gt; impairment loss.
 For those compounds that reach commercialization, the IPR&amp;amp;D
 assets will be amortized over their estimated useful lives.&lt;/p&gt;
 &lt;/div&gt;</sls:IntangibleAssetsIndefinitelivedPolicyPolicyTextBlock>
  <sls:ComprehensiveLossPolicyPolicyTextBlock contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_3F0A528E-90FD-4C05-899F-5D5B8D5638B7_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Comprehensive Loss&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company has no items of comprehensive income or loss other than
 net loss.&lt;/p&gt;
 &lt;/div&gt;</sls:ComprehensiveLossPolicyPolicyTextBlock>
  <sls:BusinessCombinationProFormaTransactionCosts contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-5" id="id_10184323_4828D19F-FB8A-4A68-A803-4CA2B717ED01_1_6" unitRef="iso4217_USD">8700000</sls:BusinessCombinationProFormaTransactionCosts>
  <sls:BusinessCombinationFairValueOfSharesOutstanding contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_02BA9B88-9563-4EF2-AA2B-2AE073CCF50A_1_0" unitRef="iso4217_USD">12487000</sls:BusinessCombinationFairValueOfSharesOutstanding>
  <sls:BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_02BA9B88-9563-4EF2-AA2B-2AE073CCF50A_1_1" unitRef="iso4217_USD">32000</sls:BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding>
  <sls:AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_7005_800031" unitRef="iso4217_USD">32000</sls:AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition>
  <sls:SharesIssuedInConnectionWithAcquisition contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_1_31" unitRef="iso4217_USD">12487000</sls:SharesIssuedInConnectionWithAcquisition>
  <sls:FairValueOfStockOptionsAssumedInConnectionWithAcquisition contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_1_32" unitRef="iso4217_USD">32000</sls:FairValueOfStockOptionsAssumedInConnectionWithAcquisition>
  <sls:SharesIssuedToSettlerElatedPartyAccountsPayable contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_1_33" unitRef="iso4217_USD">228000</sls:SharesIssuedToSettlerElatedPartyAccountsPayable>
  <sls:SharesIssuedToSettleAccountsPayable contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_1_34" unitRef="iso4217_USD">150000</sls:SharesIssuedToSettleAccountsPayable>
  <sls:DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_1_39" unitRef="iso4217_USD">675000</sls:DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance>
  <sls:OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="INF" id="id_10184323_D18C8AE4-37F3-40E4-9EA6-0C8EF1735FC6_1_1" unitRef="pure">0.50</sls:OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage>
  <sls:MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="INF" id="id_10184323_FF1169F2-4481-44E9-82B6-4E32DB0850BA_1_0" unitRef="pure">0.80</sls:MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss>
  <sls:OperatingLossAndTaxCreditCarryforwardsLimitationsOnUsePeriodOfOwnershipPercentage contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" id="id_10184323_D18C8AE4-37F3-40E4-9EA6-0C8EF1735FC6_1_0">P3Y</sls:OperatingLossAndTaxCreditCarryforwardsLimitationsOnUsePeriodOfOwnershipPercentage>
  <sls:DeemedDividendOnDebtConversion contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_4057F5D7-0584-4138-8CED-8368A48EFB93_1_9" unitRef="iso4217_USD">675000</sls:DeemedDividendOnDebtConversion>
  <sls:AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_7005_800034" unitRef="iso4217_USD">-675000</sls:AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion>
  <sls:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInAcquisitionGrantDateIntrinsicValue contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0" decimals="0" id="id_10184323_18A7C5E6-643A-43B9-96BE-7B5CEADC0C13_7001_5" unitRef="iso4217_USD_per_shares">0</sls:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInAcquisitionGrantDateIntrinsicValue>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2433098x2438181" decimals="0" id="id_10184323_89149E78-1DB1-40DA-95B5-345B45F730E2_1001_1" unitRef="shares">10</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2433098x2447533" decimals="0" id="id_10184323_89149E78-1DB1-40DA-95B5-345B45F730E2_2001_2" unitRef="shares">13</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2433098x2450820" decimals="0" id="id_10184323_89149E78-1DB1-40DA-95B5-345B45F730E2_3001_0" unitRef="shares">963</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2433414x2666068" id="id_10184323_F0588A4C-1948-49EE-820D-9A0244D94BB5_1001_2">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2433414x2666068" decimals="INF" id="id_10184323_F0588A4C-1948-49EE-820D-9A0244D94BB5_1001_4" unitRef="shares">102279</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <sls:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2433414x2666068" decimals="2" id="id_10184323_F0588A4C-1948-49EE-820D-9A0244D94BB5_1001_0" unitRef="pure">0.15</sls:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants>
  <sls:PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2433414x2666068" decimals="2" id="id_10184323_F0588A4C-1948-49EE-820D-9A0244D94BB5_1001_3" unitRef="pure">0.01</sls:PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2433414x3049142" decimals="-3" id="id_10184323_D93819D1-11DB-4503-A4A0-55D8D07DE92D_7001_7" unitRef="shares">58000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2433414x3049142" decimals="-3" id="id_10184323_D93819D1-11DB-4503-A4A0-55D8D07DE92D_7001_5" unitRef="shares">58000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2433414x3049142" decimals="-3" id="id_10184323_D93819D1-11DB-4503-A4A0-55D8D07DE92D_7001_6" unitRef="shares">46000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2433414x3049142" decimals="2" id="id_10184323_964D25B1-77A6-4A1B-9793-F1EFEA20AD93_7001_6" unitRef="iso4217_USD_per_shares">52.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2433414x3049142" decimals="2" id="id_10184323_964D25B1-77A6-4A1B-9793-F1EFEA20AD93_7001_7" unitRef="iso4217_USD_per_shares">3.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2433414x3049142" decimals="2" id="id_10184323_964D25B1-77A6-4A1B-9793-F1EFEA20AD93_7001_5" unitRef="iso4217_USD_per_shares">3.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:RestrictedStockExpense contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2433414x3049145" decimals="INF" id="id_10184323_002F933B-EDA0-48E1-A36F-DB5DC2656C4E_1001_0" unitRef="iso4217_USD">0</us-gaap:RestrictedStockExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2433414x3049145" id="id_10184323_824BC712-964B-4512-8CC5-5C9CC7E5B950_1001_0">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2433414x3049145" decimals="-3" id="id_10184323_C82FDB47-92A3-46C4-A21E-3367B6C36CF4_7001_6" unitRef="shares">8000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2433414x3049145" decimals="-3" id="id_10184323_C82FDB47-92A3-46C4-A21E-3367B6C36CF4_7001_5" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2433414x3049145" decimals="2" id="id_10184323_E1E0D8FA-4A9F-405E-8BE5-5925DE89D6F4_7001_6" unitRef="iso4217_USD_per_shares">52.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
  <sls:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2433414x3049145_2450814x3049554" id="id_10184323_824BC712-964B-4512-8CC5-5C9CC7E5B950_2001_1">2018-01-01</sls:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate>
  <sls:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2433414x3049145_2450814x3049582" id="id_10184323_824BC712-964B-4512-8CC5-5C9CC7E5B950_3001_2">2019-01-01</sls:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate>
  <sls:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2433414x3049145_2450814x3049583" id="id_10184323_824BC712-964B-4512-8CC5-5C9CC7E5B950_4001_3">2020-01-01</sls:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate>
  <sls:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2433414x3049145_2450814x3049584" id="id_10184323_824BC712-964B-4512-8CC5-5C9CC7E5B950_5001_4">2018-02-27</sls:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate>
  <sls:BusinessCombinationProFormaTransactionCosts contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2433694x2884874" decimals="-5" id="id_10184323_4828D19F-FB8A-4A68-A803-4CA2B717ED01_1001_0" unitRef="iso4217_USD">5700000</sls:BusinessCombinationProFormaTransactionCosts>
  <sls:SuccessFeeAndOtherTransactionCosts contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2433694x2884874" decimals="-5" id="id_10184323_4828D19F-FB8A-4A68-A803-4CA2B717ED01_1001_1" unitRef="iso4217_USD">4800000</sls:SuccessFeeAndOtherTransactionCosts>
  <sls:ChangeInFairValueOfWarrantLiabilities contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2434520x2884867" decimals="-3" id="id_10184323_4B76D830-5163-4ACC-B094-4F802F4CE47B_4001_4" unitRef="iso4217_USD">0</sls:ChangeInFairValueOfWarrantLiabilities>
  <sls:FairValueOfWarrantsExercised contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2434520x2884867" decimals="-3" id="id_10184323_4B76D830-5163-4ACC-B094-4F802F4CE47B_4001_3" unitRef="iso4217_USD">1305000</sls:FairValueOfWarrantsExercised>
  <sls:ClassOfWarrantOrRightGranted contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2434520x2884867" decimals="-3" id="id_10184323_1DED8646-51CA-4296-813D-28D45E65FF74_4002_2" unitRef="shares">0</sls:ClassOfWarrantOrRightGranted>
  <sls:ClassOfWarrantOrRightExpired contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2434520x2884867" decimals="-3" id="id_10184323_1DED8646-51CA-4296-813D-28D45E65FF74_4002_4" unitRef="shares">0</sls:ClassOfWarrantOrRightExpired>
  <sls:ClassOfWarrantOrRightAssumedInAcquisition contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2434520x2884867" decimals="-3" id="id_10184323_1DED8646-51CA-4296-813D-28D45E65FF74_4002_3" unitRef="shares">567000</sls:ClassOfWarrantOrRightAssumedInAcquisition>
  <sls:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2434520x2884867" id="id_10184323_7D1D15E3-211A-4DE0-83DD-923D2AC9F85F_1_3">P4Y1M13D</sls:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
  <sls:ClassOfWarrantOrRightExpirationMonthAndYear contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2434520x2884867" id="id_10184323_1DED8646-51CA-4296-813D-28D45E65FF74_4002_6">2022-02</sls:ClassOfWarrantOrRightExpirationMonthAndYear>
  <sls:FairValueofWarrantsGranted contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2434520x2884867" decimals="-3" id="id_10184323_4B76D830-5163-4ACC-B094-4F802F4CE47B_4001_2" unitRef="iso4217_USD">0</sls:FairValueofWarrantsGranted>
  <sls:ChangeInFairValueOfWarrantLiabilities contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2434520x2884905" decimals="-3" id="id_10184323_4B76D830-5163-4ACC-B094-4F802F4CE47B_4002_4" unitRef="iso4217_USD">0</sls:ChangeInFairValueOfWarrantLiabilities>
  <sls:FairValueOfWarrantsExercised contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2434520x2884905" decimals="-3" id="id_10184323_4B76D830-5163-4ACC-B094-4F802F4CE47B_4002_3" unitRef="iso4217_USD">4000</sls:FairValueOfWarrantsExercised>
  <sls:ClassOfWarrantOrRightGranted contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2434520x2884905" decimals="-3" id="id_10184323_1DED8646-51CA-4296-813D-28D45E65FF74_4003_2" unitRef="shares">0</sls:ClassOfWarrantOrRightGranted>
  <sls:ClassOfWarrantOrRightExpired contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2434520x2884905" decimals="-3" id="id_10184323_1DED8646-51CA-4296-813D-28D45E65FF74_4003_4" unitRef="shares">0</sls:ClassOfWarrantOrRightExpired>
  <sls:ClassOfWarrantOrRightAssumedInAcquisition contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2434520x2884905" decimals="-3" id="id_10184323_1DED8646-51CA-4296-813D-28D45E65FF74_4003_3" unitRef="shares">80000</sls:ClassOfWarrantOrRightAssumedInAcquisition>
  <sls:ClassOfWarrantOrRightExpirationDateDescription contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2434520x2884905" id="id_10184323_99AC1363-65CB-44E4-8DA7-29BD37179407_1003_6">Various to 2022</sls:ClassOfWarrantOrRightExpirationDateDescription>
  <sls:FairValueofWarrantsGranted contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2434520x2884905" decimals="-3" id="id_10184323_4B76D830-5163-4ACC-B094-4F802F4CE47B_4002_2" unitRef="iso4217_USD">0</sls:FairValueofWarrantsGranted>
  <sls:ClassOfWarrantOrRightGranted contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2434520x3050116" decimals="-3" id="id_10184323_1DED8646-51CA-4296-813D-28D45E65FF74_4001_2" unitRef="shares">316000</sls:ClassOfWarrantOrRightGranted>
  <sls:ClassOfWarrantOrRightExpired contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2434520x3050116" decimals="-3" id="id_10184323_1DED8646-51CA-4296-813D-28D45E65FF74_4001_4" unitRef="shares">0</sls:ClassOfWarrantOrRightExpired>
  <sls:ClassOfWarrantOrRightAssumedInAcquisition contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2434520x3050116" decimals="-3" id="id_10184323_1DED8646-51CA-4296-813D-28D45E65FF74_4001_3" unitRef="shares">0</sls:ClassOfWarrantOrRightAssumedInAcquisition>
  <sls:ClassOfWarrantOrRightExpirationMonthAndYear contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2434520x3050116" id="id_10184323_1DED8646-51CA-4296-813D-28D45E65FF74_4001_6">2022-12</sls:ClassOfWarrantOrRightExpirationMonthAndYear>
  <sls:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2434520x3054786" id="id_10184323_7D1D15E3-211A-4DE0-83DD-923D2AC9F85F_2_3">P2Y8M26D</sls:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
  <us-gaap:DebtInstrumentDescription contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2435412x2653900_2435465x2895689" id="id_10184323_605916AC-C5ED-4608-88F5-0ECE677D1051_1003_13">The principal amount of the 2013 Loan Agreement, together with accrued interest, was re-assigned on a 50:50 basis to the Company&#x2019;s co-founders, Drs. Angelos M. Stergiou (M.D., Sc.D. h.c.) and Miltiadis Sougioultzoglou (M.D.).</us-gaap:DebtInstrumentDescription>
  <sls:MilestonePayments contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2435412x2684763" decimals="-5" id="id_10184323_9E13EC7A-0FC3-4BA2-8AB0-17855F0E6F6F_1_1" unitRef="iso4217_USD">700000</sls:MilestonePayments>
  <sls:MinimumAnnualRoyaltyPayment contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2435412x2684763" decimals="INF" id="id_10184323_5F9BC149-0B54-4ECF-8EF0-02C65FCB12FC_4_6" unitRef="iso4217_USD">100000</sls:MinimumAnnualRoyaltyPayment>
  <sls:ResearchFundingCosts contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2435412x2684763" decimals="-5" id="id_10184323_5F9BC149-0B54-4ECF-8EF0-02C65FCB12FC_4_7" unitRef="iso4217_USD">200000</sls:ResearchFundingCosts>
  <sls:LicenseAgreementOutstandingAmountPayable contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2435412x2684763" decimals="-5" id="id_10184323_9E13EC7A-0FC3-4BA2-8AB0-17855F0E6F6F_1_0" unitRef="iso4217_USD">1000000</sls:LicenseAgreementOutstandingAmountPayable>
  <us-gaap:DebtInstrumentPaymentTerms contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2435412x3053914_2435465x3053912_2442761x2442444" id="id_10184323_605916AC-C5ED-4608-88F5-0ECE677D1051_3003_6">Single payment</us-gaap:DebtInstrumentPaymentTerms>
  <sls:DebtInstrumentPercentageofVolumeWeightedAveragePrice contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2435465x2668673_2442761x2448459" decimals="3" id="id_10184323_8A8B3170-494D-440B-ABC2-82EA63A3B7DE_1001_4" unitRef="pure">0.925</sls:DebtInstrumentPercentageofVolumeWeightedAveragePrice>
  <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2435465x2743860_2442761x2448459" decimals="2" id="id_10184323_8A8B3170-494D-440B-ABC2-82EA63A3B7DE_2001_0" unitRef="pure">0.80</us-gaap:DebtInstrumentRedemptionPricePercentage>
  <sls:DebtInstrumentPercentageofVolumeWeightedAveragePrice contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2435465x2743860_2442761x2448459" decimals="2" id="id_10184323_8A8B3170-494D-440B-ABC2-82EA63A3B7DE_2001_1" unitRef="pure">0.80</sls:DebtInstrumentPercentageofVolumeWeightedAveragePrice>
  <sls:DebtInstrumentPercentageofPriorDayVolumeWeightedAveragePrice contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2435465x2743860_2442761x2448459" decimals="2" id="id_10184323_8A8B3170-494D-440B-ABC2-82EA63A3B7DE_2001_3" unitRef="pure">1.15</sls:DebtInstrumentPercentageofPriorDayVolumeWeightedAveragePrice>
  <sls:NumberofDaysAveragedforExercisePrice contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2435465x2743860_2442761x2448459" id="id_10184323_8A8B3170-494D-440B-ABC2-82EA63A3B7DE_2001_2">P20D</sls:NumberofDaysAveragedforExercisePrice>
  <sls:DebtRepaymentsDescription contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2435465x2884877_2442761x2448459" id="id_10184323_4AE9789E-26BF-45DC-9023-B98209369792_2_1">The Company does not have the right to prepay.</sls:DebtRepaymentsDescription>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2435465x3049445" id="id_10184323_73988A1A-61DF-48A4-8418-E24491ABE072_1002_3">2017-04-02</us-gaap:DebtInstrumentMaturityDate>
  <sls:GainLossOnExtinguishmentOfDebt contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2435465x3049445" decimals="-5" id="id_10184323_6E24AB61-4C80-4B3E-B627-7E6A479B0DF2_1002_2" unitRef="iso4217_USD">-700000</sls:GainLossOnExtinguishmentOfDebt>
  <us-gaap:DebtConversionDescription contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2435465x3049453" id="id_10184323_2EB30C43-4544-40D7-B257-5BD00BD9BD61_1002_2">The 2016 Note was issued at par and had an interest rate of 8%. The 2016 Note was issued with similar terms to the 2015 Notes (excluding the warrant coverage) whereby the 2016 Note is mandatorily convertible into equity upon the earlier to occur: a) the closing of a qualified IPO, b) a change in the Company&#x2019;s domicile from Switzerland to Bermuda or c) the six-month anniversary of the note.</us-gaap:DebtConversionDescription>
  <us-gaap:BusinessCombinationIntegrationRelatedCosts contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2440346x2439323" decimals="-5" id="id_10184323_BF0EBC9F-18BC-43AE-B674-4F5E7C7200E4_1001_0" unitRef="iso4217_USD">5700000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2440346x2447512" decimals="-3" id="id_10184323_229FFD7D-7F91-4834-828C-8E345BAB60A3_1001_0" unitRef="iso4217_USD">729000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2440346x2448625" decimals="-3" id="id_10184323_229FFD7D-7F91-4834-828C-8E345BAB60A3_2001_1" unitRef="iso4217_USD">2440000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:LitigationSettlementAmountAwardedToOtherParty contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2442228x2448785_2442667x3049464" decimals="-5" id="id_10184323_FEDA0F9D-0F7A-4B18-8DB6-829684118B3E_1001_0" unitRef="iso4217_USD">7600000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
  <us-gaap:PaymentsForLegalSettlements contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2442667x3048903" decimals="-5" id="id_10184323_EBE3AF3E-3D0E-4502-A0D9-5B760EBCC562_1001_0" unitRef="iso4217_USD">100000</us-gaap:PaymentsForLegalSettlements>
  <sls:IssuanceofCommonStockforLitigationSettlement contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2442667x3048903" decimals="-5" id="id_10184323_EBE3AF3E-3D0E-4502-A0D9-5B760EBCC562_1001_1" unitRef="iso4217_USD">200000</sls:IssuanceofCommonStockforLitigationSettlement>
  <sls:DebtInstrumentCommonStockMinimumPriceCondition contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2442761x2448459" decimals="2" id="id_10184323_8CF5BA34-FCF6-4604-9160-A4FC926041DB_1001_0" unitRef="iso4217_USD_per_shares">10.50</sls:DebtInstrumentCommonStockMinimumPriceCondition>
  <sls:DebtInstrumentRedemptionRedemptionPayments contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2442761x2448459" decimals="-5" id="id_10184323_707591D2-3D9C-49D9-9F8B-74368CF7D8DF_1_1" unitRef="iso4217_USD">800000</sls:DebtInstrumentRedemptionRedemptionPayments>
  <us-gaap:StockIssued1 contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2442761x3049779" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_1001_37" unitRef="iso4217_USD">1294000</us-gaap:StockIssued1>
  <us-gaap:StockIssued1 contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2442761x3049991" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_2001_38" unitRef="iso4217_USD">6064000</us-gaap:StockIssued1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2445234x2909678" id="id_10184323_A45D835C-6822-427B-9692-1F4FF43EBB55_1001_0">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2445234x2909678" decimals="INF" id="id_10184323_FFAC4CFC-19C8-4B2E-9186-C7FE5A6F4884_1001_3" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <sls:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2445234x2909678" decimals="INF" id="id_10184323_FFAC4CFC-19C8-4B2E-9186-C7FE5A6F4884_1001_1" unitRef="shares">10171</sls:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger>
  <sls:ShareBasedCompensationExercisePeriod contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2445234x2909678" id="id_10184323_FFAC4CFC-19C8-4B2E-9186-C7FE5A6F4884_1001_2">P1Y</sls:ShareBasedCompensationExercisePeriod>
  <sls:PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2445234x2909678" decimals="2" id="id_10184323_A45D835C-6822-427B-9692-1F4FF43EBB55_1001_1" unitRef="pure">0.04</sls:PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards>
  <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2446922x2684763" decimals="INF" id="id_10184323_01D9D5C4-C799-4CF0-A8BB-86DCB738BD4C_1001_0" unitRef="shares">38321</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued>
  <us-gaap:ManagementFeeExpense contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2446922x3049598" decimals="-5" id="id_10184323_0944809B-2ACB-4431-8932-A05505810103_1002_2" unitRef="iso4217_USD">300000</us-gaap:ManagementFeeExpense>
  <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2446922x3049598" decimals="INF" id="id_10184323_01D9D5C4-C799-4CF0-A8BB-86DCB738BD4C_2001_2" unitRef="shares">30094</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued>
  <sls:StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2446922x3049598" decimals="0" id="id_10184323_4828D19F-FB8A-4A68-A803-4CA2B717ED01_2001_2" unitRef="shares">119672</sls:StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares>
  <sls:StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2446922x3049598" decimals="-5" id="id_10184323_4828D19F-FB8A-4A68-A803-4CA2B717ED01_2001_3" unitRef="iso4217_USD">900000</sls:StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod>
  <sls:PercentageOfOwnershipOutstandingShareCapital contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2446922x3049599_2446928x2684763" decimals="3" id="id_10184323_2AC2EA9D-5B68-4BAE-B408-C0DF750D0729_1001_0" unitRef="pure">0.037</sls:PercentageOfOwnershipOutstandingShareCapital>
  <sls:PercentageOfOwnershipOutstandingShareCapital contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2446922x3049599_2449718x3049969" decimals="3" id="id_10184323_A50E923D-2A36-4308-82A0-601B525AA7EA_1001_0" unitRef="pure">0.078</sls:PercentageOfOwnershipOutstandingShareCapital>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2448914x2432358" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_7003_600039" unitRef="iso4217_USD">3169000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2448914x2432358" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_7003_600029" unitRef="iso4217_USD">12486000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2448914x2432358" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_7003_600021" unitRef="iso4217_USD">1294000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2448914x2432358" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_7003_600023" unitRef="iso4217_USD">6007000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <sls:StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2448914x2432358" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_7003_600019" unitRef="iso4217_USD">388000</sls:StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue>
  <sls:StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2448914x2432358" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_7003_600025" unitRef="iso4217_USD">378000</sls:StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable>
  <sls:StockIssuedForAntiDilutionProvisions contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2448914x2432358" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_7003_600037" unitRef="iso4217_USD">61000</sls:StockIssuedForAntiDilutionProvisions>
  <sls:StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2448914x2432358" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_7003_600035" unitRef="iso4217_USD">941000</sls:StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod>
  <sls:SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2448914x2432358" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_7003_600032" unitRef="iso4217_USD">6739000</sls:SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod>
  <sls:AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2448914x2432358" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_7003_600031" unitRef="iso4217_USD">32000</sls:AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition>
  <sls:AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2448914x2432358" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_7003_600034" unitRef="iso4217_USD">-675000</sls:AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2448914x2434572" decimals="INF" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_7001_400022" unitRef="shares">330551</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2448914x2434572" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_7001_500029" unitRef="iso4217_USD">1000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2448914x2434572" decimals="INF" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_7001_400030" unitRef="shares">1588605</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2448914x2434572" decimals="INF" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_7001_400027" unitRef="shares">46373</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2448914x2434572" decimals="INF" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_7001_400024" unitRef="shares">1534711</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <sls:StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2448914x2434572" decimals="INF" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_7001_400020" unitRef="shares">83594</sls:StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares>
  <sls:StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2448914x2434572" decimals="INF" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_7001_400026" unitRef="shares">96662</sls:StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable>
  <sls:StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2448914x2434572" decimals="INF" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_7001_400036" unitRef="shares">119672</sls:StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares>
  <sls:StockIssuedForAntiDilutionProvisionsShares contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2448914x2434572" decimals="INF" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_7001_400038" unitRef="shares">7700</sls:StockIssuedForAntiDilutionProvisionsShares>
  <sls:SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2448914x2434572" decimals="INF" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_7001_400033" unitRef="shares">632326</sls:SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares>
  <sls:StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2448914x2434572" decimals="INF" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_7001_400028" unitRef="shares">58208</sls:StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares>
  <us-gaap:NetIncomeLoss contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2448914x2447681" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_7004_700040" unitRef="iso4217_USD">-23754000</us-gaap:NetIncomeLoss>
  <sls:CommonStockConversionRatio contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2448914x3049260" decimals="4" id="id_10184323_D5995E5A-4042-43AF-A402-DA196989731F_1002_2" unitRef="pure">43.9972</sls:CommonStockConversionRatio>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="eol_PE735624--1710-K0010_STD_365_20171231_0_2449718x2434781" decimals="INF" id="id_10184323_01D9D5C4-C799-4CF0-A8BB-86DCB738BD4C_3001_4" unitRef="shares">28246</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="eol_PE735624--1710-K0010_STD_365_20181231_0_2449305x2447800" decimals="INF" id="id_10184323_76E94FD5-B2F3-422B-85BD-DEBDE822DEF6_1001_0" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_229FFD7D-7F91-4834-828C-8E345BAB60A3_2_2" unitRef="iso4217_USD">354000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="0" id="id_10184323_89149E78-1DB1-40DA-95B5-345B45F730E2_2_3" unitRef="shares">122</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_4005_800014" unitRef="iso4217_USD">354000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_38CF6218-B6A1-4D37-B903-AD80F2D9E61B_2_1" unitRef="iso4217_USD">28389000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
  <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_38CF6218-B6A1-4D37-B903-AD80F2D9E61B_2_0" unitRef="iso4217_USD">0</us-gaap:BusinessAcquisitionsProFormaRevenue>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_2_27" unitRef="iso4217_USD">4565000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_E3D64427-1A16-404F-9FF3-EE7F3DD5B1A6_2_3" unitRef="iso4217_USD">0</us-gaap:CurrentForeignTaxExpenseBenefit>
  <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_E3D64427-1A16-404F-9FF3-EE7F3DD5B1A6_2_4" unitRef="iso4217_USD">42000</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_E3D64427-1A16-404F-9FF3-EE7F3DD5B1A6_2_2" unitRef="iso4217_USD">42000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_E3D64427-1A16-404F-9FF3-EE7F3DD5B1A6_2_8" unitRef="iso4217_USD">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
  <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_2_10" unitRef="iso4217_USD">-41000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_E3D64427-1A16-404F-9FF3-EE7F3DD5B1A6_2_6" unitRef="iso4217_USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_E3D64427-1A16-404F-9FF3-EE7F3DD5B1A6_2_9" unitRef="iso4217_USD">-41000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_E3D64427-1A16-404F-9FF3-EE7F3DD5B1A6_2_7" unitRef="iso4217_USD">-41000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_2_3" unitRef="iso4217_USD">3000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="2" id="id_10184323_4057F5D7-0584-4138-8CED-8368A48EFB93_2_11" unitRef="iso4217_USD_per_shares">-18.66</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="3" id="id_10184323_7AD9BED1-97A1-4F8A-8327-635515D3BD72_2_8" unitRef="pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="INF" id="id_10184323_7AD9BED1-97A1-4F8A-8327-635515D3BD72_2_0" unitRef="pure">0.340</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="3" id="id_10184323_7AD9BED1-97A1-4F8A-8327-635515D3BD72_2_6" unitRef="pure">0.104</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="3" id="id_10184323_7AD9BED1-97A1-4F8A-8327-635515D3BD72_2_2" unitRef="pure">0.255</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="3" id="id_10184323_7AD9BED1-97A1-4F8A-8327-635515D3BD72_2_7" unitRef="pure">0.020</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_2_7" unitRef="iso4217_USD">-201000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_D7BD0BE0-D0A7-43F4-81C4-877F346A4120_2_0" unitRef="iso4217_USD">108000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_D7BD0BE0-D0A7-43F4-81C4-877F346A4120_2_2" unitRef="iso4217_USD">-17680000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_D7BD0BE0-D0A7-43F4-81C4-877F346A4120_2_1" unitRef="iso4217_USD">-17788000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_2_15" unitRef="iso4217_USD">1830000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_4057F5D7-0584-4138-8CED-8368A48EFB93_2_7" unitRef="iso4217_USD">1000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_2_13" unitRef="iso4217_USD">477000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_2_19" unitRef="iso4217_USD">85000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:InterestIncomeExpenseNet contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_4057F5D7-0584-4138-8CED-8368A48EFB93_2_5" unitRef="iso4217_USD">-1166000</us-gaap:InterestIncomeExpenseNet>
  <us-gaap:LeaseAndRentalExpense contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-5" id="id_10184323_7B554A29-1BC5-4FC7-BF72-947781049FD1_2_0" unitRef="iso4217_USD">200000</us-gaap:LeaseAndRentalExpense>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_4057F5D7-0584-4138-8CED-8368A48EFB93_2_10" unitRef="iso4217_USD">-17681000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_2_20" unitRef="iso4217_USD">-85000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_2_26" unitRef="iso4217_USD">16500000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_2_16" unitRef="iso4217_USD">-11850000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_4005_800015" unitRef="iso4217_USD">-17681000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_4057F5D7-0584-4138-8CED-8368A48EFB93_2_4" unitRef="iso4217_USD">-15988000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNonoperatingExpense contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_4057F5D7-0584-4138-8CED-8368A48EFB93_2_6" unitRef="iso4217_USD">526000</us-gaap:OtherNonoperatingExpense>
  <us-gaap:PaidInKindInterest contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_2_5" unitRef="iso4217_USD">1166000</us-gaap:PaidInKindInterest>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_2_23" unitRef="iso4217_USD">15000000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_2_24" unitRef="iso4217_USD">1500000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_4057F5D7-0584-4138-8CED-8368A48EFB93_2_1" unitRef="iso4217_USD">11395000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentInProcess contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_2_8" unitRef="iso4217_USD">1974000</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_2_6" unitRef="iso4217_USD">354000</us-gaap:ShareBasedCompensation>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_4057F5D7-0584-4138-8CED-8368A48EFB93_2_2" unitRef="iso4217_USD">4593000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="2" id="id_10184323_A4ABC7FA-8304-4E13-94A0-97527A012220_2_1" unitRef="iso4217_USD_per_shares">38.03</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="2" id="id_10184323_A30F3FDC-E7BB-4D8B-8348-6E7E5CF4A544_4001_3" unitRef="iso4217_USD_per_shares">52.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="0" id="id_10184323_18A7C5E6-643A-43B9-96BE-7B5CEADC0C13_4001_3" unitRef="iso4217_USD_per_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_F20F2A7E-6CA6-4B06-A237-1C397810BBCA_4001_3" unitRef="shares">55000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_4005_800010" unitRef="iso4217_USD">15411000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="0" id="id_10184323_4057F5D7-0584-4138-8CED-8368A48EFB93_2_12" unitRef="shares">947401</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-5" id="id_10184323_FF1169F2-4481-44E9-82B6-4E32DB0850BA_2_2" unitRef="iso4217_USD">1800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <sls:NonCashResearchAndDevelopmentExpense contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_D1FD7F93-6E56-41A5-BD57-0B64D64478F1_2_4" unitRef="iso4217_USD">821000</sls:NonCashResearchAndDevelopmentExpense>
  <sls:StockIssuedDuringPeriodValueLicenseAgreement contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_4005_800006" unitRef="iso4217_USD">1976000</sls:StockIssuedDuringPeriodValueLicenseAgreement>
  <sls:BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="2" id="id_10184323_38CF6218-B6A1-4D37-B903-AD80F2D9E61B_2_2" unitRef="iso4217_USD_per_shares">8.61</sls:BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted>
  <sls:EffectiveIncomeTaxRateReconciliationPermanentDifferences contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="3" id="id_10184323_7AD9BED1-97A1-4F8A-8327-635515D3BD72_2_3" unitRef="pure">0.001</sls:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
  <sls:StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_4005_800004" unitRef="iso4217_USD">900000</sls:StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee>
  <sls:StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_4005_800008" unitRef="iso4217_USD">502000</sls:StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue>
  <sls:StockIssuedDuringPeriodValueCancellationOfLongTermDebt contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_4005_800012" unitRef="iso4217_USD">5803000</sls:StockIssuedDuringPeriodValueCancellationOfLongTermDebt>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2433098x2438181" decimals="0" id="id_10184323_89149E78-1DB1-40DA-95B5-345B45F730E2_1002_1" unitRef="shares">55</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2433098x2447533" decimals="0" id="id_10184323_89149E78-1DB1-40DA-95B5-345B45F730E2_2002_2" unitRef="shares">67</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2433414x2828147" decimals="2" id="id_10184323_611D698F-9052-4A4C-B3B1-277A00B91669_1001_6" unitRef="pure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2433414x2828147_2447194x2442860" id="id_10184323_611D698F-9052-4A4C-B3B1-277A00B91669_2001_5">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2433414x2828147_2447194x2442860" decimals="INF" id="id_10184323_611D698F-9052-4A4C-B3B1-277A00B91669_2001_1" unitRef="pure">0.0232</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2433414x2828147_2447194x2442860" decimals="INF" id="id_10184323_611D698F-9052-4A4C-B3B1-277A00B91669_2001_3" unitRef="pure">0.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2433414x2828147_2447194x2443301" id="id_10184323_611D698F-9052-4A4C-B3B1-277A00B91669_3001_4">P5Y1M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2433414x2828147_2447194x2443301" decimals="INF" id="id_10184323_611D698F-9052-4A4C-B3B1-277A00B91669_3001_0" unitRef="pure">0.0182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2433414x2828147_2447194x2443301" decimals="INF" id="id_10184323_611D698F-9052-4A4C-B3B1-277A00B91669_3001_2" unitRef="pure">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2433414x3049142" decimals="-3" id="id_10184323_D93819D1-11DB-4503-A4A0-55D8D07DE92D_4001_3" unitRef="shares">46000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2433414x3049142" decimals="2" id="id_10184323_964D25B1-77A6-4A1B-9793-F1EFEA20AD93_4001_3" unitRef="iso4217_USD_per_shares">52.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:RestrictedStockExpense contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2433414x3049145" decimals="INF" id="id_10184323_002F933B-EDA0-48E1-A36F-DB5DC2656C4E_1002_0" unitRef="iso4217_USD">0</us-gaap:RestrictedStockExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2433414x3049145" decimals="-3" id="id_10184323_C82FDB47-92A3-46C4-A21E-3367B6C36CF4_4001_3" unitRef="shares">21000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2433414x3049145" decimals="2" id="id_10184323_E1E0D8FA-4A9F-405E-8BE5-5925DE89D6F4_4001_3" unitRef="iso4217_USD_per_shares">52.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <sls:MilestonePayments contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2435412x2684763" decimals="-5" id="id_10184323_3C236253-2E80-4E55-9F1C-2E8FA2C9777D_1_1" unitRef="iso4217_USD">300000</sls:MilestonePayments>
  <sls:MinimumAnnualRoyaltyPayment contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2435412x2684763" decimals="INF" id="id_10184323_5F9BC149-0B54-4ECF-8EF0-02C65FCB12FC_3_6" unitRef="iso4217_USD">100000</sls:MinimumAnnualRoyaltyPayment>
  <sls:ResearchFundingCosts contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2435412x2684763" decimals="-5" id="id_10184323_5F9BC149-0B54-4ECF-8EF0-02C65FCB12FC_3_7" unitRef="iso4217_USD">200000</sls:ResearchFundingCosts>
  <sls:LicenseAgreementOutstandingAmountPayable contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2435412x2684763" decimals="-5" id="id_10184323_3C236253-2E80-4E55-9F1C-2E8FA2C9777D_1_0" unitRef="iso4217_USD">600000</sls:LicenseAgreementOutstandingAmountPayable>
  <sls:MilestonePayment contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2435412x2684763_2450320x3049265" decimals="-5" id="id_10184323_3C236253-2E80-4E55-9F1C-2E8FA2C9777D_1001_4" unitRef="iso4217_USD">700000</sls:MilestonePayment>
  <sls:NumberOfInstallmentsToMakePayments contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2435412x2684763_2450320x3049265" decimals="INF" id="id_10184323_3C236253-2E80-4E55-9F1C-2E8FA2C9777D_1001_5" unitRef="Installment">2</sls:NumberOfInstallmentsToMakePayments>
  <sls:MaximumNumberOfDaysToMakePayments contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2435412x2684763_2450320x3049265" id="id_10184323_3C236253-2E80-4E55-9F1C-2E8FA2C9777D_1001_6">P60D</sls:MaximumNumberOfDaysToMakePayments>
  <sls:LicenseTerminationFeesPaid contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2435412x3049272_2450320x3049275" decimals="-5" id="id_10184323_C0E3BA2A-BB33-4C8E-BD26-84BCA3FBF1FD_2003_3" unitRef="iso4217_USD">100000</sls:LicenseTerminationFeesPaid>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2440346x2447512" decimals="-3" id="id_10184323_229FFD7D-7F91-4834-828C-8E345BAB60A3_1002_0" unitRef="iso4217_USD">23000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2440346x2448625" decimals="-3" id="id_10184323_229FFD7D-7F91-4834-828C-8E345BAB60A3_2002_1" unitRef="iso4217_USD">331000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ManagementFeeExpense contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2446922x3049598" decimals="-5" id="id_10184323_0944809B-2ACB-4431-8932-A05505810103_1003_2" unitRef="iso4217_USD">200000</us-gaap:ManagementFeeExpense>
  <sls:PercentageOfOwnershipOutstandingShareCapital contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2446922x3049599_2446928x2684763" decimals="3" id="id_10184323_2AC2EA9D-5B68-4BAE-B408-C0DF750D0729_1002_0" unitRef="pure">0.054</sls:PercentageOfOwnershipOutstandingShareCapital>
  <sls:PercentageOfOwnershipOutstandingShareCapital contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2446922x3049599_2449718x3049969" decimals="3" id="id_10184323_A50E923D-2A36-4308-82A0-601B525AA7EA_1002_0" unitRef="pure">0.240</sls:PercentageOfOwnershipOutstandingShareCapital>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2448914x2432358" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_4003_600014" unitRef="iso4217_USD">354000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2448914x2432358" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_4003_600010" unitRef="iso4217_USD">15411000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <sls:StockIssuedDuringPeriodValueLicenseAgreement contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2448914x2432358" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_4003_600006" unitRef="iso4217_USD">1976000</sls:StockIssuedDuringPeriodValueLicenseAgreement>
  <sls:StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2448914x2432358" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_4003_600004" unitRef="iso4217_USD">900000</sls:StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee>
  <sls:StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2448914x2432358" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_4003_600008" unitRef="iso4217_USD">502000</sls:StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue>
  <sls:StockIssuedDuringPeriodValueCancellationOfLongTermDebt contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2448914x2432358" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_4003_600012" unitRef="iso4217_USD">5803000</sls:StockIssuedDuringPeriodValueCancellationOfLongTermDebt>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2448914x2432358_2449305x2447520" decimals="-3" id="id_10184323_316093F4-0A93-43A3-8E21-CC3759FEB2D1_5002_5" unitRef="iso4217_USD">54000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <sls:StockIssuedDuringPeriodValueLicenseAgreement contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2448914x2432358_2449305x2447520" decimals="-3" id="id_10184323_316093F4-0A93-43A3-8E21-CC3759FEB2D1_5002_3" unitRef="iso4217_USD">9000</sls:StockIssuedDuringPeriodValueLicenseAgreement>
  <sls:StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2448914x2432358_2449305x2447520" decimals="-3" id="id_10184323_316093F4-0A93-43A3-8E21-CC3759FEB2D1_5002_2" unitRef="iso4217_USD">3000</sls:StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee>
  <sls:StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2448914x2432358_2449305x2447520" decimals="-3" id="id_10184323_316093F4-0A93-43A3-8E21-CC3759FEB2D1_5002_4" unitRef="iso4217_USD">2000</sls:StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue>
  <sls:StockIssuedDuringPeriodValueCancellationOfLongTermDebt contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2448914x2432358_2449305x2447520" decimals="-3" id="id_10184323_316093F4-0A93-43A3-8E21-CC3759FEB2D1_5002_6" unitRef="iso4217_USD">20000</sls:StockIssuedDuringPeriodValueCancellationOfLongTermDebt>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2448914x2432358_2449305x2448174" decimals="-3" id="id_10184323_316093F4-0A93-43A3-8E21-CC3759FEB2D1_5001_7" unitRef="iso4217_USD">354000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2448914x2432358_2449305x2448174" decimals="-3" id="id_10184323_316093F4-0A93-43A3-8E21-CC3759FEB2D1_5001_5" unitRef="iso4217_USD">15357000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <sls:StockIssuedDuringPeriodValueLicenseAgreement contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2448914x2432358_2449305x2448174" decimals="-3" id="id_10184323_316093F4-0A93-43A3-8E21-CC3759FEB2D1_5001_3" unitRef="iso4217_USD">1967000</sls:StockIssuedDuringPeriodValueLicenseAgreement>
  <sls:StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2448914x2432358_2449305x2448174" decimals="-3" id="id_10184323_316093F4-0A93-43A3-8E21-CC3759FEB2D1_5001_2" unitRef="iso4217_USD">897000</sls:StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee>
  <sls:StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2448914x2432358_2449305x2448174" decimals="-3" id="id_10184323_316093F4-0A93-43A3-8E21-CC3759FEB2D1_5001_4" unitRef="iso4217_USD">500000</sls:StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue>
  <sls:StockIssuedDuringPeriodValueCancellationOfLongTermDebt contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2448914x2432358_2449305x2448174" decimals="-3" id="id_10184323_316093F4-0A93-43A3-8E21-CC3759FEB2D1_5001_6" unitRef="iso4217_USD">5783000</sls:StockIssuedDuringPeriodValueCancellationOfLongTermDebt>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2448914x2434572" decimals="INF" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_4001_400011" unitRef="shares">236705</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <sls:StockIssuedDuringPeriodSharesLicenseAgreement contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2448914x2434572" decimals="INF" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_4001_400007" unitRef="shares">41181</sls:StockIssuedDuringPeriodSharesLicenseAgreement>
  <sls:StockIssuedDuringPeriodSharesPartialConsiderationOfLicenseFee contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2448914x2434572" decimals="INF" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_4001_400005" unitRef="shares">13815</sls:StockIssuedDuringPeriodSharesPartialConsiderationOfLicenseFee>
  <sls:SharesIssuedInCancellationOfLicenseAgreement contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2448914x2434572" decimals="INF" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_4001_400009" unitRef="shares">7700</sls:SharesIssuedInCancellationOfLicenseAgreement>
  <sls:StockIssuedDuringPeriodSharesCancellationOfLongTermDebt contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2448914x2434572" decimals="INF" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_4001_400013" unitRef="shares">89094</sls:StockIssuedDuringPeriodSharesCancellationOfLongTermDebt>
  <us-gaap:NetIncomeLoss contextRef="eol_PE735624--1710-K0010_STD_366_20161231_0_2448914x2447681" decimals="-3" id="id_10184323_33CCB3CA-DDC9-415E-BF87-EB304CF491B4_4004_700015" unitRef="iso4217_USD">-17681000</us-gaap:NetIncomeLoss>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="eol_PE735624--1710-K0010_STD_90_20180331_0_2435465x2728214_2449888x2449609" decimals="INF" id="id_10184323_547744F2-B474-40B5-8C1C-43342EA2E4DB_1001_1" unitRef="shares">635894</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="eol_PE735624--1710-K0010_STD_90_20180331_0_2435465x2728214_2449888x2449609" decimals="-5" id="id_10184323_547744F2-B474-40B5-8C1C-43342EA2E4DB_1001_0" unitRef="iso4217_USD">2600000</us-gaap:DebtConversionOriginalDebtAmount1>
  <us-gaap:DecreaseInRestrictedCash contextRef="eol_PE735624--1710-K0010_STD_90_20180331_0_2435465x2728214_2449888x2449609" decimals="-5" id="id_10184323_547744F2-B474-40B5-8C1C-43342EA2E4DB_1001_3" unitRef="iso4217_USD">3200000</us-gaap:DecreaseInRestrictedCash>
  <us-gaap:RepaymentsOfConvertibleDebt contextRef="eol_PE735624--1710-K0010_STD_90_20180331_0_2435465x2728214_2449888x2449609" decimals="-5" id="id_10184323_547744F2-B474-40B5-8C1C-43342EA2E4DB_1001_2" unitRef="iso4217_USD">600000</us-gaap:RepaymentsOfConvertibleDebt>
  <context id="eol_PE735624--1710-K0010_STD_90_20180331_0_2435465x2728214_2449888x2449609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:DebentureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_366_20161231_0_2448914x2447681">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_366_20161231_0_2448914x2434572">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_366_20161231_0_2448914x2432358_2449305x2448174">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_366_20161231_0_2448914x2432358_2449305x2447520">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:RestatementAdjustmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_366_20161231_0_2448914x2432358">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_366_20161231_0_2446922x3049599_2449718x3049969">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sls:MskLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">sls:DrAngelosMStergiouMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_366_20161231_0_2446922x3049599_2446928x2684763">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sls:MskLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sls:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_366_20161231_0_2446922x3049598">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sls:EquilibriaCollaborationAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_366_20161231_0_2440346x2448625">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_366_20161231_0_2440346x2447512">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_366_20161231_0_2435412x3049272_2450320x3049275">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:TrojantecLtdMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:TrojantecLicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_366_20161231_0_2435412x2684763_2450320x3049265">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:SecondLicenseAmendmentWaiverAndAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_366_20161231_0_2435412x2684763">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_366_20161231_0_2433414x3049145">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sls:RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_366_20161231_0_2433414x3049142">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sls:RestrictedStockUnitsWithTimeBasedConditionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_366_20161231_0_2433414x2828147_2447194x2443301">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sls:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_366_20161231_0_2433414x2828147_2447194x2442860">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sls:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_366_20161231_0_2433414x2828147">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sls:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_366_20161231_0_2433098x2447533">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_366_20161231_0_2433098x2438181">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_366_20161231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20181231_0_2449305x2447800">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2449718x2434781">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2448914x3049260">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sls:PrivateSELLASMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2448914x2447681">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2448914x2434572">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2448914x2432358">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2446922x3049599_2449718x3049969">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sls:MskLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">sls:DrAngelosMStergiouMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2446922x3049599_2446928x2684763">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sls:MskLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sls:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2446922x3049598">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sls:EquilibriaCollaborationAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2446922x2684763">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sls:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2445234x2909678">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sls:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2442761x3049991">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sls:ConvertibleDebtTwoThousandSelyNoteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2442761x3049779">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sls:ConvertibleDebtTwoThousandFifteenShareholderNotesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2442761x2448459">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2442667x3048903">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">sls:QuiTamMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2442228x2448785_2442667x3049464">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">sls:UsattorneysofficeforthedistrictofnewjerseyanddepartmentofjusticeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2440346x2448625">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2440346x2447512">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2440346x2439323">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2435465x3049453">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:TwoZeroOneSixConvertibleTermNotesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2435465x3049445">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:TwoZeroOneFiveConvertibleTermNotesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2435465x2884877_2442761x2448459">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:FirstWaiverMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2435465x2743860_2442761x2448459">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:AmendmentAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2435465x2668673_2442761x2448459">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2435412x3053914_2435465x3053912_2442761x2442444">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:StarcoveMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:FrameworkLoanAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2435412x2684763">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2435412x2653900_2435465x2895689">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:ShareholdersMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:TwoThousandThirteenLoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2434520x3054786">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:OtherGalenaWarrantIssuesAccountedForAsLiabilitiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2434520x3050116">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:EqcWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2434520x2884905">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:OtherWarrantIssuesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2434520x2884867">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:February2017WarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2433694x2884874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sls:GalenaBiopharmaIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2433414x3049145_2450814x3049584">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sls:RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sls:ShareBasedCompensationAwardVestingDateFourMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2433414x3049145_2450814x3049583">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sls:RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sls:ShareBasedCompensationAwardVestingDateThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2433414x3049145_2450814x3049582">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sls:RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sls:ShareBasedCompensationAwardVestingDateTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2433414x3049145_2450814x3049554">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sls:RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sls:ShareBasedCompensationAwardVestingDateOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2433414x3049145">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sls:RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2433414x3049142">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sls:RestrictedStockUnitsWithTimeBasedConditionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2433414x2666068">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sls:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2433098x2450820">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2433098x2447533">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0_2433098x2438181">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20171231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20151231_0_2446928x3053942">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sls:DrsStergiouAndSougioultzoglouMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20151231_0_2435465x3053943">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:FounderLoansMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20151231_0_2435412x2684763">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_365_20141231_0_2435412x3049272_2450320x3049275">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:TrojantecLtdMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:TrojantecLicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_31_20170831_0_2435465x3049445_2446928x3049446">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:TwoZeroOneFiveConvertibleTermNotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sls:EQCBiotechSelyIFundMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-08-01</startDate>
      <endDate>2017-08-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_31_20180131_0_2449888x2449609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_31_20180131_0_2435465x2728214_2449888x2449609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:DebentureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_28_20160630_0_2435465x3049453">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:TwoZeroOneSixConvertibleTermNotesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-06-03</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_27_20161128_0_2446922x3049599">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sls:MskLicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-11-02</startDate>
      <endDate>2016-11-28</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_27_20161128_0_2433414x2679417_2446922x3049599">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sls:RestrictedStockUnitsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sls:MskLicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-11-02</startDate>
      <endDate>2016-11-28</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20180116_0_2449888x2449609_2450320x3050065">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:EngagementLetterMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-16</startDate>
      <endDate>2018-01-16</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20171229_0_2446922x3049598">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sls:EquilibriaCollaborationAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-12-29</startDate>
      <endDate>2017-12-29</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20171229_0_2435465x3049445">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:TwoZeroOneFiveConvertibleTermNotesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-12-29</startDate>
      <endDate>2017-12-29</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20171229_0_2434520x3050116">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:EqcWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-12-29</startDate>
      <endDate>2017-12-29</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20171229_0_2433694x2884874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sls:GalenaBiopharmaIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-12-29</startDate>
      <endDate>2017-12-29</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20160118_0_2435412x3049284_2450320x3049289">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:ClarendonTradingEinvestimentosLDAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:ClarendonLicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-18</startDate>
      <endDate>2016-01-18</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20170905_0_2450320x2719233">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-09-05</startDate>
      <endDate>2017-09-05</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20160930_0_2450320x3049289">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:ClarendonLicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-09-30</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20151030_0_2435412x2684763_2450320x3049264">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:LicenseAmendmentWaiverAndShareIssuanceAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-10-30</startDate>
      <endDate>2015-10-30</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20151029_0_2435412x2684763_2450320x3049264">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:LicenseAmendmentWaiverAndShareIssuanceAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-10-29</startDate>
      <endDate>2015-10-29</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20140904_0_2435412x2684763_2447194x2442860">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-09-04</startDate>
      <endDate>2014-09-04</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20140904_0_2435412x2684763_2447148x2442380">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-09-04</startDate>
      <endDate>2014-09-04</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20140904_0_2435412x2684763">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-09-04</startDate>
      <endDate>2014-09-04</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20170621_0_2432521x3049445_2435465x2685828">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">sls:TwoZeroOneFiveConvertibleTermNotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:BridgeFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-06-21</startDate>
      <endDate>2017-06-21</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20170613_0_2432521x3049445_2435465x2685828">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">sls:TwoZeroOneFiveConvertibleTermNotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:BridgeFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-06-13</startDate>
      <endDate>2017-06-13</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20160630_0_2446922x3049598">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sls:EquilibriaCollaborationAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-06-30</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20160615_0_2435412x3049272_2450320x3049275">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:TrojantecLtdMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:TrojantecLicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-06-15</startDate>
      <endDate>2016-06-15</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20160602_0_2442761x2442444">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-06-02</startDate>
      <endDate>2016-06-02</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20150714_0_2435412x3049272_2450320x3049279">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:TrojantecLtdMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:FirstTrojantecAmendmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-14</startDate>
      <endDate>2015-07-14</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20150714_0_2435412x3049272_2447194x2442860_2450320x3049279">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:TrojantecLtdMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:FirstTrojantecAmendmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-14</startDate>
      <endDate>2015-07-14</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20180409_0_2442667x3054137_2449888x2449609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">sls:JGBCaymanNewtonLtdMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-04-09</startDate>
      <endDate>2018-04-09</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20180403_0_2449888x2449609_2450320x3050035">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:HudsonBayAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-04-03</startDate>
      <endDate>2018-04-03</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20180402_0_2449888x2449609_2450320x3051911">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:AltoAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-04-02</startDate>
      <endDate>2018-04-02</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20180402_0_2449888x2449609_2450320x3050643">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:CVIAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-04-02</startDate>
      <endDate>2018-04-02</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20180402_0_2447194x2443301_2449888x2449609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-04-02</startDate>
      <endDate>2018-04-02</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20180402_0_2447194x2442860_2449888x2449609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-04-02</startDate>
      <endDate>2018-04-02</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20180309_0_2448913x2672262_2449888x2449609_2450320x2737197">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sls:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:PurchaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-03-09</startDate>
      <endDate>2018-03-09</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20180309_0_2448913x2672262_2449620x3050115_2449888x2449609_2450320x2737197">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sls:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sls:PrivatePlacementSecondClosingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:PurchaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-03-09</startDate>
      <endDate>2018-03-09</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20180309_0_2448913x2672262_2449620x3050114_2449888x2449609_2450320x2737197">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sls:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sls:PrivatePlacementFirstClosingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:PurchaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-03-09</startDate>
      <endDate>2018-03-09</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20180309_0_2448913x2672262_2449620x2731166_2449888x2449609_2450320x2737197">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sls:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sls:QualifiedPublicOfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:PurchaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-03-09</startDate>
      <endDate>2018-03-09</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20180309_0_2447194x2443301_2449888x2449609_2450320x3050049">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:VotingAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-03-09</startDate>
      <endDate>2018-03-09</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20180308_0_2448913x2672262_2449888x2449609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sls:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-03-08</startDate>
      <endDate>2018-03-08</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20180307_0_2449888x2449609_2450320x2737197">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:PurchaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-03-07</startDate>
      <endDate>2018-03-07</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20180307_0_2448913x2672262_2449888x2449609_2450320x2737197">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sls:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:PurchaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-03-07</startDate>
      <endDate>2018-03-07</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20180307_0_2448913x2672262_2449888x2449609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sls:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-03-07</startDate>
      <endDate>2018-03-07</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20180307_0_2448913x2672262_2449620x2743081_2449888x2449609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sls:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sls:FirstTrancheMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-03-07</startDate>
      <endDate>2018-03-07</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20180307_0_2448913x2672262_2449620x2678536_2449888x2449609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sls:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sls:SecondTrancheMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-03-07</startDate>
      <endDate>2018-03-07</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20160412_0_2442761x2442444">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-12</startDate>
      <endDate>2016-04-12</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20160406_0_2435412x3053914_2435465x3053912_2442761x2442444">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:StarcoveMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:FrameworkLoanAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-06</startDate>
      <endDate>2016-04-06</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20150402_0_2435465x3049445">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:TwoZeroOneFiveConvertibleTermNotesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-04-02</startDate>
      <endDate>2015-04-02</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20150302_0_2435412x2660097_2435465x3053908">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:ThirdPartyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:TwoThousandFifiteenLoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-03-02</startDate>
      <endDate>2015-03-02</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20180822_0_2449888x2449609_2450320x3050038">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:EmperyAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-08-22</startDate>
      <endDate>2018-08-22</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20180430_0_2449888x2449609_2450320x3050038">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:EmperyAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-04-30</startDate>
      <endDate>2018-04-30</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20180222_0_2449888x2449609_2450320x3050038">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:EmperyAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-02-22</startDate>
      <endDate>2018-02-22</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20180219_0_2449888x2449609_2450320x3051912">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:LincolnParkAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-02-19</startDate>
      <endDate>2018-02-19</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20180215_0_2449888x2449609_2450320x3051911">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:AltoAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-02-15</startDate>
      <endDate>2018-02-15</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20180214_0_2449888x2449609_2450320x3051912">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:LincolnParkAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-02-14</startDate>
      <endDate>2018-02-14</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20180213_0_2449888x2449609_2450320x3051911">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:AltoAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-02-13</startDate>
      <endDate>2018-02-13</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20180213_0_2449888x2449609_2450320x3050036">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:SabbyAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-02-13</startDate>
      <endDate>2018-02-13</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20180209_0_2449888x2449609_2450320x3050036">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:SabbyAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-02-09</startDate>
      <endDate>2018-02-09</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20180209_0_2449888x2449609_2450320x3050035">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:HudsonBayAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-02-09</startDate>
      <endDate>2018-02-09</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20180207_0_2449888x2449609_2450320x3050644">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:AnsonAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-02-07</startDate>
      <endDate>2018-02-07</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20180206_0_2449888x2449609_2450320x3050643">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:CVIAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-02-06</startDate>
      <endDate>2018-02-06</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20171107_0_2442667x3048903">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">sls:QuiTamMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-11-07</startDate>
      <endDate>2017-11-07</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20170525_0_2435412x2684763_2447148x3049698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sls:MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-05-25</startDate>
      <endDate>2017-05-25</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20170525_0_2435412x2684763">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-05-25</startDate>
      <endDate>2017-05-25</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20170224_0_2447194x2442860_2450320x3050216">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:AdvaxisCollaborationAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-02-24</startDate>
      <endDate>2017-02-24</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20161101_0_2445234x2694343">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sls:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-11-01</startDate>
      <endDate>2016-11-01</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20161101_0_2435465x3053943_2446928x3053941">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:FounderLoansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sls:SougioultzoglouMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-11-01</startDate>
      <endDate>2016-11-01</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20161101_0_2435465x3053943_2446928x3053940">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:FounderLoansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sls:DrsStergiouMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-11-01</startDate>
      <endDate>2016-11-01</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20161101_0_2435465x3053943">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:FounderLoansMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-11-01</startDate>
      <endDate>2016-11-01</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20161101_0_2435465x3053920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:StarcoveLoansMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-11-01</startDate>
      <endDate>2016-11-01</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20161101_0_2435465x3049453">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:TwoZeroOneSixConvertibleTermNotesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-11-01</startDate>
      <endDate>2016-11-01</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20160810_0_2435412x2684763_2450320x3049265">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:SecondLicenseAmendmentWaiverAndAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-08-10</startDate>
      <endDate>2016-08-10</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20160809_0_2435412x2684763_2450320x3049265">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:SecondLicenseAmendmentWaiverAndAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-08-09</startDate>
      <endDate>2016-08-09</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20160512_0_2442761x2442444">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-05-12</startDate>
      <endDate>2016-05-12</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20160510_0_2435465x2668673_2442761x2448459">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-05-10</startDate>
      <endDate>2016-05-10</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20150507_0_2435465x3049445_2446928x3049446">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:TwoZeroOneFiveConvertibleTermNotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sls:EQCBiotechSelyIFundMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-05-07</startDate>
      <endDate>2015-05-07</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_1_20141114_0_2435412x3049272_2450320x3049275">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:TrojantecLtdMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:TrojantecLicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-11-14</startDate>
      <endDate>2014-11-14</endDate>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20181231_0_2448913x2672262_2449305x2447800_2449888x2449609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sls:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20180101_0_2449888x2449609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-01-01</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171231_0_2449718x2434781">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171231_0_2449620x2438180">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171231_0_2448914x2447681">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171231_0_2448914x2434572">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171231_0_2448914x2432358">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171231_0_2446922x3049598">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sls:EquilibriaCollaborationAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171231_0_2446922x2684763">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sls:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171231_0_2445234x2909678">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sls:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171231_0_2442761x2884929">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sls:SeniorSecuredDebenturesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171231_0_2442761x2687738_2450320x2719233">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sls:FourthTrancheMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171231_0_2442761x2448459_2447194x2443301_2448914x2434572">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171231_0_2442761x2448459">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171231_0_2440733x2437443">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171231_0_2439166x2450820">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171231_0_2439166x2449596">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171231_0_2438028x2438072_2438324x2438356">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171231_0_2438028x2437665_2438324x2438356">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171231_0_2435465x2743860_2442761x2448459">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:AmendmentAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171231_0_2435465x2668673_2442761x2448459">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171231_0_2434520x3054786">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:OtherGalenaWarrantIssuesAccountedForAsLiabilitiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171231_0_2434520x3050116">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:EqcWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171231_0_2434520x2884905">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:OtherWarrantIssuesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171231_0_2434520x2884867">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:February2017WarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171231_0_2433414x3049145">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sls:RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171231_0_2433414x2666068">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sls:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171231_0_2433414x2447365">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171231_0_2433414x2438181">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171229_0_2448914x3049260">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sls:PrivateSELLASMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-29</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171229_0_2448914x3049254">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sls:PremergerSecurityholdersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-29</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171229_0_2446922x3049598">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sls:EquilibriaCollaborationAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-29</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171229_0_2434520x3050116">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:EqcWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-29</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171229_0_2433694x2884874_2447148x3050369">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sls:GalenaBiopharmaIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sls:NeuvaxMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-29</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171229_0_2433694x2884874_2447148x3050157">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sls:GalenaBiopharmaIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sls:GaleThreeZeroTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-29</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171229_0_2433694x2884874_2447148x3049740">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sls:GalenaBiopharmaIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sls:GaleFourZeroOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-29</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171229_0_2433694x2884874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sls:GalenaBiopharmaIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-29</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171229_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
    </entity>
    <period>
      <instant>2017-12-29</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20161231_0_2448914x2447681">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20161231_0_2448914x2434572">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20161231_0_2448914x2432358_2449305x2448174">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20161231_0_2448914x2432358_2449305x2447520">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:RestatementAdjustmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20161231_0_2448914x2432358">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20161231_0_2446922x3049598">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sls:EquilibriaCollaborationAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20161231_0_2442761x3049991">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sls:ConvertibleDebtTwoThousandSelyNoteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20161231_0_2442761x3049779">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sls:ConvertibleDebtTwoThousandFifteenShareholderNotesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20161231_0_2442761x2679970">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sls:TwoThousandFifteenNotesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20161231_0_2434520x3050116">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:EqcWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20161231_0_2434520x2884905">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:OtherWarrantIssuesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20161231_0_2434520x2884867">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:February2017WarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20161231_0_2433414x3049145">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sls:RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20161231_0_2433414x3049142">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sls:RestrictedStockUnitsWithTimeBasedConditionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20161231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20151231_0_2448914x2447681">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20151231_0_2448914x2434572">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20151231_0_2448914x2432358_2449305x2448174">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20151231_0_2448914x2432358_2449305x2447520">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:RestatementAdjustmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20151231_0_2448914x2432358">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20151231_0_2446928x3053942">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sls:DrsStergiouAndSougioultzoglouMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20151231_0_2446928x3053941">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sls:SougioultzoglouMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20151231_0_2446928x3053940">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sls:DrsStergiouMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20151231_0_2435465x3053943_2446928x3053941">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:FounderLoansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sls:SougioultzoglouMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20151231_0_2435465x3053943_2446928x3053940">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:FounderLoansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sls:DrsStergiouMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20151231_0_2435465x3053943">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:FounderLoansMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20151231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20111231_0_2447194x2442860">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171011_0_2435412x2684763_2450320x3049580">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:SecondAmendedAndRestatedExclusiveLicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-10-11</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20170905_0_2450320x2719233">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-09-05</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20170831_0_2435465x3049445_2446928x3049446">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:TwoZeroOneFiveConvertibleTermNotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sls:EQCBiotechSelyIFundMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-08-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20160930_0_2450320x3049289">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:ClarendonLicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-09-30</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20151030_0_2435412x2684763_2450320x3049264">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:LicenseAmendmentWaiverAndShareIssuanceAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-10-30</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20140904_0_2435412x2684763_2447148x2442380_2449718x3049267">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">sls:ChiefExecutiveOfficerCoFounderMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-09-04</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20140904_0_2435412x2684763_2447148x2442380_2449718x2723027">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">sls:ViceChairmanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-09-04</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20140904_0_2435412x2684763_2447148x2442380_2449718x2715035">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">sls:CoFounderMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-09-04</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20140904_0_2435412x2684763_2447148x2442380">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-09-04</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20060911_0_2450320x2659749">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2006-09-11</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20180630_0_2448913x2672262_2449305x2447800_2449888x2449609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sls:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20170630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
    </entity>
    <period>
      <instant>2017-06-30</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20170613_0_2435465x2685828">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:BridgeFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-06-13</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20170613_0_2432521x3049445_2435465x2685828">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">sls:TwoZeroOneFiveConvertibleTermNotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:BridgeFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-06-13</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20160630_0_2435465x3049453">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:TwoZeroOneSixConvertibleTermNotesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20180406_0_2435465x2728214_2449888x2449609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:DebentureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-04-06</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20180406_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
    </entity>
    <period>
      <instant>2018-04-06</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20180309_0_2448913x2672262_2449620x3050115_2449888x2449609_2450320x2737197">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sls:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sls:PrivatePlacementSecondClosingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:PurchaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-09</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20180309_0_2448913x2672262_2449620x3050114_2449888x2449609_2450320x2737197">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sls:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sls:PrivatePlacementFirstClosingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:PurchaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-09</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20180309_0_2448913x2672262_2449620x2731166_2449888x2449609_2450320x2737197">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sls:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sls:QualifiedPublicOfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:PurchaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-09</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20180309_0_2447194x2443301_2449888x2449609_2450320x3050049">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:VotingAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-09</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20180308_0_2448913x2672262_2449888x2449609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sls:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-08</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20180308_0_2447194x2442860_2448913x2672262_2449888x2449609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sls:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-08</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20180307_0_2449888x2449609_2450320x2737197">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:PurchaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-07</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20180307_0_2448913x2672262_2449888x2449609_2450320x2737197">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sls:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:PurchaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-07</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20160406_0_2435412x3053914_2435465x3053912_2442761x2442444">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:StarcoveMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:FrameworkLoanAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-04-06</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20150402_0_2435465x3049445">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:TwoZeroOneFiveConvertibleTermNotesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-04-02</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20150302_0_2435412x2660097_2435465x3053908">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:ThirdPartyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:TwoThousandFifiteenLoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-02</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20180822_0_2449888x2449609_2450320x3050038">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:EmperyAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-08-22</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20180222_0_2449888x2449609_2450320x3050038">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:EmperyAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-02-22</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20180213_0_2449888x2449609_2450320x3051911">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:AltoAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-02-13</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20180209_0_2449888x2449609_2450320x3050035">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:HudsonBayAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-02-09</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20180207_0_2449888x2449609_2450320x3050644">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:AnsonAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-02-07</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20180206_0_2449888x2449609_2450320x3050643">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:CVIAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-02-06</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20171031_0_2442761x2733354_2450320x2719233">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sls:ThirdTrancheMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-10-31</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20170525_0_2435412x2684763_2450320x3049580">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:SecondAmendedAndRestatedExclusiveLicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-05-25</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20170525_0_2435412x2684763_2447148x3049698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sls:MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-05-25</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20170525_0_2435412x2684763">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-05-25</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20161128_0_2446922x3049599">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sls:MskLicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-11-28</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20161101_0_2445234x2694343">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sls:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-11-01</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20160810_0_2435412x2684763_2450320x3049265">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sls:SecondLicenseAmendmentWaiverAndAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-08-10</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20160510_0_2435465x2668673_2442761x2448459">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-05-10</instant>
    </period>
  </context>
  <context id="eol_PE735624--1710-K0010_STD_0_20131125_0_2435412x2653900_2435465x2895689">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sls:ShareholdersMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sls:TwoThousandThirteenLoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-11-25</instant>
    </period>
  </context>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="iso4217_EUR">
    <measure>iso4217:EUR</measure>
  </unit>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Option">
    <measure>sls:Option</measure>
  </unit>
  <unit id="Holder">
    <measure>sls:Holder</measure>
  </unit>
  <unit id="Tranche">
    <measure>sls:Tranche</measure>
  </unit>
  <unit id="Installment">
    <measure>sls:Installment</measure>
  </unit>

</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>29
<FILENAME>sls-20171231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFS Xcelerate Taxonomy Schema - http://www.dfsco.com/financial-services/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 7 -->
<!-- Creation date: 2018-04-13T14:49:15Z -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<schema xmlns="http://www.w3.org/2001/XMLSchema"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31"
  xmlns:us-types="http://fasb.org/us-types/2017-01-31"
  xmlns:sls="http://imetrix.edgar-online.com/20171231"
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31"
  xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31"
  xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
  xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31"
  targetNamespace="http://imetrix.edgar-online.com/20171231"
  elementFormDefault="qualified" attributeFormDefault="unqualified">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DocumentandEntityInformation" id="DocumentandEntityInformation">
        <link:definition>101 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassified" id="Role_StatementOfFinancialPositionClassified">
        <link:definition>103 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical" id="Role_StatementOfFinancialPositionClassifiedParen">
        <link:definition>104 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfIncome" id="Role_StatementOfIncome">
        <link:definition>105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome" id="Role_StatementOfShareholdersEquityAndOtherComprehensiveIncome">
        <link:definition>106 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfCashFlowsIndirect" id="Role_StatementOfCashFlowsIndirect">
        <link:definition>107 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock" id="Role_NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock">
        <link:definition>108 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsLiquidationBasisOfAccountingTextBlock" id="Role_NotesToFinancialStatementsLiquidationBasisOfAccountingTextBlock">
        <link:definition>109 - Disclosure - Liquidity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
        <link:definition>110 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock" id="Role_NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock">
        <link:definition>111 - Disclosure - Business Combination</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock" id="Role_NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock">
        <link:definition>112 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" id="Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
        <link:definition>113 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlock" id="Role_NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlock">
        <link:definition>114 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="Role_NotesToFinancialStatementsAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
        <link:definition>115 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock" id="Role_NotesToFinancialStatementsDebtDisclosureTextBlock">
        <link:definition>116 - Disclosure - Debt</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" id="Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
        <link:definition>117 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" id="Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
        <link:definition>118 - Disclosure - Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOptionIndexedToIssuersEquityDescriptionTextBlock" id="Role_NotesToFinancialStatementsOptionIndexedToIssuersEquityDescriptionTextBlock">
        <link:definition>119 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <link:definition>120 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" id="Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
        <link:definition>121 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" id="Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
        <link:definition>122 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock" id="Role_NotesToFinancialStatementsSubsequentEventsTextBlock">
        <link:definition>123 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies" id="Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies">
        <link:definition>124 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlockTables" id="Role_NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlockTables">
        <link:definition>125 - Disclosure - Organization and Description of Business (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockTables" id="Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockTables">
        <link:definition>126 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsBusinessCombinationDisclosureTextBlockTables">
        <link:definition>127 - Disclosure - Business Combination (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlockTables">
        <link:definition>128 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlockTables">
        <link:definition>129 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlockTables" id="Role_NotesToFinancialStatementsAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlockTables">
        <link:definition>130 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsDebtDisclosureTextBlockTables">
        <link:definition>131 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
        <link:definition>132 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables">
        <link:definition>133 - Disclosure - Stockholders' Equity (Deficit) (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOptionIndexedToIssuersEquityDescriptionTextBlockTables" id="Role_NotesToFinancialStatementsOptionIndexedToIssuersEquityDescriptionTextBlockTables">
        <link:definition>134 - Disclosure - Warrants (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" id="Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
        <link:definition>135 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
        <link:definition>136 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformation" id="DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformation">
        <link:definition>137 - Disclosure - Organization and Description of Business - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessSummaryOfAdjustmentsToAdditionalPaidinCapital" id="DisclosureOrganizationAndDescriptionOfBusinessSummaryOfAdjustmentsToAdditionalPaidinCapital">
        <link:definition>138 - Disclosure - Organization and Description of Business - Summary of Adjustments to Additional Paid-in Capital (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureLiquidityAdditionalInformation" id="DisclosureLiquidityAdditionalInformation">
        <link:definition>139 - Disclosure - Liquidity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation">
        <link:definition>140 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesOutstandingExcludedFromComputationOfDilutedWeightedAverageSharesOut_Xa" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesOutstandingExcludedFromComputationOfDilutedWeightedAverageSharesOut_Xa">
        <link:definition>141 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities Outstanding Excluded from Computation of Diluted Weighted Average Shares Outstanding (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBusinessCombinationAdditionalInformation" id="DisclosureBusinessCombinationAdditionalInformation">
        <link:definition>142 - Disclosure - Business Combination - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBusinessCombinationSummaryOfPurchasePrice" id="DisclosureBusinessCombinationSummaryOfPurchasePrice">
        <link:definition>143 - Disclosure - Business Combination - Summary of Purchase Price (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBusinessCombinationTotalPurchasePriceAllocation" id="DisclosureBusinessCombinationTotalPurchasePriceAllocation">
        <link:definition>144 - Disclosure - Business Combination - Total Purchase Price Allocation (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBusinessCombinationProFormaConsolidatedFinancialInformation" id="DisclosureBusinessCombinationProFormaConsolidatedFinancialInformation">
        <link:definition>145 - Disclosure - Business Combination - Pro forma Consolidated Financial Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfChangesInCarryingAmountOfGoodwill" id="DisclosureGoodwillAndIntangibleAssetsSummaryOfChangesInCarryingAmountOfGoodwill">
        <link:definition>146 - Disclosure - Goodwill and Intangible Assets - Summary of Changes in Carrying Amount of Goodwill (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformation" id="DisclosureGoodwillAndIntangibleAssetsAdditionalInformation">
        <link:definition>147 - Disclosure - Goodwill and Intangible Assets - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation" id="DisclosureCollaborationAndLicenseAgreementsAdditionalInformation">
        <link:definition>148 - Disclosure - Collaboration and License Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueMeasurementsContingentPurchasePriceConsiderationConvertibleDebtMeasuredAtEstimatedFairValueOnRecurringBasis" id="DisclosureFairValueMeasurementsContingentPurchasePriceConsiderationConvertibleDebtMeasuredAtEstimatedFairValueOnRecurringBasis">
        <link:definition>149 - Disclosure - Fair Value Measurements - Contingent Purchase Price Consideration, Convertible Debt, Measured at Estimated Fair Value on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformation" id="DisclosureFairValueMeasurementsAdditionalInformation">
        <link:definition>150 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilities" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>151 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtSummaryOfDebtAndConvertibleDebt" id="DisclosureDebtSummaryOfDebtAndConvertibleDebt">
        <link:definition>152 - Disclosure - Debt - Summary of Debt and Convertible Debt (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformationSeniorSecuredDebenture" id="DisclosureDebtAdditionalInformationSeniorSecuredDebenture">
        <link:definition>153 - Disclosure - Debt - Additional Information - Senior Secured Debenture (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformationConvertibleDebt" id="DisclosureDebtAdditionalInformationConvertibleDebt">
        <link:definition>154 - Disclosure - Debt - Additional Information - Convertible Debt (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformationLongtermDebt" id="DisclosureDebtAdditionalInformationLongtermDebt">
        <link:definition>155 - Disclosure - Debt - Additional Information - Long-term Debt (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationLegalProceedings" id="DisclosureCommitmentsAndContingenciesAdditionalInformationLegalProceedings">
        <link:definition>156 - Disclosure - Commitments and Contingencies - Additional Information - Legal Proceedings (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalCommitmentsForOperatingLeases" id="DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalCommitmentsForOperatingLeases">
        <link:definition>157 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Rental Commitments for Operating Leases (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation" id="DisclosureStockholdersEquityAdditionalInformation">
        <link:definition>158 - Disclosure - Stockholders' Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityCommonStockAreReservedForFutureIssuance" id="DisclosureStockholdersEquityCommonStockAreReservedForFutureIssuance">
        <link:definition>159 - Disclosure - Stockholders' Equity - Common Stock are Reserved for Future Issuance (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsScheduleOfWarrantActivity" id="DisclosureWarrantsScheduleOfWarrantActivity">
        <link:definition>160 - Disclosure - Warrants - Schedule of Warrant Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsAdditionalInformation" id="DisclosureWarrantsAdditionalInformation">
        <link:definition>161 - Disclosure - Warrants - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModel" id="DisclosureWarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModel">
        <link:definition>162 - Disclosure - Warrants - Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsChangesInFairValueOfWarrantLiability" id="DisclosureWarrantsChangesInFairValueOfWarrantLiability">
        <link:definition>163 - Disclosure - Warrants - Changes in Fair Value of Warrant Liability (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsWarrantsClassifiedAsEquity" id="DisclosureWarrantsWarrantsClassifiedAsEquity">
        <link:definition>164 - Disclosure - Warrants - Warrants Classified as Equity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation" id="DisclosureStockBasedCompensationAdditionalInformation">
        <link:definition>165 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAllocatedStockbasedCompensationExpense" id="DisclosureStockBasedCompensationScheduleOfAllocatedStockbasedCompensationExpense">
        <link:definition>166 - Disclosure - Stock-Based Compensation - Schedule of Allocated Stock-based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfGrantDateFairValuesOfOptionIssuedToEmployeesAndNonEmployees" id="DisclosureStockBasedCompensationScheduleOfGrantDateFairValuesOfOptionIssuedToEmployeesAndNonEmployees">
        <link:definition>167 - Disclosure - Stock-Based Compensation - Schedule of Grant Date Fair Values of Option Issued to Employees and Non-Employees (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivity" id="DisclosureStockBasedCompensationStockOptionActivity">
        <link:definition>168 - Disclosure - Stock-Based Compensation - Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationRSUActivityForRSUsWithOnlyTimeBasedCondition" id="DisclosureStockBasedCompensationRSUActivityForRSUsWithOnlyTimeBasedCondition">
        <link:definition>169 - Disclosure - Stock-Based Compensation - RSU Activity for RSUs with Only Time-Based Condition (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationRSUActivityForRSUsWithBothTimeBasedAndPerformanceBasedCondition" id="DisclosureStockBasedCompensationRSUActivityForRSUsWithBothTimeBasedAndPerformanceBasedCondition">
        <link:definition>170 - Disclosure - Stock-Based Compensation - RSU Activity for RSUs with Both Time-Based and Performance-Based Condition (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeIncomeTaxes" id="DisclosureIncomeTaxesScheduleOfLossBeforeIncomeTaxes">
        <link:definition>171 - Disclosure - Income Taxes - Schedule of Loss Before Income Taxes (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefit" id="DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefit">
        <link:definition>172 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssets" id="DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssets">
        <link:definition>173 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilities" id="DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilities">
        <link:definition>174 - Disclosure - Income Taxes - Components of Net Deferred Tax Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionComputedByApplyingFederalStatutoryRate" id="DisclosureIncomeTaxesScheduleOfProvisionComputedByApplyingFederalStatutoryRate">
        <link:definition>175 - Disclosure - Income Taxes - Schedule of Provision Computed by Applying Federal Statutory Rate (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation" id="DisclosureIncomeTaxesAdditionalInformation">
        <link:definition>176 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfChangesToCompanysUnrecognizedTaxBenefits" id="DisclosureIncomeTaxesScheduleOfChangesToCompanysUnrecognizedTaxBenefits">
        <link:definition>177 - Disclosure - Income Taxes - Schedule of Changes to Company's Unrecognized Tax Benefits (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation" id="DisclosureRelatedPartyTransactionsAdditionalInformation">
        <link:definition>178 - Disclosure - Related Party Transactions - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation" id="DisclosureSubsequentEventsAdditionalInformation">
        <link:definition>179 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="sls-20171231_cal.xml" xlink:title="Calculation Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="sls-20171231_def.xml" xlink:title="Definition Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="sls-20171231_lab.xml" xlink:title="Label Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="sls-20171231_pre.xml" xlink:title="Presentation Links, all"/>
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2017-01-31" schemaLocation="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <element name="AccruedCompensationIncentive" id="sls_AccruedCompensationIncentive" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionalExpenseIncurredToReflectFairValueOfSharesIssued" id="sls_AdditionalExpenseIncurredToReflectFairValueOfSharesIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionalSharesIssuedInConnectionWithLicensingAgreement" id="sls_AdditionalSharesIssuedInConnectionWithLicensingAgreement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion" id="sls_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition" id="sls_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdjustmentToCommonStockInConnectionWithReverseForwardStockSplit" id="sls_AdjustmentToCommonStockInConnectionWithReverseForwardStockSplit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdvaxisCollaborationAgreementMember" id="sls_AdvaxisCollaborationAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AggregateSalesPriceOfCommonStock" id="sls_AggregateSalesPriceOfCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AltoAgreementMember" id="sls_AltoAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AmendedAndRestatedLicenseAgreementMember" id="sls_AmendedAndRestatedLicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AmendmentAgreementMember" id="sls_AmendmentAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AnnualMaintenanceFee" id="sls_AnnualMaintenanceFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AnsonAgreementMember" id="sls_AnsonAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AssetPurchaseAgreementAndRelatedLicenseAgreementAbstract" id="sls_AssetPurchaseAgreementAndRelatedLicenseAgreementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BridgeFinancingMember" id="sls_BridgeFinancingMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" id="sls_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BusinessCombinationContingentConsiderationPayableUponAchievementOfMilestones" id="sls_BusinessCombinationContingentConsiderationPayableUponAchievementOfMilestones" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding" id="sls_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BusinessCombinationFairValueOfSharesOutstanding" id="sls_BusinessCombinationFairValueOfSharesOutstanding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BusinessCombinationIncreaseDecreaseToReflectLiabilitiesAcquiredAtFairValueAbstract" id="sls_BusinessCombinationIncreaseDecreaseToReflectLiabilitiesAcquiredAtFairValueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BusinessCombinationProFormaTransactionCosts" id="sls_BusinessCombinationProFormaTransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses" id="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement" id="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" id="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability" id="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CancellationOfManagementFee" id="sls_CancellationOfManagementFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CancellationOfMilestonePayment" id="sls_CancellationOfMilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CashPaymentOnContractTermination" id="sls_CashPaymentOnContractTermination" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ChangeInFairValueOfWarrantLiabilities" id="sls_ChangeInFairValueOfWarrantLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ChangesInFairValueOfWarrantLiabilityTableTableTextBlock" id="sls_ChangesInFairValueOfWarrantLiabilityTableTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ChiefExecutiveOfficerCoFounderMember" id="sls_ChiefExecutiveOfficerCoFounderMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClarendonLicenseAgreementMember" id="sls_ClarendonLicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClarendonTradingEinvestimentosLDAMember" id="sls_ClarendonTradingEinvestimentosLDAMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantOrRightAssumedInAcquisition" id="sls_ClassOfWarrantOrRightAssumedInAcquisition" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantOrRightExpirationDateDescription" id="sls_ClassOfWarrantOrRightExpirationDateDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantOrRightExpirationMonthAndYear" id="sls_ClassOfWarrantOrRightExpirationMonthAndYear" type="xbrli:gYearMonthItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantOrRightExpired" id="sls_ClassOfWarrantOrRightExpired" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassofWarrantorRightFairValueRollForward" id="sls_ClassofWarrantorRightFairValueRollForward" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantOrRightGranted" id="sls_ClassOfWarrantOrRightGranted" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantOrRightOutstandingRollForward" id="sls_ClassOfWarrantOrRightOutstandingRollForward" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantOrRightTerm" id="sls_ClassOfWarrantOrRightTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CoFounderMember" id="sls_CoFounderMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommonStockAreReservedForFutureIssuanceTableTextBlock" id="sls_CommonStockAreReservedForFutureIssuanceTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommonStockConversionRatio" id="sls_CommonStockConversionRatio" type="xbrli:pureItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommonStockPercentageIssuedPriorToPurchaseAgreement" id="sls_CommonStockPercentageIssuedPriorToPurchaseAgreement" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ComprehensiveLossPolicyPolicyTextBlock" id="sls_ComprehensiveLossPolicyPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ContingentPurchasePriceConsiderationNetOfCurrentPortion" id="sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ContractResearchPayable" id="sls_ContractResearchPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ContractualAgreementTerminationDate" id="sls_ContractualAgreementTerminationDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ConversionPriceOfPreferredStock" id="sls_ConversionPriceOfPreferredStock" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ConvertibleDebtTwoThousandFifteenShareholderNotesMember" id="sls_ConvertibleDebtTwoThousandFifteenShareholderNotesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ConvertibleDebtTwoThousandSelyNoteMember" id="sls_ConvertibleDebtTwoThousandSelyNoteMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ConvertibleNotesConversionPricePerShareOfCommonStock" id="sls_ConvertibleNotesConversionPricePerShareOfCommonStock" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ConvertiblePreferredStockBeneficialOwnershipLimitationPercentage" id="sls_ConvertiblePreferredStockBeneficialOwnershipLimitationPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ConvertiblePreferredStockIssuedShares" id="sls_ConvertiblePreferredStockIssuedShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CVIAgreementMember" id="sls_CVIAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DateByWhichStockHolderApprovalRequired" id="sls_DateByWhichStockHolderApprovalRequired" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DebentureMember" id="sls_DebentureMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DebtConversionConvertedInstrumentGainLossRecognized" id="sls_DebtConversionConvertedInstrumentGainLossRecognized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DebtInstrumentCashInExcessOfDebenture" id="sls_DebtInstrumentCashInExcessOfDebenture" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DebtInstrumentCommonStockMinimumPriceCondition" id="sls_DebtInstrumentCommonStockMinimumPriceCondition" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DebtInstrumentConvertiblePercentageOfPrincipalAndAccruedInterest" id="sls_DebtInstrumentConvertiblePercentageOfPrincipalAndAccruedInterest" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DebtInstrumentConvertibleTermOfNotes" id="sls_DebtInstrumentConvertibleTermOfNotes" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DebtInstrumentCovenantLiquidityCovenant" id="sls_DebtInstrumentCovenantLiquidityCovenant" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DebtInstrumentCovenantPrepayLesserAccruedAndUnpaidInterest" id="sls_DebtInstrumentCovenantPrepayLesserAccruedAndUnpaidInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DebtInstrumentPercentageofPriorDayVolumeWeightedAveragePrice" id="sls_DebtInstrumentPercentageofPriorDayVolumeWeightedAveragePrice" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DebtInstrumentPercentageofVolumeWeightedAveragePrice" id="sls_DebtInstrumentPercentageofVolumeWeightedAveragePrice" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DebtInstrumentRedemptionPrincipalAmountRedeemed" id="sls_DebtInstrumentRedemptionPrincipalAmountRedeemed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DebtInstrumentRedemptionRedemptionPayments" id="sls_DebtInstrumentRedemptionRedemptionPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DebtRepaymentsDescription" id="sls_DebtRepaymentsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance" id="sls_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeemedDividendOnDebtConversion" id="sls_DeemedDividendOnDebtConversion" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife" id="sls_DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredTaxAssetsLicensingDeductionDeferral" id="sls_DeferredTaxAssetsLicensingDeductionDeferral" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DenominatorBaseForIssuanceOfCommonStockValue" id="sls_DenominatorBaseForIssuanceOfCommonStockValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DocumentAndEntityInformationAbstract" id="sls_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DrAngelosMStergiouMember" id="sls_DrAngelosMStergiouMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DrsStergiouAndSougioultzoglouMember" id="sls_DrsStergiouAndSougioultzoglouMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DrsStergiouMember" id="sls_DrsStergiouMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EffectiveIncomeTaxRateReconciliationPermanentDifferences" id="sls_EffectiveIncomeTaxRateReconciliationPermanentDifferences" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EffectivePeriodOfAgreement" id="sls_EffectivePeriodOfAgreement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EmperyAgreementMember" id="sls_EmperyAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EmployeeAndNonemployeeStockOptionsMember" id="sls_EmployeeAndNonemployeeStockOptionsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EmployeeStockPurchasePlanMember" id="sls_EmployeeStockPurchasePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EngagementLetterMember" id="sls_EngagementLetterMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EQCBiotechSelyIFundMember" id="sls_EQCBiotechSelyIFundMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EqcWarrantsMember" id="sls_EqcWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EquilibriaCollaborationAgreementMember" id="sls_EquilibriaCollaborationAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FairValueOfStockOptionsAssumedInConnectionWithAcquisition" id="sls_FairValueOfStockOptionsAssumedInConnectionWithAcquisition" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FairValueOfWarrantLiabilityAssumptionsExpectedTerm" id="sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FairValueOfWarrantsExercised" id="sls_FairValueOfWarrantsExercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FairValueofWarrantsGranted" id="sls_FairValueofWarrantsGranted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FairValueofWarrantsGrantedperShare" id="sls_FairValueofWarrantsGrantedperShare" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FairValueOfWarrantsLiabilities" id="sls_FairValueOfWarrantsLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FairValueOfWarrantsPotentiallySettleableInCash" id="sls_FairValueOfWarrantsPotentiallySettleableInCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="February2017WarrantsMember" id="sls_February2017WarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FirstTrancheMember" id="sls_FirstTrancheMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FirstTrojantecAmendmentMember" id="sls_FirstTrojantecAmendmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FirstWaiverMember" id="sls_FirstWaiverMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FounderLoansMember" id="sls_FounderLoansMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FourthTrancheMember" id="sls_FourthTrancheMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FrameworkLoanAgreementMember" id="sls_FrameworkLoanAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="GainLossOnExtinguishmentOfDebt" id="sls_GainLossOnExtinguishmentOfDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="GaleFourZeroOneMember" id="sls_GaleFourZeroOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="GalenaBiopharmaIncMember" id="sls_GalenaBiopharmaIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="GaleThreeZeroTwoMember" id="sls_GaleThreeZeroTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="GoodwillAndIntangibleAssetsLineItems" id="sls_GoodwillAndIntangibleAssetsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="GoodwillAndIntangibleAssetsTable" id="sls_GoodwillAndIntangibleAssetsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="GoodwillPolicyTextBlock" id="sls_GoodwillPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="GrossProceedsPercentage" id="sls_GrossProceedsPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="HudsonBayAgreementMember" id="sls_HudsonBayAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ImpactOnTaxProvisionFromUnrecognizedTaxBenefits" id="sls_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="Incentivefeepercentageequaltogrossvaluepaidbypurchaserincash" id="sls_Incentivefeepercentageequaltogrossvaluepaidbypurchaserincash" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncentiveFeePercentageEqualToPostMoneyMarketValue" id="sls_IncentiveFeePercentageEqualToPostMoneyMarketValue" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IntangibleAssetsIndefinitelivedPolicyPolicyTextBlock" id="sls_IntangibleAssetsIndefinitelivedPolicyPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IssuanceofCommonStockforLitigationSettlement" id="sls_IssuanceofCommonStockforLitigationSettlement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IssuanceOfWarrantsTerm" id="sls_IssuanceOfWarrantsTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="JGBCaymanNewtonLtdMember" id="sls_JGBCaymanNewtonLtdMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LiabilitiesUnderTerminationAgreementPayableInCash" id="sls_LiabilitiesUnderTerminationAgreementPayableInCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAgreementAmendmentDate" id="sls_LicenseAgreementAmendmentDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAgreementAmendmentExtendedDateForFinancing" id="sls_LicenseAgreementAmendmentExtendedDateForFinancing" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAgreementDate" id="sls_LicenseAgreementDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAgreementDateSecondAmended" id="sls_LicenseAgreementDateSecondAmended" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAgreementEffectiveDate" id="sls_LicenseAgreementEffectiveDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAgreementExpirationTerm" id="sls_LicenseAgreementExpirationTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAgreementMember" id="sls_LicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAgreementOutstandingAmountPayable" id="sls_LicenseAgreementOutstandingAmountPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAgreementTerminationDate" id="sls_LicenseAgreementTerminationDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAmendmentWaiverAndShareIssuanceAgreementMember" id="sls_LicenseAmendmentWaiverAndShareIssuanceAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAndCollaborationAgreementsLineItems" id="sls_LicenseAndCollaborationAgreementsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAndCollaborationAgreementsTable" id="sls_LicenseAndCollaborationAgreementsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="LicenseTerminationFeesPaid" id="sls_LicenseTerminationFeesPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LincolnParkAgreementMember" id="sls_LincolnParkAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LiquidityAbstract" id="sls_LiquidityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LiquidityLineItems" id="sls_LiquidityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LiquidityTable" id="sls_LiquidityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="LitigationSettlementAmountCash" id="sls_LitigationSettlementAmountCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LitigationSettlementIssuanceofCommonStockShares" id="sls_LitigationSettlementIssuanceofCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss" id="sls_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MaximumNumberOfDaysToMakePayments" id="sls_MaximumNumberOfDaysToMakePayments" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember" id="sls_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MemorialSloanKetteringCancerCenterMember" id="sls_MemorialSloanKetteringCancerCenterMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MilestoneFeePaymentsUponCommencementOfClinicalTrials" id="sls_MilestoneFeePaymentsUponCommencementOfClinicalTrials" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MilestonePayment" id="sls_MilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MilestonePayments" id="sls_MilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MilestonePaymentsReceivable" id="sls_MilestonePaymentsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MinimumAnnualRoyaltyPayment" id="sls_MinimumAnnualRoyaltyPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MinimumOwnershipPercentageOfOutstandingSharesOfCommonStockForConversionToTakeEffect" id="sls_MinimumOwnershipPercentageOfOutstandingSharesOfCommonStockForConversionToTakeEffect" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MinimumPercentageOfTradingPriceOfCommonStock" id="sls_MinimumPercentageOfTradingPriceOfCommonStock" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MinimumProceedRequiredUnderQualifiedOffering" id="sls_MinimumProceedRequiredUnderQualifiedOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ModifiedTermsOnLoanPercentageMaximum" id="sls_ModifiedTermsOnLoanPercentageMaximum" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MskLicenseAgreementMember" id="sls_MskLicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NeuvaxMember" id="sls_NeuvaxMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NonCashResearchAndDevelopmentExpense" id="sls_NonCashResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NonrefundableMilestonePayments" id="sls_NonrefundableMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NonrefundableSalesMilestonePayments" id="sls_NonrefundableSalesMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberofDaysAveragedforExercisePrice" id="sls_NumberofDaysAveragedforExercisePrice" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfInstallmentsToMakePayments" id="sls_NumberOfInstallmentsToMakePayments" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfSignificantShareholders" id="sls_NumberOfSignificantShareholders" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfStockOptionsGranted" id="sls_NumberOfStockOptionsGranted" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfTranches" id="sls_NumberOfTranches" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage" id="sls_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OperatingLossAndTaxCreditCarryforwardsLimitationsOnUsePeriodOfOwnershipPercentage" id="sls_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUsePeriodOfOwnershipPercentage" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OperatingLossCarryforwardsExpirationYearRangeEnd" id="sls_OperatingLossCarryforwardsExpirationYearRangeEnd" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OperatingLossCarryforwardsExpirationYearRangeStart" id="sls_OperatingLossCarryforwardsExpirationYearRangeStart" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OrganizationAndDescriptionOfBusinessLineItems" id="sls_OrganizationAndDescriptionOfBusinessLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OrganizationAndDescriptionOfBusinessTable" id="sls_OrganizationAndDescriptionOfBusinessTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="OtherGalenaWarrantIssuesAccountedForAsLiabilitiesMember" id="sls_OtherGalenaWarrantIssuesAccountedForAsLiabilitiesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OtherWarrantIssuesMember" id="sls_OtherWarrantIssuesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PatentsAndPatentApplicationCostsPolicyPolicyTextBlock" id="sls_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards" id="sls_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfFullyDilutedShareCapital" id="sls_PercentageOfFullyDilutedShareCapital" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfFullyDilutedShareCapitalOwned" id="sls_PercentageOfFullyDilutedShareCapitalOwned" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfMarketAveragePriceOfShares" id="sls_PercentageOfMarketAveragePriceOfShares" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfOwnershipOutstandingShareCapital" id="sls_PercentageOfOwnershipOutstandingShareCapital" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfReductionInRiskRecurrence" id="sls_PercentageOfReductionInRiskRecurrence" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PremergerSecurityholdersMember" id="sls_PremergerSecurityholdersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PreviousRoyaltyObligationPercentage" id="sls_PreviousRoyaltyObligationPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PreviousRoyaltyOnNetSalesValue" id="sls_PreviousRoyaltyOnNetSalesValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PrivatePlacementFirstClosingMember" id="sls_PrivatePlacementFirstClosingMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PrivatePlacementSecondClosingMember" id="sls_PrivatePlacementSecondClosingMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PrivateSELLASMember" id="sls_PrivateSELLASMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProceedsfromIssuanceofLongtermDebtandWarrantsNet" id="sls_ProceedsfromIssuanceofLongtermDebtandWarrantsNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProceedsFromMilestoneBasedPayments" id="sls_ProceedsFromMilestoneBasedPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProjectManagementFeesPayable" id="sls_ProjectManagementFeesPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PurchaseAgreementMember" id="sls_PurchaseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="QualifiedOfferingDescription" id="sls_QualifiedOfferingDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="QualifiedPublicOfferingMember" id="sls_QualifiedPublicOfferingMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="QuiTamMember" id="sls_QuiTamMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ResearchFundingCosts" id="sls_ResearchFundingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RestrictedCashAndCashEquivalentsFairValueDisclosure" id="sls_RestrictedCashAndCashEquivalentsFairValueDisclosure" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RestrictedStockUnitsMember" id="sls_RestrictedStockUnitsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember" id="sls_RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RestrictedStockUnitsWithTimeBasedConditionsMember" id="sls_RestrictedStockUnitsWithTimeBasedConditionsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RoyaltyOnNetSalesValue" id="sls_RoyaltyOnNetSalesValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RoyaltyRatePercentage" id="sls_RoyaltyRatePercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SabbyAgreementMember" id="sls_SabbyAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock" id="sls_ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock" id="sls_ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ScheduleOfWarrantActivityTableTableTextBlock" id="sls_ScheduleOfWarrantActivityTableTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ScheduleOfWarrantValuationAssumptionsTableTableTextBlock" id="sls_ScheduleOfWarrantValuationAssumptionsTableTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SecondAmendedAndRestatedExclusiveLicenseAgreementMember" id="sls_SecondAmendedAndRestatedExclusiveLicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SecondLicenseAmendmentWaiverAndAgreementMember" id="sls_SecondLicenseAmendmentWaiverAndAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SecondTrancheMember" id="sls_SecondTrancheMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SecuritiesPurchaseAgreementMember" id="sls_SecuritiesPurchaseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeniorSecuredDebenturesMember" id="sls_SeniorSecuredDebenturesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesAConvertiblePreferredStockMember" id="sls_SeriesAConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInAcquisitionGrantDateIntrinsicValue" id="sls_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInAcquisitionGrantDateIntrinsicValue" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger" id="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledIntrinsicValue" id="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAggregateIntrinsicValue" id="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAggregateIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants" id="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SharebasedCompensationArrangementBySharebasedPaymentAwardStockOptionsSharesOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" id="sls_SharebasedCompensationArrangementBySharebasedPaymentAwardStockOptionsSharesOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate" id="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationAwardVestingDateFourMember" id="sls_ShareBasedCompensationAwardVestingDateFourMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationAwardVestingDateOneMember" id="sls_ShareBasedCompensationAwardVestingDateOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationAwardVestingDateThreeMember" id="sls_ShareBasedCompensationAwardVestingDateThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationAwardVestingDateTwoMember" id="sls_ShareBasedCompensationAwardVestingDateTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationExercisePeriod" id="sls_ShareBasedCompensationExercisePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareholdersMember" id="sls_ShareholdersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod" id="sls_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares" id="sls_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SharesIssuableForConsiderationForLicenseTerminationAgreement" id="sls_SharesIssuableForConsiderationForLicenseTerminationAgreement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SharesIssuedInCancellationOfLicenseAgreement" id="sls_SharesIssuedInCancellationOfLicenseAgreement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SharesIssuedInConnectionWithAcquisition" id="sls_SharesIssuedInConnectionWithAcquisition" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SharesIssuedToSettleAccountsPayable" id="sls_SharesIssuedToSettleAccountsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SharesIssuedToSettlerElatedPartyAccountsPayable" id="sls_SharesIssuedToSettlerElatedPartyAccountsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SharesIssuedUnderLicenseAgreement" id="sls_SharesIssuedUnderLicenseAgreement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SignificantAccountingPoliciesLineItems" id="sls_SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SignificantAccountingPoliciesTable" id="sls_SignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="SougioultzoglouMember" id="sls_SougioultzoglouMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StarcoveLoansMember" id="sls_StarcoveLoansMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StarcoveMember" id="sls_StarcoveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockConversionLimitPercentage" id="sls_StockConversionLimitPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockholderApprovalPeriod" id="sls_StockholderApprovalPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodSharesCancellationOfLongTermDebt" id="sls_StockIssuedDuringPeriodSharesCancellationOfLongTermDebt" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithAcquisition" id="sls_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithAcquisition" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement" id="sls_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodSharesLicenseAgreement" id="sls_StockIssuedDuringPeriodSharesLicenseAgreement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodSharesPartialConsiderationOfLicenseFee" id="sls_StockIssuedDuringPeriodSharesPartialConsiderationOfLicenseFee" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable" id="sls_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodSharesShareWarrantsExercised" id="sls_StockIssuedDuringPeriodSharesShareWarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares" id="sls_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodValueCancellationOfLongTermDebt" id="sls_StockIssuedDuringPeriodValueCancellationOfLongTermDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodValueLicenseAgreement" id="sls_StockIssuedDuringPeriodValueLicenseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee" id="sls_StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable" id="sls_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedForAntiDilutionProvisions" id="sls_StockIssuedForAntiDilutionProvisions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedForAntiDilutionProvisionsShares" id="sls_StockIssuedForAntiDilutionProvisionsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod" id="sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares" id="sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue" id="sls_StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares" id="sls_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue" id="sls_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SublicenseFeePayablePercentageIfExecutedAfterFirstPatientEnrolledInPhaseThreeClinicalTrial" id="sls_SublicenseFeePayablePercentageIfExecutedAfterFirstPatientEnrolledInPhaseThreeClinicalTrial" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SublicenseFeePayablePercentageIfExecutedPriorToFirstPatientEnrolledInPhaseThreeClinicalTrial" id="sls_SublicenseFeePayablePercentageIfExecutedPriorToFirstPatientEnrolledInPhaseThreeClinicalTrial" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SuccessFeeAndOtherTransactionCosts" id="sls_SuccessFeeAndOtherTransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ThirdPartyMember" id="sls_ThirdPartyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ThirdTrancheMember" id="sls_ThirdTrancheMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TradingDays" id="sls_TradingDays" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TrojantecLicenseAgreementMember" id="sls_TrojantecLicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TrojantecLtdMember" id="sls_TrojantecLtdMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TwoThousandAndSeventeenEquityIncentivePlanMember" id="sls_TwoThousandAndSeventeenEquityIncentivePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TwoThousandAndSixteenEquityIncentivePlanMember" id="sls_TwoThousandAndSixteenEquityIncentivePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TwoThousandFifiteenLoanAgreementMember" id="sls_TwoThousandFifiteenLoanAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TwoThousandFifteenNotesMember" id="sls_TwoThousandFifteenNotesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TwoThousandThirteenLoanAgreementMember" id="sls_TwoThousandThirteenLoanAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TwoZeroOneFiveConvertibleTermNotesMember" id="sls_TwoZeroOneFiveConvertibleTermNotesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TwoZeroOneSixConvertibleTermNotesMember" id="sls_TwoZeroOneSixConvertibleTermNotesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UpfrontLicenseFees" id="sls_UpfrontLicenseFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UsattorneysofficeforthedistrictofnewjerseyanddepartmentofjusticeMember" id="sls_UsattorneysofficeforthedistrictofnewjerseyanddepartmentofjusticeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ViceChairmanMember" id="sls_ViceChairmanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="VotingAgreementMember" id="sls_VotingAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WarrantExcercisableTerm" id="sls_WarrantExcercisableTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WarrantExercisePriceAsPercentOfDebtConversion" id="sls_WarrantExercisePriceAsPercentOfDebtConversion" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WarrantLiability" id="sls_WarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WarrantsFairValueAssumptionsExpectedVolatility" id="sls_WarrantsFairValueAssumptionsExpectedVolatility" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WarrantsFairValueAssumptionsRiskFreeInterestRate" id="sls_WarrantsFairValueAssumptionsRiskFreeInterestRate" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WarrantsIssuedShares" id="sls_WarrantsIssuedShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WarrantStrikePrice" id="sls_WarrantStrikePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>30
<FILENAME>sls-20171231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFS Xcelerate Taxonomy Calculation Linkbase - http://www.dfsco.com/financial-services/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 7 -->
<!-- Creation date: 2018-04-13T14:49:15Z -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DocumentandEntityInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_StatementOfIncome" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureOrganizationAndDescriptionOfBusinessSummaryOfAdjustmentsToAdditionalPaidinCapital" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessSummaryOfAdjustmentsToAdditionalPaidinCapital"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureLiquidityAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureLiquidityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesOutstandingExcludedFromComputationOfDilutedWeightedAverageSharesOut_Xa" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesOutstandingExcludedFromComputationOfDilutedWeightedAverageSharesOut_Xa"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureBusinessCombinationAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBusinessCombinationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureBusinessCombinationSummaryOfPurchasePrice" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBusinessCombinationSummaryOfPurchasePrice"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureBusinessCombinationTotalPurchasePriceAllocation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBusinessCombinationTotalPurchasePriceAllocation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureBusinessCombinationProFormaConsolidatedFinancialInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBusinessCombinationProFormaConsolidatedFinancialInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureGoodwillAndIntangibleAssetsSummaryOfChangesInCarryingAmountOfGoodwill" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfChangesInCarryingAmountOfGoodwill"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureGoodwillAndIntangibleAssetsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureFairValueMeasurementsContingentPurchasePriceConsiderationConvertibleDebtMeasuredAtEstimatedFairValueOnRecurringBasis" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueMeasurementsContingentPurchasePriceConsiderationConvertibleDebtMeasuredAtEstimatedFairValueOnRecurringBasis"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureFairValueMeasurementsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilities" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureDebtSummaryOfDebtAndConvertibleDebt" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtSummaryOfDebtAndConvertibleDebt"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureDebtAdditionalInformationSeniorSecuredDebenture" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformationSeniorSecuredDebenture"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureDebtAdditionalInformationConvertibleDebt" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformationConvertibleDebt"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureDebtAdditionalInformationLongtermDebt" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformationLongtermDebt"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationLegalProceedings" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationLegalProceedings"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalCommitmentsForOperatingLeases" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalCommitmentsForOperatingLeases"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureStockholdersEquityAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureStockholdersEquityCommonStockAreReservedForFutureIssuance" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityCommonStockAreReservedForFutureIssuance"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureWarrantsScheduleOfWarrantActivity" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsScheduleOfWarrantActivity"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureWarrantsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureWarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModel" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModel"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureWarrantsChangesInFairValueOfWarrantLiability" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsChangesInFairValueOfWarrantLiability"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureWarrantsWarrantsClassifiedAsEquity" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsWarrantsClassifiedAsEquity"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureStockBasedCompensationAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureStockBasedCompensationScheduleOfAllocatedStockbasedCompensationExpense" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAllocatedStockbasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureStockBasedCompensationScheduleOfGrantDateFairValuesOfOptionIssuedToEmployeesAndNonEmployees" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfGrantDateFairValuesOfOptionIssuedToEmployeesAndNonEmployees"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureStockBasedCompensationStockOptionActivity" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivity"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureStockBasedCompensationRSUActivityForRSUsWithOnlyTimeBasedCondition" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationRSUActivityForRSUsWithOnlyTimeBasedCondition"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureStockBasedCompensationRSUActivityForRSUsWithBothTimeBasedAndPerformanceBasedCondition" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationRSUActivityForRSUsWithBothTimeBasedAndPerformanceBasedCondition"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureIncomeTaxesScheduleOfLossBeforeIncomeTaxes" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeIncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefit" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefit"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssets" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssets"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilities" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureIncomeTaxesScheduleOfProvisionComputedByApplyingFederalStatutoryRate" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionComputedByApplyingFederalStatutoryRate"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureIncomeTaxesAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureIncomeTaxesScheduleOfChangesToCompanysUnrecognizedTaxBenefits" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfChangesToCompanysUnrecognizedTaxBenefits"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureRelatedPartyTransactionsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureSubsequentEventsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsLiquidationBasisOfAccountingTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsLiquidationBasisOfAccountingTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsBusinessCombinationDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsOptionIndexedToIssuersEquityDescriptionTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOptionIndexedToIssuersEquityDescriptionTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsOptionIndexedToIssuersEquityDescriptionTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOptionIndexedToIssuersEquityDescriptionTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DocumentandEntityInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:label="sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationReserveCurrent" xlink:label="us-gaap_LitigationReserveCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_WarrantLiability" xlink:label="sls_WarrantLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="sls_WarrantLiability" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermDebtNoncurrent" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ConvertibleDebtNoncurrent" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1.2500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LongTermDebtCurrent" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LitigationReserveCurrent" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1.2100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1.2200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.2300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.2400" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfIncome">
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DeemedDividendOnDebtConversion" xlink:label="sls_DeemedDividendOnDebtConversion"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestIncomeExpenseNet" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingExpense" order="1.0600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.0700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="sls_DeemedDividendOnDebtConversion" order="1.0900" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0100" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1.0200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_SeveranceCosts1" order="1.0300" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_NonCashResearchAndDevelopmentExpense" xlink:label="sls_NonCashResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.2200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" order="1.2100" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" order="1.1600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sls_NonCashResearchAndDevelopmentExpense" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_PaidInKindInterest" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1.0600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DeferredIncomeTaxesAndTaxCredits" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_SeveranceCosts1" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.1100" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="1.1300" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessSummaryOfAdjustmentsToAdditionalPaidinCapital">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureLiquidityAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesOutstandingExcludedFromComputationOfDilutedWeightedAverageSharesOut_Xa">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBusinessCombinationAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBusinessCombinationSummaryOfPurchasePrice">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding" xlink:label="sls_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BusinessCombinationFairValueOfSharesOutstanding" xlink:label="sls_BusinessCombinationFairValueOfSharesOutstanding"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="sls_BusinessCombinationFairValueOfSharesOutstanding" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="sls_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding" order="1.0200" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBusinessCombinationTotalPurchasePriceAllocation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses" xlink:label="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement" xlink:label="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:label="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability" xlink:label="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_Goodwill" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" order="1.1300" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBusinessCombinationProFormaConsolidatedFinancialInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfChangesInCarryingAmountOfGoodwill">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueMeasurementsContingentPurchasePriceConsiderationConvertibleDebtMeasuredAtEstimatedFairValueOnRecurringBasis">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="sls_FairValueOfWarrantsPotentiallySettleableInCash"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_RestrictedCashAndCashEquivalentsFairValueDisclosure" xlink:label="sls_RestrictedCashAndCashEquivalentsFairValueDisclosure"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="sls_RestrictedCashAndCashEquivalentsFairValueDisclosure" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="sls_FairValueOfWarrantsPotentiallySettleableInCash" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="1.0400" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedExchangeFeeRebateCurrent" xlink:label="us-gaap_AccruedExchangeFeeRebateCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ContractResearchPayable" xlink:label="sls_ContractResearchPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_TaxesPayableCurrent" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedExchangeFeeRebateCurrent" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="sls_ContractResearchPayable" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="1.0600" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtSummaryOfDebtAndConvertibleDebt">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtCurrent" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtNoncurrent" order="1.0200" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformationSeniorSecuredDebenture">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformationConvertibleDebt">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformationLongtermDebt">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationLegalProceedings">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalCommitmentsForOperatingLeases">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0200" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityCommonStockAreReservedForFutureIssuance">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsScheduleOfWarrantActivity">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModel">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsChangesInFairValueOfWarrantLiability">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsWarrantsClassifiedAsEquity">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAllocatedStockbasedCompensationExpense">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfGrantDateFairValuesOfOptionIssuedToEmployeesAndNonEmployees">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivity">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationRSUActivityForRSUsWithOnlyTimeBasedCondition">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationRSUActivityForRSUsWithBothTimeBasedAndPerformanceBasedCondition">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeIncomeTaxes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1.0200" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefit">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1.0800" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DeferredTaxAssetsLicensingDeductionDeferral" xlink:label="sls_DeferredTaxAssetsLicensingDeductionDeferral"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOtherTaxCarryforwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="sls_DeferredTaxAssetsLicensingDeductionDeferral" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.0700" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilities">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionComputedByApplyingFederalStatutoryRate">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="sls_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="sls_EffectiveIncomeTaxRateReconciliationPermanentDifferences" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="1.0800" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfChangesToCompanysUnrecognizedTaxBenefits">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsLiquidationBasisOfAccountingTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOptionIndexedToIssuersEquityDescriptionTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOptionIndexedToIssuersEquityDescriptionTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>31
<FILENAME>sls-20171231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFS Xcelerate Taxonomy Definition Linkbase - http://www.dfsco.com/financial-services/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 7 -->
<!-- Creation date: 2018-04-13T14:49:15Z -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DocumentandEntityInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_StatementOfIncome" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureOrganizationAndDescriptionOfBusinessSummaryOfAdjustmentsToAdditionalPaidinCapital" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessSummaryOfAdjustmentsToAdditionalPaidinCapital"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureLiquidityAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureLiquidityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesOutstandingExcludedFromComputationOfDilutedWeightedAverageSharesOut_Xa" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesOutstandingExcludedFromComputationOfDilutedWeightedAverageSharesOut_Xa"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureBusinessCombinationAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBusinessCombinationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureBusinessCombinationSummaryOfPurchasePrice" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBusinessCombinationSummaryOfPurchasePrice"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureBusinessCombinationTotalPurchasePriceAllocation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBusinessCombinationTotalPurchasePriceAllocation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureBusinessCombinationProFormaConsolidatedFinancialInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBusinessCombinationProFormaConsolidatedFinancialInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureGoodwillAndIntangibleAssetsSummaryOfChangesInCarryingAmountOfGoodwill" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfChangesInCarryingAmountOfGoodwill"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureGoodwillAndIntangibleAssetsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureFairValueMeasurementsContingentPurchasePriceConsiderationConvertibleDebtMeasuredAtEstimatedFairValueOnRecurringBasis" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueMeasurementsContingentPurchasePriceConsiderationConvertibleDebtMeasuredAtEstimatedFairValueOnRecurringBasis"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureFairValueMeasurementsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilities" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureDebtSummaryOfDebtAndConvertibleDebt" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtSummaryOfDebtAndConvertibleDebt"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureDebtAdditionalInformationSeniorSecuredDebenture" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformationSeniorSecuredDebenture"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureDebtAdditionalInformationConvertibleDebt" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformationConvertibleDebt"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureDebtAdditionalInformationLongtermDebt" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformationLongtermDebt"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationLegalProceedings" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationLegalProceedings"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalCommitmentsForOperatingLeases" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalCommitmentsForOperatingLeases"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureStockholdersEquityAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureStockholdersEquityCommonStockAreReservedForFutureIssuance" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityCommonStockAreReservedForFutureIssuance"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureWarrantsScheduleOfWarrantActivity" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsScheduleOfWarrantActivity"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureWarrantsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureWarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModel" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModel"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureWarrantsChangesInFairValueOfWarrantLiability" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsChangesInFairValueOfWarrantLiability"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureWarrantsWarrantsClassifiedAsEquity" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsWarrantsClassifiedAsEquity"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureStockBasedCompensationAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureStockBasedCompensationScheduleOfAllocatedStockbasedCompensationExpense" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAllocatedStockbasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureStockBasedCompensationScheduleOfGrantDateFairValuesOfOptionIssuedToEmployeesAndNonEmployees" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfGrantDateFairValuesOfOptionIssuedToEmployeesAndNonEmployees"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureStockBasedCompensationStockOptionActivity" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivity"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureStockBasedCompensationRSUActivityForRSUsWithOnlyTimeBasedCondition" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationRSUActivityForRSUsWithOnlyTimeBasedCondition"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureStockBasedCompensationRSUActivityForRSUsWithBothTimeBasedAndPerformanceBasedCondition" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationRSUActivityForRSUsWithBothTimeBasedAndPerformanceBasedCondition"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureIncomeTaxesScheduleOfLossBeforeIncomeTaxes" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeIncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefit" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefit"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssets" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssets"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilities" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureIncomeTaxesScheduleOfProvisionComputedByApplyingFederalStatutoryRate" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionComputedByApplyingFederalStatutoryRate"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureIncomeTaxesAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureIncomeTaxesScheduleOfChangesToCompanysUnrecognizedTaxBenefits" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfChangesToCompanysUnrecognizedTaxBenefits"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureRelatedPartyTransactionsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureSubsequentEventsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsLiquidationBasisOfAccountingTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsLiquidationBasisOfAccountingTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsBusinessCombinationDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsOptionIndexedToIssuersEquityDescriptionTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOptionIndexedToIssuersEquityDescriptionTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsOptionIndexedToIssuersEquityDescriptionTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOptionIndexedToIssuersEquityDescriptionTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DocumentandEntityInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassified">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfIncome">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion" xlink:label="sls_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition" xlink:label="sls_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod" xlink:label="sls_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares" xlink:label="sls_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SharesIssuedInCancellationOfLicenseAgreement" xlink:label="sls_SharesIssuedInCancellationOfLicenseAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodSharesCancellationOfLongTermDebt" xlink:label="sls_StockIssuedDuringPeriodSharesCancellationOfLongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodSharesLicenseAgreement" xlink:label="sls_StockIssuedDuringPeriodSharesLicenseAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodSharesPartialConsiderationOfLicenseFee" xlink:label="sls_StockIssuedDuringPeriodSharesPartialConsiderationOfLicenseFee"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable" xlink:label="sls_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares" xlink:label="sls_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodValueCancellationOfLongTermDebt" xlink:label="sls_StockIssuedDuringPeriodValueCancellationOfLongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodValueLicenseAgreement" xlink:label="sls_StockIssuedDuringPeriodValueLicenseAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee" xlink:label="sls_StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable" xlink:label="sls_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedForAntiDilutionProvisions" xlink:label="sls_StockIssuedForAntiDilutionProvisions"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedForAntiDilutionProvisionsShares" xlink:label="sls_StockIssuedForAntiDilutionProvisionsShares"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod" xlink:label="sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares" xlink:label="sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue" xlink:label="sls_StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares" xlink:label="sls_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue" xlink:label="sls_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockIssuedDuringPeriodSharesPartialConsiderationOfLicenseFee" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockIssuedDuringPeriodValueLicenseAgreement" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockIssuedDuringPeriodSharesLicenseAgreement" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_SharesIssuedInCancellationOfLicenseAgreement" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockIssuedDuringPeriodValueCancellationOfLongTermDebt" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockIssuedDuringPeriodSharesCancellationOfLongTermDebt" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockIssuedForAntiDilutionProvisions" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockIssuedForAntiDilutionProvisionsShares" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ConvertibleDebtTwoThousandFifteenShareholderNotesMember" xlink:label="sls_ConvertibleDebtTwoThousandFifteenShareholderNotesMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ConvertibleDebtTwoThousandSelyNoteMember" xlink:label="sls_ConvertibleDebtTwoThousandSelyNoteMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance" xlink:label="sls_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FairValueOfStockOptionsAssumedInConnectionWithAcquisition" xlink:label="sls_FairValueOfStockOptionsAssumedInConnectionWithAcquisition"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_NonCashResearchAndDevelopmentExpense" xlink:label="sls_NonCashResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SharesIssuedInConnectionWithAcquisition" xlink:label="sls_SharesIssuedInConnectionWithAcquisition"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SharesIssuedToSettleAccountsPayable" xlink:label="sls_SharesIssuedToSettleAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SharesIssuedToSettlerElatedPartyAccountsPayable" xlink:label="sls_SharesIssuedToSettlerElatedPartyAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="sls_NonCashResearchAndDevelopmentExpense" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PaidInKindInterest" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxesAndTaxCredits" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_SeveranceCosts1" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="sls_SharesIssuedInConnectionWithAcquisition" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="sls_FairValueOfStockOptionsAssumedInConnectionWithAcquisition" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="sls_SharesIssuedToSettlerElatedPartyAccountsPayable" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="sls_SharesIssuedToSettleAccountsPayable" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_StockIssued1" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="sls_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="sls_ConvertibleDebtTwoThousandFifteenShareholderNotesMember" order="1.3800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="sls_ConvertibleDebtTwoThousandSelyNoteMember" order="1.3900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformation">
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_CommonStockConversionRatio" xlink:label="sls_CommonStockConversionRatio"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_OrganizationAndDescriptionOfBusinessLineItems" xlink:label="sls_OrganizationAndDescriptionOfBusinessLineItems"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_OrganizationAndDescriptionOfBusinessTable" xlink:label="sls_OrganizationAndDescriptionOfBusinessTable"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PercentageOfFullyDilutedShareCapitalOwned" xlink:label="sls_PercentageOfFullyDilutedShareCapitalOwned"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PremergerSecurityholdersMember" xlink:label="sls_PremergerSecurityholdersMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PrivateSELLASMember" xlink:label="sls_PrivateSELLASMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sls_PrivateSELLASMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sls_PremergerSecurityholdersMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sls_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="sls_OrganizationAndDescriptionOfBusinessTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="sls_CommonStockConversionRatio" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="sls_PercentageOfFullyDilutedShareCapitalOwned" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sls_OrganizationAndDescriptionOfBusinessTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessSummaryOfAdjustmentsToAdditionalPaidinCapital">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="us-gaap_RestatementAdjustmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="us-gaap_ScenarioPreviouslyReportedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodValueCancellationOfLongTermDebt" xlink:label="sls_StockIssuedDuringPeriodValueCancellationOfLongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodValueLicenseAgreement" xlink:label="sls_StockIssuedDuringPeriodValueLicenseAgreement"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee" xlink:label="sls_StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue" xlink:label="sls_StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="sls_StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="sls_StockIssuedDuringPeriodValueLicenseAgreement" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="sls_StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="sls_StockIssuedDuringPeriodValueCancellationOfLongTermDebt" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPreviouslyReportedMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_RestatementAdjustmentMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureLiquidityAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_2"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebentureMember" xlink:label="sls_DebentureMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DecreaseInRestrictedCash" xlink:label="us-gaap_DecreaseInRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FirstTrancheMember" xlink:label="sls_FirstTrancheMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LiquidityLineItems" xlink:label="sls_LiquidityLineItems"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LiquidityTable" xlink:label="sls_LiquidityTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SecondTrancheMember" xlink:label="sls_SecondTrancheMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SeriesAConvertiblePreferredStockMember" xlink:label="sls_SeriesAConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sls_SeriesAConvertiblePreferredStockMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sls_DebentureMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sls_LiquidityLineItems" xlink:to="sls_LiquidityTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LiquidityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LiquidityLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LiquidityLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LiquidityLineItems" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LiquidityLineItems" xlink:to="us-gaap_DecreaseInRestrictedCash" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LiquidityLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LiquidityLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LiquidityLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LiquidityLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LiquidityLineItems" xlink:to="us-gaap_LongTermDebt" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sls_LiquidityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sls_LiquidityTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sls_LiquidityTable" xlink:to="us-gaap_DebtInstrumentAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sls_LiquidityTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sls_FirstTrancheMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sls_SecondTrancheMember" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SignificantAccountingPoliciesLineItems" xlink:label="sls_SignificantAccountingPoliciesLineItems"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SignificantAccountingPoliciesTable" xlink:label="sls_SignificantAccountingPoliciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sls_SignificantAccountingPoliciesLineItems" xlink:to="sls_SignificantAccountingPoliciesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SeveranceCosts1" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sls_SignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementScenarioAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesOutstandingExcludedFromComputationOfDilutedWeightedAverageSharesOut_Xa">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBusinessCombinationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:label="us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BusinessCombinationProFormaTransactionCosts" xlink:label="sls_BusinessCombinationProFormaTransactionCosts"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_EquilibriaCollaborationAgreementMember" xlink:label="sls_EquilibriaCollaborationAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_GalenaBiopharmaIncMember" xlink:label="sls_GalenaBiopharmaIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:label="us-gaap_ProductionRelatedImpairmentsOrCharges"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod" xlink:label="sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares" xlink:label="sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SuccessFeeAndOtherTransactionCosts" xlink:label="sls_SuccessFeeAndOtherTransactionCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="sls_GalenaBiopharmaIncMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationIntegrationRelatedCosts" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sls_BusinessCombinationProFormaTransactionCosts" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sls_SuccessFeeAndOtherTransactionCosts" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_SeveranceCosts1" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ProductionRelatedImpairmentsOrCharges" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sls_EquilibriaCollaborationAgreementMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="3.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBusinessCombinationSummaryOfPurchasePrice">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBusinessCombinationTotalPurchasePriceAllocation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses" xlink:label="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement" xlink:label="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:label="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability" xlink:label="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_GalenaBiopharmaIncMember" xlink:label="sls_GalenaBiopharmaIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="sls_GalenaBiopharmaIncMember" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_Goodwill" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBusinessCombinationProFormaConsolidatedFinancialInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfChangesInCarryingAmountOfGoodwill">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_GaleFourZeroOneMember" xlink:label="sls_GaleFourZeroOneMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_GalenaBiopharmaIncMember" xlink:label="sls_GalenaBiopharmaIncMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_GaleThreeZeroTwoMember" xlink:label="sls_GaleThreeZeroTwoMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_GoodwillAndIntangibleAssetsLineItems" xlink:label="sls_GoodwillAndIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_GoodwillAndIntangibleAssetsTable" xlink:label="sls_GoodwillAndIntangibleAssetsTable"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_NeuvaxMember" xlink:label="sls_NeuvaxMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="sls_GalenaBiopharmaIncMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sls_GoodwillAndIntangibleAssetsLineItems" xlink:to="sls_GoodwillAndIntangibleAssetsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_GoodwillAndIntangibleAssetsLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sls_GoodwillAndIntangibleAssetsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sls_GoodwillAndIntangibleAssetsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sls_GaleFourZeroOneMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sls_NeuvaxMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sls_GaleThreeZeroTwoMember" order="1.0500" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AdditionalExpenseIncurredToReflectFairValueOfSharesIssued" xlink:label="sls_AdditionalExpenseIncurredToReflectFairValueOfSharesIssued"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AdditionalSharesIssuedInConnectionWithLicensingAgreement" xlink:label="sls_AdditionalSharesIssuedInConnectionWithLicensingAgreement"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AdvaxisCollaborationAgreementMember" xlink:label="sls_AdvaxisCollaborationAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AmendedAndRestatedLicenseAgreementMember" xlink:label="sls_AmendedAndRestatedLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AnnualMaintenanceFee" xlink:label="sls_AnnualMaintenanceFee"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ChiefExecutiveOfficerCoFounderMember" xlink:label="sls_ChiefExecutiveOfficerCoFounderMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ClarendonLicenseAgreementMember" xlink:label="sls_ClarendonLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ClarendonTradingEinvestimentosLDAMember" xlink:label="sls_ClarendonTradingEinvestimentosLDAMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_CoFounderMember" xlink:label="sls_CoFounderMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FirstTrojantecAmendmentMember" xlink:label="sls_FirstTrojantecAmendmentMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FourthTrancheMember" xlink:label="sls_FourthTrancheMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LiabilitiesUnderTerminationAgreementPayableInCash" xlink:label="sls_LiabilitiesUnderTerminationAgreementPayableInCash"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseAgreementAmendmentDate" xlink:label="sls_LicenseAgreementAmendmentDate"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseAgreementAmendmentExtendedDateForFinancing" xlink:label="sls_LicenseAgreementAmendmentExtendedDateForFinancing"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseAgreementDate" xlink:label="sls_LicenseAgreementDate"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseAgreementDateSecondAmended" xlink:label="sls_LicenseAgreementDateSecondAmended"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseAgreementEffectiveDate" xlink:label="sls_LicenseAgreementEffectiveDate"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseAgreementExpirationTerm" xlink:label="sls_LicenseAgreementExpirationTerm"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseAgreementMember" xlink:label="sls_LicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseAgreementOutstandingAmountPayable" xlink:label="sls_LicenseAgreementOutstandingAmountPayable"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseAgreementTerminationDate" xlink:label="sls_LicenseAgreementTerminationDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseAmendmentWaiverAndShareIssuanceAgreementMember" xlink:label="sls_LicenseAmendmentWaiverAndShareIssuanceAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseAndCollaborationAgreementsLineItems" xlink:label="sls_LicenseAndCollaborationAgreementsLineItems"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseAndCollaborationAgreementsTable" xlink:label="sls_LicenseAndCollaborationAgreementsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseCosts" xlink:label="us-gaap_LicenseCosts"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseTerminationFeesPaid" xlink:label="sls_LicenseTerminationFeesPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MaximumNumberOfDaysToMakePayments" xlink:label="sls_MaximumNumberOfDaysToMakePayments"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember" xlink:label="sls_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MemorialSloanKetteringCancerCenterMember" xlink:label="sls_MemorialSloanKetteringCancerCenterMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MilestoneFeePaymentsUponCommencementOfClinicalTrials" xlink:label="sls_MilestoneFeePaymentsUponCommencementOfClinicalTrials"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MilestonePayment" xlink:label="sls_MilestonePayment"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MilestonePayments" xlink:label="sls_MilestonePayments"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MilestonePaymentsReceivable" xlink:label="sls_MilestonePaymentsReceivable"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MinimumAnnualRoyaltyPayment" xlink:label="sls_MinimumAnnualRoyaltyPayment"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_NonrefundableMilestonePayments" xlink:label="sls_NonrefundableMilestonePayments"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_NonrefundableSalesMilestonePayments" xlink:label="sls_NonrefundableSalesMilestonePayments"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_NumberOfInstallmentsToMakePayments" xlink:label="sls_NumberOfInstallmentsToMakePayments"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_NumberOfTranches" xlink:label="sls_NumberOfTranches"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PercentageOfFullyDilutedShareCapital" xlink:label="sls_PercentageOfFullyDilutedShareCapital"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PreviousRoyaltyObligationPercentage" xlink:label="sls_PreviousRoyaltyObligationPercentage"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PreviousRoyaltyOnNetSalesValue" xlink:label="sls_PreviousRoyaltyOnNetSalesValue"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ProceedsFromMilestoneBasedPayments" xlink:label="sls_ProceedsFromMilestoneBasedPayments"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ProjectManagementFeesPayable" xlink:label="sls_ProjectManagementFeesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ResearchFundingCosts" xlink:label="sls_ResearchFundingCosts"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_RoyaltyOnNetSalesValue" xlink:label="sls_RoyaltyOnNetSalesValue"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_RoyaltyRatePercentage" xlink:label="sls_RoyaltyRatePercentage"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SecondAmendedAndRestatedExclusiveLicenseAgreementMember" xlink:label="sls_SecondAmendedAndRestatedExclusiveLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SecondLicenseAmendmentWaiverAndAgreementMember" xlink:label="sls_SecondLicenseAmendmentWaiverAndAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SharesIssuableForConsiderationForLicenseTerminationAgreement" xlink:label="sls_SharesIssuableForConsiderationForLicenseTerminationAgreement"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SharesIssuedUnderLicenseAgreement" xlink:label="sls_SharesIssuedUnderLicenseAgreement"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement" xlink:label="sls_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SublicenseFeePayablePercentageIfExecutedAfterFirstPatientEnrolledInPhaseThreeClinicalTrial" xlink:label="sls_SublicenseFeePayablePercentageIfExecutedAfterFirstPatientEnrolledInPhaseThreeClinicalTrial"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SublicenseFeePayablePercentageIfExecutedPriorToFirstPatientEnrolledInPhaseThreeClinicalTrial" xlink:label="sls_SublicenseFeePayablePercentageIfExecutedPriorToFirstPatientEnrolledInPhaseThreeClinicalTrial"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ThirdTrancheMember" xlink:label="sls_ThirdTrancheMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_2"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_TrojantecLicenseAgreementMember" xlink:label="sls_TrojantecLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_TrojantecLtdMember" xlink:label="sls_TrojantecLtdMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_UpfrontLicenseFees" xlink:label="sls_UpfrontLicenseFees"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ViceChairmanMember" xlink:label="sls_ViceChairmanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_LicenseAmendmentWaiverAndShareIssuanceAgreementMember" order="1.4300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_SecondLicenseAmendmentWaiverAndAgreementMember" order="1.4800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_SecondAmendedAndRestatedExclusiveLicenseAgreementMember" order="1.5200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_AdvaxisCollaborationAgreementMember" order="1.5400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_LicenseAgreementMember" order="1.5500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_AmendedAndRestatedLicenseAgreementMember" order="1.5600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_TrojantecLicenseAgreementMember" order="1.5700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_FirstTrojantecAmendmentMember" order="1.5800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_ClarendonLicenseAgreementMember" order="1.5900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_LicenseAndCollaborationAgreementsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_LicenseAgreementEffectiveDate" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_SharesIssuedUnderLicenseAgreement" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_PercentageOfFullyDilutedShareCapital" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_UpfrontLicenseFees" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_MinimumAnnualRoyaltyPayment" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_ResearchFundingCosts" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_MilestonePayments" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_LicenseAgreementExpirationTerm" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_LicenseAgreementAmendmentDate" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_LicenseAgreementAmendmentExtendedDateForFinancing" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_LicenseAgreementDateSecondAmended" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_LicenseAgreementOutstandingAmountPayable" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_AdditionalSharesIssuedInConnectionWithLicensingAgreement" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_MilestonePayment" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_NumberOfInstallmentsToMakePayments" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_MaximumNumberOfDaysToMakePayments" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_MilestoneFeePaymentsUponCommencementOfClinicalTrials" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_NonrefundableMilestonePayments" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_NonrefundableSalesMilestonePayments" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_LicenseCosts" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_LicenseAgreementDate" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_ProjectManagementFeesPayable" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_LicenseAgreementTerminationDate" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_LicenseTerminationFeesPaid" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_LiabilitiesUnderTerminationAgreementPayableInCash" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_SharesIssuableForConsiderationForLicenseTerminationAgreement" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_AdditionalExpenseIncurredToReflectFairValueOfSharesIssued" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_AnnualMaintenanceFee" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_PreviousRoyaltyObligationPercentage" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_RoyaltyRatePercentage" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_PreviousRoyaltyOnNetSalesValue" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_RoyaltyOnNetSalesValue" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_MilestonePaymentsReceivable" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_NumberOfTranches" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_SublicenseFeePayablePercentageIfExecutedPriorToFirstPatientEnrolledInPhaseThreeClinicalTrial" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_SublicenseFeePayablePercentageIfExecutedAfterFirstPatientEnrolledInPhaseThreeClinicalTrial" order="1.3800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_ProceedsFromMilestoneBasedPayments" order="1.3900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sls_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_CounterpartyNameAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sls_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_RangeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sls_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sls_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sls_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sls_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="6.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="sls_ThirdTrancheMember" order="1.4500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="sls_FourthTrancheMember" order="1.5000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.4200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sls_MemorialSloanKetteringCancerCenterMember" order="1.4000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sls_TrojantecLtdMember" order="1.4900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sls_ClarendonTradingEinvestimentosLDAMember" order="1.5300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sls_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember" order="1.4400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="1.4600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="sls_ChiefExecutiveOfficerCoFounderMember" order="1.4100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="sls_ViceChairmanMember" order="1.4700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="sls_CoFounderMember" order="1.5100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueMeasurementsContingentPurchasePriceConsiderationConvertibleDebtMeasuredAtEstimatedFairValueOnRecurringBasis">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="sls_FairValueOfWarrantsPotentiallySettleableInCash"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_RestrictedCashAndCashEquivalentsFairValueDisclosure" xlink:label="sls_RestrictedCashAndCashEquivalentsFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="sls_RestrictedCashAndCashEquivalentsFairValueDisclosure" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="sls_FairValueOfWarrantsPotentiallySettleableInCash" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="1.1100" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BusinessCombinationContingentConsiderationPayableUponAchievementOfMilestones" xlink:label="sls_BusinessCombinationContingentConsiderationPayableUponAchievementOfMilestones"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_TwoThousandFifteenNotesMember" xlink:label="sls_TwoThousandFifteenNotesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="sls_BusinessCombinationContingentConsiderationPayableUponAchievementOfMilestones" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtInstrumentFairValue" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ConvertibleDebt" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_RangeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="sls_TwoThousandFifteenNotesMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0400" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilities">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtSummaryOfDebtAndConvertibleDebt">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ConvertibleDebtTwoThousandFifteenShareholderNotesMember" xlink:label="sls_ConvertibleDebtTwoThousandFifteenShareholderNotesMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ConvertibleDebtTwoThousandSelyNoteMember" xlink:label="sls_ConvertibleDebtTwoThousandSelyNoteMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SeniorSecuredDebenturesMember" xlink:label="sls_SeniorSecuredDebenturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtCurrent" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConvertibleDebt" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="sls_SeniorSecuredDebenturesMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="sls_ConvertibleDebtTwoThousandFifteenShareholderNotesMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="sls_ConvertibleDebtTwoThousandSelyNoteMember" order="1.0300" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformationSeniorSecuredDebenture">
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AmendmentAgreementMember" xlink:label="sls_AmendmentAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebentureMember" xlink:label="sls_DebentureMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtInstrumentCashInExcessOfDebenture" xlink:label="sls_DebtInstrumentCashInExcessOfDebenture"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtInstrumentCommonStockMinimumPriceCondition" xlink:label="sls_DebtInstrumentCommonStockMinimumPriceCondition"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtInstrumentCovenantLiquidityCovenant" xlink:label="sls_DebtInstrumentCovenantLiquidityCovenant"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtInstrumentCovenantPrepayLesserAccruedAndUnpaidInterest" xlink:label="sls_DebtInstrumentCovenantPrepayLesserAccruedAndUnpaidInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtInstrumentPercentageofPriorDayVolumeWeightedAveragePrice" xlink:label="sls_DebtInstrumentPercentageofPriorDayVolumeWeightedAveragePrice"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtInstrumentPercentageofVolumeWeightedAveragePrice" xlink:label="sls_DebtInstrumentPercentageofVolumeWeightedAveragePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtInstrumentRedemptionPrincipalAmountRedeemed" xlink:label="sls_DebtInstrumentRedemptionPrincipalAmountRedeemed"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtInstrumentRedemptionRedemptionPayments" xlink:label="sls_DebtInstrumentRedemptionRedemptionPayments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtRepaymentsDescription" xlink:label="sls_DebtRepaymentsDescription"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DecreaseInRestrictedCash" xlink:label="us-gaap_DecreaseInRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_2"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FirstWaiverMember" xlink:label="sls_FirstWaiverMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_NumberofDaysAveragedforExercisePrice" xlink:label="sls_NumberofDaysAveragedforExercisePrice"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ProceedsfromIssuanceofLongtermDebtandWarrantsNet" xlink:label="sls_ProceedsfromIssuanceofLongtermDebtandWarrantsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt" xlink:label="us-gaap_RepaymentsOfSecuredDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SecuritiesPurchaseAgreementMember" xlink:label="sls_SecuritiesPurchaseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_ProceedsfromIssuanceofLongtermDebtandWarrantsNet" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_DebtInstrumentRedemptionRedemptionPayments" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_DebtInstrumentCovenantPrepayLesserAccruedAndUnpaidInterest" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_DebtRepaymentsDescription" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_DebtInstrumentCommonStockMinimumPriceCondition" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_DebtInstrumentCashInExcessOfDebenture" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_DebtInstrumentPercentageofVolumeWeightedAveragePrice" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_NumberofDaysAveragedforExercisePrice" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_DebtInstrumentPercentageofPriorDayVolumeWeightedAveragePrice" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_DebtInstrumentCovenantLiquidityCovenant" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_DebtInstrumentRedemptionPrincipalAmountRedeemed" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfSecuredDebt" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DecreaseInRestrictedCash" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestReceivable" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sls_SecuritiesPurchaseAgreementMember" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sls_FirstWaiverMember" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sls_AmendmentAgreementMember" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sls_DebentureMember" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_RangeAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_SecuredDebtMember" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.2500" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformationConvertibleDebt">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BridgeFinancingMember" xlink:label="sls_BridgeFinancingMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BridgeLoan" xlink:label="us-gaap_BridgeLoan"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="us-gaap_CommonStockSharesSubscriptions"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtConversionConvertedInstrumentGainLossRecognized" xlink:label="sls_DebtConversionConvertedInstrumentGainLossRecognized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionDescription" xlink:label="us-gaap_DebtConversionDescription"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionOriginalDebtInterestRateOfDebt" xlink:label="us-gaap_DebtConversionOriginalDebtInterestRateOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtInstrumentConvertibleTermOfNotes" xlink:label="sls_DebtInstrumentConvertibleTermOfNotes"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_EQCBiotechSelyIFundMember" xlink:label="sls_EQCBiotechSelyIFundMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_GainLossOnExtinguishmentOfDebt" xlink:label="sls_GainLossOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_IssuanceOfWarrantsTerm" xlink:label="sls_IssuanceOfWarrantsTerm"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_NumberOfSignificantShareholders" xlink:label="sls_NumberOfSignificantShareholders"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithAcquisition" xlink:label="sls_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithAcquisition"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_TwoZeroOneFiveConvertibleTermNotesMember" xlink:label="sls_TwoZeroOneFiveConvertibleTermNotesMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_TwoZeroOneSixConvertibleTermNotesMember" xlink:label="sls_TwoZeroOneSixConvertibleTermNotesMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_WarrantExercisePriceAsPercentOfDebtConversion" xlink:label="sls_WarrantExercisePriceAsPercentOfDebtConversion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_NumberOfSignificantShareholders" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtInterestRateOfDebt" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithAcquisition" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_IssuanceOfWarrantsTerm" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_WarrantExercisePriceAsPercentOfDebtConversion" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_DebtInstrumentConvertibleTermOfNotes" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_BridgeLoan" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SharesIssued" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_CommonStockSharesSubscriptions" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestPaid" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_GainLossOnExtinguishmentOfDebt" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionDescription" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_DebtConversionConvertedInstrumentGainLossRecognized" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sls_TwoZeroOneFiveConvertibleTermNotesMember" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sls_BridgeFinancingMember" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sls_TwoZeroOneSixConvertibleTermNotesMember" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="sls_TwoZeroOneFiveConvertibleTermNotesMember" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sls_EQCBiotechSelyIFundMember" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformationLongtermDebt">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtConversionConvertedInstrumentGainLossRecognized" xlink:label="sls_DebtConversionConvertedInstrumentGainLossRecognized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="us-gaap_DebtInstrumentPaymentTerms"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DrsStergiouAndSougioultzoglouMember" xlink:label="sls_DrsStergiouAndSougioultzoglouMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DrsStergiouMember" xlink:label="sls_DrsStergiouMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FounderLoansMember" xlink:label="sls_FounderLoansMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FrameworkLoanAgreementMember" xlink:label="sls_FrameworkLoanAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LoansReceivableNet" xlink:label="us-gaap_LoansReceivableNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermLineOfCredit" xlink:label="us-gaap_LongTermLineOfCredit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ModifiedTermsOnLoanPercentageMaximum" xlink:label="sls_ModifiedTermsOnLoanPercentageMaximum"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ShareholdersMember" xlink:label="sls_ShareholdersMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SougioultzoglouMember" xlink:label="sls_SougioultzoglouMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StarcoveLoansMember" xlink:label="sls_StarcoveLoansMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StarcoveMember" xlink:label="sls_StarcoveMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ThirdPartyMember" xlink:label="sls_ThirdPartyMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_TwoThousandFifiteenLoanAgreementMember" xlink:label="sls_TwoThousandFifiteenLoanAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_TwoThousandThirteenLoanAgreementMember" xlink:label="sls_TwoThousandThirteenLoanAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermLineOfCredit" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPaymentTerms" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtAmount" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDescription" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermLoansPayable" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LoansReceivableNet" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_ModifiedTermsOnLoanPercentageMaximum" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPayment" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_DebtConversionConvertedInstrumentGainLossRecognized" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sls_TwoThousandFifiteenLoanAgreementMember" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sls_FrameworkLoanAgreementMember" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sls_StarcoveLoansMember" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sls_TwoThousandThirteenLoanAgreementMember" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sls_FounderLoansMember" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CounterpartyNameAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LineOfCreditMember" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sls_DrsStergiouMember" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sls_SougioultzoglouMember" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sls_DrsStergiouAndSougioultzoglouMember" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sls_ThirdPartyMember" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sls_StarcoveMember" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sls_ShareholdersMember" order="1.2700" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationLegalProceedings">
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_IssuanceofCommonStockforLitigationSettlement" xlink:label="sls_IssuanceofCommonStockforLitigationSettlement"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_JGBCaymanNewtonLtdMember" xlink:label="sls_JGBCaymanNewtonLtdMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="us-gaap_LitigationCaseAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LitigationSettlementAmountCash" xlink:label="sls_LitigationSettlementAmountCash"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LitigationSettlementIssuanceofCommonStockShares" xlink:label="sls_LitigationSettlementIssuanceofCommonStockShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="us-gaap_PaymentsForLegalSettlements"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_QuiTamMember" xlink:label="sls_QuiTamMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SettledLitigationMember" xlink:label="us-gaap_SettledLitigationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_UsattorneysofficeforthedistrictofnewjerseyanddepartmentofjusticeMember" xlink:label="sls_UsattorneysofficeforthedistrictofnewjerseyanddepartmentofjusticeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="us-gaap_LitigationCaseTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="us-gaap_LitigationCaseTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LitigationCaseTypeDomain" xlink:to="sls_UsattorneysofficeforthedistrictofnewjerseyanddepartmentofjusticeMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LitigationCaseTypeDomain" xlink:to="sls_QuiTamMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LitigationCaseTypeDomain" xlink:to="sls_JGBCaymanNewtonLtdMember" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LitigationStatusDomain" xlink:to="us-gaap_SettledLitigationMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_PaymentsForLegalSettlements" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="sls_IssuanceofCommonStockforLitigationSettlement" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="sls_LitigationSettlementAmountCash" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="sls_LitigationSettlementIssuanceofCommonStockShares" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LitigationStatusAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LitigationCaseAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.1000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalCommitmentsForOperatingLeases">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation">
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BridgeFinancingMember" xlink:label="sls_BridgeFinancingMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_CancellationOfManagementFee" xlink:label="sls_CancellationOfManagementFee"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_CancellationOfMilestonePayment" xlink:label="sls_CancellationOfMilestonePayment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="us-gaap_ChiefExecutiveOfficerMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_EquilibriaCollaborationAgreementMember" xlink:label="sls_EquilibriaCollaborationAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MemorialSloanKetteringCancerCenterMember" xlink:label="sls_MemorialSloanKetteringCancerCenterMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssued" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sls_CancellationOfMilestonePayment" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sls_CancellationOfManagementFee" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sls_BridgeFinancingMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sls_MemorialSloanKetteringCancerCenterMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sls_EquilibriaCollaborationAgreementMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_ChiefExecutiveOfficerMember" order="1.0900" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityCommonStockAreReservedForFutureIssuance">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_StockOptionMember" order="1.0500" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsScheduleOfWarrantActivity">
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ClassOfWarrantOrRightAssumedInAcquisition" xlink:label="sls_ClassOfWarrantOrRightAssumedInAcquisition"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ClassOfWarrantOrRightExpirationDateDescription" xlink:label="sls_ClassOfWarrantOrRightExpirationDateDescription"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ClassOfWarrantOrRightExpirationMonthAndYear" xlink:label="sls_ClassOfWarrantOrRightExpirationMonthAndYear"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ClassOfWarrantOrRightExpired" xlink:label="sls_ClassOfWarrantOrRightExpired"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ClassOfWarrantOrRightGranted" xlink:label="sls_ClassOfWarrantOrRightGranted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ClassOfWarrantOrRightOutstandingRollForward" xlink:label="sls_ClassOfWarrantOrRightOutstandingRollForward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_EqcWarrantsMember" xlink:label="sls_EqcWarrantsMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_February2017WarrantsMember" xlink:label="sls_February2017WarrantsMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_OtherWarrantIssuesMember" xlink:label="sls_OtherWarrantIssuesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sls_EqcWarrantsMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sls_February2017WarrantsMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sls_OtherWarrantIssuesMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sls_ClassOfWarrantOrRightOutstandingRollForward" order="100.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_ClassOfWarrantOrRightOutstandingRollForward" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_ClassOfWarrantOrRightOutstandingRollForward" xlink:to="sls_ClassOfWarrantOrRightGranted" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_ClassOfWarrantOrRightOutstandingRollForward" xlink:to="sls_ClassOfWarrantOrRightAssumedInAcquisition" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_ClassOfWarrantOrRightOutstandingRollForward" xlink:to="sls_ClassOfWarrantOrRightExpired" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_ClassOfWarrantOrRightOutstandingRollForward" xlink:to="sls_ClassOfWarrantOrRightExpirationMonthAndYear" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_ClassOfWarrantOrRightOutstandingRollForward" xlink:to="sls_ClassOfWarrantOrRightExpirationDateDescription" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.0200" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModel">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" xlink:label="sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_February2017WarrantsMember" xlink:label="sls_February2017WarrantsMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_OtherGalenaWarrantIssuesAccountedForAsLiabilitiesMember" xlink:label="sls_OtherGalenaWarrantIssuesAccountedForAsLiabilitiesMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_WarrantsFairValueAssumptionsExpectedVolatility" xlink:label="sls_WarrantsFairValueAssumptionsExpectedVolatility"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_WarrantsFairValueAssumptionsRiskFreeInterestRate" xlink:label="sls_WarrantsFairValueAssumptionsRiskFreeInterestRate"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_WarrantStrikePrice" xlink:label="sls_WarrantStrikePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sls_February2017WarrantsMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sls_OtherGalenaWarrantIssuesAccountedForAsLiabilitiesMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sls_WarrantStrikePrice" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sls_WarrantsFairValueAssumptionsExpectedVolatility" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sls_WarrantsFairValueAssumptionsRiskFreeInterestRate" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsChangesInFairValueOfWarrantLiability">
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ChangeInFairValueOfWarrantLiabilities" xlink:label="sls_ChangeInFairValueOfWarrantLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_2"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ClassofWarrantorRightFairValueRollForward" xlink:label="sls_ClassofWarrantorRightFairValueRollForward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FairValueOfWarrantsExercised" xlink:label="sls_FairValueOfWarrantsExercised"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FairValueofWarrantsGranted" xlink:label="sls_FairValueofWarrantsGranted"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FairValueOfWarrantsLiabilities" xlink:label="sls_FairValueOfWarrantsLiabilities"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_February2017WarrantsMember" xlink:label="sls_February2017WarrantsMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_OtherWarrantIssuesMember" xlink:label="sls_OtherWarrantIssuesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sls_February2017WarrantsMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sls_OtherWarrantIssuesMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_ClassofWarrantorRightFairValueRollForward" xlink:to="sls_FairValueOfWarrantsLiabilities" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_ClassofWarrantorRightFairValueRollForward" xlink:to="sls_FairValueofWarrantsGranted" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_ClassofWarrantorRightFairValueRollForward" xlink:to="sls_FairValueOfWarrantsExercised" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sls_ClassofWarrantorRightFairValueRollForward" xlink:to="sls_ChangeInFairValueOfWarrantLiabilities" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sls_ClassofWarrantorRightFairValueRollForward" order="100.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsWarrantsClassifiedAsEquity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ClassOfWarrantOrRightTerm" xlink:label="sls_ClassOfWarrantOrRightTerm"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_EqcWarrantsMember" xlink:label="sls_EqcWarrantsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FairValueofWarrantsGrantedperShare" xlink:label="sls_FairValueofWarrantsGrantedperShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sls_EqcWarrantsMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sls_ClassOfWarrantOrRightTerm" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sls_FairValueofWarrantsGrantedperShare" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_EmployeeStockPurchasePlanMember" xlink:label="sls_EmployeeStockPurchasePlanMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_NumberOfStockOptionsGranted" xlink:label="sls_NumberOfStockOptionsGranted"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards" xlink:label="sls_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="us-gaap_RestrictedStockExpense"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember" xlink:label="sls_RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger" xlink:label="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants" xlink:label="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate" xlink:label="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ShareBasedCompensationAwardVestingDateFourMember" xlink:label="sls_ShareBasedCompensationAwardVestingDateFourMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ShareBasedCompensationAwardVestingDateOneMember" xlink:label="sls_ShareBasedCompensationAwardVestingDateOneMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ShareBasedCompensationAwardVestingDateThreeMember" xlink:label="sls_ShareBasedCompensationAwardVestingDateThreeMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ShareBasedCompensationAwardVestingDateTwoMember" xlink:label="sls_ShareBasedCompensationAwardVestingDateTwoMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ShareBasedCompensationExercisePeriod" xlink:label="sls_ShareBasedCompensationExercisePeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_TwoThousandAndSeventeenEquityIncentivePlanMember" xlink:label="sls_TwoThousandAndSeventeenEquityIncentivePlanMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_TwoThousandAndSixteenEquityIncentivePlanMember" xlink:label="sls_TwoThousandAndSixteenEquityIncentivePlanMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sls_TwoThousandAndSeventeenEquityIncentivePlanMember" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sls_TwoThousandAndSixteenEquityIncentivePlanMember" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sls_ShareBasedCompensationExercisePeriod" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sls_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sls_NumberOfStockOptionsGranted" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_RestrictedStockExpense" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sls_RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sls_EmployeeStockPurchasePlanMember" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="sls_ShareBasedCompensationAwardVestingDateOneMember" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="sls_ShareBasedCompensationAwardVestingDateTwoMember" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="sls_ShareBasedCompensationAwardVestingDateThreeMember" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="sls_ShareBasedCompensationAwardVestingDateFourMember" order="1.2300" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAllocatedStockbasedCompensationExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfGrantDateFairValuesOfOptionIssuedToEmployeesAndNonEmployees">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_EmployeeAndNonemployeeStockOptionsMember" xlink:label="sls_EmployeeAndNonemployeeStockOptionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sls_EmployeeAndNonemployeeStockOptionsMember" order="1.0500" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivity">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationRSUActivityForRSUsWithOnlyTimeBasedCondition">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_RestrictedStockUnitsWithTimeBasedConditionsMember" xlink:label="sls_RestrictedStockUnitsWithTimeBasedConditionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sls_RestrictedStockUnitsWithTimeBasedConditionsMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationRSUActivityForRSUsWithBothTimeBasedAndPerformanceBasedCondition">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember" xlink:label="sls_RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sls_RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeIncomeTaxes">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefit">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssets">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilities">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionComputedByApplyingFederalStatutoryRate">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife" xlink:label="sls_DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits" xlink:label="sls_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss" xlink:label="sls_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage" xlink:label="sls_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUsePeriodOfOwnershipPercentage" xlink:label="sls_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUsePeriodOfOwnershipPercentage"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_OperatingLossCarryforwardsExpirationYearRangeEnd" xlink:label="sls_OperatingLossCarryforwardsExpirationYearRangeEnd"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_OperatingLossCarryforwardsExpirationYearRangeStart" xlink:label="sls_OperatingLossCarryforwardsExpirationYearRangeStart"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="sls_OperatingLossCarryforwardsExpirationYearRangeStart" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="sls_OperatingLossCarryforwardsExpirationYearRangeEnd" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="sls_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUsePeriodOfOwnershipPercentage" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="sls_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="sls_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="sls_DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="sls_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_StatementScenarioAxis" order="2.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfChangesToCompanysUnrecognizedTaxBenefits">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AccruedCompensationIncentive" xlink:label="sls_AccruedCompensationIncentive"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_CashPaymentOnContractTermination" xlink:label="sls_CashPaymentOnContractTermination"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ContractualAgreementTerminationDate" xlink:label="sls_ContractualAgreementTerminationDate"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DrAngelosMStergiouMember" xlink:label="sls_DrAngelosMStergiouMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_EffectivePeriodOfAgreement" xlink:label="sls_EffectivePeriodOfAgreement"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_EquilibriaCollaborationAgreementMember" xlink:label="sls_EquilibriaCollaborationAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_Incentivefeepercentageequaltogrossvaluepaidbypurchaserincash" xlink:label="sls_Incentivefeepercentageequaltogrossvaluepaidbypurchaserincash"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_IncentiveFeePercentageEqualToPostMoneyMarketValue" xlink:label="sls_IncentiveFeePercentageEqualToPostMoneyMarketValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ManagementFeeExpense" xlink:label="us-gaap_ManagementFeeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ManagementFeePayable" xlink:label="us-gaap_ManagementFeePayable"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MemorialSloanKetteringCancerCenterMember" xlink:label="sls_MemorialSloanKetteringCancerCenterMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MskLicenseAgreementMember" xlink:label="sls_MskLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentForManagementFee" xlink:label="us-gaap_PaymentForManagementFee"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PercentageOfOwnershipOutstandingShareCapital" xlink:label="sls_PercentageOfOwnershipOutstandingShareCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_RestrictedStockUnitsMember" xlink:label="sls_RestrictedStockUnitsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares" xlink:label="sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sls_MemorialSloanKetteringCancerCenterMember" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sls_EquilibriaCollaborationAgreementMember" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sls_MskLicenseAgreementMember" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sls_RestrictedStockUnitsMember" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_EffectivePeriodOfAgreement" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentForManagementFee" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ManagementFeeExpense" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ManagementFeePayable" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_IncentiveFeePercentageEqualToPostMoneyMarketValue" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_Incentivefeepercentageequaltogrossvaluepaidbypurchaserincash" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_AccruedCompensationIncentive" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_PercentageOfOwnershipOutstandingShareCapital" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_ContractualAgreementTerminationDate" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_CashPaymentOnContractTermination" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="sls_DrAngelosMStergiouMember" order="1.1700" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AdjustmentToCommonStockInConnectionWithReverseForwardStockSplit" xlink:label="sls_AdjustmentToCommonStockInConnectionWithReverseForwardStockSplit"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AggregateSalesPriceOfCommonStock" xlink:label="sls_AggregateSalesPriceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AltoAgreementMember" xlink:label="sls_AltoAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AnsonAgreementMember" xlink:label="sls_AnsonAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_CommonStockPercentageIssuedPriorToPurchaseAgreement" xlink:label="sls_CommonStockPercentageIssuedPriorToPurchaseAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ConversionPriceOfPreferredStock" xlink:label="sls_ConversionPriceOfPreferredStock"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ConvertibleNotesConversionPricePerShareOfCommonStock" xlink:label="sls_ConvertibleNotesConversionPricePerShareOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ConvertiblePreferredStockBeneficialOwnershipLimitationPercentage" xlink:label="sls_ConvertiblePreferredStockBeneficialOwnershipLimitationPercentage"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ConvertiblePreferredStockIssuedShares" xlink:label="sls_ConvertiblePreferredStockIssuedShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_CVIAgreementMember" xlink:label="sls_CVIAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DateByWhichStockHolderApprovalRequired" xlink:label="sls_DateByWhichStockHolderApprovalRequired"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:label="us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtInstrumentConvertiblePercentageOfPrincipalAndAccruedInterest" xlink:label="sls_DebtInstrumentConvertiblePercentageOfPrincipalAndAccruedInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DenominatorBaseForIssuanceOfCommonStockValue" xlink:label="sls_DenominatorBaseForIssuanceOfCommonStockValue"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_EmperyAgreementMember" xlink:label="sls_EmperyAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_EngagementLetterMember" xlink:label="sls_EngagementLetterMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_GrossProceedsPercentage" xlink:label="sls_GrossProceedsPercentage"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_HudsonBayAgreementMember" xlink:label="sls_HudsonBayAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_JGBCaymanNewtonLtdMember" xlink:label="sls_JGBCaymanNewtonLtdMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LincolnParkAgreementMember" xlink:label="sls_LincolnParkAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="us-gaap_LitigationCaseAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LitigationSettlementIssuanceofCommonStockShares" xlink:label="sls_LitigationSettlementIssuanceofCommonStockShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MinimumOwnershipPercentageOfOutstandingSharesOfCommonStockForConversionToTakeEffect" xlink:label="sls_MinimumOwnershipPercentageOfOutstandingSharesOfCommonStockForConversionToTakeEffect"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MinimumPercentageOfTradingPriceOfCommonStock" xlink:label="sls_MinimumPercentageOfTradingPriceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MinimumProceedRequiredUnderQualifiedOffering" xlink:label="sls_MinimumProceedRequiredUnderQualifiedOffering"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PercentageOfMarketAveragePriceOfShares" xlink:label="sls_PercentageOfMarketAveragePriceOfShares"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PercentageOfReductionInRiskRecurrence" xlink:label="sls_PercentageOfReductionInRiskRecurrence"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="us-gaap_PreferredStockConversionBasis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredUnitsDescription" xlink:label="us-gaap_PreferredUnitsDescription"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PrivatePlacementFirstClosingMember" xlink:label="sls_PrivatePlacementFirstClosingMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PrivatePlacementSecondClosingMember" xlink:label="sls_PrivatePlacementSecondClosingMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PurchaseAgreementMember" xlink:label="sls_PurchaseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_QualifiedOfferingDescription" xlink:label="sls_QualifiedOfferingDescription"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_QualifiedPublicOfferingMember" xlink:label="sls_QualifiedPublicOfferingMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SabbyAgreementMember" xlink:label="sls_SabbyAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SeriesAConvertiblePreferredStockMember" xlink:label="sls_SeriesAConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockConversionLimitPercentage" xlink:label="sls_StockConversionLimitPercentage"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockholderApprovalPeriod" xlink:label="sls_StockholderApprovalPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodSharesShareWarrantsExercised" xlink:label="sls_StockIssuedDuringPeriodSharesShareWarrantsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_TradingDays" xlink:label="sls_TradingDays"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_VotingAgreementMember" xlink:label="sls_VotingAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_WarrantExcercisableTerm" xlink:label="sls_WarrantExcercisableTerm"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_WarrantsIssuedShares" xlink:label="sls_WarrantsIssuedShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_CVIAgreementMember" order="1.4600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_AnsonAgreementMember" order="1.5200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_SabbyAgreementMember" order="1.5500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_HudsonBayAgreementMember" order="1.5700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_AltoAgreementMember" order="1.5800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_LincolnParkAgreementMember" order="1.5900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_EmperyAgreementMember" order="1.6000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_PurchaseAgreementMember" order="1.6100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_VotingAgreementMember" order="1.6200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_EngagementLetterMember" order="1.6300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sls_SeriesAConvertiblePreferredStockMember" order="1.4700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="us-gaap_LitigationCaseTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LitigationCaseTypeDomain" xlink:to="sls_JGBCaymanNewtonLtdMember" order="1.5100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.4900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.5400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sls_PrivatePlacementFirstClosingMember" order="1.4800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sls_PrivatePlacementSecondClosingMember" order="1.5300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sls_QualifiedPublicOfferingMember" order="1.5600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" order="1.5000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_DenominatorBaseForIssuanceOfCommonStockValue" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_DebtInstrumentConvertiblePercentageOfPrincipalAndAccruedInterest" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_ConvertibleNotesConversionPricePerShareOfCommonStock" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_MinimumOwnershipPercentageOfOutstandingSharesOfCommonStockForConversionToTakeEffect" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockIssuedDuringPeriodSharesShareWarrantsExercised" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_AggregateSalesPriceOfCommonStock" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_MinimumPercentageOfTradingPriceOfCommonStock" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_PercentageOfMarketAveragePriceOfShares" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_ConvertiblePreferredStockIssuedShares" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_ConversionPriceOfPreferredStock" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_WarrantsIssuedShares" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_DateByWhichStockHolderApprovalRequired" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockholderApprovalPeriod" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_CommonStockPercentageIssuedPriorToPurchaseAgreement" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_MinimumProceedRequiredUnderQualifiedOffering" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockConversionBasis" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_QualifiedOfferingDescription" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredUnitsDescription" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_ConvertiblePreferredStockBeneficialOwnershipLimitationPercentage" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockConversionLimitPercentage" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_AdjustmentToCommonStockInConnectionWithReverseForwardStockSplit" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_TradingDays" order="1.3800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="1.3900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.4000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_WarrantExcercisableTerm" order="1.4100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_GrossProceedsPercentage" order="1.4200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_PercentageOfReductionInRiskRecurrence" order="1.4300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_LitigationSettlementIssuanceofCommonStockShares" order="1.4400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LitigationCaseAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" order="6.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="7.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.4500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsLiquidationBasisOfAccountingTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOptionIndexedToIssuersEquityDescriptionTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOptionIndexedToIssuersEquityDescriptionTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>32
<FILENAME>sls-20171231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFS Xcelerate Taxonomy Labels Linkbase - http://www.dfsco.com/financial-services/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 7 -->
<!-- Creation date: 2018-04-13T14:49:15Z -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xml:lang="en-US" id="id_10184323_2432502_1_1">Accounting Changes and Error Corrections [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xml:lang="en-US" id="id_10184323_2432502_2_1">Accounting Changes and Error Corrections [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_10184323_2432506_1_1">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_10184323_2432506_2_1">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl" xml:lang="en-US" id="id_10184323_2432521_1_1">Receivable Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl" xml:lang="en-US" id="id_10184323_2432521_2_1">Receivable Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US" id="id_10184323_2432525_1_1">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US" id="id_10184323_2432525_2_1">Accrued Expenses and Other Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US" id="id_10184323_2432526_1_1">Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US" id="id_10184323_2432526_2_1">Outstanding accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="id_10184323_2432952_1_1">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="id_10184323_2432952_2_1">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AccruedCompensationIncentive" xlink:label="sls_AccruedCompensationIncentive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_AccruedCompensationIncentive_lbl" xml:lang="en-US" id="id_10184323_2490767_3_1">Accrued Compensation Incentive</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_AccruedCompensationIncentive_lbl" xml:lang="en-US" id="id_10184323_2490767_1_1">Accrued Compensation Incentive</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_AccruedCompensationIncentive_lbl" xml:lang="en-US" id="id_10184323_2490767_2_1">Compensation payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_AccruedCompensationIncentive" xlink:to="sls_AccruedCompensationIncentive_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedExchangeFeeRebateCurrent" xlink:label="us-gaap_AccruedExchangeFeeRebateCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedExchangeFeeRebateCurrent_lbl" xml:lang="en-US" id="id_10184323_2432758_1_1">Accrued Exchange Fee Rebate, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedExchangeFeeRebateCurrent_lbl" xml:lang="en-US" id="id_10184323_2432758_2_1">Rebates and returns</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedExchangeFeeRebateCurrent" xlink:to="us-gaap_AccruedExchangeFeeRebateCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_10184323_2432564_1_1">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_10184323_2432564_2_1">Accrued expenses and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_10184323_2432564_6_1">Accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" id="id_10184323_2432762_1_1">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" id="id_10184323_2432762_2_1">Professional fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AdditionalExpenseIncurredToReflectFairValueOfSharesIssued" xlink:label="sls_AdditionalExpenseIncurredToReflectFairValueOfSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_AdditionalExpenseIncurredToReflectFairValueOfSharesIssued_lbl" xml:lang="en-US" id="id_10184323_3049442_3_1">Additional expense incurred to reflect fair value of shares issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_AdditionalExpenseIncurredToReflectFairValueOfSharesIssued_lbl" xml:lang="en-US" id="id_10184323_3049442_1_1">Additional Expense Incurred To Reflect Fair Value Of Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_AdditionalExpenseIncurredToReflectFairValueOfSharesIssued_lbl" xml:lang="en-US" id="id_10184323_3049442_2_1">Additional expense incurred to reflect fair value of shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_AdditionalExpenseIncurredToReflectFairValueOfSharesIssued" xlink:to="sls_AdditionalExpenseIncurredToReflectFairValueOfSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" id="id_10184323_2432790_1_1">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" id="id_10184323_2432790_2_1">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" id="id_10184323_2432358_1_1">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" id="id_10184323_2432358_2_1">Additional Paid-in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AdditionalSharesIssuedInConnectionWithLicensingAgreement" xlink:label="sls_AdditionalSharesIssuedInConnectionWithLicensingAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_AdditionalSharesIssuedInConnectionWithLicensingAgreement_lbl" xml:lang="en-US" id="id_10184323_3049390_3_1">Additional shares issued in connection with licensing agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_AdditionalSharesIssuedInConnectionWithLicensingAgreement_lbl" xml:lang="en-US" id="id_10184323_3049390_1_1">Additional Shares Issued In Connection With Licensing Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_AdditionalSharesIssuedInConnectionWithLicensingAgreement_lbl" xml:lang="en-US" id="id_10184323_3049390_2_1">Additional shares issued in connection with licensing agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_AdditionalSharesIssuedInConnectionWithLicensingAgreement" xlink:to="sls_AdditionalSharesIssuedInConnectionWithLicensingAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion" xlink:label="sls_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion_lbl" xml:lang="en-US" id="id_10184323_3053513_3_1">Adjustments to additional paid-in capital deemed dividend on debt conversion.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion_lbl" xml:lang="en-US" id="id_10184323_3053513_1_1">Adjustments To Additional Paid In Capital Deemed Dividend on Debt Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion_lbl" xml:lang="en-US" id="id_10184323_3053513_2_1">Deemed dividend associated with conversion of 2015 Sely Note and common stock warrant issuance to Equilibria</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion" xlink:to="sls_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US" id="id_10184323_2432803_1_1">Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US" id="id_10184323_2432803_2_1">Stock-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US" id="id_10184323_2432803_12_1">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition" xlink:label="sls_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition_lbl" xml:lang="en-US" id="id_10184323_3051722_3_1">Adjustments to additional paid in capital stock options exercised in connection with acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition_lbl" xml:lang="en-US" id="id_10184323_3051722_1_1">Adjustments To Additional Paid In Capital Stock Options Exercised In Connection With Acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition_lbl" xml:lang="en-US" id="id_10184323_3051722_2_1">Fair value of assumed options issued in connection with acquisition of Galena</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition" xlink:to="sls_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_10184323_2433031_1_1">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_10184323_2433031_2_1">Adjustment to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AdjustmentToCommonStockInConnectionWithReverseForwardStockSplit" xlink:label="sls_AdjustmentToCommonStockInConnectionWithReverseForwardStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_AdjustmentToCommonStockInConnectionWithReverseForwardStockSplit_lbl" xml:lang="en-US" id="id_10184323_3050064_3_1">Adjustment to common stock in connection with reverse forward stock split.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_AdjustmentToCommonStockInConnectionWithReverseForwardStockSplit_lbl" xml:lang="en-US" id="id_10184323_3050064_1_1">Adjustment to Common Stock in Connection with Reverse Forward Stock Split</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_AdjustmentToCommonStockInConnectionWithReverseForwardStockSplit_lbl" xml:lang="en-US" id="id_10184323_3050064_2_1">Adjustment to common stock in connection with reverse/forward stock split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_AdjustmentToCommonStockInConnectionWithReverseForwardStockSplit" xlink:to="sls_AdjustmentToCommonStockInConnectionWithReverseForwardStockSplit_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AdvaxisCollaborationAgreementMember" xlink:label="sls_AdvaxisCollaborationAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_AdvaxisCollaborationAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3050216_3_1">Advaxis collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_AdvaxisCollaborationAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3050216_1_1">Advaxis Collaboration Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_AdvaxisCollaborationAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3050216_2_1">Advaxis Collaboration Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_AdvaxisCollaborationAgreementMember" xlink:to="sls_AdvaxisCollaborationAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AggregateSalesPriceOfCommonStock" xlink:label="sls_AggregateSalesPriceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_AggregateSalesPriceOfCommonStock_lbl" xml:lang="en-US" id="id_10184323_2513949_3_1">Aggregate Sales Price of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_AggregateSalesPriceOfCommonStock_lbl" xml:lang="en-US" id="id_10184323_2513949_1_1">Aggregate Sales Price of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_AggregateSalesPriceOfCommonStock_lbl" xml:lang="en-US" id="id_10184323_2513949_2_1">Closing sale price of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_AggregateSalesPriceOfCommonStock" xlink:to="sls_AggregateSalesPriceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_10184323_2432632_1_1">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_10184323_2432632_2_1">Allocated share based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AltoAgreementMember" xlink:label="sls_AltoAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_AltoAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3051911_3_1">Alto agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_AltoAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3051911_1_1">Alto Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_AltoAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3051911_2_1">Alto Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_AltoAgreementMember" xlink:to="sls_AltoAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AmendedAndRestatedLicenseAgreementMember" xlink:label="sls_AmendedAndRestatedLicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_AmendedAndRestatedLicenseAgreementMember_lbl" xml:lang="en-US" id="id_10184323_2719233_3_1">Amended and Restated License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_AmendedAndRestatedLicenseAgreementMember_lbl" xml:lang="en-US" id="id_10184323_2719233_1_1">Amended and Restated License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_AmendedAndRestatedLicenseAgreementMember_lbl" xml:lang="en-US" id="id_10184323_2719233_2_1">BioVascular Amendment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_AmendedAndRestatedLicenseAgreementMember" xlink:to="sls_AmendedAndRestatedLicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AmendmentAgreementMember" xlink:label="sls_AmendmentAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_AmendmentAgreementMember_lbl" xml:lang="en-US" id="id_10184323_2743860_3_1">Amendment Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_AmendmentAgreementMember_lbl" xml:lang="en-US" id="id_10184323_2743860_1_1">Amendment Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_AmendmentAgreementMember_lbl" xml:lang="en-US" id="id_10184323_2743860_2_1">Amendment Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_AmendmentAgreementMember" xlink:to="sls_AmendmentAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_10184323_2432431_1_1">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_10184323_2432431_2_1">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AnnualMaintenanceFee" xlink:label="sls_AnnualMaintenanceFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_AnnualMaintenanceFee_lbl" xml:lang="en-US" id="id_10184323_2560589_3_1">Annual Maintenance Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_AnnualMaintenanceFee_lbl" xml:lang="en-US" id="id_10184323_2560589_1_1">Annual Maintenance Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_AnnualMaintenanceFee_lbl" xml:lang="en-US" id="id_10184323_2560589_2_1">Annual maintenance fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_AnnualMaintenanceFee" xlink:to="sls_AnnualMaintenanceFee_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AnsonAgreementMember" xlink:label="sls_AnsonAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_AnsonAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3050644_3_1">Anson Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_AnsonAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3050644_1_1">Anson Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_AnsonAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3050644_2_1">Anson Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_AnsonAgreementMember" xlink:to="sls_AnsonAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="id_10184323_2432677_1_1">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="id_10184323_2432677_2_1">Antidilutive securities excluded from computation of earnings per share, amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" id="id_10184323_2433098_1_1">Antidilutive Securities [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" id="id_10184323_2433098_2_1">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="id_10184323_2432447_1_1">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="id_10184323_2432447_2_1">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" id="id_10184323_2433099_1_1">Antidilutive Securities, Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" id="id_10184323_2433099_2_1">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="id_10184323_2432872_1_1">Arrangements and Non-arrangement Transactions [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="id_10184323_2432872_2_1">Arrangements and Non-arrangement Transactions [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AssetPurchaseAgreementAndRelatedLicenseAgreementAbstract" xlink:label="sls_AssetPurchaseAgreementAndRelatedLicenseAgreementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_AssetPurchaseAgreementAndRelatedLicenseAgreementAbstract_lbl" xml:lang="en-US" id="id_10184323_2468239_3_1">Asset Purchase Agreement And Related License Agreement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_AssetPurchaseAgreementAndRelatedLicenseAgreementAbstract_lbl" xml:lang="en-US" id="id_10184323_2468239_1_1">Asset Purchase Agreement And Related License Agreement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_AssetPurchaseAgreementAndRelatedLicenseAgreementAbstract_lbl" xml:lang="en-US" id="id_10184323_2468239_2_1">Asset Purchase Agreement And Related License Agreement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_AssetPurchaseAgreementAndRelatedLicenseAgreementAbstract" xlink:to="sls_AssetPurchaseAgreementAndRelatedLicenseAgreementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_10184323_2433119_1_1">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_10184323_2433119_6_1">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_10184323_2432695_1_1">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_10184323_2432695_2_1">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_10184323_2432697_1_1">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_10184323_2432697_6_1">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_10184323_2433122_1_1">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_10184323_2433122_2_1">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" id="id_10184323_2432701_1_1">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" id="id_10184323_2432701_6_1">Total assets measured and recorded at fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" id="id_10184323_2433130_1_1">Assets, Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" id="id_10184323_2433130_2_1">Assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="id_10184323_2433414_1_1">Award Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="id_10184323_2433414_2_1">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_10184323_2433655_1_1">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_10184323_2433655_2_1">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BridgeFinancingMember" xlink:label="sls_BridgeFinancingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_BridgeFinancingMember_lbl" xml:lang="en-US" id="id_10184323_2685828_3_1">Bridge Financing [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_BridgeFinancingMember_lbl" xml:lang="en-US" id="id_10184323_2685828_1_1">Bridge Financing [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_BridgeFinancingMember_lbl" xml:lang="en-US" id="id_10184323_2685828_2_1">Bridge Financing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_BridgeFinancingMember" xlink:to="sls_BridgeFinancingMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BridgeLoan" xlink:label="us-gaap_BridgeLoan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BridgeLoan_lbl" xml:lang="en-US" id="id_10184323_2433690_1_1">Bridge Loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BridgeLoan_lbl" xml:lang="en-US" id="id_10184323_2433690_2_1">Capital increase approved by BOD</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BridgeLoan" xlink:to="us-gaap_BridgeLoan_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" id="id_10184323_2433916_1_1">Business Acquisition, Acquiree [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" id="id_10184323_2433916_2_1">Business Acquisition, Acquiree [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" id="id_10184323_2433694_1_1">Business Acquisition [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" id="id_10184323_2433694_2_1">Business Acquisition [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_lbl" xml:lang="en-US" id="id_10184323_2433254_1_1">Business Acquisition, Effective Date of Acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_lbl" xml:lang="en-US" id="id_10184323_2433254_2_1">Merger completion date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:to="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" id="id_10184323_2433478_1_1">Business Acquisition [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" id="id_10184323_2433478_2_1">Business Acquisition [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xml:lang="en-US" id="id_10184323_2433257_1_1">Business Acquisition, Percentage of Voting Interests Acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xml:lang="en-US" id="id_10184323_2433257_2_1">Percentage of Voting Interests Acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:label="sls_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_10184323_2773514_3_1">Business Acquisition Pro Forma Earnings Per Share Basic And Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_10184323_2773514_1_1">Business Acquisition Pro Forma Earnings Per Share Basic And Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_10184323_2773514_2_1">Basic and diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:to="sls_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xml:lang="en-US" id="id_10184323_2433699_1_1">Business Acquisition, Pro Forma Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xml:lang="en-US" id="id_10184323_2433699_2_1">Schedule of Pro forma Consolidated Financial Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xml:lang="en-US" id="id_10184323_2433262_1_1">Business Acquisition, Pro Forma Net Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xml:lang="en-US" id="id_10184323_2433262_2_1">Net loss (in thousands)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl" xml:lang="en-US" id="id_10184323_2433485_1_1">Business Acquisition, Pro Forma Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl" xml:lang="en-US" id="id_10184323_2433485_2_1">Net revenues (in thousands)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US" id="id_10184323_2433937_1_1">Business Combination, Consideration Transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US" id="id_10184323_2433937_6_1">Total purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl" xml:lang="en-US" id="id_10184323_2433495_1_1">Business Combination, Consideration Transferred [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl" xml:lang="en-US" id="id_10184323_2433495_2_1">Business Combination, Consideration Transferred [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xml:lang="en-US" id="id_10184323_2433275_1_1">Business Combination, Contingent Consideration, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xml:lang="en-US" id="id_10184323_2433275_2_1">Contingent consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BusinessCombinationContingentConsiderationPayableUponAchievementOfMilestones" xlink:label="sls_BusinessCombinationContingentConsiderationPayableUponAchievementOfMilestones"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_BusinessCombinationContingentConsiderationPayableUponAchievementOfMilestones_lbl" xml:lang="en-US" id="id_10184323_2556211_3_1">Business combination contingent consideration payable upon achievement of milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_BusinessCombinationContingentConsiderationPayableUponAchievementOfMilestones_lbl" xml:lang="en-US" id="id_10184323_2556211_1_1">Business Combination Contingent Consideration Payable Upon Achievement Of Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_BusinessCombinationContingentConsiderationPayableUponAchievementOfMilestones_lbl" xml:lang="en-US" id="id_10184323_2556211_2_1">Future contingent payments upon achievement of certain development and commercial milestones</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_BusinessCombinationContingentConsiderationPayableUponAchievementOfMilestones" xlink:to="sls_BusinessCombinationContingentConsiderationPayableUponAchievementOfMilestones_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US" id="id_10184323_2433944_1_1">Business Combination Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US" id="id_10184323_2433944_2_1">Business Combination</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding" xlink:label="sls_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding_lbl" xml:lang="en-US" id="id_10184323_3049697_3_1">Business combination estimated fair value of stock options outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding_lbl" xml:lang="en-US" id="id_10184323_3049697_1_1">Business combination estimated fair value of stock options outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding_lbl" xml:lang="en-US" id="id_10184323_3049697_2_1">Estimated fair value of the Company's per-Merger stock options outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding" xlink:to="sls_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BusinessCombinationFairValueOfSharesOutstanding" xlink:label="sls_BusinessCombinationFairValueOfSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_BusinessCombinationFairValueOfSharesOutstanding_lbl" xml:lang="en-US" id="id_10184323_3049694_3_1">Business combination fair value of shares outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_BusinessCombinationFairValueOfSharesOutstanding_lbl" xml:lang="en-US" id="id_10184323_3049694_1_1">Business combination fair value of shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_BusinessCombinationFairValueOfSharesOutstanding_lbl" xml:lang="en-US" id="id_10184323_3049694_2_1">Fair value of the Company's pre-Merger shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_BusinessCombinationFairValueOfSharesOutstanding" xlink:to="sls_BusinessCombinationFairValueOfSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BusinessCombinationIncreaseDecreaseToReflectLiabilitiesAcquiredAtFairValueAbstract" xlink:label="sls_BusinessCombinationIncreaseDecreaseToReflectLiabilitiesAcquiredAtFairValueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_BusinessCombinationIncreaseDecreaseToReflectLiabilitiesAcquiredAtFairValueAbstract_lbl" xml:lang="en-US" id="id_10184323_2454204_3_1">Business Combination Increase Decrease To Reflect Liabilities Acquired At Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_BusinessCombinationIncreaseDecreaseToReflectLiabilitiesAcquiredAtFairValueAbstract_lbl" xml:lang="en-US" id="id_10184323_2454204_1_1">Business Combination Increase Decrease To Reflect Liabilities Acquired At Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_BusinessCombinationIncreaseDecreaseToReflectLiabilitiesAcquiredAtFairValueAbstract_lbl" xml:lang="en-US" id="id_10184323_2454204_2_1">Business Combination Increase Decrease To Reflect Liabilities Acquired At Fair Value [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_BusinessCombinationIncreaseDecreaseToReflectLiabilitiesAcquiredAtFairValueAbstract" xlink:to="sls_BusinessCombinationIncreaseDecreaseToReflectLiabilitiesAcquiredAtFairValueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:label="us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationIntegrationRelatedCosts_lbl" xml:lang="en-US" id="id_10184323_2433948_1_1">Business Combination, Integration Related Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationIntegrationRelatedCosts_lbl" xml:lang="en-US" id="id_10184323_2433948_2_1">Transaction costs associated with the Merger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:to="us-gaap_BusinessCombinationIntegrationRelatedCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BusinessCombinationProFormaTransactionCosts" xlink:label="sls_BusinessCombinationProFormaTransactionCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_BusinessCombinationProFormaTransactionCosts_lbl" xml:lang="en-US" id="id_10184323_3049686_3_1">Business combination pro forma transaction costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_BusinessCombinationProFormaTransactionCosts_lbl" xml:lang="en-US" id="id_10184323_3049686_1_1">Business combination pro forma transaction costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_BusinessCombinationProFormaTransactionCosts_lbl" xml:lang="en-US" id="id_10184323_3049686_2_1">Transaction costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_BusinessCombinationProFormaTransactionCosts" xlink:to="sls_BusinessCombinationProFormaTransactionCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xml:lang="en-US" id="id_10184323_2433716_1_1">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xml:lang="en-US" id="id_10184323_2433716_6_1">Total assets acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_lbl" xml:lang="en-US" id="id_10184323_2433717_1_1">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_lbl" xml:lang="en-US" id="id_10184323_2433717_2_1">Assets acquired:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US" id="id_10184323_2433286_1_1">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US" id="id_10184323_2433286_2_1">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_lbl" xml:lang="en-US" id="id_10184323_2433718_1_1">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_lbl" xml:lang="en-US" id="id_10184323_2433718_2_1">Contingent purchase price consideration of Apthera, Inc.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US" id="id_10184323_2433522_1_1">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US" id="id_10184323_2433522_2_1">Prepaid expenses and other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses" xlink:label="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_lbl" xml:lang="en-US" id="id_10184323_2495868_3_1">Business combination recognized identifiable assets acquired and liabilities assumed current liabilities accounts payable and accrued expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_lbl" xml:lang="en-US" id="id_10184323_2495868_1_1">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable And Accrued Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_lbl" xml:lang="en-US" id="id_10184323_2495868_2_1">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses" xlink:to="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_lbl" xml:lang="en-US" id="id_10184323_2433720_1_1">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_lbl" xml:lang="en-US" id="id_10184323_2433720_2_1">Long-term debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_10184323_2433527_1_1">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_10184323_2433527_2_1">Deferred tax liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" id="id_10184323_2433722_1_1">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" id="id_10184323_2433722_2_1">Allocation of purchase price to acquired IPR&amp;D</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" id="id_10184323_2433722_12_1">Intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xml:lang="en-US" id="id_10184323_2433297_1_1">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xml:lang="en-US" id="id_10184323_2433297_6_1">Total liabilities assumed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_lbl" xml:lang="en-US" id="id_10184323_2433955_1_1">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_lbl" xml:lang="en-US" id="id_10184323_2433955_2_1">Liabilities assumed:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement" xlink:label="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement_lbl" xml:lang="en-US" id="id_10184323_2538664_3_1">Business combination recognized identifiable assets acquired and liabilities assumed litigation settlement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement_lbl" xml:lang="en-US" id="id_10184323_2538664_1_1">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Litigation Settlement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement_lbl" xml:lang="en-US" id="id_10184323_2538664_2_1">Litigation settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement" xlink:to="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:label="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_lbl" xml:lang="en-US" id="id_10184323_2507039_3_1">Business combination recognized identifiable assets acquired and liabilities assumed restricted cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_lbl" xml:lang="en-US" id="id_10184323_2507039_1_1">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Restricted Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_lbl" xml:lang="en-US" id="id_10184323_2507039_2_1">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:to="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability" xlink:label="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability_lbl" xml:lang="en-US" id="id_10184323_2569718_3_1">Business combination recognized identifiable assets acquired and liabilities assumed warrant liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability_lbl" xml:lang="en-US" id="id_10184323_2569718_1_1">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability_lbl" xml:lang="en-US" id="id_10184323_2569718_2_1">Warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability" xlink:to="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" xml:lang="en-US" id="id_10184323_2433728_1_1">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" xml:lang="en-US" id="id_10184323_2433728_6_1">Net assets acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xml:lang="en-US" id="id_10184323_2433303_1_1">Business Combinations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xml:lang="en-US" id="id_10184323_2433303_2_1">Business Combinations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US" id="id_10184323_2433546_1_1">Business Description and Basis of Presentation [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US" id="id_10184323_2433546_2_1">Organization and Description of Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_CancellationOfManagementFee" xlink:label="sls_CancellationOfManagementFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_CancellationOfManagementFee_lbl" xml:lang="en-US" id="id_10184323_3049678_3_1">Cancellation of management fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_CancellationOfManagementFee_lbl" xml:lang="en-US" id="id_10184323_3049678_1_1">Cancellation Of Management Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_CancellationOfManagementFee_lbl" xml:lang="en-US" id="id_10184323_3049678_2_1">Cancellation of management fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_CancellationOfManagementFee" xlink:to="sls_CancellationOfManagementFee_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_CancellationOfMilestonePayment" xlink:label="sls_CancellationOfMilestonePayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_CancellationOfMilestonePayment_lbl" xml:lang="en-US" id="id_10184323_3049676_3_1">Cancellation of milestone payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_CancellationOfMilestonePayment_lbl" xml:lang="en-US" id="id_10184323_3049676_1_1">Cancellation Of Milestone Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_CancellationOfMilestonePayment_lbl" xml:lang="en-US" id="id_10184323_3049676_2_1">Milestone payment canceled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_CancellationOfMilestonePayment" xlink:to="sls_CancellationOfMilestonePayment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xml:lang="en-US" id="id_10184323_2434454_1_1">Cash Acquired from Acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xml:lang="en-US" id="id_10184323_2434454_2_1">Net cash acquired from acquisition of Galena</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_10184323_2434030_1_1">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_10184323_2434030_4_1">Cash and cash equivalents at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_10184323_2434030_5_1">Cash and cash equivalents at the beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_10184323_2434030_2_1">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" id="id_10184323_2434457_1_1">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" id="id_10184323_2434457_2_1">Cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_10184323_2434458_1_1">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_10184323_2434458_6_1">Net decrease (increase) in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" id="id_10184323_2434270_1_1">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" id="id_10184323_2434270_2_1">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" id="id_10184323_2434271_1_1">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" id="id_10184323_2434271_2_1">Restricted Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" id="id_10184323_2434712_1_1">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" id="id_10184323_2434712_2_1">Supplemental disclosure of non-cash investing and financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_CashPaymentOnContractTermination" xlink:label="sls_CashPaymentOnContractTermination"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_CashPaymentOnContractTermination_lbl" xml:lang="en-US" id="id_10184323_2510372_3_1">Cash Payment on Contract Termination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_CashPaymentOnContractTermination_lbl" xml:lang="en-US" id="id_10184323_2510372_1_1">Cash Payment on Contract Termination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_CashPaymentOnContractTermination_lbl" xml:lang="en-US" id="id_10184323_2510372_2_1">Cash payment for termination fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_CashPaymentOnContractTermination" xlink:to="sls_CashPaymentOnContractTermination_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ChangeInFairValueOfWarrantLiabilities" xlink:label="sls_ChangeInFairValueOfWarrantLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ChangeInFairValueOfWarrantLiabilities_lbl" xml:lang="en-US" id="id_10184323_2555327_3_1">Change In Fair Value Of Warrant Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ChangeInFairValueOfWarrantLiabilities_lbl" xml:lang="en-US" id="id_10184323_2555327_1_1">Change In Fair Value Of Warrant Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ChangeInFairValueOfWarrantLiabilities_lbl" xml:lang="en-US" id="id_10184323_2555327_2_1">Change in fair value of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ChangeInFairValueOfWarrantLiabilities" xlink:to="sls_ChangeInFairValueOfWarrantLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ChangesInFairValueOfWarrantLiabilityTableTableTextBlock" xlink:label="sls_ChangesInFairValueOfWarrantLiabilityTableTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ChangesInFairValueOfWarrantLiabilityTableTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2884825_3_1">Changes In Fair Value Of Warrant Liability Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ChangesInFairValueOfWarrantLiabilityTableTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2884825_1_1">Changes In Fair Value Of Warrant Liability Table Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ChangesInFairValueOfWarrantLiabilityTableTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2884825_2_1">Changes in Fair Value of Warrant Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ChangesInFairValueOfWarrantLiabilityTableTableTextBlock" xlink:to="sls_ChangesInFairValueOfWarrantLiabilityTableTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ChiefExecutiveOfficerCoFounderMember" xlink:label="sls_ChiefExecutiveOfficerCoFounderMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ChiefExecutiveOfficerCoFounderMember_lbl" xml:lang="en-US" id="id_10184323_3049267_3_1">Chief executive officer, co-founder.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ChiefExecutiveOfficerCoFounderMember_lbl" xml:lang="en-US" id="id_10184323_3049267_1_1">Chief Executive Officer Co Founder [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ChiefExecutiveOfficerCoFounderMember_lbl" xml:lang="en-US" id="id_10184323_3049267_2_1">Chief Executive Officer Co Founder [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ChiefExecutiveOfficerCoFounderMember" xlink:to="sls_ChiefExecutiveOfficerCoFounderMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="us-gaap_ChiefExecutiveOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US" id="id_10184323_2434781_1_1">Chief Executive Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US" id="id_10184323_2434781_2_1">Dr. Angelos Stergiou</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChiefExecutiveOfficerMember" xlink:to="us-gaap_ChiefExecutiveOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ClarendonLicenseAgreementMember" xlink:label="sls_ClarendonLicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ClarendonLicenseAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3049289_3_1">Clarendon license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ClarendonLicenseAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3049289_1_1">Clarendon License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ClarendonLicenseAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3049289_2_1">Clarendon License Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ClarendonLicenseAgreementMember" xlink:to="sls_ClarendonLicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ClarendonTradingEinvestimentosLDAMember" xlink:label="sls_ClarendonTradingEinvestimentosLDAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ClarendonTradingEinvestimentosLDAMember_lbl" xml:lang="en-US" id="id_10184323_3049284_3_1">Clarendon Trading E Investimentos LDA.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ClarendonTradingEinvestimentosLDAMember_lbl" xml:lang="en-US" id="id_10184323_3049284_1_1">Clarendon Trading EInvestimentos LDA [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ClarendonTradingEinvestimentosLDAMember_lbl" xml:lang="en-US" id="id_10184323_3049284_2_1">Clarendon Trading EInvestimentos LDA [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ClarendonTradingEinvestimentosLDAMember" xlink:to="sls_ClarendonTradingEinvestimentosLDAMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="id_10184323_2434354_1_1">Class of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="id_10184323_2434354_2_1">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" id="id_10184323_2434788_1_1">Class of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" id="id_10184323_2434788_2_1">Class of Stock [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ClassOfWarrantOrRightAssumedInAcquisition" xlink:label="sls_ClassOfWarrantOrRightAssumedInAcquisition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ClassOfWarrantOrRightAssumedInAcquisition_lbl" xml:lang="en-US" id="id_10184323_2612671_3_1">Class of warrant or right assumed in acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ClassOfWarrantOrRightAssumedInAcquisition_lbl" xml:lang="en-US" id="id_10184323_2612671_1_1">Class Of Warrant Or Right Assumed In Acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ClassOfWarrantOrRightAssumedInAcquisition_lbl" xml:lang="en-US" id="id_10184323_2612671_2_1">Assumed through Merger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ClassOfWarrantOrRightAssumedInAcquisition" xlink:to="sls_ClassOfWarrantOrRightAssumedInAcquisition_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" id="id_10184323_2434520_1_1">Class of Warrant or Right [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" id="id_10184323_2434520_2_1">Class of Warrant or Right [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" id="id_10184323_2434124_1_1">Class of Warrant or Right [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" id="id_10184323_2434124_2_1">Class of Warrant or Right [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" id="id_10184323_2434355_1_1">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" id="id_10184323_2434355_2_1">Exercise price (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" id="id_10184323_2434355_12_1">Exercise Price of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ClassOfWarrantOrRightExpirationDateDescription" xlink:label="sls_ClassOfWarrantOrRightExpirationDateDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ClassOfWarrantOrRightExpirationDateDescription_lbl" xml:lang="en-US" id="id_10184323_2617481_3_1">Class of warrant or right expiration date, description.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ClassOfWarrantOrRightExpirationDateDescription_lbl" xml:lang="en-US" id="id_10184323_2617481_1_1">Class Of Warrant Or Right Expiration Date Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ClassOfWarrantOrRightExpirationDateDescription_lbl" xml:lang="en-US" id="id_10184323_2617481_2_1">Expiration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ClassOfWarrantOrRightExpirationDateDescription" xlink:to="sls_ClassOfWarrantOrRightExpirationDateDescription_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ClassOfWarrantOrRightExpirationMonthAndYear" xlink:label="sls_ClassOfWarrantOrRightExpirationMonthAndYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ClassOfWarrantOrRightExpirationMonthAndYear_lbl" xml:lang="en-US" id="id_10184323_2643207_3_1">Class of warrant or right expiration month and year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ClassOfWarrantOrRightExpirationMonthAndYear_lbl" xml:lang="en-US" id="id_10184323_2643207_1_1">Class Of Warrant Or Right Expiration Month And Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ClassOfWarrantOrRightExpirationMonthAndYear_lbl" xml:lang="en-US" id="id_10184323_2643207_2_1">Expiration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ClassOfWarrantOrRightExpirationMonthAndYear" xlink:to="sls_ClassOfWarrantOrRightExpirationMonthAndYear_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ClassOfWarrantOrRightExpired" xlink:label="sls_ClassOfWarrantOrRightExpired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ClassOfWarrantOrRightExpired_lbl" xml:lang="en-US" id="id_10184323_2609401_3_1">Class of warrant or right, expired.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ClassOfWarrantOrRightExpired_lbl" xml:lang="en-US" id="id_10184323_2609401_1_1">Class Of Warrant Or Right Expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ClassOfWarrantOrRightExpired_lbl" xml:lang="en-US" id="id_10184323_2609401_2_1">Class of Warrant or Right, Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ClassOfWarrantOrRightExpired" xlink:to="sls_ClassOfWarrantOrRightExpired_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ClassofWarrantorRightFairValueRollForward" xlink:label="sls_ClassofWarrantorRightFairValueRollForward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ClassofWarrantorRightFairValueRollForward_lbl" xml:lang="en-US" id="id_10184323_2884822_3_1">Class of Warrant or Right, Fair Value [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ClassofWarrantorRightFairValueRollForward_lbl" xml:lang="en-US" id="id_10184323_2884822_1_1">Classof Warrantor Right Fair Value [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ClassofWarrantorRightFairValueRollForward_lbl" xml:lang="en-US" id="id_10184323_2884822_2_1">Class of Warrant or Right, Fair Value [Roll Forward]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ClassofWarrantorRightFairValueRollForward" xlink:to="sls_ClassofWarrantorRightFairValueRollForward_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ClassOfWarrantOrRightGranted" xlink:label="sls_ClassOfWarrantOrRightGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ClassOfWarrantOrRightGranted_lbl" xml:lang="en-US" id="id_10184323_2608954_3_1">Class of warrant or right granted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ClassOfWarrantOrRightGranted_lbl" xml:lang="en-US" id="id_10184323_2608954_1_1">Class Of Warrant Or Right Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ClassOfWarrantOrRightGranted_lbl" xml:lang="en-US" id="id_10184323_2608954_2_1">Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ClassOfWarrantOrRightGranted" xlink:to="sls_ClassOfWarrantOrRightGranted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" id="id_10184323_2434521_1_1">Class of Warrant or Right [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" id="id_10184323_2434521_2_1">Class of Warrant or Right [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" id="id_10184323_2434790_1_1">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" id="id_10184323_2434790_32_1">Warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" id="id_10184323_2434790_2_1">Number of securities called by warrants or rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" id="id_10184323_2434790_12_1">Number of shares available from warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" id="id_10184323_2434522_1_1">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" id="id_10184323_2434522_4_1">Warrants outstanding, Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" id="id_10184323_2434522_5_1">Warrants outstanding , Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" id="id_10184323_2434522_2_1">Warrants outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ClassOfWarrantOrRightOutstandingRollForward" xlink:label="sls_ClassOfWarrantOrRightOutstandingRollForward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ClassOfWarrantOrRightOutstandingRollForward_lbl" xml:lang="en-US" id="id_10184323_2909038_3_1">Class of Warrant or Right, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ClassOfWarrantOrRightOutstandingRollForward_lbl" xml:lang="en-US" id="id_10184323_2909038_1_1">Class Of Warrant Or Right Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ClassOfWarrantOrRightOutstandingRollForward_lbl" xml:lang="en-US" id="id_10184323_2909038_2_1">Class of Warrant or Right, Outstanding [Roll Forward]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ClassOfWarrantOrRightOutstandingRollForward" xlink:to="sls_ClassOfWarrantOrRightOutstandingRollForward_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" id="id_10184323_2434524_1_1">Class of Warrant or Right [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" id="id_10184323_2434524_2_1">Class of Warrant or Right [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ClassOfWarrantOrRightTerm" xlink:label="sls_ClassOfWarrantOrRightTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ClassOfWarrantOrRightTerm_lbl" xml:lang="en-US" id="id_10184323_2632620_3_1">Class of Warrant or Right, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ClassOfWarrantOrRightTerm_lbl" xml:lang="en-US" id="id_10184323_2632620_1_1">Class Of Warrant Or Right Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ClassOfWarrantOrRightTerm_lbl" xml:lang="en-US" id="id_10184323_2632620_2_1">Warrant term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ClassOfWarrantOrRightTerm" xlink:to="sls_ClassOfWarrantOrRightTerm_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_CoFounderMember" xlink:label="sls_CoFounderMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_CoFounderMember_lbl" xml:lang="en-US" id="id_10184323_2715035_3_1">Co-founder</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_CoFounderMember_lbl" xml:lang="en-US" id="id_10184323_2715035_1_1">Co Founder [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_CoFounderMember_lbl" xml:lang="en-US" id="id_10184323_2715035_2_1">Co-Founder</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_CoFounderMember" xlink:to="sls_CoFounderMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" id="id_10184323_2434377_1_1">Collaborative Arrangement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" id="id_10184323_2434377_2_1">Collaboration and License Agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" id="id_10184323_2434162_1_1">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" id="id_10184323_2434162_2_1">Commitments and contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="id_10184323_2434560_1_1">Commitments and Contingencies Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="id_10184323_2434560_2_1">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_10184323_2434393_1_1">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_10184323_2434393_2_1">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_CommonStockAreReservedForFutureIssuanceTableTextBlock" xlink:label="sls_CommonStockAreReservedForFutureIssuanceTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_CommonStockAreReservedForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2765415_3_1">Common stock are reserved for future issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_CommonStockAreReservedForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2765415_1_1">Common Stock Are Reserved For Future Issuance [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_CommonStockAreReservedForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2765415_2_1">Common Stock are Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_CommonStockAreReservedForFutureIssuanceTableTextBlock" xlink:to="sls_CommonStockAreReservedForFutureIssuanceTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" id="id_10184323_2434570_1_1">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" id="id_10184323_2434570_2_1">Total reserved for future issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_CommonStockConversionRatio" xlink:label="sls_CommonStockConversionRatio"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_CommonStockConversionRatio_lbl" xml:lang="en-US" id="id_10184323_2644498_3_1">Common Stock Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_CommonStockConversionRatio_lbl" xml:lang="en-US" id="id_10184323_2644498_1_1">Common Stock Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_CommonStockConversionRatio_lbl" xml:lang="en-US" id="id_10184323_2644498_2_1">Common stock conversion ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_CommonStockConversionRatio" xlink:to="sls_CommonStockConversionRatio_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="id_10184323_2434572_1_1">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="id_10184323_2434572_2_1">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_10184323_2434835_1_1">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_10184323_2434835_2_1">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_10184323_2434835_12_1">Common stock, par value (USD per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_CommonStockPercentageIssuedPriorToPurchaseAgreement" xlink:label="sls_CommonStockPercentageIssuedPriorToPurchaseAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_CommonStockPercentageIssuedPriorToPurchaseAgreement_lbl" xml:lang="en-US" id="id_10184323_3050109_3_1">Common stock percentage issued prior to purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_CommonStockPercentageIssuedPriorToPurchaseAgreement_lbl" xml:lang="en-US" id="id_10184323_3050109_1_1">Common Stock Percentage Issued Prior to Purchase Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_CommonStockPercentageIssuedPriorToPurchaseAgreement_lbl" xml:lang="en-US" id="id_10184323_3050109_2_1">Common stock percentage issued prior to purchase agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_CommonStockPercentageIssuedPriorToPurchaseAgreement" xlink:to="sls_CommonStockPercentageIssuedPriorToPurchaseAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_10184323_2434172_1_1">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_10184323_2434172_2_1">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_10184323_2434837_1_1">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_10184323_2434837_2_1">Common stock issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_10184323_2434837_12_1">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_10184323_2434173_1_1">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_10184323_2434173_2_1">Common stock shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_10184323_2434173_12_1">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued_lbl" xml:lang="en-US" id="id_10184323_2434410_1_1">Common Stock, Shares Subscribed but Unissued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued_lbl" xml:lang="en-US" id="id_10184323_2434410_2_1">Subscribed by certain stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesSubscribedButUnissued" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="us-gaap_CommonStockSharesSubscriptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesSubscriptions_lbl" xml:lang="en-US" id="id_10184323_2434174_1_1">Common Stock, Value, Subscriptions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesSubscriptions_lbl" xml:lang="en-US" id="id_10184323_2434174_2_1">Shares subscribed by certain stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesSubscriptions" xlink:to="us-gaap_CommonStockSharesSubscriptions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_10184323_2434840_1_1">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_10184323_2434840_2_1">Common stock, $0.0001 par value; 350,000,000 shares authorized, 5,766,891 shares issued and outstanding at December 31, 2017; 1,268,489 shares issued and outstanding at December 31, 2016</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" id="id_10184323_2434583_1_1">Compensation Related Costs, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" id="id_10184323_2434583_2_1">Severance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" id="id_10184323_2434421_1_1">Components of Deferred Tax Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" id="id_10184323_2434421_2_1">Deferred Tax Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ComprehensiveLossPolicyPolicyTextBlock" xlink:label="sls_ComprehensiveLossPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ComprehensiveLossPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_10184323_3049373_3_1">Comprehensive Loss, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ComprehensiveLossPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_10184323_3049373_1_1">Comprehensive Loss, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ComprehensiveLossPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_10184323_3049373_2_1">Comprehensive Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ComprehensiveLossPolicyPolicyTextBlock" xlink:to="sls_ComprehensiveLossPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" id="id_10184323_2434192_1_1">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" id="id_10184323_2434192_2_1">Concentration of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" id="id_10184323_2434219_1_1">Consolidation, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" id="id_10184323_2434219_2_1">Principles of Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:label="sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion_lbl" xml:lang="en-US" id="id_10184323_2498368_3_1">Contingent purchase price consideration, net of current portion.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion_lbl" xml:lang="en-US" id="id_10184323_2498368_1_1">Contingent Purchase Price Consideration Net Of Current Portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion_lbl" xml:lang="en-US" id="id_10184323_2498368_2_1">Contingent purchase price consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:to="sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ContractResearchPayable" xlink:label="sls_ContractResearchPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ContractResearchPayable_lbl" xml:lang="en-US" id="id_10184323_2884832_3_1">Contract Research Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ContractResearchPayable_lbl" xml:lang="en-US" id="id_10184323_2884832_1_1">Contract Research Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ContractResearchPayable_lbl" xml:lang="en-US" id="id_10184323_2884832_2_1">Clinical trial costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ContractResearchPayable" xlink:to="sls_ContractResearchPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ContractualAgreementTerminationDate" xlink:label="sls_ContractualAgreementTerminationDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ContractualAgreementTerminationDate_lbl" xml:lang="en-US" id="id_10184323_2619587_3_1">Contractual Agreement Termination Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ContractualAgreementTerminationDate_lbl" xml:lang="en-US" id="id_10184323_2619587_1_1">Contractual Agreement Termination Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ContractualAgreementTerminationDate_lbl" xml:lang="en-US" id="id_10184323_2619587_2_1">Contract termination date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ContractualAgreementTerminationDate" xlink:to="sls_ContractualAgreementTerminationDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2435554_1_1">Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2435554_2_1">Summary of Contractual Obligations Under Non-cancelable Operating Lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ConversionPriceOfPreferredStock" xlink:label="sls_ConversionPriceOfPreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ConversionPriceOfPreferredStock_lbl" xml:lang="en-US" id="id_10184323_2778324_3_1">Conversion Price Of Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ConversionPriceOfPreferredStock_lbl" xml:lang="en-US" id="id_10184323_2778324_1_1">Conversion Price Of Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ConversionPriceOfPreferredStock_lbl" xml:lang="en-US" id="id_10184323_2778324_2_1">Preferred stock conversion price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ConversionPriceOfPreferredStock" xlink:to="sls_ConversionPriceOfPreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US" id="id_10184323_2434933_1_1">Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US" id="id_10184323_2434933_2_1">Carrying value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US" id="id_10184323_2434933_12_1">Total convertible debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xml:lang="en-US" id="id_10184323_2434658_1_1">Convertible Debt, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xml:lang="en-US" id="id_10184323_2434658_2_1">Current portion of convertible debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US" id="id_10184323_2434935_1_1">Convertible Debt, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US" id="id_10184323_2434935_2_1">Convertible debt, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ConvertibleDebtTwoThousandFifteenShareholderNotesMember" xlink:label="sls_ConvertibleDebtTwoThousandFifteenShareholderNotesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ConvertibleDebtTwoThousandFifteenShareholderNotesMember_lbl" xml:lang="en-US" id="id_10184323_3049779_3_1">Convertible Debt Two Thousand Fifteen Shareholder Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ConvertibleDebtTwoThousandFifteenShareholderNotesMember_lbl" xml:lang="en-US" id="id_10184323_3049779_1_1">Convertible Debt Two Thousand Fifteen Shareholder Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ConvertibleDebtTwoThousandFifteenShareholderNotesMember_lbl" xml:lang="en-US" id="id_10184323_3049779_2_1">2015 Shareholder Notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ConvertibleDebtTwoThousandFifteenShareholderNotesMember" xlink:to="sls_ConvertibleDebtTwoThousandFifteenShareholderNotesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ConvertibleDebtTwoThousandSelyNoteMember" xlink:label="sls_ConvertibleDebtTwoThousandSelyNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ConvertibleDebtTwoThousandSelyNoteMember_lbl" xml:lang="en-US" id="id_10184323_3049991_3_1">Convertible Debt Two Thousand Sely Note [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ConvertibleDebtTwoThousandSelyNoteMember_lbl" xml:lang="en-US" id="id_10184323_3049991_1_1">Convertible Debt Two Thousand Sely Note [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ConvertibleDebtTwoThousandSelyNoteMember_lbl" xml:lang="en-US" id="id_10184323_3049991_2_1">2015 Sely Note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ConvertibleDebtTwoThousandSelyNoteMember" xlink:to="sls_ConvertibleDebtTwoThousandSelyNoteMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ConvertibleNotesConversionPricePerShareOfCommonStock" xlink:label="sls_ConvertibleNotesConversionPricePerShareOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ConvertibleNotesConversionPricePerShareOfCommonStock_lbl" xml:lang="en-US" id="id_10184323_2776547_3_1">Convertible Notes Conversion Price Per Share Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ConvertibleNotesConversionPricePerShareOfCommonStock_lbl" xml:lang="en-US" id="id_10184323_2776547_1_1">Convertible Notes Conversion Price Per Share Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ConvertibleNotesConversionPricePerShareOfCommonStock_lbl" xml:lang="en-US" id="id_10184323_2776547_2_1">Common stock conversion price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ConvertibleNotesConversionPricePerShareOfCommonStock" xlink:to="sls_ConvertibleNotesConversionPricePerShareOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ConvertiblePreferredStockBeneficialOwnershipLimitationPercentage" xlink:label="sls_ConvertiblePreferredStockBeneficialOwnershipLimitationPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ConvertiblePreferredStockBeneficialOwnershipLimitationPercentage_lbl" xml:lang="en-US" id="id_10184323_3050062_3_1">Convertible preferred stock beneficial ownership limitation percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ConvertiblePreferredStockBeneficialOwnershipLimitationPercentage_lbl" xml:lang="en-US" id="id_10184323_3050062_1_1">Convertible Preferred Stock Beneficial Ownership Limitation Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ConvertiblePreferredStockBeneficialOwnershipLimitationPercentage_lbl" xml:lang="en-US" id="id_10184323_3050062_2_1">Beneficial ownership limitation,percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ConvertiblePreferredStockBeneficialOwnershipLimitationPercentage" xlink:to="sls_ConvertiblePreferredStockBeneficialOwnershipLimitationPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ConvertiblePreferredStockIssuedShares" xlink:label="sls_ConvertiblePreferredStockIssuedShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ConvertiblePreferredStockIssuedShares_lbl" xml:lang="en-US" id="id_10184323_2614378_3_1">Convertible Preferred Stock Issued Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ConvertiblePreferredStockIssuedShares_lbl" xml:lang="en-US" id="id_10184323_2614378_1_1">Convertible Preferred Stock Issued Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ConvertiblePreferredStockIssuedShares_lbl" xml:lang="en-US" id="id_10184323_2614378_2_1">Number of convertible preferred stock issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ConvertiblePreferredStockIssuedShares" xlink:to="sls_ConvertiblePreferredStockIssuedShares_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" id="id_10184323_2435569_1_1">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" id="id_10184323_2435569_2_1">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xml:lang="en-US" id="id_10184323_2435412_1_1">Counterparty Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xml:lang="en-US" id="id_10184323_2435412_2_1">Counterparty Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_CounterpartyNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_10184323_2435000_1_1">Current Federal Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_10184323_2435000_2_1">Federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_10184323_2435642_1_1">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_10184323_2435642_2_1">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_10184323_2435001_1_1">Current Foreign Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_10184323_2435001_2_1">Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_10184323_2435002_1_1">Current Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_10184323_2435002_6_1">Total current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_10184323_2435643_1_1">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_10184323_2435643_2_1">Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_10184323_2435159_1_1">Current State and Local Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_10184323_2435159_2_1">State</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_CVIAgreementMember" xlink:label="sls_CVIAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_CVIAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3050643_3_1">CVI Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_CVIAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3050643_1_1">CVI Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_CVIAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3050643_2_1">CVI Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_CVIAgreementMember" xlink:to="sls_CVIAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DateByWhichStockHolderApprovalRequired" xlink:label="sls_DateByWhichStockHolderApprovalRequired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_DateByWhichStockHolderApprovalRequired_lbl" xml:lang="en-US" id="id_10184323_3050105_3_1">Date by which stock holder approval required.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_DateByWhichStockHolderApprovalRequired_lbl" xml:lang="en-US" id="id_10184323_3050105_1_1">Date by Which Stock Holder Approval Required</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_DateByWhichStockHolderApprovalRequired_lbl" xml:lang="en-US" id="id_10184323_3050105_2_1">Date by which stock holder approval required</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_DateByWhichStockHolderApprovalRequired" xlink:to="sls_DateByWhichStockHolderApprovalRequired_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebentureMember" xlink:label="sls_DebentureMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_DebentureMember_lbl" xml:lang="en-US" id="id_10184323_2728214_3_1">Debenture.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_DebentureMember_lbl" xml:lang="en-US" id="id_10184323_2728214_1_1">Debenture [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_DebentureMember_lbl" xml:lang="en-US" id="id_10184323_2728214_2_1">Debenture [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_DebentureMember" xlink:to="sls_DebentureMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtConversionConvertedInstrumentGainLossRecognized" xlink:label="sls_DebtConversionConvertedInstrumentGainLossRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_DebtConversionConvertedInstrumentGainLossRecognized_lbl" xml:lang="en-US" id="id_10184323_3049537_3_1">Debt conversion, converted instrument, gain (loss) recognized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_DebtConversionConvertedInstrumentGainLossRecognized_lbl" xml:lang="en-US" id="id_10184323_3049537_1_1">Debt Conversion Converted Instrument Gain Loss Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_DebtConversionConvertedInstrumentGainLossRecognized_lbl" xml:lang="en-US" id="id_10184323_3049537_2_1">Debt conversion, converted instrument, gain (loss) recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_DebtConversionConvertedInstrumentGainLossRecognized" xlink:to="sls_DebtConversionConvertedInstrumentGainLossRecognized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US" id="id_10184323_2435179_1_1">Debt Conversion, Converted Instrument, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US" id="id_10184323_2435179_32_1">Shares issued to satisfy debt redemption</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US" id="id_10184323_2435179_33_1">Shares of common stock issued to satisfy the redemption of notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US" id="id_10184323_2435179_2_1">Conversion of debt, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US" id="id_10184323_2435179_12_1">Number of common stock shares issued for debt conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl" xml:lang="en-US" id="id_10184323_2435030_1_1">Debt Conversion, Converted Instrument, Warrants or Options Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl" xml:lang="en-US" id="id_10184323_2435030_2_1">Warrants issued in full satisfaction of note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionDescription" xlink:label="us-gaap_DebtConversionDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionDescription_lbl" xml:lang="en-US" id="id_10184323_2435180_1_1">Debt Conversion, Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionDescription_lbl" xml:lang="en-US" id="id_10184323_2435180_2_1">Convertible note, conversion description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionDescription" xlink:to="us-gaap_DebtConversionDescription_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xml:lang="en-US" id="id_10184323_2435182_1_1">Debt Conversion, Original Debt, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xml:lang="en-US" id="id_10184323_2435182_2_1">Redemption of debt through issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionOriginalDebtInterestRateOfDebt" xlink:label="us-gaap_DebtConversionOriginalDebtInterestRateOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionOriginalDebtInterestRateOfDebt_lbl" xml:lang="en-US" id="id_10184323_2435462_1_1">Debt Conversion, Original Debt, Interest Rate of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionOriginalDebtInterestRateOfDebt_lbl" xml:lang="en-US" id="id_10184323_2435462_2_1">Convertible notes bears interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtInterestRateOfDebt" xlink:to="us-gaap_DebtConversionOriginalDebtInterestRateOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" id="id_10184323_2435671_1_1">Debt Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" id="id_10184323_2435671_2_1">Debt Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" id="id_10184323_2435672_1_1">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" id="id_10184323_2435672_2_1">Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" id="id_10184323_2435465_1_1">Debt Instrument [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" id="id_10184323_2435465_2_1">Debt Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" id="id_10184323_2435673_1_1">Long-term Debt, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" id="id_10184323_2435673_2_1">Outstanding principal balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtInstrumentCashInExcessOfDebenture" xlink:label="sls_DebtInstrumentCashInExcessOfDebenture"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_DebtInstrumentCashInExcessOfDebenture_lbl" xml:lang="en-US" id="id_10184323_2884835_3_1">Debt instrument, cash in excess of debenture,</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_DebtInstrumentCashInExcessOfDebenture_lbl" xml:lang="en-US" id="id_10184323_2884835_1_1">Debt Instrument Cash In Excess Of Debenture</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_DebtInstrumentCashInExcessOfDebenture_lbl" xml:lang="en-US" id="id_10184323_2884835_2_1">Cash in excess of debenture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_DebtInstrumentCashInExcessOfDebenture" xlink:to="sls_DebtInstrumentCashInExcessOfDebenture_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtInstrumentCommonStockMinimumPriceCondition" xlink:label="sls_DebtInstrumentCommonStockMinimumPriceCondition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_DebtInstrumentCommonStockMinimumPriceCondition_lbl" xml:lang="en-US" id="id_10184323_2884834_3_1">Debt instrument, common stock minimum price condition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_DebtInstrumentCommonStockMinimumPriceCondition_lbl" xml:lang="en-US" id="id_10184323_2884834_1_1">Debt Instrument Common Stock Minimum Price Condition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_DebtInstrumentCommonStockMinimumPriceCondition_lbl" xml:lang="en-US" id="id_10184323_2884834_2_1">Minimum price condition (per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_DebtInstrumentCommonStockMinimumPriceCondition" xlink:to="sls_DebtInstrumentCommonStockMinimumPriceCondition_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:label="us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_lbl" xml:lang="en-US" id="id_10184323_2435468_1_1">Debt Instrument, Convertible, If-converted Value in Excess of Principal</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_lbl" xml:lang="en-US" id="id_10184323_2435468_2_1">Convertible promissory note principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:to="us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtInstrumentConvertiblePercentageOfPrincipalAndAccruedInterest" xlink:label="sls_DebtInstrumentConvertiblePercentageOfPrincipalAndAccruedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_DebtInstrumentConvertiblePercentageOfPrincipalAndAccruedInterest_lbl" xml:lang="en-US" id="id_10184323_2794045_3_1">Debt Instrument Convertible, Percentage Of Principal And Accrued Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_DebtInstrumentConvertiblePercentageOfPrincipalAndAccruedInterest_lbl" xml:lang="en-US" id="id_10184323_2794045_1_1">Debt Instrument Convertible, Percentage Of Principal And Accrued Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_DebtInstrumentConvertiblePercentageOfPrincipalAndAccruedInterest_lbl" xml:lang="en-US" id="id_10184323_2794045_2_1">Accrued interest on the outstanding principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_DebtInstrumentConvertiblePercentageOfPrincipalAndAccruedInterest" xlink:to="sls_DebtInstrumentConvertiblePercentageOfPrincipalAndAccruedInterest_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtInstrumentConvertibleTermOfNotes" xlink:label="sls_DebtInstrumentConvertibleTermOfNotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_DebtInstrumentConvertibleTermOfNotes_lbl" xml:lang="en-US" id="id_10184323_3049461_3_1">Debt instrument, convertible, term of notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_DebtInstrumentConvertibleTermOfNotes_lbl" xml:lang="en-US" id="id_10184323_3049461_1_1">Debt Instrument Convertible Term Of Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_DebtInstrumentConvertibleTermOfNotes_lbl" xml:lang="en-US" id="id_10184323_3049461_2_1">Debt instrument, convertible, term of notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_DebtInstrumentConvertibleTermOfNotes" xlink:to="sls_DebtInstrumentConvertibleTermOfNotes_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtInstrumentCovenantLiquidityCovenant" xlink:label="sls_DebtInstrumentCovenantLiquidityCovenant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_DebtInstrumentCovenantLiquidityCovenant_lbl" xml:lang="en-US" id="id_10184323_2884838_3_1">Debt Instrument, Covenant, Liquidity Covenant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_DebtInstrumentCovenantLiquidityCovenant_lbl" xml:lang="en-US" id="id_10184323_2884838_1_1">Debt Instrument Covenant Liquidity Covenant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_DebtInstrumentCovenantLiquidityCovenant_lbl" xml:lang="en-US" id="id_10184323_2884838_2_1">Debt instrument, covenant, compensating cash balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_DebtInstrumentCovenantLiquidityCovenant" xlink:to="sls_DebtInstrumentCovenantLiquidityCovenant_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtInstrumentCovenantPrepayLesserAccruedAndUnpaidInterest" xlink:label="sls_DebtInstrumentCovenantPrepayLesserAccruedAndUnpaidInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_DebtInstrumentCovenantPrepayLesserAccruedAndUnpaidInterest_lbl" xml:lang="en-US" id="id_10184323_3049542_3_1">Debt instrument prepay lesser accrued and unpaid interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_DebtInstrumentCovenantPrepayLesserAccruedAndUnpaidInterest_lbl" xml:lang="en-US" id="id_10184323_3049542_1_1">Debt Instrument Covenant Prepay Lesser Accrued And Unpaid Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_DebtInstrumentCovenantPrepayLesserAccruedAndUnpaidInterest_lbl" xml:lang="en-US" id="id_10184323_3049542_2_1">Debt instrument prepay lesser accrued and unpaid interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_DebtInstrumentCovenantPrepayLesserAccruedAndUnpaidInterest" xlink:to="sls_DebtInstrumentCovenantPrepayLesserAccruedAndUnpaidInterest_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xml:lang="en-US" id="id_10184323_2435476_1_1">Debt Instrument, Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xml:lang="en-US" id="id_10184323_2435476_2_1">Debt instrument description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" id="id_10184323_2435679_1_1">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" id="id_10184323_2435679_2_1">Aggregate principal amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" id="id_10184323_2435679_12_1">Principal amount of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xml:lang="en-US" id="id_10184323_2435680_1_1">Debt Instrument, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xml:lang="en-US" id="id_10184323_2435680_2_1">Estimated fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="us-gaap_DebtInstrumentFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xml:lang="en-US" id="id_10184323_2435195_1_1">Debt Instrument, Increase, Accrued Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xml:lang="en-US" id="id_10184323_2435195_2_1">Borrowings accrued interest amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xml:lang="en-US" id="id_10184323_2435195_12_1">Convertible note, accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xml:lang="en-US" id="id_10184323_2435052_1_1">Debt Instrument, Interest Rate, Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xml:lang="en-US" id="id_10184323_2435052_2_1">Increase accrued interest on the outstanding principal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" id="id_10184323_2435053_1_1">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" id="id_10184323_2435053_32_1">Loan interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" id="id_10184323_2435053_2_1">Convertible Preferred stock stated value percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" id="id_10184323_2435053_12_1">Fixed coupon rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" id="id_10184323_2435200_1_1">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" id="id_10184323_2435200_2_1">Debt Instrument [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US" id="id_10184323_2435201_1_1">Debt Instrument, Maturity Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US" id="id_10184323_2435201_2_1">Convertible debt, maturity date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US" id="id_10184323_2435201_12_1">Debt instrument maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" id="id_10184323_2435683_1_1">Debt Instrument, Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" id="id_10184323_2435683_2_1">Debt Instrument, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="us-gaap_DebtInstrumentPaymentTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPaymentTerms_lbl" xml:lang="en-US" id="id_10184323_2435203_1_1">Debt Instrument, Payment Terms</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentPaymentTerms_lbl" xml:lang="en-US" id="id_10184323_2435203_2_1">Debt instrument frequency of payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPaymentTerms" xlink:to="us-gaap_DebtInstrumentPaymentTerms_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtInstrumentPercentageofPriorDayVolumeWeightedAveragePrice" xlink:label="sls_DebtInstrumentPercentageofPriorDayVolumeWeightedAveragePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_DebtInstrumentPercentageofPriorDayVolumeWeightedAveragePrice_lbl" xml:lang="en-US" id="id_10184323_2884842_3_1">Debt instrument, percentage of prior day volume weighted average price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_DebtInstrumentPercentageofPriorDayVolumeWeightedAveragePrice_lbl" xml:lang="en-US" id="id_10184323_2884842_1_1">Debt Instrument Percentageof Prior Day Volume Weighted Average Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_DebtInstrumentPercentageofPriorDayVolumeWeightedAveragePrice_lbl" xml:lang="en-US" id="id_10184323_2884842_2_1">Percentage of prior day VMAP</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_DebtInstrumentPercentageofPriorDayVolumeWeightedAveragePrice" xlink:to="sls_DebtInstrumentPercentageofPriorDayVolumeWeightedAveragePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtInstrumentPercentageofVolumeWeightedAveragePrice" xlink:label="sls_DebtInstrumentPercentageofVolumeWeightedAveragePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_DebtInstrumentPercentageofVolumeWeightedAveragePrice_lbl" xml:lang="en-US" id="id_10184323_2884841_3_1">Debt instrument, percentage of volume weighted average price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_DebtInstrumentPercentageofVolumeWeightedAveragePrice_lbl" xml:lang="en-US" id="id_10184323_2884841_1_1">Debt Instrument Percentageof Volume Weighted Average Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_DebtInstrumentPercentageofVolumeWeightedAveragePrice_lbl" xml:lang="en-US" id="id_10184323_2884841_2_1">Percentage of VWAPs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_DebtInstrumentPercentageofVolumeWeightedAveragePrice" xlink:to="sls_DebtInstrumentPercentageofVolumeWeightedAveragePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US" id="id_10184323_2435056_1_1">Debt Instrument, Periodic Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US" id="id_10184323_2435056_2_1">Principal and accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl" xml:lang="en-US" id="id_10184323_2435061_1_1">Debt Instrument, Redemption Price, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl" xml:lang="en-US" id="id_10184323_2435061_2_1">Debt Instrument, Redemption Price, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtInstrumentRedemptionPrincipalAmountRedeemed" xlink:label="sls_DebtInstrumentRedemptionPrincipalAmountRedeemed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_DebtInstrumentRedemptionPrincipalAmountRedeemed_lbl" xml:lang="en-US" id="id_10184323_2884849_3_1">Debt Instrument, Redemption, Principal Amount Redeemed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_DebtInstrumentRedemptionPrincipalAmountRedeemed_lbl" xml:lang="en-US" id="id_10184323_2884849_1_1">Debt Instrument Redemption Principal Amount Redeemed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_DebtInstrumentRedemptionPrincipalAmountRedeemed_lbl" xml:lang="en-US" id="id_10184323_2884849_2_1">Principal amount redeemed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_DebtInstrumentRedemptionPrincipalAmountRedeemed" xlink:to="sls_DebtInstrumentRedemptionPrincipalAmountRedeemed_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtInstrumentRedemptionRedemptionPayments" xlink:label="sls_DebtInstrumentRedemptionRedemptionPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_DebtInstrumentRedemptionRedemptionPayments_lbl" xml:lang="en-US" id="id_10184323_2884850_3_1">Debt Instrument, Redemption, Redemption Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_DebtInstrumentRedemptionRedemptionPayments_lbl" xml:lang="en-US" id="id_10184323_2884850_1_1">Debt Instrument Redemption Redemption Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_DebtInstrumentRedemptionRedemptionPayments_lbl" xml:lang="en-US" id="id_10184323_2884850_2_1">Interest under the Debenture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_DebtInstrumentRedemptionRedemptionPayments" xlink:to="sls_DebtInstrumentRedemptionRedemptionPayments_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" id="id_10184323_2435208_1_1">Schedule of Long-term Debt Instruments [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" id="id_10184323_2435208_2_1">Schedule of Long-term Debt Instruments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" id="id_10184323_2435209_1_1">Debt Instrument, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" id="id_10184323_2435209_2_1">Loan agreement period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtRepaymentsDescription" xlink:label="sls_DebtRepaymentsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_DebtRepaymentsDescription_lbl" xml:lang="en-US" id="id_10184323_2616488_3_1">Debt Repayments Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_DebtRepaymentsDescription_lbl" xml:lang="en-US" id="id_10184323_2616488_1_1">Debt Repayments Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_DebtRepaymentsDescription_lbl" xml:lang="en-US" id="id_10184323_2616488_2_1">Debt repayments description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_DebtRepaymentsDescription" xlink:to="sls_DebtRepaymentsDescription_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DecreaseInRestrictedCash" xlink:label="us-gaap_DecreaseInRestrictedCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DecreaseInRestrictedCash_lbl" xml:lang="en-US" id="id_10184323_2435512_1_1">Decrease in Restricted Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DecreaseInRestrictedCash_lbl" xml:lang="en-US" id="id_10184323_2435512_2_1">Decrease in restricted cash and cash equivalent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DecreaseInRestrictedCash" xlink:to="us-gaap_DecreaseInRestrictedCash_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance" xlink:label="sls_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance_lbl" xml:lang="en-US" id="id_10184323_3051935_3_1">Deemed dividend associated with conversion of note and common stock warrant issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance_lbl" xml:lang="en-US" id="id_10184323_3051935_1_1">Deemed Dividend Associated With Conversion Of Note And Common Stock Warrant Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance_lbl" xml:lang="en-US" id="id_10184323_3051935_2_1">Deemed dividend associated with conversion of 2015 Sely Note and common stock warrant issuance to Equilibria</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance" xlink:to="sls_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DeemedDividendOnDebtConversion" xlink:label="sls_DeemedDividendOnDebtConversion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_DeemedDividendOnDebtConversion_lbl" xml:lang="en-US" id="id_10184323_3053504_3_1">Deemed dividend on debt conversion.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_DeemedDividendOnDebtConversion_lbl" xml:lang="en-US" id="id_10184323_3053504_1_1">Deemed Dividend on Debt Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="sls_DeemedDividendOnDebtConversion_lbl" xml:lang="en-US" id="id_10184323_3053504_14_1">Deemed dividend on conversion of 2015 Sely Note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_DeemedDividendOnDebtConversion" xlink:to="sls_DeemedDividendOnDebtConversion_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_10184323_2436177_1_1">Deferred Federal Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_10184323_2436177_2_1">Federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_10184323_2435246_1_1">Deferred Foreign Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_10184323_2435246_2_1">Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl" xml:lang="en-US" id="id_10184323_2435759_1_1">Deferred Income Taxes and Tax Credits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl" xml:lang="en-US" id="id_10184323_2435759_2_1">Deferred income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_10184323_2436191_1_1">Deferred Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_10184323_2436191_6_1">Total deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_10184323_2436397_1_1">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_10184323_2436397_2_1">Deferred expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" id="id_10184323_2435251_1_1">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" id="id_10184323_2435251_2_1">Gross deferred tax liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_10184323_2436215_1_1">Deferred State and Local Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_10184323_2436215_2_1">State</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife" xlink:label="sls_DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife_lbl" xml:lang="en-US" id="id_10184323_2589394_3_1">Deferred tax asset net operating loss carryforwards indefinite life.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife_lbl" xml:lang="en-US" id="id_10184323_2589394_1_1">Deferred Tax Asset Net Operating Loss Carryforwards Indefinite Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife_lbl" xml:lang="en-US" id="id_10184323_2589394_2_1">Deferred tax assets indefinite-lived NOL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife" xlink:to="sls_DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" id="id_10184323_2435282_1_1">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" id="id_10184323_2435282_6_1">Gross deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DeferredTaxAssetsLicensingDeductionDeferral" xlink:label="sls_DeferredTaxAssetsLicensingDeductionDeferral"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_DeferredTaxAssetsLicensingDeductionDeferral_lbl" xml:lang="en-US" id="id_10184323_2570257_3_1">Deferred Tax Assets Licensing Deduction Deferral</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_DeferredTaxAssetsLicensingDeductionDeferral_lbl" xml:lang="en-US" id="id_10184323_2570257_1_1">Deferred Tax Assets Licensing Deduction Deferral</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_DeferredTaxAssetsLicensingDeductionDeferral_lbl" xml:lang="en-US" id="id_10184323_2570257_2_1">Licensing deduction deferral</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_DeferredTaxAssetsLicensingDeductionDeferral" xlink:to="sls_DeferredTaxAssetsLicensingDeductionDeferral_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" id="id_10184323_2435284_1_1">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" id="id_10184323_2435284_6_1">Net deferred tax asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" id="id_10184323_2435806_1_1">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" id="id_10184323_2435806_2_1">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US" id="id_10184323_2436440_1_1">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US" id="id_10184323_2436440_2_1">Federal operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US" id="id_10184323_2436222_1_1">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US" id="id_10184323_2436222_2_1">State operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOtherTaxCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_lbl" xml:lang="en-US" id="id_10184323_2435285_1_1">Deferred Tax Assets, Other Tax Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_lbl" xml:lang="en-US" id="id_10184323_2435285_2_1">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US" id="id_10184323_2435810_1_1">Deferred Tax Assets, Tax Credit Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US" id="id_10184323_2435810_2_1">Tax credit carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" id="id_10184323_2436445_1_1">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" id="id_10184323_2436445_2_1">Research and development tax credit carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" id="id_10184323_2436449_1_1">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" id="id_10184323_2436449_2_1">Stock based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="id_10184323_2436236_1_1">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="id_10184323_2436236_14_1">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xml:lang="en-US" id="id_10184323_2436460_1_1">Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xml:lang="en-US" id="id_10184323_2436460_2_1">In-process research and development not subject to future amortization for tax purposes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_10184323_2435826_1_1">Deferred Tax Liabilities, Net, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_10184323_2435826_2_1">Deferred tax liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DenominatorBaseForIssuanceOfCommonStockValue" xlink:label="sls_DenominatorBaseForIssuanceOfCommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_DenominatorBaseForIssuanceOfCommonStockValue_lbl" xml:lang="en-US" id="id_10184323_3050579_3_1">Denominator base for issuance of common stock value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_DenominatorBaseForIssuanceOfCommonStockValue_lbl" xml:lang="en-US" id="id_10184323_3050579_1_1">Denominator Base for Issuance of Common Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_DenominatorBaseForIssuanceOfCommonStockValue_lbl" xml:lang="en-US" id="id_10184323_3050579_2_1">Denominator base for issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_DenominatorBaseForIssuanceOfCommonStockValue" xlink:to="sls_DenominatorBaseForIssuanceOfCommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US" id="id_10184323_2436561_1_1">Deposits Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US" id="id_10184323_2436561_2_1">Deposits and other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" id="id_10184323_2436331_1_1">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" id="id_10184323_2436331_2_1">Depreciation and amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="id_10184323_2437359_1_1">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="id_10184323_2437359_2_1">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="id_10184323_2437103_1_1">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="id_10184323_2437103_2_1">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DocumentAndEntityInformationAbstract" xlink:label="sls_DocumentAndEntityInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_10184323_2455411_3_1">Document and entity information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_10184323_2455411_1_1">Document And Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_10184323_2455411_2_1">Document And Entity Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_DocumentAndEntityInformationAbstract" xlink:to="sls_DocumentAndEntityInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_10184323_2437192_1_1">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_10184323_2437192_2_1">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_10184323_2437193_1_1">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_10184323_2437193_2_1">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_10184323_2437438_1_1">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_10184323_2437438_2_1">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_10184323_2437197_1_1">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_10184323_2437197_2_1">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" id="id_10184323_2437443_1_1">Domestic Tax Authority [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" id="id_10184323_2437443_2_1">Domestic Tax Authority [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DrAngelosMStergiouMember" xlink:label="sls_DrAngelosMStergiouMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_DrAngelosMStergiouMember_lbl" xml:lang="en-US" id="id_10184323_3049969_3_1">Dr Angelos MStergiou [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_DrAngelosMStergiouMember_lbl" xml:lang="en-US" id="id_10184323_3049969_1_1">Dr Angelos MStergiou [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_DrAngelosMStergiouMember_lbl" xml:lang="en-US" id="id_10184323_3049969_2_1">Dr Angelos MStergiou [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_DrAngelosMStergiouMember" xlink:to="sls_DrAngelosMStergiouMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DrsStergiouAndSougioultzoglouMember" xlink:label="sls_DrsStergiouAndSougioultzoglouMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_DrsStergiouAndSougioultzoglouMember_lbl" xml:lang="en-US" id="id_10184323_3053942_3_1">Drs. Stergiou and Sougioultzoglou.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_DrsStergiouAndSougioultzoglouMember_lbl" xml:lang="en-US" id="id_10184323_3053942_1_1">Drs. Stergiou and Sougioultzoglou [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_DrsStergiouAndSougioultzoglouMember_lbl" xml:lang="en-US" id="id_10184323_3053942_2_1">Drs. Stergiou and Sougioultzoglou [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_DrsStergiouAndSougioultzoglouMember" xlink:to="sls_DrsStergiouAndSougioultzoglouMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DrsStergiouMember" xlink:label="sls_DrsStergiouMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_DrsStergiouMember_lbl" xml:lang="en-US" id="id_10184323_3053940_3_1">Drs. Stergiou.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_DrsStergiouMember_lbl" xml:lang="en-US" id="id_10184323_3053940_1_1">Drs. Stergiou [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_DrsStergiouMember_lbl" xml:lang="en-US" id="id_10184323_3053940_2_1">Drs. Stergiou [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_DrsStergiouMember" xlink:to="sls_DrsStergiouMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_10184323_2436947_1_1">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_10184323_2436947_2_1">Basic and diluted loss per share to common stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" id="id_10184323_2437218_1_1">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" id="id_10184323_2437218_2_1">Net Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" id="id_10184323_2436962_1_1">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" id="id_10184323_2436962_6_1">Effective income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" id="id_10184323_2437222_1_1">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" id="id_10184323_2437222_2_1">Corporate tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" id="id_10184323_2437222_12_1">U.S. federal statutory income tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" id="id_10184323_2437222_14_1">U.S. federal statutory income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="id_10184323_2437223_1_1">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="id_10184323_2437223_2_1">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US" id="id_10184323_2438132_1_1">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US" id="id_10184323_2438132_2_1">Tax rate change and true-up</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US" id="id_10184323_2438135_1_1">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US" id="id_10184323_2438135_2_1">Foreign rate differential</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" id="id_10184323_2438142_1_1">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" id="id_10184323_2438142_2_1">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="sls_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xml:lang="en-US" id="id_10184323_2804171_3_1">Effective Income Tax Rate Reconciliation Permanent Differences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xml:lang="en-US" id="id_10184323_2804171_1_1">Effective Income Tax Rate Reconciliation Permanent Differences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xml:lang="en-US" id="id_10184323_2804171_2_1">Permanent differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:to="sls_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" id="id_10184323_2437483_1_1">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" id="id_10184323_2437483_2_1">State and local taxes, net of federal benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US" id="id_10184323_2438144_1_1">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US" id="id_10184323_2438144_14_1">Tax credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_EffectivePeriodOfAgreement" xlink:label="sls_EffectivePeriodOfAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_EffectivePeriodOfAgreement_lbl" xml:lang="en-US" id="id_10184323_3049970_3_1">Effective Period Of Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_EffectivePeriodOfAgreement_lbl" xml:lang="en-US" id="id_10184323_3049970_1_1">Effective Period Of Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_EffectivePeriodOfAgreement_lbl" xml:lang="en-US" id="id_10184323_3049970_2_1">Effective period of agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_EffectivePeriodOfAgreement" xlink:to="sls_EffectivePeriodOfAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_EmperyAgreementMember" xlink:label="sls_EmperyAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_EmperyAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3050038_3_1">Empery Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_EmperyAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3050038_1_1">Empery Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_EmperyAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3050038_2_1">Empery Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_EmperyAgreementMember" xlink:to="sls_EmperyAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_EmployeeAndNonemployeeStockOptionsMember" xlink:label="sls_EmployeeAndNonemployeeStockOptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_EmployeeAndNonemployeeStockOptionsMember_lbl" xml:lang="en-US" id="id_10184323_2828147_3_1">Employee And Nonemployee Stock Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_EmployeeAndNonemployeeStockOptionsMember_lbl" xml:lang="en-US" id="id_10184323_2828147_1_1">Employee And Nonemployee Stock Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_EmployeeAndNonemployeeStockOptionsMember_lbl" xml:lang="en-US" id="id_10184323_2828147_2_1">Employee and Non-Employee Stock Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_EmployeeAndNonemployeeStockOptionsMember" xlink:to="sls_EmployeeAndNonemployeeStockOptionsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_10184323_2437004_1_1">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_10184323_2437004_2_1">Compensation and related benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" id="id_10184323_2437925_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" id="id_10184323_2437925_2_1">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US" id="id_10184323_2438180_1_1">Employee Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US" id="id_10184323_2438180_2_1">Employee Stock Purchase Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="id_10184323_2438181_1_1">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="id_10184323_2438181_2_1">Stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_EmployeeStockPurchasePlanMember" xlink:label="sls_EmployeeStockPurchasePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" id="id_10184323_2666068_3_1">Employee stock purchase plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" id="id_10184323_2666068_1_1">Employee Stock Purchase Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" id="id_10184323_2666068_2_1">Employee Stock Purchase Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_EmployeeStockPurchasePlanMember" xlink:to="sls_EmployeeStockPurchasePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_EngagementLetterMember" xlink:label="sls_EngagementLetterMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_EngagementLetterMember_lbl" xml:lang="en-US" id="id_10184323_3050065_3_1">Engagement Letter.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_EngagementLetterMember_lbl" xml:lang="en-US" id="id_10184323_3050065_1_1">Engagement Letter [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_EngagementLetterMember_lbl" xml:lang="en-US" id="id_10184323_3050065_2_1">Engagement Letter [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_EngagementLetterMember" xlink:to="sls_EngagementLetterMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_10184323_2437941_1_1">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_10184323_2437941_2_1">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_10184323_2438208_1_1">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_10184323_2438208_2_1">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="id_10184323_2438211_1_1">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="id_10184323_2438211_2_1">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_10184323_2438213_1_1">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_10184323_2438213_2_1">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" id="id_10184323_2437698_1_1">Entity Public Float</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" id="id_10184323_2437698_2_1">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_10184323_2437699_1_1">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_10184323_2437699_2_1">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" id="id_10184323_2437702_1_1">Entity Voluntary Filers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" id="id_10184323_2437702_2_1">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" id="id_10184323_2437954_1_1">Entity Well-known Seasoned Issuer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" id="id_10184323_2437954_2_1">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_EQCBiotechSelyIFundMember" xlink:label="sls_EQCBiotechSelyIFundMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_EQCBiotechSelyIFundMember_lbl" xml:lang="en-US" id="id_10184323_3049446_3_1">EQC Biotech Sely I Fund.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_EQCBiotechSelyIFundMember_lbl" xml:lang="en-US" id="id_10184323_3049446_1_1">EQC Biotech Sely I Fund [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_EQCBiotechSelyIFundMember_lbl" xml:lang="en-US" id="id_10184323_3049446_2_1">EQC Biotech Sely I Fund [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_EQCBiotechSelyIFundMember" xlink:to="sls_EQCBiotechSelyIFundMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_EqcWarrantsMember" xlink:label="sls_EqcWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_EqcWarrantsMember_lbl" xml:lang="en-US" id="id_10184323_3050116_3_1">EQC Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_EqcWarrantsMember_lbl" xml:lang="en-US" id="id_10184323_3050116_1_1">EQC Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_EqcWarrantsMember_lbl" xml:lang="en-US" id="id_10184323_3050116_2_1">2017 Equilibria</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_EqcWarrantsMember" xlink:to="sls_EqcWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_EquilibriaCollaborationAgreementMember" xlink:label="sls_EquilibriaCollaborationAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_EquilibriaCollaborationAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3049598_3_1">Equilibria Collaboration Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_EquilibriaCollaborationAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3049598_1_1">Equilibria Collaboration Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_EquilibriaCollaborationAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3049598_2_1">Equilibria Collaboration Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_EquilibriaCollaborationAgreementMember" xlink:to="sls_EquilibriaCollaborationAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="id_10184323_2437558_1_1">Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="id_10184323_2437558_2_1">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="id_10184323_2437711_1_1">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="id_10184323_2437711_2_1">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US" id="id_10184323_2438247_1_1">Equity Method Investment, Ownership Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US" id="id_10184323_2438247_2_1">Equity method investment, ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_lbl" xml:lang="en-US" id="id_10184323_2437736_1_1">Error Corrections and Prior Period Adjustments Restatement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_lbl" xml:lang="en-US" id="id_10184323_2437736_2_1">Error Corrections and Prior Period Adjustments Restatement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_lbl" xml:lang="en-US" id="id_10184323_2438295_1_1">Extinguishment of Debt, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_lbl" xml:lang="en-US" id="id_10184323_2438295_2_1">Extinguishment of debt amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtAmount" xlink:to="us-gaap_ExtinguishmentOfDebtAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" id="id_10184323_2438025_1_1">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" id="id_10184323_2438025_2_1">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" id="id_10184323_2438026_1_1">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" id="id_10184323_2438026_2_1">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="id_10184323_2437639_1_1">Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="id_10184323_2437639_2_1">Fair value assumptions, expected dividend rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xml:lang="en-US" id="id_10184323_2437786_1_1">Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xml:lang="en-US" id="id_10184323_2437786_2_1">Fair value assumptions, expected term (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="id_10184323_2438319_1_1">Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="id_10184323_2438319_2_1">Fair value assumptions, expected volatility rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_10184323_2438320_1_1">Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_10184323_2438320_2_1">Fair value assumptions, risk free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="id_10184323_2438028_1_1">Fair Value, Hierarchy [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="id_10184323_2438028_2_1">Fair Value, Hierarchy [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" id="id_10184323_2438324_1_1">Measurement Frequency [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" id="id_10184323_2438324_2_1">Measurement Frequency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" id="id_10184323_2438044_1_1">Fair Value Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" id="id_10184323_2438044_2_1">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="id_10184323_2437665_1_1">Fair Value, Inputs, Level 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="id_10184323_2437665_2_1">Quoted Prices In Active Markets (Level 1)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" id="id_10184323_2438072_1_1">Fair Value, Inputs, Level 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" id="id_10184323_2438072_2_1">Unobservable Inputs (Level 3)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" id="id_10184323_2439039_1_1">Fair Value, Measurement Frequency [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" id="id_10184323_2439039_2_1">Fair Value, Measurement Frequency [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="id_10184323_2438100_1_1">Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="id_10184323_2438100_2_1">Fair Value Hierarchy [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" id="id_10184323_2438356_1_1">Fair Value, Measurements, Recurring [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" id="id_10184323_2438356_2_1">Fair Value, Measurements, Recurring</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" id="id_10184323_2438116_1_1">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" id="id_10184323_2438116_2_1">Fair Value of Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FairValueOfStockOptionsAssumedInConnectionWithAcquisition" xlink:label="sls_FairValueOfStockOptionsAssumedInConnectionWithAcquisition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_FairValueOfStockOptionsAssumedInConnectionWithAcquisition_lbl" xml:lang="en-US" id="id_10184323_3051928_3_1">Fair value of stock options assumed in connection with acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_FairValueOfStockOptionsAssumedInConnectionWithAcquisition_lbl" xml:lang="en-US" id="id_10184323_3051928_1_1">Fair Value Of Stock Options Assumed In Connection With Acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_FairValueOfStockOptionsAssumedInConnectionWithAcquisition_lbl" xml:lang="en-US" id="id_10184323_3051928_2_1">Fair value of options assumed in connection with acquisition of Galena</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_FairValueOfStockOptionsAssumedInConnectionWithAcquisition" xlink:to="sls_FairValueOfStockOptionsAssumedInConnectionWithAcquisition_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" xlink:label="sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_lbl" xml:lang="en-US" id="id_10184323_2633071_3_1">Fair Value of Warrant Liability Assumptions Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_lbl" xml:lang="en-US" id="id_10184323_2633071_1_1">Fair Value of Warrant Liability Assumptions Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_lbl" xml:lang="en-US" id="id_10184323_2633071_2_1">Expected term (years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" xlink:to="sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FairValueOfWarrantsExercised" xlink:label="sls_FairValueOfWarrantsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_FairValueOfWarrantsExercised_lbl" xml:lang="en-US" id="id_10184323_2583886_3_1">Fair Value Of Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_FairValueOfWarrantsExercised_lbl" xml:lang="en-US" id="id_10184323_2583886_1_1">Fair Value Of Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_FairValueOfWarrantsExercised_lbl" xml:lang="en-US" id="id_10184323_2583886_2_1">Fair Value of Warrants Acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_FairValueOfWarrantsExercised" xlink:to="sls_FairValueOfWarrantsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FairValueofWarrantsGranted" xlink:label="sls_FairValueofWarrantsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_FairValueofWarrantsGranted_lbl" xml:lang="en-US" id="id_10184323_2884864_3_1">Fair Value of Warrants Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_FairValueofWarrantsGranted_lbl" xml:lang="en-US" id="id_10184323_2884864_1_1">Fair Valueof Warrants Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_FairValueofWarrantsGranted_lbl" xml:lang="en-US" id="id_10184323_2884864_2_1">Fair Value of Warrants Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_FairValueofWarrantsGranted" xlink:to="sls_FairValueofWarrantsGranted_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FairValueofWarrantsGrantedperShare" xlink:label="sls_FairValueofWarrantsGrantedperShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_FairValueofWarrantsGrantedperShare_lbl" xml:lang="en-US" id="id_10184323_2884865_3_1">Fair value of warrants granted, per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_FairValueofWarrantsGrantedperShare_lbl" xml:lang="en-US" id="id_10184323_2884865_1_1">Fair Valueof Warrants Grantedper Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_FairValueofWarrantsGrantedperShare_lbl" xml:lang="en-US" id="id_10184323_2884865_2_1">Fair value of warrants granted (in dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_FairValueofWarrantsGrantedperShare" xlink:to="sls_FairValueofWarrantsGrantedperShare_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FairValueOfWarrantsLiabilities" xlink:label="sls_FairValueOfWarrantsLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_FairValueOfWarrantsLiabilities_lbl" xml:lang="en-US" id="id_10184323_2592189_3_1">Fair value of warrant liabilities as of the balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_FairValueOfWarrantsLiabilities_lbl" xml:lang="en-US" id="id_10184323_2592189_1_1">Fair Value Of Warrants Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="sls_FairValueOfWarrantsLiabilities_lbl" xml:lang="en-US" id="id_10184323_2592189_4_1">Warrant liability, Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="sls_FairValueOfWarrantsLiabilities_lbl" xml:lang="en-US" id="id_10184323_2592189_5_1">Warrant liability, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_FairValueOfWarrantsLiabilities" xlink:to="sls_FairValueOfWarrantsLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="sls_FairValueOfWarrantsPotentiallySettleableInCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_FairValueOfWarrantsPotentiallySettleableInCash_lbl" xml:lang="en-US" id="id_10184323_2516015_3_1">Fair value of warrants potentially settleable in cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_FairValueOfWarrantsPotentiallySettleableInCash_lbl" xml:lang="en-US" id="id_10184323_2516015_1_1">Fair Value Of Warrants Potentially Settleable In Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_FairValueOfWarrantsPotentiallySettleableInCash_lbl" xml:lang="en-US" id="id_10184323_2516015_2_1">Warrants potentially settleable in cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_FairValueOfWarrantsPotentiallySettleableInCash" xlink:to="sls_FairValueOfWarrantsPotentiallySettleableInCash_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_February2017WarrantsMember" xlink:label="sls_February2017WarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_February2017WarrantsMember_lbl" xml:lang="en-US" id="id_10184323_2884867_3_1">February 2017 Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_February2017WarrantsMember_lbl" xml:lang="en-US" id="id_10184323_2884867_1_1">February 2017 Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_February2017WarrantsMember_lbl" xml:lang="en-US" id="id_10184323_2884867_2_1">Galena February 2017</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_February2017WarrantsMember" xlink:to="sls_February2017WarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" id="id_10184323_2439166_1_1">Financial Instrument [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" id="id_10184323_2439166_2_1">Financial Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_10184323_2439168_1_1">Financial Instruments Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_10184323_2439168_2_1">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FirstTrancheMember" xlink:label="sls_FirstTrancheMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_FirstTrancheMember_lbl" xml:lang="en-US" id="id_10184323_2743081_3_1">First Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_FirstTrancheMember_lbl" xml:lang="en-US" id="id_10184323_2743081_1_1">First Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_FirstTrancheMember_lbl" xml:lang="en-US" id="id_10184323_2743081_2_1">First Tranche (Expected to Occur on or about March 2018) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_FirstTrancheMember" xlink:to="sls_FirstTrancheMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FirstTrojantecAmendmentMember" xlink:label="sls_FirstTrojantecAmendmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_FirstTrojantecAmendmentMember_lbl" xml:lang="en-US" id="id_10184323_3049279_3_1">First Trojantec amendment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_FirstTrojantecAmendmentMember_lbl" xml:lang="en-US" id="id_10184323_3049279_1_1">First Trojantec Amendment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_FirstTrojantecAmendmentMember_lbl" xml:lang="en-US" id="id_10184323_3049279_2_1">First Trojantec Amendment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_FirstTrojantecAmendmentMember" xlink:to="sls_FirstTrojantecAmendmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FirstWaiverMember" xlink:label="sls_FirstWaiverMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_FirstWaiverMember_lbl" xml:lang="en-US" id="id_10184323_2884877_3_1">First Waiver [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_FirstWaiverMember_lbl" xml:lang="en-US" id="id_10184323_2884877_1_1">First Waiver [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_FirstWaiverMember_lbl" xml:lang="en-US" id="id_10184323_2884877_2_1">First Waiver</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_FirstWaiverMember" xlink:to="sls_FirstWaiverMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FounderLoansMember" xlink:label="sls_FounderLoansMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_FounderLoansMember_lbl" xml:lang="en-US" id="id_10184323_3053943_3_1">Founder loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_FounderLoansMember_lbl" xml:lang="en-US" id="id_10184323_3053943_1_1">Founder Loans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_FounderLoansMember_lbl" xml:lang="en-US" id="id_10184323_3053943_2_1">Founder Loans [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_FounderLoansMember" xlink:to="sls_FounderLoansMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FourthTrancheMember" xlink:label="sls_FourthTrancheMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_FourthTrancheMember_lbl" xml:lang="en-US" id="id_10184323_2687738_3_1">Fourth Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_FourthTrancheMember_lbl" xml:lang="en-US" id="id_10184323_2687738_1_1">Fourth Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_FourthTrancheMember_lbl" xml:lang="en-US" id="id_10184323_2687738_2_1">Payable 30 days after Merger but no later than December 31, 2017 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_FourthTrancheMember" xlink:to="sls_FourthTrancheMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FrameworkLoanAgreementMember" xlink:label="sls_FrameworkLoanAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_FrameworkLoanAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3053912_3_1">Framework loan agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_FrameworkLoanAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3053912_1_1">Framework Loan Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_FrameworkLoanAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3053912_2_1">Framework Loan Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_FrameworkLoanAgreementMember" xlink:to="sls_FrameworkLoanAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_GainLossOnExtinguishmentOfDebt" xlink:label="sls_GainLossOnExtinguishmentOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_GainLossOnExtinguishmentOfDebt_lbl" xml:lang="en-US" id="id_10184323_2511508_3_1">Gain Loss On Extinguishment Of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_GainLossOnExtinguishmentOfDebt_lbl" xml:lang="en-US" id="id_10184323_2511508_1_1">Gain Loss On Extinguishment Of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_GainLossOnExtinguishmentOfDebt_lbl" xml:lang="en-US" id="id_10184323_2511508_2_1">Gain (loss) on extinguishment of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_GainLossOnExtinguishmentOfDebt" xlink:to="sls_GainLossOnExtinguishmentOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" id="id_10184323_2439504_1_1">Gain (Loss) on Extinguishment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" id="id_10184323_2439504_14_1">Loss on extinguishment of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_GaleFourZeroOneMember" xlink:label="sls_GaleFourZeroOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_GaleFourZeroOneMember_lbl" xml:lang="en-US" id="id_10184323_3049740_3_1">Gale Four Zero One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_GaleFourZeroOneMember_lbl" xml:lang="en-US" id="id_10184323_3049740_1_1">Gale Four Zero One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_GaleFourZeroOneMember_lbl" xml:lang="en-US" id="id_10184323_3049740_2_1">GALE-401 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_GaleFourZeroOneMember" xlink:to="sls_GaleFourZeroOneMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_GalenaBiopharmaIncMember" xlink:label="sls_GalenaBiopharmaIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_GalenaBiopharmaIncMember_lbl" xml:lang="en-US" id="id_10184323_2884874_3_1">Galena Biopharma, Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_GalenaBiopharmaIncMember_lbl" xml:lang="en-US" id="id_10184323_2884874_1_1">Galena Biopharma Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_GalenaBiopharmaIncMember_lbl" xml:lang="en-US" id="id_10184323_2884874_2_1">Galena Biopharma, Inc</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_GalenaBiopharmaIncMember" xlink:to="sls_GalenaBiopharmaIncMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_GaleThreeZeroTwoMember" xlink:label="sls_GaleThreeZeroTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_GaleThreeZeroTwoMember_lbl" xml:lang="en-US" id="id_10184323_3050157_3_1">Gale Three Zero Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_GaleThreeZeroTwoMember_lbl" xml:lang="en-US" id="id_10184323_3050157_1_1">Gale Three Zero Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_GaleThreeZeroTwoMember_lbl" xml:lang="en-US" id="id_10184323_3050157_2_1">GALE-301 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_GaleThreeZeroTwoMember" xlink:to="sls_GaleThreeZeroTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_10184323_2439776_1_1">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_10184323_2439776_2_1">General and administrative expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="id_10184323_2439323_1_1">General and Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="id_10184323_2439323_2_1">General and administrative expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" id="id_10184323_2439530_1_1">Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" id="id_10184323_2439530_4_1">Balance as of December 31, 2017</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" id="id_10184323_2439530_5_1">Balance as of January 1, 2017</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" id="id_10184323_2439530_2_1">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="us-gaap_GoodwillAcquiredDuringPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAcquiredDuringPeriod_lbl" xml:lang="en-US" id="id_10184323_2439531_1_1">Goodwill, Acquired During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAcquiredDuringPeriod_lbl" xml:lang="en-US" id="id_10184323_2439531_2_1">Goodwill as a result of the Merger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="us-gaap_GoodwillAcquiredDuringPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US" id="id_10184323_2439342_1_1">Goodwill and Intangible Assets Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US" id="id_10184323_2439342_2_1">Goodwill and Intangible Assets Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_10184323_2439343_1_1">Goodwill and Intangible Assets Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_10184323_2439343_2_1">Goodwill and Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_GoodwillAndIntangibleAssetsLineItems" xlink:label="sls_GoodwillAndIntangibleAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_GoodwillAndIntangibleAssetsLineItems_lbl" xml:lang="en-US" id="id_10184323_2485072_3_1">Goodwill And Intangible Assets [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_GoodwillAndIntangibleAssetsLineItems_lbl" xml:lang="en-US" id="id_10184323_2485072_1_1">Goodwill And Intangible Assets [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_GoodwillAndIntangibleAssetsLineItems_lbl" xml:lang="en-US" id="id_10184323_2485072_2_1">Goodwill And Intangible Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_GoodwillAndIntangibleAssetsLineItems" xlink:to="sls_GoodwillAndIntangibleAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_GoodwillAndIntangibleAssetsTable" xlink:label="sls_GoodwillAndIntangibleAssetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_GoodwillAndIntangibleAssetsTable_lbl" xml:lang="en-US" id="id_10184323_2646737_3_1">Goodwill And Intangible Assets [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_GoodwillAndIntangibleAssetsTable_lbl" xml:lang="en-US" id="id_10184323_2646737_1_1">Goodwill And Intangible Assets [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_GoodwillAndIntangibleAssetsTable_lbl" xml:lang="en-US" id="id_10184323_2646737_2_1">Goodwill And Intangible Assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_GoodwillAndIntangibleAssetsTable" xlink:to="sls_GoodwillAndIntangibleAssetsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_GoodwillPolicyTextBlock" xlink:label="sls_GoodwillPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_GoodwillPolicyTextBlock_lbl" xml:lang="en-US" id="id_10184323_2764653_3_1">Goodwill [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_GoodwillPolicyTextBlock_lbl" xml:lang="en-US" id="id_10184323_2764653_1_1">Goodwill [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_GoodwillPolicyTextBlock_lbl" xml:lang="en-US" id="id_10184323_2764653_2_1">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_GoodwillPolicyTextBlock" xlink:to="sls_GoodwillPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_GrossProceedsPercentage" xlink:label="sls_GrossProceedsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_GrossProceedsPercentage_lbl" xml:lang="en-US" id="id_10184323_3050066_3_1">Gross proceeds percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_GrossProceedsPercentage_lbl" xml:lang="en-US" id="id_10184323_3050066_1_1">Gross Proceeds Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_GrossProceedsPercentage_lbl" xml:lang="en-US" id="id_10184323_3050066_2_1">Gross offering proceeds percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_GrossProceedsPercentage" xlink:to="sls_GrossProceedsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_HudsonBayAgreementMember" xlink:label="sls_HudsonBayAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_HudsonBayAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3050035_3_1">Hudson Bay Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_HudsonBayAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3050035_1_1">Hudson Bay Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_HudsonBayAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3050035_2_1">Hudson Bay Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_HudsonBayAgreementMember" xlink:to="sls_HudsonBayAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits" xlink:label="sls_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits_lbl" xml:lang="en-US" id="id_10184323_3053955_3_1">Impact on tax provision from unrecognized tax benefits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits_lbl" xml:lang="en-US" id="id_10184323_3053955_1_1">Impact On Tax Provision From Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits_lbl" xml:lang="en-US" id="id_10184323_3053955_2_1">Impact on tax provision from unrecognized tax benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits" xlink:to="sls_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_Incentivefeepercentageequaltogrossvaluepaidbypurchaserincash" xlink:label="sls_Incentivefeepercentageequaltogrossvaluepaidbypurchaserincash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_Incentivefeepercentageequaltogrossvaluepaidbypurchaserincash_lbl" xml:lang="en-US" id="id_10184323_3049608_3_1">Incentive fee percentage equal to gross value paid by purchaser in cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_Incentivefeepercentageequaltogrossvaluepaidbypurchaserincash_lbl" xml:lang="en-US" id="id_10184323_3049608_1_1">IncentiveFeePercentageEqualToGrossValuePaidByPurchaserInCash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_Incentivefeepercentageequaltogrossvaluepaidbypurchaserincash_lbl" xml:lang="en-US" id="id_10184323_3049608_2_1">Incentive fee percentage equal to gross value paid by purchaser in cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_Incentivefeepercentageequaltogrossvaluepaidbypurchaserincash" xlink:to="sls_Incentivefeepercentageequaltogrossvaluepaidbypurchaserincash_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_IncentiveFeePercentageEqualToPostMoneyMarketValue" xlink:label="sls_IncentiveFeePercentageEqualToPostMoneyMarketValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_IncentiveFeePercentageEqualToPostMoneyMarketValue_lbl" xml:lang="en-US" id="id_10184323_3049609_3_1">Incentive fee percentage equal to post - money market value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_IncentiveFeePercentageEqualToPostMoneyMarketValue_lbl" xml:lang="en-US" id="id_10184323_3049609_1_1">Incentive Fee Percentage Equal To Post Money Market Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_IncentiveFeePercentageEqualToPostMoneyMarketValue_lbl" xml:lang="en-US" id="id_10184323_3049609_2_1">Incentive fee percentage equal to post - money market value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_IncentiveFeePercentageEqualToPostMoneyMarketValue" xlink:to="sls_IncentiveFeePercentageEqualToPostMoneyMarketValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" id="id_10184323_2440070_1_1">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" id="id_10184323_2440070_2_1">U.S.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" id="id_10184323_2440071_1_1">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" id="id_10184323_2440071_6_1">Loss before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" id="id_10184323_2440073_1_1">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" id="id_10184323_2440073_2_1">Non - U.S.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_10184323_2440732_1_1">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_10184323_2440732_2_1">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_10184323_2440346_1_1">Income Statement Location [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_10184323_2440346_2_1">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_10184323_2440347_1_1">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_10184323_2440347_2_1">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" id="id_10184323_2440733_1_1">Income Tax Authority [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" id="id_10184323_2440733_2_1">Income Tax Authority [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" id="id_10184323_2440348_1_1">Income Tax Authority [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" id="id_10184323_2440348_2_1">Income Tax Authority [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" id="id_10184323_2440737_1_1">Income Tax Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" id="id_10184323_2440737_2_1">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" id="id_10184323_2440154_1_1">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" id="id_10184323_2440154_2_1">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_10184323_2440740_1_1">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_10184323_2440740_2_1">Income tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_10184323_2440740_6_1">Total income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" id="id_10184323_2440361_1_1">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" id="id_10184323_2440361_2_1">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" id="id_10184323_2440761_1_1">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" id="id_10184323_2440761_2_1">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" id="id_10184323_2440632_1_1">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" id="id_10184323_2440632_2_1">Accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="id_10184323_2440238_1_1">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="id_10184323_2440238_2_1">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" id="id_10184323_2440814_1_1">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" id="id_10184323_2440814_14_1">Prepaid expenses and other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xml:lang="en-US" id="id_10184323_2440822_1_1">Increase (Decrease) in Restricted Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xml:lang="en-US" id="id_10184323_2440822_14_1">Change in restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US" id="id_10184323_2440463_1_1">Indefinite-Lived Intangible Assets (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US" id="id_10184323_2440463_2_1">Intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_IntangibleAssetsIndefinitelivedPolicyPolicyTextBlock" xlink:label="sls_IntangibleAssetsIndefinitelivedPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_IntangibleAssetsIndefinitelivedPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_10184323_3049350_3_1">Intangible assets indefinite-lived policy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_IntangibleAssetsIndefinitelivedPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_10184323_3049350_1_1">Intangible Assets Indefinite-lived Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_IntangibleAssetsIndefinitelivedPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_10184323_3049350_2_1">Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_IntangibleAssetsIndefinitelivedPolicyPolicyTextBlock" xlink:to="sls_IntangibleAssetsIndefinitelivedPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US" id="id_10184323_2440995_1_1">Interest Income (Expense), Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US" id="id_10184323_2440995_14_1">Interest expense, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US" id="id_10184323_2441446_1_1">Interest Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US" id="id_10184323_2441446_2_1">Cumulative accrued interest paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestReceivable_lbl" xml:lang="en-US" id="id_10184323_2441457_1_1">Interest Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestReceivable_lbl" xml:lang="en-US" id="id_10184323_2441457_2_1">Senior secured debenture additional interest amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivable" xlink:to="us-gaap_InterestReceivable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract" xlink:label="us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_lbl" xml:lang="en-US" id="id_10184323_2441046_1_1">Investment Company, Capital Share Transactions [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_lbl" xml:lang="en-US" id="id_10184323_2441046_2_1">Investment Company, Capital Share Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract" xlink:to="us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xml:lang="en-US" id="id_10184323_2441321_1_1">Investments, All Other Investments [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xml:lang="en-US" id="id_10184323_2441321_2_1">Investments, All Other Investments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_IssuanceofCommonStockforLitigationSettlement" xlink:label="sls_IssuanceofCommonStockforLitigationSettlement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_IssuanceofCommonStockforLitigationSettlement_lbl" xml:lang="en-US" id="id_10184323_2884880_3_1">Issuance of Common Stock for Litigation Settlement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_IssuanceofCommonStockforLitigationSettlement_lbl" xml:lang="en-US" id="id_10184323_2884880_1_1">Issuanceof Common Stockfor Litigation Settlement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_IssuanceofCommonStockforLitigationSettlement_lbl" xml:lang="en-US" id="id_10184323_2884880_2_1">Issuance of Common Stock for Litigation Settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_IssuanceofCommonStockforLitigationSettlement" xlink:to="sls_IssuanceofCommonStockforLitigationSettlement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US" id="id_10184323_2441703_1_1">Issuance of Stock and Warrants for Services or Claims</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US" id="id_10184323_2441703_2_1">Fair value of shares issued for incentive fee to Equilibria</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_IssuanceOfWarrantsTerm" xlink:label="sls_IssuanceOfWarrantsTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_IssuanceOfWarrantsTerm_lbl" xml:lang="en-US" id="id_10184323_3049463_3_1">Conversion of warrants term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_IssuanceOfWarrantsTerm_lbl" xml:lang="en-US" id="id_10184323_3049463_1_1">Issuance Of Warrants Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_IssuanceOfWarrantsTerm_lbl" xml:lang="en-US" id="id_10184323_3049463_2_1">Conversion of warrants term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_IssuanceOfWarrantsTerm" xlink:to="sls_IssuanceOfWarrantsTerm_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_JGBCaymanNewtonLtdMember" xlink:label="sls_JGBCaymanNewtonLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_JGBCaymanNewtonLtdMember_lbl" xml:lang="en-US" id="id_10184323_3054137_3_1">JGB (Cayman) Newton, Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_JGBCaymanNewtonLtdMember_lbl" xml:lang="en-US" id="id_10184323_3054137_1_1">JGB (Cayman) Newton, Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_JGBCaymanNewtonLtdMember_lbl" xml:lang="en-US" id="id_10184323_3054137_2_1">JGB (Cayman) Newton, Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_JGBCaymanNewtonLtdMember" xlink:to="sls_JGBCaymanNewtonLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US" id="id_10184323_2442260_1_1">Operating Leases, Rent Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US" id="id_10184323_2442260_2_1">Rental expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:label="us-gaap_LegalCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalCostsPolicyTextBlock_lbl" xml:lang="en-US" id="id_10184323_2442269_1_1">Legal Costs, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LegalCostsPolicyTextBlock_lbl" xml:lang="en-US" id="id_10184323_2442269_2_1">Legal Fees and Insurance Recoveries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalCostsPolicyTextBlock" xlink:to="us-gaap_LegalCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" id="id_10184323_2442110_1_1">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" id="id_10184323_2442110_6_1">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_10184323_2442111_1_1">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_10184323_2442111_6_1">Total liabilities and stockholders' equity (deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_10184323_2441888_1_1">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_10184323_2441888_2_1">LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_10184323_2442451_1_1">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_10184323_2442451_6_1">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_10184323_2442113_1_1">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_10184323_2442113_2_1">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" id="id_10184323_2442452_1_1">Financial and Nonfinancial Liabilities, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" id="id_10184323_2442452_6_1">Total liabilities measured and recorded at fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" id="id_10184323_2442114_1_1">Liabilities, Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" id="id_10184323_2442114_2_1">Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LiabilitiesUnderTerminationAgreementPayableInCash" xlink:label="sls_LiabilitiesUnderTerminationAgreementPayableInCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_LiabilitiesUnderTerminationAgreementPayableInCash_lbl" xml:lang="en-US" id="id_10184323_3049439_3_1">Liabilities under termination agreement payable in cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_LiabilitiesUnderTerminationAgreementPayableInCash_lbl" xml:lang="en-US" id="id_10184323_3049439_1_1">Liabilities Under Termination Agreement Payable In Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_LiabilitiesUnderTerminationAgreementPayableInCash_lbl" xml:lang="en-US" id="id_10184323_3049439_2_1">Liabilities under termination agreements agreed to pay in cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_LiabilitiesUnderTerminationAgreementPayableInCash" xlink:to="sls_LiabilitiesUnderTerminationAgreementPayableInCash_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseAgreementAmendmentDate" xlink:label="sls_LicenseAgreementAmendmentDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_LicenseAgreementAmendmentDate_lbl" xml:lang="en-US" id="id_10184323_3049358_3_1">License agreement amendment date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_LicenseAgreementAmendmentDate_lbl" xml:lang="en-US" id="id_10184323_3049358_1_1">License Agreement Amendment Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_LicenseAgreementAmendmentDate_lbl" xml:lang="en-US" id="id_10184323_3049358_2_1">License agreement amendment date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_LicenseAgreementAmendmentDate" xlink:to="sls_LicenseAgreementAmendmentDate_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseAgreementAmendmentExtendedDateForFinancing" xlink:label="sls_LicenseAgreementAmendmentExtendedDateForFinancing"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_LicenseAgreementAmendmentExtendedDateForFinancing_lbl" xml:lang="en-US" id="id_10184323_3049362_3_1">License agreement amendment extended date for financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_LicenseAgreementAmendmentExtendedDateForFinancing_lbl" xml:lang="en-US" id="id_10184323_3049362_1_1">License Agreement Amendment Extended Date For Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_LicenseAgreementAmendmentExtendedDateForFinancing_lbl" xml:lang="en-US" id="id_10184323_3049362_2_1">License agreement amendment extended date for financing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_LicenseAgreementAmendmentExtendedDateForFinancing" xlink:to="sls_LicenseAgreementAmendmentExtendedDateForFinancing_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseAgreementDate" xlink:label="sls_LicenseAgreementDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_LicenseAgreementDate_lbl" xml:lang="en-US" id="id_10184323_2620563_3_1">License agreement date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_LicenseAgreementDate_lbl" xml:lang="en-US" id="id_10184323_2620563_1_1">License Agreement Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_LicenseAgreementDate_lbl" xml:lang="en-US" id="id_10184323_2620563_2_1">License agreement date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_LicenseAgreementDate" xlink:to="sls_LicenseAgreementDate_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseAgreementDateSecondAmended" xlink:label="sls_LicenseAgreementDateSecondAmended"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_LicenseAgreementDateSecondAmended_lbl" xml:lang="en-US" id="id_10184323_2620604_3_1">License Agreement Date Second Amended</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_LicenseAgreementDateSecondAmended_lbl" xml:lang="en-US" id="id_10184323_2620604_1_1">License Agreement Date Second Amended</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_LicenseAgreementDateSecondAmended_lbl" xml:lang="en-US" id="id_10184323_2620604_2_1">License agreement amendment extended date for financing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_LicenseAgreementDateSecondAmended" xlink:to="sls_LicenseAgreementDateSecondAmended_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseAgreementEffectiveDate" xlink:label="sls_LicenseAgreementEffectiveDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_LicenseAgreementEffectiveDate_lbl" xml:lang="en-US" id="id_10184323_2621295_3_1">License agreement effective date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_LicenseAgreementEffectiveDate_lbl" xml:lang="en-US" id="id_10184323_2621295_1_1">License Agreement Effective Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_LicenseAgreementEffectiveDate_lbl" xml:lang="en-US" id="id_10184323_2621295_2_1">License agreement effective date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_LicenseAgreementEffectiveDate" xlink:to="sls_LicenseAgreementEffectiveDate_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseAgreementExpirationTerm" xlink:label="sls_LicenseAgreementExpirationTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_LicenseAgreementExpirationTerm_lbl" xml:lang="en-US" id="id_10184323_2642068_3_1">License agreement expiration term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_LicenseAgreementExpirationTerm_lbl" xml:lang="en-US" id="id_10184323_2642068_1_1">License Agreement Expiration Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_LicenseAgreementExpirationTerm_lbl" xml:lang="en-US" id="id_10184323_2642068_2_1">License agreement expiration term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_LicenseAgreementExpirationTerm" xlink:to="sls_LicenseAgreementExpirationTerm_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseAgreementMember" xlink:label="sls_LicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_LicenseAgreementMember_lbl" xml:lang="en-US" id="id_10184323_2659749_3_1">License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_LicenseAgreementMember_lbl" xml:lang="en-US" id="id_10184323_2659749_1_1">License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_LicenseAgreementMember_lbl" xml:lang="en-US" id="id_10184323_2659749_2_1">The University of Texas M. D. Anderson Cancer Center and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. License Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_LicenseAgreementMember" xlink:to="sls_LicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseAgreementOutstandingAmountPayable" xlink:label="sls_LicenseAgreementOutstandingAmountPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_LicenseAgreementOutstandingAmountPayable_lbl" xml:lang="en-US" id="id_10184323_3049367_3_1">License agreement outstanding amount payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_LicenseAgreementOutstandingAmountPayable_lbl" xml:lang="en-US" id="id_10184323_3049367_1_1">License Agreement Outstanding Amount Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_LicenseAgreementOutstandingAmountPayable_lbl" xml:lang="en-US" id="id_10184323_3049367_2_1">License agreement outstanding amount payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_LicenseAgreementOutstandingAmountPayable" xlink:to="sls_LicenseAgreementOutstandingAmountPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseAgreementTerminationDate" xlink:label="sls_LicenseAgreementTerminationDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_LicenseAgreementTerminationDate_lbl" xml:lang="en-US" id="id_10184323_2620815_3_1">License Agreement Termination Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_LicenseAgreementTerminationDate_lbl" xml:lang="en-US" id="id_10184323_2620815_1_1">License Agreement Termination Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_LicenseAgreementTerminationDate_lbl" xml:lang="en-US" id="id_10184323_2620815_2_1">License agreement termination date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_LicenseAgreementTerminationDate" xlink:to="sls_LicenseAgreementTerminationDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xml:lang="en-US" id="id_10184323_2442380_1_1">License Agreement Terms [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xml:lang="en-US" id="id_10184323_2442380_2_1">License Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAgreementTermsMember" xlink:to="us-gaap_LicenseAgreementTermsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseAmendmentWaiverAndShareIssuanceAgreementMember" xlink:label="sls_LicenseAmendmentWaiverAndShareIssuanceAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_LicenseAmendmentWaiverAndShareIssuanceAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3049264_3_1">License amendment waiver and share issuance agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_LicenseAmendmentWaiverAndShareIssuanceAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3049264_1_1">License Amendment Waiver And Share Issuance Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_LicenseAmendmentWaiverAndShareIssuanceAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3049264_2_1">First MSK Amendment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_LicenseAmendmentWaiverAndShareIssuanceAgreementMember" xlink:to="sls_LicenseAmendmentWaiverAndShareIssuanceAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseAndCollaborationAgreementsLineItems" xlink:label="sls_LicenseAndCollaborationAgreementsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_LicenseAndCollaborationAgreementsLineItems_lbl" xml:lang="en-US" id="id_10184323_2461216_3_1">License And Collaboration Agreements [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_LicenseAndCollaborationAgreementsLineItems_lbl" xml:lang="en-US" id="id_10184323_2461216_1_1">License And Collaboration Agreements [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_LicenseAndCollaborationAgreementsLineItems_lbl" xml:lang="en-US" id="id_10184323_2461216_2_1">License And Collaboration Agreements [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_LicenseAndCollaborationAgreementsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseAndCollaborationAgreementsTable" xlink:label="sls_LicenseAndCollaborationAgreementsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_LicenseAndCollaborationAgreementsTable_lbl" xml:lang="en-US" id="id_10184323_2648095_3_1">License And Collaboration Agreements [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_LicenseAndCollaborationAgreementsTable_lbl" xml:lang="en-US" id="id_10184323_2648095_1_1">License And Collaboration Agreements [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_LicenseAndCollaborationAgreementsTable_lbl" xml:lang="en-US" id="id_10184323_2648095_2_1">License And Collaboration Agreements [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_LicenseAndCollaborationAgreementsTable" xlink:to="sls_LicenseAndCollaborationAgreementsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseCosts" xlink:label="us-gaap_LicenseCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseCosts_lbl" xml:lang="en-US" id="id_10184323_2442477_1_1">License Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseCosts_lbl" xml:lang="en-US" id="id_10184323_2442477_2_1">License fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseCosts" xlink:to="us-gaap_LicenseCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseTerminationFeesPaid" xlink:label="sls_LicenseTerminationFeesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_LicenseTerminationFeesPaid_lbl" xml:lang="en-US" id="id_10184323_3049436_3_1">License termination fees paid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_LicenseTerminationFeesPaid_lbl" xml:lang="en-US" id="id_10184323_3049436_1_1">License Termination Fees Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_LicenseTerminationFeesPaid_lbl" xml:lang="en-US" id="id_10184323_3049436_2_1">Termination fees paid in cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_LicenseTerminationFeesPaid" xlink:to="sls_LicenseTerminationFeesPaid_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LincolnParkAgreementMember" xlink:label="sls_LincolnParkAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_LincolnParkAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3051912_3_1">Lincoln park agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_LincolnParkAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3051912_1_1">Lincoln Park Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_LincolnParkAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3051912_2_1">Lincoln Park Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_LincolnParkAgreementMember" xlink:to="sls_LincolnParkAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xml:lang="en-US" id="id_10184323_2442536_1_1">Line of Credit Facility, Interest Rate During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xml:lang="en-US" id="id_10184323_2442536_2_1">Line of credit, interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditMember_lbl" xml:lang="en-US" id="id_10184323_2442444_1_1">Line of Credit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditMember_lbl" xml:lang="en-US" id="id_10184323_2442444_2_1">Line of Credit [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditMember" xlink:to="us-gaap_LineOfCreditMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiquidationBasisOfAccountingTextBlock" xlink:label="us-gaap_LiquidationBasisOfAccountingTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiquidationBasisOfAccountingTextBlock_lbl" xml:lang="en-US" id="id_10184323_2442545_1_1">Liquidation Basis of Accounting [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiquidationBasisOfAccountingTextBlock_lbl" xml:lang="en-US" id="id_10184323_2442545_2_1">Liquidity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiquidationBasisOfAccountingTextBlock" xlink:to="us-gaap_LiquidationBasisOfAccountingTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LiquidityAbstract" xlink:label="sls_LiquidityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_LiquidityAbstract_lbl" xml:lang="en-US" id="id_10184323_2454621_3_1">Liquidity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_LiquidityAbstract_lbl" xml:lang="en-US" id="id_10184323_2454621_1_1">Liquidity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_LiquidityAbstract_lbl" xml:lang="en-US" id="id_10184323_2454621_2_1">Liquidity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_LiquidityAbstract" xlink:to="sls_LiquidityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LiquidityLineItems" xlink:label="sls_LiquidityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_LiquidityLineItems_lbl" xml:lang="en-US" id="id_10184323_2468401_3_1">Liquidity [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_LiquidityLineItems_lbl" xml:lang="en-US" id="id_10184323_2468401_1_1">Liquidity [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_LiquidityLineItems_lbl" xml:lang="en-US" id="id_10184323_2468401_2_1">Liquidity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_LiquidityLineItems" xlink:to="sls_LiquidityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LiquidityTable" xlink:label="sls_LiquidityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_LiquidityTable_lbl" xml:lang="en-US" id="id_10184323_2648062_3_1">Liquidity [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_LiquidityTable_lbl" xml:lang="en-US" id="id_10184323_2648062_1_1">Liquidity [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_LiquidityTable_lbl" xml:lang="en-US" id="id_10184323_2648062_2_1">Liquidity [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_LiquidityTable" xlink:to="sls_LiquidityTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="us-gaap_LitigationCaseAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationCaseAxis_lbl" xml:lang="en-US" id="id_10184323_2442667_1_1">Litigation Case [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LitigationCaseAxis_lbl" xml:lang="en-US" id="id_10184323_2442667_2_1">Litigation Case [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="us-gaap_LitigationCaseAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationCaseTypeDomain_lbl" xml:lang="en-US" id="id_10184323_2443103_1_1">Litigation Case [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LitigationCaseTypeDomain_lbl" xml:lang="en-US" id="id_10184323_2443103_2_1">Litigation Case [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationCaseTypeDomain" xlink:to="us-gaap_LitigationCaseTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationReserveCurrent" xlink:label="us-gaap_LitigationReserveCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationReserveCurrent_lbl" xml:lang="en-US" id="id_10184323_2442668_1_1">Estimated Litigation Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LitigationReserveCurrent_lbl" xml:lang="en-US" id="id_10184323_2442668_2_1">Litigation settlement payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationReserveCurrent" xlink:to="us-gaap_LitigationReserveCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty_lbl" xml:lang="en-US" id="id_10184323_2443104_1_1">Litigation Settlement, Amount Awarded from Other Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty_lbl" xml:lang="en-US" id="id_10184323_2443104_2_1">Litigation settlement received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:to="us-gaap_LitigationSettlementAmountAwardedFromOtherParty_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl" xml:lang="en-US" id="id_10184323_2443105_1_1">Litigation Settlement, Amount Awarded to Other Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl" xml:lang="en-US" id="id_10184323_2443105_2_1">Total settlements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LitigationSettlementAmountCash" xlink:label="sls_LitigationSettlementAmountCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_LitigationSettlementAmountCash_lbl" xml:lang="en-US" id="id_10184323_2503019_3_1">Litigation Settlement Amount, Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_LitigationSettlementAmountCash_lbl" xml:lang="en-US" id="id_10184323_2503019_1_1">Litigation Settlement Amount Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_LitigationSettlementAmountCash_lbl" xml:lang="en-US" id="id_10184323_2503019_2_1">Paid by the company or their insurance carriers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_LitigationSettlementAmountCash" xlink:to="sls_LitigationSettlementAmountCash_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LitigationSettlementIssuanceofCommonStockShares" xlink:label="sls_LitigationSettlementIssuanceofCommonStockShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_LitigationSettlementIssuanceofCommonStockShares_lbl" xml:lang="en-US" id="id_10184323_2884886_3_1">Litigation Settlement, Issuance of Common Stock, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_LitigationSettlementIssuanceofCommonStockShares_lbl" xml:lang="en-US" id="id_10184323_2884886_1_1">Litigation Settlement Issuance of Common Stock Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_LitigationSettlementIssuanceofCommonStockShares_lbl" xml:lang="en-US" id="id_10184323_2884886_2_1">Issuance of common stock shares for litigation settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_LitigationSettlementIssuanceofCommonStockShares" xlink:to="sls_LitigationSettlementIssuanceofCommonStockShares_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationStatusAxis_lbl" xml:lang="en-US" id="id_10184323_2442228_1_1">Litigation Status [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LitigationStatusAxis_lbl" xml:lang="en-US" id="id_10184323_2442228_2_1">Litigation Status [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationStatusDomain_lbl" xml:lang="en-US" id="id_10184323_2442670_1_1">Litigation Status [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LitigationStatusDomain_lbl" xml:lang="en-US" id="id_10184323_2442670_2_1">Litigation Status [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationStatusDomain" xlink:to="us-gaap_LitigationStatusDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LoansReceivableNet" xlink:label="us-gaap_LoansReceivableNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansReceivableNet_lbl" xml:lang="en-US" id="id_10184323_2442938_1_1">Loans Receivable, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansReceivableNet_lbl" xml:lang="en-US" id="id_10184323_2442938_2_1">Loans receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansReceivableNet" xlink:to="us-gaap_LoansReceivableNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" id="id_10184323_2442628_1_1">Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" id="id_10184323_2442628_2_1">Borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" id="id_10184323_2442628_6_1">Total long-term debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" id="id_10184323_2442628_12_1">Outstanding indebtedness</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US" id="id_10184323_2442635_1_1">Long-term Debt, Current Maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US" id="id_10184323_2442635_2_1">Current portion of long-term debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US" id="id_10184323_2442635_12_1">Current portion of Senior Secured Debenture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" id="id_10184323_2443184_1_1">Long-term Debt, Excluding Current Maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" id="id_10184323_2443184_2_1">Long-term debt, net of current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" id="id_10184323_2443184_12_1">Non-current portion of Senior Secured Debenture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US" id="id_10184323_2442761_1_1">Long-term Debt, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US" id="id_10184323_2442761_2_1">Long-term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" id="id_10184323_2443186_1_1">Long-term Debt, Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" id="id_10184323_2443186_2_1">Long-term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermLineOfCredit" xlink:label="us-gaap_LongTermLineOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermLineOfCredit_lbl" xml:lang="en-US" id="id_10184323_2443188_1_1">Long-term Line of Credit, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermLineOfCredit_lbl" xml:lang="en-US" id="id_10184323_2443188_2_1">Line of credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLineOfCredit" xlink:to="us-gaap_LongTermLineOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermLoansPayable_lbl" xml:lang="en-US" id="id_10184323_2442651_1_1">Loans Payable, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermLoansPayable_lbl" xml:lang="en-US" id="id_10184323_2442651_2_1">Loans payable due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansPayable" xlink:to="us-gaap_LongTermLoansPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" id="id_10184323_2442987_1_1">Loss Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" id="id_10184323_2442987_2_1">Loss Contingencies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US" id="id_10184323_2443203_1_1">Loss Contingencies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US" id="id_10184323_2443203_2_1">Loss Contingencies [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ManagementFeeExpense" xlink:label="us-gaap_ManagementFeeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ManagementFeeExpense_lbl" xml:lang="en-US" id="id_10184323_2442828_1_1">Management Fee Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ManagementFeeExpense_lbl" xml:lang="en-US" id="id_10184323_2442828_2_1">Management fees incurred and paid in cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManagementFeeExpense" xlink:to="us-gaap_ManagementFeeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ManagementFeePayable" xlink:label="us-gaap_ManagementFeePayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ManagementFeePayable_lbl" xml:lang="en-US" id="id_10184323_2443044_1_1">Management Fee Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ManagementFeePayable_lbl" xml:lang="en-US" id="id_10184323_2443044_2_1">Outstanding fee payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManagementFeePayable" xlink:to="us-gaap_ManagementFeePayable_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss" xlink:label="sls_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss_lbl" xml:lang="en-US" id="id_10184323_3051946_3_1">Maximum indefinite-lived deferred tax liability as percentage of net operating loss.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss_lbl" xml:lang="en-US" id="id_10184323_3051946_1_1">Maximum Indefinite-Lived Deferred Tax Liability As Percentage Of Net Operating Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss_lbl" xml:lang="en-US" id="id_10184323_3051946_2_1">Maximum indefinite-lived deferred tax liability as percentage of net operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss" xlink:to="sls_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" id="id_10184323_2442860_1_1">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" id="id_10184323_2442860_2_1">Maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MaximumNumberOfDaysToMakePayments" xlink:label="sls_MaximumNumberOfDaysToMakePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_MaximumNumberOfDaysToMakePayments_lbl" xml:lang="en-US" id="id_10184323_3049404_3_1">Maximum number of days to make payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_MaximumNumberOfDaysToMakePayments_lbl" xml:lang="en-US" id="id_10184323_3049404_1_1">Maximum Number Of Days To Make Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_MaximumNumberOfDaysToMakePayments_lbl" xml:lang="en-US" id="id_10184323_3049404_2_1">Maximum number of days to make payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_MaximumNumberOfDaysToMakePayments" xlink:to="sls_MaximumNumberOfDaysToMakePayments_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember" xlink:label="sls_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3049698_3_1">MSK A&amp;R License Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3049698_1_1">Memorial Sloan Kettering Cancer Center Amended And Restated License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3049698_2_1">MSK A&amp;R License Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember" xlink:to="sls_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MemorialSloanKetteringCancerCenterMember" xlink:label="sls_MemorialSloanKetteringCancerCenterMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_MemorialSloanKetteringCancerCenterMember_lbl" xml:lang="en-US" id="id_10184323_2684763_3_1">Memorial Sloan Kettering Cancer Center [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_MemorialSloanKetteringCancerCenterMember_lbl" xml:lang="en-US" id="id_10184323_2684763_1_1">Memorial Sloan Kettering Cancer Center [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_MemorialSloanKetteringCancerCenterMember_lbl" xml:lang="en-US" id="id_10184323_2684763_2_1">MSK</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_MemorialSloanKetteringCancerCenterMember" xlink:to="sls_MemorialSloanKetteringCancerCenterMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MilestoneFeePaymentsUponCommencementOfClinicalTrials" xlink:label="sls_MilestoneFeePaymentsUponCommencementOfClinicalTrials"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_MilestoneFeePaymentsUponCommencementOfClinicalTrials_lbl" xml:lang="en-US" id="id_10184323_2591766_3_1">Milestone fee payments upon commencement of clinical trials.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_MilestoneFeePaymentsUponCommencementOfClinicalTrials_lbl" xml:lang="en-US" id="id_10184323_2591766_1_1">Milestone Fee Payments Upon Commencement Of Clinical Trials</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_MilestoneFeePaymentsUponCommencementOfClinicalTrials_lbl" xml:lang="en-US" id="id_10184323_2591766_2_1">Milestone payments due upon commencement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_MilestoneFeePaymentsUponCommencementOfClinicalTrials" xlink:to="sls_MilestoneFeePaymentsUponCommencementOfClinicalTrials_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MilestonePayment" xlink:label="sls_MilestonePayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_MilestonePayment_lbl" xml:lang="en-US" id="id_10184323_2502567_3_1">MIlestone Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_MilestonePayment_lbl" xml:lang="en-US" id="id_10184323_2502567_1_1">Milestone Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_MilestonePayment_lbl" xml:lang="en-US" id="id_10184323_2502567_2_1">Milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_MilestonePayment" xlink:to="sls_MilestonePayment_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MilestonePayments" xlink:label="sls_MilestonePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_MilestonePayments_lbl" xml:lang="en-US" id="id_10184323_2580962_3_1">Milestone payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_MilestonePayments_lbl" xml:lang="en-US" id="id_10184323_2580962_1_1">Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_MilestonePayments_lbl" xml:lang="en-US" id="id_10184323_2580962_2_1">Milestone payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_MilestonePayments" xlink:to="sls_MilestonePayments_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MilestonePaymentsReceivable" xlink:label="sls_MilestonePaymentsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_MilestonePaymentsReceivable_lbl" xml:lang="en-US" id="id_10184323_2527245_3_1">Milestone Payments Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_MilestonePaymentsReceivable_lbl" xml:lang="en-US" id="id_10184323_2527245_1_1">Milestone Payments Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_MilestonePaymentsReceivable_lbl" xml:lang="en-US" id="id_10184323_2527245_2_1">Milestone payments receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_MilestonePaymentsReceivable" xlink:to="sls_MilestonePaymentsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MinimumAnnualRoyaltyPayment" xlink:label="sls_MinimumAnnualRoyaltyPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_MinimumAnnualRoyaltyPayment_lbl" xml:lang="en-US" id="id_10184323_2582145_3_1">Minimum annual royalty payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_MinimumAnnualRoyaltyPayment_lbl" xml:lang="en-US" id="id_10184323_2582145_1_1">Minimum Annual Royalty Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_MinimumAnnualRoyaltyPayment_lbl" xml:lang="en-US" id="id_10184323_2582145_2_1">Minimum royalty payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_MinimumAnnualRoyaltyPayment" xlink:to="sls_MinimumAnnualRoyaltyPayment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" id="id_10184323_2443301_1_1">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" id="id_10184323_2443301_2_1">Minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MinimumOwnershipPercentageOfOutstandingSharesOfCommonStockForConversionToTakeEffect" xlink:label="sls_MinimumOwnershipPercentageOfOutstandingSharesOfCommonStockForConversionToTakeEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_MinimumOwnershipPercentageOfOutstandingSharesOfCommonStockForConversionToTakeEffect_lbl" xml:lang="en-US" id="id_10184323_3050652_3_1">Minimum Ownership Percentage Of Outstanding Shares Of Common Stock For Conversion To Take Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_MinimumOwnershipPercentageOfOutstandingSharesOfCommonStockForConversionToTakeEffect_lbl" xml:lang="en-US" id="id_10184323_3050652_1_1">Minimum Ownership Percentage Of Outstanding Shares Of Common Stock For Conversion To Take Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_MinimumOwnershipPercentageOfOutstandingSharesOfCommonStockForConversionToTakeEffect_lbl" xml:lang="en-US" id="id_10184323_3050652_2_1">Minimum percentage outstanding Common Stock to effect conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_MinimumOwnershipPercentageOfOutstandingSharesOfCommonStockForConversionToTakeEffect" xlink:to="sls_MinimumOwnershipPercentageOfOutstandingSharesOfCommonStockForConversionToTakeEffect_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MinimumPercentageOfTradingPriceOfCommonStock" xlink:label="sls_MinimumPercentageOfTradingPriceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_MinimumPercentageOfTradingPriceOfCommonStock_lbl" xml:lang="en-US" id="id_10184323_2787533_3_1">Minimum Percentage Of Trading Price Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_MinimumPercentageOfTradingPriceOfCommonStock_lbl" xml:lang="en-US" id="id_10184323_2787533_1_1">Minimum Percentage Of Trading Price Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_MinimumPercentageOfTradingPriceOfCommonStock_lbl" xml:lang="en-US" id="id_10184323_2787533_2_1">Minimum percentage of daily trading volume of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_MinimumPercentageOfTradingPriceOfCommonStock" xlink:to="sls_MinimumPercentageOfTradingPriceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MinimumProceedRequiredUnderQualifiedOffering" xlink:label="sls_MinimumProceedRequiredUnderQualifiedOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_MinimumProceedRequiredUnderQualifiedOffering_lbl" xml:lang="en-US" id="id_10184323_3050110_3_1">Minimum proceed required under qualified offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_MinimumProceedRequiredUnderQualifiedOffering_lbl" xml:lang="en-US" id="id_10184323_3050110_1_1">Minimum Proceed Required Under Qualified Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_MinimumProceedRequiredUnderQualifiedOffering_lbl" xml:lang="en-US" id="id_10184323_3050110_2_1">Minimum proceed required under qualified offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_MinimumProceedRequiredUnderQualifiedOffering" xlink:to="sls_MinimumProceedRequiredUnderQualifiedOffering_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US" id="id_10184323_2443090_1_1">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US" id="id_10184323_2443090_2_1">Ownership percentage by non-controlling owners</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US" id="id_10184323_2443090_12_1">Ownership percentage by Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US" id="id_10184323_2443540_1_1">Noncontrolling Interest, Ownership Percentage by Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US" id="id_10184323_2443540_2_1">Ownership percentage by parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ModifiedTermsOnLoanPercentageMaximum" xlink:label="sls_ModifiedTermsOnLoanPercentageMaximum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ModifiedTermsOnLoanPercentageMaximum_lbl" xml:lang="en-US" id="id_10184323_3053944_3_1">Modified terms on loan percentage maximum.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ModifiedTermsOnLoanPercentageMaximum_lbl" xml:lang="en-US" id="id_10184323_3053944_1_1">Modified terms on loan percentage maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ModifiedTermsOnLoanPercentageMaximum_lbl" xml:lang="en-US" id="id_10184323_3053944_2_1">Modified terms on loan percentage maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ModifiedTermsOnLoanPercentageMaximum" xlink:to="sls_ModifiedTermsOnLoanPercentageMaximum_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MskLicenseAgreementMember" xlink:label="sls_MskLicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_MskLicenseAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3049599_3_1">MSK License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_MskLicenseAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3049599_1_1">MSK License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_MskLicenseAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3049599_2_1">MSK License Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_MskLicenseAgreementMember" xlink:to="sls_MskLicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" id="id_10184323_2443831_1_1">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" id="id_10184323_2443831_6_1">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="id_10184323_2444054_1_1">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="id_10184323_2444054_2_1">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" id="id_10184323_2443642_1_1">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" id="id_10184323_2443642_6_1">Net cash provided by (used in) investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" id="id_10184323_2444056_1_1">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" id="id_10184323_2444056_2_1">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" id="id_10184323_2444057_1_1">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" id="id_10184323_2444057_6_1">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_10184323_2443644_1_1">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_10184323_2443644_2_1">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_10184323_2444061_1_1">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_10184323_2444061_2_1">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_10184323_2444061_6_1">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" id="id_10184323_2443515_1_1">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" id="id_10184323_2443515_6_1">Loss attributable to common stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_NeuvaxMember" xlink:label="sls_NeuvaxMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_NeuvaxMember_lbl" xml:lang="en-US" id="id_10184323_3050369_3_1">NeuVax [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_NeuvaxMember_lbl" xml:lang="en-US" id="id_10184323_3050369_1_1">NeuVax [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_NeuvaxMember_lbl" xml:lang="en-US" id="id_10184323_3050369_2_1">NeuVax [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_NeuvaxMember" xlink:to="sls_NeuvaxMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_10184323_2444191_1_1">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_10184323_2444191_2_1">Recently Issued Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_NonCashResearchAndDevelopmentExpense" xlink:label="sls_NonCashResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_NonCashResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_10184323_2517543_3_1">Non cash research and development expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_NonCashResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_10184323_2517543_1_1">Non Cash Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_NonCashResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_10184323_2517543_2_1">Non-cash research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_NonCashResearchAndDevelopmentExpense" xlink:to="sls_NonCashResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_NonrefundableMilestonePayments" xlink:label="sls_NonrefundableMilestonePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_NonrefundableMilestonePayments_lbl" xml:lang="en-US" id="id_10184323_3049602_3_1">Non-refundable Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_NonrefundableMilestonePayments_lbl" xml:lang="en-US" id="id_10184323_3049602_1_1">Non-refundable Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_NonrefundableMilestonePayments_lbl" xml:lang="en-US" id="id_10184323_3049602_2_1">Non refundable milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_NonrefundableMilestonePayments" xlink:to="sls_NonrefundableMilestonePayments_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_NonrefundableSalesMilestonePayments" xlink:label="sls_NonrefundableSalesMilestonePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_NonrefundableSalesMilestonePayments_lbl" xml:lang="en-US" id="id_10184323_3049605_3_1">Non-refundable Sales Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_NonrefundableSalesMilestonePayments_lbl" xml:lang="en-US" id="id_10184323_3049605_1_1">Non-refundable Sales Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_NonrefundableSalesMilestonePayments_lbl" xml:lang="en-US" id="id_10184323_3049605_2_1">Non refundable sales milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_NonrefundableSalesMilestonePayments" xlink:to="sls_NonrefundableSalesMilestonePayments_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_NumberofDaysAveragedforExercisePrice" xlink:label="sls_NumberofDaysAveragedforExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_NumberofDaysAveragedforExercisePrice_lbl" xml:lang="en-US" id="id_10184323_2884895_3_1">Exercise price is based on the average closing price over this many trading days up to the date of the grant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_NumberofDaysAveragedforExercisePrice_lbl" xml:lang="en-US" id="id_10184323_2884895_1_1">Numberof Days Averagedfor Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_NumberofDaysAveragedforExercisePrice_lbl" xml:lang="en-US" id="id_10184323_2884895_2_1">Number of days average for exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_NumberofDaysAveragedforExercisePrice" xlink:to="sls_NumberofDaysAveragedforExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_NumberOfInstallmentsToMakePayments" xlink:label="sls_NumberOfInstallmentsToMakePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_NumberOfInstallmentsToMakePayments_lbl" xml:lang="en-US" id="id_10184323_3049403_3_1">Number of installments to make payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_NumberOfInstallmentsToMakePayments_lbl" xml:lang="en-US" id="id_10184323_3049403_1_1">Number Of Installments To Make Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_NumberOfInstallmentsToMakePayments_lbl" xml:lang="en-US" id="id_10184323_3049403_2_1">Number of installments to make payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_NumberOfInstallmentsToMakePayments" xlink:to="sls_NumberOfInstallmentsToMakePayments_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_NumberOfSignificantShareholders" xlink:label="sls_NumberOfSignificantShareholders"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_NumberOfSignificantShareholders_lbl" xml:lang="en-US" id="id_10184323_3049455_3_1">Number of significant shareholders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_NumberOfSignificantShareholders_lbl" xml:lang="en-US" id="id_10184323_3049455_1_1">Number Of Significant Shareholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_NumberOfSignificantShareholders_lbl" xml:lang="en-US" id="id_10184323_3049455_2_1">Number of significant shareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_NumberOfSignificantShareholders" xlink:to="sls_NumberOfSignificantShareholders_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_NumberOfStockOptionsGranted" xlink:label="sls_NumberOfStockOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_NumberOfStockOptionsGranted_lbl" xml:lang="en-US" id="id_10184323_2629920_3_1">Number Of Stock Options Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_NumberOfStockOptionsGranted_lbl" xml:lang="en-US" id="id_10184323_2629920_1_1">Number Of Stock Options Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_NumberOfStockOptionsGranted_lbl" xml:lang="en-US" id="id_10184323_2629920_2_1">Stock options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_NumberOfStockOptionsGranted" xlink:to="sls_NumberOfStockOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_NumberOfTranches" xlink:label="sls_NumberOfTranches"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_NumberOfTranches_lbl" xml:lang="en-US" id="id_10184323_2630732_3_1">Number Of Tranches</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_NumberOfTranches_lbl" xml:lang="en-US" id="id_10184323_2630732_1_1">Number Of Tranches</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_NumberOfTranches_lbl" xml:lang="en-US" id="id_10184323_2630732_2_1">Number of tranches</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_NumberOfTranches" xlink:to="sls_NumberOfTranches_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="id_10184323_2444430_1_1">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="id_10184323_2444430_2_1">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_10184323_2444189_1_1">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_10184323_2444189_6_1">Total operating expenses and loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" id="id_10184323_2444621_1_1">Operating Leases, Future Minimum Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" id="id_10184323_2444621_6_1">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" id="id_10184323_2444839_1_1">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" id="id_10184323_2444839_2_1">2018</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" id="id_10184323_2444624_1_1">Operating Leases, Future Minimum Payments, Due in Two Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" id="id_10184323_2444624_2_1">2019</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage" xlink:label="sls_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage_lbl" xml:lang="en-US" id="id_10184323_3051945_3_1">Operating loss and tax credit carryforwards limitations on use minimum change in ownership percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage_lbl" xml:lang="en-US" id="id_10184323_3051945_1_1">Operating Loss And Tax Credit Carryforwards Limitations On Use Minimum Change In Ownership Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage_lbl" xml:lang="en-US" id="id_10184323_3051945_2_1">Change in ownership percentage, minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage" xlink:to="sls_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUsePeriodOfOwnershipPercentage" xlink:label="sls_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUsePeriodOfOwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUsePeriodOfOwnershipPercentage_lbl" xml:lang="en-US" id="id_10184323_3051947_3_1">Operating loss and tax credit carryforwards limitations on use period of ownership percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUsePeriodOfOwnershipPercentage_lbl" xml:lang="en-US" id="id_10184323_3051947_1_1">Operating Loss And Tax Credit Carryforwards Limitations On Use Period Of Ownership Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUsePeriodOfOwnershipPercentage_lbl" xml:lang="en-US" id="id_10184323_3051947_2_1">Period of ownership percentage change</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUsePeriodOfOwnershipPercentage" xlink:to="sls_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUsePeriodOfOwnershipPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_OperatingLossCarryforwardsExpirationYearRangeEnd" xlink:label="sls_OperatingLossCarryforwardsExpirationYearRangeEnd"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_OperatingLossCarryforwardsExpirationYearRangeEnd_lbl" xml:lang="en-US" id="id_10184323_2622221_3_1">Operating Loss Carryforwards Expiration Year Range End</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_OperatingLossCarryforwardsExpirationYearRangeEnd_lbl" xml:lang="en-US" id="id_10184323_2622221_1_1">Operating Loss Carryforwards Expiration Year Range End</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_OperatingLossCarryforwardsExpirationYearRangeEnd_lbl" xml:lang="en-US" id="id_10184323_2622221_2_1">Operating loss carryforwards expire end year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_OperatingLossCarryforwardsExpirationYearRangeEnd" xlink:to="sls_OperatingLossCarryforwardsExpirationYearRangeEnd_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_OperatingLossCarryforwardsExpirationYearRangeStart" xlink:label="sls_OperatingLossCarryforwardsExpirationYearRangeStart"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_OperatingLossCarryforwardsExpirationYearRangeStart_lbl" xml:lang="en-US" id="id_10184323_2621484_3_1">Operating Loss Carryforwards Expiration Year Range Start</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_OperatingLossCarryforwardsExpirationYearRangeStart_lbl" xml:lang="en-US" id="id_10184323_2621484_1_1">Operating Loss Carryforwards Expiration Year Range Start</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_OperatingLossCarryforwardsExpirationYearRangeStart_lbl" xml:lang="en-US" id="id_10184323_2621484_2_1">Operating loss carryforwards expire start year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_OperatingLossCarryforwardsExpirationYearRangeStart" xlink:to="sls_OperatingLossCarryforwardsExpirationYearRangeStart_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock" xlink:label="us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_lbl" xml:lang="en-US" id="id_10184323_2444462_1_1">Option Indexed to Issuer's Equity, Description [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_lbl" xml:lang="en-US" id="id_10184323_2444462_2_1">Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock" xlink:to="us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_OrganizationAndDescriptionOfBusinessLineItems" xlink:label="sls_OrganizationAndDescriptionOfBusinessLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_OrganizationAndDescriptionOfBusinessLineItems_lbl" xml:lang="en-US" id="id_10184323_2485457_3_1">Organization And Description Of Business [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_OrganizationAndDescriptionOfBusinessLineItems_lbl" xml:lang="en-US" id="id_10184323_2485457_1_1">Organization And Description Of Business [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_OrganizationAndDescriptionOfBusinessLineItems_lbl" xml:lang="en-US" id="id_10184323_2485457_2_1">Organization And Description Of Business [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="sls_OrganizationAndDescriptionOfBusinessLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_OrganizationAndDescriptionOfBusinessTable" xlink:label="sls_OrganizationAndDescriptionOfBusinessTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_OrganizationAndDescriptionOfBusinessTable_lbl" xml:lang="en-US" id="id_10184323_2647614_3_1">Organization And Description Of Business [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_OrganizationAndDescriptionOfBusinessTable_lbl" xml:lang="en-US" id="id_10184323_2647614_1_1">Organization And Description Of Business [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_OrganizationAndDescriptionOfBusinessTable_lbl" xml:lang="en-US" id="id_10184323_2647614_2_1">Organization And Description Of Business [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_OrganizationAndDescriptionOfBusinessTable" xlink:to="sls_OrganizationAndDescriptionOfBusinessTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_10184323_2444466_1_1">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_10184323_2444466_2_1">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_10184323_2444310_1_1">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_10184323_2444310_2_1">Basis of Presentation and Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_10184323_2444315_1_1">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_10184323_2444315_2_1">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_OtherGalenaWarrantIssuesAccountedForAsLiabilitiesMember" xlink:label="sls_OtherGalenaWarrantIssuesAccountedForAsLiabilitiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_OtherGalenaWarrantIssuesAccountedForAsLiabilitiesMember_lbl" xml:lang="en-US" id="id_10184323_3054786_3_1">Other Galena Warrant Issues Accounted for as Liabilities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_OtherGalenaWarrantIssuesAccountedForAsLiabilitiesMember_lbl" xml:lang="en-US" id="id_10184323_3054786_1_1">Other Galena Warrant Issues Accounted for as Liabilities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_OtherGalenaWarrantIssuesAccountedForAsLiabilitiesMember_lbl" xml:lang="en-US" id="id_10184323_3054786_2_1">Other Galena Warrant Issues Accounted for as Liabilities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_OtherGalenaWarrantIssuesAccountedForAsLiabilitiesMember" xlink:to="sls_OtherGalenaWarrantIssuesAccountedForAsLiabilitiesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xml:lang="en-US" id="id_10184323_2444549_1_1">Other Liabilities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xml:lang="en-US" id="id_10184323_2444549_2_1">Other Liabilities Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US" id="id_10184323_2444561_1_1">Other Nonoperating Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US" id="id_10184323_2444561_2_1">Other expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_OtherWarrantIssuesMember" xlink:label="sls_OtherWarrantIssuesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_OtherWarrantIssuesMember_lbl" xml:lang="en-US" id="id_10184323_2884905_3_1">Other Warrant Issues [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_OtherWarrantIssuesMember_lbl" xml:lang="en-US" id="id_10184323_2884905_1_1">Other Warrant Issues [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_OtherWarrantIssuesMember_lbl" xml:lang="en-US" id="id_10184323_2884905_2_1">Galena other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_OtherWarrantIssuesMember" xlink:to="sls_OtherWarrantIssuesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US" id="id_10184323_2445272_1_1">Paid-in-Kind Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US" id="id_10184323_2445272_2_1">Non-cash interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock" xlink:label="sls_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_10184323_2884907_3_1">Patents And Patent Application Costs Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_10184323_2884907_1_1">Patents And Patent Application Costs Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_10184323_2884907_2_1">Patents and Patent Application Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock" xlink:to="sls_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" id="id_10184323_2445297_1_1">Payables and Accruals [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" id="id_10184323_2445297_2_1">Payables and Accruals [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentForManagementFee" xlink:label="us-gaap_PaymentForManagementFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentForManagementFee_lbl" xml:lang="en-US" id="id_10184323_2445690_1_1">Payment for Management Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentForManagementFee_lbl" xml:lang="en-US" id="id_10184323_2445690_2_1">Quarterly management fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentForManagementFee" xlink:to="us-gaap_PaymentForManagementFee_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="us-gaap_PaymentsForLegalSettlements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForLegalSettlements_lbl" xml:lang="en-US" id="id_10184323_2445495_1_1">Payments for Legal Settlements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForLegalSettlements_lbl" xml:lang="en-US" id="id_10184323_2445495_2_1">Payments for legal settlements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForLegalSettlements" xlink:to="us-gaap_PaymentsForLegalSettlements_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards" xlink:label="sls_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_lbl" xml:lang="en-US" id="id_10184323_2796441_3_1">Percentage Increase In Number Of Shares Available For Future Issuance Under Stock Based Awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_lbl" xml:lang="en-US" id="id_10184323_2796441_1_1">Percentage Increase In Number Of Shares Available For Future Issuance Under Stock Based Awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_lbl" xml:lang="en-US" id="id_10184323_2796441_2_1">Percentage increase in number of shares available for future issuance under stock based awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards" xlink:to="sls_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PercentageOfFullyDilutedShareCapital" xlink:label="sls_PercentageOfFullyDilutedShareCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_PercentageOfFullyDilutedShareCapital_lbl" xml:lang="en-US" id="id_10184323_3050162_3_1">Percentage Of Fully Diluted Share Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_PercentageOfFullyDilutedShareCapital_lbl" xml:lang="en-US" id="id_10184323_3050162_1_1">Percentage Of Fully Diluted Share Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_PercentageOfFullyDilutedShareCapital_lbl" xml:lang="en-US" id="id_10184323_3050162_2_1">Percentage of fully diluted share capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_PercentageOfFullyDilutedShareCapital" xlink:to="sls_PercentageOfFullyDilutedShareCapital_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PercentageOfFullyDilutedShareCapitalOwned" xlink:label="sls_PercentageOfFullyDilutedShareCapitalOwned"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_PercentageOfFullyDilutedShareCapitalOwned_lbl" xml:lang="en-US" id="id_10184323_3049248_3_1">Percentage of fully diluted share capital owned.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_PercentageOfFullyDilutedShareCapitalOwned_lbl" xml:lang="en-US" id="id_10184323_3049248_1_1">Percentage of Fully Diluted Share Capital Owned</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_PercentageOfFullyDilutedShareCapitalOwned_lbl" xml:lang="en-US" id="id_10184323_3049248_2_1">Percentage of fully diluted common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_PercentageOfFullyDilutedShareCapitalOwned" xlink:to="sls_PercentageOfFullyDilutedShareCapitalOwned_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PercentageOfMarketAveragePriceOfShares" xlink:label="sls_PercentageOfMarketAveragePriceOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_PercentageOfMarketAveragePriceOfShares_lbl" xml:lang="en-US" id="id_10184323_2789372_3_1">Percentage of market average price of shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_PercentageOfMarketAveragePriceOfShares_lbl" xml:lang="en-US" id="id_10184323_2789372_1_1">Percentage of Market Average Price of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_PercentageOfMarketAveragePriceOfShares_lbl" xml:lang="en-US" id="id_10184323_2789372_2_1">Percentage of market price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_PercentageOfMarketAveragePriceOfShares" xlink:to="sls_PercentageOfMarketAveragePriceOfShares_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PercentageOfOwnershipOutstandingShareCapital" xlink:label="sls_PercentageOfOwnershipOutstandingShareCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_PercentageOfOwnershipOutstandingShareCapital_lbl" xml:lang="en-US" id="id_10184323_3049629_3_1">Percentage of ownership outstanding share capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_PercentageOfOwnershipOutstandingShareCapital_lbl" xml:lang="en-US" id="id_10184323_3049629_1_1">Percentage Of Ownership Outstanding Share Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_PercentageOfOwnershipOutstandingShareCapital_lbl" xml:lang="en-US" id="id_10184323_3049629_2_1">Percentage of ownership outstanding share capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_PercentageOfOwnershipOutstandingShareCapital" xlink:to="sls_PercentageOfOwnershipOutstandingShareCapital_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PercentageOfReductionInRiskRecurrence" xlink:label="sls_PercentageOfReductionInRiskRecurrence"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_PercentageOfReductionInRiskRecurrence_lbl" xml:lang="en-US" id="id_10184323_3053461_3_1">Percentage of reduction in risk recurrence.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_PercentageOfReductionInRiskRecurrence_lbl" xml:lang="en-US" id="id_10184323_3053461_1_1">Percentage Of Reduction In Risk Recurrence</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_PercentageOfReductionInRiskRecurrence_lbl" xml:lang="en-US" id="id_10184323_3053461_2_1">Percentage of reduction in risk recurrence</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_PercentageOfReductionInRiskRecurrence" xlink:to="sls_PercentageOfReductionInRiskRecurrence_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" id="id_10184323_2445234_1_1">Plan Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" id="id_10184323_2445234_2_1">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" id="id_10184323_2445571_1_1">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" id="id_10184323_2445571_2_1">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="us-gaap_PreferredStockConversionBasis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConversionBasis_lbl" xml:lang="en-US" id="id_10184323_2445469_1_1">Preferred Stock, Conversion Basis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConversionBasis_lbl" xml:lang="en-US" id="id_10184323_2445469_2_1">Convertible Preferred Stock, conversion basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConversionBasis" xlink:to="us-gaap_PreferredStockConversionBasis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_10184323_2445650_1_1">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_10184323_2445650_2_1">Convertible Preferred Stock, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_10184323_2445650_12_1">Preferred stock, par value (USD per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="id_10184323_2445652_1_1">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="id_10184323_2445652_2_1">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="id_10184323_2445856_1_1">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="id_10184323_2445856_2_1">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="id_10184323_2445934_1_1">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="id_10184323_2445934_2_1">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="id_10184323_2445656_1_1">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="id_10184323_2445656_2_1">Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredUnitsDescription" xlink:label="us-gaap_PreferredUnitsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredUnitsDescription_lbl" xml:lang="en-US" id="id_10184323_2446117_1_1">Preferred Units, Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredUnitsDescription_lbl" xml:lang="en-US" id="id_10184323_2446117_2_1">Preferred Units, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredUnitsDescription" xlink:to="us-gaap_PreferredUnitsDescription_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PremergerSecurityholdersMember" xlink:label="sls_PremergerSecurityholdersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_PremergerSecurityholdersMember_lbl" xml:lang="en-US" id="id_10184323_3049254_3_1">Pre-Merger Securityholders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_PremergerSecurityholdersMember_lbl" xml:lang="en-US" id="id_10184323_3049254_1_1">Pre-Merger Securityholders [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_PremergerSecurityholdersMember_lbl" xml:lang="en-US" id="id_10184323_3049254_2_1">Pre-Merger Securityholders [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_PremergerSecurityholdersMember" xlink:to="sls_PremergerSecurityholdersMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" id="id_10184323_2445671_1_1">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" id="id_10184323_2445671_2_1">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PreviousRoyaltyObligationPercentage" xlink:label="sls_PreviousRoyaltyObligationPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_PreviousRoyaltyObligationPercentage_lbl" xml:lang="en-US" id="id_10184323_2781851_3_1">Previous Royalty Obligation Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_PreviousRoyaltyObligationPercentage_lbl" xml:lang="en-US" id="id_10184323_2781851_1_1">Previous Royalty Obligation Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_PreviousRoyaltyObligationPercentage_lbl" xml:lang="en-US" id="id_10184323_2781851_2_1">Royalty rate to be eliminated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_PreviousRoyaltyObligationPercentage" xlink:to="sls_PreviousRoyaltyObligationPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PreviousRoyaltyOnNetSalesValue" xlink:label="sls_PreviousRoyaltyOnNetSalesValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_PreviousRoyaltyOnNetSalesValue_lbl" xml:lang="en-US" id="id_10184323_3053532_3_1">Previous royalty on net sales value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_PreviousRoyaltyOnNetSalesValue_lbl" xml:lang="en-US" id="id_10184323_3053532_1_1">Previous Royalty On Net Sales Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_PreviousRoyaltyOnNetSalesValue_lbl" xml:lang="en-US" id="id_10184323_3053532_2_1">Previous annual net sales for royalty rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_PreviousRoyaltyOnNetSalesValue" xlink:to="sls_PreviousRoyaltyOnNetSalesValue_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PrivatePlacementFirstClosingMember" xlink:label="sls_PrivatePlacementFirstClosingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_PrivatePlacementFirstClosingMember_lbl" xml:lang="en-US" id="id_10184323_3050114_3_1">Private placement first closing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_PrivatePlacementFirstClosingMember_lbl" xml:lang="en-US" id="id_10184323_3050114_1_1">Private Placement First Closing [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_PrivatePlacementFirstClosingMember_lbl" xml:lang="en-US" id="id_10184323_3050114_2_1">Private Placement First Closing [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_PrivatePlacementFirstClosingMember" xlink:to="sls_PrivatePlacementFirstClosingMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PrivatePlacementSecondClosingMember" xlink:label="sls_PrivatePlacementSecondClosingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_PrivatePlacementSecondClosingMember_lbl" xml:lang="en-US" id="id_10184323_3050115_3_1">Private placement second closing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_PrivatePlacementSecondClosingMember_lbl" xml:lang="en-US" id="id_10184323_3050115_1_1">Private Placement Second Closing [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_PrivatePlacementSecondClosingMember_lbl" xml:lang="en-US" id="id_10184323_3050115_2_1">Private Placement Second Closing [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_PrivatePlacementSecondClosingMember" xlink:to="sls_PrivatePlacementSecondClosingMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PrivateSELLASMember" xlink:label="sls_PrivateSELLASMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_PrivateSELLASMember_lbl" xml:lang="en-US" id="id_10184323_3049260_3_1">Private SELLAS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_PrivateSELLASMember_lbl" xml:lang="en-US" id="id_10184323_3049260_1_1">Private SELLAS [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_PrivateSELLASMember_lbl" xml:lang="en-US" id="id_10184323_3049260_2_1">Private SELLAS [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_PrivateSELLASMember" xlink:to="sls_PrivateSELLASMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" id="id_10184323_2446173_1_1">Proceeds from Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" id="id_10184323_2446173_2_1">Issued convertible term note to related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" id="id_10184323_2446173_12_1">Net proceeds from issuance of convertible debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="id_10184323_2446016_1_1">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="id_10184323_2446016_2_1">Net proceeds from issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US" id="id_10184323_2446368_1_1">Proceeds from Issuance of Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US" id="id_10184323_2446368_2_1">Net proceeds from issuance of long-term debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ProceedsfromIssuanceofLongtermDebtandWarrantsNet" xlink:label="sls_ProceedsfromIssuanceofLongtermDebtandWarrantsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ProceedsfromIssuanceofLongtermDebtandWarrantsNet_lbl" xml:lang="en-US" id="id_10184323_2884911_3_1">Proceeds from issuance of long-term debt and warrants, net.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ProceedsfromIssuanceofLongtermDebtandWarrantsNet_lbl" xml:lang="en-US" id="id_10184323_2884911_1_1">Proceedsfrom Issuanceof Longterm Debtand Warrants Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ProceedsfromIssuanceofLongtermDebtandWarrantsNet_lbl" xml:lang="en-US" id="id_10184323_2884911_2_1">Proceeds from issuance of debt and warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ProceedsfromIssuanceofLongtermDebtandWarrantsNet" xlink:to="sls_ProceedsfromIssuanceofLongtermDebtandWarrantsNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_lbl" xml:lang="en-US" id="id_10184323_2446194_1_1">Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_lbl" xml:lang="en-US" id="id_10184323_2446194_2_1">Convertible preferred stock and warrant purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" id="id_10184323_2446195_1_1">Proceeds from Issuance of Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" id="id_10184323_2446195_2_1">Aggregate gross proceeds from private placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US" id="id_10184323_2446560_1_1">Proceeds from Lines of Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US" id="id_10184323_2446560_2_1">Line of credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ProceedsFromMilestoneBasedPayments" xlink:label="sls_ProceedsFromMilestoneBasedPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ProceedsFromMilestoneBasedPayments_lbl" xml:lang="en-US" id="id_10184323_2587246_3_1">Proceeds From Milestone Based Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ProceedsFromMilestoneBasedPayments_lbl" xml:lang="en-US" id="id_10184323_2587246_1_1">Proceeds From Milestone Based Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ProceedsFromMilestoneBasedPayments_lbl" xml:lang="en-US" id="id_10184323_2587246_2_1">Proceeds from milestone</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ProceedsFromMilestoneBasedPayments" xlink:to="sls_ProceedsFromMilestoneBasedPayments_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:label="us-gaap_ProductionRelatedImpairmentsOrCharges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductionRelatedImpairmentsOrCharges_lbl" xml:lang="en-US" id="id_10184323_2446077_1_1">Production Related Impairments or Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductionRelatedImpairmentsOrCharges_lbl" xml:lang="en-US" id="id_10184323_2446077_2_1">Impairment charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:to="us-gaap_ProductionRelatedImpairmentsOrCharges_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ProjectManagementFeesPayable" xlink:label="sls_ProjectManagementFeesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ProjectManagementFeesPayable_lbl" xml:lang="en-US" id="id_10184323_3049438_3_1">Project management fees payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ProjectManagementFeesPayable_lbl" xml:lang="en-US" id="id_10184323_3049438_1_1">Project Management Fees Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ProjectManagementFeesPayable_lbl" xml:lang="en-US" id="id_10184323_3049438_2_1">Project management fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ProjectManagementFeesPayable" xlink:to="sls_ProjectManagementFeesPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PurchaseAgreementMember" xlink:label="sls_PurchaseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_PurchaseAgreementMember_lbl" xml:lang="en-US" id="id_10184323_2737197_3_1">Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_PurchaseAgreementMember_lbl" xml:lang="en-US" id="id_10184323_2737197_1_1">Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_PurchaseAgreementMember_lbl" xml:lang="en-US" id="id_10184323_2737197_2_1">Purchase Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_PurchaseAgreementMember" xlink:to="sls_PurchaseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_QualifiedOfferingDescription" xlink:label="sls_QualifiedOfferingDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_QualifiedOfferingDescription_lbl" xml:lang="en-US" id="id_10184323_3050111_3_1">Qualified offering description.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_QualifiedOfferingDescription_lbl" xml:lang="en-US" id="id_10184323_3050111_1_1">Qualified Offering Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_QualifiedOfferingDescription_lbl" xml:lang="en-US" id="id_10184323_3050111_2_1">Qualified offering description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_QualifiedOfferingDescription" xlink:to="sls_QualifiedOfferingDescription_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_QualifiedPublicOfferingMember" xlink:label="sls_QualifiedPublicOfferingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_QualifiedPublicOfferingMember_lbl" xml:lang="en-US" id="id_10184323_2731166_3_1">Qualified Public Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_QualifiedPublicOfferingMember_lbl" xml:lang="en-US" id="id_10184323_2731166_1_1">Qualified Public Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_QualifiedPublicOfferingMember_lbl" xml:lang="en-US" id="id_10184323_2731166_2_1">Qualified Public Offering [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_QualifiedPublicOfferingMember" xlink:to="sls_QualifiedPublicOfferingMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_QuiTamMember" xlink:label="sls_QuiTamMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_QuiTamMember_lbl" xml:lang="en-US" id="id_10184323_3048903_3_1">Qui Tam [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_QuiTamMember_lbl" xml:lang="en-US" id="id_10184323_3048903_1_1">Qui Tam [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_QuiTamMember_lbl" xml:lang="en-US" id="id_10184323_3048903_2_1">Qui Tam [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_QuiTamMember" xlink:to="sls_QuiTamMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="id_10184323_2447194_1_1">Range [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="id_10184323_2447194_2_1">Range [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" id="id_10184323_2446806_1_1">Range [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" id="id_10184323_2446806_2_1">Range [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivableTypeDomain_lbl" xml:lang="en-US" id="id_10184323_2447240_1_1">Receivable [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivableTypeDomain_lbl" xml:lang="en-US" id="id_10184323_2447240_2_1">Receivable [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_ReceivableTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xml:lang="en-US" id="id_10184323_2446866_1_1">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xml:lang="en-US" id="id_10184323_2446866_2_1">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" id="id_10184323_2446918_1_1">Related Party [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" id="id_10184323_2446918_2_1">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US" id="id_10184323_2446922_1_1">Related Party Transaction [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US" id="id_10184323_2446922_2_1">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" id="id_10184323_2446925_1_1">Related Party Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" id="id_10184323_2446925_2_1">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" id="id_10184323_2447475_1_1">Related Party Transactions [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" id="id_10184323_2447475_2_1">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" id="id_10184323_2446928_1_1">Related Party [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" id="id_10184323_2446928_2_1">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_10184323_2447307_1_1">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_10184323_2447307_2_1">Related Party Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US" id="id_10184323_2446937_1_1">Repayments of Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US" id="id_10184323_2446937_2_1">Redemption of debt through cash payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US" id="id_10184323_2446937_14_1">Principal payments on convertible debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US" id="id_10184323_2447320_1_1">Repayments of Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US" id="id_10184323_2447320_2_1">Principal amount paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt" xlink:label="us-gaap_RepaymentsOfSecuredDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfSecuredDebt_lbl" xml:lang="en-US" id="id_10184323_2446943_1_1">Repayments of Secured Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfSecuredDebt_lbl" xml:lang="en-US" id="id_10184323_2446943_2_1">Cash paid to satisfy debt redemption</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfSecuredDebt" xlink:to="us-gaap_RepaymentsOfSecuredDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" id="id_10184323_2446948_1_1">Counterparty Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" id="id_10184323_2446948_2_1">Counterparty Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US" id="id_10184323_2447148_1_1">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US" id="id_10184323_2447148_2_1">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US" id="id_10184323_2447339_1_1">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US" id="id_10184323_2447339_2_1">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_10184323_2447511_1_1">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_10184323_2447511_2_1">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_10184323_2447511_12_1">Research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_10184323_2447512_1_1">Research and Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_10184323_2447512_2_1">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" id="id_10184323_2447513_1_1">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" id="id_10184323_2447513_2_1">Research and Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xml:lang="en-US" id="id_10184323_2447514_1_1">Research and Development in Process</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xml:lang="en-US" id="id_10184323_2447514_2_1">Fair value of shares issued in exchange for research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ResearchFundingCosts" xlink:label="sls_ResearchFundingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ResearchFundingCosts_lbl" xml:lang="en-US" id="id_10184323_3049326_3_1">Research funding costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ResearchFundingCosts_lbl" xml:lang="en-US" id="id_10184323_3049326_1_1">Research Funding Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ResearchFundingCosts_lbl" xml:lang="en-US" id="id_10184323_3049326_2_1">Research funding costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ResearchFundingCosts" xlink:to="sls_ResearchFundingCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="us-gaap_RestatementAdjustmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestatementAdjustmentMember_lbl" xml:lang="en-US" id="id_10184323_2447520_1_1">Restatement Adjustment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestatementAdjustmentMember_lbl" xml:lang="en-US" id="id_10184323_2447520_2_1">Restatement Adjustment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestatementAdjustmentMember" xlink:to="us-gaap_RestatementAdjustmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_10184323_2447522_1_1">Restricted Cash and Cash Equivalents, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_10184323_2447522_2_1">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_10184323_2447522_12_1">Restricted cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_RestrictedCashAndCashEquivalentsFairValueDisclosure" xlink:label="sls_RestrictedCashAndCashEquivalentsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_RestrictedCashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" id="id_10184323_2577982_3_1">Restricted cash and cash equivalents, fair value disclosure.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_RestrictedCashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" id="id_10184323_2577982_1_1">Restricted Cash And Cash Equivalents Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_RestrictedCashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" id="id_10184323_2577982_2_1">Restricted cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_RestrictedCashAndCashEquivalentsFairValueDisclosure" xlink:to="sls_RestrictedCashAndCashEquivalentsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="us-gaap_RestrictedStockExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockExpense_lbl" xml:lang="en-US" id="id_10184323_2447180_1_1">Restricted Stock or Unit Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockExpense_lbl" xml:lang="en-US" id="id_10184323_2447180_2_1">Compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockExpense" xlink:to="us-gaap_RestrictedStockExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" id="id_10184323_2447533_1_1">Restricted Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" id="id_10184323_2447533_2_1">Unvested restricted stock awards [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_RestrictedStockUnitsMember" xlink:label="sls_RestrictedStockUnitsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_RestrictedStockUnitsMember_lbl" xml:lang="en-US" id="id_10184323_2679417_3_1">Restricted Stock Units [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_RestrictedStockUnitsMember_lbl" xml:lang="en-US" id="id_10184323_2679417_1_1">Restricted Stock Units [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_RestrictedStockUnitsMember_lbl" xml:lang="en-US" id="id_10184323_2679417_2_1">Restricted Stock Units [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_RestrictedStockUnitsMember" xlink:to="sls_RestrictedStockUnitsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" id="id_10184323_2447365_1_1">Restricted Stock Units (RSUs) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" id="id_10184323_2447365_2_1">Restricted stock units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember" xlink:label="sls_RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember_lbl" xml:lang="en-US" id="id_10184323_3049145_3_1">Restricted stock units with time-based and performance-based conditions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember_lbl" xml:lang="en-US" id="id_10184323_3049145_1_1">Restricted Stock Units With Time Based And Performance Based Conditions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember_lbl" xml:lang="en-US" id="id_10184323_3049145_2_1">RSUs with Time-Based and Performance-Based Conditions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember" xlink:to="sls_RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_RestrictedStockUnitsWithTimeBasedConditionsMember" xlink:label="sls_RestrictedStockUnitsWithTimeBasedConditionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_RestrictedStockUnitsWithTimeBasedConditionsMember_lbl" xml:lang="en-US" id="id_10184323_3049142_3_1">Restricted stock units with time-based conditions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_RestrictedStockUnitsWithTimeBasedConditionsMember_lbl" xml:lang="en-US" id="id_10184323_3049142_1_1">Restricted Stock Units With Time Based Conditions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_RestrictedStockUnitsWithTimeBasedConditionsMember_lbl" xml:lang="en-US" id="id_10184323_3049142_2_1">RSUs with Time Based Conditions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_RestrictedStockUnitsWithTimeBasedConditionsMember" xlink:to="sls_RestrictedStockUnitsWithTimeBasedConditionsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_10184323_2448061_1_1">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_10184323_2448061_2_1">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" id="id_10184323_2447681_1_1">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" id="id_10184323_2447681_2_1">Retained Earnings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_RoyaltyOnNetSalesValue" xlink:label="sls_RoyaltyOnNetSalesValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_RoyaltyOnNetSalesValue_lbl" xml:lang="en-US" id="id_10184323_2558645_3_1">Royalty on net sales value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_RoyaltyOnNetSalesValue_lbl" xml:lang="en-US" id="id_10184323_2558645_1_1">Royalty On Net Sales Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_RoyaltyOnNetSalesValue_lbl" xml:lang="en-US" id="id_10184323_2558645_2_1">Annual net sales for royalty rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_RoyaltyOnNetSalesValue" xlink:to="sls_RoyaltyOnNetSalesValue_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_RoyaltyRatePercentage" xlink:label="sls_RoyaltyRatePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_RoyaltyRatePercentage_lbl" xml:lang="en-US" id="id_10184323_2793427_3_1">Royalty Rate Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_RoyaltyRatePercentage_lbl" xml:lang="en-US" id="id_10184323_2793427_1_1">Royalty Rate Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_RoyaltyRatePercentage_lbl" xml:lang="en-US" id="id_10184323_2793427_2_1">Royalty rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_RoyaltyRatePercentage" xlink:to="sls_RoyaltyRatePercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SabbyAgreementMember" xlink:label="sls_SabbyAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_SabbyAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3050036_3_1">Sabby Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_SabbyAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3050036_1_1">Sabby Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_SabbyAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3050036_2_1">Sabby Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_SabbyAgreementMember" xlink:to="sls_SabbyAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" id="id_10184323_2447774_1_1">Sale of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" id="id_10184323_2447774_2_1">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US" id="id_10184323_2448141_1_1">Sale of Stock, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US" id="id_10184323_2448141_2_1">Aggregate intrinsic values outstanding and exercisable stock option Calculated based on the closing price of the Company's common stock as reported on the NASDAQ Capital Market</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioForecastMember_lbl" xml:lang="en-US" id="id_10184323_2447800_1_1">Scenario, Forecast [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScenarioForecastMember_lbl" xml:lang="en-US" id="id_10184323_2447800_2_1">Scenario, Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioForecastMember" xlink:to="us-gaap_ScenarioForecastMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="us-gaap_ScenarioPreviouslyReportedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioPreviouslyReportedMember_lbl" xml:lang="en-US" id="id_10184323_2448174_1_1">Scenario, Previously Reported [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScenarioPreviouslyReportedMember_lbl" xml:lang="en-US" id="id_10184323_2448174_2_1">Scenario, Previously Reported [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioPreviouslyReportedMember" xlink:to="us-gaap_ScenarioPreviouslyReportedMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" id="id_10184323_2447936_1_1">Scenario, Unspecified [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" id="id_10184323_2447936_2_1">Scenario, Unspecified [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2448176_1_1">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2448176_2_1">Schedule of Accrued Expenses and Other Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="id_10184323_2448340_1_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="id_10184323_2448340_2_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_10184323_2447807_1_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_10184323_2447807_2_1">Summary of Potentially Dilutive Securities Outstanding Excluded from Computation of Diluted Weighted Average Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_lbl" xml:lang="en-US" id="id_10184323_2447943_1_1">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_lbl" xml:lang="en-US" id="id_10184323_2447943_2_1">Summary of Purchase Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US" id="id_10184323_2448346_1_1">Schedule of Business Acquisitions, by Acquisition [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US" id="id_10184323_2448346_2_1">Schedule of Business Acquisitions, by Acquisition [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2447821_1_1">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2447821_2_1">Summary of Components of Federal and State Income Tax Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock" xlink:label="sls_ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2772026_3_1">Schedule Of Components Of Net Deferred Tax Assets Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2772026_1_1">Schedule Of Components Of Net Deferred Tax Assets Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2772026_2_1">Summary of Components of Net Deferred Tax Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock" xlink:to="sls_ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock" xlink:label="sls_ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2757149_3_1">Schedule Of Components Of Net Deferred Tax Liabilities Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2757149_1_1">Schedule Of Components Of Net Deferred Tax Liabilities Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2757149_2_1">Summary of Components of Net Deferred Tax Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock" xlink:to="sls_ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2447959_1_1">Schedule of Debt [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2447959_2_1">Schedule of Debt and Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2448370_1_1">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2448370_2_1">Reconciliation of Provision for Income Taxes and Provision Computed by Applying the Federal Statutory Rate to Net Loss Before Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" id="id_10184323_2448497_1_1">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" id="id_10184323_2448497_2_1">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" id="id_10184323_2447970_1_1">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" id="id_10184323_2447970_2_1">Schedule of Allocated Stock-based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_lbl" xml:lang="en-US" id="id_10184323_2448376_1_1">Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_lbl" xml:lang="en-US" id="id_10184323_2448376_2_1">Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_lbl" xml:lang="en-US" id="id_10184323_2447973_1_1">Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_lbl" xml:lang="en-US" id="id_10184323_2447973_2_1">Summary of Adjustments to Additional Paid-in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2448498_1_1">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2448498_2_1">Contingent Purchase Price Consideration, Convertible Debt, Measured at Estimated Fair Value on Recurring Basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xml:lang="en-US" id="id_10184323_2447981_1_1">Schedule of Goodwill [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xml:lang="en-US" id="id_10184323_2447981_2_1">Changes in Carrying Amount of Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2447985_1_1">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2447985_2_1">Schedule of Loss Before Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2448411_1_1">Schedule of Nonvested Performance-based Units Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2448411_2_1">RSU Activity for RSUs with Both Time-Based and Performance-Based Conditions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2448247_1_1">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2448247_2_1">RSU Activity for RSUs with Only Time-Based Conditions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2448423_1_1">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2448423_2_1">Total Purchase Price Allocation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="id_10184323_2448548_1_1">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="id_10184323_2448548_2_1">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2448440_1_1">Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2448440_2_1">Stock Option Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2448443_1_1">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2448443_2_1">Assumptions for Option Grants Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" id="id_10184323_2448553_1_1">Schedule of Stock by Class [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" id="id_10184323_2448553_2_1">Schedule of Stock by Class [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2448274_1_1">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2448274_2_1">Schedule of Changes to Company's Unrecognized Tax Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ScheduleOfWarrantActivityTableTableTextBlock" xlink:label="sls_ScheduleOfWarrantActivityTableTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ScheduleOfWarrantActivityTableTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2884923_3_1">Schedule Of Warrant Activity Table</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ScheduleOfWarrantActivityTableTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2884923_1_1">Schedule Of Warrant Activity Table Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ScheduleOfWarrantActivityTableTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2884923_2_1">Schedule of Warrant Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ScheduleOfWarrantActivityTableTableTextBlock" xlink:to="sls_ScheduleOfWarrantActivityTableTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ScheduleOfWarrantValuationAssumptionsTableTableTextBlock" xlink:label="sls_ScheduleOfWarrantValuationAssumptionsTableTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ScheduleOfWarrantValuationAssumptionsTableTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2884922_3_1">Schedule Of Warrant Valuation Assumptions Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ScheduleOfWarrantValuationAssumptionsTableTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2884922_1_1">Schedule Of Warrant Valuation Assumptions Table Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ScheduleOfWarrantValuationAssumptionsTableTableTextBlock_lbl" xml:lang="en-US" id="id_10184323_2884922_2_1">Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ScheduleOfWarrantValuationAssumptionsTableTableTextBlock" xlink:to="sls_ScheduleOfWarrantValuationAssumptionsTableTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SecondAmendedAndRestatedExclusiveLicenseAgreementMember" xlink:label="sls_SecondAmendedAndRestatedExclusiveLicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_SecondAmendedAndRestatedExclusiveLicenseAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3049580_3_1">Second Amended and Restated Exclusive License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_SecondAmendedAndRestatedExclusiveLicenseAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3049580_1_1">Second Amended and Restated Exclusive License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_SecondAmendedAndRestatedExclusiveLicenseAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3049580_2_1">Second MSK A&amp;R License Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_SecondAmendedAndRestatedExclusiveLicenseAgreementMember" xlink:to="sls_SecondAmendedAndRestatedExclusiveLicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SecondLicenseAmendmentWaiverAndAgreementMember" xlink:label="sls_SecondLicenseAmendmentWaiverAndAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_SecondLicenseAmendmentWaiverAndAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3049265_3_1">Second license amendment waiver and agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_SecondLicenseAmendmentWaiverAndAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3049265_1_1">Second License Amendment Waiver And Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_SecondLicenseAmendmentWaiverAndAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3049265_2_1">Second MSK Amendment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_SecondLicenseAmendmentWaiverAndAgreementMember" xlink:to="sls_SecondLicenseAmendmentWaiverAndAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SecondTrancheMember" xlink:label="sls_SecondTrancheMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_SecondTrancheMember_lbl" xml:lang="en-US" id="id_10184323_2678536_3_1">Second Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_SecondTrancheMember_lbl" xml:lang="en-US" id="id_10184323_2678536_1_1">Second Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_SecondTrancheMember_lbl" xml:lang="en-US" id="id_10184323_2678536_2_1">Second Tranche (Expected to Occur Early in the Second Quarter) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_SecondTrancheMember" xlink:to="sls_SecondTrancheMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuredDebtMember_lbl" xml:lang="en-US" id="id_10184323_2448459_1_1">Secured Debt [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecuredDebtMember_lbl" xml:lang="en-US" id="id_10184323_2448459_2_1">Secured Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebtMember" xlink:to="us-gaap_SecuredDebtMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SecuritiesPurchaseAgreementMember" xlink:label="sls_SecuritiesPurchaseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US" id="id_10184323_2668673_3_1">Securities Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US" id="id_10184323_2668673_1_1">Securities Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US" id="id_10184323_2668673_2_1">Securities Purchase Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_SecuritiesPurchaseAgreementMember" xlink:to="sls_SecuritiesPurchaseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_10184323_2448754_1_1">Selling, General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_10184323_2448754_2_1">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" id="id_10184323_2448625_1_1">Selling, General and Administrative Expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" id="id_10184323_2448625_2_1">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SeniorSecuredDebenturesMember" xlink:label="sls_SeniorSecuredDebenturesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_SeniorSecuredDebenturesMember_lbl" xml:lang="en-US" id="id_10184323_2884929_3_1">Senior Secured Debentures [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_SeniorSecuredDebenturesMember_lbl" xml:lang="en-US" id="id_10184323_2884929_1_1">Senior Secured Debentures [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_SeniorSecuredDebenturesMember_lbl" xml:lang="en-US" id="id_10184323_2884929_2_1">Senior Secured Debentures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_SeniorSecuredDebenturesMember" xlink:to="sls_SeniorSecuredDebenturesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SeriesAConvertiblePreferredStockMember" xlink:label="sls_SeriesAConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_SeriesAConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_10184323_2672262_3_1">Series A Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_SeriesAConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_10184323_2672262_1_1">Series A- Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_SeriesAConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_10184323_2672262_2_1">Series A- Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_SeriesAConvertiblePreferredStockMember" xlink:to="sls_SeriesAConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SettledLitigationMember" xlink:label="us-gaap_SettledLitigationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SettledLitigationMember_lbl" xml:lang="en-US" id="id_10184323_2448785_1_1">Settled Litigation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SettledLitigationMember_lbl" xml:lang="en-US" id="id_10184323_2448785_2_1">Settled Litigation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SettledLitigationMember" xlink:to="us-gaap_SettledLitigationMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US" id="id_10184323_2449187_1_1">Severance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US" id="id_10184323_2449187_32_1">Severance costs paid by Galena</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US" id="id_10184323_2449187_2_1">Exit costs severance benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US" id="id_10184323_2449187_12_1">Severance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_10184323_2448661_1_1">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_10184323_2448661_2_1">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xml:lang="en-US" id="id_10184323_2448663_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xml:lang="en-US" id="id_10184323_2448663_2_1">Continued service measurement period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" id="id_10184323_2449047_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" id="id_10184323_2449047_2_1">Vesting periods of options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" id="id_10184323_2448791_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" id="id_10184323_2448791_14_1">Number of non-vested RSUs, Canceled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_10184323_2449194_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_10184323_2449194_2_1">Weighted average grant-date fair value, Canceled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" id="id_10184323_2449051_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" id="id_10184323_2449051_2_1">Number of non-vested RSUs, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_10184323_2449196_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_10184323_2449196_2_1">Weighted average grant-date fair value, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" id="id_10184323_2449052_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" id="id_10184323_2449052_4_1">Number of non-vested RSUs, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" id="id_10184323_2449052_5_1">Number of non-vested RSUs, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" id="id_10184323_2448793_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" id="id_10184323_2448793_2_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_10184323_2448668_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_10184323_2448668_4_1">Weighted average grant-date fair value, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_10184323_2448668_5_1">Weighted average grant-date fair value, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" id="id_10184323_2449198_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" id="id_10184323_2449198_2_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" id="id_10184323_2449054_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" id="id_10184323_2449054_2_1">Number of non-vested RSUs, Vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" id="id_10184323_2449054_14_1">Number of non-vested RSUs, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_10184323_2449057_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_10184323_2449057_2_1">Weighted average grant-date fair value, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" id="id_10184323_2448669_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" id="id_10184323_2448669_2_1">Options expire from date of grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="id_10184323_2448798_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="id_10184323_2448798_2_1">Expected dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="id_10184323_2448671_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="id_10184323_2448671_2_1">Expected lives (years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="id_10184323_2449060_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="id_10184323_2449060_2_1">Volatility rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_10184323_2448801_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_10184323_2448801_2_1">Risk free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="id_10184323_2449201_1_1">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="id_10184323_2449201_2_1">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" id="id_10184323_2448675_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" id="id_10184323_2448675_2_1">Shares of common stock reserved for issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" id="id_10184323_2449070_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" id="id_10184323_2449070_2_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInAcquisitionGrantDateIntrinsicValue" xlink:label="sls_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInAcquisitionGrantDateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInAcquisitionGrantDateIntrinsicValue_lbl" xml:lang="en-US" id="id_10184323_3054050_3_1">Share-based compensation arrangement by share-based payment award, options, assumed in acquisition, grant date intrinsic value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInAcquisitionGrantDateIntrinsicValue_lbl" xml:lang="en-US" id="id_10184323_3054050_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Assumed in Acquisition, Grant Date Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInAcquisitionGrantDateIntrinsicValue_lbl" xml:lang="en-US" id="id_10184323_3054050_2_1">Assumed in connection with the Merger with Galena</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInAcquisitionGrantDateIntrinsicValue" xlink:to="sls_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInAcquisitionGrantDateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger" xlink:label="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger_lbl" xml:lang="en-US" id="id_10184323_2608771_3_1">Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger_lbl" xml:lang="en-US" id="id_10184323_2608771_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger_lbl" xml:lang="en-US" id="id_10184323_2608771_2_1">Share based compensation arrangement by share based payment award options assumed in merger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger" xlink:to="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledIntrinsicValue" xlink:label="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledIntrinsicValue_lbl" xml:lang="en-US" id="id_10184323_2554700_3_1">Share Based Compensation Arrangement By Share Based Payment Award Options Canceled Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledIntrinsicValue_lbl" xml:lang="en-US" id="id_10184323_2554700_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Canceled Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledIntrinsicValue_lbl" xml:lang="en-US" id="id_10184323_2554700_2_1">Aggregate intrinsic value,Canceled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledIntrinsicValue" xlink:to="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAggregateIntrinsicValue" xlink:label="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" id="id_10184323_2569178_3_1">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" id="id_10184323_2569178_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" id="id_10184323_2569178_2_1">Aggregate intrinsic Value, exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAggregateIntrinsicValue" xlink:to="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" id="id_10184323_2449206_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" id="id_10184323_2449206_2_1">Number of options, exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_10184323_2449207_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_10184323_2449207_2_1">Weighed average exercise price, exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" id="id_10184323_2448808_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" id="id_10184323_2448808_14_1">Number of options, Canceled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US" id="id_10184323_2449072_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US" id="id_10184323_2449072_2_1">Common stock options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US" id="id_10184323_2449072_12_1">Number of granted stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl" xml:lang="en-US" id="id_10184323_2449073_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl" xml:lang="en-US" id="id_10184323_2449073_2_1">Aggregate intrinsic value, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="id_10184323_2449211_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="id_10184323_2449211_2_1">Assumed in connection with the Merger with Galena</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="id_10184323_2449211_12_1">Number of options, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" id="id_10184323_2449079_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" id="id_10184323_2449079_4_1">Aggregate intrinsic value, Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" id="id_10184323_2449079_5_1">Aggregate intrinsic value, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_10184323_2449213_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_10184323_2449213_4_1">Number of options, Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_10184323_2449213_5_1">Number of options, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" id="id_10184323_2448684_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" id="id_10184323_2448684_2_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_10184323_2449215_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_10184323_2449215_4_1">Weighted average exercise price, Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_10184323_2449215_5_1">Weighted average exercise price, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" id="id_10184323_2448685_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" id="id_10184323_2448685_2_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_10184323_2448814_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_10184323_2448814_2_1">Weighted-average grant at fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants" xlink:label="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants_lbl" xml:lang="en-US" id="id_10184323_2781121_3_1">Share based compensation arrangement by share based payment award percentage earning of participants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants_lbl" xml:lang="en-US" id="id_10184323_2781121_1_1">Share Based Compensation Arrangement By Share Based Payment Award Percentage Earning Of Participants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants_lbl" xml:lang="en-US" id="id_10184323_2781121_2_1">Share based compensation arrangement by share based payment award percentage earning of participants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants" xlink:to="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" id="id_10184323_2448816_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" id="id_10184323_2448816_2_1">Purchase price of common stock, percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SharebasedCompensationArrangementBySharebasedPaymentAwardStockOptionsSharesOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:label="sls_SharebasedCompensationArrangementBySharebasedPaymentAwardStockOptionsSharesOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_SharebasedCompensationArrangementBySharebasedPaymentAwardStockOptionsSharesOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" id="id_10184323_3025766_3_1">Share-based compensation arrangement by share-based payment award, stock options/shares outstanding, weighted-average exercise price, and additional disclosures.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_SharebasedCompensationArrangementBySharebasedPaymentAwardStockOptionsSharesOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" id="id_10184323_3025766_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Stock Options/Shares Outstanding, Weighted-Average Exercise Price, and Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_SharebasedCompensationArrangementBySharebasedPaymentAwardStockOptionsSharesOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" id="id_10184323_3025766_2_1">Share-based Compensation Arrangement by Share-based Payment Award, Stock Options/Shares Outstanding, Weighted-Average Exercise Price, and Additional Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_SharebasedCompensationArrangementBySharebasedPaymentAwardStockOptionsSharesOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="sls_SharebasedCompensationArrangementBySharebasedPaymentAwardStockOptionsSharesOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate" xlink:label="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate_lbl" xml:lang="en-US" id="id_10184323_2621149_3_1">Share Based Compensation Arrangement By Share Based Payment Award Vesting Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate_lbl" xml:lang="en-US" id="id_10184323_2621149_1_1">Share Based Compensation Arrangement By Share Based Payment Award Vesting Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate_lbl" xml:lang="en-US" id="id_10184323_2621149_2_1">Vesting date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate" xlink:to="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="id_10184323_2448698_1_1">Equity Award [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="id_10184323_2448698_2_1">Equity Award [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_10184323_2448818_1_1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_10184323_2448818_2_1">Weighted average exercise price, Canceled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_10184323_2448819_1_1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_10184323_2448819_2_1">Assumed in connection with the Merger with Galena</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ShareBasedCompensationAwardVestingDateFourMember" xlink:label="sls_ShareBasedCompensationAwardVestingDateFourMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ShareBasedCompensationAwardVestingDateFourMember_lbl" xml:lang="en-US" id="id_10184323_3049584_3_1">2/27/2018.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ShareBasedCompensationAwardVestingDateFourMember_lbl" xml:lang="en-US" id="id_10184323_3049584_1_1">Share Based Compensation Award Vesting Date Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ShareBasedCompensationAwardVestingDateFourMember_lbl" xml:lang="en-US" id="id_10184323_3049584_2_1">February 27, 2018</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ShareBasedCompensationAwardVestingDateFourMember" xlink:to="sls_ShareBasedCompensationAwardVestingDateFourMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ShareBasedCompensationAwardVestingDateOneMember" xlink:label="sls_ShareBasedCompensationAwardVestingDateOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ShareBasedCompensationAwardVestingDateOneMember_lbl" xml:lang="en-US" id="id_10184323_3049554_3_1">1/1/2018</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ShareBasedCompensationAwardVestingDateOneMember_lbl" xml:lang="en-US" id="id_10184323_3049554_1_1">Share Based Compensation Award Vesting Date One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ShareBasedCompensationAwardVestingDateOneMember_lbl" xml:lang="en-US" id="id_10184323_3049554_2_1">January 1, 2018</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ShareBasedCompensationAwardVestingDateOneMember" xlink:to="sls_ShareBasedCompensationAwardVestingDateOneMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ShareBasedCompensationAwardVestingDateThreeMember" xlink:label="sls_ShareBasedCompensationAwardVestingDateThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ShareBasedCompensationAwardVestingDateThreeMember_lbl" xml:lang="en-US" id="id_10184323_3049583_3_1">1/1/2020.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ShareBasedCompensationAwardVestingDateThreeMember_lbl" xml:lang="en-US" id="id_10184323_3049583_1_1">Share Based Compensation Award Vesting Date Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ShareBasedCompensationAwardVestingDateThreeMember_lbl" xml:lang="en-US" id="id_10184323_3049583_2_1">January 1, 2020</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ShareBasedCompensationAwardVestingDateThreeMember" xlink:to="sls_ShareBasedCompensationAwardVestingDateThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ShareBasedCompensationAwardVestingDateTwoMember" xlink:label="sls_ShareBasedCompensationAwardVestingDateTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ShareBasedCompensationAwardVestingDateTwoMember_lbl" xml:lang="en-US" id="id_10184323_3049582_3_1">1/1/2019.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ShareBasedCompensationAwardVestingDateTwoMember_lbl" xml:lang="en-US" id="id_10184323_3049582_1_1">Share Based Compensation Award Vesting Date Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ShareBasedCompensationAwardVestingDateTwoMember_lbl" xml:lang="en-US" id="id_10184323_3049582_2_1">January 1, 2019</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ShareBasedCompensationAwardVestingDateTwoMember" xlink:to="sls_ShareBasedCompensationAwardVestingDateTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ShareBasedCompensationExercisePeriod" xlink:label="sls_ShareBasedCompensationExercisePeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ShareBasedCompensationExercisePeriod_lbl" xml:lang="en-US" id="id_10184323_2635838_3_1">Share Based Compensation Exercise Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ShareBasedCompensationExercisePeriod_lbl" xml:lang="en-US" id="id_10184323_2635838_1_1">Share Based Compensation Exercise Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ShareBasedCompensationExercisePeriod_lbl" xml:lang="en-US" id="id_10184323_2635838_2_1">Option excisable period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ShareBasedCompensationExercisePeriod" xlink:to="sls_ShareBasedCompensationExercisePeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" id="id_10184323_2448821_1_1">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" id="id_10184323_2448821_2_1">Stock-based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued_lbl" xml:lang="en-US" id="id_10184323_2449091_1_1">Share-based Goods and Nonemployee Services Transaction, Quantity of Securities Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued_lbl" xml:lang="en-US" id="id_10184323_2449091_2_1">Issuance of common stock, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ShareholdersMember" xlink:label="sls_ShareholdersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ShareholdersMember_lbl" xml:lang="en-US" id="id_10184323_2653900_3_1">Shareholders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ShareholdersMember_lbl" xml:lang="en-US" id="id_10184323_2653900_1_1">Shareholders [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ShareholdersMember_lbl" xml:lang="en-US" id="id_10184323_2653900_2_1">Shareholders [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ShareholdersMember" xlink:to="sls_ShareholdersMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod" xlink:label="sls_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod_lbl" xml:lang="en-US" id="id_10184323_3049147_3_1">Shares and Common Stock Warrants Issued Upon Conversion of Notes During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod_lbl" xml:lang="en-US" id="id_10184323_3049147_1_1">Shares and Common Stock Warrants Issued Upon Conversion of Notes During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod_lbl" xml:lang="en-US" id="id_10184323_3049147_2_1">Shares and common stock warrants issued upon conversion of 2015 Sely Note and accrued interest to Equilibria</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod" xlink:to="sls_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares" xlink:label="sls_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares_lbl" xml:lang="en-US" id="id_10184323_3049149_3_1">Shares and common stock warrants issued upon conversion of 2015 Sely Note, shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares_lbl" xml:lang="en-US" id="id_10184323_3049149_1_1">Shares and Common Stock Warrants Issued Upon Conversion of Notes During Period, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares_lbl" xml:lang="en-US" id="id_10184323_3049149_2_1">Shares and common stock warrants issued upon conversion of 2015 Sely Note and accrued interest to Equilibria, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares" xlink:to="sls_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SharesIssuableForConsiderationForLicenseTerminationAgreement" xlink:label="sls_SharesIssuableForConsiderationForLicenseTerminationAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_SharesIssuableForConsiderationForLicenseTerminationAgreement_lbl" xml:lang="en-US" id="id_10184323_3049441_3_1">Shares issuable for consideration for license termination agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_SharesIssuableForConsiderationForLicenseTerminationAgreement_lbl" xml:lang="en-US" id="id_10184323_3049441_1_1">Shares Issuable For Consideration For License Termination Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_SharesIssuableForConsiderationForLicenseTerminationAgreement_lbl" xml:lang="en-US" id="id_10184323_3049441_2_1">Shares issuable for consideration for license termination agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_SharesIssuableForConsiderationForLicenseTerminationAgreement" xlink:to="sls_SharesIssuableForConsiderationForLicenseTerminationAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" id="id_10184323_2449233_1_1">Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" id="id_10184323_2449233_2_1">Company had previously issued to CVI a warrant to purchase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" id="id_10184323_2449233_12_1">Shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SharesIssuedInCancellationOfLicenseAgreement" xlink:label="sls_SharesIssuedInCancellationOfLicenseAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_SharesIssuedInCancellationOfLicenseAgreement_lbl" xml:lang="en-US" id="id_10184323_3049112_3_1">Shares Issued In Cancellation Of License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_SharesIssuedInCancellationOfLicenseAgreement_lbl" xml:lang="en-US" id="id_10184323_3049112_1_1">Shares Issued In Cancellation Of License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_SharesIssuedInCancellationOfLicenseAgreement_lbl" xml:lang="en-US" id="id_10184323_3049112_2_1">Shares issued in cancellation of Clarendon license agreement, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_SharesIssuedInCancellationOfLicenseAgreement" xlink:to="sls_SharesIssuedInCancellationOfLicenseAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SharesIssuedInConnectionWithAcquisition" xlink:label="sls_SharesIssuedInConnectionWithAcquisition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_SharesIssuedInConnectionWithAcquisition_lbl" xml:lang="en-US" id="id_10184323_3051923_3_1">Shares issued in connection with acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_SharesIssuedInConnectionWithAcquisition_lbl" xml:lang="en-US" id="id_10184323_3051923_1_1">Shares Issued In Connection With Acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_SharesIssuedInConnectionWithAcquisition_lbl" xml:lang="en-US" id="id_10184323_3051923_2_1">Shares issued in connection with acquisition of Galena</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_SharesIssuedInConnectionWithAcquisition" xlink:to="sls_SharesIssuedInConnectionWithAcquisition_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" id="id_10184323_2449098_1_1">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" id="id_10184323_2449098_2_1">Share issue price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SharesIssuedToSettleAccountsPayable" xlink:label="sls_SharesIssuedToSettleAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_SharesIssuedToSettleAccountsPayable_lbl" xml:lang="en-US" id="id_10184323_3051931_3_1">Shares issued to settle accounts payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_SharesIssuedToSettleAccountsPayable_lbl" xml:lang="en-US" id="id_10184323_3051931_1_1">Shares Issued To Settle Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_SharesIssuedToSettleAccountsPayable_lbl" xml:lang="en-US" id="id_10184323_3051931_2_1">MSK payable settled in shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_SharesIssuedToSettleAccountsPayable" xlink:to="sls_SharesIssuedToSettleAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SharesIssuedToSettlerElatedPartyAccountsPayable" xlink:label="sls_SharesIssuedToSettlerElatedPartyAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_SharesIssuedToSettlerElatedPartyAccountsPayable_lbl" xml:lang="en-US" id="id_10184323_3051930_3_1">Shares issued to settle related party accounts payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_SharesIssuedToSettlerElatedPartyAccountsPayable_lbl" xml:lang="en-US" id="id_10184323_3051930_1_1">Shares Issued To Settle Related Party Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_SharesIssuedToSettlerElatedPartyAccountsPayable_lbl" xml:lang="en-US" id="id_10184323_3051930_2_1">Related party payable settled in shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_SharesIssuedToSettlerElatedPartyAccountsPayable" xlink:to="sls_SharesIssuedToSettlerElatedPartyAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SharesIssuedUnderLicenseAgreement" xlink:label="sls_SharesIssuedUnderLicenseAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_SharesIssuedUnderLicenseAgreement_lbl" xml:lang="en-US" id="id_10184323_3049433_3_1">Shares issued under license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_SharesIssuedUnderLicenseAgreement_lbl" xml:lang="en-US" id="id_10184323_3049433_1_1">Shares issued under license agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_SharesIssuedUnderLicenseAgreement_lbl" xml:lang="en-US" id="id_10184323_3049433_2_1">Shares issue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_SharesIssuedUnderLicenseAgreement" xlink:to="sls_SharesIssuedUnderLicenseAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" id="id_10184323_2449099_1_1">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" id="id_10184323_2449099_4_1">Ending balance, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" id="id_10184323_2449099_5_1">Beginning balance, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SignificantAccountingPoliciesLineItems" xlink:label="sls_SignificantAccountingPoliciesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" id="id_10184323_2467306_3_1">Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" id="id_10184323_2467306_1_1">Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" id="id_10184323_2467306_2_1">Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_SignificantAccountingPoliciesLineItems" xlink:to="sls_SignificantAccountingPoliciesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SignificantAccountingPoliciesTable" xlink:label="sls_SignificantAccountingPoliciesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US" id="id_10184323_2648160_3_1">Significant Accounting Policies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US" id="id_10184323_2648160_1_1">Significant Accounting Policies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US" id="id_10184323_2648160_2_1">Significant Accounting Policies [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_SignificantAccountingPoliciesTable" xlink:to="sls_SignificantAccountingPoliciesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SougioultzoglouMember" xlink:label="sls_SougioultzoglouMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_SougioultzoglouMember_lbl" xml:lang="en-US" id="id_10184323_3053941_3_1">Sougioultzoglou.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_SougioultzoglouMember_lbl" xml:lang="en-US" id="id_10184323_3053941_1_1">Sougioultzoglou [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_SougioultzoglouMember_lbl" xml:lang="en-US" id="id_10184323_3053941_2_1">Sougioultzoglou [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_SougioultzoglouMember" xlink:to="sls_SougioultzoglouMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StarcoveLoansMember" xlink:label="sls_StarcoveLoansMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_StarcoveLoansMember_lbl" xml:lang="en-US" id="id_10184323_3053920_3_1">Starcove loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_StarcoveLoansMember_lbl" xml:lang="en-US" id="id_10184323_3053920_1_1">Starcove Loans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_StarcoveLoansMember_lbl" xml:lang="en-US" id="id_10184323_3053920_2_1">Starcove Loans [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_StarcoveLoansMember" xlink:to="sls_StarcoveLoansMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StarcoveMember" xlink:label="sls_StarcoveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_StarcoveMember_lbl" xml:lang="en-US" id="id_10184323_3053914_3_1">Starcove.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_StarcoveMember_lbl" xml:lang="en-US" id="id_10184323_3053914_1_1">Starcove [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_StarcoveMember_lbl" xml:lang="en-US" id="id_10184323_3053914_2_1">Starcove [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_StarcoveMember" xlink:to="sls_StarcoveMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="id_10184323_2448913_1_1">Class of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="id_10184323_2448913_2_1">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="id_10184323_2448914_1_1">Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="id_10184323_2448914_2_1">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="id_10184323_2448916_1_1">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="id_10184323_2448916_2_1">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_10184323_2449303_1_1">Statement of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_10184323_2449303_2_1">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_10184323_2448918_1_1">Statement of Stockholders' Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_10184323_2448918_2_1">Statement of Stockholders' Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US" id="id_10184323_2449305_1_1">Scenario [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US" id="id_10184323_2449305_2_1">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" id="id_10184323_2449833_1_1">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" id="id_10184323_2449833_2_1">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockConversionLimitPercentage" xlink:label="sls_StockConversionLimitPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_StockConversionLimitPercentage_lbl" xml:lang="en-US" id="id_10184323_3050063_3_1">Stock conversion limit percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_StockConversionLimitPercentage_lbl" xml:lang="en-US" id="id_10184323_3050063_1_1">Stock Conversion Limit Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_StockConversionLimitPercentage_lbl" xml:lang="en-US" id="id_10184323_3050063_2_1">Percentage of stock conversion limit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_StockConversionLimitPercentage" xlink:to="sls_StockConversionLimitPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockholderApprovalPeriod" xlink:label="sls_StockholderApprovalPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_StockholderApprovalPeriod_lbl" xml:lang="en-US" id="id_10184323_3050108_3_1">Stockholder approval period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_StockholderApprovalPeriod_lbl" xml:lang="en-US" id="id_10184323_3050108_1_1">Stockholder Approval Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_StockholderApprovalPeriod_lbl" xml:lang="en-US" id="id_10184323_3050108_2_1">Period of stock holder approval</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_StockholderApprovalPeriod" xlink:to="sls_StockholderApprovalPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_10184323_2449320_1_1">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_10184323_2449320_4_1">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_10184323_2449320_5_1">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_10184323_2449320_6_1">Total stockholders' equity (deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_10184323_2449321_1_1">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_10184323_2449321_2_1">Stockholders' equity (deficit):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="id_10184323_2449326_1_1">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="id_10184323_2449326_2_1">Stockholders' Equity (Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" id="id_10184323_2449329_1_1">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" id="id_10184323_2449329_2_1">Reverse stock split, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US" id="id_10184323_2449470_1_1">Stockholders' Equity, Reverse Stock Split</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US" id="id_10184323_2449470_2_1">Reverse stock split, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US" id="id_10184323_2449471_1_1">Stock Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US" id="id_10184323_2449471_2_1">Shares issued upon conversion of notes and accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US" id="id_10184323_2449333_1_1">Stock Issued During Period, Shares, Acquisitions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US" id="id_10184323_2449333_2_1">Shares issued in connection with acquisition of Galena, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodSharesCancellationOfLongTermDebt" xlink:label="sls_StockIssuedDuringPeriodSharesCancellationOfLongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_StockIssuedDuringPeriodSharesCancellationOfLongTermDebt_lbl" xml:lang="en-US" id="id_10184323_3049115_3_1">Stock Issued During Period Shares Cancellation Of Long Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_StockIssuedDuringPeriodSharesCancellationOfLongTermDebt_lbl" xml:lang="en-US" id="id_10184323_3049115_1_1">Stock Issued During Period Shares Cancellation Of Long Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_StockIssuedDuringPeriodSharesCancellationOfLongTermDebt_lbl" xml:lang="en-US" id="id_10184323_3049115_2_1">Shares issued in cancellation of long term debt, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_StockIssuedDuringPeriodSharesCancellationOfLongTermDebt" xlink:to="sls_StockIssuedDuringPeriodSharesCancellationOfLongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_10184323_2448929_1_1">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_10184323_2448929_2_1">Shares issued upon conversion of 2016 convertible term note, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithAcquisition" xlink:label="sls_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithAcquisition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithAcquisition_lbl" xml:lang="en-US" id="id_10184323_3049129_3_1">Stock issued during period shares conversion of debt in connection with acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithAcquisition_lbl" xml:lang="en-US" id="id_10184323_3049129_1_1">Stock Issued During Period Shares Conversion Of Debt In Connection With Acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithAcquisition_lbl" xml:lang="en-US" id="id_10184323_3049129_2_1">Shares issued upon conversion of debt in connection with acquisition of Galena Biopharma, Inc., shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithAcquisition" xlink:to="sls_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithAcquisition_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement" xlink:label="sls_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement_lbl" xml:lang="en-US" id="id_10184323_3049388_3_1">Stock issued during period shares conversion of debt in connection with licensing agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement_lbl" xml:lang="en-US" id="id_10184323_3049388_1_1">Stock Issued During Period Shares Conversion Of Debt In Connection With Licensing Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement_lbl" xml:lang="en-US" id="id_10184323_3049388_2_1">Issuance of shares upon conversion of debt in connection with licensing agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement" xlink:to="sls_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" id="id_10184323_2449334_1_1">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" id="id_10184323_2449334_2_1">Issuance of common stock in connection with employee stock purchase plan, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US" id="id_10184323_2449857_1_1">Stock Issued During Period, Shares, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US" id="id_10184323_2449857_2_1">Issuance of shares in cancellation of net compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodSharesLicenseAgreement" xlink:label="sls_StockIssuedDuringPeriodSharesLicenseAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_StockIssuedDuringPeriodSharesLicenseAgreement_lbl" xml:lang="en-US" id="id_10184323_2610035_3_1">Stock issued during period shares license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_StockIssuedDuringPeriodSharesLicenseAgreement_lbl" xml:lang="en-US" id="id_10184323_2610035_1_1">Stock Issued During Period Shares License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_StockIssuedDuringPeriodSharesLicenseAgreement_lbl" xml:lang="en-US" id="id_10184323_2610035_2_1">Shares issued pursuant to MSK license agreement, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_StockIssuedDuringPeriodSharesLicenseAgreement" xlink:to="sls_StockIssuedDuringPeriodSharesLicenseAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_10184323_2449858_1_1">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_10184323_2449858_2_1">Sale of common shares to related parties, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodSharesPartialConsiderationOfLicenseFee" xlink:label="sls_StockIssuedDuringPeriodSharesPartialConsiderationOfLicenseFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_StockIssuedDuringPeriodSharesPartialConsiderationOfLicenseFee_lbl" xml:lang="en-US" id="id_10184323_3049108_3_1">Stock Issued During Period Shares Partial Consideration Of License Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_StockIssuedDuringPeriodSharesPartialConsiderationOfLicenseFee_lbl" xml:lang="en-US" id="id_10184323_3049108_1_1">Stock Issued During Period Shares Partial Consideration Of License Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_StockIssuedDuringPeriodSharesPartialConsiderationOfLicenseFee_lbl" xml:lang="en-US" id="id_10184323_3049108_2_1">Shares issued as partial consideration of MSK license fees, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_StockIssuedDuringPeriodSharesPartialConsiderationOfLicenseFee" xlink:to="sls_StockIssuedDuringPeriodSharesPartialConsiderationOfLicenseFee_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US" id="id_10184323_2449474_1_1">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US" id="id_10184323_2449474_2_1">Shares issued upon the acceleration of restricted stock units, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US" id="id_10184323_2449475_1_1">Stock Issued During Period, Shares, Reverse Stock Splits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US" id="id_10184323_2449475_2_1">Purchase of aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable" xlink:label="sls_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable_lbl" xml:lang="en-US" id="id_10184323_3049125_3_1">Stock Issued During Period Shares Settlement Of Related Party Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable_lbl" xml:lang="en-US" id="id_10184323_3049125_1_1">Stock Issued During Period Shares Settlement Of Related Party Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable_lbl" xml:lang="en-US" id="id_10184323_3049125_2_1">Shares issued in connection with settlement of related party payables, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable" xlink:to="sls_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodSharesShareWarrantsExercised" xlink:label="sls_StockIssuedDuringPeriodSharesShareWarrantsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_StockIssuedDuringPeriodSharesShareWarrantsExercised_lbl" xml:lang="en-US" id="id_10184323_2614369_3_1">Stock Issued During Period Shares Share Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_StockIssuedDuringPeriodSharesShareWarrantsExercised_lbl" xml:lang="en-US" id="id_10184323_2614369_1_1">Stock Issued During Period Shares Share Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_StockIssuedDuringPeriodSharesShareWarrantsExercised_lbl" xml:lang="en-US" id="id_10184323_2614369_2_1">Shares of common stock in exchange</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_StockIssuedDuringPeriodSharesShareWarrantsExercised" xlink:to="sls_StockIssuedDuringPeriodSharesShareWarrantsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares" xlink:label="sls_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares_lbl" xml:lang="en-US" id="id_10184323_3053512_3_1">Stock issued during period upon cancellation of restricted stock units, shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares_lbl" xml:lang="en-US" id="id_10184323_3053512_1_1">Stock Issued During Period Upon Cancellation of Restricted Stock Units Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares_lbl" xml:lang="en-US" id="id_10184323_3053512_2_1">Shares issued upon cancellation of Equilibria restricted stock units, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares" xlink:to="sls_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US" id="id_10184323_2448933_1_1">Stock Issued During Period, Value, Acquisitions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US" id="id_10184323_2448933_2_1">Shares issued in connection with acquisition of Galena</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodValueCancellationOfLongTermDebt" xlink:label="sls_StockIssuedDuringPeriodValueCancellationOfLongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_StockIssuedDuringPeriodValueCancellationOfLongTermDebt_lbl" xml:lang="en-US" id="id_10184323_3049114_3_1">Stock issued during period value cancellation of long term debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_StockIssuedDuringPeriodValueCancellationOfLongTermDebt_lbl" xml:lang="en-US" id="id_10184323_3049114_1_1">Stock Issued During Period Value Cancellation Of Long Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_StockIssuedDuringPeriodValueCancellationOfLongTermDebt_lbl" xml:lang="en-US" id="id_10184323_3049114_2_1">Shares issued in cancellation of long term debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sls_StockIssuedDuringPeriodValueCancellationOfLongTermDebt_lbl" xml:lang="en-US" id="id_10184323_3049114_12_1">Shares issued in cancellation of long-term debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_StockIssuedDuringPeriodValueCancellationOfLongTermDebt" xlink:to="sls_StockIssuedDuringPeriodValueCancellationOfLongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_10184323_2449341_1_1">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_10184323_2449341_2_1">Shares issued upon conversion of 2016 convertible note</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_10184323_2449341_12_1">Shares issued upon conversion of 2016 convertible term note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodValueLicenseAgreement" xlink:label="sls_StockIssuedDuringPeriodValueLicenseAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_StockIssuedDuringPeriodValueLicenseAgreement_lbl" xml:lang="en-US" id="id_10184323_2580662_3_1">Stock issued during period value license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_StockIssuedDuringPeriodValueLicenseAgreement_lbl" xml:lang="en-US" id="id_10184323_2580662_1_1">Stock Issued During Period Value License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_StockIssuedDuringPeriodValueLicenseAgreement_lbl" xml:lang="en-US" id="id_10184323_2580662_2_1">Shares issued pursuant to MSK license agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_StockIssuedDuringPeriodValueLicenseAgreement" xlink:to="sls_StockIssuedDuringPeriodValueLicenseAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="id_10184323_2449480_1_1">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="id_10184323_2449480_2_1">Issuance of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="id_10184323_2449480_12_1">Sale of common shares to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee" xlink:label="sls_StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee_lbl" xml:lang="en-US" id="id_10184323_3049107_3_1">Stock issued during period value partial consideration of license fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee_lbl" xml:lang="en-US" id="id_10184323_3049107_1_1">Stock Issued During Period Value Partial Consideration Of License Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee_lbl" xml:lang="en-US" id="id_10184323_3049107_2_1">Shares issued as partial consideration of MSK license fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee" xlink:to="sls_StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable" xlink:label="sls_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable_lbl" xml:lang="en-US" id="id_10184323_3049123_3_1">Stock Issued During Period Value Settlement Of Related Party Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable_lbl" xml:lang="en-US" id="id_10184323_3049123_1_1">Stock Issued During Period Value Settlement Of Related Party Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable_lbl" xml:lang="en-US" id="id_10184323_3049123_2_1">Shares issued in connection with settlement of related party payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable" xlink:to="sls_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedForAntiDilutionProvisions" xlink:label="sls_StockIssuedForAntiDilutionProvisions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_StockIssuedForAntiDilutionProvisions_lbl" xml:lang="en-US" id="id_10184323_3049141_3_1">Stock issued for anti dilution provisions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_StockIssuedForAntiDilutionProvisions_lbl" xml:lang="en-US" id="id_10184323_3049141_1_1">Stock Issued For Anti Dilution Provisions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_StockIssuedForAntiDilutionProvisions_lbl" xml:lang="en-US" id="id_10184323_3049141_2_1">Shares issued to MSK for anti-dilution provisions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_StockIssuedForAntiDilutionProvisions" xlink:to="sls_StockIssuedForAntiDilutionProvisions_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedForAntiDilutionProvisionsShares" xlink:label="sls_StockIssuedForAntiDilutionProvisionsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_StockIssuedForAntiDilutionProvisionsShares_lbl" xml:lang="en-US" id="id_10184323_3049131_3_1">Stock issued for anti-dilution provisions shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_StockIssuedForAntiDilutionProvisionsShares_lbl" xml:lang="en-US" id="id_10184323_3049131_1_1">Stock Issued For Anti Dilution Provisions Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_StockIssuedForAntiDilutionProvisionsShares_lbl" xml:lang="en-US" id="id_10184323_3049131_2_1">Shares issued to MSK for anti-dilution provisions, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_StockIssuedForAntiDilutionProvisionsShares" xlink:to="sls_StockIssuedForAntiDilutionProvisionsShares_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod" xlink:label="sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod_lbl" xml:lang="en-US" id="id_10184323_3049144_3_1">Stock issued for incentive fee payment in connection with the acquisition during period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod_lbl" xml:lang="en-US" id="id_10184323_3049144_1_1">Stock Issued For Incentive Fee Payment In Connection With Acquisition During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod_lbl" xml:lang="en-US" id="id_10184323_3049144_2_1">Shares issued to Equilibria for incentive fee payment in connection with the acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod_lbl" xml:lang="en-US" id="id_10184323_3049144_12_1">Shares issued to Equilibria for incentive fee payment in connection with the acquisition of Galena</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod" xlink:to="sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares" xlink:label="sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares_lbl" xml:lang="en-US" id="id_10184323_3049130_3_1">Stock issued for incentive fee payment in connection with the acquisition during period shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares_lbl" xml:lang="en-US" id="id_10184323_3049130_1_1">Stock Issued For Incentive Fee Payment In Connection With Acquisition During Period Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares_lbl" xml:lang="en-US" id="id_10184323_3049130_2_1">Shares issued to Equilibria for incentive fee payment in connection with the acquisition of Galena, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares_lbl" xml:lang="en-US" id="id_10184323_3049130_12_1">Shares issued to Equilibria for incentive fee payment in connection with the acquisition, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares" xlink:to="sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue" xlink:label="sls_StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue_lbl" xml:lang="en-US" id="id_10184323_3049110_3_1">Stock issued in cancellation of license agreement during period value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue_lbl" xml:lang="en-US" id="id_10184323_3049110_1_1">Stock Issued In Cancellation Of License Agreement During Period Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue_lbl" xml:lang="en-US" id="id_10184323_3049110_2_1">Shares issued in cancellation of Clarendon license agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue" xlink:to="sls_StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares" xlink:label="sls_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares_lbl" xml:lang="en-US" id="id_10184323_3049118_3_1">Stock Issued In Connection With Amendments To License During Period Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares_lbl" xml:lang="en-US" id="id_10184323_3049118_1_1">Stock Issued In Connection With Amendments To License During Period Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares_lbl" xml:lang="en-US" id="id_10184323_3049118_2_1">Shares issued in connection with amendments to MSK license, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares" xlink:to="sls_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue" xlink:label="sls_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue_lbl" xml:lang="en-US" id="id_10184323_3049117_3_1">Stock Issued In Connection With Amendments To License During Period Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue_lbl" xml:lang="en-US" id="id_10184323_3049117_1_1">Stock Issued In Connection With Amendments To License During Period Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue_lbl" xml:lang="en-US" id="id_10184323_3049117_2_1">Shares issued in connection with amendments to MSK license</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue" xlink:to="sls_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US" id="id_10184323_2449596_1_1">Equity Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US" id="id_10184323_2449596_2_1">Stock options outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SublicenseFeePayablePercentageIfExecutedAfterFirstPatientEnrolledInPhaseThreeClinicalTrial" xlink:label="sls_SublicenseFeePayablePercentageIfExecutedAfterFirstPatientEnrolledInPhaseThreeClinicalTrial"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_SublicenseFeePayablePercentageIfExecutedAfterFirstPatientEnrolledInPhaseThreeClinicalTrial_lbl" xml:lang="en-US" id="id_10184323_3053534_3_1">Sublicense fee payable, percentage if executed after first patient enrolled in phase three clinical trial.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_SublicenseFeePayablePercentageIfExecutedAfterFirstPatientEnrolledInPhaseThreeClinicalTrial_lbl" xml:lang="en-US" id="id_10184323_3053534_1_1">Sublicense Fee Payable, Percentage if Executed after First Patient Enrolled in Phase Three Clinical Trial</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_SublicenseFeePayablePercentageIfExecutedAfterFirstPatientEnrolledInPhaseThreeClinicalTrial_lbl" xml:lang="en-US" id="id_10184323_3053534_2_1">Sublicense fee payable percentage if executed after first patient enrolled in Phase 3 clinical trial</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_SublicenseFeePayablePercentageIfExecutedAfterFirstPatientEnrolledInPhaseThreeClinicalTrial" xlink:to="sls_SublicenseFeePayablePercentageIfExecutedAfterFirstPatientEnrolledInPhaseThreeClinicalTrial_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SublicenseFeePayablePercentageIfExecutedPriorToFirstPatientEnrolledInPhaseThreeClinicalTrial" xlink:label="sls_SublicenseFeePayablePercentageIfExecutedPriorToFirstPatientEnrolledInPhaseThreeClinicalTrial"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_SublicenseFeePayablePercentageIfExecutedPriorToFirstPatientEnrolledInPhaseThreeClinicalTrial_lbl" xml:lang="en-US" id="id_10184323_3053533_3_1">Sublicense fee payable, percentage if executed prior to first patient enrolled in phase three clinical trial.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_SublicenseFeePayablePercentageIfExecutedPriorToFirstPatientEnrolledInPhaseThreeClinicalTrial_lbl" xml:lang="en-US" id="id_10184323_3053533_1_1">Sublicense Fee Payable, Percentage if Executed prior to First Patient Enrolled in Phase Three Clinical Trial</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_SublicenseFeePayablePercentageIfExecutedPriorToFirstPatientEnrolledInPhaseThreeClinicalTrial_lbl" xml:lang="en-US" id="id_10184323_3053533_2_1">Sublicense fee payable percentage if executed prior to first patient enrolled in Phase 3 clinical trial</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_SublicenseFeePayablePercentageIfExecutedPriorToFirstPatientEnrolledInPhaseThreeClinicalTrial" xlink:to="sls_SublicenseFeePayablePercentageIfExecutedPriorToFirstPatientEnrolledInPhaseThreeClinicalTrial_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="id_10184323_2449609_1_1">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="id_10184323_2449609_2_1">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="id_10184323_2449610_1_1">Subsequent Events [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="id_10184323_2449610_2_1">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="id_10184323_2449887_1_1">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="id_10184323_2449887_2_1">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="id_10184323_2449888_1_1">Subsequent Event Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="id_10184323_2449888_2_1">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="id_10184323_2449611_1_1">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="id_10184323_2449611_2_1">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" id="id_10184323_2449620_1_1">Sale of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" id="id_10184323_2449620_2_1">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SuccessFeeAndOtherTransactionCosts" xlink:label="sls_SuccessFeeAndOtherTransactionCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_SuccessFeeAndOtherTransactionCosts_lbl" xml:lang="en-US" id="id_10184323_3049687_3_1">Success fee and other transaction costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_SuccessFeeAndOtherTransactionCosts_lbl" xml:lang="en-US" id="id_10184323_3049687_1_1">Success fee and other transaction costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_SuccessFeeAndOtherTransactionCosts_lbl" xml:lang="en-US" id="id_10184323_3049687_2_1">Success fee and other transaction costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_SuccessFeeAndOtherTransactionCosts" xlink:to="sls_SuccessFeeAndOtherTransactionCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_lbl" xml:lang="en-US" id="id_10184323_2449558_1_1">Tax Credit Carryforward [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_lbl" xml:lang="en-US" id="id_10184323_2449558_2_1">Tax Credit Carryforward [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardTable_lbl" xml:lang="en-US" id="id_10184323_2450065_1_1">Tax Credit Carryforward [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardTable_lbl" xml:lang="en-US" id="id_10184323_2450065_2_1">Tax Credit Carryforward [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US" id="id_10184323_2449942_1_1">Taxes Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US" id="id_10184323_2449942_2_1">Value added tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ThirdPartyMember" xlink:label="sls_ThirdPartyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ThirdPartyMember_lbl" xml:lang="en-US" id="id_10184323_2660097_3_1">Third Party [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ThirdPartyMember_lbl" xml:lang="en-US" id="id_10184323_2660097_1_1">Third Party [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ThirdPartyMember_lbl" xml:lang="en-US" id="id_10184323_2660097_2_1">Third Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ThirdPartyMember" xlink:to="sls_ThirdPartyMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ThirdTrancheMember" xlink:label="sls_ThirdTrancheMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ThirdTrancheMember_lbl" xml:lang="en-US" id="id_10184323_2733354_3_1">Third Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ThirdTrancheMember_lbl" xml:lang="en-US" id="id_10184323_2733354_1_1">Third Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ThirdTrancheMember_lbl" xml:lang="en-US" id="id_10184323_2733354_2_1">Payable on or Before October 31, 2017 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ThirdTrancheMember" xlink:to="sls_ThirdTrancheMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xml:lang="en-US" id="id_10184323_2449718_1_1">Title of Individual [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xml:lang="en-US" id="id_10184323_2449718_2_1">Title of Individual [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" id="id_10184323_2449719_1_1">Relationship to Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" id="id_10184323_2449719_2_1">Relationship to Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_TradingDays" xlink:label="sls_TradingDays"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_TradingDays_lbl" xml:lang="en-US" id="id_10184323_2639236_3_1">Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_TradingDays_lbl" xml:lang="en-US" id="id_10184323_2639236_1_1">Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_TradingDays_lbl" xml:lang="en-US" id="id_10184323_2639236_2_1">Trading days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_TradingDays" xlink:to="sls_TradingDays_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" id="id_10184323_2450288_1_1">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" id="id_10184323_2450288_2_1">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" id="id_10184323_2449742_1_1">Financial Instruments [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" id="id_10184323_2449742_2_1">Financial Instruments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_TrojantecLicenseAgreementMember" xlink:label="sls_TrojantecLicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_TrojantecLicenseAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3049275_3_1">Trojantec license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_TrojantecLicenseAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3049275_1_1">Trojantec License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_TrojantecLicenseAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3049275_2_1">Trojantec License Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_TrojantecLicenseAgreementMember" xlink:to="sls_TrojantecLicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_TrojantecLtdMember" xlink:label="sls_TrojantecLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_TrojantecLtdMember_lbl" xml:lang="en-US" id="id_10184323_3049272_3_1">Trojantec Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_TrojantecLtdMember_lbl" xml:lang="en-US" id="id_10184323_3049272_1_1">Trojantec Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_TrojantecLtdMember_lbl" xml:lang="en-US" id="id_10184323_3049272_2_1">Trojantec</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_TrojantecLtdMember" xlink:to="sls_TrojantecLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_TwoThousandAndSeventeenEquityIncentivePlanMember" xlink:label="sls_TwoThousandAndSeventeenEquityIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_TwoThousandAndSeventeenEquityIncentivePlanMember_lbl" xml:lang="en-US" id="id_10184323_2909678_3_1">Two Thousand And Seventeen Equity Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_TwoThousandAndSeventeenEquityIncentivePlanMember_lbl" xml:lang="en-US" id="id_10184323_2909678_1_1">Two Thousand And Seventeen Equity Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_TwoThousandAndSeventeenEquityIncentivePlanMember_lbl" xml:lang="en-US" id="id_10184323_2909678_2_1">2017 Equity Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_TwoThousandAndSeventeenEquityIncentivePlanMember" xlink:to="sls_TwoThousandAndSeventeenEquityIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_TwoThousandAndSixteenEquityIncentivePlanMember" xlink:label="sls_TwoThousandAndSixteenEquityIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_TwoThousandAndSixteenEquityIncentivePlanMember_lbl" xml:lang="en-US" id="id_10184323_2694343_3_1">Two thousand and sixteen equity incentive plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_TwoThousandAndSixteenEquityIncentivePlanMember_lbl" xml:lang="en-US" id="id_10184323_2694343_1_1">Two Thousand And Sixteen Equity Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_TwoThousandAndSixteenEquityIncentivePlanMember_lbl" xml:lang="en-US" id="id_10184323_2694343_2_1">2016 Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_TwoThousandAndSixteenEquityIncentivePlanMember" xlink:to="sls_TwoThousandAndSixteenEquityIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_TwoThousandFifiteenLoanAgreementMember" xlink:label="sls_TwoThousandFifiteenLoanAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_TwoThousandFifiteenLoanAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3053908_3_1">Two thousand fifiteen loan agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_TwoThousandFifiteenLoanAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3053908_1_1">Two Thousand Fifiteen Loan Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_TwoThousandFifiteenLoanAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3053908_2_1">2015 Loan Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_TwoThousandFifiteenLoanAgreementMember" xlink:to="sls_TwoThousandFifiteenLoanAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_TwoThousandFifteenNotesMember" xlink:label="sls_TwoThousandFifteenNotesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_TwoThousandFifteenNotesMember_lbl" xml:lang="en-US" id="id_10184323_2679970_3_1">Two Thousand Fifteen Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_TwoThousandFifteenNotesMember_lbl" xml:lang="en-US" id="id_10184323_2679970_1_1">Two Thousand Fifteen Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_TwoThousandFifteenNotesMember_lbl" xml:lang="en-US" id="id_10184323_2679970_2_1">2015 Notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_TwoThousandFifteenNotesMember" xlink:to="sls_TwoThousandFifteenNotesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_TwoThousandThirteenLoanAgreementMember" xlink:label="sls_TwoThousandThirteenLoanAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_TwoThousandThirteenLoanAgreementMember_lbl" xml:lang="en-US" id="id_10184323_2895689_3_1">Two thousand thirteen loan agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_TwoThousandThirteenLoanAgreementMember_lbl" xml:lang="en-US" id="id_10184323_2895689_1_1">Two Thousand Thirteen Loan Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_TwoThousandThirteenLoanAgreementMember_lbl" xml:lang="en-US" id="id_10184323_2895689_2_1">2013 Loan Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_TwoThousandThirteenLoanAgreementMember" xlink:to="sls_TwoThousandThirteenLoanAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_TwoZeroOneFiveConvertibleTermNotesMember" xlink:label="sls_TwoZeroOneFiveConvertibleTermNotesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_TwoZeroOneFiveConvertibleTermNotesMember_lbl" xml:lang="en-US" id="id_10184323_3049445_3_1">Two zero one five convertible term notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_TwoZeroOneFiveConvertibleTermNotesMember_lbl" xml:lang="en-US" id="id_10184323_3049445_1_1">Two Zero One Five Convertible Term Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_TwoZeroOneFiveConvertibleTermNotesMember_lbl" xml:lang="en-US" id="id_10184323_3049445_2_1">2015 Shareholder Notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_TwoZeroOneFiveConvertibleTermNotesMember" xlink:to="sls_TwoZeroOneFiveConvertibleTermNotesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_TwoZeroOneSixConvertibleTermNotesMember" xlink:label="sls_TwoZeroOneSixConvertibleTermNotesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_TwoZeroOneSixConvertibleTermNotesMember_lbl" xml:lang="en-US" id="id_10184323_3049453_3_1">2016 Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_TwoZeroOneSixConvertibleTermNotesMember_lbl" xml:lang="en-US" id="id_10184323_3049453_1_1">Two Zero One Six Convertible Term Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_TwoZeroOneSixConvertibleTermNotesMember_lbl" xml:lang="en-US" id="id_10184323_3049453_2_1">2016 Notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_TwoZeroOneSixConvertibleTermNotesMember" xlink:to="sls_TwoZeroOneSixConvertibleTermNotesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="id_10184323_2450320_1_1">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="id_10184323_2450320_2_1">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" id="id_10184323_2449810_1_1">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" id="id_10184323_2449810_4_1">End of the Year - unrecognized tax benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" id="id_10184323_2449810_5_1">Beginning of the Year - unrecognized tax benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" id="id_10184323_2449812_1_1">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" id="id_10184323_2449812_2_1">Increases - current year tax positions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" id="id_10184323_2450370_1_1">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" id="id_10184323_2450370_2_1">Increases/ (Decrease) - prior year tax positions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_UpfrontLicenseFees" xlink:label="sls_UpfrontLicenseFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_UpfrontLicenseFees_lbl" xml:lang="en-US" id="id_10184323_2499679_3_1">Represents the amount of the upfront license fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_UpfrontLicenseFees_lbl" xml:lang="en-US" id="id_10184323_2499679_1_1">Upfront License Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_UpfrontLicenseFees_lbl" xml:lang="en-US" id="id_10184323_2499679_2_1">Upfront license fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_UpfrontLicenseFees" xlink:to="sls_UpfrontLicenseFees_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_UsattorneysofficeforthedistrictofnewjerseyanddepartmentofjusticeMember" xlink:label="sls_UsattorneysofficeforthedistrictofnewjerseyanddepartmentofjusticeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_UsattorneysofficeforthedistrictofnewjerseyanddepartmentofjusticeMember_lbl" xml:lang="en-US" id="id_10184323_3049464_3_1">USAO NJ and DOJ</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_UsattorneysofficeforthedistrictofnewjerseyanddepartmentofjusticeMember_lbl" xml:lang="en-US" id="id_10184323_3049464_1_1">US Attorneys Office For The District Of New Jersey And Department Of Justice [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_UsattorneysofficeforthedistrictofnewjerseyanddepartmentofjusticeMember_lbl" xml:lang="en-US" id="id_10184323_3049464_2_1">US Attorneys Office For The District Of New Jersey And Department Of Justice [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_UsattorneysofficeforthedistrictofnewjerseyanddepartmentofjusticeMember" xlink:to="sls_UsattorneysofficeforthedistrictofnewjerseyanddepartmentofjusticeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="id_10184323_2450913_1_1">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="id_10184323_2450913_2_1">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" id="id_10184323_2450785_1_1">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" id="id_10184323_2450785_2_1">Increase in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" id="id_10184323_2450814_1_1">Vesting [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" id="id_10184323_2450814_2_1">Vesting [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" id="id_10184323_2450815_1_1">Vesting [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" id="id_10184323_2450815_2_1">Vesting [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ViceChairmanMember" xlink:label="sls_ViceChairmanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_ViceChairmanMember_lbl" xml:lang="en-US" id="id_10184323_2723027_3_1">Vice chairman.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_ViceChairmanMember_lbl" xml:lang="en-US" id="id_10184323_2723027_1_1">Vice Chairman [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_ViceChairmanMember_lbl" xml:lang="en-US" id="id_10184323_2723027_2_1">Vice Chairman</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_ViceChairmanMember" xlink:to="sls_ViceChairmanMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_VotingAgreementMember" xlink:label="sls_VotingAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_VotingAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3050049_3_1">Voting agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_VotingAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3050049_1_1">Voting Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_VotingAgreementMember_lbl" xml:lang="en-US" id="id_10184323_3050049_2_1">Voting Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_VotingAgreementMember" xlink:to="sls_VotingAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_WarrantExcercisableTerm" xlink:label="sls_WarrantExcercisableTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_WarrantExcercisableTerm_lbl" xml:lang="en-US" id="id_10184323_2865730_3_1">Warrant excercisable term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_WarrantExcercisableTerm_lbl" xml:lang="en-US" id="id_10184323_2865730_1_1">Warrant Excercisable Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_WarrantExcercisableTerm_lbl" xml:lang="en-US" id="id_10184323_2865730_2_1">Date from which warrants exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_WarrantExcercisableTerm" xlink:to="sls_WarrantExcercisableTerm_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_WarrantExercisePriceAsPercentOfDebtConversion" xlink:label="sls_WarrantExercisePriceAsPercentOfDebtConversion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_WarrantExercisePriceAsPercentOfDebtConversion_lbl" xml:lang="en-US" id="id_10184323_3049458_3_1">Warrant exercise price as percent of debt conversion.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_WarrantExercisePriceAsPercentOfDebtConversion_lbl" xml:lang="en-US" id="id_10184323_3049458_1_1">Warrant Exercise Price As Percent Of Debt Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_WarrantExercisePriceAsPercentOfDebtConversion_lbl" xml:lang="en-US" id="id_10184323_3049458_2_1">Warrant exercise price as percent of debt conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_WarrantExercisePriceAsPercentOfDebtConversion" xlink:to="sls_WarrantExercisePriceAsPercentOfDebtConversion_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_WarrantLiability" xlink:label="sls_WarrantLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_WarrantLiability_lbl" xml:lang="en-US" id="id_10184323_2528770_3_1">Warrant liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_WarrantLiability_lbl" xml:lang="en-US" id="id_10184323_2528770_1_1">Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_WarrantLiability_lbl" xml:lang="en-US" id="id_10184323_2528770_2_1">Warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_WarrantLiability" xlink:to="sls_WarrantLiability_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" id="id_10184323_2450820_1_1">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" id="id_10184323_2450820_2_1">Common stock warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xml:lang="en-US" id="id_10184323_2450975_1_1">Warrants and Rights Note Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xml:lang="en-US" id="id_10184323_2450975_2_1">Warrants and Rights Note Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_WarrantsFairValueAssumptionsExpectedVolatility" xlink:label="sls_WarrantsFairValueAssumptionsExpectedVolatility"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_WarrantsFairValueAssumptionsExpectedVolatility_lbl" xml:lang="en-US" id="id_10184323_2796656_3_1">Warrants Fair Value Assumptions Expected Volatility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_WarrantsFairValueAssumptionsExpectedVolatility_lbl" xml:lang="en-US" id="id_10184323_2796656_1_1">Warrants Fair Value Assumptions Expected Volatility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_WarrantsFairValueAssumptionsExpectedVolatility_lbl" xml:lang="en-US" id="id_10184323_2796656_2_1">Volatility%</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_WarrantsFairValueAssumptionsExpectedVolatility" xlink:to="sls_WarrantsFairValueAssumptionsExpectedVolatility_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_WarrantsFairValueAssumptionsRiskFreeInterestRate" xlink:label="sls_WarrantsFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_WarrantsFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_10184323_2781105_3_1">Warrants Fair Value Assumptions Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_WarrantsFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_10184323_2781105_1_1">Warrants Fair Value Assumptions Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_WarrantsFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_10184323_2781105_2_1">Risk-free rate %</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_WarrantsFairValueAssumptionsRiskFreeInterestRate" xlink:to="sls_WarrantsFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_WarrantsIssuedShares" xlink:label="sls_WarrantsIssuedShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_WarrantsIssuedShares_lbl" xml:lang="en-US" id="id_10184323_2608252_3_1">Warrants Issued Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_WarrantsIssuedShares_lbl" xml:lang="en-US" id="id_10184323_2608252_1_1">Warrants Issued Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_WarrantsIssuedShares_lbl" xml:lang="en-US" id="id_10184323_2608252_2_1">Warrant issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_WarrantsIssuedShares" xlink:to="sls_WarrantsIssuedShares_lbl"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_WarrantStrikePrice" xlink:label="sls_WarrantStrikePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sls_WarrantStrikePrice_lbl" xml:lang="en-US" id="id_10184323_2773928_3_1">Warrant Strike Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sls_WarrantStrikePrice_lbl" xml:lang="en-US" id="id_10184323_2773928_1_1">Warrant Strike Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sls_WarrantStrikePrice_lbl" xml:lang="en-US" id="id_10184323_2773928_2_1">Strike price (per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sls_WarrantStrikePrice" xlink:to="sls_WarrantStrikePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" id="id_10184323_2450563_1_1">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" id="id_10184323_2450563_2_1">Weighted-average common shares outstanding, basic and diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" id="id_10184323_2450829_1_1">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" id="id_10184323_2450829_2_1">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>33
<FILENAME>sls-20171231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFS Xcelerate Taxonomy Presentation Linkbase - http://www.dfsco.com/financial-services/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 7 -->
<!-- Creation date: 2018-04-13T14:49:15Z -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DocumentandEntityInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_StatementOfIncome" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureOrganizationAndDescriptionOfBusinessSummaryOfAdjustmentsToAdditionalPaidinCapital" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessSummaryOfAdjustmentsToAdditionalPaidinCapital"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureLiquidityAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureLiquidityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesOutstandingExcludedFromComputationOfDilutedWeightedAverageSharesOut_Xa" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesOutstandingExcludedFromComputationOfDilutedWeightedAverageSharesOut_Xa"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureBusinessCombinationAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBusinessCombinationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureBusinessCombinationSummaryOfPurchasePrice" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBusinessCombinationSummaryOfPurchasePrice"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureBusinessCombinationTotalPurchasePriceAllocation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBusinessCombinationTotalPurchasePriceAllocation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureBusinessCombinationProFormaConsolidatedFinancialInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBusinessCombinationProFormaConsolidatedFinancialInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureGoodwillAndIntangibleAssetsSummaryOfChangesInCarryingAmountOfGoodwill" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfChangesInCarryingAmountOfGoodwill"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureGoodwillAndIntangibleAssetsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureFairValueMeasurementsContingentPurchasePriceConsiderationConvertibleDebtMeasuredAtEstimatedFairValueOnRecurringBasis" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueMeasurementsContingentPurchasePriceConsiderationConvertibleDebtMeasuredAtEstimatedFairValueOnRecurringBasis"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureFairValueMeasurementsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilities" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureDebtSummaryOfDebtAndConvertibleDebt" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtSummaryOfDebtAndConvertibleDebt"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureDebtAdditionalInformationSeniorSecuredDebenture" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformationSeniorSecuredDebenture"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureDebtAdditionalInformationConvertibleDebt" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformationConvertibleDebt"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureDebtAdditionalInformationLongtermDebt" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformationLongtermDebt"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationLegalProceedings" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationLegalProceedings"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalCommitmentsForOperatingLeases" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalCommitmentsForOperatingLeases"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureStockholdersEquityAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureStockholdersEquityCommonStockAreReservedForFutureIssuance" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityCommonStockAreReservedForFutureIssuance"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureWarrantsScheduleOfWarrantActivity" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsScheduleOfWarrantActivity"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureWarrantsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureWarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModel" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModel"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureWarrantsChangesInFairValueOfWarrantLiability" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsChangesInFairValueOfWarrantLiability"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureWarrantsWarrantsClassifiedAsEquity" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsWarrantsClassifiedAsEquity"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureStockBasedCompensationAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureStockBasedCompensationScheduleOfAllocatedStockbasedCompensationExpense" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAllocatedStockbasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureStockBasedCompensationScheduleOfGrantDateFairValuesOfOptionIssuedToEmployeesAndNonEmployees" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfGrantDateFairValuesOfOptionIssuedToEmployeesAndNonEmployees"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureStockBasedCompensationStockOptionActivity" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivity"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureStockBasedCompensationRSUActivityForRSUsWithOnlyTimeBasedCondition" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationRSUActivityForRSUsWithOnlyTimeBasedCondition"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureStockBasedCompensationRSUActivityForRSUsWithBothTimeBasedAndPerformanceBasedCondition" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationRSUActivityForRSUsWithBothTimeBasedAndPerformanceBasedCondition"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureIncomeTaxesScheduleOfLossBeforeIncomeTaxes" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeIncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefit" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefit"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssets" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssets"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilities" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureIncomeTaxesScheduleOfProvisionComputedByApplyingFederalStatutoryRate" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionComputedByApplyingFederalStatutoryRate"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureIncomeTaxesAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureIncomeTaxesScheduleOfChangesToCompanysUnrecognizedTaxBenefits" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfChangesToCompanysUnrecognizedTaxBenefits"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureRelatedPartyTransactionsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#DisclosureSubsequentEventsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsLiquidationBasisOfAccountingTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsLiquidationBasisOfAccountingTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsBusinessCombinationDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsOptionIndexedToIssuersEquityDescriptionTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOptionIndexedToIssuersEquityDescriptionTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsOptionIndexedToIssuersEquityDescriptionTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOptionIndexedToIssuersEquityDescriptionTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sls-20171231.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DocumentAndEntityInformationAbstract" xlink:label="sls_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityVoluntaryFilers" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityPublicFloat" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:label="sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationReserveCurrent" xlink:label="us-gaap_LitigationReserveCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_WarrantLiability" xlink:label="sls_WarrantLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="sls_WarrantLiability" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ConvertibleDebtNoncurrent" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrent" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ConvertibleDebtCurrent" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LitigationReserveCurrent" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfIncome">
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DeemedDividendOnDebtConversion" xlink:label="sls_DeemedDividendOnDebtConversion"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="1.0600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="sls_DeemedDividendOnDebtConversion" order="1.1000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SeveranceCosts1" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion" xlink:label="sls_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition" xlink:label="sls_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod" xlink:label="sls_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares" xlink:label="sls_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SharesIssuedInCancellationOfLicenseAgreement" xlink:label="sls_SharesIssuedInCancellationOfLicenseAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodSharesCancellationOfLongTermDebt" xlink:label="sls_StockIssuedDuringPeriodSharesCancellationOfLongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodSharesLicenseAgreement" xlink:label="sls_StockIssuedDuringPeriodSharesLicenseAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodSharesPartialConsiderationOfLicenseFee" xlink:label="sls_StockIssuedDuringPeriodSharesPartialConsiderationOfLicenseFee"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable" xlink:label="sls_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares" xlink:label="sls_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodValueCancellationOfLongTermDebt" xlink:label="sls_StockIssuedDuringPeriodValueCancellationOfLongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodValueLicenseAgreement" xlink:label="sls_StockIssuedDuringPeriodValueLicenseAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee" xlink:label="sls_StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable" xlink:label="sls_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedForAntiDilutionProvisions" xlink:label="sls_StockIssuedForAntiDilutionProvisions"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedForAntiDilutionProvisionsShares" xlink:label="sls_StockIssuedForAntiDilutionProvisionsShares"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod" xlink:label="sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares" xlink:label="sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue" xlink:label="sls_StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares" xlink:label="sls_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue" xlink:label="sls_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockIssuedDuringPeriodSharesPartialConsiderationOfLicenseFee" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockIssuedDuringPeriodValueLicenseAgreement" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockIssuedDuringPeriodSharesLicenseAgreement" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_SharesIssuedInCancellationOfLicenseAgreement" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockIssuedDuringPeriodValueCancellationOfLongTermDebt" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockIssuedDuringPeriodSharesCancellationOfLongTermDebt" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockIssuedForAntiDilutionProvisions" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockIssuedForAntiDilutionProvisionsShares" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_2" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_2" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ConvertibleDebtTwoThousandFifteenShareholderNotesMember" xlink:label="sls_ConvertibleDebtTwoThousandFifteenShareholderNotesMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ConvertibleDebtTwoThousandSelyNoteMember" xlink:label="sls_ConvertibleDebtTwoThousandSelyNoteMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance" xlink:label="sls_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FairValueOfStockOptionsAssumedInConnectionWithAcquisition" xlink:label="sls_FairValueOfStockOptionsAssumedInConnectionWithAcquisition"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract" xlink:label="us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_NonCashResearchAndDevelopmentExpense" xlink:label="sls_NonCashResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SharesIssuedInConnectionWithAcquisition" xlink:label="sls_SharesIssuedInConnectionWithAcquisition"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SharesIssuedToSettleAccountsPayable" xlink:label="sls_SharesIssuedToSettleAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SharesIssuedToSettlerElatedPartyAccountsPayable" xlink:label="sls_SharesIssuedToSettlerElatedPartyAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="sls_NonCashResearchAndDevelopmentExpense" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PaidInKindInterest" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1.0500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxesAndTaxCredits" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_SeveranceCosts1" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="sls_SharesIssuedInConnectionWithAcquisition" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="sls_FairValueOfStockOptionsAssumedInConnectionWithAcquisition" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="sls_SharesIssuedToSettlerElatedPartyAccountsPayable" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="sls_SharesIssuedToSettleAccountsPayable" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_StockIssued1" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="sls_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.1000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="sls_ConvertibleDebtTwoThousandFifteenShareholderNotesMember" order="1.3800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="sls_ConvertibleDebtTwoThousandSelyNoteMember" order="1.3900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" order="1.2300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" order="1.1800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformation">
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_CommonStockConversionRatio" xlink:label="sls_CommonStockConversionRatio"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_OrganizationAndDescriptionOfBusinessLineItems" xlink:label="sls_OrganizationAndDescriptionOfBusinessLineItems"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_OrganizationAndDescriptionOfBusinessTable" xlink:label="sls_OrganizationAndDescriptionOfBusinessTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PercentageOfFullyDilutedShareCapitalOwned" xlink:label="sls_PercentageOfFullyDilutedShareCapitalOwned"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PremergerSecurityholdersMember" xlink:label="sls_PremergerSecurityholdersMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PrivateSELLASMember" xlink:label="sls_PrivateSELLASMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sls_PrivateSELLASMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sls_PremergerSecurityholdersMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="sls_CommonStockConversionRatio" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="sls_PercentageOfFullyDilutedShareCapitalOwned" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_OrganizationAndDescriptionOfBusinessTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_OrganizationAndDescriptionOfBusinessTable" xlink:to="sls_OrganizationAndDescriptionOfBusinessLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="sls_OrganizationAndDescriptionOfBusinessTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessSummaryOfAdjustmentsToAdditionalPaidinCapital">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="us-gaap_RestatementAdjustmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="us-gaap_ScenarioPreviouslyReportedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_2"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodValueCancellationOfLongTermDebt" xlink:label="sls_StockIssuedDuringPeriodValueCancellationOfLongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodValueLicenseAgreement" xlink:label="sls_StockIssuedDuringPeriodValueLicenseAgreement"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee" xlink:label="sls_StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue" xlink:label="sls_StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="sls_StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="sls_StockIssuedDuringPeriodValueLicenseAgreement" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="sls_StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="sls_StockIssuedDuringPeriodValueCancellationOfLongTermDebt" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_StockholdersEquity_2" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPreviouslyReportedMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_RestatementAdjustmentMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:to="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureLiquidityAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebentureMember" xlink:label="sls_DebentureMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DecreaseInRestrictedCash" xlink:label="us-gaap_DecreaseInRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FirstTrancheMember" xlink:label="sls_FirstTrancheMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LiquidityAbstract" xlink:label="sls_LiquidityAbstract"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LiquidityLineItems" xlink:label="sls_LiquidityLineItems"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LiquidityTable" xlink:label="sls_LiquidityTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SecondTrancheMember" xlink:label="sls_SecondTrancheMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SeriesAConvertiblePreferredStockMember" xlink:label="sls_SeriesAConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sls_SeriesAConvertiblePreferredStockMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sls_DebentureMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LiquidityAbstract" xlink:to="sls_LiquidityTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LiquidityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LiquidityLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LiquidityLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LiquidityLineItems" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LiquidityLineItems" xlink:to="us-gaap_DecreaseInRestrictedCash" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LiquidityLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LiquidityLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LiquidityLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LiquidityLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LiquidityLineItems" xlink:to="us-gaap_LongTermDebt" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LiquidityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LiquidityTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LiquidityTable" xlink:to="us-gaap_DebtInstrumentAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LiquidityTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LiquidityTable" xlink:to="sls_LiquidityLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sls_FirstTrancheMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sls_SecondTrancheMember" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SignificantAccountingPoliciesLineItems" xlink:label="sls_SignificantAccountingPoliciesLineItems"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SignificantAccountingPoliciesTable" xlink:label="sls_SignificantAccountingPoliciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sls_SignificantAccountingPoliciesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SeveranceCosts1" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_SignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementScenarioAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_SignificantAccountingPoliciesTable" xlink:to="sls_SignificantAccountingPoliciesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesOutstandingExcludedFromComputationOfDilutedWeightedAverageSharesOut_Xa">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBusinessCombinationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:label="us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BusinessCombinationProFormaTransactionCosts" xlink:label="sls_BusinessCombinationProFormaTransactionCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_EquilibriaCollaborationAgreementMember" xlink:label="sls_EquilibriaCollaborationAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_GalenaBiopharmaIncMember" xlink:label="sls_GalenaBiopharmaIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:label="us-gaap_ProductionRelatedImpairmentsOrCharges"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod" xlink:label="sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares" xlink:label="sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SuccessFeeAndOtherTransactionCosts" xlink:label="sls_SuccessFeeAndOtherTransactionCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="sls_GalenaBiopharmaIncMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationIntegrationRelatedCosts" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sls_BusinessCombinationProFormaTransactionCosts" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sls_SuccessFeeAndOtherTransactionCosts" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_SeveranceCosts1" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ProductionRelatedImpairmentsOrCharges" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sls_EquilibriaCollaborationAgreementMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBusinessCombinationSummaryOfPurchasePrice">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredAbstract"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding" xlink:label="sls_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BusinessCombinationFairValueOfSharesOutstanding" xlink:label="sls_BusinessCombinationFairValueOfSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="sls_BusinessCombinationFairValueOfSharesOutstanding" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="sls_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBusinessCombinationTotalPurchasePriceAllocation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses" xlink:label="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement" xlink:label="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:label="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability" xlink:label="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_GalenaBiopharmaIncMember" xlink:label="sls_GalenaBiopharmaIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="sls_GalenaBiopharmaIncMember" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_Goodwill" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBusinessCombinationProFormaConsolidatedFinancialInformation">
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:label="sls_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BusinessCombinationIncreaseDecreaseToReflectLiabilitiesAcquiredAtFairValueAbstract" xlink:label="sls_BusinessCombinationIncreaseDecreaseToReflectLiabilitiesAcquiredAtFairValueAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_BusinessCombinationIncreaseDecreaseToReflectLiabilitiesAcquiredAtFairValueAbstract" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_BusinessCombinationIncreaseDecreaseToReflectLiabilitiesAcquiredAtFairValueAbstract" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_BusinessCombinationIncreaseDecreaseToReflectLiabilitiesAcquiredAtFairValueAbstract" xlink:to="sls_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfChangesInCarryingAmountOfGoodwill">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="us-gaap_GoodwillAcquiredDuringPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_Goodwill" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAcquiredDuringPeriod" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_Goodwill_2" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_GaleFourZeroOneMember" xlink:label="sls_GaleFourZeroOneMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_GalenaBiopharmaIncMember" xlink:label="sls_GalenaBiopharmaIncMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_GaleThreeZeroTwoMember" xlink:label="sls_GaleThreeZeroTwoMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_GoodwillAndIntangibleAssetsLineItems" xlink:label="sls_GoodwillAndIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_GoodwillAndIntangibleAssetsTable" xlink:label="sls_GoodwillAndIntangibleAssetsTable"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_NeuvaxMember" xlink:label="sls_NeuvaxMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="sls_GalenaBiopharmaIncMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="sls_GoodwillAndIntangibleAssetsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_GoodwillAndIntangibleAssetsLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_GoodwillAndIntangibleAssetsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_GoodwillAndIntangibleAssetsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_GoodwillAndIntangibleAssetsTable" xlink:to="sls_GoodwillAndIntangibleAssetsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sls_GaleFourZeroOneMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sls_NeuvaxMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sls_GaleThreeZeroTwoMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AdditionalExpenseIncurredToReflectFairValueOfSharesIssued" xlink:label="sls_AdditionalExpenseIncurredToReflectFairValueOfSharesIssued"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AdditionalSharesIssuedInConnectionWithLicensingAgreement" xlink:label="sls_AdditionalSharesIssuedInConnectionWithLicensingAgreement"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AdvaxisCollaborationAgreementMember" xlink:label="sls_AdvaxisCollaborationAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AmendedAndRestatedLicenseAgreementMember" xlink:label="sls_AmendedAndRestatedLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AnnualMaintenanceFee" xlink:label="sls_AnnualMaintenanceFee"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BusinessCombinationIncreaseDecreaseToReflectLiabilitiesAcquiredAtFairValueAbstract" xlink:label="sls_BusinessCombinationIncreaseDecreaseToReflectLiabilitiesAcquiredAtFairValueAbstract"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ChiefExecutiveOfficerCoFounderMember" xlink:label="sls_ChiefExecutiveOfficerCoFounderMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ClarendonLicenseAgreementMember" xlink:label="sls_ClarendonLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ClarendonTradingEinvestimentosLDAMember" xlink:label="sls_ClarendonTradingEinvestimentosLDAMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_CoFounderMember" xlink:label="sls_CoFounderMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FirstTrojantecAmendmentMember" xlink:label="sls_FirstTrojantecAmendmentMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FourthTrancheMember" xlink:label="sls_FourthTrancheMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LiabilitiesUnderTerminationAgreementPayableInCash" xlink:label="sls_LiabilitiesUnderTerminationAgreementPayableInCash"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseAgreementAmendmentDate" xlink:label="sls_LicenseAgreementAmendmentDate"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseAgreementAmendmentExtendedDateForFinancing" xlink:label="sls_LicenseAgreementAmendmentExtendedDateForFinancing"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseAgreementDate" xlink:label="sls_LicenseAgreementDate"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseAgreementDateSecondAmended" xlink:label="sls_LicenseAgreementDateSecondAmended"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseAgreementEffectiveDate" xlink:label="sls_LicenseAgreementEffectiveDate"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseAgreementExpirationTerm" xlink:label="sls_LicenseAgreementExpirationTerm"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseAgreementMember" xlink:label="sls_LicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseAgreementOutstandingAmountPayable" xlink:label="sls_LicenseAgreementOutstandingAmountPayable"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseAgreementTerminationDate" xlink:label="sls_LicenseAgreementTerminationDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseAmendmentWaiverAndShareIssuanceAgreementMember" xlink:label="sls_LicenseAmendmentWaiverAndShareIssuanceAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseAndCollaborationAgreementsLineItems" xlink:label="sls_LicenseAndCollaborationAgreementsLineItems"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseAndCollaborationAgreementsTable" xlink:label="sls_LicenseAndCollaborationAgreementsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseCosts" xlink:label="us-gaap_LicenseCosts"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LicenseTerminationFeesPaid" xlink:label="sls_LicenseTerminationFeesPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MaximumNumberOfDaysToMakePayments" xlink:label="sls_MaximumNumberOfDaysToMakePayments"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember" xlink:label="sls_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MemorialSloanKetteringCancerCenterMember" xlink:label="sls_MemorialSloanKetteringCancerCenterMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MilestoneFeePaymentsUponCommencementOfClinicalTrials" xlink:label="sls_MilestoneFeePaymentsUponCommencementOfClinicalTrials"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MilestonePayment" xlink:label="sls_MilestonePayment"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MilestonePayments" xlink:label="sls_MilestonePayments"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MilestonePaymentsReceivable" xlink:label="sls_MilestonePaymentsReceivable"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MinimumAnnualRoyaltyPayment" xlink:label="sls_MinimumAnnualRoyaltyPayment"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_NonrefundableMilestonePayments" xlink:label="sls_NonrefundableMilestonePayments"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_NonrefundableSalesMilestonePayments" xlink:label="sls_NonrefundableSalesMilestonePayments"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_NumberOfInstallmentsToMakePayments" xlink:label="sls_NumberOfInstallmentsToMakePayments"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_NumberOfTranches" xlink:label="sls_NumberOfTranches"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PercentageOfFullyDilutedShareCapital" xlink:label="sls_PercentageOfFullyDilutedShareCapital"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PreviousRoyaltyObligationPercentage" xlink:label="sls_PreviousRoyaltyObligationPercentage"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PreviousRoyaltyOnNetSalesValue" xlink:label="sls_PreviousRoyaltyOnNetSalesValue"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ProceedsFromMilestoneBasedPayments" xlink:label="sls_ProceedsFromMilestoneBasedPayments"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ProjectManagementFeesPayable" xlink:label="sls_ProjectManagementFeesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ResearchFundingCosts" xlink:label="sls_ResearchFundingCosts"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_RoyaltyOnNetSalesValue" xlink:label="sls_RoyaltyOnNetSalesValue"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_RoyaltyRatePercentage" xlink:label="sls_RoyaltyRatePercentage"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SecondAmendedAndRestatedExclusiveLicenseAgreementMember" xlink:label="sls_SecondAmendedAndRestatedExclusiveLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SecondLicenseAmendmentWaiverAndAgreementMember" xlink:label="sls_SecondLicenseAmendmentWaiverAndAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SharesIssuableForConsiderationForLicenseTerminationAgreement" xlink:label="sls_SharesIssuableForConsiderationForLicenseTerminationAgreement"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SharesIssuedUnderLicenseAgreement" xlink:label="sls_SharesIssuedUnderLicenseAgreement"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement" xlink:label="sls_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SublicenseFeePayablePercentageIfExecutedAfterFirstPatientEnrolledInPhaseThreeClinicalTrial" xlink:label="sls_SublicenseFeePayablePercentageIfExecutedAfterFirstPatientEnrolledInPhaseThreeClinicalTrial"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SublicenseFeePayablePercentageIfExecutedPriorToFirstPatientEnrolledInPhaseThreeClinicalTrial" xlink:label="sls_SublicenseFeePayablePercentageIfExecutedPriorToFirstPatientEnrolledInPhaseThreeClinicalTrial"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ThirdTrancheMember" xlink:label="sls_ThirdTrancheMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_TrojantecLicenseAgreementMember" xlink:label="sls_TrojantecLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_TrojantecLtdMember" xlink:label="sls_TrojantecLtdMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_UpfrontLicenseFees" xlink:label="sls_UpfrontLicenseFees"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ViceChairmanMember" xlink:label="sls_ViceChairmanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_LicenseAmendmentWaiverAndShareIssuanceAgreementMember" order="1.4300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_SecondLicenseAmendmentWaiverAndAgreementMember" order="1.4800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_SecondAmendedAndRestatedExclusiveLicenseAgreementMember" order="1.5200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_AdvaxisCollaborationAgreementMember" order="1.5400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_LicenseAgreementMember" order="1.5500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_AmendedAndRestatedLicenseAgreementMember" order="1.5600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_TrojantecLicenseAgreementMember" order="1.5700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_FirstTrojantecAmendmentMember" order="1.5800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_ClarendonLicenseAgreementMember" order="1.5900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_BusinessCombinationIncreaseDecreaseToReflectLiabilitiesAcquiredAtFairValueAbstract" xlink:to="sls_LicenseAndCollaborationAgreementsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_LicenseAgreementEffectiveDate" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_SharesIssuedUnderLicenseAgreement" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_PercentageOfFullyDilutedShareCapital" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_UpfrontLicenseFees" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_MinimumAnnualRoyaltyPayment" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_ResearchFundingCosts" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_MilestonePayments" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_LicenseAgreementExpirationTerm" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_LicenseAgreementAmendmentDate" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_LicenseAgreementAmendmentExtendedDateForFinancing" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_LicenseAgreementDateSecondAmended" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_LicenseAgreementOutstandingAmountPayable" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_AdditionalSharesIssuedInConnectionWithLicensingAgreement" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_MilestonePayment" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_NumberOfInstallmentsToMakePayments" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_MaximumNumberOfDaysToMakePayments" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_MilestoneFeePaymentsUponCommencementOfClinicalTrials" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_NonrefundableMilestonePayments" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_NonrefundableSalesMilestonePayments" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_LicenseCosts" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_LicenseAgreementDate" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_ProjectManagementFeesPayable" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_LicenseAgreementTerminationDate" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_LicenseTerminationFeesPaid" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_LiabilitiesUnderTerminationAgreementPayableInCash" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_SharesIssuableForConsiderationForLicenseTerminationAgreement" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_AdditionalExpenseIncurredToReflectFairValueOfSharesIssued" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_AnnualMaintenanceFee" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_PreviousRoyaltyObligationPercentage" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_RoyaltyRatePercentage" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_PreviousRoyaltyOnNetSalesValue" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_RoyaltyOnNetSalesValue" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_MilestonePaymentsReceivable" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_NumberOfTranches" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_SublicenseFeePayablePercentageIfExecutedPriorToFirstPatientEnrolledInPhaseThreeClinicalTrial" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_SublicenseFeePayablePercentageIfExecutedAfterFirstPatientEnrolledInPhaseThreeClinicalTrial" order="1.3800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsLineItems" xlink:to="sls_ProceedsFromMilestoneBasedPayments" order="1.3900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_RangeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="15.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_LicenseAndCollaborationAgreementsTable" xlink:to="sls_LicenseAndCollaborationAgreementsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="sls_ThirdTrancheMember" order="1.4500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="sls_FourthTrancheMember" order="1.5000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.4200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sls_MemorialSloanKetteringCancerCenterMember" order="1.4000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sls_TrojantecLtdMember" order="1.4900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sls_ClarendonTradingEinvestimentosLDAMember" order="1.5300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sls_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember" order="1.4400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="1.4600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="sls_ChiefExecutiveOfficerCoFounderMember" order="1.4100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="sls_ViceChairmanMember" order="1.4700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="sls_CoFounderMember" order="1.5100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueMeasurementsContingentPurchasePriceConsiderationConvertibleDebtMeasuredAtEstimatedFairValueOnRecurringBasis">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="sls_FairValueOfWarrantsPotentiallySettleableInCash"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_RestrictedCashAndCashEquivalentsFairValueDisclosure" xlink:label="sls_RestrictedCashAndCashEquivalentsFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="sls_RestrictedCashAndCashEquivalentsFairValueDisclosure" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="sls_FairValueOfWarrantsPotentiallySettleableInCash" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BusinessCombinationContingentConsiderationPayableUponAchievementOfMilestones" xlink:label="sls_BusinessCombinationContingentConsiderationPayableUponAchievementOfMilestones"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_TwoThousandFifteenNotesMember" xlink:label="sls_TwoThousandFifteenNotesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="sls_BusinessCombinationContingentConsiderationPayableUponAchievementOfMilestones" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtInstrumentFairValue" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ConvertibleDebt" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_RangeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="sls_TwoThousandFifteenNotesMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedExchangeFeeRebateCurrent" xlink:label="us-gaap_AccruedExchangeFeeRebateCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ContractResearchPayable" xlink:label="sls_ContractResearchPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_TaxesPayableCurrent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedExchangeFeeRebateCurrent" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="sls_ContractResearchPayable" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtSummaryOfDebtAndConvertibleDebt">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ConvertibleDebtTwoThousandFifteenShareholderNotesMember" xlink:label="sls_ConvertibleDebtTwoThousandFifteenShareholderNotesMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ConvertibleDebtTwoThousandSelyNoteMember" xlink:label="sls_ConvertibleDebtTwoThousandSelyNoteMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SeniorSecuredDebenturesMember" xlink:label="sls_SeniorSecuredDebenturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtCurrent" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConvertibleDebt" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="sls_SeniorSecuredDebenturesMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="sls_ConvertibleDebtTwoThousandFifteenShareholderNotesMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="sls_ConvertibleDebtTwoThousandSelyNoteMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformationSeniorSecuredDebenture">
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AmendmentAgreementMember" xlink:label="sls_AmendmentAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebentureMember" xlink:label="sls_DebentureMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtInstrumentCashInExcessOfDebenture" xlink:label="sls_DebtInstrumentCashInExcessOfDebenture"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtInstrumentCommonStockMinimumPriceCondition" xlink:label="sls_DebtInstrumentCommonStockMinimumPriceCondition"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtInstrumentCovenantLiquidityCovenant" xlink:label="sls_DebtInstrumentCovenantLiquidityCovenant"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtInstrumentCovenantPrepayLesserAccruedAndUnpaidInterest" xlink:label="sls_DebtInstrumentCovenantPrepayLesserAccruedAndUnpaidInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtInstrumentPercentageofPriorDayVolumeWeightedAveragePrice" xlink:label="sls_DebtInstrumentPercentageofPriorDayVolumeWeightedAveragePrice"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtInstrumentPercentageofVolumeWeightedAveragePrice" xlink:label="sls_DebtInstrumentPercentageofVolumeWeightedAveragePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtInstrumentRedemptionPrincipalAmountRedeemed" xlink:label="sls_DebtInstrumentRedemptionPrincipalAmountRedeemed"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtInstrumentRedemptionRedemptionPayments" xlink:label="sls_DebtInstrumentRedemptionRedemptionPayments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtRepaymentsDescription" xlink:label="sls_DebtRepaymentsDescription"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DecreaseInRestrictedCash" xlink:label="us-gaap_DecreaseInRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FirstWaiverMember" xlink:label="sls_FirstWaiverMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_NumberofDaysAveragedforExercisePrice" xlink:label="sls_NumberofDaysAveragedforExercisePrice"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ProceedsfromIssuanceofLongtermDebtandWarrantsNet" xlink:label="sls_ProceedsfromIssuanceofLongtermDebtandWarrantsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt" xlink:label="us-gaap_RepaymentsOfSecuredDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SecuritiesPurchaseAgreementMember" xlink:label="sls_SecuritiesPurchaseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_ProceedsfromIssuanceofLongtermDebtandWarrantsNet" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_DebtInstrumentRedemptionRedemptionPayments" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_DebtInstrumentCovenantPrepayLesserAccruedAndUnpaidInterest" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_DebtRepaymentsDescription" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_DebtInstrumentCommonStockMinimumPriceCondition" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_DebtInstrumentCashInExcessOfDebenture" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_DebtInstrumentPercentageofVolumeWeightedAveragePrice" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_NumberofDaysAveragedforExercisePrice" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_DebtInstrumentPercentageofPriorDayVolumeWeightedAveragePrice" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_DebtInstrumentCovenantLiquidityCovenant" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_DebtInstrumentRedemptionPrincipalAmountRedeemed" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfSecuredDebt" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DecreaseInRestrictedCash" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestReceivable" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sls_SecuritiesPurchaseAgreementMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sls_FirstWaiverMember" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sls_AmendmentAgreementMember" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sls_DebentureMember" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_RangeAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_SecuredDebtMember" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformationConvertibleDebt">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BridgeFinancingMember" xlink:label="sls_BridgeFinancingMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BridgeLoan" xlink:label="us-gaap_BridgeLoan"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="us-gaap_CommonStockSharesSubscriptions"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtConversionConvertedInstrumentGainLossRecognized" xlink:label="sls_DebtConversionConvertedInstrumentGainLossRecognized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionDescription" xlink:label="us-gaap_DebtConversionDescription"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionOriginalDebtInterestRateOfDebt" xlink:label="us-gaap_DebtConversionOriginalDebtInterestRateOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtInstrumentConvertibleTermOfNotes" xlink:label="sls_DebtInstrumentConvertibleTermOfNotes"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_EQCBiotechSelyIFundMember" xlink:label="sls_EQCBiotechSelyIFundMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_GainLossOnExtinguishmentOfDebt" xlink:label="sls_GainLossOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_IssuanceOfWarrantsTerm" xlink:label="sls_IssuanceOfWarrantsTerm"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_NumberOfSignificantShareholders" xlink:label="sls_NumberOfSignificantShareholders"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithAcquisition" xlink:label="sls_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithAcquisition"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_TwoZeroOneFiveConvertibleTermNotesMember" xlink:label="sls_TwoZeroOneFiveConvertibleTermNotesMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_TwoZeroOneSixConvertibleTermNotesMember" xlink:label="sls_TwoZeroOneSixConvertibleTermNotesMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_WarrantExercisePriceAsPercentOfDebtConversion" xlink:label="sls_WarrantExercisePriceAsPercentOfDebtConversion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_NumberOfSignificantShareholders" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtInterestRateOfDebt" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithAcquisition" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_IssuanceOfWarrantsTerm" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_WarrantExercisePriceAsPercentOfDebtConversion" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_DebtInstrumentConvertibleTermOfNotes" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_BridgeLoan" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SharesIssued" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_CommonStockSharesSubscriptions" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestPaid" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_GainLossOnExtinguishmentOfDebt" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionDescription" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_DebtConversionConvertedInstrumentGainLossRecognized" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sls_TwoZeroOneFiveConvertibleTermNotesMember" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sls_BridgeFinancingMember" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sls_TwoZeroOneSixConvertibleTermNotesMember" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="sls_TwoZeroOneFiveConvertibleTermNotesMember" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sls_EQCBiotechSelyIFundMember" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformationLongtermDebt">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtConversionConvertedInstrumentGainLossRecognized" xlink:label="sls_DebtConversionConvertedInstrumentGainLossRecognized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="us-gaap_DebtInstrumentPaymentTerms"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DrsStergiouAndSougioultzoglouMember" xlink:label="sls_DrsStergiouAndSougioultzoglouMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DrsStergiouMember" xlink:label="sls_DrsStergiouMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FounderLoansMember" xlink:label="sls_FounderLoansMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FrameworkLoanAgreementMember" xlink:label="sls_FrameworkLoanAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LoansReceivableNet" xlink:label="us-gaap_LoansReceivableNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermLineOfCredit" xlink:label="us-gaap_LongTermLineOfCredit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ModifiedTermsOnLoanPercentageMaximum" xlink:label="sls_ModifiedTermsOnLoanPercentageMaximum"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ShareholdersMember" xlink:label="sls_ShareholdersMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SougioultzoglouMember" xlink:label="sls_SougioultzoglouMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StarcoveLoansMember" xlink:label="sls_StarcoveLoansMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StarcoveMember" xlink:label="sls_StarcoveMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ThirdPartyMember" xlink:label="sls_ThirdPartyMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_TwoThousandFifiteenLoanAgreementMember" xlink:label="sls_TwoThousandFifiteenLoanAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_TwoThousandThirteenLoanAgreementMember" xlink:label="sls_TwoThousandThirteenLoanAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermLineOfCredit" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPaymentTerms" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtAmount" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDescription" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermLoansPayable" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LoansReceivableNet" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_ModifiedTermsOnLoanPercentageMaximum" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPayment" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sls_DebtConversionConvertedInstrumentGainLossRecognized" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sls_TwoThousandFifiteenLoanAgreementMember" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sls_FrameworkLoanAgreementMember" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sls_StarcoveLoansMember" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sls_TwoThousandThirteenLoanAgreementMember" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sls_FounderLoansMember" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CounterpartyNameAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LineOfCreditMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sls_DrsStergiouMember" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sls_SougioultzoglouMember" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sls_DrsStergiouAndSougioultzoglouMember" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sls_ThirdPartyMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sls_StarcoveMember" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sls_ShareholdersMember" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationLegalProceedings">
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AssetPurchaseAgreementAndRelatedLicenseAgreementAbstract" xlink:label="sls_AssetPurchaseAgreementAndRelatedLicenseAgreementAbstract"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_IssuanceofCommonStockforLitigationSettlement" xlink:label="sls_IssuanceofCommonStockforLitigationSettlement"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_JGBCaymanNewtonLtdMember" xlink:label="sls_JGBCaymanNewtonLtdMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="us-gaap_LitigationCaseAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LitigationSettlementAmountCash" xlink:label="sls_LitigationSettlementAmountCash"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LitigationSettlementIssuanceofCommonStockShares" xlink:label="sls_LitigationSettlementIssuanceofCommonStockShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="us-gaap_PaymentsForLegalSettlements"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_QuiTamMember" xlink:label="sls_QuiTamMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SettledLitigationMember" xlink:label="us-gaap_SettledLitigationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_UsattorneysofficeforthedistrictofnewjerseyanddepartmentofjusticeMember" xlink:label="sls_UsattorneysofficeforthedistrictofnewjerseyanddepartmentofjusticeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_AssetPurchaseAgreementAndRelatedLicenseAgreementAbstract" xlink:to="us-gaap_LossContingenciesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="us-gaap_LitigationCaseTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationCaseTypeDomain" xlink:to="sls_UsattorneysofficeforthedistrictofnewjerseyanddepartmentofjusticeMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationCaseTypeDomain" xlink:to="sls_QuiTamMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationCaseTypeDomain" xlink:to="sls_JGBCaymanNewtonLtdMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationStatusDomain" xlink:to="us-gaap_SettledLitigationMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_PaymentsForLegalSettlements" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="sls_IssuanceofCommonStockforLitigationSettlement" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="sls_LitigationSettlementAmountCash" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="sls_LitigationSettlementIssuanceofCommonStockShares" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LitigationStatusAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LitigationCaseAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalCommitmentsForOperatingLeases">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation">
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_BridgeFinancingMember" xlink:label="sls_BridgeFinancingMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_CancellationOfManagementFee" xlink:label="sls_CancellationOfManagementFee"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_CancellationOfMilestonePayment" xlink:label="sls_CancellationOfMilestonePayment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="us-gaap_ChiefExecutiveOfficerMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_EquilibriaCollaborationAgreementMember" xlink:label="sls_EquilibriaCollaborationAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MemorialSloanKetteringCancerCenterMember" xlink:label="sls_MemorialSloanKetteringCancerCenterMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssued" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sls_CancellationOfMilestonePayment" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sls_CancellationOfManagementFee" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sls_BridgeFinancingMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sls_MemorialSloanKetteringCancerCenterMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sls_EquilibriaCollaborationAgreementMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_ChiefExecutiveOfficerMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityCommonStockAreReservedForFutureIssuance">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_StockOptionMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsScheduleOfWarrantActivity">
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ClassOfWarrantOrRightAssumedInAcquisition" xlink:label="sls_ClassOfWarrantOrRightAssumedInAcquisition"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ClassOfWarrantOrRightExpirationDateDescription" xlink:label="sls_ClassOfWarrantOrRightExpirationDateDescription"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ClassOfWarrantOrRightExpirationMonthAndYear" xlink:label="sls_ClassOfWarrantOrRightExpirationMonthAndYear"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ClassOfWarrantOrRightExpired" xlink:label="sls_ClassOfWarrantOrRightExpired"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ClassOfWarrantOrRightGranted" xlink:label="sls_ClassOfWarrantOrRightGranted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ClassOfWarrantOrRightOutstandingRollForward" xlink:label="sls_ClassOfWarrantOrRightOutstandingRollForward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_EqcWarrantsMember" xlink:label="sls_EqcWarrantsMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_February2017WarrantsMember" xlink:label="sls_February2017WarrantsMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_OtherWarrantIssuesMember" xlink:label="sls_OtherWarrantIssuesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sls_EqcWarrantsMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sls_February2017WarrantsMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sls_OtherWarrantIssuesMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sls_ClassOfWarrantOrRightOutstandingRollForward" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_ClassOfWarrantOrRightOutstandingRollForward" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_ClassOfWarrantOrRightOutstandingRollForward" xlink:to="sls_ClassOfWarrantOrRightGranted" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_ClassOfWarrantOrRightOutstandingRollForward" xlink:to="sls_ClassOfWarrantOrRightAssumedInAcquisition" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_ClassOfWarrantOrRightOutstandingRollForward" xlink:to="sls_ClassOfWarrantOrRightExpired" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_ClassOfWarrantOrRightOutstandingRollForward" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_ClassOfWarrantOrRightOutstandingRollForward" xlink:to="sls_ClassOfWarrantOrRightExpirationMonthAndYear" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_ClassOfWarrantOrRightOutstandingRollForward" xlink:to="sls_ClassOfWarrantOrRightExpirationDateDescription" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModel">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" xlink:label="sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_February2017WarrantsMember" xlink:label="sls_February2017WarrantsMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_OtherGalenaWarrantIssuesAccountedForAsLiabilitiesMember" xlink:label="sls_OtherGalenaWarrantIssuesAccountedForAsLiabilitiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_WarrantsFairValueAssumptionsExpectedVolatility" xlink:label="sls_WarrantsFairValueAssumptionsExpectedVolatility"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_WarrantsFairValueAssumptionsRiskFreeInterestRate" xlink:label="sls_WarrantsFairValueAssumptionsRiskFreeInterestRate"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_WarrantStrikePrice" xlink:label="sls_WarrantStrikePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sls_February2017WarrantsMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sls_OtherGalenaWarrantIssuesAccountedForAsLiabilitiesMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sls_WarrantStrikePrice" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sls_WarrantsFairValueAssumptionsExpectedVolatility" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sls_WarrantsFairValueAssumptionsRiskFreeInterestRate" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsChangesInFairValueOfWarrantLiability">
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ChangeInFairValueOfWarrantLiabilities" xlink:label="sls_ChangeInFairValueOfWarrantLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ClassofWarrantorRightFairValueRollForward" xlink:label="sls_ClassofWarrantorRightFairValueRollForward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FairValueOfWarrantsExercised" xlink:label="sls_FairValueOfWarrantsExercised"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FairValueofWarrantsGranted" xlink:label="sls_FairValueofWarrantsGranted"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FairValueOfWarrantsLiabilities" xlink:label="sls_FairValueOfWarrantsLiabilities"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FairValueOfWarrantsLiabilities" xlink:label="sls_FairValueOfWarrantsLiabilities_2"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_February2017WarrantsMember" xlink:label="sls_February2017WarrantsMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_OtherWarrantIssuesMember" xlink:label="sls_OtherWarrantIssuesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sls_February2017WarrantsMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sls_OtherWarrantIssuesMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_ClassofWarrantorRightFairValueRollForward" xlink:to="sls_FairValueOfWarrantsLiabilities" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_ClassofWarrantorRightFairValueRollForward" xlink:to="sls_FairValueofWarrantsGranted" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_ClassofWarrantorRightFairValueRollForward" xlink:to="sls_FairValueOfWarrantsExercised" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_ClassofWarrantorRightFairValueRollForward" xlink:to="sls_ChangeInFairValueOfWarrantLiabilities" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_ClassofWarrantorRightFairValueRollForward" xlink:to="sls_FairValueOfWarrantsLiabilities_2" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sls_ClassofWarrantorRightFairValueRollForward" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsWarrantsClassifiedAsEquity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ClassOfWarrantOrRightTerm" xlink:label="sls_ClassOfWarrantOrRightTerm"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_EqcWarrantsMember" xlink:label="sls_EqcWarrantsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_FairValueofWarrantsGrantedperShare" xlink:label="sls_FairValueofWarrantsGrantedperShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sls_EqcWarrantsMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sls_ClassOfWarrantOrRightTerm" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sls_FairValueofWarrantsGrantedperShare" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_EmployeeStockPurchasePlanMember" xlink:label="sls_EmployeeStockPurchasePlanMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_NumberOfStockOptionsGranted" xlink:label="sls_NumberOfStockOptionsGranted"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards" xlink:label="sls_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="us-gaap_RestrictedStockExpense"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember" xlink:label="sls_RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger" xlink:label="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants" xlink:label="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SharebasedCompensationArrangementBySharebasedPaymentAwardStockOptionsSharesOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:label="sls_SharebasedCompensationArrangementBySharebasedPaymentAwardStockOptionsSharesOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate" xlink:label="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ShareBasedCompensationAwardVestingDateFourMember" xlink:label="sls_ShareBasedCompensationAwardVestingDateFourMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ShareBasedCompensationAwardVestingDateOneMember" xlink:label="sls_ShareBasedCompensationAwardVestingDateOneMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ShareBasedCompensationAwardVestingDateThreeMember" xlink:label="sls_ShareBasedCompensationAwardVestingDateThreeMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ShareBasedCompensationAwardVestingDateTwoMember" xlink:label="sls_ShareBasedCompensationAwardVestingDateTwoMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ShareBasedCompensationExercisePeriod" xlink:label="sls_ShareBasedCompensationExercisePeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_TwoThousandAndSeventeenEquityIncentivePlanMember" xlink:label="sls_TwoThousandAndSeventeenEquityIncentivePlanMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_TwoThousandAndSixteenEquityIncentivePlanMember" xlink:label="sls_TwoThousandAndSixteenEquityIncentivePlanMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sls_TwoThousandAndSeventeenEquityIncentivePlanMember" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sls_TwoThousandAndSixteenEquityIncentivePlanMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sls_ShareBasedCompensationExercisePeriod" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sls_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sls_NumberOfStockOptionsGranted" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_RestrictedStockExpense" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_SharebasedCompensationArrangementBySharebasedPaymentAwardStockOptionsSharesOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sls_RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sls_EmployeeStockPurchasePlanMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="sls_ShareBasedCompensationAwardVestingDateOneMember" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="sls_ShareBasedCompensationAwardVestingDateTwoMember" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="sls_ShareBasedCompensationAwardVestingDateThreeMember" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="sls_ShareBasedCompensationAwardVestingDateFourMember" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAllocatedStockbasedCompensationExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SharebasedCompensationArrangementBySharebasedPaymentAwardStockOptionsSharesOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:label="sls_SharebasedCompensationArrangementBySharebasedPaymentAwardStockOptionsSharesOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_SharebasedCompensationArrangementBySharebasedPaymentAwardStockOptionsSharesOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfGrantDateFairValuesOfOptionIssuedToEmployeesAndNonEmployees">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_EmployeeAndNonemployeeStockOptionsMember" xlink:label="sls_EmployeeAndNonemployeeStockOptionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SharebasedCompensationArrangementBySharebasedPaymentAwardStockOptionsSharesOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:label="sls_SharebasedCompensationArrangementBySharebasedPaymentAwardStockOptionsSharesOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_SharebasedCompensationArrangementBySharebasedPaymentAwardStockOptionsSharesOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sls_EmployeeAndNonemployeeStockOptionsMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInAcquisitionGrantDateIntrinsicValue" xlink:label="sls_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInAcquisitionGrantDateIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledIntrinsicValue" xlink:label="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAggregateIntrinsicValue" xlink:label="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAggregateIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SharebasedCompensationArrangementBySharebasedPaymentAwardStockOptionsSharesOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:label="sls_SharebasedCompensationArrangementBySharebasedPaymentAwardStockOptionsSharesOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="sls_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInAcquisitionGrantDateIntrinsicValue" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledIntrinsicValue" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAggregateIntrinsicValue" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_SharebasedCompensationArrangementBySharebasedPaymentAwardStockOptionsSharesOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_SharebasedCompensationArrangementBySharebasedPaymentAwardStockOptionsSharesOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_SharebasedCompensationArrangementBySharebasedPaymentAwardStockOptionsSharesOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationRSUActivityForRSUsWithOnlyTimeBasedCondition">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_RestrictedStockUnitsWithTimeBasedConditionsMember" xlink:label="sls_RestrictedStockUnitsWithTimeBasedConditionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SharebasedCompensationArrangementBySharebasedPaymentAwardStockOptionsSharesOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:label="sls_SharebasedCompensationArrangementBySharebasedPaymentAwardStockOptionsSharesOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="1.0400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="1.0500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_SharebasedCompensationArrangementBySharebasedPaymentAwardStockOptionsSharesOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sls_RestrictedStockUnitsWithTimeBasedConditionsMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationRSUActivityForRSUsWithBothTimeBasedAndPerformanceBasedCondition">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember" xlink:label="sls_RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SharebasedCompensationArrangementBySharebasedPaymentAwardStockOptionsSharesOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:label="sls_SharebasedCompensationArrangementBySharebasedPaymentAwardStockOptionsSharesOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="1.0500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sls_SharebasedCompensationArrangementBySharebasedPaymentAwardStockOptionsSharesOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sls_RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeIncomeTaxes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefit">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DeferredTaxAssetsLicensingDeductionDeferral" xlink:label="sls_DeferredTaxAssetsLicensingDeductionDeferral"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOtherTaxCarryforwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="sls_DeferredTaxAssetsLicensingDeductionDeferral" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.0700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionComputedByApplyingFederalStatutoryRate">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="sls_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1.0100" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="sls_EffectiveIncomeTaxRateReconciliationPermanentDifferences" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="1.0800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife" xlink:label="sls_DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits" xlink:label="sls_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss" xlink:label="sls_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage" xlink:label="sls_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUsePeriodOfOwnershipPercentage" xlink:label="sls_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUsePeriodOfOwnershipPercentage"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_OperatingLossCarryforwardsExpirationYearRangeEnd" xlink:label="sls_OperatingLossCarryforwardsExpirationYearRangeEnd"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_OperatingLossCarryforwardsExpirationYearRangeStart" xlink:label="sls_OperatingLossCarryforwardsExpirationYearRangeStart"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_TaxCreditCarryforwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="sls_OperatingLossCarryforwardsExpirationYearRangeStart" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="sls_OperatingLossCarryforwardsExpirationYearRangeEnd" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="sls_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUsePeriodOfOwnershipPercentage" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="sls_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="sls_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="sls_DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="sls_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_StatementScenarioAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfChangesToCompanysUnrecognizedTaxBenefits">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits_2" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AccruedCompensationIncentive" xlink:label="sls_AccruedCompensationIncentive"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_CashPaymentOnContractTermination" xlink:label="sls_CashPaymentOnContractTermination"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ContractualAgreementTerminationDate" xlink:label="sls_ContractualAgreementTerminationDate"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DrAngelosMStergiouMember" xlink:label="sls_DrAngelosMStergiouMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_EffectivePeriodOfAgreement" xlink:label="sls_EffectivePeriodOfAgreement"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_EquilibriaCollaborationAgreementMember" xlink:label="sls_EquilibriaCollaborationAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_Incentivefeepercentageequaltogrossvaluepaidbypurchaserincash" xlink:label="sls_Incentivefeepercentageequaltogrossvaluepaidbypurchaserincash"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_IncentiveFeePercentageEqualToPostMoneyMarketValue" xlink:label="sls_IncentiveFeePercentageEqualToPostMoneyMarketValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ManagementFeeExpense" xlink:label="us-gaap_ManagementFeeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ManagementFeePayable" xlink:label="us-gaap_ManagementFeePayable"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MemorialSloanKetteringCancerCenterMember" xlink:label="sls_MemorialSloanKetteringCancerCenterMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MskLicenseAgreementMember" xlink:label="sls_MskLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentForManagementFee" xlink:label="us-gaap_PaymentForManagementFee"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PercentageOfOwnershipOutstandingShareCapital" xlink:label="sls_PercentageOfOwnershipOutstandingShareCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_RestrictedStockUnitsMember" xlink:label="sls_RestrictedStockUnitsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares" xlink:label="sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sls_MemorialSloanKetteringCancerCenterMember" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sls_EquilibriaCollaborationAgreementMember" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sls_MskLicenseAgreementMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sls_RestrictedStockUnitsMember" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_EffectivePeriodOfAgreement" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentForManagementFee" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ManagementFeeExpense" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ManagementFeePayable" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_IncentiveFeePercentageEqualToPostMoneyMarketValue" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_Incentivefeepercentageequaltogrossvaluepaidbypurchaserincash" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_AccruedCompensationIncentive" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_PercentageOfOwnershipOutstandingShareCapital" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_ContractualAgreementTerminationDate" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_CashPaymentOnContractTermination" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="sls_DrAngelosMStergiouMember" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AdjustmentToCommonStockInConnectionWithReverseForwardStockSplit" xlink:label="sls_AdjustmentToCommonStockInConnectionWithReverseForwardStockSplit"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AggregateSalesPriceOfCommonStock" xlink:label="sls_AggregateSalesPriceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AltoAgreementMember" xlink:label="sls_AltoAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_AnsonAgreementMember" xlink:label="sls_AnsonAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_CommonStockPercentageIssuedPriorToPurchaseAgreement" xlink:label="sls_CommonStockPercentageIssuedPriorToPurchaseAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ConversionPriceOfPreferredStock" xlink:label="sls_ConversionPriceOfPreferredStock"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ConvertibleNotesConversionPricePerShareOfCommonStock" xlink:label="sls_ConvertibleNotesConversionPricePerShareOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ConvertiblePreferredStockBeneficialOwnershipLimitationPercentage" xlink:label="sls_ConvertiblePreferredStockBeneficialOwnershipLimitationPercentage"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ConvertiblePreferredStockIssuedShares" xlink:label="sls_ConvertiblePreferredStockIssuedShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_CVIAgreementMember" xlink:label="sls_CVIAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DateByWhichStockHolderApprovalRequired" xlink:label="sls_DateByWhichStockHolderApprovalRequired"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:label="us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DebtInstrumentConvertiblePercentageOfPrincipalAndAccruedInterest" xlink:label="sls_DebtInstrumentConvertiblePercentageOfPrincipalAndAccruedInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_DenominatorBaseForIssuanceOfCommonStockValue" xlink:label="sls_DenominatorBaseForIssuanceOfCommonStockValue"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_EmperyAgreementMember" xlink:label="sls_EmperyAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_EngagementLetterMember" xlink:label="sls_EngagementLetterMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_GrossProceedsPercentage" xlink:label="sls_GrossProceedsPercentage"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_HudsonBayAgreementMember" xlink:label="sls_HudsonBayAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_JGBCaymanNewtonLtdMember" xlink:label="sls_JGBCaymanNewtonLtdMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LincolnParkAgreementMember" xlink:label="sls_LincolnParkAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="us-gaap_LitigationCaseAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_LitigationSettlementIssuanceofCommonStockShares" xlink:label="sls_LitigationSettlementIssuanceofCommonStockShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MinimumOwnershipPercentageOfOutstandingSharesOfCommonStockForConversionToTakeEffect" xlink:label="sls_MinimumOwnershipPercentageOfOutstandingSharesOfCommonStockForConversionToTakeEffect"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MinimumPercentageOfTradingPriceOfCommonStock" xlink:label="sls_MinimumPercentageOfTradingPriceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_MinimumProceedRequiredUnderQualifiedOffering" xlink:label="sls_MinimumProceedRequiredUnderQualifiedOffering"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PercentageOfMarketAveragePriceOfShares" xlink:label="sls_PercentageOfMarketAveragePriceOfShares"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PercentageOfReductionInRiskRecurrence" xlink:label="sls_PercentageOfReductionInRiskRecurrence"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="us-gaap_PreferredStockConversionBasis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredUnitsDescription" xlink:label="us-gaap_PreferredUnitsDescription"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PrivatePlacementFirstClosingMember" xlink:label="sls_PrivatePlacementFirstClosingMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PrivatePlacementSecondClosingMember" xlink:label="sls_PrivatePlacementSecondClosingMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PurchaseAgreementMember" xlink:label="sls_PurchaseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_QualifiedOfferingDescription" xlink:label="sls_QualifiedOfferingDescription"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_QualifiedPublicOfferingMember" xlink:label="sls_QualifiedPublicOfferingMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SabbyAgreementMember" xlink:label="sls_SabbyAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_SeriesAConvertiblePreferredStockMember" xlink:label="sls_SeriesAConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockConversionLimitPercentage" xlink:label="sls_StockConversionLimitPercentage"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockholderApprovalPeriod" xlink:label="sls_StockholderApprovalPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_StockIssuedDuringPeriodSharesShareWarrantsExercised" xlink:label="sls_StockIssuedDuringPeriodSharesShareWarrantsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_TradingDays" xlink:label="sls_TradingDays"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_VotingAgreementMember" xlink:label="sls_VotingAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_WarrantExcercisableTerm" xlink:label="sls_WarrantExcercisableTerm"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_WarrantsIssuedShares" xlink:label="sls_WarrantsIssuedShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_CVIAgreementMember" order="1.4600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_AnsonAgreementMember" order="1.5200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_SabbyAgreementMember" order="1.5500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_HudsonBayAgreementMember" order="1.5700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_AltoAgreementMember" order="1.5800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_LincolnParkAgreementMember" order="1.5900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_EmperyAgreementMember" order="1.6000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_PurchaseAgreementMember" order="1.6100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_VotingAgreementMember" order="1.6200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sls_EngagementLetterMember" order="1.6300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sls_SeriesAConvertiblePreferredStockMember" order="1.4700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="us-gaap_LitigationCaseTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationCaseTypeDomain" xlink:to="sls_JGBCaymanNewtonLtdMember" order="1.5100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.4900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.5400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sls_PrivatePlacementFirstClosingMember" order="1.4800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sls_PrivatePlacementSecondClosingMember" order="1.5300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sls_QualifiedPublicOfferingMember" order="1.5600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" order="1.5000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_DenominatorBaseForIssuanceOfCommonStockValue" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_DebtInstrumentConvertiblePercentageOfPrincipalAndAccruedInterest" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_ConvertibleNotesConversionPricePerShareOfCommonStock" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_MinimumOwnershipPercentageOfOutstandingSharesOfCommonStockForConversionToTakeEffect" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockIssuedDuringPeriodSharesShareWarrantsExercised" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_AggregateSalesPriceOfCommonStock" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_MinimumPercentageOfTradingPriceOfCommonStock" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_PercentageOfMarketAveragePriceOfShares" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_ConvertiblePreferredStockIssuedShares" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_ConversionPriceOfPreferredStock" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_WarrantsIssuedShares" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_DateByWhichStockHolderApprovalRequired" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockholderApprovalPeriod" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_CommonStockPercentageIssuedPriorToPurchaseAgreement" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_MinimumProceedRequiredUnderQualifiedOffering" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockConversionBasis" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_QualifiedOfferingDescription" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredUnitsDescription" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_ConvertiblePreferredStockBeneficialOwnershipLimitationPercentage" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_StockConversionLimitPercentage" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_AdjustmentToCommonStockInConnectionWithReverseForwardStockSplit" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_TradingDays" order="1.3800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="1.3900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.4000" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_WarrantExcercisableTerm" order="1.4100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_GrossProceedsPercentage" order="1.4200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_PercentageOfReductionInRiskRecurrence" order="1.4300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sls_LitigationSettlementIssuanceofCommonStockShares" order="1.4400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LitigationCaseAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" order="15.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="16.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.4500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsLiquidationBasisOfAccountingTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiquidationBasisOfAccountingTextBlock" xlink:label="us-gaap_LiquidationBasisOfAccountingTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_LiquidationBasisOfAccountingTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ComprehensiveLossPolicyPolicyTextBlock" xlink:label="sls_ComprehensiveLossPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_GoodwillPolicyTextBlock" xlink:label="sls_GoodwillPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_IntangibleAssetsIndefinitelivedPolicyPolicyTextBlock" xlink:label="sls_IntangibleAssetsIndefinitelivedPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:label="us-gaap_LegalCostsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock" xlink:label="sls_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_UseOfEstimates" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="sls_IntangibleAssetsIndefinitelivedPolicyPolicyTextBlock" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="sls_GoodwillPolicyTextBlock" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="sls_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_LegalCostsPolicyTextBlock" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="sls_ComprehensiveLossPolicyPolicyTextBlock" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_CommonStockAreReservedForFutureIssuanceTableTextBlock" xlink:label="sls_CommonStockAreReservedForFutureIssuanceTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="sls_CommonStockAreReservedForFutureIssuanceTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOptionIndexedToIssuersEquityDescriptionTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock" xlink:label="us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOptionIndexedToIssuersEquityDescriptionTextBlockTables">
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ChangesInFairValueOfWarrantLiabilityTableTableTextBlock" xlink:label="sls_ChangesInFairValueOfWarrantLiabilityTableTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ScheduleOfWarrantActivityTableTableTextBlock" xlink:label="sls_ScheduleOfWarrantActivityTableTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ScheduleOfWarrantValuationAssumptionsTableTableTextBlock" xlink:label="sls_ScheduleOfWarrantValuationAssumptionsTableTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="sls_ScheduleOfWarrantActivityTableTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="sls_ScheduleOfWarrantValuationAssumptionsTableTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="sls_ChangesInFairValueOfWarrantLiabilityTableTableTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock" xlink:label="sls_ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="sls-20171231.xsd#sls_ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock" xlink:label="sls_ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="sls_ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="sls_ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g556278001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g556278001.jpg
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M/#]X<&%C:V5T(&5N9#TB<B(_/O_M $A0:&]T;W-H;W @,RXP #A"24T$!
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M<EJTOE?+AI0N)HQ[Z #3I+::*D5J 3H/J.7V<5W(]LI(8UH.@M&MS6U)=HH
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M($E,-;PE\AYRDHH7-C(9OA;8GL=!=!\4;7/'S=6O?.^V9%^^4=(^:-S&X26
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MKAJ="DP2!A+-:4#,(2 918BB2DV.0..7&LV!MHXM= &?--+!2@P AI+*?BZ
MSD]:B@D=,*B0NY9Q&OXQ%>5]W3BT_?5KY+MTHV3(VEL?ZIB3JA9'R72)K0J$
M:D)!#S84B!,)T:H)3JB<.2.:2C '!S0J^W0+E0"S#2!9 #ECERC+)V".6"-S
M6/>X"G5D=C?7KA[N4X&H) )&A2-OKN,ES)' D-!^\T4;]["- (T@:BHU)]M=
M%2=6N6R*J(P\*7*5/LS7C6%N8BUTGEAC6&4KE28MQ+2'IY6H8D@W- (&6YR4
MI2S5"<TX//JKLERJ=U9K>-Q+W/-:Z7.IB-*TH[",3>Y<0"02K6YA>1M 9*X
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MO[HZ"30@C6#J(!!U@C0H0XQ:/ 1B0IVA"B3A6)W).%$F)391N:)&G0M[BBP
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MT@<X M&.L(C+G$L?1[' N8ZA-'&F!PQ&:/.&,.)S)2X,H-9PTD+J-&)O)<"
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MP D;.-[:DB0HH]6J<FH*S*Y"G2DG@&8,TL(0!&'.<XQG&K#87X@;<F";Q9Y
M:_ ["XG0 '4H22#0 Z5<+JV,AA$D>U:*EN(5 &NHK44^ZJ:7:]6FL9\F*LJ
M&QM,O*:U,@+F,=&QIW,\H)Y#<>[!<<H"EYQ(PC 2(S!@@YQG&.&=2G*<T$XM
MC;7 N2W$&;-^(M&@D-I6E=%:45@OK(QF831;$&F+&VE>M6M*_<7)5677"$YC
M3KK A*-1)TR-;&B%4K8DYTA1N)H2&]6QE'+P#=DRX\> $F)\&!-'G& YSG5C
M,LS*1KW,MYRV(D/(C<0PC20[1R2!I(-*=55=>6C2T.EC!> 6U<WE ZB-.FO4
MIK6^78,".=G9@*F\0-?6!,K6OK*7)68;LRHT 2QKE;LVA6Y6-J9$ X&33#@
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M*B%P_P#$.#'^)7.HS\-P'ZY/FWUZD]XVFGB8Z3ZM40_X78:3Q_\ +]1"X?\
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M5*U%%;IMW25<ZPVT+'<W,++7M<68UUL3+2 .4D32T<DCU9/<1>V)L86A4]&
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M3$[(G)6EE4H,C.#FI XNRMO-!&9%),+,-#.WN;HY@R"/")R625S![7M,YP$
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M[B8K.,&8+G[?@%80R2&3-+A\,MK)"1L8PXXX)X&R/>7.+Y&MN'EQ( >[#H8
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M&BXK2%E6TVV=,B7*9H*TVD6EM!JUW#"G5O>(O&,1N%6.%P6IT')ER7I3<B-
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MX;<'/*,2@37W5U+1TR'LL[=WE7%[-VV.M1RVGIZ1+90C-='-$LE5-H2G].>
M:A0VN2SLS1*.00IK?AD_+]VLOW?L;XEUA=7#]HZ)K0^&\%PRXBV;"&M(9<.,
M1&@/8RHPU /WU;<9O=YE-;T;<P1MH'DEKX=D6.Q&I()A >":EKG::T*XEC]5
MVVK/A49A$AKN' ;X^!C/6JTCBO*72=ZC.XRO[NC[_)#@H0#=75HA54QV"$&G
M",,+9&T)H18$+! +\NX493EE[+>V]Q-M)"Z@(%&-?:2VSV,%>2UTL\UT0* R
M/(_[QLFW[O9X6PR1,+6MH==7';-D#G'JEK&,B%?Q6]BHQ?K ;DVNY+YN&:B<
M;>,N^71IS+@]GV+,Y9#8!7#3<A]GR&D(NWO1SB$JM9G&5ZJ)JDI(4@2FH_M
M!R86 &([KA!NW+D]AE%EAM!90O;M(8HXY)9G6^Q9<O+:?/1O#9VN.*KQ0FA)
M58-_\T9?7-Y<UG%Q*"&O>YP9'M1(Z$5)^;<VK,.@!I-*+@6!U.'VV VA-YQ
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M:[!<X22:G6N]'H ?Y75K?YN$A_9*K+7F_$S^JK3_ &S^)E77[F?IT_\ L_\
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M7R!2X 4((%#FUJ-19-$VK$B; 5*<[(S,C(L:2^A;TSD^(L%%3ELMI4$2N#?
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ME!%/*!"F <[+"\H;#\+:%!Z[BU<,%X3]CGZ8,.K(,EW4DN+R.;.A'!#38/\
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M(]T6YM'9QYXUV5NB<YUQXG<# \$X8]D>6[$*'$.2*T*Q69EGQL7W#\M+;T/
M;%XQ$<32-+\?<BFK"=)IH4N=K:W*(U%&EM>TA6\D3Y&TG7,I#>=;-^*!5K%C
M00Z(CR50.TL_+,D6JS\F,W "CP+D!\T:#6)%E.[;VWQES8,=;EPMQXM,?&@
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M\DTH%$_,L^%BVX;EI-Z9"#%XQ$,+0-#\?<FIT81I%=*Y4I'9LTW'T.GD>T!
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ME4R.5*4F7$AO8QX"(!05 <[C/^*-UE&\657Y#F[IWF1/NI(W-;C;-(,5L"X
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M$@AM"!G/R-V285)CD!H.S,/#@6#<9^7YPS-+.2YMFF,-:'-=(.06N;B#M!U
M'E-J"-5>JH+JQ=93MBG.*I((9W0()!&D:ZZC0UZRMHGNF]WK;2UVNTURC=)B
MX35T2EYCT%F+^F<:513=]:6J]X_3QLM8[">")/ VU&^IHV2\&N>4J_!A U>
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M2XAC<0<XN)C<"2<.%M#ATG6:+J"C_48W,K&&UUDL>F)S93[1HBE*FL>$Q-O
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ML&74MA&HZK^=S^#S-:N7NBLZ%>L#X&Q_I+[Y_P RN;?LTT?KQ/C1_P N6_\
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MQG&<XUE,(< 6D$$=11$$$@ZU"'9:B2&)B5:U&D.<E64+<2J5)TQKBN\&4+/
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M%!73W+M.G4J>Q2K>55"F*.47>MS5<KZ%36@*%+&$^SHFMJ)*!>UK;H P'HO
M#H6G*<Y*A,DP"Q$  <X)_#<8$>5S7SVNYF:MECNF99<LOS#M X0R"X-'"WQ
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ME WFC,2'&E@5A#V.18[3CKP;.[26^R]]M!3:.I2NK7U>O]Y>G6,S+>Z9-)7
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MM&W2"[GT.WJW\^?YT.U$[>C=FO\ 667^<P\]3,RS,O)KC7]&_FJ&N&RG><+
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M"((L9"((@YX""(.<8R$0<XX9QGNXSHJ+08,)0><T6"@9QC.!&9[,.<9SPQG
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MK$9>49I0#1B%N;_+[NX;:2V4#([N'0!BB,,;7.CQL>QS>6VC>2Z$-D:YHP$
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M3[K&>I5*E!@C##!B$,8Q9$+.<YSG4C/BS@C8(X\@PQM   NP  -   MJ  :
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MM^V:'S,^=)-6/W'W* _JC+?-HN:IFYYG5?TNYU?2/[:MPY]1OJ#E\W9[YMW
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M(FB)HB:(FB)HB_,G^$'?Z7/=7_,*4_8'K;7Z8?#]_P!),J^_<_SJ9?'W%/\
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M\_&-7@"NKJJA5&6*E(@F<R@\7.#D'S'&9Y@=W/*+B+YH/$6>YGN=W4[6M%*
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M_B>];]6GZ6S7UNXUJ[V@X2>2=2O<=3I$QO1^"V9QS8V=XR'D$9S8VTRK(>S
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M'Y/W-LG]F]/8KXG_ %L?.V<Q/:/A'Y)^1]8GOU?@M'D?D_<VR?V;T]BOB?\
M6Q\[9S$]H^$?DGY'UB>_5^"T>1^3]S;)_9O3V*^)_P!;'SMG,3VCX1^2?D?6
M+.C8!N3Z$%DVW+&/9IMW% ;)25PX.DB=DU.R.$F*H.3)8PE6MWC4;N9VX37Y
M6WF9(QPYNRYN\#7/;Q;K_$+8V\4N>9D)(#+1@-Q&\!^!QK0LH.2'"OW:=5;/
M+,ZX8W4CV6-L6O#*FC2-&)HZCR=9"[;A2?:+W.:(.'Q/SND/LIKE?17&+RR/
MOX>8MMXYN%Y._O9.<N*9*=GF/GX<XY_XMD>?2=-7#*N,G4O8^_A\&J&\W!ZM
MN[O9.<J<=*]F&,9[6%N6?/\ SKDOR'7&I1E7&CJ7L7?P\Q4\=W \G?WLG.5)
M/EVQ_''MH.YY[_'\ZI1\AWQJOHKC33]-CI_AP^#5OCO#_P G?WLG.5$43/84
M'&>V@3J+T&B69])YU>W*.-9[F]B[^#P:H;[A]U;=_>R<Y1Y5..GACCX17;P+
MS^#-,/D/F-3-RCCAU+Z+OX/!JPWO#SJV[^]DYRC:J?=-0/'PBM'H7G\&.:Y_
MC7_&I6Y1QSZE_%TD'@U:;_AUU;9_>R<Y1998O2U#Q\*JQ\%Y_!@G>?XV18U*
M,FX\'5?Q=)!X-1NO^&]=-L^O^#)SE$EMF=)(/-X54<@'W^/".V%GT>])L:F;
MDO'SJ9A%TD'@U9X_PU\F?WLG/4076GT;@\?"Z:D8^_QX1FR,^9G^%E6/,U*W
M)?B ZF80]);^#5OC_#3R5_>R\]0U?;?1(#Q\,I&3#[_'A%K/SZ/SLNQJ5N2?
M$(>YS"'I+?P2#,.&G4MG][+SU#%UQ]" /'PNAY4/S^$2M;/\;,@ZE&1_$1U,
MQAZ2W\$GC_#.OZ*_O9.>H8NNOX/R'CX7M]EH^_QX0ZW<^C\[-L:D]!?$7ZQA
MZ2W\$GI#AGY,_O9>>H:NO3X.D'F\+VYS$?=SQX0NY,^;W?G9UCS=7C(OB-]9
M0]);^"3Q_AGY*_O9.>H8OOSX-6#CX7MIF@_/X0>Z\^=_"S[&J^@OB.]90]);
M^"5WI#AKY,_O9.>H>NW"?!A@\_A6V";C_AN$$O'/'\386-#D7Q'>LH>DMO!*
MX7_#;R9_>R<Y0];N+^"PAX^%;5YV+S^$ OC/F?Q-C8U:[(OB-IIS*&G^4M_!
M*\7_  YZEL_O9.<HFLW)?!/P\?"=IT^'W,\>%>W]G^-LK&HSD7Q$]7,8>DM_
M!*87O#TZK=_>R<Y1A7N7^"0XX^$;1I^+_N[W!?(LW&H79)\0OXV8P]);^"62
MR[W%=W,#NP\?W7*.J-SOP0</'MMH-@Y[_'A7NX;XO'O6EC6._)>/_P"/F$7?
MP>"68RYW._$B(_"[GJAJ-T7P/'''MMGMAB\_];W<3\BUL:Q'Y/QV_&OHN^@\
M$L^.?=K_ !;"/_&?"*DG;I/@</X[LYL//HU]N*#Z=M!U@R95QK'=WL?9B_O1
M+,9/DGX@/?\ UB[^.A3:G1ELI7N:#TE:;D53*&<FI<WN)^8K&9</A2X5B>YS
MA+[?9A*\'^+A)'KGPEP1R]OCM.?F!R^:;]6N^-MXM[62MEJ7[.F'13!C[EC=
M?)UUU+;63[1^+Q6O4KIKUZ=4_=7H4UY^L]-$31$T1-$31$T1-$31$T1-$31$
MT1-$31$T1-$31$T1-$31$T1-$31$T1-$7YD_P@[_ $N>ZO\ F%*?L#UMK],/
MA^_Z295]^Y_G4R^/N*?_ #S>_P":_@8UTQ:]E7GJ:(FB)HB:(FB)HB:(FB*X
M51U[FV[6K2K,/[/$P6-/(I"3Y7(7!(TL,61R1[1-2^2O+DO/3(D38P(5)BLX
MPPP <%DY[O'AK79OF'HG*KG--F^4V\$D@8P%SGEC2X,: "2YQ : !K*S<MM1
M?9A#9ES6"65K<3J!K<1 JZI H-9^Y5>MF,WQTZ+.66A>D/GT955C#MJ%D].&
M;1*;PJ+T]*"Z.EUJT<R4A*87'SIM*W.P_<WJ)TDH3Y&#*94L\2%&'I$F.4&O
MDRYR+B)EK+;([RWE&9S9K#F\<D<DEPSQF."Y=<LD?LHVQ;:X;#2'E-;M"&O?
MI*]VCS+=>X=+F4,L9LX[*2R<QP9&X0OEA;$YK1(\N,<6TJ_DN. $M:**SD_8
M:0RUTSM*HBPJAE[Y ^E_U"]HC<]E677S)'+,W -,[@"AZ>4$FE#RP1]J*LJ<
MD/KHQC<%1&%:$&%!8\@%CAM;&?/-M>;V9Y;WD4$^\N57Y:897/AM712!K2QC
M7.<88MFR7 TX7<DBH5L_HLVL>2Y?+;.E9E]S;BDC&M?*'.+BTN<  YY<YE3I
M%#72O,/:=7S2F)[(*SL-$T-TQBYB(IY1,4MB$Z:B!N#<D=4N$DJ@;[)HHZX$
MA7%B'E(M/P4/.2Q\I@!@#]/Y7FEEG-A'F>7N>ZSEKA+HY(G&A+35DK62-T@]
MTT5&D5!!7A-[97&7W+K.Z#1<,I4-<UXT@'NF%S3H/4)ZVM6_UL%B)HB:(FB)
MHB:(FB)HB:(N]+X/Y_E=VM_FWR+]DJL=>;\3/ZJM?]K_ (F5=AN9^G3_ .0_
MC&+US*#"R2QG'& *))*-..-,$$!11)0,F&FFF"S@)9918<B$+.<8#C&<Y[FO
M&R0-)T!>B:] UJTL9N6HY\*.@@MG0.:#ERF0H8OB*2EGD.'];$FM&^RA(V":
M52L"E2P,CDG6*@8SS%)5!9N<<@PBSB19IETQ:(9XGXW$-HYIJ0 2!0Z30CLA
M2RVMS$';6-[<(!-012M0*UZY!'X%,E*<\6 \I!V>U (9? H>>T"#&.80. ?F
MPA\W..]K;-(6*2HHX & O!HP" 4/ \A,&'(2Q8!QY\X&+@'. >;GCW/-U*-2
MC/55CT-I5C*(\_RR-6-!9!%8L8O)D\E9I:PN3#'#6M(%Q<0/SLD7FH6C*-N-
M I'X0,O@G&$WYP6!9CMKZRFB?<0S1/@C)Q.#VEK:"IQ&M!0:=/4TZE));W$;
MVQ21O;*ZE 6D$UT"@IITZ-'5T*.M4MBLV;$KS#9*PRMI<$AB]"XQUV0/"14A
M+7+&PQ80<@//"-*6YMRA,(S'S.%!!A><\Y8@XSK6XM[I@DMI&21D5!:0014B
MNCJ5!'WP1K"AFBDA)9,US7@T(((TZ^K]P@_>(*A<N>FB-H0.<@<DC*W'NS$Q
M$K7(["5*:]2EV1,,::@'&< B7/SVY)TB0OYXX\\  \<BQK*=+% S:3N#&%[6
MU.@8GN#6#[[G$-:.J2 H6L?*[!&"YU":#K-!+C]X $G[@4(> B#QY@Y#QR+&
M..,XXY#G(1<./?Y<]S/Q=9S >JL9_=+&&[+=@],,""1SM4]EI'N1MT08&V,1
M22S>2R&3O!*U2WL;#%XBUO#XZ+STC:I.R$HC. E$#$+.,8[N-F><6.26[;F_
M,F"21L;&LC?*][W D-8R-KG.) )T#4"5-96-SF$IAM@W$UA<2YS6-:T4J7.<
M0T"I TGJJR$7W"4Y:<8F,Q@\W1NT;@)8C)JY*FYZ8O:MV;#[8U1+VC?VYL7(
M53<U8&)42,K!J8THPDP(30"!BN5[R9)FMI/?6%PU]K;#YUQ#F;/D8SB#VM(+
M6UQ BK2"#0@A77>59A931V]S&6S2]P 0[%RL(H6D@U.H]4$$:"K6E7S4<J+A
M!S!-4#@79<!?K.@N0I7)/F10N,B2!D#FD J1DC*5M&5@>W0FX+7 Y#,]EP*,
MR'(LMY<CO!;&WN&N\;M7W$.APQQ1TVCA4#2VNEAH_0>3R32DF59A 91+$1L9
MFQOTCDO=7"#0ZC30X<G5ITA6F%>54OZ1V6M,P1JB61RK]H=\92.)![<LM-N8
MW6 ^%)E",M06ED*"1I!@/Y>Q*R(831 $4;@$]KO1D-TR22"X:6Q26['Z' M=
M=-8Z"H(! D;(TAW<C2'$%KJ)<IS")[6R1$%[9'-TC2(2X24-=;2TZ-9T4!J*
MXUN6ZZG%GBP28RQSB9!@TV-JBZ;M,Q)*$9*<2Q2Y1E27$QEOK8E;L>%&'ILF
M "ES@WYW/'6K9Q&W8<8\)OBV:IB(LKLB4 8BZ(B$[1H;RRYM0&<K4LX[LYL,
M5?%P8]#QMX06$F@#^7R23H --.C6JPEDC%+V)NDT8=$KTP/2;PQL<T>1Y(5)
MQ#$7G. &@*/)-*-+$6848 !I1@1 &$(L9QCL\OS"RS6RCS'+I&S6,S<3'MU$
M:1U:$$$$$$ @@@@$46FN+>>TG=;7+2R=AH6G6#_</7!%01I!5OGOZ/X_R-9_
M45@5IGG\=_!YVAZBD"M2\=\7X/,SJ-^K\*G;K_ K7NWT7H9^3J!W]]9+%;=U
M\W\'FYUBN6>SN5;IP[^?0S\G6)*LV-0=P^B^/K6R=5;6%1-=WL^AK43=M;&'
M6O<S\"9_VUZC_P#4FU?^/OW7SMQOU9=]^?\ BEV^0=R_[S?[KE[V=> KHTT1
M-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1?F3_
M  @[_2Y[J_YA2G[ ];:_3#X?O^DF5??N?YU,OC[BG_SS>_YK^!C73%KV5>>I
MHB:(FB+N/0=+.9W-7.TQIV[(&!PL^:5(PV;>S[)Y<\IBDRJ[XI<=P4\60RDM
M:YGCD';*XI-0Q$+@B\,<YDX"3' P4)(9KQM_%*SR;,<UEWA=(W+(;MT-LUD;
M3HMGV]O<5=B#GR.FN1*6TPLMV8@:AX7HYW(FOK2SBRL,\=="'RN<YPJ96RR1
MT%" T,BPUK4R$M(TM6,$PV>J*(K/<%)+W/++F4*B&V!D@<<C[@O3F,=U;E&E
MLN/$.FY:]K2#,D%8T,Q/(G]M*P,I&[KD@.W%R]WI[/?%N>YIE]MD0)LYIKUT
MKW@'%;V;G6^TCHX\B:Z='LGG2Z-KSA6EN-W/15A=3YFX>,,9 UC1BT23 2T=
M5HTMB:]KFCN7D E9?4=T=Y]?#E4+E'7EECE8V]L[17"UV%,[@J-E+:;S>X([
M+F&./4,+7K;11UJIL,A(WF'EQY0=A(?DS"KD^GAY'.^,-CD45W'<,?)F5IFY
MMW11V\[L5LV5H>]LE!"9A$7/ ,H&(4PUY*W]CP]DOWPF%X;;36FT#GRQMI(6
M$M!;I>&&0!M<!-#6M-*M+!^D=><HB["[RJW-OU-RV4NM:P^.53;4@L"/V$YV
MI<H;*4U/4!R-LKI[962>SQJK%2N2@7K4R$I&X(!GJ2\GY"#;WW%O(K6YDAM;
M3,+RTB;-(^>!D3HA!;[$3W +IFN=%$Z9K78&N<7,D#6G#4ZRUW#S.XB:^:>V
M@G>8VB.0O#S)+M-G'01D![Q&7#$0VCFU<*JM-G1UO-1[; /MZ[8(BLIV-*I'
MNF;'F86&L=-I BJS=+<0LEWH8_6+P8)X=(:PN& !C?C\DAT0G-YYA:G 0"@E
MXQ9$W9&"QS.9EW(&63FQPAM]\\V NMB^9O);(]E=MLB6.$C06Z5D,X=9J:B2
M>V8^-F*8$R5@^;,@$@;&220UP BVG*:6DAPHI-CH@;FE\T(AL?M*@9NF;5<Y
M;+.D<'5W'+T%1.T)C%;3++/+(TS4XJG\E<I+&;AC*E 5&6=]R#QGD"OP;*93
MV6-[[MV661O+BUOX7.$1A9(+>,SMD?-'B8]UP(F!C[>8.,TD7<59BQ-K>>&^
M<BX$,<UN\#'C<S:N$98V-U"T1%[BX2,ILVOUT-"'4Y,KZ3<;K"=>Y3<6Y6KH
M+8+/M$NN];&<WARE0('3%@5%?ON3Y13!V05>[O+S7LB:25!:$+,E7/*M\2FE
MX 4G$FRHLM>+%QF5CZ5RC+;F?+WYM;VT0:(]K<13VNWK&TSM:V5CB"[:.;&V
M(@U+L6'(=N'';3^(75W&R[%I)(\5?A9)',Z.CJ1N+FN HT,#G%X(I2F*GL/1
MNM2.VZSQNXIK7!].9(;AO%E5A(W%S;9$].EA3.LVBM8&Y/,*PD6V=X9#5#^:
M@5IBBD\8!E2,P)H@$YEGXQ95<Y0^XR>"X&<5.&&9@!8UL4<SII0V2HAI((@]
MI),W) I5RQXMP[^"_:R^FC\2IIDC>=+G2.C#&$LTO.$O+2!R.4370N?6?1EL
M-SVWK]SEIW755?5LLVMS6]XKXN(LE<L2RMLJ]';L,B4@4CJX<6?V9UB(U!CP
MIB[F\#9U)7@9HL+<"3YBS/C+81;Q-W9RJRNI\R;F<=K)B,(& S&"21@V^-CF
MR4$8F9'M&G&.1RE/9\/II<O?F][<,%HZU=*R@D+B1'M&M)V="2S7@+\)JUP#
MAA49%TGIS829QDE0V+6<<2NQ;2T5)3MJS=]<+LMZ;MFS^K=VU@1N&&Q*K4T)
M-,;8C8(QIS')0U)2C EHS%!AHBCU&7[U['+GMMLWM[F1[2YT]Q!&T6UO&[,)
M[")\@DG,FF2+2&"1Q%7AH +6X0W&N;QKI["6)K* 1QR.<99'"UCN7AN&,,T-
MDT%Q8*T;4FA=!)MTL+6AZRKV=!>NVJ?2*?[H4.SJ4L,#EL\=55*WX8QX?WN)
MVBI75PV(O!XLCYBU:MC&]$FJ"C2TN3Q%CX9MEQ4RF\9=2OL<R@M[?+#F#'2Q
MQ 7%KBPM?"!,XU>=+6RB,@$%V$$**YW#S&WV0%Q:O=)="W<&N?6.714/K& 0
MTFA+"\5!#22%>T_H:[C6RSHK54IO7;#!)':SHU,.WX$\?;?B2N_I"M@;98KL
MPPB-/5.I);&G.*,3TC)<2Y4A8.S<5120OM#AX#K2CCCNY)ELN:6UCF<]O:M<
MZZV3;>06K!*Z)KI'MN#&\/<UQ9L'2U8TO- %GCAGG'C+;62XM622D"+%M6[4
ME@>0T&+$TM#FAVU;'RB&BI-%M2OH=[B:[>"D=HWGMKJZ/J@1]K;IM/E]W1QA
M=K!D-EE5&GK1I;5])DR]S?@S=8F+)<R&PR.+V]1A>D<3DA1YA=UKQOW=OX3)
MEECF5S.,1,<0MGN;$V';F9SA<[-K=F#5A>)FO&S?&UY:#;)PTS>&79W%Q;1L
M(T.=M@"['LRP#98R0[27!NSP\L/+02(;+MA%85Z@O&K5$Z;K N2-[!H5O48I
M1'7&3I6NM97!WYMS>%,R)H=(W'&R0-\JBCRI.9W$KPLU(<V).88?"E 0Y5IO
M]FE_)8YH('6^3R9]+ESF/#"Z:.1I\6N&.:][F%CVM$C#A#@]^CDM23=.Q@BN
M;42"2^;ET=RUP+J,<TC:QD%K0ZK22"":$,Z[@NH[7KJ\Y31$T1-$7>E\'\_R
MN[6_S;Y%^R56.O-^)G]56O\ M?\ $RKL-S/TZ?\ R'\8Q>M.1H#75@?FHC)6
M#W5B>FLC)^1A(">XMJE$2(\1>!&!)P8?C(\AQD6 \>&,YUXO,PR1.8-9:0O1
MF.#7AQU A=4LYZ<[L[Q2M2V^:*)#8L>K&SDLNF\MESLR+LVZKVL1JA*0=XB.
MNHY%4;?$ZQ=HNE-+#E(6H$G)"J4!7+,YX</<;GW3[>)MO*!<M:XN<3A^<,0C
M:6X& 4 &N@/XQJ_2M]'G;&R/+V4A+VT: #R-J9'@XB:EU3U?N: J(\[4=U;J
M?;3H_2"OGETERB).; B;;*EL=B#K+HG+)8[M<LF\?,KQY5N#8*/O")([-WAI
MBE>>48- K:RDZ HK/.1YY(Z9\CXG/D+2 )'-:7-<\ASFX#HH6AS:DNH<)91M
M(QF&7M$;6AX:W$"<() ( (:<0TU!(--'5#JFMYZ1HJVJ]N6XK LF9BF*"9J9
MF!A4I96(Q"Z,C]/A2F((GF$F0EN,:'6OHOR,*14)X<P 1!,"67@)XN3>93EE
M]:9A<75Y)M&28\-':"'/Q-!9@%"QO(!QNT5H-.C7WMY;3VL4,#<+F8:Z-((;
M1U'8C4./*(PC3]Y0Z'TS/U=?;A W- Z\=;%O=<4IEC7%[/DJ2%O[.UQI%#(E
M"F5_;Z^C\HKN/P:(M2=(@5EDN3B<O&>O&85DT))-]AEET;.\&8Q0NN[LU>&R
M.#' -#&L#A&UT88T -(#G%Q+S2M!;<7<(G@\5?(((1R26#$"3B<X@N(>7$U(
MT"E&Z=:QODFV*^G/"J4.#_&GJSU%?L4>;YP\6+)02MF3P/<H*XHO7S])V>!M
M9$X3R:NS,1UXE0VY&M&I (\Y L"<8(>+Z S=S=JY\;K_ &#6!YD<'-$=SMFQ
MES6 /#H_FWRX0ZNDL=4DSC,K%OS8:YMMM"2T,%#BAV9< 7'#A?RVLJ130'"@
M5F)=L_O.=J685AN<'?0JK;9)Z>8"V+.(+JIB1;M)M=LA9H2G)BR-+-%LFK"2
M-C(6<O+;0MREC*"7]) G&7;)NOF]Z6>.NA>#=-D_?I1L6B\DG>V.C )"^)S(
MZN#<)C%- :1>S.+&W#O%P]OS);^]LY9,#8P7<KDAKPYU!6H<>K6MT:8@=KE5
M(X LR<2QFL>1R0[ Y A3-@7]NB$$"CK^!A,:)FV2MF0.LNB$2(>WC&4H\B<G
MI2(.0BY18Z?(;+,QE;AF$TK,PDD[H 8A''2*/DR->T%[&"1_)[N1VHK3YG<6
MGCH\5C8ZV:S4:T+G\MVEI:2&N<6MTZFA6DW%[?I9:K!2L8(LB:#]HE_QVS)1
M/"9$V06QD<7:(Q.6TX$0>X+&&5$A?4ZY_2E)\EI"1B3B-[0W.>[F_.]WKO-K
M>QM6W,W^CY@R>24/$4P8UDH^;=$QH#P7M HT:*U*IEV9PV4EQ,8H_G+5T;68
M2^,N+F'E->XDBC372=-*!8-R+9_:45S>E+58C86>A]P\JK1TEMIN-E+G*W(^
MQ-C$QMEM!/C;]$G0B:S*P%;:M.,<53D$D>7,>1DB"')>.;?N5F]MX_D64-C9
MN]F<T#I;@SEUPQC6,;<<A\;A++,0\E[GT^<-6D:%MFY_8S>+9C?%SLSM&2!D
M0C B<XEQBY37# R,$#"&UY.@]56P=-E]GMCA+4"&;MKDGA[7/WK;K8KV:@3R
MIFFT_DL5FSRURN/1N.L[ VQ9>[AD3:K+;B IC6EXR$"< @AP&1G#[.623QQ7
M+'"".9]A.\@2,FFDCE<V5D<;6-C<[;QO#!A,<NA@("N&\MB]L;WQ.!D=&VXC
M;4M+(VO8"QSG%Q>!LW#$:A[-)*@BW:1/D2:/NC<Z1IFD9<NJ))." +5*EOE-
M80>%4^D4HQF@2!R*01*>5\J6-.1!Q@Q(J/+R,/A'*'(CX?9LQL,\$D,=YXS:
M"<5);+;0Q6@(K3]\BGMW/BKK8YXJ,=!0[R6;G21R-D=!LIC'H +)9'S$'7W+
MXY U_6(::<E6.A="7]5SI3KJVPAE>5=3LCVR+ ONYV;/3'),N<2]JP%\>C;W
M#5[77A18\9483HBQXP4+"?C@(,"Q@Y%N?OGD%UE=W;6D,LN6Q2,<),UG?'+C
MAV(='$^!S;8#NL,8/)Y&H K*S#.LCS&&[BEF>QMTYKAAM(VN9A?CHY[9 9>M
M5Q&GE=59 0"'N\(A@&N0JFU7(W-^E<ND660*D#$E?)E(W&2.+<Q 5\J@+0VG
M./8$Y$$ C>3)N0!$/.->M;KY5=9/E MK]T;[^2::>79UV8DGE?,YD8=IP,+\
M+:@5IB(!)7(9K=Q7MX9;<.%NV-D;,5,1;&P,!=31B(%3UM5="ICW]'\?Y&NC
MZBP0K3//X[^#SM#U%(%:EX[XOP>9G4;]7X5.W7^!6O=OHO0S\G4#O[ZR6*V[
MKYOH?)UB.6>WN5;IP[^?0S\G6+*LV-0=P^B^/K6R=5;6%1-=WL^AK43=M;&'
M6O<S\"9_VUZC_P#4FU?^/OW7SMQOU9=]^?\ BEV^0=R_[S?[KE[V=> KHTT1
M-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1>##K
M/=*7J%[D^I)N&NBCML4ML.KY@5588U+VR35PWHG7+#4,&CSO@E(_31I=2O G
MIK4)Q=JG!S"*SD/$.<"S]W<&N*O#[=OAQE^2YYF<5OFD)GQQN9,2W%<2O;I;
M&YNEK@=!.OKKYJX@;C[T9QO9=9CEUJZ6SDV>%P<P5PQ,:=!<#K!'X%U=?O&7
M5D\BZ>?JSJ#]L;7J'OQX4>N8.CN/ KC/=IOMY"_OH^<G[QEU9/(NGGZLZ@_;
M&T]^/"CUS!T=QX%/=IOMY"_OH^<G[QEU9/(NGGZLZ@_;&T]^/"CUS!T=QX%/
M=IOMY"_OH^<G[QEU9/(NGGZLZ@_;&T]^/"CUS!T=QX%/=IOMY"_OH^<LYF79
M]UZXE6\,@$&VB2R&KHU4C/1,@G+5+JG/DM@57![H27K4D=D9:^RU#:D651+
M*T+:O1%D*5#"N,;U.3",!QKA9M[^ UWF4U_?9M%-'+=NN61.CG#(IY+<VT[V
M4A#B)X\+GM<2T2M$C:.75LR3B;%91VEO9O8YD.R+@]E7L;*)HP07D58X$ @
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MZX= (&OY4)<T1C'(&-(897F0BH%(G[O\19;::*3+P;B6!L.TK&'",2&0@4<
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M)2<'JL&"  T)6+DO&*%]M?9EG\&SRQF9W<%J^,:'106C+J 28G5,MU'C,.$
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M'@,/3JLO TKG6NWR@*TD\>/DSJD>YDKA\MA%:LDEAR^>NC>G.?U#:J3'O0B
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M&O8V-P9(*. DD ()<2V@< &DN)<T4:XGE J\YG?5:XO!<TU!+6$@TH#I;I(
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MSC/=QGQVZ<,XSWLX_+?FZIXE9_0P]XWM*GC-Q](_OCVU\S('['#&9"^XR+/
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M5EJ1OLL\7E-#::RSY&<0H>))(H:U(9&-6P)R(6Y.,QB+FT$I7D;>H,<T1B;
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MI,F6+W%K28[-.K+P<7@&!X%+/E&Z.[=S,ZYSJWM,I!;E\D;F237)9';VXDM
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M! 88I&(.19$85G/ L0<=S5^:\*]W,WLO1EW/?^BFSSRQP"2(PPFY,CIFQ,?
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M(CKLK3HH^:N"9MWV_G?RVC*>-_FE9PL?\<R9U*-^M]F]SG&:C_>Y_"*T[O9
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MYM/<:?00:<VC1DXC\AW2[>7RZXGN(JB.RI2^19UH>,/3I/1TZYS>)FQY#/B
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M%D.<YX8QK]P/A!EE;\/.0-:YP;6]U$^77*_.+CRQAXK9H2 32WZG^K0KKO\
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M>!I/Z53?D!7\CIMYOEN[)39Q_);V OHT24K(L&HR"L@X\X34X"Q X8XYYPC
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M8>ZX,?VQ., TN5A9@B##LX;Y3QVC+MT,3ZLN.0QP<][H"_#@:'NHQS6%Q?\
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MA7YOQ_3UM[?6L9W]]1=9WQ?']+6Y@6.Y199YOH9]/6X@4+]:C"SS?1SK=0*
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M765PAEE8!DK!16"N7..RP6#!7 7'.<=GR\G#.<\<]SOZRHP- IH41/W5PQA
M'A@(0!P  @ Y0A#R %R\P <N,<H!<F..,=S/#'G:S8Q2E%$X_=5-.P'Z9\R#
MZ;RX-XA#GM<!!D <&]SZ9@(,Y#C N/#&>'>UG,'_ &J)Q5+/X9P,.<!S@>!8
M'C(0YP/&08+S@>.'S6,EAP'.,\>(<8QWL:V,?6ZA_P#Y+$<?NJ)',3-B0'2O
M#<F]LA[(3&C7G.!Y6B8$SBH=R6G LCR66D"Z*S#\X"' AF9QD61<H,!RXK:
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M1@T?S_L'5XXJ<2AJSW-?.9><J>R&ZQ_5]GT3.TMG.TC:^+YZ@*CSZ,$CV?\
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M-?\ M?='#W1D>[*NKG.\?I3V\#9'?:9%X6PNG(ZD*%!F5G;]DG\'Y1!SDP/
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M<;#@<8;@6E(<%DAY<XPZG_-9XAY7V4OB$_9F[Z:U_I">^[A7ZXAZ.?P2LXY
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M6CZ80/GMVT,Q_:K9OR(1J4? ]\53M6YU]T]C_2D][_#?UK#WDW@UQQ=:WI=
M^>W=0O']JEG?8-J0? S\5YU;FWWG%C_2D'%[AN=6:P]Y-X-<876XZ60/GMW\
M)Q_:G:'V"ZE'P)_%F[5N7?\ G%C_ $I7>]WASZTA[R;P:O[MPZBVRS=U-G6N
M=N5\QZT9JQQE3,75A:6.9MBA'&D;FULZEU&?(HTS(ADE.;TE*R !HC<Y.QG
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MA(]$LCB-H=C$0PFB%D*!T*$09SX#GGQGAQQW=8-M?V=Y?7.66L@DS"S,8GC
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MT1-$31$T1-$31$T1-$31$T1-$31$T1-$7C4ZK'^7G=_\SKG]C&(:_;SX0_\
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M0FX+5JC$=JF+6;!86DA5_P 9A)K?!K>J)ZI2<0PQ8QR4A4=&G*&NQ0@I>?
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M.[:;"#Y#.P$\1,>?]QFKUN2?SG3QV\^EE[YW;380?(9V OGB%C_09I];D?\
M.=/';SZ67OG=M-A!\AG8">(6+]!6GUN1_P YU7QV]^FE[]W;5/%[?Y#.]':7
MSQ P_H(T>MJ/^<ZKX_??32]^[MIXO;_1L[T=I/:^P_H(T>MJ+^<Z>/WWTTO?
MN[:>+6_T;.]':7SVO,'Z!L_K8B_G&GC]_P#3S=^[MIXM;_1L[T=I/:['_P!
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M(KFV#LDM23[;MO\ 43!/X<V3;;Z]'VE#7]Z)?WR-,]Q1%4X.E+^+41Z?#J;
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M84+(I]@;)IDJ65K79C&C40UBF2(QF)3*$0,OA><"%@9V2B*@PCI@S^#S>JY
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MJK$#:VNWN=3PMO;6=ZDMGJEHV<0H-'XNCN8,A4LK2Q*I!)9^,$BIHUJ1+$2
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M1JZ,ML-@K+*V1-(4S!%FCVKB0L1.7;"HU4U@4PEG4#)/$:6:J:TAX\".3E#
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MHL*N9%4[U$VU' 9?)6B4RR/,B1$UHI(X-DN9)FK)>"2THR5:*1N+"40Y!R'
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7(FB)HB:(FB)HB:(FB)HB:(FB)HB__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g556278002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g556278002.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!=0(+ P$1  (1 0,1 ?_$ 0L   (" P$! 0$!
M       *" D&!PL$!0," 0$!  (#  ,! 0            @)!08' @,$ 0H0
M   %!  # @8&$0H.#P4&!P$" P0% !$&!R$2"#$305$B%!4)87'1,K46@9$C
M4Y,D5"4U=28V=K87=SFAL4+2,Z.4-Q@*P5*R8S1$M%5EI68GMSAB<I)#<X.S
M9$651E:F>!FBA(766*265V<H&O#A@G2&I]<1  $" P,%!PT,!P4&!@,!  $
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MZ0V.X935N78,PUYC6?:=QK.(C \OG,;;.<EQM66Q<8K%&^,94G%R,YBA(F2
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MCYD(9XZY]Y6.TL#22-3-Q+8QW]49NHDG]]MS&W5M Q^7F^.^0\W+[VXR3GL
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M8O%]S&ED1ADC]"W/#.J=[;8?.IQW373\O4XQV19#KMOW&?X.<H6,&4XX("'
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M=2694533!TN2]P/6:2E$G'K)>M CMTD&YYQ,R:IRJ%"/@1("A3& X)<T>-B
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MVIGQ2^<+< RB5[>\.(C_ &5VC5WU@X/X2U=W::IJ;N6/,J74,MQ<ZFEEQ<6
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M:L(NCUUM_J#Z:8;? 8MYQ+$QQSCB[HJ<LUBF;R::,WRC8[PT#(N %>%DC@V
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M2W6!TY'M<2;1QX>-[@ *G'Q^ 0K@_M,5M2W!*W&TS(2GL8'1B" 7 ')UEU3
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M]1^BU")\YB[:PGD( @3F^OC3R0,8;!>N?^T(YK\+J\._8.R[W<%;M@RS5O\
M4Q R\:W:3:^YUW)]0;5*9B<I?R=YJ',*Z @/W/2(!P U^(53A9</O"228$3F
M0ZO=!6*6PXMLFJ<,XD/A_=*2K<M"^<J>0'[LK?@/A,-7LT<]XNU '+YM*V6J
MK$2 ^\U=.>/I"\Y=W.5MKI^;&3WEJ@Y2<ULYQKE* \MQ]+)=E^%:!CY.+L%K
MQ-<>Y^Z7?,6U8/Q??:GF/RS!40CU(IQ'9RK@==9Z4&AK?%#)  _?)<0]$NP
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MYC*JDU<XI7=I505DR=.J[0J)KBZ=+GN#2=P95*+HF:G2ZM^GA0I!,(;1Q_@
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M%47(HJ=]K5XF,!#8PZG=%3F]6XW,EUB:A5*F8Q_3#CFL:P\ID%Q-Q,-K>Q7
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M1$41%$11$41%$11%YGCQI'M'+Y\Y19LF:*CETZ<J%10;H(E$ZJRRIQ B::9
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MQ@U:<^;EG"21%=(P?EM;BE9QAW7&?VIHCJ6"_3WND/'K+,O@)Y55^'8!OW9
M.;[PD[84];UY+LVAS.=Y-R32(W+W*7#]B ]H]O=$&KP::9"D8UN: 585332?
M.&NAW7&#2I;="R(!U:Z),(<0S5+Q_P![G]1Q]K::78,U0)_YZFVG+K6!#=3%
M)P&0=WV<@3)W644#]+.]2B%[Z]F^'_%DJL:XA(OE9A&?SR7M!3DO22+NUL-V
MG>/=$$G:LVY@5L'&ZX?(!4_#VJO.E3WBT6@GN=4; 57<JCDRK1K:5C823,.2
M.]&'54K>AQ$W\K'2HFX@7+D_!8 ^D5K<0]FN ^T^\/P%M76SPD__ "9:Z+@
M'NQ#HGO,3)+]3Y.LQP/7B##*FA>J +]/.X@'C? I[^Y3553<PPO50'[2S2K
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M2Y&DW]G)[[>S7PH[JR>5X%G ;H"K?G>&?PW:2I#]%W^MUTV?GDPGX4)6.MX
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MC#M /8JZFFF%]73/=WWFY[2K2M4NF6O,!RC6*D9TDI GU/:&L%K[+Q_PB/\
MOI_'7'O:'>7816N-P<7MA=%P>DL.(%$]W? NV5?)ZS7]'CUK_P#EEW'^)$O5
M9N'_ $WLKG\G;"F5?_H3:O,9VP5RYB^]+[0?K58$H!#,I^>JQO\ ^HIT?V[?
MRQQ7P3,_T*T/%  X>6N#F\S.TU;[A?EQ"LG?\[&P]=*[>(VTYLX?\B,B_5C'
M 5"JZO2.BYPW2IO6O'[KJ(9^)=H*3^40'O0N V%) W8/:<@W]G]B%7/7=F<;
M=:F#\I,@#W%6A7RR^\<]SLIUSI4CND9+N^H_4"@!8P9Q   _[:01 >'M#7)/
M: FN;A%:4IO>:D/>6^85".)UGM.83 F7.I&_Y =R6[?R;Y=\"NZK'N*XLOE9
M;FYQ72=L*<EZ^C%H<RG>3<E$DVWD 4 X@1(0[;\427[:NAL^>]]G,>\]T&Z,
MRK@$B69A?#* 3GW1E4HNBM(W\JC1YCA[W.&X%$.'_1TB(>#LX5P#VHB*C"*<
MV9E^GE/.YW328?\ X74,"\M]Q5GPSW0)ZCL^3L)B3K"+S=,.[P'C? )G^H)5
M;=R '7OLX.S>=R]H*9]ZG.9=RL<SON(=H2EZS< ,J6W#O%0X]HAWAN'CJZKC
M7-K:=S?AL.MV&A5M4T9EJ5CGYR\]M2=Z-4Q)U0:=/;B&9(DO;]CYDJ !7"/:
M2F:^#=NTWZJ6RG+>H342B5O. S2W$&G;\'NM!3*?4S?^3_MZW;\19WV?[5-5
M8-UB6WCH2,_G,O:"G?>?H_6<@[0E#?-B]X41 1$$D#>'ML%70RY\QM@49;"/
M%C9"K8J)$M];,>X=T2=*EUT'H@GU4ZF$ M?(%+W\?<+>&N#^U7->[#<#?(T!
M=7P2EL9?.21GUE83_.!OT5W4#]OM-?Z8\'J!6#/]0Z+@S_(3%)S&3^GU9PY'
MEI:YT=3?4)599ZG/])]T9?G4>_B'F-:)B?T M3FX\HQ;WACT^LOG!\F]=-&H
M$J>"*(BB(HB*(BB(HB*(BB+"MD3LOC& YAD./M4'TY#8])R$2S<F K=S(-FJ
MBC5!8PF(!4U%@ !$1 ./;1%6XSZUMGFBE$CL((F2X-&K3F?1DW'^CE)Y^.5L
M\:)@^)'9KKM73M)!X#D'21CB;R2B6PC1%)/2'41D><9]+:^SJ*;8Y-1J3@6K
M<&RH'E'(F%V*""Q3';D]%1YB$5XW,H(]G91%+Y=3NR6[M0_.!PNF7F MB"-S
M\0L VM[=>N;X)W!.A?CAW#CO KD\]3@WZENHH;"%][[?&P\!"^P<AX"'C"K&
MKL=&K.YA3^18JZ;<]=5G.YWE'+$M1!?;.K __,G!/QIBJR-=Z#/Y%^R5Z;*]
M:4O.9>V%UA\)>?<AB9?-7GWM0?E=P/+]C6P=M_8JN&J'UB:Z(\*1#=SG+UE8
MU3C6E#*!!L<J5SV9S'S[+#B42B;(ID>4P6$+RK[@(7[>%6J81D##^BY#M*OJ
M]7KJTN?_ #EBL<2[YIS (@#A ;!V\%TNSQC6<O%#\(UH/[!V@KQLSI30\LW2
M$UQ".?N-B2^;N0^YEB%Q2'E^Q:?AO;P54C6.A:,W(?#.VBK!B-60TY]9FYN9
M-W>2IDN'>2TD-A 3/7XV'@(?31AL(> :MFN3,A<J@/B&JO2_W3!_#7IQ)$ R
MS%[E$P!DL"-B^^&TJT-8H>$>%?7?N9K77J1XMVR5D+.Z1V=SAFD)JY^[OBCX
MH-G11^+;D0$R-B_8I0P (\W:%K>W51LS+5N=XT[2GZ]D9#HD9)<?=&8=5*C9
M"G>9F!$MN:0?\#<!XNE5! ?$(&JW.X+H76H-_P TD[ 5>EM>D. S?>4W:<O"
MV2 KM(>41L9N(V[1LLGV>.OGOD?R3:H\3.V5\5TNE\KE.VFRFSN^,-P\V=!?
M'TA 10'E ?1A36$;_(]NJDIHA.<^(\(1#=SY^LK% (4@/R.TN1_-_9R=^WLU
M\*.ZLEE>!9P&Z JWIWAG\-VDJ1/17_K=]-? 1_SR85P#B(_7,G96-M_U%6G[
M)-\FY9F[ C>.A!_>I>T%U,WKKFQ-X3S=T7[FW7E&1$"<(HX^^N(<>P/9JNRA
M&K4TYR&+V=C*,ZL(GM^I/?$>#.3=S)2]P01.?A;R3]H<0^;#VAXZM\L _5*
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M_P#++N/\1YBJZ</^F]E<_D[84N[_ /0FU>8SM@KERE]Z7V@_6JP)0"&93_\
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M40^2-:S?0B=A_:[79!Q$\>\5F;KRPZ_=.#OMTIIC(FQQQR:/YTX"T'(^2!B
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MZ2,58%YFI:WGKJ_==W?F)>_><_>^\_=+>3?Q47ZO=1$41%$11$41?PI[P_\
MM#?K#7KG>"=P3H7B[O3UER=>IW_66ZB_S\;?_P!(60U8Q=?)=FS1_P#7T_D6
M*NNW?7E;SN=Y1RQ73O\ &]JC\YN _C7$U]]J>JZGF\W8<O59'K>DYS*VVKK*
M8?\ >EB_X/0OP<VJN";X5W".E6+2/ MX(2S>P OF62"'[*=EU!]L95^6P>Q5
MGF%62X=#R T*"UZ/6]H<][:QAH01=(7X!WB0^#P+IUEK?Z*UO(NT+YJ+I30\
MH-(30\)]YL3^#+'X+2JK.I]-F<J[:*GG^J_1[25X?I@$D], B(^=O^'_ +P>
MK0;L&-RZ >(:H.7SZ5OY0KW8V4?C+CMPX?&"&\7]\VM9>]9!L&;R9V2OILGI
M;9G+C0F?7_WHO?P<<?!AZJEG^EOY0[2FL_T4\F="5[G"@$K(V#WSU[^JJK5K
M%Q^BEG\TE;(4&+X>OCRITKYZ2?TR 6[01 1]@525\5[#^2[4'BIVRO.ZGKEG
M#[::93X8N3V($OP>%59'P_Z?;4Y97H[1\@:%R,YO[.3WV]FOA1W5D\KP+. W
M0%6_.\,_ANTE2.Z)./6#TT?GDPSX1"L9>#U#6\VF;)6<NGTHL_G<O:"ZG#O[
MT'/X-K?!9JKRD^L&<L-I6"S_ $=_ .A*R&)P3-;C93_E?#5JERC^7) ^2-"@
MG>;UQ,ZY6;ZS3$NQ=>F +\N;8Q;Y,\TK$8BY;I58\4_9*R-PND5/RK=H)ES.
MOO%S'\$\A^!WE5>4_I+.4&D*;SN\/62N;H@BX6X?[Z?]<:MJL1_U20/LDK9"
MK_MOII/Y=VDKTQ*=I>., 7'TFP]G^WF5JU6]TS\@6OO<3/T%9FZO3RFZ[4TC
MD/WLS?VCD?[@6JKR5X9O"&E3F?X)W!.A*OR9+O%C6["#[5N]-^K5J=T3^2[*
M'BY.R% F\W2]_*=M9+@URYCBH@4/OFQF]_M_'<*]&).6Z==O>9SMARS]ROZB
MT79TA,V9L%\$RX.R^)3X?+AG=5=65Z=3<K+V@IJUWH\[@/T%*PHD$$&X %P!
MLVX\+_N"=6VTOJZGY-O:4"+3DCSJ>[=+SI6T=&IB7=FHS^/9F%C_ (\:>Y6A
M8TNC<&K&]*=LE;)A=*A>62=W7;I"8RW&%]2[.#QX!EX?X@?U6G97K.GY9FT%
M,NT_5T_D7[)2O2J?(X6*%Q !+8>']* _T:MDLT_EBD'V=F@*!5)ZXJ^%VRL^
MU:D [$PI0;@)<J@^'_Q%L%:EBP8W#K!X@Z%]MR<EO4'/_G%,N;&_B_S?\%,@
M^"G55>2_"-X0TJ=M7Z,_@E*OE1\A,0N-T&X]H?4Z56XW4,;L6=U**3L!0,O#
MT@J^6?M+9NETA_*UKTW&R>:8>8/9$<EC0XV\ 6K2L7S&Z-3R+]DK-8?C\RR.
M6;I3)6U..L-CA_D'E_XOR%5HV086M2G>J)>V%-6TO5U1R+]DI6%(GS$E@_WI
M(/WDE6RV?,/%4(W#(;H4"+5]9/AOG2MV=-*8_P H720^+8N._P!U#7,L=)FM
MAK;+?ERMH+<<+.GM+^GLE7$^LU_1X]:__EEW'^)$Q4!;@=-K*Y_)VPI2W^Z$
MVKS&=L%<N8OO2^T'ZU6!* (S*P'U5?Z1CH__ #P1_P "3E:3B1T#M7FAVFK=
M<.NG-E\Z&RY=*W=G\4>QOP0F_P"XE:@[=XPMRE/CFZ5.NT/0)W).V2E=3IF%
M4I1#@!. A[10\-6QW>F?EJG=N\2W0J^ZH_F*;PSI6].FI&V]=6G&]R9OC=NR
MP\TJW+^L-<YQJ=K87VB/%E;GA_\ U!HS\L)@;J#_ (C-N?F\ROX&=U7;<_I7
M9W/9.VU3(MSU/4\@_04L"FGY!#6X]RWX>#]P3XA5LU&84/Z)[:@/0=]7\Y?H
M4A>E HAU&Z:$0_[=-/[@D*XC[0?]+I@^5+[:WO!?I6.$%>KU7\>G'<(>/"Y$
M/U4J@'=-VK>:@=O54O:"EW;WJ:IY%VA+3*-_FSBU^"BH\>WB<WR:MJFS?KE)
MP';(4"J+UE6#<USVUO;I>*(;_P!3<.'QU;7^@WX>QPKD^/#_ .5MN#Q<CRTM
M;7@MTWE=8Z"K_NHP+Z,VB'CQ"3#Y9"U75=CI#1\X9I4RK>]35/)%+#F0Y3B7
MCY' .RXW(7MJVB21YO0\%NRH%6WZ1,X14E^D!'EZC-7C\[R5F >R!DEN/MUQ
MKV@SK7+J#XI^A=%P@]>R>4"E5_.!?T5W4!]OM-?Z8L'J&>"_]0Z/@3_(S%W?
M&3^GM;PY'EY:YT53=4)%99ZG+])]T9?G3??B%F-:'B?T M2'[N/*,6]89=/K
M+YP?)O70;ZU>L[4_0=I-;?6YX[-93#$<KQW#O-,!AH^=GS2^3J.DXXX,9.:@
M6H,B&:'[T_?\Q0M8IKU"ZZMUK1OA:HL>RW2FU1EN?&8XM;JMA'*&N,<N3)V5
M,Z]-Y[/NC91M>TVS74PF-9"6 71=&&1SFB&0[L=X%5"F_G./J^K@8,#ZG3'
M! !'7&& ( /: &_*4(@ UT\X 7P_>*"/*3/\M<S&/ET,QD5\. S_ #%([I-]
M>MT==8^^\(Z=-78MO:*SK/R9">#>9GA6-1.-I_%K&Y3*'Y9"0C\XEW;<RD=$
M*E2Y6RG,J)2CR@(F#!WDP?O+=BQIUN5LZD?22-76#'O+NZ<&" + ,[A'*,BS
M=W,7;M7FMB58E#*JVU4[6U2]C0WN6EQB0\D9 89#E5R,NM$H1CY2=6CT(?S9
M4DBI*JMT8X&BI126*\4=F*V!!0I^4W./*(#8:Y7+E3)SQ*E-<^8<P ))ZP&4
MKJ3IC)3>,>X-:-TF '9*CEBL+TIX4[EGF*SVJX=2:C7$3(IL\SQ\J*K-VJJH
MZ(5,94PI*..]Y#F*("*9"D]Z4 #.SK#O3,=J3:*OB0(#B9O8@-58\6[8LO(:
MND#@=V;+CULKE_>%:OZ4F\OCI,%B]5NIK'%5WV.-X.8AY1^Q5,NH[4<M&S>0
M<K&[E=4QRFY1!,QA$+5\5;=VVJ"7QUHT57)DCX4R3,8/=<T!>YE;9U>_ZO-D
M3#O,<UWO E2;K&+[$41%$7RYMZXCH>4?LT6SAVS8.G#5!X[38-%G"2)SHI.7
MJWS)J@=0  RAN!0&]$5=+/KNR59G-G-KN%=.\%4E9#. 9SZJ22\#'Y8AB*?Q
M70>)INUYA=XOWH)+!RF2+</?%HBD!I;J53VGELMADG!I8O-PZ"BB[)VNL1TY
M4.<RS9NS16* J*(QW*=QQ\@YK %$4I%U2)D$#7\LIP"Q1'B!1'C8!MP"O"8T
MNDO(S!AT(6DL<1N-)7)XZG! >I;J*$.P=\;?$+\!L.P<A$.'@X58O=?HS9O,
M*?R+%71;GKNLYW.\HY8KIW^-[4]__P 3<!_&N)K[[4]5U/-YNPY>%CY;8I!]
MJE;;5UA\1D&P8KBQ+J<QL<AC!\R4M;T<V[1Y:KAF-)<^9\$3".S%6+4C3-EA
MC<X;UDM=G7*?+\@4+<0-+RP@ A8;#+/^T!XU9CA3/+KCTDL@0;)[2@Y>N4&6
M]7R@<AK.VL=:!S.4>8.4 .F(B''L63&LU;DS7NM6QS\2[0OFI)(;>BB@?U@T
MA,XP;YL.)1"("IS#C3$ ^9*6X1:?AY;=@55U5>F37;C9ICV7*=KP9=.U[LSF
M9/<2R+U(HO7BI3"/TV^$ $+7NX/VWXAVU9Y=AY%S:$;U.Q0=OJW5O&Z=NZY,
M.S!>O'0^Z/'Q, @'IZ&$1#B( $DV$?UJR-[YQE6!-($8RSLE?187TMY:"><A
M;/;D["9FD'S8,6=H@*@F-C;D2_,E+6"*4/Q'EL \H55C-:75#WC-QKA[CE-1
MQUJ(OW-0CWDL=+%!64?'N/%Z[, 6[;JJ"%P&K3;H3C)NG0ZHC"CE; 4'[WRQ
M]]N=XTZ5YBD BIC\?(*F(\+\ 4(/R;5\M]'<3="L:,O'2W ]37&6'67[=-D;
M:ECY8TIGM*2:FQI,EU.8<>(;]Q5M88P#VOR]MAJKUTHBN,CQD/\ $IR2FDTP
M<,P9VER0YO[.3OV]FOA1W5D<KP3. W0%6Y.\,_ANTE2/Z(Q .L'IH$>P-R88
M(V"_9(!X XUBKP^H:WFTS9*SMTA&]-GC[7+VEU*7,BV-BKE$!4Y_BTN/%%0
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MY2?6#.6&TK!)_@'\ Z$L#QY">3X%.R_SWCV5:'=#HY(X(4'[S^M)G"*S'7:
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M9_K.0?@\<S)^D%,*J!\WFQ.34=H*6?:@ M6HB "(MFU^ ?4Y*M'IO5%+R3-
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MCX7$.R]A+XFL"[H.4.)S>+^F-5GD_P!32. S0%!ZS?657PCVUNGIW(8=V:S
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MY(K;</6ZM[Z1WRPKT]\_Q+;2_ ;(_@QQ4"KI]*+/Y[)\HU2VK_09W)/V2ER
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M+>]FK7B'A^ER<:M IC&RJ;DVZ H2UGI,WA%;)T^8I-MZN,80*4NQ\2$1'L
MFX_B-:5BZ";EU(&?BCLN6RX>=))7";I"OQVZ]:#JK9A0<)"8N!Y: @!@$0$(
M)\'Z]5Z6<"*^03NS6P_O!2VK&EU#.<,PENT%+F*%#O![!\A(;^VF6K.K.Z-T
MO(LT*$-F^NZOA=LK,->B4F<XJ(B!2AE$$(B/8'UP;!6JXL?T^K!XE?==/UU0
M<_.T4POL1TW' LV*"R8F+BT]S%Y@N%HUR _*&JY)<06O^#K 1ZL5-*K:6RBQ
MV1Q;D2VB)0[AOV#]*M@OX[()A</8&U6?7=$+M6?S.3Y,*$MO]):KEG[16PM5
M"4NR,&$1 H%S+$!$1X!QR6-"M3Q1RW5G\B[05L%RO7\CE6Z4P%LYVU'6VPR@
MX2O\1\MOY8>""?@/MV$:K^L0$VU2M'?"IE1_OM4M+58YEF3W.$&F2^']TI;M
MN4 01 ;#9!MQ]M%,?Z-6<6)ZGD\ :%"*L],F<(K;FB!*3>&G3#8H!L?&1$>P
M/[)&M QARX=UP&?4;I6T8:].:7]/95GOK,73=7U>?6N5-9,Y@Z9MQ (%, B
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MS*VVJ6%IDNLV>TG()+]DI;I +II!V?,&W_()U9U9 ++&E'/W"A-52]:KF&(
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MBJ. J%3I"(@(@7_=EN'MW&K+?.I+'2RXC6AVE"^JDS&,=D,(G2I.=()0+O\
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M.ESY,UO&2W C*=P\'>4^G4GZQ)=BM'DUOTJ%;K,%60WV7L?G*"C<4 -?XA"
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MBRBB*%NX.K!KBVP8'6FN&;?,,D:S4&XSA!L9)<&>-2"JZ*[*)4*N5);(U3%
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M5JBN;9M#0J&3N#E4@H&!D)5YB^.,%A,^329L)8ZIB.FKITIW)Q^:H$,*=Q*
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M$4">JW>6N%5 T-+Y,2!1S.+E"3&=M7B2\=A<C&"@O'-I9H@8YY(BSL"@]9W
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M>V\;U5I([.7=1TYC4G-R'G+,[+-H:2!4'&.8ZN('407.)37>\ID"*)"0PEN
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M=("IG,',!;F&B*4D]D4/C3%20FGJ3)L1-P<IE+\RQFS=5T=% @<57!D43<A
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M":2CW1L]82/>2D0K%0PJ&*W+8RBW(HF8Q#@($4W=5::P[4+*1;XPG*K.9=5
M[R0GI9S.R:;)FGW,5!-Y%Y=P2#@FWS%FA<033#M$>-$6V:(H8]4?39ENY74=
M*X=L+),>\[C1P_,L3]((+XE/8J^=%<+/U("125C',W%+E!1/O+%6( D$0X41
M;NTWI?$],8LP@8%J@M(IL6B$M/&;IIO95RB@D1=6_EG:LUG)3K$;%,*2)E#
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M-<1NMH(\8W>NYR6?NE9#(,HE$VH360R*IA$7<DJT103-W*8@FD0"@1-,H%*
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M[!@\TRG$\[P1[F['>2VW%HU_$8SGN)8P_<XD,'KAF^C)AJ9TSE$9,0()#-S
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M'=LQ/Y]C^0]-&$Y+)26 :ARS7.J,&V*PQ7"'.6OLT<;2TIB&2OY79$[,NG,
M$7DX*1Q$GD5)XRQ<,!?'(K1J(BB(HB*(BB(HB*(BB(HB*(BB(HB*(BB(HB*(
MBB(HB*(BB(HB*(BB(HB*(BB(HB14]:EZJGU@N^_6!]2VW]0]-629KK?-\GQ9
M]BN4LLLUM'M9AHPUSAL*[619S69QLH@5&4C5T1!9!,PBF(@ E$!&7>'F(ER[
M'N9069:=?+E5TJ6\/86326DS7N&5K",Q!R$YU$C$+#R^=L7RKK2LVAF3:&;,
M86/#Y0#@)3&G(YX.<$90,RK\_P#1+]:;_P#2#EW_ -^-1?\ _0JW3^*^'O\
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MNHYUQ';/_D1J#*HN(39N98[CLSIL>EXLB"JDO(,,E](GN@GWY$ 4(JU=6#A
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#1?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g556278003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g556278003.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!,@$> P$1  (1 0,1 ?_$ (T  0 " 04! 0
M       ("0<!! 4&"@(# 0$                     $   !P " 0,"! (%
M!@H'"0 ! @,$!08'  @1(1()$Q0Q(A4605%AD3(C%_!QH4(S&(&QP2345956
MF!K1\5)B<AD*DD,T)366Q]>($0$                     _]H # ,!  (1
M Q$ /P#W\<!P' <!P' <!P' <!P' <!P' <!P*\=K^13/*;=+SAG7NBV[N/V
MIH2=?-9^O>'O8(DC1R6=T1I'/]7T:T/(O.<OCFX*IKNB/WQY-%LJFJ5BH0X#
MP.H.^L7=#L0K:7/8?M[9,*HDC:H69H>1=,VC;.[76:FQ9OONJIIN\6-.W6*Z
M2\TI()%DSP;:&9I*L@%HH*:I_(;R:^([I-:6]Z2N%2U2W.-%M$3<;-)S_8W?
MW<H:?@RSH13B&=HZ,V&NLF9[*].5DQ!!E[U0\I>$T_8&MB^/_0Z@G;IGJIW?
M[*X5:[/:HFV'8Z%.->SN3M C32AGE889IKHNUZ_6)XDB4CE*(EH]8H-4/I*$
M]I@.&Q:]VM1ZZW1A0_D S.OYG!:%K[/,,$[&Y ]L]ZQ>_FL!%5*FUUAHK"?K
M?7JXRKGZ$:DG+G<0TE*JBFS>>TH!P+.45B+I$62,4Z:A2G(<ABG(<AP Q#D.
M03$.0Y1 0$!$! ?(<#]> X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@.
M X#@.!P5FLL%3X&5LUFE6,' 0C)5_*2\DX(U9,FJ0?F466/Z^1,(%(4H&.<Y
M@*4HF$ $*C&-GWOY1&B*U'E+MUD^.RX5FVP$[8UXZZ93W([ /"S:T;%S.9NU
M31SW$,/F(Z/*\:S*R9K#/,G9T0;,$S J(6;XSAF4]?:-$9QC](A*/485C&1[
M9A%(**.WJ</'-8E@\GIQ\J[GK-,$CV229WTBY=.U2D #J&\!P,L\!P' X2R5
MV$ML!-5BR13";@;!&.XB9B9-N5TPDHY\@HW=,WB!O15!9)00$/00\^0$!\#P
M*H^OC6T?'EMM*Z93KLTKTJU!)2)Z8:!;+I8;=I-$U,RDS8YKJG:32X/GLA36
M-79.7]&D!.1-A$1YXUTLJL1N8X2\U?OKT^Q*Q*TO2-_H$9>T%%$5\]K[]W?]
M$;JI%*8Z3F@9\RM%Q;*^TP"!5&13#Y] X'17'R;])(YRT;V'8WM)2>H,W2,K
MHV4[3FU<*WD#"5DJXM-[SFO5MF5?P(A]9VF(% 1'P "/ F+1M!HNGUN/N6;W
M&K7ZH2Q1/%VFF6&)L]>D2!X]QF4Q".WT>X$GN#W 503%'\0#@=PX#@. X#@.
M X#@. X#@. X#@. X#@. X#@. X#@.!TG2-&I&1T.XZ=I5FB:7GU K4Q;[G;
MIYR#.'KE:@62LA+R\@X$IA(V9,T3',!0,8WCP4!,( (549]EUG^3:>K78/LE
M#MVO2&%LV=Z]TSZ[R4?<JI<;W)PL8[D8_:^U-?DEXQG)HKRDDD[K5-<LW#-B
M5DUDEU#K*@D0+BBE]ON$1\B(^?/@//X 'K_/\/ZN!]\!P' <#:OGC2.9/)!^
MY;,F+%JX>/7CQ=)JS:-&J1UW#EVZ7,1%LV01()U%#F I"@(B( ' J8AGNG_)
MD_=V&)MEWQ#X_&3\S:FR-(D75-VON9]BY<M9"W-;FT*E9\DZT/#E,A$GB3LK
M);6HJ.ONF<<JB1R$N<CBNE_6^Q1W73&O]WO*+XNR^];Y%5)6C06FSC,$A<JS
M<C7@>A>[.X<)E%=9\Z*Y<. $53J&\B;@=\J79;K3JUHE\RH>ZXCI%U8HR:4Y
M0*EIM$M]G9I1JYF,RA*U6)F9"51)'N ,DZ*JW\(F 2J 4?3@1'OG2?+EKS:M
M!Z4WV"ZG]HZRNR<VMUEC6-5S>YO9)H$I%5OL[@,8\85>VQ%D8#]5*0^WC;*V
M2/\ <L7Y?P,'[5/Y*LGHV3Z;/]S%XOK%JO7:?KU)WZB/W$K9V3>PV\JO^'=H
MR4\/%O+#I.=;,DV56JKAJR.^64278.$4WS1PF4-Q)=^=(M7[T2Z\]!NVFRC5
M9*NL(F?M451NO5#T!O/"NHM-T6R[);8"1F8.%:E16<.!C$_<5P4$@4$J@$#=
M3?:'O9!(:#(C\:<[9&5>7A?V%&U+M5ASNU7]D[64)/N7$7/!78BJKP+<@'30
M5D7)GQS 5,2^!, <5-_*'D652-L0[4Y+V&ZC5VGKUIH\U79\S<N,/EW-G]J3
M8D%K6=O[O6#MXY]]1%ZN^%B@U!(RBARI"4Y@L0J]KKMTA(ZRU.;B;' 2S=)W
M&S,'(M92->M7")'#==L\:**(J%605*< \^X ,'D X'8> X#@. X#@. X#@.
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M\; P<<RB82%CV<3#Q$:V291T7%1C9)C'QL>S0*1!HQ9,T")))$*4A$R@4
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M[4'T/D?Z*NG7L(T=XGW0B8XZIR@52<,7 )3[9L0QA$7AH6-=*#X !%%,_KX
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MV%847]AG,K](#)'"576+K/2^L=%D:Y7I2P7.X7*QR%]U[6[RY;2.B[#I4V1
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MW;IRM6= J2SE,EKJ)E5EHSWIOFIUH]P0Z06&F,!0\B(>H@!?7^T(_@ ?TB/
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M0K8BVLUY51,LV8N(Z.BSF%==TFB%K !X  \^? ?B/XB/\1'QZ>1X&O <!P'
MT,/M*8W\@$?Z@\_P]>!6'2$%.V??"RZTZ4.]POHDK8,<RMD)A5B[;VNMT0V2
MV[1"%'^Y=DQNDR*%.CU?:;Z$I)38%,!DPX$L>S76>B=H*"C4K:ZF*S8ZU+M;
MEE6IT]R6)T7'-*ARJC7=%S^? !5C9N*44,19$WO9R3)19F[26;+*)F"K';NW
MFSM>O.I]/-N>+Y-WPD%\IR.G7FA.7U?K6\5#9=7J.2H=D.ODX0R+R-<L(^R.
M%Y^&24_4Z=,$]AO+4[-TJ%$].R2/[,T6\==ZKE>/6OJ5EN\6GL2UR>_:#V0J
MDEIEOVZW:+-1T)?;[FFA(SL]5VV2DK3A1&;92QG$@Y%8YS^SV\#.&N8-DEFS
MZBU^@_' MTEVS Y161Z_]KOC8U3,EKQG5E=M&KLKR;K%S9XG8M,IUA]Z:4I%
M2ZTF9ZF<Q2J)G.*@A/+K=\LW92Q5G#ZJ[J&?[?<*B_Q[).V5JL,+=>OEL-M^
MN]BI;!H&'S:A?IER@'+F%B*Y(3DN*[M!@\*R5.Q4(F8"$"=_>+J9O^Q;%7MF
MP62J,#=*;DQ<VK$[/RZ\<=J2_7*4K&KI&109.5OMV^46QY)LA WM7F8MHD/M
M\@H4,08[\<\O4):[4J0O]ISV-C\*G,^SRNXQN4[1Y%U&N-Z['W"O&ND/ "T<
MNXEM4="@R)N' *)H.U7:(>X0$QPR1B?7SM3UYSY[D5:RS&-&8ZA%XW*S]]OE
MT,O#9O:JMDN8Y?<XNVTA2OK26G0<.;."R%>,Q=MQ7.Y!%;[4$@7.&9NY_6_4
M-VE()S14H!4L9BVJT-R:9F/TPXV"XZ)@5EB/:F#5R)F1HO.)(RJGGRFI](G@
MWU!$H6(%'R'GP(>1_ ?Q]/3\/X?AP/K@.!B7?,[A==PW9,IL;5R^K^E99H%#
MFF;)5%N]<Q=MJDM!/D6;APDN@W>*-WQ@24.F<A%/ B40#QP(^?&M:W-SZ"=0
MYIY6K=3G2."Y[7'%8OI_JW*&6ID&WIRC2R. B8$KN4 T")E%BLFQ%Q-]0J92
MF .!-W@. X#@. X#@. X#@1E[)]4<P[-PT %M4LE/T"@R"L_D^V9K,&J>PY)
M95$RD5F*+<$4ESMVT@D0$I&+>)/(:6;A])ZT73\  1RC9SY*<*%*&G*%C_>6
MFH""+&]U*X,.MN\*L4BE]CBW9]:(^7QNQ3(% 2J.(F;@&[@X>\&:/GV\#&<-
M\G^B7#>]"ZITCH%V&>]C,NSZE:A=*7:]#Z\52J1-*T"5EX.KS@: EJ-@CWS>
M0DX%V4$VK9=R5- QS(AZ%X'>)?%.\7:A4T3V&TVI]5,-D43IV'%>K5EL%EV>
M[1JWM!2O7;LY,Q%5&G0SI'RF\0IT(SD5TCF(263*(CP)^Y?EN>8K0ZUE^4T^
M!H6?4^.3BJU4ZTP3CXF*9D,=4X)(I^3KN7;A4ZSAPJ91PY<*'55.=0YC"'?N
M X#@. X$/>\'829Z]X@Z>T)DC-[EJUEK^']<JLJ ')8]PTQ=:%IXO$O B->J
M9 <3\RIX]J$-%.E#"'M#R&2.L6$P/6K"\[Q6ONUY8E+A 2G;*]]92Z726<N)
MV]WN;4'R=>;NUQDWTFZ.81$5G0AY\ ' SUP*D/D7<8A)]F/C/J>R2>>59)CO
M&KZS%WF]R,!7%:^EF^'VJ-_28"VSRS0D-(6FSWF()]%)8BCPS0HE*8R >T(M
MV'X,\V>,829P_>FLVTAX"#A:NYV"BPMTDAK];BRQ-7BB;A@=@P'87C6(BT4&
M[5T]FI9PF@D0/<<?7@8,GOCG[UY,HI^U'FE66+)X.#W"NS]8T5$A$$@,14<9
M[MYP[DW"X&1*5-!#1S' OY 5$/ @&$,$Z]]EL@N..4VKY1-3NU:IWEMV[LX3
MM(ZA<1?3><]9\1L#P=1O#;+E-ACXN##L+V/?.V$=$J/A>E00]BR7N$X!>JIU
M3[;[.1%3LQW6L=4@' *&D<EZ85=+"ZZJ"AC ,;(:_9G=ZVV78@B;Z9U(]_73
MJ^H^TGGV@&),)ZXXUUK^3J7K..5 M::V3H2C.VJ5D)RQV^VV^=;]@R1Z4S;;
MI<I>?M=DD2,TP(51V\5$@"(%\ /C@6]\!P' <!P-!\^/3^8?R_#R'D/7^8<"
MLWXE92 4ZB*5.N6>Y6V.S+L1VPS$)>_J$5M(.JAV-TELYCG9R2\X)HZ+.O\
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M=! GO,*BQ,S74,<P?V2D(8QA_ .!]-_DVZEJIO7#R7VF"8Q[47CR2LG57M#
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M6+7.T4@\:*%$_P!$J0.H=(Q?:'D1_$>!/S@. X#@.!^2XB"1_ @4?'@!$/(
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M5G7*;1JW"5"J04>D"+.(K=<CF\3"1K=,/[*3*.:IIA_$?;Y'SY\\#MW < /
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M@. X#@5_?)=V7GNM'5JTR>>K(AM^JRL/B&",SB!U%-1TE1>*8SX-@\F689Y
M)O[(\\A[ :Q)P,( ;SP*VOA!ZSPB*]X[-((*/Z+388_4_K!(R@*.'DC2J%,G
M5WG6"*+?4!:2UG8F"C0[TIO>Y;P'O ?IK_F#T3<!P' <"*/8KIGB'95Y!VFX
M1E@J.L4TGC/MWR:R2.:[?03 H*P(U[0ZV9"4<PJBQA.M#R19"%=B(@NS5 1
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M_5>A]"2FB^X$&"06T(($;IE22 I4R 4J9"D(F1,A"@0A"$3 I"$(0H
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M9V?JDC29#+8]30>PF@U&UU>5A)^M2BVBVY"&7?,W:*GMJPIF$2E$!#S\YO\
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MY6>G*UE]68U6)F+.NS<V"40:&554D)=:-8QD:9\\<+G.<&[9! GGVIID( %
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M^.+,_HLFD+V![RUB/8MS()L87NAO:J:OO546,NY<SEMFY)RX\J" &,N/@O@
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MA8N0A4P]I0\!_ /0 *'\"E    *4/0 X'WP' <!P' <"LGO>Z;;]=<HZ#-)
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MK!(6NWS:OUU5C_>3]CE7+Q?P($^JL;V@4/  '=3$  $0]_H(F\%$0\C_ $@
MA[OP_P"'@0/N_>^H4_:[1DJ&3;C:JQF3^)A]MW>HU.(E\?Q6:FZ.IH[./O#T
M+$WMP-65+^@]E)"/BGK"&(^;%=K)"J %"'$#\R67[HUJS3KM'J%L3[<^M]6E
MX^\/:=._J>)[W9YVN1FAP@YO>[02#FCJP:@&BIH[*6BU3)?>,2_4*40LAZ::
M_9>PG5+K[N%R9Q<;:M6RJHWFP,( CI"%:2EABD'[M"+2>.7CM)DFJJ()@HJ<
MX%_$1'@91U;(,TW&ASF8ZS4(J\42Q_:&EZ],%7!NNXCWS:4C7[=RS6:R$=*Q
M<FS2<M7;99%TV<)%424(<H" ?GD6-YC@M%C,UR&G1-&I,0XDGC.$B0<J%/(3
M+Y:4F)61D'[AY*S4S+R3E1=T]>+KNW*QQ,HH8>!DW@. X#@. X#@. X#@. X
M#@. X#@. X#@. X 1\ (C_#U_G_H#UX%7_>=W'=@=*ROHNL_(VSJ?CS]C^X\
MH+K[1C#]9,NFD74+19M\!DBL6^YZ9'MXY<IE"BM7(>: 0$@&$ Y[H5$O-@D=
M7[WVF/79.^S#R*@\)B'S?[=S2NH^:NI%ECC)NU. _IZVI/7LA=WI">/<6<:(
MG ?M2>T+(N X#@. X#@=;F[=6*](UR%FYZ*BYBXR+F(JD2]?(-Y*Q23*.=2[
MYG#,SG!Q(+,8IBLY6!,I@213,<_@H>>!6?J."=0[E:=T[+2_9ZW5/%XNT*%[
M?T&H:]7X#KU9[YDE9:TV36VY5G&JV&"D:]6 9LK!'-IB-92:#-J63;K 3P8,
M!=>NOWQUO\[G[9G?=UUK^<8)<\4NSZQRNPY6O7\5@,'5EYG-JM/.*_5ZNQ:0
M"B<DJ#N9G"N9J81;I)J2!P0  ">_4+2^H]8ZZY+G_7_?Z'I>6YY^U\#J5H:7
MJNV)T\LC".*V@:M,2$6=NW+<)1HW R38R*"CD1**28^\OD)LE,!@\E'R'\P_
MHX&O <!P' <!P' <!P' <!P' <!P' <!P' <!P' ^#F]A3&]HF  \^"AY,/^
M8!\!P/.$]I>_;?H>Y=6]-QW8,KV7NYV#?3'8W7U(HLED<%\>6/&_3:=FN1;)
M6'CV">R5\I:#2 7BW!HZ:;3%QG'JC0$4RJ&#T7Q,3&04;'PT,P:1<3%,649&
M1K!!-LQCXZ.;),F+%FV2*1)NU9M$")ID* %(0H    <#D> X#@. X#@5-=JK
MM?,R[G)7^'I$WI,W!= ]F4ZPT2(:FD'-FWPVH4Y&ZQ$2R]WM"6=UAU6SN%0#
MW(PB#]41!)-7@5O6KJ!W>P7KAVNZ]S<%3M>#M#U*>.XZP]>*#?'S=OV@S9[$
MM[':=%CK=.3025PW6&MHO071.V;2#FLG2,F43D\A+7L%T.V",&/[*7:Y6#NI
MH-7TCK9(W_,*SE6>Y8TN?7;#KU:;[+4:N9S$/S1=_NK2V6Q.QMT)B24_4%H9
M!@W*E[_:H&T[)76,UOKCWBTFH=3KY@SJRT[&*WE^I:12E\AV+<^Q<+;TB8TG
M'9E),VMM9,<QOLE#-8R8DRH.GJ[E=-LD9JV!4X7F1/WGZ:Q_4A2-) T;!)"B
M  B,@""8/12 H 4$Q<@;QX]/' Y#@. X#@. X#@. X#@. X#@. X#@. X#@.
M!7;V/^1BD]==<<XL3#M_VJWQ=&KM_L1L;@:'*QM:AK7(62.@&\NM;M!ICG]0
MD5*H[.4B"*Q )[/)O<8 X&+67R\8RE)T2+N>"]K\V/H4@YAX:4M^:5 ];:3*
M4/,SK6.E9ZMZ-8&[-65CX10S8?8<IQ43\B4#>0#HK?YN<$#+(?9)?KAW.A\_
MF:H%\2L'^$M/F&;.BJ,&<JG;I$\%I\@HUAAB7Z3D1,3ZI$Q$!)[BB' [$P^8
MW")P7;RH==^Z5ZA4)ZS5YM9ZEB,1(UZ5D*=8I*K3:L:Z<7]DLLU;3$0X(0ZB
M*8F(D)@#QXX&Q<?-;US:O64&ZPWN0TNDH^BV\+GJV%-/WC.QTI&6V4+8HQF2
M['CU*^S2I$DFY7.Z3.BLAX$@@8!$)7]5^]N:=M;7HU'J&?[7FMMRZ'IM@LM?
MVFBLJ3)+PE[=V1C 242DRL5@!VW5=U)\FI[Q2,0R0>@@/D FWP' <!P' X&5
MJ]<G9& EYF#BY.5JD@O*UF2>LT'#Z D74>ZBG3V(=*$,O'N'48]6;JF2,45$
M5#$-Y*/C@<S]$GCQX$/0 \@8P#Z>/X@/GSZ<#[*0I0$H!Z"(B/D?/GS^/GS_
M #X'!S57KMC/$'L$+&S8P$TQLD($JT1?DBK!&$7)&S; CDBA6THP!R<45R@"
MB1C>XH@;UX'-D(5,H$('@H>?'\1]1\^H_B(^O ^^ X#@. X#@. X#@. X#@.
M X#@. X&U<OF;(6Y7;MLU,[6^V:E7632,Y<"FHL#=N4YBBNN*21S>PODWM*(
M^/ #P.(<6VJM&#N5=66!:Q;!TLQ?R3F7CT(]D];"8'#)X\5<$;-7C<2B"B1S
M%4)X'R <#9P=^HMG(]4K5SJEB2C4BKR2L#88B83CD3D.H19^I'.W!&:1TTS&
M R@E*)2B(#X >!#[=/C]Z\]B=(D]ALTIKU;O]CHL%09&R97L]\SU.1K-=7L#
MVO\ U8RNS"$$[>QI[2^%%T=N=7V.1#W"7QP,+0WQ$=98VQ56PS.B=IKV%/E#
MSD+ :!V)N=JJI9,(V9B$73N">B5H[49MI]R9'W^034,!@_LE\!T!Y\+_ %(B
ML[=YJOL/;*-SU:J?LTL%(]D9QW$1E09,4FZT*P1L$>_:-HE.)8D17*(>S[9(
M/>/Y0$ [U_\ **Z7(/CC'3782M!-RTQ-L(2L=JMOK$+]]+O%YR84KM?AKLQC
MF:"[QTHZ.FT1*F03^\  /'@-F^^&GJ"X?LIF,LG9:OV>,-")L[=$]C]+6M:#
M*O-K"VC(A*>G92:?)1!$;0^^HW(8J:XK>5/=[2^ D)UDZ1XUU0TK5+Y1;KJU
MOO.N5C-*_:C:KHI+NZCJKF);$SIK:#;*1S![',2+6-]]554RPN%C>I_<'C@3
M9</F;0I3NG2#<AS 0AUE"ID,<?P*!SB!1,/\ \^O ^F[QH[00<M7*#ELY3!5
MNX;JD6072,7WE5163$R:J1B^H&*(@(?AP-P @(>0]0X&O <!P' <!P' <!P'
M <!P' <!P' <!P' <!P' <!P(==YZ_<'F$KWS-:C,7W3\)NM&WC/Z77@,:=N
M$OF]@:OYJG1"1#D%Q(7&DN96*22\^%3O */H/ KKZ[=4M2K>Y9KD6D9W(3N'
M3,:\[RZI8+$Q1DZ0\[.Z/0Y#-M%RN4:NON&4C(JVJSO+$1FJ4Z!$404]@>"@
M 929=,:J_P"@/9S*RX^YHUEN4OVYDT*MG3-?,;+H2'^(FORF2P$N[HJD!-6*
MK2S*5CS,XU5Q]HY:J)(F(*!C)&#]>VUKO5+0Z"T%">[056&MT%?HK2(3JW%A
M):D^=T["V<G7VSU@C&RTPE%0EM33%<6B7Y7!DRN1!H9<>!$I>W?)U7IFZ6K6
M[3HE,>UG$;=/N8Z!H,G+9D-1A.KCZ8_6GEQ:2+7*:OI[/96ZCAPH +2R<FB5
MNBW4BU"F*'2"UGM+HDGEVGPYN]MOI45@.JMJF\UJ'4;V4_8O2>M=B4ETYFIL
MHALWD\CE+"SB6T<X?-E81.9<KMF2HM%" (=BT^"[W25ZKMBID%VC==A*% =G
M_<$M6V*G6>H5^9KL7!93(9,Z^U:1SK0GV:*KE:-T'*KI>>*[2?D37^U#@;V3
M??(]%1&53T!9>S&A1;2Y6PM9IX4#0<SG;!&%L="<Q4?=+98VUVL:"Y6?ZRDQ
M<:+"LX%S'** =R@N@@X4">_:JF=B+KVCS>"SZ;UVC9188C&HG0+OE1V4+(,(
ME"Y;-)W>+&XFC7[V*2<L48-)V9(0.BDNF=$R2A_J &.-.H6[7SJ-TY=:.GOL
MOI&==B*;+Z26FG?M-#DJW$R6D4R-G;S$5ELW/.Q:[%[%.944VX)F164=&3*4
M#B4(R(YQWPQ3!LSH&?6?L.^J0Y5U EM2?3;66MMVSMPK%:G$[%5,N8Y]&Q-W
MCVT,^BZBA(Q$)]9['1YCKMP$5%S&"Z;JF.HCUXRH=IE9><TT:T4;1+V"L?LN
M??*"^>#%K3M7%_)J0\V,']J#LBBOUCN .=4B2ACI$"0G <!P' <!P' <!P'
M<!P' <!P' <!P' <!P' <!P/DQ0-X\A^ ^0_@/G_ #AZ\#B9V02@H.9FE&[M
MTG#Q4C**-F29G#UR1@S6='0:(>?[YVN5(2IE_P!8X@' IA9_);KB*!OURM];
M6;FZY-B.M962MWO1;_*H)[;>9ZK0N>W>G5.EO+)):'&1<&94C>*(1L_=E<$^
MJV19JJF##M=^2*_W-N;=I*EPBIZ_4#2]8I'ZBS2BZ]8:UD7=:9O96-A<UQ>T
MD@M"D^OT:"K8YT'+-+V@8R@HJ$5#/LGWE[$NY^!PBSYSU8CM+N=M+6)=[<=)
MMS/%"5"P]<#[VR9K*R58"=G)U1FDYAG;7[<&KA,OWA?"15$ #&5.^7#0K;&V
MFTU?K(2-RVF4>\)$<R$\2+-&7+/,(<["98\FJ#&)?YI**M2Q; 6+0T@=@LE*
M$(+8QDR!V*S?)'KM52,-@I>43MQK.7V38VJ64:G)S>26.)G,4GM&I55L,^]K
M!I-*Q1C^ 53>&1]J(,W3.11*=-<&X!S]N^1'LGDZVA*ZIDV$C&4.YZQEJKJE
M7^\+KR%WSC,*=M*$\JE/UB,084AW2K8+!R4ZIGJ$BS%<!%JH!4P[FAWAOLCW
M1N=.!W4GG7?)*OL<398V@Q%PT[5+G;*:/7-W&R];KE(BYIX]<PZFOJ-';!JD
MO])N1==4"F3)[0QW.]G]70[+.;6YTJ]-L,2W;+<SC&U._P +5ZS465_B:4S0
MRS?NOE^A:CV0KNBV&P647"-CAGDHBS;O&BPLRMD'9.!=H5,H!X /;ZB(^!_B
M/\?/\^!]@ !^' UX#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X&W=M
MDWC5RT5%4J3INLV4,@NLU7!-=,R1Q1<MSIKMU0*8?:<ABG(/J @( / @=C7Q
MP=:LE#13/ZR76%-/:0<59O\ %B#H4^DZ@JU,2-AA(]^TB*9 ,+%)-YV35>+3
M$JD^FG;@"*+.SF(' DRSZ_8='L/TMAD6;L(SZ2C<(UE2ZXUCP;K,9^,5;E9-
MXU)L1NI'6N50,F! (*,DZ((>UPJ!@K>TK:OBVVG2:.VOTM4[3,4>W2Q4H*>Q
MZU2U&G)5RLOU_&;M+J6SIY6Y6OT.?\0*<R=V1A!2*B+=1PG]0A#!R&H[;\?M
MESC4[E;8"D,]!DL8NV>R*5 I",KMLIGKFE:*R4@\ZEV=,2L$U$*5&@S"17+9
M$\9&&8*MW!R%1,7@9"S;1?CX@,&KDQ%4?.,_SANC"IR=>D\J1K2\#8]$PYEI
MSZ.L\$G4V"J<_,Y&B5>04%OX<-4@2.(@)$Q#NT3V,Z+Z#/U&M@XJDA+;&*4]
M#(6G+K#'-IQ[IT"ZJD4I:7=HIS2/@I_6:C#G9QS684:O;#$ID*@FNW.E[@DO
M4>O>%T!>O.J/C^:4YU45I=Q5G58I-;@G-=7L,>QB; M"KQD:U5CE9Z+BVS=Z
M9(2BZ1;IE4$P$+X#D'^(8W*:+'Z[)95GDCJ<4@DWC=&?4^ONKLP2;HK-FX-;
M0O'J3:)FS5RHDD)5@%-)0Q"B!3"' REP' <!P' <!P' <!P' <!P' <!P' <
M!P' <!P' <!P' <#@(:TUVQ.)YK!S#&57J\VI6["1DJ"X1,^BS9/UXAX<@"F
MG((-)) ZB7D3)_5*!@ ?3@?A,W*K5Z6JL%-SC",F+Q+/(*HQSI04W5@F(^$D
MK(^CHU/VB*[EK P[IT<OIX10./\ #@;^9GHJOQ,E.S#H6<5$,7$E(NA0<K_;
M,VI#*.%OHMD5G"HIE(/Y2$,<?'@ $>!7A-]'LTA:*Y:2^HVEC!*YS:LQ/)_I
M$>NH5GIO8IANOZE]LV:K',[2L8IQ:9?9]/[,XJ'$#@(@'09'X\\LIL_2K19=
MUM$1-DK5XZWT%9\SK<6@XS_>E[Q*W[+&K(4E4I:Q7>UV!&70D3B9XT6@&::)
M0;@Z3<!NYKXTG5D:-82=[)WEQ5G36HR-KKS;/Z&Q3L]^I?7I_P!;(ZY'DR-U
M)*"9K4-=LX6BD5/MQE6A5@4!-0Z(AW>2^.G.WO8"I;LWL;0[Z+2R1>RQ4WFN
M>VV5GIW%JZUK=,EJ_>9Z+=V3.T7$:R:&?MXS_;*-2*H*M5#JG4"?=3N%7NT.
M,[4IQC88<DG/PAI*.5%=L66JLW(5JQ,#'\![7,1/1+EHN4?4JR)B^OC@=D!0
M@F$@&_, >1#P/H CX]?3T'SP. ?VRMQ4U7J[)3#-C.6Q640K48Y4%%U-KPK+
M]2E4(\AR@"Z[&/\ *YR /O!(AC@ E(80#L7 <!P' <!P' <!P' <!P' <!P'
M <!P' <!P' <!P' T'P(" _A_'@4!;OU@[&;1B;K*\YHL-8K16]H[G-[W/6.
M::UR:8W/1K?)VS&]&KI;0Z"L*PZU9LK)12<192D]$B@D6-2(<7!BAT/1_C\[
M87:;C5'N5Q<SI;:,V]Q.=HE^P;ME/3D+IO7V=SZF9>SJZ:R<G'N*-/2J+#[X
M#)MV:3/[]DL99XY H9GN7QP:+6U=8D,&J[&HR5FLW96$JBK;4K"U^TR+1NLD
M56J-5FX2$R]2B(S_ '@&Z\N=J0 %H\.>0 0.H?W!^E@^/_<6DDXN5$BV\1H5
MTUK>)W3[$749A)W9*'8]US2\9-'N5%9!9 6L#4ZP\%NR0(F6,4$Z28%^Y5]X
M8<J/QS]EHUW()3V<5BR5^L=A<=U*J#<[[6YN_.K!5K'I+2=T=A9HC](KMH:P
M<#=6DD@YGXJ+MLBHT,T<J+@F@<P=NPCX[.P<>C5(+9F5CGX-GM6%V36H^S:Q
M2I.GZH?.HO4E+GJ<? 46L5R7>GM%@L,4HNG8G:TI+(D(D^;"#,BB@=9J?Q^]
MMJW-62:N418];;(W)"5UJG2.T4&MTCM] C>K#.MT4V4-58RPQ[Z#92+%TD6W
MR1$@39##_P!ZR.1<@9KD.DFU.OCKS+!4<[6K=WI^X7C27&55/4JK9F<95;+J
MVJ6JOU=Y/:3&NJ5J[*!A+HP,XCI@\>DNJV]Z+Q%PW0,8,I7#K[V*M'6[K30-
M$R&M:RKC2T.GL.*PVJNJA5MJ:#E\U 0AHBV3LU)R!$LXNDHR>K-)MV9-XLP4
M70.H*30#AEFTU.__ *%TCSMY57=>NU'W2BR3E5G9I2_Q\=2\YS*RC?)8]SF3
MN9U[#R$?*'@47$N<DF^6=D44+[C^@6)@'@/ZO\_X 'K_ $\#7@. X#@. X#@
M. X#@. X#@. X#@. X#@. X#@. X ?P'_E_#_AX&U:?V#?\ Q!_Q!^/_ +W\
M_P"G@;K@. X#@. X#@.!ME?]L3_:?V2_V/\ XA_M?^Y_/^GQP-SP' <!P' <
2!P' <!P' <!P' <!P' <#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g556278004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g556278004.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!2@(W P$1  (1 0,1 ?_$ -T  0  !P$! 0
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M_(PA)*3@WRUFEI(UG%!5QV Z; 5+=/H'77GN]]CFV*Y;:RV0M'D$@==LW4Q
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ML_)*T6>Q6%E(\@ZYCB";NF<5&F?XUE,5O3OZG;Z<_6!149AN[$%>Y0""0=P
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MM=BZ[)5$\78"N6R[5NE' LBY R2Q%%#;E,  &M&V[KU7%O'<VX<+2U9%'4N
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MDF"S6\RC(3N0,P9HLA[8YS9*(.(^T5F308QR$&6!B(N3;PWP5?4CTU$$E4Q
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MPB,(Q@X$B2@%=1, T:E!H"H@)0*&^M/N7NZ??]PLMUO8M7R5LV#3B=;6N+^
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MF)V#X#OMK=O>]=OOMRDW:VVJ"*2=K0X=20X,:&\3QHM#;>SI[#;H]J9?S].
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M$$-^XH@ @ CN @ CX=?Y=8N;J%%(-$]SPW+X@7V?:'J ?C'5?22I0!*&P;E
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M<U^/D@&*A3N0(J9HO%EQSC]N^8.&;F1ME/<K,Y^/6;K@'PYV#U+R@$WVCF*
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MC*ND6M1JI$"+H=I7*A?- Q '7T&/>^VXKN%TSG2,,SG.(#VN <"2#CC1QS'
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MJ@X)*S)(EJH+8LX$@O'HM_*-L!TU![NF^O/V?<FWV'=]UW/)4L8R1\8QQ<<
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M':N8:PQ:DE+VE*17K1602D2R!=A.)13@6SLN[104Q %.H;Z?_C.X0M,PAD
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MXP-YVR51KDEK(VFKHV[YA",X>PG54D:0S7?6"&9NQB08/)5FW;F/Y*2ISF3
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M;LV\[M\G'KU,@+C44_FYUSQ6RYGDQA"J7Z3QS-W=HSN<5%?.)Z/3CIIY'P#
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M3R;X^I92?FC.25.Y8S\9B&6@ISBO/L&DG VV79"ZML&K'DGG\VD6(,JG&=D
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M7$$+&B"2&-C*  LTNU$MI\1)J5\PV;]N+]MVRZGE=I:]SC4DUJ* 4(X8+I+
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M!%$=N@[CJ=KL[C<=Y99THY[@T'/,TR]:Y^]7S=JV62^:TN#&5H#3AS]2^>G
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M3MZ[[C_IO_TZD-H:^ 'H44RQ.93M^DPC^/;4FAS 4!A'\Q4.P-]_#ZM0&M'
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MM-$TD\53"X$@%,JJBF4Q@)W',4A1$P_JO+$P^\*OAL/7?PU@)_[I4Z>-<%Z
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MG$0'KK>_3[\/<:/H*5%#@#D3A@*+GO\ D'1-O*L#78 89Y_PS5CQWF?%>5*
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MB:I"LX9@_F9*Q/FK4@@1Q.3*YG,I)+"(B*CE\L;N4,.XF'QU5)--*X.E<7.
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M2>:6;YB1SG3_ !$X^E6"*(,Z0:!'RX+*B,F::IEDVK<BQB$3,L1%,JIDT_\
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M4_P.S),.+="EN= &FB.?5J>)D)P;$N_S6I"O2?>(YSFCTF\*O'*)%*VV,/>
MF'V:PMN\MKBF#C&#@P9"HT-+>7&M5B>V]P(P?SXGCCS6S,-\,;3COD6[RU.S
MT?9(SYE/3\.^&7DVLQ'_ '@K+."<02D.#+X:4:,3M0 AU''E)I 3M3 Q1$>9
MN>]P7D+&6[0V)L+64IQ:35^&6H'/,\5U;+9)H6GK.J_56OAR7TR;E $P#<!V
MW#<H;%Z?1MT$ 'Z.FO*&5KWD-7=BBZ30.*]P\-"K*UQ4=$31$T1-$31$T1-$
M00WZ#U >@@/MT1-O^C1$T1-$31$T1-$3;V^WPWT1-$31$T1-$31$V#??;K]/
MMT1-$31$T1-$31$T1-$31$T1-$4IMNT=]P#\'0?Y-$7+?,3D/)<5N/=^SA$X
MEO6;WM+1CE6^-L;,OC+5.&D)=A%B+$H@82@S!]YZI@*/:DF8=NFB+;6.;N>[
MXYI6192"F*,G:Z5"7)_6[<5..GZF,M%M9)S#6=OW DWDX@K@4G8=W8DJD8 Z
M!OHE OSP)^L3F2VP/-9K1WV-B66 9,[GQ"+)0$T"!J4GE]#$4DSO@+KLBV"8
M*NJWDDS,5>P&[Y'WMM$5'.^L9R,GW\8]H%<HT3 4GC]FZ/S,E/PKLSYIR[Q#
MCJ6M5FJD&HH^321JM0D87_MR9@45%-^B('$-]R+ZRYJY12=(XS8!S)$SC%W(
M9"R#QRK4VXJIXN89K+Y+DJ^TLL<W%9RY:HIBO)*E,)1\U%'[/4-$HM:\;O4>
M=Y]B\M/G&$IFCOZ5@M_R$I#$;7#V,]]I;>0LL.FB*44D=6'E'LU6#HE2.0Q_
M+5+U W31%Q-=^?'+ZJ<5,$<@HW+>*;Y9.1E\I2#>B8OQ >ZV;$L!8ZC>[#(5
MTD VOH/KC+$6@6J(G<)L!;JMW'< A]@BZ5P%S5SSD7+? &)O$[A1&H\HN.F3
M;]:8.IG^(GCWRF-(AW&.8J64GW32+9NRO3@HP(BN=-T5= 5MT1'1%V&TY9@3
MEJ[XHRE%=2*[Z'4L$#>*!,EM49 L&\8B^6;9<CD6[>2QK)OE#"$<8XKMGON[
M* 8>T"+Y%V/U8LR)V[,%;3&.J$K/9:=X?PA%3%%8NJG4H>&S#5,83N2;G96E
MN5GS/HU.PF>+-)!I&,U3BEY"PAWZ(NPZGZA\MC7B<RSMR :QUPA*CR4R7@'(
M&5:8F>OU<8BEW2RTNN97:0IW4@FG$V&2AFR)R)+J)(K.#'*<P!HBQI_ZKUK2
MJ5_O:G%>P$JV+2X?"XS;^^1;1M6%\PU=O?(=Q-13=H\E2PT!4G*3N2=HMU02
M.H0@$$2F[2+Z_P!2M$?=*O6K9&.$'4;8H:+G6+J.<F=,G;268I/D3QKI(B8N
MVX]_0QBE$P!OMHBS31$T1-$31$T1-$31$T1-$7..>3"%HXX@ !VFSM%@;</;
M]RKH)!#\("&B+YFUSU N0,GZFDYQ65CJ:OB)++LUC=NJXI$[!/$X:$PE#9(6
MDHO+3FPFK=CNK:=F0(>NIQH.?EH^:501WT1?23/0&"T\70.8%!_S 1XB;8P
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M82NJ-99F(95JB8OD*4+L8*.C;34R_+FOF-/BW":YNU3KVZ(N[\]B4;7Q>$@
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M8P;6?)'#ZS3U@1C+F^@4L.<D'MRB9&"L3B18E6BI6OOZR@+IZD!0 CL"%[3
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MS9WD7E*7L%7JMDI.",<M:-3T)/)&3,X*T]_D+(,>63%S'HO:MCZL+1_Q0'7
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M//ES*[^XT^.PO7:&=9EDV=0)7WL50+%3YNKRD>L<[VXUZS/)%!^LMY@'./\
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M/,2/HB_2Q$.1=LF[CXIN]!9NW5^*;)G217,JB5454DU#JG(DH4X&(43F$I1
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M+$%Q[A#G3*D E\"+]%_EIB(&$A0-N!M]@W P!L [A[0 =M$4 11+V[)D#LW
MONA[H"(B(!TZ;B8=$4PIICON0@[F[AW*'V@VZ^'CT#1$\LFPE["[#N AL&W7
MQ^O1$\M/;M[";?1VAMX;?T:(@I)F*!1(02@)1 HE#8!(("4=MMO=$.FB)Y9-
MMNPNW7IVAMUWWZ?AWT13 4I0V*       !MT#P#^31%'1$T1:@SM/5FK8DR3
M8[M>)7&U.A:589"RWJ$<?"3%6AF\8Z%_-Q+HR#L&THQ;B)VY@15$JH (%$=M
MB+XS>G'GK(;_  V2Q*\HZ]9J#EWE1:F&+F>?KPZNF9:M@R0J[AQ4ZX$M'MU
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M^;^"KU5Q33445$$DD2&6,J8>TA2I%$YC*'$Y2E( !U$>FVCNG3V35RVBUC6
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M JQU8%Y7Y@OG+-D0!0J1E#^\42CH;A^H/&)JTY>&(]*FRB[R+9W[R23^&64
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M#C.>S!CN@)Y)NN(<4Y*3C*7D-F:*G9')N45,9EA:^BY$7OS" 'M</FP"LJ@
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M6W<J)=E73A8A"%WW.<P%#KHBJ"/ .4YBD[BIB &.4?U>_P#6+WF$/>+T_'N
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MY=4\C'?):0@,5K4B+R= .'F(YD[F+QJO%3$I#9V58U\U*87^5D&IDW508/\
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M^<'Z6FN;_;_TI2V_/]93O#\G\X/TM-<W^W_I2EM^?ZRG>'Y/YP?I::YO]O\
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%?J*__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g556278005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g556278005.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!+@(  P$1  (1 0,1 ?_$ -H   $#!0$!
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MD=B'VB:RH*$;[ 7N V5:UFE7-\;I)6-8ZLPY$13!R!?A_P!'^:&.6FZCU=\
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MIXY\"<N;8@'"(XPJ0<B !]H/M"8!$  ,Y$1 !$ ^D.6$D9X958QR##>J"JF
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M.EG F  $,B4!P)@#U$N?I].97.A:*FBQ 3.- L1UT #)E"!G X 0[A_+C.1
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M@& _]Z7&0P(C]D/S1YD=)&(W,]$8JG*E,K9-QJL)G"/:3"J9?4V!, 9+D/M
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M3:*C)Q2<-(65RUEX@96I(/\ ;-<I=9CI!O,0+QH4;O#2A7Q"BB(ILE1$A\F
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M:@G;7##%6-?'O2S9LDS::ZKZ;</P8=("HJB9-77A#I4TYR&.40_#?<;V1QT
M>G*7&M:_=R2227#F/D86 ]TD@[10C914BT/0+5L<<4#'\IY?O[M12N#OXX+
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M?>[<ASM:7'TN[1XK6\@LVSL>UP< *O&W*XG:-SA3:M'5G]6NUATUK=7GLYC
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M=<&]5BK4V@3O:S3+%6%[/)L( ]M-=U99!E#0D6_53>NIF,7ASIN4 #O(J<H
M @.1Z6H= :[HT#)KHO!=6HK6@:1B3F(QK7!<6Q^8W3VHR9(V-!\6_=YJG%/>
M>CUE;44-L:[%:E$4<7$A;? @:ME;N08JJ6$GQI#1H).C%0[EP ONCV?G].<I
MEAJ,;F"A+74IVU-!OWE>A?JFCW$#GG+0#$?7P51W=I\).KQJ>S**5W<6C=W4
MF@6J',M8VJRYD&9H1(KG_P 13=*@)4Q3$0.8!*41-Z:SM$U'.^^:7<MA&;@*
M^/LW*T'46D3@6;"W,1@/H$Q-P^2U0T?.4N"N-7OZC*Z66 J:-RA(%M*5&%L5
MMD0BX")F'GQZ$DW^/=8$?:;+ DGD3F#G8L= U+5XI?9*NDCA=)0''*P5<1B,
M M'4->TK2'1LF:T-DF:S$"E7&@W++M?R0I^I[77M=A7KYL;8=@BY*?9TO7$
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M[9<[OX>Y"I7CR6K'LW6H[8U?;S\NQAD26*$5F5 CSME)$ICD,L(''!"&$P@
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M ^,1((F;B(=X!GFJ^TN8LS75#FBI\!V;UN%]F90"&]@I_12*FS!TF57O#)@
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M^#UU)O&%XC9V.L#%Y"; KJ[X/9<-!3!<< 8Q0 <[,6N&"Z-W&#F<6U%206C
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MC=F"H02]I3%$2@&/L@?  81$P)J (F$#=>O7E\DJ4;V*ASF$O:4!*H<IO7M
MW> @  )0 >G;D<ATP'(R24KN3*SL5J)05,J(F.&#J 7(%*<"'Q@"F QC 4,?
M3@>"V5HQKBH(:#N6R"0=,F,. P4<X^S] #C\['*UD[4[O8@42&+VFR(=,?4
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M B(  8 3?3]?',"45P)E+D2_8$2]H=O0 #U]/3.>O&<)16&;D-V_:.4"J%4
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M,(?G '42AZA@!Z\UPQPF+78M49JK-W")0$  #?2 Y'&/4!$OH/,N0<$5HJ"
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M,14JD:Y?H 8_MB?N*;F+4^FY+&U-R"ZE<*U&W9_+ZUMQS/<:$"O8O7Q'O,F
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M4QW)F#';V]JAB]HD$1(8! V>XHCT^CD\R;MIXDY<7 +(9ND82B("4Q<8$IA
M0 # 80 ?J$0Z_7R,]SXCX%3V>+@M.2AHR79.XV3:)O8]^BHW?,G&3MG;=4@I
MJ(.$A'M42.0<"4>@\<RZ:<P.(\"CV:+93 I-<T^KO48-L\@HYVWKCMB_@4'#
M<BJ,.]C$SHQ[J/2. D;KLTE!*F8H9* ].9F7L\T)>'$9@:]OC2*VBA%& 42Y
M\*@81$Q1#N-D0 PAW#]K(B(" CW=V!S]'-.RFF#7AVXH^VB>X/IB%E%NED!
MHE$  H"4>W!0'/;T_N1'Z.;//<G)9P5PI%P..[KGU,(X ?4 SZ!RCYGT[NU6
M$3*U(6,6Z9C%.)?MDR!# (@) -@!* @/YH@'H.<<Q<Z>E/L5N7'P";EJI%3N
M\:2'M]?B[#&)N4G:3.3;$<)HNT?^Z<H";[:"Y $0 Y!*; B&<"/-FVOKJ!Y>
MUQ82*5&]8Y+:&8!KFB@-4K1D+%0C%K%Q#)O&1C%HFQ91[%(C9FT:(E[$T&R"
M)2)HIE]<  =1SZ\H^2:1V<&I)KBKB-H9DIW5M_"(B(#C':.2=HB7M'H.2X$
M#[09_EY=LDQKS-JI'$R&H:,'*\6J?=W]>[&,]QLXZCC\[T$1Y<RORY0L3K2)
MS\Q5IVJ"A#IJ$$Q3Y P=PAD!,)A ! 0$ $1^CUYJ^T3,-'K+[/%P3:M5$IUW
M9)1UNKL78F*+@'2365:D=)$<@F9+WR=X=Q%?:,)1$HADIA <@..;D-W.S&)S
MFFFXJ/9X2<15.5@R9QK)K'QS5NQ8,FZ35FR:(D;M6K9 @)HMVZ"12IHHI)E
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M87.HQMN@VK7]^@K$Q^5P#:DM<XM)V&F&"5YSY@'D)7X. )-:WUS V"P'!]'
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M+MG),@;L724 R:B>2AD# (#CA%L((I($3103*DBBBFBDFF0I$4TDP[2)I%*
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M*.0, B @.0X19>$1PB.$1PB.$6/W4\X[RYQGU^@?IY(:3L"Q&>%IH7"JJ*A
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M%T1JEA"3+]2;OUHD'MTVK:'(%!U9=A61;[PL<BHKV^Y\*U75%!J01P1 @%#
M<OI$+Y1F< 2!Y?\ #8K_ #4ZUCZRZ@==V9<.F+)AMK2/ -MK2,G)4#NM?0U<
M6X5. HNK2#DA1#J E*(#]>0 >=%PHXCM7@6EI:"TU:1@>(XJ[D*RH/H..HX'
M ?\ ECA%SQJGQJTEI&^;:V-J[6\)2[IORTL+?MF>B2.".[K/,FCANUDI4[E8
MR8+M2KJCVIE#(JF'U-PBZ$5/[:9SX,;M#N I0[C&$/0I0R&3&'H'"+ST\Q_%
MGQDWM8Z'9?("^KT:0BVR55I7PURA:>H^<%O%6OY4X]:30,[>N7DE6&[=VBD;
MVU62JJ9PP;/"+GQW\M_PEF8ULR1VY.IU:37>ZZ"N,=A4@T6]NQZ];ZC'Q;-]
M]S.I=&RP-?M[]LA&-W14#E$JBS910A3\(E&^>!?A\T>7"I2>]Y[4\K8*W.N;
MM!1-ZUS /W50EK,6WO3/F$I7EEFE>(\!0G9[8-E$55 4!01$P$62L_+J\*)Z
M1BJO5MD2UCG*TQ83 LH:]U5W.N8->1UA8(L\NG$0X.U8KWM7Q8HJ& ,)KK@3
M *%[2)B0_P O3P3JMPKS-]O>6=VVC7&*AXV+N-QUF915Y5(.%8Q5&4@G-6:1
M[Q:(BO@@]]-'[X*/:=1P8QS&$B[#V7H"E^4MO_6'6=IQSRN+:PNFF+0YIY*K
M;#N0<6F G8\K9:9:6&MH/X5Q'.T7 .V:RGZ<ITO;.0#<(H"F/E7>,50@#V>4
MV-MNKPE"B4+/%S#FU5]5K0KC6Z[$0;W<Z2\K5G936]6JUI!NY^+^)C4T2#[;
M4AASPBLNO@'J':J7C9KVI;QN%7INGM-W51M#TU_65;[L:L[(MU%N$-:960FJ
MY*LRP*MGI)G1SM6R'O.%2D*9,G<F)$^V7RS=;J56YU&6O5Z-'S4O0GM$EF)H
MH+'08NAR=AGF<:1:6BI.$D_OF<M;Q=^19@+98/: 4A.D"@D4<RORHO&*HU:7
M^]]A[%B:A#5,Z"SJ9D:2XCJLNVCX*.>W87,C3U%DY(\97FXC[JHLF9LJMD4C
M8$I%J5;P4\8827M%@UCNG[\"(O.M[;N-S.VJHVJ7AX2@KM; \9/[$W9-+''/
M+,_AVCIPM(NE$42I*^V0H#@I%ZNU&_4J^U]"U4NTP5HKCA5V@C-0<DVD(XZ[
M!0R+Y '+=0Z8*LU2&*J41 Q! <@'")H'W[I(A!,;:U"[@8)RHH!9HHSL(Q68
M+ )/Q9%<B[!FI,G!N"@D[!4^G "/"*6P.40 0, @8 $H@(" @.," AT$!SPB
MNX1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"+$NF95!9(AS)'4243(H3
M'>F8Y!*4Y>X#%[B".0R AGA%S+XLZ'NWC[KB2H]\WGL+R&EWEXMML1NVR#QX
MSK",LLHO(,*DR^[D6Z80M=16!%OW?:[<\(O/H/EW;NB?.-OY.5F]UYE1+5Y/
M/ML;3H[B2EEQEZK!Z_+7M?S$(W,U.S97%H_=.6CY+!4E& D$%>\,<(NIY;Q7
MW#-P'E'!V'>4U98W=U3LL#0H.8E[0_AM>.Y?XP[ 6;.0D'*,>@G[Q$3F9@F)
M4_0!P <(O,S8GB)\PE]/PK^K.&5#M>RFM=JT\CK;<TY'5>G,-.Z1C=>TNYV:
MWA5F3^>4?6HZLFE#)L0*;VQ256$3=X$76'D3X>^5%JVU*;+U;>!4&<TCIF@6
M9D7:MEH!)][K^ZNIK8->:%CX:82K[?95??F0"92(=XR.0P>V8%1,4BQ[4\,_
M)*]:@\0(M>8KMK\@='S<HZE-LV^VC)0]69V&?BUY%9Y6).IR2>U'D?4(U".;
M*J&BG2;EJ5P54!.8O"+A]?Y3'E2H[4D72NH)4&]>1UV]@GELETV%VD/NS8T>
M/DU.*C65P2VLS=7=NX2;F(=8/@^P'91!(Q2+I[>WBOYG;8WY(TRE;!L%8T[
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MB./YGN>:)N'!_+$CL32O+<O32_+35F.$OM5GRQ]WG0X__P O\EL__P#12O\
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M)N]JD00,(#W"1=H$;$S[AA$3FP8_0G:)@3!(N [?L@0F0#&,YZYX1 ,T  H
M4  O?VX I>T#F$P@42@ @&1_GQUX15%JD8>XP")^X3=^"@;J'9C(%^@GV0^G
M \(JBV3$P'#N*(>@%$ */V.P.XN/M]H=0SG \(J%:)E*4N3F I>PH&-G!?7
M].O41]?KX1!6I"Y[3'*(^H@)0-U ?0W;D.HYQZ9X17"W(("7)@ 0, ]0P(G
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MJXO9:J*Q01416K!;V5%@)%NH\> I81D;-()I>PQ*LNDW*=8P"'84Q%Q12/G
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MYB)"/AXVW!:).7BXV6B_N=(Q(YZUD;2%/P$L\!NP9KM)HIRJD7,02@F8 R;
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M$XS^3OCTFT:NC;XU$"#VK!<VC@]^K"8+5#N4(-L #R8%/ %.V5 7)?T B00
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M(VJVQ$$G8KO<R1\;-P1)B5_&LM-25E(^:/HY\SDX0CVPJ^U_\L91L;L,"G>
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M?7[AL\UDC5)E&OR3^3JSL(&$EVRC3\/MXY2HIL)2+BTUC"W4>)N78F-E997
M8(G3O/P&U3Y"WYKL2]6B_MI^.JCFKP*%>=5B'0KKGVFR1+$@]1JP3<M(M18^
MXDWD7#V.3<"!RMPP'"))U;\N33&F]@1VT*S9=ER,VT5=S;V-GIV*?1%HV&\K
M\E6_UG3C1C76+L;>E"2:[<"ME6[#VS9!N!@ 0(FMXV_+?I>B;!1-C2VTMD[
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M*FBFK0.U&?RG_H#^SEN0[TW+%S1Z)\B,_E/_ $!_9QR'>FY.:/1/D1G\I_Z
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M8%N+<X1'"(X16>VF)>T2$[0Q@O:';T'(=,8Z#PBNP'U!T'(=/0?3/\N.$0
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M=,KNKQZ7\CFR[&;4L&\CV^)KD-*0M/BZ8%&9A&MY1W[[F'GTFMO*081WDAU
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M2#L)95H4I4R6*/*57VAR)1 1S]KA%U2O_P!RI_[ AU$Q0R/0.X2@)@+GU'Z
MX1>.7DMY=;\UEY)V37L.SL,778V-BT==5J+U^VG";#&6I=HFI.\2=FDR@)J[
M5;''-V2R$6(.&@?;< )5D^$48>,/FUYQ7[86K:ULW2TP]BZYK6R16XV5;IC>
M"D-B;A2BZ3:H.P4F3MLC#P\?44JO:BCVG<)^X[17(&12[1(L5H\T_)B.J$M=
M%KBVA[;$[_DJG?/'IMK9)&]4?7D'<I&%@HFB2DPS=Q]TN5ZKZ+60.5R<R#E)
M<_P2R/: \(NW?#7:_D+LG3NS=F;NC)6,?FL]W7U[7Y"#B8%5O6Z_\=]UH?!1
MR24J!A50*F<K_O4.8!$IC%ZB1<'NO*[S-5HE"V74;B,[$./%VH[;W$$AJV.=
M,-=6C9D_#PD:U@'L>U0=3DA3FKN1?/&A@5(FW8""O:.0X13!-_,7NVD])^.L
MWMBF#9[QMZI[@GDG;9C*0#B:#5]AK3&-DD:RT8NU&PV>IV(\E[8 5%,$,D^R
M8 X1,:B?,EO_ )-,GE8UK6(2NVAMN%VR9QM8LS.WV]WJ76L+9KE<WTW'*LP7
MK+^W-:VW91"JR8E=K.SE2^VD(<(FS0/F?>2+Z8GGM@T@UF(>S["BXZE13)Q8
M8YM'PR57UX+_ %] RCFI$=V/8J\U:GCE8[Q-%FD5BLF542ICVD4I5GYF.VK)
M?J=4'7C:G LGLSL*.N%OEKLWBJI7D*8Z5(=6#EW;4J%W1C6)4W+XT;\4)4BJ
M@"13I&(!$\/)GS0V_2+?X\TC7]<C6$'LMMJR[W/9#9O8+4T7J=CN9HVWPU#C
M_P +?#2B<% H"]D';U6/<)M73<4B',; $4'6?S)\I&7R[[GO"I3I[?M5[O*0
MI>N)UA1HVNS,=KDTJ8T!(;&K,JW<UZI3AV#!8RJSALY223=MDU4O?,?L(GO?
M_/G=+#P:T]MN@T:8?;4V;^):9*3URKDC5AJETJL-,.EY)Q4&L78@2DK3+Q)F
MD<R<D2;++*% XE*)2<(HTU#YL>7=DV32(ZZE!K&RV[M<4JT51:CF@G%:5G;3
M<:T[HK:478E&45E:=#-+*9<HB9,%NP!]H2\(O?OA$<(CA$<(CA$<(CA$<(CA
M$<(CA$<(CA$<(CA$<(L9OH_\OJY0@YE,>Q<(2_\ _LCN_P#U=U!_FBR<];HO
M_;N\:\'U1_OM\+?Y)V%+DP9*80SD0*8Q!''7 '*4XE]/7 \W*CBN)F;Q"XO\
M@MM[II^U=94+4D"%@/9(-W8IJ*+7&LK'N$FEJC&#]O+3B\JQ=UE@G!/'"Y7:
M +F%1,I>S!AY5Y[IIM4@-><A(H4P7?FM:F[>O3@ZI>F-<&C5"HU ;57R*RWQ
M=YB*"VFY2T),O:@F[==Y[GP8ME!]D.\1]P0YKYG<,5?V2*NUOE26^^8;'P-(
MF+=9=6JP+V+;0DC'5MS<HU=S8()Q#2,C)OHQ9",.!W\>G$K=S17L[B@7"@"?
MMXSOKLP4^R0TVBOA3T6\V2LF$;//]1SJ5=MM]LFL=8NB62(?/M@;%KTH5@6O
M#&I-T2P"UD,@\.S,X4.B'P8ICU.'!>\CM06D-=HIX5DNOD9<:;NG>,*X(H_I
M>E]=P-P3JD?#0?Q-M6E:BO//6C^T2,FG*,I!-<@))_!LET +U-@2\9W4Q%"I
M%E&3W2"/"HYNGG=9TFWX=A]=-:I>VDO&M+3^);G7G;>&8/K16H<AXA$K5NG;
MU7;>Q$.=)#](W3*!#ADP<<PI["U*\3\P!K-N6<8SU:DE-3+HRM9,ML:N)5[[
MO96"XU]^XM5A( MJM,JJTY4R4<Y[ECHKI'*7!3" /.X8*#9,&V@*QQWGDN\^
M_P!]':MFYJ(9-4;2[0?RL/77].IQX34CEPV*S*BX6L$LC([(2 J1S)BM@XX[
M2EX#W*/9(N+?*N@](;OM6RXM^^L]-KL&]0G]E1G8PN4;-*I)42268L2JPZ22
M<DH>;)@JQ1 P-5!^T4P& 1S-?W:E,C(^Z*47+<!YL6VNQM$V'L&4J]IHU\UP
MMM&\P%59LHVP>/$:A/1K!Q^(U$%WCBQ-J^U?JMWR;E)NZ^(3.5%,0*;%\#MV
M(*#$)X*^?Y =6Q)#1]T.%3HZEGD5234*W.FFXKQ[9$%*@X 0(SFH9! 4W0 H
M!#KE[P[<\P.><Q ">RQO[Y(J5J7[SAE8^?FM;1M1CX&_Q<779-Z\;6!C:6$5
M+*2=0&QUF38MV4:!72<':$#(NDC'(H< $Y0[@Q0N?4$!3['#3:/*I A_*J4K
MNK="VZ\0:4LOMV2GXF7LR+MK"PD"_;V%U"P+5&-22<OU'=A_1II)D(8@JI&.
MJ<A3AS:%.*>QP\6^5(\5YNIV^<IM:UMK):ZVBVUFN6,([\8P<>2(5EZ#9;V\
MA91Z8CIE]\Q+:N_"';'*1555=,P=@ (<@\:X43V2'BWRILA\P.N.E(BWQ]1G
MQUF,;,_?LLLO&@D@I R5)AK7*J*+ +QFVU]9+*Y9.R$R14&BBQS@4$RCKYW<
M$]DBXCRI%OGGT((+P-1K)HBT2E=B)^&D9"7;RRD*+B2J;M6+ML,$<W$L@]J=
MF*J0I3"5$Q@!3 \NQY+A4+');1L87 BH7INND9(YB  @0#'+[)@ BB(D-^A4
MPGDHH&()@*7T#F>H6HHOV_\ \,;I_P#15/\ ]^AQ4+/:_P"^WPKN^M__ -OP
MG_T.(_\ Y!KSR#_._P!1_B5]7?\ ]JWP)=)^>/\ [(?^;F-WF^-7;_M-67E%
M".$1PB.$1PB.$1PB.$1PB.$1PB.$5HD(80,8I1,7(%$2@(@ ^H (AD,_3PBK
M@/J#^CA%:*28CW"F03"(&$1(41$Q?S1SC.0^CA%B<)E.F8IB@<IBF()!+W%,
M!\!VF#&!*8?4!Z"'")'KD!#UR,)#PL6QB(QN946\9'L4(]DW*X65<J^TS;@"
M"8K.%E#F[?439'A%ADJY 2$Y#SSR$C7LY!LY-E$2KABW6?Q;&9%H$LS8O%4C
MJ-4)8L>B"Y"" * B4#9#'")J5#3NJJ%)/9RD:SHM3F90RBLC*UVHP<%*/C+J
M'74^)?L623HQ3'5,(E$^!,(CZB/"*3")D H83*4 .)RA[92]IA^D #IG ^OT
M\(DJ4CVLBT>1CQ@T>L'[9=JY:.FR:[5=LX2,BY0<)'*)%$7:9S)F#ZA'/"+?
M:-&[5HT:(()(MVC=)LV0(D1--N@BF5))!),H=J::29 * !T  X1;'MI]HE["
M=INIB]I>T?Y0Q@>$51(00P)"B&>[M$H8[O7.!#&<\(FU(P,/+NXIY*Q+.1<P
M,@$G#*O(]LNM'RQ4Q1"3C5CD[FKI)LL9+W $!$@B <(G/PB.$1PB.$1PB.$1
MPB.$1PB.$1PB.$1PB.$1PB.$6,>6"EFQ<(ROVO)'=W;]KNKVGRACKU&&LI@#
MI](E 1_DYZO0_P#MG#PKP/57^\W_ $_R3KP<,"7.<A]8?3UZ_1TYN\KP+S>"
MP'C61GP29FC7[P33<-&[T$2'=M8\YB'/'MU3 (E;KBGGZA'D<KP*S*9@DD*G
M5Q%@(UN&33C@30:)EC&BAH] '*$@G\"8R8@04G"!%LAZ."!]/'*\"VL$DOM<
M466;I-)2E59XDF"7<U>PS-RW X%5: ""I"9!%)!8QNP?LCW" AQR_ HP6&8U
ME2+$K432, S[:/9"W*LMR(_#H,+(";ULC,"W:G;M%WOMNCJ']ST6-W_G<<OP
M)@E)]1J5*RYK#)T^ DII5J#!U(O(MFL^<L 05;I1#MX=))VY9HIK"4.XRB92
M#@.8I(Z^50Z<0"O%6O:%2GSI@^?U2L2;M@Y4=,73R#:KJ,WADT2"\.L=N9P0
M[@&:11*0# )BD.?H7F Q^15&H#BF;6=$ZCJ=8"EP^NZR6M&D%95S'OHMK(F?
M23Q\[D';R0=NB@N^7]Y\MVJG,"A05$H= 'F>**@/A5Q<"X&;A@GTI3ZJI[JA
MJW"F,[;%:N!&+9%%TV638I)-':2:)2@D4(UJ"I>I2"@0P="!C((_ IP66/JU
M?B'BTA'0,4QD7CA^Y7D(Z/:LW2CJ3,B20=&73#O14="W*=0>W](8H#USQRO
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MP'[%F@T;4V3-<Z(@ \1]J]%X%JNVB(M!=(4UD(B-;J%.)3*%52:($53.)1$
M,0Y! <"(9#GD'N:34'>5]$=C;-8// V)9*40,(B'3M .8R12G:K#",-WK)RJ
MA'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X
M1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"*S!L8*)@ZAZ]H]/ZQ
MX15P/U?X9O[.$1@?J_PS?V<(C _5_AF_LX1&!^K_  S?V<(C _5_AF_LX1&!
M^K_#-_9PB,#]7^&;^SA$8'ZO\,W]G"(P/U?X9O[.$1@?J_PS?V<(C _5_AF_
MLX1&!^K_  S?V<(C _5_AF_LX1&!^K_#-_9PB,#]7^&;^SA$8'ZO\,W]G"(P
M/U?X9O[.$1@?J_PS?V<(C'UAG_\ :$?ZAZ<(F3L'9%*U77C6J^SS6NP)'C5B
M>0=@J9(KAV?L2*)42**=I0 3&$ P4A1$>@<(FI0O(#3VSY6P05&O45/3-36.
MVLT:DF^9NH-RF!!6;/RR#5H1-PW!0HJ$*8QB%,!A "B \(I(_$E?%ZTC"S44
M>2?_ ! L8XD@S,_>D:&[7BC1F"WQ#E-F.?=,0I@3P/=C'")%@]BTJQF42A['
M%NG!):6A$V@NT47CJ2@U 1E6[)FN=-R\^#4'!S)E,4/KX1)SS;>N6,FTB%;;
M#J/G]>LEI9IM7B+Q)Q"U%W&,+ Y1<-3K-U%(YY,-TS) 851.H  7.>$5E0V[
MKV[U-&\P=D9A5%W*;1&:E1-",E%U6[5RDF566!H4PJ)O" 7'J?)?SBB $3I&
MV5<%TVPV.!!PJ[3CTD/OB/\ >5?JI>^FQ22^)[U'AT![P2 !.)!R 8X19'%F
MKC-$KAW/0[1N<Y4R.'4FR;H'4.H"14R+++D3,<RH@4  >IAP'7A%5Q9:\T6%
ML[FXEHX!DO)BW=R#1LN$:U @N9$45U4U08M_<+WJB'MER&1X16#::T59!N:?
MABK.FR;ULD:48@HNR6S[#Q$GQ'>HT7[1[%2@)#8Z#PBS*V&"0=-F2LQ%INWG
MQ(,VIG[0'#L68=SPK9 5O>7%H3[2O8403+U-@.$31F-O:N@%&2$QL"HL7$D5
M4\:V5GXT7,B5!XBP7^[VZ;@ZST47BY$S@D!Q*<P /7A$HGV+2RSL#6T[#'.I
MBRNY9A$-6*Y'WO/8-@,G*M%U&@K)LW+1D'>8BPD-]&,].$6*O;+HUICTI.%L
MD6Y:N4I1TU$SQNBLZCX5^O&2<JW;*JE<*Q31XU4(=P!?; 2#D>G"+%6=IZ\N
M* .:W<*_*)&>S#!(6\HR,+A>!<J-)4[0OO=SMJS62'N62[T@+@>['"+3E-R:
MJA%VK24V#4F;YZF19DP4GHTSYZD>2)#^XS:)N#K.RDDC@D?VP-V'Z&QPB=I[
M17TOA05EX])1^=%*/14>M2+R"[A$7#9NP2,L!GCARD BF1/N,? ]H#@>$2+%
M;)HLS6HNX,K/$?AN:*L,9*N7:3)N[,W6<(+IH_&&0.=5)9HJ42@ F_1FZ8 >
M$6#]:^LA@26D-@4T:XK$)V!.:"QQ)HX\$J<J9)D'(.A3^[!4-VBOGVP-T$0$
M.$6FGN752D%(V?\ 6#4DJ]$J2B;^97G8Y".1"&62;R:Q72K@B2[5HLN0IU4Q
M.F G .[(\(E",V=KZ9:%?15QKKYHHN^;H+HRK+V72L8"1I$&:IUB)/"L"+%%
M4R0G*0.HCCA%E8[%I<G*RL.PL$<[>0L+%V*1,@X249MX.9.\3C97X\IQ9G8N
M18*X4 XEP01$<<(M6M;4UY;F#:3K]O@G[-XI-)LU22+4@N_PX\<,)U1HF=4I
MW3>)=-3E753 R:?;DQ@#KPBVB[(H9S/ +;8##!9DV75-)M$FQG,DR3D8]NV=
MK*IM7BSUDJ"B943G[BY^H>$2ZTL4%("J$?+QL@*#LS!P#!\U>"W>D("AFB_P
MRJOLN"IB B0V# 'T<(DV#O=,LR#ES7;57YQNS?.HQVM%2[!\FVDF3E1FZCUS
M-US^T\2=HG3%,V#=Y!#U#A$I$L,$HNZ:I3$8LZ8LRR#QJ@^;+NVS X'%-ZNU
M14.X3:J@F;L4$H$-CH(\(FTXVIK=G$)SSZ\U9A$*M6CTKZ0FF#!(K1^N1JR<
MJE>+H*H(NG*A4TQ.4O<<P '7A$NFMM6(5TH>Q09$V*J"#Q0TM'@1JX=$*HW;
MN#?$8177(<!(0V#' 0[0'A$FQ^Q*+*-&3YG;:^="1:M'S,%I5DU<+LWRGLLG
M -'2R+LJ;I7[*8F('>;H&1X1+*UC@&[I1BXF8M!\@U*^<,5I!HD\;,3G]LKU
MPU.L5=%F900*"IB@01$ SPB;$[M77M;A)"Q2ULA$8F,B!GG#A&19NS*0Q3D2
M&3:(-5EEGC$%3@3W4RF)W (9R'")PJVJM(%:F6GH='X\Y4F!5I)DB=^L<YTB
MH,B*KD,Z7%9(Q (3)N\HEQD!#A%1K;:N]%J5I885R9\Y<LF9$9-DH=T\9B)7
M;1N0JXF6=-C@)5$R@)R& 0$ QPB0H;:% GT[&K&VN$.G49=]!68RTBT:A!RD
M<LB@[;2@.%DQ8BFJN0 ,IVE.)@[1'/")-@]S:SL4];JW%6^&6DZ-,Q-<L@*/
MFJ#9C8IMB63CX(KE98B3B66CE4EO8((G[%B=,C@")X?BRK^Z1#\10?OJ.E6*
M*/WJP%9=Z@E[R[-!$K@55G:*0]QTB@*A0ZB'")? 0, "'4!]!X15X1'"(X1'
M"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"))F(
MZ,E&I6LM&,99L94IO@Y!HV>(&,!394]MV0Z13)D$1SZ@ <(N&MP>&[+;D%>H
MI'9<[3EK[M=>_KS5;1^%EF%>D*_%5VU5:-437(/OV%C#D#XOM.8H=2ER.1(F
MOK_PGD*C;J!/O]K-;$\A75;L=HDWT*JVN$K8JW-6"<6/4'99'LK58M;R<%*6
M:>RN5PBD)2F #="+0N7@8YLECN4DCM9Q$1ETFYB;D'B$:H2YTU9TE)I-T:'/
M-G[9K"MW2DF"DCWI&%S["?4! 1X1:];\").+V/K?:KS9$>2;H<T]DQK,% .&
M&NI1"1A=>5IVS<5]X^=&4/+,J$,@J?W![9IV+DI?LEX12'YM:'V)M_6]/JNJ
M&M;43@K:I.RL#)R:]<BY2+/%OV!8A9)BS6*C'.G<A_\ ,J)$*NW2$RJ0@J #
MPB8CWP/(_A8E*-N$3%.'KO9+NWKHQCYZ\03V;<(.VGDJ1,EE4'+"U5-"!+%1
MD@N*I08J'#VRB;'"*.KCX%;2FW$4S;[1J,_#N)2:BS#.0$FNW@ZDZC[.DVD/
M@"369>XM5K(8"*%.BW26;I*@EW /"*=MS>%LUM*1:.8C9;JJMD=:5NB23DB<
MDZF;2-7<F>199QP#Y%NVC3.%#_$?"D2<NB'%-4YT\% BAF<^7U<T)>LDKEXA
M&T0LT(SF7:J-A<V&N+H4ZPP*9:Y+O9-PX=UI:8E$7RK%P('!0@@FH0H '")V
MM?E_6)U/-K/;-N.+!+.V4NC+(-RS\+$Q#U_(3$BV?5!FPF05;>V::.BX3=J+
M%=(-TBG'H;)%5S\NB.(-;+%6Z&:IPC-W&%5=5@';Z+:NV5/]YY5WBCPRD3*+
MR]2!=0X]Q3%<GZ=_V^$3\TWX8V+76UQVK9MJ.+0^++/GY(MI'+QK 1>5J>K"
MKT$E'C@C21>LYA,ZX) "/N-BB0H#@0(HD7^7YL&R0](CYS;;>OI4F)L4>UCH
M%@Z42>+/WUI6:DDG22\<>5AI4LV@H_17**HF2,0A\&SPBT)7Y=]]2ADDX;:\
M.P-%!>YV,KU>KKNLPK>QW ; X6C(_P"&D7!FU9<*SH)J)J@J)2(%$H9,<!(M
MNI?+IDTFE3EK/:Z>E:2-H +)]Q55T1E#?<LW4+![5!</W[AY#N9)Q7EDWZRP
MJ$="Y,H0B8].$2^T^7<X96*M6%YM>;L*5=L$L5O#2+B:8,V-!"3A7M/K\.I&
M2::J$S3V<$1JB\5]P%DW+@QPRIT(I#3\2+3+:TTW67]GA("Q4&X6.QSCQBU>
M2[(8BS3CU_+U:";K*M6)V4C&+@V.HZ15.EW&.EVG !$BB)7Y<L[)(42&F-EU
M\*AK[4#_ %;$U6*J2K2)?@>'D89F^FFIGYT)!N[*LW<O4CE$3NB*&3$@' "D
M2Q(?+WDW\9.QA+Q5XUO:H'9,7/LV5365AU27Q\^EF$$P@WS]>-CZO6)EX5TB
M")$WBOM^T97VS8*1+C3P8M$$YL#NL;#K$:K:(>29'3=4]=\UH[QT[CWY#ZW:
M+29VL V?+-54'?>FHJ9NJ'88#%ZD2O1/!Z2J&KMAT9?9*DA+WBK1<&E)'8N3
ML&*\/8I2R-4G:2SL7TC"+*R -56YE"B9H42@(";A%'=<^7&O"2#=\\O,9*-5
M&4T9S6V;>RUFJP\I*2]JEQ2J\5!SB*C.&>J6I1-\DLJH+DJ"0C@2\(HZV!X#
M;M;OM8JURV0FR6<*H1:U1%AE)&J017$3$4.'KC5)FP(^<R$6V)5UECJF.1T)
MC=IC&!4^2+K;3WBK*:4N4;*P#^MS,-*$CCVY:0;2;64:2$*RL/M3,$BB\.R<
M2<VYGQ0<*. RFW1 ?MFP!2*%[Q\N=_8E@<53;:NO%6EYV/>&I*O!"Q:R[RT3
M_P")Z8A;FS9ZW3FPHLTZ=J%-^C^+(OV'  #A%+VKO#=;6MY<SK>[@[K[&-L3
M*N@5BZ)<G!+/58.JN(ZY6%5\NC8H. 3@P>1:/LIF;.UU#"8<]2*+EOESQZD;
M()K75C*2\@T71<.YN -)L7ZB"%%&$;RS%R]5%W%Q[VD$5]HATS%,X,8ABF[A
M,1+M1\!D8BVH6.S7/\4)L=BQE\;I/33CCXU-B_GIA.%D(MY)*P0-HR3FP!@<
MB'<@W:I$-W8$>$39:_+9BBQ$@E(;!5?V9Y"K1+:UGBUOO-@<U,I]6;.T#*OU
MC"HS=U0'J(";M267,)  PF.)%(NZ?"^>W)N9;8K_ &@M$U4:DRK"-.:1ZZ8F
M2]^"5EDGSMJ[:E?,WWW+W$]P#'3,J8"B!>@D4:6[Y=4Q8["Q.RV\I#TN-<["
M7C:XUA5$E(YO>YBXO?N5L=!XDU4@(EA:$D4&JA#$2,Q(*?:!A "+;CO!:VO9
MVUS#B_'@!2V](RFMW@"\EYBD:C%NT6+6((5ED8]%]/3*SU=T+I%S[!E"'2,!
MR@/")P:I\%Y[6$MKJ69[%1<2-+MDG+RTVN:S2<I98!ZSAF0PZS>8F7<4S=2"
M,.3XIPFD!@/^D1[#B<3D3<MWR\92RV>]V)KLUG"$L=ZD;Y'L(F!=1AYIS+RI
MI%Y";%D&<D5:Q1#8#B5J*1$5DC 4PF$2APBV7/R[FS0DI^&KA%1YK#(ME9=*
M5AY&9!FW+3*'533,4_7E"22]WC5*69=E)O%%U$P?*@8!,(F$B7HCP"85^Q:H
MFF%V=.V]$!X%A9.E)=B-G?JW^1OC:TJK1<@BJM9RK/B-%E'!E4EFR!"B7M^S
MPB]%DB&(3!C=PB8YA'M*4?M',;J! *41 !]<=>$63A$<(CA$<(CA$<(CA$<(
MCA$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA$<(N9/*NI[-MM K[;5
MDS;(J9C=@U*4F4*=+1T/)3%50=JHSL8X<R;5T@K'';K@HLD %.H"> $?S1(N
M&8W6?GGK^'H]1J=SGG%/9+5!:9D7JE4E;'"?$5Q^>5BHI(L&)I*MQEE*@FNF
M</B@0,8PK_WI$]MY:/\ ))[OJ3W/JRR3Q7:6OZQ6HI%1]6DX-NX85K8QY55I
M&R4*Y>(>U9Y=@J7].8#G4'/<4@ 4B:NS:EY[/55M>0;B<L].>O=D0#VWREEJ
MR+F?HT]37[:'/+1T?7&)T)F.L;PH-ET'#82I$#[)\";A%*^X&/F(RG=40&D6
M3IG Q^N(MG<95Q88,8T\X6$=1KU%>)D8==W]YP[I!LLDY*]("QU!R0Q4S<(H
MPL]>\]T20M-8O9ZUQ+JPW)*9M<I8:>T5F*9(0B+%I$RL3%UIF*KAJ\=K*MUT
M'+-;M(7\X0X1:,(7S>COQ%3(F1G'3'3DIKJ'ATXPL$P<;&);&D=9+#"RDQ)1
M,A]TM:*S43CDGR";@%FZAO<_2%%0I%T!X[0ODG7;^]CMFE?.-?.ZK*+I-TWL
M$A%UFT!=;*Y;M8UM%QK=S,*S4([;+N%CN"'14)V 0P&$PD7>Y#@($ ![LA@3
M9#/0/4P!])OZN$51*)@$!$<&]0^D/R!PB!-@<8P': Y$0#Z<8ZCZ\(K^$1PB
M.$5IAP&>H=0Z@&<=?4?R<(J%'J/J.?7KDH>@ACZL@/"*_A$<(CA$<(CA%88_
M:(ACT*)O4.N/H_E'A%0% 'T <]X$$,ATR4!$?7T#/"*G7J(B!!Z@!AP!@#/3
M\AB\(L@9P&?7 9_EX16]_H.,%'^Z$0#'\PCGA%>/"*@#GK]'3J @/\O]'"($
M0 ,B. ^OA%0#9'&,?RB'4/H$,>N>$5W"*Q0<%_-$W4  "C@<B/U\(@HY$V>W
M(#C[)L]/4,A] \(K^$1PBM,8"@(CZ &<Y^GT ,>O7A%4!R #@0R&<#ZA^0>$
M5>$1PB.$1PB.$1PB.$1PB.$1PB.$1PB.$1PB.$1PB.$1PB.$1PB.$1PB.$1P
MB.$1PB.$7/GDYOF*\<]426QI&,2GG*4K"PL+7U)9&%/,2LO()-TT4WZJ#KV2
MM&H*N5!*DH()(F'MQPBA>2\W]=),(VPP-3M]JI3B=+$O+7$'K[6-8*)TQ&\R
M"WP,K-,)=XW913M$0!-OW'44$I,F*8 (K-@^>&GZ6S%)JJO+SSI-\TBX\[N-
M("DTW@23K6/=H$?*S"J;IJIVF6;MW":*F2G$HXX1.S8'E]K+5AIUE<0=L'=9
MI-=O3YNM)5V-^](V<:K/"-8,)Z:C%9=9B1NI[AB$ A>P$^[W! @D382\\M.&
M>K"6&O7X:;+"S&XG@VQZ^=R,Z:LF(3L?C)&Q92_ E$6^55#=R?<0#F B8COY
MB^G8^2:(/H"RL(-S!&DDQ<IQWWTC.)S?PQ6!&*;U5FX*,"J213*FX4=*%.")
M$#*Y(!%.5^\I*'1+$VK2[)XI(A&T.4+\>]91#56&O<ZS@VBT>@Z<&>N%F+AX
MG\4H=!-F@*A2+.$Q$0 B3=>>9.I]CV=*H1;2QQ4Z%%4O<BVF6,?B(B$V*\HD
M#X(^2=^X1Y$I_$MG3;WFJZ)R]JPF,!>$48P7S%M3N)-_%V""LT HM.O&M:;F
M2C'LO+U6/K]/G7%P<1[)^H=)LJ-R;%*U;BY=D3'O6(D/<4A$N$^8KH4BK%D^
M1MS"5=Q#:RJ0RL=&NI5M5I!B1_%6 &S"7=@^;/TCAW(-S*NVP#W.$DB )@(M
M>8\_=?-W,#%1%/N$A./+E6*]98AZVCVSRHQMJ=10Q4N[2*^64E%9.*FFSIHV
M9 X.<%0*H*0@(@126]\Q]7LJ/KV^F9S[B)V*RF):-09EAWCN+A*\=BG/RDP9
MO+J,DPAS2*0+MD%G#PIA,3VA.0Y2D5(3S$US8*=+W*-@+N9M'.:42/B5X9!"
M8L<?L-THRJ$U"('??#*QDNZ;+$**JJ2I/8.)R%  R1,%W\P74C6P3$,$-/N6
ME3);E;Q.-)&J.XZJHU2MLK,)W"C2><$D59%H]!(B+8RBR2X"!R@ &$I$^GWF
M-K)O0:3L 8BVNHB\*38MF+1C'*R4='UN1^[9R6?@,F2-7C&:X@ &:N5SK 8/
M:*<,B!$UZKYDPZ>K*ALO8=2FZRE=?UGS$=%Q@,Y=.(I6LW#G[SLTP^;.@1!@
M,:@1?N(43E]P"]N?4BS1?G=JF<C7\I"U^[RJ$-&14C/$8L89=6)&Q2;N*J[8
M2DFA+)FL:[%8S=5D+EN0B8BLHF. $BUKUYUZ\J<89>*KLW9IQM%2,M)51!Y$
ML9=BE&%MI7C5591TO&)/VR]-=@HFJND $[3%,;..$5I_/K4C)ZDA.5V_0+ Q
MUT5IY]#L58-!PV>NXE9#XUG)N!<').-!9X2(<PJ& X *65 (D>0^8EJ%*O(S
MT+5K_82N*G*VI)!E'1*"!2LE+$A&QRTHZER1X+6-S5W:;)=,ZC43$#W%$P'A
M%*&PO+[6>K$]??CA"2B7FQ*Z2?C(I-U!O99LHHS!TG%'C&TJ=^_=*G*=(JK1
M-=J*A.JA0$HB1,^*\W*1:;KKNCU6K6=:7N=L"L3XRZ4<P+3%<69,A)))-^Z7
M>NG+FKKE(1L51,$_MG4+T 2)M2/S"M31%[D*B^A["1D$BXAZT^(6*^+MSZ(E
M9>)M+F%C5)))<[&NNH1P50J@D>+]H>R@<! 1(M"W_,*H,:E=$J53+!>'U-CK
M@]DP82U5%DD-3K\98F_:9"9=K+%G&TF"2:9"&=H+D,55$O:."*7)?S'U?6]?
M4K85E1EH1A<;.M3BQL@:(9R\9/L9M*O2;==DXE$_O C*47( @Q,Z.9,X' HA
MG!%&LS\P#7 03EY6:G<9.PJI.9&.A)1I&Q/Q=::&B$QMOQ*\B8A8-16<:D[0
M STHJY%#!1P1/?:/FA2-:2,Y"A4;?:)2&ER5HA8@D.W8R5E;.JT2?AVKJ4E&
M:J1J^PM;1TJX722;+$/VI*',!@ B8,7\PG5[2.APO%>M%3L\H]]MI6B-V#\\
ME%+.IEJG889TD]31E(W,"Z J"?\ X@J9(>QN8.T3$4KS'F#K& UK!;4G6LS"
MUBS7!S480LP>%C)*1.TGAKJDNT8/99%9S'*/BF%,A ,Z.D'<".!X11.G\P[4
MK:8>'F&$I$U!8M25JTV]>5]K(6"/M9YA)M.,X%S+HR:D9WQ6 3(51\ * )VY
M"AGA%68^870V[R":5_7EZL!9A-5VX>"I7XYI$QAT(IY$R;D5)5PX=(3+&2%1
M--!-1=(4Q!4A.X!X1/"&\\](6.U46F09[$_G;_)HP\:V3CVY%6,@JC BLB^;
M*/"O1-&.;*T2>>RDK\*8QS*=I4SB4B;5M\_]7T38=KI\Y"SR<-6TFL4VGT B
MS!8KL:Q/X21K\6V4D$Q;I1R,:LL=P^,T(I[?:F!Q,3N(MBR?,*TM5PD'<DC+
M(1L8M),G)7B\1'SQG[21A(U@3[A>R"*T<TEUIM,R"L@HR%1,2G(0Y#E-PB?U
M6\R-86AK>WQ8JY0S/7]1F;G*N9F%(@D^C*W'MY*P(0XMW3H7K^*;ND^]+!>X
M3AVB/")I6KSEUU MVB*D/.QLX6R5R(GX6P)-&+N C)=M5I9U)O"MW+X#G9P=
MO:N2I!^>(F()BG#'")WZJ\R-4;?F*I#5)*?!6YQ<[-0CN2;1[5@_9P2S=-8L
M8Y)(K$F7CE-T18J#/WU$D1[U@3 .$75Z2@*D X!C.0P!@-@2B)1ZEZ#U#A%D
MX1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(
MX1'")'EJ_"3IH\\Q%L)(\4Z5>QIWK5!T9B[79.HU9PU%<A_965CWRR)C%P(I
MJF+Z"/"*-D= ::0!?V];4T/BG35\N0*_'E04=LDE4&[@4"HE3*K["HD4$,>\
M7 'R   $6FEXX:)0*S*WU-0$A8>_\(?\,1ASIBY,H=<QCF1]U8YU%CB!E#'$
MO>.,9X1+%FTAJ>Z+'<W#7U2LKI1BSC3N)B#9O5 9,N[V6R'OD4!L@7O,'83M
M+VF$H@("(<(J2>D=72D&^K:]*KB4._2616:M8EHA@CEX,BY$AB$ "J'?C[Q3
M8RFK]HO7A$APGC9HZOP$'6H[6=03BZXA'HQ)#P<<=P@>+,F=H[.Y%O[JK\IT
MBF,L(]YQ#J(\(G7.ZBUE:)%66L='K4W(KQS.)7=R<4U=K*QD>Z3?,V1C*D,
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M*)5C!@.X1$B5#Z>U@=N@U-1:N=LU*<K=!:&9KI) =8[@X FJF9,X&75.<0,
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M'5:"0"NN6L<W(K!!*'$[P8G)!38'5[A#N3*40)]D/L].$4E))@DF5,N1*0,
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M4?47[?U#U^G^^(_7/NC^$#;?[1/'+]\G'P+0OSNR]3>^[)^H^HOV_J'K]/\
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2[L@ZBZB) /3^H 5_OZ?[XO_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g556278dsp073.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g556278dsp073.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_X0YZ17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    O    <@$R  (    4    HH=I  0    !    M@   .    $L
M 0   2P    !36EC<F]S;V9T(%=I;F1O=W,@4&AO=&\@1V%L;&5R>2 V+C N
M-C P,2XQ.# P,   ,C Q.#HP-#HP.2 Q-SHQ-3HR,    Z !  ,    !  $
M * "  0    !   !_J #  0    !   #2       !@$#  ,    !  8   $:
M  4    !   !+@$;  4    !   !-@$H  ,    !  (   (!  0    !   !
M/@("  0    !   -,P         !    2     $   !(_]C_VP!#  @&!@<&
M!0@'!P<)"0@*#!0-# L+#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q
M-#0T'R<Y/3@R/"XS-#+_VP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "
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MR3)@8'0UHWMQ%9Q-+(N1T"A<DU)R%41LEHH=6:01@,!R20O051\'_P"LU_\
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M@   .$))300-       $    'CA"24T$&0      !    !XX0DE- _,
M  D           $ .$))300*       !   X0DE-)Q        H  0
M   !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M       ! #(    ! %H    &       ! #4    ! "T    &       !.$))
M30/X      !P  #_____________________________ ^@     ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@  #A"24T$"       $
M  $   )    "0      X0DE-!!X       0     .$))300:      ./
M!@             !_@   T@    M #0 +@ Q "  <P!T &\ 8P!K "  8P!E
M '( =  @ %( 6 !) %  7P!# #  ,P!? $8 ,  Q %\ 4 !U '( < !L &4
M7P P #$ +0 P #0 +0 Q #@ (  Q     0                         !
M              -(   !_@                     !
M         !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   !_@    !29VAT;&]N9P   T@    &<VQI8V5S5FQ,
M<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M       '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E
M3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E
M5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M ?X     4F=H=&QO;F<   -(     W5R;%1%6%0    !        ;G5L;%1%
M6%0    !        37-G951%6%0    !       &86QT5&%G5$585     $
M      YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
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M      X6     0   (    !.   !@   =0    WZ !@  ?_8_^  $$I&248
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M9WH^BH0:7PD8R!'1@SIV>'%SF22=VW?9MDR-@_=_DJ'[,Z@7"6G:\^X^I;(
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M*'#K>&'$3N= ']5WE^<K&,_JSY28Y:DD^#__TO1LYOZ7<Z0V&AIYU_2;F_\
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M %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\
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M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @_^X
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M@H * "@ H * "@ H * "@ H *5UW *8!2NNX!1==P"G==P"@ H * "@ H *
M"@ H * "BZ[@%*Z[@%.Z[@%%T 4KKN 4P"E==P"F 4 % !0 4 % !0 4KKN
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M-/A2Z=E9-RR!0,J:2X"X&_?7XMQNDK1_V.K[RLG?X--;KY%O,<]5E_9E*_\
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M"T\07MUJ%IIL-U:_:+29XHFD+:6*YE>]C](/^$0TO_A"O^$"\W4_[$_X1?\
MX1#S_P"T[K^V?[*_LG^QO._MC?\ ;O[4^Q_-]IW>;YOSYW<T^A-];G4TQ!0
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MXKX<H+#NLYXN"Y%1HXGFNWI]7Q$Z="M_U[K3A3?VI+<]IL?]4G_7).Y/8=R
M3]3R:YCYA[OU/-? 5RMYX%\,W"7BZ@LEE/B]7Q#KWBM;K9>W4?FKXB\3V.G:
M]JH.S_67,*,,;5W(JL>O'1<<773C;WEIRQA;3^6+<5\F?3\9470XGSBE*@Z3
M4U[GL*.&Y;PB[>PP\ZE&GO\ #3FUU=I-I<MX9N1/JGQ$C%Z+LVGCF6V9!KVN
M:U]@/_"-^&I_L+6NL6=K:^&VC$^_^S].>XL5$GG"3SIID2,5&U/!OEM>E_+&
M-_?EK>+;E_BE:72UDFS/Z+I8+A*?U?V?M,L4K^PHT>?_ &C$1Y^:E.4L1>UO
M;XA0K/E]FX>SITY2Q+JX'_"Q+BT^U@D^!;>Z_L_^W-98QC_A(KJ'[;_PC)L_
M^$<B$Q_=_P!H"X^WOL\DQ>2H>HE'_88RY?\ E]:_+'^5:<]^;_MVW+UO?0<J
M+_U0I8CZOI_:<H^T]C1U_P!GB^3ZSS_6';XO8.G[!7]HI^T;B?G=_P %;%1_
MV$/BPDBQM&_BKX()(LO^J*-\;OA^K^9\DN4VGD;6^AZ5]!P:VN)\G<7:2K:?
M<]_(^U\&^7_76OSM<G]BYO?_ ,-F*T^>Q^4%]/HVL?M2^ HOB1K7C^XTU_V3
M_ D_@R37],LGOM5N)-/N-0U*?6(;PD&:W\0_:&LF,-Q+<W"H)74_.?WZ$:^'
MX'S:63T,-&JL]K^T<7:UIM1<;+JK<VWNWL?@*EAZF=8&&95*GU2. I<CDMY.
M"<E=]-[/ND?9GQ$N?BKI/QD\):#\-]-OT_9I;4OAT/%%]HWA'X>7L>C:C=:I
MXL6"Q\!/<:M;1:SX8UG4I+A/$MS=QO/8)N5#LZ_EF44^'Z_#&88G.:T5QHEB
M/8J=2NN9*,;NK:+Y9I?PN726ES]"QLLVHY[0PN5*3X9G*G*HXQI\L6W+2-WJ
MG]OFV^X^0OC9IG@/0?VN_@(?A07@O)OC5!#:VOA:RTFZT>[TF[3PW;ZQ);WL
M9:;4[A;:YGBA29+JWEB>42.$4JWZ-PG6S3$\ <40S]1=&.7MWGS<RDKN":W2
MO;56Z6/CLYAEU#C'*UD\VF\2DXPBN3=7Y7=ZZZW7<\TG6P>\^/,^MW%[([W&
MK ZQK"+;^,9Q]J\6#49;^*YU&U3^VX--@FDAM49=/GG@B$ES&8XUKW:*J*'"
MJPT4O=BU%:TEI"UKJ]N9N\OB2;LFKL\:JE*IQ&YUFN9RY9/XI:R732]MD]+V
MOTOQTC"'P-X3FOWEL=<9-*BMVT2;4Y;JX\*26]HND7FKVMQ:6D&GZA?:-+YT
MPMLK+, 983.52;OIIRS3'QH152A[SDY\J2JKXE#5MQ3VOLM$[;<%37 8-5%)
M58J,4HWLX)6C*RLKO79N_5&[)_9$7Q4\)".Y=/#/V#7X]-OX[K48;B[D?3[8
M>+X-=FEM+.6PETNT8R65O9QRVSS^7'M,3RW2\<G5_L'-/W2^M^T@YQ:BTM?W
M;AJTT_M.5G;7=)'=&=*EFF704Y+!\KY9MN[E))SYG:]T]DER]+ZF9K%QJ=G\
M%?VJH='&J62R3>'8=2L/#UC;MX872)OBB-.U:YOIQ/=P:=?MIBBVBCLYI+:2
MT+J\_EKL%X>C1GQ3P#*NHR?+/EE4<N=35#FA%6233DV_>5[]+G33=6GD_%\H
MN2FU24E&W)RN=FWNT]EH^5KJ?5?P\T[1=-_9XUC5OA#'/J/Q7-O\/T\,QC1?
M"-]K^J07$/AQX8/$6E7][:6=KX=U#5&CCU>ZAFN+BVB8@.REA7YQQ!5KXKC/
M"X7BB48\,R]M[6\JD8QMSZPE%/FFE\,79-VOT/M^'Z6%P_"F)K</5)2X@<J?
M*_9P4G?DLI*3TIMJSFM;WZ&QXLCCU/X(6VM?M!'6-'^*9USQNOB3[+H7AFSU
M+3(+:]\0O!9>&A8W5S<7_@W3M4,@TJ\NG26>90C.B!6KCP%\-QC6P7!TJ=3A
MSV-'V=YU'&5^3^)S))5&OBC&Z2N>ACXT<7PHJO%,Y4\^=:HIRY(*:45/W:?+
M>\5M&4M;['P782ZI<_ #]GJVN9=:O88O&_Q$'AS3M;L(#X7FT"#QQH\5EJ"[
MW2UN-=BN[B\A>.:X6"* LJ2 9#_LM>.&I\8<92A"E&4L+A_:2A_$YO93YXM[
MV5HN]N:]M#\S=6N^&>&8>TJ2BJ]5Q@TN5)3BDTY/6;N[WTM<7XD%&\8:BNBO
M<WFAMI^AGQ/=WZ(\=G"]QJ[:%-:W+DWL'B&] BFN[13' M]YD8CFA4SI'#T&
MLMPT:K4:ZE4]DEKS-VYU)+1Q2^&6ZCJ[-V?+G$J3QV,5"O.6'<(<W/T:NU9O
M7F;^*/1Z+0\_NS(+>9;87ZZ28(_^$GO8K>*37['2?[6T%OM6DV<\=I BP7RA
M'FS&R1; 9H(")&]^2NX.:@JL6_9K7D<^65^9QUMRWTUUOHV>7"HDE&I*2@E:
M>BYE"\6K)[W:TZ,^BO#S1Q_M#?":6PN]4@62>T2UO= M([W67OKS6=;MY=/A
MFFCFDU/0[N_=X+AKQ(_W33QJ)D09_/L8N;@OB.E6A3TNVIOW%\+B^T96UBE?
M6S;39]OE[<N,LGE0G)4W&*3IKWVW>Z2>KCNI-I-WE961H?L4VG@C4)-0E\8W
M6H77C$>+O'$NN6>LZ=I4EE!K,MO8W$;6K:H\D,]U)JZI+&)BGFZB[1-&R$LW
MG^+<LWHQPT,II06 6$H*$H2ES.-W?FC%;)=K^[8^E\,:&35,54EF=3FS#VE?
M1J+3DE%QLY?:;OH_MI+9L]M\"OXZU^/XA6_[0UI<1>$X/!E]-X!N-?\ #W@_
M3#JUA%KWB]--UCQ3/::G=W6G_$",L\5M8VT8@>RPV"&._P")SRCDF">35>!J
MJEG,L1!8EPE6=I>SIODI)Q2=+>\G[U]#ZG(_[7Q:SNEQOAI_V9##3^K\\*4(
MRBJD[2JN+YHU5]F*7+\K'RCX.>SL]<_:DL?#UWXG@\++X(\"MJ)TW2[%((=8
M.MZ;9&TF@MMRVNB36=_>133P+%=&)I%,+)N1OU?.55GA?#VKC:&'>/\ K=5*
M[D_W=F[KHY\RB[2TO8_*LN=.A4XTC@ZU5X!86G)625VYQ5I=H6<E=/F:\F9N
MHC'A7X5MHL5G_P )&-;2>RTF+']E76K_ &S5!;#4X!<2E+1BK,+@?Z8]QY\<
MD4$4,<J]F'C)9GQ%[><E@W3M.;MS**2NX_WKZ<K]WELTVW8\G$02R_(:5'E>
M+]M*R6L4U=IM=I*SO>[;=]DS<9/#@\7QVTNH7Z:(-*BGD'VG56L!>$QK)C4&
MLCJYLA=[D^TFT:[51G<3A&YG',8Y1S4Z5)XKGT7NW<>CM?EYK:O6USH3P*S2
M-.C4G[%)W3YG%RZI/XK<UTNMC.TU'D\.?&&35XK!/$HNR^H:=NW:7#J7V2SG
M2/35EFMI;G26MI))Y;F3%Q#?):K +KS9&KHQ+OC>'8X>#^HQ5HS7QVNT^;S3
M5E%>[:[=M#"C.=3"YY+$^[BTFW%KW;_:LM.FKD]>;EM>[.A\7O;7NI?L<6?B
M.^\22^$9;#Q^FGK>Z79263ZA!X@-M:Z?9"_,3WGAF+3(+2*.:=99UC(180F(
MDYLH;IT_$FO@J%'^T%6I)V;3<7"_-+M/F<KI:-K?J=^.C1J4^"Z6-J5OJ?LZ
MFZ5U)R<;0[P:4;>31]C_ !#?Q]X8LOA]!^S-83S>'Y_ VI/\1#X>T#PGJ46B
MZ1+JW@V/5]=\*W-UJ=EJ-W\4(H/LZIILT2VWV)B^T<[?R;(Z62YA6SR?'E51
MQBQ,5AE.=6/-+EFXQJ-1=J+WYD[\VC/T;.?[3P.%R3_4A3E@YX5O$.,:<U&/
M/33E&[NZJ6G*]+_>O'_V^+#X>Z5I&EW?A:;4+/QPWB?P!+IMMH^F:/;6]WK1
MMM7O=2.L_P!CM%#9W2ZQ$\UPD)<V^K1I"D2Q@,OU_@_5SK$U*M+,Z<)Y:J.)
M4I3E)M1O%145+IRZ*]OW=V]3YGQ(PN4TJRG@:M2.8J6'LHI1N^6?-*5M.?FL
MY6T4]%H87BYVE_:B^)4]_-J%Q)%%=QR77BVR2TU.UN8;CP[';:>TL:PR:9X<
M@U=UM[66R2:7[$=I2-&:O2R^*_U%RB%&%-7DN6-)OE>LFVKWYIVW4FO*[1XF
M/JQGQ9G#Q-2?O*TYSTDVHQ5M/A5UT3Z-JSN?,4:8\I)A?G0$^W'PA>W%K;6_
MB/5M,FUSQ2TUQJEI8V]Q;SI+J V&?=<$(&"S31JSQ??Q3E&4XN'UF37M(IWA
M&7)!+E;U3Y=>737HGO\ %593DDE/]TKN,K)2<4W>]NTE^M[':_#<VC>,-(;Q
M#<WFF^'3'XF7P_=Z5Y)%U*;'P^?$?V^_B47KZA86G[ZRM1YD3WHCC$*V[FZ;
MRL^C)95BHX2$9UU[/VBE>ZUER\J^&S^T]U&^M_=.[*8QAB(QJ3;HQ4N5I7NW
M:_-\WIW=M4M2[K<NHVWP&_:E@MY]<TX3Z]X+;7M*\/6%O#X230&^*%S::A=W
M/DE["TUMKM+:"&*WN#;2VS,AE*$(,\/&C5XLX'==4G-4JK@Y.\U)4$XI-I-Q
M=Y;J]UL=4)U895Q+3A*?\6E=+X)+VDKN5KI6]VUKJVES]"?!D-GI/P#U36OV
M=AJFK_%E+?X=/X/SX>\(76L:HUS:^&)KRV\0PWUU%);>'M3U4P#7[J"5Y[.1
M]L<KJS;OQ_,YUJ_&&'PW%ZA2X>_?\]JE1124JG\/E3O-;TTU9K>Q^CY?"C1X
M9Q6)X?BY9TG34)*,'*5U#25WI'6SMUU,WQW9:+JW[/.EZS\>K?\ L_XOKJ7Q
M%C\11C0?!]OJ6DQQIXVEDM?"MKI]]>Q7_@[3M3%TND7MS+#/<[ &D50&K;*)
MUL+QGB:'"K4^&O9X=TWSU'!MNG:51R2M5EM**O&/0X\WA3J\.X:>>T^7/55J
M<UU!35E+2$4]87V;U/BS0I]9NOV=?V6(-4FUJXTW^U/'1TG2M<T^!/"5UI-C
M\31::/>_:8[J#[7KT5C>7MOY-Y*MI':$K',B%TD_3,9##4N,>-O84X*HZ-)R
M<&_:<SI7E%Z64;V=UKS-71\'45:.1</PE.3BYU>6+^"RG&VN[=V[WV6BW.F(
MTS_A;WC5;.;[3X:;P[HY\974]Y?PW&G3*+C_ (1@Z#<6L%S-=^(M0-O:MJ-E
M<QQVRW;R0!6MXXKL<]/VCX?RV4XN.+]K+V227O)V53G5TDDKVE&[M9[MQ,IP
MH/,\;SU']5TYFGJMU%PZJ[LK/1-OHC$L9+:7P/XSN+*[U+4O%"Q:O!;V^O\
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M>HZEXYMM4GN-/OO'/B2WCNK/3=,\+WGD_8](A\R66XC)N@J'!]/%5X8W 8C
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MDH2 H_3AH\RQ?N<S5%OX'*VL==&N6W\[NEVUNO?R##JO2XDD\+[65/*ZT_\
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MOO#7Q*G\7+-K%KX,TU-;@U>U6^U'4+JQ\*_#'R]8U+[#IOBGQ!=^-BEII?\
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M4+TX559*SYE.%K1BWHFDNMC:AF%:DIX=M0P<Y1<7.TI4K-O36,VWS-6>CO\
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M%Q[J5<%5IYG&,(TN9NK1COK!KDM?XOWD;VZ-.[[*U:K+#1<<1".&^UIRS?\
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M[?0^_P#%W"X'#U\BGA,+AJ=2I"LY.EAZE!S5Z?(VYJ\Z:5_9*K?%P7,L2VW
MYCP\UV?V@_&L;&_V)I]^TJ/-H+JELXTO[ ]W901B[L].D)/V*:%C=W'/VT#"
MU.)Y?[&P[]WXE_-OK>SV;_F3T7V1YXJ'_$)^')15+F=6FDTJZO)>TYU&<GRS
MJ+3VT)I4J>GU=N[,OXG1W;?%_P"'9BM[^2,BS*20>%= U50(M4G>]-MJM_*M
MY L-N5:\+#-G 5EM<S,PJ,$XK+,;>2OK]N2Z*UTM-_A[O26@N$IX>/A[Q@JE
M:DI>_=2Q5>EO2BH<U*"<)-RNJ*6E:=Z=>U-)G@O_  41L]-U']FBZT_6+>SN
M])O_ (V?LOV6I6M_'!-8W-A=_M'_  P@NX+N.Z5[:6VFMW97612C*2&!&:RR
M>52&.ISHMJK&$VK-IWY'M;6YGX+I2XXJ0D[1>39LMK_\RW$[GT!XG_9T^ VF
MP27]G\ _A1?6MA>S3ZC9I\.?!SWDFD^?)/=SZ2J>'RC7UG*YN!$5(G4.BX=E
M8>I2S_.IS]G+.L5&;5D_:U-'_P"!;/;R/Q!Y=@X4J<HX6FTDOLK[]B.Z^!'[
M.]I+X:NK;X(_""XT'5)X;%]0B\ >#76&35(-^AW22IH?E/9ZA=2M"YP 9+F,
MYP6!E9WGTE63SK%^UC=V]K4Z;_:*^I8*]-QPM+V;_NHZ$?LT_L\JSL/@E\*5
M;RS'(5^'G@Y6:,JB[6_XD.U@J1J .@ Z5A_K%G>G_"OBK]/WT_\ Y(T> P;O
M%T(_^ H2+]FK]GA9-]O\$_A9;'[1'=R"#P!X/C$MQ&+=!)+C0278Q6D2')_U
M:!1@ 8<L_P \LN;-L4U_U^F__;@C@,)%MQH15_[JV)V_9M_9[S,Y^"OPO:2<
M7<<K+\/_  6A\O486MKY%V^'TV1W-LQC=1\KH2&!J7G^=U-)YMB6EWJU'MM]
MH:P.%AK"C%-WO[JZCO\ AF_]GU=^/@I\+B'\I2__  @/@P2.L#K) "R^'@P6
M K\BYVC)XSS0L^SFVN;8G_P;4_\ DA?V?A%JJ$;_ .%?Y$"?LQ_LX(YD7X%_
M"42M)%*\O_"N_!OF22P1QPQRR.N@!FD6"&--PP=D:#^$4_\ 6+/NN<XJW_7Z
MI_\ )"678%.ZPT;_ .&)*?V9OV=&CV-\$?A0ZY=L'X>>#CEI"I9CNT%AGY!V
M[4UQ#GO3.,4O^XU3_P"2*>7X1[X>-O1##^RW^S;.$5O@7\)PJ2*^P?#SP;M)
M1_-&0?#[9&\D^O/%/_6//UMG6+_\'5/_ )(F66X)K_=H_P#@*_R%'[*O[-H8
M,/@7\)=R.DL3?\*Y\%;H98O.$<L)'AT%)$6XD /82-CJ:/\ 6//_ /H=8S_P
M=4_^2!Y;@6[O#0O_ (8_Y$I_9>_9W;:I^"/PJ8+-<3J6^'W@DLDUR_FRR#/A
MO+,SDGG."Q/6C_6'/.N<8K_P;4_^2'_9^">KP\+_ .%#;?\ 97_9PM!$(/@1
M\)%$+O)&%^'?@I=LDB!)6X\/C/FJ &Z9P*7^L6>=,YQ:_P"XM3_Y(%EV!MR_
M5X<J_NK_ "[ZBM^RK^S9,(_/^!'PE8Q)-$C-\._!3,L=PRO* Q\/DCS'4$XX
M) )!(!I_ZQY\OASO%V_Z_5/_ )(<LOP<U:5"+?FE_D*?V4OV:2Z2#X$_"A'3
M;\T?P]\$)N13GRV!\.$F-CG([DGUH_UDS[7_ (6<7_X-J?\ R1$LMP4I.3P\
M+_X42G]E?]FWYC_PHSX3$DEES\._!)V,2QWQD^'B5<%VP<_Q'U-0N(<\_P"A
MQBO_  ;4_P#DA_V?@O\ H'A_X"O\B/\ X95_9M(^?X'?"ML)/&O_ !;WP0"$
MN0PF0,/#@(20.01Z&F^(<\_Z&^)?_<6I_P#)#_L[!;?5X6_PHFC_ &7OV<XX
M_*3X'_"D1F&.W:-OAYX)VF"-$C6(JOAX*$"QKP ,;0!@<5+XASR__(VQ7RK5
M/_DC1X/"-*$J$'!;>Z@;]E_]G1@5/P/^%K+O6=E_X5_X-VO<QVGV*.<@Z%@R
MQVF8PW4(Q7IQ1_K!GG-&7]JXCG6E_:SNEVOS$O!89QLZ4;<U[6T;[L1OV8_V
M>67:/@Q\+4BV,GD)\/O!BQ%'!$B-&/#I1A+N._=G=G!.*/[?SV]WFV*;_P"O
ML_\ Y(GZAA+Z4(I>B(!^R[^SE%"D,?P1^%"Q)Y81!\//!FU/+55C**/#PQY2
M(%7T 'I3_P!8,\3US?%?^#9__)$PRW!0ORT(;W^%=-NA$?V7_P!G/JWP2^%#
M'S#)EOAUX+)WXC52?^*=Y,:1JJDY(  S5+B'.W?_ (5\5_X-J?\ R17]G8-Z
MJA"_^%?Y#1^R]^S8A+CX%?"4NPVNX^'/@Q&89W$DIX?4<N W3JHH?$?$'3.L
M7;_K]4_^2%_9V#ZX>'_@*&C]F']FY?-V? GX3)YP03%?AYX,!F$32/%YC?V#
MN;9),[#L&=CU)H_UBS[_ *'6+_\ !U3_ .2!9;@;W>&A?_#$9<_LP_LYW9<2
M_ WX4!9'BDE0?#OP9LE:&,Q1;Q_8'/EH2%QC'TH_UBSW=YQBW_W&J?\ R02R
M[ M66'C_ . Q_P B5/V9OV=D,I'P/^$S>?Y7F9^'?@L9\C!BVX\/97:1ZX.3
M2_UBSS_H;8K_ ,&U/_D@66X%/F^K0<^_+'_(J+^S'^S?$S$? OX3!V;<Y'PZ
M\% LWE6\)9BOAY<GRK6)<]Q&G]T8T7$7$%K+.<7;_K]4_P#D@_L[ NZ=".N_
MNK_(SM<_9\_9[T?1KR6Q^ _PBN;V[E@M=.L9?A_X-ACU'6M0F2&SCE=="5B)
M)W\R9A\WE(YSP:NCGV>U*D8RSK%J"NV_;5-$M_M?<9SR_!1AIAH7>B]V.K^X
MKZQ\!O@/;7.E:'I?P.^$4^LZB#(WF?#[PFEGIVD6D@34=7NXDT7SA GVIH+6
M,,OF7$X&[:)&%T\\SN<*M6IG.+]A%_\ /ZI[S>R^+YOLEZ!+ X.,X4X8:*J-
M?RK0GUOX%?LU:2EI<ZA\%OAD;V:]SI%A9?#OPA=:IJ&H);RP"/3;*/03<75R
MEO<.&DX6)&+.Z)DU%/.<^K2<(9OB/9I:MUII+Y\UASP.7QM*>&AS]/=5RC;?
ML\_##4)[6YE^!OP6\/V$%U+<Q6MYX!\(Z[KI,ZJ)9&DM=(M=-TJ2X RR))>!
M23SDX#EGN84^:,<XQDY>56:C\M;O\ >6T)N[P].*_P *;.F'[/?P"AC5!\%_
MAA(%-GM#^ O!SH/[-@DM=/5E.A[6CL[:9TB7&$1B  #6$<[SI2O'-<1'TJU$
M_ON:?V=@I:RP\.;ORK_(Y6Z_9[^&%O*SI\$/@;XDM?M*WD5H_@+PWH6J+=#S
MD-Q%=OH^HZ;-=)!=R@%EM@P<IN52<]<<[S"2;6<8VG*VK]K-I^MFG;[S%Y;0
M6V%I2CVY4G_D5F^%_P"S%:AX]:^"_P ,O#%Y:0%_[.USX=>$K2:>!6(6/39(
MM&N;+65:12(X[*2>3<0-H9L%K,.()2BZ.;XFI%_:C5GIZZW7SL2L-EUI1GAH
MQMNG&._Y/Y"V_P"S_P#"75;>]U"#X#?!W1&Q;G0-.U3X>>%S<R11R122R>(A
M;:,?L0OXHECC@B#RVJ*&D+/^Z0EG>9T)PA_;F,E_,U5G_P"2^]K;N[7Z=QK+
M<+.,W]5IKLN6/XF':?"_]F^[O+O0M-_9W^&MUXVT]HIM:\)'P'X'5=!FEVR6
MNIZQK/\ PC[6%OI=XZ![>X3S);@#*0%U=$Z*F9<00C'$5,\Q*P;^&?M:GO\
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M;YT#W6G>$;NR(8A6(>3)(!Z5T+'\2OWGFV)3Z7KR7YS3,OJF5K18:FU_@O\
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M%I+#)/"DLD+CQ9X:'F0O(A>)PIZJ0<5WY=)K&X=<UHN7Z,_5O!%7\6.!DO\
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M/VN;HNNR]%HC;Q.J>TXTQ<O;<\E3HIOZQ]8=U3C=2JV48R76$+PI[1;1Y?\
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M.<U&.M[>NUU5_OU*H2;I13\SZI7I^)_F:\6'PQ]!CJH H * "@ H Y7QG_R
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MRZOE&9YCE.*:>)PM>=*;2G%<U.3C*T:D*=1*ZVJ4X36TH1=TM:LS@"@ H *
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MEM)$E@?PSJ4VC?VCX1\0V$\7[M/,%NDZ;'2,CS$JMC:\W+#XVM/G6G-S-_\
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M.H"&0B'?I_DZI<J$QF01]S@"AR*@KWI4Z?/)=+MW7W^Z@;=ZLE\4Y<J]%O\
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MQ'K&D:=X9T:PT_5+$2^&)=5BM[^PL_[3B66*+RPC/^]V;)"5+&O05?!N"5+
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MEXJFYSKXJHX-1H4(*&(;UH4E2P^%<G*-9T*:C$^[O(28YM9%<D;O*=MK@$#
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M]E!1^Y&U!_N_5M_)GU6O3\3_ #->-#X8^@QU4 4 % !0 4 <KXS_ .0!<_\
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M?3K7Q;X>TS1=%GM;2.U@LHOLS9+V0I)7+L_CSX):I^T3X9\1ZE^RK;-=:?\
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MKVEZ7?:IX7\3Z)KVA^&/%D=Y=:5<7MA'>:7;W5V&;Q!I<6I:'/JEO:1/YO\
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M[Y&!(./E,F6-OG'0?+[TQ6,Z2*2-F$BE2.3N[@]"#_$#Z]Z15S\Y_P#@I?\
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M)O\ %6YF^']Y)XAUS4-8\.S2Z2,S1Z4K:.L6BI*KRM]4.6B+G_!0[Q')I/Q
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M]XHT6#QW\1-8@\:6%GIR1>(6FELK=K^S>2VM$\R5I%T"3NUW/E_X:I9>.O\
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MK6C_ !(E1W/'H)6MYH9T"EX)8Y5##*EHW#J&'=25Y]JZ>I9^/'A[_@G]X_\
M#GB?PMX0U+XV> =7_9N_9Y^-</QX^%OA"S^!L.C?'.Y\:>+_ !3X[\3:=H7C
M+XSCQG>Z3?:'9ZS\2;Y-4O\ 3]"L=8\1V,=O:WLVP3--VT*<HRP2<U[/GG-;
MZ-+UL]NW?N85I+]_9/FY8I]K7/T7\8O:KK'_  E"6\LTWAKXDZ:+JWBBD\V\
MT/PQX/M]=U:%#&"\WV5HX[V <*UQ:JG?%>AA&_9K#R^">'E9]I3G:/ZJ_9G)
MB&TW5C\4:GX1CJ>*ZMX>;5;S2_#-I=LAUZUT[X@>#+I9W?[)XCT_2!XZ>TL(
MY-SRG^W?$"7L40Y,5Q<QD[$VGVZ&(E2IU\3->[!NC4Z-Q;=/F_\  8\M^EEU
M/-KTU.I3HPNG*TX]N96?+][O8]=M[V:SMYOB1HMC'J_A37K8V?Q/\#0JC36-
MU*4\_P 0Z ;R6WB>QMOMKSW5G/L,UA<F6,JX\L^/*$9<F JRY<3!WHU.Z_EE
M;J[63756\SOC*5WBJ:_=25IP[/NO\NQ!,GA/4-1ATJXU./P]XUT6.2?P3XFU
MF:\\*:UJFBGRS=^%M>U*22PO]46VC1(IF$DRS0B&\A+RQR$-/&4J<JOLG4P<
MM)Q5II2Z3BM>7UZ:Q>X/ZM*2BZO+B-XMZ-K^5O2_I\R ^'_^)89-%\1ZQ_PC
MFGW=U_;WA:_AT;Q#K_@#Q!($>[U;P[<Q6]IJ-QI[1.TDMI'*\%U;S&>))4=X
M&KZS:=JF&7MFM)QYHJI%=);J]]+VNFM>XE14DW'$)TT]8NSY7Y=;>6QR$O@C
M0O#^O)XO/C#X>^%9]0@FNK'QYX=TZ^T70O$;7-H((Y/$]EX<\:Z2_A[4IY"F
M;RUVV+L 6VMB*NIX_$5Z"P2P>(J4U_R[E)2E"SN^1RIOF7D]5^)SSP]"E4^L
M^VIQD_M)-*7^)*6GY%G2]7^(N@VVHI%\5_%E]+:Q1M8ZBO@@^/?"3K>NULH'
MCN6>SCMXFW;U;4S'Y '+2!ERI4\MJN'M<HIJ5W=>U]G/YT]6WT]UJ_9$QGBJ
M?,HXZI?H^3FC_P"!;?>:=T/C#)96MUJOQ$\0Z=:S0&&R/@N_^&_B'Q)XHEDD
M$?\ Q+-#T[PGX?2*1HV*-Y=W>0QH,R%<%JQ7]E1;A2P-)ROO452,8>LG.2M_
MVZFS5_7:G*ZF(G9_RN+;^2BK?>S-L?!&FV&JWVI>(=&^+T^N:I936FE::][I
M.J>-O$J1S-)!#>^+;!YY_#6@61;?/#IS06\:_+/-,S"%M:V-E5@J&&J82-.-
MG*24HTX]VHOXY><M>J2W,5AE"3E7A7E*3T3LY/YK5+R7S?0[.V\.:5)?Q:;)
MX9\4>(O$T,<;:YK+:;=:C:?#O0+I L.D^%K3Q%?QVEA>ZBL8CMG\L2EB;N50
MBQ15RU*]94O:K$4HX5NT8II.I+K*?*KVC?O:WNKJ=4:<)3Y71FZUM79M17:-
M^O\ PYT<6O:Q+;6FO^'_  )!8>&?#4/]A_#W2]5UBRL;>_U2Y9]+6^L-,T5=
M7N;Y]0G*V-B3)&6ADFN"^)<CB="A%^PJ8SGKU'S5&DW:.]KNR7=^=ET-.><4
MI4\-RTHJT;Z7?IJ:\7@.[EOM!\-^)=:?Q-J;:BGC?QG%96XTWPW%J$-ZL]A:
M1V*M<3ZI)<Z[!&D;WL\S+9Z>4C6,#G*6,C%5JV'I\D%'DA?65FM7?T[):OJ7
M&A-SA"K.[;YI=O3[^_1'%^)M8G\4:5\0_&]C_IEE'8:GX,\"2P1R(=1U9IGT
M9]1L+IUD,\-A?"[G\Y$,)$AP3Y+$]E"DL+4P.&E92352:;OI:_+)=WHK;Z>9
ME4J>TAB:G*[6<8O\+KT/ESX"Z;8Z5^VG^UOX9NK."?1/ MU^S!ITS)NEGOH?
M$GP>U/X8M+>RR1#[:FBZ2;)KF57WGSHP2P*Y52O4J4\=B>:U2NXOTY4JNG;F
ME>VEMP5.,?JM*WN0BU][Y?P5OP-SPG%XIO[+P4WA>\\0>&[F37;C0=4\5:[^
MT5+XYT'Q-KWP>\6Z\?&?@E/"7]J:E8ZWXF\0VMK+!:V0MK-]&GC>9'C:T$;^
M<E%3C.WN*KWO[M1;?+7]3H;?*X_;<.W6/4[]Q"__  4<^&FHV3$Z?XI_8K^,
MGBJ"6)BT,MS>_%W]G?3YIX ,J!<6.FVC=,L<L<DUR5URQI4VO>I\T7\G?7[V
M;TGK4:^&5FOFB]^SWKVE:A\;OB)INE_ W1?A[>W]W\1'U;Q]HNK:)<V_C^?0
MOB#-86\ME9:9XRUF_,][)=27EZ;G3;%HKJ20?*2R-RWUT2-W>U^8^\&9;>-K
M:)MS$XN) <Y(P?)1NIC4_>_O-[8H>B)OW0R"V#EI'9D@BP99,\\GB.,?Q2OV
M';J:+W72Q3EVW'RW+N5V?NHXQMBC0D!%SZC!=R>K=3]*=R5^)%K&IW>F>'-=
MU)K6#5KBRT/6+ZQTB_D@A@U&6TTVYN8K:[O+H&.SLKN2(1M(YV!6)/R@UI2B
MIUJ,)2:C*<5=:M7:U2ZVW1VY70IXO-,KPE6O*E2JXFE"52*<I0C*I&+G&,?>
ME*";DHQU;22U:/STT+QSI^L?!SXIS^#])^$WPEM8/$GPRO\ 2]3\%KHMIHMY
MJVN>+4T\:!X]MCXRT:Q5M7MM/@D_?:C8V]I::LEG(&EMIP_V-?"N.:9?'$SQ
M%>;A534[MJ,87YJ=X-Z-M:1DVX.2TDK?UEFG#E;!^(7!$.(L9GV>8F>#S&%2
MGBG6G5A2HX5U'7P3^J59_NI5)Q]RA6G5JX66(A:%:ER_3_[//AW4KSX1R6OC
MW5/#GQ&O-8UK5I=36U&AZWX<N85MM,T]TFM;+Q7X\TNZEO+C3I+ZZC%[-F^N
MYG=$9L'Q,YJPAF/-A(3I*,5;=26[ZQIO2ZBO=^%*US\9\6,PP>$X\AB>%L#B
M\KI8?#4E24O;4<1!N52HG>>&P56*A&I&C2?L8VHTJ<5*21[A965IIME9Z9IU
MI;V&GZ=;06-A86D26]I8V5K&L%M9VMO&%BM[:VA0(D:@*B@ # KQYSG4G*I.
M3E4D[MO5MO=L_+,5BL3CL5B,;C<1.KC*TY3J3FW*<YR;<I2;U<I-MMO5O5FW
M"QMT(N#N1AE+1QDG(^5B3S!Z\?,:GH<SMT!PMUM,+[7  %J_"C Z0./D;/\
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MA_!W[0.O>*-.%U?6^I/X.T'P!JO@N\M?#?V.RN;F+Q&UF=MBDZ"V:267<WW
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MY&OLZ<XNE.SGNGN[+9BB&RN;61+XZ/X,\9^%95N!J:06>GVD3SH8X-5M_,,
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M7B!_R;CC?_L1XO\ ]1:A_I_C^K?SK\K?QQ]&?\YO<=5@% !0 4 % '*^,_\
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M-'*T;Y<PA-;&S&=IP,X(HKJ\<3%?#S4J?W)_Y!3WI-[VG+^OO/5KG!^$6K2
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M<<8^&=5<+@H9)E,JV%E-RCBIRI*44E.+NJ;_ 'D5HXR=1*4KWER?P_T*SM]
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MIH7@6S%[<!,1VT.JW-@UKI=B% \M(]'T-Y9Y!GY//AXYR!\T<.Y2;=>L[?\
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MB*PTZ[+:+\<_BAXM^$7A31/"NIV=RUHGA^QW3P7,:VDJ6:D.)ZERTV7Y$_\
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M@"3-"IY>:WC!'-=+C&&)K8?F]V>WKO%_UW,I-RA2J1UE'?\ 4YOXQ:;X.O\
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M/[E#<7<R*6+1VZF9X;?'S,@53G'+GCI5KWGRIZO02IRKM4H-<\VHKM>6BO\
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M:!7Z#B?X6)_P2_)G_0YX@?\ )N.-_P#L1XS_ -1:A_I_C^K?SK\K?QQ]&?\
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M.]BW$0W5O(NX@9.4I3K2A+F<I/U;*:C33CHE]R/E'XB_'G]K71/CK<0?#'X
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M3C&=U.-XON?SH_MT?MB?M,_LZ?M'>-_A=\$OV\M?@T_2],\/>+3^S_\ "?\
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M\6_$"U^'7A3Q#^TG-I'C?QIX?UK1?$7BC1?"'CO5X;CQ;<:3K\,&NZ-X<N-
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M^$7Q1_:F_9>_:;E^,7Q5_;7\ ?LW?$>S^$7@GX6>&_A)J_P;U&]U+PY/XO\
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M79;@\FI5JT:,GS8_-L2J$\1B,0YU'>E]5PM*E34'!.<JFE:I-'I'PZLM80?
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M*+G^7W[/OB[_ ()Z-\;?B/?_ !/^&_AI/A]K-QX*TKX-/'\,/BW/IMO=:-X
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MZS^R20&W4I#M7R=SJ?C\;1I7S#W(M0H4IKEU]^R3D[<NNLKIWWZV/Y3XQR_
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MFMH($VB4S*72QHHII/FTL?6?[+G[1&O_ +:?[*GBSQ_?^$)_A!\5](U/X_\
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M!X2T+7K/5+&V_96 \!21W]AJME?*-:']IW"2QNQ-F\!HZ#F?/?[-GPI_:O\
M!GQFL/$WB/P-X\72M<^.?COQ?\0?$'Q(\&?L.:9OTK7;C6VU/Q;IWBOX8:AX
M@^++7&N7:6T]EIUHGR)=& WL=I$JTD@;3TL=W^WWKXT;XM?!)?$?C#P#\-/#
M7Q T[Q];Z5\1_'W[4^N_LZQZ9XM\'Z+HU_=^"-,UB+X+?$;0]*TCQ-H-S)?O
M:M=-+J]]8[Q%";13//7R)2W5KGZ"?L]VMTGP.^%:WGBWPYXYO_\ A!O#PO\
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M9W4:#]FGQ_EI+>5%&(;1CEF0#A5)^@J)_!+T&MT?/W_!O_\ \HA_V/O^P/\
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M>"?"OP^\2-_Q3?AS1W_>00:?'!IJO<.(8D(?(AN]]4?#O_!9#XEV5OX+\ _
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MU6VT'3I;7QG827.L36MVD^JVUQ:);W:6]E=(%GMZVIJRL]R-DCZ2H&?RK_\
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MV[J1<E.*DDZ<8--2=1IM)\JAS69_6N:^,%3)N%ZGBQC_ *0?&*\,\5CL1EV
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M2C)4/K<DZ=-SYI8CV:YH+D]^-O\ 0'']6_G7YT_CCZ,_Q5[CJL H * "@ H
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M /IN"T-VD_,?5$2WMY&I$=W<H,'A)Y5'Y!P*I#ZHK23SS?ZV:67_ *Z2._\
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M.#_[9JX+*,)CJ6!PM>%"=>K/+\32Q%:6*E3A3HU50K8BK4EB(UH.:6E9NF>
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MD'B?P[%:R^!]$\3>"OBC#%XI\'Z#H_QBB\7:%)>^&?%DGA%?'^B_$[Q)JO\
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MX6UJZ5XX)8[K4S:^';*8RV\3*T8U*0ZKY1)Y;[)GT!K:%"G:]7$1CKLDY/\
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MYONO(K7_ (AL_AY%+IVB6USKNBB]>XO_  YI"QN? 2F",C49;AV2RT;PF[S
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MR:5!/I4NDR"14DO8+A9@Z=2G#FM34I6ZK;OHG;[QRC*=FY-1OT?_  #]+H?
M?@_3+2XO&\.Z7=:EJ,<-M)=ZG"=6O)+93YX26YU1KN>0 $'#,<;@/:JEB\1)
M*/M6HKHM%^ G3@VFXWL9]UX(\(R0V-S_ ,(]IMO=C[28KK3X3I=S#&\D:;8;
MC3'M)8E=HN0I&<<Y%-8K$7?[UOUU_,?L:3E?D7XG->([/7=%U)M'\%>)[_\
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M5K[W-RUJN205L=7@NHUQC;$8Q@8S66(DJU.CB$NG++U7^:L7!<DYTOFO1_\
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M?"GBVX\)OJ<6N#5?*UJXNIKJ*,PO'+,TD$M[>1\.?\%=O''[5/A#XE?!F\^
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M>CZ-X*L+8_'U_BUJGPM\1>&[<W4D'VK[397-P=4_L@BRF5M;(II*&[V/I?\
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M  L3_@E^3/\ H<\0/^3<<;_]B/%_^HM0_P!/\?U;^=?E;^./HS_G-[CJL H
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M[74I?HP'?!KT\,N7ZE'O4E+Y12_R..O+6N^J27WDFOO+')XR2">.*>>T\)>
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MF\Q^LN]?$14J*U26FG>2>_HMBY-)I?QGC2"Z2YLO"UI':2MHLR7NB>.;RYA
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M;SC2AM9):K0J5FG9GN/[8/[,WQ'^.7QA\!>,=%^&GA?XD^#- \ 7>B:A8?\
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MP7&K:TR:((H)I0I2XE17DD9C:6^8UDEJX*52G*-' Q6"O:4TI7G+?EC=[?\
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M!321_P#$[UN_>"4V!C@GW65IM6:67RHPBQVTCKX-:E#E4JK:RFA+E75U*O\
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MY[+3/#^@2:?;6VG;6.V NT2]E%>%C,YG4H+#87"4J-&]](WF_.4Y7;?F=]/
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M%XUU:R\5OX_^)G@'Q-XQ\*OK0UN*8/I=I=(NC;19M;P/"8E$3+639\E_L1_
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MOCY\,=>MO!7Q'TQ[W0/#EDN@:]'>Z0KW.FZG%!:7'GR_9IT]RHJ]UKN>[?\
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M7FT?XD3\OCN>26&_[=9>4463[7;>67!*!_.3:7 P2H;J/2NI;EG\O_[-^K>
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MK'P2O/\ A9'B.#QE8RC0;%H+'5[Y;G48KJWLIKI40UI;0:T>AQ7[&-Y?Z?\
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MRL_9QVIT5JEII%/>27O-VV;.B*:BUA4[*ZYGO*H_SMLNB^1Q_P ;?V>/A/\
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MVKQPM:M&/,E#_8U9?O*=62?H]OR9V*?[]IOW)037JMS]'+'_ (_K/_KZM_\
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MZAE"BN3$4\F5*#JX>%*I)WYX3G.#5]H\L;+3I9LZ*53&N<HTZLII+:45%_\
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MM*#T]?FI-.^K%9]ARP6A!S>1XSVMYC_0<4^FX[VW0GEZ>N,SW$C?W$@1 ?\
M@4DI/3VIZ]@MY',^.[R&Q\#>-;NR\%?\)]<6WA#Q-/!X'NKJVCC\:20Z)?2+
MX2=KFVFL43Q*5^Q$SI)"!/\ .I7(HW!)]]#YJ_8TUG]GW4? ^NZE^SG\)M2^
M$VAZA>Z+<>)(=2T*WT^\U751I'EV%HNN1^(O%;ZU:^&;%#:0QQWAM+)#LMT5
M'Y%OZ@XO>3N?7Q+DDDLQ/4G)//N<FJM$DE@D='PJ[@Y(>(KE)1Z%1@[AV(Y%
M#TV T&LE(:3>455WO#\LEP@XSA%/*#LS8XZU(KD:W'E_\>R>2.GFYW3M[^8>
M(\^B@4K@QQ>*X'[[$4W_ #W7[CYQS-'R0>.67\11>^@APM'C^>X(BB_A;[[2
M\9'DH,%\@]3@#O1:VK :+DQ_+;CR4!YQAFDZY,I(^?/I]T47$?E=_P %#_\
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M<O>C1G+YMV,7&\Y)*Z=2*^1^77[!'P^\3>!-'\?>/_$<.BW&H:9IFEZ79?\
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M?XB_#W^W;"QTQ=0@NK*?5)M=WI#"8+CSG9(TBED?8V=62E0D^U.#]73DX/\
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M(J^4@@#LS98EB>I))/3U))I.*6H$JJSL%169B< *"2?P%("TL$4>3<.2P/\
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M*:.OPIC?68;F]\5VMV8+&:#6;A;_ ,;,[<0Z9X.N66-=0M/,!:'1@L21]8I
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M[3O'&J?"^W^/'VGQ!\6;;X>>,K.^3Q'\.+7XGZ?J?PYU'Q7J7Q5M/#=Q\/\
M31\03X8DO(/#\MM+I.D6T,%D9V.HA=0OI;J>V?\ !0?Q_P")?AU=_"3QMH%[
MIG@_Q?X<UWQCH?P\\1WVK>$?$<OB32?&?@N"'XE647PN\0?#?Q]J%R^DV^FV
M41O[06TMM#.WF3FTNIK6<8EK=,]O\!V6A>&OV&O"D=@;>S\">'_@#=:IXCL?
M%FEMXV&H^!;7P=J^J^,-%N+.V3X86\D^KV#SI"([72K2UC80Q6L$*HL9H*[N
M? W[)_BF3X/^._#_ ,.OB1\'O'/@K7/B%X4^$NI> /$^KZ'X66RL=/\ $GC#
MXD?%6TA\4:S;_MG?M0>([G6?''B/3/$5_?W1MK>2YU:!6OKNX!M6CZL)_'4+
M?%"2^^+,Z^M.4K[-?FO(^O/V[?%EQX!_98_:.O$\-Z/X_P!4O[K5?#6A>!-;
M^(7@OX4Q>+$^)O@9/#<_A?3/&OQ!23PK::L;+4KZ\2*=':Y6&6.-6< '=RDZ
M4+:\]!QZ?9;?SV,HQO4:V<:M_O7ZGQ%_P22\>^._$FG?$V_UOXB>-?%OP_\
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M$8GB/PMX;\8:9_8WBO0],\0Z3]I@O?[.U:V2[M/M=LLJV]QY+_+YT*S.%;J
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MUX=!#(NT_P!W&:G'_P 6I'I",8_<C6C_  _-MO[SZJ7I^)_F:\6'PQ]!#JH
MH * /B#]K'Q9JWA+Q5\++OPWX\7X4Z]<_P!N>=XXE7Q/X]6?PY8SZ5-KGAZ+
M]GSPG8ZI=_$Q[J&56;5+K^S;?PWN69;WS)A:W'U'#^'IXBACXU\)]8I+E]SW
M:?O._++ZQ-I4O\*YG4VY;+F7]'>!^28'/<DXUH9OPR\[RR'L;8-?5\%:O-5%
M1KO/,3.G'+U%II8>G]8J8^SIRPW)3=:E]1?"[59=<^'WA369?'6B_$QM4TJ.
M^7QWX>TJWT31O$L-U)+-;W]AI-KJ6KP6$8MV6-HQ<2$.AW8;*CPL=35+&8BF
ML+*ARRM[.3YG&VZ;:5_N1^,<9X*&6\4YW@*?#6(R=4:[A]2KU)5JN'<4E*$Z
MLJ=)S?,G)2]G%6:M=6;T_&?_ " +G_KK;?\ HY:QH_Q(GS4=SYTE9K#QE8RX
MC$&O:%-8ELGS#J6A7/VZU11C:5FT_4;HGG(,(P.M>I']Y@YK[=.I=>DM'^*7
MWF>L,1%_9E#\5L0:!:VRPZ]X*U&!)K6T>=K6WD)=+WPOKS3S6T9&%;_0K@W%
MFV"=HA0@C< *Q$VW1QU/23LGY2CH_OT9,%R^TH2Z;><7_EL2:7J<V@74'ASQ
M'.S([BV\->(KEB8M:@ _T?2M3N7PL'B6TC 0[R!?J!+'ES)&DU:7UBF\10WW
ME%=/[R7\K_#TL$*GLY*G5T3V??R]3<U+P[HVJS+<WU@AOXU,<>I6TD^GZK$A
M !C34K"2UOA& /NEROM6%/%5Z*Y83?L_Y7JON9<Z5.3NXKF[HJ1>&A"K)'XB
M\6A26.)-;^TLH8YVK+=VEQ.JJ.%PW J_K<O^?%+_ ,!_X(E13:7M)V]3Y!_;
MR\&:-+^QQ^T)<7\VNZQ<:;X!N-4T^;5_$.L79L[^TU;3)+>XAB6[AMPT>YEP
M4(:-F1LJ2*[LNQV(IXRBJ7)!2=GRQ2NGT>A^K^!^%I/Q=\/W.\K8_JV_^750
M^W=.CDE6W6*-Y'\B%R(T9VVK&A9B%!.U0.3V%?-/63=S\UJI*K77]^7YLZ6T
M!#*"""&((/!!!Y!'K2D9O8Z.RY;'OWZ57<SELCY*O?VN==;Q%XZTKP]IG[/.
MA:?X"\5Z_P"#[VU^-?[2L7PL\>7UUX:O)+&[U>;P5;?#/QB?#V@ZNT1N-*GO
M+P/?:?)#=>7'%,E?64N':7L,+4K3QDYU:<9IT<-[6"4E=+G=2'-);227NRO&
M[:9_2. \",MCE'#&-S7&<58K%YI@*&*A+*,@>98*$<1!3C26+EF&%]O7I)JG
MB84J7+1KQJ4.>4Z<CZ.^%_Q)M?C!\-?!OQ+L]&OM M_%NEMJ":5J$MO=26[0
MW=SI\LEIJ%H3::QHUY+9M/I]_#B*_L9(;A JR@#P<QP4LNQN)P4JBFZ<K75U
MTOJGJI+:47K&5UT/QSC[A&MP%QCG_"&(Q]+%5<#6Y'4@I14KPC-*4)>]2JP4
ME"O1E>5&M&=*3;@V]RYZG\/YUP2ZGR2V,&\_B^A_I6;Z%]CX%_X*#0Q7'[.#
M03HLL,WQS_97BEB?.R2.7]I7X61R1N!@E'1R".X->OD[MCX-.WN5/_2)'ZWX
M*_\ )=M=\GS7_P!5N)/LWQ*W]I7TG@G23'!;C9_PDD]EMABT/P\Y8+ID'DE1
M;ZGK<*F&W11F&V\R; "Q[G1]Q?6ZB;F[J-]Y/OZ+KW>A^,OWH0H0:6BO;HO\
MQL<EE>^)04,-OHGP^T]C<B./9;VVLZC8+LCW*?)5-#\-G<44$H+Y?N[<$_>0
MHM;UJ\M/\*?ZO\@O%S:M:%-?C_P"]X2@E&AC4[B/R;KQ%=WGB.Y1HVCD!U:0
M36D4ZL%=9K;2EMH<, RB(*1Q66)DO;JDM5!*/W?I>Y=&+]FY-6;=_O.EAZM]
M*QGLC1%BLP%[?C1T'T$H$/'2J+6Q/%_4_P J3^) ]F3U9 Y?O#\?Y4GL!+4
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ME/!/[%5>EG^:'[2JM/;4W]Z_4&T[QW.SI)JOA338BH\N73M/NM1O$# AF/\
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MQ_:?6VN%U#X_?%"TU>&XM(+9#>Q?V7Y=]'?RWBW^;22X;4VN;6**S^ZKIYK
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M,HO%GQ=\?1:2/B7X(\-^)M(O[6TT[4EM+_6],_M*QFT<Z;8Y/V2[*2^8GG
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MT)1I./+KK'W>5I:J9U/$5L#*=''X:*PTXK1)25D])<TM]-[M/M8\9^+$5_\
M#OX->+M \0ZMIOBGP3KQT[3_ (<^+[*YU.\MY-:M9/AW<6<FD7=_X;N-1BT;
MQ?X3UO3Y/LC:N\:O>,&Q+;S@\N:NEF^&Q.)P5)T\RHT;UZ;M%N+<T^:TE&4H
M2B_>4$[+?5'[!]'SFPWC)X>0K5>?#2Q[49I-Z^QJ-6NM%9VM<^^?^"J'Q"\=
M^'/BOX+\*ZIXPTJ#X"Z]X3\!WOBW11^T%KOP=U/PQXHL8OC)/HNI7^DS?L]_
M'?PSJFG^-;ZTME@O+>SGNTET,Q3Q6Z_9[D_RQ>_2QY,TO:UW_?E^;/LG]JK1
MO WCC_@E7K'C7QQX.\(_&!_ O[->A?%7P;'\4(V^,^CR>,K'P);6FD^*-1N=
M4T[X:6GCV^^Q:S< 7VI6&BV-T9C/>6UK;^;&@]R%O\ST'_@E!X&\+^ /V??%
MNE>$_#]SX<T^^^+>LZQ=V5UX0_9H\%S7&HW7A+P9;SWK:=^RO\4_B]\/+QI8
M;2-/M5WJ<6K2>7MDMUMTMI)'^9G4O==SSGXR^*?!MG\6_'UE\9KSQ=\1_&.F
M^+M83P?K7PP^..D^&?#7@#PS)=?;/"7AGQ'X?LK+3?\ A7>N^'=(G@34&U,Z
MK-<SA[PR>5,D,?Z=E>'Q4LMP<LNC3HX>5-<ZJT'*525K3E&3;]I&3OR\O*DO
M=M=-O_0GPYR7/\1P'PMB/#[#X#*,@K8"D\52S')ZN(Q&-Q"CR8G$4*\YU/KU
M&O5C-T%A_JT:<''#\G/3E4G^F_P1N/%=W\&_AQ>>-_%^@>/?$MYX=AO+[Q?X
M8U33]=T/6[>ZGGN-)GL]?TFPTG2O$+P:-);PSZA;6MM!?W$3SI#&L@1?@\WC
M0CF6-CAL/.E152RA).+36CO&3DXZW:BVW%:-NQ_&'BC2R2AXA<6T.'<AQ669
M/3Q4HPPN(ISHUJ,HJ,:JE0JSJU*"E54YPH5*E2=&$HTI3FXN3[*YZG\/YUYD
MNI\(MC!O/XOH?Z5F^A?8_,/_ (*PSWUK^PU\4KG2[A[34[?Q;\#Y]-NHMQFM
MKZ'XW_#^6TGB",CF2*9 1AE.1P<U]/PC&C/B3*88E7P[K+F6R<=;IGZMX.2J
M0XUJSI3Y:L<FS9I]FLLQ7YGX'Q>$]6ELH/&/C_PSXO\ #\>F:39ZU<>*/"FI
MZ=:^*=,\(V:6FH#7M?\  ?B272]0NO"LGB.VB5)+'^S_ "U8S2)*DJ&OZQGC
M<)"K4R[*<5AZLIR<8TZT9>SE4Z0A6C=1ER_S<R>RM8_E^C@N:C"OCJ,X5%&+
M<Z;2G%/K*#>J>CNK?B=+;^'/!E_=Z;J<OQRBU35M)DLX_#5Q?6_AI=;L+Z.Y
MEEL9YK6_MS;7L.HP6BG5KC5;C2KBR1Q*PNC*53S9YAF,(U\,^%7&@[JK;G<7
M9)M*6]E?W.2ZELK6.IX7!RG"NLY:K*WLUHKIMJ]ME:UYW:Y4UO<U=-T33O&=
M^/$'A%O%_P 5M;TB]@CM-2\6ZO:Z+\/]*\8VC6EWI&A:'';ZEHNO>(]8U#P[
MK_EV]M;1V-C%+;VOGQSV[)(_-B,56RZC*GF%+"X*E4M>-).I7G2>CG-M2C32
ME%-WO+XK-,ZH86.+K*IA*U7%UELYR4::GH^1).\KQ>C3CT>VA#::Y=^,M(M?
M!7BS4UTWXA:8)U^'MSK&BVVF75E/8ZP;U_ =YJD^D:-XNT.]NKK3Q)%&&-D]
MU?XEL?E:Y-3P5/+,1+,\MINMDM7^-&,KI\T;>U2NX25WKM)6^+H0ZU;&8?\
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MX,LOC)\;[KQ3\#_B-XSU#3K65EU/6&U71]4,4ERPFA.:&1JWYG(_\$<TLE^
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MV[=N6X.KAX9A*#<L5SQ2T<N2G))^T3UOS+JD[)'HOBNZTSX>P:/#\3+RSO=
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M.3B_9W5U=632M)Z&O/@Z\\0Y9?*=X;\RA9Z>^DDUS?A;H?0/P[UGPMXX2P\
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M:Y30IY53S.ARP=6";A=.S;3O%]_3;8POB/\ $OQ?\<K/]D_2_&E]9W.A>(_
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MH66FQW(U[1].\4>,;KQ?XNU#5+6XO+_Q!J-_-J6HR7($Y8QAVHRF[M-'Q_\
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M1M\5XWY=[ZVU-\)B*^#Q?#^,CB+8E*U[]-$E)ZZ6=EKJNET>A>$/"%_^T?\
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M:;J\\,)I]GX:LM=M;F]T[3?!R"XDDDWM#.=I"L\:<.'Q-94<?C,12A1IJO\
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MS3BES7C[UVW:QZ-/$5,3"499A+V%K\E;6,M=HRM9._\ A6FI)>W>EZ)H]CX
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M* "@ H 9&'6-!*ZR2!5#NJ>6KN!\S+'N?8">V3CUH ^0OV[_  QXM\9_LO\
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M8X$5@3@F8\69"JM51X]R^$>6+YEA*FKUNDO:7TT?S9<\MQDGS/*:]]K\Z_\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M> [SQV/C%\<O!GP4MX+37X- _L&?Q?#J4R^(9I9]*U47\5@-.(^S*L32EO\
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M*<MT])+:48R4HKNZY3YH* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M%&3=E%M@64$ LH). "1DGK@#N<4!9VO9V'4""@ H * "@ H * "@ H * "@
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M:C5K3FD\YU2E)M7_ '6]G]_4\D_X**>,OB5^U+^R/^RK\?\ P!^S5^T#9OX
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M&ITIU)TIU*C]U4.27+*<)')O_P %4KKQE;OX3B_X)U?\%#;J?Q-;S:'-:2?
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M>&&I0PU.K1HU_P!]"$Z=*,DJBC-WO*,6^5?2=>,?D04 % !0 4 % !0 4 %
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M,\PG3AC(N-Z=-8.-%SC]?KJ/V#7SA^"A0 4 % !0 4 % !0 4 % !0!\/?\
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MTXG1_#7X_>//$?Q/^#_A[4/'$.H>$_&GA:RU3X@Z@/#.GV0\%_&-K7Q=<0_
M9[R.UCCTNZUM;*ZD*W?F:A:'PL+=I/.UFW88XW*,)0P.8UH85K$4JC5-<S?/
M1O#]_:^JC=;>Z_:WM:G(\GB_POX9RG@WCW-<)PW*EGF7XV=/ P^L3G];RKFP
ML7G2@Y-U(T>>FKT^6A5_M%U8QY,OJH_0^OCC^4PH * "@ H * "@ H * "@
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M6J5YU?JWM,7F<EAX2Q6,H_5H1P56$J7LH/EFIV?/]\U\F?S$% !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M?B\JS? 5L+FF'J.%6C6A*G5ISB[2A4IS49PDGHXR2:ZHU:S.(* "@#SWP/\
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M^'WMM3<K(\T* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MDHTJU*M"I;E]K1DI\_M$N=>RC-TS]PJ_+S_.(* "@ H * "@ H * "@ H *
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MC2A"4:M6BX-QJSG)<E-4W*7NQE*<U&%X)N:^:H?VC_B=I&F:9XL\33?#G4O
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M]F\.E*%&M3Q%-XFLZ=#$2JQI8>OB'B(QE/K'QQ_94U'Q!X7\0ZEX T_4;I]
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M-P^5Y?FN$?L?JN82C3J4,+3P&%PE6O-NOS^RKVI2E56(57$J5*<7*DES]O\
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MK1K4X1AB<14HTZ#5*DU2A2JQUFG.4W)R<I7G/Z,KQC\F"@#@?BCX0U/Q_P"
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MX_,:^(IQKS52LHU:DIWJ348IS;DW*RW=KO=^GUPGQH4 % !0 4 % !0 4 %
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M=ESQI4,7.E54:KI3=*$N:=-K[1KYH_GH* "@ H * "@ H * "@ H * "@ H
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MPITN2-'%2Q. HT75>,7/4Y,7[3&4G"7M:CC."7UU7SQ^$A0!Y#\?$U63X/\
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M\3:)XBTR_P#AUJ7_  C>EP6EUIGQ/\3:5#JGB'Q9XCT2T@T^,ZA!<1BZDCU
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ME=2I*F_;*,JM)0FJD7%QG'GE>]*+M&"D^:R:O&].Z:?AX#PE\.<;C\1@JO\
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MVDZ3IF@Z7IVB:+86NEZ1I%C:Z;I>FV,*6UG86%E"EO:6=K!&%CAM[>"-410
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MV?#SP3=?:6U5KC[1X7T2;SVUWQ=#X_UMIO,LF\PZOXYMH]9N2<^?JB+=/NG
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MB'6YL15E[5XN5.6*=2\WSO$RHTI5W*_M94J;GS.$;.LOA?\ #731I T[X?\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
%@ H _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>g556278dsp074.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g556278dsp074.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_X0T)17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    4    <@$R  (    4    AH=I  0    !    G    ,@   $L
M 0   2P    !061O8F4@4&AO=&]S:&]P(#<N,  R,#$X.C T.C Y(#$W.C$S
M.C,W      .@ 0 #     0 !  "@ @ $     0   HF@ P $     0   T@
M        !@$#  ,    !  8   $:  4    !   !%@$;  4    !   !'@$H
M  ,    !  (   (!  0    !   !)@("  0    !   +VP        !(
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
M @,$!08'" D*"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R
M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5
MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7
MI[?'U^?W$0 " @$"! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q(A,%,H&1%*&Q
M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S
MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_
MV@ , P$  A$#$0 _ /1<RX8US&,HI<QS227$M.G9K64VH+<XEFXX]  :-\EX
M&XG;#?U;W5?R]O\ UM2ZL_9?4Z8$$:N+1K[?ZO\ )51HT:YI:YQ$D%VL'30>
M_P!9ONW56._G/YWV>BC9[HX8]@G;F9&[:_%Q_I%IVNL=H!^;^J>[])O9M_[_
M /HTXS;2UQ.-C!P ('J/@DP8_HO[G[BK4N;(]1T0YKB=Q!@ .^C_ (:QV[_T
M9[TM7&&Z%NKB"> !["/ZWY[OYY*SW5PCL'2^V=/VASV!L\@UGP'\G=^<G=E]
M/:2',C74^D[D?V/I+.8&DNJ#A)$ ;B=KH8UA?,OI][?TG^B_FO>HM(M +7 M
M+0 W<=SG?2#F1^_^D]1_^#_1I6>ZN$=@Z8RNGD2&\$C^;.FV-SG>WVMU^FY-
M]LZ= ]AUU'Z)W_D/Y2S7D;W%K@!.YI<X[7,,AKGN/M]+Z7J?X-.XM97M]3M$
M2098X'][<_U-V_9_HO\ 2;$K/=7".P=)V5T]L$LU(W "IQ,<]F)SD8+3!8-(
M'T."1QQ_G+.%;W!I=LESVEGO(!W>Q])VCZ/YOT/T?\VDUU;@/=.X@@O>6.(=
M^D#O4;N=[MCO];$K/=7#'L&_]LZ<)ED0($UD3.FUOM]SF_G,2^V=/B=D#02:
MG=S#?S5G.DAA<X.L+"9@@2XNW;C\GNW_ /6TTL+" X:[ #ZCMW\Y^C;Z7]7\
MS?[/T;_STK/=7".P=ST*/]&WP^B$D1)*SW*N$=@__]#TK,I8XBY[G-;6/=M
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M,  X0DE-!"4      !                      .$))30/M       0 2P
M   !  $!+     $  3A"24T$)@      #@             _@   .$))300-
M       $    'CA"24T$&0      !    !XX0DE- _,       D
M  $ .$))300*       !   X0DE-)Q        H  0         !.$))30/U
M      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(
M   ! %H    &       ! #4    ! "T    &       !.$))30/X      !P
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@  #A"24T$"       $     $   )    "
M0      X0DE-!!X       0     .$))300:      ./    !@
M   #2    HD    M #0 +@ Q "  <P!T &\ 8P!K "  8P!E '( =  @ %(
M6 !) %  7P!# #  ,P!? $8 ,  Q %\ 4 !U '( < !L &4 7P P #$ +0 P
M #0 +0 Q #@ (  R     0                         !
M  *)   #2                      !                         !
M   !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG   #2     !29VAT;&]N9P   HD    &<VQI8V5S5FQ,<P    %/8FIC
M     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O
M=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M#6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !)
M;6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   T@     4F=H
M=&QO;F<   *)     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M    37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL
M5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z
M06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E
M<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +
M8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4
M   )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M#&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M.$))3001       ! 0 X0DE-!!0       0    ".$))300,      OW
M 0   &,   "    !+   E@    O; !@  ?_8_^  $$I&248  0(! $@ 2
M_^T #$%D;V)E7T--  '_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,
M$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,
M# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" "  &,# 2(  A$!
M Q$!_]T !  '_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !
M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M #A"24T$(0      50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\
M<P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  (  W
M "X ,     $ .$))300&       '  @    ! 0#_X1)(:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X])^^[OR<@:60])U<U
M33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"<_/@H\/V%D;V)E+7AA<"UF:6QT97)S
M(&5S8STB0U(B/SX*/'@Z>&%P;65T82!X;6QN<SIX/2=A9&]B93IN<SIM971A
M+R<@>#IX87!T:STG6$U0('1O;VQK:70@,BXX+C(M,S,L(&9R86UE=V]R:R Q
M+C4G/@H\<F1F.E)$1B!X;6QN<SIR9&8])VAT=' Z+R]W=W<N=S,N;W)G+S$Y
M.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,G('AM;&YS.FE8/2=H='1P.B\O;G,N
M861O8F4N8V]M+VE8+S$N,"\G/@H*(#QR9&8Z1&5S8W)I<'1I;VX@86)O=70]
M)W5U:60Z-SDY,69B-&4M,V(S,2TQ,64X+6%C8F4M.3-F,68Q8S@S,#1F)PH@
M('AM;&YS.GAA<$U-/2=H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO
M)SX*(" \>&%P34TZ1&]C=6UE;G1)1#YA9&]B93ID;V-I9#IP:&]T;W-H;W Z
M-SDY,69B-&,M,V(S,2TQ,64X+6%C8F4M.3-F,68Q8S@S,#1F/"]X87!-33I$
M;V-U;65N=$E$/@H@/"]R9&8Z1&5S8W)I<'1I;VX^"@H\+W)D9CI21$8^"CPO
M>#IX87!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TG=R<_/O_N  Y!9&]B90!D0
M  '_VP"$  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$" @(" @(" @(" @,# P,# P,# P,! 0$! 0$! 0$! 0(" 0(" P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M __  !$( T@"B0,!$0 "$0$#$0'_W0 $ %+_Q &B    !@(# 0
M   '" 8%! D#"@(!  L!   & P$! 0            8%! ,' @@!"0 *"Q
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M9/\ KW7=:Q+&L<7]O@*L48U"CG3EB2:Y?]EGZ/\ +CI_[B4_EQ6SZG8./?\
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MZ#;PY72QT=Q-6KP;XP=%.[2-L*G+OLY=@,?XYNCG:*0I3KA[#-VT"&-1YO\
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MQ#PFT>W.O-R8%LSL;IC<5;U'O38<76,>8VI/3;6Z>W'W'D(,!MJ6C.#W!L7
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M?$Y; 8B/L_$TL=555K55=DZTTE'%45"2(ONO48\3CIHPO>GP5PO57<>_MH;
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M=QX[JYNHWI<=)-@]@9BJV]B<;1OC]L5^-J,EDL9USNO%QMA?NEC\U-3R3/%
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M.P-^="[KW"0@JNM=QXH286*A'VTTDD5<[^ZJX R!3HN&YOD=VYBNN8NQ-O\
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M;7V]NS([/VSC<]N?<N]<#4;_ &W1U_CMVUFX^KLCN/JO%=9[UPF)SV0GPO\
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M1WBAE)!/NM=V<<.@QV'UY_+QP5+FJC ;RW'GL=@JCIW;NU,!N;?G;NZ*?K?
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MVHL4^:RW;'<-"_8$&TY=D4F=PV?R$U9 <7D#7TM:L<-%:=(XQ[KPU8IQZ?\
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ML:JK>M<YUAO3^_&+V_D<-58^MW7B=Q5%:E;02:Z#(JC"*:G,U/+[K0(SC!Z
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M%PS[)Z]KM_9^OA3<0W\^]*;=>Z]T;RIYQ4P5<$&+HL<M-&D[3U%1)[KVH 4
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M83<3;GHYX-R)4[AJ*6FW!%'6T\7VU5&X]UZHI\Z=#_3=9YN#M:NS._\ X_\
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ME9MU=!1;2^.67Q^UYZ?"[F^4-/NOM[%X#L$1R9:HJ*_K3M3K;9AWK1XMY?\
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MO8/CZ7WG1Q4]#MW('*CL7:W86T=MTM1C]XXW>V"JL9591YCBJVG,4$4WNM$
M#AT6;</RV^7>UM@]+9Y^Q-\;^FW;\#MW?+S?&2ZUZDZ&ER&"S5/7=44N/&2P
M>\LWMU).J]KP[MK9JU,.N0W#+"&=0_C5??NK47./.G0^/\IN^'PF\NUJKM+K
ML5O5O=/QXZ5;H'9F"P6:V_W G:N'Z::OW1MC>63E??4E=V7/VI5978E11F/&
MKBJ&E^[I:[5621^ZKI'"GY],6[OE%\O:+;/R P;5FW,-N?XK=C]/_'[<FZ=N
MX#9M=DN\=]]W]F])U&U=][2PF[L_3;3V!#0=#=FT<LV.RM5'2?WORTT33#&X
MU):SW6]*X]#TH]U]Q?)'!YF#;>8[^EZ?_NK\9NZ^_P#<.9[;V%T+FJJLR6R.
MP=MX' 4.[VZVW%EMFTNQJ3#5<S3C#Y*#*2K/>2>"954:ZT /X:YZ=.T_E+W[
MFNE_BKV%L^:#K'<W:'QMS?R$[4ZZP-)USE^T<#_#MA=>;DJ)MO[8[MS.T=M[
MMZYZ]S&[9XMU4%/EL9NEXIJ$44L;&<C?7@HJWV]-N^?D/W]M"N[Q[7VQW!3[
M]Z[V1\/>L_D]LS8-9U9M_!8:27MJ;N+%+59^O6"'L&GV'L6CV-29YJ5ZF/+&
MFAJ*>HJ6)U+[KU!@4\^N6[/D+WEL#M_ ?'*#OO;>_L?V+6= R3_)&79&QZ6J
MZ=/;9[=$>WI\)@"-A96N[/J.L*6GV0]=3R-2S95C6#*(*8R^ZV "*T_+H/\
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ME]B3;!Q63S6$W7T7N3,]$[.K-WYK&X#<W8>PMG9.IS/4^S]C[AH!7U?F6/\
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MYV+O+<%5@,'+34&VEWY#U1A@M:E1#%/DZ=YX2:F5V/NMDN* CI,[:Z=_E_\
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MH#NV/A3V_P!F=H=KTV,R>Q^ONK^W9^SVWAN'!;OWAG8-QXSL/H?.]10U=?\
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M"DE&M[KU3T[_ .B79O\ JMX?^C+[)_\ LM]^Z]7KW^B79O\ JMX?^C+[)_\
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M9W#50T&"W=79>OJ(:^HAQ^/[DWS59!X<2F#DRTGV,.]&JU&*7<^-^ZN@-/\
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M-P;#ZA[3Q^SMI=:8/?.RMV[N,V'VGM?XT=O=/9"2AFI]OXYH8-R]A;LQ&?\
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M=@^P-KY?:F5K\.]-%E*2AS%))25$]!)64]72I51QR$H9(I%O]5/OW6P:$'H
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MRF:J]TX2:DQ&%7<%5%C\C29*NDQ<TF1IZ*>CQ]%--65S96LQ%53T:Q(S553
M\40:164>Z]0]!ML_Y4?'K?N\/[A;3[9V?E]V.^8@IL2F3CII<AD-O;QW7L'/
M8?%25@IX,MF\-NO9.3IJFCIFEJ(A3>4IX9(Y']UX@CRZ$C.]D[(VWGL1M;*[
MCQ<>Y\W4T=/0[<@JX:K/&&NE:"'*5&(IWDR%+A$F71)6R1K2Q,RAG!87]UJG
M2+?Y(]"IN#:.VAVYL";([\I=PU.T9Z;<^(JL-G9-K9/:6(S&,H=P4]5)@Y,[
M%D-\XQ(L?]P*VH^YO%$ZI(5]UNAXTZ4. [DZJW1M#/;_ ,)V#M.KV1M;<.[M
MJ[DW9)FJ*BV_@]P;#W'7[1W=C<IE:^6FHZ*7!;CQ<]+,TCK'K2ZLRLK'W7J&
MM//IMVSWIUEO+L7>G5^UMQP9W<O7NU-F[RWA/C4:IP&%Q'8%-79':"S;@0G%
MS5N:PU U?'%%(Y%"\<S$)*A;W7J$"O2MQ/8>P,_C8LS@M\[/S6'G222'*XG<
MV%R.-FCAR,>(F>*NHZV:ED2++2K2L0Q"U#",^LA??NO4/IU!':G7$V(W'G,?
MOC:N9QVTF,6XI<%G\5FI,56$NL.,JX<95U,L.6K)HS%!2L!//-9$5F('OW7J
M'K++V9U[2;=@W;DMZ[7PNW9\;/ESELYG<7AJ*GH*2KI,=7SUL^2JJ:*B&,R=
M?#2U7E*FFJI5ADTR$*?=:IU@RW;/5>!=H\YV9U_AI$H,;E7CRV\]N8YTQ>8E
MA@Q&29:S)0LM!E9ZF-*:8_MSO(H0L6%_=;H?3I-83Y!=0[EJMT8[;^]<9E\Q
MLG?0ZZW9@*'S2[AP&YVW;3[($>3P)C7+4V);<54L2Y!H?L9$O(DK1@M[]UZA
MZ$+;F\=H[QBKY]H[IVYNF#%5\F*RDVW,WC,Y%C<G%'%-+CJ^3&554E'7QPS(
M[0R%9 KJ2+$>_=:H1Q'2C]^Z]T">5^1'46%I]Q562W0U/!M3MG"]'YU_X-G)
M/LNS-PT&VLGB=O!8L<[5"U5%N_'O]W&'HT\]FE!1PONMT/0<;<^<7Q@W?@NK
M=R[:[,@S.#[FV;BM^=>9"CV]NEHLUMS+]H["Z7IYJE'PJ383(TO9W9F'Q%70
MURT];15$\GGBC2GJ&B]UO2<]++JGY*]>]TXS-YW8.([/KMNX:@R61I]QY7J;
ML/;F!W13XK)9'$U:;)R>?V]CJ?=]2:[%RK%%0&:29=+(&5T)]UH@CCT$^%^?
MO0NX(I6Q6,[OFJD[)K>G8,9-\?.XZ/+9'M+$XK<.=SVQL9CZS9L%17YW;F%V
MK7U>02,&.E@IRSN+K?W6]!'I^WI4;=^:726\L[M_;6RU[.WAFL[0#(U=#MSI
MKM')2;-A3L'=W5=;#V*4VHJ[ K\5O[8.:QU9394TL]+)C)WD18E#GW7M)I7I
M=;J^2_2NR.PMX]6;JWG'AM[;"Z/K/D=NG%5.(SC08[IS&YC+8');N3*0XV3%
M5PQ^3PLZ3T=/-+7Q*8W:$)+&S>ZU0G/2 VS\Y_BYNS.]6;;Q7:-)%F.Z<E1X
M7K2FS.!W-M^/<V;R74>P^\\;@XJO.8:@I*',Y+K3LK#5U-2U3PSSS51I(U:L
MBE@3W6])S\NECN7Y4]$[/Z6H/D)N/>Z8SJ7*9'%XJAW-+A-P2RU%;F-S#:5+
M''@Z?%RY\I%EP[5#_:Z*6CAEJIBE-%)*ONM4-:>?6+=WRFZDV7ONIZ_R=3N^
MOR6'KMJ8O>.<VUU_O/=&R^O<GOLT7]S,?O\ WA@<+7X':U9N"/)TLR)43 TU
M+5P5-5X*:>*9_=>H:5ZF=4?)#87<FZ][;,VGA.TJ#-==UG\+W@V]>I.Q-AXK
M$YEL?@LS#@SFMV[=Q.*K,S4X+<U!7Q4\$LDDE%4K, 4N1[KQ4CTZ'[W[K77O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=0,KE<9@L7DLWFJ^CQ6'PU!
M697+93(5$5)08W&8^GDJZ^OKJN=D@I:.CI87DED=@B(I)( ]^Z]T!?5OR<ZK
M[=R38K;4F\\/45&&Q6Y]O2;^Z\WMUU2;UVKG*HT6'W+LFKWI@\+!N3%Y"JLJ
M+ 34JLD3O$L<\#R>ZV01T]]A_(SHCJG;6XMW=@]M;#VW@=I[=I=W;BJJG<6/
MJ:C&;7KLI282BW!-B\?-5Y5\169BNAI8IT@>.2>144EC;W[KP!/ =*^;L_K6
MF3<LM1V'L:GCV6<<N\9)MVX")-IMF/'_  D;E=\@JX(Y3S)]M]UXO/J&C5<>
M_=>H?3I#[2^2?2&\]M8;>.+[$V]0[8W)/AZ7;69W/6)M"CW)59_'4V4Q-+@&
MW/\ PI\M55E)5H5BA5Y-1TVO[]UZA].A-Q.\MH9_+9O 8+=6V\UG=M211;CP
MN)SF,R.6V_+4/4101YO'4=5-68J2:2DE5!.D99HW N5-O=:ITQ;4[4Z_WIAV
MS^ W1BJC$BNJJ&.KJ*N&A6I\&Z,OLRGKJ9*MX9)L3F-RX*KIL=5!?!D&A)IV
MD4@GW6Z'I)9GY(]%X2IP5!-VCL_)9+=%7NS';;QFWLS1[CK\YE-BX.'<N[L3
MCH,')7^7+8'!5,=544Q*S+'*GI)=0?=>H>E'C.XNL<GL&'M$[TP6(Z_FJ<A1
MC=6YZV+:F(BJ<9G*W;=7%4U6XSBTI6&:Q\L">32)64%-092?=>H:TZ"3M39_
M2/:6]L7)N'LW"XO.X'KC=%%FL-@M_4VW-T2]?;DR&T-^4>YJ?*X//8K=6U1M
MS<O7&,R]#F*:2.-$IY@2T<C%?=;!('#H)_\ 9"_B'VK@FW HSG8F,WE!E:C.
M[PI>V=R[B@[(FRM/N7"Y+.;@R]!G)\9N'*_PO<V1Q\-:@$U#!($IGA>&)H_=
M>U,.A#H_A'T-A=WT786V\%E,3O;$9"KS.&RTVXMP9*DI\P<ON7<V$DKL;491
M%RF)VWNO>.4R-)CWD6E$]=(&5D$2Q^Z]J-*="OT]3;%V'B*;H':F0JI\CTMM
M'8^-R=+D:::GR-1BLSC*M<+NB21XHZ;(1[DK<+D/)44Y:+[^FJ8_2T;*/=:-
M>/0R>_=:Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7N@PH_^9T;B_\ $8;,_P#>KWY[]UOR'0G^
M_=:Z][]U[KWOW7NO_]#?X]^Z]U[W[KW0;[Z_X^'J7_Q(53_[[O?WOW6QY]"1
M[]UKKWOW7N@(^176/8';W6N6V%U]V5C.LZC<E)G=O;GR&9V-%O[&YG9VZMI[
MAVGFL3_"QN':E?C\I2'.19+'UD%>@BKZ")*B*II9)Z>3W6P0#4CK+U_TC0=>
M]A9G>^.SU76TN1Z:Z9Z<I,-64<(EHZ#IW)=E5U%FILG%*HK*O-Q=A^.6(4\2
M1&C#*6\NE/=>)J*= WW7\/8>W<;\C:3^^6.HI._I^@ZMJ/<&SY-R;>PDG1.X
M<9N&GH,OBZ3<VWJW<N'W>^,%/61)5X^6&"1O'(6L??NMAJ4^705Y?^7C0;QP
M<U#N/>FV-CY?&=?;AVIUWE>@^OLIUL.L-XUF_<7V%MKM3::[A["[!R,6Y\'F
M*"6&LIY*MJ#,X^KGHZF,TD]1!-[K>JG1Y>H-@GJGJ7J[JXY<Y\];==;)V"<Z
M:"/%'-'9VVL9MTY<XR*HJHL:<E_#O-X%ED6'7H#L!<^ZJ34D]"+[]UKHAWR7
M^(]-V=U1C=@4G=6<V;@:?=F\LUG,QV?E]Q]C5&23L+9>ZMB'$TFZ,OOC;>[]
MNT^%GW=]SCJ.AR\%#-XOL:BGFHYY83[JP;-:=)_H+X?P_'KN&O[!I.V,/EZ:
MCZRJ,/F-DXG -A<GNBJ&#ZXP<V]=S-N'?VX<%AJ])>M[O4X2@V^F2DK%_BLM
M7)212GW6RU1PZ*%UE\%L9W'TE75>6[=VIM/%9>OWP.P6H]K4FX]T;([4VSL+
MLCH',;2Q':LNXL/B:KK#;U-GI9LEBZ>BGI*_)4]6U+DC15[DZZV6H>'1@]Z?
M";K+;,*[^G[;V/M.JVAF^P.]LYGLYLK"SX_)XF3Y=;!^855G=UI3[EQE?D\#
MM"CV-)@OO3/Z*>N:K#QE?MY-]:U&O#_53IZ[^^&6"[J[,C[RQ?;^UMNQ[P?K
M;([:Q>;PF:EPF?S&&Z^[8V!3-69;:?977F=W'0YC:7:QJ,=2PU$$M-641)DJ
M*>ID@3W7@U!2G2'R7\NG9.'V;G(MK]U8+:V4VHV;J<UN^;8V%R\N+PYZ"Z<Z
MDJ=O[HFK=S2Y2+#TF$Z@BR!:6L2MIHZQ33S0STD%7[]U[4?3KETU\!>L(=M3
M9>D[CVQOZ??-1T_VSMG<])M:"JJ<9M/ _*W?WRUI*C;F0W#O+=&YI-O;TD[$
M?"K6U%=+(\%.*J5ZB61XA[KQ8^G^KATK?C/\)Z'X_P#976V_:'NW9>5Q>-Z^
MCZZIL+MC9R;:'9TN!V1M38>)R61^^[!W;M\YG"X+8U/-/5X+'8_)ULH\-94S
M45/!3Q^Z\S5KCH%MZ_RWNE'[!W+G*[Y#T>$K>[]R=X=98':\N$PU323Q[TZ]
MWKN3J?J?&TXW$GW4?QRW#N/>>],33HD$M1+EYEE$211NWNMZSZ<.A;QOP:V#
MMFLJ]^UO8V&S%%F.TNMLSL/,[=ZNBR5=@?%\T*_Y+P8\9;#9G,RS-N#<^['P
M%9EH$H:2DQD4=74KIAE)UUK4>'^KATM?D+\)=I_(7(]P[SQ^\:=MP[UBZ^QS
MG 4N(I\[1?Z*=J]E8B+9E/OCSUT^#_O!6]CF:25Z:5<=)&':FGUD#?7@U*=%
M5V5\ ,IW/LGN:L[LS'6'6VZ.]=N=R[ V'A=F[(V#44VW:3>_5WQ>V#_?O$XK
M;>^MRX)-V[<K/CA//XL=EJMYJ>MC>2HI&B^VC]ULM2E/+_9Z.-+\7<9-U9/U
M3ANTMEG,87Y.[I^1VS):K:E)7X0Y6;M?(=QR[,[&V;2;NHY=Z4.'K=UR05%1
M3U>*F110U02*:$&7W5=6:T\NO=$_$[8G4NP^W]GT78VV-V'M;KFAP&Y:L[<P
M-/B<=34=%OG%92N7 T^:JX'V1'DMSUD%%BY9A3XZ@HUH?/)XWD]^Z\6)(Z+_
M (#^7ADL7A-O;;Q_R2VNU%N*&&AJL:=@5.;BJ=@XGL+JGM7%8/K7(YOM3)[N
M+Q5O64B39'.9+=$HH\LRP^**CI47W6]7RZ$"M_EF; .-ZOQV"W>NV(-G]49[
MK3L*DP^SJ"GQ/<=7'CMU5/5N[]UXJ'+0T]/F.I]_;WRVXJ(J9I:NMK&2:4*%
M(]U[6<]=1?RXZ7#YF3<VW^SJ&HRNW]Q=6;HZQV]O#KZ+<'7FSLCM+%5([.HL
MAMBEW5B*O/8?NC>E4-S5T:5E'+CLW24DT$C"G"O[KVO%*=)K)_RNMO'K2KV?
MA-_X:/=\[]9&C[$S&P*LYS!Q]>]4;CZR6# S;6WSM7*8_'B3=5768_'/63XF
MFHC_  JJI:ZBDFU^Z]KS6G2YB_EV8.#+[6W&O88DW#@NQ-S=B9W-Q[!P..RN
M]J[/]Z?'_NZ*DS4^)KJ"FA-#5=$)CXWCA\,291I88(5IT@?W7M9Z6GP8^+6[
MOCOLG%5O8>4V<V^<CTWTCUCE]M]=[4CVIM3!TW4N/W;)!/6R19K+KO#>-=D]
M]5L==F@M%%54]+3+'2PA6U^ZTQJ<<*]'P]^ZKT0_>7PXW%NO?V[:F+M;&8WI
M_>_=FVOD3GMBGK^2KWHG9NT]B;:V=C:+&=@?WRI\73[$K,ELW&9>JHY<#-D&
MJ(IH8ZZ*&<>'W5@U!PST#6&_E>;?VWV'M+>VWNX,WC<5@>JNF-DY78XVGCY-
MNY/?G5O<7Q\[3W)VOB%7,13;;RW:U'\><7C\S01^>F:KD.2#-5-4_=^ZWK^7
M1MOBS\5>N_BML4;8VA14%5N+)O5U&\]Z08U\37[RK9]P[AW!!69.B_B&1ABE
MI9MR3HNAR#<GBX ]UIF+<>@DR?P'V5NBCCPN]]S3;JVQ+\PNSOEED\!-B*C%
MIDINQ=C]@;/BV+_$<7GZ;(446WJC?*UT>2B=99I*)4\*"0LONO:O3TIU!Z0_
MEZ=;=4;UVCO'<-?C^QZCJK8.!ZUZ=?)[6APN8V5M[:?:?:/8VW,G7Y;'9=X=
MS;P6C[#IZ#)926EAFRT^*&0J U55U!/NO%R:_/I0=\?"+#]Y]Q47;=;O_([<
MD_A76>S\_@:' TM;'N;K3:66[0RN^^O,CD)LC"ZX3M)]]XY:PB(M2_P*,J)?
M,PC]UX-04Z#/:?\ +1V5C:6AQ6\]_5^\\-2[97"&"/;=-@,K1YBCZ0^,O4>W
M]Z[<S467R-1MO=VT\Q\;*3<>*K8$,]%D:Y1&P-(LLONMZ^E51? /&9;IGXX]
M&]G]N;SWSM#HS"[V&YZC"BKZVS/;F]-V[:S>SXMVY[(;.SE+-@J:BP.]=PB;
M&4I:EJJG*))>-:9(V]U[5DD#CU*ZQ^(W=/3]#+M[9'R:CAP6[).K*OLW.9CJ
MNES/9.5R?5VTMF]9ME=F[FJ]YOM_;]?OSJ[KC!XS+OE,-GA'6PU5?2"&2J$4
M'NM%@?P]&LZ^ZQCV'NONK="9F3)MW%V/C>PI:)Z%:1< ^.ZMZYZT&*BG6IG.
M12:/KY:SS,L)#51CT$1AV]UHFM.EZ8,Y_&9IQD<8, V(C@@QAQ-2<K'G!53O
M-D9<Q_%Q338QZ)HHUI!1)(LB,YJ&#!$]UKIOHZ3>"1;3%?G=OU,U%2LF]I*7
M;5?21[AK?X685J-MQ2[GK&VK3C,_Y08JALLQI_V=>O\ ?]^Z]UQ>CWF:+)1Q
MY_;JY"7<5/58BJ;;&0>DH=JKD<?+4X:OHQNE)<CG)L5%50ID$FIH8YYHY32.
ML30R^Z]CH,]R=X];;3W#-AMR]W]1[;J=S2?W=V'A<[E<9C\K'N[%Y&MP.=CK
M9:O=-,N?C_O%545"M)##0R05L;TS3233HL7NM@$\!T*=-2[J27;AJ\S@YX:7
M%U$.[(Z?;];329O,M3T"TM?@I)-PU*[=QT-5'5.]+.N2DD2:-!.AB9Y?=:Z3
MF$SE;N/'M!@=^;&SN6QVXJ.LR];A\6]?0)M')Y,YO%X@4%+NV>6DS-=LBI@A
MBR;5,E/+4WK%I/$PI5]UO\NGZLI-X.FZQ09W;],]90)'LIJK;5?6+M_)C'2Q
M25>Y%BW/1G=-&V5*3""G.*=8%,7E+,)E]UKIQ:'-_P 6Q\RY#&C"18S(0Y3'
MMBJALE69B6?%MBZ^BRHRRT]!CZ.FAK$GIGI*B2H>>)EFB$++/[KW0>[VZ]S'
M9'6N9ZUWEG</4XW>^'W9L_L6HQ.WZ_&-E]D;MP>XL#6X[;4<NY:^3;>=BH\K
M3%:Z>3(Q%J>7_)AYE\/NMUH:]%CJ_C!\@LY@MD8W=7R1VGF*KJ+)=89;K&GH
M^CAB=MUF9ZXRZ5$FZ.T,=_I)KL[N3<>XL"GV##"Y3;N,HWDDJ(Z1V=(XO=6U
M+_#_ #Z*_E/Y3$^1VAE]FQ]YXVAILWTU!UQF\G3]4-+)NG<M#A=MX_%;IW/@
M*_L*MVNU'C,CM>GJ47%TN*S<],$H*C*S4D,2+[K>OA4>?0F-_+ER7]XL!NI>
MT-GOE.O-U[BWAL"FJ>I'GQ>?R.]>VZCM[<M+WK"=^K5]K4>+RU;+2[?,4V'E
MQ(TU3-4U6MV]UK5T%N8_E*U]9UR>M\;\@*>@Q&2Z[K.OLYHZK;'0(:KJ[KSK
M:GW%@8=M=A;?R%"V*AV&T\&&J*VJP,B5JQU-+.U)3RCW6]>:TZ.OTG\0L!TM
MV&.Q,9N"FK<G58'O'#YQ:3:U%@ZG/U/<_P @,AWM_%<IDZ2OGJ:NJVK+DI,7
M"91(TT;-/JB+&+W[JI:HIT6O;OP"W[48'86,R'9F%V?!MW8WQYZEWSBTV6N[
M*G=^VOA[WIO;L[J#=&U]PINW!IM?(;^H]TNV>BK*'(R1/(H@$,D<CS>ZV6'I
M_J/4>K_E;[?BP^W\-MSL;$8*#$]=;3ZVK='5V.>*IQ^!Z"J>CLKG<?3T6YL:
MF.W%FPE'D?*QG2-:<TSK,&2:+W7M?J.A]WO\/<GN/H38726$[,CQ(V9V-F=\
MUF;R&U*BKAW)09RN[!K:C;\T6$W5MS<FWC23;Z66.MQ>7I*F1J 0REJ6IJ8'
M]UH-FM.J^H?Y778]7F<1TE49B@INF=J;+SL![NKL1@I=^;IW)D^C>H.JZ"CI
M6QF\1NV+9\F4ZYUY#;513T-/%BE:FAS52'IDH_=7UCCY]6H_&[HC,=![>RFW
M7W)MW,T.XMS[RWWGX,1M_=M!JW?NW,4M49\97;M[&WYE8</28JD$4L-3-55%
M56.]29XPQ@]^Z;)KT,HH=^_PO;L)W+M;^,4N;IJC==<-H9,8_-;>2:L:KQ>#
MQG]\3/M[+3P/ L=;-59&*-HW8TSB0+'[KV.@DH^M][O\EMX=OK58C#;=EZZZ
MSZPQ])40S9>LW-A]OYCLC>.Y\@(Z3)8U,#61YK>>/I:&:H%9HBHZZ]/:JBEC
M]UZHI3H:)Z7=C4NZTILU@HJVL,_]R:B;;M=/3[?#82CIZ;^\E*FXX)-T^+<2
M3U3_ &\N*UTDJ4PTO&U3)[K70>9#N;KG$Y?/G*=S]48S%]:[(S>ZNUL;D<YA
MZ+)[8Q=+F:G"P[WS60J=SQ1;/V;B,GM'/T57)6TLL4M73N@J86HITE]UNA].
MEECJC<&7V\E1B]U[5R->VY:HC-T6 JZC"O@*#>4\=;@DQ\6Z7E_CU+MRFDQ<
ME=]X8ERB-5FE\8-%[]UKJ7DLE48?)32Y;<FW<;B,V,+@=IT5=0O2UPW=4R9@
MSQSY.;-I3YM<O&:1:2AAIJ6>-Z:;]Z;SHL'NO==X^CWG%0[/CR>?V[69&A@B
M7?E51;8KZ"DW)4+A*FGGEVQ13;IKY=HQ2;B:*J5*F?,%*1&IBS.XJ4]U[&>N
MZBCWDV,W/%39[;T.7JZFL?9]=-MFOGH,%2245+'00;@QJ;H@GW+/39%)I99(
M*G&+-#(D:I&R&1_=>QTJ/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW084?\ S.C<7_B,-F?^]7OSW[K?D.A/]^ZUU[W[KW7O?NO=?__1
MW^/?NO=>]^Z]T&^^O^/AZE_\2%4_^^[W][]UL>?0D>_=:Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[HG'S3^-.Z/E%U]@=B[>W5M?;=+1YC<-5FH]
MT;7BW##74V>Z]WALFDJ\;5V:NPV1V]6[H6O'VI@FKHX7I?NJ59FF'NK*U*]%
M2JOY84\NWX/%O[:3;\?+[CRFYMVU>R*FHE["QM?L;JK;F-V'OV?^-+F-P=?U
MV6ZNC;+8^:I>.JH:R2- LH\C>ZWKZ'#;WPET]&[.Z?W55];OC\5\I\C\CMP[
M9VWL>2EZUJ<7E>Y]R=N2];XC:F1KZJ-,52-GDHUEGU0RR0&8TT:N(4]UK5FO
MRZ*M@_Y3VX,=L:@ZTR79^Q<QA(]K5V%EWA6[!KZG?>#HH=C]J;"PW6>TYZK.
MS4%!TQ58[L*GJ,AB'-G>FJX4736QRT6J=6UYK3H>_E'\'-__ "(ZQZGZ]H=]
M==[.&R>F-R=;91UV/-74F)W1G,1L6BH-Y;%J(ZFESV,Q^WY=HS1T^+CJZ#R"
MH@FEJ'-&L$V^M*P!)Z6G2GPTS76F<^3!S&Z]IU6T._,7F\6N PVUIZBHAK-Q
M;@[$SF6W'FLQN>NRVXZK[J+?[0MA9,C6XN.>*>HI?M(ZLT<'NM%JZ?4=%#HO
MY3.Z)*"MQF6[2V=$E9U9E]E#(X?;^[Z.6DJ,Q\<-O?'5]H4>(I-U8W$OU714
MN .;AQ]8*U%JIQ$D$<\"9!M4ZMK^70F;T_EL[ERF^L=E=E]@[!VCL;#]R4W;
M&V=LT'7L>,K-B_;=R[![8K<#M?(8BIIJB&@W&FSY:*:G@FH*"EJ*J2L:GJWE
M>(;Z\'QD9ITE9?Y3]+0P[<CV_N/J]8<7UGTALG,XG*=<Y2+#;@W1U_U+\H.I
M>P.R*QMM;JP&;BW7OG&_(.BJ164]93Y,' 1QR5IU12T_NO:_MZ,1MWX7;QH?
MBM_LON2[%P,&5';^#[+H,QAML14^-P6&PO:.!["CVGKH$P-=N>M>+#R0R9FL
MCCK:F6IUSB5D+2>ZUJS6GEU)Z[^"=!UUU1W=U5MK=F,VCC^X_CQUKTS)D-D;
M97;[83=>S.L-R==Y[LPT5)D((\CF-S',4U3*2\56Z421RU+G0Z>ZT6J0?GT%
M%5_+UWAE]PXC.R9KHK8*U==UQ+74G4W5V4VM+U!'UCV=2]CKF?CY72YZH7;>
M].T5IOX?N?(SP1">&.E813+2F&?W6]726J?Y4>&BV9583;^Y]B;<W56=:;+V
M//O'$]>+19-\IA^H>^^L=Z[@:II<K#D6??U1W#1U=<#/Y:B/$+%/),?$T/NO
M:^ECFOY9N"AJ]YU^P<KU[LQMQ[@WCFH\-0]>14FW\Q@\QG/C=NC#=9;UHL3D
M<<V;ZVJ<KT16PY;'H4BJ:;<50T:+)Y3/[KVOAU.V'_+H.V]V8WL++;FV,V[J
M#L3J??V%3;^R):+%]:X_9G=O=_;.[>M^K)JG)29#;6Q]P8CMY,-'%$85DCHY
M9)X3%.E+![KVKRZM(]^ZIU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=<2RK^IE7@MR0/2+ GG\
M D?[?W[KW44Y''K]T6KJ-10E!6DU4 ^S,JAXQ57?_)S(C KKM<&X]^Z]TP[1
MWQM'?FW<%NS:&X,;GMO;FPE'N7 Y2BG!AR>!KT#T>6IXY1%/]E4*?2[(HOQ]
M??NO4IUPKM][/QVY=I;/K=PXZ'<N^Z/<.0V?B?*9*C<%%M2#'5.XJG'-$KPR
M18FGRU,TI+#B9;7]^Z]U6?U1U+NR'8U1V3L#LSJ3([0W_L:?#[NW%O78]?V>
M^<ZZZ^[L[>[+PO:.QL+C\W2#,93>.W^SZS[_ !F2I=%-FDAJ56<H\%3[J]1P
M(Z0.TOC!NWM;/8_);;^3>WMTP]*]H[?Z^Q=148'L.:"*KZEW9OK<FXVR--N?
M//M;?F_%H-^C%Y*2AA\=!4T'C@R%)/3U$3>ZV33R\NC??%GHVOZ"R&3Q.2R6
MU*7;.WNH^L.IMN-@9J?'4.XEZVW!VON?*;LFP\E74RXN:"@[&I*"99)&<3T4
M[C3 8+^ZJQKT.W</R#ZEZ$HL!DNU=R5^W,?N?)08?!UE'M#>NZJ:LRU97XO%
M8[&/+L_;N?2CK\ME,U2TU%%.8GK:B98X!(]U'NM $\.A+QFY<'EL=C,K1Y&(
M4F8IL954 K4FQ=8Z9BE2LQL,^,R<='DJ&NJ:=P133PQU"D%60,I ]UKIPDR.
M/B6I:6NHXUHVC6L:2I@1:5IM/A6I+.! TNL:0UM5Q;Z^_=>Z1F#[1V%N3=F^
M-D83<=-7[EZWR>W\)O6B2FKXJ;"9S=&&BW%A,$^7J*2'#5V<J<%4PU<E'35$
MU3305$+3I&)HM?NMT.#TM?OJ'S+3?>4OW#R/"D'W$/F>:*(3R1+%KUM)' P=
ME N$-SQ[]UKIBI]Z[1J\[N+;%-N7"S;AVC%@)MT8=,C3??X"/=25;[;;*TYD
M#T7\<2AF-*'L9A&=-_?NO=)O=7<?6&R.P>L>JMV;TPV![#[GDW=#U;M7(2RQ
M9+>TVP\-#N'=\.&M"U/)-@\+4)4RH[HS1GT!B"![K=#0FF.HG7G>/4W;%#E,
MIUSOG#;MQ&%R6XL-DLSBS5'"TV5VEO'<6P-RX\9B>F@QL]7AMX;3R%#.D<KL
MLE/J_P V\;O[KQ!''H3364@GDIC54PJ885J9:<SQ">*G=F1)Y(M7D2%F0@,0
M%)!Y]^ZUUZ"LI*IG6FJJ:H:)87D6">*9HTJ(Q+3NXC9BBSQ'4A/#+R+CW[KW
M0<[ [HZJ[3BWW/U]OO;VZH.L=][@ZRW]-C:R\.UM^;5:GCW#MO*2SI"D=;BY
M*I%D92T6HD*Y*L![K9!''I7X+=>VMSS;AI]NYW%YJ;:>X*G:FY8\;60U;X/<
MM'0X[)U>"R8A9OM,I34&6II7A>SJDZ$CGW[K72@]^Z]U[W[KW7O?NO=>]^Z]
MU3]G/Y;>Z.P\&U-G]^8_;5=7=9[@Z%WW%-@USZ]D==TV^NY=^XK(9"M@RU*8
M_P"]&_MR;6S]5')'YHXZ3*43@FN$T7NKZ_ET(.Y?Y?F\<_'F,A#WGD<7N^J.
M7HL-NNGI]RM78;;.9E^1E3E-IPJFZH&CP>=F[EP\=>D#P--!MZ+2R21T;TON
MO:_ECJ1B?A%NS;5'G:_^.XC+;FW=NCINEP-+@?XGC-K]!;)VC\BLOW=NW#];
M4V:RU2\6"CH):*EHH8(()I:RAA#)'2".&F]U[5U9Q[]U3KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@PH_\ F=&XO_$8;,_]
MZO?GOW6_(="?[]UKKWOW7NO>_=>Z_]+?X]^Z]U[W[KW0;[Z_X^'J7_Q(53_[
M[O?WOW6QY]"1[]UKKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB5?+#XY]F=WU^%
MJNN=Y[0VM%5=<;_ZHW>N[,;G\@\6W]\[PZGW@VX-MK@LA0+)G\:_6#4:0U16
M%DR1F\@,'AG]U92!QZ+4W\MG(8:?;&:V[E^K,KD,4\V5WWM/=>SJY]C=Y9X]
MO[X[ QTG;,-)-4U6X8-OX??,@Q\U7%724N4H:=U0P QCW6]?038'^4OO'&84
M;:R7;&V<G12]38#84N8CQVZ,?4T,&-Z/VSTMD.NL3AJ;)AO]$50<)49J"CK,
MG5I#559!HS5(N1]ZZWK\Z=6&=M=";L7.=$[T^.B]7;+S70U+OO;FW]B[IP&1
MQG6U3L[L+;^.PU?CJ*GV/]G5;=J-OUF!H*FC2GIWIY8HY:=EB\JSQ;ZJ#Q!\
M^B@4G\L&?$;6./Q._P#;0WK#M;'[.I.Q9=IU5+N), /AYV%\=L]AX:JFRCUV
M.V]F^Q=ZP[H.-BJ33JE%'&_EJ8XJE?=;U_L_V>ID?\MS-8C<5#7;:W-UICJ2
MOWI_>JMSB[+JZ+>'6=71_)+<W?4NX.FZO'U$=+C-W]@X+.T^V-Q5508C/1XR
MED+5$$9H6]U[7UGV]_*WV#B?]'D=?C>J<I2[.H_BQ2Y*FJ.O:>H3-'I6E["7
MMAI362U!E7NNOWNLV1\_E-:86^_^ZNNG77M9S^?1L8/CEFH_C;T3T7)NVBFR
MG4&5^,M?7;DDH:R2ES<'06_>OMWU]/2TDE6U52MGZ/93TU.9)9/MVF5GUA2#
MOJM<D_;T3[O/^6OG>Q,)EJ#8^Y>L-KYS>/8?R0[!WIO&MV-$^[JS<';?8L&\
M.LMQ1[G2CK]Q5&0ZGV_"^)BIX*O&2/Y8Y8*VGAIC1U'NK!Z<>H6[_P"61D\I
M@L[!A-Q]?G,[E.<R>YGJ\-F,3'NS===WYV-VS@=S[BKJ4YFAS^3VMM[?[8N!
M<[B<_0R1120M2+%+$U-[K>OJ#OC^5_N3<M70Y>G["V0^:KZR9]XO1[2J=C8S
M)Y?)]._'KK:?M*@I-J22UU'V%M?+],9*LPPIJJBEI:;<<T4&0HW1Y9O=>#]+
MJE_EVY3;O8/2.^]GY_KO%YG8?9>[]_;]W/4;6JZS/[M_O5WE6=JY(S8_*-F,
M+E<_E=LSQX),N!B\WBFACFAKZBCC7&>_=:U8/3YW_P#!/<O9_=6_NVMOU'3>
M5H=[T.RA7[+[-VCE,GA\WE=N]:]G=7K7;L;%.6S)VE2;XI<M@&9?)!64]1!>
M S0UE/[KP:@ STK^Y_A?O3?^V.CX-I]O)B>Q?C[TQD=F;![,W1@JK/9<]JPY
MSHO*[?[.R](F5A:LCJ*;JC(TV5I//Y*N'.2*)@ ^OW6@W'&#T#6V_P"5[B<+
MG\)0Y/<6TMT=38+<>:R</7.X]KU&8Q^1Q=2/E"<+39FEKJN;$9/(T55WSC:J
M::6G99:O#O*%#O$8_=;U_MZ23?RP=]9+;XV?N+L;8&5ADQR_Q[LZ7;^XYNU]
M_4-=U;M+K7)=0[SRDV2M6=-XYL%+D**F:JG=FI\?$:>)Z>6IJ/=;U^?1D^I/
MA_O7I3N'Y ]C=<YSK+:N#[&VGNC'; VSC]IU-138;=.1R--D]G93+/5K_&,-
MMK9T=,:27!4&3J,/5K+YJ&EPZH*5_=:+ @ ] E3_ ,L_<NR*;;%'LOMJE[*V
M]1X#JF3?_7??V%H<ULKL[>G4-=N<X.NSL>T\-BF_@F<INQLW69!:ZGRU1+EJ
M##S2-.M(5]ZZWK]1T;#XK?'7=7QRD[!PQDZJEVMO[>D_8-:^QMK9C:-;!G:C
MK[JW:2XVGQ55D\W3IA:'(;1R9A:>NJZK[*6C1G,D<S/OJK$&G'HS+#?/\,J=
M!VG_ !G^\Z_9EES'\,_N9_>2#6*D!_NCN?\ NAY "A^U_B6DV\-Q[]U7'3/N
M'?\ @=E9/)U6^-[==[3VJE+MNCQD^X=QT6!R:;DRU1N#RTN3GR]=2XT4N3I:
M&#^&QQVGFDAJ[Z@JV]UNGH.G*BJMVG%[4J:^KV::J!O^,C5%%)D_X7&E/A,B
M*_\ NI)-*9(6@W*E/_P.)"T(F#?NZ??NO=<,C7;KI,7N0K6[*ILS75]31]<'
M(S9*'%U3SXBF;#4NY+2K555?+F(ZDRI0&[4@30-8<^_=>Z?F_CW\<IM!Q']V
M_P"$5GW@85G\<_CWWE!_#S3,#]A_"/L/NO,''F\WBT^G7[]UKKV"_CW\,A_O
M,<0<SY:W[@X(5HQG@^^J?X=X1D"U5Y?X;X?-J-O/KT^C3[]U[IW]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=!A
M1_\ ,Z-Q?^(PV9_[U>_/?NM^0Z$_W[K77O?NO=>]^Z]U_]/?X]^Z]U[W[KW0
M;[Z_X^'J7_Q(53_[[O?WOW6QY]"1[]UKKWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NDOA][;.W!N'=NTL%NK;V9W1L*IP]'O?;N,R]!79O:%5N'%19
MW!4VY<933R5F%FS.%G2KI5J$C,].PD2ZF_OW7J'J%-V1U_3X*/<\^]=KQ;=E
MW#4[2BSCYS'#%2[IH]P5>TZO;D==]Q]O)G*?=%!/CGI0QG6MB>$KY%*^_=;H
M>IF&WQL[<55%18#=&!S59-2U5:E-B\I1UT_VU$F%EK'DCII9&B-)%N/'M(KZ
M71:V$D 2(3[K5#TJ??NO=-+Y["1YVFVQ)EL<FXZW$UV>I,$]93KEZG"8RLQ^
M/R.6@QYD%5+CJ&ORU+#+,JF..6HC5B"Z@^Z]UWD<[A<1586ARF6QV.K=R9.3
M#;?I*VL@IJC-Y>+%Y+-R8S%0S.DE?7QX;#U=48H@SBGII9+:48CW7NN.+S^#
MSDN8APV7QN5FV_EY<!G8L?64]7)A\Y!245?/B,DD$CM19**AR5/,T,FF01SH
MQ%F!/NO=._OW7NFVCS.*R%=E\;0Y"DJ\A@:FFH\U1P3))48NJK:"FRM)3UL2
MDM3RU&-K8IT5K%HY%;Z$>_=>Z@XS=>V,UD*O%8?<&'RN1H$J7KJ/'9&EK9Z0
M4>8R6WJU:E::63PR46>PU71S(UFBJJ:6)P'1@/=;H>E![]UKKWOW7NO>_=>Z
M][]U[IHKL_@\9DL)A\CE\;09;<M36T>WL;5UE/3UV<J\=CJG+U]-BJ6619J^
M>BQ5'+4RK$&*01,YLJD^_=>Z=_?NO=-5!G<+E*[-XS&Y;'5^1VS7TV+W%0T=
M9!45>#R59B<?GJ2@RU/$[2T%94X3+4M6D<H5VIJB.0#0ZD^Z]TZ^_=>Z][]U
M[IFW!N+ [3PN1W'NC,XS;VW\13FJRF:S5=38W%XZF#*AJ*VNJY(J:FA#N!J=
M@+D>_=>X]->=W]L?;&0Q^(W'O#;."RV6R&!Q6+QF6SF-H,CD,ENFNK,9MJAH
MZ*IJ8ZFHJMP9+'5%/1(JDU,T$B1ZF1@/=>Z5OOW7NO>_=>Z9MO;BP&[</1;A
MVOFL7N' Y)97Q^9PM=39+&5J03RTLS4M;222T\ZQ5,#QL58V="#R#[]U[IY]
M^Z]TGGW;M9*2HKO[Q85Z*DS\.U:JJBR5)-!2[FJ,K38.+;]3+#*Z09ELS614
MIIG(E6>14*AC;W[KW3S65E)CZ2JKZ^JIZ&AH:>>LK:VLGBIJ2CI*:)IJFJJJ
MF9DAIZ>GA1G=W8*B@DD >_=>Z:-O[KVQNR&OJ-K[APNXJ?%9)\/DI\)DZ/*0
M4.5BI*.ODQU5+1331PUB4.1IYC&Q#>*9&MI92?=>X=/_ +]U[IHH<_@\GD<W
MA\=E\;797;531T>X<;25E/45V#J\CCJ;+T%-E:6*1IJ">MQ59%4Q+*%9X)5<
M75@??NO=._OW7NH62R6/PV.R&8R]=28S%8JBJLED\E7SQ4M#C\?0P255;75E
M5,R0TU)24T3222.0J(I)( ]^Z]TU8W=VULQAJO<>+W%AJ[;] *QJW-T^1I7Q
M-(F/C,U=+49 2_:PPTD(UR.SA$3U$VY]^Z]T]4E729"DI:^@J:>MH:VGAJZ*
MLI)HZFEJZ2IC6:GJ::HA9X9Z>>%PZ.I*LI!!(/OW7NI'OW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NJRNZOBYVAV7O;L[)8?#;:K*Z?LZ;>.T-U;@W=EMEU]-M?=?
M0&R>K'Q.#S&/VMV;M_)46!SFULLF8V]N':^2QN5H,LDD<M/*7$ONKA@*= -5
M?R]OE)+@9=@TW;NQ\5LRKI^V*?.';>ZNT=M8[=,/;=!VZ-U4E=U]2P5FWMOX
MC(Y#?N'%/0XRI@CQL&$.F2>]+'3>ZWJ7TZ$C'_$_Y.8*OW/5[@[(R6[HMS[M
MZ\DVS0TF_,OGL3LU\7WML;L'&;A7 Y[:N#BP,?3'76W*O"4573Y"JJ<Y&P\]
M/$T^A/=:U#TZMF]^ZIU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW084?_,Z-Q?\ B,-F?^]7OSW[K?D.
MA/\ ?NM=>]^Z]U[W[KW7_]3?X]^Z]U[W[KW0;[Z_X^'J7_Q(53_[[O?WOW6Q
MY]"1[]UKKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ9:CX(?);%UV
M5W_1]@[<W9N7NZJR.=^3O7%5EH]G[8W)'0]\;?[HVWL+:N\]N;,IMU9+#'9D
M.:Z_>JS4E08L)E$ 7[=)(6]TYJ7AZ=(.+^7E\@XL?L_&KB^O%BQN[<9O':"#
MMS?1I/CFM!\@>\.U]P8#9Z_W7$^_*O?.W^QL'#/7U0I9%KL2XD+14V/8:ZV7
M'3Y@_@/\A]K2R"#^Y>8V]_>V'>O8FT(>RMU8VC^08RE)\9Y-R[<W9,^ ,=%/
M-6]79S74U@JH\C:GBG"TU=5B+?6M0Z<L3\#_ )1XG%3;GI-Y[27M/&S44'7R
MY;M7MS-[<V'L2IV)WYAZOJ-<WX\=N/,;8Q%=V%MO'/7!:>ORE-@XJMVAGI:1
M4]U[4#T.'PQ^*/<G2?9>6WAO^MQ$>TWQ79V-VCMJ/=<.Y<KM>@WVOQTKX\6J
M8?9.R]JXVEEW-UGN"NGI\?3K!'+7QOJJ)IJB;W[K3$'AQZ*]3? WY.S[IGW5
MOO;'6_9&%FWEM3>.Y>L:ON;=&W]M[LW=B,%\I=NYW=N%KJ'8,F6Q<=9!W%MM
MX#FJO,9BKI\1+'5U:BGH8Q[K>H>1_P!6.N3?R\/E/)-F\;_?G T.7S4&1;L+
MN7%=K]AT6Y^\</F?CYU7U/+L3<N$IL32R;?BHM^[/K-QC*K55%4KTU-+%IJZ
MVN:/77M2]"3_ +(U\BMN[T[GW%U[O*GP^3ICO3=/1&8R7962&SJO+8G>O7V]
M/CGUMN_8F+V)%GJ;8O6N.V9-MO(/4YO*1)B*N;[&E;^(5D<>^O:@:5Z2':_P
M+^5V4V7N'9&S]]X?<$62IVR6W]RYKLS<^,W-@.SXN@NM-H8_L'[[,;6WA0XO
M&CMG#;CRU0N.HQFZ<UM))C:NB+U8]^Z\&''IV3X*=[8+<.7JJ7!;%W3UD.RN
MS-V9OI=>U]W;2P7;T?8'9OR2W[B\_G*VAVW40X#,[9K.XMNUDL+QU0J:O;C$
M2%HZ)Q[KVH?GT[57P)^0/\ K:_*]@C>7963P=9LW=N[8NW.P-J97>.QW^)O4
MW6#8&FR\V&W%2X1JON[962SJ>;'5E.\E2*RKBJ)*FL@;W7M0QC'^ST/V(^+/
M9&X?CU\>.H.R9MO5-/L/NRJW9V+M^AS^7HL=G.HH:WM"3;VS<K+@*7%XS<&7
M@QVY,*N4HJ>FQ^WIJJEF6DIH*-*> >ZK45)'IT3O=G\O/Y/0]04G6^S]Q[;J
MY\MUOLZ/<-?6]K;R&6H^_L)TAGMBU/:E)G-T[9WE3_:R[VJ:.LK:R.@;/NE+
M3ST$M%4Q,Y]U?6*]'3^)_7':V%[9^0VXM[9;<]7LC;.<DV#T;3;G.[:/R#<S
M4W9_>.9>BW%%13[@P1[BSDN*P&51&A?"X=(Z.0TQ5F]U0D4 Z)1M[X _*V2E
MW//NC+;;A.;PE%-78+;_ '#F\.U3OVJZT[:V3V)N39V>I^MJN;:R;SJMV8I:
M:HS$>XLE6T5(%SDU8-<!]U<LO0H=<_#CY/X'=G7&4W-5[-GEP&?ZAK=N;UQW
M9&Z<?END.O\ KKM'=>Y=[]<8[9.-P,.T=UUW<?762I<5EZF@_A>)EK:NIC^S
MAQV/QD/OW6M2T/3O\@OA?\@>QNWN^MW=59G;W5V1[,K&S&"[HQ?8^ZZ'=TFW
M8?C!2=.3=0979U)MZ?%XG'YSL*EILNV9AFJWHX:.*I2!ZR"G1?=:#  5%>A4
MV)\<N[MF_&'L?8>#:+#;SR7<>W.S^N-EY;M23+XW!;:VKNOK+<]3U_\ WOVQ
MUWL[%[3H]X/LK)AJ/&XB?&4<F88L9EDG'OW6B03T6;=GPI^:V[,IGMQX+?V"
MZR[%WGMWY#XVDWU3]L;HWAB^JZ/MG/?([-;6H-L8J;96%W/C=W[2D[1VZD.3
MQ.2I\-+%CI348N6?'XJ;W[[>K:E_+'25SW\O/Y%YKKZLVH]!M_+X;+T>X,5@
M.O=Z=ZYFMPO4^Z:__0G-%V_ALCM+J[:N.RM563=?Y]&Q8Q_F/\6$\E0TN3RZ
M+X_+KVH5Z-/\J_A-N#OSY';*[$@P&QLCL@'XU1[XJ\WGLMCL[+A>CNZ-\]@Y
M[;D>+H,5.F4H]RXC>L?@O5PH9:&2&<>*8'W[K2L *>?1?E^!_P M(]OOMR#>
M^"7=<.U\MBMO=QS=M=@OEMM[&@Z-W?UIA?CW'@EPS35&U:[?F0QVX)LQYC+#
M>28PR5U'2,_NMZAT&W?G37RTD[,J-S;BV/N#=N8[5W!D<KUUL796]>WL_MKH
M7.5_:_1\]/NVC[!VUM&AVG3;QDV5MK(PUL&3&$Q\&/AD6GR$E/5Y&!O=;!6G
M'H\?QX^'W8/1>$[1Q&+RN"QB[_Z..W'BPNYMRST,O<\F_P#O;/5.]F@KJ.-<
M:)]M;]P5+]W3HD^F@$/B$=+3^_=5+5IT73+? +OC 82+"[2J=N;DVU4; VKC
MJG8V4[?[$P&-IN\WZ0_T?Y7Y!'-+C<KD*G<6UM\4<.31K?=UQJ),@K1Y*"+R
M>ZWJ'GT9/8OQ6[7V7TGV)UK0Y; 46[=P?+[!=XG>F.SV6Q[;YVU+VYUMV3O7
M.YU*3'K5X;<^X\9A<I0U..!J:6>4*&G,,[:/=:U"H/RZ2GQZ^$G8_6/Q[[&Z
M>W=GL/E\AVE\,>H.H]X2U6\=Y;MQN=^0N,Z^[1V=W-V%E:O<<,N1FHMYMN+!
MJ]<@%7704 \L$9AC#>Z\6!(/SZ+_ $'\NKY 8C8&:CV%N';74>_-X83>N&W9
M_=+?^X_%D-L5NQOCU@MM; ;*OMJ:@CH99^JLS0FO7',^-ARIJHHI9)JB)O=;
MU"N>'1G&^-?=E-\2:/IVACQM7E:KN)=TY79VXM^TV:.*Z@J>QI=S2[ V_N2'
M86(V,<EC\+XDI\=6;=JML4R^2C%//3QPL?=:J-5>BC[8_E\?+;&888V+=.TM
MJ=I5FT=EXU?DGBNVM\9?=F#I=G=$[FZNJ-A-ACM7"2Y7&Y_-5N.8Y)&@*TD'
MW9@2LH<?%[]U8LOY>G0Y;>^%_?W\;VUD,/G<1TML+.]IL-^=08#LS>6\Z':/
M2.+VOUCN6CQNQ\U4XO%P3[OW%WWU3+6UJ>.FI1M_=^5C:1ZAW23W5=0],]*'
MXT_$7O+K?JCY ;*W]GOO]P=E=*XCKR.OR?9']\<3O+M&EVUOW$[N[<JJ&CZX
MVA)M<;XK]QT4D\M3)E\U5QP6K9&-- 9/=>+"HIT#&5^ OR1R><@IZO.;5RF*
MR6#[0V;D*O-]C;CR^UL9L#?>'[*PU5MZ#9-3M&/,8K,RT6[:".EJL1EZ?&RP
MPO#E,?61T>/*^ZWJ'5I'QTVUNG8_3?76P=U[0P6S*O86QMC[.I\7M[<S;HQK
M+@-G8*@KY(*Q\)A&A@@S,-3!"I1VF@A2=BC2F&/W5#Q-.AN]^ZUU[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=!A1_P#,
MZ-Q?^(PV9_[U>_/?NM^0Z$_W[K77O?NO=>]^Z]U__]7?X]^Z]U[W[KW2!WW@
M=PY<[3R&V),-_%-K[G&=6FSTE=!CZVGEV]N# 3TYJ<?3U533S*,V)4;Q.I,>
MD@:KCW6QTW>?NC_G5]8?^?[=?_V-^_=>QU[S]T?\ZOK#_P _VZ__ +&_?NO8
MZ]Y^Z/\ G5]8?^?[=?\ ]C?OW7L=>\_='_.KZP_\_P!NO_[&_?NO8Z]Y^Z/^
M=7UA_P"?[=?_ -C?OW7L=>\_='_.KZP_\_VZ_P#[&_?NO8Z]Y^Z/^=7UA_Y_
MMU__ &-^_=>QU[S]T?\ .KZP_P#/]NO_ .QOW[KV.O>?NC_G5]8?^?[=?_V-
M^_=>QU[S]T?\ZOK#_P _VZ__ +&_?NO8Z]Y^Z/\ G5]8?^?[=?\ ]C?OW7L=
M>\_='_.KZP_\_P!NO_[&_?NO8Z]Y^Z/^=7UA_P"?[=?_ -C?OW7L=>\_='_.
MKZP_\_VZ_P#[&_?NO8Z]Y^Z/^=7UA_Y_MU__ &-^_=>QU[S]T?\ .KZP_P#/
M]NO_ .QOW[KV.O>?NC_G5]8?^?[=?_V-^_=>QU[S]T?\ZOK#_P _VZ__ +&_
M?NO8Z]Y^Z/\ G5]8?^?[=?\ ]C?OW7L=>\_='_.KZP_\_P!NO_[&_?NO8Z]Y
M^Z/^=7UA_P"?[=?_ -C?OW7L=>\_='_.KZP_\_VZ_P#[&_?NO8Z]Y^Z/^=7U
MA_Y_MU__ &-^_=>QU[S]T?\ .KZP_P#/]NO_ .QOW[KV.O>?NC_G5]8?^?[=
M?_V-^_=>QU[S]T?\ZOK#_P _VZ__ +&_?NO8Z]Y^Z/\ G5]8?^?[=?\ ]C?O
MW7L=>\_='_.KZP_\_P!NO_[&_?NO8Z]Y^Z/^=7UA_P"?[=?_ -C?OW7L=>\_
M='_.KZP_\_VZ_P#[&_?NO8Z]Y^Z/^=7UA_Y_MU__ &-^_=>QU[S]T?\ .KZP
M_P#/]NO_ .QOW[KV.O>?NC_G5]8?^?[=?_V-^_=>QU[S]T?\ZOK#_P _VZ__
M +&_?NO8Z]Y^Z/\ G5]8?^?[=?\ ]C?OW7L=>\_='_.KZP_\_P!NO_[&_?NO
M8Z]Y^Z/^=7UA_P"?[=?_ -C?OW7L=>\_='_.KZP_\_VZ_P#[&_?NO8Z]Y^Z/
M^=7UA_Y_MU__ &-^_=>QU[S]T?\ .KZP_P#/]NO_ .QOW[KV.O>?NC_G5]8?
M^?[=?_V-^_=>QU[S]T?\ZOK#_P _VZ__ +&_?NO8Z]Y^Z/\ G5]8?^?[=?\
M]C?OW7L=>\_='_.KZP_\_P!NO_[&_?NO8Z]Y^Z/^=7UA_P"?[=?_ -C?OW7L
M=>\_='_.KZP_\_VZ_P#[&_?NO8Z]Y^Z/^=7UA_Y_MU__ &-^_=>QU[S]T?\
M.KZP_P#/]NO_ .QOW[KV.O>?NC_G5]8?^?[=?_V-^_=>QU[S]T?\ZOK#_P _
MVZ__ +&_?NO8Z]Y^Z/\ G5]8?^?[=?\ ]C?OW7L=>\_='_.KZP_\_P!NO_[&
M_?NO8Z]Y^Z/^=7UA_P"?[=?_ -C?OW7L=>\_='_.KZP_\_VZ_P#[&_?NO8Z]
MY^Z/^=7UA_Y_MU__ &-^_=>QU[S]T?\ .KZP_P#/]NO_ .QOW[KV.O>?NC_G
M5]8?^?[=?_V-^_=>QU[S]T?\ZOK#_P _VZ__ +&_?NO8Z]Y^Z/\ G5]8?^?[
M=?\ ]C?OW7L=>\_='_.KZP_\_P!NO_[&_?NO8Z]Y^Z/^=7UA_P"?[=?_ -C?
MOW7L=>\_='_.KZP_\_VZ_P#[&_?NO8Z]Y^Z/^=7UA_Y_MU__ &-^_=>QU[S]
MT?\ .KZP_P#/]NO_ .QOW[KV.O>?NC_G5]8?^?[=?_V-^_=>QU[S]T?\ZOK#
M_P _VZ__ +&_?NO8Z]Y^Z/\ G5]8?^?[=?\ ]C?OW7L=>\_='_.KZP_\_P!N
MO_[&_?NO8Z]Y^Z/^=7UA_P"?[=?_ -C?OW7L=>\_='_.KZP_\_VZ_P#[&_?N
MO8Z]Y^Z/^=7UA_Y_MU__ &-^_=>QU[S]T?\ .KZP_P#/]NO_ .QOW[KV.O>?
MNC_G5]8?^?[=?_V-^_=>QU[S]T?\ZOK#_P _VZ__ +&_?NO8Z]Y^Z/\ G5]8
M?^?[=?\ ]C?OW7L=<MK;?W@N\<WN[=IVU3R5VV<!MNBH-N5.4K4"XG*[CRD]
M;55.3HL>R--_&TC2-$:WC+%N0H]U[H3??NM=>]^Z]U[W[KW7_];?X]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__7W^/?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=?_T-_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW3)N;,C;FV
M]P;A-.:P8'"9;,FD640&J&+H*BN-.)F2183.(-.HJ0M[V/OW7NB!]3?.[-=@
M;)WYNS-].O@5V?T9N7O'$UE#N'<LFW=[8S [<V_GCB-O5F[NN-D9^3P5>;DQ
MM97?PQZ2.NHY13M5+<K[JY6AX^?7-?GFV%K^G-L[OV#BJ??';^V>R=QX_;-#
MN7=6UJ^EEVMA:S(;"PE)A^Z.MNI]U5];V7E\36XVGJ)<=24--40+()IHI P]
MU[3QIU/ZU^9N\>P^P.N.OAU=B,9D=PT>7K-_2QU?=-?/L>3&;F7 _P &KL4W
M0%#7[4SZ4TB3S0[S7:40+IX):B"2*H?W6BHH37IES_\ ,*HMO=H;MZOJ>I,K
M/D,7N.+:6R<E%NW%4]%V!NF'L'L;9N5VG12Y#'T=/A=SPX;8L>9I(*F7P5E)
M/4@3)]A,[^ZWHX&O35B?GMO/)9.DPK]/XB/*XK9^]]X[]HHLCW;]YMB+:45)
M518#(XRO^.V.RFR,[5TE8K.=XP[9HF4I-23UE/-%,WNO:?G_ *OV]/?3/S2[
M-[ER?5T6(ZAV-0X'>O9&:Z[W!FZWL/L'%56(JMO=9T':6:J<!MG=/1^V=QY2
M?&8R>HQDL.2I\,CY2G#0RS4D@J![K14"N?\ 5^WI497Y>[T@[4W'T]C>J,)!
MO"MWL-E]40;LWMN#;5)O&*B&8J<UO/+Y'_1OD<0NS*?&8"JDCGVW5;GJ:>M,
M..R4&.K9A&/=>TB@->F';WSAW+N?:66[,Q?3^(3KO;^7K=A9V7(=IT-!O*F[
M0PVW\3FL[B\9MR;:WV&X-FP5F2>BILC25\E?4_;FL..CHF\R>Z]I^>>E_P!!
M_,W:??\ OK+;+VQAZ(#$[C[CQ,F4H-U46<1\1UMDNNH=KY^2EHZ"(TJ=A8;L
M!:N.FDD$U U')#)Y&)*>Z\5IT&6__G+O'9F[-U;/CZ>H6RU/V'2[)V-1Y/*]
MK2Y7=&)_C>7PU7O>+#;.Z,WG5[HV[*,6LT;;/.Z30/4I39?^&5(:/W[K844K
M7_5^WH2<3\I]W56:P;Y'K+ TFQ]R]JQ],XC.1]A3Q;K7>6)W30[,W=5Y'8F8
MV;B:^DV_39R2K&/85#UTL-(IKJ;'R5,<8]UK3\^@(@_F15=1NBMPT/4$$]#3
MX"3,(D.Z]SKE_'2[/PNZJ_+2UU1U?!U]+M_'U&XZ#'31TV?J,Y'45L,S8T4S
MF5?=;T?/H5\'\K>W!D]N8C=71NW_ +G?G<78'1^RJS8O8N=W1BDWCUONNOQ>
M=J=[U65ZRVN^U<%5[-VSG\_2U,:5H:/#-1L!5U-*DGNM:1Y'J'W5\UL]U,^_
M,O2=6X[<.R]K;\J>F\/E6WAFH=S9;M>EV;C=\R15^S,'L#<N1I=B-BZV:G2M
MH9,GEY:NF'CQC0SQ2GW7@M:9Z46V?E=O'?W7O4&9V)UCM_([\[AS_9N-P.*W
M#OK-[6V(,#U55;@AS&ZTW+7==S;S2GW!'B*?^&X^LVU0Y%7K3]W%3)32O[]U
MZ@J<XZ0N&^=F:.0Q.:W3U1#0]9;G;K+^[F6V?F-]=B]BF/M3J+>';6$.7ZVV
MMU35SJ^,H]H24-::"NR$223"=7-.CM[]UXK\\](:B_F*;LRNR\YV#1],4%%M
MJCSVP-LXI\E6]XU4CY'>]7LB*6KR&3VY\<L[MNOIL/3;KFDDHL%6YK,C[4"6
MCA4SM3>ZWH'K_J_;T,N0^7^ZZK;'QPK-J=48FHW9\C]M4&X,%BMU;^K<#MW!
MI6Y/:-+!)69W%;&W)EJS%Y#%[H%;23#%Q5#1K&LU/"\CK#[K6GC4X'0,8C^9
M#N'/XSL?=>%Z!RF5VSUQ6]88:KQ>/RV]ZK=N=S>_*/J*KS%%@LHG5"]0U53M
MYNS9XZ2A.ZERV8.,5HJ2)*N,I[K>@8STNJ#YS[AS<T6ZMN]<;*SW3^0Q%/GL
M%NZA[0RIW)FL17]_R="8NOI=NMUO_!4I\A6JN74ME[K1N(B/*#[]UK3Y5STU
M];?/+?&]NN^F]^U_1'VJ=^8(Y?8-/BL_OR+'XNLQNV,9V'N;#;VR._>H=@5.
M.3%]:OD\I19/'TN2Q.8FQ$M+2SO)+ S^ZV5I7/#I@P_\S3&YVMPFU*7J.LQW
M8F\=XP;*V5M[,[QAI\/EY-Q;SV+L?8N\:O/TNW:N6CV'E\SN+,05]5%25%90
M5FW)Z5*:IFJ:8-[KQ2GGT(.]_GQBNO=D=5;USFQZ++8O?V([M_O%FMK[PEK-
ML;'W3U#7T>V<?BLAD,QM;"9EL1O;?U?38-*NIQ]#48JNK:=*NE!:01^ZUIXY
MZ:L]_,,Q>VLIT_#E^M9*7!=D-MVIW+N%]X0)3]>X3-;W[%V16Y[(T[8 ')46
M!J=AK4U(#TY$-4_T,!\GNMZ./068W^9YN+)8V;)/T!)B36T.-IL!15VY.P,A
M.^[*^KZ^U8+)5>W^E<MBZ^HAQ6_?N?X;@9\WN<_PZ<_PD0?Y0ONMZ!_%_J_;
MT/>S?F7N'/\ R%VAT)E^LZ"AK=PXC#U61R=%D>S*6NQM57]95_9&1R,.,WQT
MYLC&#!X18J/&U%)7Y''[G2HR$4S8A8 7]^ZKIP37I%[D^>F[<1+L=*+I[$5$
M'<>8R#=051W;OC.U%9M'!9?.8?-Y7?NW.O.H-\[LVUG_ "X^BFIJ''4.:I_#
M7O\ <U=,U'/?W6]/'/0K=N_,C&]7=LR])TFT8-X=@-T=G>TL9A<7NJDI\EF-
MVT35]1@>N\=A)<;+FZR7<.$VYFJY*R&"295QZ014D]3501'W6@M17Y]!HGST
MS-.*:KR/5V$CPYV)N[,/EH-X;PI*+,[]V?3;^J\ML';U1N#J?"08_/8J'8C?
MQ'";C;;^\:(532#"304=5*ONMZ/GU#S/\Q"FVK7;:K=S=<XZ'9N\\I3Y?$5^
M)WQ45F[=N=.&7?U%D^V=];6KMG8RBH<;@*O9M//DJ7%Y+*G&T%=(]3+'+2^&
M?W7M'SZ:\5_, WQG]H9[>V(Z3H?X53;LZ[V1M^FEK^[<I4Y'-[]RVTL:)WR&
MUOCMG\!GZ7&IN*:0TNV:K<&5/@7RTL"M*T'NO:!Z_P"K]O5DFU\G79K;.WLQ
MDZ2''Y'*X3%9*OH8%S"045974,%54TL*;APVW,\D=/-*4 K<?0U8 M-3PR:H
MU]U3I]]^Z]U[W[KW7O?NO=?_T=_CW[KW7O?NO=<6=44N[*B*+LS$*JC^I8D
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MW_#S/QQ_Y\!_,+_]("^3?_V!>_=>\,^H_;U[_AYGXX_\^ _F%_\ I 7R;_\
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M ?$?_95[]UNGS'7O]/-5_P ^,[__ /0'Q'_V5>_=>T_,=>_T\U7_ #XSO_\
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M>_=>I\QU[_3S5?\ /C.__P#T!\1_]E7OW7J?,=>_T\U7_/C._P#_ - ?$?\
MV5>_=>I\QU[_ $\U7_/C._\ _P! ?$?_ &5>_=>I\QU[_3S5?\^,[_\ _0'Q
M'_V5>_=>I\QU[_3S5?\ /C.__P#T!\1_]E7OW7J?,=>_T\U7_/C._P#_ - ?
M$?\ V5>_=>I\QU[_ $\U7_/C._\ _P! ?$?_ &5>_=>I\QU[_3S5?\^,[_\
M_0'Q'_V5>_=>I\QU[_3S5?\ /C.__P#T!\1_]E7OW7J?,=>_T\U7_/C._P#_
M - ?$?\ V5>_=>I\QU[_ $\U7_/C._\ _P! ?$?_ &5>_=>I\QU[_3S5?\^,
M[_\ _0'Q'_V5>_=>I\QU[_3S5?\ /C.__P#T!\1_]E7OW7J?,=>_T\U7_/C.
M_P#_ - ?$?\ V5>_=>I\QU[_ $\U7_/C._\ _P! ?$?_ &5>_=>I\QU[_3S5
M?\^,[_\ _0'Q'_V5>_=>I\QU[_3S5?\ /C.__P#T!\1_]E7OW7J?,=>_T\U7
M_/C._P#_ - ?$?\ V5>_=>I\QU[_ $\U7_/C._\ _P! ?$?_ &5>_=>I\QU[
M_3S5?\^,[_\ _0'Q'_V5>_=>I\QU[_3S5?\ /C.__P#T!\1_]E7OW7J?,=>_
MT\U7_/C._P#_ - ?$?\ V5>_=>I\QU[_ $\U7_/C._\ _P! ?$?_ &5>_=>I
M\QU[_3S5?\^,[_\ _0'Q'_V5>_=>I\QU[_3S5?\ /C.__P#T!\1_]E7OW7J?
M,=>_T\U7_/C._P#_ - ?$?\ V5>_=>I\QU[_ $\U7_/C._\ _P! ?$?_ &5>
M_=>I\QU[_3S5?\^,[_\ _0'Q'_V5>_=>I\QU[_3S5?\ /C.__P#T!\1_]E7O
MW7J?,=>_T\U7_/C._P#_ - ?$?\ V5>_=>I\QU[_ $\U7_/C._\ _P! ?$?_
M &5>_=>I\QU[_3S5?\^,[_\ _0'Q'_V5>_=>I\QU[_3S5?\ /C.__P#T!\1_
M]E7OW7J?,=>_T\U7_/C._P#_ - ?$?\ V5>_=>I\QU[_ $\U7_/C._\ _P!
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MZ4_^T[[]UZH].O?Z(=Y?]Y'=U_\ G'TI_P#:=]^Z]4>G7O\ 1#O+_O([NO\
M\X^E/_M.^_=>J/3KW^B'>7_>1W=?_G'TI_\ :=]^Z]4>G7O]$.\O^\CNZ_\
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MNZ__ #CZ4_\ M.^_=>J/3KW^B'>7_>1W=?\ YQ]*?_:=]^Z]4>G7O]$.\O\
MO([NO_SCZ4_^T[[]UZH].O?Z(=Y?]Y'=U_\ G'TI_P#:=]^Z]4>G7O\ 1#O+
M_O([NO\ \X^E/_M.^_=>J/3KW^B'>7_>1W=?_G'TI_\ :=]^Z]4>G7O]$.\O
M^\CNZ_\ SCZ4_P#M.^_=>J/3KW^B'>7_ 'D=W7_YQ]*?_:=]^Z]4>G7O]$.\
MO^\CNZ__ #CZ4_\ M.^_=>J/3KW^B'>7_>1W=?\ YQ]*?_:=]^Z]4>G7O]$.
M\O\ O([NO_SCZ4_^T[[]UZH].O?Z(=Y?]Y'=U_\ G'TI_P#:=]^Z]4>G7O\
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M=]^Z]4>G7O\ 1#O+_O([NO\ \X^E/_M.^_=>J/3KW^B'>7_>1W=?_G'TI_\
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MQ]*?_:=]^Z]4>G7O]$.\O^\CNZ__ #CZ4_\ M.^_=>J/3KW^B'>7_>1W=?\
MYQ]*?_:=]^Z]4>G7O]$.\O\ O([NO_SCZ4_^T[[]UZH].O?Z(=Y?]Y'=U_\
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M>Z]YHO\ CK'_ ,EK_P 5]^Z]U[S1?\=8_P#DM?\ BOOW7NO>:+_CK'_R6O\
MQ7W[KW7O-%_QUC_Y+7_BOOW7NO>:+_CK'_R6O_%??NO=>\T7_'6/_DM?^*^_
M=>Z]YHO^.L?_ "6O_%??NO=>\T7_ !UC_P"2U_XK[]U[KWFB_P".L?\ R6O_
M !7W[KW7O-%_QUC_ .2U_P"*^_=>Z]YHO^.L?_):_P#%??NO=>\T7_'6/_DM
M?^*^_=>Z]YHO^.L?_):_\5]^Z]U[S1?\=8_^2U_XK[]U[KWFB_XZQ_\ ):_\
M5]^Z]U[S1?\ '6/_ )+7_BOOW7NO>:+_ (ZQ_P#):_\ %??NO=>\T7_'6/\
MY+7_ (K[]U[KWFB_XZQ_\EK_ ,5]^Z]U[S1?\=8_^2U_XK[]U[KWFB_XZQ_\
MEK_Q7W[KW7O-%_QUC_Y+7_BOOW7NO>:+_CK'_P EK_Q7W[KW7O-%_P =8_\
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MGI5Y[<WQQS'1>0[PZ8^,/5V_,".[.L.JML5.5VWM+!XG>^(WEVSUSUCN+>.
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M46<^0_QMK-]Y7K;KSX?]:Y[<6*[/ZLV:<CD*#K^;;55M_<_R.V+\?>PJTYO
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M@-MW_P"M_OW7JGU/7O\ 99_CQ_SY#JS_ - ;;O\ ];_?NO5/J>O?[+/\>/\
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MV%*4RF!1'[]U[4?7ITS_ ,9^A-T9#)9;/=5;1R&3S,.Z(<K7O0-#59 ;RRV
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M -BOOW7M)Z]_LT/2'_/69+_T!NP?_L5]^Z]I/7O]FAZ0_P">LR7_ * W8/\
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M_/69+_T!NP?_ +%??NO:3U[_ &:'I#_GK,E_Z W8/_V*^_=>TGKW^S0](?\
M/69+_P! ;L'_ .Q7W[KVD]>_V:'I#_GK,E_Z W8/_P!BOOW7M)Z]_LT/2'_/
M69+_ - ;L'_[%??NO:3U[_9H>D/^>LR7_H#=@_\ V*^_=>TGKW^S0](?\]9D
MO_0&[!_^Q7W[KVD]>_V:'I#_ )ZS)?\ H#=@_P#V*^_=>TGKW^S0](?\]9DO
M_0&[!_\ L5]^Z]I/7O\ 9H>D/^>LR7_H#=@__8K[]U[2>O?[-#TA_P ]9DO_
M $!NP?\ [%??NO:3U[_9H>D/^>LR7_H#=@__ &*^_=>TGKW^S0](?\]9DO\
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MAM22T[>ZWH .3T9_L#O#>,E-\.,%N3NBF^/VUN[.K-P[SW]W*M!L*BKJ_?F
MV=UYE]O]9X#(]C8;<'7VULAO*/=6:S+?<8^IJ)J3;DT%($O+(GNM ?%BIZ!S
M*?S&\QU_BU2&+9G>V(VSLW#G^^5'5Y#K'?7<V1RW3F]>U\9VKLKJV?$9N"CZ
MA:#9AHLCE4JF@\K5E921BEI(X*CW7M->GC=G\Q#L3K+)[UQ^^^L.L,UE>NY7
MP&Y=@]:=HY?<'9$^X)/C%_LS$>YZ#;N3V5BYJ;J[&4++A:[)SH)8G\E<L9CC
M%++[KP0&E#_JKUDJ?YA^],=/OFFJ=F=-Y+&=1[7[(W+O[LC;W9^Z\YUIN%=L
MT74(VG2=8Y/!]<9G*9YLGGNYJ3'Y9Y8%&,JL35Q+YF=#'[KVCH*ML?S*>S=]
M;FP<B[7VYM_;6+WAOGJS=.W\!E*?)[PW;O[KKY:?'7INMRVP7R&,S-!6;;R6
MR^VI9:C&&^0BED=%JHG2&J]^ZWH%./\ JITJU_F7=D93!TC[6ZGZKW#N#+;"
M3MNGEQW;.;K]J;<VE+TUV=W)-U[N_*X_85364/=."I.LFQV1QJ0?;TYRM+6%
MP@-._NO:!Z]#GWG\]*OJ/J7H#MO$]19+=F.^0FP:7=&V,'_'OL,EC=Q3;=VG
MV95;5R-53X?)4A;'],?WNSSU(L'?:K4ZI_E2R1>ZT%J3GAT5'LK^8?W15T^;
MW%UO#M/:&V<MU#V]V)M5=Y55)D,E510_%K.]W]%S[8@_NU1QIE]P04M)E,GC
M<A)D&TR20162&17]UO2.C4]@_(CO>L^*7R7SV$H=D[ [ZZ>WTO4\&9QF2K=T
M[+7)5[=:Y%-WX=L[M2&I:>EVOV,ICIZS&5$"Y.E.M9:<V.NM4&H>G08[N^>V
MXJJ&'8FR6PF/W[M7*+2;ZKCF<1NO*XL[;^3V;^/.2Q&X,",#C(L3D-W46WY,
MO'*T-(\/D*1P% )/>^O:1T(':OS6W9TUU#\:=SUF+ZZSVX^U>B=Q]L;FK=];
MW/7=/DJOKKK39N^<[MG9E#0[?S*9;>6]Y=P30XVC40Q4[IJ*R*OC]^Z\%J3]
MO2#RG\S&KVVN6W7N/K; 0]?XO_21GMRXF@WC65/</3^PNG^XMK=1[USG=&PC
MM[P[9R^1&[(\QCJ&*J?_ ">EF@:21K3#W7M%?/I"2?S5][-MO;66/QR3"9AY
M-^XO>N$W'V%08FGPV_ND<;UY#W3U3B<[F,9A,96[LQN\^PQBL/4RM'35HQ%;
M.\:(H"^ZWHSQQT<.L^4V]<)T1W]WSGNN,##ANM.P^Q]E[#P-#NS(2UV9Q77W
M9>3ZIJ-U]B9&?;<-%LS&OFL5+E*[[1<HF-PJ/*SRR1LGOW5=.0*]!U\??D;W
M!WI\E3@Z^MV?ANL-C=9=E4.<QVQ,G'N7;W8G96V^V:79<6]=N;HR6U8<C7;&
MIL+ \5/#3U=*]/EOO8*C[L4\<@]UX@ ?/I X/^9I2PUN\*;?^T]B[1BVWO+=
M.&-3_I(6KQ5#@,9UW\@]Y;7R&1W='A)-C9"KW9E.A9<?%%1Y)JN">MEBJ:2G
MGI42K]UO1PIT'&#_ )EG95 V\ZK(;0ZOWHN5K][5VQMI4W:>*VQOK8U'A>E>
MK>V,=!V)0Y7;^*P>/V#YM[RXQ,[55]/+-7U&-C91_$4%-[K>CATU[@_F)=SY
M:GW-F-HP==TD+=2[?S6S,%3R9[[ZG['I,1\WZ7>DVZ:/<^SJ7,Y/8]%N;XYX
MV!X:".GEAJB$BR%1!*99_=>TC'^KTZ4_8W\R?=6-Z<R$&S(>JG[NI\%O^5ZN
MJW><GMV@I^N>FMA]LUG8T^WZ3&IDWV;N2EW:RTKL8Z>*!H9_/*K%??NO!,YX
M=*J;^8MN#;^<W'BZG9NW,YC]H[]SNVLA!D-\P4F_=]T^:[X[HZLVYD>E]NXO
M9]'0;PVAL2CZQ2LS53,\<\&,>5GDEFI))JKW6M/0M;!^7G86\NF?D5N_=^Q<
M!LW=7570>U^\<#%LG=E3N2DJL+V-T]F^R=NXN6NW-LW'Q0;FV[5X6:EJ)7Q]
M50SGQ2B(J7@'NO%144X5Z4?QY^5F^.VNS*?9FY-@[>P.UL_A>\:O9>X,=NRN
MS&Y:JH^/?9VRNL-TR[NP\NU,%A\:NZJO?$%90+0U%1X$I94E'K0K[K1  P>B
ML[-^<7R+I-^Y^IW;A>M-Y[#VKNVJV;O+ ;0K\I1[IPTF<^>/;OQ@V=+MFF.W
MZM\UNVCVUA<//D,=7U5%#,M/KA(EK+I[K>D4^?\ L5Z,1\8_FYG.^NK.V^R,
MQUIC=LGKS8&W>RL7C<7O3&9[[_&;LV;G-XT>S\Z*96R&W]X;;CPHILB9Z=(9
M#4QR0IQ)&GNO%:$9Z!#!?S*.P<UMS^.8WJ#8&[TPG7F\>Y-UUW7O9V5W1@:O
M8^U>C-F=V/LW863AV6@W/VL#O2##U-)*M)1T[M!6-)IJ!31^ZV4 \^L51_,C
M[4;8TVX,/TGU_E\OMW'=I[IW,_\ I9<;8R^U.L:/X^9">/9^3V]MO=E0NX,H
M>_H:,Q9%*9::7%25!62&HA4>Z]H'KUPWO_,3[,V!_>Z3+]=;1ESNRV?;VZ<9
M_?V.#9-%6[8[-^3&T=Q[IVP*K:5#V!N@Y'&=(TTQQ]*M97T]-5O-#03FBG^[
M]UH*#YXZR'^9]N3*YWM>DVOTGBYL1LQ]ZXG:\NZ.QL'LK,9;(;*;K0INO,8K
M=W]WZR@V-O>G['2; N\5/45*14@F,#Y.,4ONMZ.%3U81\<^[<5WWU5M/?U--
M@X,SF,3)69W 8BLRDS8:IIMP;AVO-Y*3<&'V]N"GI)\SM:NBA>HHHXY7II1!
M+41QB=_=4(H:=#M[]UKKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[K_TM_CW[KW7O?NO=1:VAHLG2S4.1HZ7(450%6>CK:>
M&JI9U5UD59J>=)(I KH& 8&Q /OW7NL%!B,3BFKWQ>+QV-?*5TV4R;T%%34;
M9')U 1:C(U[4\49K*Z=8U#S2:I&"BY-A[]U[J#)M3:TM <5+MK 2XLU4-<<;
M)AL<] :VGG%53UAHVIC3FJ@J1Y$DTZUD]0(//OW7NI@PF&6)H%Q&,6%RS/"*
M"D$3LU ,4S-&(M#%L6/MB2.8/V_T<>_=>Z@C:6U!AVV\-L[>& :@7%-@QA<;
M_!VQ:2/*F-;&?;?9&@661F$.CQAF)M<^_=>Z=J2@H:!%BH:*DHHEAIZ=8Z2G
MAID6"DB$%+ J0HBB&F@4)&OZ406  ]^Z]U&I,)A:!56AQ&+HE6I>L5:3'TE,
MJUDGW!DJE$,2 5+FKEN_ZCY'Y]1O[KW7"AV_@<9C9L-C<)B,?AZ@UAJ,50XV
MBI,;.<@\CUYFH8(8Z64USS.9M2'REB6O<^_=>ZA0[-VA3OBI*?:FVX),%1_P
M_"/#@L7$^'H/(DWV.*9*53CZ/S1J_BAT)J4&UP/?NO5/4V';^!I\@F7@PF(@
MRT=#!C(\G#C:*/(1XVF$HIL>E:D*U*4-.)GT1!O&FMK 7/OW7NH\FU-KRU&6
MJY=MX"2KSRTB9VJDP^.>HS2T!4T*Y:9J<R9%:(J/$)B_CL--O?NMU/KUQEVC
MM2:FR-%-MC;TU'E\F,UEJ27"XV2FRF966&=<MD8'IC%6Y,34\;B>4-+JC4ZK
MJ+>ZUT[)CZ".<54=%21U*FJ*U"4T*SJ:YH'K2)E02 U;TL9EY_<,:EKZ1;W7
MNHE)@<%035510X7$T5179*3,UL])CJ.FFK,O- :6;*U4L,*/49*6E8QM.Y,K
M1G26MQ[]U[KG4X7#UE-2T57B<954=#)'+14E304L]-1RPQ200R4L$L314\D4
M$K(I0 JC$#@GW[KW6&NVYM[*-3/DL%ALB]%DH,S1O78NAJVI,O31)!396F:H
M@D,&2IX(U1)UM*B* &  ]^Z]UFJ\)AJ^NH,G78G&5F2Q3O)B\A5T%+45V-DD
MCDBDDH*N:)YZ-WBE=28V4E6(/!/OW7NH$FT-I3465QLNU]NRX[.US9/.4$F$
MQKT69R3R13/D,K2M3&#(USS0(QEF5Y"R*;W ]^Z]U+KMOX')PU%/DL)B,A3U
M:5$55!78VBJX:F*KI8J*JCJ(IX9$F2IHH$AD# AXD5#=0![]U[KNKP&"K\.=
MO5V%Q-;@#3P4AP=7C:.IPYI*4QFFI3C)H7HC3TYA30FC2FD6 L/?NO=3XZ6F
MB$HBIX(Q/I\XCAC03:(8Z=/*%4>313Q+&+WLBA?H /?NO=-T.W=OT]&F/I\%
MAX*"."6F2AAQE%%1I33TJ44].E,D"PK!-11K"Z!=+1*$(T@#W[KW6:EPV(HL
M7%@Z+%8VDPL%***##TM#2T^+AHPN@4D6/BB2DCI0G'C"!+<6]^Z]UU483#5<
M-13U>(QE53U:U:54%104L\-2F0:-Z]*B*2)DF6M>%#,&!$A4%KV'OW7NO'"8
M8Z;XC&'1%X4O04IT0^22;Q+^UZ8O-,[Z1QJ<GZD^_=>ZSC'T BJ(!0T8@JT$
M57"*:'Q54:TZ4BQU$>C1,@I8UC 8$>-0OT 'OW7NH5=MS;V3E@GR6!PV0GI:
MAZRFFKL70U<M/5RTBX^6J@DG@D>&HDH$6!G4AC" A.D6]^Z]U+7%XQ""N.H5
M*E&4K24X(:*K:OC((C!!CKG,R_TE)<>HW]^Z]TU-L[:+TE50/M;;CT-=ECGJ
MVB;!XQJ2LSAE2<YFJIC2F&HRQGB5_N'4S:U!U7 ]^Z]U-RV P6>QCX7.87$Y
MK#RB(28G+8ZCR.,D%.RO 'H*R&:E<0N@*73TD CZ>_=>ZXR[>P$];#D9\'AY
MLA3XV?#4]?+C**2M@Q%25-3BH:IX#/%C:@H-<"L(GL+J??NO=)["]:;"V[NG
M=^]L-M7$4>[M^9"GRF[=Q"G\^5S%72[=V]M. 25=2TTE-2K@-J8^G-/ 8J=O
MME=D,A9V]UNO =/M-MC;5%C/X+1[>P=)AQ1U>.&)IL3008P8^OD:6OH?L(J=
M*7[.ME<M-%HT2,26!)]^ZUUU3[7VS2"A%+MW!4PQC,V-%/B,?",<SK2H[4(C
MIU%(S)0P@F/3<0H/["V]U[K)2[<V]0I41T6!PU''5UM=D:J.EQ=#3I4Y#*1F
M+)U]0L,"+-6Y&(E9Y6N\R\.2/?NO=3FQ] \-/3O14CP4@TTD#4T+0TJ_;2T>
MFGC*%(1]I,\5E _;=E_22/?NO=0JC;V JUA2JP>'J5IY(IJ=:C&44RP34]'-
MCX)81) PBDAH*B2!&6Q6%V0>DD'W7NIS4-$R5$34=*T=5+YJJ-J>(I4S 1J)
M:A"FF:73"@U-<V0?T'OW7NH$.W-O4]37UD&!PT-7E:A*S)U4.+H8ZG(U<:Q*
ME57SI LM94(L" /(68!%YX'OW7ND[GNLM@[GW)LO=NX-JXG+[@Z[BS,.RJZM
M@,R[=7<"8E,JU!1%_L%FG7!TFB1HFD@,(,10EK^Z]7RZ42;<V]'59:NCP.&2
MMSZP)G:Q,70K59I*6,Q4R9:H6 2Y%::)BL8F+A%-A8>_=>ZY5FW\!D%ITK\'
MB*Y*/*)G*1:S&T52M+FHW>2/+TZS0N(,HDDC,*A;2AF)#7/OW7NIYHZ1H)Z5
MJ6G-+4_<?<TQ@B,%1]XTCU?GA*^.7[IY6,FH'66):]S[]U[J+C<-A\-3TM'B
M,5C<524-*M#14N-H:6AIZ.B1S(E'2P4L44=/2HY+"- $!-[>_=>Z;I=G;1FB
MKX9MK;<EARN4BSF4BEP>,DBR6;A>.2',5\;TI6LRD4D*,M1(&F4J"&N![]U[
MK/\ W8VUYZ^I_N]@_N<K0#%92H_A-!Y\EBU5D7&U\OV_DK* (Y AD+1V)%N?
M?NO==TVV=MT8HA2;?PE*,;0)B\<*;$T$ H,9'J\>.HO%3K]K0)K-H8],8N;#
MGW[KU>HT6S=H0232P;4VW#+4XN#!U$D6#Q<<D^$IJ5Z&FP\SI2AI<73T4C0I
M3L3"D3% H4D>_=>ZD_W:VY]QCZO^[^$^ZQ,%=38NI_A5!]QC:;)C3DJ?'S>#
MR4<&0'$Z1E5E'Z@??NO=3UQV/1)HDH:-8ZBGCI:B-::%4GI88F@BIID"!9:>
M*%RBHUU520!;W[KW7<-!0T[I)!14D#QBH"/#3PQN@JY4GJPC(BE153Q*\EOU
MNH)N0/?NO=1XL)AJ>2IE@Q&,AEK:I:ZLDBH*6.2KK4G2J2LJ72)6GJDJ8UD$
MC$N)%#7N+^_=>Z;:G9NU:G![AVVV Q<&#W9%F(=R8^@I(L;#F?X_324F:FK6
MQPI99:S)4\K++/J$S7OJN ??NO=8MI;'VAL3;^#VML_;N)V_@-MXV#$X3&XZ
MDCBBH*"GIJ>C2&.0AIY'DIZ2-99'=I)B@,C,W/OW7N/4^BVUMS&T4>-QVW\)
MC\="M6D-!18J@I:*)*^H2KKTCI8((X$6MJHUDF 4"210S7(O[]U[KV0VUMS+
M4\U)E,!A,E2U,L,]139#%4-93U$]/5O7T\TT-1!)'++!72-,C,"5E8N+,2??
MNO=>J-L[;JZK)5U5M_"5-;F<:N'R]748J@FJLKB%UA<5DJB2G:6NQJ^5K02E
MHAJ/IY/OW7NIE#BL7BTCBQF-H,='%1T>/BCH:.GI$BH,>LBT%#&E/'&J4="L
MSB&(62(.=(%S[]U[J?[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[K__T]_CW[KW7O?NO==,RHI9V55479F(50!^238
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M?A^Y=U45-6YAZ*JGW5N*CC$V165I,]4XZHR.J9)A4S>Z\V>&3T=/_9B/C_\
M\_SZ=_\ 1F[*_P#KW[]U6A].O?[,1\?_ /G^?3O_ *,W97_U[]^Z]0^G7O\
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M/_/.X+_ST8__ .I_?NO=>_NOMG_GG<%_YZ,?_P#4_OW7NO?W7VS_ ,\[@O\
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M?"+INBBRN*@KM]KLW([7W)MNCZ]_O)"NR]N56Y,%5;.;=NVL?'BDK\7NO!;
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MZ]U[[RC_ .5NF_ZGQ?\ 1WOW7NO?>4?_ "MTW_4^+_H[W[KW7OO*/_E;IO\
MJ?%_T=[]U[KWWE'_ ,K=-_U/B_Z.]^Z]U[[RC_Y6Z;_J?%_T=[]U[KWWE'_R
MMTW_ %/B_P"CO?NO=>^\H_\ E;IO^I\7_1WOW7NO?>4?_*W3?]3XO^CO?NO=
M>^\H_P#E;IO^I\7_ $=[]U[KWWE'_P K=-_U/B_Z.]^Z]U[[RC_Y6Z;_ *GQ
M?]'>_=>Z]]Y1_P#*W3?]3XO^CO?NO=>^\H_^5NF_ZGQ?]'>_=>Z]]Y1_\K=-
M_P!3XO\ H[W[KW7OO*/_ )6Z;_J?%_T=[]U[KWWE'_RMTW_4^+_H[W[KW7OO
M*/\ Y6Z;_J?%_P!'>_=>Z]]Y1_\ *W3?]3XO^CO?NO=>^\H_^5NF_P"I\7_1
MWOW7NO?>4?\ RMTW_4^+_H[W[KW7OO*/_E;IO^I\7_1WOW7NO?>4?_*W3?\
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M_=>J?7KW^RV_'K_GQ_4W_HO]K?\ UK]^Z]4^O7O]EM^/7_/C^IO_ $7^UO\
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M"8[.XG)86O2I6@RU')0UO\-R&1PE<::6,Q,*;+86JQ^5H)EC-DEIYHI8_JK
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MS1D8?[%A"[5)E;W5M(SU(PGSN^3FQ.N-LXGL;$=9ONS&],[2[%G[*W+M7?\
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M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5?&V?^WJ7<_\ XH1\=/\
MX(#Y,>_=6_!^?5@_OW5>O>_=>Z][]U[K_]'?X]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>M?Z\^_=>ZZ(!M<
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M45)229*K;(9%Z:GB@>OKGIZ>D:MK&C134U34M)%&9'U/XXU6]E 'NO=2P
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M!K,C-&'>[GU*BBWCPRJ7FC1/^SJ[AQNZ:[$;DV'B,7145#G<EF: 9#<#[HV
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M^=[(R5=N:GW-BZ+8VX\ABIO[KSY&''Q&AH<Q/E=K?WX2DBEI'E^]BC64J95
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M'QN4JRZ(* Q_B\2E02A5:!CJ8*LBDT ,C*66E.I ;=_NMM)N0V_9BBO8:O\
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MFOXW-E(<K4XQZEI6-$M.B5E'0O'XBGVS0DE!J#B_OP)KP\\];-"#G%,?ZO\
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M>%9@-X3OBB-K]Y9JC4TV,V3*LE55UBLGW:(CR*:)R-,\\D'UK=@2I\%\L[Z
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MAW:[(1H)Y'ALTG$D=Q#&;O3I4+T/_P >?D]N?O#>TFS,]U5@*3/;!ZGVOO\
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M]N<_P''=CB"H['VYO#:-+'AZ?-[TV3M67[C;V#W U/D::)986J(YI(I7*-#
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MZ&BKNWM_)G,-B**OR\$U309.H2G>"(0R>)[7]GL@O>5[:>],MJ9C'([3*Y\
M-&$/::11Z6<JAHRC4":BH5\Y<I^SD?.7W;^7MZYQ?=.6'WA['<;R7=X+A_W,
MD^WI9R:H'=-KLC#+=2PVKI'/;H95E<R+K5UR7RQ^7>!V_MS+P].Q[LCRW9&"
MVC00TG3?;-)D<SL_&;;Z_P CNW>.7<Y>*3:57N*LW?6OB4DQLM/3IAJF.82.
M'\-4V#EZ::>,[CX96%G-9HB Y:0(@[>X*$&ONJ=:D4Q5%:>QWL3N>Z;M82<_
M&Q>#:)KIRVZ[8T<5U)<7L=M:Q#PB+E8%M8A<E;A7<W<+(44KXD#=OR]^:VV=
MK5F?B^.^+R<\E=M;+45#0==]NU>2I-L9C-]V86OVZ,7#4&GS>^8/]&V%J@\]
M=A:-8=R0IIDD:F^XM;<O<M3SK$V[LHHP),D5"P6%@U:55/U'&%<UC)P-5%.Q
M>P_W>-XWJ#;']UIH8Q'<Q.[WVUK&UQ%#M$R3^(5U0V;?7W<=$ANY2UA(U502
M^%CP?R!^:>S^S,CB\OUAE]];9WWV]V?4XFJS6Q]VXJ+;&Q-O9;!X':VS<$<#
M%5TV$J*3;IJ,Z^1R?W=/F7#T\,L1#3IN7:.6KFQ1X[U8IXK:(&DB'5(P9F=M
M66JU$TK0I@D'AU?<O:W[O._<GVE[8\Y0;;O&V;#MRRK%>6LAN+R>*::YNYO&
M*M,K3Z+,06_A/: K+(CBD;3<E\IOG-B-LYG/5?1>U9CBME_'K,U H>MNV)I*
M3-=TQ9G*[P*XK^\39+-X_I2BQ<./R]'2#[^2NKTGE^SBB:%Z1[%RO)/%$-SD
M&J6X7,L65AH%SIHIF)+(Q[=*D#434)K3V6^[=?;SM^V0>Y-ZHGW'?(EUW^V
M-#M)BBM:R>!X<+[N\CSVLLGZ*PPM&GU#N)%$;JCO+Y-]B?)79VW-\=?Y+K;8
M-#M#?<VZ-M4NQ]Z28[^)OM#IO-;1SF7[1SN*I=M96/+9G/[@I\=C:%**OHOX
M=-'7I),"L*._VO9+/9+F:UNQ-=F1-+%TK37,KJ(E.H4"QEF;4K:@4('$)\\>
MV_L[RI[0\P;MRWS1#N_,\E_9BVN&O+02>&+K=8KJ&+;H9&N(S%%#8O//,9H9
MO'C>V98R#(B.E_DY\N*[,=/[1[ ZS?-UF>S[8??>5?J'LW:53,M5V9V5MW<U
M319EXSLG9M-TWM+;F&R50^2\B;JI\S$,:ZNA>53N6Q\OI%N-Q:7NE42J#QHF
M']G&R@K76YF=G4:?[(H=>, 1^X7LY[%VUAS[OO*_. M[>UM?%LXQNFWW*C3M
M^WSVZO$#]7=MNMS/=VZ"WTG;9+5S=J58*C;V'WA\U]K=Q=G2[8VU+NS9W7.Z
M.T*O%;/;J7>*X[=.P:7:GQVK]EXV@W-BB/X[NC)Y+<FYA05M)--'%-2UB5%+
M.(8X87+/:^69]ML1/,([F:.(%_&2JR%[@.2I^%0%CU*0*@K1A4DJ^5?;C[N^
M]<@\FIO.[K8[_N]EMRR77[SM?$MKUKG?4NY'MY/[&WCCM]O\:&5%9DDMVBFC
M\1Y)!UZV^1G?NXJ#Y29/?'25=MR/J"FW55]<8?&[8WA6;AW/4X.NW[3XS +2
M530T/8-=F<1MO%9*"HP=1 DRYA:<1(1%/.57NS;3"^Q);;F'^I*"0ET"J&"5
M:HJ8P"S*0X)&BM>($:\W^TWMAM5S[+6?+?N+'=OOSVRW\LEQ:K!;K,EDTDVI
M:O8I%+<7-NZ7B.4-J9=; O%&5'J_Y>]Z;>JMF=98/X[[-V541?;[@RG7VVNG
M^T=MKN'#[J[\W9M'.;KPRTLKX#JK'G:E+-NZ?(9]JJDR,J5,:3L\HD0^ON7M
MKF%U>R[Q)*/A$C31-I*P*RJU>Z4ZJ1!8Z%<8Q0S=SG[$>VNZP\P<X[E[J[AN
M,3:H([ZXW3;K@P2VVRVUU#;2Z@)MR?ZEDVQ(+(1RP*86:,*FAE?U;\SOESVC
MM3;>ZMN=&8#/8O,[&RO8L>5I-C=J;?QF?:CZ7PW85)U7MIMQ5D1;<=9O/*+@
MZ?<;//A<CKUTD$CPR(4]]RWR_8SS03;HRNLHCIXD3%:S&,RMI'PA!K,>'7\1
M (Z(>=/N^^Q7)F][OLF[>Y%U:WEON45@8VO-MGDAU[M+8MN5QX"&D"VD9O)+
M !+N"FF>15D1AC?YP?)2#-[ VK'U+A\OG-T-O3)XU8NK>Z,#7=G8/:>[NB-O
MD;;VCF)&W'U1 3VIF*:7,[F$V+2HV[Y[_;U487?]6-E,=Y.;]ECCT _JPL(V
M9)V[G';+_9(0D='I)IX@]77[N/M#)M_-.]-SS<0;;9"TCDKN6TS)M\US:[S/
M^O=1#P-R/^ZVUD6UV\I<E+[PO[6!B>MU_*;YF;4VY/O9NEJ_*[BSVP\)E=N[
M/Q'5W9.7VOA,E-O+MR,;>W%1TV0BW%%NVNV_L_&1S5R5 @CFRU&JT!5T>;=O
ML/+=Q,+;]Y!84E8,YEC#,-$7<IIIT!G8@4K1&[\8WL?LM]W[>]VBY='N%%!M
M-KN<T<]U+N-A%<S1BTVP^/ [1F VJ3W5PR0E"[+;3DW5598^>R_E1\T(>PH]
ML;AZ=FSN&W%\AMR8*.OR'6F_L!!M?K&:;JK^ZNWZ+-8^D-!+4G;F[,QEEW!6
M15%&[X>:EG$3%WI=7.P\MFS,\.XA94LU:@EC;5)^KJ8J37XD1/#%#WAA7 :O
M,/LI]WR3E5]YVOGY;;<+3E2WF*)N%E,USN &Y?4SO"[:POCVUK;&RB:.4"ZC
MGB+KI69;_)'Y'?*W:G8W;G7?6'6\B;?V[LO:>Y]D]CXWJ[?.^[2KG>OY=Z+G
M?%-0XNO8X+,Y>&BH\32Y*:1Z-B94FBEA1-LNR[!<66WWE]>CQGE=7C,J)^&3
M1IXD=P0DN5&>!!!(<]H_:7V1WSE+D7FOG+FT'=;O<;FWN["3<;.SQX-Z+3P:
MAY$_6BM6EEN9+=%$H 1HW21D!F/EW\QJ[=N3?;/2.7;:6T^R\U1T-%-T[V-B
M,KV1MS_1O\@9MM[3JJC*5.6BV_69#L#KS;R?QJ I3Q_QZC6>*%)-$ZJ/E[EU
M;>,3;FOU$D"DGQHR(V\2#4PIIU 1R2=AJ3H:A)%0*+#V(]@K;8K-=X]Q8!OE
M]L\+.XW6PECL+CZ_9!<7*B-8C.B65]?'Z1ZN?HK@QO(RZHSM_%_N3?G;&Q**
MM[4V=-LW?<KYFM%)2;0WWMS!Y';5)FIL5BLNL>[\??"Y.LDAD5\9)7U=2$B^
MY4FGFC(#.^[;:[?=,MA<"2TP*ET9@Q6I'8>X#^+2!G3Q!ZQT]YN0.6>1^9KF
MWY)W]=PY:41)J:ZLYYH[AHA+)$3:O^K&@((N%ACCJWA$"5&'1G/9'U#G7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U5)\D-L?)K#?S"NI.V^
MANCH>S*2I^(O:/49WENC<M'M/J_8.[L[VGL?<]!7=A92-:[=%3C%Q.%FE2BQ
M%#4UM8ZB-3$"94J1GJXII-3Y]/F2^ G:G=R/5_+KYI?('?(K%CDJ>KOCSG)/
MB[TOC#(1+)CJ2'8$LG:FY*.D>RQSY;<DTSA;E5U,ONV<9ZKJ X+T?7I[J;9?
M1?6FS^I.NZ3*4.RMBXE,+MZES>?S6ZLM%0K//4DY#<6XZ_*9W,54M14N[S55
M1-*Q;EK6]Z Z\34D]"5[WUKK_];?FQ.5H<WCJ'+XNJ@KL9DZ*DR..K:<EH:N
MAK8$J:6JB8_6*H@E5U/Y4^]#.>MD4)'3E[WUKKWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J)44%#5ST55545)4U.,GDJ<=4
M5%-#-/CZF:FGHI:BBFD1I*6>6CJ9(F>,JS12,I.EB#8.ZAE5B%84(KQ%:Y]<
M@'[>GXKJY@CN88;ATAF4+(JL0'4,'"N :, ZJP#5 90W$ ]2_=>F.HE%04.-
M@^UQU%24%,9ZJI-/14T-+ :FNJ9JVMJ/# D<?GK*RHDEE>VJ25V9B6))LSNY
MU.Q+4 J37 %!^P8'RZ?N+JYO)/&N[AY9M*KJ=BQTHH1%JQ)HJ*JJ."J HH !
MUCRF*Q><QM=A\WC:#,8C)TTU%DL5E*.GR&-R%'4(8YZ2NH:N.:FJZ::,E7CD
M5D8&Q!][CDDB=9(G*R*:@@T(/J",@]7LKV]VV[MK_;KN6WOX7#QR1NR2(ZFH
M9'4AE8'(92"#P/4J""&FAAIZ>&*GIZ>*.""""-(H888D$<4,,485(XHT4!5
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26P__ $,MN_\ UR]^QT_IZ__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>g556278dsp1a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g556278dsp1a.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( 'T ?@,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /W\H * "@ Z>V/PQB@ _P _E0!X#KO[47P%T#7KCPBOQ&TG
MQ-XRM([U[CP3\/+75?B9XR@;3G,5[#<>%_A]8:QJ5I/#*-CQSVT10YW[0"0
M>9>-/VLO$>A6UQ=^&/V:_C'K%E +Y$UOQU<> _@KX?FFMXBUI(LWQ,\5Z?JB
M:>[1W!GG?1UDMH8!.8)%EC#@'@-Y^W'\;[W3[:ZLOAA^S3X"M)VCE@\3>,OV
MN_!OC7P_J,3HY33["U^&V@W5\+V8?OX[J0?9%BLIT9O-EA! +^G_ +</QKMU
MTJ*_^!7P:\70W5Y;V@UWP%^UW\+K9-?$DK&1_"7A/QE9:=JES>BVCG,>GWLU
MK+*]I)\Z1G>H!](^&OVGYKJT6Z\>? ?X[?#V"3R7M=1@\&1_%;0;NUN)(XH;
MF#5?@OJ'BIHT!<M(;BV@5%C)WL,9 /1O '[0?P1^*6JS^'_ 7Q0\'>(?$MG]
MJ^V^$X-8@M/&%@;"62"_74/".HFWUBP>UFBDCG2XL8FA9<2!210!['0 4 %
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MAO;KPY?"<V#8^]OA9\3/"OQ?\!>&_B'X-NVN-%\1Z=;WBV]QY4>IZ->M&O\
M:&@:[:12R?V=K^FW?FV=Y:,Q:&>WD3) #$ ]!Z?A_2@ Z>P'X8Q0!^9VB1:;
M\:?C9XW^*>G13:IJWQ _X2O]G'X3ZM"MP]M\._A3\,KW5=,^,OQ+M=8L].NH
MK#5]<\5ZAK.GZ,[)$ES-;:7 U\+>\F^S@'U9XUTK5O'G_"2>'_AU_8VCZO\
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MPM\+O!GE"1KS^W?B7XGTKP:)],6)E+:K9Z;J^HWUL"\8\VP3++C- &W^S_\
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MOX?_ ./J3X@-#OU'PR@QXC3XIKI6[&LG:=WB[0_,_P">?[\\^1\QL&Q]$?\
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MF'5//MY?#7A"/4M6\5>*O&.OS10O'X<BT#P5<-=2SWQ2V35Y].TQI'GOH4F
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MK:VT206]M;P1K%!!;P1*J0PQQ(J(B*%55   &* )^GM^E !0 4 % !0 4 %
M!0 ?T_3% 'C_ ,0?V??@;\5S-)\1_A)\/?&-Y/"(&U76_"FCW6N)")DGV6VO
MFT&HV@,J*3Y%U&3R#D,03] _0^>C_P $XOV1HYKJ33_A]X@T*&[N9;MM.\._
M%+XIZ!I$,TV#(;32M*\906MFA('R0Q(HZ  #% &AI_\ P3T_9-LI96N?AUJW
MB"WFA,$FF^+/B/\ $SQ3I#CS8I5D?2-=\77-I).CPH4D:%F0Y*D$YH ]W^&G
MP"^"WP;MY;;X8?#'P=X+$]T;V:XT?1K6/49KDPM;B2759EDO)-L#R1HK3E46
6614"B1@QL&QZ]0 4 % !0 4 % '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>g556278dsp1b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g556278dsp1b.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M22"./F(R< $X/\0&<9%  KHXRCHP]58,..#R#VH >".WZ>U !0 4 % !0 4
M% !0 4 % !0 C*&5E/1@5/T(P: /S"_9DU.W^%/QO\?Z4VB:5HOPV_:(\9>,
M/%'PLU*SDQ!:ZMX5U6?0M5\+S/(=L7VZRM+?7;.WA*QJ+^\2-<QO@V\@V\C]
M/=R^HZXZCJ.WU]J %Z?A_2@#\G/@GX/\5Z'_ ,%!_B/H]_X<U!/"WA70OB;X
MV\/^)Y;>9-/OS\5[_P"&EU>627C1B&6[MM1TF\41*Y=8PYQA3@V\@V\C]8Z
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ME'< #'4@8STH 7^GZ4 % !0 4 %  ".W;T[8H * "@ H PO%.HRZ/X8\1ZM
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M7D4=S:WVGW$-U:3QR@NLD=Q"[(P9"IQG(SR!0!N@CL1Z\>E "T &0/8#\,4
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B0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>g556278g0327071551902.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g556278g0327071551902.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !< 14# 2(  A$! Q$!_\0
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MO\6V^I6PT;4$B^U1#]TY4?.O^->TYQC24Z<;H\2,)2JN%25F>9_:?$WI<_\
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M3^-I%B)(:411CZ<5[]H^D16'AZ#3M@"B+:X]21S7D?PZ\':B?$RWNJ6C1QQ
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M0KL8%<$D?W?6G^&$OFAO;B>29K9LB!91@D>M=++9VT[AY;>)V'0LH)%3  #
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0'I[T5NT5#G)]2U"*Z'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6841019680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Apr. 06, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SLS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SELLAS LIFE SCIENCES GROUP, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001390478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,572,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,640,272<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and entity information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6841349728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,319<span></span>
</td>
<td class="nump">$ 5,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash and cash equivalents</a></td>
<td class="nump">10,431<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">337<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">13,087<span></span>
</td>
<td class="nump">6,379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">17,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits and other assets</a></td>
<td class="nump">925<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">33,526<span></span>
</td>
<td class="nump">6,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">8,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Current portion of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">11,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">3,201<span></span>
</td>
<td class="nump">4,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Litigation settlement payable</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">24,569<span></span>
</td>
<td class="nump">5,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liability</a></td>
<td class="nump">1,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_WarrantLiability', window );">Warrant liability</a></td>
<td class="nump">1,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion', window );">Contingent purchase price consideration</a></td>
<td class="nump">1,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion</a></td>
<td class="nump">2,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible debt, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,659<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">31,456<span></span>
</td>
<td class="nump">11,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 350,000,000 shares authorized, 5,766,891 shares issued and outstanding at December 31, 2017; 1,268,489 shares issued and outstanding at December 31, 2016</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">56,254<span></span>
</td>
<td class="nump">25,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(54,185)<span></span>
</td>
<td class="num">(30,431)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="nump">2,070<span></span>
</td>
<td class="num">(4,997)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity (deficit)</a></td>
<td class="nump">$ 33,526<span></span>
</td>
<td class="nump">$ 6,420<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent purchase price consideration, net of current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31958-109318<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 55<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6396582&amp;loc=d3e15243-108350<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819062144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">5,766,891<span></span>
</td>
<td class="nump">1,268,489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">5,766,891<span></span>
</td>
<td class="nump">1,268,489<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6840983632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 6,067<span></span>
</td>
<td class="nump">$ 11,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">15,089<span></span>
</td>
<td class="nump">4,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="nump">1,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating expenses and loss from operations</a></td>
<td class="num">(23,039)<span></span>
</td>
<td class="num">(15,988)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense, net</a></td>
<td class="nump">462<span></span>
</td>
<td class="nump">1,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">253<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(23,754)<span></span>
</td>
<td class="num">(17,681)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_DeemedDividendOnDebtConversion', window );">Deemed dividend on conversion of 2015 Sely Note</a></td>
<td class="num">(675)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Loss attributable to common stockholders</a></td>
<td class="num">$ (24,429)<span></span>
</td>
<td class="num">$ (17,681)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted loss per share to common stockholders</a></td>
<td class="num">$ (10.44)<span></span>
</td>
<td class="num">$ (18.66)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares outstanding, basic and diluted</a></td>
<td class="nump">2,340,368<span></span>
</td>
<td class="nump">947,401<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_DeemedDividendOnDebtConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend on debt conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_DeemedDividendOnDebtConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6841881216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2015</a></td>
<td class="num">$ (12,262)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 488<span></span>
</td>
<td class="num">$ (12,750)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">879,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee', window );">Shares issued as partial consideration of MSK license fees</a></td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedDuringPeriodSharesPartialConsiderationOfLicenseFee', window );">Shares issued as partial consideration of MSK license fees, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedDuringPeriodValueLicenseAgreement', window );">Shares issued pursuant to MSK license agreement</a></td>
<td class="nump">1,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedDuringPeriodSharesLicenseAgreement', window );">Shares issued pursuant to MSK license agreement, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue', window );">Shares issued in cancellation of Clarendon license agreement</a></td>
<td class="nump">502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_SharesIssuedInCancellationOfLicenseAgreement', window );">Shares issued in cancellation of Clarendon license agreement, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Shares issued upon conversion of 2016 convertible term note</a></td>
<td class="nump">15,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares issued upon conversion of 2016 convertible term note, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedDuringPeriodValueCancellationOfLongTermDebt', window );">Shares issued in cancellation of long term debt</a></td>
<td class="nump">5,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedDuringPeriodSharesCancellationOfLongTermDebt', window );">Shares issued in cancellation of long term debt, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation expense</a></td>
<td class="nump">354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(17,681)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,681)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2016</a></td>
<td class="num">(4,997)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,434<span></span>
</td>
<td class="num">(30,431)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,268,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue', window );">Shares issued in connection with amendments to MSK license</a></td>
<td class="nump">388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares', window );">Shares issued in connection with amendments to MSK license, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Shares issued upon conversion of 2016 convertible term note</a></td>
<td class="nump">1,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares issued upon conversion of 2016 convertible term note, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common shares to related parties</a></td>
<td class="nump">6,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common shares to related parties, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,534,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable', window );">Shares issued in connection with settlement of related party payables</a></td>
<td class="nump">378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable', window );">Shares issued in connection with settlement of related party payables, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued upon the acceleration of restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares', window );">Shares issued upon cancellation of Equilibria restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Shares issued in connection with acquisition of Galena</a></td>
<td class="nump">12,487<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">12,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued in connection with acquisition of Galena, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,588,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition', window );">Fair value of assumed options issued in connection with acquisition of Galena</a></td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod', window );">Shares and common stock warrants issued upon conversion of 2015 Sely Note and accrued interest to Equilibria</a></td>
<td class="nump">6,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares', window );">Shares and common stock warrants issued upon conversion of 2015 Sely Note and accrued interest to Equilibria, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">632,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion', window );">Deemed dividend associated with conversion of 2015 Sely Note and common stock warrant issuance to Equilibria</a></td>
<td class="num">(675)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(675)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod', window );">Shares issued to Equilibria for incentive fee payment in connection with the acquisition of Galena</a></td>
<td class="nump">941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares', window );">Shares issued to Equilibria for incentive fee payment in connection with the acquisition of Galena, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedForAntiDilutionProvisions', window );">Shares issued to MSK for anti-dilution provisions</a></td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedForAntiDilutionProvisionsShares', window );">Shares issued to MSK for anti-dilution provisions, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation expense</a></td>
<td class="nump">3,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(23,754)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,754)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2017</a></td>
<td class="nump">$ 2,070<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 56,254<span></span>
</td>
<td class="num">$ (54,185)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,766,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid-in capital deemed dividend on debt conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_AdjustmentsToAdditionalPaidInCapitalDeemedDividendOnDebtConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital stock options exercised in connection with acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_AdjustmentsToAdditionalPaidInCapitalStockOptionsExercisedInConnectionWithAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares and Common Stock Warrants Issued Upon Conversion of Notes During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares and common stock warrants issued upon conversion of 2015 Sely Note, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_SharesAndCommonStockWarrantsIssuedUponConversionOfNotesDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_SharesIssuedInCancellationOfLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Issued In Cancellation Of License Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_SharesIssuedInCancellationOfLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_StockIssuedDuringPeriodSharesCancellationOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Cancellation Of Long Term Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_StockIssuedDuringPeriodSharesCancellationOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_StockIssuedDuringPeriodSharesLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_StockIssuedDuringPeriodSharesLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_StockIssuedDuringPeriodSharesPartialConsiderationOfLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Partial Consideration Of License Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_StockIssuedDuringPeriodSharesPartialConsiderationOfLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Settlement Of Related Party Accounts Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_StockIssuedDuringPeriodSharesSettlementOfRelatedPartyAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period upon cancellation of restricted stock units, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_StockIssuedDuringPeriodUponCancellationOfRestrictedStockUnitsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_StockIssuedDuringPeriodValueCancellationOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value cancellation of long term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_StockIssuedDuringPeriodValueCancellationOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_StockIssuedDuringPeriodValueLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_StockIssuedDuringPeriodValueLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value partial consideration of license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Value Settlement Of Related Party Accounts Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_StockIssuedDuringPeriodValueSettlementOfRelatedPartyAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_StockIssuedForAntiDilutionProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued for anti dilution provisions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_StockIssuedForAntiDilutionProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_StockIssuedForAntiDilutionProvisionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued for anti-dilution provisions shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_StockIssuedForAntiDilutionProvisionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued for incentive fee payment in connection with the acquisition during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued for incentive fee payment in connection with the acquisition during period shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued in cancellation of license agreement during period value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued In Connection With Amendments To License During Period Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued In Connection With Amendments To License During Period Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_StockIssuedInConnectionWithAmendmentsToLicenseDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation for stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6841681760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (23,754)<span></span>
</td>
<td class="num">$ (17,681)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustment to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_NonCashResearchAndDevelopmentExpense', window );">Non-cash research and development expense</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">3,169<span></span>
</td>
<td class="nump">354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Fair value of shares issued in exchange for research and development</a></td>
<td class="nump">449<span></span>
</td>
<td class="nump">1,974<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Fair value of shares issued for incentive fee to Equilibria</a></td>
<td class="nump">941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs paid by Galena</a></td>
<td class="nump">1,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">73<span></span>
</td>
<td class="num">(477)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">8,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(2,374)<span></span>
</td>
<td class="nump">1,830<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(10,989)<span></span>
</td>
<td class="num">(11,850)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Net cash acquired from acquisition of Galena</a></td>
<td class="nump">1,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Change in restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(85)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">1,812<span></span>
</td>
<td class="num">(85)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">6,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Net proceeds from issuance of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Net proceeds from issuance of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Principal payments on convertible debt</a></td>
<td class="num">(473)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">5,534<span></span>
</td>
<td class="nump">16,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net decrease (increase) in cash and cash equivalents</a></td>
<td class="num">(3,643)<span></span>
</td>
<td class="nump">4,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at the beginning of period</a></td>
<td class="nump">5,962<span></span>
</td>
<td class="nump">1,397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">2,319<span></span>
</td>
<td class="nump">$ 5,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_SharesIssuedInConnectionWithAcquisition', window );">Shares issued in connection with acquisition of Galena</a></td>
<td class="nump">12,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_FairValueOfStockOptionsAssumedInConnectionWithAcquisition', window );">Fair value of options assumed in connection with acquisition of Galena</a></td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_SharesIssuedToSettlerElatedPartyAccountsPayable', window );">Related party payable settled in shares</a></td>
<td class="nump">228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_SharesIssuedToSettleAccountsPayable', window );">MSK payable settled in shares</a></td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance', window );">Deemed dividend associated with conversion of 2015 Sely Note and common stock warrant issuance to Equilibria</a></td>
<td class="nump">675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=sls_ConvertibleDebtTwoThousandFifteenShareholderNotesMember', window );">2015 Shareholder Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Shares issued upon conversion of notes and accrued interest</a></td>
<td class="nump">1,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=sls_ConvertibleDebtTwoThousandSelyNoteMember', window );">2015 Sely Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Shares issued upon conversion of notes and accrued interest</a></td>
<td class="nump">$ 6,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend associated with conversion of note and common stock warrant issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_DeemedDividendAssociatedWithConversionOfNoteAndCommonStockWarrantIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_FairValueOfStockOptionsAssumedInConnectionWithAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of stock options assumed in connection with acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_FairValueOfStockOptionsAssumedInConnectionWithAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_NonCashResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_NonCashResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_SharesIssuedInConnectionWithAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued in connection with acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_SharesIssuedInConnectionWithAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_SharesIssuedToSettleAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued to settle accounts payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_SharesIssuedToSettleAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_SharesIssuedToSettlerElatedPartyAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued to settle related party accounts payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_SharesIssuedToSettlerElatedPartyAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sls_ConvertibleDebtTwoThousandFifteenShareholderNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sls_ConvertibleDebtTwoThousandFifteenShareholderNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sls_ConvertibleDebtTwoThousandSelyNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sls_ConvertibleDebtTwoThousandSelyNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822884992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Organization and Description of Business</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <b>1. Organization and Description of Business</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <b>Merger of Galena Biopharma, Inc. and SELLAS Life Sciences Group
 Ltd.</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 As used in this annual report on Form 10-K, the words the
 &#x201C;Company,&#x201D; and &#x201C;SELLAS&#x201D; refer to SELLAS
 Life Sciences Group, Inc. and its consolidated subsidiaries
 following completion of the Merger. Said references before the
 completion of the Merger refer to Private SELLAS.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On December&#xA0;29, 2017, Galena Biopharma. Inc.
 (&#x201C;Galena&#x201D;) completed the business combination with the
 privately held Bermuda exempted company, Sellas Life Sciences Group
 Ltd. (&#x201C;Private SELLAS&#x201D;), in accordance with the terms
 of the Agreement and Plan of Merger and Reorganization, dated as of
 August&#xA0;7, 2017 and amended November&#xA0;5, 2017 the
 (&#x201C;Merger Agreement&#x201D;), by and among the Company, Sellas
 Intermediate Holdings I, Inc., Sellas Intermediate Holdings II,
 Inc., Galena Bermuda Merger Sub, Ltd., and Private SELLAS. The
 Company refers to this business combination throughout this annual
 report on Form&#xA0;<font style="WHITE-SPACE: nowrap">10-K</font>&#xA0;as the Merger.
 As a result of the Merger, the Company&#x2019;s business is now
 substantially comprised of the business of Private SELLAS, and
 although the Company is considered the legal acquiror of Private
 SELLAS, for accounting purposes, Private SELLAS is considered to
 have acquired the Company in the Merger. Consequently, the Merger
 is accounted for as a reverse acquisition.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 Immediately prior to the Merger, the Galena effected
 a&#xA0;<font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">1-for-30</font></font>&#xA0;reverse
 stock split of the Company&#x2019;s outstanding common stock. Under
 the terms of the Merger Agreement, the Galena issued shares of the
 its common stock to Private SELLAS&#x2019; securityholders at an
 exchange ratio of 43.9972 shares of the its common stock in
 exchange for each common share of Private SELLAS outstanding
 immediately prior to the Merger. The Company also assumed all of
 the restricted stock units (&#x201C;RSU&#x201D;) issued and
 outstanding under the Private SELLAS Stock Incentive Plan #1, and
 all of the issued and outstanding warrants of Private SELLAS.
 Accordingly, such RSUs will now be settled in, and such warrants
 now are exercisable for, shares of the Company&#x2019;s common
 stock. Accordingly, immediately after the Merger, there were
 approximately 5,766,891 shares of the Company&#x2019;s common stock
 outstanding, with the former Private SELLAS securityholders owning
 approximately 67.5% of the Company&#x2019;s fully diluted common
 stock, and the Company&#x2019;s&#xA0;<font style="WHITE-SPACE: nowrap">pre-Merger</font>&#xA0;securityholders
 owning the remaining approximately 32.5%. The number of shares and
 per share amounts of common stock in the accompanying financial
 statements and notes to the consolidated financial statements have
 been restated to give retroactive effect to the common stock
 conversion ratio and reverse stock split for all periods presented,
 including common stock options, restricted stock units, and common
 stock warrants. The prior year amounts for outstanding common stock
 at the $10.00 par value of Private SELLAS&#x2019; common stock and
 related additional paid-in capital have been retroactively
 presented at a $0.0001 par value. These reclassifications had no
 effect on total equity, or net loss per share.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 Common stock as included in the consolidated statement of
 stockholders&#x2019; equity (deficit) was adjusted to reflect the
 $0.0001 par value per share and additional paid-in capital was
 adjusted as follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="76%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Retroactive<br />
 Effect</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016&#xA0;Revised</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Balance at January 1, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">288</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">200</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">488</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Shares issued as partial consideration of MSK license fees</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">897</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">900</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Shares issued pursuant to MSK license agreement</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,967</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,976</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Shares issued in cancellation of Clarendon license agreement</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">500</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">502</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Shares issued upon conversion of 2016 convertible note</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,357</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">54</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,411</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Shares issued in cancellation of long-term debt</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,783</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,803</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Stock-based compensation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">354</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">354</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Balance at December 31, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">25,146</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">288</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">25,434</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 Upon completion of the Merger, the Company changed the
 Company&#x2019;s name from &#x201C;Galena Biopharma, Inc.&#x201D; to
 &#x201C;SELLAS Life Sciences Group, Inc.&#x201D;, the Company&#x2019;s
 common stock began trading on The Nasdaq Capital Market under a new
 ticker symbol &#x201C;SLS&#x201D; on January&#xA0;2, 2018 and the
 Company&#x2019;s financial statements became those of Private
 SELLAS.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <b>Overview</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The Company is a clinical-stage biopharmaceutical company focused
 on novel cancer immunotherapeutics for a broad range of cancer
 indications. The Company&#x2019;s lead product candidate,
 galinpepimut-S (&#x201C;GPS&#x201D;), is a cancer immunotherapeutic
 agent licensed from Memorial Sloan Kettering Cancer Center
 (&#x201C;MSK&#x201D;), that targets the Wilms tumor 1
 (&#x201C;WT1&#x201D;), protein, which is present in 20 or more cancer
 types. Based on its mechanism of action as a directly immunizing
 agent, GPS has the potential as a monotherapy or in combination
 with other immunotherapeutic agents to address a broad spectrum of
 hematologic, or blood, cancers and solid tumor indications. Phase 2
 clinical trials for GPS have been completed and the Company&#x2019;s
 planned Phase 3 clinical trials (pending funding availability) for
 two indications, acute myeloid leukemia (&#x201C;AML&#x201D;), and
 malignant pleural mesothelioma (&#x201C;MPM&#x201D;). GPS is also in
 development as a potential treatment for multiple myeloma
 (&#x201C;MM&#x201D;), and ovarian cancer. The Company plans to study
 GPS in up to four additional indications: as a combination therapy
 in small cell lung cancer, colorectal cancer, triple-negative
 breast cancer; and, as a monotherapy in chronic myelogenous
 leukemia (&#x201C;CML&#x201D;). The Company received Orphan Drug
 Product Designations from the U.S. Food and Drug Administration
 (&#x201C;FDA&#x201D;) as well as Orphan Medicinal Product
 Designations from the European Medicines Agency
 (&#x201C;EMA&#x201D;), for GPS in AML and MPM, as well as Fast Track
 designation for AML and MPM from the FDA.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The Company&#x2019;s pipeline also includes the legacy development
 programs of the&#xA0;<font style="WHITE-SPACE: nowrap">pre-Merger</font>&#xA0;company
 Galena, including novel cancer immunotherapy programs for
 NeuVax&#x2122; (nelipepimut-S; a vaccine against the E75 peptide
 derived from the human epidermal growth factor
 2&#xA0;<font style="WHITE-SPACE: nowrap">-or</font>&#xA0;HER2-
 protein),&#xA0;<font style="WHITE-SPACE: nowrap">GALE-301</font>&#xA0;(a vaccine
 against the E39 peptide derived from the folate binding protein
 (&#x201C;FBP&#x201D;)) and&#xA0;<font style="WHITE-SPACE: nowrap">GALE-302</font>&#xA0;(a vaccine
 against the J65 peptide derived from FBP)
 and&#xA0;<font style="WHITE-SPACE: nowrap">GALE-401</font>&#xA0;(a
 controlled release version of the approved drug anagrelide). NeuVax
 is currently in multiple investigator-sponsored Phase 2 clinical
 trials in breast cancer.&#xA0;<font style="WHITE-SPACE: nowrap">GALE-301</font>&#xA0;and&#xA0;<font style="WHITE-SPACE: nowrap">GALE-302</font>&#xA0;have
 completed early stage trials in ovarian, endometrial and breast
 cancers.&#xA0;<font style="WHITE-SPACE: nowrap">GALE-401</font>&#xA0;is being
 developed for the treatment of elevated platelets in patients with
 myeloproliferative neoplasms (&#x201C;MPNs&#x201D;), and a completed
 Phase 2 clinical trial in patients with essential thrombocythemia
 (&#x201C;ET&#x201D;) for this clinical candidate. Since the closing
 of the Merger, management has been
 evaluating,&#xA0;<font style="WHITE-SPACE: nowrap">GALE-301,</font>&#xA0;<font style="WHITE-SPACE: nowrap">GALE-302,</font>&#xA0;and&#xA0;<font style="WHITE-SPACE: nowrap">GALE-401</font>&#xA0;for
 potential internal development, strategic partnership, or other
 types of product rationalizations.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823215984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiquidationBasisOfAccountingTextBlock', window );">Liquidity</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <b>2. Liquidity</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The Company has not generated any revenues from product sales and
 has funded operations primarily from the proceeds of private
 placements of its equity interests (prior to the Merger) and
 convertible notes, as well as through the Merger. Substantial
 additional financing will be required by the Company to continue to
 fund its research and development activities. No assurance can be
 given that any such financing will be available when needed or that
 the Company&#x2019;s research and development efforts will be
 successful.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The Company regularly explores alternative means of financing its
 operations and seeks funding through various sources, including
 public and private securities offerings, collaborative arrangements
 with third parties and other strategic alliances and business
 transactions. On March&#xA0;7, 2018, the Company entered into a
 definitive securities purchase agreement to issue shares of its
 convertible preferred stock (&#x201C;Series A Convertible
 Preferred&#x201D;) and warrants to purchase shares of its common
 stock in a private placement transaction to a select group of
 institutional investors. The Series A Convertible Preferred is
 expected to close in two tranches and result in aggregate gross
 proceeds to the Company of approximately $10.7&#xA0;million. The
 Company closed the first tranche for approximately
 $6.0&#xA0;million on March&#xA0;9, 2018. The remaining
 $4.7&#xA0;million will be received at the second closing, which is
 subject to stockholder approval, and is expected to occur early in
 the second quarter.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 In addition to the proceeds from the Series A Convertible
 Preferred, in the first quarter of 2018, JGB (Cayman) Newton Ltd
 (&#x201C;JGB&#x201D;) the holder the Company&#x2019;s senior secured
 debenture due November 2018 redeemed $2.6&#xA0;million of
 outstanding principal that was satisfied by the Company with
 635,894 shares of the Company&#x2019;s common stock and redeemed
 $0.6&#xA0;million of outstanding principal, which the Company
 satisfied in cash. As a result of the redemptions, the Company was
 able to transfer $3.2&#xA0;million out of restricted cash and cash
 equivalents and into unrestricted cash and cash equivalents to be
 used to fund the Company&#x2019;s ongoing operations. The
 outstanding principal balance on the senior secured debenture as of
 April 6, 2018 is $7.0&#xA0;million and is maintained by the Company
 as restricted cash.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 Other than as described in Note 15, the Company currently does not
 have any commitments to obtain additional funds and may be unable
 to obtain sufficient funding in the future on acceptable terms, if
 at all. If the Company cannot obtain the necessary funding, it will
 need to delay, scale back or eliminate some or all of its research
 and development programs or enter into collaborations with third
 parties to: commercialize potential products or technologies that
 it might otherwise seek to develop or commercialize independently;
 consider other various strategic alternatives, including a merger
 or sale of the Company; or cease operations. If the Company engages
 in collaborations, it may receive lower consideration upon
 commercialization of such products than if it had not entered into
 such arrangements or if it entered into such arrangements at later
 stages in the product development process.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The Company has prepared its financial statements assuming that it
 will continue as a going concern, which contemplates realization of
 assets and the satisfaction of liabilities in the normal course of
 business. The Company has incurred net losses since inception and
 it expects to generate losses from operations for the foreseeable
 future primarily due to research and development costs for its
 potential product candidates, which raises substantial doubt about
 the Company&#x2019;s ability to continue as a going concern. Various
 internal and external factors will affect whether and when the
 Company&#x2019;s product candidates become approved drugs and how
 significant their market share will be, some of which are outside
 of the Company&#x2019;s control. The length of time and cost of
 developing and commercializing these product candidates and/or
 failure of them at any stage of the drug approval process will
 materially affect the Company&#x2019;s financial condition and
 future operations. The consolidated financial statements do not
 include any adjustments relating to the recoverability and
 classification of recorded asset amounts or the amounts and
 classification of liabilities that might result from the outcome of
 this uncertainty.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 As of December&#xA0;31, 2017, the Company had a cash balance of
 approximately $2.3&#xA0;million and restricted cash at $10.4
 million. In addition, the Company had outstanding accounts payable
 and accrued expenses of $14.9&#xA0;million and indebtedness of
 $11.0&#xA0;million as of December&#xA0;31, 2017, which consists of
 the Company&#x2019;s senior secured debenture with JGB. The Company
 expects its existing cash as of December&#xA0;31, 2017, together
 with&#xA0;the proceeds from the initial&#xA0;closing of its Series
 A Convertible Preferred in March 2018, will enable the Company to
 fund its operating expenses and capital expenditure requirements
 through June 2018. Assuming that all conditions to the initial
 closing are met, the Company expects an additional $4.7 million of
 cash proceeds from the second closing of the sale of the
 Company&#x2019;s Series A Convertible Preferred and warrants in the
 second quarter of 2018.</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiquidationBasisOfAccountingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the liquidation basis of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 30<br> -URI http://asc.fasb.org/subtopic&amp;trid=35686142<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiquidationBasisOfAccountingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831978000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <b>3.&#xA0;Basis of Presentation and Summary of Significant
 Accounting Policies</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>Basis of Presentation</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The accompanying consolidated financial statements have been
 prepared in conformity with accounting principles generally
 accepted in the United States (&#x201C;U.S. GAAP&#x201D;). Any
 reference in these notes to applicable guidance is meant to refer
 to U.S.&#xA0;GAAP as found in the Accounting Standards Codification
 (&#x201C;ASC&#x201D;) and Accounting Standards Updates
 (&#x201C;ASU&#x201D;) of the Financial Accounting Standards Board
 (&#x201C;FASB&#x201D;).</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>Principles of Consolidation</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The consolidated financial statements include the financial
 statements of the Company and its wholly owned subsidiaries, SELLAS
 Bermuda, SELLAS Life Sciences Group UK Ltd (&#x201C;SELLAS
 UK&#x201D;), Apthera, Inc. (&#x201C;Apthera&#x201D;) and Mills
 Pharmaceuticals, LLC (&#x201C;Mills&#x201D;). All significant
 intercompany accounts and transactions have been eliminated upon
 consolidation.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>Use of Estimates</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The preparation of these consolidated financial statements in
 accordance with U.S. GAAP requires management to make estimates and
 assumptions that affect the reported amounts of assets and
 liabilities and disclosure of contingent assets and liabilities at
 the date of the financial statements and the reported amounts of
 expenses during the reporting period.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On an ongoing basis, the Company evaluates its estimates using
 historical experience and other factors, including the current
 economic environment. Significant items subject to such estimates
 are assumptions used for purposes of determining stock-based
 compensation, the fair value of the warrants, beneficial conversion
 features associated with convertible notes, fair value of
 intangible assets acquired, carrying value of goodwill, fair value
 of contingent purchase price consideration, fair value of deferred
 tax liability assumed and accounting for research and development
 activities. Management believes its estimates to be reasonable
 under the circumstances. Actual results could differ significantly
 from those estimates.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>Fair Value of Financial Instruments</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The carrying amounts of the Company&#x2019;s financial instruments,
 including cash equivalents, accounts payable, and accrued expenses
 approximate fair value due to the short-term nature of those
 instruments. The carrying amounts of the Company&#x2019;s
 outstanding convertible notes approximate fair value due to the
 debt carrying a variable interest rate that is tied to the current
 London Interbank Offer Rate (&#x201C;LIBOR&#x201D;) rate. The fair
 value of the convertible notes is determined using a binomial
 lattice model that utilizes certain unobservable inputs that fall
 within Level&#xA0;3 of the fair value hierarchy. The fair value of
 the warrants is determine using a Black-Scholes pricing model.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>Concentration of Credit Risk</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 Financial instruments that potentially expose the Company to
 concentrations of credit risk consist principally of cash on
 deposit with multiple financial institutions, the balances of which
 frequently exceed federally insured limits.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>Cash and Cash Equivalents</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The Company considers any highly liquid investments, such as money
 market funds, with an original maturity of three months or less to
 be cash and cash equivalents.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>Restricted Cash and Cash Equivalents</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 Restricted cash consists of the minimum cash covenant as required
 by the debenture and certificates of deposit on hand with the
 Company&#x2019;s financial institutions as collateral for its
 corporate credit cards.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>Intangible Assets</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 Intangible assets are comprised of
 identifiable&#xA0;<font style="WHITE-SPACE: nowrap">in-process</font>&#xA0;research
 and development (&#x201C;IPR&amp;D&#x201D;) assets and are considered
 indefinite-lived intangible assets and are assessed for impairment
 annually on October&#xA0;1 or more frequently if impairment
 indicators exist. If the associated research and development effort
 is abandoned, the related assets will
 be&#xA0;<font style="WHITE-SPACE: nowrap">written-off</font>&#xA0;and the
 Company will record a&#xA0;<font style="WHITE-SPACE: nowrap">non-cash</font>&#xA0;impairment
 loss. For those compounds that reach commercialization, the
 IPR&amp;D assets will be amortized over their estimated useful
 lives.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>Goodwill</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 Goodwill is the excess of the cost of an acquired entity over the
 net amounts assigned to tangible and intangible assets acquired and
 liabilities assumed. Goodwill is not amortized but is subject to an
 annual impairment test. The Company has a single reporting unit and
 all goodwill relates to that reporting unit.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The Company performs its annual goodwill impairment test at the
 reporting unit level on October&#xA0;1 of each fiscal year or more
 frequently if changes in circumstances or the occurrence of events
 suggest that an impairment exists. Goodwill is evaluated for
 impairment using the simplified test of goodwill impairment as
 defined by the FASB Accounting Standards
 Update&#xA0;<font style="WHITE-SPACE: nowrap">No.&#xA0;2017-04.</font>&#xA0;Under
 the new guidance, goodwill impairment will be measured by the
 amount by which the carrying value of a reporting unit exceeds its
 fair value, without exceeding the carrying amount of goodwill
 allocated to that reporting unit. If the fair value of the
 reporting unit is less than its carrying value, an impairment loss
 is recorded to the extent that the implied fair value of the
 reporting unit&#x2019;s goodwill is less than the carrying value of
 the reporting unit&#x2019;s goodwill. The Company did not recognize
 any impairment of goodwill during the year ended December&#xA0;31,
 2017.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>Severance Costs</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The Company recognized and paid $1.9&#xA0;million of exit costs
 during 2017 related to severance benefits for former Galena
 employees terminated immediately prior to the consummation of the
 Merger.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>Patents and Patent Application Costs</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 Although the Company believes that its patents and underlying
 technology have continuing value, the amount of future benefits to
 be derived from the patents is uncertain. Patent costs are,
 therefore, expensed as incurred.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>Legal Fees and Insurance Recoveries</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 There can be a significant time lag between the time that legal
 fees are incurred and the insurance reimbursement available to
 offset the related costs. The legal fees are recorded in the period
 they are incurred, and the insurance recoveries for those costs are
 recorded in the period when the insurance reimbursement is deemed
 probable.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>Stock-based Compensation</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The Company follows the provisions of the FASB ASC Topic 718,
 &#x201C;<i>Compensation</i><i>&#xA0;&#x2014; Stock
 Compensation&#x201D;</i>&#xA0;(&#x201C;ASC 718&#x201D;),
 which requires the measurement and recognition of compensation
 expense for all stock-based payment awards made to
 employees,&#xA0;<font style="WHITE-SPACE: nowrap">non-employee</font>&#xA0;directors,
 and consultants, including stock options and warrants. Stock
 compensation expense based on the grant date fair value estimated
 in accordance with the provisions of ASC&#xA0;718 is recognized as
 an expense over the requisite service period.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 For stock options and warrants granted as consideration for
 services rendered by&#xA0;<font style="WHITE-SPACE: nowrap">non-employees,</font>&#xA0;the
 Company recognizes compensation expense in accordance with the
 requirements of FASB ASC Topic&#xA0;<font style="WHITE-SPACE: nowrap">505-50</font>&#xA0;(&#x201C;ASC&#xA0;<font style="WHITE-SPACE: nowrap">505-50&#x201D;),</font>&#xA0;&#x201C;<i>Equity
 Based Payments to&#xA0;<font style="WHITE-SPACE: nowrap">Non-</font>&#xA0;Employees</i>.&#x201D;&#xA0;<font style="WHITE-SPACE: nowrap">Non-employee</font>option
 and warrant grants that do not vest immediately upon grant are
 recorded as an expense over the vesting period. At the end of each
 financial reporting period prior to vesting, the value of these
 options and warrants, as calculated using the Black-Scholes
 option-pricing model, will be&#xA0;<font style="WHITE-SPACE: nowrap">re-measured</font>&#xA0;using
 the fair value of the Company&#x2019;s common stock and
 the&#xA0;<font style="WHITE-SPACE: nowrap">non-cash</font>&#xA0;compensation
 recognized during the period will be adjusted accordingly. Since
 the fair market value of options and warrants granted
 to&#xA0;<font style="WHITE-SPACE: nowrap">non-employees</font>&#xA0;is
 subject to change in the future, the amount of the future
 compensation expense will include fair
 value&#xA0;<font style="WHITE-SPACE: nowrap">re-measurements</font>&#xA0;until
 the stock options are fully vested.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>Research and Development Expenses</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 Research and development costs are expensed as incurred. Research
 and development costs that are paid in advance of performance are
 capitalized as a prepaid expense and amortized over the service
 period as the services are provided. Clinical study costs, a
 component of research and development expenses, are accrued over
 the service periods specified in the contracts and adjusted as
 necessary based on an ongoing review of the level of effort and
 costs actually incurred. Payments for a product license prior to
 regulatory approval of the product and payments for milestones
 achieved prior to regulatory approval of the product are expensed
 in the period incurred as research and development expenses.
 Milestone payments made in connection with regulatory approvals are
 capitalized and amortized to cost of revenue over the remaining
 useful life of the asset.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 Research and development expenses primarily consist of the
 intellectual property and research and development materials
 acquired, expenses from third parties who conduct research and
 development activities on behalf of the Company as well as related
 wages, benefits and other operating costs. The Company expenses
 in-process research and development projects acquired as asset
 acquisitions which have not reached technological feasibility and
 which have no alternative future use.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>Income Taxes</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The Company uses the asset and liability method of accounting for
 income taxes. Deferred tax assets and liabilities are recognized
 for the estimated future tax consequences attributable to
 differences between the financial statement carrying amounts of
 existing assets and liabilities and their respective tax bases and
 operating loss and credit carryforwards. Deferred tax assets and
 liabilities are measured using enacted tax rates expected to apply
 to taxable income in the years in which those temporary differences
 are expected to be recovered or settled. A valuation allowance is
 provided when it is more likely than not that some portion or all
 of a deferred tax asset will not be realized. The Company
 recognizes the benefit of an uncertain tax position that it has
 taken or expects to take on its income tax return it files, if such
 a position is more likely than not to be sustained.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The Company recognizes liabilities or assets for the deferred tax
 consequences of temporary differences between the tax basis of
 assets or liabilities and their reported amounts in the financial
 statements in accordance with FASB&#xA0;<font style="WHITE-SPACE: nowrap">ASC&#xA0;740-10,</font>&#xA0;&#x201C;<i>Accounting
 for Income Taxes&#x201D; (&#x201C;ASC&#xA0;<font style="WHITE-SPACE: nowrap">740-10&#x201D;).</font></i>These temporary
 differences will result in taxable or deductible amounts in future
 years when the reported amounts of the assets or liabilities are
 recovered or
 settled.&#xA0;<i>ASC&#xA0;<font style="WHITE-SPACE: nowrap">740-10</font></i>&#xA0;requires
 that a valuation allowance be established when management
 determines that it is more likely than not that all or a portion of
 a deferred asset will not be realized. The Company evaluates the
 realizability of its net deferred income tax assets and valuation
 allowances as necessary, at least on an annual basis. During this
 evaluation, the Company reviews its forecasts of income in
 conjunction with other positive and negative evidence surrounding
 the realizability of its deferred income tax assets to determine if
 a valuation allowance is required. Adjustments to the valuation
 allowance will increase or decrease the Company&#x2019;s income tax
 provision or benefit. The recognition and measurement of benefits
 related to the company&#x2019;s tax positions requires significant
 judgment, as uncertainties often exist with respect to new laws,
 new interpretations of existing laws, and rulings by taxing
 authorities. Differences between actual results and the
 Company&#x2019;s assumptions or changes in the Company&#x2019;s
 assumptions in future periods are recorded in the period they
 become known.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On December&#xA0;22, 2017 the President of the United States signed
 into law the Tax Cuts and Jobs Act (&#x201C;The 2017 Tax
 Act&#x201D;).&#xA0;This legislation makes significant changes in the
 United States tax laws including, but not limited to, reducing the
 corporate tax rate to 21% starting in 2018. The 2017 Tax Act
 required the Company to revalue its deferred tax assets and
 liabilities to the new rate of 21%.&#xA0;For the years ended
 December&#xA0;31, 2017 and 2016, the Company recognized income tax
 expense of $253,000 and $1,000, respectively. Staff Accounting
 Bulletin No. 118 (&#x201C;SAB 118&#x201D;) was issued to address the
 application of U.S. GAAP in situations when a registrant does not
 have the necessary information available, prepared, or analyzed
 (including computations) in reasonable detail to complete the
 accounting for certain income tax effects of the Tax Act. In
 accordance with SAB 118, we determined that the adjustment to
 deferred taxes was a provisional amount and a reasonable estimate
 at December 31, 2017. We do not expect any impact on recorded
 deferred tax balances as the remeasurement of net deferred tax
 assets will be offset by a change in valuation allowance. We are
 analyzing certain aspects of the Tax Act which could potentially
 affect the remeasurement of the net deferred tax assets.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>Net Loss Per Share</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 Basic loss per share is computed by dividing net loss applicable to
 common stockholders by the weighted average number of shares of
 common stock outstanding during each period. Diluted loss per share
 includes the effect, if any, from the potential exercise or
 conversion of securities, such as convertible debt, warrants, stock
 options and unvested restricted stock that would result in the
 issuance of incremental shares of common stock. In computing the
 basic and diluted net loss per share, the weighted average number
 of shares remains the same for both calculations due to the fact
 that when a net loss exists, dilutive shares are not included in
 the calculation as the impact is anti-dilutive.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The following potentially dilutive securities outstanding have been
 excluded from the computation of diluted weighted average shares
 outstanding, as they would be anti-dilutive:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="78%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">
 <b>Year&#xA0;ended&#xA0;December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Common stock warrants</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">963</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Stock options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">55</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Unvested restricted stock awards</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">67</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">986</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">122</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 Amounts in the table reflect the common stock equivalents of the
 noted instruments.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>Comprehensive Loss</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The Company has no items of comprehensive income or loss other than
 net loss.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>Recently Issued Accounting Pronouncements</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 In July 2017, the FASB issued ASU&#xA0;<font style="WHITE-SPACE: nowrap">2017-11,</font>&#xA0;<i>Earnings
 Per Share (Topic 260); Distinguishing Liabilities from Equity
 (Topic 480); Derivatives and Hedging (Topic 815): (Part I)
 Accounting for Certain Financial Instruments with Down Round
 Features, (Part II) Replacement of the Indefinite Deferral for
 Mandatorily Redeemable Financial Instruments of Certain Nonpublic
 Entities and Certain Mandatorily Redeemable Noncontrolling
 Interests with a Scope Exception.&#xA0;</i>The first
 part of this update addresses the complexity of accounting for
 certain financial instruments with down round features and the
 second part addresses the complexity of distinguishing liabilities
 from equity. The guidance is applicable to public business entities
 for fiscal years beginning after December&#xA0;15, 2018 and interim
 periods within those years. The Company is currently evaluating the
 potential impact of the adoption of this standard on its
 consolidated results of operations, financial position and cash
 flows and related disclosures.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 In May 2017, the FASB issued Accounting Standard Update
 No.&#xA0;<font style="WHITE-SPACE: nowrap">2017-09,</font><i>&#xA0;Compensation&#x2014;Stock
 Compensation (Topic 718): Scope of Modification Accounting</i>.
 ASU&#xA0;<font style="WHITE-SPACE: nowrap">2017-09</font>&#xA0;provides
 guidance about which changes to the terms or conditions of a
 share-based payment award require an entity to apply modification
 accounting in Topic 718. Specifically, an entity would not apply
 modification accounting if the fair value, vesting conditions, and
 classification of the awards are the same immediately before and
 after the modification. The guidance is applicable to public
 business entities for fiscal years beginning after
 December&#xA0;15, 2017 and interim periods within those years.
 Early adoption is permitted, including adoption in any interim
 period. The Company does not expect this new guidance to have a
 material impact on its consolidated financial statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 In November 2016, the FASB issued
 ASU&#xA0;<font style="WHITE-SPACE: nowrap">No.&#xA0;2016-18,</font>&#xA0;<i>Restricted
 cash</i>, amending the presentation of restricted cash within the
 statement of cash flows. The new guidance requires that restricted
 cash be included within cash and cash equivalents on the statement
 of cash flows. The ASU is effective retrospectively for reporting
 periods beginning after December&#xA0;15, 2017, with early adoption
 permitted. The Company is currently evaluating the impact of its
 pending adoption of the new standard on the consolidated financial
 statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 In March 2016, the FASB issued Accounting Standards
 Update&#xA0;<font style="WHITE-SPACE: nowrap">2016-09,</font><i>&#xA0;Compensation-Stock
 Compensation</i>. ASU&#xA0;<font style="WHITE-SPACE: nowrap">2016-09</font>&#xA0;includes
 several areas of simplification to stock compensation including
 simplifications to the accounting for income taxes, classification
 of excess tax benefits on the Statement of Cash Flows and
 forfeitures. ASU&#xA0;<font style="WHITE-SPACE: nowrap">2016-09</font>&#xA0;is effective
 for annual reporting periods beginning after December&#xA0;15,
 2016. An entity that elects early adoption must adopt all of the
 amendments in the same period. The Company adopted this ASU on
 January&#xA0;1, 2017. There was no impact to the Company&#x2019;s
 consolidated financial statements upon adoption.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 In February 2016, the FASB issued Accounting Standards Update
 No.&#xA0;<font style="WHITE-SPACE: nowrap">2016-02,</font><i>&#xA0;Leases</i>, which
 establishes a&#xA0;<font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">right-of-use</font></font>&#xA0;(&#x201C;ROU&#x201D;)
 model that requires a lessee to record a ROU asset and a lease
 liability on the balance sheet for all leases with terms longer
 than 12 months. Leases will be classified as either finance or
 operating, with classification affecting the pattern of expense
 recognition in the income statement. The new standard is effective
 for fiscal years beginning after December&#xA0;15, 2018, including
 interim periods within those fiscal years. A modified retrospective
 transition approach is required for lessees for capital and
 operating leases existing at, or entered into after, the beginning
 of the earliest comparative period presented in the financial
 statements, with certain practical expedients available. The
 Company is currently evaluating the impact of its pending adoption
 of the new standard on the consolidated financial statements.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823329872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combination</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <b>4. Business Combination</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On December&#xA0;29, 2017, the Company completed the Merger with
 Private SELLAS as discussed in Note 1. The Merger was accounted for
 as reverse merger under the acquisition method of accounting
 whereby Private SELLAS was considered to have acquired the Company
 for financial reporting purposes because, immediately upon
 completion of the Merger, Private SELLAS stockholders held a
 majority of the voting interest of the combined company.
 Immediately after the Merger, stockholders of Private SELLAS and
 the Company&#x2019;s common stock, warrants and options owned
 approximately 67.5% and 32.5% of the fully diluted common stock of
 the Company, respectively.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The purchase consideration in a reverse acquisition is determined
 with reference to the value of equity that the accounting acquirer,
 in this case, Private SELLAS, would have had to issue to the owners
 of the accounting acquiree, the Company, to give
 the&#xA0;<font style="WHITE-SPACE: nowrap">pre-acquisition</font>&#xA0;equity
 holders of the Company the same percentage interest in Private
 SELLAS that such&#xA0;<font style="WHITE-SPACE: nowrap">pre-acquisition</font>&#xA0;equity
 holders held in the Company immediately following the Merger. The
 purchase price was calculated as follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="88%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Fair value of the Company&#x2019;s&#xA0;<font style="WHITE-SPACE: nowrap">pre-Merger</font>&#xA0;shares
 outstanding</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12,487</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Estimated fair value of the
 Company&#x2019;s&#xA0;<font style="WHITE-SPACE: nowrap">per-Merger</font>&#xA0;stock
 options outstanding</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">32</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total purchase price</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12,519</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The Merger transaction has been accounted for using the acquisition
 method of accounting, which requires that assets acquired and
 liabilities assumed be recognized at their fair values as of the
 acquisition date. See Note 5 for the valuation technique utilized
 to value the IPR&amp;D.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The following table summarizes the allocation of the purchase price
 to the assets acquired and liabilities assumed as of the
 acquisition date (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="88%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Assets acquired:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,812</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Restricted cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,346</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Prepaid expenses and other assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,103</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Intangible assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17,600</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Goodwill</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,914</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total assets acquired</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">34,775</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Liabilities assumed:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accounts payable and accrued expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,692</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Litigation settlement</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,300</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Long-term debt</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,988</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Contingent purchase price consideration of Apthera, Inc.</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,294</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Warrant liability</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,309</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred tax liability</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,673</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total liabilities assumed</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">22,256</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net assets acquired</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12,519</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 Qualitative factors supporting the recognition of goodwill due to
 the Merger include the Company&#x2019;s anticipated enhanced ability
 to secure additional capital and gain access to capital market
 opportunities as a public company. The goodwill is not deductible
 for income tax purposes.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The following summary pro forma consolidated financial information
 reflects the Merger as if it had occurred on January&#xA0;1, 2016
 for purposes of the statements of operations. This summary pro
 forma information is not necessarily representative of what the
 Company&#x2019;s results of operations would have been had the
 Merger in fact occurred on January&#xA0;1, 2016, and is not
 intended to project the Company&#x2019;s results of operations for
 any future period. In addition, transaction costs associated with
 the Merger of $5.7&#xA0;million are included in general and
 administrative expense in the statement of operations for the year
 ended December 31, 2017.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 Pro forma consolidated financial information for 2017 and 2016
 (unaudited):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="80%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">
 <b>Year&#xA0;ended&#xA0;December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net revenues (in thousands)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net loss (in thousands)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">24,089</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">28,389</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Basic and diluted net loss per share</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5.15</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8.61</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <font style="WHITE-SPACE: nowrap">Non-recurring</font>&#xA0;pro
 forma transaction costs directly attributable to the Merger were
 $5.7&#xA0;million for the year ended December&#xA0;31, 2017 and
 have been deducted from the net loss presented above. The costs
 deducted from the year ended December&#xA0;31, 2017 period included
 a success fee and other transaction costs&#xA0;of $4.8 million and
 issued 119,672 shares of common stock with a fair value of
 $0.9&#xA0;million as a fee to Equilibria Capital Management Limited
 (&#x201C;Equilibria&#x201D;). Additionally, the Company incurred
 approximately $1.9&#xA0;million in severance costs as a result of
 resignations of executive officers immediately prior to the Merger.
 These costs are excluded from the pro forma financial information
 for the year ended December&#xA0;31, 2017. The Company excluded a
 $5.2&#xA0;million impairment charge incurred by the Company as well
 as combined transaction costs from Galena and the Company in the
 amount of $8.7&#xA0;million from the pro forma financial
 information for the year ended December&#xA0;31, 2017.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823377616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>5. Goodwill and Intangible Assets</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company completes its annual impairment test on October&#xA0;1
 each year, or more frequently if triggering events indicate a
 possible impairment. The Company continually evaluates financial
 performance, economic conditions and other relevant developments in
 assessing if an interim period impairment test is necessary.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Changes in the carrying amount of goodwill for the period ended
 December&#xA0;31, 2017 consisted of the following (in
 thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="68%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="89%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Balance as of January 1, 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Goodwill as a result of the Merger</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,914</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Balance as of December&#xA0;31, 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,914</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Intangible assets consist of IPR&amp;D acquired as part of the
 Merger. IPR&amp;D assets represent research and development assets
 that have not yet reached commercialization. At December&#xA0;31,
 2017, the significant components of the Company&#x2019;s IPR&amp;D
 assets consist of the NeuVax program for the prevention of
 recurrence in breast cancer, the <font style="white-space:nowrap">GALE-401</font> program for treatment of
 essential thrombocythemia, and the <font style="white-space:nowrap">GALE-301</font> &amp; <font style="white-space:nowrap">GALE-302</font> programs for prevention of
 cancer recurrent in ovarian and endometrial cancer patients in the
 adjuvant setting.</p>
 <p style="font-size:1px;margin-top:12px;margin-bottom:0px">
 &#xA0;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company&#x2019;s allocation of purchase price to acquired
 IPR&amp;D was $17.6&#xA0;million. The estimated fair value of the
 <font style="white-space:nowrap">GALE-401</font> and NeuVax
 IPR&amp;D assets were determined using a &#x201C;income
 approach,&#x201D; which is a valuation technique that provides an
 estimate of the fair value of an asset based on market participant
 expectations of the cash flows an asset would generate over its
 remaining useful life. The fair values of the <font style="white-space:nowrap">GALE-401</font> and NeuVax programs were
 $9.1&#xA0;million and $5.7&#xA0;million, respectively. Some of the
 more significant assumptions inherent in the development of those
 asset valuations include the estimated net cash flows for each year
 for the asset or product (including net revenues, cost of sales,
 research and development costs, selling and marketing costs and
 working capital/asset contributory asset charges), the appropriate
 discount rate to select in stream, the assessment of the
 asset&#x2019;s life cycle, the potential regulatory and commercial
 success risks, competitive trends impacting the asset cash flow
 stream as well as other factors. The fair value of the <font style="white-space:nowrap">GALE-301</font> &amp; <font style="white-space:nowrap">GALE-302</font> programs was $2.8&#xA0;million
 as determined using the replacement cost approach given the Phase
 1/2a development status of the programs and the lack of projected
 financial information.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 IPR&amp;D assets are required to be classified as indefinite-lived
 assets until the successful commercialization of the asset or the
 abandonment of the associated R&amp;D effort. These assets are
 assessed for impairment annually on October&#xA0;1 or more
 frequently if impairment indicators exist. Accordingly, during the
 development period after the date of acquisition, these assets will
 not be amortized until commercialization is reached. For those
 programs that reach commercialization, the Company will determine
 the useful life of the asset, reclassify the asset out of IPR&amp;D
 and begin amortization. If the associated R&amp;D effort is
 abandoned, the related IPR&amp;D assets will likely be <font style="white-space:nowrap">written-off,</font> and the Company will
 record a <font style="white-space:nowrap">non-cash</font>
 impairment loss.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final.  May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823294896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <b>6. Collaboration and License Agreements</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 As part of its business, the Company enters into licensing
 agreements with third parties that often require milestone and
 royalty payments based on the progress of the licensed asset
 through development and commercial stages. Milestone payments may
 be required, for example, upon approval of the product for
 marketing by a regulatory agency, and the Company may be required
 to make royalty payments based upon a percentage of net sales of
 the product. The expenditures required under these arrangements in
 any period may be material and are likely to fluctuate from period
 to period.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 These arrangements sometimes permit the Company to unilaterally
 terminate development of the product and thereby avoid future
 contingent payments; however, the Company is unlikely to cease
 development if the compound successfully achieves clinical testing
 objectives.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>Memorial Sloan Kettering Cancer Center</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On September&#xA0;4, 2014, (the &#x201C;MSK Effective Date&#x201D;)
 the Company entered into a license agreement (the &#x201C;Original
 MSK License Agreement&#x201D;) with MSK under which the Company was
 granted an exclusive license to develop and commercialize
 MSK&#x2019;s WT1 peptide vaccine technology. Under the terms of the
 Original MSK License Agreement, the Company is required to obtain
 certain levels of financing. If such financing is not met, MSK will
 have the right to terminate the Original MSK License Agreement with
 prior written notice, unless the Company manages to overcome the
 shortfall during the term of the notice period.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 As part of the consideration for the rights, privileges and
 licenses granted under the Original MSK License Agreement, the
 Company agreed to issue 13,199 shares to MSK representing 1.5% of
 the Company&#x2019;s fully diluted share capital as of the MSK
 Effective Date, which obligation was satisfied by assignment of
 6,599&#xA0;shares from each of the Company&#x2019;s Chief Executive
 Officer,&#xA0;<font style="WHITE-SPACE: nowrap">co-founder</font>&#xA0;and Vice
 Chairman of the Board, Dr.&#xA0;Angelos&#xA0;M. Stergiou (M.D.,
 Sc.D. h.c), and the Company&#x2019;s
 other&#xA0;<font style="WHITE-SPACE: nowrap">co-founder,</font>&#xA0;Dr.&#xA0;Miltiadis
 Sougioultzoglou (M.D.), to MSK for which they received no
 consideration. Additionally, the Company was obligated to pay
 upfront license fees in an amount equal to $1.3&#xA0;million. The
 Company recognized this amount as research and development expense
 during the year ended December&#xA0;31, 2014, as it had no
 alternative future use. The Company would further be obligated to
 pay minimum royalty payments in the amount of $0.1&#xA0;million
 each year commencing in 2015 and research funding costs of
 $0.2&#xA0;million in each year and for three years commencing in
 January 2015. In addition, to the extent certain development and
 commercial milestones are achieved, the Company will be required to
 pay MSK up to $17.4&#xA0;million in milestone payments for each
 licensed product, in addition to royalties in the event of
 commercial sales of any licensed products.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The Original MSK License Agreement, unless terminated earlier in
 accordance with the terms of the Original MSK License Agreement,
 will continue on a&#xA0;<font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">country-by-country</font></font>&#xA0;and
 licensed&#xA0;<font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">product-by-licensed</font></font>&#xA0;product
 basis, until the later of: (a)&#xA0;expiration of the last valid
 claim embracing such licensed product; (b)&#xA0;expiration of any
 market exclusivity period granted by law with respect to such
 licensed product; or (c)&#xA0;ten (10)&#xA0;years from the first
 commercial sale in such country.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On October&#xA0;30, 2015, the Company and MSK entered into the
 License Amendment, Waiver and Share Issuance Agreement (the
 &#x201C;First MSK Amendment&#x201D;). The First MSK Amendment
 extended the date required for the Company to obtain financing from
 August&#xA0;1, 2015 to December&#xA0;31, 2016, modified the amount
 of required financing and waived
 past&#xA0;<font style="WHITE-SPACE: nowrap">non-compliance</font>&#xA0;with
 certain related provisions of the Original MSK License Agreement.
 In exchange for the First MSK Amendment, the Company agreed to
 issue an aggregate of 10,867 shares to MSK, which represented 1% of
 the fully diluted share capital of the Company at such date. The
 First MSK Amendment added certain anti-dilution protection clauses
 and entitled MSK to issuance of additional shares to the extent the
 Company was not able to obtain the required financing.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On August&#xA0;10, 2016, the Company and MSK entered into the
 Second License Amendment, Waiver and Agreement
 (the&#xA0;&#x201C;Second MSK Amendment&#x201D;). The Second MSK
 Amendment extended further the date required for the Company to
 obtain financing from December&#xA0;31, 2016 to June&#xA0;30, 2017,
 amended the anti-dilution provisions of the First MSK Amendment and
 waived past&#xA0;<font style="WHITE-SPACE: nowrap">non-compliance</font>&#xA0;with
 certain related provisions of the First MSK Amendment. Under the
 Second MSK Amendment, outstanding obligations of the Company to MSK
 in an amount of $0.9&#xA0;million were converted into 13,815 shares
 effective November&#xA0;1, 2016 upon the
 Company&#x2019;s&#xA0;<font style="WHITE-SPACE: nowrap">re-domiciliation</font>&#xA0;to
 Bermuda. In consideration for this amendment and pursuant to the
 anti-dilution provisions in the Original MSK License Agreement as
 amended by the First MSK Amendment and the Second MSK Amendment,
 the Company issued MSK 30,314 additional shares and incurred
 accordingly $2.0&#xA0;million of research and development expense,
 which reflected the fair value of the Company&#x2019;s shares at
 such date.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 For the year ended December&#xA0;31, 2017, the Company incurred
 $1.0&#xA0;million of expenses relating to $0.7&#xA0;million of
 milestone payments, $0.1&#xA0;million of guaranteed minimum royal
 payments and $0.2&#xA0;million of research funding costs. For the
 year ended December&#xA0;31, 2016 the Company incurred
 $0.6&#xA0;million of expenses relating to $0.3&#xA0;million of
 milestone payments, $0.1&#xA0;million of guaranteed minimum royal
 payments and $0.2&#xA0;million of research funding costs. Such
 expenses have been included in research and development costs.
 Further, under the Second MSK Amendment, the Company is obligated
 to pay MSK $0.7&#xA0;million in milestone payments in two equal
 installments, within 60 days following the initiation of its Phase
 3 AML and mesothelioma clinical studies.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On May&#xA0;25, 2017, the Company and MSK entered into an Amended
 and Restated Exclusive License Agreement (the &#x201C;MSK A&amp;R
 License Agreement&#x201D;). Under the MSK A&amp;R License Agreement,
 the Company expanded its license under the original MSK License
 Agreement, as amended, to include a license to commercially develop
 certain additional WT1 peptides through a program of exploiting
 certain patents and other rights covering such peptides.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The MSK A&amp;R License Agreement, amongst others, added certain
 milestone payments for each additional patent licensed product as
 defined in the MSK A&amp;R License Agreement, and amended the
 milestone payments due upon commencement of the Phase 3 AML and
 mesothelioma clinical trials from $0.3&#xA0;million to
 $0.4&#xA0;million. In consideration for the MSK A&amp;R License
 Agreement, the Company issued 8,799 shares to MSK. Pursuant to a
 side letter to the MSK A&amp;R License Agreement, dated
 May&#xA0;25, 2017 (the &#x201C;MSK Side Letter&#x201D;), MSK
 converted the next milestone payment of $0.2&#xA0;million, which
 was due June&#xA0;30, 2017, into shares. Further, in consideration
 for the MSK Side Letter, Dr.&#xA0;Angelos&#xA0;M. Stergiou (M.D.,
 Sc.D. h.c.), the Company&#x2019;s Chief Executive Officer, assigned
 15,399 of his shares to MSK, for which Dr.&#xA0;Stergiou received
 no cash consideration.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On October&#xA0;11, 2017, the Company and MSK entered into a second
 Amended and Restated Exclusive License Agreement (the &#x201C;Second
 MSK A&amp;R License Agreement&#x201D;). Under the Second MSK A&amp;R
 License Agreement, the Company and MSK extended the dates for the
 Company to have obtained necessary financing, and certain milestone
 dates, in exchange for increased milestone payments, clarification
 regarding MSK&#x2019;s anti-dilution rights, and termination of the
 MSK Side Letter dated May&#xA0;25, 2017. In connection with the MSK
 A&amp;R License Agreement, the Company issued 74,795 shares to MSK.
 Prior to the Merger, the Company issued an additional 7,700 shares
 to MSK in connection with their anti-dilution rights.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>Merck&#xA0;&amp; Co., Inc.</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On September&#xA0;21, 2017, the Company entered into a clinical
 trial collaboration and supply agreement through a Merck&#xA0;&amp;
 Co., Inc. subsidiary, Merck Sharp&#xA0;&amp; Dohme B.V.
 (&#x201C;Merck subsidiary&#x201D;), whereby the Company agreed with
 the Merck subsidiary to collaborate in a research program to
 evaluate GPS as it is administered in combination with
 Merck&#x2019;s PD1 blocker pembrolizumab (Keytruda<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>) in a Phase 1/2
 clinical trial enrolling patients in up to five cancer indications,
 including both hematologic malignancies and solid tumors.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The purpose of the clinical trials is to determine if the
 administration of GPS in combination with pembrolizumab has the
 potential to demonstrate clinical activity in the presence of
 macroscopic disease, where monotherapy with either agent would have
 a more limited effect. The rationale for the study is based upon
 the presumed immunobiologic and pharmacodynamic synergy between the
 two agents, whereby the negative influence of tumor
 microenvironment factors on the immune response is mitigated by PD1
 inhibition (by pembrolizumab) thus allowing the patients&#x2019; own
 immune cells to invade and destroy cancerous growth deposits
 specifically sensitized against WT1 by GPS.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The Phase 1/2 clinical trial will utilize a combination of GPS plus
 pembrolizumab (Keytruda) in patients with WT1+ relapsed or
 refractory tumors. Specifically, the study is expected to explore
 the following cancer indications: colorectal (arm enriched in but
 not exclusive to patients with
 microsatellite&#xA0;<font style="WHITE-SPACE: nowrap">instability-low),</font>&#xA0;ovarian,
 small cell lung, triple-negative breast, and AML. This study will
 assess the efficacy and safety of the combination, comparing
 overall response rates and immune response markers achieved with
 the combination compared to prespecified rates based on those seen
 with pemrolizumab alone in comparable patient populations. The
 trial is anticipated to begin in the third quarter of 2018 (pending
 funding availability).</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>Advaxis, Inc.</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On February&#xA0;24, 2017, the Company and Advaxis, Inc.
 (&#x201C;Advaxis&#x201D;) entered into a research and development
 collaboration agreement, whereby both parties will collaborate in a
 research program to evaluate, through a &#x201C;proof of
 principle&#x201D; trial or trials (&#x201C;PoP Clinical
 Trial&#x201D;), a clinical candidate comprised of the combination of
 Advaxis&#x2019; proprietary<i>&#xA0;Lm-</i>based antigen delivery
 technology and the Company&#x2019;s patented WT1 targeted
 heteroclitic peptide antigen mixture (GPS). The term of the Advaxis
 agreement will expire upon the earlier of: (a)&#xA0;completion of
 the PoP Clinical Trial, (b)&#xA0;a decision by the parties to cease
 further development of the clinical candidate and (c)&#xA0;early
 termination of the Advaxis agreement pursuant to the terms
 thereof.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The Advaxis agreement provides for cost-sharing between the
 parties, with Advaxis being responsible for the costs of performing
 the research activities and filing any investigational new drug
 application (&#x201C;IND&#x201D;), cost-sharing for preparation of
 the IND, and the Company being responsible for the costs (exclusive
 of product costs) of conducting the PoP trial. The Company also
 agreed to make certain&#xA0;<font style="WHITE-SPACE: nowrap">non-refundable</font>&#xA0;milestone
 payments to Advaxis having an aggregate amount of up to
 $108.0&#xA0;million, upon meeting certain clinical, regulatory and
 commercial milestones. In addition, if net sales exceed certain
 targets, the Company agreed to make&#xA0;<font style="WHITE-SPACE: nowrap">non-refundable</font>&#xA0;sales
 milestone payments up to $250.0&#xA0;million and royalty payments
 based on specific royalty rates, with a maximum rate capped at a
 percentage rate in the low double digits if net sales exceed
 $1.0&#xA0;billion.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>Trojantec Ltd.</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On November&#xA0;14, 2014, the Company entered into a license
 agreement with Trojantec Ltd., (&#x201C;Trojantec&#x201D;), a company
 incorporated in Cyprus, under which the Company was granted an
 exclusive license to develop and commercialize Trojantec&#x2019;s
 TR1 Antenapedia/p21 protein treatment. In consideration for
 entering into the Trojantec License Agreement and for the rights,
 privileges and licenses granted, the Company incurred
 $0.3&#xA0;million of license fees during the year ended
 December&#xA0;31, 2014. Under the license agreement, the Company
 would be obligated to pay Trojantec royalties on net sales, if any,
 and milestone payments related to the achievement of certain
 clinical and regulatory goals.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On July&#xA0;14, 2015, the Company and Trojantec entered into the
 First Amended and Restated Exclusive License Agreement. The
 amendment reinstated the obligations of the Company under the
 original license agreement and further obligated the Company to pay
 project management fees of up to $0.4&#xA0;million.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On June&#xA0;15, 2016, the Company entered into an agreement with
 Trojantec to terminate the license agreement. In consideration for
 the termination agreement, the Company incurred and paid in cash
 $0.1&#xA0;million of termination fees. Such fees were included in
 research and development expenses for the year ended
 December&#xA0;31, 2016.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>Clarendon Trading e Investimentos LDA</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On January&#xA0;18, 2016, the Company entered into a license
 arrangement with Clarendon Trading e Investimentos LDA
 (&#x201C;Clarendon&#x201D;), a company incorporated in Portugal.
 Under the license agreement, the Company was granted an exclusive
 license to&#xA0;<font style="WHITE-SPACE: nowrap">know-how</font>&#xA0;to use for
 development and to manufacture products involving therapeutic use
 of Clarendon&#x2019;s intellectual property. In consideration for
 this assignment, the Company incurred expenses of EUR
 0.5&#xA0;million. Under the license agreement, in the event that
 the Company was successful in obtaining regulatory approval for any
 commercial exploitation of the therapeutic uses of Zolpidem, the
 Company would be obligated to pay Clarendon a yearly success fee
 and guaranteed minimum royalty payments.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 Effective September&#xA0;30, 2016, the Company entered into
 termination agreement with Clarendon to terminate the license
 agreement. In consideration for the termination agreement and in
 complete satisfaction of the Company&#x2019;s outstanding
 liabilities, the Company agreed to pay Clarendon $0.3&#xA0;million
 in cash and issue Clarendon 7,700 shares. In extinguishment of the
 Company&#x2019;s outstanding liabilities to Clarendon, the Company
 incurred an additional $0.2&#xA0;million of expense to reflect the
 fair value of the shares issued to Clarendon.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The Company&#x2019;s predecessor company, Galena entered into the
 following licensing and/or supply agreements, which the Company
 acquired through the Merger:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>The University of Texas M. D. Anderson Cancer Center and The
 Henry M. Jackson Foundation for the Advancement of Military
 Medicine, Inc.</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On September&#xA0;11, 2006, the Company acquired rights and assumed
 obligations under a license agreement among Apthera and The
 University of Texas M. D. Anderson Cancer Center
 (&#x201C;MDACC&#x201D;) and The Henry M. Jackson Foundation for the
 Advancement of Military Medicine, Inc. (&#x201C;HJF&#x201D;) which
 grants exclusive worldwide rights to a United States patent
 covering the nelipepimut-S peptide and several United States and
 foreign patents and patent applications covering methods of using
 the peptide as a vaccine. Under the terms of this license, the
 Company is required to pay an annual maintenance fee
 of&#xA0;$0.2&#xA0;million, clinical milestone payments and royalty
 payments based on sales of NeuVax or other therapeutic products
 developed from the licensed technologies.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>Biovascular, Inc.</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On December&#xA0;20, 2013, Mills and BioVascular, Inc.
 (&#x201C;BioVascular&#x201D;) entered into an exclusive license
 agreement. In 2014, through the Company&#x2019;s acquisition of
 Mills, the Company&#x2019;s wholly owned subsidiary, the Company
 acquired worldwide rights to to develop and commercialize
 anagrelide controlled release
 formulation,&#xA0;<font style="WHITE-SPACE: nowrap">GALE-401.</font>&#xA0;<font style="WHITE-SPACE: nowrap">GALE-401</font>&#xA0;contains
 the active ingredient anagrelide, an&#xA0;<font style="WHITE-SPACE: nowrap">FDA-approved</font>&#xA0;product
 that has been in use since the late 1990s for the treatment of
 myleoproliferative neoplasms. Under the terms of the license
 agreement, Mills has agreed to pay BioVascular
 a&#xA0;<font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">mid-to-low</font></font>&#xA0;single
 digit royalty on net revenue from the sale of licensed products,
 pay future cash milestone payments based on the achievement of
 specified regulatory milestones and is responsible for patent
 prosecution and maintenance.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On September&#xA0;5, 2017, Mills and BioVascular entered into an
 amendment to license agreement to modify the certain terms of the
 license agreement, including but not limited to,
 (i)&#xA0;eliminating the 3% royalty rate on annual net sales of
 $50.0&#xA0;million and the 4% royalty now applies to annual net
 sales of up to $100.0&#xA0;million, (ii)&#xA0;making an advance
 payment of approximately $0.4&#xA0;million for the milestone
 related to the initiation of the Phase 3 clinical trial payable in
 two tranches with the first payment of $0.2&#xA0;million payable on
 or before October&#xA0;31, 2017 and the second payment of
 approximately $0.2&#xA0;million payable 30 days after the
 consummation of the Merger but no later than December&#xA0;31,
 2017, (iii) adding a payment for a sublicense by Mills to a third
 party of 25% of any cash received for upfront fees or milestone
 payments if the sublicense is executed prior to first patient
 enrolled in the Phase 3 clinical trial and 17.5% of any cash
 received for upfront fees or milestone payments if the sublicense
 is executed after the first patient is enrolled in the Phase 3
 clinical trial, and (iv)&#xA0;if the first patient is not enrolled
 in the Phase 3 clinical trial by December&#xA0;31, 2018,
 BioVascular shall have the right to terminate the license agreement
 and the advance payment shall not be repaid to Mills. Under the
 terms of a September&#xA0;5, 2017 consent between Comerica Bank,
 BioVascular and Mills, Comerica Bank shall receive
 $0.1&#xA0;million of the approximately $0.4&#xA0;million advance
 payment from Mills.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>Teva Pharmaceuticals</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 In conjunction with the Merger, acquisition of NeuVax, and
 effective December&#xA0;3, 2012, the Company entered into a license
 and supply agreement with ABIC Marketing Limited
 (&#x201C;ABIC&#x201D;), a subsidiary of Teva Pharmaceuticals. Under
 the agreement, the Company granted ABIC exclusive rights to seek
 marketing approval in Israel for NeuVax for the treatment of breast
 cancer following its approval by the FDA or the EMA, and to market,
 sell and distribute NeuVax in Israel assuming such approval is
 obtained. ABIC&#x2019;s rights also include a right of first refusal
 in Israel for all future indications for which NeuVax may be
 approved.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 Under the license and supply agreement, ABIC will assume
 responsibility for regulatory registration of NeuVax in Israel,
 provide financial support for local development, and commercialize
 the product in the region in exchange for making royalty payments
 to us based on future sales of NeuVax. ABIC also agrees in the
 license and supply agreement to purchase all supplies of NeuVax
 from the Company at a price determined according to a specified
 formula.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>Dr.&#xA0;Reddy&#x2019;s Laboratories Ltd.</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 In conjunction with the Merger, acquisition of NeuVax, and
 effective January&#xA0;14, 2014, the Company entered into a
 strategic development and commercialization partnership with
 Dr.&#xA0;Reddy&#x2019;s Laboratories Ltd.
 (&#x201C;Dr.&#xA0;Reddy&#x2019;s&#x201D;), under which the Company
 licensed commercial rights in India to Dr.&#xA0;Reddy&#x2019;s for
 NeuVax in breast and gastric cancers. The Company has an agreement
 with Dr.&#xA0;Reddy&#x2019;s to conduct a Phase 2 investigational
 study in gastric cancer in India. To date, Dr.&#xA0;Reddy&#x2019;s
 has not initiated the Phase 2 study with NeuVax.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>Kwang Dong Pharmaceutical Co., Ltd.</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 In conjunction with the Merger, acquisition of NeuVax, and
 effective April&#xA0;30, 2009, the Company entered into a license
 agreement with Kwang Dong Pharmaceutical Co, Ltd. (&#x201C;Kwang
 Dong&#x201D;). Under the agreement, the Company granted Kwang Dong
 exclusive rights to seek marketing approval in The Republic of
 Korea, or South Korea for NeuVax for the treatment of breast cancer
 following its approval by the FDA or the EMA, and to market, sell
 and distribute NeuVax in South Korea assuming such approval is
 obtained.</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6820285296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <b>7. Fair Value Measurements</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The following tables present information about the Company&#x2019;s
 assets and liabilities measured at fair value on a recurring basis
 in the consolidated balance sheets (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="55%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom" nowrap="nowrap">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; WIDTH: 39.5pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt; DISPLAY: inline">
 <b>Description</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">December&#xA0;31,<br />
 2017</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Quoted&#xA0;Prices&#xA0;In<br />
 Active Markets<br />
 (Level 1)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Significant&#xA0;Other<br />
 Observable<br />
 Inputs (Level 2)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Unobservable<br />
 Inputs<br />
 (Level 3)</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,662</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,662</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Restricted cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,245</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,245</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total assets measured and recorded at fair value</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,907</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,907</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Liabilities:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Warrants potentially settleable in cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,309</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,309</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Contingent consideration</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,294</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,294</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total liabilities measured and recorded at fair value</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,603</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,603</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The Company did not transfer any financial instruments into or out
 of Level&#xA0;3 classification during the year ended
 December&#xA0;31, 2017. The contingent consideration was assumed by
 the Company in connection with the Merger and recorded at fair
 value as of the consummation of the Merger, which approximates fair
 value as of December&#xA0;31, 2017. The fair value of the
 contingent consideration is measured at the end of each reporting
 period using Level 3 inputs in a probability-weighted, discounted
 cash-outflow model. The contingent consideration relates to
 Galena&#x2019;s acquisition of Apthera, Inc. in 2011 and the future
 contingent payments of up to $32 million based on the achievement
 of certain development and commercial milestones relating to the
 Company&#x2019;s NeuVaxTM product candidate. The contingent
 consideration is payable at the election of the Company in either
 cash or shares of common stock, provided that the Company may not
 issue any shares in satisfaction of any contingent consideration
 unless it has first obtained approval of its stockholders in
 accordance with Rule 5635(a) of the Nasdaq Marketplace Rules. The
 significant unobservable assumptions include the probability of
 achieving each milestone, the date we expect to reach the
 milestone, and a determination of present value factors used to
 discount future expected cash outflows.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 At December&#xA0;31, 2016, the estimated fair value of the 2015
 Notes was $7.3&#xA0;million, which compared to a carrying value of
 $7.4&#xA0;million. See also Note 9.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 See Note 12 for discussion of the Level&#xA0;3 liabilities relating
 to warrants accounted for as liabilities.</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823215984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>8. Accrued Expenses and Other Current Liabilities</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Accrued expenses and other current liabilities consist of the
 following (in thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="82%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">
 <b>Year&#xA0;Ended&#xA0;December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Professional fees</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,744</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,077</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Value added tax</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">426</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Rebates and returns</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">223</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Compensation and related benefits</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">566</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">249</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Clinical trial costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">51</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,496</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">191</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">227</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Accrued expenses and other current liabilities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,201</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,049</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6820242576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <b>9. Debt</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 Debt and convertible debt consist of the following (in
 thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="81%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">
 <b>Year&#xA0;Ended&#xA0;December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Debt</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Current portion of Senior Secured Debenture</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,377</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Non-current portion of Senior Secured Debenture</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,611</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total debt</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,988</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Convertible debt</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2015 Shareholder Notes</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,709</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2015 Sely Note</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,659</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total convertible debt</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7,368</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>Senior Secured Debenture</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On May&#xA0;10, 2016, the Company&#x2019;s predecessor company,
 Galena entered into a securities purchase agreement, with JGB
 pursuant to which Galena sold to JGB, at a 6.375% original issue
 discount, a $25.5&#xA0;million senior secured debenture
 (the&#xA0;&#x201C;Senior Secured Debenture&#x201D;) and warrants to
 purchase up to 3,333 shares of Galena&#x2019;s common stock, $0.0001
 par value per share. Net proceeds to Galena from sale of the Senior
 Secured Debenture and warrants, after payment of commissions and
 legal fees, was approximately $23.4 million. The Senior Secured
 Debenture contained no conversion features to shares of common
 stock. The Senior Secured Debenture remains outstanding for the
 Company through the consummation of the Merger with Galena on
 December&#xA0;29, 2017.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The Senior Secured Debenture matures on November&#xA0;10, 2018, and
 accrues interest at&#xA0;9%&#xA0;per year, payable monthly. In
 addition, on the maturity date of the Senior Secured Debenture (or
 such earlier date that the principal amount of the Senior Secured
 Debenture is paid in full by acceleration or otherwise) a fixed
 amount, which shall be deemed interest under the Senior Secured
 Debenture, equal to&#xA0;$0.8&#xA0;million will be due and payable
 to JQB of the Senior Secured Debenture on such date in, at the
 option of the Company, cash and, subject to the same conditions for
 the payment of interest in shares of the Company&#x2019;s common
 stock, or a combination of cash and the Company&#x2019;s common
 stock</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The Company&#x2019;s obligations under the Senior Secured Debenture
 are secured under the security purchase agreement by a senior lien
 on all of the Company&#x2019;s assets, including all of the
 Company&#x2019;s interests in its consolidated subsidiaries. Under
 the subsidiary guarantee agreement, each subsidiary guarantees the
 performance of the Company of the securities purchase agreement,
 Senior Secured Debenture and related agreements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The Senior Secured Debenture was amended in August 2016, May 2017,
 July 2017 and August 2017. After giving effect to the amendments,
 the Senior Secured Debenture contains the following modified and/or
 additional terms, among others:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">JGB can from time to time during the
 term of the Senior Secured Debenture require the Company to prepay
 in cash all or a portion of the outstanding principal plus accrued
 and unpaid interest (the &#x201C;Outstanding Amount&#x201D;) on
 written notice to the Company, provided, that such prepayment
 amount shall not exceed the lesser of $18.5&#xA0;million and the
 outstanding principal amount. If JGB elects such prepayment of the
 Senior Secured Debenture, then the number of shares subject to the
 warrants issued to the holder will be reduced in proportion to the
 percentage of principal and accrued interest required to be prepaid
 by the Company. The Company does not have the right to prepay.</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">JGB has the right, which commenced on
 November&#xA0;10, 2016, to require the Company to redeem the
 outstanding principal amount, up to the outstanding principal
 amount of the Senior Secured Debenture by written notice to the
 Company and may deliver an unlimited number of redemption notices
 during any calendar month.</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">The Company has the option to pay
 outstanding principal redemptions and monthly interest in shares of
 common stock, cash, or a combination of shares of common stock and
 cash. Among the various conditions that must be satisfied (or
 waived) in order for the Company to be able to elect to satisfy the
 redemption amounts in shares of common stock: (a)&#xA0;the VWAP
 of&#xA0;$10.50 per share on any trading day that a redemption
 notice is delivered (b)&#xA0;no event of default has occurred and
 is continuing and (c)&#xA0;the Company&#x2019;s cash on hand exceeds
 the outstanding principal amount by at least $10.0&#xA0;million. In
 the event that any of these conditions are not met, the Company
 does not have the option to pay outstanding principal redemptions
 and monthly interest in cash.</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">The stock payment price to satisfy
 outstanding principal redemptions and monthly interest is the lower
 of (a)&#xA0;80%&#xA0;of the VWAP for the trading day immediately
 prior to the date of the applicable redemption notice
 (the&#xA0;&#x201C;Prior Day VWAP&#x201D;) and (b)&#xA0;80%&#xA0;of
 the average of the three lowest VWAPs during
 the&#xA0;20&#xA0;consecutive trading day period immediately
 preceding the date of the applicable redemption notice (the
 &#x201C;Twenty Day VWAP&#x201D;); provided, however, to the extent
 that, on any given trading day, the price per share of common stock
 on such trading day equals or exceeds&#xA0;115%&#xA0;of the Prior
 Day VWAP or Twenty Day VWAP, then for the such trading day, and
 such trading day only, each reference to 80% shall be deemed, for
 such trading day only, to be 92.5%</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">The Company was required to maintain
 a minimum of the lesser of $18.5&#xA0;million or the outstanding
 principal amount of unencumbered cash in a restricted account. As
 of December&#xA0;31, 2017, the Company maintained
 $10.2&#xA0;million of cash and cash equivalents in a restricted
 account equal to the outstanding principal amount.</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 As of December&#xA0;31, 2017, the outstanding principal balance of
 the Senior Secured Debenture was $10.2&#xA0;million. In addition to
 the outstanding principal balance, on the earlier of the maturity
 date or the date that the principal amount is paid in full, the
 Senior Secured Debenture has a $0.8 million additional interest
 amount that is included in the current portion of long-term debt as
 of December 31, 2017. Subsequent to December 31, 2017, the holder
 of the Senior Secured Debenture redeemed an additional
 $2.6&#xA0;million of outstanding principal, which the Company
 satisfied with a combination of 623,749 shares of the
 Company&#x2019;s common stock and redeemed $0.6&#xA0;million of
 outstanding principal, which the Company satisfied with
 $0.6&#xA0;million in cash. As of result of the redemptions, the
 Company was able to transfer $3.2 million out of restricted cash
 and cash equivalents and into unrestricted cash and cash
 equivalents to be used to fund the Company&#x2019;s ongoing
 operations. The principal redemptions of $2.6 million subsequent to
 December 31, 2017 that were satisfied with shares of the
 Company&#x2019;s common stock are classified as long-term debt, as
 of December 31, 2017, as the amounts were not satisfied with
 working capital.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>2015 Convertible Term Notes, as of December 31, 2017</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On April&#xA0;2, 2015, the Company issued an aggregate of
 $1.5&#xA0;million in principal amount of convertible term notes to
 certain stockholders of the Company (the &#x201C;2015 Shareholder
 Notes&#x201D;) and on May&#xA0;7, 2015, the Company issued a
 convertible term note in the principal amount of $5.0&#xA0;million
 to EQC Biotech Sely I Fund (&#x201C;EQC Sely I Fund&#x201D;), a
 related party of the Company (the&#xA0;&#x201C;2015 Sely Note&#x201D;
 and, together with the 2015 Shareholder Notes, the &#x201C;2015
 Notes&#x201D;). The holders of the 2015 Shareholder Notes include
 two of the significant stockholders and founding investors of the
 Company, Drs. Angelos M. Stergiou (M.D., ScD h.c.), the
 Company&#x2019;s CEO and Miltiadis Sougioultzoglou (M.D.). The 2015
 Notes were issued at par and bear an interest rate of 8%. The 2015
 Shareholder Notes matured on April&#xA0;2, 2017 and the 2015 Sely
 Note originally matured on May&#xA0;7, 2017.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 In August 2017, the Company and EQC Sely I Fund further amended the
 2015 Sely Note to agree the number of shares issuable upon
 consummation of the Merger. Accordingly, contingent upon and
 effective immediately prior to completion of the Merger, the
 Company will issue to EQC Sely I Fund 632,328 of its common
 shares&#xA0;<font style="WHITE-SPACE: nowrap">and&#xA0;5-year&#xA0;warrants</font>&#xA0;to
 purchase 316,163 of its common shares at a post-Merger price equal
 to 105% of the volume weighted average price of Galena common stock
 for the 30&#xA0;calendar days following the closing date of the
 Merger (described above in Note 1), in full satisfaction of the
 2015 Sely Note.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On June&#xA0;13, 2017, the Board of Directors approved a
 $7.3&#xA0;million capital increase (the &#x201C;Bridge
 Financing&#x201D;), pursuant to which an aggregate of 1,865,261
 shares were issued at a price per share equal to approximately
 $3.91.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 As part of the Bridge Financing, an aggregate of $1.3&#xA0;million
 (330,551 shares) was subscribed by certain stockholders who are
 also the holders of the 2015 Shareholder Notes. The cash proceeds
 were used to partially offset the principal ($1.2 million) and
 cumulative accrued interest ($0.1 million) due on the 2015
 Shareholder Notes. Following the Bridge Financing, the Company
 extinguished in cash its remaining obligations on the 2015
 Shareholder Notes, which included $0.3&#xA0;million of principal
 and $0.2&#xA0;million of cumulative accrued interest as of
 June&#xA0;21, 2017.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On December&#xA0;29, 2017, the Company issued 632,326 shares of
 common stock and warrants to purchase 316,163 of its common stock
 in full satisfaction of the 2015 Sely Note. The 2015 Sely Note
 conversion was considered to be an induced conversion and
 extinguishment and the Company realized a loss of $0.7&#xA0;million
 during the year ended December&#xA0;31, 2017. The Company
 considered the extinguishment to be a capital transaction and it
 was therefore recorded in the Company&#x2019;s consolidated
 statements of stockholders&#x2019; equity (deficit).</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>2016 Convertible Term Note</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On June&#xA0;30, 2016, the Company issued a $15.0&#xA0;million
 convertible term note to EQC Sely I Fund (the &#x201C;2016
 Note&#x201D;). The 2016 Note was issued at par and had an interest
 rate of 8%. The 2016 Note was issued with similar terms to the 2015
 Notes (excluding the warrant coverage) whereby the 2016 Note is
 mandatorily convertible into equity upon the earlier to occur: a)
 the closing of a qualified IPO, b) a change in the Company&#x2019;s
 domicile from Switzerland to Bermuda or c)
 the&#xA0;<font style="WHITE-SPACE: nowrap">six-month</font>&#xA0;anniversary
 of the note.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On November&#xA0;1, 2016, the Company redomiciled its operations
 from Switzerland to Bermuda and therefore, the 2016 Note, together
 with accrued interest, was converted into 236,705 shares of its
 common stock based upon a&#xA0;<font style="WHITE-SPACE: nowrap">pre-agreed</font>&#xA0;valuation,
 which represented fair value at the commitment date. Interest
 accrued on the 2016 Note up to the date of conversion was
 $0.4&#xA0;million. No gain or loss was recognized upon the
 conversion.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>Long-term Debt</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On March&#xA0;2, 2015, the Company entered into a loan agreement
 with a third party whereby the third party granted a $2.5 million
 loan to the Company (the &#x201C;2015 Loan Agreement&#x201D;). On
 December&#xA0;24, 2015, the counterparty to the 2015 Loan Agreement
 reassigned all of its rights, interests and benefits under such
 agreement to Starcove Ltd., a company incorporated in Cyprus and a
 shareholder of the Company (&#x201C;Starcove&#x201D;). There were no
 further changes made to the 2015 Loan Agreement as a result of the
 reassignment. The term of the loan granted under the 2015 Loan
 Agreement was 24 months with an interest rate of 8%.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On April&#xA0;6, 2016, the Company entered into a second loan
 agreement with Starcove (the &#x201C;Framework Loan
 Agreement&#x201D;), whereby Starcove extended a line of credit to
 the Company of $1.5 million with an interest rate of 6%. The term
 of the Framework Loan Agreement was three years. All principal and
 accrued interest would be payable in a single payment on
 April&#xA0;6, 2019 unless earlier paid but no sooner than six
 months from the date of the Framework Loan Agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 As of December&#xA0;31, 2016, the Company had made three
 withdrawals under the credit line: (1)&#xA0;$0.6 million on
 April&#xA0;12, 2016, (2)&#xA0;$0.6&#xA0;million on May&#xA0;12,
 2016 and (3)&#xA0;$0.3 million on June&#xA0;2, 2016.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On November&#xA0;1, 2016, an aggregate amount of $4.4 million,
 which represented the principal and accrued interest under the 2015
 Loan Agreement and the Framework Loan Agreement (together, the
 &#x201C;Starcove Loans&#x201D;), was extinguished upon the issuance
 of 67,140 shares of the Company&#x2019;s common stock with an
 estimated fair value equal to the carrying value of the debt.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On November&#xA0;25, 2013, the Company entered into a loan
 agreement with a shareholder, whereby the shareholder granted a EUR
 1.8&#xA0;million loan to the Company (the &#x201C;2013 Loan
 Agreement&#x201D;). The term of the loan was open-ended and had an
 interest rate of 5%. On January&#xA0;1, 2014, the principal amount
 of the 2013 Loan Agreement, together with accrued interest, was
 re-assigned on a 50:50 basis to the Company&#x2019;s co-founders,
 Drs.&#xA0;Angelos M. Stergiou (M.D., Sc.D. h.c.) and Miltiadis
 Sougioultzoglou (M.D.).</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On December&#xA0;31, 2015, the Company entered into an agreement
 with each of Drs. Stergiou and Sougioultzoglou, whereby the
 Company&#x2019;s aggregate obligation of EUR 1.8&#xA0;million,
 together with accrued interest equal to EUR 0.1&#xA0;million as of
 such date, as well as an additional EUR 0.1&#xA0;million of
 payables due to them from the Company, were offset by an aggregate
 amount of EUR 0.7&#xA0;million representing receivables due to the
 Company from Drs. Stergiou and Sougioultzoglou pursuant to various
 other agreements that were entered into in 2012 and 2013. As a
 result, as of December&#xA0;31, 2015, the amount of the
 Company&#x2019;s outstanding loans to Drs. Stergiou and
 Sougioultzoglou were EUR 0.7&#xA0;million and EUR 0.6&#xA0;million,
 respectively (each, a &#x201C;Founder Loan&#x201D; and together, the
 &#x201C;Founder Loans&#x201D;). The interest rate on the Founder
 Loans was 2.5% and the term of the Founder Loans was three years.
 The original and modified loans were not considered substantially
 different as the difference between the present value of the
 remaining cash flows under the original and the modified terms was
 less than 10%. As such, extinguishment accounting did not
 apply.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On November&#xA0;1, 2016, an aggregate amount of EUR
 0.7&#xA0;million and EUR 0.6&#xA0;million, which represented the
 principal and accrued interest under each respective Founder Loan,
 were converted into 11,571 and 10,383 shares, respectively. The
 number of shares issued was based on the fair value of the
 Company&#x2019;s shares at the conversion date and therefore no gain
 or loss was recognized upon the cancellation of the loans.</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823329872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>10. Commitments and Contingencies</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <i>Legal Proceedings</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 From time to time, the Company is subject to various pending or
 threatened legal actions and proceedings, including those that
 arise in the ordinary course of its business, which may include
 employment matters, breach of contract disputes and stockholder
 litigation. Such actions and proceedings are subject to many
 uncertainties and to outcomes that are not predictable with
 assurance and that may not be known for extended periods of time.
 The Company records a liability in its consolidated financial
 statements for costs related to claims, including future legal
 costs, settlements and judgments, when the Company has assessed
 that a loss is probable and an amount can be reasonably estimated.
 If the reasonable estimate of a probable loss is a range, the
 Company records the most probable estimate of the loss or the
 minimum amount when no amount within the range is a better estimate
 than any other amount. The Company discloses a contingent liability
 even if the liability is not probable or the amount is not
 estimable, or both, if there is a reasonable possibility that a
 material loss may have been incurred. In the opinion of management,
 as of the date hereof, the amount of liability, if any, with
 respect to these matters, individually or in the aggregate, will
 not materially affect the Company&#x2019;s consolidated results of
 operations, financial position or cash flows.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company&#x2019;s predecessor company, Galena was involved in
 multiple legal proceedings and administrative actions, including
 stockholder class actions, both state and federal, some of which
 are ongoing and to which the Company is now subject as a result of
 the Merger. They are as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 Settled Matters</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 On December&#xA0;16, 2015, Galena received a subpoena issued by the
 U.S. Attorney&#x2019;s Office for the District of New Jersey
 (&#x201C;USAO NJ&#x201D;), requesting the production of a broad range
 of documents pertaining to Galena&#x2019;s marketing and promotional
 practices for Abstral. Through its communications with the USAO NJ
 and the U.S. Department of Justice (&#x201C;DOJ&#x201D;), Galena came
 to understand that the investigation being undertaken by the USAO
 NJ and DOJ was a criminal investigation in addition to a civil
 investigation that could ultimately involve Galena as well as one
 or more former employees. Pursuant to Galena&#x2019;s charter,
 Galena was reimbursing certain former employees&#x2019;
 attorney&#x2019;s fees with respect to the investigation but stopped
 on May&#xA0;1, 2017. Galena cooperated with the civil, and is
 continuing to cooperate with the criminal, investigations, and on
 September&#xA0;8, 2017, DOJ announced a settlement agreement with
 Galena regarding the USAO NJ&#x2019;s and DOJ&#x2019;s investigation.
 The settlement agreement involves a <font style="WHITE-SPACE: nowrap">non-criminal</font> resolution and a civil
 payment in equal installments over twelve months of approximately
 $7.6&#xA0;million, plus interest accrued since the date of reaching
 an agreement in principle, in return for a release of government
 claims in connection with the investigation. The $7.6&#xA0;million
 civil payment is payable over four equal quarterly installments,
 with the first payment being made in the third quarter of 2017. As
 set forth in that settlement agreement, for a release of all claims
 against Galena and its officers and directors and dismissal with
 prejudice of the qui tam lawsuit described below, the relator
 received a portion of the civil payment to the federal government.
 On December&#xA0;29, 2017, Galena made the remaining three payments
 to the federal government, which has advised us that all sums due
 and payable under the settlement agreement have been paid.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 In addition, there is a qui tam action pending in the U.S. District
 Court of the District of New Jersey related to the investigation by
 USAO NJ and DOJ. On September&#xA0;18, 2017, Galena executed a
 settlement agreement with the attorneys for the relator in the qui
 tam action to settle the statutorily mandated attorney fees award
 by payment of $0.1 million in cash and $0.2 million in Galena
 common stock subject to court approval, which amounts were accrued
 during the second quarter 2017. Galena also obtained the consent of
 Private SELLAS under the terms of the Merger Agreement. However on
 November&#xA0;7, 2017, attorneys for the qui tam relator agreed to
 have Galena pay the $0.2 million in cash. Galena also obtained the
 consent of Private SELLAS under the terms of the Merger Agreement.
 Galena paid the $0.3 million in cash for the statutorily mandated
 attorney fees award in the fourth quarter of 2017. As a result of
 receiving the portion of the civil settlement payment noted above
 and the settlement payment of the statutorily mandated attorney
 fees award, the relator will dismiss with prejudice the claims
 against Galena in the qui tam lawsuit.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 Open Matters</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 On October&#xA0;13, 2016, Galena filed a complaint in the Circuit
 Court for the County of Multnomah for the State of Oregon against
 Aon Risk Insurance Services West, Inc. (Aon) where Galena is
 seeking attorney&#x2019;s fees, costs and expenses incurred by
 Galena related to its coverage dispute with a certain insurer and
 for amounts Galena was required to contribute to the settlements of
 In re Galena Biopharma, Inc. Derivative Litigation and In re Galena
 Biopharma, Inc. Securities Litigation as a direct result of certain
 insurer&#x2019;s failure to pay its full policy limits of liability
 and other relief. Galena and Aon are currently engaged in written
 discovery.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 On February&#xA0;13, 2017, a putative stockholder securities class
 action complaint was filed in the U.S. District Court for the
 District of New Jersey captioned, Miller v. Galena Biopharma, Inc.,
 et al. On February&#xA0;15, 2017, a putative stockholder securities
 class action complaint was filed in the U.S. District Court for the
 District of New Jersey entitled, Kattuah v. Galena Biopharma, Inc.,
 et al. The actions assert that the defendants failed to disclose
 that Galena&#x2019;s promotional practices for Abstral<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">&#xAE;</sup> (fentanyl
 sublingual tablets were allegedly improper and that Galena may be
 subject to civil and criminal liability, and that these alleged
 failures rendered Galena&#x2019;s statements about its business
 misleading. Two groups of stockholders and one individual
 stockholder filed three motions to be appointed lead plaintiff on
 April&#xA0;14, 2017 and April&#xA0;17, 2017.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Subsequently, one of the stockholders groups withdrew its motion
 for lead plaintiff status and the individual stockholder notified
 the Court that he does not object to the appointment of the
 remaining stockholder group, GALE investor group, as lead
 plaintiff. On July&#xA0;17, 2017, the Court approved the GALE
 investor group as named lead plaintiff and its counsel as lead and
 liaison counsel. The Court also consolidated both actions. An
 amended complaint was filed on October&#xA0;6, 2017. On
 December&#xA0;15, 2017, Galena and the former officers and
 employees filed a motion to dismiss the amended complaint. The
 plaintiffs have responded to a former officer&#x2019;s motion to
 dismiss on February&#xA0;13, 2018 and will respond to
 Galena&#x2019;s and the other former officers&#x2019; and
 employees&#x2019; motion to dismiss on March&#xA0;2, 2018. Galena
 and the former officers and employees are expected to file a reply
 in April of 2018. Thereafter, Galena will take the matter under
 advisement. It is not known when the Court will issue a ruling in
 this matter.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 On March&#xA0;16, 2017, a complaint captioned Keller v. Ashton et
 al., CA No. <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">2:17-cv-01777</font></font> was filed in the
 U.S. District Court for the District of New Jersey against
 Galena&#x2019;s former directors and the Company, as a nominal
 defendant. The complaint purports to assert derivative claims for
 breach of fiduciary duty on Galena&#x2019;s behalf against its
 former directors based on substantially similar facts as alleged in
 the putative stockholder securities class action complaints
 mentioned above. Galena&#x2019;s response to the complaint was due
 on June&#xA0;1, 2017; however, the Court on May&#xA0;21, 2017,
 entered a stay of the proceedings pending resolution of motions to
 dismiss in the securities litigations described above.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Galena also received a stockholder demand dated April&#xA0;14,
 2017, pursuant to 8 Del. C. Sec. 220, from a stockholder (Albert
 Zhang) demanding access to Galena&#x2019;s books and records
 relating to its sales of Abstral and the U.S. Attorney&#x2019;s
 investigation into Galena&#x2019;s sale of Abstral in order for
 Mr.&#xA0;Zhang to determine, among other things, whether to file a
 derivative lawsuit against Galena&#x2019;s former management and
 directors. Galena has responded to the demand and Mr.&#xA0;Zhang
 has indicated that he will file a derivative complaint soon.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 On April&#xA0;27, 2017, a putative stockholder class action was
 filed in the Court of Chancery of the State of Delaware captioned
 Patel vs. Galena Biopharma, Inc. et. al, CA No. <font style="WHITE-SPACE: nowrap">2017-0325-JTL</font> seeking relief under
 Section&#xA0;225 of the Delaware General Corporation Law (DGCL) and
 alleging breaches of fiduciary duties by Galena&#x2019;s former
 board of directors and former interim chief executive officer
 regarding proposals to amend Galena&#x2019;s certificate of
 incorporation to increase the amount of authorized shares of common
 stock and effectuate a reverse stock split at the July 2016 and
 October 2016 stockholder meetings, respectively. On June&#xA0;2,
 2017, an amended verified complaint was filed along with a motion
 to expedite the proceedings. On June&#xA0;5, 2017, Galena filed a
 verified petition under Section&#xA0;205 of the DGCL and a motion
 to expedite the proceedings. On June&#xA0;8, 2017, the Court denied
 a request by the plaintiff to schedule a preliminary injunction
 motion and ordered a prompt trial on both the plaintiff and
 Galena&#x2019;s claims. On June&#xA0;20, 2017, the Court
 consolidated the claims into In re Galena Biopharma, Inc., C. A.
 No. <font style="WHITE-SPACE: nowrap">2017-0423-JTL.</font> On
 July&#xA0;10, 2017, the Court ordered that the trial of the claims
 be held on August&#xA0;28, 30 and 31, 2017. On July&#xA0;24, 2017,
 Galena entered into a binding settlement term sheet, which the
 Court enforced on November&#xA0;30, 2017, over the objection of the
 plaintiff. On December&#xA0;8, 2017, the Court set the hearing on
 the settlement for March&#xA0;15, 2018. On December&#xA0;11, 2017,
 the Court also granted an order validating the ratification votes
 at the special stockholder meeting held on July&#xA0;6, 2017 and
 the certificate of amendments filed by Galena for the increase in
 authorized shares in 2011, 2013, 2015, and 2016 as well as for the
 reverse stock split in 2016. On February&#xA0;22, 2018, the
 plaintiff filed his brief in support of the settlement as well as
 his request for attorneys&#x2019; fees and an incentive award. On
 March&#xA0;1, 2018, the former directors and former interim chief
 executive officer responded to plaintiff&#x2019;s brief. On
 February&#xA0;28, 2018, the former directors and former interim
 chief executive officer requested the Court continue the date of
 the hearing to approve the settlement as the Company was working
 with the staff of the SEC to obtain the <font style="WHITE-SPACE: nowrap">no-action</font> letter required by the
 binding settlement term sheet. The Plaintiff objected to such
 continuance. On March&#xA0;15, 2018, the Court ruled in favor of
 the Company and continued the settlement hearing for 90 days.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Under the terms of the settlement, the class will receive a
 settlement payment of $1.3&#xA0;million, in addition to attorney
 fees in an amount to be approved by the Court. The settlement
 payment of $1.3&#xA0;million consists of $50,000 in cash to be paid
 by the Company or its insurers and $1,250,000 in unrestricted
 shares of the Company&#x2019;s common stock (&#x201C;Settlement
 Stock&#x201D;), which valuation will be based on the volume-weighted
 average closing price for the 20 trading days immediately preceding
 the day before the transfer of the Settlement Stock to the
 settlement fund pursuant to the terms and conditions of the
 settlement. The Company anticipates that the Settlement Stock will
 be issued, pursuant to the terms of the Stipulation of Settlement,
 in a transaction that is exempt from the registration requirements
 of the Securities Act of 1933, as amended (the &#x201C;Securities
 Act&#x201D;), pursuant to Section&#xA0;3(a)(10) of the Securities
 Act. Any amounts awarded by the Court for attorneys&#x2019; fees
 will be paid in part by the settlement fund and in part by the
 Company&#x2019;s insurance carriers. Upon the effectiveness of the
 proposed settlement, the individual defendants will be released
 from the claims that were asserted or could have been asserted in
 the class action by class members participating in the
 settlement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 On July&#xA0;6, 2017, a complaint captioned Jacob v. Schwartz et
 al., Case No. C17-01222, was filed in the Superior Court of
 California, County of Contra Costa against Galena&#x2019;s former
 directors and the Company, as a nominal defendant. The complaint
 purports to assert derivative claims for breach of fiduciary duty
 on Galena&#x2019;s behalf against its former directors based on
 substantially similar facts as alleged in the derivative complaint
 mentioned above. Galena&#x2019;s response to the complaint was due
 on July&#xA0;7, 2017; however, the Court on September&#xA0;5, 2017,
 entered a stay of the proceedings pending resolution of motions to
 dismiss in the securities litigations described above.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 On November&#xA0;7, 2017, a written demand was made on Galena by a
 stockholder requesting that additional financial projections and
 valuation analyses be made in Galena&#x2019;s Form <font style="WHITE-SPACE: nowrap">S-4</font> relating to the Merger, which was
 declared effective on November&#xA0;6, 2017. The demand stated,
 among other thing, that, if such disclosures are not made within a
 reasonable period of time, the stockholder intends to file a
 securities class action lawsuit in federal court. Galena has
 resolved the matters raised in the demand letter through a nominal
 monetary payment and additional disclosures in the Form
 <font style="WHITE-SPACE: nowrap">S-4.</font></p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 On January&#xA0;23, 2018, a complaint captioned Johnson v Schwartz
 et al., CA No. <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">2:18-cv-00903</font></font> was filed in the
 U.S. District Court for the District of New Jersey against
 Galena&#x2019;s former directors, officers and employees and the
 Company as a nominal defendant. The complaint purports to assert
 derivative claims for breach of fiduciary duty on Galena&#x2019;s
 behalf against its former directors, officers and employees based
 on substantially similar facts as alleged in the putative
 stockholder securities class action complaints and derivative
 complaints mentioned above, as well as making demand futility
 allegations against the current board of directors, who are not
 named as defendants. It is expected that the Company and the
 individual defendants will respond to the complaint through an
 appropriate pleading or motion and, if necessary, seek an order
 from the Court staying the proceedings pending further developments
 in the securities litigations described above.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 On or about April 9, 2018, JGB filed a lawsuit in the U.S. District
 Court for the Southern District of New York captioned <i>JGB
 (Cayman) Newton, Ltd. v. Sellas Life Sciences Group, Inc., et
 al.</i>, Case 1:18-cv-3095 (DLC), or the JGB Action. The complaint
 in the JGB Action asserts claims under state law and federal
 securities law against us, our Chief Executive Officer, Angelos M.
 Stergiou, M.D., ScD H.C, and our Interim Chief Financial Officer,
 Aleksey N. Krylov (Mr. Krylov together with the Company and
 Dr.&#xA0;Stergiou, the Defendants). The complaint in the JGB Action
 alleges, among other things, that we breached a contractual
 obligation to deliver certain shares of our common stock to JGB and
 that, in the course of negotiations related to the senior secured
 debenture agreement, the Defendants failed to disclose to JGB
 certain information regarding positive clinical trial results that
 was not then public. According to the complaint, JGB seeks to
 receive 2,483,500 shares of our common stock, damages, and costs
 and expenses incurred in the JGB action, among other things. We
 dispute the claims in the JGB Action and intend to defend against
 them vigorously.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Contingent Consideration related to Development, Regulatory and
 Commercial Milestone Payments and Business Combinations</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company acquires assets still in development and enters into
 research and development arrangements with third parties that often
 require milestone and royalty payments based on the progress of the
 asset through development stages. Milestone payments may be
 required, for example, upon approval of the product for marketing
 by a regulatory agency. In certain agreements, the Company is
 required to make royalty payments based upon a percentage of the
 sales. Because of the contingent nature of these payments, they are
 not included in the table of contractual obligations shown
 below.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 These arrangements may be material individually, and in the
 unlikely event that milestones for multiple products covered by
 these arrangements were reached in the same period, the aggregate
 charge to expense could be material to the results of operations.
 In addition, these arrangements often give the Company the
 discretion to unilaterally terminate development of the product,
 which would allow the Company to avoid making the contingent
 payments; however, the Company is unlikely to cease development if
 the compound successfully achieves clinical testing objectives. For
 additional information on the Company&#x2019;s commitments under
 collaboration and license agreements read Note 6 to these
 consolidated financial statements. For additional information on
 the Company&#x2019;s commitments of contingent consideration read
 Note 7 to these consolidated financial statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Commitments</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company rents office space under a <font style="WHITE-SPACE: nowrap">non-cancelable</font> operating lease. Rental
 expense amounted to $0.2&#xA0;million for the years ended
 December&#xA0;31, 2017 and 2016. The Company&#x2019;s contractual
 obligations that may require future cash payments as of
 December&#xA0;31, 2017 under the <font style="WHITE-SPACE: nowrap">non-cancelable</font> operating lease are as
 follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="88%"></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Operating<br />
 Leases</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">223</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2019</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">76</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">299</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6663374224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity (Deficit)</a></td>
<td class="text"><div>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>11. Stockholders&#x2019; Equity (Deficit)</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 On June&#xA0;13, 2017, the Board of Directors approved the Bridge
 Financing, pursuant to which an aggregate of 1,865,262 shares were
 issued at a price per share equal to approximately $3.91.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Under the same valuation terms as the Bridge Financing, the Company
 issued 38,321 shares to MSK in cancellation of a $0.2&#xA0;million
 milestone payment due June&#xA0;30, 2017, as contemplated by the
 MSK Side Letter. In addition, the Company issued 30,094 shares in
 cancellation of a $0.1&#xA0;million Equilibria management fee that
 was payable for March to June 2017, and 28,246 shares in
 cancellation of net compensation of $0.1&#xA0;million due to
 Dr.&#xA0;Angelos Stergiou (M.D., Sc.D. h.c.), the Company&#x2019;s
 Chief Executive Officer.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Shares of common stock as of December&#xA0;31, 2017 for future
 issuance are reserved for as follows (in thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="68%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="91%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Warrants outstanding</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">963</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Stock options outstanding</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Restricted stock units</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Options reserved for future issuance under the Company&#x2019;s 2017
 Equity Incentive Plan</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">575</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Shares reserved for future issuance under the Employee Stock
 Purchase Plan</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">58</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Total reserved for future issuance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,619</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6608641184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock', window );">Warrants</a></td>
<td class="text"><div>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>12. Warrants</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The following is a summary of warrant activity for the years ended
 December&#xA0;31, 2017 (in thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="49%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom" nowrap="nowrap">
 <p style="margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:61.50pt; display:inline; font-size:8pt; font-family:Times New Roman;">
 <b>Warrant Issuance</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Outstanding,<br />
 January&#xA0;1,<br />
 2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Granted</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Assumed</b><br />
 <b>through<br />
 Merger</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Expired</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Outstanding,<br />
 December&#xA0;31,<br />
 2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Expiration</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 2017 Equilibria</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">316</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">316</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">December&#xA0;2022</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Galena February 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">567</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">567</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">February 2022</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Galena other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">80</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">80</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">Various&#xA0;to&#xA0;2022</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">316</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">647</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">963</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 </table>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Warrants assumed in connection with the acquisition of Galena
 consist of warrants that may be settled in cash, which are
 liability-classified warrants, and equity-classified warrants.
 Subsequent to December&#xA0;31, 2017, 501,000 the Company&#x2019;s
 February 2017 warrants to purchase shares of common stock were
 cancelled under various warrant exchange agreements as disclosed in
 Note&#xA0;16.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <i>Warrants classified as liabilities</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Liability-classified warrants consist of warrants to purchase
 common stock issued in connection with previous equity financings
 for the February 2017 financing and various other equity financings
 (the Company) that were assumed by the Company at the consummation
 of the Merger. These warrants may settle in cash and were
 determined not to be indexed to the Company&#x2019;s common
 stock.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The estimated fair value of outstanding warrants accounted for as
 liabilities is determined at each balance sheet date. Any decrease
 or increase in the estimated fair value of the warrant liability
 since the most recent balance sheet date is recorded in the
 consolidated statement of operations as other income (expense). The
 fair value of the warrants as of December&#xA0;31, 2017 is
 estimated using a Black-Scholes pricing model with the following
 inputs:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="50%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom" nowrap="nowrap">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:61.50pt; display:inline; font-size:8pt; font-family:Times New Roman;">
 <b>Warrant Issuance</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Outstanding&#xA0;(in<br />
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">
 <b>Strike&#xA0;price&#xA0;(per<br />
 share)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Expected&#xA0;term<br />
 (years)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Volatility%</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b><font style="white-space:nowrap">Risk-free&#xA0;rate</font><br />
 %</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Galena February 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">567</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">33.00</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4.12</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">79.29</td>
 <td nowrap="nowrap" valign="bottom">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2.09</td>
 <td nowrap="nowrap" valign="bottom">%&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Galena other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">76</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">888.22</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2.74</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">72.46</td>
 <td nowrap="nowrap" valign="bottom">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2.00</td>
 <td nowrap="nowrap" valign="bottom">%&#xA0;</td>
 </tr>
 </table>
 <p style="font-size:1px;margin-top:12px;margin-bottom:0px">
 &#xA0;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The expected volatility assumptions are based on the
 Company&#x2019;s implied volatility in combination with the implied
 volatilities of similar publicly traded entities. The expected term
 assumptions are based on the remaining contractual terms of the
 warrants. The risk-free rate is based on the <font style="white-space:nowrap">zero-coupon</font> rates in effect at the time
 of valuation. The dividend yield used in the pricing model is zero,
 because the Company has no present intention to pay cash
 dividends.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The changes in fair value of the warrant liability for the year
 ended December&#xA0;31, 2017 were as follows (in thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="56%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom" nowrap="nowrap">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:61.50pt; display:inline; font-size:8pt; font-family:Times New Roman;">
 <b>Warrant Issuance</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Warrant<br />
 liability,<br />
 January&#xA0;1,<br />
 2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">
 <b>Fair&#xA0;value&#xA0;of<br />
 warrants<br />
 granted</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">
 <b>Fair&#xA0;value&#xA0;of<br />
 warrants<br />
 acquired</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">
 <b>Change&#xA0;in&#xA0;fair<br />
 value of<br />
 warrants</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Warrant<br />
 liability,<br />
 December&#xA0;31,<br />
 2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Galena February 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,305</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,305</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Galena other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$<br /></td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;<br /></td>
 <td nowrap="nowrap" valign="bottom">&#xA0;<br /></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,309</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,309</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <i>Warrants classified as equity</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company issued 316,163 warrants to purchase shares of the
 Company&#x2019;s common stock at an exercise price of $7.42,
 maturing five years from issuance, to EQC Private Markets SAC Fund
 Ltd&#x2014;EQC Biotech Sely I Fund on December&#xA0;29, 2017. These
 warrants are recorded in equity at fair value upon issuance, and
 not as liabilities, and are not subject to adjustment to fair value
 in subsequent reporting periods. The fair value of the warrants
 granted was&#xA0;$5.60&#xA0;per share using the Black-Scholes
 pricing model with the fair value assumptions for the grant
 including a volatility of&#xA0;90.10%, expected term
 of&#xA0;five&#xA0;years, risk free rate of&#xA0;2.20%, and a
 dividend rate of&#xA0;0.00.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for freestanding option contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock. Includes disclosure on the strike price and the number of shares to which the contract is indexed, the settlement date or dates of the contract, and the issuer's accounting for the contract. If the terms of the contract provide settlement alternatives, those settlement alternatives are disclosed, including who controls the settlement alternatives, and the maximum number of shares that could be required to be issued, to net share settle the contract, if applicable. If a contract does not have a fixed or determinable maximum number of shares that could be required to be issued, the fact that a potentially infinite number of shares that may be required to be issued to settle the contract is disclosed. Disclosure also includes the contract's current fair value for each settlement alternative and how changes in the price of the issuer's equity instruments affect those settlement amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=2229355<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817753920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <b>13. Stock-Based Compensation</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 Share and per share amounts below have been retroactively adjusted
 to reflect the exchange ratio and reverse stock split as described
 in Note 1.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>2017 Equity Incentive Plan</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On December&#xA0;29, 2017. the 2017 Equity Incentive Plan was
 approved, and currently allows for the issuance of up to a maximum
 of approximately 575,000 shares of common stock in connection with
 the grant of stock-based awards, including stock options,
 restricted stock, restricted stock units, stock appreciation rights
 and other types of awards as deemed appropriate, not including
 shares subject to awards assumed in connection with certain
 transactions, including the Merger. As of December&#xA0;31, 2017,
 an aggregate of approximately 575,000 shares of common stock were
 reserved for issuance under the Company&#x2019;s 2017 Equity
 Incentive Plan. Upon the consummation of the Merger, the Company
 assumed approximately 10,171 shares subject to outstanding common
 stock options granted under the Company&#x2019;s 2016 Incentive Plan
 that will remain exercisable for one year for former Company
 employees and directors. There are approximately 575,000 shares
 available for future grants based on adjustments in the 2017 Equity
 Incentive Plan. There were no common stock options granted under
 the 2017 Equity Incentive Plan for the years ended
 December&#xA0;31, 2017.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The amount of shares reserved for issuance under the 2017 Equity
 Incentive Plan will automatically increase on January 1<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">st</sup>&#xA0;of each year,
 for a period of not more than ten years, commencing on January
 1<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">st</sup>&#xA0;of
 the year following the year in which the Effective Date occurs and
 ending on (and including) January&#xA0;1, 2027, in an amount equal
 to 4% of the total number of shares of common stock outstanding on
 December 31<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">st</sup>&#xA0;of the
 preceding calendar year. Notwithstanding the foregoing, the board
 of directors may act prior to January 1<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">st</sup>&#xA0;of a given
 year to provide that there will be no January 1<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">st</sup>&#xA0;increase in
 the share reserve for such year or that the increase in the share
 reserve for such year will be a lesser number of shares of common
 stock than would otherwise occur pursuant to the preceding
 sentence.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On November&#xA0;1, 2016, the Board of Directors approved the
 Company&#x2019;s 2016 Incentive Plan under which 189,627 shares were
 reserved for issuance. The 2017 Equity Incentive Plan replaced the
 2016 Incentive Plan.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 In accordance with the 2016 Incentive Plan, the Company&#x2019;s
 employees, directors and consultants are eligible
 to&#xA0;<font style="WHITE-SPACE: nowrap">receive&#xA0;non-qualified&#xA0;and</font>&#xA0;incentive
 stock options and RSUs. The stock options generally vest
 over&#xA0;<font style="WHITE-SPACE: nowrap">a&#xA0;3-year&#xA0;period</font>&#xA0;and
 expire 10 years from the date of the grant.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The following table summarizes the components of stock-based
 compensation expense in the consolidated statements of operations
 for the years ended December&#xA0;31, 2017 and 2016, respectively
 (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="84%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Research and development</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">729</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">23</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 General and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,440</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">331</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total stock-based compensation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,169</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">354</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>Options to Purchase Shares of Common Stock</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 There were no stock options granted during the year ended
 December&#xA0;31, 2017. The weighted-average grant date fair value
 of options granted during the year ended December&#xA0;31, 2016 was
 $38.03. The Company uses the Black-Scholes option-pricing model and
 the following assumptions were used to determine the fair value of
 all its stock options granted in 2016:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="84%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Risk free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right"><font style="WHITE-SPACE: nowrap">1.82-2.32%</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Volatility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right"><font style="WHITE-SPACE: nowrap">85-94%</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected lives (years)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right"><font style="WHITE-SPACE: nowrap">5.13-10.00</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected dividend yield</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0%</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 As of December&#xA0;31, 2017, there was no unrecognized
 compensation cost related to outstanding stock options.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The following table summarizes stock option activity of the
 Company:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="63%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b><br />
 <b>Number of</b><br />
 <b>Shares</b><br />
 <b>(In&#xA0;Thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted</b><br />
 <b>Average</b><br />
 <b>Exercise</b><br />
 <b>Price</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Aggregate<br />
 Intrinsic Value<br />
 (In&#xA0;Thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Balance as of January 1, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">55</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">52.94</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at December 31, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">55</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">52.94</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Assumed in connection with the Merger with Galena</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,240.55</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Canceled</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(55</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">52.94</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at December&#xA0;31, 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,240.55</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Options exercisable at December&#xA0;31, 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,240.55</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The aggregate intrinsic values of outstanding and exercisable stock
 options at December&#xA0;31, 2017 were calculated based on the
 closing price of the Company&#x2019;s common stock as reported on
 the Nasdaq Capital Market on December&#xA0;31, 2017 of $7.86 per
 share. The aggregate intrinsic value equals the positive difference
 between the closing fair market value of the Company&#x2019;s common
 stock and the exercise price of the underlying stock options.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>Restricted Stock Units with Time-Based Conditions</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On August&#xA0;7, 2017, the Board of Directors accelerated the
 vesting of all outstanding restricted stock units (&#x201C;
 RSUs&#x201D;) with time-based conditions and all $1.2&#xA0;million
 of unrecognized stock-based compensation was recognized upon
 acceleration.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The following table outlines RSU activity with only a time-based
 condition:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b><br />
 <b>Number of</b><br />
 <b>Shares</b><br />
 <b>(In&#xA0;Thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted</b><br />
 <b>Average</b><br />
 <b>Grant&#xA0;Date&#xA0;Fair<br />
 Value</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at January 1, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">46</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">52.94</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at December 31, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">46</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">52.94</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">58</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3.91</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Vested</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(46</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">52.94</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Canceled</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(58</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3.91</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at December&#xA0;31, 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>RSUs with Time-Based and Performance-Based Conditions</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 In addition to the RSUs with time-based conditions, the Company
 granted RSUs subject to both time-based and performance-based
 vesting conditions to certain of its
 employees&#xA0;<font style="WHITE-SPACE: nowrap">and&#xA0;non-employees&#xA0;pursuant</font>&#xA0;to
 the 2016 Incentive Plan. These RSUs vest based on both
 (i)&#xA0;continued service either over a three-year measurement
 period or at the end of the required service period and
 (ii)&#xA0;the achievement of a liquidity event. The vesting dates
 for these RSUs are January&#xA0;1, 2018, January&#xA0;1, 2019,
 January&#xA0;1, 2020 or February&#xA0;27, 2018. The liquidity
 event, as defined in the relevant RSU grant agreements, will be
 satisfied upon the earlier of either: a) change of control or b) a
 qualified initial public offering.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b><br />
 <b>Number of</b><br />
 <b>Shares</b><br />
 <b>(In&#xA0;Thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted</b><br />
 <b>Average</b><br />
 <b>Grant&#xA0;Date&#xA0;Fair<br />
 Value</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at January 1, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">52.94</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at December 31, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">52.94</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Vested</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">NA</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Canceled</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(8</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">52.94</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at December&#xA0;31, 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">52.94</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The Company recognizes compensation expense related to these RSUs
 when the liquidity event is deemed probable. As such, no
 compensation expense was recorded during the years ended
 December&#xA0;31, 2017 and 2016, as the liquidity event is outside
 the Company&#x2019;s control and not deemed probable until it
 occurs.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>2017 Employee Stock Purchase Plan</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The Company also has an employee stock purchase plan
 (&#x201C;ESPP&#x201D;) which allows employees to contribute up
 to&#xA0;15%&#xA0;of their cash earnings, subject to certain
 maximums, to be used to purchase shares of the Company&#x2019;s
 common stock on each semi-annual purchase date. On each offering
 date, each eligible employee, pursuant to an offering made under
 the ESPP, will be granted a right to purchase up to that number of
 shares of Common Stock purchasable either with a percentage or with
 a maximum dollar amount, as designated by the Board, but in either
 case not exceeding fifteen percent (15%) of such employee&#x2019;s
 earnings (as defined by the Board in each offering) during the
 period that begins on the offering date (or such later date as the
 Board determines for a particular offering) and ends on the date
 stated in the offering, which date will be no later than the end of
 the Offering. As of December&#xA0;31, 2017, the board of directors
 has not established the various parameters under the ESPP and no
 shares have been delivered under the ESPP. There are approximately
 57,000 shares of common stock reserved for issuance under the ESPP
 , plus the number of shares of common stock that are automatically
 added on January 1<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">st</sup>&#xA0;of each year
 for a period of up to ten years, commencing on the first January
 1<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">st</sup>&#xA0;following the
 effective date and ending on (and including) January&#xA0;1, 2027,
 in an amount equal to the lesser of (i) 1% of the total number of
 shares of common stock outstanding on December 31<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">st</sup>&#xA0;of the
 preceding calendar year, and (ii)&#xA0;102,279 shares of Common
 Stock.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6832039760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <b>14. Income Taxes</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The loss before income taxes is as follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="78%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">As of December 31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 U.S.</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">265</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">108</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Non - U.S.</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(23,766</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(17,788</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(23,501</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(17,680</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The components of federal and state income tax expense are as
 follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="86%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">As&#xA0;of&#xA0;December&#xA0;31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Current</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Federal</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">76</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 State</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">138</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">42</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Foreign</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total current</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">214</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">42</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Federal</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 State</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">39</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(41</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Foreign</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total deferred</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">39</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(41</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total income tax expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">253</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The components of net deferred tax assets are as follows (in
 thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="80%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">As of December&#xA0;31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net operating loss carryforwards</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,028</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,145</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Tax credit carryforwards</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">345</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">295</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Stock based compensation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,550</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">28</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Licensing deduction deferral</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,105</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">395</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">81</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Gross deferred tax assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,423</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,549</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Valuation allowance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(4,658</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,508</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net deferred tax asset</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,765</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">41</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The components of net deferred tax liabilities are as follows (in
 thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="84%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">As&#xA0;of&#xA0;December&#xA0;31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <font style="WHITE-SPACE: nowrap">In-process</font>&#xA0;research
 and development not subject to future amortization for tax
 purposes</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,438</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Gross deferred tax liability</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,438</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The provision for income taxes differs from the provision computed
 by applying the federal statutory rate to net loss before income
 taxes as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="84%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">As&#xA0;of&#xA0;December&#xA0;31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 U.S. federal statutory income tax rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(34.0</td>
 <td valign="bottom" nowrap="nowrap">)%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(34.0</td>
 <td valign="bottom" nowrap="nowrap">)%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 State and local taxes, net of federal benefit</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.4</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Foreign rate differential</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">34.4</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">25.5</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Permanent differences</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.1</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.1</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Tax rate change and true-up</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.3</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.2</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Valuation allowance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.1</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10.4</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Tax credits</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1.4</td>
 <td valign="bottom" nowrap="nowrap">)%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2.0</td>
 <td valign="bottom" nowrap="nowrap">)%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Effective income tax rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.1</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 At December 31, 2017, the Company had domestic federal and state
 net operating loss carryforwards of approximately $3.7 million and
 $3.7 million, respectively, available to reduce future taxable
 income, which expire at various dates beginning in 2027. The
 Company also had federal research and development tax credit
 carryforwards of approximately $0.4 million, respectively,
 available to reduce future tax liabilities and which expire at
 various dates beginning in 2027. The income tax expense for the
 year ended December 31, 2016 relates to both the indefinite lived
 deferred tax liabilities and the December 22, 2017 enactment of the
 Tax Cuts and Jobs Act.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 Under the provisions of the Internal Revenue Code, the net
 operating losses (&#x201C;NOL&#x201D;) and tax credit carryforwards
 are subject to review and possible adjustment by the Internal
 Revenue Service and state tax authorities. NOL and tax credit
 carryforwards may become subject to an annual limitation in the
 event of certain cumulative changes in the ownership interest of
 significant shareholders over a three-year period in excess of 50%,
 as defined under Sections&#xA0;382 and 383 of the Internal Revenue
 Code of 1986, respectively, as well as similar state tax
 provisions. This could limit the amount of tax attributes that the
 Company can utilize annually to offset future taxable income or tax
 liabilities. The amount of the annual limitation, if any, will be
 determined based on the value of the Company immediately prior to
 the ownership change. Subsequent ownership changes may further
 affect the limitation in future years. The Company has completed
 several financings since its inception, which may have resulted in
 a change in control as defined by Sections 382 and 383 of the
 Internal Revenue Code or could result in a change in control in the
 future. Utilization of the net operating loss and tax credits
 carryforwards may be limited by &#x201C;ownership change&#x201D;
 rules, as defined in Section 382 of the Internal Revenue Code of
 1986, as amended, and similar state provisions. This annual
 limitation may result in the expiration of the net operating losses
 and credits before utilization.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 In assessing the need for a valuation allowance the Company may
 utilize indefinite-lived deferred tax liabilities from an
 indefinite-lived intangible asset as a future source of
 income.&#xA0;The Company&#x2019;s IPR&amp;D, as recorded in
 acquisition accounting, can be utilized as a source of income
 arising from the future reversal of temporary difference that can
 be offset against post 2017 indefinite-lived NOLs.&#xA0;Therefore,
 the Company is permitted to offset the indefinite-lived DTL up to
 the 80 percent limitation for NOL&#x2019;s generated subsequent to
 January 1, 2018.&#xA0;As such, an indefinite-lived NOL was recorded
 in acquisition accounting as a reduction to the valuation allowance
 related to deferred tax assets in the amount of $1.8 million. The
 valuation allowance increased by $1.2 million and $1.8 million for
 the years ended December 31, 2017 and 2016, respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The Company files income tax returns in the United States and
 various state jurisdictions. The Company is subject to tax
 examinations for the 2012 tax year and beyond. The Company does not
 recognize tax benefits that are not more-likely-than-not to be
 supported based upon the technical merits of the tax position
 taken. In assessing its unrecognized tax benefits, the Company has
 analyzed its tax return filing positions in all of the federal,
 state and foreign filing jurisdictions where it is required to file
 income tax returns, as well as all open years in those
 jurisdictions.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The following table indicates the changes to the Company&#x2019;s
 unrecognized tax benefits (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="85%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">As&#xA0;of&#xA0;December&#xA0;31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Beginning of the Year - unrecognized tax benefits</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$<br />
 &#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">&#x2014;<br />
 &#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap"><br />
 &#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Increases/ (Decrease) - prior year tax positions</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">44</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Increases - current year tax positions</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">28</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 End of the Year - unrecognized tax benefits</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">72</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The unrecognized tax benefits, if recognized and in absence of full
 valuation allowance, would impact the income tax provision by
 $28,000 and $44,000 as of December 31, 2017 and 2016, respectively.
 As of December 31, 2017, the Company does not believe that it is
 reasonably possible that its unrecognized tax benefits would
 significantly change in the following 12 months.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 In assessing the realizability of deferred tax assets, management
 considers whether it is more-likely-than-not that some portion or
 all of the deferred tax assets will not be realized in the near
 term. The ultimate realization of deferred tax assets is dependent
 upon the generation of future taxable income during the periods in
 which those temporary differences become deductible.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On December 22, 2017, the Tax Cuts and Jobs Act (the &#x201C;2017
 Tax Act&#x201D;) was enacted. The 2017 Tax Act includes a number of
 changes to existing United States tax laws that impact the company,
 most notably a reduction of the United States corporate income tax
 rate from 34% to 21% for tax years beginning after December 31,
 2017. The 2017 Tax Act also provides for a one-time transition tax
 on certain foreign earnings and the acceleration of depreciation
 for certain assets placed into service after September 27, 2017 as
 well as prospective changes beginning in 2018, including repeal of
 the domestic manufacturing deduction, acceleration of tax revenue
 recognition, capitalization of research and development
 expenditures, additional limitations on executive compensation and
 limitations on the deductibility of interest.</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6698964240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>15. Related Party Transactions</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <i>Management and Strategic Collaboration Agreement</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Effective in June&#xA0;2016, the Company and Equilibria, a company
 incorporated in Bermuda and a significant stockholder of the
 Company, entered into the management and strategic collaboration
 agreement. Under the Equilibria collaboration agreement,
 Equilibria, amongst other services, is engaged to provide certain
 strategic, management and capital raising advice to the Company.
 The Equilibria collaboration agreement is effective for three years
 and will be renewable thereafter only upon the mutual written
 agreement of both parties. The Equilibria collaboration agreement
 will automatically terminate upon the closing of an IPO or a
 strategic sale. During the term of the Equilibria collaboration
 agreement, the Company, in exchange for the services received, paid
 Equilibria a quarterly fee of $0.1&#xA0;million (the
 &#x201C;Equilibria Management Fee&#x201D;). The Equilibria Management
 Fee can be paid in cash or, at the mutual agreement of the parties,
 in shares of the Company at a valuation equal to the
 Company&#x2019;s most recent financing round. In addition to the
 Equilibria Management Fee, the Company has agreed to pay Equilibria
 any expenses reasonably incurred in performing the services agreed.
 For the years ended December&#xA0;31, 2017 and 2016, the Company
 had incurred and paid in cash $0.3&#xA0;million and
 $0.2&#xA0;million, respectively, of Equilibria Management Fees.
 These amounts are included in general and administrative expense in
 the consolidated statements of operations. As of December&#xA0;31,
 2017, the Company had an outstanding payable of $0.1&#xA0;million
 payable to Equilibria. As of December&#xA0;31, 2016, there was no
 outstanding fee payable to Equilibria.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 For the provision of the management and strategic collaboration
 services, the Company also agreed to pay Equilibria an incentive
 fee equal to 2% of the post-money market value of the Company on
 the date of its IPO. Such fee will be payable in shares with a
 <font style="white-space:nowrap">per-share</font> price equal to
 the price set for the sale of the Company&#x2019;s shares to other
 investors in its IPO. The Company and Equilibria, may jointly agree
 to settle the incentive fee earlier, if deemed appropriate for
 achieving a successful IPO, through either a cash payment, issuance
 of shares, or a combination of the two. In the event that the
 Company is sold as part of a strategic sale, the incentive fee will
 be equal to 2% of the gross value paid by the purchaser in
 cash.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 In February 2017, the Company and Equilibria entered into an
 amendment of the Equilibria collaboration agreement. Under the
 amendment, in the event that the Company entered into a reverse
 merger transaction in lieu of an initial public offering, the
 incentive fee to Equilibria was 2% of the post-merger fully diluted
 market value of the Company immediately after the closing of the
 reverse merger transaction, payable in a combination of cash and
 shares of common stock of the Company. The cash payment was based
 on the per share price equaling the intrinsic value of the
 Company&#x2019;s shares in the Merger. The share-based component of
 the incentive fee was based on the post-closing fully diluted
 number of shares outstanding.</p>
 <p style="font-size:1px;margin-top:12px;margin-bottom:0px">
 &#xA0;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 In August 2017, the Company and Equilibria further amended the
 Equilibria collaboration agreement to fix the compensation payable
 to Equilibria in connection with the completion of the Merger,
 described above in Note 1. Accordingly, upon consummation of the
 Merger on December&#xA0;29, 2017, the Company incurred
 $0.1&#xA0;million to Equilibria and issued 119,672 shares of common
 stock to Equilibria at a fair value of $0.9&#xA0;million. These
 amounts are included in general and administrative expense in the
 consolidated statements of operations. Also, upon consummation of
 the Merger and pursuant to the amended Equilibria collaboration
 agreement, such agreement was terminated.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <i>Debt</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company has entered into several related party debt
 transactions with stockholders, which are described in Note 9.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <i>MSK License Agreement</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 See Note 6 for information regarding the MSK License Agreement
 entered into by the Company. MSK owned 3.7% and 5.4% of the
 Company&#x2019;s outstanding share capital as of December&#xA0;31,
 2017 and 2016, respectively.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <i>Other Related Party Transactions</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company&#x2019;s Chief Executive Officer,
 Dr.&#xA0;Angelos&#xA0;M. Stergiou (M.D., Sc.D. h.c.) is a
 significant stockholder of the Company owning 7.8% and 24.0% of the
 Company&#x2019;s outstanding share capital as of December&#xA0;31,
 2017 and 2016, respectively. Further transactions involving the
 Company and Dr.&#xA0;Stergiou are described in Note 6 and Note
 9.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 On November&#xA0;28, 2016, the Company granted 3,651 stock options
 to a prior member of the Company&#x2019;s Board of Directors. Such
 prior director is additionally a full-time employee of MSK. The
 option was terminated on August&#xA0;6, 2017 in consideration of an
 approximately $30,000 cash payment.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 On November&#xA0;28, 2016, the Company granted 9,107 RSUs to a
 member of the Company&#x2019;s Scientific Advisory Board pursuant to
 a consulting agreement for scientific advisory services to be
 performed on behalf of the Company (see Note 13). Additionally,
 such member and consultant is a full-time employee of MSK (see Note
 6).</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6664068576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <b>16. Subsequent Events</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>Warrant Exchange Agreements</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On February&#xA0;6, 2018, the Company and CVI Investments, Inc.
 (&#x201C;CVI&#x201D;) entered into a warrant exchange agreement (the
 &#x201C;CVI Agreement&#x201D;). The Company had previously issued to
 CVI a warrant to purchase 99,333 shares (on a post-reverse split
 basis) (the &#x201C;CVI Warrant&#x201D;) of its common stock, par
 value $0.0001 per share (the &#x201C;Common Stock&#x201D;) pursuant
 to the registered offering described in the Company&#x2019;s
 prospectus filed with the Securities and Exchange Commission
 pursuant to Rule 424(b)(5) under the Securities Act of 1933 on
 February&#xA0;9, 2017 (the &#x201C;2017 Offering&#x201D; and the
 warrants issued in such offering, the &#x201C;2017 Warrants&#x201D;).
 Pursuant to the CVI Agreement, in exchange for CVI&#x2019;s
 agreement to surrender the CVI Warrant for cancellation, the
 Company agreed to issue to CVI a number of shares of Common Stock
 equal to the quotient resulting from dividing $232,440 by the
 closing sale price of the Common Stock on the first completed
 trading day following the first public announcement by the Company
 of the material terms and conditions of a Company financing
 transaction.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The CVI Agreement contained a &#x201C;Most Favored Nations&#x201D;
 (&#x201C;MFN&#x201D;) clause, allowing CVI to opt to substitute terms
 of warrant exchange agreements entered with other warrant holders
 from the 2017 Offering if CVI deemed those terms more favorable.
 Pursuant to this MFN provision, effective as of March 1, CVI
 Agreement was deemed modified as follows: Pursuant to the CVI
 Agreement, in exchange for the surrender and cancellation of the
 CVI Warrants, the Company issued to CVI a convertible promissory
 note in the aggregate principal amount of $232,440.00 (the
 &#x201C;CVI Note&#x201D;). The CVI Note accrues interest on the
 outstanding principal amount at a rate of 5.0% per annum and the
 entire principal and accrued interest is due and payable on August
 13, 2018. The interest rate increases to 18% per annum during a
 period in which there is an &#x201C;event of default&#x201D; under
 the CVI Note. The holder has the right, from time to time after
 April 30, 2018, to convert the outstanding principal and accrued
 interest into shares of Common Stock at a conversion price equal to
 $7.00 per share (subject to adjustments for stock splits,
 combinations and the like) (the &#x201C;Conversion Price&#x201D;),
 provided that CVI may not affect any such conversions to the extent
 it would beneficially own in excess of 4.99% of the Company&#x2019;s
 outstanding Common Stock. At any time after an event of default has
 occurred (whether or not the Company has cured such default), CVI
 may elect to convert the outstanding principal and accrued interest
 into shares of Common Stock at an alternate conversion price equal
 to the lower of (i) the Conversion Price then in effect at the time
 of such conversion, or (ii) 70% of the lowest VWAP of the Common
 Stock on a trading day during the 10-trading period prior to such
 conversion. For purposes of the CVI Note, an &#x201C;event of
 default&#x201D; is deemed to have occurred upon (A) the suspension
 of trading of the Common Stock on the Nasdaq Capital Market for a
 period of five consecutive trading days, (B) the Company&#x2019;s
 failure to timely deliver shares of Common Stock upon a conversion
 within five trading days of the applicable conversion date or upon
 the Company&#x2019;s notice that it does not intend to comply a
 request by Empery to convert, (C) the Company&#x2019;s or any of its
 subsidiaries&#x2019; failure to timely pay any amount due under the
 CVI Note or the CVI Agreement, (D) the Company&#x2019;s bankruptcy,
 insolvency, liquidation, or similar proceeding, or (E) a breach by
 the Company of any representation, warranty or covenant contained
 in the CVI Note or the CVI Agreement that remains uncured for a
 period of three consecutive trading days. On April 2, 2018, the
 Company and CVI mutually agreed to waive the April 30, 2018 start
 date for the conversion right of the CVI Note, and CVI converted
 the entire outstanding balance of principal and interest on the CVI
 Note into 33,356 shares of Company&#x2019;s Common Stock. As a
 result, the CVI Note is fully paid.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On February&#xA0;7, 2018, the Company entered into a warrant
 exchange agreement (the &#x201C;Anson Agreement&#x201D;) with Anson
 Investments Master Fund LP (&#x201C;Anson&#x201D;). The Company
 previously issued to Anson a warrant to purchase 30,000 shares (on
 a post-reverse split basis) of Common Stock (the &#x201C;Anson
 Warrant&#x201D;) in the 2017 Offering. Pursuant to the Anson
 Agreement, on February&#xA0;8, 2018, the Company issued to Anson
 Investments 12,536 shares of Common Stock in exchange for the
 surrender and cancellation of the Anson Warrant.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On February&#xA0;9, 2018, the Company entered into a warrant
 exchange agreement (the &#x201C;Sabby Agreement&#x201D;) with Sabby
 Healthcare Master Fund Ltd. and Sabby Volatility Warrant Master
 Fund Ltd (collectively, &#x201C;Sabby&#x201D;). The Company had
 previously issued to Sabby warrants to purchase an aggregate of
 83,333 shares (on a post-reverse split basis) of Common Stock (the
 &#x201C;Sabby Warrants&#x201D;) pursuant to the 2017 Offering.
 Pursuant to the Sabby Agreement, in exchange for the surrender and
 cancellation of the Sabby Warrants, the Company will issue to Sabby
 a number of shares of Common Stock determined by dividing $195,000
 by the closing sale price of the Common Stock on the date of the
 closing date of the exchange. Such closing is expected to occur on
 or before February&#xA0;13, 2018, and the Sabby Agreement will
 terminate if such closing does not occur by such date. The Sabby
 Agreement also provides that during
 the&#xA0;<font style="WHITE-SPACE: nowrap">30-trading</font>&#xA0;day
 period following the closing of the exchange, Sabby will not sell
 in open market transactions more than 2% of the daily trading
 volume of Common Stock on any one trading day. Further, the Sabby
 Agreement provides that if the Company enters into an agreement
 with a holder of the 2017 Warrants that provides for the exchange
 of such warrants on terms more favorable than those contained in
 the Sabby Agreement, as determined in the reasonable discretion of
 Sabby, then the Company will provide written notice to Sabby and
 the Sabby Agreement will be deemed to have been modified in an
 economically and legally equivalent manner such that Sabby would
 receive such more favorable terms, unless Sabby elects not to
 accept such terms. For purposes of determining whether terms are
 more favorable than the terms contained in the Sabby Agreement, an
 exchange ratio that is based upon 100% of the then market price of
 the Common Stock, even if less than the price applicable to the
 exchange of the Sabby Warrants, is not more favorable than the
 terms of the Sabby Agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 Also on February&#xA0;9, 2018, the Company entered into a warrant
 exchange agreement (the &#x201C;Hudson Bay Agreement&#x201D;) with
 Hudson Bay Master Fund Ltd (&#x201C;Hudson Bay&#x201D;). The Company
 had previously issued to Hudson Bay a warrant to purchase an
 aggregate of 146,666 shares (on a post-reverse split basis) of
 Common Stock (the &#x201C;Hudson Bay Warrant&#x201D;) pursuant to the
 2017 Offering. Pursuant to the Hudson Bay Agreement, in exchange
 for the surrender and cancellation of the Hudson Bay Warrant, the
 Company issued to Hudson Bay a convertible promissory note in the
 principal amount of $343,200 (the &#x201C;Hudson Bay Note&#x201D;).
 The Hudson Bay Agreement also provides that provides that if the
 Company enters into an agreement with a holder of the 2017 Warrants
 that provides for the exchange of such warrants on terms more
 favorable than those contained in the Hudson Bay Agreement,
 including without limitation, with respect to ratio of any cash
 paid, or principal amount of notes or value of Common Stock paid in
 exchange for such warrants, then the Company is to provide notice
 to Hudson Bay within one trading day of such agreement and the
 terms of the Hudson Bay Agreement will be deemed to have been
 modified in an economically and legally equivalent manner such that
 Hudson Bay would receive the benefit of such more favorable terms,
 unless Hudson Bay elects not to accept such terms by a notice
 delivered to the Company within 10 trading days.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The Hudson Bay Note accrues interest on the outstanding principal
 amount at a rate of 5% per annum and the entire principal and
 accrued interest is due and payable on August&#xA0;9, 2018. The
 interest rate increases to 18% per annum during a period in which
 there is an &#x201C;event of default&#x201D; under the Hudson Bay
 Note. The holder has the right, from time to time after
 April&#xA0;30, 2018, to convert the outstanding principal and
 accrued interest into shares of Common Stock at a conversion price
 equal to $7.00 per share (subject to adjustments for stock splits,
 combinations and the like) (the &#x201C;Conversion Price&#x201D;),
 provided that Hudson Bay may not affect any such conversions to the
 extent it would beneficially own in excess of 9.99% of the
 Company&#x2019;s outstanding Common Stock. At and any time after an
 event of default has occurred (whether or not the Company has cured
 such default), Hudson Bay may elect to convert the outstanding
 principal and accrued interest into shares of Common Stock at an
 alternate conversion price equal to the lower of (i)&#xA0;the
 Conversion Price then in effect at the time of such conversion, or
 (ii) 70% of the lowest volume-weighted average price of the Common
 Stock on a trading day during the&#xA0;<font style="WHITE-SPACE: nowrap">10-trading</font>&#xA0;period
 prior to such conversion. For purposes of the Hudson Bay Note, an
 &#x201C;event of default&#x201D; is deemed to have occurred upon
 (A)&#xA0;the suspension of trading of the Common Stock on the
 Nasdaq Capital Market for a period of five consecutive trading
 days, (B)&#xA0;the Company&#x2019;s failure to timely deliver shares
 of Common Stock upon a conversion within five trading days of the
 applicable conversion date or upon the Company&#x2019;s notice that
 it does not intend to comply a request by Hudson Bay to convert,
 (C)&#xA0;the Company&#x2019;s or any of its subsidiaries&#x2019;
 failure to timely pay any amount due under the Hudson Bay Note or
 the Hudson Bay Agreement, (D)&#xA0;the Company&#x2019;s bankruptcy,
 insolvency, liquidation, or similar proceeding, or (E)&#xA0;a
 breach by the Company of any representation, warranty or covenant
 contained in the Hudson Bay Note or the Hudson Bay Agreement that
 remains uncured for a period of three consecutive trading days. On
 April 3, 2018, the Company and Hudson Bay mutually agreed to waive
 the April 30, 2018 start date for the conversion right of the
 Hudson Bay Note, and Hudson Bay converted the entire outstanding
 balance of principal and interest on the Hudson Bay Note into
 49,390 shares of Company&#x2019;s Common Stock. As a result, the
 Hudson Bay Note is fully paid.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On February 13, 2018, the Company and Alto Opportunity Master Fund,
 SPC &#x2013; Segregated Master Portfolio B (&#x201C;Alto&#x201D;)
 entered into a warrant exchange agreement (the &#x201C;Alto
 Agreement&#x201D;). The Company had previously issued to Alto a
 warrant to purchase 106,667 shares (on a post-reverse split basis)
 (the &#x201C;Alto Warrant&#x201D;) of its Common Stock pursuant to
 the 2017 Offering. Pursuant to the Alto Agreement, in exchange for
 Alto&#x2019;s agreement to surrender the Alto Warrant for
 cancellation, the Company agreed to issue to Alto a number of
 shares of Common Stock equal to the quotient resulting from
 dividing $249,600 by the closing sale price of the Common Stock on
 the closing date of the exchange. Pursuant to the Alto Agreement,
 on February 15, 2018, the Company issued to Alto 45,464 shares of
 Common Stock in exchange for the surrender and cancellation of the
 Alto Warrant.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The Alto Agreement contained a MFN clause, allowing Alto to opt to
 substitute terms of Warrant Exchange Agreements entered with other
 warrant holders from the 2017 Offering if Alto deemed those terms
 more favorable. Pursuant to this MFN clause, effective as of
 February 13, 2018, shares previously issued to Alto under the Alto
 Agreement were returned/cancelled and the Alto Agreement was deemed
 modified as follows: Pursuant to the Alto Agreement, in exchange
 for the surrender and cancellation of the Alto Warrants, the
 Company issued to Alto a convertible promissory note in the
 aggregate principal amount of $249,600.00 (the &#x201C;Alto
 Note&#x201D;). The Alto Note accrues interest on the outstanding
 principal amount at a rate of 5.0% per annum and the entire
 principal and accrued interest is due and payable on August 13,
 2018. The interest rate increases to 18% per annum during a period
 in which there is an &#x201C;event of default&#x201D; under the Alto
 Note. The holder has the right, from time to time after April 30,
 2018, to convert the outstanding principal and accrued interest
 into shares of Common Stock at the Conversion Price provided that
 Alto may not affect any such conversions to the extent it would
 beneficially own in excess of 9.99% of the Company&#x2019;s
 outstanding Common Stock. At any time after an event of default has
 occurred (whether or not the Company has cured such default), Alto
 may elect to convert the outstanding principal and accrued interest
 into shares of Common Stock at an alternate conversion price equal
 to the lower of (i) the Conversion Price then in effect at the time
 of such conversion, or (ii) 70% of the lowest volume-weighted
 average price of the Common Stock on a trading day during the
 10-trading period prior to such conversion. For purposes of the
 Alto Note, an &#x201C;event of default&#x201D; is deemed to have
 occurred upon (A) the suspension of trading of the Common Stock on
 the Nasdaq Capital Market for a period of five consecutive trading
 days, (B) the Company&#x2019;s failure to timely deliver shares of
 Common Stock upon a conversion within five trading days of the
 applicable conversion date or upon the Company&#x2019;s notice that
 it does not intend to comply a request by Empery to convert, (C)
 the Company&#x2019;s or any of its subsidiaries&#x2019; failure to
 timely pay any amount due under the Alto Note or the Alto
 Agreement, (D) the Company&#x2019;s bankruptcy, insolvency,
 liquidation, or similar proceeding, or (E) a breach by the Company
 of any representation, warranty or covenant contained in the Alto
 Note or the Alto Agreement that remains uncured for a period of
 three consecutive trading days. On April 2, 2018, the Company and
 Alto mutually agreed to waive the April 30, 2018 start date for the
 conversion right of the Alto Note, and Alto converted the entire
 outstanding balance of principal and interest on the Alto Note into
 35,998 shares of Company&#x2019;s Common Stock. As a result, the
 Alto Note is fully paid.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On February 14, 2018, the Company entered into a warrant exchange
 agreement (the &#x201C;Lincoln Park Agreement&#x201D;) with Lincoln
 Park Capital Fund LLC (&#x201C;Lincoln Park&#x201D;). The Company
 previously issued to Lincoln Park a warrant to purchase 8,333
 shares (on a post-reverse split basis) of Common Stock (the
 &#x201C;Lincoln Park Warrant&#x201D;) in the 2017 Offering. Pursuant
 to the Lincoln Park Agreement, on February 19, 2018, the Company
 issued to Lincoln Park Capital 3,421 shares of Common Stock in
 exchange for the surrender and cancellation of the Lincoln Park
 Warrant.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On February&#xA0;22, 2018, the Company entered into a warrant
 exchange agreement (the &#x201C;Empery Agreement&#x201D;) with Empery
 Asset Master Ltd., Empery Tax Efficient, LP and Empery Tax
 Efficient II, LP (collectively, &#x201C;Empery&#x201D;). The Company
 had previously issued to Empery warrants to purchase an aggregate
 of 26,668 shares (on a post-reverse split basis) (the &#x201C;Empery
 Warrants&#x201D;) of its common stock, par value $0.0001 per share
 (the &#x201C;Common Stock&#x201D;) pursuant to the registered
 offering described in the Company&#x2019;s prospectus filed with the
 Securities and Exchange Commission pursuant to Rule 424(b)(5) under
 the Securities Act of 1933 on February&#xA0;9, 2017 (the
 &#x201C;2017 Offering&#x201D; and the warrants issued in such
 offering, the &#x201C;2017 Warrants&#x201D;). Pursuant to the Empery
 Agreement, in exchange for the surrender and cancellation of the
 Empery Warrants, the Company issued to Empery convertible
 promissory notes in the aggregate principal amount of $64,403.12
 (the &#x201C;Empery Notes&#x201D;). The Empery Agreement also
 provides that if the Company enters into an agreement with a holder
 of the 2017 Warrants that provides for the exchange of such
 warrants on terms more favorable than those contained in the Empery
 Agreement, including without limitation, with respect to ratio of
 any cash paid, or principal amount of notes or value of Common
 Stock paid in exchange for such warrants, then the Company is to
 provide notice to Empery within one trading day of such agreement
 and the terms of the Empery Agreement will be deemed to have been
 modified in an economically and legally equivalent manner such that
 Empery would receive the benefit of such more favorable terms,
 unless Empery elects not to accept such terms by a notice delivered
 to the Company within 10 trading days.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The Empery Notes accrue interest on the outstanding principal
 amount at a rate of 4.75% per annum and the entire principal and
 accrued interest is due and payable on August&#xA0;22, 2018. The
 interest rate increases to 18% per annum during a period in which
 there is an &#x201C;event of default&#x201D; under the Empery Notes.
 The holder has the right, from time to time after April&#xA0;30,
 2018, to convert the outstanding principal and accrued interest
 into shares of Common Stock at the Conversion Price, provided that
 Empery may not affect any such conversions to the extent it would
 beneficially own in excess of 9.99% of the Company&#x2019;s
 outstanding Common Stock. At any time after an event of default has
 occurred (whether or not the Company has cured such default),
 Empery may elect to convert the outstanding principal and accrued
 interest into shares of Common Stock at an alternate conversion
 price equal to the lower of (i)&#xA0;the Conversion Price then in
 effect at the time of such conversion, or (ii) 70% of the lowest
 volume-weighted average price of the Common Stock on a trading day
 during the&#xA0;<font style="WHITE-SPACE: nowrap">10-trading</font>&#xA0;period
 prior to such conversion. For purposes of the Empery Notes, an
 &#x201C;event of default&#x201D; is deemed to have occurred upon
 (A)&#xA0;the suspension of trading of the Common Stock on the
 Nasdaq Capital Market for a period of five consecutive trading
 days, (B)&#xA0;the Company&#x2019;s failure to timely deliver shares
 of Common Stock upon a conversion within five trading days of the
 applicable conversion date or upon the Company&#x2019;s notice that
 it does not intend to comply a request by Empery to convert,
 (C)&#xA0;the Company&#x2019;s or any of its subsidiaries&#x2019;
 failure to timely pay any amount due under the Empery Notes or the
 Empery Agreement, (D)&#xA0;the Company&#x2019;s bankruptcy,
 insolvency, liquidation, or similar proceeding, or (E)&#xA0;a
 breach by the Company of any representation, warranty or covenant
 contained in the Empery Notes or the Empery Agreement that remains
 uncured for a period of three consecutive trading days.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The Company&#x2019;s entry into each of the warrant exchange
 agreements were the result of separate private negotiations between
 the Company and each of the named companies.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>Series A Convertible Preferred</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On March&#xA0;7, 2018, the Company entered into a Securities
 Purchase Agreement with investors, pursuant to which the Company
 agreed to sell to the Investors, in a private placement pursuant to
 Rule 4(a)(2) and Regulation S under the Securities Act of 1933, as
 amended, an aggregate of 10,700 shares of the Company&#x2019;s
 newly-created&#xA0;<font style="WHITE-SPACE: nowrap">non-voting</font>&#xA0;Series A
 Convertible Preferred, and warrants to acquire an aggregate
 1,383,631 shares of the Company&#x2019;s common stock, par value
 $0.0001 per share at an aggregate purchase price of $10,700,000.
 The Series A Convertible Preferred is initially convertible into
 1,844,835 shares of common stock based on an initial conversion
 price of $5.80 per share.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 At the first closing of the Series A Convertible Preferred on
 March&#xA0;9, 2018, the Company issued an aggregate 5,987 shares of
 Series A Convertible Preferred and 774,186 Warrants for aggregate
 gross proceeds of $5,987,000. The second closing of the remaining
 4,713 shares of the Series A Convertible Preferred and 609,445
 shares of common stock, for aggregate gross proceeds of $4,713,000
 will occur within five business days of receipt of necessary
 stockholder approval under the applicable rules and regulations of
 the Nasdaq Stock Market LLC. Under the Series A Convertible
 Preferred, the Company is obligated to seek stockholder approval no
 later than May&#xA0;7, 2018 (within 60 days of the date of the
 Series A Convertible Preferred), and will file proxy materials with
 the U.S. Securities and Exchange Commission in connection
 therewith.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The Company&#x2019;s directors, executive officers and beneficial
 owners of more than 10% of the Company&#x2019;s common stock, who
 collectively hold more than 50% of the Company&#x2019;s outstanding
 voting power, entered into voting agreements dated March&#xA0;9,
 2018, pursuant to which they agreed to vote in favor of any
 resolution presented to the stockholders of the Company to approve
 the issuance, in the aggregate, of greater than 19.99% of the
 common stock outstanding prior to the entry into the Series A
 Convertible Preferred, for less than the greater of the book or
 market value of the common stock as required by the listing rules
 of The Nasdaq Stock Market. In addition, such persons also entered
 into&#xA0;<font style="WHITE-SPACE: nowrap">lock-up</font>&#xA0;agreements
 pursuant to which they agreed to refrain from certain transactions
 in the Company&#x2019;s equity securities until the earlier of
 (i)&#xA0;September&#xA0;9, 2018 (the six month anniversary of the
 first closing) and (ii)&#xA0;the initial closing date of a
 Qualified Offering (as such term is defined in the purchase
 agreement). Under the Series A Convertible Preferred, the Company
 also agreed to refrain from issuing, or entering into any agreement
 to issue, or announcing the issuance or proposed issuance of any
 shares of common stock or common stock equivalents (subject to
 certain exclusions) prior to obtaining such stockholder
 approval.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 Qualified Offering is defined in the purchase agreement and the
 Certificate of Designation (as defined below) as a public offering
 raising aggregate gross proceeds of no less than
 $20.0&#xA0;million. In the event of a Qualified Offering, under the
 Series A Convertible Preferred, investors have the right to acquire
 the securities sold in such Qualified Offering by converting their
 shares of Series A Convertible Preferred into the same securities
 on a $1.00 for $1.00 basis based on the stated value of their
 shares of Series A Convertible Preferred.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <u>Series A Convertible Preferred</u>: On March&#xA0;8, 2018, the
 Company filed a Certificate of Designation of Preferences, Rights
 and Limitations of Series A 20% Convertible Preferred Stock (the
 &#x201C;Certificate of Designation&#x201D;) with the Secretary of
 State of the State of Delaware, which designated up to 17,500
 shares of Series A Convertible Preferred. The shares of Series A
 Convertible Preferred have a stated value equal to $1,000 and bear
 cumulative dividends, payable in cash or shares of common stock at
 the Company&#x2019; option, at a rate of 20% per annum, payable
 semiannually in arrears on June&#xA0;30 and December&#xA0;31,
 beginning on the first such date after issuance, and upon
 conversion if accrued and unpaid at such time. Such dividends cease
 to accrue upon the consummation of a Qualified Offering.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 Shares of Series A Convertible Preferred are convertible into
 common stock at the option the holder from time to time. Prior to
 receipt of stockholder approval, such conversion is limited to an
 Investor&#x2019;s&#xA0;<i>pro
 rata</i>&#xA0;share of the aggregate 19.99% limit
 under applicable Nasdaq rules and regulations. Following receipt of
 stockholder approval, conversion is subject to a beneficial
 ownership limitation of 4.99% (or 9.99% at the option of the
 Investor).</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The initial conversion price is $5.80 per share of common stock,
 subject to standard adjustments for certain transactions affecting
 the Company&#x2019;s securities (such as stock dividends, stock
 splits, and the like). Until consummation of a Qualified Offering,
 such conversion price is also subject to anti-dilution price
 protection in the event of&#xA0;<font style="WHITE-SPACE: nowrap">non-exempt</font>&#xA0;equity
 issuances at a price per share lower than the then applicable
 conversion price. If the Company has not consummated a Qualified
 Offering (as defined in the Certificate of Designation) on or
 before September&#xA0;9, 2018 (the six month anniversary of the
 first closing), on each of the six month anniversary of the first
 and the second closings, the Conversion Price shall be reduced to
 the lesser of (x)&#xA0;the then applicable Conversion Price, as
 adjusted, (y) $3.00 (subject to adjustment for forward and reverse
 stock splits and the like) and (z)&#xA0;the lowest VWAP for any
 trading day during the five trading days immediately following each
 such adjustment date.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The Series A Convertible Preferred generally have no voting rights.
 However, for so long as any shares of Series A Convertible
 Preferred are outstanding, the affirmative vote of the holders of a
 majority of the then outstanding shares of the Series A Convertible
 Preferred is required to: (a)&#xA0;alter or change adversely the
 powers, preferences or rights given to the Series A Convertible
 Preferred or alter or amend the Certificate of Designation,
 (b)&#xA0;authorize or create any class of stock ranking as to
 dividends, redemption or distribution of assets upon a Liquidation
 (as defined in the Certificate of Designation) senior to, or
 otherwise&#xA0;<i>pari
 passu</i>&#xA0;with, the Series A Convertible
 Preferred (c)&#xA0;amend its certificate of incorporation or other
 charter documents in any manner that adversely affects any rights
 of the holders of Series A Convertible Preferred, (d)&#xA0;increase
 the number of authorized shares of Series A Convertible Preferred,
 or (e)&#xA0;enter into any agreement with respect to any of the
 foregoing.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 Upon any liquidation, dissolution or&#xA0;<font style="WHITE-SPACE: nowrap">winding-up</font>&#xA0;of the
 Company, whether voluntary or involuntary that is not a Fundamental
 Transaction (as defined in the Certificate of Designation), the
 holders of Series A Convertible Preferred are entitled to receive
 out of the assets the Company the same amount they would have
 received on an as converted basis, disregarding any conversion
 limitations. Such amounts are paid on
 a<i>&#xA0;pari</i><i>&#xA0;passu&#xA0;</i>basis with
 all holders of Common Stock.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <u>Warrants</u>: Under the Purchase Agreement, the Company agreed
 to issue Warrants to acquire an aggregate of 1,383,631 shares of
 Common Stock, or approximately 75% of the shares of Common Stock
 into which the Series A Convertible Preferred are initially
 exercisable. The Warrants have an initial exercise price of $6.59
 per share, subject to adjustment in certain circumstances, may not
 be exercised until the date that is six months after issuance, and
 have a term of five years from the initial exercise date. Prior to
 receipt of stockholder approval, exercise of the Warrants is
 limited to an Investor&#x2019;s pro rata share of the aggregate
 19.99% limit under applicable Nasdaq rules and regulations.
 Exercise is also subject to a beneficial ownership limitation of
 4.99% (or 9.99% at the option of the Investor.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <u>Placement Agent</u>: Cantor Fitzgerald&#xA0;&amp; Co.
 (&#x201C;Cantor&#x201D;) acted as placement agent pursuant to an
 engagement letter dated January&#xA0;16, 2018 (the
 &#x201C;Engagement Letter&#x201D;). Under the engagement letter, the
 Company agreed to pay Cantor a fee equal to 7% of the gross
 proceeds received by the Company from United States based
 Investors. The Company also agreed to reimburse Cantor for its
 actual,&#xA0;<font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">out-of-pocket</font></font>&#xA0;accountable
 expenses (including legal fees and expenses) incurred in connection
 with the Private Placement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>Neuvax Phase 2b Clinical Trial</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On April 2, 2018 and in connection with the Company&#x2019;s
 single-blinded, controlled Phase 2b independent
 investigator-sponsored clinical trial of Herceptin:
 Genentech/Roche) +/- NeuVax in HER2 1+/2+ breast cancer patients,
 we announced the interim efficacy analysis, conducted by an
 independent Data Safety Monitoring Board of the efficacy and safety
 data for the study in an overall population of 275 patients as well
 as the two primary study target patient populations (node-positive
 and triple negative breast cancer (&#x201C;TNBC&#x201D;)) after a
 median follow-up of 19 months, demonstrated a clinically meaningful
 difference in median disease-free survival in favor of the active
 arm (NeuVax + Herceptin), a primary endpoint of the study, with
 hazard ratios of 0.67 and 0.61 in the intent to treat and modified
 intent to treat populations (i.e., those who received at least one
 dose of vaccine or control) as well as a 34.9% and 39.5% reduction
 in relative risk of recurrence in the active versus control arms in
 the intent to treat and modified intent to treat populations,
 respectively. A clinically meaningful and also statistically
 significant difference was found between the two arms in the cohort
 of patients (n= 98) with TNBC, with a hazard ratio of 0.26 and a
 p-value of 0.023 in favor of the NeuVax + Herceptin combination.
 Similarly, a clinically meaningful and statistically significant
 difference was found between the two arms in favor of the
 combination in the cohort of patients not receiving hormonal
 therapy (n = 110), with a hazard ratio of 0.24 and a p-value of
 0.009. This pre-specified interim analysis also showed an adverse
 event profile with no notable differences between treatment arms.
 This analysis confirmed the 2016 data showing that the addition of
 NeuVax to Herceptin did not result in any additional cardiotoxicity
 compared to Herceptin alone. Based on these results, and the
 independent Data Safety Monitoring Board&#x2019;s recommendation,
 the Company plans to expeditiously seek regulatory guidance by the
 FDA for further development of the combination of NeuVax +
 Herceptin in TNBC, considering the statistically significant
 benefit of the combination therapy seen in this population with
 large unmet medical need.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>JGB Action</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On or about April 9, 2018, JGB filed a lawsuit in the U.S. District
 Court for the Southern District of New York
 captioned&#xA0;<i>JGB (Cayman) Newton, Ltd. v. Sellas
 Life Sciences Group, Inc., et al.</i>, Case 1:18-cv-3095 (DLC), or
 the JGB Action. The complaint in the JGB Action asserts claims
 under state law and federal securities law against the Company, the
 Company&#x2019;s Chief Executive Officer, Dr. Stergiou and Angelos
 M. Stergiou, M.D., ScD H.C, and the Company&#x2019;s Interim Chief
 Financial Officer, Aleksey N. Krylov (Mr.&#xA0;Krylov together with
 the Company and Dr.&#xA0;Stergiou, the &#x201C;Defendants&#x201D;).
 The complaint in the JGB Action alleges, among other things, that
 we breached a contractual obligation to deliver certain shares of
 the Company&#x2019;s common stock to JGB and that, in the course of
 negotiations related to the senior secured debenture agreement, the
 Defendants failed to disclose to JGB certain information regarding
 positive clinical trial results that was not then public. According
 to the complaint, JGB seeks to receive 2,483,500 shares of the
 Company&#x2019;s common stock, damages, and costs and expenses
 incurred in the JGB action, among other things. The Company
 disputes the claims in the JGB Action and intends to defend against
 them vigorously. The Company has retained the law firm Skadden,
 Arps, Slate, Meagher &amp; Flom LLP, as its defense counsel for the
 JGB Action.</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6841203680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <i>Basis of Presentation</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The accompanying consolidated financial statements have been
 prepared in conformity with accounting principles generally
 accepted in the United States (&#x201C;U.S. GAAP&#x201D;). Any
 reference in these notes to applicable guidance is meant to refer
 to U.S.&#xA0;GAAP as found in the Accounting Standards Codification
 (&#x201C;ASC&#x201D;) and Accounting Standards Updates
 (&#x201C;ASU&#x201D;) of the Financial Accounting Standards Board
 (&#x201C;FASB&#x201D;).</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <i>Principles of Consolidation</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The consolidated financial statements include the financial
 statements of the Company and its wholly owned subsidiaries, SELLAS
 Bermuda, SELLAS Life Sciences Group UK Ltd (&#x201C;SELLAS
 UK&#x201D;), Apthera, Inc. (&#x201C;Apthera&#x201D;) and Mills
 Pharmaceuticals, LLC (&#x201C;Mills&#x201D;). All significant
 intercompany accounts and transactions have been eliminated upon
 consolidation.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <i>Use of Estimates</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The preparation of these consolidated financial statements in
 accordance with U.S. GAAP requires management to make estimates and
 assumptions that affect the reported amounts of assets and
 liabilities and disclosure of contingent assets and liabilities at
 the date of the financial statements and the reported amounts of
 expenses during the reporting period.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 On an ongoing basis, the Company evaluates its estimates using
 historical experience and other factors, including the current
 economic environment. Significant items subject to such estimates
 are assumptions used for purposes of determining stock-based
 compensation, the fair value of the warrants, beneficial conversion
 features associated with convertible notes, fair value of
 intangible assets acquired, carrying value of goodwill, fair value
 of contingent purchase price consideration, fair value of deferred
 tax liability assumed and accounting for research and development
 activities. Management believes its estimates to be reasonable
 under the circumstances. Actual results could differ significantly
 from those estimates.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <i>Fair Value of Financial Instruments</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The carrying amounts of the Company&#x2019;s financial instruments,
 including cash equivalents, accounts payable, and accrued expenses
 approximate fair value due to the short-term nature of those
 instruments. The carrying amounts of the Company&#x2019;s
 outstanding convertible notes approximate fair value due to the
 debt carrying a variable interest rate that is tied to the current
 London Interbank Offer Rate (&#x201C;LIBOR&#x201D;) rate. The fair
 value of the convertible notes is determined using a binomial
 lattice model that utilizes certain unobservable inputs that fall
 within Level&#xA0;3 of the fair value hierarchy. The fair value of
 the warrants is determine using a Black-Scholes pricing model.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <i>Concentration of Credit Risk</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Financial instruments that potentially expose the Company to
 concentrations of credit risk consist principally of cash on
 deposit with multiple financial institutions, the balances of which
 frequently exceed federally insured limits.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <i>Cash and Cash Equivalents</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company considers any highly liquid investments, such as money
 market funds, with an original maturity of three months or less to
 be cash and cash equivalents.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash and Cash Equivalents</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <i>Restricted Cash and Cash Equivalents</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Restricted cash consists of the minimum cash covenant as required
 by the debenture and certificates of deposit on hand with the
 Company&#x2019;s financial institutions as collateral for its
 corporate credit cards.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_IntangibleAssetsIndefinitelivedPolicyPolicyTextBlock', window );">Intangible Assets</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <i>Intangible Assets</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Intangible assets are comprised of identifiable <font style="white-space:nowrap">in-process</font> research and development
 (&#x201C;IPR&amp;D&#x201D;) assets and are considered
 indefinite-lived intangible assets and are assessed for impairment
 annually on October&#xA0;1 or more frequently if impairment
 indicators exist. If the associated research and development effort
 is abandoned, the related assets will be <font style="white-space:nowrap">written-off</font> and the Company will record
 a <font style="white-space:nowrap">non-cash</font> impairment loss.
 For those compounds that reach commercialization, the IPR&amp;D
 assets will be amortized over their estimated useful lives.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_GoodwillPolicyTextBlock', window );">Goodwill</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <i>Goodwill</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Goodwill is the excess of the cost of an acquired entity over the
 net amounts assigned to tangible and intangible assets acquired and
 liabilities assumed. Goodwill is not amortized but is subject to an
 annual impairment test. The Company has a single reporting unit and
 all goodwill relates to that reporting unit.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company performs its annual goodwill impairment test at the
 reporting unit level on October&#xA0;1 of each fiscal year or more
 frequently if changes in circumstances or the occurrence of events
 suggest that an impairment exists. Goodwill is evaluated for
 impairment using the simplified test of goodwill impairment as
 defined by the FASB Accounting Standards Update <font style="white-space:nowrap">No.&#xA0;2017-04.</font> Under the new
 guidance, goodwill impairment will be measured by the amount by
 which the carrying value of a reporting unit exceeds its fair
 value, without exceeding the carrying amount of goodwill allocated
 to that reporting unit. If the fair value of the reporting unit is
 less than its carrying value, an impairment loss is recorded to the
 extent that the implied fair value of the reporting unit&#x2019;s
 goodwill is less than the carrying value of the reporting
 unit&#x2019;s goodwill. The Company did not recognize any impairment
 of goodwill during the year ended December&#xA0;31, 2017.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Severance Costs</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <i>Severance Costs</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company recognized and paid $1.9&#xA0;million of exit costs
 during 2017 related to severance benefits for former Galena
 employees terminated immediately prior to the consummation of the
 Merger.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock', window );">Patents and Patent Application Costs</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <i>Patents and Patent Application Costs</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Although the Company believes that its patents and underlying
 technology have continuing value, the amount of future benefits to
 be derived from the patents is uncertain. Patent costs are,
 therefore, expensed as incurred.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalCostsPolicyTextBlock', window );">Legal Fees and Insurance Recoveries</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <i>Legal Fees and Insurance Recoveries</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 There can be a significant time lag between the time that legal
 fees are incurred and the insurance reimbursement available to
 offset the related costs. The legal fees are recorded in the period
 they are incurred, and the insurance recoveries for those costs are
 recorded in the period when the insurance reimbursement is deemed
 probable.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <i>Stock-based Compensation</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company follows the provisions of the FASB ASC Topic 718,
 &#x201C;<i>Compensation</i><i>&#xA0;&#x2014; Stock
 Compensation&#x201D;</i> (&#x201C;ASC 718&#x201D;), which requires the
 measurement and recognition of compensation expense for all
 stock-based payment awards made to employees, <font style="white-space:nowrap">non-employee</font> directors, and
 consultants, including stock options and warrants. Stock
 compensation expense based on the grant date fair value estimated
 in accordance with the provisions of ASC&#xA0;718 is recognized as
 an expense over the requisite service period.</p>
 <p style="font-size:1px;margin-top:12px;margin-bottom:0px">
 &#xA0;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 For stock options and warrants granted as consideration for
 services rendered by <font style="white-space:nowrap">non-employees,</font> the Company recognizes
 compensation expense in accordance with the requirements of FASB
 ASC Topic <font style="white-space:nowrap">505-50</font>
 (&#x201C;ASC <font style="white-space:nowrap">505-50&#x201D;),</font>
 &#x201C;<i>Equity Based Payments to <font style="white-space:nowrap">Non-</font> Employees</i>.&#x201D; <font style="white-space:nowrap">Non-employee</font> option and warrant grants
 that do not vest immediately upon grant are recorded as an expense
 over the vesting period. At the end of each financial reporting
 period prior to vesting, the value of these options and warrants,
 as calculated using the Black-Scholes option-pricing model, will be
 <font style="white-space:nowrap">re-measured</font> using the fair
 value of the Company&#x2019;s common stock and the <font style="white-space:nowrap">non-cash</font> compensation recognized during
 the period will be adjusted accordingly. Since the fair market
 value of options and warrants granted to <font style="white-space:nowrap">non-employees</font> is subject to change in
 the future, the amount of the future compensation expense will
 include fair value <font style="white-space:nowrap">re-measurements</font> until the stock options
 are fully vested.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Research and Development Expenses</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Research and development costs are expensed as incurred. Research
 and development costs that are paid in advance of performance are
 capitalized as a prepaid expense and amortized over the service
 period as the services are provided. Clinical study costs, a
 component of research and development expenses, are accrued over
 the service periods specified in the contracts and adjusted as
 necessary based on an ongoing review of the level of effort and
 costs actually incurred. Payments for a product license prior to
 regulatory approval of the product and payments for milestones
 achieved prior to regulatory approval of the product are expensed
 in the period incurred as research and development expenses.
 Milestone payments made in connection with regulatory approvals are
 capitalized and amortized to cost of revenue over the remaining
 useful life of the asset.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Research and development expenses primarily consist of the
 intellectual property and research and development materials
 acquired, expenses from third parties who conduct research and
 development activities on behalf of the Company as well as related
 wages, benefits and other operating costs. The Company expenses
 in-process research and development projects acquired as asset
 acquisitions which have not reached technological feasibility and
 which have no alternative future use.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <i>Income Taxes</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The Company uses the asset and liability method of accounting for
 income taxes. Deferred tax assets and liabilities are recognized
 for the estimated future tax consequences attributable to
 differences between the financial statement carrying amounts of
 existing assets and liabilities and their respective tax bases and
 operating loss and credit carryforwards. Deferred tax assets and
 liabilities are measured using enacted tax rates expected to apply
 to taxable income in the years in which those temporary differences
 are expected to be recovered or settled. A valuation allowance is
 provided when it is more likely than not that some portion or all
 of a deferred tax asset will not be realized. The Company
 recognizes the benefit of an uncertain tax position that it has
 taken or expects to take on its income tax return it files, if such
 a position is more likely than not to be sustained.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The Company recognizes liabilities or assets for the deferred tax
 consequences of temporary differences between the tax basis of
 assets or liabilities and their reported amounts in the financial
 statements in accordance with FASB&#xA0;<font style="WHITE-SPACE: nowrap">ASC&#xA0;740-10,</font>&#xA0;&#x201C;<i>Accounting
 for Income Taxes&#x201D; (&#x201C;ASC&#xA0;<font style="WHITE-SPACE: nowrap">740-10&#x201D;).</font></i>These temporary
 differences will result in taxable or deductible amounts in future
 years when the reported amounts of the assets or liabilities are
 recovered or
 settled.&#xA0;<i>ASC&#xA0;<font style="WHITE-SPACE: nowrap">740-10</font></i>&#xA0;requires
 that a valuation allowance be established when management
 determines that it is more likely than not that all or a portion of
 a deferred asset will not be realized. The Company evaluates the
 realizability of its net deferred income tax assets and valuation
 allowances as necessary, at least on an annual basis. During this
 evaluation, the Company reviews its forecasts of income in
 conjunction with other positive and negative evidence surrounding
 the realizability of its deferred income tax assets to determine if
 a valuation allowance is required. Adjustments to the valuation
 allowance will increase or decrease the Company&#x2019;s income tax
 provision or benefit. The recognition and measurement of benefits
 related to the company&#x2019;s tax positions requires significant
 judgment, as uncertainties often exist with respect to new laws,
 new interpretations of existing laws, and rulings by taxing
 authorities. Differences between actual results and the
 Company&#x2019;s assumptions or changes in the Company&#x2019;s
 assumptions in future periods are recorded in the period they
 become known.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On December&#xA0;22, 2017 the President of the United States signed
 into law the Tax Cuts and Jobs Act (&#x201C;The 2017 Tax
 Act&#x201D;).&#xA0;This legislation makes significant changes in the
 United States tax laws including, but not limited to, reducing the
 corporate tax rate to 21% starting in 2018. The 2017 Tax Act
 required the Company to revalue its deferred tax assets and
 liabilities to the new rate of 21%.&#xA0;For the years ended
 December&#xA0;31, 2017 and 2016, the Company recognized income tax
 expense of $253,000 and $1,000, respectively. Staff Accounting
 Bulletin No. 118 (&#x201C;SAB 118&#x201D;) was issued to address the
 application of U.S. GAAP in situations when a registrant does not
 have the necessary information available, prepared, or analyzed
 (including computations) in reasonable detail to complete the
 accounting for certain income tax effects of the Tax Act. In
 accordance with SAB 118, we determined that the adjustment to
 deferred taxes was a provisional amount and a reasonable estimate
 at December 31, 2017. We do not expect any impact on recorded
 deferred tax balances as the remeasurement of net deferred tax
 assets will be offset by a change in valuation allowance. We are
 analyzing certain aspects of the Tax Act which could potentially
 affect the remeasurement of the net deferred tax assets.</p>


 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <i>Net Loss Per Share</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Basic loss per share is computed by dividing net loss applicable to
 common stockholders by the weighted average number of shares of
 common stock outstanding during each period. Diluted loss per share
 includes the effect, if any, from the potential exercise or
 conversion of securities, such as convertible debt, warrants, stock
 options and unvested restricted stock that would result in the
 issuance of incremental shares of common stock. In computing the
 basic and diluted net loss per share, the weighted average number
 of shares remains the same for both calculations due to the fact
 that when a net loss exists, dilutive shares are not included in
 the calculation as the impact is anti-dilutive.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The following potentially dilutive securities outstanding have been
 excluded from the computation of diluted weighted average shares
 outstanding, as they would be anti-dilutive:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="78%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">
 <b>Year&#xA0;ended&#xA0;December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Common stock warrants</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">963</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Stock options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">55</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Unvested restricted stock awards</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">67</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">986</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">122</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Amounts in the table reflect the common stock equivalents of the
 noted instruments.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ComprehensiveLossPolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <i>Comprehensive Loss</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company has no items of comprehensive income or loss other than
 net loss.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <i>Recently Issued Accounting Pronouncements</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 In July 2017, the FASB issued ASU <font style="white-space:nowrap">2017-11,</font> <i>Earnings Per Share (Topic
 260); Distinguishing Liabilities from Equity (Topic 480);
 Derivatives and Hedging (Topic 815): (Part I) Accounting for
 Certain Financial Instruments with Down Round Features, (Part II)
 Replacement of the Indefinite Deferral for Mandatorily Redeemable
 Financial Instruments of Certain Nonpublic Entities and Certain
 Mandatorily Redeemable Noncontrolling Interests with a Scope
 Exception.</i> The first part of this update addresses the
 complexity of accounting for certain financial instruments with
 down round features and the second part addresses the complexity of
 distinguishing liabilities from equity. The guidance is applicable
 to public business entities for fiscal years beginning after
 December&#xA0;15, 2018 and interim periods within those years. The
 Company is currently evaluating the potential impact of the
 adoption of this standard on its consolidated results of
 operations, financial position and cash flows and related
 disclosures.</p>
 <p style="font-size:1px;margin-top:12px;margin-bottom:0px">
 &#xA0;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 In May 2017, the FASB issued Accounting Standard Update No.
 <font style="white-space:nowrap">2017-09,</font><i>&#xA0;Compensation&#x2014;Stock
 Compensation (Topic 718): Scope of Modification Accounting</i>. ASU
 <font style="white-space:nowrap">2017-09</font> provides guidance
 about which changes to the terms or conditions of a share-based
 payment award require an entity to apply modification accounting in
 Topic 718. Specifically, an entity would not apply modification
 accounting if the fair value, vesting conditions, and
 classification of the awards are the same immediately before and
 after the modification. The guidance is applicable to public
 business entities for fiscal years beginning after
 December&#xA0;15, 2017 and interim periods within those years.
 Early adoption is permitted, including adoption in any interim
 period. The Company does not expect this new guidance to have a
 material impact on its consolidated financial statements.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 In November 2016, the FASB issued ASU <font style="white-space:nowrap">No.&#xA0;2016-18,</font> <i>Restricted
 cash</i>, amending the presentation of restricted cash within the
 statement of cash flows. The new guidance requires that restricted
 cash be included within cash and cash equivalents on the statement
 of cash flows. The ASU is effective retrospectively for reporting
 periods beginning after December&#xA0;15, 2017, with early adoption
 permitted. The Company is currently evaluating the impact of its
 pending adoption of the new standard on the consolidated financial
 statements.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 In March 2016, the FASB issued Accounting Standards Update
 <font style="white-space:nowrap">2016-09,</font><i>&#xA0;Compensation-Stock
 Compensation</i>. ASU <font style="white-space:nowrap">2016-09</font> includes several areas of
 simplification to stock compensation including simplifications to
 the accounting for income taxes, classification of excess tax
 benefits on the Statement of Cash Flows and forfeitures. ASU
 <font style="white-space:nowrap">2016-09</font> is effective for
 annual reporting periods beginning after December&#xA0;15, 2016. An
 entity that elects early adoption must adopt all of the amendments
 in the same period. The Company adopted this ASU on January&#xA0;1,
 2017. There was no impact to the Company&#x2019;s consolidated
 financial statements upon adoption.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 In February 2016, the FASB issued Accounting Standards Update No.
 <font style="white-space:nowrap">2016-02,</font><i>&#xA0;Leases</i>, which
 establishes a <font style="white-space:nowrap"><font style="white-space:nowrap">right-of-use</font></font> (&#x201C;ROU&#x201D;)
 model that requires a lessee to record a ROU asset and a lease
 liability on the balance sheet for all leases with terms longer
 than 12 months. Leases will be classified as either finance or
 operating, with classification affecting the pattern of expense
 recognition in the income statement. The new standard is effective
 for fiscal years beginning after December&#xA0;15, 2018, including
 interim periods within those fiscal years. A modified retrospective
 transition approach is required for lessees for capital and
 operating leases existing at, or entered into after, the beginning
 of the earliest comparative period presented in the financial
 statements, with certain practical expedients available. The
 Company is currently evaluating the impact of its pending adoption
 of the new standard on the consolidated financial statements.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ComprehensiveLossPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Comprehensive Loss, Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ComprehensiveLossPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_GoodwillPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_GoodwillPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_IntangibleAssetsIndefinitelivedPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets indefinite-lived policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_IntangibleAssetsIndefinitelivedPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Patents And Patent Application Costs Policy Policy [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75027168&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=75032840&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75027451&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75032840&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149975-122751<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823279504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock', window );">Summary of Adjustments to Additional Paid-in Capital</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 Common stock as included in the consolidated statement of
 stockholders&#x2019; equity (deficit) was adjusted to reflect the
 $0.0001 par value per share and additional paid-in capital was
 adjusted as follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="76%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Retroactive<br />
 Effect</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016&#xA0;Revised</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Balance at January 1, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">288</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">200</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">488</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Shares issued as partial consideration of MSK license fees</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">897</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">900</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Shares issued pursuant to MSK license agreement</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,967</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,976</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Shares issued in cancellation of Clarendon license agreement</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">500</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">502</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Shares issued upon conversion of 2016 convertible note</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,357</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">54</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,411</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Shares issued in cancellation of long-term debt</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,783</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,803</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Stock-based compensation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">354</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">354</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Balance at December 31, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">25,146</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">288</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">25,434</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <br class="Apple-interchange-newline" />

 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22663-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6832101008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Potentially Dilutive Securities Outstanding Excluded from Computation of Diluted Weighted Average Shares Outstanding</a></td>
<td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The following potentially dilutive securities outstanding have been
 excluded from the computation of diluted weighted average shares
 outstanding, as they would be anti-dilutive:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="78%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">
 <b>Year&#xA0;ended&#xA0;December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Common stock warrants</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">963</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Stock options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">55</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Unvested restricted stock awards</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">67</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">986</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">122</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831895344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Summary of Purchase Price</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 The purchase price was calculated as follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="88%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Fair value of the Company&#x2019;s <font style="WHITE-SPACE: nowrap">pre-Merger</font> shares outstanding</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12,487</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Estimated fair value of the Company&#x2019;s <font style="WHITE-SPACE: nowrap">per-Merger</font> stock options
 outstanding</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">32</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total purchase price</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12,519</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Total Purchase Price Allocation</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The following table summarizes the allocation of the purchase price
 to the assets acquired and liabilities assumed as of the
 acquisition date (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="88%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Assets acquired:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,812</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Restricted cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,346</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Prepaid expenses and other assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,103</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Intangible assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17,600</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Goodwill</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,914</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total assets acquired</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">34,775</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Liabilities assumed:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accounts payable and accrued expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,692</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Litigation settlement</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,300</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Long-term debt</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,988</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Contingent purchase price consideration of Apthera, Inc.</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,294</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Warrant liability</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,309</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred tax liability</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,673</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total liabilities assumed</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">22,256</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net assets acquired</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12,519</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Schedule of Pro forma Consolidated Financial Information</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 Pro forma consolidated financial information for 2017 and 2016
 (unaudited):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="80%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">
 <b>Year&#xA0;ended&#xA0;December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net revenues (in thousands)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net loss (in thousands)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">24,089</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">28,389</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Basic and diluted net loss per share</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5.15</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8.61</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 </table>
 <br class="Apple-interchange-newline" />

 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)-(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831947008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Changes in Carrying Amount of Goodwill</a></td>
<td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Changes in the carrying amount of goodwill for the period ended
 December&#xA0;31, 2017 consisted of the following (in
 thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="68%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="89%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Balance as of January 1, 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Goodwill as a result of the Merger</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,914</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Balance as of December&#xA0;31, 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,914</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823252384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Contingent Purchase Price Consideration, Convertible Debt, Measured at Estimated Fair Value on Recurring Basis</a></td>
<td class="text"><div>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The following tables present information about the Company&#x2019;s
 assets and liabilities measured at fair value on a recurring basis
 in the consolidated balance sheets (in thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="55%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom" nowrap="nowrap">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; display:inline; font-size:8pt; font-family:Times New Roman;">
 <b>Description</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">December&#xA0;31,<br />
 2017</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">
 Quoted&#xA0;Prices&#xA0;In<br />
 Active Markets<br />
 (Level 1)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Significant&#xA0;Other<br />
 Observable<br />
 Inputs (Level 2)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Unobservable<br />
 Inputs<br />
 (Level 3)</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,662</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,662</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Restricted cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,245</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,245</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Total assets measured and recorded at fair value</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,907</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,907</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Liabilities:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Warrants potentially settleable in cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,309</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,309</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Contingent consideration</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,294</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,294</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Total liabilities measured and recorded at fair value</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,603</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,603</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831947008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Accrued expenses and other current liabilities consist of the
 following (in thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="82%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">
 <b>Year&#xA0;Ended&#xA0;December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Professional fees</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,744</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,077</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Value added tax</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">426</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Rebates and returns</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">223</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Compensation and related benefits</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">566</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">249</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Clinical trial costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">51</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,496</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">191</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">227</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Accrued expenses and other current liabilities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,201</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,049</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6724448336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Debt and Convertible Debt</a></td>
<td class="text"><div>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Debt and convertible debt consist of the following (in
 thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="81%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">
 <b>Year&#xA0;Ended&#xA0;December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Debt</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Current portion of Senior Secured Debenture</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,377</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Non-current portion of Senior Secured Debenture</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,611</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Total debt</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,988</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Convertible debt</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 2015 Shareholder Notes</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,709</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 2015 Sely Note</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,659</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Total convertible debt</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7,368</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831947008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Summary of Contractual Obligations Under Non-cancelable Operating Lease</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company&#x2019;s contractual obligations that may require future
 cash payments as of December&#xA0;31, 2017 under the <font style="WHITE-SPACE: nowrap">non-cancelable</font> operating lease are as
 follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="88%"></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Operating<br />
 Leases</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">223</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2019</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">76</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">299</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the aggregate amount of payments due on known contractual obligations for the five years following the date of the latest balance sheet and the combined aggregate amount of maturities of known contractual obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 303<br> -Paragraph a<br> -Subparagraph 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6663948384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_CommonStockAreReservedForFutureIssuanceTableTextBlock', window );">Common Stock are Reserved for Future Issuance</a></td>
<td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Shares of common stock as of December&#xA0;31, 2017 for future
 issuance are reserved for as follows (in thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="68%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="91%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Warrants outstanding</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">963</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Stock options outstanding</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Restricted stock units</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Options reserved for future issuance under the Company&#x2019;s 2017
 Equity Incentive Plan</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">575</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Shares reserved for future issuance under the Employee Stock
 Purchase Plan</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">58</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Total reserved for future issuance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,619</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_CommonStockAreReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock are reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_CommonStockAreReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823349600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ScheduleOfWarrantActivityTableTableTextBlock', window );">Schedule of Warrant Activity</a></td>
<td class="text"><div>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The following is a summary of warrant activity for the years ended
 December&#xA0;31, 2017 (in thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="49%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom" nowrap="nowrap">
 <p style="margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:61.50pt; display:inline; font-size:8pt; font-family:Times New Roman;">
 <b>Warrant Issuance</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Outstanding,<br />
 January&#xA0;1,<br />
 2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Granted</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Assumed</b><br />
 <b>through<br />
 Merger</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Expired</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Outstanding,<br />
 December&#xA0;31,<br />
 2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Expiration</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 2017 Equilibria</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">316</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">316</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">December&#xA0;2022</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Galena February 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">567</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">567</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">February 2022</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Galena other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">80</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">80</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">Various&#xA0;to&#xA0;2022</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">316</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">647</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">963</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ScheduleOfWarrantValuationAssumptionsTableTableTextBlock', window );">Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model</a></td>
<td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The fair value of the warrants as of December&#xA0;31, 2017 is
 estimated using a Black-Scholes pricing model with the following
 inputs:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="50%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom" nowrap="nowrap">
 <p style="margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:61.50pt; display:inline; font-size:8pt; font-family:Times New Roman;">
 <b>Warrant Issuance</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Outstanding&#xA0;(in<br />
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">
 <b>Strike&#xA0;price&#xA0;(per<br />
 share)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Expected&#xA0;term<br />
 (years)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Volatility%</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b><font style="white-space:nowrap">Risk-free&#xA0;rate</font><br />
 %</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Galena February 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">567</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">33.00</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4.12</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">79.29</td>
 <td nowrap="nowrap" valign="bottom">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2.09</td>
 <td nowrap="nowrap" valign="bottom">%&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Galena other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">76</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">888.22</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2.74</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">72.46</td>
 <td nowrap="nowrap" valign="bottom">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2.00</td>
 <td nowrap="nowrap" valign="bottom">%&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ChangesInFairValueOfWarrantLiabilityTableTableTextBlock', window );">Changes in Fair Value of Warrant Liability</a></td>
<td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The changes in fair value of the warrant liability for the year
 ended December&#xA0;31, 2017 were as follows (in thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="56%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom" nowrap="nowrap">
 <p style="margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:61.50pt; display:inline; font-size:8pt; font-family:Times New Roman;">
 <b>Warrant Issuance</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Warrant<br />
 liability,<br />
 January&#xA0;1,<br />
 2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">
 <b>Fair&#xA0;value&#xA0;of<br />
 warrants<br />
 granted</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">
 <b>Fair&#xA0;value&#xA0;of<br />
 warrants<br />
 acquired</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">
 <b>Change&#xA0;in&#xA0;fair<br />
 value of<br />
 warrants</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Warrant<br />
 liability,<br />
 December&#xA0;31,<br />
 2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Galena February 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,305</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,305</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Galena other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$<br /></td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;<br /></td>
 <td nowrap="nowrap" valign="bottom">&#xA0;<br /></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,309</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,309</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ChangesInFairValueOfWarrantLiabilityTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes In Fair Value Of Warrant Liability Table [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ChangesInFairValueOfWarrantLiabilityTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ScheduleOfWarrantActivityTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Warrant Activity Table</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ScheduleOfWarrantActivityTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ScheduleOfWarrantValuationAssumptionsTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Warrant Valuation Assumptions Table [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ScheduleOfWarrantValuationAssumptionsTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6663913776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Allocated Stock-based Compensation Expense</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The following table summarizes the components of stock-based
 compensation expense in the consolidated statements of operations
 for the years ended December&#xA0;31, 2017 and 2016, respectively
 (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="84%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Research and development</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">729</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">23</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 General and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,440</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">331</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total stock-based compensation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,169</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">354</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions for Option Grants Issued</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company uses the Black-Scholes option-pricing model and the
 following assumptions were used to determine the fair value of all
 its stock options granted in 2016:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="84%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Risk free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right"><font style="WHITE-SPACE: nowrap">1.82-2.32%</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Volatility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right"><font style="WHITE-SPACE: nowrap">85-94%</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected lives (years)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right"><font style="WHITE-SPACE: nowrap">5.13-10.00</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected dividend yield</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0%</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The following table summarizes stock option activity of the
 Company:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="63%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b><br />
 <b>Number of</b><br />
 <b>Shares</b><br />
 <b>(In&#xA0;Thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted</b><br />
 <b>Average</b><br />
 <b>Exercise</b><br />
 <b>Price</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Aggregate<br />
 Intrinsic Value<br />
 (In&#xA0;Thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Balance as of January 1, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">55</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">52.94</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at December 31, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">55</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">52.94</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Assumed in connection with the Merger with Galena</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,240.55</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Canceled</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(55</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">52.94</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at December&#xA0;31, 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,240.55</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Options exercisable at December&#xA0;31, 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,240.55</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">RSU Activity for RSUs with Only Time-Based Conditions</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The following table outlines RSU activity with only a time-based
 condition:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b><br />
 <b>Number of</b><br />
 <b>Shares</b><br />
 <b>(In&#xA0;Thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted</b><br />
 <b>Average</b><br />
 <b>Grant&#xA0;Date&#xA0;Fair<br />
 Value</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at January 1, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">46</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">52.94</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at December 31, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">46</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">52.94</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">58</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3.91</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Vested</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(46</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">52.94</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Canceled</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(58</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3.91</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at December&#xA0;31, 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 </table>
 <br class="Apple-interchange-newline" />

 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock', window );">RSU Activity for RSUs with Both Time-Based and Performance-Based Conditions</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The liquidity event, as defined in the relevant RSU grant
 agreements, will be satisfied upon the earlier of either: a) change
 of control or b) a qualified initial public offering.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b><br />
 <b>Number of</b><br />
 <b>Shares</b><br />
 <b>(In&#xA0;Thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted</b><br />
 <b>Average</b><br />
 <b>Grant&#xA0;Date&#xA0;Fair<br />
 Value</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at January 1, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">52.94</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at December 31, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">52.94</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Vested</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">NA</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Canceled</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(8</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">52.94</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at December&#xA0;31, 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">52.94</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested performance-based units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6832690128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Loss Before Income Taxes</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The loss before income taxes is as follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="78%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">As of December 31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 U.S.</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">265</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">108</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Non - U.S.</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(23,766</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(17,788</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(23,501</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(17,680</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Summary of Components of Federal and State Income Tax Expense</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The components of federal and state income tax expense are as
 follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="86%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">As&#xA0;of&#xA0;December&#xA0;31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Current</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Federal</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">76</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 State</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">138</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">42</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Foreign</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total current</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">214</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">42</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Federal</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 State</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">39</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(41</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Foreign</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total deferred</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">39</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(41</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total income tax expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">253</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock', window );">Summary of Components of Net Deferred Tax Assets</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The components of net deferred tax assets are as follows (in
 thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="80%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">As of December&#xA0;31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net operating loss carryforwards</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,028</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,145</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Tax credit carryforwards</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">345</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">295</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Stock based compensation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,550</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">28</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Licensing deduction deferral</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,105</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">395</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">81</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Gross deferred tax assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,423</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,549</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Valuation allowance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(4,658</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,508</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net deferred tax asset</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,765</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">41</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock', window );">Summary of Components of Net Deferred Tax Liabilities</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 The components of net deferred tax liabilities are as follows (in
 thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="84%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">As&#xA0;of&#xA0;December&#xA0;31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <font style="WHITE-SPACE: nowrap">In-process</font> research and
 development not subject to future amortization for tax purposes</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,438</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Gross deferred tax liability</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,438</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Provision for Income Taxes and Provision Computed by Applying the Federal Statutory Rate to Net Loss Before Income Taxes</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The provision for income taxes differs from the provision computed
 by applying the federal statutory rate to net loss before income
 taxes as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="84%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">As&#xA0;of&#xA0;December&#xA0;31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 U.S. federal statutory income tax rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(34.0</td>
 <td valign="bottom" nowrap="nowrap">)%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(34.0</td>
 <td valign="bottom" nowrap="nowrap">)%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 State and local taxes, net of federal benefit</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.4</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Foreign rate differential</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">34.4</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">25.5</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Permanent differences</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.1</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.1</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Tax rate change and true-up</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.3</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.2</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Valuation allowance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.1</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10.4</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Tax credits</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1.4</td>
 <td valign="bottom" nowrap="nowrap">)%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2.0</td>
 <td valign="bottom" nowrap="nowrap">)%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Effective income tax rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.1</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Changes to Company's Unrecognized Tax Benefits</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The following table indicates the changes to the Company&#x2019;s
 unrecognized tax benefits (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="85%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">As&#xA0;of&#xA0;December&#xA0;31,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Beginning of the Year - unrecognized tax benefits</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$<br />
 &#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">&#x2014;<br />
 &#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap"><br />
 &#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Increases/ (Decrease) - prior year tax positions</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">44</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Increases - current year tax positions</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">28</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 End of the Year - unrecognized tax benefits</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">72</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 &#xA0;</p>
 <div>&#xA0;</div>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Components Of Net Deferred Tax Assets Table [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ScheduleOfComponentsOfNetDeferredTaxAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Components Of Net Deferred Tax Liabilities Table [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ScheduleOfComponentsOfNetDeferredTaxLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=96868398&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6841320640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 29, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_OrganizationAndDescriptionOfBusinessLineItems', window );"><strong>Organization And Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, shares</a></td>
<td class="nump">0.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split, description</a></td>
<td class="text">Immediately prior to the Merger, the Galena effected a 1-for-30 reverse stock split of the Company&#226;&#8364;&#8482;s outstanding common stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding | shares</a></td>
<td class="nump">5,766,891<span></span>
</td>
<td class="nump">5,766,891<span></span>
</td>
<td class="nump">1,268,489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=sls_PrivateSELLASMember', window );">Private SELLAS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_OrganizationAndDescriptionOfBusinessLineItems', window );"><strong>Organization And Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_CommonStockConversionRatio', window );">Common stock conversion ratio</a></td>
<td class="nump">43.9972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_PercentageOfFullyDilutedShareCapitalOwned', window );">Percentage of fully diluted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=sls_PremergerSecurityholdersMember', window );">Pre-Merger Securityholders [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_OrganizationAndDescriptionOfBusinessLineItems', window );"><strong>Organization And Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_PercentageOfFullyDilutedShareCapitalOwned', window );">Percentage of fully diluted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_CommonStockConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_CommonStockConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_OrganizationAndDescriptionOfBusinessLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization And Description Of Business [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_OrganizationAndDescriptionOfBusinessLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_PercentageOfFullyDilutedShareCapitalOwned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of fully diluted share capital owned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_PercentageOfFullyDilutedShareCapitalOwned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=sls_PrivateSELLASMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=sls_PrivateSELLASMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=sls_PremergerSecurityholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=sls_PremergerSecurityholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6842390032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business - Summary of Adjustments to Additional Paid-in Capital (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">$ (4,997)<span></span>
</td>
<td class="num">$ (12,262)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee', window );">Shares issued as partial consideration of MSK license fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedDuringPeriodValueLicenseAgreement', window );">Shares issued pursuant to MSK license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue', window );">Shares issued in cancellation of Clarendon license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Shares issued upon conversion of 2016 convertible note</a></td>
<td class="nump">1,294<span></span>
</td>
<td class="nump">15,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedDuringPeriodValueCancellationOfLongTermDebt', window );">Shares issued in cancellation of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">3,169<span></span>
</td>
<td class="nump">354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">2,070<span></span>
</td>
<td class="num">(4,997)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">25,434<span></span>
</td>
<td class="nump">488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee', window );">Shares issued as partial consideration of MSK license fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedDuringPeriodValueLicenseAgreement', window );">Shares issued pursuant to MSK license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue', window );">Shares issued in cancellation of Clarendon license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Shares issued upon conversion of 2016 convertible note</a></td>
<td class="nump">1,294<span></span>
</td>
<td class="nump">15,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedDuringPeriodValueCancellationOfLongTermDebt', window );">Shares issued in cancellation of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">3,169<span></span>
</td>
<td class="nump">354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">56,254<span></span>
</td>
<td class="nump">25,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital | Scenario, Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">25,146<span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee', window );">Shares issued as partial consideration of MSK license fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedDuringPeriodValueLicenseAgreement', window );">Shares issued pursuant to MSK license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue', window );">Shares issued in cancellation of Clarendon license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Shares issued upon conversion of 2016 convertible note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedDuringPeriodValueCancellationOfLongTermDebt', window );">Shares issued in cancellation of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital | Restatement Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">$ 288<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee', window );">Shares issued as partial consideration of MSK license fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedDuringPeriodValueLicenseAgreement', window );">Shares issued pursuant to MSK license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue', window );">Shares issued in cancellation of Clarendon license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Shares issued upon conversion of 2016 convertible note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedDuringPeriodValueCancellationOfLongTermDebt', window );">Shares issued in cancellation of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 288<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_StockIssuedDuringPeriodValueCancellationOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value cancellation of long term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_StockIssuedDuringPeriodValueCancellationOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_StockIssuedDuringPeriodValueLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_StockIssuedDuringPeriodValueLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value partial consideration of license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_StockIssuedDuringPeriodValuePartialConsiderationOfLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued in cancellation of license agreement during period value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_StockIssuedInCancellationOfLicenseAgreementDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation for stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6842669472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 07, 2018</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Apr. 06, 2018</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LiquidityLineItems', window );"><strong>Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Redemption of debt through cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Outstanding principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,962<span></span>
</td>
<td class="nump">$ 1,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Outstanding accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Outstanding indebtedness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LiquidityLineItems', window );"><strong>Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares of common stock issued to satisfy the redemption of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">623,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sls_DebentureMember', window );">Debenture [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LiquidityLineItems', window );"><strong>Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Redemption of debt through issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares of common stock issued to satisfy the redemption of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">635,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Redemption of debt through cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInRestrictedCash', window );">Decrease in restricted cash and cash equivalent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Outstanding principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sls_SeriesAConvertiblePreferredStockMember', window );">Series A- Convertible Preferred Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LiquidityLineItems', window );"><strong>Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Aggregate gross proceeds from private placement</a></td>
<td class="nump">$ 10,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sls_FirstTrancheMember', window );">First Tranche (Expected to Occur on or about March 2018) [Member] | Series A- Convertible Preferred Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LiquidityLineItems', window );"><strong>Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Aggregate gross proceeds from private placement</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sls_SecondTrancheMember', window );">Second Tranche (Expected to Occur Early in the Second Quarter) [Member] | Series A- Convertible Preferred Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LiquidityLineItems', window );"><strong>Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Aggregate gross proceeds from private placement</a></td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_LiquidityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_LiquidityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(1),(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sls_DebentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sls_DebentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sls_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sls_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sls_FirstTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sls_FirstTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sls_SecondTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sls_SecondTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823715088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Exit costs severance benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Corporate tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 253<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember', window );">Scenario, Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Corporate tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6840952400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities Outstanding Excluded from Computation of Diluted Weighted Average Shares Outstanding (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">986<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted stock awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828741536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage by parent</a></td>
<td class="nump">67.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage by non-controlling owners</a></td>
<td class="nump">32.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_BusinessCombinationProFormaTransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod', window );">Shares issued to Equilibria for incentive fee payment in connection with the acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductionRelatedImpairmentsOrCharges', window );">Impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationIntegrationRelatedCosts', window );">Transaction costs associated with the Merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sls_GalenaBiopharmaIncMember', window );">Galena Biopharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1', window );">Merger completion date</a></td>
<td class="text">Dec. 29,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_BusinessCombinationProFormaTransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_SuccessFeeAndOtherTransactionCosts', window );">Success fee and other transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=sls_EquilibriaCollaborationAgreementMember', window );">Equilibria Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares', window );">Shares issued to Equilibria for incentive fee payment in connection with the acquisition, shares</a></td>
<td class="nump">119,672<span></span>
</td>
<td class="nump">119,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod', window );">Shares issued to Equilibria for incentive fee payment in connection with the acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_BusinessCombinationProFormaTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination pro forma transaction costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_BusinessCombinationProFormaTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued for incentive fee payment in connection with the acquisition during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued for incentive fee payment in connection with the acquisition during period shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_SuccessFeeAndOtherTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Success fee and other transaction costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_SuccessFeeAndOtherTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the acquirer obtains control of the acquiree, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84229725&amp;loc=d3e845-128460<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=84229725&amp;loc=d3e848-128460<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationIntegrationRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationIntegrationRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductionRelatedImpairmentsOrCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nonrecurring impairment charges related to the write-off of production-related equipment and inventory. This tag is used when an Entity charges this cost to cost of goods sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductionRelatedImpairmentsOrCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sls_GalenaBiopharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sls_GalenaBiopharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=sls_EquilibriaCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=sls_EquilibriaCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807153520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination - Summary of Purchase Price (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Business Combination, Consideration Transferred [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_BusinessCombinationFairValueOfSharesOutstanding', window );">Fair value of the Company's pre-Merger shares outstanding</a></td>
<td class="nump">$ 12,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding', window );">Estimated fair value of the Company's per-Merger stock options outstanding</a></td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total purchase price</a></td>
<td class="nump">$ 12,519<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination estimated fair value of stock options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_BusinessCombinationEstimatedFairValueOfStockOptionsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_BusinessCombinationFairValueOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination fair value of shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_BusinessCombinationFairValueOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828981456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combination - Total Purchase Price Allocation (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 1,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sls_GalenaBiopharmaIncMember', window );">Galena Biopharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,914<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses', window );">Accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement', window );">Litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability', window );">Contingent purchase price consideration of Apthera, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,673<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,256<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,519<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination recognized identifiable assets acquired and liabilities assumed current liabilities accounts payable and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination recognized identifiable assets acquired and liabilities assumed litigation settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination recognized identifiable assets acquired and liabilities assumed restricted cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination recognized identifiable assets acquired and liabilities assumed warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=84160947&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary difference assumed at the acquisition date that are classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sls_GalenaBiopharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sls_GalenaBiopharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6832021536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination - Pro forma Consolidated Financial Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_BusinessCombinationIncreaseDecreaseToReflectLiabilitiesAcquiredAtFairValueAbstract', window );"><strong>Business Combination Increase Decrease To Reflect Liabilities Acquired At Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Net revenues (in thousands)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss (in thousands)</a></td>
<td class="nump">$ 24,089<span></span>
</td>
<td class="nump">$ 28,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share</a></td>
<td class="nump">$ 5.15<span></span>
</td>
<td class="nump">$ 8.61<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition Pro Forma Earnings Per Share Basic And Diluted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_BusinessCombinationIncreaseDecreaseToReflectLiabilitiesAcquiredAtFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination Increase Decrease To Reflect Liabilities Acquired At Fair Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_BusinessCombinationIncreaseDecreaseToReflectLiabilitiesAcquiredAtFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)-(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)-(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6832078736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Summary of Changes in Carrying Amount of Goodwill (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill as a result of the Merger</a></td>
<td class="nump">$ 1,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of December 31, 2017</a></td>
<td class="nump">$ 1,914<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6664873888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Additional Information (Detail) - Galena Biopharma, Inc<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 29, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill And Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Allocation of purchase price to acquired IPR&amp;D</a></td>
<td class="nump">$ 17.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sls_GalenaBiopharmaIncMember', window );">GALE-401 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill And Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Allocation of purchase price to acquired IPR&amp;D</a></td>
<td class="nump">9.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sls_GalenaBiopharmaIncMember', window );">NeuVax [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill And Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Allocation of purchase price to acquired IPR&amp;D</a></td>
<td class="nump">5.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sls_GalenaBiopharmaIncMember', window );">GALE-301 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill And Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Allocation of purchase price to acquired IPR&amp;D</a></td>
<td class="nump">$ 2.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_GoodwillAndIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill And Intangible Assets [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_GoodwillAndIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sls_GalenaBiopharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sls_GalenaBiopharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sls_GaleFourZeroOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sls_GaleFourZeroOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sls_NeuvaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sls_NeuvaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sls_GaleThreeZeroTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sls_GaleThreeZeroTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6854357408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Additional Information (Detail)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 05, 2017 </div>
<div>USD ($) </div>
<div>Tranche</div>
</th>
<th class="th">
<div>May 25, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 24, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 10, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Aug. 09, 2016</div></th>
<th class="th"><div>Jun. 15, 2016</div></th>
<th class="th">
<div>Jan. 18, 2016 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 30, 2015 </div>
<div>shares</div>
</th>
<th class="th"><div>Oct. 29, 2015</div></th>
<th class="th">
<div>Jul. 14, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Nov. 14, 2014</div></th>
<th class="th">
<div>Sep. 04, 2014 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>Installment</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 11, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 11, 2006 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,067,000<span></span>
</td>
<td class="nump">$ 11,395,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sls_LicenseAgreementMember', window );">The University of Texas M. D. Anderson Cancer Center and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_AnnualMaintenanceFee', window );">Annual maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sls_AmendedAndRestatedLicenseAgreementMember', window );">BioVascular Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_PreviousRoyaltyObligationPercentage', window );">Royalty rate to be eliminated</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_RoyaltyRatePercentage', window );">Royalty rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_PreviousRoyaltyOnNetSalesValue', window );">Previous annual net sales for royalty rate</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_RoyaltyOnNetSalesValue', window );">Annual net sales for royalty rate</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_MilestonePaymentsReceivable', window );">Milestone payments receivable</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_NumberOfTranches', window );">Number of tranches | Tranche</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_SublicenseFeePayablePercentageIfExecutedPriorToFirstPatientEnrolledInPhaseThreeClinicalTrial', window );">Sublicense fee payable percentage if executed prior to first patient enrolled in Phase 3 clinical trial</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_SublicenseFeePayablePercentageIfExecutedAfterFirstPatientEnrolledInPhaseThreeClinicalTrial', window );">Sublicense fee payable percentage if executed after first patient enrolled in Phase 3 clinical trial</a></td>
<td class="nump">17.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ProceedsFromMilestoneBasedPayments', window );">Proceeds from milestone</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sls_AmendedAndRestatedLicenseAgreementMember', window );">BioVascular Amendment | Payable on or Before October 31, 2017 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_MilestonePaymentsReceivable', window );">Milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sls_AmendedAndRestatedLicenseAgreementMember', window );">BioVascular Amendment | Payable 30 days after Merger but no later than December 31, 2017 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_MilestonePaymentsReceivable', window );">Milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sls_ClarendonLicenseAgreementMember', window );">Clarendon License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LicenseAgreementTerminationDate', window );">License agreement termination date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 30,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LiabilitiesUnderTerminationAgreementPayableInCash', window );">Liabilities under termination agreements agreed to pay in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_SharesIssuableForConsiderationForLicenseTerminationAgreement', window );">Shares issuable for consideration for license termination agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_AdditionalExpenseIncurredToReflectFairValueOfSharesIssued', window );">Additional expense incurred to reflect fair value of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Advaxis Collaboration Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_NonrefundableMilestonePayments', window );">Non refundable milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_NonrefundableSalesMilestonePayments', window );">Non refundable sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sls_MemorialSloanKetteringCancerCenterMember', window );">MSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LicenseAgreementEffectiveDate', window );">License agreement effective date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep.  04,  2014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_SharesIssuedUnderLicenseAgreement', window );">Shares issue | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_UpfrontLicenseFees', window );">Upfront license fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_MinimumAnnualRoyaltyPayment', window );">Minimum royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ResearchFundingCosts', window );">Research funding costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_MilestonePayments', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LicenseAgreementExpirationTerm', window );">License agreement expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LicenseAgreementOutstandingAmountPayable', window );">License agreement outstanding amount payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_MilestoneFeePaymentsUponCommencementOfClinicalTrials', window );">Milestone payments due upon commencement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sls_MemorialSloanKetteringCancerCenterMember', window );">MSK | MSK A&amp;R License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_SharesIssuedUnderLicenseAgreement', window );">Shares issue | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_MilestonePayments', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_MilestoneFeePaymentsUponCommencementOfClinicalTrials', window );">Milestone payments due upon commencement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sls_MemorialSloanKetteringCancerCenterMember', window );">MSK | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_SharesIssuedUnderLicenseAgreement', window );">Shares issue | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_PercentageOfFullyDilutedShareCapital', window );">Percentage of fully diluted share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sls_MemorialSloanKetteringCancerCenterMember', window );">MSK | License Agreement | Chief Executive Officer Co Founder [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_SharesIssuedUnderLicenseAgreement', window );">Shares issue | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sls_MemorialSloanKetteringCancerCenterMember', window );">MSK | License Agreement | Vice Chairman</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_SharesIssuedUnderLicenseAgreement', window );">Shares issue | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sls_MemorialSloanKetteringCancerCenterMember', window );">MSK | License Agreement | Co-Founder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_SharesIssuedUnderLicenseAgreement', window );">Shares issue | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sls_MemorialSloanKetteringCancerCenterMember', window );">MSK | First MSK Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_SharesIssuedUnderLicenseAgreement', window );">Shares issue | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_PercentageOfFullyDilutedShareCapital', window );">Percentage of fully diluted share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LicenseAgreementAmendmentDate', window );">License agreement amendment date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 30,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LicenseAgreementAmendmentExtendedDateForFinancing', window );">License agreement amendment extended date for financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2016<span></span>
</td>
<td class="text">Aug.  01,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sls_MemorialSloanKetteringCancerCenterMember', window );">MSK | Second MSK Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LicenseAgreementAmendmentDate', window );">License agreement amendment date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 10,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LicenseAgreementDateSecondAmended', window );">License agreement amendment extended date for financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2017<span></span>
</td>
<td class="text">Dec. 31,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LicenseAgreementOutstandingAmountPayable', window );">License agreement outstanding amount payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement', window );">Issuance of shares upon conversion of debt in connection with licensing agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_AdditionalSharesIssuedInConnectionWithLicensingAgreement', window );">Additional shares issued in connection with licensing agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_MilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_NumberOfInstallmentsToMakePayments', window );">Number of installments to make payments | Installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_MaximumNumberOfDaysToMakePayments', window );">Maximum number of days to make payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sls_MemorialSloanKetteringCancerCenterMember', window );">MSK | Second MSK A&amp;R License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_SharesIssuedUnderLicenseAgreement', window );">Shares issue | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_AdditionalSharesIssuedInConnectionWithLicensingAgreement', window );">Additional shares issued in connection with licensing agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sls_MemorialSloanKetteringCancerCenterMember', window );">MSK | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_MilestonePayments', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sls_TrojantecLtdMember', window );">Trojantec | Trojantec License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseCosts', window );">License fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LicenseAgreementDate', window );">License agreement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 14,  2014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LicenseAgreementTerminationDate', window );">License agreement termination date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 15,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LicenseTerminationFeesPaid', window );">Termination fees paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sls_TrojantecLtdMember', window );">Trojantec | First Trojantec Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LicenseAgreementDate', window );">License agreement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 14,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sls_TrojantecLtdMember', window );">Trojantec | Maximum | First Trojantec Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ProjectManagementFeesPayable', window );">Project management fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sls_ClarendonTradingEinvestimentosLDAMember', window );">Clarendon Trading EInvestimentos LDA [Member] | Clarendon License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseCosts', window );">License fees | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LicenseAgreementDate', window );">License agreement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 18,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_AdditionalExpenseIncurredToReflectFairValueOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional expense incurred to reflect fair value of shares issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_AdditionalExpenseIncurredToReflectFairValueOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_AdditionalSharesIssuedInConnectionWithLicensingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares issued in connection with licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_AdditionalSharesIssuedInConnectionWithLicensingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_AnnualMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Maintenance Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_AnnualMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_LiabilitiesUnderTerminationAgreementPayableInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liabilities under termination agreement payable in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_LiabilitiesUnderTerminationAgreementPayableInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_LicenseAgreementAmendmentDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement amendment date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_LicenseAgreementAmendmentDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_LicenseAgreementAmendmentExtendedDateForFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement amendment extended date for financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_LicenseAgreementAmendmentExtendedDateForFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_LicenseAgreementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_LicenseAgreementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_LicenseAgreementDateSecondAmended">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement Date Second Amended</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_LicenseAgreementDateSecondAmended</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_LicenseAgreementEffectiveDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement effective date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_LicenseAgreementEffectiveDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_LicenseAgreementExpirationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement expiration term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_LicenseAgreementExpirationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_LicenseAgreementOutstandingAmountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement outstanding amount payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_LicenseAgreementOutstandingAmountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_LicenseAgreementTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement Termination Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_LicenseAgreementTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_LicenseAndCollaborationAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License And Collaboration Agreements [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_LicenseAndCollaborationAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_LicenseTerminationFeesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License termination fees paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_LicenseTerminationFeesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_MaximumNumberOfDaysToMakePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of days to make payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_MaximumNumberOfDaysToMakePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_MilestoneFeePaymentsUponCommencementOfClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone fee payments upon commencement of clinical trials.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_MilestoneFeePaymentsUponCommencementOfClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>MIlestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_MilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_MilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_MinimumAnnualRoyaltyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum annual royalty payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_MinimumAnnualRoyaltyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_NonrefundableMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-refundable Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_NonrefundableMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_NonrefundableSalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-refundable Sales Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_NonrefundableSalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_NumberOfInstallmentsToMakePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of installments to make payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_NumberOfInstallmentsToMakePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_NumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Tranches</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_NumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_PercentageOfFullyDilutedShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Fully Diluted Share Capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_PercentageOfFullyDilutedShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_PreviousRoyaltyObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Previous Royalty Obligation Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_PreviousRoyaltyObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_PreviousRoyaltyOnNetSalesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Previous royalty on net sales value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_PreviousRoyaltyOnNetSalesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ProceedsFromMilestoneBasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Milestone Based Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ProceedsFromMilestoneBasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ProjectManagementFeesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Project management fees payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ProjectManagementFeesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ResearchFundingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research funding costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ResearchFundingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_RoyaltyOnNetSalesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty on net sales value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_RoyaltyOnNetSalesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_RoyaltyRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Rate Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_RoyaltyRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_SharesIssuableForConsiderationForLicenseTerminationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issuable for consideration for license termination agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_SharesIssuableForConsiderationForLicenseTerminationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_SharesIssuedUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued under license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_SharesIssuedUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares conversion of debt in connection with licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithLicensingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_SublicenseFeePayablePercentageIfExecutedAfterFirstPatientEnrolledInPhaseThreeClinicalTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sublicense fee payable, percentage if executed after first patient enrolled in phase three clinical trial.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_SublicenseFeePayablePercentageIfExecutedAfterFirstPatientEnrolledInPhaseThreeClinicalTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_SublicenseFeePayablePercentageIfExecutedPriorToFirstPatientEnrolledInPhaseThreeClinicalTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sublicense fee payable, percentage if executed prior to first patient enrolled in phase three clinical trial.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_SublicenseFeePayablePercentageIfExecutedPriorToFirstPatientEnrolledInPhaseThreeClinicalTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_UpfrontLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of the upfront license fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_UpfrontLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicenseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sls_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sls_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sls_AmendedAndRestatedLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sls_AmendedAndRestatedLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sls_ThirdTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sls_ThirdTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sls_FourthTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sls_FourthTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sls_ClarendonLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sls_ClarendonLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sls_AdvaxisCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sls_AdvaxisCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=sls_MemorialSloanKetteringCancerCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=sls_MemorialSloanKetteringCancerCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sls_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sls_MemorialSloanKetteringCancerCenterAmendedAndRestatedLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=sls_ChiefExecutiveOfficerCoFounderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=sls_ChiefExecutiveOfficerCoFounderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=sls_ViceChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=sls_ViceChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=sls_CoFounderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=sls_CoFounderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sls_LicenseAmendmentWaiverAndShareIssuanceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sls_LicenseAmendmentWaiverAndShareIssuanceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sls_SecondLicenseAmendmentWaiverAndAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sls_SecondLicenseAmendmentWaiverAndAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sls_SecondAmendedAndRestatedExclusiveLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sls_SecondAmendedAndRestatedExclusiveLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=sls_TrojantecLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=sls_TrojantecLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sls_TrojantecLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sls_TrojantecLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sls_FirstTrojantecAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sls_FirstTrojantecAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=sls_ClarendonTradingEinvestimentosLDAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=sls_ClarendonTradingEinvestimentosLDAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828828256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Contingent Purchase Price Consideration, Convertible Debt, Measured at Estimated Fair Value on Recurring Basis (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 1,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_RestrictedCashAndCashEquivalentsFairValueDisclosure', window );">Restricted cash equivalents</a></td>
<td class="nump">10,245<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured and recorded at fair value</a></td>
<td class="nump">11,907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrants potentially settleable in cash</a></td>
<td class="nump">1,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">1,294<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured and recorded at fair value</a></td>
<td class="nump">2,603<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Prices In Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_RestrictedCashAndCashEquivalentsFairValueDisclosure', window );">Restricted cash equivalents</a></td>
<td class="nump">10,245<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured and recorded at fair value</a></td>
<td class="nump">11,907<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrants potentially settleable in cash</a></td>
<td class="nump">1,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">1,294<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured and recorded at fair value</a></td>
<td class="nump">$ 2,603<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_FairValueOfWarrantsPotentiallySettleableInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants potentially settleable in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_FairValueOfWarrantsPotentiallySettleableInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_RestrictedCashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted cash and cash equivalents, fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_RestrictedCashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828352496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2011</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Carrying value</a></td>
<td class="nump">$ 7,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_BusinessCombinationContingentConsiderationPayableUponAchievementOfMilestones', window );">Future contingent payments upon achievement of certain development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=sls_TwoThousandFifteenNotesMember', window );">2015 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Estimated fair value</a></td>
<td class="nump">7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Carrying value</a></td>
<td class="nump">$ 7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_BusinessCombinationContingentConsiderationPayableUponAchievementOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination contingent consideration payable upon achievement of milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_BusinessCombinationContingentConsiderationPayableUponAchievementOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13433-108611<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13476-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sls_TwoThousandFifteenNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sls_TwoThousandFifteenNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6842979024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">$ 1,744<span></span>
</td>
<td class="nump">$ 1,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Value added tax</a></td>
<td class="nump">426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedExchangeFeeRebateCurrent', window );">Rebates and returns</a></td>
<td class="nump">223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and related benefits</a></td>
<td class="nump">566<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ContractResearchPayable', window );">Clinical trial costs</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">2,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">191<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 3,201<span></span>
</td>
<td class="nump">$ 4,049<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ContractResearchPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract Research Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ContractResearchPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedExchangeFeeRebateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for rebates of an exchange fee some mutual funds impose on shareholders if they exchange (transfer) to another fund within the same fund group. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedExchangeFeeRebateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6842707248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Summary of Debt and Convertible Debt (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of Senior Secured Debenture</a></td>
<td class="nump">$ 8,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current portion of Senior Secured Debenture</a></td>
<td class="nump">2,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">10,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Total convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,368<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=sls_SeniorSecuredDebenturesMember', window );">Senior Secured Debentures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of Senior Secured Debenture</a></td>
<td class="nump">8,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current portion of Senior Secured Debenture</a></td>
<td class="nump">$ 2,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=sls_ConvertibleDebtTwoThousandFifteenShareholderNotesMember', window );">2015 Shareholder Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Total convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,709<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=sls_ConvertibleDebtTwoThousandSelyNoteMember', window );">2015 Sely Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Total convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,659<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sls_SeniorSecuredDebenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sls_SeniorSecuredDebenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sls_ConvertibleDebtTwoThousandFifteenShareholderNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sls_ConvertibleDebtTwoThousandFifteenShareholderNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sls_ConvertibleDebtTwoThousandSelyNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sls_ConvertibleDebtTwoThousandSelyNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6849426000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Additional Information - Senior Secured Debenture (Detail) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 10, 2016</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Apr. 06, 2018</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_DebtInstrumentCovenantPrepayLesserAccruedAndUnpaidInterest', window );">Debt instrument prepay lesser accrued and unpaid interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Outstanding principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Senior secured debenture additional interest amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares available from warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">501,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_DebtInstrumentRedemptionPrincipalAmountRedeemed', window );">Principal amount redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued to satisfy debt redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">623,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSecuredDebt', window );">Cash paid to satisfy debt redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sls_DebentureMember', window );">Debenture [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Outstanding principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued to satisfy debt redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">635,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInRestrictedCash', window );">Decrease in restricted cash and cash equivalent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Fixed coupon rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_DebtInstrumentRedemptionRedemptionPayments', window );">Interest under the Debenture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_DebtInstrumentCommonStockMinimumPriceCondition', window );">Minimum price condition (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Common Stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_DebtInstrumentCashInExcessOfDebenture', window );">Cash in excess of debenture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Fixed coupon rate</a></td>
<td class="nump">6.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of debt</a></td>
<td class="nump">$ 25.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares available from warrants</a></td>
<td class="nump">3,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ProceedsfromIssuanceofLongtermDebtandWarrantsNet', window );">Proceeds from issuance of debt and warrants</a></td>
<td class="nump">$ 23.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_DebtInstrumentPercentageofVolumeWeightedAveragePrice', window );">Percentage of VWAPs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_DebtInstrumentCovenantLiquidityCovenant', window );">Debt instrument, covenant, compensating cash balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | First Waiver</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_DebtRepaymentsDescription', window );">Debt repayments description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company does not have the right to prepay.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Amendment Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt Instrument, Redemption Price, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_DebtInstrumentPercentageofVolumeWeightedAveragePrice', window );">Percentage of VWAPs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_NumberofDaysAveragedforExercisePrice', window );">Number of days average for exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_DebtInstrumentPercentageofPriorDayVolumeWeightedAveragePrice', window );">Percentage of prior day VMAP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_DebtInstrumentCovenantLiquidityCovenant', window );">Debt instrument, covenant, compensating cash balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_DebtInstrumentCashInExcessOfDebenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, cash in excess of debenture,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_DebtInstrumentCashInExcessOfDebenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_DebtInstrumentCommonStockMinimumPriceCondition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, common stock minimum price condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_DebtInstrumentCommonStockMinimumPriceCondition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_DebtInstrumentCovenantLiquidityCovenant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Liquidity Covenant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_DebtInstrumentCovenantLiquidityCovenant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_DebtInstrumentCovenantPrepayLesserAccruedAndUnpaidInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument prepay lesser accrued and unpaid interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_DebtInstrumentCovenantPrepayLesserAccruedAndUnpaidInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_DebtInstrumentPercentageofPriorDayVolumeWeightedAveragePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, percentage of prior day volume weighted average price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_DebtInstrumentPercentageofPriorDayVolumeWeightedAveragePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_DebtInstrumentPercentageofVolumeWeightedAveragePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, percentage of volume weighted average price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_DebtInstrumentPercentageofVolumeWeightedAveragePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_DebtInstrumentRedemptionPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption, Principal Amount Redeemed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_DebtInstrumentRedemptionPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_DebtInstrumentRedemptionRedemptionPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption, Redemption Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_DebtInstrumentRedemptionRedemptionPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_DebtRepaymentsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Repayments Description</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_DebtRepaymentsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_NumberofDaysAveragedforExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price is based on the average closing price over this many trading days up to the date of the grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_NumberofDaysAveragedforExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ProceedsfromIssuanceofLongtermDebtandWarrantsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of long-term debt and warrants, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ProceedsfromIssuanceofLongtermDebtandWarrantsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sls_DebentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sls_DebentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sls_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sls_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sls_FirstWaiverMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sls_FirstWaiverMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sls_AmendmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sls_AmendmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6843453904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Additional Information - Convertible Debt (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 29, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 21, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 13, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 01, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 07, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 02, 2015 </div>
<div>USD ($) </div>
<div>Holder</div>
</th>
<th class="th">
<div>Aug. 31, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Issued convertible term note to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sls_TwoZeroOneFiveConvertibleTermNotesMember', window );">2015 Shareholder Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_NumberOfSignificantShareholders', window );">Number of significant shareholders | Holder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt', window );">Convertible notes bears interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Convertible debt, maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr.  02,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Conversion of debt, shares | shares</a></td>
<td class="nump">632,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Warrants issued in full satisfaction of note | shares</a></td>
<td class="nump">316,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_GainLossOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sls_TwoZeroOneFiveConvertibleTermNotesMember', window );">2015 Shareholder Notes | EQC Biotech Sely I Fund [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Issued convertible term note to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithAcquisition', window );">Shares issued upon conversion of debt in connection with acquisition of Galena Biopharma, Inc., shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">632,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_IssuanceOfWarrantsTerm', window );">Conversion of warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_WarrantExercisePriceAsPercentOfDebtConversion', window );">Warrant exercise price as percent of debt conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_DebtInstrumentConvertibleTermOfNotes', window );">Debt instrument, convertible, term of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sls_BridgeFinancingMember', window );">Bridge Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BridgeLoan', window );">Capital increase approved by BOD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,865,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issue price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sls_BridgeFinancingMember', window );">Bridge Financing | 2015 Shareholder Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscriptions', window );">Shares subscribed by certain stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Subscribed by certain stockholders | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Principal amount paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cumulative accrued interest paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sls_TwoZeroOneSixConvertibleTermNotesMember', window );">2016 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt', window );">Convertible notes bears interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Conversion of debt, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionDescription', window );">Convertible note, conversion description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The 2016 Note was issued at par and had an interest rate of 8%. The 2016 Note was issued with similar terms to the 2015 Notes (excluding the warrant coverage) whereby the 2016 Note is mandatorily convertible into equity upon the earlier to occur: a) the closing of a qualified IPO, b) a change in the Company&#8217;s domicile from Switzerland to Bermuda or c) the six-month anniversary of the note.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Convertible note, accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_DebtConversionConvertedInstrumentGainLossRecognized', window );">Debt conversion, converted instrument, gain (loss) recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_DebtConversionConvertedInstrumentGainLossRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt conversion, converted instrument, gain (loss) recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_DebtConversionConvertedInstrumentGainLossRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_DebtInstrumentConvertibleTermOfNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, convertible, term of notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_DebtInstrumentConvertibleTermOfNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_GainLossOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Loss On Extinguishment Of Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_GainLossOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_IssuanceOfWarrantsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of warrants term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_IssuanceOfWarrantsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_NumberOfSignificantShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of significant shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_NumberOfSignificantShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares conversion of debt in connection with acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_StockIssuedDuringPeriodSharesConversionOfDebtInConnectionWithAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_WarrantExercisePriceAsPercentOfDebtConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant exercise price as percent of debt conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_WarrantExercisePriceAsPercentOfDebtConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BridgeLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short-Term financing which is expected to be paid back relatively quickly, such as by a subsequent longer-term loan. Also called swing loan or bridge financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BridgeLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscribedButUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscribedButUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The rate of interest that was being paid on the original debt issue that is being converted in the noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtInterestRateOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest. Includes, but is not limited to, payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sls_TwoZeroOneFiveConvertibleTermNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sls_TwoZeroOneFiveConvertibleTermNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sls_EQCBiotechSelyIFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sls_EQCBiotechSelyIFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sls_BridgeFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sls_BridgeFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=sls_TwoZeroOneFiveConvertibleTermNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=sls_TwoZeroOneFiveConvertibleTermNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sls_TwoZeroOneSixConvertibleTermNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sls_TwoZeroOneSixConvertibleTermNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6845684400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Additional Information - Long-term Debt (Detail)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 01, 2016 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 01, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 02, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 12, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 12, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 06, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 02, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Nov. 25, 2013 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Borrowings | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,988,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,007,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sls_StarcoveLoansMember', window );">Starcove Loans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of debt amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sls_FounderLoansMember', window );">Founder Loans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Loan agreement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Loan interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ModifiedTermsOnLoanPercentageMaximum', window );">Modified terms on loan percentage maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_DebtConversionConvertedInstrumentGainLossRecognized', window );">Debt conversion, converted instrument, gain (loss) recognized</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sls_ThirdPartyMember', window );">Third Party [Member] | 2015 Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Borrowings | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Loan agreement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Loan interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sls_ShareholdersMember', window );">Shareholders [Member] | 2013 Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Loan interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Debt instrument description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The principal amount of the 2013 Loan Agreement, together with accrued interest, was re-assigned on a 50:50 basis to the Company&#8217;s co-founders, Drs. Angelos M. Stergiou (M.D., Sc.D. h.c.) and Miltiadis Sougioultzoglou (M.D.).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Line of credit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit [Member] | Starcove [Member] | Framework Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Loan agreement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Line of credit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Line of credit, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPaymentTerms', window );">Debt instrument frequency of payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Single payment<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr.  06,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sls_DrsStergiouMember', window );">Drs. Stergiou [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sls_DrsStergiouMember', window );">Drs. Stergiou [Member] | Founder Loans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Principal and accrued interest</a></td>
<td class="nump">&#8364; 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Conversion of debt, shares | shares</a></td>
<td class="nump">11,571<span></span>
</td>
<td class="nump">11,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sls_SougioultzoglouMember', window );">Sougioultzoglou [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sls_SougioultzoglouMember', window );">Sougioultzoglou [Member] | Founder Loans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Principal and accrued interest</a></td>
<td class="nump">&#8364; 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Conversion of debt, shares | shares</a></td>
<td class="nump">10,383<span></span>
</td>
<td class="nump">10,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sls_DrsStergiouAndSougioultzoglouMember', window );">Drs. Stergiou and Sougioultzoglou [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Borrowings accrued interest amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Loans payable due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansReceivableNet', window );">Loans receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_DebtConversionConvertedInstrumentGainLossRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt conversion, converted instrument, gain (loss) recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_DebtConversionConvertedInstrumentGainLossRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ModifiedTermsOnLoanPercentageMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Modified terms on loan percentage maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ModifiedTermsOnLoanPercentageMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allowance and deduction of deferred interest and fees, unamortized costs and premiums and discounts from face amounts, of loans and leases held in portfolio, including but not limited to, commercial and consumer loans. Includes loans held for sale. Excludes loans and leases covered under loss sharing agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.7(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sls_StarcoveLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sls_StarcoveLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sls_FounderLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sls_FounderLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=sls_ThirdPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=sls_ThirdPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sls_TwoThousandFifiteenLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sls_TwoThousandFifiteenLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=sls_ShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=sls_ShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sls_TwoThousandThirteenLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sls_TwoThousandThirteenLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=sls_StarcoveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=sls_StarcoveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sls_FrameworkLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sls_FrameworkLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sls_DrsStergiouMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sls_DrsStergiouMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sls_SougioultzoglouMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sls_SougioultzoglouMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sls_DrsStergiouAndSougioultzoglouMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sls_DrsStergiouAndSougioultzoglouMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6842707584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information - Legal Proceedings (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 09, 2018</div></th>
<th class="th"><div>Nov. 07, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_IssuanceofCommonStockforLitigationSettlement', window );">Issuance of Common Stock for Litigation Settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Litigation settlement received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LitigationSettlementAmountCash', window );">Paid by the company or their insurance carriers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rental expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=sls_QuiTamMember', window );">Qui Tam [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_IssuanceofCommonStockforLitigationSettlement', window );">Issuance of Common Stock for Litigation Settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=sls_JGBCaymanNewtonLtdMember', window );">JGB (Cayman) Newton, Ltd [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LitigationSettlementIssuanceofCommonStockShares', window );">Issuance of common stock shares for litigation settlement</a></td>
<td class="nump">2,483,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember', window );">Settled Litigation [Member] | US Attorneys Office For The District Of New Jersey And Department Of Justice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Total settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_IssuanceofCommonStockforLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Common Stock for Litigation Settlement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_IssuanceofCommonStockforLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_LitigationSettlementAmountCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement Amount, Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_LitigationSettlementAmountCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_LitigationSettlementIssuanceofCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Issuance of Common Stock, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_LitigationSettlementIssuanceofCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded from other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedFromOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=sls_QuiTamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=sls_QuiTamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=sls_JGBCaymanNewtonLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=sls_JGBCaymanNewtonLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=sls_UsattorneysofficeforthedistrictofnewjerseyanddepartmentofjusticeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=sls_UsattorneysofficeforthedistrictofnewjerseyanddepartmentofjusticeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831978544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Minimum Rental Commitments for Operating Leases (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2018</a></td>
<td class="nump">$ 223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2019</a></td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">$ 299<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6842752464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jun. 13, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember', window );">Dr. Angelos Stergiou</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_CancellationOfManagementFee', window );">Cancellation of management fee</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of shares in cancellation of net compensation</a></td>
<td class="nump">28,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=sls_MemorialSloanKetteringCancerCenterMember', window );">MSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued', window );">Issuance of common stock, shares</a></td>
<td class="nump">38,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_CancellationOfMilestonePayment', window );">Milestone payment canceled</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=sls_EquilibriaCollaborationAgreementMember', window );">Equilibria Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued', window );">Issuance of common stock, shares</a></td>
<td class="nump">30,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_CancellationOfManagementFee', window );">Cancellation of management fee</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sls_BridgeFinancingMember', window );">Bridge Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,865,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issue price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.91<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_CancellationOfManagementFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cancellation of management fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_CancellationOfManagementFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_CancellationOfMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cancellation of milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_CancellationOfMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares or units of entity securities issued in the transaction in which equity securities were issued to pay for goods or nonemployee services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=sls_MemorialSloanKetteringCancerCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=sls_MemorialSloanKetteringCancerCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=sls_EquilibriaCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=sls_EquilibriaCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sls_BridgeFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sls_BridgeFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819283568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Common Stock are Reserved for Future Issuance (Detail)<br> shares in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total reserved for future issuance</a></td>
<td class="nump">1,619<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total reserved for future issuance</a></td>
<td class="nump">963<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_StockOptionMember', window );">Stock options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total reserved for future issuance</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total reserved for future issuance</a></td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total reserved for future issuance</a></td>
<td class="nump">575<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total reserved for future issuance</a></td>
<td class="nump">58<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6854468240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Schedule of Warrant Activity (Detail)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassOfWarrantOrRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassOfWarrantOrRightGranted', window );">Granted</a></td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassOfWarrantOrRightAssumedInAcquisition', window );">Assumed through Merger</a></td>
<td class="nump">647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassOfWarrantOrRightExpired', window );">Class of Warrant or Right, Expired</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, Ending balance</a></td>
<td class="nump">963<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sls_EqcWarrantsMember', window );">2017 Equilibria</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassOfWarrantOrRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassOfWarrantOrRightGranted', window );">Granted</a></td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassOfWarrantOrRightAssumedInAcquisition', window );">Assumed through Merger</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassOfWarrantOrRightExpired', window );">Class of Warrant or Right, Expired</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, Ending balance</a></td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassOfWarrantOrRightExpirationMonthAndYear', window );">Expiration</a></td>
<td class="text">2022-12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sls_February2017WarrantsMember', window );">Galena February 2017</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassOfWarrantOrRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassOfWarrantOrRightGranted', window );">Granted</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassOfWarrantOrRightAssumedInAcquisition', window );">Assumed through Merger</a></td>
<td class="nump">567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassOfWarrantOrRightExpired', window );">Class of Warrant or Right, Expired</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, Ending balance</a></td>
<td class="nump">567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassOfWarrantOrRightExpirationMonthAndYear', window );">Expiration</a></td>
<td class="text">2022-02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sls_OtherWarrantIssuesMember', window );">Galena other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassOfWarrantOrRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassOfWarrantOrRightGranted', window );">Granted</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassOfWarrantOrRightAssumedInAcquisition', window );">Assumed through Merger</a></td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassOfWarrantOrRightExpired', window );">Class of Warrant or Right, Expired</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, Ending balance</a></td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassOfWarrantOrRightExpirationDateDescription', window );">Expiration</a></td>
<td class="text">Various to 2022<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ClassOfWarrantOrRightAssumedInAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right assumed in acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ClassOfWarrantOrRightAssumedInAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ClassOfWarrantOrRightExpirationDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right expiration date, description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ClassOfWarrantOrRightExpirationDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ClassOfWarrantOrRightExpirationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right expiration month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ClassOfWarrantOrRightExpirationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ClassOfWarrantOrRightExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ClassOfWarrantOrRightExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ClassOfWarrantOrRightGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ClassOfWarrantOrRightGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ClassOfWarrantOrRightOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Outstanding [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ClassOfWarrantOrRightOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sls_EqcWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sls_EqcWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sls_February2017WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sls_February2017WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sls_OtherWarrantIssuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sls_OtherWarrantIssuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817828640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants - Additional Information (Detail)<br></strong></div></th>
<th class="th">
<div>Jan. 01, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="nump">501,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6845872288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model (Detail) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">963<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sls_February2017WarrantsMember', window );">Galena February 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">567<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_WarrantStrikePrice', window );">Strike price (per share)</a></td>
<td class="nump">$ 33.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">4 years 1 month 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility%</a></td>
<td class="nump">79.29%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="nump">2.09%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sls_OtherGalenaWarrantIssuesAccountedForAsLiabilitiesMember', window );">Other Galena Warrant Issues Accounted for as Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_WarrantStrikePrice', window );">Strike price (per share)</a></td>
<td class="nump">$ 888.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">2 years 8 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility%</a></td>
<td class="nump">72.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Warrant Liability Assumptions Expected Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_WarrantStrikePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Strike Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_WarrantStrikePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_WarrantsFairValueAssumptionsExpectedVolatility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Fair Value Assumptions Expected Volatility</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_WarrantsFairValueAssumptionsExpectedVolatility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_WarrantsFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Fair Value Assumptions Risk Free Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_WarrantsFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sls_February2017WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sls_February2017WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sls_OtherGalenaWarrantIssuesAccountedForAsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sls_OtherGalenaWarrantIssuesAccountedForAsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828865696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Changes in Fair Value of Warrant Liability (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_FairValueofWarrantsGranted', window );">Fair Value of Warrants Granted</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_FairValueOfWarrantsExercised', window );">Fair Value of Warrants Acquired</a></td>
<td class="nump">1,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">1,309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sls_February2017WarrantsMember', window );">Galena February 2017</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_FairValueofWarrantsGranted', window );">Fair Value of Warrants Granted</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_FairValueOfWarrantsExercised', window );">Fair Value of Warrants Acquired</a></td>
<td class="nump">1,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">1,305<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sls_OtherWarrantIssuesMember', window );">Galena other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_FairValueofWarrantsGranted', window );">Fair Value of Warrants Granted</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_FairValueOfWarrantsExercised', window );">Fair Value of Warrants Acquired</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">$ 4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ChangeInFairValueOfWarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value Of Warrant Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ChangeInFairValueOfWarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ClassofWarrantorRightFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Fair Value [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ClassofWarrantorRightFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_FairValueOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_FairValueOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_FairValueOfWarrantsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant liabilities as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_FairValueOfWarrantsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_FairValueofWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Warrants Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_FairValueofWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sls_February2017WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sls_February2017WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sls_OtherWarrantIssuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sls_OtherWarrantIssuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6811262640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants - Warrants Classified as Equity (Detail) - 2017 Equilibria<br></strong></div></th>
<th class="th">
<div>Dec. 29, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued | shares</a></td>
<td class="nump">316,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 7.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassOfWarrantOrRightTerm', window );">Warrant term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_FairValueofWarrantsGrantedperShare', window );">Fair value of warrants granted (in dollars per share)</a></td>
<td class="nump">$ 5.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Fair value assumptions, expected volatility rate</a></td>
<td class="nump">90.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Fair value assumptions, expected term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Fair value assumptions, risk free interest rate</a></td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Fair value assumptions, expected dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ClassOfWarrantOrRightTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ClassOfWarrantOrRightTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_FairValueofWarrantsGrantedperShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants granted, per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_FairValueofWarrantsGrantedperShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sls_EqcWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sls_EqcWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6849245616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 01, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>Option </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_NumberOfStockOptionsGranted', window );">Stock options granted | Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant at fair value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Aggregate intrinsic values outstanding and exercisable stock option Calculated based on the closing price of the Company's common stock as reported on the NASDAQ Capital Market | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sls_TwoThousandAndSeventeenEquityIncentivePlanMember', window );">2017 Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger', window );">Share based compensation arrangement by share based payment award options assumed in merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ShareBasedCompensationExercisePeriod', window );">Option excisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Common stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options expire from date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards', window );">Percentage increase in number of shares available for future issuance under stock based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sls_TwoThousandAndSixteenEquityIncentivePlanMember', window );">2016 Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock reserved for issuance</a></td>
<td class="nump">189,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options expire from date of grant</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting periods of options granted</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sls_RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember', window );">RSUs with Time-Based and Performance-Based Conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Continued service measurement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sls_RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember', window );">RSUs with Time-Based and Performance-Based Conditions | January 1, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate', window );">Vesting date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sls_RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember', window );">RSUs with Time-Based and Performance-Based Conditions | January 1, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate', window );">Vesting date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sls_RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember', window );">RSUs with Time-Based and Performance-Based Conditions | January 1, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate', window );">Vesting date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sls_RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember', window );">RSUs with Time-Based and Performance-Based Conditions | February 27, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate', window );">Vesting date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 27,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sls_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options expire from date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards', window );">Percentage increase in number of shares available for future issuance under stock based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants', window );">Share based compensation arrangement by share based payment award percentage earning of participants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock in connection with employee stock purchase plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_NumberOfStockOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Stock Options Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_NumberOfStockOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Increase In Number Of Shares Available For Future Issuance Under Stock Based Awards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_PercentageIncreaseInNumberOfSharesAvailableForFutureIssuanceUnderStockBasedAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Merger</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award percentage earning of participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageEarningOfParticipants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Vesting Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ShareBasedCompensationExercisePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Exercise Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ShareBasedCompensationExercisePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash expense that represents the cost of restricted stock or unit distributed to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sls_TwoThousandAndSeventeenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sls_TwoThousandAndSeventeenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sls_TwoThousandAndSixteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sls_TwoThousandAndSixteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sls_RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sls_RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=sls_ShareBasedCompensationAwardVestingDateOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=sls_ShareBasedCompensationAwardVestingDateOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=sls_ShareBasedCompensationAwardVestingDateTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=sls_ShareBasedCompensationAwardVestingDateTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=sls_ShareBasedCompensationAwardVestingDateThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=sls_ShareBasedCompensationAwardVestingDateThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=sls_ShareBasedCompensationAwardVestingDateFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=sls_ShareBasedCompensationAwardVestingDateFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sls_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sls_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823270432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Allocated Stock-based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="nump">$ 3,169<span></span>
</td>
<td class="nump">$ 354<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="nump">729<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="nump">$ 2,440<span></span>
</td>
<td class="nump">$ 331<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828826960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Grant Date Fair Values of Option Issued to Employees and Non-Employees (Detail) - Employee and Non-Employee Stock Options<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">1.82%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected lives (years)</a></td>
<td class="text">5 years 1 month 17 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">2.32%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="nump">94.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected lives (years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sls_EmployeeAndNonemployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sls_EmployeeAndNonemployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819337808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Detail) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Beginning balance</a></td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Assumed in connection with the Merger with Galena</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, Canceled</a></td>
<td class="num">(55)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Ending balance</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, exercisable</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Beginning balance</a></td>
<td class="nump">$ 52.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Assumed in connection with the Merger with Galena</a></td>
<td class="nump">1,240.55<span></span>
</td>
<td class="nump">$ 52.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Canceled</a></td>
<td class="nump">52.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Ending balance</a></td>
<td class="nump">1,240.55<span></span>
</td>
<td class="nump">$ 52.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighed average exercise price, exercisable</a></td>
<td class="nump">$ 1,240.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInAcquisitionGrantDateIntrinsicValue', window );">Assumed in connection with the Merger with Galena</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue', window );">Aggregate intrinsic value, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledIntrinsicValue', window );">Aggregate intrinsic value,Canceled</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic Value, exercisable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Canceled Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInAcquisitionGrantDateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, options, assumed in acquisition, grant date intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInAcquisitionGrantDateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6840987776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - RSU Activity for RSUs with Only Time-Based Condition (Detail) - RSUs with Time Based Conditions - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of non-vested RSUs, Beginning Balance</a></td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of non-vested RSUs, Granted</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of non-vested RSUs, Vested</a></td>
<td class="num">(46)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of non-vested RSUs, Canceled</a></td>
<td class="num">(58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of non-vested RSUs, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value, Beginning Balance</a></td>
<td class="nump">$ 52.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value, Granted</a></td>
<td class="nump">3.91<span></span>
</td>
<td class="nump">$ 52.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value, Vested</a></td>
<td class="nump">52.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value, Canceled</a></td>
<td class="nump">$ 3.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52.94<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sls_RestrictedStockUnitsWithTimeBasedConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sls_RestrictedStockUnitsWithTimeBasedConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6696970576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - RSU Activity for RSUs with Both Time-Based and Performance-Based Condition (Detail) - RSUs with Time-Based and Performance-Based Conditions - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of non-vested RSUs, Beginning Balance</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of non-vested RSUs, Vested</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of non-vested RSUs, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of non-vested RSUs, Canceled</a></td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of non-vested RSUs, Ending Balance</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value, Beginning Balance</a></td>
<td class="nump">$ 52.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value, Canceled</a></td>
<td class="nump">52.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value, Ending Balance</a></td>
<td class="nump">$ 52.94<span></span>
</td>
<td class="nump">$ 52.94<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sls_RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sls_RestrictedStockUnitsWithTimeBasedAndPerformanceBasedConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828519904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Loss Before Income Taxes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S.</a></td>
<td class="nump">$ 265<span></span>
</td>
<td class="nump">$ 108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Non - U.S.</a></td>
<td class="num">(23,766)<span></span>
</td>
<td class="num">(17,788)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (23,501)<span></span>
</td>
<td class="num">$ (17,680)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6841907824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Income Tax Expense (Benefit) (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">214<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">39<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="nump">39<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense</a></td>
<td class="nump">$ 253<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831920432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Net Deferred Tax Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred Tax Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 1,028<span></span>
</td>
<td class="nump">$ 3,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">345<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">2,550<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_DeferredTaxAssetsLicensingDeductionDeferral', window );">Licensing deduction deferral</a></td>
<td class="nump">2,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards', window );">Other</a></td>
<td class="nump">395<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">6,423<span></span>
</td>
<td class="nump">3,549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(4,658)<span></span>
</td>
<td class="num">(3,508)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="nump">$ 1,765<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_DeferredTaxAssetsLicensingDeductionDeferral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Licensing Deduction Deferral</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_DeferredTaxAssetsLicensingDeductionDeferral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOtherTaxCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807591312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Net Deferred Tax Liabilities (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">In-process research and development not subject to future amortization for tax purposes</a></td>
<td class="nump">$ 3,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred tax liability</a></td>
<td class="nump">$ 3,438<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823652784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Provision Computed by Applying Federal Statutory Rate (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory income tax rate</a></td>
<td class="num">(34.00%)<span></span>
</td>
<td class="num">(34.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and local taxes, net of federal benefit</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="nump">34.40%<span></span>
</td>
<td class="nump">25.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_EffectiveIncomeTaxRateReconciliationPermanentDifferences', window );">Permanent differences</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Tax rate change and true-up</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">10.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="num">(1.40%)<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_EffectiveIncomeTaxRateReconciliationPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation Permanent Differences</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_EffectiveIncomeTaxRateReconciliationPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819501536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_OperatingLossCarryforwardsExpirationYearRangeStart', window );">Operating loss carryforwards expire start year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_OperatingLossCarryforwardsExpirationYearRangeEnd', window );">Operating loss carryforwards expire end year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUsePeriodOfOwnershipPercentage', window );">Period of ownership percentage change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage', window );">Change in ownership percentage, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss', window );">Maximum indefinite-lived deferred tax liability as percentage of net operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife', window );">Deferred tax assets indefinite-lived NOL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits', window );">Impact on tax provision from unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000<span></span>
</td>
<td class="nump">$ 44,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember', window );">Scenario, Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax asset net operating loss carryforwards indefinite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impact on tax provision from unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ImpactOnTaxProvisionFromUnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum indefinite-lived deferred tax liability as percentage of net operating loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_MaximumIndefinitelivedDeferredTaxLiabilityAsPercentageOfNetOperatingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss and tax credit carryforwards limitations on use minimum change in ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUseMinimumChangeInOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUsePeriodOfOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss and tax credit carryforwards limitations on use period of ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_OperatingLossAndTaxCreditCarryforwardsLimitationsOnUsePeriodOfOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_OperatingLossCarryforwardsExpirationYearRangeEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards Expiration Year Range End</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_OperatingLossCarryforwardsExpirationYearRangeEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_OperatingLossCarryforwardsExpirationYearRangeStart">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards Expiration Year Range Start</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_OperatingLossCarryforwardsExpirationYearRangeStart</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823368112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Changes to Company's Unrecognized Tax Benefits (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases/ (Decrease) - prior year tax positions</a></td>
<td class="nump">$ 44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases - current year tax positions</a></td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">End of the Year - unrecognized tax benefits</a></td>
<td class="nump">$ 72<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828943504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Nov. 28, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=sls_EquilibriaCollaborationAgreementMember', window );">Equilibria Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_EffectivePeriodOfAgreement', window );">Effective period of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForManagementFee', window );">Quarterly management fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ManagementFeeExpense', window );">Management fees incurred and paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ManagementFeePayable', window );">Outstanding fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_IncentiveFeePercentageEqualToPostMoneyMarketValue', window );">Incentive fee percentage equal to post - money market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_Incentivefeepercentageequaltogrossvaluepaidbypurchaserincash', window );">Incentive fee percentage equal to gross value paid by purchaser in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_AccruedCompensationIncentive', window );">Compensation payable</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares', window );">Shares issued to Equilibria for incentive fee payment in connection with the acquisition, shares</a></td>
<td class="nump">119,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=sls_MskLicenseAgreementMember', window );">MSK License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of granted stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ContractualAgreementTerminationDate', window );">Contract termination date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug.  06,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_CashPaymentOnContractTermination', window );">Cash payment for termination fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=sls_MskLicenseAgreementMember', window );">MSK License Agreement [Member] | Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=sls_MskLicenseAgreementMember', window );">MSK License Agreement [Member] | Dr Angelos MStergiou [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_PercentageOfOwnershipOutstandingShareCapital', window );">Percentage of ownership outstanding share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.80%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=sls_MskLicenseAgreementMember', window );">MSK License Agreement [Member] | MSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_PercentageOfOwnershipOutstandingShareCapital', window );">Percentage of ownership outstanding share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">5.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_AccruedCompensationIncentive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Compensation Incentive</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_AccruedCompensationIncentive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_CashPaymentOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Payment on Contract Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_CashPaymentOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ContractualAgreementTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Agreement Termination Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ContractualAgreementTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_EffectivePeriodOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Period Of Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_EffectivePeriodOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_IncentiveFeePercentageEqualToPostMoneyMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incentive fee percentage equal to post - money market value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_IncentiveFeePercentageEqualToPostMoneyMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_Incentivefeepercentageequaltogrossvaluepaidbypurchaserincash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incentive fee percentage equal to gross value paid by purchaser in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_Incentivefeepercentageequaltogrossvaluepaidbypurchaserincash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_PercentageOfOwnershipOutstandingShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of ownership outstanding share capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_PercentageOfOwnershipOutstandingShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued for incentive fee payment in connection with the acquisition during period shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_StockIssuedForIncentiveFeePaymentInConnectionWithAcquisitionDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagementFeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses related to the managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagementFeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagementFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of the unpaid portion of the fee payable to the managing member or general partner for management of the fund or trust.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagementFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForManagementFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount paid to managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForManagementFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=sls_EquilibriaCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=sls_EquilibriaCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=sls_MskLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=sls_MskLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sls_RestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sls_RestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=sls_DrAngelosMStergiouMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=sls_DrAngelosMStergiouMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sls_MemorialSloanKetteringCancerCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sls_MemorialSloanKetteringCancerCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6951766992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 22, 2018</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Apr. 09, 2018</div></th>
<th class="th"><div>Apr. 03, 2018</div></th>
<th class="th"><div>Apr. 02, 2018</div></th>
<th class="th"><div>Mar. 09, 2018</div></th>
<th class="th"><div>Mar. 08, 2018</div></th>
<th class="th"><div>Mar. 07, 2018</div></th>
<th class="th"><div>Feb. 22, 2018</div></th>
<th class="th"><div>Feb. 19, 2018</div></th>
<th class="th"><div>Feb. 15, 2018</div></th>
<th class="th"><div>Feb. 14, 2018</div></th>
<th class="th"><div>Feb. 13, 2018</div></th>
<th class="th"><div>Feb. 09, 2018</div></th>
<th class="th"><div>Feb. 07, 2018</div></th>
<th class="th"><div>Feb. 06, 2018</div></th>
<th class="th"><div>Jan. 16, 2018</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,766,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,268,489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage by Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible Preferred Stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of common stock shares issued for debt conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">623,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants or rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">501,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Series A- Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredUnitsDescription', window );">Preferred Units, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Series A Convertible Preferred: On March 8, 2018, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series A 20% Convertible Preferred Stock (the &#8220;Certificate of Designation&#8221;) with the Secretary of State of the State of Delaware, which designated up to 17,500 shares of Series A Convertible Preferred.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible Preferred Stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible Preferred stock stated value percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ConvertiblePreferredStockBeneficialOwnershipLimitationPercentage', window );">Beneficial ownership limitation,percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockConversionLimitPercentage', window );">Percentage of stock conversion limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_AdjustmentToCommonStockInConnectionWithReverseForwardStockSplit', window );">Adjustment to common stock in connection with reverse/forward stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_TradingDays', window );">Trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_PercentageOfReductionInRiskRecurrence', window );">Percentage of reduction in risk recurrence</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_PercentageOfReductionInRiskRecurrence', window );">Percentage of reduction in risk recurrence</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Maximum | Series A- Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible Preferred Stock, Shares Issued upon Conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Scenario, Forecast [Member] | Series A- Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible Preferred stock stated value percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | JGB (Cayman) Newton, Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_LitigationSettlementIssuanceofCommonStockShares', window );">Issuance of common stock shares for litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,483,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | CVI Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Company had previously issued to CVI a warrant to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_DenominatorBaseForIssuanceOfCommonStockValue', window );">Denominator base for issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 232,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal', window );">Convertible promissory note principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 232,440.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_DebtInstrumentConvertiblePercentageOfPrincipalAndAccruedInterest', window );">Accrued interest on the outstanding principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Increase accrued interest on the outstanding principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ConvertibleNotesConversionPricePerShareOfCommonStock', window );">Common stock conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_MinimumOwnershipPercentageOfOutstandingSharesOfCommonStockForConversionToTakeEffect', window );">Minimum percentage outstanding Common Stock to effect conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt Instrument, Redemption Price, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of common stock shares issued for debt conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Anson Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedDuringPeriodSharesShareWarrantsExercised', window );">Shares of common stock in exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Sabby Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Purchase of aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_AggregateSalesPriceOfCommonStock', window );">Closing sale price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 195,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_MinimumPercentageOfTradingPriceOfCommonStock', window );">Minimum percentage of daily trading volume of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_PercentageOfMarketAveragePriceOfShares', window );">Percentage of market price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Hudson Bay Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal', window );">Convertible promissory note principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 343,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_DebtInstrumentConvertiblePercentageOfPrincipalAndAccruedInterest', window );">Accrued interest on the outstanding principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Increase accrued interest on the outstanding principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ConvertibleNotesConversionPricePerShareOfCommonStock', window );">Common stock conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_MinimumOwnershipPercentageOfOutstandingSharesOfCommonStockForConversionToTakeEffect', window );">Minimum percentage outstanding Common Stock to effect conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt Instrument, Redemption Price, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of common stock shares issued for debt conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Purchase of aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Alto Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal', window );">Convertible promissory note principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 249,600.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_DebtInstrumentConvertiblePercentageOfPrincipalAndAccruedInterest', window );">Accrued interest on the outstanding principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Increase accrued interest on the outstanding principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_MinimumOwnershipPercentageOfOutstandingSharesOfCommonStockForConversionToTakeEffect', window );">Minimum percentage outstanding Common Stock to effect conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt Instrument, Redemption Price, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of common stock shares issued for debt conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedDuringPeriodSharesShareWarrantsExercised', window );">Shares of common stock in exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Purchase of aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_AggregateSalesPriceOfCommonStock', window );">Closing sale price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 249,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Lincoln Park Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedDuringPeriodSharesShareWarrantsExercised', window );">Shares of common stock in exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Purchase of aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Empery Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Company had previously issued to CVI a warrant to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal', window );">Convertible promissory note principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,403.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_DebtInstrumentConvertiblePercentageOfPrincipalAndAccruedInterest', window );">Accrued interest on the outstanding principal amount</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Increase accrued interest on the outstanding principal</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt Instrument, Redemption Price, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants or rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,383,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Convertible preferred stock and warrant purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible Preferred Stock, Shares Issued upon Conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,844,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ConversionPriceOfPreferredStock', window );">Preferred stock conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Purchase Agreement [Member] | Series A- Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ConvertiblePreferredStockIssuedShares', window );">Number of convertible preferred stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants or rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,383,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_DateByWhichStockHolderApprovalRequired', window );">Date by which stock holder approval required</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May  07,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockholderApprovalPeriod', window );">Period of stock holder approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_WarrantExcercisableTerm', window );">Date from which warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Voting Agreement [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage by Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of Voting Interests Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_CommonStockPercentageIssuedPriorToPurchaseAgreement', window );">Common stock percentage issued prior to purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Engagement Letter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_GrossProceedsPercentage', window );">Gross offering proceeds percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Private Placement First Closing [Member] | Purchase Agreement [Member] | Series A- Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ConvertiblePreferredStockIssuedShares', window );">Number of convertible preferred stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Convertible preferred stock and warrant purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,987,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_WarrantsIssuedShares', window );">Warrant issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">774,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Private Placement Second Closing [Member] | Purchase Agreement [Member] | Series A- Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ConvertiblePreferredStockIssuedShares', window );">Number of convertible preferred stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Convertible preferred stock and warrant purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,713,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_WarrantsIssuedShares', window );">Warrant issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">609,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Qualified Public Offering [Member] | Purchase Agreement [Member] | Series A- Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_MinimumProceedRequiredUnderQualifiedOffering', window );">Minimum proceed required under qualified offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConversionBasis', window );">Convertible Preferred Stock, conversion basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On a $1.00 for $1.00 basis<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_QualifiedOfferingDescription', window );">Qualified offering description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Qualified Offering is defined in the purchase agreement and the Certificate of Designation (as defined below) as a public offering raising aggregate gross proceeds of no less than $20.0 million.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_AdjustmentToCommonStockInConnectionWithReverseForwardStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to common stock in connection with reverse forward stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_AdjustmentToCommonStockInConnectionWithReverseForwardStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_AggregateSalesPriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Sales Price of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_AggregateSalesPriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_CommonStockPercentageIssuedPriorToPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock percentage issued prior to purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_CommonStockPercentageIssuedPriorToPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ConversionPriceOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion Price Of Preferred Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ConversionPriceOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ConvertibleNotesConversionPricePerShareOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Notes Conversion Price Per Share Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ConvertibleNotesConversionPricePerShareOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ConvertiblePreferredStockBeneficialOwnershipLimitationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock beneficial ownership limitation percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ConvertiblePreferredStockBeneficialOwnershipLimitationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ConvertiblePreferredStockIssuedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock Issued Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ConvertiblePreferredStockIssuedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_DateByWhichStockHolderApprovalRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date by which stock holder approval required.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_DateByWhichStockHolderApprovalRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_DebtInstrumentConvertiblePercentageOfPrincipalAndAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Convertible, Percentage Of Principal And Accrued Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_DebtInstrumentConvertiblePercentageOfPrincipalAndAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_DenominatorBaseForIssuanceOfCommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Denominator base for issuance of common stock value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_DenominatorBaseForIssuanceOfCommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_GrossProceedsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_GrossProceedsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_LitigationSettlementIssuanceofCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Issuance of Common Stock, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_LitigationSettlementIssuanceofCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_MinimumOwnershipPercentageOfOutstandingSharesOfCommonStockForConversionToTakeEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum Ownership Percentage Of Outstanding Shares Of Common Stock For Conversion To Take Effect</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_MinimumOwnershipPercentageOfOutstandingSharesOfCommonStockForConversionToTakeEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_MinimumPercentageOfTradingPriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum Percentage Of Trading Price Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_MinimumPercentageOfTradingPriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_MinimumProceedRequiredUnderQualifiedOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum proceed required under qualified offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_MinimumProceedRequiredUnderQualifiedOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_PercentageOfMarketAveragePriceOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of market average price of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_PercentageOfMarketAveragePriceOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_PercentageOfReductionInRiskRecurrence">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of reduction in risk recurrence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_PercentageOfReductionInRiskRecurrence</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_QualifiedOfferingDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Qualified offering description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_QualifiedOfferingDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_StockConversionLimitPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock conversion limit percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_StockConversionLimitPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_StockIssuedDuringPeriodSharesShareWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Share Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_StockIssuedDuringPeriodSharesShareWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_StockholderApprovalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholder approval period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_StockholderApprovalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_TradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading Days</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_TradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_WarrantExcercisableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant excercisable term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_WarrantExcercisableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_WarrantsIssuedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Issued Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_WarrantsIssuedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the convertible debt's if-converted value exceeds its principle amount at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConversionBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConversionBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredUnitsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the various rights, preferences, and privileges of the preferred partners' ownership units including: redemption, conversion, liquidation, tax status of distribution per unit and the sharing in distributions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70434-108055<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB TOPIC 4.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187171-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredUnitsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sls_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sls_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=sls_JGBCaymanNewtonLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=sls_JGBCaymanNewtonLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sls_CVIAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sls_CVIAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sls_AnsonAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sls_AnsonAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sls_SabbyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sls_SabbyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sls_HudsonBayAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sls_HudsonBayAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sls_AltoAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sls_AltoAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sls_LincolnParkAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sls_LincolnParkAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sls_EmperyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sls_EmperyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sls_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sls_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sls_VotingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sls_VotingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sls_EngagementLetterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sls_EngagementLetterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sls_PrivatePlacementFirstClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sls_PrivatePlacementFirstClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sls_PrivatePlacementSecondClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sls_PrivatePlacementSecondClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sls_QualifiedPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sls_QualifiedPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>122
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( +"*C4P?(\\#P    !,"   +    7W)E;',O+G)E;'.MDD^+
MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V
M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F'
M.>RGGD7E2B.5^S3%":4A+<TXP)6E/S/WJVR;A5ND9T*YKCM+1[873T$7LF<;
M!I99-G\LCNVW<+ZT+/0:S>,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C
M-R."?S]PN -02P,$%     @ L(J-3&;S"V""    L0   !    !D;V-0<F]P
M<R]A<' N>&UL38Y-"\(P$$3_2NG=;BGB06) L$?!D_>0;FP@R8;-"OGYIH(?
MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M^L/O*NP[ZW;N'QM?!%4#O^Y"?0%02P,$%     @ L(J-3)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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MBZXRZ0:*MWW5%0VEW^H?4$L#!!0    ( +"*C4S/;OTZK@,  . 0   8
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M"T+^;*HT#>21B04<65K3&5%"-R:!E@>91\"!I"F00" 2V#S4"3)O@ -'4^"
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MP&9'01VB>8^V&]=L=(+MIA?$YF=<_ 902P,$%     @ L(J-3+TZ9LFR 0
MT@,  !@   !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q]4V%OFS 0_2N6?T!-
M2-9T$2 UG:9-:J6HT[;/#AQ@U?8QVX3VW\\VA+$.[0N^.^Z]>W<^9P.:%]L"
M./*JI+8Y;9WK#HS9L@7%[0UVH/V?&HWBSKNF8;8SP*L(4I*E27++%!>:%EF,
MG4R18>^DT' RQ/9*<?-V!(E#3C?T&G@63>M"@!59QQOX!NY[=S+>8S-+)11H
M*U 3 W5.[S>'XR[DQX0? @:[L$GHY(SX$IRO54Z3( @DE"XP<']<X &D#$1>
MQJ^)D\XE W!I7]D_Q]Y]+V=NX0'E3U&Y-J=WE%10\UZZ9QR^P-3/!TJFYA_A
M M*G!R6^1HG2QB\I>^M032Q>BN*OXRET/(>)_PI;!Z03('T'8&.AJ/P3=[S(
M# [$C+/O>+CBS2'ULRE#,(XB_O/BK8]>BLWMQXQ= M&4<QQSTF7.G,$\^UPB
M72MQ3/^!I^OP[:K";81O_U*X7R?8K1+L(L'NORVNY.R3=T788J8*3!.WR9(2
M>QTW>1&=%_8^C7?R)WW<]B=N&J$M.:/S-QOG7R,Z\%*2&[]"K7]@LR.A=L'<
M>]N,:S8Z#KOI!;'Y&1>_ 5!+ P04    " "PBHU,/F8LH+,!  #2 P  &0
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M7C;UOT'T$*3L[L((=>&#+8:"QL?C?3C;:<PFPV,__R"V?./R%U!+ P04
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MCV;X!E,]UY1,Q=_#!22&!R68HS32Q964O?-&32PH1?'G<1<Z[L-X<YU.L'5
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M(]3Y#[88$AH7CN_]V4QC-AD.^_D'L>4;E[\ 4$L#!!0    ( +"*C4R<_0T
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M-AL2:A>.G_S9C&,V&@Z[Z0>Q^1L7?P%02P,$%     @ L(J-3/=96F"U 0
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MH7;AN/=G,X[9:#CLIA_$YF]<O %02P,$%     @ L(J-3%]-U/"S 0  T@,
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MGMTT9I,1;#__(+9\X_(W4$L#!!0    ( +"*C4P]QVO[M $  -(#   9
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M"BH7CGM_-N.8C8;#;OI!;/[&^3M02P,$%     @ L(J-3%5#L3^W 0  T@,
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MY<+QVI_-.&:CX;";?A";OW'^%U!+ P04    " "PBHU,P'W._]4!  "<!
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M700>)W '3X '"M@090R:+4H8+'<R9<*".#:4PQ,%+) "=S %>*B !57@'JP
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MX@&(,D4\ @@KR!.4RM\PD9ZRX[QA<-[P$(!, E X  $#D"$ G01(K,D8,6S
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M9!/0V9C:)ES?OK8A7 *^M'_ 7F9F9Q>\I!WCKZ($D,X;);78N*64S1HA491
ML7AB#=3JR8EQBJ7:\C,2#0=\-"1*D.]Y,:*XJMTL-;$]SU+62E+5L.>.:"G%
M_$\.A'4;=^%> R_5N90Z@+*TP6?X#O)'L^=JAT:58T6A%A6K'0ZGC?N\6.]6
M&F\ /ROHQ,W:T94<&'O5FR_'C>MI0T"@D%H!J]L%MD"(%E(V?@^:[IA2$V_7
M5_5/IG95RP$+V#+RJSK*<N,FKG.$$VZ)?&'=9QCJB5QG*/XK7( HN':B<A2,
M"'-UBE9(1@<5987BM_Y>U>;>#?I7FIW@#P1_)"SBAX1@( 3OA/ A(1P(X82
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M?1"E^C&,&P(GJ9=+M>;]>.PWDC7#Y$?C[R?["U!+ P04    " "PBHU,(,)
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MW1;]5:/O*-X.URAOO,OE?P!02P,$%     @ L(J-3(I3W?OB 0  H00  !D
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MF?N":!SYZK_R"V\,W&9B-':B4>XWVIV5%JUG,:FT['7XUIW[7CW_6Q@<@'T
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M?&.\(WIM"C-IE\*^T\5+/7O)HS!*T<6 IIC]&$/N8N(Y!FG^+$*<(L0"5G>
MM1NP<@)6%A#= 9(/58XQ>+32V2"<! ]D(J=,Y)#9N &Q$Q O-[IV M8+C(XQ
MF-P8W0;8K9(X51*'RM8-V#@!F^4^MT[ =H'/[6>?<9"X57#HWMWA9QT</D \
M."!XN5?LWOZ8+' [!=WM7Q)\W'WHYER;>_,G%:>FD]Z1*WU%V(-<<:Y $\-
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M,3XC42!N[ @_#O 39)H(B4CW=00R!]I9R X>$B7+_@)%Q"@=P=4!7 ,Q2D]
M]*+[*>4)B![L:M/#?PI%Y(3RA%8/:$T/_RD4)?O9#U!DR&P(T;[#?O;4Y_O9
MV/;HA)#O04\,,<V5WYZ6.DAR5GEB$!X81,R6E1N$%EJR(T@,PJ-G3RI-Q1X^
ML4/('C\!_F-REE[X_!Z;;\M%?,(#NJ-*<^7WV(@=>6( 'AA U&D:)"*%"L0E
M FC7D3V[(RX1>K3K0 P@=&C7/T/>KGW=:MET"=T!T)UB<!+RBU!^FS00M@-@
M.Q(;#P3:T&._&PB- >UWDVNULY#3*'W;%50@. :$(^D'@3T/[K'G#82A@/!(
MVL5ER*\:VVX 1()11!@E+OX-B"Q-1%B+Z*%1XC\?@<@*]CB= !ES(*U(C2ZB
MV]TM1X\0&7,BK2#7W)&P%GOLH"-A+:(&F53Q*Q!905PW$B!C#J05Q,8BP2SZ
M'@LFF,6\FUGAT@7G-W':;"&R%S1R'*V@;U_0UR]Z[&JE8.]6" 1(]B9:HY+Z
MU<K%&_:X7K!7*P1H;>E9]0FIK$BO(D>O7C-<O8+];;RXF\R7@U]E596S]6N%
MMV59%77$>J+#P7TQOME]F!:WU>K/U0YOL7GS>?.A*A\.-Z]UCW;OEA_]#U!+
M P04    " "PBHU,Q$KQ7V "   A"0  &0   'AL+W=O<FMS:&5E=',O<VAE
M970T."YX;6R5EMV.FS 0A5\%\0 +8_XC@M1L5;52*T5;M;UV$B>@!4QM)VS?
MOK8A:99,*G(3;#-SOAE'!SOON7B5)6/*>6OJ5B[=4JENX7ER6[*&RB?>L5:_
MV7/14*6GXN#)3C"ZLTE-[1'?C[V&5JU;Y'9M+8J<'U5=M6PM''EL&BK^K%C-
M^Z4+[GGAI3J4RBQX1=[1 _O.U(]N+?3,NZCLJH:ULN*M(]A^Z7Z Q0HRDV C
M?E:LEU=CQ[2RX?S53+[LEJYO*F(UVRHC0?7CQ)Y971LE7<?O4=2],$WB]?BL
M_LDVKYO94,F>>?VKVJERZ::NLV-[>JS5"^\_L[&AR'7&[K^R$ZMUN*E$,[:\
MEO;7V1ZEXLVHHDMIZ-OPK%K[[$?]<QJ>0,8$<DD@0R\#R%;^D2I:Y(+WCA@V
MOZ/F/X8%T7NS-8MV*^P[7;S4JZ<B C_W3D9HC%D-,>0J)DC_Q7A:_P(A*(18
M@> =!'"! !4(K$#X3H!,JAQB8AO3VAB(8X)30I02(I1@0AEBHFN*3\((QT0H
M)D(PX003W6(@\Q,<$Z.8&-GT.W4FJ$""U!E/ZDQNZPS\#*>D*"5%*,F$DMY2
M2!;BE RE9 @EG5"R&PJ)_0"G@(^[R4<X=[8#[A@2YIL%<+L!F6&7,2B:Y1?
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MG4OF]#@Q)D$EC)Y448VZ3^X3"B>IAX4:\^E4G2:2#?.%@>ZW5OT'4$L#!!0
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MRI0QBV-/0Y?09PE\E@Y/RWE_\H7"+BS&:,=S'QF[W,:S@A2GY*(]4RO/*L*
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MZW35?V,W5FBXR41K''@A[;=SN$K%RXY%IU+2U_::5_;:M$](U(7! ;@+P'T
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M+#M83IPKII/QGW3)%_VNT2\*=E+F-M;WHAVX[4+QNGN9\/HWFNP?4$L#!!0
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M^SF@4$F]W:L]'R?>&$C63],<S9^4_!]02P,$%     @ L(J-3'G]BPP& P
M,0X  !D   !X;"]W;W)K<VAE971S+W-H965T-3DN>&ULE9=O;YLP$,:_"N(#
M%'P._ZHD4M-IVJ1-JCIM>TT2)T$%S(R3=-]^QE"6<H?DOBG8G._Q.<^O<,NK
M5"_M20CMO59EW:[\D];-?1"TNY.H\O9.-J(V3PY25;DV0W4,VD:)?&\7564
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M%_L=,+OSU=#T D7OU.]DT(S3@.87*'[GMDJC";&[WX&F#C!UV._@_+H$&DS
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MS/LSO9](UMK[BC=<FG;_ %!+ P04    " "PBHU,:A:SE@P"   E!@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6QUE=N.FS 0AE\%\0 QYT,$2,U6
MJU9JI6BK;J^=9 AH#69M)VS?OK9A$2+3F_C /_\WX^"A&+EXDPV <CXZULO2
M;90:]H3(<P,=E3L^0*^?U%QT5.FEN!(Y"* 7&]0Q$GA>0CK:]FY5V+VCJ I^
M4ZSMX2@<>>LZ*OX>@/&Q='WW<^.EO3;*;)"J&.@5?H'Z/1R%7I'%Y=)VT,N6
M]XZ NG2_^/N#[YD JWAM892KN6-*.7'^9A;?+Z7KF8R P5D9"ZJ'.SP!8\9)
MY_$^F[H+TP2NYY_NS[9X7<R)2GCB[$][44WI9JYS@9K>F'KAXS>8"XI=9Z[^
M!]R!:;G)1#/.G$G[ZYQO4O%N=M&I=/1C&MO>CN/T),GF,#P@F .")2"T'#*!
M;.9?J:)5(?CHB.GP!VK^8W\?Z+,YFTU[%/:93E[JW7N5AD%![L9HUAPF3;#2
MA%ZV:(CV7R !"@FL0;B&^#YN$*(&H36(5@:)YVVRG#2QU?13EG[B)R'.B5!.
M],!)PW##F339BI/NH@"GQ"@E1BC1AO*HB?,<AR0H)$$@\0:2/)02[Q(<DJ*0
M%($D&PBF27%(AD(RQ"#;0!XU_SVN'(7D""3?0!!-Y.$0W:C0V^8A%O[VNF&B
M[0M&5A?<--"?5%S;7CHGKG2OL#>ZYER!-O1V^F5J=,]>%@QJ9::IGHNI<4T+
MQ8>Y*9/ERU#] U!+ P04    " "PBHU,G5P!B74#  !"$0  &0   'AL+W=O
M<FMS:&5E=',O<VAE970V-"YX;6R5F-N.VC 417\ER@>0^!(GC "IPZAJI58:
M3=7V.0,&HDEBFAB8_GV="Q$XVU-X(1?V.=O'SHKMS$ZJ>JMW4FKOO<C+>N[O
MM-X_!$&]VLDBK2=J+TOSST951:K-9;4-ZGTETW4;5.0!#4,1%&E6^HM9>^^Y
M6LS40>=9*9\KKSX415K]?92Y.LU]XI]OO&3;G6YN!(O9/MW*'U+_W#]7YBH8
MLJRS0I9UIDJODINY_XD\//$VH%7\RN2IOCCWFE)>E7IK+KZNYW[8M$CF<J6;
M%*DY'.52YGF3R;3C3Y_4'SR;P,OS<_;/;?&FF->TEDN5_\[6>C?W$]];RTUZ
MR/6+.GV1?4&1[_75?Y-'F1MYTQ+CL5)YW?YZJT.M5=%G,4TITO?NF)7M\=3G
M/X?A -H'T"& ?AS ^@ V!'#V80#O _@0P+K>ZDII^^8IU>EB5JF35W7#NT^;
MIX@\<-/[J^9FV]GM?Z9[:G/WN(@YFP7')E&O>>PT]$K#KS5+I(FN-4]((P9-
M8-HY-);"QM(V ;M*$.,$#"9@;0)^E2"Q*NDT4:LI6TV(+3BTX,!B:G5$ITDN
M+%@R"1FVB:!--+:)0JN2:&033Q)'APOH(H +P0EBF""^?<02F" !+:!6G<EH
MQ"+3&:%CV*;09PI\+ Z6TY$/"4GLZ \28MY"8#2""8DBAX^#:P)2"-N'W/JL
M$PPDH< EMEW&(BZF#A_,+0'@1C:X0,29RP?#2P"]D2L%!I-$MS_R!%-'$';4
M?BF+\=.83 5U66$^2?S_ 7P$(O< 8HP)X%B$ML]8)!AW^&",">!8. BEF% :
MWCZ %,-' 7S"?FL!D;-:ZI@/ 7["?FOU(@$A[^:C#R77#<%\4L"G<-6"T:/\
MCF['Z%$P*8K([@XD<JU",)\4\"E<3<7<T3LF1HJ1H@BI4;5(E#A\,%(4(>6@
MGV&DV!U(,8P40TC9U2)1['B2&4:* :1<4SQS+#+9'=5B&!B8A\;5 E%,'3Z8
M&#:&04P=W#(, Q-W5(MA8&@2LE^7O>AZE>=<Y#',#$/+27N] D3.Z8YA9AA:
M3HXV&F,13UQ[#0P6!PO%V)X H,@QR!S3QQ%8]O/(QZM)$E(:VUT77.Q-FZ\+
MW]-JFY6U]ZJTV>:VF]&-4EJ:G.'$9-O)=#U<Y'*CF]/8G%?=KKZ[T&K??[$(
MAL\FBW]02P,$%     @ L(J-3.#GZ=,G @  ? 8  !D   !X;"]W;W)K<VAE
M971S+W-H965T-C4N>&ULC571CILP$/P5Q ><P1!((H)T275JI5:*KFK[[, F
MH+,Q9SOA^O>U#>$(L:J\Q/8R,YY=LDO6<?$F*P#E?3#:R(U?*=6N$9)%!8S(
M)]Y"HY\<N6!$Z:,X(=D*(*4E,8IP$"2(D;KQ\\S&]B+/^%G1NH&]\.29,2+^
M;H'R;N.'_C7P6I\J90(HSUIR@I^@?K5[H4]H5"EK!HVL>>,).&[\YW"]"P-#
ML(C?-71RLO=,*@?.W\SA6[GQ ^,(*!3*2!"]7& 'E!HE[>-]$/7'.PUQNK^J
MO]CD=3('(F''Z9^Z5-7&7_I>"4=RINJ5=U]A2&CA>T/VW^$"5,.-$WU'P:FT
MOUYQEHJS045;8>2C7^O&KMV@?Z6Y"7@@X)$0)O\E1 ,A^B3$-OG>F4WU"U$D
MSP3O/-&_K9:8/T6XCG0Q"Q.TM;//=+921R]YFB89NABA ;/M,7B""4<$TNKC
M%=AUQ1;?T?'M!;M[1(3=-T3.)"++CVZ22-T"L5,@M@+QC<!R5H4>DUA,TYL,
MD]4L$P=H$;N=+)Q.%O=.$C<_<?*3QTN1.@72!TK18Q:3+%,\K\0]!D=N'TNG
MCZ7#AYN_<O)7CQ="CR%G:P0/E&( 3=\XCN-@5@P'*HKF380F/<M G.QXDU[!
MSXTRW3&)CB/T&9N>G\6W9K3:6? IT\_E'T2<ZD9Z!Z[T1+%]?^1<@?88/.EW
M5>E/P7B@<%1FF^J]Z.=A?U"\'68]&C\X^3]02P,$%     @ L(J-3*_30]$K
M @  0P<  !D   !X;"]W;W)K<VAE971S+W-H965T-C8N>&ULC55ACYLP#/TK
MB!]P(8&6]D21VINF3=JDZJ9MGU/J%G2!L"1M;_]^2: ,<4;JER8QS^_93F-G
M-ZG>= E@@O=:-'H3EL:TSX3HHH2:ZR?90F._G*2JN;%'=2:Z5<"/WJD6A$71
MDM2\:L(\\[:]RC-Y,:)J8*\"?:EKKO[N0,C;)J3AW?!:G4OC#"3/6GZ&'V!^
MMGME3V1@.58U-+J23:#@M FW]'E'$^?@$;\JN.G1/G"I'*1\<X>OQTT8N8A
M0&$<!;?+%5Y ",=DX_C3DX:#IG,<[^_LGWWR-ID#U_ BQ>_J:,I-N J#(YSX
M19A7>?L"?4*+,.BS_P97$!;N(K$:A13:_P;%11M9]RPVE)J_=VO5^/76\]_=
M< ?6.[#!@?GBD$[(1_Z)&YYG2MX"U16_Y>Z.Z3.SM2F<T9?"?[/!:VN]YFFZ
MSLC5$?6878=A(PP=$,2R#Q(,D]BQ#^XQP_UC-,38^\?C$),4)TA0@L03)&."
M533)$<$D,U$N4)$%(C)3IB5*L'P\S10E2)$(V"1-#!/C(BM49(40)!,1#+/
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M5VT^W0531[)AON? <MG6?P%02P,$%     @ L(J-3$G,%L>M 0  P0,  !D
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M,-Z(<"3[&,+'0NS\F;O_&& _1P0^'B% DPBT?S"-X"Y(#%&"4!.$#Z>0&J>
M859&(I]C'H1$J)!H3A"YAA ,LY!MC :)$0*C)#L,$QC98I@0%Y*@0A*$(#*$
M8)C8$()A$EQ(B@I)$0*S_AAFH;8K-,AJ1A %9K9S3!J[>!#/Q3]H%[F#9G4Q
M4&1\]GL,%"]<-&^ANW@(Q4P,!C+O&@I:N&P>VH>VGH]0F 7 0+/[AH"2T.Q8
MSJ0%U\ N>EIQ*Z?71JAF-[&.$W&K!Z)AWZE)J5O[!TT_9G\2=BD;;AVID -"
MM_$SI0*D1O=)MHE"3O9Q4\%9J&4BUZP?;_U&T'88W<[X_R'[#U!+ P04
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M!>A#1) 3*/+$$,O.ZO<;ZJ05^7U"Z*(H$F@4B#0F2$M(%(DA$AH4B TF24-
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M*&*L%&HB@1=9I+ ;-Z^)YGJ[=:&FD3F D?N5LQPN04ZLB @^<^ ([HU7 9B
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MQA<8%FCE$,U+T(#^$%6-:H7W)L8=B.O_6DA$P8D)0)4_"CF"NK3_ NNV$GO
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MPD>M&X=+C/ 0]#\Z!@Q^L )SC70N7Q\=?<4\LE)])=B*KTR \U)-GB$XQD
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M&?5<P/?W)M2"P;#FY>,(-_;FQE+9R^T280;6Y!^93$Y#$/S\)?[;1P>PYB!
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MX@&[<]N3Y[JJCTGM\=IAE+2"&3FM+%W[)(_BV?L.+$:F6M*5?;[+8QYR7CI
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M^2,*7@64Z@$JK1F"BU-<&:-=1TEZ,%/I)$N@H[5>Q)#82EI@53YF2^[V),T
M-$67.1=0A"E?\O#WG(*H "01?XY@BQAZ"*MU^Y)8'YU!Z668Z?QKABI(RLTL
MAI)K47%F@XI*R1\YC\*GOA*4=:@#T T4!#Y?J*:U^ -[P#/ RXC1)4%00OV/
M89/%PR=3$@X:H%I"05QP]-8QR"TI'USKA-==IJ<IKFSRF[0P4*F76TR6;:2/
MA59 E+[$_G/W&Y@YAV4;I+&NBL@\20@*LI J.DP-U+*;Z$A[4J4;<4AG]PA=
MS_:+L_7ALI4_(JP6.C-C4J;BEK NPL>+.&#AO<(;0@$)8@"]P9R/71L0?FZ@
MYDJJ7\/PVL@]LSG#AW5RA:@GI!P<DIX#_[N/7P]M&Y)+2AM .^D5[(XF ;G.
M]<P51[BG;8L=\X-4=3H<O,,00I(1WFA\A$FH R]*^*"^;H-:6RZW%#;5SQL(
MQ#:@6.ZD(06I$;]]G@"%;)IB@9[ .8+"A_3AQU'RJX]6$ *EZ@6ZD*1W(9U3
MM]H (U0ZS72AS/\8C9J8?@M-6YP"!%B$WR3!YQ.F*-I$+FI/R?CKW;-D,YJ3
M^T44X#<*M"F 3"6OR["1-8$<XA+N"9F$\Z:H<!Y+M2T,!GG>-/F&QO27]3Q2
MBKLU-V%!=4J0SL!";W/-K9NS"U //P23GG$B'C*9B-/X]B>S=')V9OJ;XQA>
M*<<U33C\T1M<B<,A;!Q[SYB7(3"DBZ^3.L++ZZ6Z,3N(OEP(JPVKCM.C,$WB
MA:2L#*CM%\ N;I++KZ!X4QN(#PBXRBTC#@ADB! U]<>4M.RG=E'I(M0I(EQS
M02ZD3A)<^]8\-7H+V)+$$/F#J\>#Z\<#^5$9,OY*!3.R,U5/9V/B9BTT6\+D
M@:]&[ IIPD\#^[CQ(G_+BGO!6.0$B#>:BW0><36M3GM-0-(XNA\D;I'1\X!#
MF$=VH:FBZYF$7@(CK@36-O #/'UM1\=FZA$^UVDOE2*4@532WFE=IJ.J%_U:
MZ+Q)97%DD&S0.B.5$%TCA#6/>ZP?'*<]B:F#6WS%D&6[=]IOK;,"0U[=L;?A
M">>?2/SFWFRKYLY:$SLVV?5N<D_'+E@68<\)I9VD3IL TA8/M/?V98Y=8N"R
M%-KYI&?GL?AO@1Z>8LDMK)W-'^YQ$O9$^;7XRNU9P$*J89:HBL6;W!O'@'>K
MCAJ;XC,3.]#M-B.F#'-1L 32,)W7+RD?>6Q!O$U=GH) 2^F0K-#M6.'QP );
MF.5#"YS]SR[P"JLA_-R"9][ZK7>CV([<:Z;NU(C!O@O344=$XK M +.GQZ,S
MAX]WMT2;&\ 5@E5CKAM(?=DL@6DY'L,U>ZQM;/1.H1?5=X&F'O63<C/?)"?J
MZ#2W!9T(>N0^2-[341]I]_(=T K/^5*298TQ3Q)7EUY5[.I#;>WWG*SG3VY0
M4;7JH7FA3[1%*O-7^ \=<5-[C34<8=DC)9V1P>C-Y*51>H''C[7*;U!XE[YS
MD%<Y303/J+^AZTSF77E\?99E06:&OF^1 <3)3.I:PM7F%(6C_&0>ET-TN_>'
M&Z#6 F6.Q;@+W"#Y8L_U9*L9M9^HR2;!!7ASW9MN 2="'-9/S68=&KLB%^KY
M/L96I?,D;/4Z3B_4=FE"WJZ?O+4O&TJ9B"&!+()_'R86VK9?3^Y9AQLT0RB1
M[30]::NZH^2CZ>.9.?P.V"5-DX?61;OWB^)<SE[1SF6ZPD'?TJ"A1AZEMF22
MB_1<@^CNLAZ*\!G&*JJS0WT9#R(6QP+73DL$2:),LFAMHK.;:*:7)J\J!/>\
MA4M3)^^P6B:O;HMRF^R_&[T:I>YJ#O])[D;ST8O>[I=MS3OQFK?BVCAL10K'
M ,NB>+ ]#78(L6F $_%?U]XK;ET:C")=S<CJP)->':"?40ILK1-VF?PI=LEB
MQ^TDDSZN:<75$+<=6$1;?_9!6F?T9I*KK-=1%--WA% =+_4P39F5>4X@X MR
M+G 1BV0@8.2"5("NQC!?9E5 9L5./^3R3JS#(58/U<XEYY(851;7):9,Z45M
M[YGRAJ@>7NW-'3>VAS.<' )K.&JQ!DP"[>_.W'H[1DP^24_&8RT($(.ZIW"_
MH>2MOBU!1U8U_Y+0"N!;(T[$B?U6TUXR;Y&WLEM'[#9N-$'[CLDTRT?;XLK+
M03,'Y^<0 &8?4WD"S<2-S/55>;?*DY>COX]L^V]X*+P6&*!FN$84SMX)F^00
MO9U$;45R39T455%%-\@0C1Q3$T,,.W')B"1 Y!XN.6[9SAOOZ?7CJPEV'Z56
MO!O8]JI<%G]L5]EULO]+_MA4V$[\W_[WY.3P1TWOW$@_7?+NM&1=4;-K3E'X
M"LEHB[H^XLO2=[$]N=84I#VKZ>- HX,NP1U,PO<%[. Q].A WPXCSZ^R>576
M<\IW7Q1U3GFA=#)1ATSZ?EZ0PL-M<4-6C<NTEIG+4;G>2EIJ97PI<B^U&:BD
ML!YW31#ES#!N&WM=,(8!HW0PE'"Y>%QG&.RO']=P&1]MT3*U6N7^LC%E:2=0
MS#]9;A6]BUK'@FH#BS?@L#['3&(A-)6<$GE+2I2I@?4U;#Z@APKH TR!N^*:
MT\_VKQ_C,\(F65L.UWI[ /0T;/SCFZZ7#VLGW\$&IS6KM??9(A?+!TZS?)1H
M,?:GN:W*A^9.T?1J)Z@L<U)W:PP1<2 PPZPTT"I1S86) 5&Q,LKZV>3[:8M
M.4(FV9^M7JQ"E!N0AV[@(E"EJ2Z.Z06^_/^0Y;FA^%*%N685[? C'P":@F;V
M:4P@%FQ >AD2I03[2CLWVSZRIB?L/E -<,2JH"0!C+QO&\<5H2K9R08T<V:2
MJ#$%?%D0?P%E@-, #^"C+U)WOKC/OB*,L;+D4#QQ.*1XQ._XZG7^K??\MWCW
M(")NBXL'N:9D3\5Y'@Z%_8HQRW0]+-,GVZ1&",A4X2G,";MQ'D3>]TPGTL&[
M+4V1Y8V/Y4</3N0^X]],#^% >;Z?283#J($@0W_.[!9>&\2.J8J\P8U_NSH@
MRI9'C#03Q E6C]!Q<(!BF0*(AG7(5@D IXYRG3-4$=U]RGM1%L8Y>0'RB:#A
M*/:L)Q;09?#P;HHENQ@?!0M47-ZP?JR.Q^XL406Y[N&;]Z_"ID6SI[S+"+Z<
M)@ O=$.@3ZUCW]\&=(WZ1C/XMQ=<FT=8.LJ_\&#IK..L+6S=ZT)L@8*LJEFN
M*3\.?4 9@^?:?P)QE+^C:VF. /1THWP5U<0'YYZ.NH6H.!]C/&P:H!KT]Q$]
M2L4,)MD*= (QC(O'3;6MTUVQN("A)N6CSX[%)=%4"#3Y\Z<)&%\@S[,-%L)\
MOYE.M -\:-;=;Q([VA:ILV&-U6Q!QX ANHP#3BX.."7M@-.04S5V)_JE$XJ?
M"8L%;V8G ^[0FD6=*&KT7>>+:;TC+Q%'7E@N1_<%W,F'[WT%.'G%>MP:!KN2
MG-D<<U8;7/TQ0:TBU"J?@G!;PAT@^J5R4Z'=GE!,F&<G6L#^\6^U1KGU8N8]
MZE5.8DO="B'&UNDAX1UOSCO>ND%L(A6))9A-CX,TL(E.LZ%-[P,B O@H-X"/
M'#N\4VMNOMB-J+0]FO'U-ERC$_GMK&#@PFB(3H5,/\'%.)>*^T?5FFTGN1T,
M%\Z.;MZ#ASS.RW:#_NV ;=8)='0NSO'(78#=G1/.^><J(XL;*WQ)RN!P99V\
M?75.>ZVYHJ=/;W=@JB&OA-GJ\SZGS-8_W<-LDS:S_8A5$K<@6-QSF4&+_P:]
MSAG^^V5=/AQ@I[<0@0Y6]*PWFF<WP_622'LSAHC0/4&$R2 1<LF!K\3LMBGL
M<[X9^ %;0=;B05Y*(]<,:[",W F-2^$#)@J$!ZV#@Y:5?]6R>.,([E1G6,B%
M%E"0'SOF]>;J12VI6F$FK6/@MD(*6^"ZW3;$O1,P?/QW1[UYMAMLTHMN,VXE
MRE6-#%S<Y=W!+/&9>KA[WR,T6LO+4O>U#38EO)6'*&:GTP\TNU_7!0&3<&'M
MY_QK1A[:5^BOQ9I8!#FV>4XL;&!F?P4;Z!$?_3F;?\''7F/:0TR#YPQDJN?W
M#@\'N(5[!WH()@;UN:#8TSINA\)U'1(8H7@"5WTY*XI8]O1E35$\1(O0_"J^
M=?G! _7J_"+N#X6[^8Q-<0.;DL2;XE7+O_[\.J1QD8_^EFN-@U[X4%;+Q0-Z
M-65WB-O&D%\<R7$^H,1>C&6QR3?%:ML<7/FD+?+@$<KVLC4&!EX0*;JXC4-6
M$B4RUH:)7''%*LOK6HT:_ZV:FG!0EMA :ECA(WIQRE$K"0RY#EYH+C6A1L[8
M46!.*J/K1#N\OM6CL9$*QJF<KIO.JDF;FJ1?5AY+!+U:U)G*M\K57,3<@+_X
M8)KM/SQR+XOR/JL1F*8*UR(@#;!(F:7<!XOF"&_\/7Y#:<;\9< 1T)/BUY(J
M:B)5;63SX'@W5;-@*]+$^L,W_=W$'M-^5M5'SCO3#U$S!#4;WU#T#^04^9+2
M0=&8%KB?U%<=C$+]P>M7YP>^C>NJ6!PT)7IE8J[DX^2]V]_>7*,V^QQKRXO0
MEL4D(G8F>IA(FP_9HZ,$,+8>K#ZW7[SP#<OT@L^^\SG)C);G+TB4?KQW-&[U
M0L>7#\/+H.SP[98V?'X,YV^#Z.*3L1D*[.,"9@5F.XLM!;9V)@C9:E)J='DO
M14(,J65+Q5D0-DS<<D)J\3.6/3V45 HYO\OK$-NY(1-I(#;J7P<-!E&J""T_
M9,=9<$'2!S@"%P9K-V+M&WHF:1Z^5,/U="70&BL^?NZ4G1#*9T]5$FP][#TJ
M.-251Z?#"-<UE0H3@5T_"DV3T B=U$D@3AFC@MO!UW<^8LH(!1O@:=X<,TC7
M@6M*^K7Y'+E@,8R;&QALW7[RF3J0H7R#);(P<*BXWY.343Q#][P9)L,S=':&
MH7(FFB*MHG^6+IXE>\[VB_L7^J7.0-P^G0=SNY<,9]4VUDY39QD1**/+9?)4
M&G.'N3@E7H6>5W+A\3P(+EFJ&'U$BC$"VWG>E769)H,I4WLU=H\"Q\^Q 5_R
M,EM_B>=/P6@6)-%3,A$YW:Z1?)?OXB1MOD.RF-?@/N?W6=)J*^G8JOI]NV['
M@"5<&XL^407HK%T>4I+]4=$^3)]G&_?%3]F%_/+-!0(Y2;'*6^;]P?$/?[8&
ML0EODF;;7:6<'RED Z:PFL'T[: Q!+E<Y_D74T'CZVR CM_4599SM:JH2MXT
M5:<CSHP+%YU$78*]0X7#.IPVHWEUKGUS+M^=BU>Z%$B$U-6Y%"<O,/*)B-V^
ME#+,)]/.Q@R\Z"=<.\UJ&"6ZEUQR+Q;'LK:I87RSJ,@ [S.ZGFO*X;/K1I*5
MFGP33C+I*#([KMAQJH7T^BIZZ"+E<Y&*7#2&G/?(,V &-T'TWD3%B(WI-FQ.
MJFC:%LJ<D3%H*"P075J_4MJCC7'<E1W^PL[PNYP#&>5^B&+0+IO"](:MT;AE
M!UN*-Y\2'POMB,<ZWK5E9"IH:2L>#SU0V(&=U]2]\=E0!A_67!CHV4P+,%ER
M^CX6JG".'"8;?<H7BZ (O^5X64D=9"@R\2_A--X+]XS0AN- /D;!A\OMM+X3
M%0&$9[HK-NPA?<Z2E"-UG@WL:2#TX;QM9"K_Y/XAD<(=RB@IOS,+=+T&:I9B
M:$91(6P>B>JV6BA0US'C'F,TK.[H36C^D(ELGK:C;DY"S.O6)_W$X=,EY1NE
MW2\XQJYL5*455[A^BH>FR0GQNU\>X!HEK]"G$;-U3NWYU]'6.1#^4ER:B 3X
M[4&S75/EF7IG!SWJ\-&^W+8GA%3XCAL254F_J$*:^)0+?@XH[+^ @I\1$,55
MN<45X+^?*<GDV-U_1Y(E*,G<H"2SDWJ&.&L7$YLFL^],!Z3V8V]LATGLI?V!
MW!SFUSO@0DY&R<!G^I"^ZD3A&B)X\FNLZ>[Q)VAU?QO8R_>PH%:GP4_+Z5P"
MI<)-"%31CF!E!*@;=,T<AV^#@+W*ZWE5$+I?K(;_;4M8M1\KZJ4$M\YV@^9=
M^]6T9!4T,0$1L]"W"(MQ?#P-_^T!G6F#C=GW)^-T>G@D__%OZ'\C_+"P5Q1P
ME+YE\<;MH3/V;'QB?NB9D,$=^T$!O>H(*IFQQ,0"YUGO,=!7WX#Z-XLM%H<X
M&#NLM3SY;1<<['DKG:;'X]G =.AO$;[-HEAP9PT$5;HAK_AC?[-EYHWH)-Q2
ME9BVW57\"LG.>%Y(^T2Z)0]MS$-F</T>HQ*)_EQ1C\W5LS72J#@47 Y[)#3R
M8$RPNCO&P&JZ&"&#ZROB.XX3R->4VT.%"QZ,5-N<,8:B;KET0J;L3NZSQRE8
M"KN=$AHK0S 2<NX!G-D-\"EI7KQ[[T-34L?!G $_:0L'CUMF3+SW:+@$WGC9
M9L&!%,$LF.0"%Y(+=L$JA.YD43577Z2-Y<_G=R&;1].LVCOC.J?FT0?ET)9Y
M7\21# 1*!W7<F+D: *=/?;.ZQ".36G &0E2C^"+^1@-TZTZT,R!#=0_4264N
MM^H1,\\GOEM "93O$8QL3^7NIRVL_NAX=K2?O? H/UF]R/XI)CT!:M-CK*,Z
MBR@4-?2F"RX8LQ9]T) T.1V)%GQO W_0K#M1=MR#]E[B(&?&RK@SCU*8S1L]
M 1Q(I#7?6LUOW5)0 ]MC\2U2P\VG7/*A\IVJ1^Z\VV)#HGX[ (0H_<6]IU;I
M!#]T$N++J6]GL:)F)FR8>2@MW\,<WC&E0(A@2E8DP9B>81-;@32=3$G1$XQF
M0Z_*4:R8T>N#UFO  XX@7;.HQ5)'+SL76,Y+BQ?*ZL,%-Y^WX/#MMS_R%>.W
M:"C,G!S6T$Y'R;=]T)VW84-#N=I<'K<;TFK2%Z&/17H5 ?-=[@+F^UB5-WDM
MK5O(F8LZPLGA(?UW?'+B6,_D&C=$LSR<'AN-Z5K#E])&JTZFT]#MX,("F?-#
M'&;P'?F.CH^3Z2%H)+$[EE,=CR:@(!R>'3O>N<D9_'MZ\JV[M9?,4E@K_/<P
M'1^>M4_K57[=]/WN>>!]9]@'[KIQ] 9+@+C92!N ;!@J[NG#HB\I_?A6:S=P
MS];H[K\BT%-\6]NZ[R6GZ>S$XLPA]N'\&T8 !6TR:>FYM*P]P:DU8U^TENZH
MTI]@"9A_)\Q<8GWT!/11?A"=R_B$__-1>GQT)A_M[*L=Y22='9^ZH45H26XO
M%,#.Y!'7ESR2V;XDP>-E\KI1+/W\TTNW,:6*S#]E/#",B(7"0RG[P(Y'LQ.,
MMVA:'\E8S^_1Z[PW/1H=>>6DYK76LM:%7VM<Z=:_(5%RA>>H(%_\:E@;FJ6S
MV<PH"BWM*]8;]L:C\7@\P0B7R ./OSE*$,^3.FGF"_(8R#Z0/Q"]CWH[>,:N
M2X=VIJD$CTQ0$:=2U+7B2;K0F#IEU3V.8$QG5DQ]]A_6K7+APZC$2$5>F9A>
M0S?2O"/QY9M!E7+2YZ<[L%F1]NFQ:5:=JD"3([ C:DD$)UL*7^\T4>!LJ<&9
MK&0EI4WE'DL,C(%HB>/6H24 T.S9=W3 #"RJ6B@LOKG#KFW89\P#Y(H.3=]!
M'4JQ\II=L]K'EM;H>5'4E@7'V$0IE<J&T'"L=SQSD*0K<S8HHN 08LU\#OJR
M.NTEV^2AJ'.X&:"6?L6"_!7?/[Z^'"JCGO#YBOD![X<%->C_?LI0!))6>^HO
MLG8B6VQSR?BAG41=Y^>_O7QRE_#^X28MN%0D%3M .EJUK(#4YPAB<ZSKWT4_
MI2@M=HHRH*R:<&ONF%\LJON>XOM8J;T%W/:N79WD<Q6?>KTWSZ^;EK9KCZ@3
MJC+*\+@P\<<>%LYP=<)B@?;6KJ16<$/K9<>/32,)#W>,/=U&,IL*02CUCC(?
M6T0UUD013<S18WM8F4,F1M]#4G1HFIVW+$/-M=PITP9E:Z35A83))SC.0\"%
MP%T0J!Z6S;YID/-MH%CQ]@^=@'Y- N"V8"M,.NI)&8 F"-6,9#$X">'L=4LM
M\QA$G SJ3"(KA>(%_T'0'WY@8*7C'U&6H]TNV6C%BMMPX'\-A*C%&MLA&1@&
MTIX2@9?GF+7O,WV72[Y:1HW#-ZP\"4P22P&U.P&YO[=KX89RJ2/H.S,$=QOS
M&@/<RQA_3;?=LQCU'Z3,JQE>@Z;.Z1#,K4/V0_YUGDM0!KT" I$^.37*CC *
MU[\T'I& Z/ ,<H;';WU7;^/0II-.R&*JT^0P9I7.*TPA+QE?$Q57^3DU>&7R
MQMHW.2,9(@:L-$LQ+23\R;3@>3><*^+B2NPX^J9M2GO257A+1A'9WFG[3'S(
MF/J$%8(N,-?6"XY3=FST$FI%7<.>/+%4M,Q!HG6[)+NY+[ 3O309,/36#-VY
MR)>"X478EISA%XX;Y\WN'QFG=G)U.0<*]*M%5K&.$S:P'?6DY6STM/'&]F]"
M^!H;L*(Z]8M9%^O:R #Z!6N_5X^4.'QIA/=9O.'W(&2P0-E(?;JQ*V2SU[D!
M]T-5C"&_J&H8?=E5'_(; AMS5U&^A:0;TRA$J\YLL.D^W3_E'Q+TY^$'_O[;
M^4=*,YZ,1T=C@^I/G.$1(P7<;S23;DJ9V5LG%$&MF>CT<3W7+U";)\AO_.XB
MO\D0;QV/S[>5P"VC5JH$\:>8<_OS%_TZ"SG@L%G%>B$LK7;#[%@H^YHR()84
MW,3EC8-1\H;+['F.O"POK.M(5=-FG(2W:4/^72X0T>7 U Q=NB&Z)%**;@"3
MF3);CVPNI_^GKP!?)Y#,W.(42>)T[)M[(668@'$@ ],?S6TL*(BU/$P;W,[-
MC\QHAA5Y!>/B!R/C&2F))\2Y7M)=5+X YEO.LX>UX+M:8.G8W<KI>P*\8^?O
M^QK898!5M]!(UG/7$6$_?GZ LWGL+.1'([(#%##O%R'7<'/85.\;]@A;V^FF
M:I#-<WL[X_OLU%*QZR23B/)'Y<HDDTGHW4;[[G2Z^%1K!2*T/51%:WBV73L?
M+=<(72!A+=.=#<^Q9> 1OM'0",SPSK#;7*\P>,CB.@JJG,"*U,QC\LE"A_0>
M69>M$NLS>[=K6 )),8T$*,R*AK/%60[<G]K!/8&_J!,E!,96[98WW#H1\M8W
MM4=Y,'N?XH8$MSL\N_Y7-;% +N!.BR-:3-3#1SM/[?R&]V.H0T).3]T:CB^E
M ? <=E:TG!'I3MV4DZEBMX&Q2I1;JKI$7RU\!,NG4?>X?9=QY[&LGSJP+O:Z
MYO8)?<"M<D"L +NGK1MQGD1%@FYO&D-A]AY%7QU>4%.D$VU+(SJ>SM*3P[/8
M9=&QRMO:4IAF"Z.S7Y3U3"R))Q9C?:H,39CDXWXO1BS&A5ED-HN"Y?,C]F;V
MAG*KABK.9'&]%Y8+5@E?OO6\O^#./L_\3D*1!!':JPD!294$]!YU$LL'Q#[R
M/'ORM:6TGM8[W*8\K_+6]G[3\5;M)B?Q/4B'+H*V"/?:*TT$-:S663^4U1<&
MO"%H[1$'.&Q\Y#-^C,(AZ5 .!X$84XK@M ^:P&"9W=XB?EO#$=B)$2!D?'8%
MAHVET*K7I>17:%Y#NW>K_;!5C=H1'@X?1RI2R<&7DUUK<+TS"OA7W27L'05E
M&7VEEW^[P+(Q+/SC0-*;Y#52J*8_XM_-[TTZOR]]\J4YNQ>K42H9PI$WM2EO
M<PI ^O2?_M@7+]^,%V\8WY36O@]$T82]4]F5^O!,8D-T@HP>(J"^G%U;5NW+
M@LFS]2XPR>1J_LI 278NV<7E!ZTR:0K0EFI,I\3WE\T?Y>U2QY%5VFP# EL0
M6L"T'$Z;NL[I!^,)$:WW]#LS1'=G.)Y!E&?O3Z@C\P=)W_=!M^6C?340[0GE
M^QK_8Q<CI$5>'G_# K/&Y$,9%.@O[?<YX6X0JY?VSD.QGU:W(I-RP[U1HH1C
MVS;:FT4"6-"3>1:)'NYT*=V%V\L]GDW3V?144W;4@<]+P?TY.J#<.W6=!2R1
MF=4@7I;8!QYY88&08$BBOGPT<S8?Q3<M4)#+Z**^K(K%+:*S"'!FN.W=B&R+
M?V+?V>.C='H\T>FWB#/K&#I>P8V"C [D\MFDTT*"IY:\MIB>\02 @0=8A_W9
M;)P>'4V$+%YPUP60D?.JN*94Q*2793_<E=PK"[-OFN?R%,DV0PU @[6.EJ]"
MGY"WN,?6S0VVAHK9\S[,W>LB+]CIM.4*8>IYWG)L[MM:LQ<4 1,-N_]B(]*Z
MA>;K[J75"P/(1>XA8(@Z.?"*@T1(.[N^K.J=5ZG;($K&9]F#J[YK$TCX.[H,
M4]^<,ZI//^O%R&>"Y(MW/. H;,?W0V1G-CE.)\>S^,**H:X!TCX DYB'!2YL
MDC=,C!R)53/_O/^:&#K[QLVCQ*AB6)(V,!K<\R4C)7)[3ZXE]CCPKC?1=R@U
M5JG$3H_]'78*,F//;6RG5U*?&X)U1E;/I<L^TU=4EZX>&F)]+NZ\:^^OHN9)
MC_A]1 2?%\T+4B2/^Q5)SU/[,7*4@P%_L:I3O^+5P^);BM"Q,SI0D.C'+-MP
M4[KR'!OY&G'N>L1Y]WU6[@N8+XS"M;#B2S *!&/B>>^8D#PC962W^8L(831\
MIJC=*D,0D9(Z%]N](,-(MI\DJ37\,>T<W<0_)!DWF,(\,6(H6*6+XH MBS<?
M/Z3)-2832&E>/U4X:9@A/<.N8,E_Y-52"E=>PIH1N!;3DOAK=?'U@%RE,?A>
MWZD#7<O8C. ?C#*WZUN9]@]#HD[C70O*+M=TM3E:JM=>D-)I)Z>SX_1D?&2L
M-(1"C7A5W-&MR@\8]\AT1Z?T-\KE0ARN7J.H7395=FO0I!)?U'U+&/;W'J4*
MS5-O4#D:,(YX=DV$M_A0#Y3X!YN:$\'-<2IKQ9\VY-T:RJ&JPZCLFF%  DV
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MVX6II]&UH5PX4+81<4(ZO58YV#)4\T39 &@,.6WH*9L9+AL=_3)[J+<%!A"
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M-S'N=G4K5'(,&4]UL98,/"K-P:@*8JQWOHL3; $UQ?:"U\EC>Y $.1$ (J2
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MH._MSPY'P'&^\S_(-:2BEY**;/"[*<W*\"%I\Y6,1X?)=SZ]Y3N]M3RX;V>
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MFDS]$^6;%_W[I$*:!ETE]W="\QCR=H"KN.=9%@YCEH6XK4 E; 6&PYU@U='
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MU,.!%52UF#\<!407$IH$(]?B*D4[8>7>AOE[4Y<%6M1.4Y=#DZE4_K)D<EG
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MX<)%3M!&*,01.J,4_T!&0&/CMD<&JAN6;(G$;\$3;]O.+ <WP:EN[)>LD4,
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MF)\PE;OXPM8!W SF5J!'5C:=.3/@D?=@RE@_R1 999B=:?G*2GH48:O'NUD
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M\ZSN*=!G-W0AF+TY'!SIO<&!P'S?B>AOV2$W#@-\KQ5W4HRLD%TG-O:S3@]
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M9#"^,'DHEM^MB*LX8EIGKDLGWV\P'-L+>J\AP^B=B(]*+[4[S#6^?>IG>TF
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M^1N&1R0^CR<*!AS+BLU&XTDV/)ZP/2XB@ _SR:2?#8_46XRIP[P/4[^ YU5
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M-WR7'-[X[AL;)I !P&-6>0M)1$=B#,F9U;@^K;*/C'@B]_K$9"B?;&3 ;/K
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M$^ ,]E MQPJA(:E$5 BN%EK_V:O)'!J8_=K,\8]-#=KXT[#B\D[KF*BU_!S
M@-:"S6VEE(,))BHIQVWCH=H<$%Y#6>7ZN\E2RH%F&59FC<T[;.GKMBD*@]&\
M0Z+<\3H%T@LYPM7V"O&1 #J53+3%/4 S_"IP=:%>Z7;]L(I4!&@JG+P#=VHI
MB)PHAISR$W4K(5S_:H_J+X4I]+O4%0X]8N.(DRU5:[C^(I0>#C^'2L018-A8
M8>+07!+Q0T:=DPU5C,/O1[%&(][%070Y1#7C8$\&\$&P)7O#Z$XE2Q^W4.*S
M(PAAY!PK?RIX5J,!T-#R+KR12'"7+SXTO&M</?IDK#=1_U&7K]&@%_F6"Y&"
M\2-6=XG(*;B2;:A"[*,\NX\;"2=1A[.!BX.RC3?ZPTUY #:]6:J^NTMV9:R
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MF$@? ;,^MF5^XF@N/86C$W. ]!$PZP.G@()B(G\$S/[8D5QMPDDQD58"9JW
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MNG[Z5Y*?WA]>YK/ES]?7OP%02P$"% ,4    " "PBHU,'R// \     3 @
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M2P$"% ,4    " "PBHU,[#G9&T "  "R!P  &               @ &Z#P
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ L(J-3- SLZ',
M @  "0H  !@              ( !,!(  'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+ 0(4 Q0    ( +"*C4P9VR(3O 0   P8   8              "
M 3(5  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " "PBHU,
M9X./2& $    %0  &               @ $D&@  >&PO=V]R:W-H965T<R]S
M:&5E=#8N>&UL4$L! A0#%     @ L(J-3$R<D7ZT 0  T@,  !@
M     ( !NAX  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (
M +"*C4R'Z3\?L0$  -(#   8              "  :0@  !X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"% ,4    " "PBHU,O3IFR;(!  #2 P  &
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M970Q,RYX;6Q02P$"% ,4    " "PBHU,"WZ[[;,!  #2 P  &0
M    @ $<+   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (
M +"*C4S")+LFM $  -(#   9              "  08N  !X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L! A0#%     @ L(J-3'VMXOZV 0  T@,  !D
M             ( !\2\  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"
M% ,4    " "PBHU,Z[ 6_K0!  #2 P  &0              @ '>,0  >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( +"*C4R<_0T M $
M -(#   9              "  <DS  !X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L! A0#%     @ L(J-3/=96F"U 0  T@,  !D              ( !
MM#4  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " "PBHU,
M7TW4\+,!  #2 P  &0              @ &@-P  >&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;%!+ 0(4 Q0    ( +"*C4P]QVO[M $  -(#   9
M      "  8HY  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%
M  @ L(J-3++TF FU 0  T@,  !D              ( !=3L  'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " "PBHU,:5YO])<"  "K"@
M&0              @ %A/0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M 0(4 Q0    ( +"*C4R+L0Y@MP$  -(#   9              "  2]   !X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ L(J-3,>$);VT
M 0  T@,  !D              ( !'4(  'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6Q02P$"% ,4    " "PBHU,)O"?8],!  "<!   &0
M@ $(1   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( +"*
MC4PI,G)VN $  -(#   9              "  1)&  !X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L! A0#%     @ L(J-3+JS;NNR 0  T@,  !D
M         ( ! 4@  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M    " "PBHU,(ZT[(+@!  #2 P  &0              @ 'J20  >&PO=V]R
M:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( +"*C4SZ"M*^MP$  -(#
M   9              "  =E+  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL
M4$L! A0#%     @ L(J-3%F&-[ZW 0  T@,  !D              ( !QTT
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " "PBHU,54.Q
M/[<!  #2 P  &0              @ &U3P  >&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;%!+ 0(4 Q0    ( +"*C4S ?<[_U0$  )P$   9
M  "  :-1  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @
ML(J-3$M'OA7N 0  9@4  !D              ( !KU,  'AL+W=O<FMS:&5E
M=',O<VAE970S-"YX;6Q02P$"% ,4    " "PBHU,Y1\KA_8!  #+!0  &0
M            @ '450  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4
M Q0    ( +"*C4S[R>V@B0(  /X(   9              "  0%8  !X;"]W
M;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ L(J-3$4$FF3# P
M;Q,  !D              ( !P5H  'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6Q02P$"% ,4    " "PBHU,0YJ9PBL#   Y#@  &0              @ &[
M7@  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( +"*C4P.
M+,Q()P(  (H&   9              "  1UB  !X;"]W;W)K<VAE971S+W-H
M965T,SDN>&UL4$L! A0#%     @ L(J-3"#"0%5$ @  : <  !D
M     ( !>V0  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +"*C4RE4Z^=RP$  #L$   9              "
M ?EP  !X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ L(J-
M3)Q_T<C\ 0  ' 8  !D              ( !^W(  'AL+W=O<FMS:&5E=',O
M<VAE970T-BYX;6Q02P$"% ,4    " "PBHU,\W(@J3H'  !G+@  &0
M        @ $N=0  >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0
M   ( +"*C4S$2O%?8 (  "$)   9              "  9]\  !X;"]W;W)K
M<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ L(J-3*\[" /^ 0  Z@4
M !D              ( !-G\  'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q0
M2P$"% ,4    " "PBHU,9!2-P2X"  #!!@  &0              @ %K@0
M>&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( +"*C4P8(!V2
M3@(  ! (   9              "  ="#  !X;"]W;W)K<VAE971S+W-H965T
M-3$N>&UL4$L! A0#%     @ L(J-3&CI*E_* P   1,  !D
M ( !588  'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " "P
MBHU,NFJHH0($   .%   &0              @ %6B@  >&PO=V]R:W-H965T
M<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( +"*C4P,5KJDA00  %<9   9
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M970U."YX;6Q02P$"% ,4    " "PBHU,>?V+# 8#   Q#@  &0
M    @ 'CG   >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    (
M +"*C4P,)2A-JP$  )X#   9              "  2"@  !X;"]W;W)K<VAE
M971S+W-H965T-C N>&UL4$L! A0#%     @ L(J-3%Z@^OZ( @  >PD  !D
M             ( ! J(  'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"
M% ,4    " "PBHU,(!*TTG "  ! "0  &0              @ '!I   >&PO
M=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( +"*C4QJ%K.6# (
M "4&   9              "  6BG  !X;"]W;W)K<VAE971S+W-H965T-C,N
M>&UL4$L! A0#%     @ L(J-3)U< 8EU P  0A$  !D              ( !
MJZD  'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    " "PBHU,
MX.?ITR<"  !\!@  &0              @ %7K0  >&PO=V]R:W-H965T<R]S
M:&5E=#8U+GAM;%!+ 0(4 Q0    ( +"*C4ROTT/1*P(  $,'   9
M      "  ;6O  !X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%
M  @ L(J-3-JME(3@ @  J0L  !D              ( !%[(  'AL+W=O<FMS
M:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    " "PBHU,[M1X7WD"  !K"
M&0              @ $NM0  >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+
M 0(4 Q0    ( +"*C4QQ'D&A80(    (   9              "  =ZW  !X
M;"]W;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @ L(J-3*@+@!\2
M @  @ 4  !D              ( !=KH  'AL+W=O<FMS:&5E=',O<VAE970W
M,"YX;6Q02P$"% ,4    " "PBHU,<+15?GL"  #%"   &0
M@ &_O   >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    ( +"*
MC4RKFEDM3 (  '@'   9              "  7&_  !X;"]W;W)K<VAE971S
M+W-H965T-S(N>&UL4$L! A0#%     @ L(J-3$G,%L>M 0  P0,  !D
M         ( !],$  'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q02P$"% ,4
M    " "PBHU,7*X/V5X"  !+"   &0              @ '8PP  >&PO=V]R
M:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    ( +"*C4P&T"!;RP(  /T*
M   9              "  6W&  !X;"]W;W)K<VAE971S+W-H965T-S4N>&UL
M4$L! A0#%     @ L(J-3%354\K< 0  FP0  !D              ( !;\D
M 'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6Q02P$"% ,4    " "PBHU,:!O"
M%_\"  "W#   &0              @ &"RP  >&PO=V]R:W-H965T<R]S:&5E
M=#<W+GAM;%!+ 0(4 Q0    ( +"*C4QBUI7B0@@  "4T   9
M  "  ;C.  !X;"]W;W)K<VAE971S+W-H965T-S@N>&UL4$L! A0#%     @
ML(J-3%D\8B^TP0  -.(" !0              ( !,=<  'AL+W-H87)E9%-T
M<FEN9W,N>&UL4$L! A0#%     @ L(J-3(QCJ$R* @  0@\   T
M     ( !%YD! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "PBHU,V;A'"X(%
M  #X,@  #P              @ ',FP$ >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ L(J-3%<'2!YV @  KRX  !H              ( !>Z$! 'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ L(J-3(L <+8> @
MA"T  !,              ( !*:0! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     %< 5P#3%P  >*8!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>254</ContextCount>
  <ElementCount>482</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>116</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>103 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassified</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>104 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/StatementOfIncome</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>106 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome</Role>
      <ShortName>CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>107 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/StatementOfCashFlowsIndirect</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>108 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>109 - Disclosure - Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsLiquidationBasisOfAccountingTextBlock</Role>
      <ShortName>Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>110 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>111 - Disclosure - Business Combination</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock</Role>
      <ShortName>Business Combination</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>112 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>113 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>114 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlock</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>115 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>116 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>117 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>118 - Disclosure - Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock</Role>
      <ShortName>Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>119 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOptionIndexedToIssuersEquityDescriptionTextBlock</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>120 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>121 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>122 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>123 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>124 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>125 - Disclosure - Organization and Description of Business (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlockTables</Role>
      <ShortName>Organization and Description of Business (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>126 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>127 - Disclosure - Business Combination (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlockTables</Role>
      <ShortName>Business Combination (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>128 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlockTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>129 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlockTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlock</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>130 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlockTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>131 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>132 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>133 - Disclosure - Stockholders' Equity (Deficit) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables</Role>
      <ShortName>Stockholders' Equity (Deficit) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>134 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOptionIndexedToIssuersEquityDescriptionTextBlockTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOptionIndexedToIssuersEquityDescriptionTextBlock</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>135 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>136 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>137 - Disclosure - Organization and Description of Business - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformation</Role>
      <ShortName>Organization and Description of Business - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>138 - Disclosure - Organization and Description of Business - Summary of Adjustments to Additional Paid-in Capital (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessSummaryOfAdjustmentsToAdditionalPaidinCapital</Role>
      <ShortName>Organization and Description of Business - Summary of Adjustments to Additional Paid-in Capital (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>139 - Disclosure - Liquidity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureLiquidityAdditionalInformation</Role>
      <ShortName>Liquidity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>140 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>141 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities Outstanding Excluded from Computation of Diluted Weighted Average Shares Outstanding (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesOutstandingExcludedFromComputationOfDilutedWeightedAverageSharesOut_Xa</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities Outstanding Excluded from Computation of Diluted Weighted Average Shares Outstanding (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>142 - Disclosure - Business Combination - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureBusinessCombinationAdditionalInformation</Role>
      <ShortName>Business Combination - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>143 - Disclosure - Business Combination - Summary of Purchase Price (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureBusinessCombinationSummaryOfPurchasePrice</Role>
      <ShortName>Business Combination - Summary of Purchase Price (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>144 - Disclosure - Business Combination - Total Purchase Price Allocation (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureBusinessCombinationTotalPurchasePriceAllocation</Role>
      <ShortName>Business Combination - Total Purchase Price Allocation (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>145 - Disclosure - Business Combination - Pro forma Consolidated Financial Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureBusinessCombinationProFormaConsolidatedFinancialInformation</Role>
      <ShortName>Business Combination - Pro forma Consolidated Financial Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>146 - Disclosure - Goodwill and Intangible Assets - Summary of Changes in Carrying Amount of Goodwill (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfChangesInCarryingAmountOfGoodwill</Role>
      <ShortName>Goodwill and Intangible Assets - Summary of Changes in Carrying Amount of Goodwill (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>147 - Disclosure - Goodwill and Intangible Assets - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformation</Role>
      <ShortName>Goodwill and Intangible Assets - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>148 - Disclosure - Collaboration and License Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation</Role>
      <ShortName>Collaboration and License Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>149 - Disclosure - Fair Value Measurements - Contingent Purchase Price Consideration, Convertible Debt, Measured at Estimated Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueMeasurementsContingentPurchasePriceConsiderationConvertibleDebtMeasuredAtEstimatedFairValueOnRecurringBasis</Role>
      <ShortName>Fair Value Measurements - Contingent Purchase Price Consideration, Convertible Debt, Measured at Estimated Fair Value on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>150 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformation</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>151 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>152 - Disclosure - Debt - Summary of Debt and Convertible Debt (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtSummaryOfDebtAndConvertibleDebt</Role>
      <ShortName>Debt - Summary of Debt and Convertible Debt (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>153 - Disclosure - Debt - Additional Information - Senior Secured Debenture (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformationSeniorSecuredDebenture</Role>
      <ShortName>Debt - Additional Information - Senior Secured Debenture (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>154 - Disclosure - Debt - Additional Information - Convertible Debt (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformationConvertibleDebt</Role>
      <ShortName>Debt - Additional Information - Convertible Debt (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>155 - Disclosure - Debt - Additional Information - Long-term Debt (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformationLongtermDebt</Role>
      <ShortName>Debt - Additional Information - Long-term Debt (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>156 - Disclosure - Commitments and Contingencies - Additional Information - Legal Proceedings (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationLegalProceedings</Role>
      <ShortName>Commitments and Contingencies - Additional Information - Legal Proceedings (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>157 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Rental Commitments for Operating Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalCommitmentsForOperatingLeases</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Minimum Rental Commitments for Operating Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>158 - Disclosure - Stockholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation</Role>
      <ShortName>Stockholders' Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>159 - Disclosure - Stockholders' Equity - Common Stock are Reserved for Future Issuance (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityCommonStockAreReservedForFutureIssuance</Role>
      <ShortName>Stockholders' Equity - Common Stock are Reserved for Future Issuance (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>160 - Disclosure - Warrants - Schedule of Warrant Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsScheduleOfWarrantActivity</Role>
      <ShortName>Warrants - Schedule of Warrant Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>161 - Disclosure - Warrants - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsAdditionalInformation</Role>
      <ShortName>Warrants - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>162 - Disclosure - Warrants - Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModel</Role>
      <ShortName>Warrants - Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>163 - Disclosure - Warrants - Changes in Fair Value of Warrant Liability (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsChangesInFairValueOfWarrantLiability</Role>
      <ShortName>Warrants - Changes in Fair Value of Warrant Liability (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>164 - Disclosure - Warrants - Warrants Classified as Equity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureWarrantsWarrantsClassifiedAsEquity</Role>
      <ShortName>Warrants - Warrants Classified as Equity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>165 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>166 - Disclosure - Stock-Based Compensation - Schedule of Allocated Stock-based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAllocatedStockbasedCompensationExpense</Role>
      <ShortName>Stock-Based Compensation - Schedule of Allocated Stock-based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>167 - Disclosure - Stock-Based Compensation - Schedule of Grant Date Fair Values of Option Issued to Employees and Non-Employees (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfGrantDateFairValuesOfOptionIssuedToEmployeesAndNonEmployees</Role>
      <ShortName>Stock-Based Compensation - Schedule of Grant Date Fair Values of Option Issued to Employees and Non-Employees (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>168 - Disclosure - Stock-Based Compensation - Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivity</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>169 - Disclosure - Stock-Based Compensation - RSU Activity for RSUs with Only Time-Based Condition (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationRSUActivityForRSUsWithOnlyTimeBasedCondition</Role>
      <ShortName>Stock-Based Compensation - RSU Activity for RSUs with Only Time-Based Condition (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>170 - Disclosure - Stock-Based Compensation - RSU Activity for RSUs with Both Time-Based and Performance-Based Condition (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockBasedCompensationRSUActivityForRSUsWithBothTimeBasedAndPerformanceBasedCondition</Role>
      <ShortName>Stock-Based Compensation - RSU Activity for RSUs with Both Time-Based and Performance-Based Condition (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>171 - Disclosure - Income Taxes - Schedule of Loss Before Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeIncomeTaxes</Role>
      <ShortName>Income Taxes - Schedule of Loss Before Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>172 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefit</Role>
      <ShortName>Income Taxes - Components of Income Tax Expense (Benefit) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>173 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssets</Role>
      <ShortName>Income Taxes - Components of Net Deferred Tax Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>174 - Disclosure - Income Taxes - Components of Net Deferred Tax Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilities</Role>
      <ShortName>Income Taxes - Components of Net Deferred Tax Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>175 - Disclosure - Income Taxes - Schedule of Provision Computed by Applying Federal Statutory Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionComputedByApplyingFederalStatutoryRate</Role>
      <ShortName>Income Taxes - Schedule of Provision Computed by Applying Federal Statutory Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>176 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>177 - Disclosure - Income Taxes - Schedule of Changes to Company's Unrecognized Tax Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfChangesToCompanysUnrecognizedTaxBenefits</Role>
      <ShortName>Income Taxes - Schedule of Changes to Company's Unrecognized Tax Benefits (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>178 - Disclosure - Related Party Transactions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation</Role>
      <ShortName>Related Party Transactions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="sls-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>179 - Disclosure - Subsequent Events - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation</Role>
      <ShortName>Subsequent Events - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>sls-20171231.xml</File>
    <File>sls-20171231.xsd</File>
    <File>sls-20171231_cal.xml</File>
    <File>sls-20171231_def.xml</File>
    <File>sls-20171231_lab.xml</File>
    <File>sls-20171231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>128
<FILENAME>0001193125-18-117053-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-18-117053-xbrl.zip
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M7 IZ'*1-B&QL840E$=QS;.D%;%MD5M&@9D>D487.7I!<Q6-WN?AUFAQR GP
M-(W2HC\V3;M;L*] GG2C4B6U:F5GR?@F?IM&^^[W2PCLPPPB,$.'AQ[R'0':
M( 2J98C!LI-@X0@L" _-[22-JE2H,\.&AM8#?NTA.7!_U8/2YOC7WJ3VV4_1
M"QLW'_97:!LJQ.'X1#>Z:R2W"&^ALZ;;/RRO)LDHG*31_LD!6JIW)$?T4N3T
MB]UJ*&/.3%C?975>&O-C^956"FS;R /AH72YD.:6AW,@/Q-I#+5]@)])IU),
MI["S>!<E<+&J7Q&'\9ZHF$ ASE,@"E.66[9@G1:-SZCTA2.1<#$(:QODM LP
MPBMDX N7A%S:';*KG/+01,C1$H:8:9ML1\*0<M?2'@DQ5FB['F8VK K06BQ0
MSNP@!$X@'K="S\4D]+:C#C8'2_CI<Z=Z0J'7A,!2)<18M7C6PZ%A;<<@P(+/
M$!E"0<0-@XQ5]TL_9V3RS-^!D.%MF8BG@(R%3=J= ]V=B" \#\Q9)T1FB$'=
M>M)!#N,.(CAP9> %MD=E>TXF-B47AT.ATLSRZ-IY,E:%G6 7 9^+.TN)K(=G
MBML%2B54>M3LL*5%+3.@R%9; T9 R=I2^"@$#2L$)QYU&M)TM_,/'T+J$X9#
M"%,6N8J5T+@BUUD6GWGWT8;-7$OE;?IV ,M, (*N% Q9I@?\Y0=@ '@["EI@
MCOG )2T&SND$\625#9H!<SBW4J8J!@W;(X?S*(G00 SN$#^U1-\&6[]OFF^S
M52.8L*U]A<_J9 ?V[%?%BE.)\\GT)H]5WJQ.0%-!J(ZEG=%M$G_5#[J\7L.]
M[ZK"JF#2]E%]A5OX-DC8YRYL)T!#,4_I*A- (MA#IL]]VY<NMZCH,'\I*1\>
M# E!54A%\UMG.E;_J'/:K]%$<:.S=ACJ0\>]]9P&K0)20_:-CV%_&,*F@ <6
MAZV1WC5: O0[9SY7NZT0YT8@D>W>+EM4O5U]Z!FFAL=E[D$KN9EA4Y8E,!>C
M(Z*&I2,\*^"(,^H@1ET;V=P-8*-E>8'C>Z:'Z4Y7">PK!RC=T45\%6+E9KM-
M)\"C\SP:X#C84.IY+O4<Y/O*18BM +FA%$CYF)D7,AN[3&%C?=%5J5K+Z""L
M=OX5OMHFX9%2'M8"J!3NW2.CO%]\-U7O(HW);>1)2YBUD%VR9M1GLTMK]T.!
MJ5?C)N^4+F$F^B8Y')U>/ R]EI[U)LVCZ>6/2N\1YI/K^6RRP_8L23<X@0--
MH- $-H5 'DB@.A"8%Y;#((2280B5FE#12FA;_DF)G!J]\,/&U'X?#S.M@U+;
M9.NTR*$Z,4=1NH5#7-F^0(HEAU+""I5=2IA)N8\&/A:Y%?^_1;IM$.W "!DR
M'5ME9#H4R8!@Y'E46'88N,3'VV60&CW?)T2YQ((-1?FN^H5[SOD# U4:"&>6
M()W&55\6U]L7F.J6RF@VJY_>M86L'&&*8>LO\5!KF7T170:UL/9BZB*_^&T2
M7263W$>DRYGO[4WLMW,(N.?##E\BWW5"!)M\%SF<>\@E7'(70)"$?R'-.K=P
M[C"[0E\K 54RY_-X<1*DM5+&J:A15AYSTZ1]R-+K>#[7-=S"^,@S)QSJ$!R:
MR')=@ACLA4'J^!;R \J#P%<GK#27M^TA,Z8037/70D>5Y'6UN@]1HJK41;-D
M$4U*X25/.JN4M^=N@["K4MU)2@/K/BEUK0$%G!&S@6>/[OD:EKQ6!XYEU[P3
M^WN]U*PF.A%CKFY<^1)'R=XNTC7-AU+9YC WOL^3U]-D\N=7"UB-M1+R6_%;
M#ZBANS5GS15(>JZXIG-9:JU#P7L0L)O0P\V=H2FUFDX7U:F"M'?0V6;C-!X5
M#4ILHSO5#WS)&4<6!C.'$9LCB:F/B/29%7 K#$5AX30%89D=)UVMM&X"M-6>
M_!3T/VXO\Z".S%I2 TNC/W+F\M#,^SAYR4/4+QR:\L;,XLYE^V8[(+;&!\=A
MWS PB7+'(RF$K:HNAL@.)$:V< //)1(6<&'?M5JP@G*YBX%W$:6RG$Y@=9)V
M6X!;.U?GAH#:@46>%O(Y^I[;1K]DZ?Q(UIRTA8V)31!GI@=3Z+C(M>T A1(+
M$I 0&(\"C:VF*K5J>ZOFP>^F;W]?W[#4M1YA,KR;MKI?;^N"R\5MG,$G;>Q=
MIYDZGGO:F6Q=B;*#UD92.JB?Z8/OZ<U;8('3@:#5%4(QLSI :*5H-Q(*-UUR
MZ710:)5:Q.X H9F8W0 H19R?7T\FZ3?=:O IB6\ZMBCDF2EW4[]-2>?4K[X+
MOJMC_+ARG#\=N_$TODX6\^;S?B_=NWSAL%"UVIZD Z@!"*\A.TOG<'DA>D]#
M^?=7'<V#K]:=N)M-TOLX_AA/E/'Z6 [6_FZZ=EZH60&=E%2/_C8_/ZTEU[[/
MP@Q7_9"E,;?1 BS^X,.!@5V._;UR772T$7T2^^56\6X)2[:1V<29VNAYY/..
M_LNQU98CI,JLN\DX?FV7@;?)I&5^=SH(#JC=TE1<Z51\F:0I]7XKVWHW!3N(
M?9"'_5"2VG:9.[W-,.Y9E*Q,#)!5.;.?S.%=:\PYI:0^5UV$='+G*3BQB+W;
M&]L^[D[R3L>_WA1 WT%CF\/Y8SQ?9,D()-'I'WNU&DBRNF?<DZ8:'HLHF<*F
M(<JF<,$<]-;R;JGM2-A/)*/]RS0/"T&K<8&HR2BNX=!%RTG&N_<]H.D3[[Y5
M,?.)X]V'>TN>*W4DUSHQ0^*( ''/X8BY)D<.H0)AC]I"8M-U/:>]&*E578V#
MTWPL1/\>JY.Y>.Q\C;/H)JY4V7XXS@TE !QJAC3T/10(U\V+6DO*).*!""PO
M9([%V$X.KA8U)1=;<6/'!V;8:+2!A66K?P0V-K7TH)8]9E$T2_=B!;421]GH
M]K!PZ,'W7^TM(57YB5*Q[J;!KXE[<S>#7R^GGZ/O'[+T:Z*"FL(LO?MUFL6C
M]&:J+'7X;>4M>SC1#18ZPZ$7VDP@'S,+II/QHCZAQRPF,::">AV16HRM*=Z3
MHF&D2<XRFU28XL#B-IH6R^E]J@N<QN/:8OI%!07XH)+#*,D>H"U5@@AEF.ED
M35P-/&\0/39G/K%<C(10$M[!+D!N4Q3B( P<8CJ^O5MY'D7T#(CB8T_K0]3Q
MKKEKS(^TJ<2VCQ'&/N@-RZ3(80Z(#,N7OBG\P"9^NWIF?!CUO"\V/^9"Z^I\
M&.# ]*4JE>S8H*I4]7+I!A:R;&+Y@;1]'CZ!CG]9:%MSU[30/$E"WP7%9!.'
M(L8]T$D$!XA2+ESN4>XU3=YJL@@^@85VG."Y+SHA0A5)D)+):HV6AP33-9?H
M.SB8[OBTVV8G$_6EG3XGVO/"MGPHVILKV0T41'DPJ47?+"[49J$KDX\"3;8E
M0!4+KHIL8QN!L>X@0H- 6D*&=B ZDIP$JSG0=X6CU4N9/E2I'8G8_A4H6P@Z
MXLPJ+2"$W>D-Z1-H2'<W1.N(E#TRD;;=F=#5BTBV<]_9%7!8K:@?3:-<[85Q
M_* ==9%R2_(R-79G]5339DR:MHN(XX'US"A&TJ8$.:9EF9:$ZT 4ZUK:K=-9
MKHC?0,=1?")'R;:EJVQ;O$<ZT+&S3EL(/DJ^K5ZVK6ZB?;-.'X'RP?)MM=G:
M3KF%Z_O$XV;<-I ^7,8M767<5F(S6D/<CYQRNTWJ<"FW=)5RV[Z@&PZ*.N9V
MP$PC 3K&[G$2ZENV;046V!8F4PT/G! YS"3(=[#-;6D+BL,OS:4N+<&YM'=5
M]&ZW&X?.31F8W$,B3_9-37FL5C<-T#2YN@(_8)YK(8^X H )/"29[R/IN,03
MH0B(2=J[ -%RK:*']:[9ZRD ]"%5^(8%I*F7#Q?[ I*3TMA4JE1R[N/:L_YF
M#)<GUXFR@_+HD55#)6=:COZ"W\#.7QW0EP[G#T-->W:XJL.G'!+=*A)0LD)5
M!!1$*D;,42><H6\AQ\%A0)EGPF[FRXZM&I:X&C]S7%".AO_AP:]'!K[]=(L0
MBQ\-^K; VD&G-P^GRJ_<%7=U4C/2NAFBJGCQT99"7ZR.-ENES(+2CP<G !QY
MV;1[(+@XWBQU872TR3G!==*>K,B$L(XV!4=>!9N:LJO?]MWU')GQVS4UL=GQ
MQ-,V+,=6&Z4?'E"%\,BSL:.BCEWSJ3P>1$>;&3"@H^E-LKYX?3[W2YJ.OR63
MR1$FIZE9'/6);PJ.;$>53;8\AFPN)'*$:=F^94F+^QU.>2SJ-3X?%:<A9FCU
MK,81[)_K?>2%TII$@XF%[2%FH@N/"N9'9-C#06K'R,95T5[AHY;JZ ,*%V<T
M4LT#5P5%X:XBRZFP4$_+,&GU]5K<)KOJR3\F8D>9N6H^P$E-2FL>/&RJ&#_*
MK%31. K@;^'#C7[$IWBQF!S6D^*8L+=FHJZ;9#X&)$?!O@B1.%$SO9W?:7%"
M?FP\GKL5N&Z7I:,7NBNC][(*MSSHE;FQZ^6TGYU1>"(39IG8ZNPOWVO"](GF
M[N(8+Q,VQ(3!#X-,&-O9>,6JEW!_N@EKC+2KI/RL?UQWX\*' ]\63=C<@LP)
M;$Q9B() "L2(1Y#MV0S)0%@6"]W0#<*=,7:5DU)QH?K$/XCNIVSK=G0,F[*,
MC]7&;1WNEZY!UJ'F\7CVH)/W7? T->7M#4Z+[*U&ZU_PPJ#I)F_3FC??$)5C
MQ-],U7%L\O5P#/8*D.,>]7T!5 ONA2J])$"N0WTD7"89%BX/I;5]Q%S;O6RL
MZ%T$K:G>'#E?7H?+R>3>3R9+@$=C4]2;5N?3>[?@WD"@8VUTSTB+=1VR]PG'
MT"K8:HLZV(NHQXE"J8+ AXI*43"T''I45@-6D2G[QZ4\.G?PSA",WK T=>[6
M(1B'<T>K!V6[L@[\]I!CRJULU:98VL!E\!@?69Z* _=YJ.2E@R@-0Y"ZW'-D
MV-%S#NOB7;4B^P>1>)0V$4U ')J1O,O?2^%=C]PF8EC2VKVTU)2U+@KM?2+T
M+VMMZ2?ST22=+P^1>+U*2%BPXG' $35%@)BG+'='4N39+I&^9U/'$;M"'S"V
MS2;2&@AH8L[@^^A6)7^%JE3=%8B_H\YCW\SR'6N5$-K$HVUT'*\%R. D[S@1
M8ZR)YB=I 3+LBFUO 0(CL![6 J0JPD]!/K5'E,&VP-Z2O0W#?WB3DV$I:G5B
M4VH1WB"6NAPSFV@&K]PX^ &NY &%<"NS]@GPZ*+LZ/U?AIWY=@%-:X?&3]G_
M94WSH50^<?^7ACD[O&H;/N7^+T-3VM3_Y0%I&8T\?&I&8GL &N_5DZG+9APX
MH;LO\7T2N'724=.<V[QJ+^Z9Q;WFC\+:R-E$53+*OL;C,,W"Y0)@4N4;#ZCI
MWA,![IM68 H;!1H!C_A($MCM>[;%L$,<,W3)MA-D[?3@=8&\+U7']PT-NO2?
M3_><H2EO+(77*?0:N^>LKWEZ4X.VR[4VOMZV*5;QX6^FH_0NKD:)'X<ZB[D^
M#2P7"1-;RC%EPL[/LE%(1> SR2S'"78);<IH<X.!)A*&[Y_3D\I>311VF,Z<
MU3;TC],_9UCJ6N/:L. =O40>I8/.L-2V.Q"[&J?T::%3KL"QVB(X=VHO?"3_
M,0^$%((A+"G85I3;2#H6 2'D2.$09KJ!R'/T=QPUU;MB[R+CD5H&#3OG.T1P
M5QN4)VT9-"P*K9M>VM4W:;^600-E>0WINFH7<?6LKKTRL?;@%FV2J>B2=!0=
M$&;31Q908IM"<HD(#B5B#FAKEV.! MOW.7$8#US:44")UL-H#J7PR.VDAET8
MK27!&;<&;B?5#I\/5M%\D8R>FC=:]<1#>&-%W*GUVAJ6C]K#"75%[\?MMM4D
MQNJOR/?/RC&VJFX,;_+CK_$DG6G5#X]]VOU%.S>V[2\&H/@8?<N&56BM^LPF
M=57^!(W+!C]<;%U8%J\>T^S7N.SPJ-<!I[)5^>Q.SEI]^68Z!KD #XC?)E^W
M0U6#[Z/)4GD&3X+6]B.HK;3)?>FJ@9(79/D8C^+DZP&5\0;??;7W;=VBNS[T
M@7KM#7R MJ.:!:N5%WFD7GL#N^WV.!Q^W&9[ V^-6N4/@7FTV^CLZ -Y:F=+
M[43R6NV5W414Z7U0]8 ^U/6/#FR/L-JJ%]":T5_^X218L]5A(:D0K30UL^8J
M>; X)CH)^MK58;VT;]OX6^?O1.Q4TNII(!SCUBELL5,';><YN)&Z*\O^T':>
MFQUU#%N^>7ZP^0[,HKOE75'A?NX?ZX#+IL25MF6AT",42 \PDKZ#42A\T_&P
MZ_I6T!7O:%<U2$]Z#L'@S?3SM_0?L*4[DF'4'XWV\N3\$# VA!T"RU$71W],
M6O?Q]8C8_<@Z?N_;@0^YGV7OVZ$Q.+W>MP^.M#N1WK?#:N\=O6]%?:Z>IO?M
MT)QYBKUOAPZS>3:];P?>T+?OD+;;OIY0^]N!46AO?VLQO-4&>+_VMX#.Y76N
MHU2Z]W :MR'1V,<AIZ'JKQ$0'ZF&!LB5/D>^I &6H>?YH;?3]*AELDM>JN;>
M0LA)-OOMZRCIT^S74GBU<LBS:_9;%!]03M2#FI[UA+97LU^KWBUBD]4[:+/?
M+9J/A>B S7[[K?A>S7ZW8&Y-IB;,O+"LHP#?O]WO$W>S'IS!&[N##,O@S[&;
M]= ,WF<3.3B#/TD_ZX&MG_9V/3H-N7]'EV&Z._>DCM)0M=%4P1%$M:NU762'
M 7PDGL-H0 *;D(YC %'-H.G3RAF^CQ\E_[2_B[75L\9J)W(-8Z]T(\]3&3\L
ML]%M5/!M):_Q?;RXO"YN_)!FZJNG]:.W1^^NDC<?0-IV$:%-I:8/Z4)5FHDF
MD_N\[J*"5*4O'U('=, 3O5W5$C9U$/<C:(W#PTM #GE,M*O6YH;4QC*-ZH>'
MRGU/135.= C&">U26L_."CB.0_5@H):L1>?F)HMO8%-]6@"WJLJ! .Y&8 WV
M5K3D6Q!J<-GTQH_'RY%Z7'[)()'5A\=_MK?<P::U7JA[4+-&H,LC=6KQ%CNJ
M,A.V@>( LEJ90NFUUOCC<C39]9&"P<)0U<$(P8)A$L-_P$"3Q(7]4D")[YK2
M,EVGPXS!JVBP!Q*X2Z$?/8*,N8+[DH(YASE%S/% HYDV@V4C35@J7L"$F_=-
M/5B'UR/*U&7KFHG*<"]D3%$B\$@.=X<YKB="!W9I)I 78(ILYIC(%A81CHD)
M(>:V"S(?VEJ,[AAVQ6+-HM%B%;)\6+??P:WQ]C[&N&*1-@R]M(HKJ6;IUW@*
MM.OSI/NW,;#]*E "A,.OTYDNG9,'2!YG$3,GL(4$T4ZXJTHWPF[<-@D%<2^)
M:5,.BH!T%3R25F45'TK@&J,W=S- \'(*@N!#EGY-5,VD,$OOCK8';3@'93CT
M0IL)Y&-F@7!C'-@<N-[QF 7B#E-!=[O;BYK*.2A[4O0450UT36.6]]&5N+NY
M;*\J![2^;#9I[M63E\&*'#P21$Q0;@T"$:N[,=;^+#H@0@<;KVMQ/4A$Q09!
MSKG)9:?*"4U+2H=Y"-M,JH";0$'H@PT&=A7S;>:ZUG8M^@V7#>.);0-A&(AS
M;]M&9F[*;1?J\7TZ_0KR,1[7W)!:;?JPC5A;# ^<%57-%,1=A]LVP('I2S #
MF&.#R@ >1](-+&39Q/(#:?L\9*I%?#^WK44N;#; ' V(XF-/ZT..,G;-79-,
M\J3RK()>LXD#QBJ'_0Q8/P&BE N7>Y1[39/7(I,>#9M'J&NTKONM:_IST;DQ
M[%GGB#36.;)X533UJG-TK W.OJ3WW?#L=EI:^VYXBM\^P0[ZMX><2NTBMT'<
M"1_[V HH(ABKG(3 A/V/#RJ(4)\XGAU**\Q54)]*1I1>U!R8)7KJI&[\ ;HQ
M0[XT/B;SW\(LCM>)4R"ZA@>"/02(IAKG)FPG*G3W)JX7*BH43_E5_I9.0 @=
M[L,^&B9-E;UA;]4#DVW2'EL<VF:G7NDK#FFC.)3FB4K#'I3WE88[<B+9/J+P
MD>:]H?W%0^8=-\X[Q7S_B7\\ )B0G0#TE0"D<8<B#J#_*+JP@=H'Z$+22Q=*
M*2\(.35EV(#$ P0_:5.&YG-2AD-CTJ@,">,'*\-VS^/;!/8:8[AN]<7A4%B,
M6\IS 68!51U B.!8^8(DLSI;?DD<VK9EV<CT A^T!#&1[1")O- ".>L)WZ=B
M #_K%K6/C8Y@5'+S*.CL;CFXJ>JV+SHKX3MP*PF%"5@ 4CE4!>>6_DQ)[F"%
MVP<Y>23#MYHX\H'K(\%RK.+*CWHX_4A8'?GP>@7TH_4/*,,F34&. AM[Q/X"
MQR@T\4@@#5J(XK%"]AX)FZ.%]#W!N9@-<E5I>]NR.^'I=2YFU3UJ+>'US^;D
ML$#(,B49IH0\;SOVVBJB_R"(>A9'704\' P0,P6E6M,Q1@<I[TAV1HBSKNJ.
MN^G<40>YO%_+\]8WG?L.AZ?-GF[:IIO"LK%/$/5M#S';MQ%LOEP$QCF77BA\
MZ3=T;%UO3NVVRLB["&O;:(!,>C,-OH]BY=B W^"[A^BL"@QYWV5;'\A3JN1%
MT991[UL%Z=QVP/["=2A#H1=RQ+@)<AIS$SDL]%1;1X9]MW/;8;9O.YII7R/U
M+ID F.DT7M5Y>&CYM@T^7 I!Y1<E;JAR90)*A':NJL 5(%D"M9:HB5B(.7(<
MGR+?"3@/F(2U)17?T!V1GR4T=M!WG#I,&_J5ZY;876(V#$R"">$(T+*!7AHB
M.U IML(-/%#5V ]H1]_:_2LS#5BTZ'CT#EK&Z'2"3YA%*$@'VU3MUKN#3T+'
M8UZH@D\\4#(N"4 \2(X\$0:6PT,&J&^S1UN(TW&B3W3,H0[=G^CG75[75]WA
M8.D6T"!*F."T$RP3^[:O.ME[P@;>\D(0H])UD>2^YX(L<GWFY<%.[;Q5DAV[
M::JPU[MH&N4(AG'\H%#1??M>FS;H&]-V$7$\%X$.PDC:E"#'M"S3DG"=27.'
MYXYB#%4KI(F8MHDN7SH\P8?/LM51H*]UELL$'26MLFP@$&K)+H%)J>>Y%$QP
M'W9MB&$K0&XHP<QT 3 O9#9V=88J5<8XF O]VV-VI%L.5$-EET'4.+]]"<9J
M*9NL:7^VU<%H=TF58TSMENWW@*G%ZC\[IA;O-:W#$PO"N3M8MR^Q[(O826Q#
MS90.BA]O@\ULKBQ=';T\S 9;M!U;UYHD'+:_/II MP76GBLFJHQQN$#GNV.Y
M#A#HC0?=:T,G!BLR+Q$932;QV+U?.;Z*"_>-[)#P:06.E%+[J;AI=X+CXA!V
M/2K<V&( 3A# 7SX8S3YLH#&GCG(U;.^C-Q7>:@W/'D;SXS@<9$7 4##_!&P8
MB(:.FI86.,#]NZ!L<$BXA#F4,!.9-K5 _G 7N9)A%(:A904JQ09;>710T\DP
M:6W5U,LAD:<;QLY-%FM>]/>*$5"YZ)AAC-GJF!/GYA+1?N%\?YU_;CS8A!]<
M@I'P@@ XR!%@'(8A$BSP;?A(L!>N<N3^HEZ$,$:8Y8NI:>"UNFOI*(['<Y5*
MXJF(V6RA*L;O5Y]9$PCFJBE*Y[B*(-@M%?:A+#[S+H-84& *!SN(8S]$3#H,
MP31+%"@VP8X;:&?Z3@="0UW$5B+74[RZYAJN60G9]%IM31?%UA0LC]6"VJO]
MG$:'FQ9\?' ,@/ L8=I6B+@;*'<3]I MX2,0[UD<4Q:L8@#:&ZM05I*V^Y+=
MRCQOU?'4Y77N[CP '%+US<'_L2XPX#8;<\=#GJ6._+DID92AA<S "[@0/H;'
M?@%)8[4G9M=;*+12M%,4@.1-IV,'/H[W\2P4M,/VKR07BLUR52[P!NH=U[-Y
M& HD+:).B$R,7,?ER!1^Z'FFH)SQLES@"!-$<;M<J%!1KUG8T/>E*%VY/[V;
MA;"+WMUSWY?Z'2&3I"XF=I)Y3 ;H!\CA$.0,()"ICA/W88"F*_7O!RK!1Z#5
M+)@=A %NH;5"02N=I=UFWL9Q;[_0T_![:RB&71+[?8G=%.]06Y.\;JL/5N;T
M!JRD)!WGNY1<I\ZUP9Y;5_#---9U&?Z>+&[7U1K6[SL^B,WIY[U1;$ZGE-@J
M*GD,"\>68;YY1&&OJ*HJ*Y.U7$07[XLD7NUC2E::U>V;M3W3]4,;(^(3#\QO
MG<(/YC=V3"Z%YP4F\=OW,81R85I5$[P_B3NW+:-,%3TO$L+W3W3O"TK3FNR/
M27L1KJT3Y![45<Y)=\+X2Y1,5=V+C^L4\2,@PQ^"3*NT*AV'[DEBM4_;=Q4C
MM4SFMUK,Z?6X;W/A%B0L:I/.X@B];%3@ O&EM605JS-).TW;GL)M&:4#@=['
MW_0O>[A!^J+04 FA/PBX]924"\SJ/L,NXIYTH0 PU2"40X&![:RL-@!8 1/\
M^G&PA5*5/#F:R6CO \!=8)1< >KS,&N':W2:? $:G>T&K#O(?$HUW(E0HUK>
M R+>9-%@2^ CJ.7'8!\\"/L(C4W3'E&S3]T_\*S8I]MUOP=$S66*J:2#L(_^
MY:H[LN%JJPS ]UF2QSWGDW$PD$5<!P<865/1 ^YR::H-=$ )8I84R/',$'';
M=R7'CA.8;.UM^8#-?]0.+X>@;9B(&/V?OZG6TBNE>3CW#08:[-H_T#IF U&W
M*7>63K/X>CD=JYWM5F39GB (DY#<G[^.'R1YVM)J2VJ9I)K\VKRQ\ETS,"F&
MU:>:,A#?1*ZJF&@+$IJVI>+FV/;&JG9Z)LL1A+O);$9#M6^8/S](VN. ++,5
MDF9:MT,J\^@9_>.O,R7/[N#O4>XNN?8FR30919//60*$[ V41:QM=T:70B.A
M3XGCF,BQ56PE [GM>):+*)>!+[%T3+&[_W=38.4>5+9'G0Y#?\XX+#\JXMVQ
M4_WPV'T8LBO6] 18XGB0=+HD'L0EZ_.4XJ8PS=[&-]$DSS4YB&= Z8CBC(AS
MH0"1MMDC'CF@3D@#1'TS !5DJM ZWT:6*[@9N)X';UPYCCN630^:>AZPK_PZ
M?IS_NR<4TB0FWXY%J,A97MU[-ARHFS:ACN=ZB)L^1\SD(& =X2+7";%)A,48
M;FA5N3I0Q[+/@7J=T!WX?(S'<9Z@O>H?M'?TP9. TY2;+UIW#*U4[D"F=&+]
MYGIM56M/QR8U !XW'26S?:HY/PE<[:4NJ<K?N6C?;.T'0[D0[.JV]^FB[)RO
M]*D"*;8)P3IQ#%NT6:T[5ZF<[-X E!QGT_1.Y9NFF3*U0>2M@@0JU^]9.?!0
MU!H\:,*C(>?,03QT&&*>*BCL2X8<EP5@%_NVY':'ISGGO)47K3^]_<[&]']7
M 12KKB_[;E,55J(3*];E;01C//!<']EPK<K=\%6:DD A%Z B/5OXOMPV#C;-
M<2S*>YQ^-1/\>)K1[L#)I%W5*:5',./40R[V0MB$.!PYDH'AX$KBA0$3U&DX
MUWD6FO$QP6FLT/*\-..><#6L.>I+FSBAATPW<!%3S8@D]4-$I.LYPF38=7&'
M04[AKD'58L<9RBKR6&F)..]H.IOL523[4/R:\PEZ(]AT\@R\"O_K/#=JH_FQ
MS8C'7)]]ZFL-8$:<$K=U^YXLGP:,"X&D=)4#RG%4'7N!+$P=:A/F!_Z.. =)
MX7\/9[9U<Q?MJM+X'I^Q>(<DZX],>Z*+O2D%TT7C)C!WK0E4-D#V6[PHJBX7
M]^1H'A^2AK76'Q*ZI0OQ>F7U([#DC)HF=\N[\EV?LTA%;@W!*)@^&BJDT;%@
MDI7KJ3^9CV9<=J&#;8P[T/$X\V%S(I'I>3YBM@NB.7 MY+IA:#F.%5J"/$^W
MRZ."\_R-RT>%J]WMHMX[L-OET33^OA V:GSANRX5)D>AE!9BKBV0+=09.#4]
MVY$>=K"UP[XTP;P4IZCR]P6GR;G2&YKV@SC-7WNH_,=C'M:)3X]D9QEZ(24<
M^: 887/BV<B6+@6$",&V9$(Z.]+[Y"#6XJ.XG[#U:-Q$&FMV,8MQ]C#WT^.!
MU6%:UEFKR6_0D[&::T)36(#'<-4=6R<2TFE]R@Z=&% ?M)YE(TL2 "[P,'),
M&B+I.9;@IBN!VSH<PIPQDUY@<@25>"SCBU'SP<C9KG"PQSSD"U>QG.3(=F&E
M>IZI,MVMT QDN]T^K/$UJ-DN!V"KON \DD]8E4O:.S^7FJ0280"*V1;5&$)3
M'A@D2%:A;X2]:Z-5#7I'C.1EEMPDTVB2W[2!)0]PWYM:MJ%VDXW<5?6N3_)Q
MZ^;,E&VQD+M)V^['F=Q,D^MD%!4ADT5MC.$A:#:(>X-09O6_ZC&6LBI[$+2#
MP=]%"U7,X/Z@)$-6'"RN,NV!L<':JS Z)MO9Q@<QOF[+(732H8U,ADS>QOYE
MDH9=VD] L54+V.Q8Z2J7>I5*'48C79^XO!#*MLEC$;]3$O1'HLD346:"?4@_
M4G8].V9V/1LJN[[IJLWI.]@.7P&M#Y-H=$@&J03M)UJ*DNBB/UQ(B_)=14F:
M0,(D-%T1$ 1P$-7(D"(7VPP%GAE@3"3\;758FZR>HM*/_A. 3(#5*?%1(-M=
M09+O*O!QJI -#1'MB D?@*T.SESXL,Q&M_#EMH^GL/Z/@^O:IB>""FQWM>5S
M.<&>[_LHT%FJOG21ZW.&".6JF(H/%I39;M,+:X 4CTZ@ZLUZU/92;=-5(/L!
MEL+!0!Z.'05+P?I'I2U/G8A>"[.HK9V#HS^I"&3]T=F4J#D<C[Z,U&@S2\]Q
M0%?ZR%*];)GGA4BZMHFP%([)0L\-PJZZ//U7;#\D:J 6-_T*[Y[[\7R4)7I+
M?@!>LH^ .ZA\URH5Z!,80_'<<(R2I\58D_#:N)P:[W2A>'ENJ$&=&XO;V%!+
M+YK>&]?))!X;D>&I.]6F W80Z;4!1,,N1"],]7$#W/S<*$K"1=.Q\3:Y2Q;Z
MJKFZ;#T48OY[\W",W#__1S6$__BW[S >[^?V5^=7^#__R?B6+&[UN#^I[?XB
MRN[U^Q;%/?J7Q?H!DPC$17QN?+M-@.YQ\4!X^W)F+%(#BW-8<$;N_ZN,NW',
M%V4F:^&,M>0ICEW]Z/Z0U740MQ"&71G8!)F>Z2(6"($<;H7(M@+,?5=:W"ME
MVUE^+EU* VV*VZDN'#>>QC!#232Y_#:%O>AM,MM,_0,\<3TIWMD%S8-+7"Q@
M,^FK'ME"$F0'0#[VN*^*9[K<:P@:6V\^F&UOQ>P<1'S5:[YQ9^AKGPU&C>?H
M]@JCW:1MSN?&_[N<+_3>-BUIZ7IIE^*8)LP[/6Q.:XX/48-]TW\5M>>^K*-4
M'@A :4'631R .3^@ ",HS3ZG*YOHT&)!"CR[FH:XZNS0[@!F7?QFV9R#AK<1
MQ\11]6_5Z97)D"--V^',#P+A]N&W ^AOUN0UQG6C>7*(?+9W[O HQGQK4]QM
M'4K'LR0+;>0+CA$+30^Y@8I)%,1F1-@XE!OY#=H\,OZ@XJ&,ZS0K_KI2Y#1H
MJ2:JU[SU/\MH FHW'E]>P]5*%3S(T'EB:,BKOZP),E84&3#)8Y#=4_@NF6HK
M85;PBQ&M%XPR9+1)U&X"_3':/.@JGJ3?_F3 -Q$\[6J2C.#JXGU9E*A25?#P
MXO#>N,G2^=R8%<:I>NXT-28Q?+>XC:;&'PBH(.,NF4S@-1<YT^^:F*<U_G?-
M<=Z_F#UX<V Y5%(/+%YA8=C.4^$@EP44.320 0XX=1US^RRW6M+4EF+HO4&Y
M3VHN@ X,I1P<Q:;HT]X8-@4/",&PK+6&+9-\ZCQH/1H/TAV)P0+39\V#>Z'X
M !ZDC3S(5:L/JX,'=0X:"%GW_N]JHZ<QRT_6G!E(W*_1Y&/\SV62'1"5TH[0
M7OJK+PC:\:->C$P+F:)(K^M%6G7;<5NYYJ CHB<@GL&^E)M^:8_11$=CD/O'
M>+S4]O2;J6K?_3'.&R+MT]=@%152G/_6RW'L5\*>^@*[/C%12$R)F&V&R*68
M(V8QYCD4R&9L.X5^9?E2V]H.<V\E\;$!:=H8# 9(<V\\RNQ] 7F4FE(E=/KF
MXS:W@^B9QTR^-%4DHQ2&.%A%LJ<$JU?P<=\(;M+81(1:MMT:<W):8'6GE70'
MIOBFY*$?."IU&:M:'A))X4ADV<SR'<?$9)6_W!1LRVQJFP\"*R^<O$AN] YJ
M4_9C4S>_M+D_T(YA*T55%#FQ&%9]Z]LE5(.=XF&/TM!GR 065 U9?&3;(:@J
MSR;8E%C8MMV.$V&26ILZT7N16^ZF\+_Q:%'IWC(_K("V98J6QAEM5:;4[YUG
MK)X9@+8F@(I+*8 D P0RG2/)7)#AH1OBL"N=K=9'H97@(=N(M*-1H_X@>HLS
M966W*:/ML#8B#XM5X>818U5X>ZS*5I6?O3M!J)/,HC7[05%K'%N=$WLH(Y-\
M9UR4QN=H5<>\@X:F6DYAFAW896I%YRI6>? ^B1W9I\UUG.KTK.?WS5299\E7
MV,#&L[6M!GN4:+)(M1/LJPKYGD7)^.I^Y8134=][-8WO"TI3HF5@42&%ZNJ!
M;<"$4&2KUKM4@K; S/$%::B35T^T? B9VUBI0F'KAP3J(9_3#^E\\2Z=QO=Y
M=NLAQ6*.#5!C$^LZ0'UI6Z,27%^KDY&O<;[;N[P^O/]!"_F'+Y-5Q<W=XZP(
M@%74X@=@A;W+V_$B'XT2B^!2<ZA5.R1I2=)=WDX0X5D6@_V6:D+(9(AL;&&8
M4- 6GF-++RBVHKV[I9:)JC6]F16%WBZO=<6#P\R71Z>\-= 0DQKI;10...D$
M/Q[I/<H\/N*D/R[EK9->-VMVSKF2!;_.KC.@M3 ,E!6[;Z,[TS;+%FK/XJ96
M:+L>9C8R72"8!2J"*@A-9!*/6Z'G8A)Z7W:UD"Q7-]TFHM5J6\N^0WKZM9%:
M)PY43VC#I@S9U(+M*X/_2-4*TK<M+P3[U@*#[<O*\E;[-F2V6-Z5X;83M:X<
M?4",8&^J>DZ9O2J(W3W21O=?N)Q,[OUDLEP4KO*B0^HP9.7[2*;WUH16V[X>
M3'.KS84;G*%M] U6;G<GY9L==/<94A_:=>1VZRX+B\;RLEL5=UM;=@7?%[H]
MF6)_U107-BO3T5[-K?-M-#9)=]>]AC 0X<$R-IT0F2$6:K?E((=Q!Q$<N!)V
MF[#*Y>HLM]A&2V2V=-WKI.HH3=B =MK=3.L!M&]<"/#RMH9S_9JP'6'>CTU[
MCVZ+_>?]"'*P-P2[,R5[X[%=^DC)P0/$X-#^%KN H42V;'"<V=*BEAF [E;V
M%R,,(UL*'X4!MH3@Q*.;$@^%?\5NY?HF_TI^772E,L.2>/XK,$16NFY];V&I
MO9EZAS@86JCMZ'#6F_;VZH65KH-[4ED*OQPGZK)H4K3CA$VY.B$;?T[AE1,P
MB<(HR?3N>U4P*_?<GQI.O2K1'TSM&J^/Z7TT6=Q?3M_'"UUMY1"GBP"[P2J!
M0<!:(+3[!#!PA1DJ/XO+51'Z$):$X_@4J<8-/&#2]WF#;&C8I:\!:29GJW>S
M\M6N;8IR:Y#]J_%W4MY<;+XOX>T&4D-OYG:RMC+'/V>@0&[WWK,=?Z;+^[9B
MD,#SU2SQU>!+\QI_3=+E?#7]5Y/B,.K@V/,>A#;5%.E-9J,?D:ZFLY.:^OI5
M^<$G2VMS[D%EP5;'WSJO)RZE6ITKU28SNZG:!#7I -O"+U%HNU(D^'7P/1XI
M&ZB(!@^33/FI0&>"N3C-TLE$'5)_4$[XS[>@,RO--TZ,0W@#AY!5!]TCPK W
MUL[U(LZ>&.D&9T-_I$4#TECL"?7^*-1J/.AW>.E\;WW+38QE_?!3LKW-,-.B
M(7,]Y&,J85-"5*E[Z2';M^ ;FULFWU$/43?\LVK^TC)10Y[C]Z;X<!I7&U$3
M(U5_J-<YOKN<J[/NN3/ZYS*9:R.TXG&\O"[]LF\<D,!DY72A7/F=I&12-&RV
M_< /F.=:R",N;"YIX"')?!])QR6>"$5 S'49GKRS/6RVB;V9M?W(J""PMJP=
ML*CSLE5S986/8('XR==D#!OVC_O/=XEV9JTCDBNE=!N <)W QI2%* @D $$\
M@FS/9D@&PK)8Z()P"+\TK_XJ&_>EJC<4!_B56R$XD&JK2"SO.]S>M/TMG8#\
M4W5:3FVBFVK-V/#Z?B!4Z>J$0P6BAB HRL5J3@F,)NO")*0#C":J-LF)DTC5
M[BO"\R\SG1=^ JQ.2C446L>X7T#G*@7A,KO,@3DLMK-$Z5Y%QGA F..J##A/
M@FGCT@",'"*0"+C#A.V:?MA09&P=^(HYYOMTGFVC]O&"8(\/5%,P)X='D&'B
MJ7^)IW$639SIV!G?@0T(=T1*GQ8NJH/AV"L,C'O4]P4L$,%5=PO+!#0<ZB/A
M,LFP<'DHN^HMV34+KX.NILJQJBU4.2@H]\;44Z%+)L9VZ=7AX6IJ^-0;K<:&
M3]CF@FR5D1V ^#6FOZCPLI6;ZP$%!4"V=L67\Z[:CZ'O4\<&G !JBIC).)*6
M'Z 08!*FE*:-&Z*FUXJGR'!JH6B8ULV%[/HESQTKND+K-_9'C(BBA3,IMA^4
M8=7"&=@$BQI_=:?">(XI0Y,+0,ER07^%P&&6;R/F"&G2(!#$:FC\M^(P&YNB
M5D1I6%B."/OAB.^'<&"9C@@<&]& $,14^H/-8%=DAQADOR<"S]Q189QR"Q\+
MX7*-%9"9H\42I.B##^<ZT#H<'EQL%=5Y/%_71^D:^"/4JP5"*R&>)?O ZO+%
MD<"EIL>HSCT#H>4+Y!)+(,OU3=/U;=?GNRK%/*1@[>;&O%KQF^E'N"A+U$YC
MOQ-*NI+B%)< (()(LITWWADHS@,AA6 (2S"5&.4VDHY% !9'"H<PTPW$*D6S
M[<BR'B[81N*C6(]U=/;+5>P%!ZD;3&OSD5#![$',QW+@X2>5WAB/]ULFO7$X
MF"O(SB/)>C'3%H)*K5-;BZ#GA>&=NW29_P""9P]]\DA M+?TX*5#CSVI[->'
MH22'KO,7M!J7^\(&EEQ%RFPB<Y6BD<7GKEYH+N@82YH,^78 8E<('[D20+5,
MC^# #PBWO(Y-F>S1GV$/'+;K1.;=''1A26=EB>:/V3SV$=!KJKO9&[W&MFG5
M&@K]"&U9E:4":4KO%R'11T/E<"!4.0&Z*B?0AX9-9LZZ,,?*![*?/^O12,0E
M'U?SH <X;0)[6$?$8K(A9U>RW6YA*C%<YA*,A!> , T<@1PS#)%@@6_#1X*]
M<+LRPL[X_,;SIJ(7GC.=@J5:'"\7YOG>I%LUTAO"\Q\0_%MQRK8&MNR@9Q,!
M$<]C5>,S7$Y54<?#YKD'L0?G(I#*L4MK+%<3'8-5_V\B<U7RGC4<*/?*D[74
MTPGI5^!?3V<ZUL6]U)?SR^G;-"J%M+R+OJNY'HZFAY?MSPELBDO%*P;M0='.
M[C7Y?L$9C;*E,H_S#=0#,%A)684!Z722]@%!'1M]P4W+59^#U]/D>A&H(1G'
MR>MU@',XB?8(T2[(%CG9#2XZT^4^]TSDV@$&94)@LT],E5432L_"ML2N_*(U
MR36 $__G3UMCJ4P:C%[9IJL4J(*84I"J,QU?+F[CK/25G\Q'DW0._.+I"BVP
M$KXOW,E>'?JZR#0M)_"%RY!K.C!_TH/YLSV,7-?S M,-'2Q$GBWT'Y/%S^/D
MZW_<+'X^,]2'F3%?W$_B/[^ZBS+8P*-%.GN-Y6SQLU%\<94N%NG=:U-]=0T#
M1O/D7_%KO/E\'=TED_O7GY,[,(3>Q]^,C^E=-'VU><65^E->& 5<1N$GSZLG
M:[B, AJCA)NZ\R=]J_YKMGO(?+ 1KT89ET>9ZE&.BE%.-J-4<SA/8*7F!9C/
MX 632?I-Y1G\45=;3)=S>,#\3Z];J2@-D< 02T29FX\;FE; 1G>SG__MNV-N
MP;/(TP_CR60^BU1N@-Z0J,^S:#Q>??Z6C!>W?WXE^+^_,J[2;!QG^NMB3.[E
M1S_XB+S+MV^=#Y^"UZL_=@)81_N5$4V2F^F?7RDQ&&<ECEADI;_'J[%(\N^O
MUO.]&%<N^5H\*L=A/7S6>L<@7S_):W^JH).MIF0&B@1=@1#]#27 <N/X=?0U
M3<9&[RF1&]YI)$X/ILI5N]&HW;#/K;!L%'?"%[S.)2MZ<Z9<,;XJ\3I;&/-T
M B3_6QY$61<Q_P"S:3.*0*7);#[Z\2A60<.;;R@^K\F8O<C]?4\;>>"TK2=-
MJ;4AI^$9T,N/R797-S#F%(3YOX'J#\+PU6",B,TV3@1=5?IAK=B,JBHS&A5T
M\=4DOEYH].*[GPUE%,$@QX#T:[3Z<G]-_B%+K^/Y7*?%&-=Q85+,RM@=BW'4
M;W_HPV#%QTR%Y.B[\+E@K.G.:?HMBV9_?I7_^^HIE\5#J#.%&)ZZ8\G>9\?R
M>3H$F'E@P"ZB[X_+\/N)UBW>8(2?&M\_^-T=#]@&86W8*Y_C(XWS186TKJ>/
M\56T*/: 6;Q89M-'5B(/7%.$T)<U=0IKZG>[@LIQ0\4RFN@V5%>ZH]#B>:TG
MBY^<CCJ"T&#VBY)YS"52),@9BR)/</[<5@7^'2R*<V8?8>V_Z(EB,/H<X%EQ
M/;9_#VQ/'F^[7F*:V?>?NYV>1\?ND"52^ /U,9IR!GYO]EFWGMX\CV$]-A>?
M ,DG.JS?D=E%A]4X^QWT/JYJ.LR[2L]AA_L,=-)AU+%S\S$V)C^H,J*YK!FG
M2Q4=<#HR<)!Q/3-U]'N>B\IR^TG'JI0^%Z%)FRBR82.NJL%<$_@J6M6.W$IR
MVSM+N1ZD50JY:PBL),0.0U_X2(0V1DQ2AB21'I(!99;KN-QTZ)==9;HQMROQ
M=OW(J2(P721C53\S^1KKA!0-7_!]-%F.X[$J(J>>L,R;?%]>!U$V3:8W*F)>
MOR-/U!@"H(:0-FEC9@="(NR[6.6I.<BV7 LI=)@5"FH&Y$LUWG^=)"I+^>N#
MT%A%;=W7>OXYW11>5)7A50U*78*T>0YTZD:1&:E;%\Z3!0PJ^YJ,BD8*'^-1
M>C/=-T]E+\:CU/-<ZCG(]U6)>&P%R VE0"HOD'DAL['+O@C3M%3[&Y/:_1GP
M<7#IJCZD<JG#-+N+WL<JZC2]B]_NE>Z\)YK2"SG!$KG< 3;UJ4"N;5+D^-(,
MB6\''+M?=J5&,5-68>Q-4F\@5(?UZ3Y5\HX"06M"0T_:"RH:J2XUAP9]H%M\
MZ[:R<Q5_G9>*'SSF5DB3<(O;B&)I@8!R/.1X(,JI&3J!M(C%G,Z8VW?.QU_>
MO$?NY>?/E^]>&UH?AY?O/Z-/;_Y?\-K FR]"Y]V;M_]XG:OA?R[3Q<^U3<WF
MAY^-O__US>< ??K@>/"0J0)O E]>?O3U=V_>_Z)>]?UGXW/P?S^CSQ^=]Y_"
MRX_OU*73N'C?WX,WO_SU\VN#F>;/AG?Y]O+C:R.[N?JC>0[_[T^K47[^Q]O2
M&RX_?O@K/.NU0>!M;_S+O^=_%D1^OOP %*D(5^-M\/ES\'$SF-4#]'C>O/>#
M]Y^+$6HK_&N4)1'\JZM?@E:?;^ZH_#Z*9J6?T+?XZK=D@?1N<;[(TM]BI,,W
MBT?K[X&ST[R9 -)3\MI(E)11]]=_U_OF]>_UV$-\85QF-]$T^=?FI*O<2SZ]
M-E;,J@V=3?174TCP[XXO^ _*%N_B[";.U.S_$DWB:62X23H#'7@7G1L@R2\T
MGWP*WKYU/AEOD^O8^#1*5!/7N?%+EBYG9\;;Q?CBA6%^>(9QYL82C")#IPPD
MRA6E$MV,+)ZEV<( ^:%4H*'TT[E*,S"^P:9MGB<<;&(;O)^5415-[\\WW_D_
M:Q8K7Y2S6^623+5<-Q9IP8IG3;Q88M@D3ZS3?DM]EC]?7LW!R@;\XGDY!0),
ME=DD7@E -?!\05P8GU1SJ&S5Z7UN7,77:1;G%+7=M1GFARSYJFJ$Y,.]>%D6
M/ZI^O9P:VX'[Q#XWE&5VOB54+S2/GAE_+/-[?E&9W_^T8C$5)0GL=55H9O7U
M55'*Q?B6+&YS?ISEW#:Y-V[CR=APX^QN.8Z,^+NJ7*#K,.2KSO@43R;1O%V0
M5\=59>+*^,Z5((A&@,U8)36OQP*@97>PPHIEL6D.J%;EATFD%TRQ6-17'^.T
M9)2<&_EJA2&FUR!SEC>P7]O *G)4]8W1G>XR8KQ/O]; MXJK-#(5>HKWK@=5
MH^CJOGAR"H)!C=ZKPG9FZ*3 NQCD"*#RUW2B<I7FQIM<\*S1;;GJS?E9<=V*
M*8II*H;U:7EUKB?A/ >K*D&,SXJ<8D2YG)DK0:.%<2-[+&YA7F]NT^6B++'/
M:B*[Z@A3JVDEFFHR1'NNM2$),E[+,W5QU9<6S<LB5"N-"-XW7TX654%Y7L9W
M,PWVSR5:8,CPUC,MNA>PNF'- 8,K5LX2I8F*!ZZOA\]5S#2.9T8T43EN-[?E
M5ZJ'Z[RX,8CW?(E-XAO09Y':UV5I5GK:V?IQH  TSR]A,, BLV4V2^?Q_+SV
MWOK#TS/C-OH:%\\N7K<>R+2B=3RX+_[G$IAS<G]>^N5,/;1X-SQ!CR0'5U6#
M*)Z=[T=?E,T/JVS>W!5B!1;"3!61SR5 =545TB76Q:%CM0#V7^.]90$"3D34
MK,J#9N%0L"HL:.5,,^:S2;*6"HV2 "276OCCPDX#L9S?>F'H3CMG&WU3L\+6
M KX"2)(WS\E]L.MLV-Q2W#Q\VW@K#\J8YP[:^UL0ZTH"1TJSG8&F'=VJ@G.&
MGCWU<$8O;%N0ZNNVWY:4;U:K.HY&M^M+U+W;<JT,#!"PFR>TXEA+FV@R3T%P
MS)>J.A/(4ZUFU<79N@A8,3#E"9M7U>?'3[]6;90"42UERY.U5-.C'UL;N':C
M&NM2F[E!\&]X+:@G:YS63ZX\^%M1.64;DPM]6@[6"%RF).=\"3#"@.=@F<!C
M@67!@(?96RPF>A.3ZUA]U>JA9_HJA7B<U]_16<HP)^>U26QDUGS*SE8<6AE,
M>8HBU9"@OF;AG=_@/P#!;):EWY.[_%KK7'!^+FW<?P#Y^RO3<;XQSH"8.WA[
M;5;J/)U^FVK.J@Z&BPOKWW>.X%IU.S/&>;NS*B YW&UW[B^?9EF,<OQ:A$V-
MIK."J(+7[Z)$?ZI22 E0F*^7J6[?HZ@MD-<,.H.O\C49Z4,7/2&UY:S?H!2U
M)E.]Y#KO@*=,+YB219PW;U)X3'5EIF*Y5K:KZWO*MR@CX@S8.)[JY:HOA)MO
MU$K*8E YD6X&4$C^S7/+?#':U,G*154>\)X;$67!K"T,6#DS?;HQ!]&B?=7Q
M&*S89*K.INIBV4CS\Y'S%F&2\T"%+=9K+T<]%U_W<92M 5;#:-,#9TKZ*A+_
M@%5O &,&]^F^[MOBH2+#*X/6$[N*^(_69T*&Z@V/8#I'14-";<$5V*^AGMR?
M;8#1NL#X@VY3@#>#T:3-U0R-5)7SY#H9:0VOYE.QP-EJOI3)GJI7J?.E!8@-
M('T:+XR).AQ:L]Z+=??#6G=>A2_GQ3);^=QJ$F(M%[0*U_<4LJ["ZSDO&7\<
MQ\!WR>)/L.) ]NAST%QZ9'GSO=P8VF+>LLB;[EP?W]3^>/W@:%[XV.:]BXQT
ML2_YT=C7_+&XMSW\)B_W4DSS$!)I>_;JU6!4680)8!"W36S+_/2?CB-CVK<Z
M#C;-?]\J_+"IEE..&ZR$9I6*Z_0,#OR1"]J<5AV=TA*1AZV02I2TH<.DN^-#
MCQ6=6"W8M)+O&P%JX%4]DNU,V?;J)BM CU*RY.0)_KBQ0?5WF?%3/H2\)=CO
M"@L]^>M!?(R_*N_PD AT+]-#-5G3.MU.@&@<>DO*PI$V <5CWP8AZ#^LLAFV
M+)F*BD1P33$\-YKH$R+8'?U7-%U&V;V!]0D-/R!\^-%#^HF4?>ZK!?@_=K3W
M@;29Y@]+&SO&O#VN('C>R[YH";5RY,[5GG)1-)G5)V/1*GSBW:?_-HI>KD]0
M ^N!V:?2;LP^/;$U]$ B&RNT_%@DVL>0A2^&PW 29+;,5/U\[=8N2XQH'<SQ
MG,0&/K?Y[T!P-"9#_E@DPDR*QJH;STET_$B"0ONDI\I=MK8PO E<,!W#A^<M
M-:QG8; _D$CRXY-HF4<@\L78&$Z&+&=Y=N/JJ!QDB')8%%_IOD3Z\/Y920]L
MG5/K=V!T6(W%B7\L&F$N&6XLI/&<A,B/)#(:S(Y).KU!*C[1&,=7S\S2.!?R
M=[#K)[\#>\HZE^81IO+%W'B0[%#Q.NA*E1G0&0VK.@//2DC0D]>T#W[W5N6F
M+1#.#BK=?$(8G2HC]! PL^_=40U'QZZ'K"E.O[58J!Q]%Y7UM@1'E;,&J;3T
M).-Z;#X^!9I/=5PO<W$ZXSHIV^IY6U*E\))5'K9!GU. B76.V1$.$$Z%O!\Y
M?L8Z9_3%\GF1\"_:]J3']3(7IS.N?41?O?;J2Z;;CY(K]&M^OM9<1*E2&\3(
M4^/'>7Y:8]KQ-+J+C>LLO:O4D&JN9K:YPO]9%^8HW])>Y6S[YO8")F?5_-*K
M^"::&HLLTNFK\+5*='T?S<?1/XVBY*CQ+LI^BQ=%VGQD3.-O9\8B&?VF<N_N
M[Z[22768;ZNEL>"916#U9F$1;0#+5=9U"W*-6<97\4@!NKA-YW%#%927_-/-
MJI0_UJI4LWFE_KS\JBK;QM_T5%^MC<F72?_QROJ5BX.H"D/&J&CU!8^+;F+C
M:B4_1_%RH5N %94-8.0C51#P3,F?:?HUGN3GGYFJ=K&<ZBX5T4S?E&?Q1\95
MED9C(].E3E3A!'VYJB8P7J7$5XJ55&75)(9[9UDZ7HX6ZM:QSH,^/S-NP-"9
MSN)9<K=<H$^UPFH?MJJ6:1I;!GIF ,FZJ8:.$AOG6N5=?)?JMF>?)BF(\O^.
M%XLX4\+<RQ_CZ9RD>JFQ3_]=>_/B5E4KB$##+?(J67]/)G?PUQ*>;N#:[7__
MC&NW ^F+6-4M^7:;C&X5'47A 77R3$Q5+.!.U2=<H;JXG\6 IZYDK:9(57.Y
MBY4V3>9W"GZ5/:;*P"I QDD6CQ:3^QR2Y%]Y^8\;74$',#1NB\)>,QB#+L25
MWP9:KH#O7KT_F9;KCYWE94?R=B5;4.=/U\4OHO$X4_6[5@PRG\%8LN6=3FR_
MC>^B!3#N33+2!1&N)FDZ/B^HS*MHY,UI<APKO/0!AAT;Y&S-TWG[NIP=<[)6
M-1TVU?9VU2DY,V:3:#J%J_)'TZTG_W$6YW4JKI?YO]'7*)GD=?_O_Z1>##/S
M+2V/\QQF8KF(C;O[>*+:V4SBY6_Q71)5&<)Y][;&$+IPQ9VV\E58- Q_F<%
M0*0JG"<)B-0:2WYX5WG$A<9 +0A5%$@5(AK'L(S365ZO3TW(9KX761SIRND:
MO+OE9)' &_-!WT5UYG^W/58CS:5<,775LD0*5LT+\\5R?'^6#VQJ+&?JN^MT
MF94K#Y2P>YT/LUKU3O.C$BO&_$Y5,%$Q&<9DJ8J'Z%>?&UH2 I-%D_57,']
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M0C&!N?WC%,A<F[&@<(ROT6BD";^)DND\KW05",N BQ;).%:",=,*8RT$;Y?
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M]HI.?2E:6M2MY$UU*TMQ%O^(HU+?*MW/:O-QNZL8+?:25SW9X<%AQB\3V;<
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M.WC#'U/COZ+I$EZQ82VL:^GR7+RL*\D669NEYJOP33HK_.QS):R2>7F\9\6
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M6T5QZP;;79,*W6"B(Z<JJ"OY?_R$*UY9+_<$6$"Q]2.KZGC3:NY4Z<X 4?,
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MN&_D=\WB!=E+>/OH![X^LI%[-K6.[MB!#<;-X8+=O)DMF\;*5:G\].TMW?V
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MJ4<*:)2&%<!4/7TW5J129Z'(45$0O/ 5, W0L*G1//HXX#E4)[& RU^DE(/
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M<Z\8_J]_B;2JR2YSKZB5529-5PKEKQ <6V1.27)0Z+SU-SC7_3%!^>N2=LN
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MU4NU_ [J@NG;^11RD_4=<+OO:J]6"L?L@<1,%)NU] .2QH13B#Y;N7TS/U[
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M%/[O'?0&CRK\;S5FG81N0<W;3@[7B&'CCG*X00P;V\CAQM7,65.\2[I (5O
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MZ1Q9X]$S3@!_:BK(8_ H/=9Y/2HQ\-B8_I=XNLK)IJUZ]4AX_I>I5Q-K,'X
M?^!38?6/PIOQ:"?VK4GX42SZT4[L+E?NJR#S=BFO'R'_GD=B__.MZ]FUVHU
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MND.?D1<BVT2IT^@'Q8!2U"1 ,:#DK6X7&9:(IC0*4V.CVU*3Y,"':P5D'B5
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M/O5K]?AETG/(Q]WA=-S6F/CN2OMCG5=K3.R0/O3DLV_O@8_;@R>@\K1LO$V
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M4]H]3"DBQ[4/]S=,7W7DAW=7$F:Z2BLUQ2>57'0PKLTN*N=I?\L;\M7OOF6
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M,^ W+R)E+<'>7T"8GT"DYKAGTV)!CL9$#?6C60B2=1J)_Z9PGP\J%)!RY%V
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M; MZW5.@DH>6!7YG%#,DANB-/=B5Q)(A-I?=<"JDC]$V"K5E#[D.4W]B7X@
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MS2/X5[]_TN[TAIUFJT&9 26+T>IU<VOQ@"D^=*E&/Y/()?;G1C>GB9C%'\.
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M)WF-<^<R'Z!:!U@"O#ER UEK08/ OGVR>E5E-\.; RH95#7D[G@L?(,9 +L
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M*D![BA+#,;\<B[ ,)!1#:V"L3P)4S GQVQP64M"AM*$QP![ &(SE.9$VC8'
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MZS%ZTJ:I7V79O) LFXO4=R,XI>+G'*[%,^U3^Q>*9,^$RY'0C!@I<FN<<^H
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MX^4\#$17L'(SU$D\Y+?0"TC4[TVY7FC"&26&]63QY:9)A\/G&W)FUO)U&(F
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M_V:KC$7@I\RM+Y_#3C<SHHI8!47GK48'S?7'J2]S^50D,U?=KFYV<E7N-14
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MT9:M2*IN_UNH?#SVZVC(CC'IV$J3R(\@ZXP@P^JH[^74OIRZ3_2X (\GZ[Y
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M_W \*KA\"VPS]":O;IOM0N3V[N4I#/66W"IG)8^*XK,9([.;<\PJ\6&,2[L
MU G$"%_T%JDM>\4Y_OD?X1J.*?)891\+/5<TU/,5R>&.!:HV<N6-;!5MI-Y&
M=/T\YL;LPH1[3TN)]Y5^1:1HGU^0_/C]U?\='8U&)R?%Q)F$<^.'39L!\K'O
M1R<@,YMB5J#]Y,2J ]?(X1V9!J^R(Q?5BD<DL(<2LZ*L"!5DNOV@UU[E/LX#
M^?V5D0^RL5/TV.]>?,#R(IA(-ITG&N?3'KS=/F9G9AGO3ATOF3"UO:?K$>;8
M[>[ZZ=@WL?2MU&G)6%6[=82V74 ]PAQ[_6<Y0O.?=QL'&U^Z%4Z35*B)\'/:
M]$_6II>.QIVNGAT9UU.3\3;,>5O'M542ZU;YM/7L[F#0VW^>WFRU*J:^_H%M
MPX&=A.FY+[:,DSSBP':'K5>[D3]ROU&,Z.F,@.V-"NY;B'J8KXOC6& DIK[*
ML\LEMV!F[16VW=$Y>Q:F/U#> XPPI3*6*J%A_[/M,'<Y$I<"M+,K07EWM.E5
MMMT^9]N9)8/8,38(;2\1,Y7:91"$S*G&:DW,GN+J.ZQ=M'1*5<4E]I]+?!%C
M;M)ZRD4%1H/3SU$8A%C\ET%:5LQCGYG':6#_F0(I8.BZEO56D.4FP[-OZY=F
M4U/;9K.TLEZ1X<B-$, MMK+<</LU-W1H]7"'CKEN-/7B2Z3-]T8-$"7=*81G
M>5-G0#=A\RZJ(.:4V7^(R07>+2\:-+MOWMJO/[M18I^^L4S:QT34(UD!<:+Q
M7$XS#8HK3([#ZP (-L6RI!/!^UE33SQ]8W\1<]\=Y^H?3@/J*XS- QB2!1&Q
M,$'X [833D+"*?LBL-T-*7K%;X>'J>%]#(,Y6!O>V+)'V.)<H2NHWTN>"[<1
M(F+H^U2+=(H1?1&KF;GVV3B<"WOT<RPHNK50K:_A!NRI%\6)17!G/$?LC$8-
MD55YDLR8YE*?G[).>Q'*1]6;9.@YWN)J3W"UJ?P;,<1HL;/2WU@@R!H/X[;W
M3O*$9!2364Q)@BB)J]94EV7*"#93TFU><OL<07*P DO(I6<P"*,C-A8M ]$%
MA/,SA34NJ#YK=JE4:* ZS@/9SBQ=;8QS)]T?L7/HD7EH $RFI^;9R,952;[*
MU\ZRT57!D01KF'#04F]9+-M92ZP9QOU ]Z0KPS54:4WPSQ+Y'B@]VRR-.4,(
M1&Z,N.#4M(7!]+@L'=9^#(H%;EQ5%5U51;\<16'/$I5/4:J4Z@D98S]3/.4;
MR0/+SC6\7TN':!PLZ!#^4M>FX@Y-G7<%#9R4!M!O#D #8$D'K.U#.*&::;HD
MFT<F[^K6 ]2@QD&)%B11RX#G:GGCGH>I+K*4Y=NR! ;K6!G( N2=IY$U7(N+
M"8I:0*EZ:VKQ@(+J1F.W8<,$/>=< 2Z('+U(=?N,X93'6!I1,Y[#-0I87R.A
MX,SGY1XW76B94-/-);*)U"2<LN_&<?84);*XFQ6JAKI@R.QM<4[=5OD)+&FI
MJ98QGM6$NK4LU>\4ZD4UY5*J]TVI?IM0!_W-C6 >6C1[5%,U\Y($ZZRSRNKL
M@H!+B?,:0UX[4,7=JO:8A#W6R^ME@(E3+0M0D *W-:J3L10_IPH4P!M6GH+]
M]3Z?HH5QQ27M&3""P?#OR1)SH@ ?[#0'=YJ)7W36D&7K5BCT"W .H,2);G2"
M6,9!5H!EI!OA?=GQ$P:Z'#G)\%?27/D8Y4Z*T:W/38QG\F"P4DL7&<H7T/=*
M)<[[Y@/9!T2^W"IZ.ZPL<@&N-46O721@FS-0">)+NNM.9C*L;'+T:VQ:B1SG
ML3*^L[*I8=@79#[,Y6[D#0U>4-/6D-#\!?S%JAC,"V$P'PAUO)"[%*F30%VL
M4-Y+$>NMJTLZ11U ,Y7PWAIAKUPC5)7FZ-; 2E$?M1Z7]+P8SIF?Z48@O#GN
MEVMPI'4%:^%ZK44N(*V80,JU!?W+8N V@H@G8!*%-2]/[YG)/X^0@YTHRY^\
M(5/A$<EM9J4,[LB^%XE7N-B+;$6F:!$9PE S31EYO? )!"7/)NU9&B?\B7$>
M9;B5))&&*]6Z:I%V1C<3)@U,!+D]+O>?+LP@,OH':B29K]1*_%H&=ICAR@TM
MQK&[4W/CCG!J1A6;W6<V>R+.(R2L-3CM@RUW.+JM.[GM>P3)C$UECBQ?RX!B
M!7:R_OM7O8Y2XYQPZJ2Q6!KK70TMOWSZEGT\?O?&XAZ$2D>4&J-K^^B1%HQR
MAH!/\!7<:@#>NP2[*C* LQO%8244%!CX JY5'9_I:ND:9Z> 'P87W \)#/1F
M"P82))? =]^K*QD72K%W[N,!W!E#O\P<&*M$@\I+[7#!'F>()ZUJNPDV[& A
M07AH&@E=&:FD'K*$T9PG4Z^U-KC,R^_I1Z^9 O!6R]M\ 0++L[> '-Z&H@TK
M&KF!<G!CRR*$BS$P8FFPO,'L*Y"-C)8P^GDC,N#_A/#3J)J2,G30+8.3JTD$
M>3EC2VG/*( \;.I)T*X1H^/J9IMD\V20I(6:M-I2&6Z98TLL:LN"FS?Q2"9H
MG#?:)&M]]7])^[?65_]OT_Y_FWA7^.EOOZ6Q<^&Z\[>?H@LW\/Y'!'JDGP<?
MAL'DLV$,?IKJ@)K66^)C'9> J\\RY,2,(WZ&YXUAX;\"JSWT0=_ZNV7;?],O
MISEB9.^GF'P-*90>Q1R2/!;Q./+H GTS]2*##U_$]/=7(O2_?Q[UV]U>J^,X
MS7ZSX?RST6@VOI]]/?[>[G6_H^AOMMK-[XU7MC?Y_94W^=X$(N^T6^WOW<'!
ML-$>'CM'K9.>T^GW1\YAH]MUAIUF<]CHPK_[O>]XY]]QV>2J+8CVF1L!F3E)
M.']+4EQ^YF1(_HJ$5^S]3[QM9I^G[LSS;]XN2/?%<O9FJV[_VZP_S<J#B_0,
M8S"]1QM,'N0%W7YVG,YF* J!+%7_7-F"Z4;CX*^*&?F:V4D: UG';\KQ68R!
MHW*QL.Y+,UT1%61%F(MFH_&K"6RQ4!*N<3_4'[>NZ^(FE$,:%*-F= [61LWH
M/ ]J1O7:ZK7W^KJD'F+N7@@G5S=#93/VRL=MD#&&XLD5E&W<RO#M0B;+C$)]
MU:PW&@H@POZ_!OWO'2_CVUZSWJ5;)EX\]]V;MU[@>VB=Y<9\^_P6A884&)24
MAEIIN>#88'5_.>Z%6LB[%RD/D?')0/FB+R/[-QY"@<F?OV"[X$0VOU1_<#_Q
MES3E(?8<6)QR1@'ZNN0R"M.+R_RO'T0$IM]+6J[1SSF:7B]IRN7\HQ07ZN5R
M$**/S%G_2+->%.M+^ R/)NB;C3))7X+V8*\BU^57OI@FM(:(WD#^0R_ )@9O
M'?7E^E86V4)H]/K>>>2Y&Y34B[ Y:Q/N'0]X+!R>!X]SJ\J&V\W"VNCGG&1%
M"-4:58?EV299T!JG48PM\+!Y;\J6WCD1^P<F#[FY0%Z_DK,5>]WR-=H LELQ
M+E5%"!4A[.$D#7[_%.*ULFD7!2Y5QU>"MN*O6[Y&C\]Z!H4PL14=5'2P?W/\
MEQMY81IG3TG"9[)L#4$U__FN6&(^)VK>2F)9.NSQ&O+6_RSPUEN/BM+V',-Z
M:AK?@BEOZ;"JG=B6854[L2W#JG9B6X;UY+K09B][/I=\94[L@:K](L)CO<[6
M^28K:G\.0BAI9;5MDWP6B;%OIFZ;=05& -\B'>91QK5CZF2U%]5>5'M1[46U
M%R]D+YY2A2EMN&$L-(-(/$H-JZJA1<  +!/!(N]Q& 18H1X&$@6 @%W^FWJR
M5#V<R@ V X%X<6+4NTH4JYF+R'EV+)+$ET]UXTN)P("P,P8>@6,@!ZBG$&2?
M!,TM^KUNV6?I>0P7($),$MY22%NSNXUF#<CL%D"37.J;,14$[XO&EVXL& 91
M(=X;37 %SF6,Y60^SC0-@-3M*X[YZ")@\9/A%FWW(A(2(L6-%7(M+1""89C8
M0\U>.6R*20N#1RVN)J ,311Y2 <#U)A&=CML^T9*KM_?1C/%U)AMH97?.8E/
M4D#P\TA<T?8Q_2GP  (25U7<>8K15Q#9JMWG[@<%#WEM4.(;/C!(1_H0GM^8
MM&J[B08TP/KR'/(!5V@1HD(LLFGC^>/#9YMX<4RM$X' 'EX@&&(3EH@PY@AG
MX#;@'[E^%B_@:N3Y>*P*R^T1VG/&@ X:\9/0H[,2IFP-)!B5Q-%P8\ND8*S7
M-]8!P9@0?2./B8+8$0C:= .7CB.&46%8*_J@$#'*1H6_*0Z@N1UB9Q$^)J&(
MQ@CF@B5)!6]F*! $=='@&PO02SF,P0Q!&P\KTYZ$1WDM(53>2.2-TF'RK=/;
M8 F\V#(FC)"F0/3VH>^.?SAGX\O0A[6=1QX=!H:LT4)$@R4@?,H<MJP"-;@;
MU*#;6!O4H/\\A>_5:W?]M5N,+K".H2&_JN %<HSF$<J#LZ&\]JC^-:L#SI!J
M%J;]R&[PK5@;8]//DLC[8:CM*/J,CZ_GG.&;+139$2]AD?02C0@B7$R,##A0
MN_*K\II0D5[4LOPK]$%=0Y7PUR>=]K-,%O\P,1.O+[U$.*B+B;<&T__BQ3^<
M*9C(V7@C1.3%,9OHB1GA/.K:524+VU(C^%)+>GZYU]S:Z%;=@=D]< L[]>8&
MDJ6W;9;]@WKKX)[3_'6S@WV$V;7JC4U,KJKESO/I39>6;8#L=R%UZW[L>3 8
MU#=1YK%M6]BJ]SO[/\M^J]ZY+ZWN!'^^KR:Q,G\NC7'FL[;R882?2U[?GW=Z
M?3<+1DP!"6G;VE?:FN,HSEQZXB/$6<<(7R@=^(6!%>JFD7\*Q:5FYU[@YB.Q
M\E(KN]83JH6'Y[N1;#?FWR"Z.$8.5+>Q>G[ :(-;MX[5CL3,]0+92RU!2&]L
M@2$[Q<FN%#H@2T^/E/UF1S* D7O@BE;@_T04.N,0>TCD+#]Z*'6_8$!W%1A+
M8'LH(';%V.&J)=O$PP9XP<2^\82/L8H,Q#P?H8!QXCMKEGTNQBY<EPN_R8[G
M$@B=D-\#U25E[M[(OJ3J9;<T%=I<7$PU\\-.MW>'H')0U!9#4=\6\I&Q21F_
MB2MDZO6#.+VU@SCE=SS*U]5K]_6U51"G"N(L^5_EM.BS]IUJ@5#!1M\5YCD!
MJ9J-@L1K]C&<YI?GVFA,D7U[\6*PIQ]WW2CU\&5 ,AL+=T0:738.+\C^1A4O
MOT9*WRM?SSU?N?LQNF? MZY"3-L28EK!HU'H[GL!M8K5TFS>*=RLM1O=;9M=
MM?$[N_%5!.QI(V!5S7NU1ML9H-JZ&%Q%!GM"!B\$;*'"BZIVHMJ):B>JG:AV
MHMJ);?=B/I&=KUS"]]+%5M%&;WO!VFK;&J-]9$V^\@\]@G_HOBG2E6.PVO@7
M:K15B$?57E1[4>U%M1?57E1[L89*L!+BW-.AC#%<%@WL&0#&OAIY_Q(@K-WL
MU9J]]EVH<.7%'3G4,3>QW< 6/T4T]F*N0Z!$_5_Z]4ZK9L$LDC3"RH2I=\4)
M^K$]C<(9C0834FOX_M'_<V1_CKPK+++XX$8_! SK;'ADGZ3!Q++?)Y-L!)UW
M>/&A%R9B?&F?"?_&/J7KL"BCH-7N 2?]2T0QRT"&BD0.CDKBFL&$C)(#K-DP
MANKB<!!C+ \?Q^A^^$#\+4[/_\)J#IB7._DKC9.9Q/3+GHN 47B= OR+Q#R,
M$ERFN8B\<"++3\IQK73Z)7QCM&+ZI5OO-;*/\##>48EKA4_((5M9I=!6V9O-
MDAI5:$$OQTF,_73"B%E&J4\XS89PT*@W&[_6%NMTS$N0,K)/1"(UJKRQL\H;
M\_I6O85/I"7/ZE26KVL YUDJ7OD-KL=/?_LMC9T+UYV__41S.V6XN*\A)DJ+
M*!X1-1R+>!QY=,%7\3,Y]('D_V[9]M_4S9^C<"S$)#X!DE8IUI^F1W1"SNB
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M.\DG17X1&>@ -D!]!>$$RH-/'UUN6TK2&3@AO07%B*#[E.E&5MT,4ZWP$N"
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M=84#*JTS.E^9:28C;.M[P79A4$\M-9Y]PELYJ$J[NZ]]_C5$;(?QLUCI#U.
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M8]>R3O3\&$M!]SH=\+0R4G3S26W?S*TS4O2730QY19;S=KJ;73\G*T3^>B3
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M3+#\C[7[M+RI347XZ^PN3=O:[C)>IFU)_]I#&[>SX(8(UPD)_A1"VKWY(Q7
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MA'Y'J3P:L],!NOLCX@1KTI& 0!WW[@!!CY7# X@8MB,"%X*'DAG '%6*P+P
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MQC-E_GG[F_)!H)(7NGL]*I(#L83907Y\D# 0MI2P-CU\#&9PUGJH&NO(?,
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MP7+P)(/LC8=/:GC8+8"R1=O/Y@ *MU4"?FLDA>N>@-\22>&V2<!OB:1PQYB
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MT#=RF496\<IFIGJC<Q8S&_..2R64S3[?P1*$U>;?#;ZGVW!6J11AR=ZXS/>
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M)3 34$8R^_+E054:0-558_UN-H%2 '\QH_(ZNOD4I^D0M8"LN#VE:*(<_5_
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MT^K)U0VMP,S>H"WP=S$CV+@END'E$&[Y%CP,P7P-YT.XX1'LOQ]!,DX_A7?
MPIGTBWY+R6<P1.X6=VPJX'ET\2."-]^&LTM@ZR $@IN]H//\B]^$3W-HVIXJ
M*(8/LE^$ORS/U@5Q:'J^!._PA_J2[)\M$O+N%_%,R[!X*)@+I'X.'O#2)9/-
M)1."H\C@=<7,1#LM;X=M(_/:V@Z&1-^7)-T"M4E530G^XUF"*3M GIXBNXYH
M:J*SK%SF2#0S).X+QB=2(G/U74SV2H([TAR8MY?*OYY"8VN@:>%X%Y%+KN?E
MV3_8.$U1,WS-!;ZEF2JP,<44S*'G"J:BF[8*:' L!5"P Q=;AF KG?IED+&E
M!MTJ](0J5IX.;ET1N Y OT;['XQ_UL\8)< -#5HYC^4E64#"1H)<UK\J&A=M
M$NB"L#F/Y@GF&X_V%@=M.'&2:1M#S=,%755L054<2[!TQQ,,1QMZMCL4AY*"
M&):^MX1COL/Y^TZ''Z7%(-=G1 O=BD4JW 3!["/&Q\8T/G9/KLAHD<"=!&R@
MT70Q!BLSB>]P/0O&""XF7I!$P#B0:]+EV&QHYHZ(_BZKBB):Y@/\:TJFM 'Q
MIB6IEF>8@N0Z(!E$UP8CV]$$1=4<5?,-1?1DN%JL2]@<T1)@>J]0'R4>54-#
M1?[I>)01CW(3'I6W@$=--.5-C* 3'A7$H]B 1TL_*")W9BAEO\2GA68I,E5)
M?9!U71=ULT'3 WD- GHH2)9J"H!*#S0]T14L6P1"=BW5<31VGF707B3Q7R6^
M]@9='6?-617,YO/N9M/XD1!ZT>4B&=W"LR^GP>[)$:L8VJ0:=T:8VL@ 9=FP
M*CC<#=JZ)'<V[X&SO >EXIC1\<4$?0?A*)S1N;L'0*?\%&0VF1J25I';!T!"
M.;F\N.X\&B4$'G,>?5E@M[7<-V[?!^$4'0]^G/AT='5N2?^&0[#I#M+7T_<>
M'WJ5!O2*4C;[>M_0K_+(738/NYO.'\^C=)XLJ%9\@>&O;V!^9^H8+&9"P/ $
MA6Q/7!2T=Q W\D:7C@6:E.5*@@1"20 QI@BV:HN"IKFF*QJN9\DN4TZ-!A:A
M,4??"^#GF?;E5Y:D<[2;HKWDIM21\TP[\CM)C_J8Z T[HNK/M"-UY+S(COQ!
ML'P-V"<8\L"&"YNR"(\<8LL:Y(FEJZZL@9YM&+8NJ+;D")9A*8(O>;YGRZ(-
M6[JZ8VU6MR:?6>KS[^!&9#ZO> )AF9[>_K8D =?V5SFSI&>48YT0^2(B[O2V
MMXO3[+FV=TM<UG;X*YS\),1IWU0'Q='?4;HO=&L;;451E'U+41S!<T&NJ:8G
M";:B^X+K:.Y0UC5]J'JKYDW-!5P1<<W [(>BZ7^^$N:V)%<DN0]'6;1!VA^Z
M5IPWLNH,X6H!*!,U /C+' XU01M:PZ'A:8ZEB3E^6.CDH(">N%VB;5*XAJ;L
MNXYJ")9L*X(*U"?8LN0)BJ(;CCY4]*&OMBM<K]TL.8@2O,<]:3)+7J\"_ +:
MD;9!?'J2)[JFCTFGEB^HHN8)IN,!M[)DS?5,R]6;CL^+:[];JT=/<JDAL831
M#3YU7]ORG48"LL^:INXH1V06E/H%7F0*HB3D[JU]@'H">#,;*+H3WI3,^0\O
MLMXBWAJ8=B>\J<RO"GB3Q;>(MUW/J<9B)]DYE079. #>GJ&0@:)'M]0'V315
MTU#W4]BPUEC0GEK;<+48816<3S [D F2H\=&:UZU:E:PL1FRLC@JR^"K)!]G
MV9%YREI(GH0'59-%A@?=V)A7Y1BZ:RJBH$E8RF /AX(C6JJ@^B88E^K04PV'
ML9K6+*(, YW :DHKS\MJBZ3\XX.]-6U:4D2M*9M\!:9R]Z=!FA877"1?467*
M)J ^%^"2Z[FFKNH ^!"(7[9TP9045X CH6J>KOF^H2+@<F-R2+[?:P!9#VTV
MS?/XH&V*J*^#-@-D/;1-65O'![K2%)32R[*1SJ"M.>&5C%RX+Z_$F1%T.7TC
MR=W^L+*,!\.57$GS%$&6),"#ZXF"J;@N&,6**]M#RS<U_SO5IB[5?TF? 45M
M)WH3#!THGXK*SP#J+8B*?Y$@.1S<W?=?IXJD# K1)GI?6?[JCL<%_WMFQM:=
MH[=6!RWS\A587D".6^)&/T]7R.53D^-[A;U5CJM')L0[0-WU;"O'+\3W"NUI
M"?&]@MXDQ$WQ"3)\@Q1 D]<EZ2@)9_M%R$IDT;*'D@*'6]>&#M8+J8+IVH8@
M6XZK@+5FJ:*!UIJ"<BP;[<+/8SI#K9,\6X+DN43:7IG;/D3:(?D:FDJ2I.^+
MW)LSUQ5)7T_OS\K<]@[RZ3"WO8/>Q-P.Q=CVJIT7F-@=]EP[E_:AG3^?/0:0
MJX;9 'DG>TRF]IC\+_.SK#_-'LN#8%BN5D:R]B2Y-%62'V1=P^9Q[+.N 7.W
M--VT5B'71<V2='LH##7/%51=- 73]#5!](:>;@!>1$UBDDP"Z+%5SRP)(TP8
MGV)S)RQ\B5D'+5B%PG^*@XBW;Q)"/=0#D'DWA';I^1'.;_E@-$H6K/,7@?,"
MO_\(4CXA E!/>!-AEZB(#WA-_*B)_'60AE1H5CI@_1_::,SZ&<T888(MJDB2
M#G@W2<]X&ZR$:9SRG\_X*WC\#<A<_OWG,_=LP%^-X!_^]FQT]H'VU/H<3N=A
M,(;'7\4+O' Z_RN^F>8W?#@KXY2M6U06-X=3 "6.\DZ&3S*QLLTS54-7-KF,
M+4]2O*%A"Z(_!$GLV+)@VHX(+S$US1<]W=?]=5U?JL[S%2 JX-$R;YMV7OL:
M/P;3^6-VT2$ ;<PKTGS+&4JJ)8B.!IJ&-_0%T_-%092'P)6&CB3[P^]J>P\D
MJ09I*SP%S%^S#G#^@G:U>7(@8)M=[0AK:U=2N0)K$QP%D%E[V^*P5MKXL-*N
M)[;(.! YMS=X$BN0=P5N#3O.B *9]M,W'R2/8DEJP8_99]"1554V= F+*.'_
M&T*(G?BSDED:5P >;-B,K;R-B54!JU31URXI2F#BR>_Q%+Y;2J6X3,+=6X24
M4DG73=U0JE@P5<VJ4DI3--HV'44R1$&U5$")*CJ"[0R!6F3/UA5;<0S76ZU(
MRZM\+%G+J^ZWAW@-N7PE8\+D/;WRZ6T72BP9JF+JXCHL->4Z=,&2W%9J9HIM
MU-,*YPN3TH&1U-0_Q12?2$GK;X;KXL0-'D\8:ZME=E)1Q?@4P OLL;J\> )7
MI]D%XTF<Y![2 V-I=\1@<;$L9E9$%R!J]/*59"P^W9O-0&T$S%0P-H.IVIYE
MF)8GR+KC"ZKF#@5+E!7!L4Q9M!3=,BR0;)A[5FWM.8X)]O:<\[?!/6%=<W%C
M4<.?)0C064D7C0"N8;Z?@SF6KS\^-;TGD\VP?4WIVX9BF:8-!J(NN0"W::N"
MJ4JFX &F+,EV/-&@O2!DE@8E&8*HT@#6YD47V_MK$$;8(N<B\AXPBV<1IK>L
MK3[>O#_8UNMB.H!D.[HDJ$,3J-E1/,'194,P/-U6#<L173^#M-7))U3-B_50
MK6QLV<)EG_1-8=<:% H9^]0,55 Z-57%G@J&X,B:(6B.*XJ.:SFN+N704I*&
MA^L\]A2C]FM(R]GY8 Z*5T+MR]L /D:%F<LG2)9@)IL_G?&M]U,+.0WOPBD\
M94ZUSLSXA<LU>GG*OR>T/0/V$L5??C"G Z"&L8T/_ \PMLGU8WY?]AJP=.]@
M8=CX.IP^(B;A^CEMO0V+C'E"DVKYQ0S0C'>"U3 -L;=NS,>CT2+YR <?Z \C
ML+#QY0!,P/\;+*AP$L+:SR\O!OPU&-?\B$;KX*G-9OLXO@M'8&ORDR2^XZ\
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M"8%[QAEI'.>NMU8UUIJ!=0&D$?;B6NJ,@'^'\&6X7>'N 5B;U&[?JO7 UB9
MFG><Z?/'N>.M'3.;=GPM(.MW_*B ;@UC;MSO#B#7>,)QPM\JRMO@[P+3$C)F
M":R4=;(GLRFAIFTT!FLDF8=_!8>T#SJ>^E9QKBRA8#,D==?&D@$&UD(X@ANH
MFWJ[&JHVJ!OJ&551,WS-!2@U4P6@%5,PAYXKF(INVJKI^8Z%QKC4HLC7>C8(
MDGFF5_P\&R#JX-@9 LQAM("'7,"+@JW#^&V(:-A]PW8MQW,EP3)0F_=-&W
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MZ(1@(R3[WMHQ_#5*@XS]3VJ753%[ +N8^ OOM7[G4^%!Z[/?_^'YWR\]\\C
M?GV0OK1=Z^IAPE!M]Q/3+<@ID)CQ0E:=LGT)I*US@VA4ZL/OP+ZTBTG67]M\
MX)JW#8W>/=D^CXT>OTMU"%8J"4F8"-.\)C6,'#,(KA[^,#GST>K*O[$?GU)J
MO5H]6?XOIF.Y9CPD[)P3C!:+$'_+N>>/@DO;O+>=T.+JJYX!A&W6\^RO1?Q6
M/S7(W3$&D-K!5F6E9M9H;Q7)[K$M5N3<NO?7IK_AD^OKFL0:YYL)7:127P['
MZX!=AP)V'$:=RC.)N]&Q.;:]%V:0/9L7[J)W:DRQR87,E#1^3:C4:CT/N]PQ
M3_B-/0Z[N.T9_?&O/O/(9Q0JY1.)QW)=S[UU[RYX!T H]26^LR"\>V)WP@&%
M"0JESJ[I+@I_> ,&MQ@DPW%\#@Q>N;W>!P?,]4/1G3O@>JY5I&D:T*0NO3Q
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MY",:#W>L?>L)DOQ5TS[V91$HR<"/+U09'GU_?2IFV@#JO<>+*.%"_,L,%;M
MP EYMZ6!6.FP_33$6U@<O'#0 P^96 K_^&*%?.GB2$#A^A#J+25J/+^'R:L'
MY,-L_^,+EV$/=A # C7[P%D)!1NB+\3"2W@O$?#Q$Z/1+FF=B%9KY$S796KK
M3_ ?R0T&*IPF'[NA=C0@+DT?9\%IG7 \B9-[R(N86M<6NLC##YWWD,[[% J
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MBLEXC/CF/#U=;.-L?6SG %1=2ZGK3BZWT@=3'@-%/TX!$SXR"M!:OLY%"(Q
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MLI-_ED/I:+=C]!'Y]SC>&\WD:0IOS\2:WM!=5$WIA55ZR9VK4M\$Q(H%%Q'
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MU:M'M,7K15_@!Q8)OJ#R>9V?88*Q:C(FC(=0&LC=E)*-JMY9R#O]#88(-ZV
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M?Z\2OPF6G>IO> -]8X0^I OIPBQI7.)4G3$LIT,V NZKU&SBPUX3+*[WK7K
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M* I$P8?M@MF^3!O\SH0<CC._< &\ (J*Z<4F\U2/\+4/!??D$CHD:R2VK;=
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MR9DK[TP!\D1UO@H.A59,("V>Y6D=E;J21BCF'OA;4' Y/<6#!/5DRXH;"G]
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MNCCVE:L9N7(J8A7^!XN'"(0[5<+)FH)FKL@2'Z& \>W+5GR<C/"&&J81E(M
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M2/H\HZH%O&U$)M&"5#<1P2L7,ZR&)V*Z.>674U4)@A0^G?EK#(=/6?>T*7;
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MJ"WPVQO%5/"C*'QL6]N[91Q3<8;NC0J)4O$XNP [&<QZ.U#@ KA$!?9V++S
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M0@,':8STA#5ECIYS\*50@)W5>HC H?-HRJ=T+L*XS\\>/)).D2EOE]S#:U+
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M,F$A)2=2HX3M[)M(/1()+^%$"H[((BDG5FM$%A [D:HC_5&%B948Z0;:)U9
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MGF;0G'N@:!K8;%5.OI7:C4KP["OS'E"Y(--1;%KQCJ=,F*G'#*Z]?[JVA L
M:5F9=+4'%Z#!LISQW7[FH<"JA]2A(<C>OUTCQOS>53RDAK#IWB'%LC0["0L\
MA=EX#@HWX[7?&.U"&MBFWX3S7A4%I.8O="$W5DT 0B/;A3Q9.7;5@VDN),IJ
M7NO[40 7TFCEI[_/R^Y"WNQQW H=^"[DTBJN=W94UW@FK30T4^RX%2ELKD&*
MAW!*[6QW,,7R?')]B\:1Q9(F58]SM(=7QPPK'<RZ8E[U>E\%W![Z!9QX74:
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M82([&&6B2!#NN#VF>'H1S^X"KXC*H185+X\*S,G%)OJ0106/**2"; $E7,@
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MP?TCC.4^>/Z.>;1EAD@DW:*<?&L"[7T%-/ UDVIJ*XI"3]OP:GEJ(;R:V2B
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M\HS3]NKOQV 7/,:!9XZ,59%81<M*OI69D6"_Z:2M^> ES8TD9 1[>R '+;]
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M%M+SHP!0%T:8<)_&;\<6O_G<,(WSA# ^!-&O7N(?=UX,B!ZCYQDD 5MRB$R
M5!$+%BM()+1'31 'Q0[AG%DN3M?S&E$03-C "N.=<HPXU0_Y\9ZY#,^, IP#
MG :@6>X/'TLGT/_I*7KY>0,#/(Q>XA\PNI>UT3/Z5:7^X\Y[:GV=[M\UC($[
M2B4&>\MR@T29!UB"WIP>ZX KYL#4.<Q,#IRX=!]5-#=A>/1VG[P@3"&^6 ,7
M!J1Q!NTQW<T,Q0;AZ<'U?'5:S/<2.: F"-?(TMNXC'?%T>P*OTD9[X];\V=?
M\V=+]T=+B\+!1MF:L#Q7@LU$:$V7]IAV;'9MD%C@6R^+32Q8CO&NWWAG'.W.
M].!SM$>NK$=Z$,I&2(50AN]&UDW"--@$NR.N9GT/_6-,MM]=??=W1S3(_(@<
MPW/(QPQGM]LK+PZ#\"FY@S&993[?X[KWK*E\);)UKKJH,%AF:>*DJ/U>4PPJ
MS:!0#7"&@9IRO'Y8J,>G!;/%G!G(3#"T<F,@>FXG>DD5/=B(GM^,'BRB=T#1
M2[+H><SH:5O]40G'QN*0LH_S!EGJPRM= .^"RPDUOAU&X[DALZ'^[)3/<T:O
MR;0F1%TR$PK1&^$F$1 J9*S>[_(&>>PF".%U"O<3D58E_NTP5&FSS!S;4FVW
M"WS%5@!BQMLDL:%1Y#*6ZBB^$9[K@%0AJ36_DST,]MG;P\L(SY))Y6?M->.,
M4]DBU6J?<9ED!K!8\#43;!4W#/:7AWD!?\VBN)NH_>AL1<H(ZG -L"<R7Y1D
M-V]ZU6\>T$^)1\[Y)/SJPY)2=&)2SC29*C@GQ<;7F@JR_04I>5_3 NIJ3$-V
MTG"X:L.A#='#0-  ^("XJE@W21*8WJ$L>?9JVW3(#IX=;0,/HXC"*%&ZUU\&
MVBF<RNM3=U&LGV)=H%!66PTX)YO<=JP];M-6.6 NYNB)C&-O9/@K0WK"XTX6
M'BW+3",)I5R*&A-L(QTA;#!S^B/[H\YN"]$HT8%VG#HR35TN.,1J<I/@ Q:-
MZT(Q;-?6%6BD0:.%KWPSEY]]19":#VG/5_F2..[Z;%7/6_,5@L8XDG'__?W5
MP[WY).96U.EZ:2ZI>VZQ;#RC/:7E;VY<GYW4,WKB"RG%*'F8%S5F+JYSM86A
M>3=.=CPVGMI"M-U^UE2J#ZAKYI0%-)LI;PF;CW,L.VC?R'^S5==XF<4$@B5<
M7]YQ>!DD_BY*CC'SZ#SS>>W H!@A<WW>W&F"HW8-:"709.LPWK].'Q[LH8?E
M9.<!<8'#F!P.K-_Q:1Y$G&SL HD5):O )-32\-ZS 5Q#B'HQ%P"9)>V1.I>K
MR28;VB2!?!2"E?FV"A>R>T!:>/OX&L_HA$U=L42^+)UBLSXI5X@EF-T>-\(/
M5]@/;0B@I4PCVSONFLCL#UX2)+?;<]_'VVZ#\.DNV@7^:_;_#_![^F''OM=9
M\&6-6!"S2"*YUJM\.HI(QON)*MDSD,D%7_-_L0) -!B"T"3NNPWW[Y#AQ6J<
M27S))6X=>!)!4K B^R$.-D_P8X!/R"%=S*-L].<TKZ52C1!-E_7IZM0]S19*
M,T&@E&3F-)L*=QS][G!7+57XY-)\,K7"R 5(L7S(]MI(HTFLN8D\UB;$V@,Z
M&[]2JPS#%S<9Y_F 7S?4> TU/YN0RR_B"4(_AGB-W3L<XN@ENX7BP^VET;:J
MDR^-]JCIMY&$/B9!").D=D<,^3&&_,VV_>_I3/\^8R32ZJRH,UT(K=_:- .%
M7,.;]U1[[([T6!N>1-.U 3.A8-F"/O8\ ^MIPTB3&[.OSY9L?!F=A5#C&Q-)
M%LQ,]*1;'V:,SE9T[;G:;O'-$R_PTDLA'M65?W'$OS!/B%E<<2R32$EWQ8';
M#)1* -:237(8NJ-02R@(.C_!^ G&Y+#^#A)H;I!<RX ID-T]>.V+FB4PONDY
M<,I]Q2Q$;^2/-"Z6)Z>\]N_&]"E/A6YRFL(>-PWBKI../2AK!L<23-U!E!9A
MZCTAW/\:X9G.ZQ!]>9BD2=[SW8A_?A%A9G$H8*%4.W'":S(K9;BYS-2!4E\Q
M7-I8@U[UP2&X'A$&@^B6 $8/[D7#JF(A@:(]CCY&\=[K5*3PDL _#S>7^(1I
M!^0CA>E>DAALJ7!1WY/%RLF+\%';*:0/$(6T6@)$*3G&DZO5N\*A*SKLSHH%
MT>$OF.@*4;E.ZI,];IM,2'6%;UG^R]A*RV@&*9=CQL74EOY1;O)UN,7_X%_U
M[GB0E&*X1\0Q36I"ZXS;%2H)H*8'?'WP'G?0@BT1DX:%8/[>?X:;XPYFVR,B
M0*3BRW23:!=LR-'.?.72V]5C9%NO2  .?=VAOLA:@ORD,+1Q9[AX!C'>-XMV
MNE$RO?JU*X9SI !D&L [K.-':Z"M) 8$U)^+9OM=$(+T.3HFJ%&G>VH0L_Q$
M[D$K)UBVX11?*1T>64=#1-ZT!)NY.3)S:*<K,53FHNW#XC"?2Q3&V>MO!8FM
M5!7%8#U()M%W$>T?46<%VX9[,,$&9A<SDYHU6QC'<-.WL"8DP@ >1>R2V3&Q
M:,\0UA3,0$,%J.DP<[)KPB#4#GL=B@HGY.YA&R JD\\TK K'RW+0]AP$&R+)
M3@@/.#FU/&LWL6)(-GY\;/JPN.K#8B$#\$ZE#8VQ/7R ER5@F#:LO@F\QV 7
MI*]2F<679)P/N.;)# )/^O@@U]3$P R4RFRB Y51R;9:5_[[=:'V@5TH\_O!
MWA]!A>M[_:KOO%<\M_K+ >]@?0[0P $OH-UN/P4[F*01$L)9!E$BWM :H K;
MA>]F6ZW=XD;VD@;\R@"<^E04@$-F S@B(X!768&GA_>E'7KO=3<802:1,GD4
MY#8 ; 2H60%NMZ"RP]Q2HH$H$N+]>$QQT8):YJ%<R^KJTI+-AW'J!2'8H-_M
MH@/Y-5Z91%F\AS%9C=ASHZES45(E[;67*95]+TOZ=%5E!-'URIZ7S?;<*!;)
MS$ LV[L3ZAQ3K_5AS5JD4M^9(S3+NF.<I.WI@;%B-$VGZRI)@SU>M"T+D=QN
M[U.D\_9 )FQOCVF2(AI%+"+61,@(--^QDK!6^!K-Y1FN'LCN2L%"9ZT8%&[
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ML1FS%G(:(&7?-M\W8YDF,Q Y77,&IH?RW$O:3E?C8U)%SK/'HQSGK>CP* H
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M#XN!=3=9<#!6Y*1B;(8/CB%*FH,7IZ^?O3T\_QZPZX52'M6*Z*Y^B=Q<.N5
MH9(#L"#P%8LRMBU[M%>NK%?Z\,1.KB9@&#$P@HAL]?PCQ*<Y=P_>]ZOON+0:
MS 8*S'T@/6_IQ G?%(GDFL^+>J#YWHA<)BG2E4L%[W*YU(O=-.!'J;<$2KDL
MH\@12\(&B 0",1Q/"?1_>HI>?M[  $-IB7_ "%K6$(1^55I1'FFX"C>4\XW<
M1S5@A:=?(F762[<%D-I1("3.P&D^A9ZY0SR;&B$B289AT1L'DVU+%,/@*91M
M6UAO&6A;&*9(L:W3@DXFT\:V18VW6=N2R;*A;>E)0EK;P@N$03Q=AWZTAY)P
M8KVD'TT,2Z32J]4.92)U8@D?SQ# DAI?U[43(>R=R9H!U9.%%#SQ@F$?G"Y(
MY9MC$#[E)W2CL+=T\W"!UL"09Z54AVHA#M$9J+2"2JWY\L^Z(E7O>MH+;1%$
MB,.^-WP&*8'<>'X>;FZ0)MDYD9YW]0.=;Y!$ICJKLR:FB61RI0>1;6%?5JGO
M69F'U-!(<%"*4N H$!(5"_^_7I?E8]A;R;L/Z5[2[U@@L;\$,W>V?O_K=:V\
MD9E-X&,=<30[PE^&'^N-*^>-EM5U)B+*I72ZUPK0B&>!/KS^]ASXSV1E[M_(
MN9+SPR&.7KS=%_CW8Q!W+K.4>%$S:L6LDD@99[[*D(PEXQOEOF'9^::,_-21
MEXL'<2Y?[Q[#27QVZCX3V?DVG$PZ*,2#0KY^*IC$;U?V6YLB#3G@%D0B$3,5
MY (?$5:/,?O(6/L)W7315"^\P]X]=9V\7E(I0C/H1UGN-"PWV)R/<\,5=T,+
M).GI7F*/XJL:D*75_IE\RPW<7(=HP$R2_R]>$.*[4[Y /WH*\16.] \A+44_
M6&5-E#C:MUJ<E(!.:T=E9L6V3+@!0:EJ!I[PM;+O=DC=CZ@M*!1J)X&)(^*4
M$:F=IBH5@4H3P*K(#4.@4F:$3R:.B#LZ1PS2TU"BJ%'8H/":F+#KM;6^"=%A
M3!9)"M$XA2=GF<Q\5E%ZH@7[&17WK4VLDR#^$"5!BB\ ,Q6.1?V"\?RZXC0"
M^);19/M*JN<@?&_@_C#9W19%#![ZIC>G#<2B%@AR8J%VO+0;F/09UN*"7PA9
M!3JFG_>=-#"UO=Y)[FI64RF9[KB*0+W!:4FB<WREE@S-N[VW49RAI&HS34Z4
M#VL:ZC/F P)K91OXFQ?''KZC-;XE&!W;'#+EV=0RLHR4V7NQF$LUDH5*@("0
M*YVRQ1Q/AHIB1"BB=#YG ]0IWAYWN[R9\/QZXV U+?2A18HAN!$V3Q:7,/'C
MX$ 9B_<_;PSL-2-D&K-3%IAK\FS Z7#W.F?1,-9F]8H@&[ZK9C!(24(VQMK1
M,8^AVSAX"D)OAW][OL=G>\0:5MI[QC!%,48J^5P&M@JY>6W53+0-*!OO,$';
ME\; A_1^T^<X.CX]DW807_/1[C7; SQ.YK(!R J<74"\QB?L8))^\5)XN^54
M[I<2804\NW;)'*!<"R*UT *P&IS"YBX&F# 4U!8S 8_0BU%'M@A!;'C+UY T
M%P,P(X"FL'P9)/XN2HXQ[-EIS7A8,SZ[%LCL^SUQ:DBL1!G?]:S$,U?>,YUH
M8B=:&S>,2)A'2-_%=JRGC6%DR.UJZQ.7 1+C%\RI<:[$B3V(X-[HQO/:%":J
MV19..0_*@YJ1T-0NU5%9U4!06XTW6<ACM$>NG$<ZL4!/J#8,*-Z;1T!Q U8V
M,A/Z=JU7C*&B:8<4C^;;UV^B\.D]OGLW'\/\)8X2@^N0BEPC0+D]IDGJA1M\
M0NX0!Z$?'-!0[=';X1D&>_!"3S\V<BB!4;19KJXC>;X.K[[[,$G(&"?;G\?8
M5]3_GH$-<;U&25U<OZIM@:MO9/*1;+QL XGT?#XKDS_3ON--M<O4!A2+1O\-
M,N&X8'@IWLRN-M5>Y[<B,K^KR5UJP@BM[TL3"Y!Z#JGJBW\*PF!_W),"Y!<1
M8F0QW/8),,LJ/=9)9=V212_UG2/[3$U6HAZO4&6*].^LG2P(=,*IW4< <BWY
MO06E'N/,HS8.A((^T3\W>'> <;:+B'I.V  5"0*=P4DBH;-@D%!->%]ORTT+
MO^([<RM&O2MZF6(]7#F1Y@894G9*#6E/J9 O]PIAE3-PO7U?[2(G:G'+?%6V
MS*5J*X8M4P:KL_1R0) ,DB2*7\DJ3&V8XS%7C0V-<@;AAS,*DH_S!#V<JHIO
M>0U 3>MYN#GW_?B(-S=E:T8"#8FT2,.](%E[A4^RG2WGR_JPJ]$EJ-%#I1</
M1DK- *D&N>YR9=9H5VGB2#$Z3S9%2JI'-7&X")<67I?+UJA_A??F1]2I(W.<
MJI)[6-VP0?&>DE,?8+R_W9)+K&32I?Z:+=Q8LTGB5-UR[3#'A358D]G;X@B)
MV=&@ H?[: Q@T9B_F%?:&J*IX2Z[DM_8.@:B(+679=KAFH!)7F#HA>E-\/=C
M@,:2K\4O!#XJZTW#?,(P2VIVX93:I<)#KDS8#)3RR]\9Y10U3C-H)9.ERV4I
M8E'C-XM;BH_M1WM<RPQE(.KJD-4,@PMD T#,XAE>]":CFKL8'KS7&S3VA''>
M6T+]IE_"@Q?(# $EA%E!2"*6RA036+K4;@^^^@OI 3NB"'AYWQW74CP2764W
MWFPG:+*@\#DL4P@RC>5X#H_M,J46#>TFBQ"-[<33QB[*DR$3/@L*!]K\-+O8
MX3KZ\\8FR(>=/EN>K!FSWU8<KE/A'A6.%IVGX^8=>^[9EO-TE44?/1]*;%^K
M/6X,-)4-4GN[SAB8P>*,'Y53X%TV+?GT%,,G3W!!9[1O@O4R5'P[XMY=RZGB
M&* ]=-#%$YL-6L&P@0R"F"R$"7[+XFF#5)";()--C:/I328(XGR9N-IU;P<G
M#'.38.8J28.]AU? M]B_%RS')KRT4HX'EWH4S*/E.O1CZ"60OU(K]ZXQ)#$,
MDCFE?49?2<2G6S/9,\-KA5-Z3J#V(8KCZ%L0/B7E8+%<'[2I%5;TL1D5,-JN
MVT,V/8AE4P\O8#80476NN+#T$F;_"N8#1X!!2F);)5,S:46?_VJ=NJ]H"KPK
MM!BZ3F6R,!# EFYV*(JWA<$F$/=G.P_)/=&T"\[D_IA-M:]".F,Z JR <]LJ
MJ3Q>B,$YTU';NF2TD.HD<<B*J-Y$7MA?/L,D;8UTL]//N$/8@W&,OFY>&3/[
MU&1H P[3?O !G2UU>9]=\QI\1\[ZT?& "-N&:BERU"7&S=1(F>?FFR"$URG<
MBQU\KYXVQKJE"1*IAO0PCL!C:8"(L^(@_%#GZ*?A>YPS@ZA.PK'ATXR&>:Q\
M\M)C'*2O]=O3N9^S\8(QQ-2MD,HK^@[$&2@$,J^UUPV;$1YVFF(\^SX#^\+%
MS50N2C>[8SXC=?6QUT<S!$%#&9LC.E$Q3Q.?O3V\C/9>(+9N7WO<&$54-DA-
MR+,&+E@<^)H)M*)='>P?K6$5\,\,<KJ)Q\9-*R+F47/GO>)_\%YHL;YHXP5C
MR*E;(<7*+.SD LG>?BNJSXSPD-KL;/&MB##T7_%:]R$3;F0?OW@>LF'4"8[R
M#;75B#'"1Y"B^-)[_37:H;_]!H.G9S2F/$=="?1G<E:\]45'BS.ZJ5;.5IG=
MX(QMM;/:7 O)3JP4=8]>P0M1"[[E>H&7*<XJ$IC<8SMIC*ACYKI&0%2B<< K
MR)2"0BO(U6;E*4SOLYTT2ME&'D;B_/KI_,Z.S;3#B(2^G79 /"<E1D6$^!:(
M4%':LHY3-@GP3=">LHCTT]V;(3EE,:&0VZ^_G=]9<O!2C@/ZN4PIATTR2H*(
M;3>!G_<[Q3KPK7?,C96:ADBM%;$."!0RBW&3%2.F47ZV]P6'&XLW(#'RD3-@
MHL3&/*RJ>U@(V"6W)[#?-@8UIDDRR<@H03 #M6MKB/C9U)L2) &HRGOZ[)^L
M]V:0V9O2;(SRPZ>\(]]0EY=8(7M+\1_@GGD5O8P$H]WW7O.D^F1GC*H%E999
MO:!1=JRDT&2PRZXZ"M3>>A.;&F,@T4]7'0CZ0:*8XZW^CKHPQNE]=+&03<A,
M-0/R&6N)STQYV1(^ZEHFDWNKN0 5U1')F>S73D*C7>_C'UV.#V*>T=[G.Z_S
M/9K'< -CLM?ZTJ[:X"(([J,<1JS,CUH>O,>=V @E>]+8:(2HEUH[S*L4W?O/
M<'/<D6FGYO4<-= EX"M18,5.@R&NNFI<-3/.:"0A>TQ1Q<4"W*#(BGU,_* Y
MU"#M4IG$*@B !5F!#7F'JO, WE.,>WJXB V90K(( ;5TX@"@<%Y1+_4++/9.
ML O%\)\UT >E&B*:$FMGO3RMU^RKI$U>)X;7NU3AE&/"J=Z>HPK/JCFTN/+,
M<.$;(0S5NX7L0)AIS;+C?=>H:XKH)?!3N,'WV3!)F/&XUI:-;H-$<[!RR@TI
M^7G/  ^R"FGD-B93K9P2Y]RV<W'E'"E'B9>"R _P[\?@Q=LQEKOTM8+\-&RV
MA9P0*6D1\2S09? 2;&"X.4^2R _P>:O?@O2Y=G<U*;)['FYJ-ZW\YL6Q%Z;7
M27+$M3ZI3*A*MO865Y'APJ4'5\Y9=3\<5@XVN7;@E>K!-Z0_K^F,#2B*.6?Y
M7;_FZ5MF!@AR.W3O.#$3/J<6OD([J-0#K!]4!A0%P$E]R\8-4;D9H+##1"?"
M3 A=^0Q$E+("]W#WF@6S-Q=!&H$KQ,.[X#$./'.]&,6\5_5Z5'XYY0Q_&^)N
M665(;^YU7C#*Q6UKQ--[L9HOZ02+,A6?7:NEM4FZ'.DAE0.1AV0@44E5Z^!9
MYF!(Z@UNQ#AMK)]+QJ?DD9,=9,."()U!J'$R,WC**BU\A!L8>[OK$+$\?/"^
M7WW'Q=_A!QC";<#>6"?TLM:!E8A%XB.1M7-R4J O+TF1BP:9;("$@UPZ>)?+
M-U97: +GLY(4F42SPRN91&T.MH3#8A2!40R#IW @ ODOFT @UR*9>>_ENHW
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M_([7H=("DE(-6:Y BHQ3I[H@\*BTI@54:LAR%E)DQ:R,ND"X-?KI^_X6,9
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M"&-O=QYNSC?[( SPC4?XRAF\>RU,6/?+]KVE<T#*-T5B<'9RDN_PST4"+]R
MIE"02S6S^5BMJV[;5:_I*F2[JFTH*I:<C8&H0(PLQ!FWQKO8N_9@3K;6^1G^
M5Q!YAHN\3^&Y(!"-MF^#TE@"EZ9;P2C:? MVS*]>_%DGQG*=,K.+BV)V)7]7
M?\F,D=:3J=$/>7&3K-Q)9[N!B?(8(]U:==WZ=R\D1U"G=*J?S8:YX_;EF#8V
M:L&V03AUWTQR2E$6\O*(+[:X(XG6\SVHKQC@'IH=4KGB-/EH5M;(!)E(D,DT
MF_T*O&P@ B/< \CDXRXM"C9ENZELP HO'6GX84;'**;"S768HB\3/.[@>9+
M^N'"GENGY6280)V(83)]S*7;A"'I9%8J0*:C<=#6\%754X;"51D*[>B527PJ
MG(4C:BV^^P[-2PJQ#>%##I$OBN,"$GEM_"S]I-$00+GU>.8>L!\0/14+0FRM
M-T$(KU.XI]7N%'I-]V*1@$W"27>ZPE=-+QI)=TZ%X%<L'!#IFE>2U/OKV. O
M?YE)O=.N J>U+$=)0+5<G!(-U[14\H#/H\A]S>P5>RB$V"-\&F>Y/EF<B-$'
M$6P-<PQQ4X@U)G1S*&$,\56(+-B^&N:)!@X%.***D$)^R"Z89'7Z>4\:8H.6
M&<*E9%#*K!8M$M!U;6H?],?YY!CQ20CGXQPS/A,N )0V;FD>JX!K'"7)71SY
M$&Z2.XB^%4+*$[459SRI&ZYT,R2V(,W7^7U>1!0XY++PQ0^Y,+T'']5XY%0>
M%;) )<P 4I5XY59>1=LM)(L/E ]F#,-\])08YL1" 8;_[;A)HO"#]]I_C)GY
MJ&84L^R028]%7CT^DP60L.H$K%X$*_+&87EC<,.G(M?<0:[I@' ?> H,<P.A
M ,37^X/GI[?A@_<=,<5+D"#@?$16_A+&T(^>PN ?<(/^]@&&<!NDM-DZ60F:
M(2]IGLQY^%7.!)D*?#XO];[C=B+3 O#7!L>:'O+WQUR37JZ8-@Q.+0RW(4""
M0*D%8#6@KH?\O="DGUNF#84[/"-,<=% #B@H:D@\53!7B/LSP0O<0EAUR>#?
MC]XNC9YPUX=<[7+P@LWCZP%ET+.7X)Z<3[\,9Y0XW9PVPE:)DXKKHFQ#J0\@
MA;7^+R J<<E:HC2_2P>K!8^OH%1LYNH<C4%R&D'Z"&'5V;["^AXBTA4GY;KO
MD+X/KW>%ONS"%0,DJ"\ZKL(4,D:1"LBFY,NQH5=)GK1DO8N2]%,4PM=/7OP[
M3$G:\E)(6(8IFA0U4"JQST2Y\8 T@?=@CY6!/=&6I;DA/IPH&DT2!$A+;2((
M$#W@(0)8$R"J0*8KN\7 ( -.% ]!VF-FAW&JDZ6&#K])!=;$!C)D:;2'N! )
M[J]>1,CJ\!B$3[?H0Q%223[ ;13#[#G4AX7))?HA20._E5 J)&K<6C;"3.']
M#\OY_&1>L@)ZNZC90P9!E4Y0*44C(:P5Y,\3O3-0:#:S[TQ?J AA_/+3/;59
MT+753 $DZOO.QD;OC;#"U?<T]J)X$X1>_$KVO7Q&H49OHK C^YZN0Y1GR"MU
M.2:LT6Y6$75#"DJ."M9IV@$*0Z8AH2CU=HI):*+(KLMR9'G4@BQJ*=;YQHA+
M%K4CB4WJB[P1XON(_C-X:@^^% BTF[9R*Z6PLU#!2KGB-],5&A8HTA-"X$#C
MHC?8'VIA8B1KU"-HCA3N4R\EJX\]Q^583VN'<\<$B10\6;@-K):RC)]T4^.;
M.\ WO7ACIEL73/1@6("4&ZP)09ISU3'O#7.(J9LAD5F+Y9J!FD*@T7N/U3E)
MAX^ DX8P1$M$#HXZD;$(2Y?1W@OXO4W6.^;QE!DBE6PGO8C*A-J%J4&.]J&*
MXZAA7#634@!9M?B8PQ;J7)X?T^<H#M+7WB:J\[!V-+4MD.KR-(=>>/=1*<N"
M-FFD:^X U_0BAI5J7:A00V$'1@2:'LKC1G$R@(=/>4BQH*T9[1X'+=:T,.RT
MXR/&EG9%N+@.[PT3R!E1+09S\4D'/!85R5'G9!M"UI6_$4A$*I L*FU#L:FO
MD WW%;-HDB_+LIP[JR473L8+TBCTLX4H&Q;2^*G7 Y\QQT45XR>O&)MO/N_[
ME*VG3:"F:8(,-2_G'< 499#?Y>)^- R54<[548*/37!*CNM:D1_K$EE-?\"Z
M:NOH-M12[\$/%?^42!B%/K\41._C)L _L+X 'MNLG3;Z9R OG6"\A()B/^UL
M+CD%%83\-X25&'H)O(39O]?AN>]'QS!-\FN^V1^RYSV]Z.$;(T/*-1@18>!=
M(?9'? :ED QRT<9PI-1C JC2M0/;-8V@$LO+%KH$HF(-S.(CW-P$WF.P"](
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MEV6'^/UY:!AZDJ$7R0+O,FD_@DS>#"")T]Y(RH*P(L\<<YYQP:S(/7>P>SI
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M+QKX(ML<B+Y:V7+C#='X(##&77OH)>3D!HY*#/THWN#_2,&VW.YA"0XY:<S
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M#L>4_0PL^QXBHS>$'V"[PIC8.Q; MF&01)ZLY\LFAIMY#S*Y(!=L'-%CW.3
M6X>;TF@?X^L?H<EG8I-'%-V@3< :5]LM]/%I7\&VO?F\8;9H&".>5HY[MF*U
M]K 0:4&[/\8]!D.4(BWI"HQQD4$,S2]H"P-0<<9"?S<J4R#_^R&("=(81])[
M7C"-_88UPJFS1(T*<U(2EC(-'%17ZB +_I6#9@ZN*W6210#-KV@- U#QQJ2
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M%I^^$559V0-RT4)05(DL:=Y,)W_*6#19IHQ%I@H/T_-+)\J*F3;-4DP9F*S
M;A G*?AT_]<J-*8;]D$LT&[NY0.GD,?"S46T0UY&<7/S=G(3A/ ZA9VBUY(O
M&V*L?LN$V\:UXSKKUI !(;$AOP(BZ@U@%8#H,#,)JMQWQQ[?A9A(>0!<90'0
M24[BT&XSDF  ==#00\\,:,^+MM'/@\P]<NOEZ;R]HX*??42\9:PSQ&4)QIG0
MY7%D,\1O":)A^VT%QSSPICT%8F9PGH,4LN0/MK-'],]D$+TRA0U.6LL(1(#1
M>8HA+C1@L86F:P1ULX0R"5'YJ:Z9K$T(XL*QE.N.>QXVTQQ2+)$Z:MOJ?==G
M=W$RD$N$C4P&C'>L <[Z[#PI#*S_SF>ESF5;#VA?R_SYYSX\M9HL5C"48#OT
MHUUXY\6_BTP;,A_6CFV6)>+W*SAG3GDDD4A#R1'_;FZ&3Y%'3MTC+,Z2>3I%
M[KD#W=,#[#XP5<#FAL-,_S.$M]N+&&Z"]*/GXSU4K^55VUX*+X]Q$#[=P3B(
MVNW^(!%:^Z_B=DET#E=5$QIFMRD2#:!0@;>=%=?)XT,LF1J0Z3'5#9XL$FX]
M$C[1,*LNEX\-+82/R>YFOUHR<*8AW+-"WGG0$!REEXJ7RR45=*:7P4>ZY$JZ
M9 (WO*5OJOMF,/#W8Y#M#_[@)4%RNSWW?;RI#<&S]T8;H7>U(D7 (!F>7I:S
MFZ5@0"3CM*MD@Z_FK[N9P'6W<IUQ88,^6$ED:1-IHF%1,CC,0\6H@$E_1OM0
ML&6 <%*LEFO7*4: N9"IRU>RAW_CO'"T>M$SU!OGBBOCBIYA'0,&U6B.YK%*
M -YP]T-T'C(%P1OY)>[3Y;R+P1MCFQA&.M*&X=2.B %QJ#=M)/9XHQ6+'41T
MP'BC?KM +IF]+:#Q@"D42J_]5J79RD]M9"U_A/UMX)E;F!_A1!MOIE?9:>G>
M@9GI5?,T>"*(N,!WJ7X/V&OGG0>U#N3:VB6&+NOJ.%XA!1<UQJ76D2!CX[.1
M'KER'ND;F;$2JCD,HWIO'@$/2-UEM/>"=@O1^[@Q-%0VB&?0PIDO&)C(1%F!
MBL&>T;'!\<P,.KK)QL9(*Q9FD?(%)C!^@7WWMC$>-X*4I@U27)L7CKE*TF#O
MI7 #:IE5E%)_G?A:-W'@C'*T#9P$INDN6QPV>%A;- 'IZ*$$Q"QZ[LN@9L?%
MS[]Y^%ZBC\C7V_09QG=>S+D;6$Z*$:P)F29%Z<M.8U7IF!6%%'(U "<-((H
MT60:D5.$@P/4&/HP>*$7N=2/5*EDIP-8/'Y6XOHA&H_JA@R;,%TW3"J%5S*(
M3J,W@.<1H7"KZ^LJ(!O>)ST@JZ7@VPF7DAE&EE+F]5C<%[3/0/*L$<VIU7PQ
M=\H*;Q1XY>B:37>S$WN*4J&#;/XHZ,/4S54*G23,@#<L@\=74JO-C_8'+WP%
M6>FV( 9!F!QC<I[<]^(X0):9F_ 405\U =H;IHD8H3B<'6TOHOT>_05?CDZ.
M;=.7!^4D6, 9'/-$T^_T='EZNN:0R*RJ8X!W7!$]@"B:974.ICFH),,LZL+
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M-0Z]Q?)<D,U5UHR$$!@&&>9!C1VF]$ -\\/<:,$S.')K+;^!RK*W$R"N,T\
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M<+H3[VCJ"IAN"Z7;6![6B7<)<A+;@[JJY6",N]J)FXN,M!.7X=S%3EP!!\,
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M@U^C,*^C(K_YJO=QVWB3V*#3Y+++FWF3*PN#N>/)L&\E. '>WZ3:QAI0:0N
MJ;2]TCMVY^6R1R$2;XD=&L7R5]E=++Q-U'(CN*QYO%<S&*_Z4][QKC$0BVPV
M@AJ&JV"FDG^V^0W1N=WXP>8J_)\@)/\E7PPG;0FEY$&+'5I3NSK=+[QSL8>3
M2GD7A.^H')0)@NG%1CM4O9LPZ'#&5A_6WI3*O5>+XP;ZK1L_90M[X8;_[7*_
MWP5K,?6<J-TV/%R.Y1YOD)%:["HV60I%;"L+_SLJZ4),67;[<'8)\=3+2VT=
MIHV@S%P-2F=_:R,R7CDR?D=DH#KI4021]>##(PG3O;_2K5C47#;=[^_Z-CAU
MO6&UPV\U0Z>C7.6 Y>)8N\P$@L\1F7/2&^JDO>2@MR%6LX3NR !AB?;(GZ/X
M-S_T']@:]6?<-@W4]K1=#,E,T&A:R]5ICA]VU35=&2B$(2(-##D&7&.H^<?!
MCXF^W2N]"S%S;"MWS"):NII:#2FMD0!$24(,^H(?_-TM3M,=EMV1I_*&?;3(
MS-!H5O/LELF\9BJ%#!.(2A)!46/ 1:_AXHZYF'2[:!D_78U0@J'6N)@8G.:%
M6*["=4P+.%Z%^=4T],:IY/+9#W:TTR-6\-J.=(+()[Y^#S<X9O?7O*=7NUZR
M<\:R)-^X#MN#6M,.J+;J\]5R/A>560HC4&8%K<I7NM^)68)R4Q"Q):NRFEF#
MF#GB*BAF$.(6V1T/ \=S=J3Q[!Y* P?5JP4UR((:A"@L[N7C0?7SH%*.WO*@
M!EE0#RRH"0LJOS7:;PVJE0'Z5"29#]XG^79&NX?K[>?#;O?Z,=@=4KQA1GWP
M]T'J=[?%CM? 2+S=)O6M2Z>SI=?@94(:3#(2HCF%("$<B&*->5MG30!O%0G0
MF,MU3B,$MF4N;X3+C,[0NMUEN_34#](FX_0$RQ*)T,J LII\ZN\Z2"?,,(U[
M;+WY18-3NIL<JT&YL5O9="K/Z_P2=?(+*TD*4'%O*N][J68=/3U%(<^*7&::
M"I)UZ*:(FF'.^<V/_\3IY3..R3]OXF"-LZRJY_MVO C(-NU6*6?L%ZNS\V;Z
M0IK<$Y--TG,F'.VI]")MA^,98SY+2(;+1D(XNLE\YO)A&<:8WQ)Z$=^:?6,7
M"*4?IC(VZ8F082K)"QA?'](D]<--$#YHC(5Z7P>DE3[;-/JSI;>2D4M1+SLJ
M5/2GT%8(QK#WDK%244*]I,*E,9/A$$@89V #L$U$JB"7T9%2$ V3TC>\.:QY
MH<!O0?+G-[QFYR77]25@]?< ::C5*/6A^]E\V9PS)\TOSD33*<F8""<_R:3#
MI3:F')903BZ:3FQ3X:B0#LLUIIR6D$S75W:!77K1*J.5[GB!K*>3[_/5?\*7
M+T'K GKY$9LKYB6].ON5SD2E./H^H@+0#RH":A/6<"\\52^LK7M+&DMEH;ON
M*V2+_A@]^4&]FVIY"*!5<\T:+6)Q/FNT:RX$N&4/\J3>MCL\L=VZJPU'UKY+
M'H.T<"(+DWYCPY8+/T0A&34GI%-A%87:/E;G.S;;?Y<A.MN$EMGP+!/(E^]9
MD2LA$S&A0.@PZ">_I9")2 .ZVM[P>5WX?-_FLS4<J33/"JQZ0P6/LAL_OHY9
M[:C-[_[N0*_"8N-!I:_?^C(8[MHLTMGANCAM 2 1CJ*8%Y#;(":?WC?')TE<
M0*,A[_MAN2>1>*8:)O&:Z+V/ /R>>=7/GM2<1;]\O_U(+]/C<T*_ND-&?2AN
M9Z7.T,'3D]A==$@?HSCX=V,)7O$E,#JJ6Z+5(+T6&LHV_N527:">D9[*D9?M
MQNOT% 9Q;0VS'6G2"+F",':H7@==X@5@9'$K--K:Q6+9C2HNT1U$#?*P$TU!
MJX>02*HVP#X4E:+B"H)*"RH:G[?\%C"62J9H-+=5/BO9 JB26'=0-=S73FA%
MW;Y"XDO2//M 5@\2/-)8AJKTF?F38(ABZK52H+9NB4DZ<:A;&N*:'#3_U^E?
M3D]/9\7XZK_1XH3\A/Z_F?K]-PJC:A?&SFL[";E*.VV'61%*4&A]#X,T*=U'
MT]<,&L]#P*QNA'J+7,YFYW6P,6F5FRB!H3;2/6^(>]:QTM;PI(B11L3$3I48
M/^'X <>W=-$Z2%\?H]V&?*?6XGT]+]C>F])IC<XF[X6X@HU(?/<;$XEJ,BUO
M0C'IV:S;,\"2?D;=]$:X:66CB1+8\ATF_:$!ZCCW?K 1Y4,OPPV_%B!)<-IS
M<87*FW8[TSYS=!*]?!V?B\W*W;(T35QKP40#WV1AWFNO[+6HBLNK";'BFHAO
MADJ1SW0 =[VJ3;?6"2N%S$QW_!Q$A^1;].KOTM?K^UWPP/J^8KN9G$1[W[+?
M,?>9I'Y&8G:QF.6],Q.+A%Q4"$:%9-L=M6%/9\">]G78AMUE_)%Y&?LI1FF$
M[C'"N^ I".G2'&!_K8K&4J>M%)X)N"+\BM-;?X<3V3R1P@O #%&U1F.G\>+,
MJY%#+!H3@4J(4Y10J7R.Q7H.;\[%%E8($1&*F%0^6P9/":/<]"IN^F%X\'>E
MKT@+DL0EKG"%&N3@:V,%282,$$+P3$)RL_/7O*!;$"?IAUV4!.%#QWB^]R7K
MQ-!GD4Z=B%D^KF=2T3X3B[94+EISP;:)P;"+L[*+N5C$Y"(A&'24;]A?;ZR_
M=CA"%8\%3RC%:0*NN,7$F8TN6<C> F8+B4E:;6O11A<)$^P&7XQWLH4PN& '
M&6.\QRV4H>$Q!&=TX+*---I"98XU;C]]^7)YV\<2E:=@6*%L@LY<\O*TR@)<
M#@3D1W@P:WH #^@1_GB:_EB$JPP0-7@V'(>9NX_6&&^2S\2!T@[WC_B^?<Z^
M_0VK<_6M9NBL#9^?9:C@XA#]DJB\UY]*A)J8-^4B PK?,B-.$''?B E/*(SX
M!%N,=^P<Q]Z/TU>X<PS&/BN_V8A5S"E_V[QJ:;2MQ&+3\IWM+47T(K&Z!-$=
M*&@RR<J=7F\_L$)H;(./PD>7OP=$+%)C--KAZ6PIHY>K4A/D@OGN-GB:,>&P
M$NY@:^-I-]@VY+7'RQW\?8G"ASM"](I]>LN+X @L6Z/1(L^6%WT0I)+?L:[0
MC;[>B,\**-SE?KO4]W4WW'X@-F)F9)3+-6U+FB*F*16:_' CKN-,2-"EHQU-
M$=;'QWKVZ5SJ-LO7ZM6:(MLJ\E/H.J%K/;8GUR:-186.*FPDR"CG(AJ'3 ]=
MU8,8I$\:"J^[630: ]RH?A@!%$/^ 6%T)X6H'9%F_Z+5K-@_+PO+M3HW9:'@
MJ8>JI3HCU-6\+RUIEEO(%6<_*?.#2WG+1 %KU&'85X_0E*D"[8FOC_0^$[""
MN68QU9_Y:$7=)7*IKE9HMK3:RPZ01=4BK3:^Z">%VG*56[ ?Y3J#]^7#0XP?
MJ(L/<90DM>'+OKX(ZR*NY<U9!;^2\$'C]$L0XN1Z^X'02J "S>KS0&BL&*'1
M"A?%(EFYU3%Q;+*."82'W!C_&,JH #81U^H0!(BD;:T--\T8&!SH4P6_!3M,
MTHH0LWNZLKL=.\9('2\!#>;;+5)M-(N+<V^^K W?J5B4RQ7WZ&6204;JQAR=
M 3NJ-!@WYJUD^/V4R84>:O=#L#ZX[@D+4$\J"D%_XZNK5T][/XB94=?QAT<_
M?FC<:J/WKMT>MM\@G<6B\_S<>288"<FH))J6&!3"P7I>XW[S%?E<#EJW.VBQ
M)U9OJ[5>63$^9GKH?^)U6KFD/"$XIW=MRBFS_7'[O7*K+1H[G^9G%WE_3.75
M[ILG0R8NTOJ<N2GG9F7G"H&(2D1")$CG:\I!K^/K 7:[O;@J=;C=H3"!<S%]
M=_D08Z:C?7-IRY.VT2TW0_GHX]GY;'4N@)U-7>:RIMVFV8II(R[-(%SJAK(1
MO[P!?EE!<C=R<A!W!,$ ?O]Q\'?!-L";Z^T6QT'XT%Y0J?=QRTCNLD7KB(%8
M]L[EH4@(1)M"HMUNVJ!OLZIOF4"XHE&&_?/ZOQT4Q%7 E>&\-R(FP7YSN-\%
MZTQ3:Y?=_3P4W&7&J/<)L]ER6<<[EUA  Z07-^G?#- _-=P;<-(;[J15\'>!
MK8'^UK@8@7]PYS]UH+WT:^O@+G2KC](N5J=G&98#1 1 (7>P\3-KQO? <K '
MGJH'=C#7;.$%Q&H^0DPT?R,A[;K;K_B]Q0GC7*GZY.AYOC&*O0QZH]]0\ST5
M\VW-ZC8:1GGFMNHA6+N5]ARR)VRW7;WT83Y?7IPN*ZT7]-Z^X2YX:BY8;<--
M\FWS$Z0=XS4.GND$Z!U1U7DEI?11FRU;HE^#X;RYV"-3R(%NY^,=\C0<LM;J
M.YI4I?FWN0^$ ^)9L M80GZ]_1[&Y"</(:U8?^>_O,<AW@9I\NEEO3O0&O67
M3]$A3),;'*?$;/*#N^C3B_\4A.SQ;S@]Q&'R+=KM/D?Q3S]NNY%G<K5V\3FI
M+SI]03;DK]I$=XZ5K2(I^@O*[#I!N65(F(8*V^A!\\PZ]IJP#_V@%B)A(AR1
MN!1YSY7(6V0\*^118\_IOSD,$[.]&#>TFD-//M)XT"K;U;5KH&0UN\CXB6\;
M8F+ TY&1'GEZ'ME#9UN#JN))ZCTT NYB/TQ\MDFI:Y:DXPT@3-3,T&E*GB<#
M1TD@[.R*,2<E>%%S$@(Y+0VQ#4*RR#B$)>6.I?D./)[TR=E;]"+*F:YGK*-]
MJ'*L1VIME K(<K.?2B[ODS0F?]?[V,5K\ C+;=&8CIF?]X&,#%DRN6[A;*B[
MW5#K<Q<8;8UFJ@"X:J!<PMS[U_)O]%-%F0 '<-BT2JLWD(^RW$L>Q_LI&WNY
MFC]V-%85#+;$RB4T?@P26EW[$.,[_)*^W[67$-21X  >)69I]!EGI^>]762A
M ?V@.A!3XAA<QX>AI^MT$;4=C5H%MFTQ@\'M7IRPI 405:H'=[UA%9>M9NAT
M&&<Y#C-QO*2G"]6#S;DH,+;!3_ML#8(5YDH?X^CP\(C6?O*(A#*SOJZXKR$K
M"+*QXRV].X55%0_7P=[?H>++AD[5"U; 7I5.N@,$31]?H[3M'&?OXT#$4;9!
MI]OR3F6LP:3!'&\T[)Q7!9#/5LP0O3#3%;S(&EL;6!J!@$8*N_P7;Q0[V?+3
M0#@IF:##Q?,S&4R$,$<ZUN&N\5IVO.<,-G1Q/O'3(-F^\KXUSKM;5S C:79M
MD*E'!0@Q]0..'R@/X9C=;_#5?^K;I:?ZOEU4J1FEU1C%[$Y9$J*BP!<SIG'6
MTW?6(M[T&FT-@1KQ@L%D@DDT'B]#P@W/>!?MJ9&7M"KE@[ W9-/"=]$-CK=1
M_/0YBMG5VLG[5[JYL7,^UH1LJU@V8+#.R81Y/HO+%;-JJ275J*3[!&7::<\D
M]+.K5KD%)XA: #P%;#]^GK7XV6,<@Y"LLI&ISW-D3*6P_]^$[.-@JD$;\L_.
M5N:9"CB5L1]!XUSE1'YD$):&V,J)0Q<RZS^]['&8M$^F=;T#SB["$(TVO\A*
MDK2V>2'3)0H8YF83VIM")-3-?4:_8Z>'"+=_2%@FJD&NGV'*X7&..;J/Y2J\
MZ0J+Z)Z!)6W04^,2H-(*TWFM32U. *[C;+!BA)P#WTVT"]:O0[Z[>-,5\'%S
MM)KAF1KX3A"7C7Z(/QW8YV(Z$-U9O) ,O,U%N14K [,4*G> >16R0N.)W@QD
M\18X('-3M-K@O >,08B$6)<P-]17AK?/?A"C9W]W8'=D)(\^,9S=2X<WU%W\
MLGYDM3'H&#D^FKZRT7[[X5B-HH%*89F:SX>0'J;]$"72&S6DCUFN'":S0:/.
M\YDGJ@'FP-ER06A-)=FM^FG ERH)"$&(2;)?5LR /U[[MX$J,M8%CJS86*OG
M0/TD@0^;'[O<_/.0I*UUNE7>L-L_MIFATU\4&[ER<:B0!S\V-.2C-]!'B]U=
M7S.L=76=@8%"4ARL4[RA6X)()TS_^/2O0T"R$+JGYC+]X,?Q*T'\[S0MZ?CD
M.E(L(T[#-*T66LS5"!6([:NB"1G[2TG-"?IPB..I9DF5,#E=%+Q:%.B^;,#9
MX"F_M\Q5]L'97W"A!YJ7!H"ZSE6Z8323IG>JI0,DIK XC"+/TK2EV$_R=4U4
MOF+M_'QUX>5C@-Z6>H*VQ;!SDZNS/E"8.!Y2JKZ44#5BHW"FK'28#62L,7%(
MI&0&S&$C6: T7!D4/-@<C%V8W;M\+GL8)*,J6Z"SH>WBM(%&)HI>N/<]#. 7
MS,?[)_;Z/M%W>0$]-]:..QJ:O/MOQ, !A/2.])O/PN%#?^1[=M8"#_AQ_5B_
M&"R^A\]$%/$J+AQ,F(,^+5R8.#.V;VUR'5 Q>\%%33@EQZ3UNHN.A\&RV[HE
MJNUE>;Z:S\X;22S' 9,'<S.&,<_D"+?@F6+..=*]>FJIZI[=]+(-5,TL4AH.
M![I"9M*WV^\Z76+M';BNL6J(SC;CY:(30+\0H<FO;O67HYRMPXEWEP<JTJ%.
M4MX8.SI+24PFZC3_"-+'N^")W\Y.AH-B,[5/7&0_^A"%FX"5.='J7K7%.M 1
MZ]JLL;XYFR\:77:IJ:*?1#5*B>YW]U03FX[:%^K%3]>Y 5!S4-:"U45B5#6B
MNA'3Q.:J2NK%3PL#'$L;)HX<9T1"\[Q144WOWN>-JJ3L73U.+J4=0VFI*T$9
M%'@;M&N"8YTGU%'-NCEKW\6>SO+DR!CHD.)QT-_(@$BXKN&^LZPVFL(,\)6I
MH1>]>0-O/ODQO7\CN5P3KCBP8GD?\398!^UE<7I?M#H(Z[-&?7!R<;K,#[]Q
MJ2@3BWXI"49"\J]00S'#+C-$EOW;<#&P@S'5YED=D2F%Q@6\]<QQ2!\&Q)7V
M0']YT8HEZ)D, YYY4L]< DS7M$5K $PDSM&KOTM?K\.O.+WU=SB1;;7K>-!V
M"BRU0GGKP>)BF<\2<$FTP&6(4Y1087P?BN6$UH1'L[)'UR$BLA 3QK>2 &2E
M)KSB'5T8'OQ=Z1NQ\R?"U9AT%6#)9R=R\@RS/1#FT/N-A(&,M-<4. \=X*T]
M!X/=JA&J3>)\=3;WSJO0I9)0(0H"MJ.<F=EV1@6RHSSRRAXY $XY,&K8E'AL
M )JW_OW]:UZ3KG722?J896#*;%">)5@0->+0%Y.#<D%V^U$#3LPD3@#.[!CP
MR-/UR 8VNY"10;/5=XBQ(.VWK[=LAHC6D[S>JMX%I_"BQ3%BOS4:HZKS\WF&
MEQT[,"QVB8%6'#/NH:?GH:W!HWJ#+ \D%:,#C+";.%C3[OB6'D#O_\[5QV'0
M5+%!8S)O-I]),'2"F#R:"R(F$1Q+8_SC8[@'PN3T-@L4A&D<A$FPYD/M!$6'
M-$E]?@Z9+I[B%Y*)!0FM.R_6GR)^_\8'?[<6\YU\!8K\+'W$B&Z@IR_O6=!(
M$.D/Z>9G/WS]KP2MHZ<G\J38XIF@&.^C."U>_WIY^_'R'T3Z/DC),/,W/_X3
M@\ZD]D&A!='-;P2"8Y)$^W$0?8YBO/:3[F/1+0_;Q+#4 HT^XN)4G";())V@
M3!;PM*D1U[P!KEG#26=3JZ"D/120&+F)\7,0'9+=ZS?!24IH:7T- #=MMNCT
M$7D>F3>S0BK*Q#H")D/^>N/\M8VPOH8JPUIGI"!1]SU,]G@=; .\Z1ZZM3X/
M@+.&$1H\OLHG-O(&5Q('/6 SY* WS$';2&IM?#((R6,"@YU'O#G05/-RO8X/
M>/,E\.^#79 &.+FCF7K?/:4: JRB2]4J+7[/X<:ETR&)D(]*"M /I@*^>N-D
M4?#:HI#5;V3C/59./*M/4@X0+%YU&WP5P%H1!49TF :;8'=(@V?,;K!B9GYZ
M6>\.&[SY3,)"Q]('OG9PO<TV(60CS;N.FPL-*X%A!@.6:^#F;'XJ88^2#:@P
M F56(-IX4<D.^E*^>R>?1A*, T\S]D/:I*+I0PK 50:AW,)GIC[=<7.>>K9C
M2M%1<M^ R\TOLCO>IP.K4QD73(0Y'1Z>GOSXE<;J)DI)\A7XN]TK^B@)]'5I
MCKXSZ.QE\KL_</#P2/]R^8QC_P'S#U 1]#8H4S$--/F98:GS_2$)0IPDE^M_
M'8*$GXQX_UKZ%[TRB!C/+P]*@@WY_O3'ZIPY7@,(68XV6V?&([LDN,R2F0&H
M; &B&S^*?_-+K[@5J&*&@^1H.Z(-5A3WBO+E6#?XRAC\Y$1E)N2.,Y3:D%51
MC)M<HS]&DDQ:20GEI,8HK@PJ)PE)8]@X.B0.,H;"L$\CN+#8IVE4%&)V'?M5
MN(Z>R)#S14PWOL<AW@:IYGRUOD001M V4V?$X,V:Y% HI/_B*A'1F5\1]HM0
M^ZN#F<74T:IG$M5@?<:TV]RQV>];6I-=$CXWN&,PG.0T,BSL)K;B2TWXBM./
M>(OC&&^('9=)@M/NU:Q1HFQOZ1]HI_)YCW/O-+OK)>>%ZTI3)_^BQ] RA:QY
M<Y6(,\*/J2E!QIT6@S-S.CC=1P_L1*B;*%L"!'9L822+Y$<;QL36$ANJ+O"/
ME^<@+XY> #]?G,_F*VUR+.\.. *&-!4F79H$"--HKC05*TW"!-Y.88QM=*C3
MY<T6'_&][@!4\@K("+-IA\[TZJ(.<[I81"0Z.#@<[6ACUH@YRNYEBL)G'*<!
M]9C^T(U17GNCE _C6@($BZQ/VRU>T_6U?&!)3W5_PS02A W\?)9*'7D#1((@
M4]].G6G0<\F&I%QC>>:"U2^H:G40W9,'2U0:JH2!+B;%T7.0T'_0\B5%V,0N
MR.+7?"68'G)[19?[_8[><L4.JF731G3*Z$#P)"I&I!'K]K]$28+>8R(<5Z2[
M03'#T2FGH(%?$9BBGO:[Z!7C6QP_!VO,EO9%C<'BII;+';.%[0.@_CR$P;\Q
MK:(:1!MV[:G:ZI5)73"D9LX!#0#/5Y+M1YDI2-C"-[.(,JAE<TY081!]L3 )
M<9OXQ<&N+)G!A;B1(=D,,0#[F0=^"RT:_J)O@B_5\SW#^HZ9-X<,?:29XC3
M=BJC!(UX<V<[UY15KI:$VJTUQHE0/BE!NI14QG$4?XCB&+,R+@DMN4\,C;FY
MQ4W?WXKKOQ4SR*&"86AOH+5:@SO)'BFF%Y44B]$<49WQ5NG:^))V9Y) .X%K
M9GQ3! Z O4;"KX6FQGR4X^ CG;Q,7Z33'#2PKY=L^=8"D9.YT]0AJZ^7E<.1
M1N2?_'('?X=N_&#S+@BS0E#'12_*^<^P>,-22GY;-M\406PN+?']AGUZ??;F
M.OQ&#];$0?A $KI MRR!"1T@I&/ <*W)FXLF"Q4WUI]D6Y@H#967Z3-#:-&U
MW!3$;'&0E>S'5%S8G1_-J1X]J9[4.6DL(YX4\?53]"E)@R<V "P^C"3N;A"<
M06S+&<_4MX2EP+]%T>9GL-NI$UKS#1!Z:IBATW]?2/:=9P(=I(VQOG(2>"2/
M$L9DF4@<L]6_RZ?H0$BAY+T;X&UME7(HRN,#"RR^?LC73?.UQ(_D#T*B:T(6
MM&1@\*"[<V"85!" #C)5JV$OFB 6"]3W]>7J$Y1I9AF$T.T@U&U$K3%EXO82
M_R@DR0EC>)1A2>4KS<^2%#<N/V77"U[2C0M!^JK)*8.$@E#*$$MU\N69)"W(
M=58NW^5K'_SNSDRO@VQB(6#9)9Y%&.@VI.)6S_>1^]<8FP6:G'(&?PI'&$=V
MG^E8PM&0"<LWZH9JH,>;2[8$%733<E/P,;#-9.'J(YOK</=:)AMG:44?33VL
MHAER6%(IUKZO-K0\%"U$*V91Z,G_F-WO7II-(;\[/-$C&%HT8T8+"/$8,5VG
M(_<D:T"EC3*%%=D\;&9'8T)6F.(@/4$$E1'6743O_ZC-O!9[0=R@)J.8E).5
MN0\ 2U\MFWOBF$ZPL46N]Z_%,S?^*_W9Y4\_WJAMD!DK'X2R1AJM@:O%7+)4
MU+;[#Y4MH"<?R@\**Q SPY5],W8#V9@+FC:0]GG-$%CEC&;B6[G(92R'O-[S
ME?QA@[S!@AUBKWYK==*!O !WZT9E/LX3"D]<'NI9BA=GIU)4\IBX3"[JZ-%A
M%<7@ND(G9;(KFTZ7S#E+TNR._VPPM8Q0 DPSPRW7@I!D6-?:;S?X)[<%E8QQ
MFHRL197?/5F*"IV'$A3U-]+[DQ3IBOP6;USCJ?&P[..LD=\ F+^HP>]?/^S\
M1/$\;/,-&&:IFZ$S#EC(:()Q <GSF4AG!D<CW6P.=Y3=!$!M6V-L@: T-K!X
M^A[&^:3/G?\B:C$FWZ+=[G,4YP,A];Y?6R (&G6MU%D&*6ZU+%IQ61\KF9%I
M1%0E$CH=[+HG#E0#[MDFN#0J7>3<&CTW:& HAN0L,2CB1FL#_N'3^9&T.H;I
M8@'MU\$J__7;IMJ +R[F*_)GH]"?T%#,#3#Q0!7\C+O;*-@G=]>QXGS&P]"@
MK7H8X$ONJ8.X66%/,5Y3D$[[($2;@%1%09.1HIU:3=1K)R;YI($EP"I3UC1!
M::6OKJ XR673Q(?Q6OGL4!ZA! 5)Z7S1]X2=)MKYZS_?$=N(_4DVNT)7S^DO
M?XLV&.2T@@E>:>5$G;B;X$=:UVQS2?ADPQ;?Q;'O#;M + F>\9=@30MZ7#[$
MF*UG5:]G+[>@@9)LL^,P,Q7;^=GI?+6X.!7DR%0AH8OMD\FTH5P=$OI0KA#]
MX"HM$Z25N,R<C4LW.UH)CE<*SF^W_X,N_Q__:?_?WYJ1 ".]<621<]Z(:!JC
MO$P'M8+J^,,GBF-BC2K3*0L (3A5ZS2:J+=<5'AM)YJEG^E /YD2!F@_4_,7
M !:;R/DR>>68S)WG2M E939G*&NB2#28*I,/RTRZF*X2DE:LC/'0'4GZ2 [8
M0S;5IT 8I6*":MJ_/+]8G"TKM"'D0&8Y8UR9V79% >5C_/$D_OQ"J_BQ<R=I
MA*[7ZT-,K[S>O=*3X[1<M'C\'P<_)M;]VNF_/?1+D52%>#-0((MCM" $WM#R
M&E+8MS]G<RFKKEQG?T1^)0,7(JYC $&)*7^\NC^@2T-M+:BRXB/UV$S'):X9
MSTXT*.7,/>_8[]2Z#5+FT>7%\OPL[^*R>^WSPQ[PXWJC?LZ _>SK#HTZZ_4Z
M"]CEJ6&PU $JA :F.]P1F0]_PR&]@X+FVYNG( R2E-:D>L:BHG KK2N];+7C
M5+%(H_<Y7V3[/;CD$R1DLX%V57I7_64;?>P$KC,,ECWV*T)ANV&=EEOMFY4C
MY2XDDY[L54>&<P!-M+/$I;?0QFD"GA5/%XNC!V[2E5OKQLU(WAT&45RD]:3K
M)G^3H[#_>>OY=H<Q6JO(V>6G3" J#<F$2*@\VYQ_,T#_>O)K<TYZG4["Y=4*
M&"MRZKYP&$%]3$_"EPJSWL3B1E*VW[L#_DHO6N<!%:O4)S$];YGM16*2T66E
MAFTN7.SS!^*&"7R>E7U^!^=T#V%,X+EGQG,[=*(#WH)7E*,&,SI(TQW>? G2
MX('!O&<<('_::L8O-4%G()J7&N6B4"$+/(,WX9LWP#=[R7IG<ZNFY>W!@$$*
M 3"M\\?N=IJU?L+J4U:145&MWFI6LXNL=ETF@M^B-@D*]E$2T'%5-Q#&N'+F
M57U9LQOA]G[ +LO]F[_#H0\%\#%^,;<^O02I\"C)/;SO..(TVBNBY#Z:TJ^9
M['O!LI04ZE5V:GH,PDK2ZA)MGTG^L$V.DEJ@,QFUG'7770$"M@F_BOHHPJ]U
MCU_6\-#9R"JP:(^#.^@H571J*^C$_O,-_^L0D,XJNP:2WW[4VO-/H@L<FR,=
MT(+ 63>TRT7+.FN6G8C29;E-^;6RW"J7.,)N?$L7"!U(U!(1EB=^P0V+X+XU
M1+!T8PBU_6QEXHL<']G]3F]+"!^FY+B:BJ.AMJK=&LGM:5X3W!2C"5..F,=&
M!9/15Q8#3E0)/7<8B3.8#_34'7"9I@E0:(ZS)-$_*JKZ1"@W?;T*DS1F*Q/)
M=?J(X[M'/Q1UJ3Y'\1833MY<A=Q)TXUX@ 7'0'3Z;NG,2JYZ!FT:/,@-125+
M$3,5I<36HMI=;B[=YSX%6Z[XQPCQ SWN-@E?3O]-YO2C?#W0>55*HV$4OLON
MJ[C]3J+X@<YP[(Z44(=SA1&^'?CUWB0=TY7T/W#P\$B\O:039P^8U57\2+"3
MW[P)!1\UX]X2B2MYK#.)NYH#\3OUY 1EOB#A#"_:B:@[I<MMCRQ;AOR8+,_.
MH^J+J++L^MV&1G5+H_K,[W+^C^@DM!C,:O^A_OW?5M?""_."I?DU]6^B>ZCZ
MI#,V7UA/\$5=YHFR>WAV'_4MO)Z\_F]'/$\RD!CL<++DJ[UEUG4OI]>U[PWR
MMMED< E-[/^IZ?VT'U4KP_\/ZBX<R_&'-(*WU>'D=Z+R=,8Z#.OZWT2'47-*
M*[OT;'<(N;'DK\S<:;:E,H1]"H&F\L=]D;YY?.(6*\'J[^A<S83QNTW].#W&
M""YZ(O@>/P1AV!/$X^\,6]C63F<G^X)OM#/[5ES0  >4LA%OJULK>::U)&IN
M ^+0OBV_TRU!/[Z5;GN!.I'D\K?RCNE;O:&^04)>ECN(>IMYH[V$>]-K&J:]
MK1[%X/S+Q7)Y =C/ ,ZFN3+&,OTQYSJ3:?]18S'3D5[H1/H_;<SFV-RE9B/X
M3^W#G1@*:EGY']:S#QJ@K&8K]SMY]./RGI8Y6Z=O=W@YX>>%&W\:^;S_23T?
M_)!5NQV^K?[P=Q8$L-UZ-?5OH@>K^J2UWF%]NS:W]>WNUAOU+?IVZW'A;^_X
MTK@&W+?FV1ZUX^_XY&QJIT>3?+6WW%6Y-P>K:]\;[.Q,[H8[79@[I#^P-_Q/
MW>(X[4?5VN+XG]-;.#9+.*0-@/4W]_T1N&]$X&4?Q.SA_K&/$?FV^=Z$T5K+
M "MS?)V; 3\N 0@C8TB!0X2I+$**A)00HT>25#.R!"=%DZAKD)JQL!]5$ISS
M:>EF^NRBR(_!<[#!X>8;:02F4P)EO<>0M*HZH[6MR=RJ06DBN&0@(SU^(6AF
M(Z)&'EEN.5'L18E=$:!-%J#7 .^.,SG4!;J1I$_KXQQ5,M?EV1V.GSH+YTVC
M\!C2O5XO=!*7<W-GS7LIDAIW9#FAZ5A7*7$7/.,$_?**_3CY%9P1)X6PD511
M[6N\F=SQ]VA'Q.S(D-]V]EC3?.SY8]4=G9FOY:D]>BRL?&LYY*CX\S*E16SB
MEM@<=?8HA_KD^:/DPQP]>WX+DC\_QQA?A:2QXR2UQ9U2O<?*G#)G-%*=B]/I
MTTIJ(J(VHLS(MT*;!H+/2)-%:$LC%&01>E/DV87TR:BS]>,<%7%^"4)\E>*G
MQ'1[+@0? _7EUFKD))XQ;D,_J'[$##BV/<-#(V=FFV]OY)SGLP8 C1!6]:L<
M%2/QS6?76_;;Y/*0/D9Q\&]L?'=KJYYCX*LVX[5FH1;&4K/&R>W"HB.C,T.!
M+=B-W:2QCIZ>2$ 3=N,N^1F.GTD0MU&, I)0'.TANCZH&J&RSB]R5,PF]@1<
M;C8!_8N_^Q@DZUU$[XA*LC,EIMNSDLYC8#P51W0FE,[-3>CE.Q +XU#)NN,]
M#S9!S$V=[AH7<^>958<JC+"L\J?68]QDES :G7F"1-GE[4.7?3(CZ2"<[FZ\
M7/.[XL@/\SV-9#@>!V$2K&7;R&UK-TRLFVC-MGLRBV%=4X3]V>EB?KHX_?_/
MZK!?EV'O5V&?E)[;"]C['/91!GN?FTIW>_N%L2=\;QW?:1=D!O/=R'^9A'QE
M?9W;G\)\KU=\BLORIRAMML\-AMAQ[_;G8!UB*82D5PGQFGV+GT'ZB-)'C'[#
M\0,97K%_MU^T/G6G!D3=M'N#^(2F.KHQO7%F,F\ ;>W:H :(#LN<^:JYZ/+T
MXOQ\5NJ4T/MN)GPOF% \5YV"S+9Z9R"^"@5@[7<X8*&<'6,H^WL,L'@6PR2D
MF"\A2;Z4W^!:RI:>6N-IK?\PSXB5/L+P1W.@'\CN E,;VYA7=&2]@MP+500N
M%O/STU/3G4-FDY54>*H^PDA@#7<55@,[:8]A)+I\./'P$+,2%/4Q\ GDK8+3
M,Z&I;J#C2SC0&WQZP?$Z2/S['<X_].0]@X+2(^LE^CU2AMYR-3N_,-UCE.Q#
M!:"/N?LP'G'#70E<Q"?M5XR'O;6/^9U7?<"%PF/M9]0YUE2?H_B5CG'!N^3:
M--=-M>HYHH7MAO%:^^G,W2>83^N7#)KTBJC)EZ_'1K962"Y?@@*FN<G1:7)=
M6?X-CIS,:F5UQ&_P31RLC1\TT=1^G,37Y9(6:,W5'I/38:.P6&8J8K8>/4\:
M_!!%O;!2N3"<A6M/);Y%*E7AAHD(MO?C'2/M?H[B+0Y2NAUIJG+''9J.B$XE
MYFL=&3-7*2>GSI))4]4JME!XUUQ\YRT))>3DK 6<FJ2[MJ]PC-16O8UZHF9;
M4W)$A%:U7&N[L;E+E7,NX]:4B\Q^Q2E%<:E%'F?Z-RK.+,O[4#[EDFT]8!LR
M)SH&1!*<^\CAJ,QJ4P<B%M4('3/;RZG+)-%+XG_\'*^V6=VN[J/M$<9MP^50
M-7=#<4='X<I^:)<_0\_V!1[#X\Z0M:A@.BHUM_7938:-$N,E+3HT'3%[$O-U
MIO1FY@KZ='(E,>MMT*)^?,T="3F^#'M0>VQ;H7N#O46)UJ;L&[*/<(P]P?4A
M35*?W0=M);]NUW=$O4*K$UH)G+D[)/*^H638B96\>=KKU V'>]Z3+XMKT>^/
M^%ITPQ%;]$2LN-Z\(VC'TGOT4J')/J3["QUY3S+IQK6FGN/L.?2W5\TFF'FI
M]!@3;ERSW5$,BF[;6N.;[!@&16C1$J&WVA%,M\E/_B6.G/B_->\XGZX!EY4=
M9Q?PK7;?NF+)O MS=V?+^@'T@]J%A&%'6H;+2)2-U]_2B_(1\J6$ "8BS?I7
M/7+F!-@>K:K].+G5U*[<F;G"K_*D&V)[M.ULW.#'F$NO5*[OD7Z3&;O!*"Z4
MHOA6LWK;^\UUON$;[L=HE[VU-3I0->3M]6XE[[3R7>".[N@K_T[^>:8<CBA\
MGK<X7M&D*X!.H=Y<CNJN6N'J[S@AWM6\S/=4Y?<%=>'2@O9CN,56SR6=LS:S
M"2:5N)D2:BGM[BPN*CNR2VXG_11>.3]_E^7GO%ZSGZ(M#=IS6]"<O_]V&"T8
MN0QWP%>#K&)U0WH"\G?:*?@Q'8E=;V_(@#-8!WNZ!ZG6IB=5=2P5JWK\4 7B
M^<5LYE7*WG*N&U9;=)\;A3"WBBZ?[4MV 51<AX^NH9I4A5%(6(6NMZALUQ$5
MHC(;84.U<?O;[]$5KU*DUM$EJU2^YU$E]3<$)X^^&)Y<;_E!QEMZ2D^X:CK3
MZE=X#*E[KQ=:*:*Y&E:976*83V MCJ8RVTXR<CVR[-QTM!F/YJ':9Z%:ET[Q
MGF0L>90YN3*JC:3A:I\'\OHD9HP8+; G5"=L+L.-SJ5UCAIY+)<Q318!Y9MI
MO,7Y<FGLSJ;*:?>_L@<3%)7G:7_69P7JJW;D0>07%[UM"M^.Y%8G5[ZIJ1Z6
M^9/-BOV5>R2?>W\GGWOGW]2Q"Q/?Q"<VM:0"^8F=OLIJ\FYT](U7TS9%R,E#
M.LE)?* SFB8G*,IBCV52L&2S\N5"WFPV7YDJ5"\,8&L>QS'3-SQDAF;U)@_9
M-/-WP^/&.J/,ZTV+UT[/J4D89_3\63V>3FZ02MJL9_^Y(_:1WN*&M(*O_A/^
M&#WY09W>)E7ETB:G ?;K[)-9B9J<G_YU"-)7024_N!Q7-Q9-'Q)/*R3.;.09
M 2NMK3I#/\!Q<5%[.= I3A^8-N,H.&R8;UIST1HUAY-118>/M7([[,?QE';6
M'T7UXHF(Q PSC_B81\G:U:)#$(2M8<$Q<;6Z6UI,H%'=1YFFFZ7?WB9#3_9)
MS!6+.QJ2UN<-H_RL^2FGFRZM325\)LW^-RPI4S-(A!O3H*WV*2^*S%>+BSF?
M\O3^ZIW3[NW"B8V)IESKF9ILS#LBJ@G]X+J@%MBF"P?CP\_X/C[X\2ORSD\0
M_>*.33OV(K=GBK$[6-88YSK$(PFGD. DW^3FZ33"A:";V5]G?VUK>\!D,]0O
M;:XABIRGFJ'!8$SS=S]D1#,[!IYIX%6/9JJ!LL8R=T3"6)XIRW"2:4H&:G5X
M9V6N\4Y=S&R&NZ9--TR5\X0S/"!-RO%.W:8<"7CU2*<>+'NT\S,:2SJY!#<I
M)S-/JQ%ZE>1FY23A#'1,GVY^1NZ3S<!@2+*;E>-44P>L)M%4 C49S>031++;
M_I1?<X)0JC8I[PPZ(SW91<\FM&+.=X++0@>1S"AGNYG%AK,#F&24QXP^^(0I
MPB_B9F*T;W40CD;D@.SF#DEHW%F!XU&_##=7(3UV%#QCNLTCN8EVP?I5:WVC
M6Q+XBEBG>3K+*%[/G4;9>A7;T)XK0TP;XNK0#_'G'7Y)T7ORT?]T:FN6R5CQ
M$P9TC[DD5NZM+"GAH7^%J#^"L!3PMRC:),2\KU&(G_:[Z!7C6QP_!VN<W,7$
M4)\M"O[CX!/;T]?K[2U>'^(@#7!RE20'W%^_;K0"$,(8:[7.]2(K"8\P_8PX
M2A:@S 14LN$$95;08[B%'8@; LTFE@/)2(:^2;<5-<\E)^Q8BQMD8PIY<@XR
M$G=3PYG':+<A3:9[8J3Z$,10I6*!<N:Z.%N=GI8&)D(*P!3'&/MG=?NAIRC&
M..-I.6-M$"&%067(T'3:% 0I%Y2*"_S!#F*G NS?]U'X(0J?B6J:LFR_1BE.
M/A(^"!^Z)QQ&2H4 ^3B3-:;#9O/S$BOPSKQ<4 1EJD5/C:AR5&BGO1?3C[@!
M8),:5B,V.Y*(]1.8U;!YM;"5TQ[T,PM;P,-VH&%;5\)&2&-!DL?=*PL@KYRP
M7L<'MCN0^(J3%*41H@=G=L%]'(!L!31,9A7F-?"UW*!J+F*:1BED'Q]M<Q%:
MF%HUR'L<IK+!!T!>"!"["6C\A.\,AZI@"!!$ZZ0..4">A/X,4GSI"QHC>C91
M<;_#GZ.8Z$X"DOLS$B3__D)&ZF&"[W#\%(1\Y?$AQFRG>6L+'2@.A,Z'V:H!
MH/E\5F'P0"A$VRBF."E4LI_LN%*4%EJ1GZF%X&PK 2K3=*:0GH%$%97L)T(I
M*FE%N5HH3K82),]0*X)EU7%<4R72$6$'6^U06*^ 6G'0G^KVSLK;'),3^,G^
M83XP:-'E,C]\18_^!NUC_!Q$AX3D+"*O(0G*A]^OD)\E//0'>U$T<Q)_20IP
M'TWF\:S.)@X<?>Y;4)AB24#(O KY ? =7RS="OI0RW447@?+;?IMTQD,S+Q*
M+B/&35<A*JN@I=ZS7GK:GKD_<S'N?CU3@71?,3$Q'H,F=;"CN^48T*+5._)
MN"'_R+*1/ -Q8WRGA_QFYJ$85_-,E9^1_B-('R_79-B<!&I$T/HF+#^UF:7<
M+A>SE7?6&&;)CY3[A7RH\91)IUL(J7":BD<E^>!49,CQ%A9J_]J4E.#J!PS
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M!QORW&MZ7D?2_W(+2MUSO0Y.\-9-HC<*? R2]2Y*#C&F%[ZR^UZ5OW3;^Z#
M:S%*JS4N.W#(+JXH%* ?\!?E3A0#"2)%#'[YZ&3?UM.>N_'9%3-WX,I^>KO?
M!6DQJ?"-CK!G6HVC0PPX>-MMTVJ_JQX,GXB-FTS327E&C2ES"<K&(B**(E$1
M6 R\$^Z^ Q4/!K;W?E3WA,\-<(NO4MBJW$*:;X)"N&&.1AN=GW>,[T]0UG)+
MP'4%IF.];D?F!B?K.-B#7TFOWF*[$2F/%!@(>9&DSMXS>\0VK(1>K994'D'"
M7L$RW -).6_)57(ANX]/=H,<.$QJ;:J!AW)8@!M^\SZY4AGQ]NT_JN_#0*;;
M*)V<Z>RLB2?Y'9 GY<+ZEF^$G#H$(^KK.Y-9ZC3W%L JQ-346FZ;PMHE(U'X
M0*\U^XCOI44W!TJ"6 ?6-U/KIII%>7>(#,8"Q<WK>XA&=L$@HCKMKR1/'I<>
M>@.,2_]B].3!4;O>:$=C0>]7)+GZ/?R-1N/XH[+ /3# SN4TY6MT^=_3X'Z'
M;_&:/)H&C<O)#0EU)?OIM51GNWYE8JTG):K>H%U2C0K=#J9*IN.E-J A#7LI
M?L1CQ"@E+%W4[FP2I8POY<Q*[1-,GFZ5K*#LIGGCFBG13B5DZG;K=+8$):4,
M38!DPUF%;T\1&*B!AO:X;EWM!A,\U32N"!Y)XJ@)[ET1!Q- -8Y6:&[%V!>]
M#Z(]D?A$1L%7X?HO;F>&^E2GEBIJ?C%H2N>5\LE+G==9&-9P3 3?-%\#:6<7
M%V9Y?I=9 W;!!F@LC=)^;@WH9<6@\62] -5.![AL=SH/H$97(&F11TGX[41H
MA/=;/I5S4P>?GO:[Z!7S]<H;TM0?_03?D,8T:,Z@0YHKDP7M)FJM&LS59PDR
MC6)=/].)F%('IP>,1:C!-NOHZ8GP"%__EW +SB+%G]AGD=H3=<Y/$O0C27EV
MH.<+.$<B_.>?H_@6Q\^$^ 9Q1U.(*Y31L$SG//?B7)TIQ&^W48PR50[RP]AP
MM"4ADJ6'$*>4-/:D*_6=V"&DC0!ES,NC.O5P4>5N0ZWW71KJ#;P?SUO.B/Z%
MZD .^@;$"2.@./P26IP=5HV,@F3JC&0FE+Y2>E")W@;=: -.SX7U7J^H'4SG
M,I*O^"?[U:!,I'C9E0PDMTBKJ^V=/RDR#Z* /^%BPC'4>PY<?U<9>W <$]R6
MK\T.: P<'U\TFK1R:E&-W]0I!;V;.?!W'Z(P"38XSC91<-KXC%NK]@R6YU+*
MT6>LSJI-I?9'9P<LM***6K:-2?1+1+,[28GA&"DF*6 Q&IZW& Z4)(_Q$TY_
M)"[K2EP(89;SFBV&)4ACI*.4XBC%W;F4YQM.TCA8DRZ-/7;YTX\W?XNC9% *
MU"[,E92HU4*MTQ@:T[B%0C&1RU2>(*;4P:S)5(#:=@ZDCY@>3<&[$F?$18SX
M%.XA#%+W4ZM>Z"BG6MU!=Y S:H?5!I)%0XH[+%$W3:OU]TZ!E.FA<7C33588
M&1!>WBQ;F2&8]Q\>8OQ AE+NH[RML6O 6QJ]J8=4MSA-=Z*T]C<^;*4YRJNX
MF98D+*]M%TN;$.O2 $O19JW=<<JG9PKE=. @U+.1Q6MVZS$=:# +W!EO31,R
MQ6$7>,B&#[^FB9O:8<.D"!M+JXJIJE?R7Z;7[0&9)F4IC<MT/LCDE$S_^X<?
MQSY1_.D%Q^L@P:WU:#6E.$6X4A/5EU#F9\N5,K_2/U"F#.7:'.)2$]%0I4Z;
MT1A!DR9"4F9%R48A_$+2S5!>_!N>ZCJI0(W9VF,X'9%])Z/XZDG'VNCU.QV\
M<P/5&X665#>(3L=DC2N%%S.O=P\!WWA;V_72/8OBQ/:""4/6QXY4=?6\=K1M
M3LXQ_8))G2',":/6>KZG%BA:I&@7W,>![^!DG6&RZJ%>[:_AT/3=[_[N@(>7
MLFF^#C]AU[!)YQ2R2B$;IL#A.C9C S"BC(V#<W:M+5QALDX>R>DR*:;/1.V:
M/D%NY$L]5FH5(9GWIDC/5%M/41(G<B*S8>E+@YBV8ZE;8S8T0\K63!**9QS?
M1\#!F*E'XUUG- "3.T7^[,GG5.+J6@IGN'*/HDQ'DCV#=6A69W-):="6#/#H
MRO9,$JV!57MHP1[;9 K2F,96-7(UIS99S$@C\A-GW\,/,LE?=RC3'GI\97%Q
MNESV3T'R_-K-4TPF_%=+I-T]PV0B!D..,+F8(PX\N=0>0M?RP8'GEFKO.I+?
M#3FW,[\X5<[C'#VT-,KWSIH)+N9=@S^RUNDL5Y.I(8>R)&&;.#DR=R1+39Q#
MR9/1,S3GBLE4ZYF:TGD:=_(KPR%2R[>.ZCC6%&$:>1K+Q>S,T"$L]6A/3)O&
MMUUK276(1*?8"7O6NRF0$P7X!N(AE#I-P-28%3Q@@QEVFJB9VW#M(N>:W6>M
M_1G,,O#G*+X,T^!CL#O0+W,31\]!(MG=HOP:'(>VVJ33>N<S2<))JX/Y1#3:
M"-EHGPL'2RI-N=ND."(94=$HDXT*X:#T9<IE"3^)*;GL2[^3?&D'N*@7K1*R
MZ0Z:)391V=+<][*#S**Y;Y2TOK,N?I&U.N@MR&9]UR,;%S83F_5_&/,XM$%8
M$>$Z/#1XNZ\"&UT1OXC29SI^)4D4Q7O'=0'EO*RW58P0#<IDP^W6ZF5ENPQI
M&P\R]71.A>;Y;  @&1[P8A?%SMG*K!\D'5H+H)PL<_5TO@X) WKN7*F.6J'Y
MU%H Y6Q;.H\QID$";V^TVA G#23LGO@I^@QY[S?R<SG4-RIF\Z,5'&D_.2 S
M/)VTMW1@#&$YFE-UG8Z,2"Q'TQ+]=PUSCJ5G'=9:)PVP6Z-'4[V.Z3YVLE'H
M5>W$:WU37&,QH+MUZHN#ZT6U;=4ZB"/K,V7'<.J[+&7[1\"ZQJE#U.P(K\+F
M$;;Z3ES9*B=HGS=UF-1.='W8D0?"#?F'BUMW!Q.-A$J'Q=LX<5:)FRC>4.7)
M723LT1V4#!,)2J#Z]FHU?5G!<UE"G"M&=U'.%]928S4BG3Q4<C)U*U0:C#IY
MO!3+(Q0!JQZ,<"AQ'<5%<GX=&'U0CE7+3_4E'@W#ZN<6Y^8(=KHTS#R_#@F4
M,7IU(E^=.EHCR?7X2%4A9QT6<[ 3:==[:NMO^.D>Q[7VU/Z<[9-F9>4:!XX6
MJR4'-)W%2E\1%X-^<$'_'^#QL1$.>05#14Q*@J)#FJ1^N"'M"OS$E*P]-4Y'
M-=PWD5$<[G?Y.0&Q696@C,[%^0_X:OOI!:\/*=Y<;LDG^AS$27I#^F;RVT\A
M<7!'L7M#B]O?$1WX ]$6K/W=71SX4IJ=3IGM/&0R3W1*&9YE6S5R:[()9FK/
M"9TG$Q:A8(NPL GYU"BTI5:19YE9" N[:$^T9[<5I-0TM!:VH90:9WFRS94@
MSVI!%FM0/,@WE2!_J@:9686$6>A3*<C,,L1,0YEMB!D'D/ZX$FBOO34/;<P\
MSF>UA@R60TU.MWEZ->TWM=CUW)"<+[Z+;'4^@]0YVOT,\44+LF>#.J ]-8N.
M:MY.'V0ATD-ZH3S2;ZLCLA#M 5V10K,^SMYH# /K]D>#/RW(7,#A/L'_.E ;
MG\E_NN<#I,_:G!.0&: QC%Z>KG(.$H(0DP0]-6# +T_;+VO3 UU-K#)%T!H&
M!Y"17-XG:>ROZZ7F>A^'PT=N@TY3RO=MU)I2@GYDXMQ R5#OI$#I\PX(*XU&
MUP&7:CQ<0,P=?DG?$WU_*G[0XGE S.1&:#2KBXOS5M!0>8@)= 0V0QV4X\8E
ML#3:6Q=:JF%P "YW1-_E2]!:"K#E:3BH9"9HM:.+E@2,"B,<3,2Y 9.!SLFS
ML![G@/!2;W =:*E$PQ&L?(R>_* ^M=3_/"Q>N!%:&<NL$S%<H#N8&>1@%VHZ
M' 3$3;7Q]2"G%!,H[ 2;P(]?:?G-ZRU;B>WI:>3/6\:.U B=IN5E8QE1=I2O
MGD/W,B;<\G3<LHF3SH96QTE[)(PLSJS7.$D^8WP9;J[31QS?Q7Z8^&R/SH<H
M2:7[M?M?LKY0TF>1QMZMY46V)9!+97/"?KA!$16,TD(R6E/1ME<J#+LZTW 5
M8JG L+O>2'?M3-BKHK*8=E<*$T3/>N>_?(CQ)D@_^''\NHWBGWZ\^1*$^"K%
M3VW=:\]+%OO8;DMTMJ<MQ+".2$1<)"K+1#^H5,3$ G6\1GWUQOAJJS=6:YSE
M+EDA1LZ@[$Y2BE?A!6ATW6E4-/7FB]/3Y:('64RB2Z :XF(WH-I=!,727;W2
MJF)8@#"$LTJN'PYQC!M7)G4]:1<U=?4:Y+R:>SE<<%+L+1&2P% RTB4&#U[N
MV=]L:($&_P48#FVMJ88#J>,&!G=WCT',RQ1+=RQ('[$\<*OK5_WFR^7IZ4H,
MTY@,4<Q[TBT*;4.RD4[,K#K1.=H:Z8FGXXF-@50; K)AD]1?4\BC([#U(^[&
M7O4A"/15+%#]X.=G9V>+>1E_0@P@ L<X,K/L2#\*QWC#<"CZ%$0K8\3H/28I
M%D;7ZS0B\M#9[(1>TWGN!D*E2*E@M!D-D 0Q2.DL[%6X"9Z#S<'?=2P0R)^U
MF23*#-#(J<ZS>@I,$)U"+T2!+@^8<,S3=\Q:WMC5R"J98VL<G, &/>'+KLJ@
MIS ?@_U=]"E,@_2U<TE:5PHDGKI-TVJ08L=M61JK+\?D :]?3^NW-]!O,#2J
M->M.G"H$T$0.&OOTS/-'_U6VAE?^K>VLLU"M/+XX6WEG2Y%N\M<1?=]NDCG8
M[ID5N[MSRL'&>V7C-RW&6TD5FPTZSQ%KW@WO !.\_LM#]/S7#0YHWS>G?Z'8
MFI>Z//*C3./MZ]-]5(]W\_<6NJF&4HW992_;<9A]9B[!;BL=ZX"GYL#4+;6U
M<="V*O<1)%VCR\-;\BTNP\TMCI^#-;'I>OLY",E *_!W5V&2Q@=>G(78DLA_
MU9W+F51A,]$S:+=.-I1-R^?24$D<=!((%Q-O6$RL)8@3 *F2/9J.O)'4,OJG
M'Z9X7:\ZVC[7V?.&]12TTQR-+47>^2)+2X7(9NE9NQO$S/HVJ_K6+$0,.$UJ
MU%%OC*-VTE\ET!4I<7]TC%)!NE% ?_X0&. S"[2:AU?'.!$#A>J!#M2!G&Z<
M@.Y ;ZIHA8=DO?$W45AQU 3P?D9WC]$A\<,-RPSH.0J,0U[,+[]EX89$LQV6
MNB)L@U;3/M7$<G6Z6IZ+NMI$!\J4(*(%Y6J0J(M8W$E#-0&M;TX;B9E[D>BF
MCVG#P<B%K8X*QZDD,(X9B/.<@8;$RCP_!2\CV:E/ "PW]5BG/.6ZFI_-SPIF
M2C,\TO\G7 G"O%$6MPWMB5#+V<B4WK>PD?#><2XR&XJ,B98Z_@*PDB*Z6SA)
M)69F&>ESL VHSB^1'RI,7JB]",= '59IE$-;G5Y(F&<K9*,=$0XVIS&%KTV>
MR60C*MR-.8XI',]89:'CIV5644"HA$WZ8F2<1:BRKU&*$T7RJ#\/RADU8Y3[
MIO/5ZOQ4,GP2(A&3"3Y0&NV@E!]L.:C!"N.\+,B R7 #^BVPDB->YK]9H-,M
MJ(/2A:X7X:#?895JX[E8+987*TFZD K9KJ0+YGQMTD$FV\ETP9SC&4.<.9PN
M*"!40AY],3+#(O\OCJ/K$'\F@YH/4?B,XS2XW^$['#_U9@YJK]IG$B6[-*;T
MY_-%P27_)L)1%&(R]"##W74A'Y&V_X1"JL$ZGTSA<<XH5#@BTA$5CTKR$57@
M0KHQA?M%YL$NR7J,=AL<@V<A6F@M<8IZA(RRRFWP,I!4NM\$XY1.LW1:V$+,
MH[+IL]9698$S3'K4I PBW67&,.F\U_\Y[9*$$OB:'-$?$Y =H43!]?8RCLFG
M8(E0U^$VZ;,V]VC*#-#8,'R65;UC]1.C+2J)8HLM7Z/PG5_Z6:F<4@)[^LV
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M-6Z1&ZS=\#A B;L=&(TU'.#"K8DD83GLN")A5^&W\P46M&+'\]5CF*#X)HV
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M"%-S),SP$;@"_/,^>$5Q=N0#KZB:6C_^-SAV_3!.(R3@.9V'U1#,6//!(NK
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M;.]FM@\)NHXZ:"$I=!'RXKLHW!Y.T)43(X^SP24ZZ2'MG\A-/CN!DUO(\N<
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ME$1G>JIZ/E_EUV2\#$F" R?8QZP;P( EZBC68,4@[?;-]5,/Y*C\JB=B:>*
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M &PAW5NDP&E;,JS";[PR?XL:215L8WP!J*<XK? :MZC/37I9@31&25Z<)>^
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M'!QE07:UN[2*+>-S+KF^&@[RSV'H?<.^+SZYK)8FH+T/0.9!2^=-;G<PFVL
M\!X$IF!-(KIF<8R2^!YDMQ4.<()\X'">+%]L-8P)Z!_0VO$5+B5V>Q/4/Z)O
M-8DN I$Y#?(B)5(W6.MA+NZ9/$#E ?7X+6#0W*R=_VNVVP'R!5VQW*JV'\?$
MLH+XBN#=3@37&_2*_'!'0+U](Z(?XEXJ,CV-&)+(C7UU'%DV+ZUW]YF0!5QP
MX3L!_]IL,Y*)&7^)B>TG3O 6-MMQM7=&(RNU/[)/=-M+M/0&,/])8'LYE]Y@
M/3[ MM=YZ0U(R4>2[35@^CS_;*6&[55A^D-53@-K>PV9,^,KJPNVO02-=MC;
MZS%L+TO3"]1,G9OM56MZO.4D[2:=*MR,$>$..A;;B^7TY_W%5K':7DFG-TQ;
MZ9AL+\#3&]I2.DK;2_?TAB[;^F5[=9_>(!5:G6VO!M2+X"#K)6)[!:'>MJVZ
M.?-\588FYT>#L66VV7YU1ZS-8,$\[*=$Y*N*<]V^N7X*NX\4GR*\*RTG<GP]
MR,>Q:?N0E?RKCP49M7MW&?\*8+W 7PD%%=\R&LHB21G]/$EV-AG(7B--Q$"Y
M74R><YFYT,+316LZ'4DA2.9$A2M*K:0HO NCK7,?K,C_R*]D3ZCL*%8=52,B
M# 7Q^&I?^PEN:B*5PAXD=S:&(RBUDCJ_8!:A)^2&(*;_@;Q[CVCW2/+5W+A5
M5OP"^>4!.R_8SZ0-^%NZ1=XRSQXMBY*>KUP2V]>Z!VWW[&H/KJ;M:[N/5UNA
M1?J^.Y]OUP"EE])6G=E(FAX" WE82%$HN.;5QC!QJRFN0X=I#N-.:K6J]6.N
M"MBHWRAJ8)E[JXSCK%<B0$FKO#1ZVN.B3S$7BE$?V>O0ATT0$GGZ%=4R? [D
M5E8AC[ZG54:8PNM&DQI+:6.-FD/0XBD&PAUD2:.?#MG>9B+3RQ*H\<SWY\D&
M1?5?\8^]9&>3YUIM?HU(']DUGPZM&"5S(OA9-[@1H?L0DE8HVQI*ML_((0OA
MS8.\0AP.UED,JZ+26,<W+I,-:,9YU,RB<#V*%\Z>P (_1BEJJ(0#+UN;VJ\J
M9G*=%3A,AI#&7M<,Z,=.\T=,<*>"=$)I1K[CBU@MKX=)SB$QDT;M"LT;9.(7
MVL T)X/T=!K,>"*>+(*B*"$<X().NPHLHS[)-^AE*)J^)BF"<\AH;.((LB"4
M(7P8AXN/?/U<,><Z':(AO:TO]2A5;)L0I7A_4;I<QJ'BSWK4)XM4A,=)67#N
MX 3F-N1)P_8I"0H%)U!M#$/YI%76H<,TAW%X6ZWJ42())<"F4RX-EKEK=2QG
M/<@^#F^L^8M?U("_ ]H<_S^0$WUV$A)4M2]O+:E;NMN8%\X).L$Y:L:0U>7=
MA#Y $)/\7,F>M!W(S9\3)#CN1XV,"-72(#(D;.G^)L\I?36:%=6E<9@.G0Q.
M;2YB5A&0;1CD=;HC1'*^1*_(NPNCNQ28([J/XQ2(Y-\T[<<Q4IRB"^\8U.GJ
ML'ZC/F5YQBB2'/$-><N08'0X;[6BPV:K!JK22-_'RL,8\<)DFJM$+I;BCD;]
M)Z7GU2BFI[SRTV%6@$O?S;DA;JOQ?5!+?_W5(<ZL2;GF^YSM"N_.EB-9>U;;
M+TJESRT G+D)?I5>":7N?9!+5C]G4200--NY<4O298>Z' ZIOL"V!R9KP$]Z
MQ]D>@ZR.9>L;8-31R!6N\Q4KYW.5Z77A[+->9MTC9$E^J9,LLOUV&]2(NT7'
MI>L(!&-4HY9F+3NCX>;1%>-1OP8ZHF?0;61B,4<.&;?;G1_N$7I&T2MV$3WY
M]\S/:,F"$*M<*PL$6S>?GKP/B^[OF47O,<Q".3+:LH0H@9O/YDN B1-Q76B6
MAJC5H /!H2H\DRE+M<"@,*99%.B;.2,ZUY^TA:+UP$/!HV!ZLV].Y-7)9C^+
M6F#3X2-V"3<]<G?;G_I]+H:>XV"[@N \*Z#*H&VO6MDGZJV$ ]O+6)X%<"6I
M]'PE+@?XHCT4BAF(ZQ6%'F'" '8/,^D].(A*3V$8(IK$:E"K#DVN5RKGS&2F
MCDL_;17S)Y=)&&0V^]6!RJ*>V!4*T JKAAVICZC59EO__"-*;HKC C3DV3 4
M;+:*0YUI&K(!S=W',ZQJ7*T0D3W081,] 5L@+TY@$C[.DPFK;<T60YK%(*?S
M"H%85M%\ _^+$^S. N)2B/!:%89VHYI%XDL0'70-0&W!2.*GT/>!7/(R5@1!
M>< +DB@Z;R#;]3:M\6QQ7=JN@9'$LMLM;;M"13.(4MD][-24M#[:;>2-\RE!
M+@Q,]>NZ@K+O.K #?.<6:KR%$R7[9>0$,0!,],L#42^QR!.\>H7=3(B4*E"K
M36MH:BC956O6%U= 9]2JJ>?T)4:_I_#/VU?COI#'Q @.)K.YD3<>$T@YXH=Q
MV$0KT+@FV3,V?*3^]H$02VQ(\,/_!U!+ 0(4 Q0    ( +"*C4P6D>*BT\<!
M '9K$0 0              "  0    !S;',M,C Q-S$R,S$N>&UL4$L! A0#
M%     @ L(J-3"MRX%N()0  M[\! !               ( ! <@! '-L<RTR
M,#$W,3(S,2YX<V102P$"% ,4    " "PBHU,2<LS7A49  "@;P$ %
M        @ &W[0$ <VQS+3(P,3<Q,C,Q7V-A;"YX;6Q02P$"% ,4    " "P
MBHU,OVTO[2M5  "AX 4 %               @ '^!@( <VQS+3(P,3<Q,C,Q
M7V1E9BYX;6Q02P$"% ,4    " "PBHU,](Z0 )#/   KU@L %
M    @ %;7 ( <VQS+3(P,3<Q,C,Q7VQA8BYX;6Q02P$"% ,4    " "PBHU,
M\&&: >UM  !/C0@ %               @ $=+ , <VQS+3(P,3<Q,C,Q7W!R
;92YX;6Q02P4&      8 !@"$ 0  /)H#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
